Cat No	Product Name	Cas Number	SMILES	Primary Action	Biological Description	References	Product Type	Public Caveats	URL	Previous Order	UK Controlled	USA Controlled	Date Added
0101	DL-AP4	[20263-07-4]	O=C(C(N)CCP(O)(O)=O)O	Broad spectrum EAA antagonist	Broad spectrum EAA ligand. Separate isomers D-AP4 and L-AP4 also available (Cat. No's. 0102 and 0103 respectively).	Evans et al (1979) Antagonism of excitatory amino acid-induced responses and of synaptic excitation in the isolated spinal cord of the frog. Br.J.Pharmacol. 67 591. PMID:316343. Evans et al (1982) The effect of a series of _-phosphonic-_-carboxylic amino acids on electrically evoked and amino acid induced responses in isolated spinal cord preparations. Br.J.Pharmacol. 75 65. PMID:7042024.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1184				Jan-1901
0102	D-AP4	[78739-01-2]	N[C@@]([H])([C@](O)=O)CCP(O)(O)=O	Broad spectrum EAA antagonist	Broad spectrum excitatory amino acid receptor antagonist. Also agonist at the quisqualate-sensitized AP6 site in hippocampus where it is less potent than L-AP4. DL Mixture (Cat. No. 0101) and L-isomer (Cat. No. 0103) also available.	Davies and Watkins (1982) Actions of D and L forms of 2-amino-5-phosphonovalerate and 2-amino-4-phosphonobutyrate in the cat spinal cord. Brain Res. 235 378. PMID:6145492. Evans et al (1982) The effect of a series of _-phosphonic-_-carboxylic amino acids on electrically evoked and amino acid induced responses in isolated spinal cord preparations. Br.J.Pharmacol. 75 65. PMID:7042024. Schulte et al (1994) Utilization of the resolved L-isomer of 2-amino-6-phosphonhexanoic acid (L-AP6) as a selective agonist for a quisqualate-sensitized site in hippocampal CA1 pyramidal neurons. Brain Res. 649 203. PMID:7953634.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1185				Jan-1901
0103	L-AP4	[23052-81-5]	[H][C@@](CCP(O)(O)=O)(N)C(O)=O	Selective group III mGlu agonist	Selective group III metabotropic glutamate receptor agonist. Synaptic depressant. Agonist at the quisqualate-sensitized AP6 site in hippocampus. Also available as part of the Group III mGlu Receptor Tocriset and Mixed mGlu Receptor Tocriset. DL Mixture (Cat. No. 0101) and D-isomer (Cat. No. 0102) also available.	"Evans et al (1982) The effect of a series of _-phosphonic-_-carboxylic amino acids on electrically evoked and amino acid induced responses in isolated spinal cord preparations. Br.J.Pharmacol. 75 65. PMID:7042024. Nakanishi (1992) Molecular diversity of glutamate receptors and implications for brain functions. Science 258 597. PMID:1329206. Tones et al (1995) The agonist selectivity of a class III metabotropic glutamate receptor, human mGluR4a, is determined by the N-terminal extracellular domain. NeuroReport 7 117. PMID:8742431. Bushell et al (1995) Antagonism of the synaptic depressant actions of L-AP4 in the lateral perforant path by MAP4. Neuropharmacology 34 239. PMID:7617150."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1186				Jan-1995
0104	DL-AP7	[78966-69-5]	NC(C(O)=O)CCCCCP(O)(O)=O	Specific NMDA antagonist	First generation phosphono NMDA antagonist. Anticonvulsant. Separate isomer D-AP7 also available (Cat. No. 0164).	Evans et al (1982) The effect of a series of _-phosphonic-_-carboxylic amino acids on electrically evoked and amino acid induced responses in isolated spinal cord preparations. Br.J.Pharmacol. 75 65. PMID:7042024. Meldrum and Chapman (1994) Competitive NMDA antagonists as drugs. In The NMDA Receptor (2nd edition). Eds. G. L. Col 457.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1243	SQ1070			Jan-1901
0105	DL-AP5	[76326-31-3]	NC(C(O)=O)CCCP(O)(O)=O	"Potent, selective NMDA antagonist"	"Potent NMDA antagonist. Separate isomers D-AP5 (Cat. No. 0106), L-AP5 (Cat. No. 0107) and sodium salt DL-AP5 Sodium salt (Cat. No. 3693) also available."	Davies and Watkins (1982) Actions of D and L forms of 2-amino-5-phosphonovalerate and 2-amino-4-phosphonobutyrate in the cat spinal cord. Brain Res. 235 378. PMID:6145492. Evans et al (1982) The effect of a series of _-phosphonic-_-carboxylic amino acids on electrically evoked and amino acid induced responses in isolated spinal cord preparations. Br.J.Pharmacol. 75 65. PMID:7042024.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1191				Sep-1994
0106	D-AP5	[79055-68-8]	N[C@@]([H])([C@](O)=O)CCCP(O)(O)=O	"Potent, selective NMDA antagonist; more active form of DL-AP5 (Cat. No. 0105)"	"Widely used competitive NMDA antagonist. More active form of AP5. Also agonist at quisqualate-sensitized AP6 site where it is less potent than the L-isomer, L-AP5 (Cat. No. 0107). Also available as part of the Mixed NMDA Receptor Tocriset or as a mixed isomer DL-AP5 (Cat. No. 0105)."	Davies and Watkins (1982) Actions of D and L forms of 2-amino-5-phosphonovalerate and 2-amino-4-phosphonobutyrate in the cat spinal cord. Brain Res. 235 378. PMID:6145492. Evans et al (1982) The effect of a series of _-phosphonic-_-carboxylic amino acids on electrically evoked and amino acid induced responses in isolated spinal cord preparations. Br.J.Pharmacol. 75 65. PMID:7042024. Schulte et al (1994) Utilization of the resolved L-isomer fo 2-amino-6-phosphonohexanoic acid (L-AP6) as a selective agonist for a quisqualate-sensitized site in hippocampal CA1 pyramidal neurons. Brain Res. 649 203. PMID:7953634.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1192				Sep-1994
0107	L-AP5	[79055-67-7]	[H][C@@](CCCP(O)(O)=O)(N)C(O)=O	"Potent, selective NMDA antagonist. Less active form of DL-AP5 (Cat. No. 0105)"	"NMDA antagonist. Also agonist at quisqualate-sensitized AP6 site, where it is more potent than the isomer D-AP5 (Cat. No. 0106). Mixture DL-AP5 (Cat. No. 3693) also available."	Davies and Watkins (1982) Actions of D and L forms of 2-amino-5-phosphonovalerate and 2-amino-4-phosphonobutyrate in the cat spinal cord. Brain Res. 235 378. PMID:6145492. Evans et al (1982) The effect of a series of _-phosphonic-_-carboxylic amino acids on electrically evoked and amino acid induced responses in isolated spinal cord preparations. Br.J.Pharmacol. 75 65. PMID:7042024. Schulte et al (1994) Utilization of the resolved L-isomer fo 2-amino-6-phosphonohexanoic acid (L-AP6) as a selective agonist for a quisqualate-sensitized site in hippocampal CA1 pyramidal neurons. Brain Res. 649 203. PMID:7953634.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1193				Jan-1901
0109	(-)-Bicuculline methobromide	[73604-30-5]	[H][C@](C(C=CC6=C5OCO6)=C5C(O4)=O)4[C@]2([H])C1=CC3=C(OCO3)C=C1CC[N+](C)2C.[Br-]	Water-soluble GABAA antagonist	Methobromide salt of (+)-bicuculline (Cat. No. 0130). Water soluble and more stable than bicuculline. Non-GABA receptor-mediated actions reported.	Bowery et al (1983) Characteristics of GABAB receptor binding sites on rat whole brain synaptic membranes. Br.J.Pharmacol. 78 191. PMID:6297646. Sperber et al (1987) Nigral infusions of muscimol or bicuculline facilitate seizures in developing rats. Brain Res. 465 243. PMID:3440204. Seutin and Johnson (1999) Recent advances in the pharmacology of quaternary salts of bicuculline. TiPS 20 268. PMID:10390643.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=2029				Jan-1901
0111	Dihydrokainic acid	[52497-36-6]	O=C(C[C@H]1[C@@H]([C@H](C)C)CN[C@@H]1[C@](O)=O)O	EAAT2 (GLT-1)-selective non-transportable inhibitor of L-glutamate and L-aspartate uptake	EAAT2(GLT1)-selective non-transportable inhibitor of L-glutamate and L-aspartate uptake (Ki = 23 _M). 130-fold selective over EAAT1 and EAAT3 (Ki > 3 mM). Also available as part of the Excitatory Amino Acid Transporter Inhibitor Tocriset.	"Munoz et al (1987) Effects of dihydrokainic acid on extracellular amino acids and neuronal excitability in the in vivo rat hippocampus. Neuropharmacology 26 1. PMID:2882438. Arriza et al (1994) Functional comparisons of three glutamate transporter subtypes cloned from human motor cortex. J.Neurosci. 14 5559. PMID:7521911. Kanal et al (1994) The neuronal and epithelial high affinity glutamate transporter, insights into structure and mechanism of transport. J.Biol.Chem. 269 20599. PMID:7914198."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1298				Aug-2000
0112	_DGG	[6729-55-1]	N[C@@]([H])([C@](O)=O)CCC(NCC(O)=O)=O	Broad spectrum glutamate receptor antagonist	Broad spectrum glutamate receptor antagonist.	Jones et al (1984) Structure-activity relations of dipeptide antagonists of excitatory amino acids. Neuroscience 13 573. PMID:6392929. Aksenov et al (2005) Glutamate neurotransmission in the cerebellar interposed nuclei: involvement in classical conditioned eyeblinks and neuronal activity. J.Neurophysiol. 93 44. PMID:15331619.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1273				Jan-1901
0114	NMDA	[6384-92-5]	O=C(C(NC)CC(=O)O)O	Selective NMDA agonist	Prototypic NMDA receptor agonist. Also available as part of the Mixed NMDA Receptor Tocriset. Caged version also available (Cat. No 2224).	Watkins (1978) Excitatory amino acids. Kainic acid as a Tool in Neurobiology. Edited by E 37. Watkins and Evans (1981) Excitatory amino acid transmitters. Annu.Rev.Pharmacol.Toxicol. 21 165. PMID:6112965.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1710				Sep-1994
0125	DL-AP3	[20263-06-3]	NC(CP(O)(O)=O)C(O)=O	Group I mGlu antagonist	Competitive group I metabotropic glutamate receptor antagonist and inhibitor of phosphoserine phosphatase.	Evans et al (1982) The effect of a series of _-phosphonic-_-carboxylic amino acids on electrically evoked and amino acid induced responses in isolated spinal cord preparations. Br.J.Pharmacol. 75 65. PMID:7042024. Saugstad et al (1995) L-2-Amino-3-phosphonopropionic acid completely antagonizes metabotropic glutamate receptors 1_ and 5 in Xenopus oocytes. Eur.J.Pharmacol. 289 395. PMID:7621916. Hawkinson et al (1996) The metabotropic glutamate receptor antagonist L-2-amino-3-phosphonopropionic acid inhibits phosphoserine phosphatase. Eur.J.Pharmacol. 307 219. PMID:8832224.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1177				Jan-1901
0130	(+)-Bicuculline	[485-49-4]	[H][C@](C(C=CC6=C5OCO6)=C5C(O4)=O)4[C@]2([H])C1=CC3=C(OCO3)C=C1CCN2C	Potent GABAA antagonist	"Classical GABAA antagonist. Methoiodide salt (Cat. No. 2503), Methobromide salt (Cat. No. 0109) and Methochloride salt (Cat. No. 0131) also available."	"Merck Index 12 1250. Curtis et al (1970) GABA, bicuculline and central inhibition. Nature 226 1222. PMID:4393081. Olsen et al (1976) Studies on the neuropharmacological activity of bicuculline and related compounds. Brain Res. 102 283. PMID:1247886. Piredda et al (1985) Intracerebral site of convulsant action of bicuculline. Life Sci. 36 1295. PMID:3982215. Sieghart et al (1989) Multiplicity of GABAA-benzodiazepine receptors. TiPS 10 407. PMID:2559519."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=2028	SQ1070			Jan-1901
0131	(-)-Bicuculline methochloride	[53552-05-9]	[H][C@](C(C=CC6=C5OCO6)=C5C(O4)=O)4[C@]2([H])C1=CC3=C(OCO3)C=C1CC[N+](C)2C.[Cl-]	Water-soluble GABAA antagonist	Methochloride salt of (+)-bicuculline (Cat. No. 0130). Water soluble and more stable than bicuculline. Non-GABA receptor-mediated actions reported.	Kemp et al (1986) Quantitative evaluation of the potencies of GABA-receptor agonists and antagonists using the rat hippocampal slice preparation. Br.J.Pharmacol. 87 677. PMID:3011168. Seutin et al (1997) Evidence for a non-GABAergic action of quaternary salts of bicuculline on dopaminergic neurones. Neuropharmacology 36 1653. PMID:9517436. Seutin and Johnson (1999) Recent advances in the pharmacology of quaternary salts of bicuculline. TiPS 20 268. PMID:10390643.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=2030				Jan-1901
0162	S-Sulfo-L-cysteine sodium salt	[7381-67-1]	[Na+].[H][C@](N)(CSS([O-])(=O)=O)C(O)=O	Group I agonist	EAA receptor agonist. Agonist at mGlu1_ and mGlu5a subtypes expressed in clonal RGT cell lines.	Mewett et al (1983) Pharmacology of the excitatory actions of sulphonic and sulphinic amino acids. CNS Receptors: From Molecular Pharmacology to Beha 163-174. Kingston et al (1998) Sulphur-containing amino acids are agonists for group 1 metabotropic receptors expressed in clonal RGT cell lines. Neuropharmacology 37 277. PMID:9681926.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1887				Jan-1901
0164	D-AP7	[81338-23-0]	N[C@@]([H])([C@](O)=O)CCCCCP(O)(O)=O	Specific NMDA antagonist. More active form of DL-AP7 (Cat. No. 0104)	More active form of AP7. DL Mixture (Cat. No. 0104) also available.	Perkins et al (1982) Isomers of 2-amino-7-phosphonoheptanoic acid as antagonists of neuronal excitants. Neurosci.Lett. 32 65. PMID:6755315.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1244				Jan-1901
0169	(RS)-AMPA	[74341-63-2]	CC1=C(CC(N)C(O)=O)C(O)=NO1	Selective AMPA agonist	"Prototypical and defining agonist for the AMPA subgroup of ionotropic glutamate receptors. Active enantiomer (S)-AMPA (Cat. No. 0254), inactive enantiomer (R)-AMPA (Cat. No. 0253) and hydrobromide salt (RS)-AMPA hydrobromide (Cat. No. 1074) also available."	"Krogsgaard-Larsen et al (1980) New class of glutamate agonist structurally related to ibotenic acid. Nature 284 64. PMID:6101908. Honore et al (1982) The binding of 3H-AMPA, a structural analogue of glutamic acid, to rat brain membranes. J.Neurochem. 38 173. PMID:6125564."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1167	SQ1070			Sep-1994
0173	(RS)-CPP	[100828-16-8]	O=C(C1NCCN(CCCP(O)(O)=O)C1)O	Potent NMDA antagonist	Potent NMDA antagonist. Separate isomer (R)-CPP also available (Cat. No. 0247).	"Davies et al (1986) CPP, a new potent and selective NMDA antagonist. Depression of central neuron responses, affinity for [3H]-D-AP5 binding sites on brain membranes and anti-convulsant activity. Brain Res. 382 169. PMID:2876749."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=2221				Jan-1901
0178	Phaclofen	[114012-12-3]	ClC1=CC=C(C(CN)CP(O)(O)=O)C=C1	"Weak, selective GABAB antagonist"	Selective GABAB antagonist. Phosphono analog of GABAB agonist baclofen (Cat. No. 0417).	Kerr et al (1987) Phaclofen: a peripheral and central baclofen antagonist. Brain Res. 405 150. PMID:3032346. Hasuo and Gallagher (1988) Comparison of antagonism by phaclofen of baclofen induced hyperpolarization and synaptically mediated late hyperpolarizing potentials recorded intracellularly from rat dorsolateral septal neurons. Neurosci.Lett. 86 77. PMID:3362432. Karlsson et al (1988) Phaclofen: a GABAB blocker reduced long-duration inhibition in the neocortex. Eur.J.Pharmacol. 148 485. PMID:2838310.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1741				Jan-1901
0180	ZAPA sulfate	[371962-01-5]	OS(O)(=O)=O.NC(=N)S\C=C/C(O)=O	Agonist at 'low affinity' GABAA receptor. More potent than GABA/muscimol	More potent than either GABA or muscimol as an agonist at low affinity GABAA receptors and is thus a useful ligand to investigate GABA receptors linked to benzodiazepine receptors. Also a GABAC receptor antagonist.	"Allan et al (1986) Isothiouronium compounds as _-aminobutyric acid agonists. Br.J.Pharmacol. 88 379. PMID:3015310. Holden-Dye and Walker (1988) ZAPA, (Z)-3-[(aminoiminomethyl)thio]-2-propenoic acid hydrochloride, a potent agonist at GABA-receptors on the Ascaris muscle cell. Br.J.Pharmacol. 95 3. PMID:2851353. Johnston (1996) GABAC receptors: relatively simple transmitter-gated ion channels? TiPS 17 319. PMID:8885697."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1981				Sep-1994
0181	TACA	[38090-53-8]	NC/C=C/C(O)=O	GABAA agonist. Also GABA-T substrate and GABA uptake inhibitor	"The trans-isomer of CACA. Potent GABAA agonist, GABA uptake inhibitor and substrate for GABA-T. Also GABAC agonist."	Johnston et al (1975) cis and trans-4-Aminocrotonic acid as GABA analogues of restricted conformation. J.Neurochem. 24 157. PMID:234147. Johnston et al (1996) GABAC receptors: relatively simple transmitter-gated ion channels. TiPS 17 319. PMID:8885697. Chebib et al (1997) Analogues of _-aminobutyric acid (GABA) and trans-4-aminocrotonic acid (TACA) substituted in the 2 position as GABAC receptor antagonists. Br.J.Pharmacol. 122 1551. PMID:9422798.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1892	SQ1533			Jan-1901
0183	L-(-)-threo-3-Hydroxyaspartic acid	[7298-99-9]	[H][C@@]([C@]([H])(O)C(O)=O)(N)C(O)=O	Transportable EAAT1-4 inhibitor/non-transportable EAAT5 inhibitor	"Potent, competitive, transportable EAAT1-4 inhibitor/non-transportable EAAT5 inhibitor. Also available as part of the Excitatory Amino Acid Transporter Inhibitor Tocriset."	"Johnston et al (1980) Potentiation of L-glutamate and L-aspartate excitation of cat spinal neurones by the stereoisomers of threo-3-hydroxyaspartate. J.Neurochem. 34 241. PMID:7452241. McBean and Roberts (1985) Neurotoxicity of L-glutamate and DL-threo-3-hydroxyaspartate in the rat striatum. J.Neurochem. 44 247. PMID:2856883. Nakamura et al (1993) (2S,3S,4R)-2-(carboxycyclopropyl)glycine, a potent and competitive inhibitor of both glial and neuronal uptake of glutamate. Neuropharmacology 32 833. PMID:7901789."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1464				Sep-1994
0186	cis-ACPD	[477331-06-9]	[H][C@@]1(CC[C@](N)(C1)C(O)=O)C(O)=O.[H][C@]1(CC[C@@](N)(C1)C(O)=O)C(O)=O	Potent NMDA agonist. Also group II mGluR agonist	"1:1 mixture of (1R,3R)- and (1S,3S)-ACPD. Potent NMDA receptor agonist and selective group II mGluR agonist (EC50 values are 13, 50, >300 and >300 _M at mGluR2, mGluR4, mGluR1 and mGluR5 respectively). Exhibits proconvulsant activity in vivo. ()-trans-ACPD (Cat. No. 0187) and (1S,3R)-ACPD (Cat. No. 0284) also available."	"Schoepp et al (1991) In vitro and in vivo pharmacology of trans- and cis-()-1-amino-1,3-cyclopentanedicarboxylic acid: Dissociation of metabotropic and ionotropic excitatory amino acid receptor effects. J.Neurochem. 56 1789. PMID:1849553. Sunter et al (1991) Actions of the four isomers of 1-aminocyclopentane-1,3-dicarboxylate (ACPD) in the hemisected spinal cord of the neonatal rat. Br.J.Pharmacol. 104 337P. Conti et al (2002) Synthesis and pharmacology of 3-hydroxy-_2-isoxazoline-cyclopentane analogues of glutamic acid. Farmaco 57 889. PMID:12484537."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1028				Sep-1994
0187	()-trans-ACPD	[67684-64-4]	[H][C@@]1(CC[C@@](N)(C1)C(O)=O)C(O)=O.[H][C@]1(CC[C@](N)(C1)C(O)=O)C(O)=O	Group I/group II mGlu agonist	"Equimolecular mixture of (1S,3R)- and (1R,3S)-ACPD. Selective agonist for metabotropic glutamate receptors; active at both group I and group II mGlu receptors (EC50 values are 2, 15, 23 and ~800 _M at mGluR2, mGluR1, mGluR5 and mGluR4 respectively). (1S,3R)-ACPD (Cat. No. 0284) and cis-ACPD (Cat. No. 0186) also available."	Nakanishi (1992) Molecular diversity of glutamate receptors and implications for brain functions. Science 258 597. PMID:1329206. Pin and Duvoisin (1995) The metabotropic glutamate receptors: structure and functions. Neuropharmacology 34 1. PMID:7623957. Knopfel et al (1995) Metabotropic glutamate receptors: novel targets for drug development. J.Med.Chem. 38 1417. PMID:7738999. Conti et al (2002) Synthesis and pharmacology of 3-hydroxy-_2-isoxazoline-cyclopentance analogues of glutamic acid Farmaco 57 889. PMID:12484537.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1041				Sep-1994
0188	L-Quisqualic acid	[52809-07-1]	O=C1N(C[C@]([H])(N)C(O)=O)OC(N1)=O	AMPA/group I mGlu agonist	Glutamate receptor agonist acting at AMPA receptors and metabotropic glutamate receptors positively linked to phosphoinositide hydrolysis. Sensitizes neurons in hippocampus to depolarization by L-AP6 (the so called 'quis' effect). Also available as part of the Group I mGlu Receptor Tocriset.	Porter et al (1992) (S)-Homoquisqualate: a potent agonist at the glutamate metabotropic receptor. Br.J.Pharmacol. 106 509. PMID:1324071. Schulte et al (1994) Utilization of the resolved L-isomer of 2-amino-6-phosphohexanoic acid (L-AP6) as a selective agonist for a quisqualate-sensitized site in hippocampal CA1 pyramidal neurons. Brain Res. 649 203. PMID:7953634. Littman et al (1995) Effects of quisqualic acid analogs on metabotropic glutamate receptors coupled to phosphoinositide hydrolysis in rat hippocampus. Neuropharmacology 34 829. PMID:8532164.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1831				Sep-1994
0189	DNQX	[2379-57-9]	[O-][N+](=O)C1=C(C=C2NC(=O)C(=O)NC2=C1)[N+]([O-])=O	Selective non-NMDA antagonist	Selective non-NMDA receptor antagonist. DNQX disodium salt (Cat. No. 2312) also available.	Honore et al (1988) Quinoxalinediones: potent competitive non-NMDA glutamate receptor antagonists. Science 241 701. PMID:2899909. Watkins et al (1990) Structure-activity relationships in the development of excitatory amino acid receptor agonists and competitive antagonists. TiPS 11 25. PMID:2155495.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1337				Sep-1994
0190	CNQX	[115066-14-3]	[O-][N+](=O)C1=C(C=C2NC(=O)C(=O)NC2=C1)C#N	Potent AMPA/kainate antagonist	Potent AMPA/kainate receptor antagonist. Also antagonist at glycine modulatory site on NMDA receptor complex. CNQX disodium salt (Cat. No. 1045) also available.	"Honore et al (1988) Quinoxalinediones: potent competitive non-NMDA glutamate receptor antagonists. Science 241 701. PMID:2899909. Long et al (1990) Effect of 6-cyano-2,3-dihydroxy-7-nitro-quinoxaline (CNQX) on dorsal root-, NMDA-, kainate and quisqualate-mediated depolarization of rat motoneurones in vitro. Br.J.Pharmacol. 100 850. PMID:1976402. Watkins et al (1990) Structure-activity relationships in the development of excitatory amino acid receptor agonists and competitive antagonists. TiPS 11 25. PMID:2155495. King et al (1992) Antagonism of synaptic potentials in ventral horn neurones by 6-cyano-7-nitroquinoxaline-2,3-dione: a study in the rat spinal cord in vitro. Br.J.Pharmacol. 107 375. PMID:1358390."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=2212				Jul-1998
0197	Homoquinolinic acid	[490-75-5]	OC(=O)CC1=CC=CN=C1C(O)=O	"Selective, potent NMDA agonist"	Potent NMDA receptor agonist; subtype-selective.	Stone (1984) Excitant activity of methyl derivatives of quinolinic acid on rat cortical neurones. Br.J.Pharmacol. 81 175. PMID:6546701. Olverman et al (1988) Structure/activity relations of NMDA receptor ligands as studied by their inhibition of [3H]-D-2-amino-5-phosphonopentanoic acid binding in rat brain membranes. Neuroscience 26 17. PMID:2901691. Prado de Carvalho et al (1996) The endogenous agonist quinolinic acid and the non-endogenous homoquinolinic acid discriminate between NMDAR2 receptors subunits. Neurochem.Int. 28 445. PMID:8740453.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1454				Jan-1901
0205	L-Alanine	[56-41-7]	[H][C@@](C)(N)C(O)=O	Glycine receptor agonist	Agonist at the inhibitory glycine receptor. D-alanine (Cat. No. 0204) also available.	"Saitoh et al (1994) A novel antagonist, phenylbenzene _-phosphono-_-amino acid, for strychnine-sensitive glycine receptors in the rat spinal cord. Br.J.Pharmacol. 113 165. PMID:7812607. Schieden and Betz (1995) Pharmacology of the inhibitory glycine receptor: agonist and antagonist actions of amino acids and piperidine carboxylic acid compounds. Mol.Pharmacol. 48 919. PMID:7476923."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1053	SQ1533			Jan-1901
0206	_-Alanine	[107-95-9]	NCCC(O)=O	"Endogenous glycine agonist, more selective than taurine (Cat. No. 0209)"	"Non-specific endogenous agonist at the inhibitory glycine receptor. More selective than taurine (Cat. No. 0209). Also distinguishes between GABA transporters (IC50 values are 19, 58, 110, 1320 and 5690 _M for rGAT-2, hGAT-3, rGAT-3, hBGT-3 and hGAT-1 respectively)."	"Borden et al (1994) Tiagabine, SK&F 89976-A, CI 966, and NNC-711 are selective for the cloned GABA transporter GAT-1. Eur.J.Pharmacol. 269 219. PMID:7851497. Saitoh et al (1994) A novel antagonist, phenylbenzene _-phosphono-_-amino acid, for strychnine-sensitive glycine receptors in the rat spinal cord. Br.J.Pharmacol. 113 165. PMID:7812607. Schieden and Betz (1995) Pharmacology of the inhibitory glycine receptor: agonist and antagonist actions of amino acids and piperidine carboxylic acid compounds. Mol.Pharmacol. 48 919. PMID:7476923."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1054				Jan-1901
0208	Hypotaurine	[300-84-5]	NCCS(O)=O	Non-selective endogenous glycine receptor agonist	Endogenous inhibitory amino acid.	"Okamoto and Sakai (1981) Inhibitory actions of taurocyamine, hypotaurine, homotaurine, taurine and GABA on spike discharges of purkinje cells, and localization of sensitive sites in guinea pig cerebellar slices. Brain Res. 206 371. PMID:7214140."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1449				Jan-1901
0209	Taurine	[107-35-7]	NCCS(=O)(O)=O	"Non-selective, endogenous glycine receptor partial agonist"	One of the most abundant free amino acids in the brain. A partial agonist at the inhibitory glycine receptor.	Schmieden and Betz (1995) Pharmacology of the inhibitory glycine receptor: agonist and antagonist actions of amino acids and piperidine carboxylic acid compounds. Mol.Pharmacol. 48 919. PMID:7476923. Chung et al (1996) Saturable disposition of taurine in the rat cerebrospinal fluid. J.Pharmacol.Exp.Ther. 276 676. PMID:8632336. Palmi et al (1999) Potentiation of mitochondrial Ca2+ sequestration by taurine. Biochem.Pharmacol. 58 1123. PMID:10484070. Boldyrev et al (1999) Carnosine and taurine protect rat cerebellar granular cells from free radical damage. Neurosci.Lett. 263 169. PMID:10213162.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1898				Jan-1901
0213	D-Aspartic acid	[1783-96-6]	N[C@@]([H])([C@](O)=O)CC(O)=O	NMDA agonist	"Endogenous NMDA receptor agonist with similar activity to the L-isomer (L-aspartic acid, Cat. No. 0214). Also a non-metabolizable substrate for EAA uptake systems. Modulates melatonin synthesis in the pineal gland."	Olverman et al (1988) Structure/activity relations of NMDA receptor ligands as studied by their inhibition of 3H-D-AP5 binding in rat brain membranes. Neuroscience 26 17. PMID:2901691. Hashimoto et al (1997) Free D-aspartate and D-serine in the mammalian brain and periphery. Prog.Neurobiol. 53 325. PMID:9247969. Ishio et al (1998) D-Aspartate modulates melatonin synthesis in rat pinealocytes. Neurosci.Lett. 249 143. PMID:9682837.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1255				Sep-1994
0214	L-Aspartic acid	[56-84-8]	[H][C@@](CC(O)=O)(N)C(O)=O	NMDA agonist	Endogenous NMDA receptor agonist. D-Aspartic acid also available (Cat. No. 0213).	Olverman et al (1988) Structure/activity relations of N-methyl-D-aspartate receptor ligands as studied by their inhibition of [3H]D2-amino-5-phosphonopentanoic acid binding in rat brain membranes. Neuroscience 26 17. PMID:2901691.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1256				Jan-1901
0216	L-Cysteinesulfinic acid	[1115-65-7]	[H][C@](N)(CS(O)=O)C(O)=O	NMDA and mGlu agonist	Agonist at mGlu1a and mGlu5a subtypes expressed in clonal RGT cell lines. Also agonist at NMDA and PLD-coupled mGlu receptors.	Mewett et al (1983) Pharmacology of the excitatory actions of sulphonic and sulphinic amino acids. CNS Receptors: From Molecular Pharmacology to Beha 163-174. Gorman and Griffiths (1994) Sulphur-containing excitatory amino acid-stimulated inositol phosphate formation in primary cultures of cerebellar granule cells is mediated predominately by N-methyl-D-aspartate receptors. Neuroscience 59 299. PMID:8008194. Kingston et al (1998) Sulphur-containing amino acids are agonists for group 1 metabotropic receptors expressed in clonal RGT cell lines. Neuropharmacology 37 277. PMID:9681926.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1259				Jan-1901
0217	D-Glutamic acid	[6893-26-1]	N[C@@]([H])([C@](O)=O)CCC(O)=O	"Endogenous, non-selective agonist. Less active enantiomer"	"Excitatory amino acid acting at NMDA receptors; less active than the L-isomer, L-glutamic acid (Cat. No. 0218)."	Watkins (1986) Twenty five years of excitatory amino acid research. Excitatory Amino Acids. Eds. Roberts et al. Macmil p1-39. Olverman et al (1988) Structure/activity relations of N-methyl-D-aspartate receptor ligands as studied by their inhibition of [3H]-D-2-amino-5-phosphonopentanoic acid binding in rat brain membranes. Neuroscience 26 17. PMID:2901691.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1420				Jan-1901
0218	L-Glutamic acid	[56-86-0]	[H][C@@](CCC(O)=O)(N)C(O)=O	"Endogenous, non-selective agonist"	The predominant excitatory transmitter in the mammalian central nervous system. Acts at ionotropic and metabotropic glutamate receptors. MNI-caged-L-glutamate (Cat. No. 1490) and D-Glutamic acid (Cat. No. 0217) are also available.	"Watkins and Evans (1981) Excitatory amino acid transmitters. Annu.Rev.Pharmacol.Toxicol. 21 165. PMID:6112965. Monaghan et al (1989) The excitatory amino acid receptors: their classes, pharmacology and distinct properties in the function of the central nervous system. Annu.Rev.Pharmacol.Toxicol. 29 365. PMID:2543272."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1421				Jan-1901
0219	Glycine	[56-40-6]	NCC(O)=O	"Endogenous potentiator, co-transmitter"	"One of the major inhibitory neurotransmitters in the mammalian CNS, predominantly active in the spinal cord and brain stem. Also acts as a modulator of excitatory amino acid transmission mediated by NMDA receptors. Also available as part of the NMDA Receptor - Glycine Site Tocriset."	"Johnson and Ascher (1987) Glycine potentiates the NMDA response in cultured mouse brain neurons. Nature 325 529. Ascher and Johnson (1989) The NMDA receptor, its channel and its modulation by glycine. The NMDA Receptor (2nd edition). Eds. G.L.Collingr 109. Betz (1991) Glycine receptors: heterogeneous and widespread in the mammalian brain. Trends Neurosci. 14 458. PMID:1722365. Kuhse et al (1995) The inhibitory glycine receptor: architecture, synaptic localization and molecular pathology of a postsynaptic ion-channel complex. Curr.Opin.Neurobiol. 5 318. PMID:7850154."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1426	SQ1533			Jan-1901
0222	Kainic acid	[487-79-6]	C=[C@@](C)[C@@H]1[C@H](CC(O)=O)[C@@H]([C@](O)=O)NC1	Potent excitant and neurotoxin	Selective agonist at kainate receptors. Potent excitant and neurotoxin. Also available as part of the Kainate Receptor Tocriset.	Watkins (1978) Excitatory amino acids. Kainic acid as a Tool in Neurobiology. Edited by E 37. Watkins and Evans (1981) Excitatory amino acid transmitters. Annu.Rev.Pharmacol.Toxicol. 21 165. PMID:6112965.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1535	SQ1533			Jan-1901
0223	Kynurenic acid	[492-27-3]	OC(=O)C1=CC(O)=C2C=CC=CC2=N1	Broad spectrum EAA antagonist	Broad spectrum EAA antagonist. Putative GPR35 ligand. Kynurenic acid sodium salt also available (Cat. No. 3694).	"Perkins and Stone (1982) An iontophoretic investigation of the actions of convulsant kynurenines and their interaction with the endogenous excitant quinolinic acid. Brain Res. 247 184. PMID:6215086. Stone and Burton (1988) NMDA receptors and ligands in the vertebrate CNS. Prog.Neurobiol. 30 333. PMID:2830636. Pittaluga et al (1997) The 'kynurenate test,' a biochemical assay for putative cognition enhancers. J.Pharmacol.Exp.Ther. 283 82. PMID:9336311. Wang et al (2006) Kynurenic acid as a ligand for orphan G protein-coupled receptor GPR35. J.Biol.Chem. 281 22021. PMID:16754668."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1529				Jan-1901
0225	Quinolinic acid	[89-00-9]	OC(=O)C1=C(N=CC=C1)C(O)=O	Endogenous NMDA agonist and transmitter candidate	Endogenous NMDA agonist and transmitter candidate. May distinguish between NMDA receptor subtypes.	Stone and Perkins (1981) Quinolinic acid: a potent endogenous excitant at amino acid receptors in the rat CNS. Eur.J.Pharmacol. 72 411. PMID:6268428. Stone and Burton (1988) NMDA receptors and ligands in the vertebrate CNS. Prog.Neurobiol. 30 333. PMID:2830636. Monaghan and Beaton (1991) Quinolinate differentiates between forebrain and cerebellar NMDA receptors. Eur.J.Pharmacol. 194 123. PMID:1676371. Prada de Carvalho et al (1996) The endogenous agonist quinolinic acid and the non-endogenous homoquinolinic acid discriminate between NMDAR2 receptor subunits. Neurochem.Int. 28 445. PMID:8740453.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1824				Sep-1994
0226	D-Serine	[312-84-5]	N[C@@]([H])([C@](O)=O)CO	"Potentiator, acts glycine site"	Glycine agonist at the NMDA receptor. L-Serine (Cat. No. 0227) also available.	Lodge (1989) Non-competitive NMDA antagonists. The NMDA Receptor (2nd edition). Eds. G.L.Collingr 37. Schell et al (1997) D-Serine as a neuromodulator: regional and developmental localizations in rat brain glia resemble NMDA receptors. J. Neurosci. 17 1604. PMID:9030620. Mothet et al (2000) D-serine is an endogenous ligand for the glycine site of the N-methyl-D-aspartate receptor. Proc.Natl.Acad.Sci.USA 97 4926. PMID:10781100.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1854				Jan-1901
0227	L-Serine	[56-45-1]	OC[C@]([H])(N)C(O)=O	Weak endogenous glycine receptor agonist	Endogenous agonist at the inhibitory glycine receptor. D-Serine (Cat. No. 0226) also available.	"Saitoh et al (1994) A novel antagonist, phenylbenzene _-phosphono-_-amino acid, for strychnine-sensitive glycine receptors in the rat spinal cord. Br.J.Pharmacol. 113 165. PMID:7812607. Schmeiden and Betz (1995) Pharmacology of the inhibitory glycine receptor: agonist and antagonist actions of amino acids and piperidine carboxylic acid compounds. Mol.Pharmacol. 48 919. PMID:7476923."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1855				Jan-1901
0234	Guvacine hydrochloride	[6027-91-4]	Cl.O=C(C=1CNCCC1)O	Specific GABA uptake inhibitor	"Specific GABA uptake inhibitor. IC50 values are 14, 58, 119 and 1870 _M for hGAT-1, rGAT-2, hGAT-3 and hBGT-1 respectively."	"Krogsgaard-Larsen et al (1978) Structure-activity studies on the inhibition of GABA binding to rat brain membranes by muscimol and related compounds. J.Neurochem. 30 1377. PMID:670980. Borden et al (1994) Tiagabine, SK&F 89976-A, CI 966, and NNC-711 are selective for the cloned GABA transporter GAT-1. Eur.J.Pharmacol. 269 219. PMID:7851497."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1433	SQ1070			Jan-1901
0235	Isoguvacine hydrochloride	[68547-97-7]	Cl.OC(=O)C=1CCNCC1	Selective GABAA agonist	Specific GABAA receptor agonist. Suppresses low magnesium induced seizure like events in organotypic hippocampal brain slices.	"Krogsgaard-Larsen et al (1978) Structure-activity studies on the inhibition of GABA binding to rat brain membranes by muscimol and related compounds. J.Neurochem. 30 1377. PMID:670980. Krogsgaard-Larsen et al (1979) Dihydromuscimol, thiomuscimol and related heterocyclic compounds as GABA analogues. J.Neurochem. 32 1717. PMID:448364. Wahab et al (2009) Effects of gamma-aminobutyric acid (GABA) agonists and a GABA uptake inhibitor on pharmacoresistant seizure like events in organotypic hippocampal slice cultures. Epilepsy Res. 86 113. PMID:19535226."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1532	SQ1070			Jan-1901
0236	()-Nipecotic acid	[60252-41-7]	O=C(C1CNCCC1)O	GABA uptake inhibitor	"GABA uptake inhibitor. IC50 values are 8, 38, 106 and 2370 _M for hGAT-1, rGAT-2, hGAT-3 and hBGT-1 respectively."	"Schousboe et al (1979) Effects of GABA analogues of restricted conformation on GABA transport in astrocytes and brain cortex slices and on GABA binding. J.Neurochem. 33 181. PMID:458448. Krogsgaard-Larsen et al (1981) GABA agonists, antagonists and uptake inhibitors. Design and therapeutic aspects. J.Med.Chem. 24 1377. PMID:6118436. Borden et al (1994) Tiagabine, SK&F 89976-A, CI 966, and NNC-711 are selective for the cloned GABA transporter GAT-1. Eur.J.Pharmacol. 269 219. PMID:7851497."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1699				Jan-1901
0237	7-Chlorokynurenic acid	[18000-24-3]	OC(=O)C1=CC(O)=C2C=CC(Cl)=CC2=N1	Potent competitive inhibitor of L-glutamate uptake	NMDA receptor antagonist acting at the glycine site. Potent competitive inhibitor of L-glutamate transport into synaptic vesicles. Also available as part of the NMDA Receptor - Glycine Site Tocriset. 7-Chlorokynurenic acid sodium salt (Cat. No. 3697) also available.	"Kemp et al (1988) 7-Chlorokynurenic acid is a selective antagonist of the glycine modulatory site of the NMDA receptor complex. Proc.Natl.Acad.Sci.U.S.A. 85 6547. PMID:2842779. Donald et al (1988) Characterization of [3H]-glycine binding to a modulatory site within the NMDA receptor complex from rat brain. Br.J.Pharmacol. 95 892P. Kretschmer et al (1995) Behavioral and neurochemical actions of the strychnine-insensitive glycine receptor antagonist, 7-chlorokynurenate, in rats. Eur.J.Pharmacol. 280 37. PMID:7498252. Bartlett et al (1998) Substituted quinolines as inhibitors of L-glutamate transport into synaptic vesicles. Neuropharmacology 37 839. PMID:9776380."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=2157				Sep-1994
0238	O-Phospho-L-serine	[407-41-0]	[H][C@@](COP(O)(O)=O)(N)C(O)=O	Group III mGlu agonist	Group III metabotropic glutamate receptor agonist; analog of L-AP4 (Cat. No. 0103). Inhibits proliferation and enhances neuronal differentiation in progenitor cells.	"Eriksen and Thomsen (1995) [3H]-L-2-amino-4-phosphonobutyrate labels a metabotropic glutamate receptor, mGluR4a. Br.J.Pharmacol. 116 3279. PMID:8719808. Thoreson and Ulphani (1995) Pharmacology of selective and non-selective metabotropic glutamate receptor agonists at L-AP4 receptors in ON bipolar cells. Brain Res. 676 93. PMID:7796182. Bruno et al (1996) Activation of group III metabotropic glutamate receptors is neuroprotective in cortical cultures. Eur.J.Pharmacol. 310 61. PMID:8880068. Saxe et al (2007) A phenotypic small-molecule screen identifies an orphan ligand-receptor pair that regulates neural stem cell differentiation. Chem.Biol. 14 1019. PMID:17884634."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1773				Jan-1901
0245	2-Hydroxysaclofen	[117354-64-0]	NCC(O)(CS(O)(=O)=O)C1=CC=C(Cl)C=C1	"Selective GABAB antagonist, more potent than saclofen (Cat. No. 0246)"	Selective antagonist at GABAB receptors.	Curtis et al (1988) Baclofen antagonism by 2-hydroxysaclofen in the cat spinal cord. Neurosci.Lett. 92 97. PMID:2847093. Kerr et al (1988) 2-Hydroxysaclofen: an improved antagonist at central and peripheral GABAB receptors. Neurosci.Lett. 92 92. PMID:2847092.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1497				Jan-1901
0246	Saclofen	[125464-42-8]	NCC(CS(O)(=O)=O)C1=CC=C(Cl)C=C1	Selective GABAB antagonist	Selective antagonist at GABAB receptors.	Bowery (1989) GABAB receptors and their significance in mammalian pharmacology. TiPS 10 401. PMID:2559518. Jane et al (1990) Use of the neonatal rat spinal cord in studies of the GABAB receptor. GABAB receptors in Mammalian Function. 42b.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1848				Jan-1995
0247	(R)-CPP	[126453-07-4]	[H][C@@]1([C@](O)=O)NCCN(CCCP(O)(O)=O)C1	Potent NMDA antagonist; more active enantiomer of (RS)-CPP (Cat. No. 0173)	"Highly potent NMDA antagonist; more active isomer. Shows some selectivity for NR2A-containing receptors (Ki values are 0.041, 0.27, 0.63 and 1.99 _M for inhibition of NR2A-, NR2B-, NR2C- and NR2D-containing recombinant NMDA receptors respectively). (RS)-CPP (Cat. No. 0173) also available."	"Aebischer et al (1989) Synthesis and NMDA antagonistic properties of the enantiomers of 4-(3-phosphonopropyl)piperazine-2-carboxylic acid (CPP) and of the unsaturated analogue (E)-4-(3-phosphono-2-enyl)piperazine-2-carboxylic acid (CPP-ene). Helv.Chim.Acta 72 1043. Feng et al (2004) Structure-activity analysis of a novel NR2C/NR2D-preferring NMDA receptor antagonist: 1-(phenanthrene-2-carbonyl) piperazine-2,3-dicarboxylic acid. Br.J.Pharmacol. 141 508. PMID:14718249."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=2222				Jan-1901
0253	(R)-AMPA	[83654-13-1]	N[C@@]([H])([C@@](O)=O)CC1=C(C)ON=C1O	Inactive isomer of (RS)-AMPA (Cat. No. 0169)	Inactive enantiomer of AMPA. Active enantiomer (S)-AMPA (Cat. No 0254) and racemate (RS)-AMPA (Cat. No. 0169) also available.	"Hansen et al (1983) Enzymic resolution and binding to rat brain membranes of the glutamic acid agonist _-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid. J.Med.Chem. 26 901. PMID:6133955. Lauridsen et al (1985) Ibotenic acid analogues. Synthesis, molecular flexibility, and in vitro activity of agonists and antagonists at central glutamic acid receptors. J.Med.Chem. 28 668. PMID:2859375."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1168	SQ1070			Jan-1901
0254	(S)-AMPA	[83643-88-3]	[H][C@@](N)(C(O)=O)CC1=C(C)ON=C1O	Selective AMPA agonist. Active isomer of (RS)-AMPA (Cat. No. 0169)	"Active enantiomer of AMPA (EC50 = 3.5 _M). Also available as part of the AMPA Receptor Tocriset (Cat. No. 1822). NPEC-caged-(S)-AMPA (Cat. No. 3840), inactive enantiomer (R)-AMPA (Cat. No. 0253) and racemate (RS)-AMPA (Cat. No. 0169) are also available."	"Hansen et al (1983) Enzymic resolution and binding to rat brain membranes of the glutamic acid agonist _-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid. J.Med.Chem. 26 901. PMID:6133955. Lauridsen et al (1985) Ibotenic acid analogues. Synthesis, molecular flexibility, and in vitro activity of agonists and antagonists at central glutamic acid receptors. J.Med.Chem. 28 668. PMID:2859375. Falch et al (1998) Heteroaryl analogues of AMPA. 2. Synthesis, absolute stereochemistry, photochemistry, and structure-activity relationships. J.Med.Chem. 41 2513. PMID:9651156."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1169	SQ1070			Jan-1901
0258	ACBC	[22264-50-2]	NC1(CCC1)C(O)=O	"NMDA antagonist, acts at glycine site"	"NMDA receptor partial agonist, acting at the glycine site of NR1."	"Hood et al (1989) 1-Aminocyclobutane-1-carboxylic acid (ACBC): a specific antagonist of the NMDA receptor coupled glycine receptor. Eur.J.Pharmacol. 161 281. PMID:2542048. Rao et al (1990) Neuropharmacological characterization of 1-aminocyclopropane-1-carboxylate and 1-aminocyclobutane-1-carboxylate, ligands of the N-methyl-D-aspartate-associated glycine receptor. Neuropharmacology 29 305. PMID:2158004. Inanobe et al (2005) Mechanism of partial agonist action at the NR1 subunit of NMDA receptors. Neuron 47 71. PMID:15996549."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1075				Jan-1901
0262	"2,4-Dihydroxyphenylacetyl-L-asparagine"	[111872-98-1]	OC1=CC=C(CC(N[C@@]([H])(CC(N)=O)C(O)=O)=O)C(O)=C1	Component of Joro spider toxin	Constituent of various spider toxins. Reported to be specific blocker of glutamate receptors.	"Pan-Hou et al (1987) Inhibitory effect of 2,4-dihydroxyphenylacetylasparagine, a common moiety of spider toxin, on glutamate binding to rat brain synaptic membranes. Neurosci.Lett. 81 199. PMID:2827066. Pan-Hou et al (1989) A spider toxin (JSTX) inhibits L-glutamate uptake by rat brain synaptosomes. Brain Res. 476 354. PMID:2564797. Usherwood et al (1990) Mechanisms of neurotoxicity of low molecular weight spider toxins. Basic Science in Toxicology. Ed. G.N. Volans 569."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1305				Jan-1901
0271	cis-ACBD	[73550-55-7]	[H][C@@]1([C@@](O)=O)C[C@@](N)([C@](O)=O)C1	"Potent, selective L-glutamate uptake inhibitor"	"Potent, competitive and selective inhibitor of glutamate uptake. Certain confusion exists over the naming of this compound because of apparent contradictions in the literature. This is the isomer which has the carboxylic acid and the amino groups on the same side of the cyclobutyl ring."	"Allan et al (1990) Synthesis and activity of a potent NMDA agonist, trans-1-aminocyclobutane-1,3-dicarboxylic acid, and related phosphonic and carboxylic acids. J.Med.Chem. 33 2905. PMID:2145435. Fletcher et al (1991) Inhibition of L-glutamic acid uptake into rat cortical synaptosomes by the conformationally restricted analogue of glutamic acid, cis-1-aminocyclobutane-1,3-dicarboxylic acid. Neurosci.Lett. 121 133. PMID:1673544. Koch et al (1999) Differentiation of substrate and nonsubstrate inhibitors of the high-affinity, sodium-dependent glutamate transporters. Mol.Pharmacol. 56 1095. PMID:10570036."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1581				Jan-1901
0281	(R)-(+)-HA-966	[123931-04-4]	N[C@@H]1CCN(O)C1=O	NMDA partial agonist/antagonist; acts at glycine site	Antagonist/partial agonist at the glycine site of the NMDA receptor; able to cross the blood-brain barrier. Also available as part of the NMDA Receptor - Glycine Site Tocriset. S-enantiomer (Cat. No. 0282) available.	Pullan et al (1990) Stereoselectivity for the (R)-enantiomer of HA-966 (1-hydroxy-3-aminopyrrolidone-2) at the glycine site of the N-methyl-D-aspartate receptor complex. J.Neurochem. 55 1346. PMID:1975835. Pullan et al (1991) Agonist-like character of the (R) enantiomer of 1-hydroxy-3-amino-pyrrolid-2-one (HA-966). Eur.J.Pharmacol. 208 25. PMID:1834473. Kemp and Priestley (1991) Effects of (+)-HA-966 and 7-chlorokynurenic acid on the kinetics of N-methyl-D-aspartate receptor agonist responses in cat cultured cortical neurons. Mol.Pharmacol. 39 666. PMID:1674587.	Small Molecule	Sold with the permission of Merck Sharp and Dohme Ltd.	http://www.tocris.com/dispprod.php?ItemId=1437				Sep-1994
0282	(S)-(-)-HA-966	[111821-58-0]	N[C@H]1CCN(O)C1=O	NMDA antagonist/partial agonist	"Possesses potent sedative and ataxic action, probably through disruption of striatal dopaminergic mechanisms. R-enantiomer (Cat. No. 0281) also available."	"Singh et al (1990) Enantiomers of HA-966 (3-amino-1-hydroxypyrrolidin-2-one) exhibit distinct central nervous system effects: (+)-HA-966 is a selective glycine/N-methyl-D-aspartate receptor antagonist, but (-)-HA966 is a potent _-butyrolactone-like sedative. Proc.Natl.Acad.Sci.U.S.A. 87 347. PMID:2153294. Shepard and Lehmann (1992) ()-1-Hydroxy-3-aminopyrrolidone-2 (HA-966) inhibits the activity of substantia nigra dopamine neurons through a non-N-methyl-D-aspartate receptor mediated mechanism. J.Pharmacol.Exp.Ther. 261 387. PMID:1578355. Grobaski et al (1997) Responses of rat substantia nigra dopamine-containing neurones to (-)-HA-966 in vitro. Br.J.Pharmacol. 120 575. PMID:9051293."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1438				Jan-1901
0284	"(1S,3R)-ACPD"	[111900-32-4]	N[C@]1([C@@](O)=O)C[C@]([H])([C@](O)=O)CC1	Group I/group II mGlu agonist	"Active isomer of ()-trans-ACPD (Cat. No. 0187). Agonist at both group I and II mGlu receptors (EC50 values are 5, 15, 42 and 60 _M at mGluR2, mGluR5, mGluR1 and mGluR6 respectively). NPEC-caged-(1S,3R)-ACPD also available (Cat. No. 3331). ()-trans-ACPD (Cat. No. 0187) and cis-ACPD (Cat. No. 0186) also available."	Knopfel et al (1995) Metabotropic glutamate receptors: novel targets for drug development. J.Med.Chem. 38 1417. PMID:7738999. Mistry and Challis (1996) Differences in agonist and antagonist activities for two indicies of metabotropic glutamate receptor-stimulated phosphoinositide turnover. Br.J.Pharmacol. 117 1735. PMID:8732284. Conti et al (2002) Synthesis and pharmacology of 3-hydroxy-_2-isoxazoline-cyclopentance analogues of glutamic acid. Farmaco 57 889. PMID:12484537.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1042				Jul-1995
0285	Ibotenic acid	[2552-55-8]	NC(C(O)=O)C1=CC(O)=NO1	Non-selective NMDA agonist	NMDA and metabotropic glutamate receptor agonist.	Johnston et al (1968) Central actions of ibotenic acid and muscimol. Biochem.Pharmacol. 17 2488. PMID:5752907. Watkins and Evans (1981) Excitatory amino acid transmitters. Annu.Rev.Pharmacol.Toxicol. 21 165. PMID:6112965. Nakanishi (1992) Molecular diversity of glutamate receptors and implications for brain functions. Science 258 597. PMID:1329206. Pin and Duvoisin (1995) The metabotropic glutamate receptors: structure and functions. Neuropharmacology 34 1. PMID:7623957.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1498				Jan-1901
0286	"5,7-Dichlorokynurenic acid"	[131123-76-7]	OC(=O)C1=NC2=CC(Cl)=CC(Cl)=C2C(O)=C1	"Potent NMDA antagonist, acts glycine site"	Potent antagonist at the glycine site of the NMDA receptor (Ki = 79 nM vs. [3H]-glycine). Sodium salt (Cat. No. 3698) also available.	"Baron et al (1990) Activity of 5,7-dichlorokynurenic acid. A potent antagonist at the NMDA receptor-associated glycine binding site. Mol.Pharmacol. 38 554. PMID:2172769. Moore et al (1990) Substituted kynurenic acid derivatives. Potent and selective antagonists at the glycine site on the NMDA receptor. Eur.Fed.Med.Chem. (under auspices of IUPAC) XIth I 29."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1284				Jan-1901
0289	Muscimol	[2763-96-4]	NCC1=CC(O)=NO1	Potent GABAA agonist	Potent GABAA receptor agonist and partial GABAC receptor agonist. Inhibits memory retention and attenuates airway constriction in vivo.	Johnston et al (1968) Central actions of ibotenic acid and muscimol. Biochem.Pharmacol. 17 2488. PMID:5752907. Akhondzadeh and Stone (1995) Induction of a novel form of hippocampal long-term depression by muscimol: involvement of GABAA but not glutamate receptors. Br.J.Pharmacol. 115 527. PMID:7582468. Johnstone (1996) GABAC receptors: relatively simple transmitter-gated ion channels? TiPS 17 319. PMID:8885697. Gleason et al (2009) The GABAA agonist muscimol attenuates induced airway constriction in guinea pigs in vivo. J.Appl.Physiol. 106 1257. PMID:19213928. Jafari-Sabet and Jannat-Dastjerdi (2009) Muscimol state-dependent memory: involvement of dorsal hippocampal _-opioid receptors. Behav.Brain Res. 202 5. PMID:19447274.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1670				Jan-1901
0298	"L-trans-2,4-PDC"	[64769-66-0]	O=[C@]([C@H]1NC[C@H]([C@@](O)=O)C1)O	Transportable EAAT1-4 inhibitor/non-transportable EAAT5 inhibitor	"Potent, competitive, transportable EAAT1-4 inhibitor/non-transportable EAAT5 inhibitor. Also available as part of the Excitatory Amino Acid Transporter Inhibitor Tocriset."	"Bridges et al (1991) Conformationally defined neurotransmitter analogues. Selective inhibition of glutamate uptake by one pyrrolidine-2,4-dicarboxylate diastereomer. J.Med.Chem. 34 717. PMID:1671706. Mitrovic and Johnston (1994) Regional differences in the inhibition of L-glutamate amd L-aspartate sodium-dependent high affinity uptake systems in rat CNS synaptosomes by L-trans-pyrrolidine-2,4-dicarboxylic threo-3-hydroxy-D-aspartate and D-aspartate. Neurochem.Int. 24 583. PMID:7981641. Zuiderwijk et al (1996) Effects of uptake carrier blockers SK & F 89976-A and L-trans-PDC on in vivo release of amino acids in rat hippocampus. Eur.J.Pharmacol. 307 275. PMID:8836615."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1740				Oct-1995
0306	(S)-(-)-5-Fluorowillardiine	[140187-23-1]	O=C(C(F)=CN1C[C@@](N)([H])C(O)=O)NC1=O	Very potent AMPA agonist	"A more potent and selective AMPA receptor agonist (at hGluR1 and hGluR2) than AMPA itself (Ki = 14.7, 25.1, and 1820 nM for hGluR1, hGluR2 and hGluR5 respectively). Also available as part of the AMPA Receptor Tocriset."	Patneau et al (1992) Activation and desensitization of AMPA/kainate receptors by novel derivatives of willardiine. J.Neurosci. 12 595. PMID:1371315. Wong et al (1994) Willardiines differentiate agonist binding sites for kainate-versus AMPA-preferring glutamate receptors in DRG and hippocampal neurones. J.Neurosci. 14 3881. PMID:7515954. Hawkins et al (1995) Binding of the new radioligand (S)-[3H]-AMPA to rat brain synaptic membranes: effects of a series of structural analogues of the non-NMDA receptor agonist willardine. Neuropharmacology 34 405. PMID:7566471. Jane et al (1997) Synthesis of willardiine and 6-azawillardiine analogs: pharmacological characterization on cloned homomeric human AMPA and kainate receptor subtypes. J.Med.Chem. 40 3645. PMID:9357531.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1401				Jan-1901
0307	(S)-(-)-5-Iodowillardiine	[140187-25-3]	O=C(N1)N(C[C@]([H])(N)C(O)=O)C=C(I)C1=O	"Highly potent, subtype-selective kainate agonist"	Demonstrates high affinity for the kainate receptor subtype hGluR5 (Ki = 0.24 nM) and 600-4000-fold selectivity over both the AMPA receptor subtypes and the homomeric kainate receptor hGluR6.	Patneau et al (1992) Activation and desensitization of AMPA/kainate receptors by novel derivatives of willardiine. J.Neurosci. 12 595. PMID:1371315. Wong et al (1994) Willardiines differentiate agonist binding sites for kainate-versus AMPA-preferring glutamate receptors in DRG and hippocampal neurones. J.Neurosci. 14 3881. PMID:7515954. Thompson et al (1996) Depolarising effects of certain derivatives of (S) willardiine upon in vitro neonatal rat dorsal roots. Br.J.Pharmacol. 117 331P. Jane et al (1997) Synthesis of willardiine and 6-azawillardiine analogs: pharmacological characterization on cloned homomeric human AMPA and kainate receptor subtypes. J.Med.Chem. 40 3645. PMID:9357531. Swanson et al (1998) Kainate receptors exhibit differential sensitivities to (S)-5-iodowillardiine. Mol.Pharmacol. 53 942. PMID:9584222.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1530				Jan-1901
0310	(RS)-4-Carboxy-3-hydroxyphenylglycine	[134052-66-7]	NC(C(O)=O)C1=CC(O)=C(C=C1)C(O)=O	Broad spectrum EAA ligand	Broad spectrum EAA agonist/antagonist. Separate isomer (S)-4-Carboxy-3-hydroxyphenylglycine also available (Cat. No. 0320).	"Watkins et al (1987) Recent advances in the pharmacology of excitatory amino acids. Excitatory Amino Acid Transmission. Eds. Hicks, Lo 19-26."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=2116				Sep-1994
0312	(RS)-(Tetrazol-5-yl)glycine	[138199-51-6]	NC(C(O)=O)C1=NN=NN1	Highly potent NMDA receptor agonist	"Potent NMDA receptor agonist, approximately 20 times more active than NMDA. Also available as part of the Mixed NMDA Receptor Tocriset."	"Schoepp et al (1991) D,L-(Tetrazol-5-yl)glycine a novel and highly potent NMDA receptor agonist. Eur.J.Pharmacol. 203 237. PMID:1686860. Arnt et al (1995) Diffentiation of in vivo effects of AMPA and NMDA receptor ligands using drug discrimination methods and convulsant/anticonvulsant activity. Eur.J.Pharmacol. 285 289. PMID:8575516. Moroni et al (1995) NMDA receptor heterogeneity in mammalian tissues: focus on two agonists, (2S,3R,4S)cyclopropylglutamate and the sulfate ester of 4-hydroxy-(S)-pipecolic acid. Naunyn Schmiedebergs Arch.Pharmacol. 351 371. PMID:7543185."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1899				Jan-1901
0320	(S)-4-Carboxy-3-hydroxyphenylglycine	[85148-82-9]	OC1=C(C(O)=O)C=CC([C@]([H])(N)C(O)=O)=C1	Group I antagonist/group II agonist	"Competitive antagonist at group I mGlu1a/1a receptors, mixed effect at mGlu5a/5b receptors; agonist at group II metabotropic glutamate receptors. (RS)-4-Carboxy-3-hydroxyphenylglycine (Cat. No. 0310) also available."	Birse et al (1993) Phenylglycine derivatives as new pharmacological tools for investigating the role of metabotropic glutamate receptors in the central nervous system Neuroscience 52 481. PMID:7680790. Hayashi et al (1994) Analysis of agonist and antagonist activities of phenylglycine derivatives for different cloned metabotropic glutamate receptor sub-types. J.Neurosci. 14 3370. PMID:8182479. Kingston et al (1995) Pharmacological analysis of 4-carboxyphenylglycine derivatives: comparison of effects mGluR1_ and mGluR5a subtypes. Neuropharmacology 34 887. PMID:8532170. Sekiyama et al (1996) Structure-activity relationships of new agonists and antagonists of different metabotropic glutamate receptor subtypes. Br.J.Pharmacol. 117 1493. PMID:8730745.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=2118				Jan-1901
0321	(RS)-4-Carboxyphenylglycine	[7292-81-1]	NC(C(O)=O)C1=CC=C(C(O)=O)C=C1	Broad spectrum EAA ligand	Broad spectrum EAA ligand. Separate isomers (R)-4-Carboxyphenylglycine and (S)-4-Carboxyphenylglycine also available (Cat. Nos. 0322 and 0323 respectively).		Small Molecule		http://www.tocris.com/dispprod.php?ItemId=2125				Sep-1994
0322	(R)-4-Carboxyphenylglycine	[134052-68-9]	N[C@@]([H])([C@@](O)=O)C1=CC=C(C(O)=O)C=C1	Moderately potent NMDA antagonist	Moderately potent NMDA receptor antagonist. (RS)-4-Carboxyphenylglycine (Cat. No. 0321) and (S)-4-Carboxyphenylglycine (Cat. No. 0323) also available.	"Jones et al (1993) Agonist and antagonist actions of phenylglycine derivatives at depolarization-mediating (1S,3R)-ACPD receptors in neonatal rat motoneurones. Br.J.Pharmacol. 108 86P."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=2126				Sep-1994
0323	(S)-4-Carboxyphenylglycine	[134052-73-6]	[H][C@@](N)(C(O)=O)C1=CC=C(C(O)=O)C=C1	Competitive group I mGlu antagonist/weak group II agonist	"Competitive group I metabotropic glutamate receptor antagonist, with selectivity for mGlu1a/1a over mGlu5a/5b. (RS)-4-Carboxyphenylglycine (Cat. No. 0321) and (R)-4-Carboxyphenylglycine (Cat. No. 0322) also available."	Birse et al (1993) Phenylglycine derivatives as new pharmacological tools for investigating the role of metabotropic glutamate receptors in the central nervous system. Neuroscience 52 481. PMID:7680790. Eaton et al (1993) Competitive antagonism at metabotropic glutamate receptors by (S)-4-carboxyphenylglycine (CPG) and (RS)-_-methyl-4-carboxyphenylglycine (MCPG). Eur.J.Pharmacol. 244 195. PMID:8381746. Brabet et al (1995) Phenylglycine derivatives discriminate between mGluR1-and mGluR5-mediated responses. Neuropharmacology 34 895. PMID:8532171. Doherty et al (1999) Antagonist activity of _-substituted 4-carboxyphenylglycine analogues at group I metabotropic glutamate receptors expressed in CHO cells. Br.J.Pharmacol. 126 205. PMID:10051137.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=2127				Jan-1995
0324	(RS)-3-Hydroxyphenylglycine	[31932-87-3]	OC1=CC=CC(C(C(O)=O)N)=C1	Group I mGlu agonist	Agonist at PI-linked metabotropic glutamate receptors. Separate isomer (S)-3-Hydroxyphenylglycine (Cat. No. 0326) also available.	Birse et al (1993) Phenylglycine derivatives as new pharmacological tools for investigating the role of metabotropic glutamate receptors in the central nervous system. Neuroscience 52 481. PMID:7680790.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1478				Jan-1901
0326	(S)-3-Hydroxyphenylglycine	[71301-82-1]	OC1=CC=CC([C@@](N)([H])C(O)=O)=C1	"Group I mGlu agonist, active isomer"	Agonist at group I metabotropic glutamate receptors (mGlu1) having no effect at mGlu2 or mGlu4. (RS)-3-Hydroxyphenylglycine (Cat. No. 0324) also available.	Birse et al (1993) Phenylglycine derivatives as new pharmacological tools for investigating the role of metabotropic glutamate receptors in the central nervous system. Neuroscience 52 481. PMID:7680790. Hayashi et al (1994) Analysis of agonist and antagonist activities of phenylglycine derivatives for different cloned metabotropic glutamate receptor subtypes. J.Neurosci. 14 3370. PMID:8182479.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1480				Jan-1901
0328	(R)-3-Carboxy-4-hydroxyphenylglycine	[13861-03-5]	OC1=C(C(O)=O)C=C([C@]([H])([C@](O)=O)N)C=C1	Ionotropic glutamate receptor antagonist	Moderately potent NMDA and AMPA/kainate receptor antagonist. (S)-3-Carboxy-4-hydroxyphenylglycine (Cat. No. 0329) also available.	"Watkins et al (1987) Recent advances in the pharmacology of excitatory amino acids. Excitatory Amino Acid Transmission. Eds. Hicks, Lo 19-26."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=2114				Jan-1901
0329	(S)-3-Carboxy-4-hydroxyphenylglycine	[55136-48-6]	OC1=C(C(O)=O)C=C([C@]([H])(N)C(O)=O)C=C1	Group I antagonist/group II agonist	Mixed group I metabotropic glutamate receptor antagonist and group II mGlu agonist. (R)-3-Carboxy-4-hydroxyphenylglycine (Cat. No. 0328) also available.	"Watkins et al (1987) Recent advances in the pharmacology of excitatory amino acids. Excitatory Amino Acid Transmission. Eds. Hicks, Lo 19-26. Watkins and Collingridge (1994) Phenylglycine derivatives as antagonists of metabotropic glutamate receptors. TiPS 15 333. PMID:7992387. Hayashi et al (1994) Analysis of agonist and antagonist activities of phenylglycine derivatives for different cloned metabotropic glutamate receptor sub-types. J.Neurosci. 14 3370. PMID:8182479. Sekiyama et al (1996) Structure-activity relationships of new agonists and antagonists of different metabotropic glutamate receptor subtypes. Br.J.Pharmacol. 117 1493. PMID:8730745."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=2115				Jan-1901
0332	L-CCG-lll	[117857-95-1]	N[C@]([H])(C(O)=O)[C@@]([H])(C1)[C@@]([H])1C(O)=O	"Potent, competitive glutamate uptake inhibitor"	"Potent and competitive inhibitor of both glial and neuronal uptake of glutamate, aspartate and cysteate."	"Shinozaki et al (1989) Potent NMDA-like actions and potentiation of glutamate responses by conformational variants of a glutamate analogue in the rat spinal cord. Br.J.Pharmacol. 98 1213. PMID:2692753. Kawai et al (1992) 2-Carboxycyclopropyl)glycine: binding, neurotoxicity and induction of intracellular free Ca2+ increase. Eur.J.Pharmacol. 211 195. PMID:1319341. Nakamura et al (1993) (2S,3S,4R)-2-(Carboxycyclopropyl)glycine, a potent and competitive inhibitor of both glial and neuronal uptake of glutamate. Neuropharmacology 32 833. PMID:7901789. Yamashita et al (1995) Inhibition by folded isomers of L-2-(carboxycyclopropyl)glycine of glutamate uptake via the human glutamate transporter hGluT-I. Eur.J.Pharmacol. 289 387. PMID:7621914."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=2134				Sep-1994
0333	L-CCG-l	[117857-93-9]	N[C@]([H])(C(O)=O)[C@@]([H])(C1)[C@]1([C@@](O)=O)[H]	Potent group II mGlu agonist	Potent group II metabotropic glutamate receptor agonist. More active than glutamate or ()-trans-ACPD (Cat. No. 0187).	"Shinozaki et al (1989) Potent NMDA-like actions and potentiation of glutamate responses by conformational variants of a glutamate analogue in the rat spinal cord. Br.J.Pharmacol. 98 1213. PMID:2692753. Hayashi et al (1992) Agonist analysis of 2-(carboxycyclopropyl)glycine isomers for cloned metabotropic glutamate receptor subtypes expressed in Chinese hamster ovary cells. Br.J.Pharmacol. 107 539. PMID:1330184. Wright and Schoepp (1996) Differentiation of group 2 and group 3 metabotropic glutamate receptor cAMP responses in the rat hippocampus. Eur.J.Pharmacol. 297 275. PMID:8666060. Brabet et al (1998) Comparative effect of L-CCG-I, DCG-IV and _-carboxy-L-glutamate on all cloned metabotropic glutamate receptor subtypes. Neuropharmacology 37 1043. PMID:9833633."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=2132				Jan-1901
0336	(RS)-MCPG	[146669-29-6]	NC(C(O)=O)(C)C1=CC=C(C(O)=O)C=C1	Non-selective mGlu antagonist	Non-selective group I/group II metabotropic glutamate receptor antagonist. (S)-isomer and sodium salt also available (Cat. No's. 0337 and 3696 respectively).	"Eaton et al (1993) Competitive antagonism at metabotropic glutamate receptors by (S)-4-carboxyphenylglycine (CPG) and (RS)-_-methyl-4-carboxyphenylglycine (MCPG). Eur.J.Pharmacol. 244 195. PMID:8381746. Collingridge and Watkins (1994) Phenylglycine derivatives as metabotropic glutamate receptor antagonists. TiPS 15 333. PMID:7992387. Joly et al (1995) Molecular, functional and pharmacological characterization of the metabotropic glutamate receptor Type 5 splice variants: comparison with mGluR1. J.Neurosci. 15 3970. PMID:7751958."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1609				Sep-1994
0337	(S)-MCPG	[150145-89-4]	N[C@](C)(C(O)=O)C1=CC=C(C(O)=O)C=C1	Non-selective mGlu antagonist. Active isomer of Cat. No. 0336	"Active isomer of (RS)-MCPG (Cat. No. 0336). Non-selective group I/group II metabotropic glutamate receptor antagonist. Also available as part of the Group I mGlu Receptor Tocriset, Group II mGlu Receptor Tocriset and Mixed mGlu Receptor Tocriset."	"Jane et al (1993) Stereospecific antagonism by (+)-_-methyl-4-carboxyphenylglycine (MCPG) of 1S,3R-ACPD induced effects in neonatal rat motoneurones and rat thalamic neurones. Neuropharmacology 32 725. PMID:7689710. Collingridge and Watkins (1994) Phenylglycine derivatives as metabotropic glutamate receptor antagonists. TiPS 15 333. PMID:7992387. Bordi et al (1996) Effects of the metabotropic glutamate receptor antagonist MCPG on spatial and context-specific learning. Neuropharmacology 35 1557. PMID:9025103. Sekiyama et al (1996) Structure-activity relationships of new agonists and antagonists of different metabotropic glutamate receptor subtypes. Br. J. Pharmacol. 117 1493. PMID:8730745."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1610				Sep-1994
0341	L-AP6	[78944-89-5]	[H][C@@](CCCCP(O)(O)=O)(N)C(O)=O	Selective agonist of the 'quis' effect	Selective agonist for 'quis'-sensitized site.	Schulte et al (1994) Utilization of the resolved L-isomer of 2-amino-6-phosphonohexanoic acid (L-AP6) as a selective agonist for a quisqualate-sensitized site in hippocampal CA1 pyramidal neurons. Brain Res. 649 203. PMID:7953634. Venkatraman et al (1994) Synthesis of oxadiazolidinedione derivatives as quisqualic acid analogues and their evaluation at a quisqualate-sensitized site in the rat hippocampus. J.Med.Chem. 37 3939. PMID:7966155. Johansen et al (1995) Type 4a metabotropic glutamate receptor: identification of new potent agonists and differentiation from the L-(+)-2-amino-4-phosphonobutanoic acid-sensitive receptor in the lateral perforant pathway in rats. Mol.Pharmacol. 48 140. PMID:7623768.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1196				Aug-1998
0342	"(RS)-3,5-DHPG"	[19641-83-9]	NC(C(O)=O)C1=CC(O)=CC(O)=C1	Selective group I mGlu agonist	"Selective group I metabotropic glutamate receptor agonist which activates both mGlu1 and mGlu5. Also reported to be an antagonist at metabotropic glutamate receptors linked to phospholipase D. (S)-3,5-DHPG (Cat. No. 0805) also available."	"Ito et al (1992) 3,5-Dihydroxyphenylglycine: a potent agonist of metabotropic glutamate receptors. NeuroReport 3 1013. PMID:1362358. Pellegrini-Giampietro et al (1996) Pharmacological characterization of metabotropic glutamate recpetors coupled to phopholipase D in the rat hippocampus. Br.J.Pharmacol. 118 1035. PMID:8799579. Palmer et al (1997) The group I mGlu receptor agonist DHPG induces a novel form of LTD in the CA1 region of the hippocampus. Neuropharmacology 36 1517. PMID:9517422. Mistry et al (1998) Regulation of phosphoinositide turnover in neonatal rat cerebral cortex by group I- and II-selective metabotropic glutamate receptor agonists. Br.J.Pharmacol. 123 581. PMID:9504400."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1306				Jan-1901
0344	GABA	[56-12-2]	NCCCC(O)=O	Endogenous agonist	Endogenous inhibitory neurotransmitter. Caged RuBi GABA is also available (Cat. No. 3400).	"Curtis et al (1970) GABA, bicuculline and central inhibition. Nature 226 1222. PMID:4393081. Decavel and van den Pol (1990) GABA: a dominant transmitter in the hypothalamus. J.Comp.Neurol. 302 1019. PMID:2081813. Johnston (1996) GABAC receptors: relatively simple transmitter-gated ion channels? TiPS 17 319. PMID:8885697. Malcangio and Bowery (1996) GABA and its receptors in the spinal cord. TiPS 17 457. PMID:9014500."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1339				Jan-1901
0347	nor-Binaltorphimine dihydrochloride	[113158-34-2]	OC1=CC=C2C([C@]34CCN5CC6CC6)=C1O[C@H]4C%11=C(C7=C(N%11)[C@H]%10[C@@]8(CC%13)[C@@]([C@H](N%13CC%12CC%12)CC9=C8C(O%10)=C(O)C=C9)(O)C7)C[C@@]3(O)[C@H]5C2.Cl.Cl	Standard _ selective antagonist	A selective _-opioid receptor antagonist.	Portoghese et al (1994) Structure-activity relationship of N17'-substituted norbinaltorphimine congeners. Role of the N17'-basic group in the interaction with a putative address subsite on the _ opioid receptor. J.Med.Chem. 37 1495. PMID:8182708. Blake et al (1997) Differential agonist regulation of the human _-opioid receptor. J.Neurochem. 68 1846. PMID:9109509. Feng et al (1997) Nor-binaltorphimine precipitates withdrawal and excitatory amino acid release in the locus ceruleus of butorphanol- but not morphine-dependent rats. J.Pharmacol.Exp.Ther. 283 932. PMID:9353416.	Small Molecule	Sold with the permission of the University of Minnesota	http://www.tocris.com/dispprod.php?ItemId=2033	SQ1533			Apr-1999
0348	2-BFI hydrochloride	[89196-95-2]	Cl.C1CN=C(N1)C1=CC2=CC=CC=C2O1	"Potent, selective I2 ligand. Putative agonist"	High affinity I2 ligand (Ki = 9.8 nM). Putative I2 agonist; potentiates morphine antinociception. Produces ipsiversive rotational behavior in rats with a full 6-OHDA lesion of the nigrostriatal tract.	"Alemany et al (1997) Labelling of I2B-imidazoline receptors by [3H]2-(2-benzofuranyl)-2-imidazoline (2-BFI) in rat brain and liver: characterization, regulation and relation to monoamine oxidase enzymes. Naunyn Schmiedebergs Arch.Pharmacol. 356 39. PMID:9228188. Sanchez-Blasquez et al (2000) Activation of I2-imidazoline receptors enhances supraspinal morphine analgesia in mice: a model to detect agonist and antagonist activities at these receptors. Br.J.Pharmacol. 130 146. PMID:10781010. MacInnes and Duty (2004) Locomotor effects of imidazoline I2-site-specific ligands and monoamine oxidase inhibitors in rats with a unilateral 6-hydroxydopamine lesion of the nigrostriatal pathway. Br.J.Pharmacol. 143 952. PMID:15545290."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=2027				Nov-1995
0351	1-Acetyl-4-methylpiperazine hydrochloride	[144205-68-5]	CC(N1CCN(C)CC1)=O.Cl	Nicotinic agonist	Structural analog of acetylcholine that acts as a nAChR agonist.	Garcha et al (1993) Behavioural and ligand binding studies in rats with 1-acetyl-4-methylpiperazine a novel nicotinic agonist. Psychopharmacology 110 347. PMID:7831430. Warpman et al (1998) Regulation of nicotinic receptor subtypes following chronic nicotinic agonist exposure in M10 and SH-SY5Y neuroblastoma cells. J.Neurochem. 70 2028. PMID:9572289.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1026				Oct-1994
0352	"4-Acetyl-1,1-dimethylpiperazinium iodide"	[75667-84-4]	C[N+]1(C)CCN(CC1)C(=O)C.[I-]	Nicotinic agonist	Structural analog of acetylcholine that acts as a nicotinic agonist (Ki = 29.9 nM at _4_2). Upregulates the number of _4_2 binding sites in M10 cells in vitro by 440%.	Spivak et al (1986) Structural and electronic requirements for potent agonists at a nicotinic receptor. Eur.J.Pharmacol. 120 127. PMID:3485051. Spivak et al (1988) Binding of semirigid nicotinic agonists to nicotinic and muscarinic receptors. Mol.Pharmacol. 36 177. PMID:2747625. Warpman et al (1998) Regulation of nicotinic receptor subtypes following chronic nicotinic agonist exposure in M10 and SH-SY5Y neuroblastoma cells. J.Neurochem. 70 2028. PMID:9572289.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1023				Oct-1994
0355	()-Acetylcarnitine chloride	[2504-11-2]	C[N+](CC(OC(C)=O)CC(O)=O)(C)C.[Cl-]	Intermediate in lipid metabolism	Weak cholinergic agonist. Acylcarnitines are important intermediates in lipid metabolism.	Chalmers et al (1984) Urinary excretion of l-carnitine and acylcarnitines by patients with disorders of organic acid metabolism: evidence for secondary insufficiency of l-carnitine. Pediatr.Res. 18 1325. PMID:6441143. Coates and Tanaka (1992) Molecular basis of mitochondrial fatty acid oxidation defects. J.Lipid.Res. 33 1099. PMID:1431593. Poorthuis et al (1993) Determination of acylcarnitines in urine of patients with inborn errors of metabolism using HPLC after derivatization with 4'-bromophenacyl bromide. Clin.Chim.Acta. 216 53. PMID:8222273.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1022				Oct-1994
0357	N-Acetyltryptamine	[1016-47-3]	CC(=O)NCCC1=CNC2=CC=CC=C12	Melatonin partial agonist (MT1/MT2). Also MT3 antagonist	A partial agonist for melatonin receptors in the retina. Also used for determination of serotonin N-acetyl transferase.	Dubocovich (1985) Characterization of a retinal melatonin receptor. J.Pharmacol.Exp.Ther. 234 395. PMID:2991499. Dubocovich (1988) Luzindole (NO 774): a novel melatonin receptor antagonist. J.Pharmacol.Exp.Ther. 246 902. PMID:2843633. Thomas et al (1990) Arylalkylamine (serotonin) N-acetyl transferase assay using high-performance liquid-chromatography with fluorescence or electrochemical detection of N-acetyltryptamine. Anal.Biochem. 184 228. PMID:2327568. Dubocovich (1995) Melatonin receptors: are there multiple subtypes? TiPS 16 50. PMID:7762083.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1027				Oct-1994
0360	"()-1-(1,2-Diphenylethyl)piperidine maleate"	[207461-99-2]	OC(=O)\C=C/C(O)=O.C(C(N1CCCCC1)C1=CC=CC=C1)C1=CC=CC=C1	"NMDA antagonist, acts ion channel site"	High affinity antagonist at the ion channel on the NMDA receptor.	"Ragawski (1993) Therapeutic potential of excitatory amino acid antagonists: channel blockers and 2,3-benzodiazepines. TiPS 14 325. PMID:7504360."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1332				Sep-1994
0361	W-13 hydrochloride	[88519-57-7]	Cl.NCCCCNS(=O)(=O)C1=CC=C2C(Cl)=CC=CC2=C1	Calmodulin antagonist	Calmodulin antagonist (inhibits calmodulin activated PDE activity with an IC50 of 68 _M). Inhibits growth of tamoxifen-resistant breast cancer cells.	"Hidaka and Tanaka (1983) Naphthalenesulfonamides as calmodulin antagonists. Methods Enzymol. 102 185. PMID:6139736. Stroble and Peterson (1992) Tamoxifen-resistant human breast cancer cell growth: inhibition by thionidazine, pimozide and the calmodulin antagonist, W-13. J.Pharmacol.Exp.Ther. 263 186. PMID:1403784. Bosch et al (1998) Calmodulin inhibitor W13 induces sustained activation of ERK2 and expression of p21cip1. J.Biol.Chem. 273 22145. PMID:9705360."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1966				Oct-1994
0368	W-5 hydrochloride	[61714-25-8]	Cl.NCCCCCCNS(=O)(=O)C1=C2C=CC=CC2=CC=C1	Calmodulin antagonist	Calmodulin antagonist (inhibits Ca2+-calmodulin dependent PDE with an IC50 of 240 _M).	"Hidaka et al (1981) Activity-structure relationship of calmodulin antagonists. Naphthalenesulfonamide derivatives. Mol.Pharmacol. 20 571. PMID:7329399. Hidaka et al (1981) N-(6-aminohexyl)-5-chloro-1-naphthalenesulfonamide, a calmodulin antagonist, inhibits cell proliferation. Proc.Natl.Acad.Sci.U.S.A. 78 4354. PMID:6945588. Hidaka and Tanaka (1983) Naphthalenesulfonamides as calmodulin antagonists. Methods Enzymol. 102 185. PMID:6139736."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1963	SQ1070			Oct-1994
0369	W-7 hydrochloride	[61714-27-0]	Cl.NCCCCCCNS(=O)(=O)C1=CC=CC2=C(Cl)C=CC=C12	Calmodulin antagonist. Inhibits myosin light chain kinase	Calmodulin antagonist. Inhibits Ca2+-calmodulin-dependent phosphodiesterase (IC50 = 28 _M) and myosin light chain kinase (IC50 = 51 _M).	"Tanaka and Hidaka (1980) Hydrophobic regions function in calmodulin-enzyme(s) interactions. J.Biol.Chem. 255 11078. PMID:6254958. Hidaka et al (1981) N-(6-aminohexyl)-5-chloro-1-naphthalenesulfonamide, a calmodulin antagonist, inhibits cell proliferation. Proc.Natl.Acad.Sci.U.S.A. 78 4354. PMID:6945588. Itoh and Hidaka (1984) Direct interaction of calmodulin antagonists with Ca2+/calmodulin-dependent cyclic nucleotide phosphodiesterase. J.Biochem. 96 1721. PMID:6099352. Asano et al (1989) Divergent pharmacological effects of three calmodulin antagonists, N-(6-aminohexyl)-5-chloro-1-naphthalenesulfonamide (W 7), chlorpromazine and calmidazolium, on isometric tension development and myosin light chain phosphorylation in intact bovine tracheal smooth muscle. J.Pharmacol.Exp.Ther. 251 764. PMID:2810127."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1964				Oct-1994
0370	W-9 hydrochloride	[69762-85-2]	Cl.NCCCCCCNS(=O)(=O)C1=CC=C2C(Cl)=CC=CC2=C1	Calmodulin antagonist	Calmodulin antagonist (inhibits calmodulin-activated PDE activity with an IC50 of 72 _M).	"Hidaka et al (1979) Selective inhibitors of Ca2+-binding modulator of phosphodiesterase produce vascular relaxation and inhibit actin-myosin interaction. Mol.Pharmacol. 15 49. PMID:218093. Hidaka et al (1981) N-(6-aminohexyl)-5-chloro-1-naphthalenesulfonamide, a calmodulin antagonist, inhibits cell proliferation. Proc.Natl.Acad.Sci.U.S.A. 78 4354. PMID:6945588."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1108				Oct-1994
0373	NBQX	[118876-58-7]	NS(=O)(=O)C1=CC=CC2=C3NC(=O)C(=O)NC3=CC(=C12)[N+]([O-])=O	Potent AMPA antagonist. More selective than CNQX (Cat. No. 0190)	"Potent, selective and competitive AMPA receptor antagonist. Neuroprotective and anticonvulsant; active in vivo. NBQX disodium salt (Cat. No. 1044) also available."	"Gill et al (1992) The neuroprotective actions of 2,3-dihydroxy-6-nitro-7-sulfamoylbenzo(f)quinoxaline (NBQX) in a rat focal ischaemia model. Brain Res. 580 35. PMID:1504814. Zeman and Lodge (1992) Pharmacological characterization of non-NMDA subtypes of glutamate receptors in the neonatal rat hemisected spinal cord in vitro. Br.J.Pharmacol. 106 367. PMID:1382781. Sheardown et al (1993) The pharmacology of AMPA receptors and their antagonists. Stroke 24 146. PMID:7504337. Namba et al (1994) Antiepileptogenic and anticonvulsant effects of NBQX, a selective AMPA receptor antagonist, in the rat kindling model of epilepsy. Brain Res. 638 36. PMID:8199874."	Small Molecule	Sold with the permission of Novo Nordisk A/S	http://www.tocris.com/dispprod.php?ItemId=1691				Jun-1997
0378	A-7 hydrochloride	[79127-24-5]	Cl.NCCCCCCCCCCNS(=O)(=O)C1=C2C=CC=C(Cl)C2=CC=C1	Calmodulin antagonist	Potent calmodulin antagonist (inhibits calmodulin-activated PDE activity with an IC50 of 3 _M).	Hidaka and Tanaka (1983) Naphthalenesulfonamides as calmodulin antagonists. Methods Enzymol. 102 185. PMID:6139736. Itoh and Hidaka (1984) Direct interaction of calmodulin antagonists with Ca2+/calmodulin-dependent cyclic nucleotide phosphodiesterase. J.Biochem. 96 1721. PMID:6099352.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1094				Oct-1994
0379	SKF 97541	[127729-35-5]	NCCCP(O)(C)=O	Extremely potent GABAB agonist	"Very potent GABAB agonist, at least ten times more active than baclofen (Cat. No. 0417). Also GABAC antagonist."	Seabrook et al (1990) Electrophysiological characterization of potent agonists and antagonists on pre- and postsynaptic GABAB receptors on neurones in brain slices. Br.J.Pharmacol. 101 949. PMID:1964824. Froestl et al (1995) Phosphinic acid analogues of GABA. 1. New potent and selective GABAB agonists. J.Med.Chem. 38 3297. PMID:7650684. Johnston (1996) GABAC receptors: relatively simple transmitter-gated ion channels? TiPS 17 319. PMID:8885697. Bon and Galvan (1996) Electrophysiological characterization of GABAB agonists and antagonists in dorso-lateral septal neurones in vitro. Br.J.Pharmacol. 118 961. PMID:8799569.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1866				Sep-1994
0380	Y-25130 hydrochloride	[123040-16-4]	Cl.CN1C(=O)COC2=C(C=C(Cl)C=C12)C(=O)NC1CN2CCC1CC2	"Potent, selective 5-HT3 antagonist"	A selective and potent 5-HT3 antagonist (Ki = 2.9 nM).	"Fukuda et al (1991) The antiemetic profile of Y-25130, a new selective 5-HT3 receptor antagonist. Eur.J.Pharmacol. 196 299. PMID:1654255. Sato et al (1992) Antagonistic activity of Y-25130 on 5-HT3 receptors. Jpn.J.Pharmacol. 59 443. PMID:1331590. Haga et al (1993) The effects of orally administered Y-25130, a selective serotonin3 receptor antagonist on chemotherapeutic agent-induced emesis. Jpn.J.Pharmacol. 63 377. PMID:8107329."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1980	SQ1533			Oct-1994
0382	Arecaidine but-2-ynyl ester tosylate	[119630-77-2]	CC1=CC=C(C=C1)S(O)(=O)=O.CC#CCOC(=O)C1=CCCN(C)C1	Muscarinic agonist	"Potent muscarinic agonist, 4.6-fold selective for M2 receptors in the atrium versus those in the ileum."	"Barlow and Weston-Smith (1985) The relative potencies of some agonists at M2 muscarinic receptors in guinea pig ileum, atria and bronchi. Br.J.Pharmacol. 85 437. PMID:3896364. Moser et al (1989) Structure-activity relationships of new analogues of arecaidine propargyl ester at muscarinic M1 and M2 receptor subtypes. Br.J.Pharmacol. 96 319. PMID:2924082."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1252				Oct-1994
0383	Arecaidine propargyl ester tosylate	[147202-94-6]	CC1=CC=C(C=C1)S(O)(=O)=O.CN1CCC=C(C1)C(=O)OCC#C	Muscarinic agonist	A potent muscarinic receptor agonist. Shows some selectivity for cardiac versus ileal M2 receptors.	"Barlow and Weston-Smith (1985) The relative potencies of some agonists at M2 muscarinic receptors in guinea pig ileum, atria and bronchi. Br.J.Pharmacol. 85 437. PMID:3896364. Moser et al (1989) Structure-activity relationships of new analogues of arecaidine propargyl ester at muscarinic M1 and M2 receptor subtypes. Br.J.Pharmacol. 96 319. PMID:2924082."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1253				Oct-1994
0384	N-Acetyl-L-leucyl-L-leucyl-L-methional	[136632-32-1]	O=C(C)NC(C(NC(C(NC(C([H])=O)CCSC)=O)CC(C)C)=O)CC(C)C	Cathepsin inhibitor	Very potent inhibitor of cathepsin L (Ki = 0.6 nM) and the strongest inhibitor of cathepsin B (Ki = 100 nM) amongst the peptide aldehydes. Also inhibits processing of malaria aspartic hemoglobinases plasmepsins I and II in vitro.	Sasaki et al (1990) Inhibitory effect of di- and tripeptidyl aldehydes on calpains and cathepsins. J.Enzyme Inhib. 3 195. PMID:2079636. Francis et al (1997) Biosynthesis and maturation of the malaria aspartic hemogloninases plasmepsins I and II. J.Biol.Chem. 272 14961. PMID:9169469.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1025	SQ1070			Sep-1994
0386	3-Methyl-GABA	[71424-95-8]	CC(CN)CC(O)=O.CC(CN)CC(O)=O.OS(=O)(=O)C1=CC=CC2=C(C=CC=C12)S(O)(=O)=O	Activator of GABA amino-transferase	Activator of GABA aminotransferase. Anticonvulsant.	Silverman et al (1991) 3-Alkyl-4-aminobutyric acids: the first class of anticonvulsant agents that activate L-glutamic acid decarboxylase. J.Med.Chem. 34 2295. PMID:2067001.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1622				Dec-1994
0387	(RS)-Atenolol	[29122-68-7]	CC(C)NCC(O)COC1=CC=C(CC(N)=O)C=C1	_1 antagonist	"Cardioselective _-adrenergic blocker. Antihypertensive, antianginal, antiarrhythmic. S-enantiomer (Cat. No. 0393) also available."	Merck Index 12 892. Kahonen et al (1994) Enhancement of arterial relaxation by long-term atenolol treatment in spontaneously hypertensive rats. Br.J.Pharmacol. 112 925. PMID:7921622.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1202	SQ1533			Sep-1994
0388	Ambenonium dichloride	[115-79-7]	[Cl-].[Cl-].CC[N+](CC)(CCNC(=O)C(=O)NCC[N+](CC)(CC)CC1=C(Cl)C=CC=C1)CC1=C(Cl)C=CC=C1	Cholinesterase inhibitor	"Extremely potent, selective and rapidly reversible inhibitor of acetylcholinesterase (AChE) (IC50 values are 0.000698 and 8.20 _M at AChE and BChE respectively)."	"Lands et al (1958) An investigation of the structure-activity correlations within a series of ambenonium analogs. J.Pharmacol.Exp.Ther. 123 121. PMID:13550066. Web (1965) Affinity for benzoquinonium, and ambenonium derivatives for the acetylcholine receptor, tested on the electroplax, and for acetylcholinesterase in solution. Biochim.Biophys.Acta. 102 172. PMID:5833399. Hodge et al (1992) Ambenonium is a rapidly reversible noncovalent inhibitor of acetylcholinesterase, with one of the highest known affinities. Mol.Pharmacol. 41 937. PMID:1588924. Bolognesi et al (2003) Design, synthesis and biological evaluation of ambenonium derivatives as AChE inhibitors. Farmaco 58 917. PMID:13679187."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1064	SQ1533			Oct-1994
0389	Arcaine sulfate	[14923-17-2]	O=[SH2]([O])O[O].NC(NCCCCNC(N)=N)=N	Competitive NMDA antagonist	NO synthase inhibitor. An NMDA antagonist acting as a competitive inhibitor at the polyamine site.	Reynolds (1990) Arcaine is a competitive antagonist of the polyamine site on the NMDA receptor. Eur.J.Pharmacol. 177 215. PMID:2155812. Yokoi et al (1994) Structure-activity relationships of arginine analogues on nitric oxide synthase activity in the rat brain. Neuropharmacology 33 1261. PMID:7532812. Doyle and Shaw (1998) Investigation of the actions and antagonist activity of some polyamine analogues in vivo. Br.J.Pharmacol. 124 386. PMID:9641557.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1251				Oct-1994
0391	Spaglumic acid	[3106-85-2]	CC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O	Selective mGlu3 agonist	"The most abundant peptide neurotransmitter in the mammalian CNS. A weak activator of NMDA receptors, and a highly selective agonist for mGlu3 receptors. Neuroprotective under non-hydrolysing conditions in vivo."	Wroblewska et al (1997) N-Acetylaspartylglutamate selectively activates mGluR3 receptors in transfected cells. J.Neurochem. 69 174. PMID:9202308. Neale et al (2000) N-Acetylaspartylglutamate: the most abundant peptide neurotransmitter in the mammalian central nervous system. J.Neurochem. 75 443. PMID:10899918. Thomas et al (2000) N-Acetylated _-linked acidic dipeptidase converts N-acetylaspartylglutamate from a neuroprotectant to a neurotoxin. J.Pharmacol.Exp.Ther. 295 16. PMID:10991955.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1021				Oct-1994
0393	(S)-(-)-Atenolol	[93379-54-5]	O[C@@H](CNC(C)C)COC1=CC=C(CC(N)=O)C=C1	_1-antagonist. Active isomer of atenolol (Cat. No. 0387)	"The active enantiomer of (RS)-atenolol (Cat. No. 0387), a cardioselective _-adrenergic blocker."	"Merck Index 12 892. Stoschitzky et al (1993) Stereoselective features of (R)- and (S)-atenolol: clinical pharmacological, pharmacokinetic, and radioligand binding studies. Chirality 5 15. PMID:8383518."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1204	SQ1533			Sep-1994
0395	N-Acetylglycyl-D-glutamic acid	[135701-69-8]	CC(=O)NCC(=O)N[C@H](CCC(O)=O)C(O)=O	Potent convulsant	"Excitatory peptide, more potent than L-glutamic acid at inducing seizures in mice."	Garyaev et al (1991) Excitatory action of some aspartate- and glutamate-containing dipeptides after intracerebroventricular injection in mice. Eur.J.Pharmacol. 197 157. PMID:1655472.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1024				Oct-1994
0396	H-9 dihydrochloride	[116700-36-8]	Cl.Cl.NCCNS(=O)(=O)C1=CC=CC2=CN=CC=C12	Protein kinase inhibitor	"Protein kinase inhibitor. Inhibits PKA (Ki = 1.9 _M), PKG (Ki = 0.9 _M), CaMK II (Ki = 60 _M), PKC (Ki = 18 _M), casein kinase I (Ki = 110 _ M) and casein kinase II (Ki > 300 _M)."	"Hidaka et al (1984) Isoquinolinesulfonamides, novel and potent inhibitors of cyclic nucleotide dependent protein kinase and protein kinase C. Biochemistry 23 5036. PMID:6238627. Hidaka and Koybashi (1992) Pharmacology of protein kinase inhibitors. Annu.Rev.Pharmacol.Toxicol. 32 377. PMID:1605572."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1435				Oct-1994
0405	_-CCB	[84454-35-3]	CCCCOC(=O)C1=CC2=C(NC3=C2C=CC=C3)C=N1	"Benzodiazepine inverse agonist, putative endogenous ligand"	An endogenous proconvulsant and anxiogenic benzodiazepine receptor ligand.	"Pena et al (1986) Isolation and identification in bovine cerebral cortex of n-butyl _-carboline-3-carboxylate, a potent benzodiazepine binding inhibitor. Proc.Natl.Acad.Sci.U.S.A. 83 4952. PMID:3014522. Izquierdo (1989) A game with shifting mirrors. TiPS 10 473. PMID:2575813."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=2130				Sep-1994
0411	MDL 73005EF hydrochloride	[102908-60-1]	Cl.O=C1CC2(CCCC2)CC(=O)N1CCNCC1COC2=C(O1)C=CC=C2	Potent and selective 5-HT1A partial agonist	Potent and selective 5-HT1A receptor antagonist. Has partial agonist properties.	"Gartside et al (1990) Effects of MDL 73005EF on central pre-and-postsynaptic 5HT1A receptor function in the rat in vivo. Eur.J.Pharmacol. 191 391. PMID:1964908. Van der Hooff and Galvan (1991) Electrophysiology of the 5-HT1A ligand MDL 73005EF in the rat hippocampal slice. Eur.J.Pharmacol. 196 291. PMID:1893914. Buisson Defferier and Van den Buuse (1992) Cardiovascular effects of the 5-HT1A receptor ligand, MDL 73005EF, in conscious hypertensive rats. Eur.J.Pharmacol. 223 133. PMID:1362161."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1574	SQ1533			Oct-1994
0412	MDL 72832 hydrochloride	[113777-40-5]	Cl.O=C1CC2(CCCC2)CC(=O)N1CCCCNCC1COC2=CC=CC=C2O1	Potent 5-HT1A ligand	"A potent ligand at 5-HT1A receptors, with mixed agonist and antagonist properties. An agonist at post-synaptic 5-HT1A receptors."	Mir et al (1988) MDL 72832: a potent and stereoselective ligand at central and peripheral 5-HT1A receptors. Eur.J.Pharmacol. 149 107. PMID:2840295. Millan et al (1993) Induction of hypothermia as a model of 5-hydroxytryptamine1A receptor-mediated activity in the rat - a pharmacological characterization of the actions of novel agonists and antagonists. J.Pharmacol.Exp.Ther. 264 1364. PMID:8450471.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1573				Oct-1994
0414	AG 490	[133550-30-8]	OC1=C(O)C=C(\C=C(/C#N)C(=O)NCC2=CC=CC=C2)C=C1	"EGFR-kinase inhibitor. Also JAK2, JAK3 inhibitor"	"Selective inhibitor of EGF receptor tyrosine kinase (IC50 values are 2 and 13.5 _M for EGFR and ErbB2 respectively). Inhibitor of JAK2, JAK3/STAT, JAK3/AP-1 and JAK3/MAPK pathways and potently inhibits cytokine-independent cell growth in vitro and tumor cell invasion in vivo."	"Gazit et al (1991) Tyrphostins. 2. Heterocyclic and _-substituted benzylidenemalononitrile tyrophostins as potent inhibitors of EGF receptor and ErbB2/neu tyrosine kinases. J.Med.Chem. 34 1896. PMID:1676428. Meydan et al (1996) Inhbition of acute lymphoblastic leukaemia by a JAK-2 inhibitor. Nature 379 645. PMID:8628398. Wang et al (1999) JAK3, STAT, and MAPK signaling pathways as novel molecular targets for the tyrphostin AG-490 regulation of IL-2-mediated T cell response. J.Immunol. 162 3897. PMID:10201908. Abe et al (2009) The polycythemia vera-associated Jak2 V617F mutant induces tumorigenesis in nude mice. Int.Immunopharmacol. 9 870. PMID:19327411."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1938	SQ1533			Nov-1994
0415	Ro 20-1724	[29925-17-5]	CCCCOC1=CC(CC2CNC(=O)N2)=CC=C1OC	PDE4 inhibitor	"Widely used inhibitor of cyclic nucleotide phosphodiesterase, selective for PDE4 (IC50 = 2.0 _M). Also available as part of the Phosphodiesterase Inhibitor Tocriset."	Reeves et al (1987) The identification of a new cyclic nucleotide phosphodiesterase activity in human and guinea-pig cardiac ventricle. Biochem.J. 241 535. PMID:3036066. Nicholson et al (1991) Differential modulation of tissue function and therapeutic potential of selective inhibitors of cyclic nucleotide phosphodiesterase isoenzymes. TiPS 12 19. PMID:1848733. Soderling et al (1998) Cloning and characterization of a cAMP-specific cyclic nucleotide phosphodiesterase. Proc.Natl.Acad.Sci.U.S.A. 95 8991. PMID:9671792.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1839				Nov-1994
0416	YS-035 hydrochloride	[89805-39-0]	Cl.COC1=CC=C(CCN(C)CCC2=CC=C(OC)C(OC)=C2)C=C1OC	Inhibits K+ outward/pacemaker current	A Ca2+ blocker that strikingly prolongs cardiac action potentials by inhibiting pacemaker current and K+ outward currents.	Deana et al (1984) Properties of a new calcium ion antagonist on cellular uptake and mitochondrial efflux of calcium ions. Biochem.J. 218 899. PMID:6721841. Berger et al (1991) Inhibition of potassium outward currents and pacemaker current in sheep cardiac Purkinje fibres by the verapamil derivative YS-035. Naunyn Schmiedebergs Arch.Pharmacol. 344 653. PMID:1775198.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1979				Nov-1994
0417	(RS)-Baclofen	[1134-47-0]	OC(CC(CN)C1=CC=C(Cl)C=C1)=O	Selective GABAB agonist	Selective GABAB receptor agonist. Skeletal muscle relaxant. (R)-Baclofen (Cat. No. 0796) also available.	Hill et al (1981) 3H-Baclofen and 3H-GABA bind to bicuculline-insensitive GABAB sites in rat brain. Nature 290 149. PMID:6259535. Berthelot et al (1991) 3-Thienylaminobutyric acid and 3-furylaminobutyric acids - synthesis and GABAB receptor binding studies. J.Med.Chem. 34 2557. PMID:1652022. Bowery et al (1993) GABAB receptor pharmacology. Annu.Rev.Pharmacol.Toxicol. 33 109. PMID:8388192.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1991	SQ1533			Oct-1994
0420	GBR 13069 dihydrochloride	[67469-45-8]	FC(C=C2)=CC=C2C(OCCN3CCN(C/C=C/C4=CC=CC=C4)CC3)C1=CC=C(F)C=C1.Cl.Cl	Potent dopamine uptake inhibitor	A potent inhibitor of dopamine uptake (IC50 = 40 nM). Centrally active following systemic administration in vivo.	"Heikkila et al (1984) Behavioural properties of GBR12909, GBR13069 and GBR13098: specific inhibitors of dopamine uptake. Eur.J.Pharmacol. 103 241. PMID:6237922. Van der Zee and Hespe (1985) Interaction between substituted 1-[2-diphenylmethoxyethyl]piperazines and dopamine receptors. Neuropharmacology 24 1171. PMID:4094653. Mayer et al (1986) Prevention of the nigrostriatal toxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine by inhibitors of 3,4-dihydroxyphenylethylamine transport. J.Neurochem. 47 1073. PMID:3489072."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1417				Sep-1995
0421	GBR 12909 dihydrochloride	[67469-78-7]	Cl.Cl.FC1=CC=C(C=C1)C(OCCN1CCN(CCCC2=CC=CC=C2)CC1)C1=CC=C(F)C=C1	Selective DA uptake inhibitor. Also _ ligand	"Potent, competitive inhibitor of dopamine uptake (Ki = 1 nM for inhibition of striatal dopamine uptake). Has > 100-fold lower affinity for the noradrenalin and 5-HT uptake carriers. Also a potent sigma ligand (IC50 = 48 nM). Centrally active following systemic administration."	"Heikkila and Manzino (1984) Behavioral properties of GBR 12909, GBR 13069 and GBR 13098: specific inhibitors of dopamine uptake. Eur.J.Pharmacol. 103 241. PMID:6237922. Andersen (1989) The dopamine uptake inhibitor GBR12909: selectivity and molecular mechanism of action. Eur.J.Pharmacol. 166 493. PMID:2530094. Contreras et al (1990) GBR-12909 and fluspirilene potently inhibited binding of [3H] (+)3-PPP to sigma receptors in rat brain. Life Sci. 47 PL133. PMID:1980329. Spealman and Melia (1991) Pharmacological characterization of the discriminative-stimulus effects of GBR 12909. J.Pharmacol.Exp.Ther. 258 626. PMID:1678014."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1415	SQ1533			Oct-1994
0424	Benzoquinonium dibromide	[311-09-1]	[Br-].[Br-].CC[N+](CC)(CCCNC1=CC(=O)C(NCCC[N+](CC)(CC)CC2=CC=CC=C2)=CC1=O)CC1=CC=CC=C1	Nicotinic antagonist	"Nicotinic antagonist, ganglion blocker. Activates single channels but blocks open channels at nicotinic receptors."	Bowman and Webb (1972) Neuromuscular blocking and ganglia blocking activities of some acetylcholine antagonists in the cat. J.Pharm.Pharmacol. 24 762. PMID:4403972. Pereira et al (1993) Identification and functional characterization of a new agonist site on nicotinic acetylcholine receptors of cultured hippocampal neurons. J.Pharmacol.Exp.Ther. 265 1474. PMID:8510023.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=2000				Oct-1994
0425	"UK 14,304"	[59803-98-4]	BrC1=C(NC2=NCCN2)C=CC2=NC=CN=C12	_2 agonist	"Full _2 adrenergic agonist. Centrally active following systemic administration in vivo. Also available as part of the _2-Adrenoceptor Tocriset and Mixed Adrenergic Tocriset. Water soluble salt version UK 14,304 tartrate (Cat. No. 2466) also available."	"Andorn et al (1988) Specific [3H]UK-14,304 binding in human cortex occurs at multiple high affinity states with _2-adrenergic selectivity and different affinities for GTP. Life Sci. 43 1805. PMID:2904634. Macdonald et al (1997) Gene trageting - homing in on _2-adrenoceptor-subtype function. TiPS 18 211. PMID:9227000. Chopin et al (1999) Effects of alpha-2 adrenoceptor agonists and antagonists on circling behavior in rats with unilateral 6-hydroxydopamine lesions of the nigrostriatal pathway. J.Pharmacol.Exp.Ther. 288 798. PMID:9918591."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1958	SQ1533			Oct-1994
0426	"L-693,403 maleate"	[207455-21-8]	OC(=O)\C=C/C(O)=O.C(N1CCC2(CCC3=C2C=CC=C3)CC1)C1=CC=CC=C1	High affinity _ ligand	High affinity _ ligand with excellent selectivity over the dopamine D2 receptor.	Chambers et al (1992) Spiropiperidines as high affinity selective sigma ligands. J.Med.Chem. 35 2033. PMID:1317923.	Small Molecule	Sold with the permission of Merck Sharp and Dohme Ltd.	http://www.tocris.com/dispprod.php?ItemId=2015				Nov-1994
0427	Bromocriptine mesylate	[22260-51-1]	[H][C@]4([C@@](N[C@]([C@H](C)C)5C(N([C@@]([H])(CC(C)C)C(N(CCC7)[C@@]76[H])=O)[C@@]6(O)O5)=O)=O)CN([C@](C3=C4)([H])CC1=C(Br)NC2=C1C3=CC=C2)C.CS(=O)(O)=O	Selective D2-like agonist	"Selective D2-like dopamine receptor agonist (Ki values are ~ 8, ~ 5, ~ 290, ~ 440 and ~ 450 nM for D2, D3, D4, D1 and D5 receptors respectively)."	Lieberman and Goldstein (1985) Bromocriptine in Parkinson disease. Pharmacol.Rev. 37 217. PMID:3901046. Traub et al (1985) The effects of chronic bromocriptine treatment on behaviour and dopamine receptor binding in the rat striatum. Eur.J.Pharmacol. 118 147. PMID:3936723. Aubner et al (1990) Bromocriptine produces decreases in cocaine self-administration in the rat. Neuropsychopharmacology 3 101. PMID:2317262. Seeman and Van Tol (1994) Dopamine receptor pharmacology. TiPS 15 264. PMID:7940991.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=2061	SQ1070			Nov-1994
0430	SC-10	[102649-79-6]	CCCCCCCNS(=O)(=O)C1=CC=CC2=C(Cl)C=CC=C12	Protein kinase C activator	Activator of protein kinase C.	"Ito et al (1986) N-(6-Phenylhexyl)-5-chloro-1-naphthalenesulfonamide, a novel activator of protein kinase C. Biochemistry 25 4179. PMID:3756133. Hidaka and Hagiwara (1987) Pharmacology of the isoquinoline sulfonamide protein kinase C inhibitors. Trends Pharmacol.Sci. 8 162."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1853				Nov-1994
0431	ML 9 hydrochloride	[105637-50-1]	Cl.ClC1=C2C=CC=C(C2=CC=C1)S(=O)(=O)N1CCCNCC1	Myosin light chain kinase inhibitor	"Selective inhibitor of myosin light chain kinase (MLCK). Ki values are 32, 4, and 54 _M for PKA, MLCK, and PKC respectively. Also inhibits STIM1-plasma membrane interactions, preventing store-operated Ca2+ entry (SOCE)."	"Hidaka and Hagiwara (1987) Pharmacology of the isoquinoline sulfonamide protein kinase C inhibitors. Trends Pharmacol.Sci. 8 162. Seto et al (1991) Effects of HA1077, a protein kinase inhibitor, on myosin phosphorylation and tension in smooth muscle. Eur.J.Pharmacol. 195 267. PMID:1874276. Hidaka and Koybashi (1992) Pharmacology of protein kinase inhibitors. Annu.Rev.Pharmacol.Toxicol. 32 377. PMID:1605572. Varnai et al (2009) STIM and Orai: the long-awaited constituents of store-operated calcium entry. TiPS 30 118. PMID:19187978."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1661	SQ1070			Nov-1994
0432	MY-5445	[78351-75-4]	ClC1=CC(NC2=C3C=CC=CC3=C(N=N2)C2=CC=CC=C2)=CC=C1	PDE5 inhibitor	"Specific inhibitor of cyclic GMP phosphodiesterase, selective for PDE5 (IC50 = 0.5 _M)."	"Hagiwara et al (1984) Effect of 1-(3-chloroanilino)-4-phenylphthalazine (MY-5445), a specific inhibitor of cyclic GMP phosphodiesterase, on human platelet aggregation. J.Pharmacol.Exp.Ther. 228 467. PMID:6141286. Hidaka and Endo et al (1984) Selective inhibitors of three forms of cyclic nucleotide phosphodiesterase, basic and potential clinical applications. Adv.Cyclic Nucleotide Protein Phosphorylation Res. 16 245. PMID:6144253."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1671				Sep-1994
0433	SC-9	[102649-78-5]	ClC1=C2C=CC=C(C2=CC=C1)S(=O)(=O)NCCCCCCC1=CC=CC=C1	Protein kinase C activator	A potent activator of protein kinase C.	"Ito et al (1986) N-(6-Phenylhexyl)-5-chloro-1-naphthalenesulfonamide, a novel activator of protein kinase C. Biochemistry 25 4179. PMID:3756133. Nishino et al (1986) N-(6-Phenylhexyl)-5-chloro-1-naphthalenesulfonamide is one of a new class of activators for Ca2+ -activated, phospholipid-dependent protein kinase. Biochim.Biophys.Acta. 889 236. PMID:3778949."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1852				Nov-1994
0435	Cimaterol	[54239-37-1]	CC(C)NCC(O)C1=CC=C(N)C(=C1)C#N	_ agonist	_-Adrenergic agonist.	Merck Index 12 2336. Engelhardt (1984) Structure activity relationships in further series of amino-halogen substituted phenyl-aminoethanols. Arzneimittelforschung 11A 1625. PMID:6152155. Lafontan et al (1988) Mechanisms of actions of _-adrenergic agonists - lipomobilization and anabolism. Reprod.Nutr.Develop. 28 61. Strosberg and Pietri-Rouxel (1996) Function and regulation of the _3-adrenoceptor. TiPS 17 373. PMID:8979772.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=2192	SQ1533			Sep-1995
0438	Etazolate hydrochloride	[35838-58-5]	CCN2C1=NC=C(C(OCC)=O)C(NN=C(C)C)=C1C=N2.Cl	PDE4 inhibitor	"Phosphodiesterase inhibitor, selective for PDE4 (IC50 = 2.0 _M)."	"Chesin et al (1972) 1-Ethyl-4-(isopropylidenehydrazinol-H-pyrazolo-(3,4-b)-pyridin-5-carboxylic acid, ethyl ester, hydrochloride (SQ 20009) - potent new inhibitor of cyclic 3'5-nucleotide phosphodiesterase. Biochem.Pharmacol. 21 2443. PMID:4345859. Rhoads (1982) Selective inhibition of cyclic AMP and cyclic GMP phosphodiesterases of cardiac nuclear fraction. Biochem.Pharmacol. 31 665. PMID:6177320. Ahluwalia and Nicholson et al (1991) Differential modulation of tissue function and therapeutic potential of selective inhibitors of cyclic nucleotide phosphodiesterase isoenzymes. TiPS 12 19. PMID:1848733."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1372	SQ1533			Oct-1994
0439	DPCPX	[102146-07-6]	CCCN1C2=C(N=C(N2)C2CCCC2)C(=O)N(CCC)C1=O	A1 selective antagonist	"Potent and selective A1 adenosine receptor antagonist, both in vitro and in vivo. Ki values are 3.9, 130, 50 and 4000 nM for human A1, A2A, A2B and A3 receptors respectively."	"Von der Leyen (1989) Effects of 1,3-dipropyl-8-cyclopentylxanthine (DPCPX), a highly selective adenosine receptor antagonist, on force of contraction in guinea-pig atrial and ventricular cardiac preparations. Naunyn Schmiedebergs Arch.Pharmacol. 340 204. PMID:2554151. Kuan et al (1992) An experimental paradigm for investigating the role of endogenous adenosine/A1 receptor interactions in vivo. J.Pharmacol.Exp.Ther. 263 657. PMID:1432696. Klotz (2000) Adenosine receptors and their ligands. Naunyn Schmiedebergs Arch.Pharmacol. 362 382. PMID:11111832. Canals et al (2008) Metabolic challenge to glia activates and adenosine-mediated safety mechanism that promotes neuronal survival by delaying the onset of spreading depression waves. J.Cereb.Blood Flow Metab. 28 1835. PMID:18612316."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1349	SQ1070			Sep-1994
0440	m-Chlorophenylbiguanide hydrochloride	[2113-05-5]	Cl.NC(=N)NC(=N)NC1=CC(Cl)=CC=C1	Potent and specific 5-HT3 agonist	Prototypical potent and selective 5-HT3 receptor agonist.	"Kilpatrick et al (1990) 1-(m-Chlorophenyl)biguanide, a potent high affinity 5-HT3 receptor agonist. Eur.J.Pharmacol. 182 193. PMID:2144822. Sepulveda et al (1991) The agonist properties of m-chlorophenylbiguanide and 2-methyl-5-hydroxytryptamine on 5-HT3 receptors in N1E-115 neuroblastoma cells. Br.J.Pharmacol. 104 536. PMID:1797317. Boess et al (1992) 5HT3 receptors in NG108-15 neuroblastoma X glioma cells: effect of the novel agonist 1-(m-chlorophenyl)biguanide. Neuropharmacology 31 561. PMID:1407396. Niemeyer and Lummis (1998) Different efficacy of specific agonists at 5-HT3 receptor splice variants: the role of the extra six amino acid segment. Br.J.Pharmacol. 123 661. PMID:9517385."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=2165				Oct-1994
0442	4-Chlorophenylguanidine hydrochloride	[14279-91-5]	Cl.NC(=N)NC1=CC=C(Cl)C=C1	Urokinase inhibitor	Potent and specific inhibitor of urokinase.	Yang et al (1990) Selective inhibition of urokinase by substituted phenylguanidines: quantitative structure-activity relationship analyses. J.Med.Chem. 33 2956. PMID:2231595.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=2170				Oct-1994
0443	6-Chloromelatonin	[63762-74-3]	COC1=C(Cl)C=C2NC=C(CCNC(C)=O)C2=C1	Melatonin agonist	Potent melatonin agonist (pKi values are 9.10 and 9.77 for human recombinant MT1 and MT2 receptors respectively). Displays higher affinity for binding to hamster brain membrane and chicken retina than melatonin.	Dubocovich (1988) Luzindole (NO 774): A novel melatonin receptor antagonist. J.Pharmacol.Exp.Ther. 246 902. PMID:2843633. Duncan et al (1988) 2-[125I]Iodomelatonin binding sites in hamster brain membranes: pharmacological characteristics and regional distribution. Endocrinology 122 1825. PMID:2834175. Dubocovich (1995) Melatonin receptors: are there multiple subtypes? TiPS 16 50. PMID:7762083. Browning et al (2000) Pharmacological characterization of human recombinant melatonin mt1 and MT2 receptors. Br.J.Pharmacol. 129 877. PMID:10696085.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=2158				Nov-1994
0444	Clozapine	[5786-21-0]	CN1CCN(CC1)C1=NC2=C(NC3=C1C=CC=C3)C=CC(Cl)=C2	Dopamine antagonist with some D4 selectivity. Also 5-HT2A/2C antagonist	"Atypical antipsychotic drug, with a much lower tendency to cause extrapyramidal side effects than conventional neuroleptics. Displays a broad range of pharmacological actions; the antipsychotic effects are thought to be mediated principally by 5-HT2A/2C and dopamine receptor blockade (Ki values are 21, 170, 170, 230 and 330 nM for D4, D3, D1, D2 and D5 receptors respectively)."	"Canton et al (1990) Binding of typical and atypical antipsychotics to 5-HT1C and 5-HT2 sites: clozapine potently interacts with 5-HT1C sites. Eur.J.Pharmacol. 191 93. PMID:1982659. Ellenbroek et al (1991) The involvement of dopamine D1 and D2 receptors in the effects of the classical neuroleptic haloperidol and the atypical neuroleptic clozapine. Eur.J.Pharmacol. 196 103. PMID:1678712. Seeman and Van Tol (1994) Dopamine receptor pharmacology. Trends Pharmacol.Sci. 15 264. PMID:7940991. Jensen et al (2013) Design, synthesis, and pharmacological characterization of N- and O-substituted 5,6,7,8-tetrahydro-4H-isoxazolo[4,5-dazepin-3-ol analogues: novel 5-HT2A/5-HT2C receptor agonists with pro-cognitive properties. J.Med.Chem. 56 1211. PMID:23301527."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=2211	SQ1533			Sep-1994
0448	Calpeptin	[117591-20-5]	O=C(OCC1=CC=CC=C1)N[C@H](C(N[C@H](C([H])=O)CCCC)=O)CC(C)C	Calpain and cathepsin L inhibitor	"Potent, cell-permeable inhibitor of the Ca2+-dependent protease, calpain. Prevents collagen- and thrombin-induced platelet aggregation, probably by blocking calpain induced phospholipase C and thromboxane synthase activation. Potent cathepsin L inhibitor. Recently shown to preferentially inhibit a subset of protein-tyrosine phosphatases."	Tsujinaka et al (1988) Synthesis of a new cell penetrating calpain inhibitor (calpeptin). Biochem.Biophys.Res.Commun. 153 1201. PMID:2839170. Sasaki et al (1990) Inhibitory effect of di-and tripeptidyl aldehydes on calpains and cathepsins. J.Enzyme Inhib. 3 195. PMID:2079636. Mehdi (1991) Cell-penetrating inhibitors of calpain. TiBS 16 150. PMID:1877091. Schoenwaelder and Burridge (1999) Evidence for a calpeptin-sensitive protein-tyrosine phosphatase upstream of the small GTPase Rho. J.Biol.Chem. 274 14359. PMID:10318859.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=2089	SQ1533			Nov-1994
0452	CCCP	[555-60-2]	ClC1=CC=CC(NN=C(C#N)C#N)=C1	Oxidative phosphorylation uncoupler	Widely used uncoupler of oxidative phosphorylation.	Heytler and Pritchard (1962) A new class of uncoupling agents - carbonyl cyanide phenylhydrazones. Biochem.Biophys.Res.Commun. 7 272. PMID:13907155.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=2108				Nov-1994
0453	FCCP	[370-86-5]	N#CC(C#N)=NNC1=CC=C(OC(F)(F)F)C=C1	Oxidative phosphorylation uncoupler	A very potent uncoupler of oxidative phosphorylation in mitochondria.	Heytler and Pritchard (1962) A new class of uncoupling agents - carbonyl cyanide phenylhydrazones. Biochem.Biophys.Res.Commun. 7 272. PMID:13907155. Connop et al (1999) Novel effects of FCCP [carbonyl cyanide p-(trifluoromethoxy)phenylhydrazone] on amyloid precursor protein processing. J.Neurochem. 72 1457. PMID:10098849.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=2109				Nov-1994
0454	Carbetapentane citrate	[23142-01-0]	OC(=O)CC(O)(CC(O)=O)C(O)=O.CCN(CC)CCOCCOC(=O)C1(CCCC1)C1=CC=CC=C1	High affinity _1 ligand	A selective ligand for the _1 -site.	"Rothman et al (1991) Labelling by [3H]1,3-di(2-tolyl)guanidine of two high affinity binding sites in guinea pig brain: evidence for allosteric regulation by calcium channel antagonists and pseudoallosteric modulation by _ ligands. Mol.Pharmacol. 39 222. PMID:1847495. Quirion et al (1992) A proposal for the classification of sigma binding sites. TiPS 13 85. PMID:1315463."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=2098	SQ1533			Oct-1994
0455	(S)-(-)-Carbidopa	[28860-95-9]	OC1=C(O)C=CC(C[C@@](NN)(C)C(O)=O)=C1	Aromatic L-amino acid decarboxylase inhibitor	"Peripheral decarboxylase inhibitor, used in combination with levodopa for treatment of Parkinsonism."	Merck Index 12 1843. Kopfhammer et al (1985) L-Dopa infusion experiments in combination with the L-dopa decarboxylase inhibitors benserazide and carbidopa - L-dopa metabolism and neuroendocrinological effects. Pharmacopsychiatry 18 143. Cheng et al (1992) Carbidopa inhibition of aromatic L-amino acid decarboxylase in rat brain capilliaries. FASEB J. 6 A1589.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=2099	SQ1533			Nov-1994
0456	Chlormezanone	[80-77-3]	CN1C(C2=CC=C(Cl)C=C2)S(=O)(=O)CCC1=O	Skeletal muscle relaxant	Anxiolytic and skeletal muscle relaxant that acts at the benzodiazepine site of GABAA receptors.	Merck Index 12 2155. Ervin and Cooper (1988) Use of conditioned taste aversion as a conflict model: effects of anxiolytic drugs. J.Pharmacol.Exp.Ther. 245 137. PMID:2896235. Simiand et al (1989) Comparative study in mice of tetrazepam and other centrally active skeletal muscle relaxants. Arch.Int.Pharmacodyn.Ther. 297 272. PMID:2567153.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=2148	SQ1533			Oct-1994
0457	Clomipramine hydrochloride	[17321-77-6]	Cl.CN(C)CCCN1C2=CC(Cl)=CC=C2CCC2=C1C=CC=C2	5-HT re-uptake inhibitor	"Potent, selective 5-HT uptake blocker. Antidepressant. Binds to the human 5-HT transporter with a Ki of 0.05 nmol/l. Also available as part of the Serotonin Uptake Inhibitor Tocriset."	Merck Index 12 2447. McTavish and Benfield (1990) Clomipramine. An overview of its pharmacological properties and a review of its therapeutic use in obsessive compulsive disorder and panic disorder. Drugs 39 136. PMID:2178909. Ortiz and Artiga (1992) Effects of monoamine uptake inhibitors on extracellular and platelet 5-hydroxytryptamine in rat blood: different effects of clomipramine and fluoxetine. Br.J.Pharmacol. 105 941. PMID:1387022. Owens et al (1997) Neurotransmitter receptor and transporter binding profile of antidepressants and their metabolites. J.Pharmacol.Exp.Ther. 283 1305. PMID:9400006.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=2204	SQ1533			Nov-1994
0458	5-Carboxamidotryptamine maleate	[74885-72-6]	OC(=O)\C=C/C(O)=O.NCCC1=CNC2=CC=C(C=C12)C(N)=O	5-HT1 agonist. Also has high affinity for 5-ht5a and 5-HT7	"5-HT1 agonist with high affinity at 5-HT1A, 5-HT1B , 5-HT1D, 5-ht5 and 5-HT7 receptors."	"Beer et al (1992) An investigation of the 5-HT1D receptor binding affinity of 5-hydroxytryptamine, 5-carboxyamidotryptamine and sumatriptan in the central nervous system of seven species. Eur.J.Pharmacol. 213 193. PMID:1325915. Zifa and Fillion (1992) 5-Hydroxytryptamine receptors. Pharmacol.Rev. 44 401. PMID:1359584. Nowak et al (1993) [3H]-5-carboxamidotryptamine labels 5HT1D binding sites in bovine substantia nigra. Br.J.Pharmacol. 109 1206. PMID:8401931. Wood et al (2000) Antagonist activity of meta-chlorophenylpiperazine and partial agonist activity of 8-OH-DPAT at the 5-HT7 receptor. Eur.J.Pharmacol. 396 1. PMID:10822046."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=2110	SQ1070			Oct-1994
0460	Cinanserin hydrochloride	[54-84-2]	O=C(/C=C/C2=CC=CC=C2)NC1=CC=CC=C1SCCCN(C)C.Cl	Selective 5-HT2 antagonist	5-HT2 antagonist.	"Leysen et al (1981) Receptor binding profile of R-41-468, a novel antagonist at 5HT2 receptors. Life Sci. 28 1015. PMID:6261070. Pierce et al (1992) Molecular structure basis of ligand selectivity for 5-HT2 versus 5-HT1C cortical receptors. Naunyn Schmiedebergs Arch.Pharmacol. 346 4. PMID:1407003."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=2194	SQ1533			Oct-1994
0462	(E)-Capsaicin	[404-86-4]	COC1=C(O)C=CC(CNC(=O)CCCC\C=C\C(C)C)=C1	Prototypic vanilloid receptor agonist	"Prototypic vanilloid receptor agonist (pEC50 values are 7.97 and 7.10 at rat and human VR1 receptors respectively). Excites a subset of primary afferent sensory neurons, with subsequent antinociceptive and anti-inflammatory effects. Reversibly inhibits aggregation of platelets. Also available as part of the Vanilloid TRPV1 Receptor Tocriset."	"Bevan and Szolcsani (1990) Sensory neuron-specific actions of capsaicin: mechanisms and application. TiPS 11 330. PMID:2203194. Hogaboam and Wallace (1991) Inhibition of platelet aggregation by capsaicin. An effect unrelated to actions on sensory afferent neurons. Eur.J.Pharmacol. 202 129. PMID:1786800. Holzer (1991) Capsaicin-cellular targets, mechanism of actions, and selectivity for thin sensory neurons. Pharmacol.Rev. 43 143. PMID:1852779. Ralevic et al (2001) Cannabinoid activation of recombinant and endogenous vanilloid receptors. Eur.J.Pharmacol. 424 211. PMID:11672565."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=2094	SQ1533			Sep-1994
0464	Capsazepine	[138977-28-3]	OC1=C(O)C=C2CN(CCCC2=C1)C(=S)NCCC1=CC=C(Cl)C=C1	Vanilloid receptor antagonist; also activator of ENaC_	Selective vanilloid receptor antagonist (Ki = 3.2 _M). Inhibits carrageenan inflammation-induced hyperalgesic responses in the rat. Also activates amiloride-sensitive epithelial Na+ channel ENaC_. Also available as part of the Vanilloid TRPV1 Receptor Tocriset.	"Dickenson and Dray (1991) Selective antagonism of capsaicin by capsazepine: evidence for a spinal receptor site in capsaicin-induced antinociception. Br.J.Pharmacol. 104 1045. PMID:1810591. Kwak et al (1998) A capsaicin-receptor antagonist, capsazepine, reduces inflammation-induced hyperalgesic responses in the rat: evidence for an endogenous capsaicin-like substance. Neuroscience 86 619. PMID:9881874. Yamamura et al (2004) Capsazepine is a novel activator of the _ subunit of the human epithelial Na+ channel. J.Biol.Chem. 279 44483. PMID:15308635."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=2096	SQ1070			Sep-1994
0468	"N1,N11-Diethylnorspermine tetrahydrochloride"	[156886-85-0]	CCNCCCNCCCNCCCNCC.Cl.Cl.Cl.Cl	Spermine and spermidine acetyltransferase potentiator	"Highly potent inducer of spermidine/spermine N1-acetyltransferase, able to increase enzyme activity 200-1000 fold."	"Libby et al (1991) Characterization of human spermidine spermine N1-acetyltransferase purified from cultured melanoma cells. Arch.Biochem.Biophys. 284 238. PMID:1989509. Bernacki et al (1992) Antitumour activity of N1,N12-bis(ethyl)spermine homologs against human MALME-3 melanoma xenografts. Cancer Res. 52 2424. PMID:1568212. Porter et al (1993) Antitumour activity of N1,N12-bis(ethyl)-norspermine against human melanoma xenografts and possible biochemical correlates of drug action. Cancer Res. 53 581. PMID:8425191. Fogel-Petrovic et al (1997) Structural basis for differential induction of spermidine/spermine N1-acetyltransferase activity by novel spermine analogs. Mol.Pharmacol. 52 69. PMID:9224814."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1289				Nov-1994
0469	Nitrocaramiphen hydrochloride	[98636-73-8]	O=C(OCCN(CC)CC)C2(CCCC2)C1=CC=C([N+]([O-])=O)C=C1.Cl	"Muscarinic antagonist, M1 > M2"	Muscarinic antagonist with 71-fold selectivity for M1 over M2.	"Hudkins et al (1991) Muscarinic receptor binding. Profile of para-sustituted caramiphen analogues. J.Med.Chem 34 2984. PMID:1920350. Hudkins et al (1993) Caramiphen, iodocaramiphen and nitrocaramiphen are potent, competitive, muscarine M1 receptor selective agents. Eur.J.Pharmacol. 231 485. PMID:8449241."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1702				Nov-1994
0471	(+)-U-50488 hydrochloride	[114528-81-3]	O=C(CC3=CC(Cl)=C(Cl)C=C3)N([C@H]1[C@H](N2CCCC2)CCCC1)C.Cl	Standard selective _ agonist. Less active enantiomer of ()-U-50488 (Cat. No. 0495)	Less active enantiomer of ()-U-50488 (Cat. No. 0495). (-)-U-50488 hydrochloride (Cat. No. 0496) also available.	De Costa et al (1987) Synthesis and absolute configuration of optically pure enantiomers of a _-opioid receptor selective antagonist. FEBS Lett. 223 335. PMID:2822490.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1954				Nov-1994
0474	Dihydroergocristine mesylate	[24730-10-7]	CS(=O)(O)=O.[H][C@]4([C@@]([H])3C[C@@H]([C@@](N[C@@]5([C@H](C)C)C(N([C@@]([H])(CC8=CC=CC=C8)C(N7[C@]([H])6CCC7)=O)[C@@]6(O)O5)=O)=O)CN4C)CC1=CNC2=C1C3=CC=C2	Partial _ agonist. Non-selective	5-HT receptor antagonist; partial agonist at adrenergic and dopaminergic receptors.	Drago (1988) Dihydroergocristine and memory alterations of aged male rats. Pharmacol.Biochem.Behav. 30 961. PMID:3147464.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1293	SQ1070			Nov-1994
0475	Dihydroergotamine mesylate	[6190-39-2]	CS(=O)(O)=O.[H][C@]4([C@@]([H])3C[C@@H]([C@@](N[C@@]5(C)C(N([C@@]([H])(CC8=CC=CC=C8)C(N7[C@]([H])6CCC7)=O)[C@@]6(O)O5)=O)=O)CN4C)CC1=CNC2=C1C3=CC=C2	Partial _ agonist. Non-selective	Partial _-adrenergic agonist. Partial D2 dopaminergic receptor agonist. Competitive 5-HT antagonist.	"de Boer et al (1991) Carotid vascular effects of ergotamine and dihydroergotamine in the pig: no exclusive mediation via 5-HT1-like receptors. Br.J.Pharmacol. 104 183. PMID:1664762. Doggrell et al (1992) Further analysis of the inhibitory effects of dihydroergotamine, cyproheptadine and ketanserin on the responses of the rat aorta to 5-hydroxytryptamine. J.Auton.Pharmacol. 12 223. PMID:1512277. Villalon et al (1992) Effects of S9977 and dihydroergotamine in an animal experimental model for migraine. Pharmacol.Res. 25 125. PMID:1635891. Lesage et al (1998) Agonistic properties of alniditan, sumatriptan and dihydroergotamine on human 5-HT1B and 5-HT1D receptors expressed in various mammalian cell lines. Br.J.Pharmacol. 123 1655. PMID:9605573."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1297	SQ1533			Nov-1994
0476	"2,4-Diamino-6-hydroxypyrimidine"	[56-06-4]	NC1=NC(N)=NC(O)=C1	Inhibits tetrahydrobiopterin synthesis and thus NOS activity	GTP cyclohydrolase I (GCH1) inhibitor. Prevents the de novo synthesis of tetrahydrobiopterin (BH4) and thus suppresses the activity of NO synthase. Exhibits more potent inhibition of GCH1 in the presence of GFRP (GTP cyclohydrolase feedback-regulatory protein).	"Werner-Felmayer et al (1993) Pteridine biosynthesis in human endothelial cells. Impact of NO-mediated formation of cyclic GMP. J.Biol.Chem. 268 1842. PMID:7678411. Moore and Handy (1997) Selective inhibitors of neuronal nitric oxide synthase - is no NOS really good NOS for the nervous system? TiPs 18 204. PMID:9226999. Xie et al (1998) GTP cyclohydrolase I inhibition by the prototypic inhibitor 2,4-diamino-6-hydroxypyrimidine. J.Biol.Chem. 273 21091. PMID:9694862."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1276	SQ1533			Sep-1994
0477	()-Decanoylcarnitine chloride	[14919-36-9]	O=C(CCCCCCCCC)OC(CC(O)=O)C[N+](C)(C)C.[Cl-]	Intermediate in lipid metabolism	Homolog of acetylcarnitine chloride (Cat. No. 0355).	Chalmers et al (1984) Urinary excretion of l-carnitine and acylcarnitines by patients with disorders of organic acid metabolism: evidence for secondary insufficiency of l-carnitine. Pediatr.Res. 18 1325. PMID:6441143. Coates and Tanaka (1992) Molecular basis of mitochondrial fatty acid oxidation defects. J.Lipid.Res. 33 1099. PMID:1431593. Poorthuis et al (1993) Determination of acylcarnitines in urine of patients with inborn errors of metabolism using HPLC after derivatization with 4'-bromophenacyl bromide. Clin.Chim.Acta 216 53. PMID:8222273.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1270				Oct-1994
0478	Flurofamide	[70788-28-2]	NP(N)(=O)NC(=O)C1=CC=C(F)C=C1	Urease inhibitor	Urease inhibitor.	Millner et al (1982) Flurofamide: a potent inhibitor of bacterial urease with potential clinical utility in the treatment of infection induced urinary stones. J.Urol. 127 346. PMID:7038144.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1371	SQ1533			Nov-1994
0479	Malonoben	[10537-47-0]	OC1=C(C(C)(C)C)C=C(\C=C(C#N)/[N+]#[C-])C=C1C(C)(C)C	Oxidative phosphorylation uncoupler	Potent uncoupler of oxidative phosphorylation.	"Muraoka and Terada (1972) 3,5-Di-tert-butyl-4-hydroxybenzylidemalonitrile: a new powerful uncoupler of respiratory-chain phosphorylation. Biochim.Biophys.Acta 275 271. PMID:4263281. Terada et al (1975) Some biochemical and physiochemical properties of the potent uncoupler SF 6847 hydroxybenzylidemalonitrile. Biochim.Biophys.Acta 387 519. PMID:237542. Terada et al (1981) The interaction of highly active uncouplers with mitochondria. Biochim.Biophys.Acta 639 225. PMID:7039674."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1558				Nov-1994
0481	Dilazep dihydrochloride	[20153-98-4]	Cl.Cl.COC1=CC(=CC(OC)=C1OC)C(=O)OCCCN1CCCN(CCCOC(=O)C2=CC(OC)=C(OC)C(OC)=C2)CC1	Adenosine uptake inhibitor	"Coronary and cerebral vasodilator, suppresses the effects of ischemia. Inhibitor of platelet aggregation and of membrane transport of nucleosides. Inhibits adenosine uptake."	Zhang et al (1991) Dilazep potentation of adenosine-mediated superior mesenteric arterial vasodilation. J.Pharmacol.Exp.Ther. 258 767. PMID:1890619. Kawagoe et al (1992) Effect of dilazep dihydrochloride against ischemia and reperfusion-induced disruption of blood-brain barrier in rats: a quantitative study. Naunyn Schmiedebergs Arch.Pharmacol. 345 485. PMID:1620248.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1314	SQ1533			Oct-1994
0482	4-DAMP	[1952-15-4]	[I-].C[N+]1(C)CCC(CC1)OC(=O)C(C1=CC=CC=C1)C1=CC=CC=C1	Muscarinic M3 antagonist	Antagonist at the M3 cholinergic receptor. [3H]-4-DAMP selectively labels M1 and M3 receptors.	Barlow and Shepherd (1986) A further search for selective antagonists at M2- muscarinic receptors. Br.J.Pharmacol. 89 837. PMID:3814912. Michel et al (1989) Direct labelling of rat M3-muscarinic receptors by [3H]4-DAMP. Eur.J.Pharmacol. 166 459. PMID:2806372.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1260				Nov-1994
0483	OR-486	[7659-29-2]	OC1=CC(=CC(=C1O)[N+]([O-])=O)[N+]([O-])=O	Catechol O-methyltransferase inhibitor	Potent and selective inhibitor of catechol-O-methyl-transferase.	Borgulya et al (1989) Catechol-O-methyltransferase-inhibiting pyrocatechol derivatives: synthesis and structure-activity studies. Helv.Chim.Acta 72 952. Mannisto and Kaakola (1990) Rationale for selective COMT inhibitors as adjuncts in the drug treatment of Parkinson's disease. Pharmacol.Toxicol. 66 317. PMID:2196554.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1325				Nov-1994
0485	Alrestatin	[51411-04-2]	OC(=O)CN1C(=O)C2=CC=CC3=CC=CC(C1=O)=C23	Aldose reductase inhibitor	Specific inhibitor of aldose reductase (IC50 = 148 _M). Attenuates glucose-induced angiotensin II production in rat vascular smooth muscle in vitro.	Ehrig et al (1994) Mechanism of aldose reductase inhibition: binding of NADP+/NADPH and alrestatin-like inhibitors. Biochemistry 33 7157. PMID:8003482. Barski et al (1996) The C-terminal loop of aldehyde reductase determines the substrate and inhibitor specificity. Biochemistry 35 14276. PMID:8916913. Lavrentyev et al (2007) Mechanism of high glucose-induced angiotensin II production in rat vascular smooth muscle cells. Circ.Res. 101 455. PMID:17626897.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1057	SQ1533			Nov-1994
0486	"1,3-Dipropyl-8-phenylxanthine"	[85872-53-3]	CCCN1C2=C(N=C(N2)C2=CC=CC=C2)C(=O)N(CCC)C1=O	A1 selective antagonist	Selective A1 adenosine antagonist.	"Dal (1985) 1,3-Dialkyl-8-(p-sulfophenyl)xanthines: potent water-soluble antagonists for A1 and A2 adenosine receptors. J.Med Chem. 28 487. PMID:2984420."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1334				Sep-1994
0493	AG 18	[118409-57-7]	OC1=C(O)C=C(\C=C(/C#N)C#N)C=C1	EGFR/PDGFR-kinase inhibitor	Inhibitor of epidermal growth factor receptor (EGFR) and platelet-derived growth factor receptor (PDGFR) kinase (IC50 values are 35 and 25 _M respectively). Inhibits EGF-stimulated cell proliferation. Also acts as a mitochondrial uncoupler that alters phosphorylation-dependent cell signaling.	Gazit et al (1988) Blocking of EGF-dependent cell proliferation by EGF receptor kinase inhibitors. Science 242 933. PMID:3263702. Gazit et al (1989) Tyrphostins inhibit epidermal growth factor (EGF)-receptor tyrosine kinase activity in living cells and EGF-stimulated cell proliferation. J.Biol.Chem. 264 14503. PMID:2788167. Gazit et al (1989) Tyrphostins I: synthesis and biological activity of protein tyrosine kinase inhibitors. J.Med.Chem. 32 2344. PMID:2552117. Levitzki and Gazit (1995) Tyrosine kinase inhibition: an approach to drug development. Science 267 1782. PMID:7892601. Soltoff (2004) Evidence that tyrphostins AG10 and AG18 are mitochondrial uncouplers that alter phosphorylation-dependent cell signaling. J.Biol.Chem. 279 10910. PMID:14688271.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1935	SQ1533			Nov-1994
0495	()-U-50488 hydrochloride	[67197-96-0]	O=C(CC3=CC(Cl)=C(Cl)C=C3)N([C@H]1[C@H](N2CCCC2)CCCC1)C.O=C(CC6=CC(Cl)=C(Cl)C=C6)N([C@@H]4[C@@H](N5CCCC5)CCCC4)C.Cl.Cl	Standard selective _ agonist	Selective _-opioid agonist. At higher concentrations blocks Na+ channels. Separate isomers (+)-U-50488 and (-)-U-50488 also available (Cat. Nos. 0471 and 0496 respectively).	"Pugsley et al (1992) Cardiovascular actions of the _-agonist, U-50-488H, in the absence and presence of opioid receptor blockade. Br.J.Pharmacol. 105 521. PMID:1320979. Suarez-Roca and Maixner (1993) Activation of kappa opioid receptors by U-50488H and morphine enhances the release of substance P from rat trigeminal nucleus slices. J.Pharmacol.Exp.Ther. 264 648. PMID:7679733. Pao-Luh Tao et al (1994) U-50,488 blocks the development of morphine tolerance and dependence at a very low dose in guinea pigs. Eur.J.Pharmacol. 256 281. PMID:8045272. Su et al (1998) Blockade of the development of morphine tolerance by U-50,488, an AVP antagonist or MK 801 in the rat hippocampal slice. Br.J.Pharmacol. 123 625. PMID:9517380."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1949				Nov-1994
0496	(-)-U-50488 hydrochloride	[114528-79-9]	O=C(CC3=CC(Cl)=C(Cl)C=C3)N([C@@H]1[C@@H](N2CCCC2)CCCC1)C.Cl	Standard selective _ agonist. More active enantiomer of ()-U-50488 (Cat. No. 0495)	More active enantiomer of ()-U-50488 (Cat. No. 0495). (+)-U-50488 hydrochloride (Cat. No. 0471) also available.	"De Costa et al (1987) Synthesis and absolute configuration of optically pure enantiomers of a _-opioid receptor selective antagonist. FEBS Lett. 223 335. PMID:2822490. Morrone et al (1993) Withdrawal contractures of guinea-pig isolated ileum after acute activation of _ opioid receptors. Br.J.Pharmacol. 109 48. PMID:8388301. Reddy and Bhargava (1993) Effect of chronic administration of U-50,488H, a kappa opioid receptor agonist on central dopamine (D2) receptors of the rat. Eur.J.Pharmacol. 235 23. PMID:8390939. Zhu et al (1998) Agonist-induced desensitization and down-regulation of the human kappa opioid receptor expressed in chinese hamster ovary cells. J.Pharmacol.Exp.Ther. 285 28. PMID:9535991."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1955				Sep-1995
0497	AG 99	[122520-85-8]	NC(=O)C(=C\C1=CC(O)=C(O)C=C1)\C#N	EGFR-kinase inhibitor	Epidermal growth factor receptor (EGFR) kinase inhibitor (IC50 = 10 _M) that is selective over insulin receptor kinase. Blocks tyrosine phosphorylation of p145met and promotes cell death of normal and cancer cells via activation of caspase-like proteases in vitro.	Gazit et al (1989) Tyrphostins. I. Synthesis and biological activity of protein tyrosine kinase inhibitors. J.Med.Chem. 32 2344. PMID:2552117. Levitzki and Gilon (1991) Tyrphostins as molecular tools and potential antiproliferative drugs. TiPS 12 171. PMID:1862529. Gazit (1996) Tyrphostins. 6. Dimeric benzylidenemalononitrile tyrphostins: potent inhibitors of EGF receptor tyrosine kinase in vitro. J.Med.Chem. 39 4905. PMID:8960549. Yamamoto et al (2006) Tyrosine phosphorylation of p145met mediated by EGFR and Src is required for serum-independent survival of human bladder carcinoma cells. J.Cell Sci. 119 4623. PMID:17062641.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1936				Nov-1994
0498	U-54494A hydrochloride	[112465-94-8]	O=C(C3=CC(Cl)=C(Cl)C=C3)N([C@H]1[C@@H](N2CCCC2)CCCC1)C	_ agonist	_-opioid agonist and anticonvulsant. Perhaps acts as an NMDA antagonist.	"Voigtlander et al (1987) U-54494A: a unique anticonvulsant related to kappa opioid agonists. J.Pharmacol.Exp.Ther. 243 542. PMID:2824750. Proietti et al (1991) In vitro depressant effects of U-54494A, an anticonvulsant related to kappa opioids in the hippocampus. Neuropharmacology 30 637. PMID:1656303. Sethy and Sage (1992) Modulation of release of acetylcholine from the striatum by a proposed excitatory amino acid antagonist U-54494A: comparison with known antagonists, diazepam and phenytoin. Neuropharmacology 31 111. PMID:1348110."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1956	SQ1070			Nov-1994
0500	"N1,N12-Diethylspermine tetrahydrochloride"	[113812-15-0]	CCNCCCNCCCCNCCCNCC.Cl.Cl.Cl.Cl	Polyamine synthase inhibitor	Powerful antineoplastic agent in cultured cells and animal tumors (IC50 = 0.2 _M in L1210 cells). Inhibitor of polyamine synthases. Suppressor of mitochondrial DNA synthesis.	"Bergeron et al (1988) Synthetic polyamine analogues as antineoplastics. J.Med.Chem. 31 1183. PMID:3373487. Porter et al (1990) Combined regulation of arginine and S-adenosylmethionine decarboxylases by spermine and the spermine analogue N1,N12-bis(ethyl)spermine. Biochem.J. 268 207. PMID:2344358. Vertino et al (1991) Selective cellular depletion of mitochondrial DNA by the polyamine analog N1,N12-bis(ethyl)spermine and its relationship to polyamine structure and function. Mol.Pharmacol. 39 487. PMID:2017149. Bergeron et al (2005) Synthesis and bioloigcal evaluation of aminopolyamines. J.Med.Chem. 48 3099. PMID:15857111."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1290				Nov-1994
0504	Diphenyleneiodonium chloride	[4673-26-1]	[Cl-].c1c2c3ccccc3[i+]c2ccc1	GPR3 agonist; also inhibits NOS and NADPH oxidases	"GPR3 agonist (EC50 = 1 _M); activates adenylate cyclase through GPR3 but not GPR6 or GPR12. Also induces Ca2+ mobilization and _-arrestin receptor internalization. Binds strongly to flavoproteins; inhibits several enzymes, including NO synthase, NADPH oxidases and NADPH cytochrome P450 oxidoreductase. Also inhibits platelet aggregation."	Yea et al (1990) Purification and some properties of the 45 kDa diphenylene iodonium-binding flavoprotein of neutrophil NADPH oxidase. Biochem.J. 265 95. PMID:2154184. Stuehr et al (1991) Inhibition of macrophage and endothelial cell nitric oxide synthase by diphenyleneiodonium and its analogs. FASEB J. 5 98. PMID:1703974. Wang et al (1993) Inhibitory actions of diphenyleneiodonium dependent vasodilations in vitro and in vivo. Br.J.Pharmacol. 110 1232. PMID:7507779. Tew (1993) Inhibition of cytochrome P450 reductase by the diphenyliodonium cation. Kinetic analysis and covalent modifications. Biochemistry 32 10209. PMID:8399148. Ye et al (2014) Identification of a novel small-molecule agonist for human G protein-coupled receptor 3. J.Pharmacol.Exp.Ther. 349 437. PMID:24633425.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1331				Sep-1994
0506	Dimaprit dihydrochloride	[23256-33-9]	CN(C)CCCSC(N)=N.Cl.Cl	Standard H2 selective agonist	Selective H2 agonist with central effects upon systemic administration. Also inhibits nNOS (IC50 = 49 _M).	"Durant et al (1977) Dimaprit-(S-[3-(N,N-dimethylamino)propyl]isothiourea) a highly specific histamine H2-receptor agonist. Part 2. Structure activity considerations. Agents Actions 7 39. PMID:860674. Parsons et al (1977) Dimaprit-(S-[3-(N,N-dimethylamino)propyl]isothiourea)-a highly specific histamine H2-receptor agonist. Part 1. Pharmacology. Agents Actions 7 31. PMID:871093. Paquay et al (1999) Nitric oxide synthase inhibition by dimaprit and dimaprit analogues. Br.J.Pharmacol. 127 331. PMID:10385230. Farzin and Attarzadeh (2000) Influence of different histamine receptor agonists and antagonists on apomorphine-induced licking behavior in rats. Eur.J.Pharmacol. 404 169. PMID:10980276."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1316				Nov-1994
0507	"Dantrolene, sodium salt"	[14663-23-1]	O=C([N-]3)N(CC3=O)/N=C/C1=CC=C(C2=CC=C([N+]([O-])=O)C=C2)O1.[Na+]	Ca2+ release inhibitor	"Inhibits release of Ca2+ from sarcoplasmic reticulum via inhibition of ryanodine receptor (RYR) channels. Displays selectivity for RYR1 and RYR3 over RYR2. Protective against the effects of a variety of conditions and agents, including excitatory amino acids. Skeletal muscle relaxant and neuroprotectant."	Merck Index 12 2879. Hotchkiss and Karl (1994) Dantrolene ameliorates the metabolic hallmarks of sepsis in rats and improves survival in a mouse model of endotoxemia. Proc.Natl.Acad.Sci.U.S.A. 91 3039. PMID:8159702. O'Mara et al (1995) Dantrolene inhibits long-term depression and depotentiation of synaptic transmission in the rat dentate gyrus. Neuroscience 68 621. PMID:8577362. Zhao et al (2001) Dantrolene inhibition of ryanodine receptor Ca2+ release channels. J.Biol.Chem. 276 13810. PMID:11278295.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1267	SQ1533			Nov-1994
0508	Doxepin hydrochloride	[1229-29-4]	Cl[H].CN(C)CC\C=C1\C2=C(COC3=C1C=CC=C3)C=CC=C2	Highly potent H1 antagonist. Also binds to H4 receptor	Highly potent H1 histamine receptor antagonist (Kd = 310 pM) and tricyclic antidepressant. Also binds to the H4 histamine receptor (pKi = 6.79).	Merck Index 12 3492. Tran et al (1981) [3H]Doxepin interactions with histamine H1-receptors and other sites in guinea pig brain homogenates. Eur.J.Pharmacol. 70 501. PMID:7238574. Lurchins (1983) Review of clinical and animal studies comparing the cardiovascular effects of doxepin and other tricyclic antidepressants. Am.J.Psychiatry 140 1006. PMID:6346907. Nguyen et al (2001) Discovery of a novel member of the histamine receptor family. Mol.Pharmacol. 59 427. PMID:11179435.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1348	SQ1533			Nov-1994
0511	BD 1008 dihydrobromide	[138356-09-9]	Br.Br.CN(CCN1CCCC1)CCC1=CC=C(Cl)C(Cl)=C1	"Potent, selective _ ligand"	Potent and selective _-ligand (Ki against [3H]-(+)-3-PPP = 0.34 nM).	"De Costa et al (1992) Synthesis, characterization, and biological evaluation of a novel class of N-(arylethyl)-N-alkyl-2-(1-pyrrolidinyl)ethylamines - structural requirements and binding affinity at the _ receptor. J.Med.Chem. 35 38. PMID:1310114. Monnet et al (1996) Differentiation of _ ligand-activated receptor subtypes that modulate NMDA-evoked [3H]-noradrenaline release in rat hippocampal slices. Br.J.Pharmacol. 119 65. PMID:8872358. Whittemore et al (1997) Antagonism of N-methyl-D-aspartate receptors by _ site ligands: potency, subtype-selectivity and mechanisms of inhibition. J.Pharmacol.Exp.Ther. 282 326. PMID:9223571."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1286				Oct-1994
0512	SKF 91488 dihydrochloride	[68941-21-9]	CN(CCCCSC(=N)N)C.Cl.Cl	Histamine N-methyltransferase inhibitor	Homolog of dimaprit (Cat. No. 0506); strong inhibitor of histamine N-methyltransferase. Exhibits no histamine agonist activity.	"Beaven and Shaff (1979) New inhibitors of histamine N-methyl-transferase. Biochem.Pharmacol. 28 183. PMID:34400. Beaven and Shaff (1979) Inhibition of histamine methylation in vivo by the dimaprit analog SKF compound 91488. Agents Actions 9 455. PMID:161853. Ohuri et al (1992) Histamine N-methyl transferase controls the contractile response of guinea pig trachea to histamine. J.Pharmacol.Exp.Ther. 261 1268. PMID:1534842. Aiello et al (1997) Effects of two histamine-N-methyltransferase inhibitors, SKF 91488 and BW 301U, in rodent antinociception. Naunyn Schmiedebergs Arch.Pharmacol. 355 354. PMID:9089666."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1865				Nov-1994
0513	GBR 12783 dihydrochloride	[67469-75-4]	Cl[H].Cl[H].C(CN1CCN(C\C=C\C2=CC=CC=C2)CC1)OC(C1=CC=CC=C1)C1=CC=CC=C1	"Potent, selective dopamine uptake inhibitor"	A very potent and selective inhibitor of dopamine uptake (IC50 for inhibition of [3H]-dopamine uptake in rat striatal synaptosomes is 1.8 nM).	"Bonnet and Constentin (1986) GBR 12783, a potent and selective inhibitor of dopamine uptake: biochemical studies in vivo and ex vivo. Eur.J.Pharmacol. 121 199. PMID:3754516. Giros et al (1992) Cloning, pharmacological characterization and chromosome assignment of the human dopamine transporter. Mol.Pharmacol. 42 383. PMID:1406597. Vaugeois et al (1992) In vivo labelling of the neuronal dopamine uptake complex in the mouse striatum by [3H]GBR 12783. Eur.J.Pharmacol. 210 77. PMID:1350989. Do-Rego et al (1999) Evidence for the sequential formation of two complexes between an uptake inhibitor, GBR 12783 [1-[2-(diphenylmethoxy)ethyl]-4-(3-phenyl-2-propenyl)piperazine], and the neuronal transporter of dopamine. J.Neurochem. 72 396. PMID:9886093."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1410				Oct-1994
0514	GBR 12935 dihydrochloride	[67469-81-2]	Cl.Cl.C(CN1CCN(CCOC(C2=CC=CC=C2)C2=CC=CC=C2)CC1)CC1=CC=CC=C1	Selective dopamine uptake inhibitor	Potent and selective inhibitor of dopamine uptake (KD = 5.5 nM in rat striatal membranes).	"Andersen et al (1987) Biochemical and pharmacological characterization of [3H]GBR 12935 binding in vitro to rat striatal membranes: labelling of the dopamine uptake complex. J.Neurochem. 48 1887. PMID:2952763. Reith et al (1992) Evidence for mutually exclusive binding of cocaine, BTCP, GBR 12935, and dopamine to the dopamine transporter. Eur.J.Pharmacol. 227 417. PMID:1446712. Reith et al (1994) GBR 12909 and 12935 block dopamine uptake into brain synaptic vesicles as well as nerve endings. Eur.J.Pharmacol. 253 175. PMID:8013544."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1416	SQ1533			Sep-1994
0515	Dobutamine hydrochloride	[49745-95-1]	Cl.CC(CCC1=CC=C(O)C=C1)NCCC1=CC=C(O)C(O)=C1	"_1, _1 and _2 agonist"	_1- and _2-adrenoceptor agonist with some action at the _1-adrenoceptor.	"Merck Index 12 3456. Brown et al (1987) Dobutamine: positive inotropy by nonselective adrenoceptor agonism in isolated guinea pig and human myocardium. Naunyn Schmiedebergs Arch.Pharmacol. 335 385. PMID:3600817. Deighton et al (1992) Characterization of the beta adrenoceptor subtype(s) mediating the positive inotropic effects of epinine, dopamine, dobutamine, denopamine and xamoterol in isolated human right atrium. J.Pharmacol.Exp.Ther. 262 532. PMID:1354251."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1338	SQ1533			Sep-1994
0518	EBPC	[4450-98-0]	CCOC(=O)C1=C(O)C(=O)N(CC2=CC=CC=C2)C1	Aldose reductase inhibitor	Potent aldose reductase inhibitor. Improves the cytotoxicity of anticancer reagents such as cisplatin (Cat.No. 2251) and doxorubicin (Cat.No. 2252) in HeLa cervical carcinoma cells through an increase in ERK activity.	"Mylari et al (1991) A highly specific aldose reductase inhibitor, ethyl 1-benzyl-3-hydroxy-2(5H)-oxopyrrole-4-carboxylate and its congeners. J.Med.Chem. 34 1011. PMID:1900532. Kyoung et al (2002) Inhibition of aldose reductase enhances HeLa cell sensitivity to chemotherapeutic drugs and involves activation of extracellular signal-regulated kinases. Anti-cancer Drugs 13 859. PMID:12394272."	Small Molecule	Sold for research purposes under agreement from Pfizer Inc.	http://www.tocris.com/dispprod.php?ItemId=1375	SQ1533			Nov-1994
0522	Flunarizine dihydrochloride	[30484-77-6]	Cl[H].Cl[H].FC1=CC=C(C=C1)C(N1CCN(C\C=C\C2=CC=CC=C2)CC1)C1=CC=C(F)C=C1	Dual Na+/Ca2+ channel (T-type) blocker	Dual Na+/Ca2+ channel blocker; a cerebral and peripheral vasodilator. Neuroprotective.	Pauwels et al (1991) Ca+ and Na+ channels involved in neuronal cell death - protection by flunarizine. Life.Sci. 48 1881. PMID:1850815. Eichler et al (1994) The ability of diphenylpiperazines to prevent neuronal death in dorsal root ganglion neurons in vitro after axotomy. J.Neurochem. 62 2148. PMID:8189223. Urenjak and Obrenovitch (1996) Pharmacological modulation of voltage gated Na+ channels: a rational and effective strategy against ischemic brain damage. Pharmacol.Rev. 48 21. PMID:8685246.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1392	SQ1533			Nov-1994
0523	4F 4PP oxalate	[144734-36-1]	OC(=O)C(O)=O.FC1=CC=C(C=C1)C(=O)C1CCN(CCCCC2=CC=CC=C2)CC1	Selective 5-HT2A antagonist	A selective 5-HT2A antagonist with almost as high affinity (Ki = 5.3 nM) as ketanserin but with a much lower affinity for 5-HT2C sites (Ki = 620 nM).	Herndon et al (1992) Ketanserin analogues - structure affinity relationships of 5HT2 and 5HT1C serotonin receptor binding. J.Med.Chem. 35 4903. PMID:1479590. Hagberg et al (1998) Stimulation of 5-HT2A receptors on astrocytes in primary culture opens voltage-independent Ca2+ channels. Neurochem.Int. 32 153. PMID:9542727.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1393				Sep-1994
0524	AMI-193	[510-74-7]	FC(C=C4)=CC=C4OCCCN1CCC2(N(C3=CC=CC=C3)CNC2=O)CC1	D2-like receptor antagonist	"Selective 5-HT antagonist, which binds to 5-HT2 sites as potently as spiperone but has lower affinity for 5-HT2C receptors. Also a high affinity D2 receptor antagonist (Ki = 3 nM). Lacks the disruptive effect of spiperone on animal behavior."	"Ismaiel et al (1993) Antagonism of 1-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane stimulus with a newly identified 5HT2 versus 5HT1C selective antagonist. J.Med.Chem. 36 2519. PMID:8355253. Czoty et al (2000) Behavioural effects of AMI-193, a 5-HT2A- and dopamine D2-receptor antagonist, in the squirrel monkey. Pharmacol.Biochem.Behav. 67 257. PMID:11124389."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1400	SQ1533			May-1999
0526	()-Hexanoylcarnitine chloride	[6920-35-0]	O=C(CCCCC)OC(CC(O)=O)C[N+](C)(C)C.[Cl-]	Intermediate in lipid metabolism	Homolog of acetylcarnitine chloride (Cat. No. 0355).	Chalmers et al (1984) Urinary excretion of l-carnitine and acylcarnitines by patients with disorders of organic acid metabolism: evidence for secondary insufficiency of l-carnitine. Pediatr.Res. 18 1325. PMID:6441143. Coates and Tanaka (1992) Molecular basis of mitochondrial fatty acid oxidation defects. J.Lipid.Res. 33 1099. PMID:1431593. Poorthuis et al (1993) Determination of acylcarnitines in urine of patients with inborn errors of metabolism using HPLC after derivatization with 4'-bromophenacyl bromide. Clin.Chim.Acta 216 53. PMID:8222273.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1447				Oct-1994
0529	8-Hydroxy-DPAT hydrobromide	[76135-31-4]	Br.CCCN(CCC)C1CCC2=CC=CC(O)=C2C1	Selective 5-HT1A agonist; also has moderate affinity for 5-HT7	The standard selective 5-HT1A agonist. Also has moderate affinity for 5-HT7 receptors (pKi is 6.6 at the human 5-HT7 receptor expressed in HEK 293 cells). Reduces hippocampal 5-HT levels following systemic administration in rats in vivo. (R)-(+)-8-Hydroxy-DPAT hydrobromide (Cat. No. 1080) and 7-Hydroxy-DPAT hydrobromide (Cat. No. 0706) also available.	"Middlemiss et al (1983) 8-OH-DPAT discriminates between subtypes of the 5HT1 recognition site. Eur.J.Pharmacol. 90 151. PMID:6223827. Helton and Colbert (1994) Alteration of in-vitro 5-HT receptor pharmacology as a function of multiple treatment with 5-hydroxytryptamine of 8-hydroxy-2-(di-N-propylamino)tetralin in rat isolated aorta, uterus and fundus, and guinea pig isolated trachea. J.Pharm.Pharmacol. 46 902. PMID:7897596. Wood et al (2000) Antagonist activity of meta-chlorophenylpiperazine and partial agonist activity of 8-OH-DPAT at the 5-HT7 receptor. Eur.J.Pharmacol. 396 1. PMID:10822046. Yoshitake and Kehr (2004) Differential effects of (R)-, (R, S)- and (S)-8-hydroxy-2-(di-n-propylamino)tetralin on hippocampal serotonin release and induction of hypothermia in awake rats. Life Sci. 74 2865. PMID:15050424."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1468				Oct-1998
0532	W-84 dibromide	[21093-51-6]	O=C1N(CCC[N+](C)(C)CCCCCC[N+](C)(C)CCCN(C(C4=C3C=CC=C4)=O)C3=O)C(C2=C1C=CC=C2)=O.[Br-].[Br-]	Stabilizer of cholinergic antagonist-receptor complexes	Stabilizes cholinergic antagonist-receptor complexes by an allosteric effect. Increases the protective effect of atropine against organophosphate poisoning.	"Mitchelson (1975) Antimuscarinic action of an alkane-bis ammonium compound alone and in combination with (+)-bensetimide. Eur.J.Pharmacol. 33 237. PMID:1242377. Jepsen et al (1988) Allosteric stabilisation of [3H]-N-methylscopolamine binding in guinea pig myocardium by an antidote against organophosphate intoxication. Pharmacol.Toxicol. 63 163. PMID:3054859. Mohr et al (1992) Equipotent allosteric effect of W84 on [3H]-NMS binding to cardiac muscarinic receptors from guinea-pig, rat and pig. Pharmacol.Toxicol. 70 198. PMID:1579545."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1967				Oct-1994
0535	HEAT hydrochloride	[30007-39-7]	Cl.OC1=CC=C(CCNCC2CCC3=CC=CC=C3C2=O)C=C1	Highly selective _1 antagonist	"Very selective _1-adrenoceptor antagonist, precursor of the 3-[125I]-derivative."	"Baumgarten et al (1972) Mechanisms of pressor effect of 5,6-dihydroxytryptamine in pithed rats. Naunyn Schmiedebergs Arch.Pharmacol. 274 375. PMID:4404780. Williams et al (1978) Interaction of 2-[_-(4-hydroxyphenyl)ethylaminomethyl]tetralone (BE 2254: 'HEAT') with catecholamine receptors in rat brain membranes. J.Pharm.Pharmacol. 30 390. PMID:26778."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1441				Oct-1994
0537	MR 16728 hydrochloride	[207403-36-9]	Cl.O=C(NCCCN1CCCCCC1)C(C1CCCCC1)C1=CC=CC=C1	Stimulates ACh release	This analog of cetiedil stimulates the release of acetylcholine from synaptosomes.	"Moulian et al (1993) The effect of MR 16728, a cetiedil analogue, on acetylcholine release in torpedo synaptosomes. Eur.J.Pharmacol. 231 407. PMID:8449232."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1446				Oct-1994
0538	trans-4-Hydroxycrotonic acid	[24587-49-3]	OC\C=C\C(O)=O	GHB receptor ligand	Binds to the _-hydroxybutyric acid (GHB) receptor with higher affinity than GHB itself.  May be an endogenous ligand.	Vayer et al (1985) Natural occurrence of trans-gamma hydroxycrotonic acid in rat brain. Biochem.Pharmacol. 34 2401. PMID:4015683. Bourguignon et al (1988) Analogues of _-hydroxybutyric acid. Synthesis and binding studies. J.Med.Chem. 31 893. PMID:3361576. Hechler et al (1993) Gamma hydroxybutyrate ligands posses antidopaminergic and neuroleptic-like activities. J.Pharmacol.Exp.Ther. 264 1406. PMID:8095552.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1465				Nov-1994
0541	Fasudil hydrochloride	[105628-07-7]	Cl.O=S(=O)(N1CCCNCC1)C1=C2C=CN=CC2=CC=C1	Inhibitor of cyclic nucleotide dependent- and Rho-kinases	Cyclic nucleotide-dependent protein kinase inhibitor and Rho-associated kinase inhibitor (IC50 = 10.7 _M). Ca2+ antagonist and vasodilator. Also inhibits proliferation of vascular smooth muscle cells.	"Shirotani et al (1991) A new type of vasodilator, HA1077, an isoquinoline derivative, inhibits proliferation of bovine vascular smooth muscle cells in culture. J.Pharmacol.Exp.Ther. 259 738. PMID:1941621. Arai et al (1993) Inhibition by the protein kinase inhibitor HA-1077 of the activation of NADPH oxidase in human neutrophils. Biochem.Pharmacol. 46 1487. PMID:8240400. Satoh et al (1996) Neuroprotective properties of a protein kinase inhibitor against ischaemia-induced neuronal damage in rats and gerbils. Br.J.Pharmacol. 118 1592. PMID:8842419. Sward et al (2000) Inhibition of Rho-associated kinase blocks agonist-induced Ca2+ sensitization of myosin phosphorylation and force in guinea-pig ileum. J.Physiol. 522 33. PMID:10618150."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1439	SQ1533			Nov-1994
0542	H-7 dihydrochloride	[108930-17-2]	Cl.Cl.CC1CNCCN1S(=O)(=O)C1=CC=CC2=CN=CC=C12	Protein kinase inhibitor	"Protein kinase inhibitor. IC50 values for inhibition of PKC, PKG, PKA and myosin light chain kinase are 6.0, 5.8, 3.0 and 97.0 _M respectively."	"Hidaka et al (1984) Isoquinolinesulfonamides, novel and potent inhibitors of cyclic nucleotide dependent protein kinase and protein kinase C. Biochemistry 23 5036. PMID:6238627. Ratz et al (1990) Effect of the kinase inhibitor, H-7, on stress, crossbridge phosphorylation, muscle shortening and inositol phosphate production in rabbit arteries. J.Pharmacol.Exp.Ther. 252 253. PMID:2299593. Quick et al (1992) The structure and biological activities of the widely used protein kinase inhibitor, H7, differ depending on the commercial source. Biochem.Biophys.Res.Commun. 187 657. PMID:1530632."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1434	SQ1070			Jul-1998
0543	C-1	[84468-24-6]	O=S(=O)(N1CCNCC1)C1=C2C=CN=CC2=CC=C1	Protein kinase C inhibitor	Inhibitor of protein kinase C. Vasodilator.	Gerard et al (1986) Role of protein kinases in stimulation of human polymorphonuclear leukocyte oxidation metabolism by various agonists. J.Clin.Invest. 77 61. PMID:3003155.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=2087				Nov-1994
0544	IPAG	[193527-91-2]	IC1=CC=C(NC(=N)NC2C3CC4CC(C3)CC2C4)C=C1	Potent _ antagonist	Potent _-receptor antagonist.	"Wilson et al (1991) Radiosynthesis of _ receptor ligands for positron emission tomography: 11C- and 18F-labelled guanidines. J.Med.Chem. 34 1867. PMID:1648140. Whittemore et al (1997) Antagonism of N-methyl-D-aspartate receptors by _ site ligands: potency, subtype-selectivity and mechanisms of inhibition. J.Pharmacol.Exp.Ther. 282 326. PMID:9223571."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1525				Oct-1994
0545	Ifenprodil hemitartrate	[23210-56-2]	OC(C=C3)=CC=C3[C@@H](O)[C@H](C)N2CCC(CC2)CC1=CC=CC=C1.OC(C=C6)=CC=C6[C@@H](O)[C@H](C)N5CCC(CC5)CC4=CC=CC=C4.O=C(O)C(O)C(O)C(O)=O.OC(C=C9)=CC=C9[C@H](O)[C@@H](C)N8CCC(CC8)CC7=CC=CC=C7.OC(C=C%12)=CC=C%12[C@H](O)[C@@H](C)N%11CCC(CC%11)CC%10=CC=CC=C%10.O=C(O)C(O)C(O)C(O)=O	Non-competitive NMDA antagonist. Also _ ligand	"NMDA receptor antagonist, acting at the polyamine site. Also an _-adrenergic vasodilator. _2 ligand displaying about 3-fold selectivity over _1 sites."	"Gotti et al (1988) Ifenprodil and SL-82,0715 as cerebral anti-ischemic agents. 1. Evidence for efficacy in models of focal cerebral ischemia. J.Pharmacol.Exp.Ther. 247 1211. PMID:2849668. Reynolds and Miller (1989) Ifenprodil is a novel type of N-methyl-D-aspartate receptor antagonist: interaction with polyamines. Mol.Pharmacol. 36 758. PMID:2555674. Schoemaker et al (1990) Polyamine-sensitive binding of [3H]ifenprodil, a novel NMDA antagonist to the rat cerebral cortex. Eur.J.Pharmacol. 176 249. PMID:2178949. Shalaby et al (1992) Neuroprotective effects of the N-methyl-D-aspartate receptor antagonists ifenprodil and SL-82,0715 on hippocampal cells in culture. J.Pharmacol.Exp.Ther. 260 925. PMID:1346650."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1514	SQ1533			Sep-1994
0546	L-NIO dihydrochloride	[159190-44-0]	N[C@H](C(O)=O)CCCNC(C)=N.Cl.Cl	NOS inhibitor	"Inhibitor of nitric oxide (NO) synthase. Inhibits iNOS, eNOS and nNOS. Active in vivo."	Rees et al (1990) Characterization of three inhibitors of endothelial nitric oxide synthase in vitro and in vivo. Br.J.Pharmacol. 101 746. PMID:1706208. Mulligan et al (1992) Protective effects of inhibitors of nitric oxide synthase in immune complex-induced vasculitis. Br.J.Pharmacol. 107 1159. PMID:1281719. Moncada et al (1997) XIV. International Union of Pharmacology nomenclature in nitric oxide research. Pharmacol.Rev. 49 137. PMID:9228663.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1517				Sep-1994
0548	()-Lauroylcarnitine chloride	[7023-03-2]	O=C(CCCCCCCCCCC)OC(CC(O)=O)C[N+](C)(C)C.[Cl-]	Intermediate in lipid metabolism	Homolog of acetylcarnitine chloride (Cat. No. 0355). Acylcarnitines are important intermediates in lipid metabolism.	Chalmers et al (1984) Urinary excretion of l-carnitine and acylcarnitines by patients with disorders of organic acid metabolism: evidence for secondary insufficiency of l-carnitine. Pediatr.Res. 18 1325. PMID:6441143. Coates and Tanaka (1992) Molecular basis of mitochondrial fatty acid oxidation defects. J.Lipid.Res. 33 1099. PMID:1431593. Poorthuis et al (1993) Determination of acylcarnitines in urine of patients with inborn errors of metabolism using HPLC after derivatization with 4'-bromophenacyl bromide. Clin.Chim.Acta 216 53. PMID:8222273.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1550				Oct-1994
0549	Methylergometrine maleate	[57432-61-8]	OC(=O)\C=C/C(O)=O.[H][C@](CC)(CO)NC(=O)[C@@]1([H])CN(C)[C@]2([H])CC3=CNC4=C3C(=CC=C4)C2=C1	Active metabolite of methysergide (Cat. No. 1064)	Active metabolite of methysergide (Cat. No. 1064); uterotonic agent and oxytocic.	"Merck Index 12 6147. Muller-Schweinitzer and Tapparelli (1986) Methylergometrine, an active metabolite of methysergide. Cephalalgia 6 35. PMID:3698092. MacLennan and Martin (1990) Actions of non-peptide ergot alkaloids at 5-HT1-like and 5-HT2 receptors mediating vascular smooth muscle contraction. Naunyn Schmiedebergs Arch.Pharmacol. 342 120. PMID:2234096. Pertz (1993) 5-Hydroxytryptamine (5-HT) contracts the guinea-pig isolated iliac artery via 5-HT1-like and 5-HT2 receptors. Naunyn Schmiedebergs Arch.Pharmacol. 348 558. PMID:8133899."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1619	SQ1533			Nov-1994
0552	MMPX	[78033-08-6]	COCC1=NC2=C(N1)N(CC(C)C)C(=O)N(C)C2=O	PDE1 inhibitor	Specific inhibitor of calmodulin-sensitive cyclic GMP phosphodiesterase (IC50 = 5.2 _M).	Wells and Mille (1988) Methylxanthine inhibitors of phosphodiesterases. Methods Enzymol. 159 489. PMID:2457788.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1591				Sep-1994
0553	NAN-190 hydrobromide	[115338-32-4]	Br.COC1=C(C=CC=C1)N1CCN(CCCCN2C(=O)C3=CC=CC=C3C2=O)CC1	5-HT1A antagonist	5-HT1A antagonist.	Glennon et al (1988) Arylpiperazine derivatives as high affinity 5-HT1A serotonin ligands. J.Med.Chem. 31 1968. PMID:3172131. Williams and Glennon (1988) NAN-190: an arylpiperazine analog that antagonizes the stimulus effects of the 5-HT1A agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT). Eur.J.Pharmacol. 154 339. PMID:2976673. Douris (1992) Effects of the putative 5-HT1A receptor antagonist NAN-190 on free feeding and on feeding induced by the 5-HT1A receptor agonist 8-OH-DPAT in the rat. Eur.J.Pharmacol. 219 105. PMID:1397037.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1682				Jul-1995
0554	FG 7142	[78538-74-6]	CNC(=O)C1=CC2=C(NC3=C2C=CC=C3)C=N1	Benzodiazepine inverse agonist	Inverse agonist and anxiogenic agent. Increases tyrosine hydroxylation and causes upregulation of _-adrenoceptors in mouse cerebral cortex.	Stanford et al (1987) A single dose of FG 7142 causes long term increases in mouse cortical _-adrenoceptors. Eur.J.Pharmacol. 134 313. PMID:3032657. Wettstei (1989) Behavioural studies with the _-carboline FG 7142 combined with related drugs in monkeys. Eur.J.Pharmacol. 163 219. PMID:2498110. Donner et al (1989) Evidence for an excitatory action of benzodiazepine receptor inverse agonist FG 7142 on C-fibre afferents. Naunyn Schmiedebergs Arch.Pharmacol. 340 352. PMID:2478895. Knorr et al (1989) The anxiogenic _-carboline FG-7142 increases in vivo and in vitro tyrosine hydroxylation in the prefrontal cortex. Brain Res. 495 355. PMID:2765936.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1599	SQ1070			Oct-1994
0556	BP 554 maleate	[1221401-95-1]	OC(=O)\C=C/C(O)=O.C(COC1=CC=C2OCOC2=C1)CN1CCN(CC1)C1=CC=CC=C1	Selective 5-HT1A agonist	Selective 5-HT1A agonist.	"Matsuda et al (1989) Agonist activity of a novel compound, 1-[3-(3,4-methylenedioxyphenoxy)propyl]-4-phenyl piperazine (BP-554) at central 5-HT1A receptors. Eur.J.Pharmacol. 170 75. PMID:2533078."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1618				Nov-1994
0557	_-Methyl-5-hydroxytryptamine maleate	[97469-12-0]	OC(=O)\C=C/C(O)=O.CC(N)CC1=CNC2=C1C=C(O)C=C2	5-HT2B agonist	"5-HT2B receptor selective agonist with pKi values of 8.4, 6.1 and 7.3 at 5-HT2B, 5-HT2A and 5-HT2C receptors respectively."	Richardson et al (1985) Identification of serotonin M-receptor sub-types and their specific blockade by a new class of drugs. Nature 316 126. PMID:3839291. Wilson et al (1990) 5-Hydroxytryptamine3 receptors mediate tachycardia in conscious instrumented dogs. J.Pharmacol.Exp.Ther. 252 683. PMID:1968974. Baxter et al (1995) 5-HT2 receptor subtypes: a family re-united? TiPS 16 105. PMID:7792930.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1638				Jun-1998
0558	2-Methyl-5-hydroxytryptamine hydrochloride	[845861-49-6]	Cl.CC1=C(CCN)C2=CC(O)=CC=C2N1	5-HT3 agonist/potent 5-HT6 ligand	5-HT3 agonist (Ki = 1200 nM) and potent 5-HT6 ligand (Ki = 46 nM).	Craig et al (1990) 5-Methoxytryptamine and 2-methyl-5-hydroxytryptamine-induced desensitization as a discriminative tool for the 5-HT3 and putative 5-HT4 receptors in guinea pig ileum. Naunyn Schmiedebergs Arch.Pharmacol. 342 9. PMID:2402303. Ismaiel et al (1990) 5-HT1 and 5-HT2 binding profiles of the serotonergic agents _-methyl serotonin and 2-methylserotonin. J.Med.Chem. 33 755. PMID:2299641. Wilson et al (1990) 5-Hydroxytryptamine3 receptors mediate tachycardia in conscious instrumented dogs. J.Pharmacol.Exp.Ther. 252 683. PMID:1968974. Glennon et al (2000) 2-substituted tryptamines: agents with selectivity for 5-HT6 serotonin receptors. J.Med.Chem. 43 1011. PMID:10715164.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1637				Sep-1994
0566	N-Methylquipazine dimaleate	[171205-17-7]	OC(=O)\C=C/C(O)=O.OC(=O)\C=C/C(O)=O.CN1CCN(CC1)C1=NC2=C(C=CC=C2)C=C1	5-HT3 agonist	"5-HT3 agonist. Has almost the same affinity for 5-HT3 sites as quipazine but unlike the latter, does not bind to 5-HT1B sites."	Glennon et al (1989) Binding of arylpiperazines to 5-HT3 serotonin receptors: results of a structure-affinity study. Eur.J.Pharmacol. 168 387. PMID:2583244.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1651				Dec-1994
0567	()-Myristoylcarnitine chloride	[14919-38-1]	O=C(CCCCCCCCCCCCC)OC(CC(O)=O)C[N+](C)(C)C.[Cl-]	Intermediate in lipid metabolism	Homolog of acetylcarnitine chloride (Cat. No. 0355). Acylcarnitines are important intermediates in lipid metabolism.	Chalmers et al (1984) Urinary excretion of l-carnitine and acylcarnitines by patients with disorders of organic acid metabolism: evidence for secondary insufficiency of l-carnitine. Pediatr.Res. 18 1325. PMID:6441143. Coates and Tanaka (1992) Molecular basis of mitochondrial fatty acid oxidation defects. J.Lipid.Res. 33 1099. PMID:1431593. Poorthuis et al (1993) Determination of acylcarnitines in urine of patients with inborn errors of metabolism using HPLC after derivatization with 4'-bromophenacyl bromide. Clin.Chim.Acta 216 53. PMID:8222273.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1672				Oct-1994
0568	Metaphit	[96316-00-6]	S=C=NC1=CC(=CC=C1)C1(CCCCC1)N1CCCCC1	Acylator of PCP and _ receptors	Acylator of PCP and _-receptors.	"Rafferty et al (1985) A specific acylating agent for the [3H]-phencyclidine receptors in rat brain. FEBS Lett. 181 318. PMID:2982662. Contreras et al (1986) Metaphit, an acylating ligand for phencyclidine receptors: characterization of in vivo actions in the rat. J.Pharmacol.Exp.Ther. 238 1101. PMID:3018219. Debler et al (1989) Metaphit, an isothiocyanate analog of PCP, induces audiogenic seizures in mice. Eur.J.Pharmacol. 165 155. PMID:2548879. Reith et al (1991) Effect of metaphit on dopaminergic neurotransmission in rat striatal slices: involvement of the dopamine transporter and voltage-dependent sodium channel. J.Pharmacol.Exp.Ther. 259 1188. PMID:1662274."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1577				Dec-1994
0569	(R)-(-)-_-Methylhistamine dihydrobromide	[868698-49-1]	N[C@H](C)CC1=CNC=N1.Br.Br	"Potent, standard H3 agonist"	"Very potent, high affinity H3 agonist (KD = 50.3 nM) that displays > 200-fold selectivity over H4 receptors. Inhibits H3-mediated histamine synthesis and release in the CNS and stimulates H4-mediated eosinophil shape change (EC50 = 66 nM). Part of the Histamine H3 Receptor Tocriset. (S)-(+)-_-Methylhistamine dihydrobromide (Cat. No. 0572) also available."	"Oishi et al (1989) Effects of histamine H3-agonist (R)-_-methylhistamine and the antagonist thioperamide on histamine modulation in the mouse and rat brain. J.Neurochem. 52 1388. PMID:2540269. Schwartz et al (1990) A third histamine receptor subtype - characterization, localization and functions of the H3-receptor. Agents Actions 30 13. PMID:1695431. Hew et al (1990) Characterization of histamine-H3 receptors in guinea pig ileum with H3-selective ligands. Br.J.Pharmacol. 101 621. PMID:1963802. Buckland et al (2003) Histamine induces cytoskeletal changes in human eosinophils via the H4 receptor. Br.J.Pharmacol. 140 1117. PMID:14530216. Shahid et al (2009) Histamine, histamine receptors, and their role in immunomodulation: An updated systematic review. Open Immunol.J. 2 9."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1631				Sep-1994
0571	PCA 4248	[123875-01-4]	COC(=O)C1=C(C)NC(C)=C(C1C)C(=O)OCCSC1=CC=CC=C1	PAF receptor antagonist	"A specific PAF antagonist, more potent than the ginkolide BN-52021. Inhibits rabbit platelet aggregation with an IC50 value of 1.05 _M and has no significant activity on Ca2+ channels. Active in vivo, antagonizing PAF-induced systemic hypotension and protein-plasma extravasation in rats."	"Fernandez-Gallardo et al (1990) Pharmacological actions of PCA 4248, a new platelet-activating factor receptor antagonist: in vivo studies. J.Pharmacol.Exp.Ther. 255 34. PMID:2170626. Sunkel et al (1990) 4-Alkyl-1,4-dihydropyridine derivatives as specific PAF-acether antagonists. J.Med.Chem. 33 3205. PMID:2175357. Sunkel et al (1990) 1,4-Dihydropyridines, a new class of platelet activating factor receptor antagonists: in vitro pharmacological studies. J.Pharmacol.Exp.Ther. 255 28. PMID:2170624."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1649				Sep-1994
0572	(S)-(+)-_-Methylhistamine dihydrobromide	[75614-93-6]	N[C@@H](C)CC1=CNC=N1.Br.Br	"H3 agonist, less active enantiomer"	Less active enantiomer of H3 agonist R-(-)-_-methylhistamine (Cat. No. 0569); 120-fold less potent than R-(-) at H3.	"Hill (1990) Distribution, properties and functional characteristics of three classes of histamine receptor. Pharmacol.Rev. 42 45. PMID:2164693."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1632				Oct-1994
0573	N_-Methylhistamine dihydrochloride	[16503-22-3]	Cl.Cl.CNCCC1=CNC=N1	Non-selective H3 agonist	"Potent histamine agonist, particularly at H3 receptors (potency relative to histamine is 81, 185, and 270% at H1, H2 and H3 respectively). Also displays agonist properties at H4 receptors to which it binds with moderate affinity (Ki = 23 nM)."	"Hill et al (1990) Distribution, properties, and functional characteristics of three classes of histamine receptor. Pharmacol.Rev. 42 45. PMID:2164693. Schwartz et al (1990) A third histamine receptor subtype - characterization, localization and functions of the H3-receptor. Agents Actions 30 13. PMID:1695431. Zweig et al (1992) Characterization of digitonin-solubilized bovine brain H3 histamine receptor coupled to a guanine nucleotide-binding protein. J.Neurochem. 59 1661. PMID:1328529."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1633				Oct-1994
0577	"Methyl 2,5-dihydroxycinnamate"	[63177-57-1]	COC(=O)\C=C\C1=C(O)C=CC(O)=C1	EGFR-kinase inhibitor	Erbstatin analog. Inhibitor of EGF receptor-associated tyrosine kinases.	Isshiki et al (1990) Inhibition of epidermal growth factor-induced DNA synthesis by tyrosine kinase inhibitors. FEBS Lett. 260 198. PMID:2298299.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1615				Jan-1995
0578	"Tyrphostin B44, (-) enantiomer"	[133550-32-0]	OC1=C(O)C=CC(\C=C(C(N[C@H](C)C2=CC=CC=C2)=O)/C#N)=C1	EGFR-kinase inhibitor	"Potent inhibitor of epidermal growth factor receptor (EGFR) kinase (IC50 = 0.4 _M), more active than the (+) enantiomer (Cat. No. 0579). Selective over ErbB2."	Gazit et al (1991) Tyrphostins. 2. Heterocyclic and _-substituted benzylidenemalononitrile tyrophostins as potent inhibitors of EGF receptor and ErbB2/neu tyrosine kinases. J.Med.Chem. 34 1896. PMID:1676428.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1939				Jan-1995
0579	"Tyrphostin B44, (+) enantiomer"	[133550-37-5]	OC1=C(O)C=CC(\C=C(C(N[C@@H](C)C2=CC=CC=C2)=O)/C#N)=C1	EGFR-kinase inhibitor	Epidermal growth factor receptor (EGFR) kinase inhibitor (IC50 = 0.86 _M). Slightly less active than the (-) enantiomer (Cat. No. 0578).	Gazit et al (1991) Tyrphostins. 2. Heterocyclic and _-substituted benzylidenemalononitrile tyrophostins as potent inhibitors of EGF receptor and ErbB2/neu tyrosine kinases. J.Med.Chem. 34 1896. PMID:1676428.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1940				Jan-1995
0581	3-MPPI	[133399-65-2]	COC1=C(C=CC=C1)N1CCN(CCN2C(=O)NC3=C(NC4=CC=CC=C34)C2=O)CC1	_1 ligand	"Very potent ligand for _1 sites (Ki for displacement of prazosin = 0.2 nM). Displays different binding properties for each _1 subtype (pKi values are 8.74, 9.44 and 9.57 for _1B, _1D and _1A adrenoceptors respectively). Also binds to 5-HT1A sites (Ki = 50 nM)."	"Russo et al (1991) Pyrimido[5,4-b]indole derivatives. 1. A new class of potent and selective _1 adrenoceptor ligands. J.Med.Chem. 34 1850. PMID:1648138. Romeo et al (2003) New pyrimido[5,4-b]indoles as ligands for _1-adrenoceptor subtypes. J.Med.Chem. 46 2877. PMID:12825930."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1594				Sep-1994
0582	Methiothepin maleate	[19728-88-2]	[H]OC(=O)\C=C/C(=O)O[H].CSC1=CC2=C(SC3=C(CC2N2CCN(C)CC2)C=CC=C3)C=C1	Has moderate affinity for 5-ht5 and high affinity for 5-ht6 and 5-HT7. Also antagonist at 5-HT1 and 5-HT2	"Potent 5-HT2 antagonist, also active as 5-HT1 antagonist. Differentiates 5-HT1D sub-types. Also displays affinity for rodent 5-HT5B, 5-HT5A, 5-HT7 and 5-HT6 receptors (pK1 values are 6.6, 7.0, 8.4 and 8.7 respectively)."	Hoyer (1989) The peripheral actions of 5-HT. Ed. Fozard. Oxford.. Wilkinson and Middlemiss (1992) Metitepine distinguishes two receptors mediating inhibition of [3H]-5-hydroxytryptamine release in guinea pig hippocampus. Naunyn Schmiedebergs Arch.Pharmacol. 345 696. PMID:1321958.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1582	SQ1533			Sep-1994
0583	Minoxidil	[38304-91-5]	NC1=CC(=NC(N)=[N+]1[O-])N1CCCCC1	Kir6 channel (KATP) opener	Antihypertensive. Antialopecia agent. Kir6 channel (KATP) activator.	Merck Index 12 6290. Meisheri et al (1993) Enzymatic and non-enzymatic sulfation mechanisms in the biological actions of minoxidil. Biochem.Pharmacol. 45 271. PMID:8435087. Tsoporis et al (1993) Effects of the arterial vasodilator minoxidil on cardiovascular structure and sympathetic activity in spontaneously hypertensive rats. J.Hypertens. 11 1337. PMID:8133016. Lachgar et al (1998) Minoxidil upregulates the expression of vascular endothelial growth factor in human hair dermal papilla cells. Br.J.Dermatol. 138 407. PMID:9580790.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1657	SQ1533			Dec-1994
0584	L-(-)-_-Methyldopa	[555-30-6]	OC1=C(O)C=C(C[C@@](N)(C)C(O)=O)C=C1	Aromatic L-amino acid decarboxylase inhibitor	L-aromatic amino acid decarboxylase inhibitor. Antihypertensive.	"Merck Index 12 6132. Van Zwieten et al (1984) The hypotensive activity and side effects of methyldopa, clonidine, and guanfacine. Hypertension 6 II-28. PMID:6094346. Kapoor and Chalmers (1989) Correlation between fall in blood pressure and in vivo amine release after _-methylDOPA. Eur.J.Pharmacol. 164 531. PMID:2767124."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1616	SQ1533			Dec-1994
0588	5-Methylfurmethiodide	[1197-60-0]	[I-].CC1=CC=C(C[N+](C)(C)C)O1	Potent muscarinic agonist	A potent muscarinic agonist.	Newberry and Priestley (1987) Pharmacological differences between two muscarinic responses of the rat superior cervical ganglion in vitro. Br.J.Pharmacol. 92 817. PMID:3427281. Roberts and Newberry (1990) A pharmacological study of the responses induced by muscarinic agonists on the isolated superior cervical ganglion of the guinea pig. Eur.J.Pharmacol. 186 257. PMID:2289527.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1621				Oct-1994
0589	PRE-084 hydrochloride	[138847-85-5]	Cl.O=C(OCCN1CCOCC1)C1(CCCCC1)C1=CC=CC=C1	Highly selective _1 agonist	"High affinity, selective _1 agonist (Ki values are 2.2 and 13091 nM for _1 and _2 receptors respectively). Selective over PCP receptors (IC50 > 100000 nM) and several other receptor systems. Produces antiamnesic and antitussive effects in vivo. Also exhibits protective effects in PC6.3 cells expressing mutant huntingtin by activating NF-_B signaling."	"Su et al (1991) Sigma compounds derived from phencyclidine. Identification of PRE-084, a new selective sigma ligand. J.Pharmacol.Exp.Ther. 259 543. PMID:1658302. Maurice et al (1999) The attenuation of learning impairments induced after exposure to CO or trimethyltin in mice by sigma (_) receptor ligands involves both _1 and _2 sites. Br.J.Pharmacol. 127 335. PMID:10385231. Brown et al (2004) Antitussive activity of sigma-1 receptor agonists in the guinea-pig. Br.J.Pharmacol. 141 233. PMID:14691051. Hyrskyluoto et al (2013) Sigma-1 receptor agonist PRE084 is protective against mutant huntingtin-induced cell degeneration: involvement of calpastatin and the NF-_B pathway. Cell Death Dis. 4 e646. PMID:23703391."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1810				Nov-1994
0590	Metergoline	[17692-51-2]	[H][C@](CNC(OCC5=CC=CC=C5)=O)1C[C@@](C2=CC=CC3=C2C(C4)=CN3C)([H])[C@]4([H])N(C1)C	5-HT2 antagonist. Also 5-HT1 antagonist and 5-HT1D ligand. Has moderate affinity for 5-HT6 and high affinity for 5-HT7	Antagonist at 5-HT1/5-HT2 with activity at 5-HT1D. Has moderate affinity for 5-HT6 and high affinity for 5-HT7.	Aulakh et al (1992) Effects of various serotonin receptor subtype selective antagonists alone and on m-chlorophenylpiperazine-induced neuroendocrine changes in rats. J.Pharmacol.Exp.Ther. 263 588. PMID:1432690. Bagdy et al (1992) Pharmacological characterization of serotonin receptor subtypes involved in vasopressin and plasma renin activity responses to serotonin agonists. Eur.J.Pharmacol. 210 285. PMID:1535317. Miller et al (1992) Agonist activity of sumatriptan and metergoline at the human 5-HT1D_ receptor in the action of sumatriptan. Eur.J.Pharmacol. 227 99. PMID:1330643.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1578	SQ1533			Sep-1994
0591	Naloxonazine dihydrochloride	[880759-65-9]	OC(C(N(CC=C)CC%10)C6)7C2%10C1=C6C=CC(O)=C1OC2/C(CC7)=N/N=C3CCC8(O)C49C/3OC5=C(O)C=CC(CC8N(CC=C)CC9)=C45.Cl.Cl	Selective _1 antagonist	"Potent opioid antagonist, selective for _1 receptors."	Paul et al (1988) Differential blockade by naloxonazine of two _ opiate actions: analgesic and inhibition of gastrointestinal transit. Eur.J.Pharmacol. 149 403. PMID:2842168.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1677				Dec-1994
0593	NPPB	[107254-86-4]	OC(=O)C1=CC(=CC=C1NCCCC1=CC=CC=C1)[N+]([O-])=O	Inhibits calcium-sensitive chloride currents	Inhibits calcium-sensitive chloride currents (10 _M). Putative GPR35 agonist.	Wangemann et al (1986) Cl--channel blockers in the thick ascending limb of the loop of Henle. Structure-activity relationship. Pflugers Arch. 407 S128. PMID:2434915. Keeling et al (1991) Effects of NPPB (5-nitro-1-(3-phenylpropylamino)benzoic acid on chloride transport in intestinal tissues and the T84 cell line. Biochim.Biophys.Acta 115 42. PMID:1720331. Kirkup et al (1996) Investigation of the effects of 5-nitro-2-(3-phenylpropylamino)-benzoic acid (NPPB) on membrane currents in rat portal vein. Br.J.Pharmacol. 117 175. PMID:8825360. Taniguchi et al (2008) 5-nitro-2-(3-phenylpropylamino)benzoic acid is a GPR35 agonist Pharmacology 82 245. PMID:18818509.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1715	SQ1070			Oct-1994
0597	Naftopidil hydrochloride	[1164469-60-6]	Cl.COC1=C(C=CC=C1)N1CCN(CC(O)COC2=C3C=CC=CC3=CC=C2)CC1	_1 antagonist	"An _1-adrenoceptor antagonist with only weak antagonism at post-junctional _2 receptors; a potent, persistent antihypertensive and vasodilator."	Borbe and Peter (1990) Alpha-1-adrenoceptor-binding material in rat plasma following single oral administration of naftopidil. Arzneimittelforschung 40 253. PMID:1971750. Muramatsu et al (1991) Pharmacological profile of the novel alpha-adrenoceptor antagonist KT-611 (naftopidil). Jpn.J.Pharmacol. 55 391. PMID:1677438.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1676	SQ1533			Sep-1994
0598	SNAP	[79032-48-7]	O=NSC(C)(C)C(NC(C)=O)C(O)=O	A stable analog of endogenous S-nitroso compounds	A stable analog of endogenous S-nitroso compounds. A source of NO in vivo which unlike organic O-nitrates does not induce tolerance. Decomposes slowly in solution with a t_ of 37h.	"Bauer and Fung (1991) Differential thermodynamic effects and tolerance properties of nitroglycerin and S-nitrosothiol in experimental heart failure. J.Pharmacol.Exp.Ther. 256 249. PMID:1899118. Cross et al (1994) Neurotoxicity in conscious rats following intraventricular SNAP, a nitric oxide donor. Neuropharmacology 33 915. PMID:7969812. Ekblad and Sundler (1997) Motor responses in rat ileum evoked by nitric oxide donors vs. field stimulation: modulation by pituitary adenylate cyclase-activating peptide, forskolin and guanylate cyclase inhibitors. J.Pharmacol.Exp.Ther. 283 23. PMID:9336304. Ferrero et al (1999) Comparative effects of several nitric oxide donors on intracellular cyclic GMP levels in bovine chromaffin cells: correlation with nitric oxide production. Br.J.Pharmacol. 127 779. PMID:10401570."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1867				Aug-1998
0599	Naloxone hydrochloride	[357-08-4]	O=C3[C@H]4[C@]25C1=C(O4)C(O)=CC=C1C[C@@H](N(CC5)CC=C)[C@@](O)2CC3.Cl	Broad spectrum opioid antagonist	Opioid antagonist.	"Merck Index 12 6449. Olson et al (1996) Endogenous opiates: 1995. Peptides 17 1421. Pinelli and Trivulzio (1997) Quantitative evaluation of opioid withdrawal signs in rats repeatedly treated with morphine and injected with naloxone, in the absence or presence of the antiabstinence agent clonidine. J.Pharmacol.Toxicol.Methods 38 117. PMID:9523765. Spivak et al (1997) Naloxone activation of mu-opioid receptors mutated at a histidine residue lining the opioid cavity. Mol.Pharmacol. 52 983. PMID:9415708."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1678	SQ1533			Jan-1995
0600	Nimodipine	[66085-59-4]	COCCOC(=O)C1=C(C)NC(C)=C(C1C1=CC=CC(=C1)[N+]([O-])=O)C(=O)OC(C)C	Ca2+ channel blocker (L-type)	L-type Ca2+ channel blocker.	"Izquierdo (1990) Nimodipine and the recovery of memory. TiPS 11 309. PMID:2203191. Kappelle et al (1994) Beneficial effect of the Ca2+ antagonist, nimodipine, on existing diabetic neuropathy in the BB/Wor rat. Br.J.Pharmacol. 111 887. PMID:8019766. Batuecas et al (1998) Effects of chronic nimodipine on working memory of old rats in relation to defects in synaptosomal calcium homeostasis. Eur.J.Pharmacol. 350 141. PMID:9696401. Fleming et al (2011) Chemical modulators of autophagy as biological probes and potential therapeutics. Nat.Chem.Biol. 7 9. PMID:21164513."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1697	SQ1533			Oct-1994
0601	Nitrendipine	[39562-70-4]	CCOC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OC	Ca2+ channel blocker (L-type)	L-type calcium channel blocker.	Merck Index 12 6667. Watanabe et al (1995) L-type calcium channel block by highly hydrophilic dihydropyridines in single ventricular cells of guinea-pig hearts. J.Mol.Cell.Cardiol. 27 1271. PMID:8531209. Costa et al (1996) Characterization of a voltage-dependent L-type calcium channel from rabbit and turtle brain. Neurochem.Res. 21 537. PMID:8726959. Fleming et al (2011) Chemical modulators of autophagy as biological probes and potential therapeutics. Nat.Chem.Biol. 7 9. PMID:21164513.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1700	SQ1533			Oct-1994
0602	7-Nitroindazole	[2942-42-9]	[O-][N+](=O)C1=C2NN=CC2=CC=C1	Non-selective NOS inhibitor	"Reversible, competitive and non-selective NOS inhibitor. Monosodium salt 7-NINA (Cat. No. 0800) also available."	"Babbedge et al (1993) Inhibition of rat cerebellar nitric oxide synthase by 7-nitroindazole and related substituted indazoles. Br.J.Pharmacol. 110 225. PMID:7693279. Moore et al (1993) 7-nitroindazole, an inhibitor of nitric oxide synthase, exhibits antinociceptive activity in the mouse without increasing blood pressure. Br.J.Pharmacol. 108 296. PMID:7680591. Moore et al (1993) Characterisation of the novel nitric oxide synthase inhibitor 7-nitroindazole and related indazoles: antinociceptive and cardiovascular effects. Br.J.Pharmacol. 110 219. PMID:7693278. Moore and Handy (1997) Selective inhibitors of neuronal nitric oxide synthase - is no NOS really good NOS for the nervous system? TiPS 18 204. PMID:9226999."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1704				May-1995
0603	SNOG	[57564-91-7]	N[C@@H](CCC(N[C@@H](CSN=O)C(NCC(O)=O)=O)=O)C(O)=O	NO carrier. Breaks down to release NO	"A carrier of NO, relaxing smooth muscle and inhibiting platelet aggregation."	"Gibson et al (1992) An investigation of some S-nitrosothiols, and of hydroxy-arginine, on the mouse anococcygeus. Br.J.Pharmacol. 107 715. PMID:1472969. Radomski et al (1992) S-Nitroso-glutathione inhibits platelet activation in vitro and in vivo. Br.J.Pharmacol. 107 745. PMID:1335336. Bannenberg et al (1995) Characterization of the bronchodilator effects and fate of S-nitrosothiols in the isolated perfused and ventilated guinea pig lung. J.Pharmacol.Exp.Ther. 272 1238. PMID:7891339."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1708				Sep-1996
0604	Nicergoline	[27848-84-6]	[H][C@](COC(C5=CN=CC(Br)=C5)=O)1C[C@@](C2=CC=CC3C2C(C4)=CN3C)(OC)[C@]4([H])N(C1)C	_ antagonist	"_-adrenergic, vasodilator. Cognitive enhancer."	Merck Index 12 6580. Chopin and Briley (1992) Effects of four non-cholinergic cognitive enhancers in comparison with tacrine and galanthamine on scopolamine-induced amnesia in rats. Psychopharmacology 106 26. PMID:1738791. Carfagna et al (1995) Modulation of hippocampal ACh release by chronic nicergoline treatment in freely moving young and aged rats. Neurosci.Lett. 197 195. PMID:8552297. Carfagna et al (1996) Modulation of phosphoinositide turnover by chronic nicergoline in rat brain. Neurosci.Lett. 209 189. PMID:8736642.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1696				Jan-1995
0605	()-Octanoylcarnitine chloride	[18822-86-1]	O=C(CCCCCCC)OC(CC(O)=O)C[N+](C)(C)C.[Cl-]	Intermediate in lipid metabolism	Homolog of acetylcarnitine chloride (Cat. No. 0355). Acylcarnitines are important intermediates in lipid metabolism.	Chalmers et al (1984) Urinary excretion of l-carnitine and acylcarnitines by patients with disorders of organic acid metabolism: evidence for secondary insufficiency of l-carnitine. Pediatr.Res. 18 1325. PMID:6441143. Coates and Tanaka (1992) Molecular basis of mitochondrial fatty acid oxidation defects. J.Lipid.Res. 33 1099. PMID:1431593. Poorthuis et al (1993) Determination of acylcarnitines in urine of patients with inborn errors of metabolism using HPLC after derivatization with 4'-bromophenacyl bromide. Clin.Chim.Acta 216 53. PMID:8222273.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1722				Oct-1994
0606	OBAA	[221632-26-4]	CCCCCCCCCCCCCCCCCCC1=CC=C(C=C1)C(=O)\C=C\C(O)=O	Phospholipase A2 inhibitor	A potent inhibitor of phospholipase A2 (IC50 = 70 nM). Reduces bronchospasm in guinea pigs in vivo.	Kohler et al (1991) Phospholipase-A2 inhibition by alkylbenzoyl acrylic acids. Agents Actions 32 70. PMID:2058477. Madi et al (1991) Allergen-induced bronchospasm in passively sensitized guinea-pigs - influence of new substances in comparison to reference compounds. Agents Actions 32 144. PMID:2058463. Kohler et al (1992) Phospholipase A2 inhibition by alkylbenzoyl acrylic acids. Biochem.Pharmacol. 44 805. PMID:1324685.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1720				Aug-1998
0607	17-ODYA	[34450-18-5]	C#CCCCCCCCCCCCCCCCC(O)=O	LTB-_-Hydroxylase inhibitor	Potent suicide inhibitor of LTB4 _-hydroxylase.	Shak et al (1985) Leukotriene B4 _-hydroxylase in human polymorphonuclear leukocytes. J.Biol.Chem. 260 13023. PMID:2997155. Edwards et al (1996) Effects of cytochrome P450 inhibitors on potassium currents and mechanical activity in rat portal vein. Br.J.Pharmacol. 119 691. PMID:8904643.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1721				Jan-1995
0609	()-Palmitoylcarnitine chloride	[6865-14-1]	[Cl-].CCCCCCCCCCCCCCCC(=O)OC(CC(=O)O)C[N+](C)(C)C	Protein kinase C inhibitor	Intermediate in mitochondrial fatty acid oxidation. Has a wide range of biological actions including the inhibition of protein kinase C and cell membrane disruption.	Nakadate and Blumberg (1987) Modulation by palmitoylcarnitine of protein kinase C activation. Cancer Res. 47 6537. PMID:3479247. Criddle et al (1990) The effects of novel vasodilator long chain acyl carnitine esters in the isolated perfused heart of the rat. Br.J.Pharmacol. 99 477. PMID:1691947. Dainty et al (1990) Interactions of palmitoyl carnitine with the endothelium in rat aorta. Br.J.Pharmacol. 100 241. PMID:1696151. Requero et al (1995) The membrane-perturbing properties of palmitoyl-coenzyme A and palmitoylcarnitine. A comparative study. Biochemistry 34 10400. PMID:7654694.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1736	SQ1070			Oct-1994
0610	Parthenolide	[20554-84-1]	C/C1=C\CC[C@]2(C)[C@@H](O2)[C@@H](OC([C@]3=C)=O)[C@H]3CC1	5-HT release inhibitor	"The active principle of feverfew (Chrysanthemum parthenium), widely used as a herbal remedy for arthritis and migraine and as a febrifuge. Antisecretory, anti-inflammatory and spasmolytic; inhibits the release of 5-HT from blood platelets. Also inhibits generation of leukotriene B4 and thromboxane B2."	"Heptinstall et al (1986) Compounds extracted from feverfew that have anti-secretory activity contain an _-methylene butyrolactone unit. J.Pharm.Pharmacol. 38 709. PMID:2877077. Murphy et al (1988) Randomized double-blind placebo controlled trial of feverfew in migraine prevention. Lancet 2 189. PMID:2899663. Groenewegen and Heptinstall (1990) A comparison of the effects of an extract of feverfew and parthenolide, a component of feverfew, on human platelet activity in vitro. J.Pharm.Pharmacol. 42 553. PMID:1981582. Sumner et al (1992) Inhibition of 5-lipoxygenase and cyclo-oxygenase in leukocytes by feverfew. Involvement of sesquiterpene lactones and other components. Biochem.Pharmacol. 43 2313. PMID:1319159."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1739	SQ1533			Nov-1994
0611	()-Propionylcarnitine chloride	[18828-58-5]	O=C(CC)OC(CC(O)=O)C[N+](C)(C)C.[Cl-]	Intermediate in lipid metabolism	Homolog of acetylcarnitine chloride (Cat. No. 0355). Acylcarnitines are important intermediates in lipid metabolism.	Chalmers et al (1984) Urinary excretion of l-carnitine and acylcarnitines by patients with disorders of organic acid metabolism: evidence for secondary insufficiency of l-carnitine. Pediatr.Res. 18 1325. PMID:6441143. Coates and Tanaka (1992) Molecular basis of mitochondrial fatty acid oxidation defects. J.Lipid.Res. 33 1099. PMID:1431593. Poorthuis et al (1993) Determination of acylcarnitines in urine of patients with inborn errors of metabolism using HPLC after derivatization with 4'-bromophenacyl bromide. Clin.Chim.Acta 216 53. PMID:8222273.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1813				Oct-1994
0616	AG 556	[133550-41-1]	OC1=C(O)C=C(\C=C(/C#N)C(=O)NCCCCC2=CC=CC=C2)C=C1	EGFR-kinase inhibitor	Epidermal growth factor receptor (EGFR) kinase inhibitor (IC50 = 1.1 _M). Selective over ErbB2 (IC50 > 500 _M).	Gazit et al (1991) Tyrphostins. 2. Heterocyclic and _-substituted benzylidenemalononitrile tyrophostins as potent inhibitors of EGF receptor and ErbB2/neu tyrosine kinases. J.Med.Chem. 34 1896. PMID:1676428. Gamett et al (1997) Secondary dimerization between members of the epidermal growth factor receptor family. J.Biol.Chem. 272 12052. PMID:9115272.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1948				Dec-1994
0618	AG 555	[133550-34-2]	OC1=CC=C(\C=C(/C#N)C(=O)NCCCC2=CC=CC=C2)C=C1O	Potent EGFR-kinase inhibitor	Potent epidermal growth factor receptor (EGFR) kinase inhibitor (IC50 = 0.7 _M) that displays 50-fold and >140-fold selectivity over ErbB2 and insulin receptor kinase respectively. Induce G1 growth arrest selectively in transformed cells (IC50 values are 6.4 and 9.4 _M in HPV16-immortalized and normal keratinocytes respectively).	Gazit et al (1991) Tyrphostins. 2. Heterocyclic and _-substituted benzylidenemalononitrile tyrophostins as potent inhibitors of EGF receptor and ErbB2/neu tyrosine kinases. J.Med.Chem. 34 1896. PMID:1676428. Levitzki and Gazit (1995) Tyrosine kinase inhibition: an approach to drug development. Science 267 1782. PMID:7892601. Ben-Bassat et al (1999) Tyrphostins that suppress the growth of human papilloma virus 16-immortalized human keratinocytes. J.Pharmacol.Exp.Ther. 290 1442. PMID:10454524.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1941				Dec-1994
0619	AG 494	[133550-35-3]	OC1=C(O)C=C(\C=C(/C#N)C(=O)NC2=CC=CC=C2)C=C1	Potent EGFR-kinase inhibitor	"Potent inhibitor of epidermal growth factor receptor (EGFR) kinase (IC50 = 0.7 _M). Selective over ErbB2, PDGFR and insulin receptor kinase (IC50 values are 42, 6 and > 100 _M respectively)."	Gazit et al (1991) Tyrphostins. 2. Heterocyclic and _-substituted benzylidenemalononitrile tyrophostins as potent inhibitors of EGF receptor and ErbB2/neu tyrosine kinases. J.Med.Chem. 34 1896. PMID:1676428. Ben-Bassat et al (1999) Tyrphostins that suppress the growth of human papilloma virus 16-immortalized human keratinocytes. J.Pharmacol.Exp.Ther. 290 1442. PMID:10454524. Tomlins et al (2005) Cross-talk between the calcium-sensing receptor and the epidermal growth factor receptor in Rat-1 fibroblasts. Exp.Cell Res. 308 439. PMID:15950968.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1942				Dec-1994
0620	4-PPBP maleate	[201216-39-9]	OC(=O)\C=C/C(O)=O.C(CCC1=CC=CC=C1)CN1CCC(CC1)C1=CC=CC=C1	"Specific _ ligand, NMDA antagonist"	_ ligand and selective non-competitive antagonist at recombinant NR1a/2B NMDA receptors expressed in Xenopus oocytes.	"Glennon et al (1991) Novel 1-phenylpiperazine and 4-phenylpiperidine derivatives as high affinity _ ligands. J.Med.Chem. 34 3360. PMID:1662725. Whittemore et al (1997) Antagonism of N-methyl-D-aspartate receptors by _ site ligands: potency, subtype-selectivity and mechanisms of inhibition. J.Pharmacol.Exp.Ther. 282 326. PMID:9223571."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1755				Nov-1994
0622	Physostigmine hemisulfate	[64-47-1]	OS(O)(=O)=O.CNC(=O)OC1=CC=C2N(C)C3N(C)CCC3(C)C2=C1.CNC(=O)OC1=CC=C2N(C)C3N(C)CCC3(C)C2=C1	Cholinesterase inhibitor	Cholinesterase inhibitor.	Merck Index 12 7540. Millard and Broomfield (1995) Anticholinesterases: medical applications of neurochemical principles. J.Neurochem 64 1909. PMID:7722478.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1779	SQ1533			Oct-1994
0623	Prazosin hydrochloride	[19237-84-4]	Cl.COC1=CC2=NC(=NC(N)=C2C=C1OC)N1CCN(CC1)C(=O)C1=CC=CO1	_1 and _2B antagonist. MT3 antagonist	_1 and _2B-adrenoceptor antagonist. Also a potent antagonist at the melatonin MT3 receptor (Ki = 10.2 nM). Also available as part of the _1-Adrenoceptor Tocriset and Mixed Adrenergic Tocriset.	Merck Index 12 7897. Pickering and Niles (1990) Pharmacological characterization of melatonin binding sites in Syrian hamster hypothalamus. Eur.J.Pharmacol. 175 71. PMID:2157597. Mathe et al (1996) Prazosin inhibits MK-801-induced hyperlocomotion and dopamine release in the nucleus accumbens. Eur.J.Pharmacol. 309 1. PMID:8864686. Paul et al (1999) Characterisation of 2-[125I]iodomelatonin binding sites in syrian hamster peripheral organs. J.Pharmacol.Exp.Ther. 290 334. PMID:10381796.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1809	SQ1533			Sep-1994
0624	Propranolol hydrochloride	[3506-09-0]	Cl.CC(C)NCC(O)COC1=C2C=CC=CC2=CC=C1	_ antagonist	_-adrenergic antagonist. Separate isomers (S)-(-)-Propranolol hydrochloride and (R)-(+)-Propranolol hydrochloride also available (Cat. No's. 0834 and 0835 respectively).	Merck Index 12 8025. Xie et al (1998) The inhibitory effect of propranolol on ATP-sensitive potassium channels in neonatal rat heart. Br.J.Pharmacol. 123 599. PMID:9517376. Litwin et al (1999) Effects of propranolol treatment on left ventricular function and intracellular calcium regulation in rats with postinfarction heart failure. Br.J.Pharmacol. 127 1671. PMID:10455325.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1819	SQ1533			Sep-1994
0625	PPADS tetrasodium salt	[192575-19-2]	[Na+].[Na+].[Na+].[Na+].CC1=C(O)C(C=O)=C(COP([O-])([O-])=O)C(\N=N\C2=C(C=C(C=C2)S([O-])(=O)=O)S([O-])(=O)=O)=N1	P2 purinergic antagonist	"A non-selective P2 purinergic antagonist. Blocks recombinant P2X1, P2X2, P2X3, P2X5 (IC50 = 1 - 2.6 _M), native P2Y2-like (IC50 ~ 0.9 mM), and recombinant P2Y4 (IC50 ~ 15 mM) receptors. Delays onset of calcium responses to mild hypoosmotic stress in cortical slices. iso-PPADS (Cat. No. 0683) also available."	"Lambrecht et al (1992) PPADS, a novel functionally selective antagonist of P2 purinoceptor-mediated responses. Eur.J.Pharmacol. 217 217. PMID:1330591. McLaren et al (1994) Investigation of the actions of PPADS, a novel P2x-purinoceptor antagonist, in the guinea-pig isolated vas deferens. Br.J.Pharmacol. 111 913. PMID:8019769. Ziganshin et al (1994) Selective antagonism by PPADS at P2x-purinoceptors in rabbit isolated blood vessels. Br.J.Pharmacol. 111 923. PMID:8019770. Ralevic and Burnstock (1998) Receptors for purines and pyrimidines. Pharmacol.Rev. 50 413. PMID:9755289. Thrane et al (2011) Critical role of aquaporin-4 (AQP4) in astrocytic Ca2+ signaling events elicited by cerebral edema. Proc.Natl.Acad.Sci.U S A 108 846. PMID:21187412."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1805				Jul-1998
0627	2-PMDQ	[139047-55-5]	O=C1NC2=C(C=CC=C2)C2=NC(CN3CCN(CC3)C3=CC=CC=C3)CN12	"Potent, selective _1 antagonist"	Potent and selective _1-adrenoceptor antagonist and antihypertensive.	"Chern et al (1993) Studies on quinazolines. 5. 2,3-dihydroimidazo[1,2-c]quinazoline derivatives - a novel class of potent and selective _1-adrenoceptor antagonists and antihypertensive agents. J.Med.Chem. 36 2196. PMID:8101878."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1756				Dec-1994
0629	Quipazine dimaleate	[150323-78-7]	OC(=O)\C=C/C(O)=O.OC(=O)\C=C/C(O)=O.C1CN(CCN1)C1=NC2=C(C=CC=C2)C=C1	5-HT3 agonist	Selective 5-HT3 receptor agonist. Also displays antagonist activity at peripheral 5-HT3 receptors. [3H]-Quipazine labels 5-HT3 sites in the cortical membranes.	"Ireland and Tyers (1987) Pharmacological characterization of 5-hydroxytryptamine-induced depolarization of the rat isolated vagus nerve. Br.J.Pharmacol. 90 229. PMID:3814920. Peroutka and Hamik (1988) [3H]Quipazine labels 5-HT3 recognition sites in rat cortical membranes. Eur.J.Pharmacol. 148 297. PMID:3378579. Sharif et al (1991) Characteristics of 5-HT3 binding sites in NG108-15, NCB-20 neuroblastoma cells and rat cerebral cortex using [3H]-quipazine and [3H]-GR65630 binding. Br.J.Pharmacol. 102 919. PMID:1830236."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1825	SQ1533			Sep-1995
0630	Rosmarinic acid	[20283-92-5]	O=C(/C=C/C2=CC(O)=C(O)C=C2)O[C@@H](C(O)=O)CC1=CC(O)=C(O)C=C1	"Anti-inflammatory, cytostatic and antiviral; GPR35 agonist"	"Anti-inflammatory, cytostatic and antiviral. Also displays agonist activity at GPR35."	"Bult et al (1985) Modification of endotoxin-induced haemodynamic and haematological changes in the rabbit by methylprednisolone, F(ab')2 fragments and rosmarinic acid. Br.J.Pharmacol. 84 317. PMID:3838489. Rampart et al (1986) Complement-dependent stimulation of prostacyclin biosynthesis: inhibition by rosmarinic acid. Biochem.Pharmacol. 35 1397. PMID:3516156. Van Kessel et al (1986) Rosmarinic acid inhibits external oxidative effects of human polymorphonuclear granulocytes. Agents Actions. 17 375. PMID:3962787. Sahu et al (1999) Inhibition of complement by covalent attachment of rosmarinic acid to activated C3b. Biochem.Pharmacol. 57 1439. PMID:10353266. Deng et al (2012) Multiple tyrosine metabolites are GPR35 agonists. Sci.Rep. 2 373. PMID:22523636."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1841				Sep-1994
0631	Spiroxatrine	[1054-88-2]	O=C1NCN(C2=CC=CC=C2)C11CCN(CC2COC3=CC=CC=C3O2)CC1	Potent _2C antagonist	5-HT1A antagonist. More active and selective than spiperone. Also a very potent _2C adrenergic receptor antagonist.	Nelson and Taylor (1986) Spiroxatrine: a selective serotonin 1A receptor antagonist. Eur.J.Pharmacol. 124 207. PMID:3720840. Schoeffter and Hoyer (1988) Centrally acting hypotensive agents with affinity for 5-HT1A binding sites inhibit forskolin-stimulated adenylate cyclase activity in calf hippocampus. Br.J.Pharmacol. 95 975. PMID:3207999. Bylund et al (1992) Pharmacological characteristics of _2-adrenergic receptors: comparison of pharmacologically defined subtypes with subtypes identified by molecular cloning. Mol.Pharmacol. 42 1. PMID:1353247.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1873	SQ1533			Oct-1994
0633	D-erythro-Sphingosine (synthetic)	[123-78-4]	N[C@H]([C@@H](/C=C/CCCCCCCCCCCCC)O)CO	Protein kinase C inhibitor	"Inhibitor of protein kinase C and calmodulin-dependent enzymes, but may stimulate mast cells by activation of protein kinase C."	Merrill et al (1989) Structural requirements for long-chain (sphingoid) base inhibition of protein kinase C in vitro and for the cellular effects of these compounds. Biochemistry 28 3138. PMID:2742830. Grossman (1990) Sphingosine inhibition and promotion of histamine release from isolated rat mast cells. Agents Actions 31 171. PMID:1707581.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1872	SQ1070			Oct-1995
0634	Salbutamol hemisulfate	[51022-70-9]	OS(O)(=O)=O.CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1.CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1	_ agonist (_2 > _1)	"Non-selective _-adrenergic agonist, more potent at _2 than _1 receptors."	"Merck Index 12 217. Strosberg and Pietri-Rouxel (1996) Function and regulation of the _3-adrenoceptor. TiPS 17 373. PMID:8979772. January et al (1998) Salmeterol-induced desensitisation, internalization and phosphorylation of the human _2-adrenoceptor. Br.J.Pharmacol. 123 701. PMID:9517390. Prior et al (1998) Effects of the enantiomers of R,S-salbutamol on incompletely fused tetanic contractions of slow- and fast-twitch skeletal muscles of the guinea-pig. Br.J.Pharmacol. 123 558. PMID:9504397."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1849	SQ1533			Sep-1994
0635	Synthalin sulfate	[182285-12-7]	NC(NCCCCCCCCCCNC(N)=N)=N	Non-competitive NMDA antagonist	"An effective non-competitive NMDA receptor antagonist in vivo and in vitro; may bind to more than one site, one of which is the polyamine site."	"Reynolds et al (1991) 1,10-Bis(guanidino)decane inhibits N-methyl-D-aspartate responses in vitro and in vivo. J.Pharmacol.Exp.Ther. 259 626. PMID:1658306. Reynolds (1992) Interactions between zinc and spermidine on the N-methyl-D-aspartate receptor complex: clues to the mechanism of action of 1,10-bis(guanidino)decane and pentamidine. J.Pharmacol.Exp.Ther. 263 632. PMID:1432693."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1891				Oct-1994
0636	Salsolinol-1-carboxylic acid	[57256-34-5]	CC1(NCCC2=CC(O)=C(O)C=C12)C(O)=O	Endogenous amino acid	An amino acid that occurs naturally in the CNS.	Sjoquist et al (1985) Identification and quantification of 1-carboxysalsolinol and salsolinol in biological samples by gas chromatography mass-spectrometry. J.Chromatogr. 343 1. PMID:4066844.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1850				Jan-1995
0638	CGS 12066B dimaleate	[109028-10-6]	O=C(O)/C=C\C(O)=O.O=C(O)/C=C\C(O)=O.FC(C1=CC3=C(N2C=CC=C2C(N4CCN(CC4)C)=N3)C=C1)(F)F	5-HT1B agonist	"5-HT1B full agonist, 10-fold selective over 5-HT1A and 1000-fold selective over 5-HT2C receptors. Centrally active following systemic administration."	"Neale et al (1987) Biochemical and pharmacological characterization of CGS 12066B, a selective serotonin-1B agonist. Eur.J.Pharmacol. 136 1. PMID:3496228. Schoeffter and Hoyer (1989) Interaction of arylpiperazines with 5-HT1A, 5-HT1B, 5-HT1C and 5-HT1D receptors: do discriminatory 5-HT1B receptor ligands exist? Naunyn Schmiedebergs Arch.Pharmacol. 339 675. PMID:2770889. Tomkins and O'Neill (2000) Effect of 5-HT1B receptor ligands on self-administration of ethanol in an operant procedure in rats. Pharmacol.Biochem.Behav. 66 129. PMID:10837852."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=2145				Dec-1994
0640	MDL 72222	[40796-97-2]	CN1C2CCC1CC(C2)OC(=O)C1=CC(Cl)=CC(Cl)=C1	5-HT3 antagonist	5-HT3 antagonist.	Fozard (1984) MDL 72222: a potent and highly selective antagonist at neuronal 5-hydroxytryptamine receptors. Naunyn Schmiedebergs Arch.Pharmacol. 326 36. PMID:6472484. Richardson and Engel (1986) The pharmacology and function of 5-HT3 receptors. Trends Neurosci. 9 424.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1565	SQ1533			Oct-1994
0641	"Tropanyl-3,5-dimethylbenzoate"	[85181-40-4]	CN1C2CCC1CC(C2)OC(=O)C1=CC(C)=CC(C)=C1	5-HT3 antagonist	5-HT3 antagonist.	Fozard and Gitto (1983) Selective blockade of 5-hydroxytryptamine neuronal receptors by benzoic acid esters of tropine. Br.J.Pharmacol. 80 511P.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1922	SQ1070			Jan-1995
0644	Thioperamide	[106243-16-7]	S=C(NC3CCCCC3)N(CC2)CCC2C1=CNC=N1	H3 antagonist and H4 inverse agonist	Potent histamine H3 and H4 antagonist/inverse agonist. Ki values are 25 and 27 nM for human recombinant H3 and H4 receptors respectively. Blocks eosinophil shape change (IC50 = 1.4 _M) and chemotaxis (IC50 = 519 nM) induced by histamine. Freely crosses the blood-brain barrier. Also available as part of the Histamine H3 Receptor Tocriset.	Hew et al (1990) Characterisation of histamine H3 receptors in guinea pig ileum with H3 selective ligands. Br.J.Pharmacol. 101 621. PMID:1963802. Liu et al (2001) Cloning and pharmacological characterization of a fourth histamine receptor (H4) expressed in bone marrow. Mol. Pharmacol. 59 420. PMID:11179434. Ling et al (2004) Histamine H4 receptor mediates eosinophil chemotaxis with cell shape change and adhesion molecule upregulation. Br.J.Pharmacol. 142 161. PMID:15131002. Gbahou et al (2006) Compared pharmacology of human H3 and H4 receptors: structure-activity relationships of histamine derivatives. Br.J.Pharmacol. 147 744. PMID:16432504.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1907	SQ1070			May-1996
0645	2-TEDC	[132465-10-2]	OC1=C(O)C=C(\C=C(/C#N)C(=O)OCCC2=CC=CS2)C=C1	"5-, 12-, 15-Lipoxygenase inhibitor"	"Potent inhibitor of 5-, 12-, and 15-lipoxygenase (IC50 values are 0.09, 0.013 and 0.5 _M respectively)."	Cho et al (1991) Novel caffeic acid derivatives - extremely potent inhibitors of 12-lipoxygenase. J.Med.Chem. 34 1503. PMID:2016727.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1902				Sep-1994
0646	HTMT dimaleate	[195867-54-0]	[H]OC(=O)\C=C/C(=O)O[H].[H]OC(=O)\C=C/C(=O)O[H].CC(CCCCC(=O)NC1=CC=C(C=C1)C(F)(F)F)NCCC1=CNC=N1	H1 / H2 agonist	"H1 and H2 receptor agonist. 4x104 times more active than histamine in H2-mediated effects in natural suppressor cells. Increases intracellular Ca2+ and IP3 in lymphocytes through a binding site other than H1, H2 or H3."	"Khan et al (1986) The effects of derivatives of histamine on natural suppressor cells. J.Immunol. 137 308. PMID:3011908. Khan et al (1987) Congener derivatives and conjugates of histamine: synthesis and tissue receptor selectivity of the derivatives. J.Med.Chem. 30 2115. PMID:2959777. Shahid et al (2009) Histamine, histamine receptors and their role in immunomodulation: An updated systematic review. Open Immunol.J. 2 9."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1457				Jan-1995
0649	(S)-Timolol maleate	[26921-17-5]	[H]OC(=O)\C=C/C(=O)O[H].CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1	_1 antagonist	_1-adrenergic blocker.	Merck Index 12 9585. Karhuvaara et al (1989) _-Adrenoceptor antagonist activities and binding affinities of timolol enantiomers in rat atria. J.Pharm.Pharmacol. 41 649. PMID:2573714.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1905	SQ1533			Sep-1994
0652	Thalidomide	[50-35-1]	O=C1N(C2CCC(=O)NC2=O)C(=O)C2=C1C=CC=C2	TNF-_ synthesis inhibitor	"Teratogen, sedative-hypnotic with inherent anti-inflammatory properties. A selective inhibitor of tumor necrosis factor _ (TNF-_) synthesis."	"Merck Index 12 9390. Sampaio et al (1991) Thalidomide selectively inhibits tumor necrosis factor _ production by stimulated human monocytes. J.Exp.Med. 173 699. PMID:1997652. Makonkawkeyoon et al (1993) Thalidomide inhibits the replication of human-immunodeficiency-virus type 1. Proc.Natl.Acad.Sci.U.S.A. 90 5974. PMID:8327469. Kanbayashi et al (1996) Thalidomide, a hypnotic with immune modulating properties, increases cataplexy in canine narcolepsy. Neuroreport 7 1881. PMID:8905685. Boireau et al (1997) Thalidomide reduces MPTP-induced decrease in striatal dopamine levels in mice. Neurosci.Lett. 234 123. PMID:9364513. Zhang et al (2008) Thalidomide influences growth and vasculogenic mimicry channel formation in melanoma. J.Exp.Clin.Cancer Res. 27 60. PMID:18983651."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1901	SQ1533			Jul-1996
0653	()-Vesamicol hydrochloride	[120447-62-3]	O[C@@H]1CCCC[C@H]1N(CC3)CCC3C2=CC=CC=C2.Cl	Inhibits ACh transport	Inhibitor of acetylcholine transport (Ki = 2 nM). Centrally active following systemic administration in vivo.	"Varoqui and Erickson (1996) Active transport of acetylcholine by the human vesicular acetylcholine transporter. J.Biol.Chem. 271 27229. PMID:8910293. Efange et al (1997) N-hydroxyalkyl derivatives of 3_-phenyltropane and 1-methylspiro[1H-indoline-3,4'-piperidine]: vesamicol analogues with affinity for monoamine transporters. J.Med.Chem. 40 3905. PMID:9397171. Kobayashi et al (1997) Effects of systemic administration of 2-(4-phenyl-piperidino)-cyclohexanol (vesamicol) and an organophosphate DDVP on the cholinergic system in brain regions of rats. Brain Res.Bull. 43 17. PMID:9205789."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1960				Mar-1997
0654	Verapamil hydrochloride	[152-11-4]	Cl.COC1=CC=C(C=C1OC)C(CCCN(C)CCC1=CC(OC)=C(OC)C=C1)(C#N)C(C)C	Ca2+ channel blocker (L-type)	"L-type calcium channel blocker. Vasodilator, adrenergic antagonist."	Ishibashi et al (1995) Block of P-type Ca2+ channels in freshly dissociated rat cerebellar Purkinje neurons by diltiazem and verapamil. Brain Res. 695 88. PMID:8574653. Lacinova et al (1995) Interaction of RO-40-5967 and verapamil with the stably expressed _1-subunit of the cardiac L-type calcium channel. J.Pharmacol.Exp.Ther. 274 54. PMID:7616442. Ustunes et al (1996) Effects of verapamil on intimal thickening and vascular reactivity in the collared carotid artery of the rabbit. Br.J.Pharmacol. 118 1681. PMID:8842432. Fleming et al (2011) Chemical modulators of autophagy as biological probes and potential therapeutics. Nat.Chem.Biol. 7 9. PMID:21164513.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1959	SQ1533			Jan-1995
0658	FGIN-1-27	[142720-24-9]	O=C(N(CCCCCC)CCCCCC)CC2=C(C3=CC=C(F)C=C3)NC1=CC=CC=C12	"Potent, specific ligand for mitochondrial DBI receptor"	"Binds specifically and with high affinity to the peptide DBI receptor (benzodiazepine receptor) on mitochondrial membranes, inducing production of neurosteroids, which modulate GABA receptors (EC50 = 3 nM for increase in production of pregnenolone in glial cells). Thus it reduces anxiety without causing sedation."	Romeo et al (1992) 2-Aryl-3-indoleacetamides (FGIN-1): a new class of potent and specific ligands for the mitochondrial DBI receptor (MDR). J.Pharmacol.Exp.Ther. 262 971. PMID:1326631. Kozikowski et al (1992) Synthesis of (2-arylindol-3-yl)acetamides as probes for mitochondrial steroidogenesis - a new mechanism of GABAA receptor modulation. Angew.Chem.Int.Ed. 31 1060.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1389				Sep-1994
0659	FGIN-1-43	[145040-29-5]	O=C(N(CCCCCC)CCCCCC)CC2=C(C3=CC=C(Cl)C=C3)NC1=CC=C(Cl)C=C12	"Potent, specific ligand for mitochondrial DBI receptor"	Most active of the 2-aryl-3-indoleacetamides; a new class of potent and specific ligands as probes for the mitochondial DBI receptor (peripheral benzodiazepine receptor).	"Romeo et al (1992) 2-Aryl-3-indoleacetamides (FGIN-1): a new class of potent and specific ligands for the mitochondrial DBI receptor (MDR). J.Pharmacol.Exp.Ther. 262 971. PMID:1326631. Kozikowski et al (1993) Chemistry, binding affinities, and behavioural properties of a new class of ""antineophobic"" mitochondrial DBI receptor (mDRC) ligands. J.Med.Chem. 36 2908. PMID:8411007."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1390				Sep-1994
0660	Mepyramine maleate	[59-33-6]	OC(=O)\C=C/C(O)=O.COC1=CC=C(CN(CCN(C)C)C2=CC=CC=N2)C=C1	Selective H1 inverse agonist	"Selective inverse agonist for the H1 receptor. Inhibits histamine induced inositol phosphate (InsP) production (log EC50 = -7.94) and intracellular calcium mobilization. Sequesters Gq/11 protein, reducing its availability for other receptors associated with the same signaling pathway."	"Hill (1990) Distribution, properties and functional characteristics of three classes of histamine receptor. Pharmacol.Rev. 42 45. PMID:2164693. Liu et al (1994) Does the [3H] mepyramine binding site represent the histamine H1 receptor? Re-examination of the histamine H2 receptor with quinine. J.Pharmacol.Exp.Ther. 268 959. PMID:8114011. Carlos et al (2004) Mepyramine, a histamine H1 receptor inverse agonist, binds perferentially to a G protein-coupled form of the receptor and sequesters G protein. J.Biol.Chem. 279 34431. PMID:15192105."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1576	SQ1533			Sep-1994
0661	2-MPMDQ	[149847-77-8]	COC1=C(C=CC=C1)N1CCN(CC2CN3C(=N2)C2=CC=CC=C2N(C)C3=O)CC1	"Potent, selective _1 antagonist. Also _2 ligand"	Potent and selective _1-adrenoceptor antagonist; hypotensive.	"Chern et al (1993) Studies on quinazolines. 2,3-Dihydroimidazo[1,2c]quinazoline derivatives. A novel class of potent and selective _1-adrenoceptor antagonists and antihypertensive agents. J.Med.Chem. 36 2196. PMID:8101878."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1595				Sep-1994
0662	trans-Triprolidine hydrochloride	[550-70-9]	Cl[H].CC1=CC=C(C=C1)C(=C/CN1CCCC1)\C1=CC=CC=N1	"Standard H1 antagonist, highly potent"	Potent H1 receptor antagonist.	Merck Index 12 9877. Hill (1990) Distribution properties and functional characteristics of three classes of histamine receptor. Pharmacol.Rev. 42 45. PMID:2164693.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1919	SQ1533			Sep-1994
0663	L-Arginine	[74-79-3]	NC(NCCC[C@H](N)C(O)=O)=N	Endogenous substrate for NOS	Precursor in the formation of nitric oxide.	Palmer et al (1988) Vascular endothelial cells synthesise NO from L-arginine. Nature 333 664. PMID:3131684. Schmidt et al (1992) Insulin secretion from pancreatic B cells caused by L-arginine-derived nitrogen oxides. Science 255 721. PMID:1371193.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1201	SQ1533			Sep-1994
0664	L-NNA	[2149-70-4]	N[C@H](C(O)=O)CCCNC(N[N+]([O-])=O)=N	NOS inhibitor (nNOS = eNOS >> iNOS)	NO synthase inhibitor.	Dwyer et al (1991) Nitric oxide synthase: irreversible inhibition by L-NG-nitroarginine in brain in vitro and in vivo. Biochem.Biophys.Res.Commun. 176 1136. PMID:1710109. Knowles et al (1994) Nitric oxide synthases in mammals. Biochem.J. 298 249. PMID:7510950.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1694				Sep-1994
0665	L-NAME hydrochloride	[51298-62-5]	N=C(NCCC[C@H](N)C(OC)=O)N[N+]([O-])=O.Cl	Non-selective NOS inhibitor	NO synthase inhibitor.	"Knowles et al (1994) Nitric oxide synthases in mammals. Biochem.J. 298 249. PMID:7510950. Pfeiffer et al (1996) Inhibition of nitric oxide synthesis by NG-nitro-L-arginine methyl ester (L-NAME): requirement for bioactivation to the free acid, NG-nitro-L-arginine. Br.J.Pharmacol. 118 1433. PMID:8832069. Moore and Handy (1997) Selective inhibitors of neuronal nitric oxide synthase - is no NOS really good NOS for the nervous system? TiPS 18 204. PMID:9226999."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1673	SQ1533			Sep-1994
0666	3-AQC	[201216-42-4]	OC(=O)\C=C/C(O)=O.C=CCN1CCN(CC1)C1=NC2=CC=CC=C2N=C1C#N	5-HT3 antagonist	"A competitive 5-HT3 antagonist, almost 100 times more potent than tropisetron, but with widely differing activity in various tissues."	Monge et al (1993) Novel antagonists of 5-HT3 receptors. Synthesis and biological evaluation of piperazinylquinoxaline derivatives. J.Med.Chem. 36 2745. PMID:8410988. Buznikov et al (2005) The pre-nervous serotonergic system of developing sea urchin embryos and larvae: pharmacologic and immunocytochemical evidence. Neurochem.Res. 30 825. PMID:16187217. Durk et al (2005) 5-Hydroxytryptamine modulates cytokine and chemokine production in LPS-primed human monocytes via stimulation of different 5-HTR subtypes. Int.Immunol. 17 599. PMID:15802305.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1056				Sep-1994
0668	Amthamine dihydrobromide	[142457-00-9]	Br.Br.CC1=C(CCN)SC(N)=N1	Highly selective standard H2 agonist	"Highly selective H2 agonist, slightly more potent than histamine itself. Only a weak antagonist at H3 and has no activity at H1 receptors. Induces vasodilation of cerebral arteries and decreases myogenic tone in vitro."	"Eriks et al (1992) Histamine H2-receptor agonists. Synthesis, in vitro pharmacology, and qualitative structure-activity relationships of substituted 4- and 5-(2-aminoethyl)thiazole. J.Med.Chem. 35 3239. PMID:1507209. Coruzzi et al (1993) The new potent and selective histamine H2 receptor agonist amthamine as a tool to study gastric secretion. Naunyn Schmiedebergs Arch.Pharmacol. 348 77. PMID:8377843. Poli et al (1993) In vitro cardiac pharmacology of the new histamine H2 receptor agonist amthamine; comparisons with histamine and dimaprit. Agents Actions 40 44. PMID:8147269. Jarajapu et al (2006) Histamine decreases myogenic tone in rat cerebral arteries by H2-receptor-mediated Kv channel activation, independent of endothelium and cyclic AMP. Eur.J.Pharmacol. 547 116. PMID:16920098."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1171				Sep-1994
0670	PK 11195	[85532-75-8]	CCC(C)N(C)C(=O)C1=NC(C2=CC=CC=C2Cl)=C2C=CC=CC2=C1	Antagonist at peripheral benzodiazepine receptors	"Possesses high affinity for the peripheral benzodiazepine receptor (PBR, TSPO) without binding to other known neurotransmitter receptors. Also inhibits the human constitutive androstane receptor (hCAR)."	"Le Fur et al (1983) Differentiation between two ligands for peripheral benzodiazpine binding sites [3H]-Ro 5-4864 and [3H]-PK11195, by thermodynamic studies. Life Sci. 33 449. PMID:6308375. Conway et al (1998) Temporal changes in glial fibrillary acidic protein messenger RNA and [3H]PK11195 binding in relation to imidazoline-I2-receptor and _2-adrenoceptor binding in the hippocampus following transient global forebrain ischaemia in the rat. Neuroscience 82 805. PMID:9483537. Li et al (2008) The peripheral benzodiazepine receptor ligand 1-(2-chlorophenyl-methylpropyl)-3-isoquinoline-carboxamide is a novel antagonist of human androstane receptor. Mol.Pharmacol. 74 443. PMID:18492798."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1804	SQ1533			Sep-1994
0671	AH 6809	[33458-93-4]	CC(C)OC1=CC=C2C(OC3=C(C=C(C=C3)C(O)=O)C2=O)=C1	EP1 and EP2 receptor antagonist	Antagonist at prostaglandin EP1 (pA2 = 6.8) and EP2 (Ki = 350 nM) receptors. Also weakly inhibits DP receptors (pA2 = 4.45).	"Coleman et al (1985) AH6809, a prostanoid EP1-receptor blocking drug. Br.J.Pharmacol. 85 273P. Keery and Lumley (1988) AH 6809, a prostaglandin DP-receptor blocking drug on human platelets. Br.J.Pharmacol. 94 745. PMID:2460179. Kiriyama et al (1997) Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells. Br.J.Pharmacol. 122 217. PMID:9313928. van der Merwe et al (2009) Prostaglandin E2 derived from cyclooxygenases 1 and 2 mediates intestinal epithelial ion transport stimulated by the activation of protease-activated receptor 2. J.Pharmacol.Exp.Ther. 329 747. PMID:19190238."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1050				Mar-1996
0673	L-Canavanine sulfate	[2219-31-0]	OS(O)(=O)=O.NC(NOCC[C@H](N)C(O)=O)=N	NOS inhibitor	NO synthase inhibitor.	Dokita et al (1994) Involvement of nitric oxide and cyclic GMP in rabbit urethral relaxation. Eur.J.Pharmacol. 269 269. PMID:7851504. Knowles et al (1994) Nitric oxide synthases in mammals. Biochem.J. 298 249. PMID:7510950. Teale and Atkinson (1994) L-Canavanine restores blood pressure in a rat model of endotoxic shock. Eur.J.Pharmacol. 271 87. PMID:7535234. Moore and Handy (1997) Selective inhibitors of neuronal nitric oxide synthase - is no NOS really good NOS for the nervous system? TiPS 18 204. PMID:9226999.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=2093				Sep-1994
0675	NPC 15199	[35661-60-0]	O=C(N[C@H](CC(C)C)C(O)=O)OCC1C(C=CC=C3)=C3C2=C1C=CC=C2	Increases intracellular Ca2+ levels	Anti-inflammatory agent; increases intracellular Ca2+ levels.	"Burch et al (1991) N-(Fluorenyl-9-methoxycarbonyl) amino acids, a class of anti-inflammatory agents with a different mechanism of action. Proc.Natl.Acad.Sci.U.S.A. 88 355. PMID:1824872. Miller et al (1993) Guinea pig ileitis is attenuated by the leumidin N-(fluorenyl-9-methoxycarbonyl)leucine (NPC 15199). J.Pharmacol.Exp.Ther. 266 468. PMID:8392562. Jan et al (2000) NPC-15199, a novel anti-inflammatory agent, mobilizes intracellular Ca2+ in bladder female transitional carcinoma (BFTC) cells. Chin.J.Physiol. 43 29. PMID:10857466."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1714				Sep-1994
0677	Naltrexone hydrochloride	[16676-29-2]	O=C3[C@H]5C24C1=C(O5)C(O)=CC=C1CC(N(CC6CC6)CC4)[C@@](O)2CC3.Cl	Broad spectrum opioid antagonist	Opioid antagonist.	"Gold et al (1982) Naltrexone, opiate addiction, and endorphins. Med.Res.Rev. 2 211. PMID:6289026. Tempel et al (1982) Supersensitivity of brain opiate receptor subtypes after chronic naltrexone treatment. Life Sci. 31 1401. PMID:6292636. Zukin et al (1982) Naltrexone-induced opiate receptor supersensitivity. Brain Res. 245 285. PMID:6289965."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1679	SQ1533			Sep-1994
0678	(+)-AJ 76 hydrochloride	[85378-82-1]	Cl.CCCN[C@@H]1CCC2=C(OC)C=CC=C2[C@@H]1C	Antagonist; preferential action at D2-like autoreceptors	"Dopamine receptor antagonist with preferential action at presynaptic receptors (pKi values are 6.95, 6.67, 6.37, 6.21 and 6.07 at hD3. hD4, hD2S, hD2L and rD2 receptors respectively)."	"Johansson et al (1987) Resolved cis and trans-2-amino-5-methoxy-1-methyltetralins: central dopamine receptor agonists and antagonists. J.Med.Chem. 30 602. PMID:3560156. Kullingsjo et al (1991) Effects of repeated administration of the preferential dopamine autoreceptor antagonist, (+)-AJ76, on locomotor activity and brain DA metabolism in the rat. Eur.J.Pharmacol. 205 241. PMID:1817961. Waters et al (1994) Intracerebral infusion of (+)-AJ76 and (+)-UH232: effects on dopamine release and metabolism in vivo. Eur.J.Pharmacol. 251 181. PMID:8149975. Millan et al (2004) The role of dopamine D3 compared with dopamine D2 receptors in the control of locomotor activity: a combined behavioural and neurochemical analysis with novel, selective antagonists in rats. Psychopharmacology 174 341. PMID:14985929."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1051				Jun-1997
0680	2-Phenylmelatonin	[151889-03-1]	COC1=CC=C2NC(=C(CCNC(C)=O)C2=C1)C1=CC=CC=C1	Potent melatonin agonist	Highly potent melatonin agonist; displays higher affinity and greater potency than melatonin itself. The EC50 values for G protein activation in MT1 and MT2-transfected cells are 65 and 58 pM respectively.	"Spadoni et al (1993) 2-Substituted 5-methoxy-N-acetyltryptamines: synthesis, binding affinity for the melatonin receptor, and evaluation of the biological activity. J.Med.Chem. 36 4069. PMID:8258829. Nonno et al (1998) Pharmacological characterization of the human melatonin Mel1a receptor following stable transfection into NIH3T3 cells. Br.J.Pharmacol. 124 485. PMID:9647472. Nonno et al (1999) Ligand efficacy and potency at recombinant human MT2 melatonin receptors: evidence for agonist activity of some mt1-antagonists. Br.J.Pharmacol. 127 1288. PMID:10455277."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1754				Jun-1995
0681	"L-690,330"	[142523-38-4]	CC(OC1=CC=C(O)C=C1)(P(O)(O)=O)P(O)(O)=O	Inositol monophosphatase inhibitor	A potent inhibitor of inositol monophophatase; stable to hydrolysis. Induces autophagy in COS-7 cells independently of mTOR inhibition.	"Atack et al (1993) In vitro and in vivo inhibition of inositol monophosphatase by the bisphosphonate L-690,330. J.Neurochem. 60 652. PMID:8380439. Atack et al (1994) Effects of L-690,488, a pro-drug of the bisphosphonate inisotol monophosphatase inhibitor L-690,330, on phosphatidylinisotol cycle markers. J.Pharmacol.Exp.Ther. 270 70. PMID:8035344. Sarkar et al (2005) Lithium induces autophagy by inhibiting inositol monophosphatase. J.Cell.Biol. 170 1101. PMID:16186256. Fleming et al (2011) Chemical modulators of autophagy as biological probes and potential therapeutics. Nat.Chem.Biol. 7 9. PMID:21164513."	Small Molecule	Sold with the permission of Merck Sharp and Dohme Ltd.	http://www.tocris.com/dispprod.php?ItemId=1542	SQ1533			Sep-1994
0683	iso-PPADS tetrasodium salt	[207572-67-6]	[Na+].[Na+].CC1=C(O)C(C=O)=C(CCP([O-])([O-])=O)C(\N=N\C2=C(C=CC(=C2)S(O)(=O)=O)S(O)(=O)=O)=N1	P2X antagonist	P2X-purinoceptor antagonist (pKi = 6.5) with similar activity to PPADS (Cat. No. 0625).	"Khakh et al (1994) Estimates of antagonist affinities at P2X purinoceptors in rat vas deferens. Eur.J.Pharmacol. 263 301. PMID:7843268. Trezise et al (1994) The use of antagonists to characterize the receptors mediating depolarization of the rat isolated vagus nerve by _,_-methylene adenosine 5'-triphosphate. Br.J.Pharmacol. 112 282. PMID:8032652. Connolly (1995) Differentiation by pyridoxal 5-phosphate, PPADS and isoPPADS between responses mediated by UTP and those evoked by _,_-methylene-ATP on rat sympathetic ganglia. Br.J.Pharmacol. 114 727. PMID:7735699."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1806				Sep-1994
0684	()-Epibatidine	[148152-66-3]	ClC(N=C3)=CC=C3C2C1CCC(C2)N1	High affinity nicotinic agonist	High affinity nicotinic agonist (Ki values are 0.02 and 233 nM for _4_2 and _7 nicotinic receptors respectively). Analgesic.	"Spande et al (1992) Epibatidine: a novel (chloropyridyl)azabicycloheptane with potent analgesic activity. J.Am.Chem.Soc. 114 3475. Badio and Daly (1994) Epibatidine, a potent analgesic and nicotinic agonist. Mol.Pharmacol. 45 563. PMID:8183234. Gerzarich et al (1995) Comparative pharmacology of epibatidine; a potent agonist for neuronal nicotinic acetylcholine receptors. Mol.Pharmacol. 48 774. PMID:7476906. Marks et al (1998) Differential agonist inhibition identifies multiple epibatidine binidng sites in mouse brain. J.Pharmacol.Exp.Ther. 285 377. PMID:9536034. Sharples et al (2000) UB-165 implicates _4_2 nAChR in striatal dopamine release. J.Neurosci. 20 2783. PMID:10751429."	Small Molecule	"Sold under license from the NIH, US Patent 5,314,899"	http://www.tocris.com/dispprod.php?ItemId=1367				Nov-1995
0685	Diltiazem hydrochloride	[33286-22-5]	[H][C@]2(C3=CC=C(OC)C=C3)[C@@]([H])(OC(C)=O)C(N(CCN(C)C)C1=CC=CC=C1S2)=O.Cl	Ca2+ channel blocker (L-type)	Antihypertensive and cardioprotective agent; an inhibitor of L-type Ca2+ channels.	"Merck Index 12 3247. Dagani et al (1989) Effects of diltiazem on bioenergetics, K+ gradients, and free cytosolic Ca2+ levels in rat brain synaptosomes submitted to energy metabolism inhibition and depolarization. J.Neurochem. 53 1379. PMID:2795006. Ishibashi et al (1995) Block of P-type Ca2+ channels in freshly dissociated rat cerebellar Purkinje neurons by diltiazem and verapamil. Brain Res. 695 88. PMID:8574653. Gandia et al (1996) Inhibition of nicotinic receptor-mediated responses in bovine chromaffin cells by diltiazem. Br.J.Pharmacol. 118 1301. PMID:8818357. Kraus et al (1998) Molecular mechanisms of diltiazem interaction with L-type Ca2+ channels. J.Biol.Chem. 273 27205. PMID:9765241."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1315	SQ1533			Sep-1994
0686	Galanthamine hydrobromide	[1953-04-4]	O[C@H]1C=C[C@]([C@]2=C(O4)C(OC)=CC=C2CN(CC3)C)3[C@@H]4C1.Br	Cholinesterase inhibitor	"Long-acting, centrally active acetylcholinesterase inhibitor (IC50 = 410 nM) and allosteric potentiator at neuronal nicotinic ACh receptors. Prevents _-amyloid-induced apoptosis in SH-SY5Y and bovine chromaffin cells. Long-term administration reduces amyloid precursor protein deposition and neurodegeneration in a mouse model of Alzheimer's disease."	"Sweeney et al (1989) Galanthamine, an acetylcholinesterase inhibitor: a time course of the effects on performance and neurochemical parameters in mice. Pharmacol.Biochem.Behav. 34 129. PMID:2626444. Harvey (1995) The pharmacology of galanthamine and its analogues. Pharmacol.Ther. 68 113. PMID:8604434. Capsoni et al (2002) Nerve growth factor and galantamine ameliorate early signs of neurodegeneration in anti-nerve growth factor mice. Proc.Natl.Acad.Sci.U.S.A. 99 12432. PMID:12205295. Samochocki et al (2003) Galantamine is an allosterically potentiating ligand of neuronal nicotinic but not of muscarinic acetylcholine receptors. J.Pharmacol.Exp.Ther. 305 1024. PMID:12649296. Arias et al (2004) Galantamine prevents apoptosis induced by _-amyloid and thapsigargin: involvement of nicotinic acetycholine receptors. Neuropharmacology 46 103. PMID:14654102."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1407	SQ1533			Sep-1994
0690	Clonidine hydrochloride	[4205-91-8]	Cl[H].ClC1=CC=CC(Cl)=C1\N=C1/NCCN1	_2 agonist. Also I1 ligand	Prototypical I1 imidazoline receptor ligand. _2-adrenergic receptor agonist. Antihypertensive. Also thought to enhance autophagy; shown to increase LC3-II levels in PC12 cells.	Merck Index 12 2450. Ernsberger et al (1987) Clonidine binds to imidazole binding sites as well as _2-adrenoceptors in the ventrolateral medulla. Eur.J.Pharmacol. 134 1. PMID:3030779. Greney et al (1994) Isolation of a human cerebral imidazoline-specific binding protein. Eur.J.Pharmacol. 265 R1. PMID:7883019. Silva et al (1996) Dual effect of clonidine on mesenteric artery adrenoreceptors: agonistic (alpha-2) and antagonistic (alpha-1). J.Pharmacol.Exp.ther. 277 872. PMID:8627569. Armitsu et al (1998) Mechanism of relaxant effect of clonidine in isolated bovine tracheal smooth muscle. J.Pharmacol.Exp.Ther. 286 681. PMID:9694921. Williams et al (2008) Novel targets for Huntington's disease in an mTOR-independent autophagy pathway. Nat.Chem.Biol. 4 295. PMID:18391949.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=2210	SQ1533			Sep-1994
0691	Dipyridamole	[58-32-2]	OCCN(CCO)C1=NC(N2CCCCC2)=C2N=C(N=C(N3CCCCC3)C2=N1)N(CCO)CCO	Adenosine transport inhibitor	"Coronary vasodilator; adenosine transport inhibitor. Phosphodiesterase inhibitor (IC50 values are 0.37, 0.38, 0.45, 0.9 and 4.5 _M  for PDE11, 6, 10, 5 and 8 respectively). Inhibits ENT1 and ENT2 (IC50 = 144.8 nM and Ki = 8.18 nM for ENT1)."	"Meester et al (1998) Pharmacological analysis of the activity of the adenosine uptake inhibitor, dipyridamole, on the sinoatrial and atrioventricular nodes of the guinea-pig. Br.J.Pharmacol. 124 729. PMID:9690865. Soderling et al (1998) Cloning and characterization of a cAMP-specific cyclic nucleotide phosphodiesterase. Proc.Natl.Acad.Sci.U.S.A. 95 8991. PMID:9671792. Fujishige et al (1999) Cloning and characterization of a novel human phosphodiesterase that hydrolyzes both cAMP and cGMP (PDE10A). J.Biol.Chem. 274 18438. PMID:10373451. Lin and Buolamwini et al (2007) Synthesis, flow cytometric evaluation, and identification of highly potent dipyridamole analogues as equilibrative nucleoside transporter 1 inhibitors. J.Med.Chem. 50 3906. PMID:17636949."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1335	SQ1533			Sep-1994
0692	Ipratropium bromide	[22254-24-6]	O=C(C(CO)C3=CC=CC=C3)O[C@@H]1CC2CCC([N+](C)2C(C)C)C1.[Br-]	Muscarinic antagonist	"Muscarinic antagonist, bronchodilator. N-Isopropyl salt of atropine."	Merck Index 12 5089. Fryer and Maclagan (1987) Ipratropium bromide potentiates bronchoconstriction induced by vagal nerve stimulation in the guinea-pig. Eur.J.Pharmacol. 139 187. PMID:2958300.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1531	SQ1533			Sep-1994
0693	Pancuronium dibromide	[15500-66-0]	[H][C@]34C2([H])CC[C@@]1([H])C[C@H](OC(C)=O)C([N+]6(C)CCCCC6)CC(C)1[C@]([H])2CCC(C)3C(OC(C)=O)C([N+]5(C)CCCCC5)C4.[Br-].[Br-]	Nicotinic (neuromuscular) antagonist	Nicotine (neuromuscular) antagonist. Skeletal muscle relaxant.	Merck Index 12 7139. Fryer and Maclagan (1987) Pancuronium and gallamine are antagonists for pre- and post-junctional muscarinic receptors in the guinea-pig lung. Naunyn Schmiedebergs Arch.Pharmacol. 335 367. PMID:3600815. Maestrone et al (1994) Extracellular pancuronium affects sodium current in chick embryo sensory neurones. Br.J.Pharmacol. 111 283. PMID:8012707. Lowenick et al (2001) Open channel and competitive block of nicotinic receptors by pancuronium and atracurium. Eur.J.Pharmacol. 413 31. PMID:11173060.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1738	SQ1533			Sep-1994
0694	Pilocarpine hydrochloride	[54-71-7]	O=C1[C@@]([H])(CC)[C@](CC2=CN=CN2C)([H])CO1.Cl	Muscarinic agonist	Muscarinic agonist.	"Merck Index 12 7578. Brown and Taylor (1996) Muscarinic receptor agonists and antagonists. The Pharmacological Basis of Therapeutics. Eds Goo Chapter 7, p147. ten Berge et al (1996) Differences in the prejunctional effects of methacholine and pilocarpine on the release of endogenous acetylcholine from guinea-pig trachea. Naunyn Schmiedebergs Arch.Pharmacol. 354 606. PMID:8938659. Wang et al (1999) Pilocarpine modulates the cellular electrical properties of mammalian hearts by activating a cardiac M3 receptor and a K+ current. Br.J.Pharmacol. 126 1725. PMID:10372814."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1780	SQ1533			Sep-1994
0695	Retinoic acid	[302-79-4]	CC(/C=C/C1=C(C)CCCC1(C)C)=C\C=C\C(C)=C\C(O)=O	Endogenous retinoic acid receptor agonist	"Endogenous agonist for retinoic acid receptors (IC50 = 14 nM for RAR_, RAR_ and RAR_ receptors). Also promotes differentiation of mouse embryonic stem cells (ESCs) into adipocytes, neurons and glia in vitro. Proposed ligand of ROR_ (Kd = 280 nM)."	Merck Index 12 8333. Apfel et al (1992) A retinoic acid receptor alpha antagonist selectively counteracts retinoic acid effects. Proc.Natl.Acad.Sci.U.S.A. 89 7129. PMID:1323127. Sanquer and Gilchrest (1994) Characterisation of human cellular retinoic acid binding proteins-1 and -2: ligand binding affinities and distribution in skin. Arch.Biochem.Biophys. 311 86. PMID:8185324. Dani et al (1997) Differentiation of embryonic stem cells into adipocytes in vitro. J. Cell Sci. 110 1279. PMID:9202388. Stehlin-Gaon et al (2003) All-trans retinoic acid is a ligand for the orphan nuclear receptor ROR_. Nat.Struct.Biol. 10 820. PMID:12958591.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1835	SQ1533			Sep-1994
0699	BRL 52537 hydrochloride	[112282-24-3]	Cl.ClC1=CC=C(CC(=O)N2CCCCC2CN2CCCC2)C=C1Cl	Potent and selective _ agonist	The most _/_-selective and among the most potent _ ligands known (25 times more potent than morphine in vivo).	"Vecchietti et al (1991) (2S)-1-(Arylacetyl)-2-(aminomethyl)piperidine derivatives: novel, highly selective _ opioid analgesics. J.Med.Chem. 34 397. PMID:1846921."	Small Molecule	Sold with the permission of GlaxoSmithKline	http://www.tocris.com/dispprod.php?ItemId=2043				Feb-1999
0701	3'-Fluorobenzylspiperone maleate	[1135278-61-3]	OC(=O)\C=C/C(O)=O.FC1=CC=C(C=C1)C(=O)CCCN1CCC2(CC1)N(CN(CC1=CC=CC(F)=C1)C2=O)C1=CC=CC=C1	D2-like receptor ligand	"A very potent and selective ligand for the D2 receptor (Ki = 0.023 nM). Compared with spiperone, displays a 2.5-fold greater affinity at D2 and a 12-fold lower affinity at 5-HT2 receptors."	Mach et al (1992) Effect of N-alkylation on the affinities of analogues of spiperone for dopamine D2 and serotonin 5-HT2 receptors. J.Med.Chem. 35 423. PMID:1531364.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1394				Sep-1994
0702	BTCP maleate	[207455-25-2]	OC(=O)\C=C/C(O)=O.C1CCN(CC1)C1(CCCCC1)C1=CC2=CC=CC=C2S1	Potent dopamine uptake inhibitor	A potent dopamine re-uptake inhibitor with a behavioral profile different from that of PCP and similar to that of cocaine.	"Vignon et al (1988) [3H]N-[1-(2-benzo[b]thiophenyl)cyclohexyl]piperidine ([3H]BTCP): a new phencyclidine analogue selective for the dopamine uptake complex. Eur.J.Pharmacol. 148 427. PMID:3384005. Koek et al (1989) The phencyclidine (PCP) analogue N-[1-(2-benzo(b)thiophenyl)cyclohexyl]piperidine shares cocaine-like but not other characteristic behavioural effects with PCP, ketamine and MK-801. J.Pharmacol.Exp.Ther. 250 1019. PMID:2674416. Chergui et al (1992) Inhibition of the locus coeruleus neurons by the phenylcyclidine analog, N-[1-(2-benzo(b thiophenyl)cyclohexyl]-piperidine: evidence for potent indirect adrenoceptor agonist properties. Eur.J.Pharmacol. 219 169. PMID:1397045."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=2076				Sep-1994
0703	Anpirtoline hydrochloride	[99201-87-3]	Cl.ClC1=NC(SC2CCNCC2)=CC=C1	Highly potent 5-HT1B agonist. Also 5-HT3 antagonist	"Highly potent 5-HT1B receptor agonist (Ki values are 28, 150 and 1490 nM at 5-HT1B, 5-HT1A and 5-HT2 receptors respectively). Decreases central serotonin synthesis and attenuates aggressive behavior in vivo. Also acts as an antagonist at 5-HT3 receptors (Ki = 29.5 nM) and is brain penetrant."	"Swedberg et al (1992) D-16949 (anpirtoline): a novel serotonergic (5-HT1B) psychotherapeutic agent assessed by its discriminative effect in the rat. J.Pharmacol.Exp.Ther. 263 1015. PMID:1335050. Gthert et al (1995) 5HT3 receptor antagonism by anpirtoline, a mixed 5HT1 receptor agonist/5HT3 receptor antagonist. Br.J.Pharmacol. 114 269. PMID:7881726. Almeida and Miczek (2002) Aggression escalates by social instigation or by discontinuation of reinforcement (""frustration"") in mice: inhibition by anpirtoline: a 5-HT1B receptor agonist. Neuropsychopharmacology 27 171. PMID:12093591. Watanabe et al (2006) Effects of anpirtoline on regional serotonin synthesis in the rat brain: an autoradiographic study. Nucl.Med.Biol. 33 325. PMID:16631081."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1173	SQ1533			Jul-1996
0705	"L-701,252"	[151057-13-5]	OC1=C(C(=O)C2CC2)C(=O)NC2=C1C=CC(Cl)=C2	"NMDA antagonist, acts glycine site"	An antagonist at the glycine-NMDA site (IC50 = 420 nM). Also a potent systemic anticonvulsant.	Rowley et al (1993) 3-Acyl-4-hydroxyquinolin-2(1H)-ones. Systemically active anticonvulsants acting by antagonism at the glycine site of the NMDA receptor complex. J.Med.Chem. 36 3386. PMID:8230129. Stone (2000) Development and therapeutic potential of kynurenic acid and kynurenine derivatives for neuroprotection. TiPS 21 149. PMID:10740291.	Small Molecule	Sold with the permission of Merck Sharp and Dohme Ltd.	http://www.tocris.com/dispprod.php?ItemId=1545				Mar-1995
0706	7-Hydroxy-DPAT hydrobromide	[76135-30-3]	Br.CCCN(CCC)C1CCC2=CC=C(O)C=C2C1	Dopamine agonist (D3  D2 < > D4)	"D3 dopamine receptor agonist (Ki values are ~ 1, 10, 650 and ~ 5000 nM for D3, D2, D4 and D1 receptors respectively). (R)-(+)-8-Hydroxy-DPAT hydrobromide (Cat. No. 1080) and 8-Hydroxy-DPAT hydrobromide (Cat. No 0529) also available."	"Levesque et al (1992) Identification, characterization, and localization of the dopamine D3 receptor in rat brain using [3H]-7-hydroxy-N,N-di-n-propyl-2-aminotetralin. Proc.Natl.Acad.Sci.U.S.A. 89 8155. PMID:1518841. Daly and Waddington (1993) Behavioural effects of the D3 dopamine receptor agonist 7-OH-DPAT in relation to other D2-like agonists. Neuropharmacology 32 509. PMID:8321432. Seeman and Van Tol (1994) Dopamine receptor pharmacology. TiPS 15 264. PMID:7940991. Levesque (1996) Aminotetralin drugs and D3 receptor fuctions. Biochem.Pharmacol. 52 511. PMID:8759022."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1467				Nov-1995
0711	MAP4	[157381-42-5]	N[C@](CCP(O)(O)=O)(C)C(O)=O	Potent group II mGlu agonist. Also specific group III mGlu antagonist	Selective group III metabotropic glutamate receptor antagonist in some electrophysiological systems. Group II/group III agonist in certain neurochemical systems.	"Jane et al (1994) Actions of two new sub-type selective metabotropic glutamate receptor antagonists in the neonatal rat spinal cord. Br.J.Pharmacol. 112 809. PMID:7921606. Salt and Eaton (1995) Distinct presynaptic metabotropic receptors for L-AP4 and CCGl on GABAergic terminals: pharmacological evidence using novel _-methyl derivative mGluR antagonists, MAP4 and MCCG, in the rat thalamus in vivo. Neuroscience 65 5. PMID:7753406. Sekiyama et al (1996) Structure-activity relationships of new agonists and antagonists of different metabotropic glutamate receptor subtypes. Br.J.Pharmacol. 117 1493. PMID:8730745. Kemp et al (1996) Agonists of cyclic AMP-coupled metabotropic glutamate receptors in adult rat cortical slices. Eur.J.Pharmacol. 309 79. PMID:8864697."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1559				Jan-1901
0713	Cyclothiazide	[2259-96-3]	NS(=O)(=O)C1=C(Cl)C=C2NC(NS(=O)(=O)C2=C1)C1CC2CC1C=C2	AMPA selective desensitization inhibitor	Positive allosteric modulator of AMPA receptors that potently inhibits AMPA receptor desensitization. Selective for the flip variant of each of the four receptor subunits. Also available as part of the AMPA Receptor Tocriset.	"Desai et al (1995) Cyclothiazide acts at a site on the _-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptor complex that does not recognise competitive or noncompetitive AMPA receptor antagonists. J.Pharmacol.Exp.Ther. 272 38. PMID:7529311. Donevan and Rogawski (1998) Allosteric regulation of a-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptors by thiocyanate and cyclothiazide at a common modulatory site distinct from that of 2,3-benzodiazepines. Neuroscience 87 615. PMID:9758228. Kessler et al (2000) The norbornenyl moiety of cyclothiazide determines the preference for flip-flop variants of AMPA receptor subunits. Neurosci.Lett. 287 161. PMID:10854736."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=2237	SQ1070			Sep-1994
0719	7-Hydroxy-PIPAT maleate	[200722-46-9]	OC(=O)\C=C/C(O)=O.CCCN(C\C=C\I)C1CCC2=CC=C(O)C=C2C1	D3 agonist (D3 > D2)	This ligand has uniquely high affinity and selectivity for the D3 receptor. 8-Hydroxy-PIPAT maleate (Cat. No. 0797) also available.	"Chumpradit et al (1993) Synthesis and optical resolution of (R)- and (S)-trans-7-hydroxy-2-[N-propyl-N-(3'-iodo-2'-propenyl)amino]tetralin: a new D3 dopamine receptor ligand. J.Med.Chem. 36 4308. PMID:8277513. Foulon et al (1993) Synthesis of (R,S)-2'-trans-7-hydroxy-2-[N-n-propyl-N-(3'-iodo-2'-amino]tetralin (trans-7-OH-PIPAT): a new D3 dopamine receptor ligand. J.Med.Chem. 36 1499. PMID:8098771. Kung et al (1993) In vitro binding of a novel dopamine D3 receptor ligand: [125I]-trans-7-OH-PIPAT. Eur.J.Pharmacol. 235 165. PMID:8519278."	Small Molecule	Sold with the permission of the University of Pennsylvania	http://www.tocris.com/dispprod.php?ItemId=1483				Sep-1998
0721	Aminopotentidine	[140873-26-3]	O=C(C3=CC=C(N)C=C3)NCCNC(NCCCOC1=CC(CN2CCCCC2)=CC=C1)=NC#N	H2 antagonist	H2 antagonist (KB values are 220 and 280 nM at human and guinea pig H2 receptors respectively) and precursor for the synthesis of the [125I]-iodo derivative.	Ruat et al (1990) Reversible and irreversible labeling and autoradiographic localisation of the cerebral histamine H2 receptor using [125I]iodinated probes. Proc.Natl.Acad.Sci.USA 87 1658. PMID:2308927. Hirschfield et al (1992) Iodoaminopotentidine and related compounds: a new class of ligands with high affinity and selectivity for the histamine H2 receptor. J.Med.Chem. 35 2231. PMID:1613748. Xie et al (2006) Synthesis and pharmacological characterization of novel fluorescent histamine H2-receptor ligands derived from aminopotentidine. Bioorg.Med.Chem.Lett. 16 3886. PMID:16730977.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1145				Feb-2008
0722	N-Acetyl-N-acetoxy-4-chlorobenzenesulfonamide	[142867-52-5]	ClC1=CC=C(S(N(C(C)=O)OC(C)=O)(=O)=O)C=C1	Nitroxyl precursor	"A pro-drug of the potent vasorelaxant nitroxyl, H-N=O, which it slowly releases in neutral solution. HNO eventually dimerizes and dehydrates to N2O, without producing NO. Also a powerful inhibitor of aldehyde dehydrogenase."	"Fukuto et al (1992) N,O-Diacylated-N-hydroxyarylsulfonamides: nitroxyl precursors with potent smooth muscle relaxant properties. Biochem.Biophys.Res.Commun. 187 1367. PMID:1417812. Lee et al (1992) Prodrugs of nitroxyl as inhibitors of aldehyde dehydrogenase. J.Med.Chem. 35 3648. PMID:1433175."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1020				Dec-1994
0723	Tetrindole mesylate	[170964-68-8]	CS(O)(=O)=O.C1CCC(CC1)C1=CC=C2N3CCNC4CCCC(=C34)C2=C1	MAO-A inhibitor	"Novel antidepressant, a selective inhibitor of MAO-A."	"Medvedev et al (1994) Monoamine oxidase inhibition by novel antidepressant tetrindole. Biochem.Pharmacol. 47 303. PMID:8304974. Bos et al (1995) Resolution, EPC-syntheses, absolute stereochemistry, and pharmacology of the (S)-(+)- and (R)-(-)-isomers of the MAO-A inhibitor tetrindole hydrochloride. Arch.Pharm. (Wenheim) 328 619. PMID:7492268. Korshunov et al (2000) Hemodynamic effects of tetrindol in alert normotensive mice and rats after blockade of nitric oxide synthesis. Bull.Exp.Biol.Med. 130 777. PMID:11177242."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1900				Nov-1994
0724	Pirlindole mesylate	[207572-66-5]	CS(O)(=O)=O.CC1=CC=C2N3CCNC4CCCC(C2=C1)=C34	MAO-A inhibitor	A highly selective reversible inhibitor of monoamine oxidase type A.	"Mashkovsky and Andreeva (1981) Pharmacological properties of 2,3,3_,4,5,6-hexahydro-8-methyl-1H-pyrazino[3,2,1-j,k]carbazole hydrochloride (pirlindole), a new antidepressant. Arzneim.-Forsch.Drug Res. 31 75. PMID:7194096. Medvedev et al (1992) Efficacy of pirlindole, a highly selective reversible inhibitor of monoamine oxidase type A in the prevention of experimentally induced epiletic seizures. Drug Investigation. 4 501."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1798	SQ1533			Nov-1994
0725	BU 224 hydrochloride	[205437-64-5]	Cl.C1CN=C(N1)C1=NC2=CC=CC=C2C=C1	"Potent, selective I2 ligand. Putative antagonist"	High affinity ligand for the imidazoline I2 binding site (Ki = 2.1 nM). Putative I2 antagonist; antagonizes the effects of imidazoline ligands on morphine antinociception. Produces ipsiversive rotational behavior in rats with a full 6-OHDA lesion of the nigrostriatal tract.	Hudson et al (1994) Affinity and selectivity of BU224 and BU239 for rabbit brain non-adrenoceptor idazoxan binding sites (I2) sites). Br.J.Pharmacol. 112 320P. Hudson et al (1999) Novel selective compounds for the investigation of imidazoline receptors. Ann.N.Y.Acad.Sci. 881 81. PMID:10415900. Sanchez-Blasquez et al (2000) Activation of I2-imidazoline receptors enhances supraspinal morphine analgesia in mice: a model to detect agonist and antagonist activities at these receptors. Br.J.Pharmacol. 130 146. PMID:10781010. MacInnes and Dut (2004) Locomotor effects of imidazoline I2-site-specific ligands and monoamine oxidase inhibitors in rats with a unilateral 6-hydroxydopamine lesion of the nigrostriatal pathway. Br.J.Pharmacol. 143 952. PMID:15545290.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=2082				Sep-1998
0726	BU 239 hydrochloride	[1217041-98-9]	Cl.C1CN=C(N1)C1=NC2=CC=CC=C2N=C1	"Potent, highly selective I2 ligand"	High affinity ligand for the imidazoline I2 binding site.	Hudson et al (1994) Affinity and selectivity of BU224 and BU239 for rabbit brain non-adrenoceptor idazoxan binding sites (I2 sites). Br.J.Pharmacol. 112 320P. Lione et al (1996) Affinity and selectivity of BU 224 and BU 239 for rat and guinea-pig brain I2 imidazoline sites. Br.J.Pharmacol. 117 297P.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=2083				Jan-1996
0727	Pyrrolidinedithiocarbamate ammonium	[5108-96-3]	[NH4+].[S-]C(N1CCCC1)=S	"Inhibits NF-_B, prevents increase in NOS mRNA"	"This inhibitor of nuclear factor _B (NF-_B) prevents the increase in NO-synthase mRNA by interleukin-1, without affecting the formation of NO-synthase mRNA produced by cAMP."	"Bessho et al (1994) Pyrrolidine dithiocarbamate, a potent inhibitor of nuclear factor _B (NF-_B) activation, prevents apoptosis in human promyelocytic leukemia HL-60 cells and thymocytes. Biochem.Pharmacol. 48 1883. PMID:7986199. Eberhardt et al (1994) Pyrrolidine dithiocarbamate differentially affects 1_- and cAMP-induced NO-synthase expression in rat renal mesangial cells. Biochem.Biophys.Res.Commun. 200 163. PMID:7513157. Schini-Kerth (1994) Pyrrolidine dithiocarbamate selectively prevents the expression of the inducible nitric oxide synthase in the rat aorta. Eur.J.Pharmacol. 265 83. PMID:7533726."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1161				Nov-1994
0728	RS 23597-190 hydrochloride	[149719-06-2]	Cl.COC1=CC(N)=C(Cl)C=C1C(=O)OCCCN1CCCCC1	5-HT4 antagonist	"A high affinity, selective competitive antagonist at 5-HT4 receptors."	Eglen et al (1993) RS 23597-190: a potent and selective 5-HT4 receptor antagonist. Br.J.Pharmacol. 110 119. PMID:8220871. Eglen et al (1995) Central 5-HT4 receptors. TiPS 16 391. PMID:8578609.	Small Molecule	Sold with the permission of Roche Bioscience	http://www.tocris.com/dispprod.php?ItemId=1842				Jul-1998
0729	Imetit dihydrobromide	[32385-58-3]	Br.Br.NC(=N)SCCC1=CNC=N1	Standard H3 and H4 agonist (H3 > H4)	"An extremely potent, high affinity agonist at H3 and H4 receptors (Ki values are 0.3 and 2.7 nM respectively). Induces shape change in eosinophils with an EC50 of 25 nM. Centrally active following systemic administration. Also available as part of the Histamine H3 Receptor Tocriset."	"Garbarg et al (1992) S-[2-(4-Imidazolyl)ethyl]isothiourea, a highly specific and potent histamine H3 receptor agonist. J.Pharmacol.Exp.Ther. 263 304. PMID:1383495. Farzin and Attarzadeh (2000) Influence of different histamine receptor agonists and antagonists on apomorphine-induced licking behavior in rats. Eur.J.Pharmacol. 404 169. PMID:10980276. Ling et al (2004) Histamine H4 receptor mediates eosinophil chemotaxis with cell shape change and adhesion molecule upregulation. Br.J.Pharmacol. 142 161. PMID:15131002."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1515				Nov-1994
0730	"4-Phenyl-1,2,3,4-tetrahydroisoquinoline hydrochloride"	[6109-35-9]	Cl.C1NCC2=C(C=CC=C2)C1C1=CC=CC=C1	DA release inhibitor	Inhibitor of release of dopamine induced by methamphetamine.	"Tateyama et al (1993) 4-Phenyltetrahydroisoquinoline, but not nomifensine or cocaine, inhibits methamphetamine-induced dopamine release. Eur.J.Pharmacol. 240 51. PMID:8405121."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1759				Dec-1994
0731	Sulfisoxazole	[127-69-5]	CC1=NOC(NS(=O)(=O)C2=CC=C(N)C=C2)=C1C	Endothelin ETA antagonist	A selective ETA endothelin receptor antagonist (IC50 values are 600 and 2200 nM for ETA and ETB receptors respectively).	Chan et al (1994) Identification of a new class of ETA selective endothelin antagonists by pharmacophore directed screening. Biochem.Biophys.Res.Commun. 201 228. PMID:8198578.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1885	SQ1070			Nov-1994
0735	3-Bromo-7-nitroindazole	[74209-34-0]	[O-][N+](=O)C1=C2NN=C(Br)C2=CC=C1	Selective nNOS inhibitor	Potent inhibitor of rat cerebellar nitric oxide synthase; more potent than 7-nitroindazole (Cat. No. 0602).	"Bland-Ward et al (1994) Isoform selectivity of indazole-based nitric oxide synthase inhibitors. Br.J.Pharmacol. 112 351P. Bland-Ward and Moore (1995) 7-Nitroindazole derivatives are potent inhibitors of brain, endothelium and inducible isoforms of nitric oxide synthase. Life Sci. 57 PL131. PMID:7544863."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=2068				Oct-1994
0736	2-[1-(4-Piperonyl)piperazinyl]benzothiazole	[155106-73-3]	C(N1CCN(CC1)C1=NC2=CC=CC=C2S1)C1=CC2=C(OCO2)C=C1	5-HT4 agonist. Also 5-HT3 antagonist	5-HT4 receptor agonist with moderate activity as a 5-HT3 antagonist. Has no affinity at 5-HT1 or dopamine D2 receptors. Potential gastrokinetic agent.	Monge et al (1994) Synthesis of 2-piperazinybenzothiazole and 2-piperazinylbenzoxazole derivatives with 5-HT3 antagonist and 5-HT4 agonist properties. J.Med.Chem. 37 1320. PMID:8176710.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1797				Jan-1995
0737	2-Iodomelatonin	[93515-00-5]	COC1=CC=C2NC(I)=C(CCNC(C)=O)C2=C1	High affinity melatonin agonist	"Potent melatonin agonist (pKi values are 10.55 and 9.87 at human recombinant MT1 and MT2 receptors respectively). 2-[125I]-iodomelatonin has been used to identify, characterize and localize melatonin binding sites in the brain and peripheral tissues."	Dubocovich and Takahashi (1987) Use of 2-[125l]-iodomelatonin to characterize melatonin sites in chicken retina. Proc.Natl.Acad.Sci.U.S.A. 84 3916. PMID:3035559. Suiciak et al (1991) Quantitative pharmacological analysis of 2-[125l]-iodomelatonin binding sites in discrete areas of the chicken brain. J.Neurosci. 11 2855. PMID:1652626. Browning et al (2000) Pharmacological characterization of human recombinant melatonin mt1 and MT2 receptors. Br.J.Pharmacol. 129 877. PMID:10696085.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1523				Apr-1998
0740	Naltrindole hydrochloride	[111469-81-9]	O[C@@]24[C@]3([C@@H]7C(N6)=C(C5=C6C=CC=C5)C4)C1=C(O7)C(O)=CC=C1CC2N(CC8CC8)CC3.Cl	_ selective non-peptide antagonist	"Highly selective non-peptide _ opioid antagonist, showing 223- and 346-fold greater activity at _ than at _  and _ opioid receptors."	"Portoghese et al (1990) Design of peptidomimetic _ opioid receptor antagonists using the message-address concept. J.Med.Chem. 33 1714. PMID:2160538. Ossipov et al (1994) Naltrindole, an opioid _ antagonist, blocks the enhancement of morphine-antinociception induced by a CCKB antagonist in the rat. Neurosci. Lett. 181 9. PMID:7898778. Shippenberg and Heidbreder (1995) The _-opioid receptor antagonist naltrindole prevents sensitization to the conditioned rewarding effects of cocaine. Eur.J.Pharmacol. 280 55. PMID:7498254."	Small Molecule	Sold with the permission of the University of Minnesota.	http://www.tocris.com/dispprod.php?ItemId=1681				Aug-1997
0741	GF 109203X	[133052-90-1]	CN(C)CCCN1C=C(C2=CC=CC=C12)C1=C(C(=O)NC1=O)C1=CNC2=CC=CC=C12	Protein kinase C inhibitor	"Very potent and selective inhibitor of protein kinase C, selective for the _ and _1 isoforms (IC50 values are 0.0084, 0.0180, 0.210, 0.132, and 5.8 _M for _, _1, _, _ and _ isoforms respectively). Selective over MLCK, PKG and PKA (IC50 values are 0.6, 4.6, and 33 _M respectively). Potent antagonist at the 5-HT3 receptor (Ki = 29.5 nM). Anti-inflammatory in vivo."	"Toullec et al (1991) The bisindolylmaleimide GF 109203X is a potent and selective inhibitor of protein kinase C. J.Biol.Chem. 266 15771. PMID:1874734. Martiny-Baron et al (1993) Selective inhibition of protein kinase C isozymes by the indolocarbazole Go 6976. J.Biol.Chem. 268 9194. PMID:8486620. Jacobson et al (1995) Anti-inflammatory properties of Go 6850: a selective inhibitor of protein kinase C. J.Pharmacol.Exp.Ther. 275 995. PMID:7473193. Coultrap et al (1999) Competitive antagonism of the mouse 5-hydroxytryptamine3 receptor by bisindolylmaleimide I, a ""selective"" protein kinase C inhibitor. J.Pharmacol.Exp.Ther. 290 76. PMID:10381762. Jiang et al (2011) Heat shock protein 90-mediated inactivation of nuclear factor-_B switches autophagy to apoptosis through becn1 transcriptional inhibition in selenite-indeced NB4 cells. Mol.Biol.Cell. 22 1167. PMID:21346199."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1418	SQ1070			Oct-1998
0742	"L-689,560"	[139051-78-8]	ClC1=C2C(N[C@@H]([C@](O)=O)C[C@@H]2NC(NC3=CC=CC=C3)=O)=CC(Cl)=C1	Very potent NMDA antagonist	Very potent antagonist at the glycine-NMDA site. Also available as part of the NMDA Receptor - Glycine Site Tocriset.	Leeson et al (1991) trans-2-Carboxy-4-substituted tetrahydroquinolines. Potent glycine-site NMDA receptor antagonists. Med.Chem.Res. 1 64. Leeson et al (1992) 4-Amido-2-carboxytetrahydroquinolines. Structure-activity relationship for antagonism at the glycine site of the NMDA receptor. J.Med.Chem. 35 1954. PMID:1534584. Stone (2000) Development and therapeutic potential of kynurenic acid and kynurenine derivatives for neuroprotection. TiPS 21 149. PMID:10740291.	Small Molecule	Sold with the permission of Merck Sharp and Dohme Ltd.	http://www.tocris.com/dispprod.php?ItemId=1541				Jul-1998
0743	DPPE fumarate	[1185241-83-1]	[H]OC(=O)\C=C\C(=O)O[H].CCN(CC)CCOC1=CC=C(CC2=CC=CC=C2)C=C1	Inhibitor of histamine binding at the intracellular binding site	Binds with high affinity to the antiestrogen binding site but not to the estrogen receptor. Induces of sterol accumulation in MCF7 cells. An inhibitor of histamine binding at the intracellular histamine (Hlc) site.	Brandes and Hermonat (1984) A diphenylmethane derivative specific for the antiestrogen binding site found in rat liver microsomes. Biochem.Biophys.Res.Commun. 123 724. PMID:6548377. Brandes et al (1990) Histamine as an intracellular messenger. Biochem.Pharmacol. 40 1677. PMID:2242003. Sturman et al (1994) Modulation of the intracellular and H3-histamine receptors and chemically-induced seizures in mice. Agents Actions 41 C68. PMID:7976808. Kedjouar et al (2004) Molecular characterization of the microsomal tamoxifen binding site. J.Biol.Chem. 279 34048. PMID:15175332.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1350	SQ1533			Nov-1994
0744	Ceramide	[3102-57-6]	OC[C@@](NC(C)=O)([H])[C@H](O)/C([H])=C([H])/CCCCCCCCCCCCC	Ser/Thr protein phosphatase activator	"A potent modulator of cell proliferation and differentiation. Activates protein phosphatase-1 (PP1) and -2A (PP2A), as well as ceramide-activated protein phosphatase (CAPP) in vitro."	"Kim et al (1991) Identification of sphingomyelin turnover as an effector mechanism for the action of tumor necrosis factor _ and _-interferon. J.Biol.Chem. 266 484. PMID:1845977. Dobowsky and Hannun (1992) Ceramide stimulates a cytosolic protein phosphatase. J.Biol.Chem. 267 5048. PMID:1312082. Quintans et al (1994) Ceramide mediates the apoptotic response of WEHI 231 cells to anti-immunoglobulin, corticosteroids and irradiation. Biochem.Biophys.Res.Commun. 202 710. PMID:8048941. Xie and Johnson (1997) Ceramide selectively decreases tau levels in differentiated PC12 cells through modulation of calpain I. J.Neurochem. 69 1020. PMID:9282924."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=2144				Sep-1995
0746	Zinc protoporphyrin IX	[15442-64-5]	C=CC1=C(/C=C3\N=C(/C=C(N5[Zn]6)/C(C)=C(CCC(O)=O)/C5=C4)C(C=C)=C3C)N6C(/C=C2/C(C)=C(CCC(O)=O)C/4=N2)=C1C	Heme oxygenase and guanylyl cyclase inhibitor	"Inhibitor of heme oxygenase, which generates the putative neurotransmitter CO."	Brune and Ullrich (1987) Inhibition of platelet aggregation by carbon monoxide is mediated by activation of guanylate cyclase. Mol.Pharmacol. 32 497. PMID:2890093. Verma et al (1993) Carbon monoxide a putative neural messenger. Science 259 381. PMID:7678352. Luo and Vincen (1994) Metalloporphyrins inhibit nitric oxide-dependent cGMP formation in vivo. Eur.J.Pharmacol. 267 263. PMID:7522180. Grundemar and Ny (1997) Pitfalls using metalloporphyrins in carbon monoxide research. TiPS 18 193. PMID:9226997.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1984				Nov-1994
0747	Tin protoporphyrin IX dichloride	[14325-05-4]	C=CC1=C(/C=C3\N=C(/C=C(N5[Sn](Cl)6Cl)/C(C)=C(CCC(O)=O)/C5=C4)C(C=C)=C3C)N6C(/C=C2/C(C)=C(CCC(O)=O)C/4=N2)=C1C	Heme oxygenase inhibitor	A potent inhibitor of heme oxygenase. Prevents hyperbilirubinemia in neonates.	"Drummond and Kappas (1981) Prevention of neonatal hyperbilirubinemia by tin protoporphyrin IX, a potent competitive inhibitor of haem oxidation. Proc.Natl.Acad.Sci.U.S.A. 78 6466. PMID:6947237. Grundemar and Ny (1997) Pitfalls using metalloporphyrins in carbon monoxide research. TiPS 18 193. PMID:9226997."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1908				Nov-1994
0748	4-IBP	[155798-08-6]	IC1=CC=C(C=C1)C(=O)NC1CCN(CC2=CC=CC=C2)CC1	"_ ligand, _1 > _2"	Combines high affinity for _1 and moderate affinity for _2 sites. Centrally active following systemic administration in vivo.	"John et al (1994) Synthesis and characterisation of [125I]-N-(N-benzylpiperidin-4-yl)-4-iodobenzamide, a new sigma receptor radiopharmaceutical: high affinity binding to MCF-7 breast tumor cells. J.Med.Chem. 37 1737. PMID:8021913. Whittemore et al (1997) Antagonism of N-methyl-D-aspartate receptors by _ site ligands: potency, subtype-selectivity and mechanisms of inhibition. J.Pharmacol.Exp.Ther. 282 326. PMID:9223571. Bermack and Debonnel (2001) Modulation of serotonergic neurotransmission by short- and long-term treatments with sigma ligands Br.J.Pharmacol. 134 691. PMID:11588125."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=2021				Nov-1994
0749	Dihydrosphingosine	[3102-56-5]	OC[C@](N)([H])[C@H](O)CCCCCCCCCCCCCCC	Protein kinase C inhibitor	Protein kinase C inhibitor.	"Yung et al (1993) Differential regulation of protein kinase C isoenzymes during sphinganine potentiation of retinoic acid-induced granulocytic differentiation in human leukemia HL-60 cells. Biochem.Biophys.Res.Commun. 196 1390. PMID:8250895. Yung et al (1994) Sphinganine potentiation of dimethyl sulfoxide-induced granulocyte differentiation, increase of alkaline phosphatase activity and decrease of protein kinase C activity in a human leukemia cell line (HL-60). Biochem.Biophys.Res.Commun. 199 888. PMID:8135836."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1300	SQ1533			Nov-1994
0750	PG-9 maleate	[155649-00-6]	OC(=O)\C=C/C(O)=O.CC(C(=O)OC1CC2CCC(C1)N2C)C1=CC=C(Br)C=C1	Presynaptic cholinergic modulator	A potent analgesic and nootropic agent. Increases release of acetylcholine.	Gualtieri et al (1994) Presynaptic cholinergic modulators as potent cognition enhancers and analgesic drugs. 1. Tropic and 2-phenylpropionic acid esters. J.Med.Chem. 37 1704. PMID:8201605. Ghelardini et al (1998) Antinociceptive and antiamnesic properties of the presynaptic cholinergic amplifier PG-9. J.Pharmacol.Exp.Ther. 284 806. PMID:9495837.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1920				Nov-1994
0751	SM-21 maleate	[155059-42-0]	OC(=O)\C=C/C(O)=O.CCC(OC1=CC=C(Cl)C=C1)C(=O)OC1CC2CCC(C1)N2C	Presynaptic cholinergic modulator	Potent and selective _2 antagonist with central effects following systemic administration. Causes increased release of acetylcholine at central muscarinic synapses. Potent analgesic (efficacy comparable to morphine) and nootropic agent.	"Ghelardini et al (1997) Antinociceptive profile of 3-_-tropanyl-(2-Cl)-acid phenoxybutyrate (SM-21): a novel analgesic with a presynaptic cholinergic mechanism of action. J.Pharmacol.Exp.Ther. 282 430. PMID:9223584. Ghelardini et al (2000) Pharmacological identification of SM-21, the novel _2 antagonist. Pharmacol.Biochem.Behav. 67 659. PMID:11164098. Matsumoto and Mack (2001) ()-SM 21 attenuates the convulsive and locomotor stimulatory effects of cocaine in mice. Eur.J.Pharmacol. 417 R1. PMID:11301071."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1921				Nov-1994
0752	Clobenpropit dihydrobromide	[145231-35-2]	Br.Br.ClC1=CC=C(CNC(=N)SCCCC2=CNC=N2)C=C1	Highly potent H3 antagonist and H4 partial agonist	An extremely potent histamine H3 antagonist/inverse agonist (pA2=9.93). Also displays partial agonist activity at H4 receptors; induces eosinophil shape change with an EC50 of 3 nM. Also available as part of the Histamine H3 Receptor Tocriset.	"Van der Goot et al (1992) Isothiourea analogues of histamine as potent agonists or antagonists of the histamine H3 receptor. Eur.J.Med.Chem. 27 511. Yokoyama et al (1994) Clobenpropit (VUF-9153), a new histamine H3 receptor antagonist, inhibits electrically induced convulsions in mice. Eur.J.Pharmacol. 260 23. PMID:7957622. Liu et al (2001) Cloning and pharmacological characterization of a fourth histamine receptor (H4) expressed in bone marrow. Mol. Pharmacol. 59 420. PMID:11179434. Buckland et al (2003) Histamine induces cytoskeletal changes in human eosinophils via the H4 receptor. Br.J.Pharmacol. 140 1117. PMID:14530216."	Small Molecule	"Sold with the permission of SCI, Amsterdam"	http://www.tocris.com/dispprod.php?ItemId=2197				Nov-1994
0754	N-Benzylnaltrindole hydrochloride	[1206487-81-1]	O[C@@]24[C@]3([C@@H]8C(N6CC7=CC=CC=C7)=C(C5=C6C=CC=C5)C4)C1=C(O8)C(O)=CC=C1CC2N(CC9CC9)CC3.Cl	_2 selective non-peptide antagonist	Potent _2-selective opioid receptor antagonist with a long duration of action in vivo.	Korlipara et al (1994) N-Benzylnaltrindoles as long acting _-opioid receptor antagonists. J.Med.Chem. 37 1882. PMID:8021928.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=2018				Jun-1996
0756	SIN-1 chloride	[16142-27-1]	NC1=C[N+](N2CCOCC2)=NO1.[Cl-]	Water-soluble NO donor	"This compound (the active product of the prodrug SIN-10, molsidomine) acts as a vasodilator and inhibitor of platelet aggregation; longer acting than nitroprusside or nitroglycerin. Decreases myocardial necrosis and reperfusion-induced endothelial dysfunction in models of myocardial ischemia-reperfusion."	"Tanayama et al (1974) Biotransformation of molsidomine (SIN-10), a new anti-anginal agent in rats. Xenobiotica 4 175. Nishikawa et al (1982) Inhibition of platelet aggregation and stimulation of guanylate cyclase by an anti-anginal agent molsidomine and its metabolite. J.Pharmacol.Exp.Ther. 220 183. PMID:6118429. Maurice and Heslam (1990) Molecular basis of the synergistic inhibition of platelet function by nitrovasodilators and activators of adenylate cyclase: inhibition of cyclic AMP breakdown by cyclic GMP. Mol.Pharmacol. 37 671. PMID:2160060. Siegfried et al (1992) Cardioprotection and attenuation of endothelial dysfunction by organic nitric oxide donors in myocardial ichemia-reperfusion. J.Pharmacol.Exp.Ther. 260 668. PMID:1738117."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1863				Jun-1998
0757	Vinpocetine	[42971-09-5]	O=C(OCC)C5=C[C@@]2(CC)[C@@]1([H])C4=C(C3=CC=CC=C3N45)CCN1CCC2	Na+ channel blocker	"Phosphodiesterase inhibitor, selective for PDE1 (IC50 = 21 _M). Also blocks voltage-gated Na+ channels."	Merck Index 12 10128. Hagiwara et al (1984) Effect of vinpocetine on cyclic nucleotide metabolism in vascular smooth muscle. Biochem.Pharmacol. 33 453. PMID:6322804. Molnar and Erdo (1995) Vinpocetine is as potent as phenytoin to block voltage-gated Na+ channels in rat cortical neurons. Eur.J.Pharmacol. 273 303. PMID:7737339.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1962	SQ1533			Feb-1995
0759	Castanospermine	[79831-76-8]	[H][C@]12[C@@H](O)CCN1C[C@H](O)[C@@H](O)[C@@H]2O	Glucosidases _ and _ inhibitor	"Potent inhibitor of _- and _-glucosidases, especially glucosidase l (required for glucoprotein processing by transfer of mannose and glucose from asparagine-linked lipids). Inhibits HIV syncytium formation and replication."	Saul et al (1984) Studies on the mechanism of castanospermine inhibition of _- and _-glucosidases. Arch.Biochem.Biophys. 230 668. PMID:6424575. Welker et al (1987) Inhibition of human immunodeficiency virus syncytium formation and virus replication by castanospermine. Proc.Natl.Acad.Sci.U.S.A. 84 8120. PMID:2825177. Gruters et al (1987) Interference with HIV-induced syncytium formation and viral infectivity by inhibitors of trimming glucosidase. Nature 330 74. PMID:2959866.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=2129	SQ1070			Feb-1995
0760	AM 580	[102121-60-8]	CC1(C)CCC(C)(C)C2=CC(=CC=C12)C(=O)NC1=CC=C(C=C1)C(O)=O	Retinoic acid analog; RAR_ agonist	"An analog of retinoic acid that acts as a selective RAR_ agonist (EC50 values are 0.3, 8.6 and 13 nM for RAR_, RAR_ and RAR_ respectively). Significantly induces IL-4, IL-5 and IL-13 and inhibits IL-12 and IFN_ synthesis, and induces cell differentiation with over 7 times the activity of retinoic acid in vitro."	"Kagechika et al (1988) Retinobenzoic acids. 1. Structure-activity relationships of aromatic amides with retinoidal activity. J.Med.Chem. 31 2182. PMID:3184125. Dawson et al (2008) The retinoic acid receptor-_ mediates human T-cell activation and Th2 cytokine and chemokine production. BMC Immunol. 9 16. PMID:18416830. Charton et al (2009) Novel non-carboxylic acid retinoids: 1,2,4-oxadiazol-5-one derivatives. Bioorg.Med.Chem.Lett. 19 489. PMID:19058965. Wang et al (2011) Rapid and efficient reprogramming of somatic cells to induced pluripotent stem cells by retinoic acid receptor gamma and liver receptor homolog 1. Proc.Natl.Acad.Sci.U.S.A. 108 18283. PMID:21990348."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1058	SQ1070			Jul-1996
0761	TTNPB	[71441-28-6]	C\C(=C/C1=CC=C(C=C1)C(O)=O)C1=CC=C2C(=C1)C(C)(C)CCC2(C)C	Retinoic acid analog; RAR agonist	"Extremely potent analog of retinoic acid, selective for the retinoic acid receptor (RAR) subtype. Enhances reprogramming efficiency in chemically induced pluripotent stem cells (CiPSCs)."	"Loeliger et al (1980) Arotinoids, a new class of highly active retinoids. Eur.J.Med.Chem.-Chim.Ther. 15 9. Minucci et al (1996) Retinoid X receptor-selective ligands produce malformations in Xenopus embryos. Proc.Natl.Acad.Sci.U.S.A. 93 1803. PMID:8700839. Hou et al (2013) Pluripotent stem cells induced from mouse somatic cells by small-molecule compounds. Science 341 651. PMID:23868920."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1926				Jul-1996
0763	N-[2-(Piperidinylamino)ethyl]-4-iodobenzamide	[155054-42-5]	IC1=CC=C(C=C1)C(=O)NCCN1CCCCC1	_1 selective ligand	_-1 selective ligand which binds with high affinity to human malignant melanoma cells A 2058.	John et al (1994) [125I]N-(2-Piperidinylaminoethyl)-4-iodobenzamide and related analogues as sigma receptor imaging agents; high affinity binding to human malignant melanoma and rat C6 glioma cell lines. J.Labelled Comp.Radiopharm. 35 242.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1796				Feb-1995
0764	SNC 80	[156727-74-1]	[H][C@@](N1C[C@@H](C)N(CC=C)C[C@@H]1C)(C1=CC=C(C=C1)C(=O)N(CC)CC)C1=CC=CC(OC)=C1	Highly selective non-peptide _ agonist	"A highly selective and potent non-peptide _-opioid agonist, 2000-fold selective over _-opioid receptors."	"Calderon et al (1994) Probes for narcotic receptor mediated phenomena. 19. Synthesis of (+)-4-[(_R)-_-((2S,5R)-4-allyl-2,5-dimethyl-1-piperazinyl)-3-methoxybenzyl]-N,N-diethylbenzamide (SNC80): a highly selective nonpeptide _ opioid receptor agonist. J.Med.Chem. 37 2125. PMID:8035418. Bilsky et al (1995) SNC 80, a selective, nonpeptidic and systemically active opioid _ agonist. J.Pharmacol.Exp.Ther. 273 359. PMID:7714789. Knapp et al (1996) Structure-activity relationships for SNC80 and related compounds at cloned human delta and mu opioid receptors. J.Pharmacol.Exp.Ther. 277 1284. PMID:8667189."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1868	SQ1533			Jan-1999
0767	Bifemelane hydrochloride	[62232-46-6]	Cl.CNCCCCOC1=CC=CC=C1CC1=CC=CC=C1	MAO-A and MAO-B inhibitor	Antidepressant MAO inhibitor. Reverses catalepsy induced by tetrabenazine in mice and increases locomotor activity in MPTP-treated marmosets.	"Tobe et al (1981) Pharmacological evaluation of 2-(4-methylaminobutoxy)diphenylmethane hydrochloride (MCl-2016), a new psychotropic drug with antidepressant activity. Arzneimittelforschung 31 1278. PMID:7197535. Naoi et al (1988) 4-(o-benzylphenoxy)-N-methylbutylamine (bifemelane) and other 4-(o-benzylphenoxy)-N-methylalkylamines as new inhibitors of type A and B monoamine oxidase. J.Neurochem. 50 243. PMID:3335842. Nomoto et al (1994) Effects of bifemelane on parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the common marmoset. Neurosci.Lett. 178 95. PMID:7816348."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=2032	SQ1533			Feb-1995
0768	Riluzole hydrochloride	[850608-87-6]	Cl.NC1=NC2=CC=C(OC(F)(F)F)C=C2S1	Glutamate release inhibitor/GABA uptake inhibitor	"Novel psychotropic agent with anticonvulsant, hypnotic, anxiolytic, anti-ischemic and anesthetic properties. Inhibits glutamate release from presynaptic terminals and increases Na+-dependent glutamate uptake in rat cortical synaptosomes. Blocks voltage-dependent Na+ channels and inhibits GABA uptake by striatal synaptosomes; neuroprotective."	"Taylor and Meldrum (1995) Na+ channels as targets for neuroprotective drugs. TiPS 16 309. PMID:7482996. Umeniya and Berger (1995) Inhibition by riluzole of glycinergic postsynaptic currents in rat hypoglossal motoneurones. Br.J.Pharmacol. 116 3227. PMID:8719800. Song et al (1997) Differential action of riluzole on tetrodotoxin-sensitive and tetrodotoxin-resistant sodium channels. J.Pharmacol.Exp.Ther. 282 707. PMID:9262334. Fumagalli et al (2008) Riluzole enhances the activity of glutamate transporters GLAST, GLT1 and EAAC1. Eur.J.Pharmacol. 578 171. PMID:18036519."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1837	SQ1533			May-1999
0771	L-NMMA acetate	[53308-83-1]	CC(O)=O.N=C(NCCC[C@H](N)C(O)=O)NC	Non-selective NOS inhibitor	"Competitive, irreversible inhibitor of all three NOS isoforms."	Saksuma et al (1988) Identification of arginine as a precursor of endothelium-derived relaxing factor. Proc.Natl.Acad.Sci.U.S.A. 85 8664. PMID:3263652. Rees et al (1990) Characterisation of three inhibitors of endothelial nitric oxide synthase in vivo and in vitro. Br.J.Pharmacol. 101 746. PMID:1706208. Olken et al (1991) Inactivation of macrophage nitric oxide synthase activity by N(G)-methyl-L-arginine. Biochem.Biophys.Res.Commun. 177 828. PMID:2049105. Reif and McCreedy et al (1995) N-nitro-L-arginine and N-monomethyl-L-arginine exhibit a differential pattern of inactivation toward the three nitric oxide synthases. Arch.Biochem.Biophys. 320 170. PMID:7540822.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1654				Feb-1995
0772	"Carboxy-PTIO, potassium salt"	[148819-94-7]	[K+].CC1(C)N([O])C(C2=CC=C(C=C2)C([O-])=O)=[N+]([O-])C1(C)C	"Stable, water-soluble deactivator of NO"	"A stable, water-soluble free radical that reacts stoichiometrically with NO. Almost twice as strong an inhibitor as N(_)-nitroarginine or N-methylarginine."	"Akaike et al (1993) Antagonistic action of imidazolineoxy N-oxides against endothelium-derived relaxing factor/NO through a radical reaction. Biochemistry 32 827. PMID:8422387. Tsunoda et al (1994) Vasodilator effect of carboxy-2-phenyl-4,4,5,5-tetramethylimidazoline-1-oxyl in the coronary circulation: in vivo and in vitro studies. Eur.J.Pharmacol. 262 55. PMID:7813579. Rand and Li (1995) Discrimination by the NO-trapping agent, carboxy-PTIO, between NO and the nitrergic transmitter but not between NO and EDRF. Br.J.Pharmacol. 116 1906. PMID:8528578."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=2128				Feb-1995
0773	Memantine hydrochloride	[41100-52-1]	NC12CC3(CC(C1)(CC(C2)C3)C)C.Cl	NMDA antagonist; acts at ion channel site	"An antagonist at the NMDA receptor, binding to the ion channel site. Used in the treatment of Parkinsonism."	"Zajaczkowski et al (1997) Uncompetitive NMDA receptor antagonists attenuate NMDA-induced impairment of passive avoidance learning and LTP. Neuropharmacology 36 961. PMID:9257940. Chen et al (1998) Neuroprotective concentrations of the N-methyl-D-aspartate open-channel blocker memantine are effective without cytoplasmic vacuolation following post-ischemic administration and do not block maze learning or long-term potentiation. Neuroscience 86 1121. PMID:9697119. Parsons et al (1999) Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist - a review of preclinical data. Neuropharmacology 38 735. PMID:10465680. Parsons et al (2007) Memantine: A NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system - too little activation is bad, too much is even worse. Neuropharmacology 53 699. PMID:17904591."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1575	SQ1533			Feb-1995
0775	(+)-UH 232 maleate	[1217473-50-1]	OC(=O)\C=C/C(O)=O.CCCN(CCC)[C@@H]1CCC2=C(C=CC=C2OC)[C@@H]1C	D2 autoreceptor antagonist. Also D3 partial agonist	D2 antagonist (Ki = 72.7 nM in a ligand binding assay; apparent KB = 14.5 nM in a cAMP accumulation assay); displays preferential activity at central dopamine autoreceptors. Stimulates a marked acceleration of dopamine synthesis and turnover. Produces locomotor stimulation. Exhibits little or no activity at central noradrenalin and 5-HT receptors. Also D3 partial agonist.	"Johansson et al (1985) Novel dopamine receptor agonists and antagonists with preferential action on autoreceptors. J.Med.Chem. 28 1049. PMID:3927002. Svensson et al (1986) (+)-AJ 76 and (+)-UH 232: central stimulants acting as preferential dopamine autoreceptor antagonists. Naunyn Schmiedebergs Arch.Pharmacol. 334 234. PMID:2880302. Griffon et al (1995) The preferential dopamine D3 receptor ligand, (+)-UH 232, is a partial agonist. Eur.J.Pharmacol. 282 R3. PMID:7498261. Hall and Strange (1997) Evidence that antipsychotic drugs are inverse agonists at D2 dopamine receptors. Br. J. Pharmacol. 121 731. PMID:9208141."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1957				Feb-1995
0776	(S)-Methylisothiourea sulfate	[867-44-7]	NC(SC)=[NH2+].NC(SC)=[NH2+].[O-]S([O-])(=O)=O	Highly selective iNOS inhibitor	"Highly selective, potent competitive inhibitor of iNOS."	Southan et al (1995) Isothioureas - potent inhibitors of nitric oxide synthases with variable isoform selectivity. Br.J.Pharmacol. 114 510. PMID:7533622. Iuvone et al (1997) Differential effect of L-NAME and S-methyl-isothiourea on leukocyte emigration in carrageenin-soaked sponge implants in rat. Br.J.Pharmacol. 121 1637. PMID:9283697.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1639				Feb-1995
0778	"ICI 199,441 hydrochloride"	[115199-84-3]	ClC1=C(Cl)C=C(CC(N([C@@]([H])([C@]3=CC=CC=C3)CN2CCCC2)C)=O)C=C1.Cl	Potent _ agonist	"Highly potent _ agonist, 146-fold more active than U-50488 (Cat. No. 0495) in vitro."	"Barlow et al (1991) Structure/activity studies related to 2-(3,4-dichlorophenyl)-N-methyl-N-[2-(1-pyrrolidinyl)-1-substituted-ethyl]acetamides: a novel series of potent and selective _-opioid agonists. J.Med.Chem. 34 3149. PMID:1659636. Costello et al (1991) 2-(3,4-Dichlorophenyl)-N-methyl-N-[2-(1-pyrrolidinyl)-1-substituted-ethyl]-acetamides: the use of conformational analysis in the development of a novel series of potent opioid _ agonists. J.Med.Chem. 34 181. PMID:1846918."	Small Molecule	Sold with the permission of AstraZeneca UK Ltd.	http://www.tocris.com/dispprod.php?ItemId=1506				Oct-1996
0779	Iodophenpropit dihydrobromide	[145196-87-8]	Br.Br.IC1=CC=C(CCNC(=N)SCCCC2=CNC=N2)C=C1	"Potent, selective H3 antagonist"	Selective H3 antagonist with high affinity (KD = 0.3 nM). Also available as part of the Histamine H3 Receptor Tocriset.	"Jansen et al (1992) The first radiolabelled histamine H3 receptor antagonist, [125I]iodophenpropit: saturable and reversible binding to rat cortex membranes. Eur.J.Pharmacol. 217 203. PMID:1330590. Menge et al (1992) Synthesis of S-[3-(4(5)-imidazolyl)propyl]-N-[2-(4-[125I]-iodophenylethyl]isothiourea sulfate [125I]-iodophenpropit), a new probe for histamine H3 receptor binding sites. J.Labelled Comp.Radiopharm. XXXI 10 781. Jansen et al (1994) Characterisation of the binding of the first selective radiolabelled histamine H3 receptor antagonist, [125I]-iodophenpropit, to rat brain. Br.J.Pharmacol. 113 355. PMID:7834183. Shahid et al (2009) Histamine, histamine receptors, and their role in immunomodulation: An updated systematic review. Open Immunol.J. 2 9."	Small Molecule	"Sold with the permission of SCI, Amsterdam"	http://www.tocris.com/dispprod.php?ItemId=1524				Feb-1995
0780	NCS-382	[520505-01-5]	OC1C2=C(CCC\C1=C/C(O)=O)C=CC=C2	Antagonist of _-hydroxybutyric acid	"_-Hydroxybutyric acid antagonist, anticonvulsant."	"Maitre et al (1990) A specific _-hydroxybutyrate receptor ligand possesses both antagonist and anticonvulsant properties. J.Pharmacol.Exp.Ther. 255 657. PMID:2173754. Schmidt et al (1991) Anti-sedative and anti-cataleptic properties of NCS-382, a _-hydroxybutyrate receptor antagonist. Eur.J.Pharmacol. 203 393. PMID:1773824. King et al (1997) Gammahydroxybutyrate (GHB) receptor ligand effects on evoked synaptic field potentials in CA1 of the rat hippocampal slice. J.Neural Transm. 104 1177. PMID:9503264."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1695				Jan-1998
0781	"L-694,247"	[137403-12-4]	CS(=O)(=O)NC1=CC=C(CC2=NOC(=N2)C2=CC=C3NC=C(CCN)C3=C2)C=C1	5-HT1D agonist	Selective and extremely potent 5-HT1D receptor agonist.	"Beer et al (1993) L-694,247: a potent 5-HT1D receptor agonist. Br.J.Pharmacol. 110 1196. PMID:8298808. Street et al (1993) Synthesis and serotonergic activity of 5-(oxadiazoyl)tryptamines: potent agonists of 5-HT1D receptors. J.Med.Chem. 36 1529. PMID:8496922. Heald et al (1994) [3H]L-694,247 labels the 5-HT1D_ receptor in pig caudate membranes. Eur.J.Pharmacol. 264 213. PMID:7851485. Buhlen et al (1996) Evidence for presynaptic location of inhibitory 5-HT1D_ -like autoreceptors in the guinea-pig brain cortex. Naunyn Schmiedebergs Arch.Pharmacol. 353 281. PMID:8692282."	Small Molecule	Sold with the permission of Merck Sharp and Dohme Ltd.	http://www.tocris.com/dispprod.php?ItemId=1543				Aug-1998
0782	2-CMDO	[24140-98-5]	[H]OC(=O)\C=C\C(=O)O[H].CN1CCN(CC1)C1=CC2=C(OC3=C1C=C(Cl)C=C3)C=CC=C2	D2-like antagonist. Displays some D4 selectivity	Dopamine D2-like receptor antagonist that displays some selectivity for D4 receptors (Ki values are 0.54 and 2.5 nM for D4 and D2 receptors respectively).	"Phillips et al (1994) Binding of 5H-dibenzo[b,e][1,4]diazepine and chiral 5H-dibenzo[a,d]cycloheptane analogues of clozapine to dopamine and serotonin receptors. J.Med.Chem. 37 2686. PMID:8064797. Phillips et al (1995) Binding of 5H-dibenzo[a,d]cycloheptane and dibenz[b,f]oxapin analogues of clozapine to dopamine and serotonin receptors. J.Med.Chem. 38 708. PMID:7861418. Zawilska et al (2003) L-745,870 suppresses the nighttime serotonin N-acetyltransferase activity in chick retina: in vivo evidence for agonist activity at D4-dopamine receptors. J.Neural Transm. 110 219. PMID:12658371."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=2159				Mar-1995
0783	N-MPPP Hydrochloride	[207452-97-9]	O=C(CC3=CC=CC=C3)N([C@]([C@]2=CC=CC=C2)([H])CN1CCCC1)C.Cl	Selective _ agonist	High affinity _ agonist with no measured binding at _ or _ sites.	Weerawarna et al (1994) Isothiocyanate-substituted _-selective opioid receptor ligands derived from N-methyl-N-[(1S)-1-phenyl-2-(1-pyrrolidinyl)ethyl]phenylacetamide. J.Med.Chem. 37 2856. PMID:8071934.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1648				Jan-1995
0784	Ketotifen fumarate	[34580-14-8]	OC(=O)\C=C\C(O)=O.CN1CCC(CC1)=C1C2=C(SC=C2)C(=O)CC2=C1C=CC=C2	H1 antagonist	An H1 receptor antagonist.	"Merck Index 5319. Martin and Rmer (1978) The pharmacological properties of a new orally active antianaphylactic compound: ketotifen, a benzocycloheptathiophene. Arzneimittelforschung 28 770. PMID:35171. Abu-Dalu et al (1996) The actions of ketotifen on intestinal smooth muscles. Eur.J.Pharmacol. 309 189. PMID:8874138."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1540	SQ1533			Jan-1997
0785	SB 203186 hydrochloride	[207572-69-8]	Cl.O=C(OCCN1CCCCC1)C1=CNC2=CC=CC=C12	5-HT4 antagonist	Potent 5-HT4 receptor antagonist with high affinity for human atrial 5-HT4 receptors.	"Midhurst and Kaumann et al (1993) Characterisation of 5-HT4 receptor mediating tachycardia in piglet isolated right atrium. Br.J.Pharmacol. 110 1023. PMID:8298790. Parker et al (1995) Blockade of human and porcine myocardial 5-HT4 receptors by SB 203186. Naunyn Schmiedebergs Arch.Pharmacol. 353 28. PMID:8750913. McLean and Coupar (1995) 5-HT4 receptor antagonist affinities of SB207710, SB205008 and SB 203186 in the human colon, rat oesophagus and guinea-pig ileum peristaltic reflex. Naunyn Schmiedebergs Arch.Pharmacol. 352 132. PMID:747435."	Small Molecule	Sold with the permission of GlaxoSmithKline	http://www.tocris.com/dispprod.php?ItemId=1851				Feb-1998
0786	Edaravone	[89-25-8]	CC1=NN(C(=O)C1)C1=CC=CC=C1	Anti-ischemic and antioxidant	"A radical scavenger and antioxidant which is able to protect against the effects of ischemia, probably by inhibiting the lipoxygenase system. Protects against MPTP-induced neurotoxicity."	"Watanabe et al (1994) Protective effects of MCI-186 on cerebral ischemia: possible involvement of free radical scavenging and antioxidant actions. J.Pharmacol.Exp.Ther. 268 1597. PMID:8138971. Kawai et al (1997) Effects of a novel free radical scavenger, MC-186, on ischemic brain damage in rat distal middle cerebral artery occlusion model. J.Pharmacol.Exp.Ther. 281 921. PMID:9152402. Kawasaki et al (2007) Edaravone (3methyl-1-phenyl-2-pyrazolin-5-one), a radical scavenger, prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in the substantia nigra but not the striatum. J.Pharmacol.Exp.Ther. 322 274. PMID:17429058."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1562	SQ1533			Jun-1995
0787	Aminoguanidine hydrochloride	[1937-19-5]	Cl.N=C(NN)N	Irreversible iNOS inhibitor	Irreversible inhibitor of iNOS that displays some selectivity over eNOS and nNOS. Exhibits antioxidant and radioprotective effects in vivo.	Griffiths et al (1993) Aminoguanidine selectively inhibits inducible nitric oxide synthase. Br.J.Pharmacol. 110 963. PMID:7507781. Laszlo et al (1995) Aminoguanidine inhibits both constitutive and inducible nitric oxide synthase isoforms in rat intestinal microvasculature in vivo. Eur.J.Pharmacol. 272 169. PMID:7536162. Moore and Handy (1997) Selective inhibitors of neuronal nitric oxide synthase - is no NOS really good NOS for the nervous system? TiPS 18 204. PMID:9226999. Huang et al (2009) Aminoguanidine alleviates radiation-induced small-bowel damage through its antioxidant effect. Int.J.Radiat.Oncol.Biol.Phys. 74 237. PMID:19362242.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1107	SQ1533			Jan-1901
0788	3-Aminobenzamide	[3544-24-9]	NC(=O)C1=CC=CC(N)=C1	PARP inhibitor	"An inhibitor of poly(ADP-ribose) polymerase, which protects cells from UV-B-induced apoptosis via influence on the cytoskeleton."	"Malorni et al (1995) 3-Aminobenzamide protects cells from UV-B-induced apoptosis by acting on cytoskeleton and substrate adhesion. Biochem.Biophys.Res.Commun. 207 715. PMID:7864864. Cuzzocrea et al (1997) Beneficial effects of 3-aminobenzamide, an inhibitor of poly (ADP-ribose) synthetase in a rat model of splanchnic artery occlusion and reperfusion. Br.J.Pharmacol. 121 1065. PMID:9249240."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1069	SQ1533			Jan-1901
0789	()-Anatoxin A fumarate	[1219922-30-1]	O=C(C)C1=CCCC2CCC1N2.O=C(O)/C=C/C(O)=O	Nicotinic agonist	A potent nicotinic agonist (Ki values are 1.25 and 1840 nM for _4_2 and _7 nicotinic receptors respectively). Stimulates [3H]-dopamine release from rat striatal synaptosomes (EC50 = 136 nM).	"Gordon et al (1992) Induced release of acetylcholine from guinea pig ileum longitudinal muscle myenteric plexus by anatoxin-A. J.Pharmacol.Exp.Ther. 263 997. PMID:1469655. Stolerman et al (1992) Behavioural effects of anatoxin, a potent nicotinic agonist in rats. Neuropharmacology 31 311. PMID:1630597. Thomas et al (1993) (+)-Anatoxin is a potent agonist at neuronal nicotinic acetylcholine receptors. J.Neurochem. 60 2308. PMID:8492133. Sharples et al (2000) UB-165 implicates _4_2 nAChR in striatal dopamine release. J.Neurosci. 20 2783. PMID:10751429."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1172				Jan-1901
0790	Rilmenidine hemifumarate	[207572-68-7]	OC(=O)\C=C\C(O)=O.C1CC1C(NC1=NCCO1)C1CC1.C1CC1C(NC1=NCCO1)C1CC1	_2 agonist. Also I1 ligand	"I1-imidazoline binding site selective ligand and _2-adrenoceptor agonist. Possesses greater I1 vs _2 selectivity than the prototypical compound, clonidine. Also thought to enhance autophagy; shown to increase LC3-II levels in PC12 cells."	Bricca et al (1989) Rilmenidine selectivity for imidazoline receptors in human brain. Eur.J.Pharmacol. 163 373. PMID:2566507. Michel and Ernsberger (1992) Keeping an eye on the I site: imidazoline-preferring receptors. TiPS 13 369. PMID:1413085. Bricca et al (1994) Human brain imidazoline receptors: Further characterisation with [3H] clonidine. Eur.J.Pharmacol. 266 25. PMID:8137880. Mammoto et al (1996) Antiarrhythmic action of rilmenidine on adrenaline-induced arrhythmia via central imidazoline receptors in halothane-anaesthetized dogs. Br.J.Pharmacol. 117 1744. PMID:8732285. Williams et al (2008) Novel targets for Huntington's disease in an mTOR-independent autophagy pathway. Nat.Chem.Biol. 4 295. PMID:18391949.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1836	SQ1533			Jan-1997
0791	Antazoline hydrochloride	[2508-72-7]	Cl.C(N(CC1=CC=CC=C1)C1=CC=CC=C1)C1=NCCN1	Imidazoline ligand	Imidazoline binding site ligand; a potent inducer of insulin secretion in rat pancreas. Also an antihistamine.	Merck Index 11 709. Berdeu et al (1995) Evidence for two different imidazoline sites on pancreatic B cells and vascular bed in rat. Eur.J.Pharmacol. 275 91. PMID:7774667.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1086	SQ1533			Jan-1901
0792	Efaroxan hydrochloride	[89197-00-2]	Cl.CCC1(CC2=CC=CC=C2O1)C1=NCCN1	"_2 antagonist and I1, I3 ligand"	"Potent, highly selective _2 adrenoceptor antagonist and imidazoline I1 receptor ligand (pKi values are 7.87, 7.42, 5.74, 7.28 and < 5 for _ 2A, _2B, _2C, I1, and I2 receptors respectively). Promotes insulin secretion, at a site distinct from I1 or I2 (the putative I3 receptor) in vitro and in vivo."	"Chapleo et al (1984) _-Adrenoceptor reagents 2. Effects of modification of the 1,4-benzodioxan ring system on _-adrenoceptor activity. J.Med.Chem. 27 570. PMID:6143826. Olmos et al (1994) Imidazolines stimulate release of insulin from RIN-5AH cells independently from imidazoline I1 and I2 receptors. Eur.J.Pharmacol. 262 41. PMID:7813577. Eglen et al (1998) 'Seeing through a glass darkly': casting light on imidazoline 'I' sites. TiPS 19 381. PMID:9786027. Mayer and Taberner (2002) Effects of the imidazoline ligands efaroxan and KU14R on blood glucose in the mouse. Eur.J.Pharmacol. 454 95. PMID:12409010."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1352	SQ1533			Jun-2000
0793	Idazoxan hydrochloride	[79944-56-2]	Cl.C1CN=C(N1)C1COC2=CC=CC=C2O1	_2 antagonist. Also I2 ligand	"_2-adrenoceptor antagonist, and I2 ligand, selective over I1 sites (pKi values are 5.90, 7.22, 8.01, 7.43, and 7.7 for I1, I2, _2A, _2B, and _2C receptors respectively)."	Dabir (1986) Idazoxan: a novel pharmacological tool for the study of _2-adrenoceptors. J.Pharmacol. 17 113. PMID:2875218. Michel and Ernsberger (1992) Keeping an eye on the I site: imidazoline-preferring receptors. TIPS 13 369. PMID:1413085. Berdeu et al (1995) Evidence for two different imidazoline sites on pancreatic B cells and vascular bed in rat. Eur.J.Pharmacol. 275 91. PMID:7774667. Eglen et al (1998) 'Seeing through a glass darkly': casting light on imidazoline 'I' sites. TiPS 19 381. PMID:9786027.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1513	SQ1533			Jun-2000
0794	DIPPA hydrochloride	[155512-52-0]	ClC1=C(Cl)C=C(CC(N([C@@](CN3CCCC3)([H])C2=CC=CC(N=C=S)=C2)C)=O)C=C1.Cl	Selective irreversible _ antagonist	"An irreversible and selective antagonist at the _ receptor, with persistent effect in vivo."	"Chang et al (1994) 2-(3,4-Dichlorophenyl)-N-methyl-N-[(1S)-1-(3-isothiocyanatophenyl)-2-(1-pyrrolidinyl)ethyl]acetamide: an opioid receptor affinity label that produces selective and long lasting _ antagonism in mice. J.Med.Chem. 37 1547. PMID:8201586. Chang et al (1994) _ opioid receptor selective affinity labels: Electrophilic benzeneacetamides as _-selective opioid antagonists. J.Med.Chem. 37 4490. PMID:7799399."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1333				Jul-1996
0796	(R)-Baclofen	[69308-37-8]	NC[C@@](CC(O)=O)([H])C1=CC=C(Cl)C=C1	Selective GABAB agonist. Active enantiomer of (RS)-Baclofen (Cat. No. 0417)	"More active enantiomer of (RS)-Baclofen (Cat. No. 0417), a selective GABAB agonist."	Falch et al (1986) Comparative stereostructure-activity studies on GABAA and GABAB receptor sites and GABA uptake using rat brain membrane preparations. J.Neurochem. 47 898. PMID:3016189. Hong et al (1991) Effects of phaclofen and the enantiomers of baclofen on cardiovascular responses to intrathecal administration of L- and D-baclofen in the rat. Eur.J.Pharmacol. 196 267. PMID:1654254.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1950	SQ1533			Jan-1998
0797	8-Hydroxy-PIPAT oxalate	[1451210-48-2]	[H]OC(=O)C(=O)O[H].CCCN(C\C=C\I)C1CCC2=CC=CC(O)=C2C1	High affinity 5-HT1A agonist	High affinity 5-HT1A receptor agonist (Kd = 0.38 nM). 7-Hydroxy-PIPAT maleate (Cat. No. 0719) also available.	"Zhuang et al (1993) Synthesis of (R,S)-trans-8-Hydroxy-2-[N-n-propyl-N-(3'-iodo-2'-propenyl)amino]tetralin (trans-8-OH-PIPAT): a new 5-HT1A receptor ligand. J.Med.Chem. 36 3161. PMID:8230102."	Small Molecule	Sold with the permission of the University of Pennsylvania	http://www.tocris.com/dispprod.php?ItemId=1491				Jun-1995
0800	7-NINA	[161467-34-1]	[Na+].[O-][N+](=O)C1=C2[N-]N=CC2=CC=C1	Non-selective NOS inhibitor. Sodium salt of 7-nitroindazole (Cat. No. 0602)	Sodium salt of the non-selective NOS inhibitor 7-nitroindazole (Cat. No. 0602).	Silva et al (1995) Increased striatal dopamine efflux in vivo following inhibition of cerebral nitric oxide synthase by the novel monosodium salt of 7-nitroindazole. Br.J.Pharmacol. 114 257. PMID:7533610. O'Neill et al (1996) Neuroprotective effects of 7-nitroindazole in the gerbil model of global cerebral ischaemia. Eur.J.Pharmacol. 310 115. PMID:8884206.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1698				Feb-1998
0803	MSOP	[66515-29-5]	NC(COP(O)(O)=O)(C)C(O)=O	Specific group III mGlu antagonist	"Selective group III metabotropic glutamate receptor antagonist. Displays an apparent KD of 51 _M for the L-AP4-sensitive presynaptic mGluR on primary afferent terminals in spinal cord compared to > 700 _M for the (1S,3S)-ACPD-sensitive presynaptic mGlu in the same system. Has no activity on postsynaptic mGlu receptors or on ionotropic glutamate receptors on neonatal rat motoneurons. Also available as part of the Group III mGlu Receptor Tocriset."	"Thomas et al (1995) Serine-O-phosphate derivatives as novel, potent and selective metabotropic glutamate receptor (mGluR) antagonists. Soc.Neurosci.Abstr. 21 P616. Thomas et al (1996) _-Methyl derivatives of serine-O-phosphate as novel, selective competitive metabotropic glutamate receptor antagonists. Neuropharmacology 35 637. PMID:8887973. Jane et al (1996) Phosphono substituted amino acids as selective metabotropic glutamate receptor antagonists. Phosphorous, Sulphur and Silicon 109-110 313."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1666				Jan-1901
0805	"(S)-3,5-DHPG"	[162870-29-3]	OC1=CC([C@]([H])(N)C(O)=O)=CC(O)=C1	"Selective group I mGlu agonist. Active enantiomer of 3,5-DHPG (Cat. No. 0342)"	"Selective group I mGlu receptor agonist. Also available as part of the Group I mGlu Receptor Tocriset and Mixed mGlu Receptor Tocriset. (RS)-3,5-DHPG (Cat. No. 0342) also available."	"Schoepp et al (1994) 3,5-Dihydroxyphenylglycine is a highly selective agonist for phosphoinositide-linked metabotropic glutamate receptors in the rat hippocampus. J.Neurochem. 63 769. PMID:8035201. Baker et al (1995) Enzymatic resolution and pharmacological activity of the enantiomers of 3,5-dihydroxyphenylglycine, a metabotropic glutamate receptor agonist. Bioorg.Med.Chem.Lett. 5 223. Sekiyama et al (1996) Structure-activity relationships of new agonists and antagonists of different metabotropic glutamate receptor subtypes. Br.J.Pharmacol. 117 1493. PMID:8730745. Wisniewski and Car (2002) (S)-3,5-DHPG: a review. CNS Drug Rev. 8 101. PMID:12070529."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1307				Jan-1901
0806	Gabapentin	[60142-96-3]	NCC1(CC(O)=O)CCCCC1	Anticonvulsant. Increases brain GABA	Anticonvulsant with several possible mechanisms of action. Increases GABA in the brain and binds to a novel site associated with voltage-sensitive Ca2+ channels. Prevents neuronal death and is antinociceptive and anxiolytic.	Upton (1994) Mechanisms of action of new antiepileptic drugs: rational design and serendipitous findings. TiPS 15 456. PMID:7886818. Taylor et al (1998) A summary of mechanistic hypotheses of gabapentin pharmacology. Epilepsy Res. 29 233. PMID:9551785. Timmerman et al (2000) A microdialysis study on the mechanism of action of gabapentin. Eur.J.Pharmacol. 398 53. PMID:10856447. Fink et al (2000) Inhibition of Ca2+ influx by gabapentin and subsequent reduction of neurotransmitter release from rat neocortical slices. Br.J.Pharmacol. 130 900. PMID:10864898.	Small Molecule	Sold for research purposes under agreement from Pfizer Inc.	http://www.tocris.com/dispprod.php?ItemId=2038	SQ1533			Oct-2001
0807	THIP hydrochloride	[85118-33-8]	Cl.OC1=NOC2=C1CCNC2	GABAA agonist	"Systemically active GABAA receptor agonist and GABAC receptor antagonist. Displays antinociceptive, anticonvulsant and sedative effects. Hypnotic agent that enhances delta activity within non-REM sleep in rats."	"Krogsgaard-Larson (1983) 4,5,6,7-Tetrahydroisothiazolo[5,4-c]pyridin-3-ol and related analogues of THIP. Synthesis and biological activity. J.Med.Chem. 26 895. PMID:6304315. Krogsgaard-Larson (1984) Chemistry and pharmacology of the GABA antagonists THIP (Gaboxadol) and isoguvacine. Drugs Future. 9 597. Johnston (1996) GABAC receptors: relatively simple transmitter-gated ion channels? TiPS 17 319. PMID:8885697. Huckle (2004) Gaboxadol. Lundbeck/Merck Curr.Opin.Investig.Drugs 5 766. PMID:15298075."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1904	SQ1533			Jan-1901
0808	Vigabatrin	[60643-86-9]	NC(C=C)CCC(O)=O	GABA-T inhibitor	Selective GABA-T (transaminase) inhibitor. Anticonvulsant.	Larsson et al (1986) Differential effect of gamma-vinyl GABA and valproate on GABA transaminase from cultured neurones and astrocytes. Neuropharmacology 25 617. PMID:3092125. Halonen et al (1991) Effects of vigabatrin (_-vinyl GABA) on neurotransmission-related amino acids and on GABA and benzodiazepine receptor binding in rats. Epilepsia 32 242. PMID:1672276. Schmid et al (1996) Vigabatrin modulates benzodiazepine receptor activity in vivo: a positron emission tomography study in baboon. J.Pharmacol.Exp.Ther. 276 977. PMID:8786578.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1924				Jan-1999
0811	()-threo-3-Methylglutamic acid	[63088-04-0]	N[C@@]([C@@]([H])(C)CC(O)=O)([H])C(O)=O.[H][C@](CC(O)=O)(C)[C@@](N)([H])C(O)=O	EAAT2 and EAAT4 blocker	"A potent blocker of glutamate transport; selective for EAAT2 and EAAT4 (IC50 values are 90, 109, 1600 and 1080 _M for EAAT2, EAAT4, EAAT1 and EAAT3 respectively)."	"Vandenberg et al (1997) Contrasting modes of action of methylglutamate derivatives on the excitatory amino acid transporters, EAAT1 and EAAT2. Mol.Pharmacol. 51 809. PMID:9145919. Mitrovic et al (1998) Identification of functional domains of the human glutamate transporters EAAT1 and EAAT2. J.Biol.Chem. 273 14698. PMID:9614067. Eliasof et al (2001) Pharmacological characterization of threo-3-methylglutamic acid with excitatory amino acid transporters in native and recombinant systems. J.Neurochem. 77 550. PMID:11299317."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1625				Jan-1901
0817	"(2R,3S)-Chlorpheg"	[140924-23-8]	N[C@@]([H])([C@@](O)=O)[C@@](CC(O)=O)([H])C1=CC=C(Cl)C=C1	Weak NMDA antagonist	A weakly active NMDA receptor antagonist.	"Chalmers et al (1995) Differential actions of 3-(4-chlorophenyl)glutamic acid stereoisomers and L-trans-pyrrolidine-2,4-dicarboxylic acid upon L-homocysteic acid and L-glutamic acid-induced responses from rat spinal motoneurones. Neuropharmacology 34 1589. PMID:8788956. Jane et al (1996) Diastereoselective synthesis of all four isomers of 3-(4-chlorophenylglutamic acid: identification of the isomers responsible for the potentiation of L-homocysteic acid-evoked depolarizations in neonatal rat motoneurons. J.Med.Chem. 39 4738. PMID:8941386."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=2250				Jan-1901
0821	"ICI 118,551 hydrochloride"	[72795-01-8]	CC1=C(CCC2)C2=C(OC[C@@H](O)[C@H](C)NC(C)C)C=C1.Cl	Very selective _2 antagonist	"Very selective _2 adrenergic antagonist (Ki values are 1.2, 120 and 257 nM for _2, _1 and _3 receptors respectively). Active in vivo. Also available as part of the _-Adrenoceptor Antagonist Tocriset."	"Bilski et al (1983) The pharmacology of a _2-selective adrenoceptor antagonist (ICI-118,551). J.Cardiovasc.Pharmacol. 5 430. PMID:6191142. Cook et al (1993) _-Adrenoceptor subtypes and the opening of plasmalemmal K+-channels in trachealis muscle: electrophysiological and mechanical studies in guinea-pig tissue. Br.J.Pharmacol. 109 1140. PMID:8104643. Ten Berge et al (1995) _2-but not _3-adrenoceptors mediate prejunctional inhibition of non-adrenergic non cholinergic contraction of guinea pig main bronchi. Eur.J.Pharmacol. 275 199. PMID:7796855. Strosberg and Pietri-Rouxel (1996) Function and regulation of the _3-adrenoceptor. TiPS 17 373. PMID:8979772."	Small Molecule	Sold with the permission of AstraZeneca UK Ltd.	http://www.tocris.com/dispprod.php?ItemId=1500	SQ1070			Jan-1901
0822	"ICI 204,448 hydrochloride"	[121264-04-8]	Cl.CN(C(CN1CCCC1)C1=CC(OCC(O)=O)=CC=C1)C(=O)CC1=CC(Cl)=C(Cl)C=C1	"_ agonist, acts peripherally"	Peripherally acting _ agonist.	"Shaw et al (1989) ICI-204,448: a _-opioid agonist with limited access to the CNS. Br.J.Pharmacol. 96 986. PMID:2568146. Keta et al (1995) Antinociceptive effect of a _-opioid receptor agonist that minimally crosses the blood-brain barrier (ICI 204448) in a rat model of mononeuropathy. Eur.J.Pharmacol. 277 275. PMID:7493620."	Small Molecule	Sold with the permission of AstraZeneca UK Ltd.	http://www.tocris.com/dispprod.php?ItemId=1507				Jul-1995
0825	Clofibric acid	[882-09-7]	CC(C)(OC1=CC=C(Cl)C=C1)C(O)=O	PPAR agonist	PPAR agonist. Antihyperlipoproteinemic.	"Merck Index 12 2437. Shepherd (1993) Mechanism of action of fibrates. Postgrad.Med.J. 69 S34. PMID:8497455. Forman et al (1997) Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors _ and _. Proc.Natl.Acad.Sci.U.S.A. 94 4312. PMID:9113986. Bishop-Bailey (2000) Peroxisome proliferator-activated receptors in the cardiovascular system. Br.J.Pharmacol. 129 823. PMID:10696077."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=2203	SQ1533			Jan-1901
0826	Tiotidine	[69014-14-8]	CN\C(NCCSCC1=CSC(\N=C(/N)N)=N1)=N/C#N	"Potent, selective H2 antagonist"	Potent histamine H2-receptor antagonist with negligible activity against H1- and H3- receptors.	"Yellin et al (1979) ICI 125,211: A new gastric antisecretory agent acting on histamine H2- receptors. Life Sci. 25 2001. PMID:43449. Trzeciakowski and Levi (1980) The cardiac pharmacology of tiotidine (ICI 125,211): A new histamine H2- receptor antagonist. J.Pharmacol.Exp.Ther. 214 629. PMID:6105207. Hill (1990) Distribution, properties, and functional characteristics of three classes of histamine receptor. Pharmacol.Rev. 42 45. PMID:2164693."	Small Molecule	Sold with the permission of AstraZeneca UK Ltd.	http://www.tocris.com/dispprod.php?ItemId=1909	SQ1533			Jan-1901
0829	Pronethalol hydrochloride	[51-02-5]	Cl.CC(C)NCC(O)C1=CC=C2C=CC=CC2=C1	_ antagonist	"_-adrenergic antagonist, clinically effective in the treatment of angina pectoris and some arrhythmias."	Merck Index 12 7974. Main (1990) _-Adrenergic receptors. Comprehensive Medicinal Chemistry. Ed Hansch 3 187.	Small Molecule	Sold with the permission of AstraZeneca UK Ltd.	http://www.tocris.com/dispprod.php?ItemId=1812	SQ1533			Jan-1901
0830	Primidone	[125-33-7]	CCC1(C(=O)NCNC1=O)C1=CC=CC=C1	Potentiates GABAA receptor function	Anticonvulsant.	Merck Index 12 7927. Loscher and Honack (1989) Comparison of the anticonvulsant efficacy of primidone and phenobarbital during chronic treatment of amygdala-kindled rats. Eur.J.Pharmacol. 162 309. PMID:2721568.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1811	SQ1533			Jan-1901
0832	ICI 89406	[53671-71-9]	OC(CNCCNC(=O)NC1=CC=CC=C1)COC1=C(C=CC=C1)C#N	_ antagonist	_-adrenergic antagonist and low efficacy partial agonist; does not affect resting cardiac parameters.	Mai (1990) _-Adrenergic Receptors. Comprehensive Medicinal Chemistry. Ed. Hansch. 3 187.	Small Molecule	Sold with the permission of AstraZeneca UK Ltd.	http://www.tocris.com/dispprod.php?ItemId=1499				Jan-1901
0833	"ICI 162,846"	[84545-30-2]	NC(=O)CCCCN1C=CC(=N1)\N=C(/N)NCC(F)(F)F	"Potent H2 antagonist, active in vivo"	A potent histamine H2 receptor antagonist.	"Wilson et al (1986) Inhibition of human gastric secretion by ICI 162,846 - a new histamine H2 receptor antagonist. Br.J.Clin.Pharmacol. 21 685. PMID:2874823. Streett et al (1988) Morphological stomach findings in rats and mice treated with the H2 receptor antagonists, ICI 125,211 and ICI 162,846. Toxicol.Pathol. 16 299. PMID:2903545. Gompertz et al (1991) Acid blockade by omeprazole or ICI 162846 in a chronic duodenal ulcer model. Agents Actions 33 161. PMID:1716826."	Small Molecule	Sold with the permission of AstraZeneca UK Ltd.	http://www.tocris.com/dispprod.php?ItemId=1502				Jan-1901
0834	(S)-(-)-Propranolol hydrochloride	[4199-10-4]	CC(C)NC[C@]([H])(O)COC2=CC=CC1=CC=CC=C12.Cl	_ antagonist. More active enantiomer of propranolol (Cat. No. 0624)	More active enantiomer of the _-adrenoceptor antagonist propranolol (Cat. No. 0624). (R)-(+)-Propranolol hydrochloride (Cat. No. 0835) also available.	"Bond et al (1967) Metabolism of propranolol (Inderal) a potent, specific _-adrenergic receptor blocking agent. Nature 213 721. PMID:6031788. Barrett et al (1968) The biological properties of the optical isomers of propranolol and their effects on cardiac arrhythmias. Br.J.Pharmacol. 34 43. PMID:19108278."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1821	SQ1533			Jan-1901
0835	(R)-(+)-Propranolol hydrochloride	[13071-11-9]	CC(C)NC[C@@]([H])(O)COC2=CC=CC1=CC=CC=C12.Cl	_ antagonist. Less active enantiomer of propranolol (Cat. No. 0624)	Less active enantiomer of the _-adrenoceptor antagonist propranolol (Cat. No. 0624). (S)-(-)-Propranolol hydrochloride (Cat. No. 0834) also available.	"Bond et al (1967) Metabolism of propranolol (Inderal) a potent, specific _-adrenergic receptor blocking agent. Nature 213 721. PMID:6031788. Barrett et al (1968) The biological properties of the optical isomers of propranolol and their effects on cardiac arrhythmias. Br.J.Pharmacol. 34 43. PMID:19108278."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1820	SQ1533			Jan-1901
0836	"ICI 185,282"	[106393-80-0]	OC(=O)CCC\C=C/C[C@@H]1CO[C@@H](O[C@@H]1C1=C(O)C=CC=C1)C(F)(F)F	Potent thromboxane receptor antagonist	Potent thromboxane receptor antagonist.	"Birch et al (1988) Studies in the guinea-pig with ICI 185,282: a thromboxane A2 receptor antagonist. J.Pharm.Pharmacol. 40 706. PMID:2907537."	Small Molecule	Sold with the permission of AstraZeneca UK Ltd.	http://www.tocris.com/dispprod.php?ItemId=1504				Jan-1901
0837	"ICI 192,605"	[117621-64-4]	OC(=O)CC\C=C/C[C@@H]1CO[C@@H](O[C@@H]1C1=C(O)C=CC=C1)C1=C(Cl)C=CC=C1	Potent thromboxane A2/TP receptor antagonist	Potent thromboxane A2 receptor (TP receptor) antagonist. Competitively inhibits contractile responses to U 46619 (Cat. No. 1932).	"Brewster et al (1988) The synthesis of a novel thromboxane receptor antagonist 4(Z)-6-(2-o-chlorophenyl-4-o-hydroxyphenyl-1,3-dioxan-cis-5-yl)hexenoic acid ICI 192605. Prostaglandins 36 173. PMID:2973084. Arakawa et al (1993) Leukotriene D4 and prostaglandin F2a- induced airflow obstruction and airway plasma exudation in guinea pig: role of thromboxane and its receptor. Br.J.Pharmacol. 110 127. PMID:8220872. Cao et al (2004) Thromboxane A2 (TP) receptor in the non-pregnant porcine myometrium and its role in regulation of spontaneous contractile activity. Eur.J.Pharmacol. 485 317. PMID:14757156."	Small Molecule	Sold with the permission of AstraZeneca UK Ltd.	http://www.tocris.com/dispprod.php?ItemId=1505				Jan-1901
0839	DHBP dibromide	[6159-05-3]	[Br-].[Br-].CCCCCCC[N+]1=CC=C(C=C1)C1=CC=[N+](CCCCCCC)C=C1	Ca2+ release inhibitor	Blocks calcium release from sarcoplasmic reticulum by direct interaction with the ryanodine receptor.	Kang et al (1994) Effects of bipyridylium compounds on calcium release from triadic vesicles isolated from rabbit skeletal muscle. Br.J.Pharmacol. 112 1216. PMID:7952884.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1291				Jan-1901
0840	Loperamide hydrochloride	[34552-83-5]	Cl.CN(C)C(=O)C(CCN1CCC(O)(CC1)C1=CC=C(Cl)C=C1)(C1=CC=CC=C1)C1=CC=CC=C1	Peripherally acting _ agonist. Also Ca2+ channel blocker	"High affinity _-opioid receptor agonist with peripheral selectivity (Ki values are 2, 48 and 1156 nM for _-, _- and _-opioid receptors respectively). Antidiarrhoeal and antihyperalgesic agent. Also a Ca2+ channel blocker; at low micromolar concentrations it blocks broad spectrum neuronal HVA Ca2+ channels and at higher concentrations it reduces Ca2+ flux through NMDA receptor operated channels."	"Awouters et al (1983) Pharmacology of antidiarrheal drugs. Annu.Rev.Pharmacol.Toxicol. 23 279. PMID:6307123. Church et al (1994) Loperamide blocks high-voltage activated calcium channels and N-Methyl-D-aspartate -evoked responses in rat and mouse cultured hippocampal pyramidal neurons. Mol.Pharmacol. 45 747. PMID:8183255. Daly et al (1995) Maitotoxin-elicited calcium influx in cultured cells - effect of calcium channel block. Biochem.Pharmacol. 50 1187. PMID:7488233. Dehaven-Hudkins et al (1999) Loperamide (ADL 2-1294), an opioid antihyperalgesic agent with peripheral selectivity. J.Pharmacol.Exp.Ther. 289 494. PMID:10087042."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1555	SQ1533			Jan-1901
0841	DTG	[97-39-2]	CC1=C(NC(=N)NC2=C(C)C=CC=C2)C=CC=C1	High affinity ligand (_1 = _2)	Displays high and roughly equal affinity for both _1 and _2 receptors.	Quirion et al (1992) A proposal for the classification of sigma binding sites. TiPS 13 85. PMID:1315463. He et al (1993) Synthesis and binding characteristics of potential SPECT imaging agents for _1 and _2 binding sites. J.Med.Chem. 36 566. PMID:8496936.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1351				Jan-1901
0842	Agmatine sulfate	[2482-00-0]	NCCCCNC(N)=N	_2 ligand. Also imidazoline ligand	Arginine metabolite that is synthesized within bovine brain and exhibits clonidine-displacing substance (CDS) activity. Putative endogenous ligand for the imidazoline binding site.	Merck Index 12 186. Li et al (1994) Agmatine: an endogenous clonidine-displacing substance in the brain. 263 966. PMID:7906055. Piletz et al (1995) Comparison of the properties of agmatine and endogenous clonidine-displacing substance at imidazoline and alpha-2-adrenergic receptors. J.Pharmacol.Exp.Ther. 272 581. PMID:7853171. Reis and Regunathan (2000) Is agmatine a novel neurotransmitter in brain? TiPs 21 187. PMID:10785653.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1045				Jan-1901
0843	Oxotremorine sesquifumarate	[17360-35-9]	OC(=O)\C=C\C(O)=O.OC(=O)\C=C\C(O)=O.OC(=O)\C=C\C(O)=O.O=C1CCCN1CC#CCN1CCCC1.O=C1CCCN1CC#CCN1CCCC1	Muscarinic agonist	Muscarinic agonist.	Merck Index 12 7085. Fisher et al (1984) Differential stimulation in inositol phospholipid turnover in brain by analogs of oxotremorine. J.Neurochem. 43 1171. PMID:6088696. Moroi-Fetters et al (1988) Muscarinic receptor-mediated phosphoinositide hydrolysis in the rat retina. J.Pharmacol.Exp.Ther. 246 553. PMID:2841451.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1735				Jan-1901
0845	Evans Blue tetrasodium salt	[314-13-6]	[Na+].[Na+].[Na+].[Na+].CC1=CC(=CC=C1\N=N\C1=C(O)C2=C(C=C1)C(=CC(=C2N)S([O-])(=O)=O)S([O-])(=O)=O)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S([O-])(=O)=O)S([O-])(=O)=O	Potent inhibitor of L-glutamate uptake into synaptic vesicles	Potent inhibitor of L-glutamate uptake into synaptic vesicles. Also inhibits AMPA and kainate receptor-mediated currents (IC50 values are 220 and 150 nM respectively). P2X-selective purinoceptor antagonist.	Merck Index 12 3952. Roseth et al (1995) Uptake of L-glutamate into rat brain synaptic vesicles: effect of inhibitors that bind specifically to the glutamate transporter. J.Neurochem. 65 96. PMID:7790899. Wittenburg et al (1996) P2-purinoceptor antagonists:II blockade of P2-purinoceptor subtypes and ecto-nucleotidase by compounds related to Evans blue and trypan blue. Naunyn Schmiedebergs Arch.Pharmacol. 354 491. PMID:8897453. Price and Raymond (1996) Evans blue antagonizes both _-amino-3-hydroxy-5-methyl-4-isoxazolepropionate and kainate receptors and modulates desensitization. Mol. Pharmacol. 50 1665. PMID:8967991. Schurmann et al (1997) Differential modulation of AMPA receptor mediated currents by Evans Blue in postnatal rat hippocampal neurones. Br.J.Pharmacol. 121 237. PMID:9154333.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1386				Jan-1901
0846	Chicago Sky Blue 6B	[2610-05-1]	[Na+].[Na+].[Na+].[Na+].COC1=CC(=CC=C1\N=N\C1=C(O)C2=C(C=C1)C(=CC(=C2N)S([O-])(=O)=O)S([O-])(=O)=O)C1=CC(OC)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S([O-])(=O)=O)S([O-])(=O)=O	Potent inhibitor of L-glutamate uptake into synaptic vesicles; also inhibits MIF	Potent inhibitor of L-glutamate uptake into synaptic vesicles. Allosterically inhibits macrophage migration inhibitory factor (MIF) (IC50 = 0.81 _M); inhibits MIF proinflammatory activity.	Fonnum et al (1994) Inhibitors of amino acid uptake into vesicles. J.Neurochem. 63 Suppl. 1 S49A. Roseth et al (1995) Uptake of L-glutamate into rat brain synaptic vesicles: effect of inhibitors that bind specifically to the glutamate transport. J.Neurochem. 65 96. PMID:7790899. Bai et al (2012) A novel allosteric inhibitor of macrophage migration inhibitory factor (MIF). J.Biol.Chem. 287 30653. PMID:22782901.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=2147				Jan-1901
0851	Propranolol glycol	[36112-95-5]	OC(CO)COC2=CC=CC1=CC=CC=C12	Propranolol (Cat. No. 0624) metabolite	Metabolite of propranolol (Cat. No. 0624).	Bourne (1981) The metabolism of _-adrenoceptor blocking drugs. Drug Metabolism 6 77.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1815				Jan-1901
0853	MPPG	[169209-65-8]	NC(C(O)=O)(C)C1=CC=C(P(O)(O)=O)C=C1	Group III/group II mGlu antagonist. More selective for group III than group II	"Potent antagonist of L-AP4-induced effects in rat spinal cord, thalamic and hippocampal neurons, showing selectivity over (1S,3S)-ACPD-induced effects. Potent antagonist of mGlu receptors linked to adenylyl cyclase in adult rat cortical slices."	Jane et al (1995) New phenylglycine derivatives with potent and selective antagonist activity at presynaptic glutamate receptors in neonatal rat spinal cord. Neuropharmacology 34 851. PMID:8532166. Salt and Turner (1996) Antagonism of the presumed presynaptic action of L-AP4 on GABAergic transmission in the ventrobasal thalamus by the novel mGluR anatagonist MPPG. Neuropharmacology 35 239. PMID:8734494. Bedingfield et al (1996) Novel potent selective phenylglycine antagonists of metabotropic glutamate receptors. Eur.J.Pharmacol. 309 71. PMID:8864696. Bushell et al (1996) Pharmacological antagonism of the actions of group II and group III mGluR agonists in the lateral perforant path of rat hippocampal slices. Br.J.Pharmacol. 117 1457. PMID:8730739.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1665				May-1995
0854	MSPG	[169209-64-7]	NC(C)(C(O)=O)C1=CC=C(S(=O)(O)=O)C=C1	Group II/group III mGlu antagonist	Relatively non-selective antagonist of presynaptic mGlu receptors in neonatal rat spinal cord and adult rat cerebrocortical mGlu receptors.	"Jane et al (1995) New phenylglycine derivatives with potent and selective antagonist activity at presynaptic glutamate receptors in neonatal rat spinal cord. Neuropharmacology 34 851. PMID:8532166. Thomas et al (1995) Antagonism of L-AP4- and (1S,3S)-ACPD-induced depression of dorsal root-evoked monosynaptic excitation of neonatal rat motoneurones by the novel antagonists MSPG and MPPG. Br.J.Pharmacol. 114 9P. Bedingfield et al (1996) Novel potent selective phenylglycine antagonists of metabotropic glutamate receptors. Eur.J.Pharmacol. 309 71. PMID:8864696."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1668				Jan-1901
0855	MTPG	[169209-66-9]	CC(N)(C(O)=O)C1=CC=C(C=C1)C1=NN=NN1	Group II/group III mGlu antagonist. More selective for group II than group III	"Group II/group III metabotropic glutamate receptor antagonist, showing selectivity for group II in electrophysiological studies."	Jane et al (1995) New phenylglycine derivatives with potent and selective antagonist activity at presynaptic glutamate receptors in neonatal rat spinal cord. Neuropharmacology 34 851. PMID:8532166. Bedingfield et al (1996) Novel potent selective phenylglycine antagonists of metabotropic glutamate receptors. Eur.J.Pharmacol. 309 71. PMID:8864696. Bushell et al (1996) Pharmacological antagonism of the actions of group II and group III mGluR agonists in the lateral perforant path of rat hippocampal slices. Br.J.Pharmacol. 117 1457. PMID:8730739.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1669				Jan-1901
0864	GR 46611	[185259-85-2]	O=C(/C=C/C2=CC=C(NC=C3CCN(C)C)C3=C2)NCC1=CC=C(OC)C=C1	5-HT1D agonist	5-HT1D receptor agonist. Blockade of GR 46611-induced hypothermia in the guinea pig provides a useful model with which to study the potency and duration of action of centrally acting 5-HT1D receptor ligands.	"Clitherow et al (1994) Evolution of a novel series of [(N,N-Dimethylamino)propyl]- and piperazinylbenzanilides as the first selective 5-HT1D antagonists. J.Med.Chem. 37 2253. PMID:8057272. Skingle et al (1994) Stimulation of central 5-HT1D receptors causes hypothermia in the guinea pig. J.Psychopharmacol. 8 14."	Small Molecule	Sold with the permission of GlaxoSmithKline	http://www.tocris.com/dispprod.php?ItemId=1430				Aug-1996
0867	Aniracetam	[72432-10-1]	COC1=CC=C(C=C1)C(=O)N1CCCC1=O	Desensitization inhibitor (AMPA > kainate)	"Nootropic, with modulatory actions through allosteric potentiation of AMPA specific receptors, reduction of glutamate receptor desensitization and potentiation of metabotropic glutamate receptor activity. Anxiolytic following systemic administration."	Ito et al (1990) Allosteric potentiation of quisqualate receptors by a nootropic drug aniracetam. J.Physiol. 424 553. PMID:1975272. Isaacson and Nicholl (1991) Aniracetam reduces glutamate receptor desensitisation and slows the decay of fast excitatory synaptic currents in the hippocampus. Proc.Natl.Acad.Sci.U.S.A. 88 10936. PMID:1660156. Nakamura and Kurasawa (2001) Anxiolytic effects of aniracetam in three different mouse models of anxiety and the underlying mechanism. Eur.J.Pharmacol. 420 33. PMID:11412837.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1085	SQ1533			Jun-1995
0868	"L-732,138"	[148451-96-1]	O=C(N[C@@](CC2=CNC3=C2C=CC=C3)([H])C(OCC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1)=O)C	"Potent, selective NK1 antagonist"	Potent and highly selective competitive tachykinin NK1 receptor antagonist (IC50 = 2.3 nM).	MacLeod et al (1993) N-Acyl-L-tryptophan benzyl esters: potent substance P receptor antagonists. J.Med.Chem. 36 2044. PMID:8393115. MacLeod et al (1994) Identification of L-tryptophan derivatives with potent and selective antagonist activity at the NK1 receptor. J.Med.Chem. 37 1269. PMID:7513763. Cascieri et al (1994) Characterization of the interaction of N-acyl-L-tryptophan benzyl ester neurokinin antagonists with the human neurokinin-1 receptor. J.Biol.Chem. 269 6587. PMID:7509807. Kuo et al (1998) Lipopolysaccharide enhances neurogenic plasma exudation in guinea-pig airways. Br.J.Pharmacol. 125 711. PMID:9831906.	Small Molecule	Sold with the permission of Merck Sharp and Dohme Ltd.	http://www.tocris.com/dispprod.php?ItemId=1549				Jun-1995
0869	Felbamate	[25451-15-4]	NC(=O)OCC(COC(N)=O)C1=CC=CC=C1	"NMDA antagonist, acts glycine site"	"Anticonvulsant, acting as an antagonist at the NMDA-associated glycine binding site."	Coffin et al (1994) Selective antagonism of the anticonvulsant effects of felbamate by glycine. Eur.J.Pharmacol. 256 R9. PMID:8050461. De Sarro et al (1994) Excitatory amino acid neurotransmission through both NMDA and non-NMDA receptors is involved in the anticonvulsant activity of felbamate in DBA/2 mice. Eur.J.Pharmacol. 262 11. PMID:7529182. Serra et al (1994) Felbamate antagonises isoniazid- and FG7142-induced reduction of GABAA receptor function in the mouse brain. Eur.J.Pharmacol. 265 185. PMID:7875235. Upton (1994) Mechanisms of action of new antiepileptic drugs: rational design and serendipitous findings. TiPS 15 456. PMID:7886818.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1387	SQ1533			Jun-1995
0870	"MDL 11,939"	[107703-78-6]	OC(C1CCN(CCC2=CC=CC=C2)CC1)C1=CC=CC=C1	5-HT2A antagonist	"Orally active 5-HT2A receptor antagonist; displays selectivity for 5-HT2A receptors over 5-HT2C receptors (Ki values are 0.54, 2.5, 81.6 and ~10,000 nM at rabbit 5-HT2A, human 5-HT2A, rabbit 5-HT2C and human 5-HT2C receptors respectively)."	"Dudley et al (1988) Pharmacological effects of MDL 11,939: a selective, centrally acting antagonist of 5-HT2 receptors. Drug Dev.Res. 13 29. Aloyo and Harvey (2000) Antagonist binding at 5-HT2A and 5-HT2C receptors in the rabbit: high correlation with the profile for the human receptors. Eur.J.Pharmacol. 406 163. PMID:11020478. Jensen et al (2013) Design, synthesis, and pharmacological characterization of N- and O-substituted 5,6,7,8-tetrahydro-4H-isoxazolo[4,5-dazepin-3-ol analogues: novel 5-HT2A/5-HT2C receptor agonists with pro-cognitive properties. J.Med.Chem. 56 1211. PMID:23301527."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1563	SQ1070			Jun-1995
0871	AMT hydrochloride	[21463-31-0]	NC1=NCCC(S1)C.Cl	"Potent, selective iNOS inhibitor"	"Potent, selective and reversible inhibitor of iNOS (IC50 = 3.6 nM; approximately 30 and 40 times selective over nNOS and eNOS respectively)."	Nakane et al (1995) Novel potent and selective inhibitors of inducible nitric oxide synthase. Mol.Pharmacol. 47 831. PMID:7536889. Yu et al (2005) Inhibition of sarcoplasmic reticular function by chronic interleukin-6 exposure via iNOS in adult ventricular myocytes. J.Physiol. 566 327. PMID:15845578. Liao et al (2006) Nitric oxide signaling in stretch-induced apoptosis of neonatal rat cardiomyocytes. FASEB J. 20 E1196. PMID:16877524.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1170				Mar-1998
0873	EIT hydrobromide	[1071-37-0]	NC(SCC)=N.Br	"Selective iNOS inhibitor, acts arginine binding site"	"Potent, selective and reversible inhibitor of isoform II NO synthase (IC50 = 13 nM; approximately 20- and 30-fold selective over isoforms I and III respectively)."	"Garvey et al (1994) Potent and selective inhibition of human nitric oxide synthase. J.Biol.Chem. 269 26669. PMID:7523409. Nakane et al (1995) Novel potent and selective inhibitors of inducible nitric oxide synthase. Mol.Pharmacol. 47 831. PMID:7536889. Squadrito et al (1996) Effects of S-ethylisothiourea, a potent inhibitor of nitirc oxide synthase, alone or in combination with a nitric oxide donor in splanchnic artery occlusion shock. Br.J.Pharmacol. 119 23. PMID:8872352."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1355				Jul-1995
0876	AM 92016 hydrochloride	[133229-11-5]	Cl.CN(CCC1=CC(Cl)=C(Cl)C=C1)CC(O)COC1=CC=C(NS(C)(=O)=O)C=C1	KV channel blocker	"A specific blocker of the time dependent delayed rectifier potassium current, devoid of any _-adrenoceptor blocking activity. Exhibits proarrhythmic and prohypertensive activity in vivo."	"Conners et al (1992) Actions and mechanisms of action of novel analogues of sotalol on guinea-pig and rabbit ventricular cells. Br.J.Pharmacol. 106 958. PMID:1393293. Hagerty et al (1996) The in vivo cardiovascular effects of a putative class III anti-arrhythmic drug, AM 92016. J.Pharm.Pharmacol. 48 417. PMID:8794994. Lei and Brown (1998) Inhibition by compound II, a sotalol analogue, of delayed rectifier current (iK) in rabbit sino-atrial node cells. Naunyn Schmiedebergs Arch.Pharmacol. 357 260. PMID:9550297. Palen et al (2005) Role of SHP-1, Kv1.2 and cGMP in nitric oxide-induced ERK1/2 MAP kinase dephosphorylation in rat vascular smooth muscle cells. Cardiovasc.Res. 68 268. PMID:15967421."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1579				Aug-1995
0877	Luzindole	[117946-91-5]	CC(=O)NCCC1=C(CC2=CC=CC=C2)NC2=CC=CC=C12	Competitive melatonin MT1/MT2 antagonist	Melatonin antagonist.	"Dubocovich (1988) Luzindole (N-0774): a novel melatonin receptor antagonist. J.Pharmacol.Exp.Ther. 246 902. PMID:2843633. Dubocovich et al (1990) Anti-depressant-like activity of the melatonin receptor antagonist, luzindole (N-0774), in mouse behavioural despair test. Eur.J.Pharmacol. 182 313. PMID:2168835. Dubocovich (1995) Melatonin receptors: are there multiple subtypes? TiPS 16 50. PMID:7762083."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1556				Jan-1901
0878	Oleamide	[301-02-0]	CCCCCCCC\C=C/CCCCCCCC(N)=O	CB1 receptor agonist	"Endogenous sleep-inducing lipid. Acts as an agonist at the CB1 cannabinoid receptor (EC50 = 1.64 _M). Also appears to potentiate the actions of 5-HT on 5-HT2A and 2C receptors, and act via an allosteric regulatory site on 5-HT7 receptors."	Cravatt et al (1995) Chemical characterisation of a family of brain lipids that induces sleep. Science 268 1506. PMID:7770779. Huidobro-Toro and Harris (1996) Brain lipids that induce sleep are novel modulators of 5-hydroxytryptamine receptors. Proc.Natl.Acad.Sci.U.S.A. 93 8078. PMID:8755606. Hedlund et al (1999) Allosteric regulation by oleamide of the binding properties of 5-hydroxytryptamine7 receptors. Biochem.Pharmacol. 58 1807. PMID:10571256. Leggett et al (2004) Oleamide is a selective endogenous agonist of rat and human CB1 cannabinoid receptors. Br.J.Pharmacol. 141 253. PMID:14707029.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1719	SQ1070			Jan-1997
0879	Palmitoylethanolamide	[544-31-0]	O=C(CCCCCCCCCCCCCCC)NCCO	Selective GPR55 agonist. FAAH and PAA substrate	"Endogenous lipid that acts as a selective GPR55 agonist (EC50 values are 4, 19 800 and > 30 000 nM at GPR55, CB2 and CB1 receptors respectively). Substrate for fatty acid amide hydrolase (FAAH) and PEA-preferring acid amidase (PAA) and exhibits antinociceptive and anticonvulsant in vivo. Directly activates PPAR_ (EC50 = 3 _M) producing robust anti-inflammatory actions."	"Lambert et al (2001) Anticonvulsant activity of N-palmitoylethanolamide, a putative endocannabinoid, in mice. Epilepsia 42 321. PMID:11442148. Lambert et al (2002) The palmitoylethanolamide family: a new class of anti-inflammatory agents? Curr.Med.Chem. 9 663. PMID:11945130. Lo Verme et al (2005) The search for the palmitoylethanolamide receptor. Life Sci. 77 1685. PMID:15963531. Re et al (2005) Palmitoylethanolamide, endocannabinoids and related cannabimimetic compounds in protection against tissue inflammation and pain: potential use in companion animals. Vet.J. 173 21. PMID:16324856. Ryberg et al (2007) The orphan receptor GPR55 is a novel cannabinoid receptor. Br.J.Pharmacol. 152 1092. PMID:17876302."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1737	SQ1533			Apr-1999
0880	ODQ	[41443-28-1]	O=C1ON=C2C=NC3=C(C=CC=C3)N12	Selective inhibitor of NO-sensitive guanylyl cyclase	A potent and selective inhibitor of NO-sensitive guanylyl cyclase.	"Boulton et al (1995) Nitric oxide-dependent long-term potentiation is blocked by a specific inhibitor of soluble guanylyl cyclase. Neuroscience 69 699. PMID:8596640. Garthwaite et al (1995) Potent and selective inhibition of nitric oxide-sensitive guanylyl cyclase by 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one. Mol.Pharmacol. 48 184. PMID:7544433. Fedele et al (1996) In vivo microdialysis study of a specific inhibitor of soluble guanylyl cyclase on the glutamate receptor/nitric oxide/cyclic GMP pathway. Br.J.Pharmacol. 119 590. PMID:8894183. Hwang et al (1998) Comparison of two soluble guanylyl cyclase inhibitors, methylene blue and ODQ, on sodium nitroprusside-induced relaxation in guinea-pig trachea. Br.J.Pharmacol. 125 1158. PMID:9863642."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1725				Oct-1995
0881	Chlormethiazole hydrochloride	[6001-74-7]	ClCCC1=C(C)N=CS1.Cl	Potentiates GABAA receptor function	Sedative and anticonvulsant which is neuroprotective in a number of animal models. Prevents the degeneration of serotonergic nerve terminals induced by MDMA ('Ecstasy').	"Hewitt and Green (1994) Chloromethiazole, dizocilpine and haloperidol prevent the degeneration of serotonergic nerve terminals induced by the administration of MDMA ('Ecstasy') to rats. Neuropharmacology 33 1589. PMID:7539115. Cross et al (1995) The protective action of chloromethiazole against ischaemia induced neurodegeneration in gerbils when infused at doses having little sedative or anticonvulsant activity. Br.J.Pharmacol. 114 1625. PMID:7599932."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=2149	SQ1533			Sep-1995
0882	ZM 226600	[147695-92-9]	CC(O)(C(=O)NC1=CC=C(C=C1)S(=O)(=O)C1=CC=CC=C1)C(F)(F)F	Kir6 (KATP) channel opener	"Potent Kir6 (KATP) channel opener (EC50 = 0.5 _M), devoid of antiandrogen properties."	Grant et al (1994) Anilide tertiary carbinols: a novel series of K+ channel openers. TiPS 15 402. PMID:7855900.	Small Molecule	Sold with the permission of AstraZeneca UK Ltd.	http://www.tocris.com/dispprod.php?ItemId=1985				Sep-1995
0883	BD 1063 dihydrochloride	[206996-13-6]	Cl.Cl.CN1CCN(CCC2=CC=C(Cl)C(Cl)=C2)CC1	"Selective _1 ligand, putative antagonist"	"_1 receptor antagonist, approximately 50-fold selective over _2 sites and 100-fold selective over opioid, PCP, muscarinic, dopamine, _1, _2, _ adrenoceptor, 5-HT1 and 5-HT2 receptors. Prevents hyperlocomotion following cocaine administration in mice."	Matsumoto et al (1995) Characterisation of two novel _ receptor ligands: antidystonic effects in rats suggest _ receptor antagonism. Eur.J.Pharmacol. 280 301. PMID:8566098. McCracken et al (1999) Novel _ receptor ligands attenuate the locomotor stimulatory effects of cocaine. Eur.J.Pharmacol. 365 35. PMID:9988120. Liu et al (2005) Cocaine up-regulated fra-2 and _-1 receptor gene and protein expression in brain regions involved in addiction and reward. J.Pharmacol.Exp.Ther. 314 770. PMID:15879001.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1997				Sep-1995
0884	Dihydrexidine hydrochloride	[158704-02-0]	OC1=C(O)C=C(CC[C@]3([H])[C@@]([H])2C4=C(C=CC=C4)CN3)C2=C1.Cl	Selective D1-like agonist	"A potent, full efficacy dopamine D1 agonist which shows no agonist activity at peripheral D2 receptors or adrenoceptors at doses which cause maximal stimulation of D1 sites. The compound appears to be fully bioavailable in brain and exhibits profound antiparkinsonism effects in vivo."	"Lovenberg et al (1989) Dihydrexidine, a novel selective high potency, full dopamine D-1 receptor agonist. Eur.J.Pharmacol. 166 111. PMID:2572425. Brewster et al (1990) Trans-10,11-dihydroxy-5,6,6a,7,8,12b-hexahydrobenzo[a]phenanthridine: a highly potent selective dopamine D1 full agonist. J.Med.Chem. 33 1756. PMID:1971308. Taylor et al (1991) Dihydrexidine, a full dopamine D1 agonist, reduces MPTP-induced parkinsonism in monkeys. Eur.J.Pharmacol. 199 389. PMID:1680717. Kholi et al (1993) Dihydrexidine: a new potent peripheral dopamine D1 receptor agonist. Eur.J.Pharmacol. 235 31. PMID:8100195."	Small Molecule	"Sold under license, US Patent 5,047,536"	http://www.tocris.com/dispprod.php?ItemId=1292	SQ1070			Sep-1995
0885	Guanabenz acetate	[23256-50-0]	CC(O)=O.ClC1=C(/C=N/NC(N)=N)C(Cl)=CC=C1	_2 agonist. Also I2 selective ligand	_2-adrenergic agonist and IGRS (imidazoline I2 binding site) selective ligand.	Merck Index 12 4585. Holmes et al (1983) Guanabenz. A review of its pharmacodynamic properties and therapeutic efficacy in hypertension. Drugs 26 212. PMID:6352237. Michel and Insel (1989) Are there multiple imidazoline binding sites? Trends Pharmacol.Sci. 10 342. PMID:2690423. Evans and Anderson (1995) Renal effects of infusion of rilmenidine and guanabenz in conscious dogs: contribution of peripheral and central nervous system _2-adrenoceptors. Br.J.Pharmacol. 116 1557. PMID:8564219.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1432	SQ1533			Nov-1995
0888	Cirazoline hydrochloride	[40600-13-3]	Cl.C(OC1=C(C=CC=C1)C1CC1)C1=NCCN1	Selective _1 agonist	Selective _1 agonist. Also available as part of the _1-Adrenoceptor Tocriset and Mixed Adrenergic Tocriset.	"Gellai and Ruffolo (1987) Renal effects of selective alpha-1 and alpha-2 adrenoreceptor agonists in conscious normotensive rats. J.Pharmacol.Exp.Ther. 240 723. PMID:2882013. Wikberg and Uklen (1990) Further characterisation of the guinea pig cerebral cortex idazoxan receptor: solubilization, distinction from the imidazole site, and demonstration of cirazoline as an idazoxan receptor-selective drug. J.Neurochem. 55 192. PMID:1972387. Le Rouzic et al (1995) Binding of [3H]cirazoline to an imidazoline site in rat brain and kidney membranes. Eur.J.Pharmacol. 278 261. PMID:7589165."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=2195	SQ1533			Oct-1998
0889	RS 45041-190 hydrochloride	[204274-74-8]	Cl.ClC1=C2CN(CC2=CC=C1)C1=NCCN1	High affinity I2 ligand. Highly selective	Highly selective I2 imidazoline receptor ligand.	"Brown et al (1995) RS-45041-190: a selective, high affinity ligand for I2 imidazoline receptors. Br.J.Pharmacol. 116 1737. PMID:8528553. Jett et al (1999) Behavioral effects of RS-45041-190, a selective I2 imidazoline ligand in rats. Ann.N.Y.Acad.Sci. 881 369. PMID:10415939."	Small Molecule	Sold with the permission of Roche Bioscience	http://www.tocris.com/dispprod.php?ItemId=1846				Oct-1998
0890	Amiloride hydrochloride	[2016-88-8]	Cl.NC(=N)NC(=O)C1=NC(Cl)=C(N)N=C1N	Na+ channel blocker; also I2 imidazoline ligand	"Na+ channel blocker. Defines the I2A-amiloride sensitive and I2B-amiloride insensitive imidazoline binding Blocks TRPP3, acid sensing- (ASIC) and mechanogated membrane-ion channels, as well as the Na+/H+ exchanger. Also inhibits urokinase-type plasminogen activator (uPA); has no effect on tissue-type plasminogen activator."	Vassalli et al (1987) Amiloride selectively inhibits the urokinase-type plasminogen activator. 214 187. PMID:3106085. Kleyman et al (1988) Amiloride and its analogues as tools in the study of ion transport. J.Membr.Biol. 105 1. PMID:2852254. Ernsberger et al (1992) A second generation of centrally acting antihypertensive agents act on putative I1-imidazoline receptors. J.Cardiovasc.Pharmacol. 20 S1. Hamill and McBride (1996) The pharmacology of mechanogated membrane ion channels. Pharmacol.Rev. 48 231. PMID:8804105. Dai et al (2007) Inhibition of TRPP3 channel by amiloride and analogs. Mol.Pharmacol. 72 1576. PMID:17804601. Jetti et al (2010) Evaluation of the role of nitric oxide in acid sensing ion channel mediated cell death. Nitric Oxide 22 213. PMID: 20045740.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1068	SQ1533			Jan-1901
0891	Rauwolscine hydrochloride	[6211-32-1]	[H][C@]12C4=C(C(C=CC=C5)=C5N4)CCN1C[C@]3([H])[C@]([C@H]([C@](OC)=O)[C@@H](O)CC3)([H])C2.Cl	_2 antagonist	"Standard _2-adrenergic antagonist (Ki values are 3.5, 4.6, and 0.6 nM at cloned human _2A, _2B, and _2C-adrenoceptors respectively). Partial agonist at 5-HT1A receptors. Also available as part of the _2-Adrenoceptor Tocriset. Diastereomer Yohimbine hydrochloride (Cat. No. 1127) also available."	"Arthur et al (1993) Partial agonist properties of rauwolscine and yohimbine for the inhibition of adenylyl cyclase by recombinant human 5-HT1A receptors. Biochem.Pharmacol. 45 2337. PMID:8517875. Hieble et al (1995) _- and _-Adrenoceptors: from the gene to the clinic. 1. Molecular biology and adrenoceptor subclassification. J.Med.Chem. 38 3415. PMID:7658428. Uhlen et al (1998) [3H]RS79948-197 binding to human, rat, guinea pig and pig _2A-, _2B-, and _2C-adrenoceptors. Comparison with MK912, RX821002, rauwolscine and yohimbine. Eur.J.Pharmacol. 343 93. PMID:9551719."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1832	SQ1533			Jan-1901
0892	Naltriben mesylate	[122517-78-6]	CS(=O)(O)=O.O[C@@]24[C@]3([C@@H]7C(O6)=C(C5=C6C=CC=C5)C4)C1=C(O7)C(O)=CC=C1CC2N(CC8CC8)CC3	Standard _2 selective antagonist	"Selective and potent _-opioid receptor antagonist (Ki values are 0.013, 19 and 152 nM for _, _ and _ receptors respectively). Displays selectivity for the _2 subtype in vivo."	Portoghese et al (1991) Role of spacer and address components in peptidomimetic _ opioid receptor antagonists related to naltrindole. J.Med.Chem. 34 1715. PMID:1851846. Miyamoto et al (1993) Involvement of delta2 opioid receptors in the development of morphine dependence in mice. J.Pharmacol.Exp.Ther. 264 1141. PMID:8383738. Thorat and Hammond (1997) Modulation of nociception by microinjection of delta-1 and delta-2 opioid receptor ligands in the ventromedial medulla of the rat. J.Pharmacol.Exp.Ther. 283 1185. PMID:9399992.	Small Molecule	Sold with the permission of the University of Minnesota	http://www.tocris.com/dispprod.php?ItemId=1680				Jan-1997
0894	(RS)-()-Sulpiride	[15676-16-1]	CCN1CCCC1CNC(=O)C1=C(OC)C=CC(=C1)S(N)(=O)=O	Standard selective D2-like antagonist	Standard D2-like dopamine receptor antagonist. (S)-(-)-Sulpiride (Cat. No. 0895) also available.	"Merck Index 12 9163. Seeman and Van Tol (1993) Dopamine D4 receptors bind inactive (+)-aporphines, suggesting neuroleptic role. Sulpiride not stereoselective. Eur.J.Pharmacol. 233 173. PMID:8097160. Seeman and Van Tol (1994) Dopamine receptor pharmacology. TiPS 15 264. PMID:7940991."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1888	SQ1070			Nov-1995
0895	(S)-(-)-Sulpiride	[23672-07-3]	NS(C1=CC(C(NC[C@]2([H])CCCN2CC)=O)=C(OC)C=C1)(=O)=O	Standard selective D2-like antagonist	"Active enantiomer. Selective D2-like dopamine antagonist (Ki values are ~ 0.015. ~ 0.013, 1, ~ 45 and ~ 77 _M at D2, D3, D4, D1 and D5 receptors respectively). (RS)-()-Sulpiride (Cat. No. 0894) also available."	"Merck Index 12 9163. Seeman and Van Tol (1993) Dopamine D4 receptors bind inactive (+)-aporphines, suggesting neuroleptic role. Sulpiride not stereoselective. Eur.J.Pharmacol. 233 173. PMID:8097160. Seeman and Van Tol (1994) Dopamine receptor pharmacology. TiPS 15 264. PMID:7940991."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1889	SQ1070			Nov-1995
0896	GR 135531	[190277-13-5]	COC(=O)NC1=CC=C2NC=C(CCNC(C)=O)C2=C1	High affinity melatonin MT3 ligand	"Binds with high affinity to MT3 melatonin sites in hamster brain, and low affinity (and no efficacy) at MT1 and MT2 melatonin receptors and thus can be used to discriminate between the melatonin receptor subtypes."	Dubocovich (1995) Melatonin receptors: are there multiple subtypes? TiPS 16 50. PMID:7762083. Lucchelli et al (1997) Investigation into the contractile response of melatonin in the guinea-pig isolated proximal colon: the role of 5-HT4 and melatonin receptors. Br.J.Pharmacol. 121 1775. PMID:9283717.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1431	SQ1341			Jun-1998
0897	S-Isopropylisothiourea hydrobromide	[4269-97-0]	Br.CC(C)SC(=N)N	"iNOS inhibitor, acts at arginine binding site"	"Potent inhibitor of NO synthase, with selectivity for the inducible form."	"Garvey et al (1994) Potent and selective inhibition of human nitric oxide synthases. J.Biol.Chem. 269 26669. PMID:7523409. Handy et al (1995) Effect of S-methylisothiourea on neuronal nitric oxide synthase, nociception and blood pressure in the mouse. Br.J.Pharmacol. 115 68P. Moore and Handy (1997) Selective inhibitors of neuronal nitric oxide synthase - is no NOS really good NOS for the nervous system? TiPS 18 204. PMID:9226999."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1533				Nov-1995
0898	Clocinnamox mesylate	[117332-69-1]	CS(=O)(O)=O.OC1=C(O5)C([C@]([C@@H]5C(CC3)=O)4[C@]3(NC(/C=C/C6=CC=C(Cl)C=C6)=O)C(N(CC7CC7)CC4)C2)=C2C=C1	Irreversible _ antagonist	"Systemically active, irreversible _-opioid receptor antagonist (apparent Ki values are 0.7, 1.9 and 5.7 nM for mouse _, _ and _ receptors respectively)."	"Aceto et al (1989) Very long-acting narcotic antagonists. The 14_-p-substituted cinnamoylaminomorphinones and their partial mu agonist codeinone relatives. Arzneimittelforschung 39 570. PMID:2547389. Burke et al (1994) Irreversible opioid antagonist effects of clocinnamox on opioid analgesia and mu receptor binding in mice. J.Pharmacol.Exp.Ther. 271 715. PMID:7965787. Zernig et al (1996) Mechanism of clocinnamox blockade of opioid receptors: evidence from in vitro and ex vivo binding and behavioural assays. J.Pharmacol.Exp.Ther. 279 23. PMID:8858971. Broadbear et al (2000) Methocinnamox is a potent, long-lasting, and selective antagonist of morphine-mediated antinociception in the mouse: comparison with clocinnamox, _-funaltrexamine, and _-chlornaltrexamine. J.Pharmacol.Exp.Ther. 294 933. PMID:10945843."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=2198				May-2012
0899	BNTX maleate	[864461-31-4]	OC(=O)\C=C/C(O)=O.OC1=C(O7)C([C@]([C@@H]7C(/C(C4)=C/C3=CC=CC=C3)=O)5[C@]4(O)C(N(CC6CC6)CC5)C2)=C2C=C1	Standard _1 selective antagonist	Standard selective _1 opioid receptor antagonist. Also inhibits neurogenic ion transport mediated by a putative novel opioid receptor in porcine ileal mucosa.	Portoghese et al (1992) A _1-opioid receptor antagonist: 7-benzylidenenaltrexone. Eur.J.Pharmacol. 218 195. PMID:1327826. Hammond et al (1995) Antinociception and d-1 opioid receptors in the rat spinal cord: studies with intrathecal 7-benzylidenenaltrexone. J.Pharmacol.Exp.Ther. 274 1317. PMID:7562504. Poonyachoti et al (2001) Pharmacological evidence for a 7-benzylidenenaltrexone-preferring opioid receptor mediating the inhibitory actions of peptidic _- and _-opioid agonists on neurogenic ion transport in porcine ileal mucosa. J.Pharmacol.Exp.Ther. 297 672. PMID:11303057.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=2041				Sep-1997
0900	MRS 2179 tetrasodium salt	[1454889-37-2]	[Na+].[Na+].[Na+].[Na+].CNC1=NC=NC2=C1N=CN2[C@@H]1C[C@H](OP([O-])([O-])=O)[C@@H](COP([O-])([O-])=O)O1	Selective P2Y1 antagonist	"A competitive antagonist at P2Y1 receptors (KB = 100 nM). Selective over P2X1 (IC50 = 1.15 _M), P2X3 (IC50 = 12.9 _M), P2X2, P2X4, P2Y2, P2Y4 and P2Y6 receptors. Inhibits the upregulation of NTPDase1 by ATP_S."	"Boyer et al (1998) Competitive and selective antagonism of P2Y1 receptors by N6-methyl 2'-deoxyadenosine 3',5'-bisphosphate. Br.J.Pharmacol. 124 1. PMID:9630335. Nandanan et al (2000) Synthesis, biological activity, and molecular modeling of ribose-modified deoxyadenosine bisphosphate analogues as P2Y1 receptor ligands. J.Med.Chem. 43 829. PMID:10715151. Brown et al (2000) Activity of novel adenine nucleotide derivatives as agonists and antagonists at recombinant rat P2X receptors. Drug Dev.Res. 49 253. Lu et al (2007) Stimulation of the P2Y1 receptor up-regulates nucleoside-triphosphate diphosphohydrolase-1 in human retinal pigment epithelial cells. J.Pharmacol.Exp.Ther. 323 157. PMID:17626796."	Small Molecule	"Sold under license from the NIH, US Patent 60/029,855"	http://www.tocris.com/dispprod.php?ItemId=1340				Oct-2000
0901	5-Nonyloxytryptamine oxalate	[157798-13-5]	OC(=O)C(O)=O.CCCCCCCCCOC1=CC=C2NC=C(CCN)C2=C1	Selective 5-HT1B agonist	"5-HT1B selective agonist, several times more potent than sumatriptan and inactive as a 5-HT1A agonist (Ki at 5-HT1B = 1 nM, selectivity over 5-HT1A > 300-fold). Mimics polysialic acid activity, stimulates neuritogenesis, myelination and Schwann cell migration in vitro."	Glennon et al (1994) 5-(Nonyloxy)tryptamine: a novel high affinity-5-HT1D_ serotonin receptor agonist. J.Med.Chem. 37 2828. PMID:8071931. Glennon et al (1996) Binding of O-Alkyl derivatives of serotonin at human 5-HT1D_ receptors. J.Med.Chem. 39 314. PMID:8568822. Loers et al (2013) Nonyloxytryptamine mimics polysialic acid and modulates neuronal and glial functions in cell culture. J.Neurochem. 128 88. PMID:23957498.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1713				Sep-1997
0902	Cimetidine	[51481-61-9]	CN\C(NCCSCC1=C(C)NC=N1)=N\C#N	"H2 antagonist, I1 agonist"	Widely used H2 histamine antagonist which has more recently been described as an inverse agonist. Also a potent I1 imidazoline binding site ligand.	"Hill (1990) Distribution, properties and functional characteristics of three classes of histamine receptor. Pharmacol.Rev. 42 45. PMID:2164693. Ernsberger et al (1992) A second generation of centrally acting antihypertensive agents act on putative I1-imidazoline receptors. J.Cardiovasc.Pharmacol. 20 S1. Tsoli et al (1995) The imidazoline I1 receptor agonist, moxonidine, inhibits insulin secretion from isolated rat islets of langerhans. Eur.J.Pharmacol. 284 199. PMID:8549627. Smit et al (1996) Inverse agonism of histamine H2 antagonists accounts for upregulation of spontaneously active receptors. Proc.Natl.Acad.Sci.U.S.A. 93 6802. PMID:8692899."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=2193	SQ1533			Jan-1901
0903	SYM 2081	[31137-74-3]	[H][C@@](N)(C(O)=O)C[C@]([H])([C@](O)=O)C	Highly selective kainate agonist	"Potent and highly selective kainate receptor agonist, with an IC50 for inhibition of [3H]-kainate binding of 35 nM and almost 3,000- and 200-fold selectivity for kainate receptors over AMPA and NMDA receptors respectively. Also selectively inhibits the cloned excitatory amino acid transporter EAAT2 at higher concentrations. Also available as part of the Excitatory Amino Acid Transporter Inhibitor Tocriset and Kainate Receptor Tocriset."	"Jones et al (1997) Desensitization of kainate receptors by kainate, glutamate and diastereomers of 4-methylglutamate. Neuropharmacology 36 853. PMID:9225313. Zhou et al (1997) (2S,4R)-4-Methylglutamic acid (SYM 2081): a selective, high affinity ligand for kainate receptors. J.Pharmacol.Exp.Ther. 280 422. PMID:8996224. Donevan et al (1998) The methylglutamate, SYM 2081, is a potent and highly selective agonist at kainate receptors. J.Pharmacol.Exp.Ther. 285 539. PMID:9580595. Savidge et al (1999) Characterisation of kainate receptor mediated whole-cell currents in rat cultured cerebellar granule cells. Neuropharmacology 38 375. PMID:10219975."	Small Molecule	Sold with the permission of Annovis Inc.	http://www.tocris.com/dispprod.php?ItemId=1629				Jan-1901
0904	AIDA	[168560-79-0]	NC2(C(O)=O)C1=CC=C(C(O)=O)C=C1CC2	"Potent, selective group I mGlu antagonist"	"A relatively potent and selective antagonist of group I metabotropic glutamate receptors (mGlu1a), having no effect on group II (mGlu2) or group III (mGlu4) receptors expressed individually in baby hamster kidney cells. Has no effect on ionotropic glutamate receptors. Centrally active following systemic administration in vivo."	"Pellicciari et al (1995) 1-Aminoindan-1,5-dicarboxylic acid: a novel antagonist at phospholipase C-linked metabotropic glutamate receptors. J.Med.Chem. 38 3717. PMID:7562903. Moroni et al (1997) Pharmacological characterization of 1-aminoindan-1,5-dicarboxylic acid, a potent mGluR1 antagonist. J.Pharmacol.Exp.Ther. 281 721. PMID:9152378. Nielsen et al (1997) Class I mGlu receptor antagonist 1-aminoindan-1,5-dicarboxylic acid blocks contextual but not cue conditioning in rats. Eur.J.Pharmacol. 326 105. PMID:9196260."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1116				Jan-1901
0905	Rolipram	[61413-54-5]	COC1=CC=C(C=C1OC1CCCC1)C1CNC(=O)C1	PDE4 inhibitor	Selective inhibitor of cAMP phosphodiesterase (PDE4) (IC50 = 2.0 _M). Discriminates between two conformational states of PDE4 isoenzymes. Separate isomers (R)-(-)-Rolipram and (S)-(+)-Rolipram are available (Cat. Nos. 1349 and 1350 respectively).	"O'Donnell (1993) Antidepressant-like effects of rolipram and other inhibitors of cyclic adenosine monophosphate phosphodiesterase on behaviour maintained by differential reinforcement of low response rate. J.Pharmacol.Exp.Ther. 264 1168. PMID:8383740. Kato et al (1995) Rolipram, a cyclic AMP-selective phosphodiesterase inhibitor, reduces neuronal damage following cerebral ischemia in the gerbil. Eur.J.Pharmacol. 272 107. PMID:7713141. Teixeira et al (1997) Phosphodiesterase (PDE)4 inhibitors: anti-inflammatory drugs of the future? Trends Pharmacol.Sci. 18 164. PMID:9184477."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1840	SQ1533			Nov-1995
0906	Betaxolol hydrochloride	[63659-19-8]	Cl.CC(C)NCC(O)COC1=CC=C(CCOCC2CC2)C=C1	Selective _1 antagonist	Selective _1-adrenoceptor antagonist.	"Merck Index 12 1229. Beresford and Heel (1986) Betaxolol. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in hypertension. Drugs 31 6. PMID:2866947. Satoh et al (1993) The affinity of betaxolol, a _1-adrenoceptor-selective blocking agent, for _-adrenoceptors in the bovine trachea and heart Br.J.Pharmacol. 108 484. PMID:8383566. Setoguchi et al (1995) Inhibitory action of betaxolol, a _1-selective adrenoceptor antagonist, on voltage-dependent calcium channels in guinea pig artery and vein. Br.J.Pharmacol. 115 198. PMID:7647977."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=2026	SQ1533			Nov-1995
0907	"L-701,324"	[142326-59-8]	OC1=C(C(=O)NC2=CC(Cl)=CC=C12)C1=CC=CC(OC2=CC=CC=C2)=C1	NMDA antagonist; acts at glycine site	An orally active and long acting anticonvulsant with high affinity and selectivity for the glycine site on the NMDA receptor.	"Kulagowski et al (1994) 3'-(Arylmethyl)- and 3'-(aryloxy)-3-phenyl-4-hydroxyquinolin-2(1H)-ones: orally active antagonists of the glycine site on the NMDA receptor. J.Med.Chem. 37 1402. PMID:8182696. Obrenovitch and Zilkha (1996) Inhibition of cortical spreading depression by L-701,324, a novel antagonist at the glycine site of the N-methyl-D-aspartate receptor complex. Br.J.Pharmacol. 117 931. PMID:8851513. Bristow et al (1996) The atypical neuroleptic profile of the glycine/N-methyl-D-aspartate receptor antagonist, L-701,324 in rodents. J.Pharmacol.Exp.Ther. 277 578. PMID:8627534. Bristow et al (1996) Anticonvulsant and behavioral profile of L-701,324, a potent, orally active antagonist at the glycine modulatory site on the N-methyl-D-aspartate receptor complex. J.Pharmacol.Exp.Ther. 279 492. PMID:8930150."	Small Molecule	Sold with the permission of Merck Sharp and Dohme Ltd.	http://www.tocris.com/dispprod.php?ItemId=1548	SQ1070			Mar-1993
0908	Ketanserin tartrate	[83846-83-7]	OC(C(O)C(O)=O)C(O)=O.FC1=CC=C(C=C1)C(=O)C1CCN(CCN2C(=O)NC3=CC=CC=C3C2=O)CC1	Selective 5-HT2A antagonist. Also antagonist at 5-HT1D	Selective 5-HT2A serotonin receptor antagonist; can also be used to discriminate between 5-HT1D and 5-HT1B receptor subtypes.	"Leyson et al (1981) Receptor binding profile of R41 468, a novel antagonist at 5-HT2 receptors. Life Sci. 28 1015. PMID:6261070. Van Nueten et al (1981) Vascular effects of ketanserin (R41 468), a novel antagonist of 5-HT2 serotonergic receptors. J.Pharmacol.Exp.Ther. 218 217. PMID:6113280. Zgombick et al (1995) Ketanserin and ritanserin discriminate between recombinant human 5-HT1D_ and 5-HT1D_ receptor subtypes. Eur.J.Pharmacol. 291 9. PMID:8549648. Razzaque et al (1995) Differences in the effects of ketanserin and GR 127935 on 5-HT-receptor mediated responses in rabbit saphenous vein and guinea-pig jugular vein. Eur.J.Pharmacol. 283 199. PMID:7498311."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1539	SQ1533			Dec-1995
0909	Tropicamide	[1508-75-4]	CCN(CC1=CC=NC=C1)C(=O)C(CO)C1=CC=CC=C1	Selective M4 muscarinic antagonist	M4 selective muscarinic receptor antagonist.	"Lazareno et al (1990) Characterisation of muscarinic M4 binding sites in rabbit lung, chicken heart and NG 108-15 cells. Mol.Pharmacol. 38 805. PMID:2250662. Hernandez et al (1993) Different muscarinic receptor subtypes mediating the phasic activity and basal tone of pig isolated intravesical ureter. Br.J.Pharmacol. 110 1413. PMID:7905771."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1925	SQ1533			Dec-1995
0911	Glibenclamide	[10238-21-8]	COC1=C(C=C(Cl)C=C1)C(=O)NCCC1=CC=C(C=C1)S(=O)(=O)NC(=O)NC1CCCCC1	Kir6 (KATP) channel blocker	"ATP-dependent K+ channel (Kir6, KATP) and CFTR Cl- channel blocker. Inhibits Kir6 currents in the pancreas, causing an increase in intracellular Ca2+ and insulin secretion. Inhibits recombinant CFTR Cl- channels with an IC50 of 20 _M."	Brogden et al (1979) Glibenclamide: a review. Drugs 18 329. PMID:389600. Robertson et al (1990) Potassium channel modulators: scientific applications and therapeutic promise. J.Med.Chem. 33 1529. PMID:2187993. Sheppard and Welsh (1992) Effect of ATP-sensitive K+ channel regulators on cystic fibrosis transmembrane conductance regulator chloride channels. J.Gen.Physiol. 100 573. PMID:1281220.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1419	SQ1070			Nov-1999
0912	RU 24969 hemisuccinate	[66611-27-6]	OC(=O)CCC(O)=O.COC1=CC=C2NC=C(C2=C1)C1=CCNCC1.COC1=CC=C2NC=C(C2=C1)C1=CCNCC1	5-HT1B/1A agonist	Potent 5-HT1A/1B and moderate 5-HT2C agonist that may also release 5-HT. Centrally active following systemic administration.	"Guillaume et al (1987) Synthesis of 3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indoles and study of their serotonergic and antidopaminergic properties. Eur.J.Med.Chem. 22 33. Gudermann et al (1993) Human S31 serotonin receptor clone encodes a 5-hydroxytryptamine1E-like serotonin receptor. Mol.Pharmacol. 43 412. PMID:8450834. Tomkins and O'Neill (2000) Effect of 5-HT1B receptor ligands on self-administration of ethanol in an operant procedure in rats. Pharmacol.Biochem.Behav. 66 129. PMID:10837852."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1847				May-1998
0914	()-Bisoprolol hemifumarate	[104344-23-2]	OC(=O)\C=C\C(O)=O.CC(C)NCC(O)COC1=CC=C(COCCOC(C)C)C=C1.CC(C)NCC(O)COC1=CC=C(COCCOC(C)C)C=C1	_1 antagonist	A selective _1-adrenergic antagonist. Has a Kd of 2-3 nM at the _1 receptor and a _1/_2 selectivity of approximately 100-fold.	Kaumann and Lemoine (1985) Direct labelling of myocardial _1-adrenoceptors. Comparison of binding affinity of 3H-(-)-bisoprolol with its blocking potency. Naunyn Schmiedebergs Arch.Pharmacol. 331 27. PMID:2866449. Klockow et al (1986) Studies on the receptor profile of bisoprolol. Arzneimittelforschung 36 197. PMID:2870719. Heible et al (1995) _-and _-Adrenoceptors: from the gene to the clinic. 1. Molecular biology and adrenoceptor subclassification. J.Med.Chem. 38 3415. PMID:7658428.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=2036	SQ1533			Jan-1996
0915	Cilostamide	[68550-75-4]	CN(C1CCCCC1)C(=O)CCCOC1=CC=C2NC(=O)C=CC2=C1	PDE3 inhibitor	Selective inhibitor of type III phosphodiesterase (PDE3). Displays moderate selectivity for PDE3A isozyme vs. PDE3B (IC50 values are 0.027 and 0.050 _M for PDE3A and PDE3B respectively). Inhibits ADP-induced platelet aggregation (IC50 = 16.8 _M); antithrombotic. Also available as part of the Phosphodiesterase Inhibitor Tocriset.	"Hidaki et al (1979) Selective inhibitor of platelet cyclic adenosine monophosphate phosphodiesterase, cilostamide, inhibits platelet aggregation. J.Pharmacol.Exp.Ther. 211 26. PMID:226672. Christensen and Torphy (1994) Isozyme-selective phosphodiesterase inhibitors as antiasthmatic agents. Annu.Rep.Med.Chem. 29 185. Sudo et al (2000) Potent effects of novel anti-platelet aggregatory cilostamide analogues on recombinant cyclic nucleotide phosphodiesterase isozyme activity. Biochem.Pharmacol. 59 347. PMID:10644042."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=2191	SQ1533			Jan-1996
0916	Remoxipride hydrochloride	[73220-03-8]	BrC1=CC=C(OC)C(C(NC[C@@]2(CCCN2CC)[H])=O)=C1OC.Cl	Selective D2-like antagonist	"Dopamine D2 receptor antagonist showing selectivity over D3 and D4 receptors (Ki values are ~ 300, ~ 1600, and ~ 2800 nM for D2, D3 and D4 receptors respectively). Exhibits antipsychotic activity in vivo with no extrapyramidal side effects. 50-fold more potent than sulpiride in antagonising the effects of apomorphine in the rat."	Sedvall (1990) Development of a new antipsychotic remoxipride. Acta Psychiatr.Scand.Suppl. 358 1. PMID:1978466. Mohell et al (1993) Binding characteristics of remoxipride and its metabolites to dopamine D2 and D3 receptors. Eur.J.Pharmacol. 238 121. PMID:8405075. Seeman and Van Tol (1994) Dopamine receptor pharmacology. TiPS 15 264. PMID:7940991. Ahlenius et al (1997) In vivo effects of remoxipride and aromatic ring metabolites in the rat. J.Pharmacol.Exp.Ther. 283 1356. PMID:9400011.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1834	SQ1533			Jan-1901
0917	3-CPMT	[14008-79-8]	Cl.CN1C2CCC1CC(C2)OC(C1=CC=CC=C1)C1=CC=C(Cl)C=C1	Dopamine uptake inhibitor	"This cocaine analog binds with high affinity to the dopamine transporter (Ki = 30 nM) and blocks re-uptake of dopamine. However, it is a weak psychomotor stimulant and does not substitute for cocaine in addicted rats."	"Newman et al (1994) Novel 3_-(diphenylmethoxy)tropane analogs: potent dopamine uptake inhibitors without cocaine-like behavioural profiles. J.Med.Chem. 37 2258. PMID:8057273. Newman et al (1995) Novel 4'-substituted and 4'4""-disubstituted 3_-(diphenylmethoxy)tropane analogs as potent and selective dopamine uptake inhibitors. J.Med.Chem. 38 3933. PMID:7562926."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=2172	SQ1070			Jan-1996
0918	3_-Bis-(4-fluorophenyl) methoxytropane hydrochloride	[202646-03-5]	Cl.CN1C2CCC1CC(C2)OC(C1=CC=C(F)C=C1)C1=CC=C(F)C=C1	Potent dopamine uptake inhibitor	Potent inhibitor of dopamine uptake and transport (Ki = 11.8 nM).	"Newman et al (1994) Novel 3_-(diphenylmethoxy)tropane analogs: potent dopamine uptake inhibitors without cocaine-like behavioural profiles. J.Med.Chem. 37 2258. PMID:8057273. Newman et al (1995) Novel 4'-substituted and 4'4""-disubstituted 3_-(diphenylmethoxy)tropane analogs as potent and selective dopamine uptake inhibitors. J.Med.Chem. 38 3933. PMID:7562926."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=2035				Jan-1996
0919	TRIM	[25371-96-4]	FC(F)(F)C1=C(C=CC=C1)N1C=CN=C1	nNOS/iNOS inhibitor	"A potent inhibitor of neuronal and inducible NO synthases, with much lower affinity for the endothelial isoform (displays IC50 values of 28.2, 27.0 and 1057.5 _M respectively). Antinociceptive in vivo."	"Handy et al (1995) The antinociceptive effect of 1-(2-trifluoromethylphenyl)imidazole (TRIM), a potent inhibitor of neuronal nitric oxide synthase in vitro, in the mouse. Br.J.Pharmacol. 116 2349. PMID:8581267. Handy et al (1996) Inhibition of nitric oxide synthase by 1-(2-trifluoromethylphenyl)imidazole (TRIM) in vitro: antinociceptive and cardiovascular effects. Br.J.Pharmacol. 119 423. PMID:8886430. Tooker et al (2013) Nitric oxide mediates activity-dependent plasticity of retinal bipolar cell output via S-nitrosylation. J.Neurosci. 33 19176. PMID:24305814."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1916	SQ1533			Jan-1901
0921	SB 205607 dihydrobromide	[1217628-73-3]	[H][C@@](C1)2[C@](CC(N=C(C=CC=C4)C4=C3)=C3C2)([C@]5=CC=CC(O)=C5)CCN1C.Br.Br	"_1 selective, high affinity non-peptide agonist"	"The first described non-peptide _1 opioid receptor agonist with very high affinity and selectivity for the _1 subtype (Ki values are 1.12, 2320 and 1790 nM at _1, _ and _ receptors respectively)."	"Nagase et al (1994) Syntheses of non-peptidic delta opioid agonists and their structure-activity relationships. Jpn.J.Pharmacol. 64 Suppl. 1, 35P. Kamei et al (1995) Antinociceptive effects of the selective non-peptidic _-opioid receptor agonist TAN-67 in diabetic mice. Eur.J.Pharmacol. 276 131. PMID:7781682. Knap et al (1995) Properties of TAN-67, a non-peptidic _-opioid receptor agonist, at cloned human _- and _-opioid receptors. Eur.J.Pharmacol. 291 129. PMID:8566162. Nagase et al (2001) The pharmacological profile of _ opioid receptor ligands (+) and (-) TAN-67 on pain modulation. Life Sci. 68 2227. PMID:11358331."	Small Molecule	Sold under license	http://www.tocris.com/dispprod.php?ItemId=1893				Jan-2002
0922	SKF 38393 hydrobromide	[20012-10-6]	Br.OC1=CC2=C(C=C1O)C(CNCC2)C1=CC=CC=C1	Selective D1-like agonist	"Prototypical D1-like dopamine receptor selective partial agonist (Ki values are 1, ~ 0.5, ~ 150, ~ 5000 and ~ 1000 nM for D1, D5, D2, D3 and D4 receptors respectively)."	Sibley et al (1982) Interactions of novel dopaminergic ligands with D1 and D2 dopamine receptors. Life Sci. 31 637. PMID:6127585. Seeman and Van Tol (1994) Dopamine receptor pharmacology. TiPS 15 264. PMID:7940991. Geter-Douglass et al (1997) Characterization of unconditioned behavioral effects of dopamine D3/D2 receptor agonists. J.Pharmacol.Exp.Ther. 283 7. PMID:9336302. Habuchi et al (1997) Dopamine stimulation of cardiac _-adrenoceptors: the involvement of sympathetic amine transporters and the effect of SKF38393. Br.J.Pharmacol. 122 1669. PMID:9422813.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1864				Apr-1996
0923	SR 141716A	[158681-13-1]	O=C(NN4CCCCC4)C1=NN(C3=CC=C(Cl)C=C3Cl)C(C2=CC=C(Cl)C=C2)=C1C.Cl	Selective CB1 receptor antagonist	"Potent and selective cannabinoid CB1 receptor antagonist (Ki = 1.98 nM). Also acts as an inverse agonist reversing adenylyl cyclase inhibition by WIN 55,212-2 (Cat.No. 1038) (IC50 = 48 nM). Displays no activity at CB2 receptors. Reduces food intake and body weight in orally dosed non-obese Wistar rats."	"Rinaldi-Carmona et al (1994) SR 141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett. 350 240. PMID:8070571. Rinaldi-Carmona et al (1995) Biochemical and pharmacological characterisation of SR 141716A, the first potent and selective brain cannabinoid receptor antagonist. Life Sci. 56 1941. PMID:7776817. Colombo et al (1998) Appetite suppression and weight loss after the cannabinoid antagonist SR 141716. Life Sci. 63 113. PMID:9718088. Janiak et al (2007) Blockade of cannabinoid CB1 receptors improves renal function, metabolic profile, and increased survival of obese Zucker rats. Kidney Int. 72 1345. PMID:17882151."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1874	SQ1533			Dec-2012
0924	(+)-MK 801 maleate	[77086-22-7]	O=C(O)/C=C\C(O)=O.C[C@]1(N4)C3=C(C=CC=C3)C[C@@H]4C2=C1C=CC=C2	Non-competitive NMDA antagonist; acts at ion channel site	"A potent, selective and non-competitive NMDA receptor antagonist. Acts by binding to a site located within the NMDA associated ion channel and thus prevents Ca2+ flux. An effective anti-ischemic agent in several animal models. Part of the Mixed NMDA Receptor Tocriset. (-)-MK 801 maleate (Cat. No. 0955) also available."	Wong et al (1986) The anticonvulsant MK 801 is a potent N-methyl-D-aspartate antagonist. Proc.Natl.Acad.Sci.U.S.A. 83 7104. PMID:3529096. Gill et al (1991) The neuroprotective action of dizocilpine (MK-801) in the rat middle cerebral artery occlusion model of focal ischaemia. Br.J.Pharmacol. 103 2030. PMID:1912992. Hatfield et al (1992) The dose-response relationship and therapeutic window for dizocilpine (MK-801) in a rat focal ischaemia model. Eur.J.Pharmacol. 216 1. PMID:1526248. Zajaczkowski et al (1997) Uncompetitive NMDA receptor antagonists attenuate NMDA-induced impairment of passive avoidance learning and LTP. Neuropharmacology 36 961. PMID:9257940.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1659				Oct-1999
0925	SCH 23390 hydrochloride	[125941-87-9]	ClC1=C(O)C=C([C@](C3=CC=CC=C3)([H])C2)C(CCN2C)=C1.Cl	Standard selective D1-like antagonist; also 5-HT2C agonist	Potent dopamine receptor antagonist (Ki values are 0.2 nM and 0.3 nM at D1 and D5 receptor sub-types respectively). Also an agonist at 5-HT1C and 5-HT2C receptors in vitro (Ki values are 6.3 nM and 9.3 nM respectively).	"Briggs et al (1991) Activation of the 5-HT1C receptor expressed in Xenopus oocytes by the benzazepines SCH 23390 and SKF 38393. Br.J.Pharmacol. 104 1038. PMID:1687364. Millan et al (2001) The ""selective"" dopamine D1 receptor antagonist, SCH23390, is a potent and high efficacy agonist against cloned human serotonin2C receptors. Psychopharmacology 156 58. PMID:11465634. Bourne et al (2001) SCH 23390: The first selective dopamine D1-like receptor antagonist. CNS Drug Rev. 7 399. PMID:11830757."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=2267	SQ1070			Oct-1996
0926	_-Funaltrexamine hydrochloride	[72786-10-8]	OC1=C(O4)C([C@]([C@@H]4[C@@](NC(/C=C/C(OC)=O)=O)([H])CC3)5[C@]3(O)[C@H](N(CC6CC6)CC5)C2)=C2C=C1.Cl	Irreversible _-selective antagonist	Selective _ opioid receptor antagonist.	Takemorei et al (1981) The irreversible narcotic antagonist and reversible agonist properties of the fumarate methyl ester derivative of naltrexone. Eur.J.Pharmacol. 70 445. PMID:6263637. Jiang et al (1990) _ Antagonist and _ agonist properties of _-funaltrexamine (_-FNA) in vivo: long lasting spinal analgesia in mice. J.Pharmacol.Exp.Ther. 252 1006. PMID:2156986.	Small Molecule	Sold with the permission of the University of Minnesota	http://www.tocris.com/dispprod.php?ItemId=1404				Aug-1997
0927	Fluoxetine hydrochloride	[56296-78-7]	Cl.CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1	5-HT re-uptake inhibitor	"Selective serotonin reuptake inhibitor. Binds to the human 5-HT transporter with a Ki of 0.9 nmol/l and is between 150- and 900- fold selective over 5-HT1A, 5-HT2A, H1, _1, _2-adrenergic, and muscarinic receptors. Antidepressant. Induces differentiation of neuronal precursors, enhancing neuronal characteristics. Also available as part of the Serotonin Uptake Inhibitor Tocriset."	"Benfield et al (1986) Fluoxetine. A review of its pharmacodynamic properties, and therapeutic efficacy in depressive illness. Drugs 32 481. PMID:2878798. Owens et al (1997) Neurotransmitter receptor and transporter binding profile of antidepressants and their metabolites. J.Pharmacol.Exp.Ther. 283 1305. PMID:9400006. Beck et al (1997) Fluoxetine selectively alters 5-hydroxytryptamine1A and _-aminobutyric acidB receptor-mediated hyperpolarization in area CA1, but not area CA3, hippocampal pyramidal cells. J.Pharmacol.Exp.Ther. 281 115. PMID:9103487. Chang et al (2010) Increased cellular turnover in response to fluoxetine in neuronal precursors derived from human embryonic stem cells. Int.J.Dev.Biol. 54 707. PMID:19598107."	Small Molecule	Sold with the permission of Eli Lilly and Company	http://www.tocris.com/dispprod.php?ItemId=2304	SQ1533			Mar-1997
0928	ARC 239 dihydrochloride	[55974-42-0]	Cl.Cl.COC1=CC=CC=C1N1CCN(CCN2C(=O)C3=C(C=CC=C3)C(C)(C)C2=O)CC1	_2B antagonist	"Selective _2B adrenoceptor antagonist (pKD values are 8.8, 6.7 and 6.4 at _2B, _2A, and _2D receptors respectively). Also available as part of the _2-Adrenoceptor Tocriset."	Bylund et al (1988) Alpha-2A and alpha-2B adrenergic subtypes: antagonist binding in tissues and cell lines containing only one subtype. J.Pharmacol.Exp.Ther. 245 600. PMID:2835476. Fuder and Selback (1993) Characterisation of sensory neurotransmission and its inhibition via _2B-adrenoceptors and via non-_2 adrenoceptors in rabbit iris. Naunyn Schmiedebergs Arch.Pharmacol. 347 394. PMID:7685502.	Small Molecule	Sold with the permission of Boehringer Ingelheim GmbH	http://www.tocris.com/dispprod.php?ItemId=1247	SQ1070			Nov-1996
0929	"ICI 215,001 hydrochloride"	[140850-02-8]	O[C@H](COC2=CC=CC=C2)CNCCOC1=CC=C(OCC(O)=O)C=C1.Cl	_3 agonist	The active metabolite of ZD 7114 (Cat. No. 0930).	How (1993) _3Adrenergic agonists. Drugs Future 18 529.	Small Molecule	Sold with the permission of AstraZeneca UK Ltd.	http://www.tocris.com/dispprod.php?ItemId=1511				Feb-1996
0930	ZD 7114 hydrochloride	[129689-28-7]	O[C@H](COC2=CC=CC=C2)CNCCOC1=CC=C(OCC(NCCOC)=O)C=C1.Cl	_3 agonist	"_3-adrenoceptor agonist. Active metabolite ICI 215,001 hydrochloride (Cat. No. 0929) also available."	"Growcott et al (1993) Evaluation of ICI D7114, a putative stimulant of brown adipocytes, on histamine-contracted guinea-pig ileum. Br.J.Pharmacol. 109 1212. PMID:8104647. How (1993) _3-Adrenergic agonists. Drugs Future 18 529. Savontaus et al (1998) Effects of ZD7114, a selective _3-adrenoceptor agonist, on neuroendocrine mechanisms controlling energy balance. Eur.J.Pharmacol. 347 265. PMID:9653893."	Small Molecule	Sold with the permission of AstraZeneca UK Ltd .	http://www.tocris.com/dispprod.php?ItemId=1983				Feb-1996
0931	Haloperidol hydrochloride	[1511-16-6]	Cl.OC1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)C1=CC=C(Cl)C=C1	"Antagonist, partly D2 selective"	"Dopamine antagonist with selectivity for D2-like receptors (Ki values are 1.2, ~ 7, 2.3, ~ 80 and ~ 100 nM for D2, D3, D4, D1 and D5 receptors respectively). Subtype-selective NMDA antagonist."	Merck Index 12 4629. Beresford and Ward (1987) Haloperidol decanoate. A preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in psychosis. Drugs 33 31. PMID:3545764. Seeman and Van Tol (1994) Dopamine receptor pharmacology. TiPS 15 264. PMID:7940991. IIyin et al (1996) Subtype-selective inhibition of N-methyl-D-aspartate receptors by haloperidol. Mol.Pharmacol. 50 1541. PMID:8967976. Lynch and Gallagher (1996) Inhibition of N-methyl-D-aspartate receptors by haloperidol: development and pharmacological characterization in native and recombinant receptors. J.Pharmacol.Exp.Ther. 279 154. PMID:8858988.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1440	SQ1533			Feb-1996
0932	Immepip dihydrobromide	[164391-47-3]	Br.Br.C(C1CCNCC1)C1=CNC=N1	Standard H3 agonist. Also H4 agonist	Potent histamine H3 receptor agonist. Also binds to H4 receptors (Ki values are 0.4 and 9 nM at human recombinant H3 and H4 receptors respectively). Equipotent to or slightly more active than (R)-_-methylhistamine at H3 receptors.	Vollinga et al (1994) A new potent and selective histamine H3 receptor agonist. J.Med.Chem. 37 332. PMID:8308858. Coruzzi et al (1995) Cardiovascular effects of selective agonists and antagonists of histamine H3 receptors in the anaesthetized rat. Naunyn Schmiedebergs Arch.Pharmacol. 351 569. PMID:7675114. Liu et al (2001) Cloning and pharmacological characterization of a fourth histamine receptor (H4) expressed in bone marrow. Mol. Pharmacol. 59 420. PMID:11179434.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1519				Jan-1901
0933	MM 77 dihydrochloride	[159187-70-9]	Cl.Cl.COC1=CC=CC=C1N1CCN(CCCCN2C(=O)CCC2=O)CC1	5-HT1A (postsynaptic) antagonist	"A highly potent and fairly selective 5-HT1A ligand, which may be a full antagonist at postsynaptic receptors."	"Mokrosz et al (1994) 1-(2-Methoxyphenyl)-4-(4-succinimidobutyl)piperazine (MM 77): a new, potent, postsynaptic antagonist of 5-HT1A receptors. Med.Chem.Res. 4 161."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1662				May-1996
0934	Olvanil	[58493-49-5]	CCCCCCCC\C=C/CCCCCCCC(=O)NCC1=CC=C(O)C(OC)=C1	Potent vanilloid receptor agonist	Potent vanilloid receptor agonist (pEC50 values are 8.1 and 7.7 at rat and human VR1 receptors respectively). Also blocks anandamide uptake (IC50 = 9 _M) and may bind to CB1 cannabinoid receptors. Antinociceptive following systemic administration. Also available as part of the Vanilloid TRPV1 Receptor Tocriset.	"Dray et al (1990) NE-19550 and NE-21610, antinociceptive capsaicin analogues: studies on nociceptive fibres of the neonatal rat tail in vitro. Eur.J.Pharmacol. 181 289. PMID:2384136. Janusz et al (1993) Vanilloids. 1. Analogs of capsaicin with antinociceptive and antiinflammatory activity. J.Med.Chem. 36 2595. PMID:8410971. Di Marzo et al (1998) Interactions between synthetic vanilloids and the endogenous cannabinoid system. FEBS Lett. 436 449. PMID:9801167. Ralevic et al (2001) Cannabinoid activation of recombinant and endogenous vanilloid receptors. Eur.J.Pharmacol. 424 211. PMID:11672565."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1726	SQ1533			Mar-1996
0935	Maprotiline hydrochloride	[10347-81-6]	Cl.CNCCCC12CCC(C3=CC=CC=C13)C1=CC=CC=C21	Noradrenalin re-uptake inhibitor	Selective noradrenalin re-uptake inhibitor.	"Merck Index 11 5633. Pinder et al (1977) Maprotiline: A review of its pharmacological properties and therapeutic efficacy in mental depressive states. Drugs 13 321. PMID:326531. Pawlowski and Nowak (1987) Biochemical and pharmacological tests for the prediction of ability of monoamine uptake blockers to inhibit the uptake of noradrenaline in-vivo: the effects of desipramine, maprotiline, femoxetine and citalopram. J.Pharm.Pharmacol. 39 1003. PMID:2894425. Rodgers et al (1997) Behavioural effects in mice of subchronic chlordiazepoxide, maprotiline and fluvoxamine. II. The elevated plus-maze. Pharmacol.Biochem.Behav. 57 127. PMID:9164563."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1560	SQ1533			Jan-1901
0937	Pimozide	[2062-78-4]	FC1=CC=C(C=C1)C(CCCN1CCC(CC1)N1C(=O)NC2=CC=CC=C12)C1=CC=C(F)C=C1	D2-like antagonist	Dopamine D2-receptor antagonist and antipsychotic which binds with very high affinity to the cloned rat 5-HT7 receptor (Ki = 0.5 nM).	Merck Index 12 7589. Roth et al (1994) Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors. J.Pharmacol.Exp.Ther. 268 1403. PMID:7908055.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1774	SQ1533			Jan-1901
0938	p-Chlorophenylalanine	[7424-00-2]	NC(C(O)=O)CC1=CC=C(Cl)C=C1	Tryptophan hydroxylase inhibitor	Binds irreversibly to tryptophan hydroxylase to cause depletion of serotonin in the brain.	"Koyuncuoglu et al (1975) The effects of DL-p-chlorophenylalanine and DL-_-methyl-p-tyrosine on the brain catecholamine, serotonin and free amino acid contents in rat. Psychopharmacologia 45 163. PMID:129787. Datla and Curzon (1996) Effect of p-chlorophenylalanine at moderate dosage on 5-HT and 5-HIAA concentrations in brain regions of control and p-chloroamphetamine treated rats. Neuropharmacology 35 315. PMID:8783206."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=2164	SQ1533			Jan-1901
0940	4-Aminopyridine	[504-24-5]	NC1=CC=NC=C1	Non-selective KV channel blocker	Non-selective voltage-dependent K+-channel blocker (IC50 values are 170 and 230 _M at KV1.1 and KV1.2 respectively). Caged 4-AP (Cat. No. 3557) is also available.	"Bouchard and Fedida (1995) Closed and open state binding of 4-aminopyridine to the cloned human potassium channel Kv1.5. J.Pharmacol.Exp.Ther. 275 864. PMID:7473178. Tseng et al (1996) Reverse use dependence of Kv4.2 blockade by 4-aminopyridine. J.Pharmacol.Exp.Ther. 279 865. PMID:8930194. Tseng (1999) Different state dependencies of 4-aminopyridine binding to rKv1.4 and rKv4.2: role of the cytoplasmic halves of the fifth and sixth transmembrane segments. J.Pharmacol.Exp.Ther. 290 569. PMID:10411564. Smith et al (2009) In vitro electrophysiological activity of nerispirdine, a novel 4-aminopyridine derivative. Clin.Exp.Pharmacol.Physiol. 36 1104. PMID:19413590."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1151	SQ1533			Jan-1901
0941	MK 212 hydrochloride	[61655-58-1]	ClC1=CN=CC(N2CCNCC2)=N1.Cl	5-HT2C agonist	5-HT receptor agonist; displays selectivity for 5-HT2C over 5-HT2A (IC50 values are 0.028 and 0.42 _M for human 5-HT2C and 5-HT2A receptors expressed in HEK293 cells respectively).	"Conn and Sanders-Bush (1987) Relative efficacies of piperazines at the phosphoinositide hydrolysis-linked serotonergic (5-HT2 and 5-HT1C) receptors. J.Pharmacol.Exp.Ther. 242 552. PMID:3039120. Hemrick-Luecke and Fuller (1996) Involvement of 5-HT2A receptors in the elevation of rat serum corticosterone concentration by quipazine and MK-212. Eur.J.Pharmacol. 311 207. PMID:8891601. Jensen et al (2013) Design, synthesis, and pharmacological characterization of N- and O-substituted 5,6,7,8-tetrahydro-4H-isoxazolo[4,5-dazepin-3-ol analogues: novel 5-HT2A/5-HT2C receptor agonists with pro-cognitive properties. J.Med.Chem. 56 1211. PMID:23301527."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1658	SQ1070			Feb-1996
0942	NS 398	[123653-11-2]	CS(=O)(=O)NC1=C(OC2CCCCC2)C=C(C=C1)[N+]([O-])=O	Cyclooxygenase-2 (COX-2) inhibitor	Selective cyclooxygenase-2 inhibitor (IC50 values are 3.8 and > 100 _M for COX-2 and COX-1 respectively). Induces apoptosis in colorectal tumor cells and elevates COX-2 protein expression in vitro. Orally active and non-ulcerogenic analgesic and anti-inflammatory in vivo.	"Futaki et al (1993) NS-398, a novel non-steroidal anti-inflammatory drug with potent analgesic and antipyretic effects, which causes minimal stomach lesions. Gen.Pharmacol. 24 105. PMID:8482483. Futaki et al (1994) NS-398, a new anti-inflammatory agent, selectively inhibits prostaglandin G/H synthase/cyclooxygenase (COX-2) activity in vitro. Prostaglandins 47 55. PMID:8140262. Elder et al (2002) The MEK/ERK pathway mediates COX-2-selective NSAID-induced apoptosis and induced COX-2 protein expression in colorectal carcinoma cells. Int.J.Cancer 99 323. PMID:11992399."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1716				Jul-2002
0946	WB 4101 hydrochloride	[2170-58-3]	Cl.COC1=CC=CC(OC)=C1OCCNCC1COC2=C(O1)C=CC=C2	_1A antagonist	_1A-adrenergic selective antagonist. Also available as part of the _1-Adrenoceptor Tocriset.	"Green et al (1969) The synthesis and pharmacological properties of a series of 2-substituted aminomethyl-1,4-benzodioxanes. J.Med.Chem. 12 326. PMID:5791620. Morrow and Creese (1986) Characterisation of _1-adrenergic receptor subtypes in rat brain: a re-evaluation of 3H-WB 4101 and 3H-prazosin binding. Mol.Pharmacol. 29 321. PMID:3010073. Heible et al (1995) _ and _-adrenoceptors: from the gene to the clinic. 1. Molecular biology and adrenoceptor subclassification. J.Med.Chem. 38 3415. PMID:7658428."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1968	SQ1341			Jan-1901
0947	Zaprinast	[37762-06-4]	CCCOC1=C(C=CC=C1)C1=NC2=C(NN=N2)C(=O)N1	GPR35 agonist	"Phosphodiesterase inhibitor, selective for PDE6, 5, 11 and 9 (IC50 values are 0.15, 0.76, 12.0 and 29.0 _M respectively). Putative GPR35 agonist."	"Christensen and Torphy (1994) Isozyme-selective phosphodiesterase inhibitors as antiasthmatic agents. Annu.Rep.Med.Chem. 29 185. Soderling et al (1998) Identification and characterization of a novel family of cyclic nucleotide phosphodiesterases. J.Biol.Chem. 273 15553. PMID:9624145. Taniguchi et al (2006) Zaprinast, a well-known cyclic guanosine monophosphate-specific phosphodiesterase inhibitor, is an agonist for GPR35. FEBS Lett. 580 5003. PMID:16934253. Lugnier (2006) Cyclic nucleotide phosphodiesterase (PDE) superfamily: a new target for the development of specific therapeutic agents. Pharmacol.Ther. 109 366. PMID:16102838."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1982	SQ1533			Jan-1901
0948	"BRL 37344, sodium salt"	[127299-93-8]	[Na+].C[C@H](CC1=CC=C(OCC([O-])=O)C=C1)NC[C@H](O)C1=CC(Cl)=CC=C1	_3 agonist	"Potent and selective _3 adrenoceptor agonist (Ki values are 287, 1750 and 1120 nM for _3, _1 and _2 receptors respectively). Also available as part of the _-Adrenoceptor Agonist Tocriset."	"Arch et al (1984) Atypical _-adrenoceptor on brown adipocytes as target for anti-obesity drugs. Nature 309 163. PMID:6325935. Ayo Oriowo et al (1996) The selectivity in vitro of the sterioisomers of the beta-3 adrenoreceptor agonist BRL 37344. J.Pharmacol.Exp.Ther. 277 22. PMID:8613923. Strosberg and Pietri-Rouxel (1996) Function and regulation of the _3-adrenoceptor. TiPS 17 373. PMID:8979772. Board et al (2000) BRL37344, but not CGP12177, stimulates fuel oxidation by soleus muscle in vitro. Eur.J.Pharmacol. 406 33. PMID:11011029."	Small Molecule	Sold with the permission of GlaxoSmithKline	http://www.tocris.com/dispprod.php?ItemId=2042	SQ1341			May-1997
0950	Xamoterol hemifumarate	[73210-73-8]	[H]OC(=O)\C=C\C(=O)O[H].OC(CNCCNC(=O)N1CCOCC1)COC1=CC=C(O)C=C1.OC(CNCCNC(=O)N1CCOCC1)COC1=CC=C(O)C=C1	_1 selective partial agonist	_1-adrenoceptor-selective partial agonist (pA2 values are 7.4 - 7.8 and 5.2 - 6.2 at _1- and _2-adrenoceptors respectively).	"Barlow et al (1981) _-Adrenoceptor stimulant properties of aminoalkylamino-substituted 1-aryl-2-ethanols and 1-(aryloxy)-2-propanols. J.Med.Chem. 24 315. PMID:6115058. Nuttall and Snow (1982) The cardiovascular effects of ICI 118,587: a _1-adrenoceptor partial agonist. Br.J.Pharmacol. 77 381. PMID:6128041. Malta et al (1985) The in vitro pharmacology of xamoterol (ICI 118,587). Br.J.Pharmacol. 85 179. PMID:2862938."	Small Molecule	Sold with the permission of AstraZeneca UK Ltd.	http://www.tocris.com/dispprod.php?ItemId=1972	SQ1070			Jan-1901
0951	2-Iminopiperidine hydrochloride	[16011-96-4]	N=C1NCCCC1.Cl	Selective iNOS inhibitor	"An inhibitor of NO synthases, more potent than NG-methyl-L-arginine and selective for iNOS."	Southan et al (1995) Amidines are potent inhibitors of nitric oxide synthases: preferential inhibition of the inducible isoform. Eur.J.Pharmacol. 291 311. PMID:8719415. Moore et al (1996) 2-Iminopiperidine and other 2-iminoazaheterocycles as potent inhibitors of human nitric oxide synthase isoforms. J.Med.Chem. 39 669. PMID:8576908. Moore and Handy (1997) Selective inhibitors of neuronal nitric oxide synthase - is no NOS really good NOS for the nervous system? TiPS 18 204. PMID:9226999.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1518				Jan-1901
0952	Sotalol hydrochloride	[959-24-0]	Cl.CC(C)NCC(O)C1=CC=C(NS(C)(=O)=O)C=C1	_ antagonist	"A relatively potent pure _ adrenergic antagonist, unique in possessing additional class III antiarrhythmic activity. Also available as part of the Mixed Adrenergic Tocriset."	Merck Index 12 8876. Uloth et al (1966) Sulfonanilides. I. Monoalkyl- and arylsulfonamidophenethanolamines. J.Med.Chem. 9 88. PMID:6006227. Claudel and Touboul (1995) Sotalol: from 'just another beta blocker' to 'the prototype class III antidysrhythmic compound'. Pacing Clin.Electrophysiol. 18 451. PMID:7770366. Fiset et al (1997) Block of Iks by the diuretic agent indapamide modulates cardiac electrophysiological effects of the class III antiarrhythmic drug dl-sotalol. J.Pharmacol.Exp.Ther. 283 148. PMID:9336319.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1869	SQ1070			Jan-1901
0955	(-)-MK 801 maleate	[121917-57-5]	O=C(O)/C=C\C(O)=O.C[C@@]14C3=C(C=CC=C3)C[C@H](N4)C2=C1C=CC=C2	"NMDA antagonist, less active enantiomer"	Less active enantiomer (10-fold less potent in behavioral studies) than (+)-MK 801 maleate (Cat. No. 0924).	"Thompson et al (1990) Synthesis and pharmacological evaluation of a series of dibenzo[a,d]cycloalkenimines as N-Methyl-D-aspartate antagonists. J.Med.Chem. 33 789. PMID:1688947. Genovese and Lu (1991) Effects of MK-801 stereoisomers on schedule-controlled behavior in rats. Psychopharmacology. 105 477. PMID:1771215."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1660	SQ1070			Apr-1996
0956	BD 1047 dihydrobromide	[138356-21-5]	Br.Br.CN(C)CCN(C)CCC1=CC=C(Cl)C(Cl)=C1	_1 selective antagonist	"_1 receptor antagonist, exhibiting a similar binding profile to that of BD 1063 (Cat. No. 0883) but with higher affinity (approximately 10-fold) at both _1 and _2 sites."	Matsumoto et al (1995) Characterisation of two novel _ receptor ligands: antidystonic effects in rats suggest _ receptor antagonism. Eur.J.Pharmacol. 280 301. PMID:8566098. Romieu et al (2000) Involvement of the sigma1 receptor in the cocaine-induced conditioned place preference. Neuroreport 11 2885. PMID:11006959. Garrone et al (2000) Effects of trazodone on neurotransmitter release from rat mossy fibre cerebellar synaptosomes. Eur.J.Pharmacol. 400 35. PMID:10913582.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1996	SQ1533			Mar-1996
0958	Spermine tetrahydrochloride	[306-67-2]	NCCCNCCCCNCCCN.Cl.Cl.Cl.Cl	Modulator at polyamine site	"Polyamine which produces a variety of modulatory effects on the NMDA receptor channel, acting through a specific site on the complex which can cause both agonist and antagonist effects."	Benveniste and Mayer (1993) Multiple effects of spermine on N-methyl-D-aspartic acid receptor responses of rat cultured hippocampal neurones. J.Physiol. 464 131. PMID:8229795. Munir et al (1993) Polyamines modulate the neurotoxic effects of NMDA in vivo. Brain Res. 616 163. PMID:8358608. Johnson (1996) Modulation of channel function by polyamines. TiPS 17 22. PMID:8789355. Doyle and Shaw (1998) Investigation of the actions and antagonist activity of some polyamine analogues in vivo. Br.J.Pharmacol. 124 386. PMID:9641557.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1871				Jan-1901
0959	Spermidine trihydrochloride	[334-50-9]	Cl.Cl.Cl.NCCCCNCCCN	Agonist at polyamine site	Binds to the polyamine modulatory site of the NMDA receptor and has been described as an agonist based on its ability to enhance the binding of [3H]-MK801.	"Williams et al (1989) Effects of polyamines on the binding of [3H]-MK801 to the N-methyl-D-aspartate receptor: pharmacological evidence for the existence of a polyamine recognition site. Mol.Pharmacol. 36 375. PMID:2554112. Munir et al (1993) Polyamines modulate the neurotoxic effects of NMDA in vivo. Brain Res. 616 163. PMID:8358608. Kishi et al (1998) Spermidine, a polyamine site agonist, attenuates working memory deficits caused by blockade of hippocampal muscarinic receptors and mGluRs in rats. Brain Res. 793 311. PMID:9630697."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1870	SQ1533			Jan-1901
0960	Piroxicam	[36322-90-4]	CN1C(C(=O)NC2=CC=CC=N2)=C(O)C2=C(C=CC=C2)S1(=O)=O	Cyclooxygenase-1 (COX-1) inhibitor	Anti-inflammatory; highly selective inhibitor of COX-1 (ratio of IC50 values for COX-2/COX-1 ~ 600).	Merck Index 12 7661. Mitchell et al (1995) Cyclooxygenase-2. Regulation and relevance in inflammation. Biochem.Pharmacol. 50 1535. PMID:7503754.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1802	SQ1070			Jan-1901
0961	SYM 2206	[173952-44-8]	CCCNC(=O)N1N=C(C2=CC=C(N)C=C2)C2=C(C=C3OCOC3=C2)C1C	Non-competitive AMPA antagonist	"Novel, potent, non-competitive AMPA receptor antagonist (IC50 = 2.8 _M ). Acts allosterically at the same regulatory site as GYKI 52466 and 53655 and other benzodiazepines but does not bind to the central diazepine binding site. Selective for AMPA relative to kainate receptor sub-types. Similar potency to GYKI 53655. Anticonvulsant in vivo."	"Pelletier et al (1996) Substituted 1,2-dihydrophthalazines: potent, selective and non-competitive inhibitors of the AMPA receptor. J.Med.Chem. 39 343. PMID:8558499. Li et al (1999) Kainate-receptor-mediated sensory synaptic transmission in mammalian spinal cord. Nature 397 161. PMID:9923678. Bleakman et al (2002) Kainate receptor agonists, antagonists and allosteric modulators. Curr.Pharm.Des. 8 873. PMID:11945137."	Small Molecule	Sold with the permission of Annovis Inc.	http://www.tocris.com/dispprod.php?ItemId=1890				Jan-1901
0962	Buspirone hydrochloride	[33386-08-2]	Cl.O=C1CC2(CCCC2)CC(=O)N1CCCCN1CCN(CC1)C1=NC=CC=N1	5-HT1A partial agonist	Classic 5-HT1A partial agonist with relatively high affinity (Ki = 9.3 - 29.5 nM). A clinically effective anxiolytic.	"Merck Index 12 1528. Goa and Ward (1986) Buspirone - a preliminary review on its pharmacological properties and therapeutic efficacy as an anxiolytic. Drugs 32 114. PMID:2874976. Cao and Rodgers (1997) Comparative behavioural profiles of buspirone and its metabolite 1-(2-pyrimidinyl)-piperazine (1-PP) in the murine elevated plus-maze. Neuropharmacology 36 1089. PMID:9294974. Gobert et al (1999) Buspirone modulates basal and fluoxetine-stimulated dialysate levels of dopamine, noradrenaline and serotonin in the frontal cortex of freely moving rats: activation of serotonin1A receptors and blockade of _2-adrenoceptors underlie its action. Neuroscience 93 1251. PMID:10501449."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=2298	SQ1533			Jan-1997
0963	9-AC	[723-62-6]	OC(=O)C1=C2C=CC=CC2=CC2=CC=CC=C12	Chloride transport inhibitor	Cl- transport inhibitor with a moderate to strong inhibitory action on PKA activated cardiac IcI.	Cabantchik and Greger (1992) Chemical probes for anion transporters of mammalian cell membranes. Am.J.Physiol. 262 C803-C827. PMID:1566811. Gadsby et al (1995) The CFTR chloride channel of mammalian heart. Annu.Rev.Physiol. 57 387. PMID:7539989. Estvez et al (2003) Conservation of chloride channel structure revealed by an inhibitor binding site in ClC-1. Neuron 38 47. PMID:12691663. Pusch et al (2006) Channel or transporter? The CLC saga continues. Exp.Physiol. 91 149. PMID:16179405.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=2268				Feb-1997
0964	Diazoxide	[364-98-7]	CC1=NC2=C(C=C(Cl)C=C2)S(=O)(=O)N1	Blocks desensitization of AMPA receptors	"Antihypertensive, activates ATP-dependent K+ channels (Kir6). Induces activation of PKC_, an intermediate in the opening of mitoKATP channels, results in cardioprotection against hypoxia-induced death. Blocks desensitization of AMPA receptors."	"Merck Index 12 3051. Trube et al (1986) Opposite effects of tolbutamide and diazoxide on the ATP-dependent K+ channel in mouse pancreatic _-cells. Pflugers Arch. 407 493. PMID:2431383. Yamada and Rothman (1992) Diazoxide blocks glutamate desensitization and prolongs excitatory postsynaptic currents in rat hippocampal neurons. J.Physiol. 458 409. PMID:1302270. Kim et al (2006) Diazoxide acts more as a PKC-_ activator, and indirectly activates the mitochondiral KATP channel conferring cardioprotection against hypoxic injury. Br.J.Pharmacol. 149 1059. PMID:17043673."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=2269	SQ1070			Feb-1997
0965	Tacrine hydrochloride	[1684-40-8]	Cl.NC1=C2CCCCC2=NC2=CC=CC=C12	Cholinesterase inhibitor	"Potent cholinesterase inhibitor, a cognition enhancer in vivo."	"Merck Index 12 9199. Summers and Kaufman (1980) THA- A review of the literature and its use in treatment of five overdose patients. Clin.Toxicol. 16 269. PMID:6994999. Freeman and Dawson (1991) Tacrine: a pharmacological review. Prog.Neurobiol. 36 257. PMID:1714613. Osborne and Christie (1996) Tetrahydro-9-aminoacridine has mixed actions on muscarinic currents and blocks opioid currents in rat locus ceruleus neurons. J.Pharmacol.Exp.Ther. 276 137. PMID:8558423. Snape et al (1999) A comparative study in rats of the in vitro and in vivo pharmacology of the acetylcholinesterase inhibitors tacrine, donepezil and NXX-066. Neuropharmacology 38 181. PMID:10193909."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=2270	SQ1533			Feb-1997
0969	1-Phenylbiguanide hydrochloride	[55-57-2]	Cl.NC(=N)NC(=N)NC1=CC=CC=C1	5-HT3 agonist	5-HT3 receptor agonist.	Ireland and Tyer (1987) Pharmacological characterization of 5-hydroxytryptamine induced depolarization of the rat isolated vagus nerve. Br.J.Pharmacol. 90 229. PMID:3814920.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=2272				Feb-1997
0970	Cycloheximide	[66-81-9]	O=C(N1)CC(C[C@@H](O)[C@]2([H])C[C@@H](C)C[C@H](C)C2=O)CC1=O	Inhibitor of protein synthesis	"Selective inhibitor of eukaryotic (over prokaryotic) protein synthesis, blocking tRNA binding and release from ribosomes. Induces apoptosis in a variety of transformed and normal cell lines, including T cells. Competitively inhibits the PPIase hFKBP12 (Ki = 3.4 _M). Antifungal antibiotic."	Obrig et al (1971) The mechanism by which cycloheximide and related glutarimide antibiotics inhibit peptide synthesis on reticulocyte ribosomes. J.Biol.Chem. 246 174. PMID:5541758. Tang et al (1999) Cycloheximide-induced T-cell death is mediated by a Fas-associated death domain-dependent mechanism. J.Biol.Chem. 274 7245. PMID:10066786. Christner et al (1999) Synthesis and cytotoxic evaluation of cycloheximide derivatives as potential inhibitors of FKBP12 with neuroregenerative properties. J.Med.Chem. 42 3615. PMID:10479292.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=2273	SQ1533			Feb-2001
0971	EGLU	[170984-72-2]	N[C@](CCC(O)=O)(CC)C(O)=O	Highly selective group II mGlu antagonist	"Selective antagonist of presynaptically-mediated (1S,3S)-ACPD-induced depression of motoneuron excitation in neonatal rat spinal cord; presumed group II mGlu receptor antagonist. Also available as part of the Group II mGlu Receptor Tocriset."	"Jane et al (1996) Potent antagonists at L-AP4- and (1S,3S)-ACPD-sensitive presynaptic metabotropic glutamate recpetors in neonatal rat spinal cord. Neuropharmacology 35 1029. PMID:9121605. Thomas et al (1996) (S)-_-Ethylglutamic acid and (RS)-_-cyclopropyl-4-phosphonophenylglycine as antagonists of L-AP4- and (1S,3S)-ACPD-induced depression of monosynaptic excitation of neonatal rat motoneurones. Br.J.Pharmacol. 117 70P."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1377				Jan-1901
0972	CPPG	[183364-82-1]	NC(C2CC2)(C(O)=O)C1=CC=C(P(O)(O)=O)C=C1	Very potent group III mGlu antagonist	"Potent group II/III mGlu receptor antagonist, with approximately 20-fold selectivity for group III over group II (IC50 values of 2.2 and 46.2 nM respectively). A much less potent antagonist at group I receptors in neonatal rat cortical slices (KB = 0.65  0.07 nM). Also available as part of the Group III mGlu Receptor Tocriset."	"Jane et al (1996) Potent antagonists at the L-AP4- and (1S, 3S)-ACPD-sensitive presynaptic metabotropic glutamate receptors in the neonatal rat spinal cord. Neuropharmacology 35 1029. PMID:9121605. Toms et al (1996) The effects of (RS)-_-cyclopropyl-4-phosphonophenylglycine ((RS)-CPPG), a potent and selective metabotropic glutamate receptor antagonist. BrJ.Pharmacol. 119 851. PMID:8922731. Kemp et al (1996) _-Methyl-3-phosphonophenylglycine and _-cyclopropyl-4-phosphonophenylglycine are potent antagonists at mGluRs negatively coupled to adenylyl cyclase. Br.J.Pharmacol. 117 (in press)."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=2228				Jan-1901
0973	MPDC	[159262-32-5]	[H][C@]1([C@H]2[C@@](O)=O)[C@]2([H])CN[C@@H]1[C@](O)=O	"Potent inhibitor of L-glutamate uptake. Less activity as a substrate compared to its parent compound, L-trans-2,4-PDC (Cat. No. 0298)"	Potent inhibitor of the Na+-dependent high-affinity synaptosomal glutamate transporter.	"Bridges et al (1994) A conformationally constrained competitive inhibitor of the sodium-dependent glutamate transporter in forebrain synaptosomes: L-anti-endo-3,4-methanopyrrolidine carboxylate. Neurosci.Lett. 174 193. PMID:7970177."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1568				Jan-1901
0975	DCG IV	[147782-19-2]	N[C@]([H])(C(O)=O)[C@]1(C([H])(C(O)=O)C([H])1C(O)=O)[H]	"Very potent, selective group II mGlu agonist. Also NMDA agonist"	Presynaptic depressant; highly potent agonist for group II mGlu receptors. Also available as part of the Group II mGlu Receptor Tocriset and Mixed mGlu Receptor Tocriset.	"Ishida et al (1993) A novel metabotropic receptor agonist: marked depression of monosynaptic excitation in the isolated rat spinal cord. Br.J.Pharmacol. 109 1169. PMID:8401927. Ohfune et al (1993) Synthesis of L-2-(2,3-dicarboxycyclopropyl)-glycines. Novel conformationally restricted glutamate analogues. Bioorg.Med.Chem.Lett. 3 15. Brabet et al (1998) Comparative effect of L-CCG-I, DCG-IV and _-carboxy-L-glutamate on all cloned metabotropic glutamate receptor subtypes. Neuropharmacology 37 1043. PMID:9833633. Cartmell et al (1998) Characterization of [3H]-(2S,2'R,3'R)-2-(2',3'-dicarboxycyclopropyl)glycine ([3H]-DCG IV) binding to metabotropic mGlu2 receptor-transfected cell membranes. Br.J.Pharmacol. 123 497. PMID:9504391."	Small Molecule	Sold with the permission of Suntory Ltd.	http://www.tocris.com/dispprod.php?ItemId=1269				Feb-1997
0984	SCH 50911	[733717-87-8]	[H][C@]1(CC(O)=O)CNC(C)(C)CO1	"Selective, competitive, orally active GABAB antagonist"	"A selective, competitive and orally active GABAB antagonist. Displays an IC50 of 1.1 _M at GABAB, approximately 60 times that of CGP 35348 (Cat. No. 1245) and no binding affinity for GABAA at concentrations up to 100 _M."	"Bolser et al (1995) The pharmacology of SCH 50911: a novel, orally active GABA-B receptor antagonist. J.Pharmacol.Exp.Ther. 274 1393. PMID:7562513. Hosford et al (1995) Characterization of the antiabsence effects of SCH 50911, a GABAB receptor antagonist, in the lethargic mouse, _-hydroxybutyrate, and pentylenetetrazole models. J.Pharmacol. Exp.Ther. 274 1399. PMID:7562514. Blythin et al (1996) Substituted morpholine-2S-acetic acid derivatives: SCH 50911 and related compounds as novel GABAB antagonists. Bioorg.Med.Chem.Lett. 6 1529. Ong et al (1998) The morpholino-acetic acid analogue Sch 50911 is a selective GABAB receptor antagonist in rat neocortical slices. Eur.J.Pharmacol. 362 35. PMID:9865527."	Small Molecule	Sold with the permission of Schering Plough Corporation	http://www.tocris.com/dispprod.php?ItemId=2276	SQ1533			Aug-1997
0985	RS 17053 hydrochloride	[169505-93-5]	Cl.CC(C)(CC1=CNC2=CC=C(Cl)C=C12)NCCOC1=C(OCC2CC2)C=CC=C1	_1A antagonist	"_1A-adrenoceptor antagonist, with very high affinity for _1A receptors (pKi and pA2 estimates of 9.1 - 9.9) and a 30 - 100 fold selectivity over the _1B and _1D subtypes (pKi and pA2 estimates 7.7 - 7.8)."	"Ford et al (1995) Do _1A (_1C)-adrenoceptors (AR) mediate prostatic smooth muscle contraction in man? Studies with a novel, selective _1A-AR antagonist, RS 17053. Br.J.Pharmacol. 114 C25. Ford et al (1996) RS 17053 (N-[2-(2-cyclopropylmethoxyphenoxy)ethyl]-5-chloro-_,_-dimethyl-1H-indole-3-ethanamine hydrochloride, a selective _1A-adrenoceptor antagonist, displays low affinity for functional _1-adrenoceptors in human prostate: implications for adrenoceptor classification. Mol.Pharmacol. 49 209. PMID:8632751. Marshall et al (1996) Different subtypes of _1A-adrenoceptor mediating contraction of rat epididymal vas deferens, rat hepatic portal vein and human prostate distinguished by the antagonist RS 17053. Br.J.Pharmacol. 119 407. PMID:8886428."	Small Molecule	Sold with the permission of Roche Bioscience	http://www.tocris.com/dispprod.php?ItemId=2265	SQ1341			Dec-1996
0986	Imiloxan hydrochloride	[81167-22-8]	Cl.CCN1C=CN=C1CC1COC2=CC=CC=C2O1	Highly selective _2B antagonist	"A moderately potent, but highly selective _2-adrenoceptor antagonist, the only reported selective antagonist at the _2B-adrenoceptor not having potent _1-adrenoceptor antagonist activity."	"Michel and Whiting (1981) 2-(2-Imidazolylmethyl)-1,4-benzodioxans, a series of selective alpha2-adrenoceptor antagonists. Br.J.Pharmacol. 74 255P. Michel et al (1990) Assessment of imiloxan as a selective _2B-adrenoceptor antagonist. Br.J.Pharmacol. 99 560. PMID:1970500."	Small Molecule	Sold with the permission of Roche Bioscience	http://www.tocris.com/dispprod.php?ItemId=2263	SQ1533			Aug-1996
0987	RS 79948 hydrochloride	[186002-54-0]	[H][C@]12C4=C(C=C(OC)C=C4)CCN1C[C@]3([H])[C@](N(S(=O)(CC)=O)CCC3)([H])C2.Cl	"Potent, selective _2 antagonist"	"_2-adrenoreceptor antagonist (Kd values are; 0.18, 0.19 and 0.42 nM for _2B _2C and _2A, respectively in rat)."	"Clark et al (1989) (8a_,12a_,13a_)-5,8,8a,9,10,11,12,12a,13,13a-Decahydro-3-methoxy-12-(ethylsulphonyl)-6H-isoquino[2,1-g][1,6]-naphthyridine, a potent and highly selective _2-adrenoceptor antagonist. J. Med. Chem. 32 2034. PMID:2570150. Hume et al (1996) Evaluation in rat of RS-79948-197 as a potential PET ligand for central _2-adrenoceptors. Eur.J.Pharmacol. 317 67. PMID:8982721. Uhlen et al (1998) [3H]RS79948-197 binding to rat, guinea pig and pig _2A-, _2B and _2C-adrenoceptors. Comparison with MK912, RX821002, rauwolscine and yohimbine. Eur.J.Pharmacol. 343 93. PMID:9551719."	Small Molecule	Sold with the permission of Roche Bioscience	http://www.tocris.com/dispprod.php?ItemId=2282	SQ1341			Nov-1996
0988	RS 56812 hydrochloride	[143339-12-2]	O=C(C(N[C@@H]3C(CC4)CCN4C3)=O)C1=CN(C)C2=C1C=CC=C2.Cl	5-HT3 partial agonist	"A highly potent and selective 5-HT3 partial agonist, with a pKi at 5-HT3 receptors in rat brain of 9.6, and greater than 1000-fold selectivity over a wide range of other neurotransmitter receptors."	Clark et al (1995) N-(Quinuclidin-3-yl)-2-(1-methyl-1H-indol-3-yl)-2-oxoacetamide: a high affinity 5-HT3 receptor partial agonist. Bioorg.Med.Chem.Lett. 5 1853.	Small Molecule	Sold with the permission of Roche Bioscience	http://www.tocris.com/dispprod.php?ItemId=2312	SQ1341			Mar-1997
0989	RS 67333 hydrochloride	[168986-60-5]	Cl.CCCCN1CCC(CCC(=O)C2=CC(Cl)=C(N)C=C2OC)CC1	5-HT4 partial agonist	"A potent and highly selective 5-HT4 partial agonist, with pKi values of 8.7 at 5-HT4 sites in guinea pig striatum and > 6 at various other receptors, including 5-HT1A, 1D, 2A, 2C, D1, D2 and M1-3. Active in vivo, with an intrinsic activity relative to 5-HT of 0.5."	"Eglen et al (1995) Pharmacological characterization of two novel and potent 5-HT4 receptor agonists, RS 67333 and RS 67506, in vitro and in vivo. Br.J.Pharmacol. 115 1387. PMID:8564196. Eglen et al (1995) Central 5-HT4 receptors. TiPS 16 391. PMID:8578609. Fontana et al (1997) The effects of novel, selective 5-hydroxytryptamine (5HT)4 receptor ligands in rat spatial navigation. Neuropharmacology 36 689. PMID:9225295."	Small Molecule	Sold with the permission of Roche Bioscience	http://www.tocris.com/dispprod.php?ItemId=2311	SQ1341			Mar-1997
0990	RS 67506 hydrochloride	[168986-61-6]	Cl.COC1=C(C=C(Cl)C(N)=C1)C(=O)CCC1CCN(CCNS(C)(=O)=O)CC1	5-HT4 partial agonist	"A potent and selective 5-HT4 partial agonist, with a pKi of 8.8 at 5-HT4 sites in guinea pig striatum, but < 6.0 at several other receptors including 5-HT1A, 1D, 2A, 2C, D1, D2 and M1-3. It is active in vivo and has an intrinsic activity compared to 5-HT of 0.6."	"Eglen et al (1995) Pharmacological characterization of two novel and potent 5-HT4 receptor agonists, RS 67333 and RS 67506, in vitro and in vivo. Br.J.Pharmacol. 115 1387. PMID:8564196. Eglen et al (1995) Central 5-HT4 receptors. TiPS 16 391. PMID:8578609. Fontana et al (1997) The effects of novel, selective 5-hydroxytryptamine (5HT)4 ligands in rat spatial navigation. Neuropharmacology 36 689. PMID:9225295."	Small Molecule	Sold with the permission of Roche Bioscience	http://www.tocris.com/dispprod.php?ItemId=2310	SQ1341			Mar-1997
0991	RS 39604 hydrochloride	[167710-87-4]	Cl.COC1=CC(OC)=CC(COC2=CC(N)=C(Cl)C=C2C(=O)CCC2CCN(CCNS(C)(=O)=O)CC2)=C1	5-HT4 antagonist	"A potent and selective 5-HT4 antagonist, with a pKi of 9.1 at 5-HT4 receptors in guinea pig striatal membranes and greater than 1000-fold selectivity over 5-HT1A, 2C, 3 and D1, D2, M1, M2, AT1, B1 and _1C receptors. The ketone group gives RS 39604 a relatively long half life; it is also orally active and so suitable for in vivo studies."	"Eglen et al (1995) Central 5-HT4 receptors TiPS 16 391. PMID:8578609. Hegde (1995) RS 39604: a potent, selective and orally active 5-HT4 receptor antagonist. Br.J.Pharmacol. 115 1087. PMID:7582507."	Small Molecule	Sold with the permission of Roche Bioscience	http://www.tocris.com/dispprod.php?ItemId=1038	SQ1341			May-1997
0992	Isamoltane hemifumarate	[874882-92-5]	[H]OC(=O)\C=C\C(=O)O[H].CC(C)NCC(O)COC1=CC=CC=C1N1C=CC=C1.CC(C)NCC(O)COC1=CC=CC=C1N1C=CC=C1	5-HT1B antagonist	"5-HT1B antagonist, approximately 30-fold selective over 5-HT1A. Also possesses affinity for _-adrenergic receptors."	"Waldmeier et al (1988) Interactions of isamoltane (CGP 361A), an anxiolytic phenoxypropanolamine derivative, with 5-HT1 receptor subtypes in the rat brain. Naunyn Schmiedebergs Arch.Pharmacol. 337 609. PMID:2905765."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=2256	SQ1070			Jan-1901
0993	Cyanopindolol hemifumarate	[69906-86-1]	[H]OC(=O)\C=C\C(=O)O[H].CC(C)(C)NCC(O)COC1=C2C=C(NC2=CC=C1)C#N.CC(C)(C)NCC(O)COC1=C2C=C(NC2=CC=C1)C#N	5-HT1A/1B antagonist. Also _-adrenergic antagonist	5-HT1A/1B antagonist with roughly equal affinity at each receptor; also a _-adrenoceptor antagonist.	"Engel et al (1986) Identity of presynaptic 5-hydroxytryptamine (5-HT) autoreceptors in the rat brain cortex with 5-HT1B binding sites. Naunyn Schmiedebergs Arch.Pharmacol. 332 1. PMID:2936965. Blue et al (1989) Interaction of dihydroalprenolol and cyanopindolol with atypical _-adrenoceptors in guinea-pig ileum. Br.J.Pharmacol. 96 246P. Giles et al (1996) Characterization of a 5-HT1B receptor on CHO cells: functional responses in the absence of radioligand binding. Br.J.Pharmacol. 117 1119. PMID:8882605. Hoey et al (1996) Atypical responses of rat ileum to pindolol, cyanopindolol and iodocyanopindolol. Br.J.Pharmacol. 117 712. PMID:8646418."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1162				Apr-1997
0994	Pindolol	[13523-86-9]	CC(C)NCC(O)COC1=C2C=CNC2=CC=C1	_3 partial agonist	"5-HT1A/1B receptor antagonist, with roughly equal affinity for each subtype. A partial agonist at mouse and human _3-adrenoceptors. (S)-(-)-Pindolol (Cat. No. 1060) also available."	Merck Index 12 7597. Blin et al (1993) Structural and conformational features determining selective signal transduction in the _3-adrenergic receptor. Mol.Pharmacol. 44 1094. PMID:7903415. Hoyer et al (1994) VII. International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (serotonin). Pharmacol.Rev. 46 157. PMID:7938165. Clifford et al (1998) Electrophysiological and neurochemical evidence that pindolol has agonist properties at the 5-HT1A autoreceptor in vivo. Br.J.Pharmacol. 124 206. PMID:9630361. Corradetti et al (1998) Antagonist properties of (-)-pindolol and WAY 100635 at somatodendritic and postsynaptic 5-HT1A receptors in the rat brain. Br.J.Pharmacol. 123 449. PMID:9504386.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=2247	SQ1533			Apr-1997
0995	Spiperone hydrochloride	[2022-29-9]	Cl.FC1=CC=C(C=C1)C(=O)CCCN1CCC2(CC1)N(CNC2=O)C1=CC=CC=C1	5-HT2A antagonist. Also D2-like antagonist	"5-HT2A serotonin and selective D2-like dopamine receptor antagonist (Ki values are 0.06, 0.6, 0.08, ~ 350, ~ 3500 nM for D2, D3, D4, D1 and D5 receptors respectively). Antipsychotic."	Merck Index 12 8903. Hoyer et al (1994) VII. International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (serotonin). Pharmacol.Rev. 46 157. PMID:7938165. Seeman and van Tol (1994) Dopamine receptor pharmacology. TiPS 15 264. PMID:7940991.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=2277	SQ1533			Feb-1997
0996	Cyproheptadine hydrochloride	[969-33-5]	Cl[H].CN1CC\C(CC1)=C1/C2=C(C=CC=C2)C=CC2=C1C=CC=C2	5-HT2 antagonist	"Non-selective 5HT2 antagonist, migraine prophylactic."	Merck Index 12 2842. Hoyer et al (1994) VII. International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (serotonin). Pharmacol.Rev. 46 157. PMID:7938165. Moran et al (1994) Inhibitory 5-hydroxytryptamine receptors involved in pressor effects obtained by stimulation of sympathetic outflow from spinal cord in pithed rats. Br.J.Pharmacol. 113 1358. PMID:7889292.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=2278	SQ1533			Feb-1997
0997	Mianserin hydrochloride	[21535-47-7]	Cl.CN1CCN2C(C1)C1=CC=CC=C1CC1=C2C=CC=C1	5-HT2 antagonist. Has moderate affinity for 5-ht6	Non-selective 5-HT2 receptor antagonist (Ki values are 0.0080 and 0.0081 _M for human 5-HT2A and 5-HT2C receptors expressed in HEK293 cells respectively). Has moderate affinity for 5-HT6. Antidepressant.	"Merck Index 12 6260. Leonard (1982) On the mode of action of mianserin. Adv.Biochem.Psychopharmacol. 31 301. PMID:6282060. Hoyer et al (1994) VII. International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (serotonin). Pharmacol.Rev. 46 157. PMID:7938165. Jensen et al (2013) Design, synthesis, and pharmacological characterization of N- and O-substituted 5,6,7,8-tetrahydro-4H-isoxazolo[4,5-dazepin-3-ol analogues: novel 5-HT2A/5-HT2C receptor agonists with pro-cognitive properties. J.Med.Chem. 56 1211. PMID:23301527."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=2279	SQ1533			Feb-1997
0998	AH 11110 hydrochloride	[179388-65-9]	Cl.OC(COC1=C(C=CC=C1)C1=CC=CC=C1)CC(=N)N1CCCCC1	Subtype-selective _1B ligand	"A subtype-selective ligand for the _1B-adrenoceptor. The pKi values for binding to rat fibroblast cell membranes expressing _1B (hamster), _1A (bovine) and _1D (rat) are 7.1, 5.59, and 5.68 respectively. Appears to be non-selective between _1 subtypes and _2 receptors in smooth muscle preparations."	"King et al (1994) AH 11110A is selective for the _1B-subtype of _1-adrenoceptors. Soc.Neurosci.Abstr. 20 526. Saussy et al (1996) Structure-activity relationships of a series of buspirone analogs at alpha-1 adrenoceptors: further evidence that rat aorta alpha-1 adrenoceptors are of the alpha-1D subtype. J.Pharmacol.Exp.Ther. 278 136. PMID:8764344. Eltze et al (2001) Failure of AH11110A to functionally discriminate between _1-adrenoceptor subtypes A, B and D or between _1- and _2-adrenoceptors. Eur.J.Pharmacol. 415 265. PMID:11275009."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1604	SQ1341			Feb-2000
0999	Tamoxifen citrate	[54965-24-1]	CC/C(C2=CC=CC=C2)=C(C3=CC=CC=C3)/C1=CC=C(OCCN(C)C)C=C1.O=C(O)CC(O)(C(O)=O)CC(O)=O	Estrogen receptor partial agonist/antagonist	Estrogen receptor antagonist/partial agonist. Selective and potent inhibitor of mammalian sterol isomerase. Neuroprotective in female rats in vivo. Also high affinity agonist at the membrane estrogen receptor GPR30.	"Merck Index 12 9216. Wakeling et al (1984) Non-steroidal anti-estrogens - receptor binding and biological response in rat uterus, rat mammary carcinoma and human breast cancer cells. J.Steroid.Biochem. 20 111. PMID:6538611. Paul et al (1998) Both the immunosuppressant SR31747 and the antioestrogen tamoxifen bind to an emopamil-insensitive site of mammalian _8-_7 sterol isomerase. J.Pharmacol.Exp.Ther. 285 1302. PMID:9618436. Mehta et al (2003) Tamoxifen, a selective estrogen receptor modulator, reduces ischemic damage caused by middle cerebral artery occlusion in the ovariectomized female rat. Neuroendocrinology 77 44. PMID:12624540. Thomas et al (2005) Identity of an estrogen membrane receptor coupled to a G protein in human breast cancer cells. Endocrinology 146 624. PMID:15539556."	Small Molecule	Sold with the permission of AstraZeneca UK Ltd.	http://www.tocris.com/dispprod.php?ItemId=2264	SQ1533			Jan-1901
1000	ZD 7288	[133059-99-1]	[Cl-].CCN(C1=CC=CC=C1)C1=CC(NC)=[N+](C)C(C)=N1	Sino-atrial node function modulator (If inhibitor)	Sino-atrial node function modulator; blocks the hyperpolarization activated cation current If (HCN channel). Blocks Ih in central neurons. Increases NMDA-evoked noradrenalin release in rat brain in vitro.	BoSmith et al (1993) Inhibitory actions of ZENECA ZD7288 on whole cell hyperpolarization activated inward current (If) in guinea-pig dissociated sinoatrial node cells. Br.J.Pharmacol. 110 343. PMID:7693281. Harris and Constanti (1995) Mechanism of block by ZD7288 of the hyperpolarization-activated inward rectifying current in guinea-pig substantia nigra neurons in vitro. J.Neurophysiol. 74 2366. PMID:8747199. Green et al (1996) Pharmacological characterization of the inwardly rectifying current in the smooth muscle cells of the rat bladder. Br.J.Pharmacol. 119 1509. PMID:8982495. Klar et al (2003) Ih channels as modulators of presynaptic terminal function: ZD7288 increases NMDA-evoked [3H]-noradrenaline release in rat neocortex slices. Naunyn Schmiedebergs Arch.Pharmacol. 367 422. PMID:12690435.	Small Molecule	Sold with the permission of AstraZeneca UK Ltd.	http://www.tocris.com/dispprod.php?ItemId=2251	SQ1533			Jan-1901
1001	Chlorisondamine diiodide	[96750-66-2]	[I-].[I-].C[N+](C)(C)CC[N+]1(C)CC2=C(Cl)C(Cl)=C(Cl)C(Cl)=C2C1	Nicotinic antagonist; slow offset	An exceptionally long lasting nicotinic antagonist (IC50 ~ 1.6 mM); blockade of central nicotinic responses induced by chlorisondamine can persist for several weeks.	"Clarke et al (1994) The pharmacology of the nicotinic antagonist, chlorisondamine investigated in rat brain and autonomic ganglion. Br.J.Pharmacol. 111 397. PMID:7911713. El-Bizri and Clarke (1994) Blockade of nicotinic receptor-mediated release of dopamine from striatal synaptosomes by chlorisondamine and other nicotinic antagonists administered in vitro. Br.J.Pharmacol. 111 406. PMID:8004384. El-Bizri and Clarke (1994) Regulation of nicotinic receptors in rat brain following quasi-irreversible nicotinic blockade by chlorisondamine and chronic treatment with nicotine. Br.J.Pharmacol. 113 917. PMID:7858886."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=2163	SQ1533			Jan-1997
1002	"L-745,870 trihydrochloride"	[866021-03-6]	Cl.Cl.Cl.ClC1=CC=C(C=C1)N1CCN(CC2=CNC3=NC=CC=C23)CC1	Highly selective D4 antagonist	"A highly potent and selective D4 dopamine receptor antagonist; L-745,870 has Ki values of 0.51, 2300 and 960 nM for D4, D3 and D2 subtypes respectively and > 1000-fold selectivity over 5-HT2, D1 and D5 receptors."	"Kulagowski et al (1996) 3-[[4-(4-Chlorophenyl)piperazin-1-yl]methyl-1H-pyrrolo[2,3-b]pyridine: an antagonist with high affinity and selectivity for the human D4 receptor. J.Med.Chem. 39 1941. PMID:8642550. Patel et al (1997) Biological profile of L-745,870, a selective antagonist with high affinity for the dopamine D4 receptor. J.Pharmacol.Exp.Ther. 283 636. PMID:9353380. Bristow et al (1997) Schizophrenia and L-745, 870 a novel dopamine D4 receptor antagonist. TiPS 18 186. PMID:9226994. Pillai et al (1998) Human D2 and D4 dopamine receptors couple through __ G-protein subunits to inwardly rectifying K+ channels (GIRK1) in a Xenopus oocyte expression system: selective antagonism by L-741,626 and L-745,870 respectively. Neuropharmacology 37 983. PMID:9833627."	Small Molecule	Sold with the permission of Merck Sharp and Dohme Ltd.	http://www.tocris.com/dispprod.php?ItemId=2258	SQ1341			Jan-1901
1003	"L-741,626"	[81226-60-0]	OC1(CCN(CC2=CNC3=CC=CC=C23)CC1)C1=CC=C(Cl)C=C1	High affinity D2 antagonist	"A potent D2 dopamine receptor selective antagonist, with affinities of 2.4, 100 and 220 nM for D2, D3 and D4 receptors respectively. Centrally active following systemic administration in vivo."	"Bowery et al (1996) Antagonism of the effects of (+)-PD 128907 on midbrain dopamine neurones in rat brain slices by a selective D2 receptor antagonist L-741,626. Br.J.Pharmacol. 119 1491. PMID:8968560. Kulagowski et al (1996) 3-[[4-(4-Chlorophenyl)piperazin-1-yl]methyl]-1H-pyrrolo[2,3-b]pyridine: an antagonist with high affinity and selectivity for the human dopamine D4 receptor. J.Med.Chem. 39 1941. PMID:8642550. Pillai et al (1998) Human D2 and D4 dopamine receptors couple through __ G-protein subunits to inwardly rectifying K+ channels (GIRK1) in a Xenopus oocyte expression system: selective antagonism by L-741,626 and L-745,870 respectively. Neuropharmacology 37 983. PMID:9833627. Millan et al (2000) S33084, a novel, potent, selective, and competitive antagonist at dopamine D3-receptors: II. Functional and behavioral profile compared with GR218,231 and L741,626. J.Pharmacol.Exp.Ther. 293 1063. PMID:10869411."	Small Molecule	Sold with the permission of Merck Sharp and Dohme Ltd.	http://www.tocris.com/dispprod.php?ItemId=2307	SQ1341			Mar-1997
1004	"L-741,742 hydrochloride"	[874882-93-6]	Cl.CC1=C(ON=C1C1CCN(CCC2=CC=CC=C2)CC1)C1=CC=C(Cl)C=C1	Highly selective D4 antagonist	"A potent and highly selective D4 dopamine receptor antagonist, with Ki values of > 1700, 770 and 3.5 nM at cloned human D2, D3 and D4 receptors."	"Rowley et al (1996) 5-(4-Chlorophenyl)-4-methyl-3-(1-(2-phenylethyl)piperidin-4-yl)isoxazole: a potent, selective antagonist at human cloned dopamine D4 receptors. J. Med. Chem. 39 1943. PMID:8642551. Rowley et al (1997) 4-Heterocyclylpiperidines as selective high-affinity ligands at the human dopamine D4 receptor. J.Med.Chem. 40 2374. PMID:9240352."	Small Molecule	Sold with the permission of Merck Sharp and Dohme Ltd.	http://www.tocris.com/dispprod.php?ItemId=2266	SQ1341			Oct-1996
1006	BMY 7378 dihydrochloride	[21102-95-4]	O=C1CC4(CCCC4)CC(N1CCN(CC3)CCN3C2=CC=CC=C2OC)=O.Cl.Cl	Selective _1D antagonist	"5-HT1A partial agonist and high affinity _1D adrenoceptor antagonist (Ki values are 2, 800 and 600 nM at cloned rat _1D, rat _1A and hamster _1B receptors respectively). Also available as part of the _1-Adrenoceptor Tocriset."	"Sharp et al (1990) Further investigation of the in vivo pharmacological properties of the putative 5-HT1A antagonist, BMY 7378. Eur.J.Pharmacol. 176 331. PMID:1970304. Gruel and Glaser (1992) The putative 5-HT1A receptor antagonists NAN-190 and BMY 7378 are partial agonists in the rat dorsal raphe nucleus in vitro. Eur.J.Pharmacol. 211 211. PMID:1535319. Piascik et al (1995) The specific contribution of the novel alpha-1D adrenoceptor to the contraction of vascular smooth muscle. J.Pharmacol.Exp.Ther. 275 1583. PMID:8531132. Yang and Endoh (1997) Pharmacological evidence for _1D-adrenoceptors in the rabbit ventricular myocardium: analysis with BMY 7378. Br.J.Pharmacol 122 1541. PMID:9422797."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=2281	SQ1341			Feb-1997
1007	N-Desmethylclozapine	[6104-71-8]	ClC1=CC=C2NC3=C(C=CC=C3)C(=NC2=C1)N1CCNCC1	5-HT2C antagonist	A major metabolite of clozapine; a potent and selective 5-HT2C serotonin receptor antagonist.	Kuoppamki et al (1993) Clozapine and methylclozapine are potent 5-HT1C receptor antagonists. Eur.J.Pharmacol. 245 179. PMID:8387927. Wong et al (1996) Effects of clozapine metabolites and chronic clozapine treatment on rat brain GABAA receptors. Eur.J.Pharmacol. 314 319. PMID:8957253. Fox and Brotchie (1996) Normethylclozapine potentiates the action of quinpirole in the 6-hydroxydopamine lesioned rat. Eur.J.Pharmacol. 301 27. PMID:8773443.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1303	SQ1070			Nov-1997
1009	E4CPG	[170846-89-6]	NC(C(O)=O)(CC)C1=CC=C(C(O)=O)C=C1	Group I/group II mGlu antagonist	"Novel group I/group II metabotropic glutamate receptor antagonist, more potent than (RS)-MCPG (Cat. No. 0336)."	Bedingfield et al (1995) Structure-activity relationships for a series of phenylglycine derivatives acting at metabotropic glutamate receptors (mGluRs). Br.J.Pharmacol. 116 3323. PMID:8719814. Sekiyama et al (1996) Structure-activity relationships of new agonists and antagonists of different metabotropic glutamate receptor subtypes. Br.J.Pharmacol. 117 1493. PMID:8730745.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=2300				Feb-1997
1014	QX 314 bromide	[24003-58-5]	[Br-].CC[N+](CC)(CC)CC(=O)NC1=C(C)C=CC=C1C	Na+ channel blocker	"Membrane impermeable quaternary derivative of lidocaine, a blocker of voltage-activated Na+ channels. Intracellular QX 314 bromide also inhibits calcium currents in hippocampal CA1 pyramidal neurons."	Stichartz et al (1973) The inhibition of sodium currents in myelinated nerve by quaternary derivatives of lidocaine. J.Gen.Physiol. 62 37. PMID:4541340. Alreja and Aghajanian (1994) QX-314 blocks the potassium but not the sodium dependent components of the opiate response in locus coeruleus neurons. Brain.Res. 639 320. PMID:8205485. Perkins and Wong (1995) Intracellular QX-314 blocks the hyperpolarization activated inward current Iq in hippocampal CA1 pyramidal cells. J.Neurophysiol. 73 911. PMID:7760149. Talbot and Sayer (1996) Intracellular QX-314 inhibits calcium currents in hippocampal CA1 pyramidal neurons. J.Neurophysiol. 76 2120. PMID:8890325.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=2315	SQ1341			Mar-1997
1015	RS 16566 dihydrochloride	[1217788-97-0]	ClC1=CC(C(N[C@@H]3C4CCN(CC4)C3)=O)=C2C(N(C(C)C)C=N2)=C1.Cl.Cl	5-HT3 ligand. Also shows affinity for zacopride binding site	High affinity ligand for the (R)-zacopride binding site (pKi 9.84 ).	Flippin et al (1996) (R)-3-(6-Chloro-1-isopropylbenzimidazole-4-carboxamido)quinuclidine: a high affinity ligand for the (R)-zacopride binding site. Bioorg.Med.Chem.Lett. 6 477.	Small Molecule	Sold with the permission of Roche Bioscience	http://www.tocris.com/dispprod.php?ItemId=2308	SQ1341			Mar-1997
1018	LY 225910	[133040-77-4]	CC(C)OC1=CC=CC(=C1)N1C(CCC2=CNC3=CC=C(Br)C=C23)=NC2=C(C=CC=C2)C1=O	Potent CCK2 antagonist	Potent CCK2 receptor antagonist (IC50 = 9.3 nM for inhibition of 125I-labeled CCK-8 sulfate binding at mouse brain membranes).	Yu et al (1991) Quinazolinone cholecystokinin receptor ligands. J.Med.Chem. 34 1505. PMID:2016728. Suman-Chauhan et al (1996) The influence of guanyl nucleotide on agonist and antagonist affinity at guinea-pig CCK-B / gastrin receptors: binding studies using [3H]PD140376. Regul.Pept. 65 37. PMID:8876034.	Small Molecule	Sold with the permission of Eli Lilly and Company.	http://www.tocris.com/dispprod.php?ItemId=2301	SQ1341			Mar-1997
1019	LY 235959	[137433-06-8]	[H][C@]12[C@](CC[C@H](CP(O)(O)=O)C2)([H])CN[C@H]([C@](O)=O)C1	Competitive NMDA antagonist	Competitive NMDA receptor antagonist.	"Ellison (1994) Competitive and non-competitive NMDA antagonists induce similar limbic degeneration. Neuroreport 5 2688. PMID:7696633. Borowicz et al (1996) Competitive NMDA-receptor antagonists, LY 235959 and LY 233053, enhance the protective efficacy of various antiepileptic drugs against maximal electroshock-induced seizures in mice. Epilepsia 37 618. PMID:8681893."	Small Molecule	Sold with the permission of Eli Lilly and Company.	http://www.tocris.com/dispprod.php?ItemId=2305	SQ1070			Mar-1997
1024	CGP 20712 dihydrochloride	[1216905-73-5]	Cl.Cl.CN1C=C(N=C1C1=CC=C(OCC(O)CNCCOC2=CC=C(O)C(=C2)C(N)=O)C=C1)C(F)(F)F	Highly potent and selective _1 antagonist	"Highly selective and potent _1-adrenoceptor antagonist (IC50 = 0.7 nM). Displays 10,000-fold selectivity over _2-adrenoceptors. Also available as part of the _-Adrenoceptor Antagonist Tocriset."	Dooley et al (1986) CGP 20712A: a useful tool for quantitating _1- and _2-adrenoceptors. Eur.J.Pharmacol. 130 137. PMID:2877892. Hieble et al (1995) _-and _-adrenoceptors. From the gene to the clinic. 1. Molecular biology and adrenoceptor subclassification. J.Med.Chem. 38 3415. PMID:7658428. Kitagawa et al (1995) Determination of _-adrenoceptor subtype on rat isolated ventricular myocytes by use of highly selective _-antagonists. Br.J.Pharmacol. 116 1635. PMID:8564230.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1605	SQ1341			Apr-2003
1025	Nisoxetine hydrochloride	[57754-86-6]	Cl.CNCCC(OC1=CC=CC=C1OC)C1=CC=CC=C1	Noradrenalin re-uptake inhibitor	A potent and selective inhibitor of noradrenalin uptake with little or no affinity for a range of other neurotransmitter receptors.	"Wong et al (1975) dl-N-Methyl-3-(o-methoxyphenoxy)-3-phenylpropylamine hydrochloride, Lilly 94939, a potent inhibitor for uptake of norepinephrine into rat brain synaptosomes and heart. Life Sci. 17 755. PMID:1207394. Cheetham et al (1996) [3H]Nisoxetine - a radioligand for noradrenaline reuptake sites: correlation with inhibition of [3H]noradrenaline uptake and effect of DSP-4 lesioning and antidepressant treatments. Neuropharmacology 35 63. PMID:8684598. Zhu et al (1997) Down-regulation of norepinephrine transporters on PC12 cells by transporter inhibitors. J.Neurochem. 68 134. PMID:8978719. Shearman and Meyer (1998) Norepinephrine transporters in rat placenta labeled with [3H]nisoxetine. J.Pharmacol.Exp.Ther. 284 736. PMID:9454822."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=2243	SQ1533			Jul-1997
1027	PHCCC	[179068-02-1]	O=C(NC4=CC=CC=C4)C3(C2C3)OC1=CC=CC=C1/C2=N/O	Potent group I mGlu antagonist	Group I metabotropic glutamate receptor antagonist (IC50 ~ 3 _M); 67 times more potent than (S)-4-carboxyphenylglycine (Cat. No. 0323). Also a positive allosteric modulator for mGlu4a; potentiates L-AP4-mediated inhibition of striatopallidal synaptic transmission in vitro. Displays antiParkinsonian effects in rats in vivo.	"Annoura et al (1996) A novel class of antagonists for metabotropic glutamate receptors, 7-(hydroxyimino)cyclopropa[b]chromen-1a-carboxylates. Bioorg.Med.Chem.Lett. 6 763. Mao and Wang (2001) Selective activation of group I metabotropic glutamate receptors upregulates preprodynorphin, substance P and preproenkephalin mRNA expression in rat dorsal striatum. Synapse 39 82. PMID:11071713. Flor et al (2002) Positive allosteric modulators of metabotropic glutamate receptor subtype 4: pharmacological and molecular characterization. Neuropharmacology 43 286 Abstr.No. 47. Marino et al (2003) Allosteric modulation of group III metabotropic glutamate receptor 4: a potential approach to Parkinson's disease treatment. Proc.Natl.Acad.Sci.USA 100 13668. PMID:14593202."	Small Molecule	Sold for research purposes under license from Suntory Ltd.	http://www.tocris.com/dispprod.php?ItemId=1040				Apr-1997
1028	CPCCOEt	[179067-99-3]	O=C(OCC)C3(C2C3)OC1=CC=CC=C1/C2=N/O	Selective non-competitive mGlu1 receptor antagonist	"hmGlu1 subtype-selective non-competitive antagonist (IC50 = 6.5 _M). Has no agonist or antagonist activity at hmGlu2, 4a, 5a, 7b, 8a or ionotropic receptors at concentrations of up to 100 _M."	"Annoura et al (1996) A novel class of antagonists for metabotropic glutamate receptors, 7-(hydroxyimino)cyclopropa[b]chromen-1a-carboxylates. Bioorg.Med.Chem.Lett. 6 763. Hermans et al (1998) Reversible and non-competitive antagonist profile of CPCCOEt at the human type 1_ metabotropic glutamate receptor. Neuropharmacology 37 1645. PMID:9886688. Litschig et al (1999) CPCCOEt, a noncompetitive metabotropic glutamate receptor 1 antagonist, inhibits receptor signaling without affecting glutamate binding. Mol.Pharmacol. 55 453. PMID:10051528."	Small Molecule	Sold for research purposes under license from Suntory Ltd.	http://www.tocris.com/dispprod.php?ItemId=2314	SQ1341			Mar-1997
1029	Methyllycaconitine citrate	[112825-05-5]	OC(=O)CC(O)(CC(O)=O)C(O)=O.[H][C@@]12C[C@H]3[C@H](OC)[C@]1([H])[C@](O)(C[C@@H]3OC)[C@]1(O)[C@@H](OC)C3[C@@]22[C@H]1N(CC)C[C@]3(COC(=O)C1=CC=CC=C1N1C(=O)C[C@H](C)C1=O)CC[C@@H]2OC	_7 neuronal nicotinic receptor antagonist	Potent antagonist for _7-containing neuronal nicotinic receptors (Ki = 1.4 nM). Interacts with _4_2 and _6_2 receptors at concentrations > 40 nM. Attenuates METH-induced neurotoxicity in mouse striatum in vivo.	Ward et al (1990) Methyllycaconitine: a selective probe for neuronal a-bungarotoxin binding sites. FEBS Lett. 270 45. PMID:2226787. Dobelis et al (1999) Effects of delphinium alkaloids on neuromuscular transmission. J.Pharmacol.Exp.Ther. 291 538. PMID:10525069. Escubedo et al (2005) Methyllycaconitine prevents methamphetamine-induced effects in mouse striatum: involvement of _7 nicotinic receptors. J.Pharmacol.Exp.Ther. 315 658. PMID:16076935.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1065	SQ1341			Mar-1998
1030	Guanfacine hydrochloride	[29110-48-3]	Cl.NC(=N)NC(=O)CC1=C(Cl)C=CC=C1Cl	_2A agonist	Selective _2A-adrenoceptor agonist (Kd = 31 nM). Displays 60-fold selectivity over _2B-adrenoceptors. Also available as part of the _2-Adrenoceptor Tocriset.	Merck Index 12 4590. Uhlen and Wikberg (1991) Delineation of rat kidney _2A- and _2B-adrenoceptors with [3H]RX821002 radioligand binding: computer modelling reveals that guanfacine is an _2A -selective compound. Eur.J.Pharmacol. 202 235. PMID:1666366. Intengan and Smyth (1997) Alpha-2a/d adrenoceptor subtype stimulation by guanfacine increases osmolar clearance. J.Pharmacol.Exp.Ther. 281 48. PMID:9103479.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1059	SQ1533			Oct-1997
1031	Piribedil dihydrochloride	[1451048-94-4]	Cl.C(N1CCN(CC1)C1=NC=CC=N1)C1=CC=C2OCOC2=C1	Dopamine agonist	"A direct dopamine agonist, in clinical use for treatment of dopaminergic system dysfunction. Recent work suggests that it is selective for the D3 subtype, for which it has 20 times higher affinity than for D2, and possesses no significant affinity for D1 receptors."	"Merck Index 12 7648. Offermeier and van Rooyen (1986) A comparative study of the locomotor activity effects of apomorphine and the 'atypical dopamine agonists' (piribedil and S36080). Life Sci. 38 895. PMID:3081774. Jenne (1992) Parkinson's disease: pathological mechanisms and actions of piribedil. J.Neurol. 239 S2. PMID:1634907. Cagnotto et al (1996) In vitro affinity of piribedil for dopamine D3 receptor subtypes, an autoradiographic study. Eur.J.Pharmacol. 313 63. PMID:8905329."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1744	SQ1533			Oct-1997
1032	CP 93129 dihydrochloride	[879089-64-2]	Cl.Cl.O=C1NC2=C(NC=C2C2=CCNCC2)C=C1	5-HT1B agonist	"Potent and highly selective 5-HT1B agonist (Ki values are 8.1, 1100, 1500 and 7200 nM for 5-HT1B, 5-HT1D, 5-HT1A, 5-HT1c and 5-HT2, respectively)."	"Koe et al (1992) Biochemical and behavioral studies of the 5-HT1B receptor agonist, CP-94,253. Drug Development Research 26 241. Lee et al (1998) Infusion of the serotonin1B (5-HT1B) agonist CP-93,129 into the parabrachial nucleus potently and selectively reduces food intake in rats. Psychopharmacology 136 304. PMID:9566817. Hamid et al (2014) Modulation of neurotransmission by GPCRs is dependent upon the microarchitecture of the primed vesicle complex. J Neurosci. 34 260. PMID:24381287 ."	Small Molecule	Sold for research purposes under agreement from Pfizer Inc.	http://www.tocris.com/dispprod.php?ItemId=2309	SQ1341			Mar-1997
1033	Fluvoxamine maleate	[61718-82-9]	OC(=O)\C=C/C(O)=O.COCCCC\C(C1=CC=C(C=C1)C(F)(F)F)=N/OCCN	5-HT re-uptake inhibitor	Selective serotonin reuptake inhibitor; antidepressant. Binds to the human 5-HT transporter with a Ki of 1.6 nmol/l. Also available as part of the Serotonin Uptake Inhibitor Tocriset.	"Classen et al (1977) Fluvoxamine, a specific 5-hydroxytryptamine uptake inhibitor. Br.J.Pharmacol. 60 505. PMID:302726. Benfield and Ward (1986) Fluvoxamine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness. Drugs 32 313. PMID:3096686. Narita et al (1996) Interactions of selective serotonin reuptake inhibitors with subtypes of _ receptors in rat brain. Eur.J.Pharmacol. 307 117. PMID:8831113. Owens et al (1997) Neurotransmitter receptor and transporter binding profile of antidepressants and their metabolites. J.Pharmacol.Exp.Ther. 283 1305. PMID:9400006."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=2303	SQ1533			Mar-1997
1034	4-P-PDOT	[134865-74-0]	CCC(=O)NC1CC(C2=CC=CC=C2)C2=C(C1)C=CC=C2	MT2 antagonist	"Melatonin receptor antagonist, >300-fold selective for the MT2 (vs MT1) subtype."	Dubocovich et al (1995) Melatonin receptors: are there multiple subtypes? TiPS 16 50. PMID:7762083. Dubocovich et al (1997) Melatonin receptor antagonists that differentiate between the human Mel1a and Mel1b recombinant subtypes are used to assess the pharmacological profile of the rabbit retina ML1 presynaptic heteroceptor. Naunyn Schmiedebergs Arch.Pharmacol. 355 365. PMID:9089668.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=2318	SQ1341			Apr-1997
1035	8-M-PDOT	[134865-70-6]	CCC(=O)NC1CCC2=C(C1)C(OC)=CC=C2	Melatonin agonist	"Melatonin receptor agonist, 20-fold selective for the MT2 (vs MT1) subtype. At human recombinant MT1 and MT2 receptors, displays pKi values of 8.23 and 8.95 respectively."	Dubocovich et al (1995) Melatonin receptors: are there multiple subtypes? TiPS 16 50. PMID:7762083. Dubocovich et al (1997) Melatonin receptor antagonists that differentiate between the human Mel1a and Mel1b recombinant subtypes are used to assess the pharmacological profile of the rabbit retina ML1 presynaptic heteroceptor. Naunyn Schmiedebergs Arch.Pharmacol. 355 365. PMID:9089668. Browning et al (2000) Pharmacological characterization of human recombinant melatonin mt1 and MT2 receptors. Br.J.Pharmacol. 129 877. PMID:10696085.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=2313	SQ1341			Mar-1997
1036	ZM 241385	[139180-30-6]	NC1=NC(NCCC2=CC=C(O)C=C2)=NC2=NC(=NN12)C1=CC=CO1	"Potent, highly selective A2A antagonist"	"Potent and highly selective A2A adenosine antagonist, with a pA2 of 9.02 for A2A receptors in guinea pig cardiac vasculature and selectivities of 1000, 91 and 500,000 over A1, A2B and A3 sites respectively. Active in vivo."	"Poucher et al (1995) The in vitro pharmacology of ZM 241385, a potent, non-xanthine, A2a selective adenosine receptor antagonist. Br.J.Pharmacol. 115 1096. PMID:7582508. Poucher et al (1996) Pharmacodynamics of ZM 241385, a potent A2a adenosine receptor antagonist, after enteric administration in rat, cat and dog. J.Pharm.Pharmacol. 48 601. PMID:8832494. Keddie et al (1996) In vivo characterisation of ZM 241385, a selective adenosine A2A receptor antagonist. Eur.J.Pharmacol. 301 107. PMID:8773453."	Small Molecule	Sold with the permission of AstraZeneca UK Ltd.	http://www.tocris.com/dispprod.php?ItemId=2285	SQ1341			Jan-1997
1037	PD 153035 hydrochloride	[183322-45-4]	BrC1=CC=CC(NC3=NC=NC2=CC(OC)=C(OC)C=C23)=C1.Cl	EGFR-kinase inhibitor	"An extremely potent inhibitor of epidermal growth factor (EGF) receptor tyrosine kinase, with an IC50 of 25 pM. Inhibits other purified tyrosine kinases only at micromolar or higher concentrations."	"Fry et al (1994) A specific inhibitor of the epidermal growth factor receptor tyrosine kinase. Science 265 1093. PMID:8066447. Bridges et al (1996) Tyrosine kinase inhibitors. 8. An unusually steep structure-activity relationship for analogues of 4-(3-bromoanilino)-6,7-dimethoxyquinazoline (PD 153035), a potent inhibitor of the epidermal growth factor receptor. J.Med.Chem. 39 267. PMID:8568816. Bos et al (1997) PD153035, a tyrosine kinase inhibitor, prevents epidermal growth factor receptor activation and inhibits growth of cancer cells in a receptor number-dependent manner. Clin.Cancer Res. 3 2099. PMID:9815602."	Small Molecule	Sold with the permission of AstraZeneca UK Ltd.	http://www.tocris.com/dispprod.php?ItemId=2302	SQ1533			Mar-1997
1040	TPMPA	[182485-36-5]	OP(C1=CCNCC1)(C)=O	Selective GABAC antagonist	"A selective, competitive GABAC antagonist with only minimal effects on GABAA and GABAB receptors (Kb values are 2.1 _M (antagonist), 320 _M (antagonist) and EC50 ~ 500 _M (weak agonist) respectively). Displays 8-fold selectivity for human recombinant _1 receptors over _2 receptors."	Ragozzino et al (1996) Design and in vitro pharmacology of a selective _-aminobutyric acidc receptor antagonist. Mol.Pharmacol. 50 1024. PMID:8863850. Murata et al (1996) The first selective antagonist for a GABAc receptor. Bioorg.Med.Chem.Lett. 6 2073. Chebib et al (1998) GABAC receptor antagonists differentiate between human r1 and r2 receptors expressed in Xenopus oocytes. Eur.J.Pharmacol. 357 227. PMID:9797041. Xu et al (2009) The involvement of GABA-C receptors in paired pulse depression of inhibitory postsynaptic currents in rat hippocampal CA1 pyramidal neurons. Exp.Neurol. 216 243. PMID:19100735.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=2162				Apr-1997
1041	1-EBIO	[10045-45-1]	CCN1C(=O)NC2=C1C=CC=C2	Activator of epithelial KCa channels	"Activator of epithelial KCa channels, stimulates a large and sustained trans-epithelial Cl- secretory response across T84 monolayers. Induces hyperpolarization to the same magnitude as ACh in aortic value endothelial cells. Promotes embryonic stem cell (ESC) differentiation into cardiomyocytes."	Devor et al (1996) Modulation of Cl- secretion by benzimidazolones. I. Direct activation of a Ca2+ - dependent K+ channel. Am.J.Physiol. 271 L775. PMID:8944721. Ayotunde and Adeagbo (1999) 1-Ethyl-2-benzimidazolinone stimulates endothelial KCa channels and nitric oxide formation in rat mesenteric vessels. Eur.J.Pharmacol. 379 151. PMID:10497901. Kusama et al (2005) Reduced hyperpolarisation in endothelial cells of rabbit aortic value following chronic nitroglycerine administration. Br.J.Pharmacol. 146 487. PMID:16056232. Kleger et al (2010) Modulation of calcium-activated potassium channels induces cardiogenesis of pluripotent stem cells and enrichment of pacemaker-like cells. Circulation. 122 1823. PMID:20956206.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=2287	SQ1070			Jan-1997
1042	N-Methyllidocaine iodide	[1462-71-1]	[I-].CC[N+](C)(CC)CC(=O)NC1=C(C)C=CC=C1C	Enhances biosynthesis of phosphatidylinositol	Antiarrhythmic. Enhances the biosynthesis of phosphatidylinositol in hamster heart.	Tardi et al (1992) The effect of methyl-lidocaine on the biosynthesis of phospholipids de novo in the isolated hamster heart. Biochem.J. 285 161. PMID:1322123. Lee et al (1995) The modulation of phosphatidylinositol in hamster hearts by methyl lidocaine. Biochem.J. 309 871. PMID:7639704.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=2316				May-1997
1043	QX 222	[5369-00-6]	[Cl-].CC1=CC=CC(C)=C1NC(=O)C[N+](C)(C)C	Na+ channel blocker	Sodium channel blocker.	Cuevas and Adams (1994) Local anaesthetic blockade of neuronal nicotinic ACh receptor-channels in rat parasympathetic ganglion cells. Br.J.Pharmacol. 11 663. PMID:7517326. Hanck et al (1994) Kinetic effects of quaternary lidocaine block of cardiac sodium channels: a gating current study. J.Gen.Physiol. 103 19. PMID:8169596.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=2321				Apr-1997
1044	NBQX disodium salt	[479347-86-9]	[Na+].[Na+].NS(=O)(=O)C1=C2C(=CC=C1)C1=NC([O-])=C([O-])N=C1C=C2[N+]([O-])=O	Potent AMPA antagonist. More water soluble form of NBQX (Cat. No. 0373)	"Potent, selective and competitive AMPA receptor antagonist. Neuroprotective and anticonvulsant; active in vivo. More water soluble disodium salt of NBQX (Cat. No. 0373). Also available as part of the AMPA Receptor Tocriset."	"Gill et al (1992) The neuroprotective actions of 2,3-dihydroxy-6-nitro-7-sulfamoylbenzo(f)quinoxaline (NBQX) in a rat focal ischaemia model. Brain Res. 580 35. PMID:1504814. Zeman and Lodg (1992) Pharmacological characterization of non-NMDA subtypes of glutamate receptors in the neonatal rat hemisected spinal cord in vitro. Br.J.Pharmacol. 106 367. PMID:1382781. Sheardown et al (1993) The pharmacology of AMPA receptors and their antagonists. Stroke 24 146. PMID:7504337. Namba et al (1994) Antiepileptogenic and anticonvulsant effects of NBQX, a selective AMPA receptor antagonist, in the rat kindling model of epilepsy. Brain Res. 638 36. PMID:8199874."	Small Molecule	Sold with the permission of Novo Nordisk A/S	http://www.tocris.com/dispprod.php?ItemId=2317				Apr-1997
1045	CNQX disodium salt	[479347-85-8]	[Na+].[Na+].[O-]C1=C([O-])N=C2C=C(C(=CC2=N1)C#N)[N+]([O-])=O	Potent AMPA/kainate antagonist. More water soluble form of CNQX (Cat. No. 0190)	More water soluble disodium salt of the AMPA/kainate antagonist CNQX (Cat. No. 0190). Also available as part of the Kainate Receptor Tocriset.	"Honore et al (1988) Quinoxalinediones: potent competitive non-NMDA glutamate receptor antagonists. Science 241 701. PMID:2899909. Long et al (1990) Effect of 6-cyano-2,3-dihydroxy-7-nitro-quinoxaline (CNQX) on dorsal root-, NMDA-, kainate and quisqualate-mediated depolarization of rat motoneurones in vitro. Br.J.Pharmacol. 100 850. PMID:1976402. Watkins et al (1990) Structure-activity relationships in the development of excitatory amino acid receptor agonists and competitive antagonists. TiPS 11 25. PMID:2155495. King et al (1992) Antagonism of synaptic potentials in ventral horn neurones by 6-cyano-7-nitroquinoxaline-2,3-dione: a study in the rat spinal cord in vitro. Br.J.Pharmacol. 107 375. PMID:1358390."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1036				Apr-1997
1046	Zardaverine	[101975-10-4]	COC1=C(OC(F)F)C=CC(=C1)C1=NNC(=O)C=C1	PDE3/4 inhibitor	"Phosphodiesterase inhibitor, selective for PDE3 and 4 (IC50 values are 0.5 and 0.8 _M respectively). Also available as part of the Phosphodiesterase Inhibitor Tocriset."	Kilian et al (1989) Is phosphodiesterase inhibition a relevant bronchospasmolytic principle? Agents Actions Suppl. 28 331. PMID:2683636. Galvan and Schudt (1990) Actions of the phosphodiesterase inhibitor zardaverine on guinea pig ventricular muscle. Naunyn Schmiedebergs Arch.Pharmacol. 342 221. PMID:1700309.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=2299	SQ1533			Feb-1997
1047	"ICI 182,780"	[129453-61-8]	OC1=CC=C2C(C[C@@H](CCCCCCCCCS(CCCC(F)(C(F)(F)F)F)=O)C3([H])[C@@]([H])2CC[C@@]4(C)[C@@](CC[C@@H]4O)3[H])=C1	Estrogen receptor antagonist	"A high affinity estrogen receptor antagonist (IC50 = 0.29 nM), devoid of any partial agonism both in vitro and in vivo. Also high affinity agonist at the membrane estrogen receptor GPR30."	"Wakeling et al (1991) A potent specific pure antiestrogen with clinical potential. Cancer Res. 51 3867. PMID:1855205. de Cupis et al (1995) Comparison between novel steroid-like and conventional nonsteroidal antioestrogens in inhibiting oestradiol and IGF-I induced proliferation of human breast cancer-derived cells. Br.J.Pharmacol. 116 2391. PMID:8581274. Howell et al (2000) ICI 182,780 (FaslodexTM): Development of a novel, ""pure"" antiestrogen. Cancer 89 817. PMID:10951345. Thomas et al (2005) Identity of an estrogen membrane receptor coupled to a G protein in human breast cancer cells. Endocrinology. 146 624. PMID:15539556."	Small Molecule	Sold with the permission of AstraZeneca UK Ltd.	http://www.tocris.com/dispprod.php?ItemId=2320	SQ1533			Apr-1997
1048	1-BCP	[34023-62-6]	O=C(N1CCCCC1)C1=CC2=C(OCO2)C=C1	Modulates AMPA-mediated responses	A centrally active selective potentiator of AMPA-mediated responses. Facilitates memory retention in rats.	"Arai et al (1994) A centrally active drug that modulates AMPA receptor gated currents. Brain Res. 638 343. PMID:7911064. Desai et al (1995) 1-BCP, a memory-enhancing agent, selectively potentiates AMPA-induced [3H]norepinephrine release in rat hippocampal slices. Neuropharmacology 34 141. PMID:7542369. Vanove (1997) Effects of AMPA receptor positive modulators on amphetamine- and dizocilpine-induced locomotion. Eur.J.Pharmacol. 332 115. PMID:9286612. Yamada et al (1998) AMPA receptor activation potentiated by the AMPA modulator 1-BCP is toxic to cultured rat hippocampal neurons. Neurosci.Lett. 249 119. PMID:9682831."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1037	SQ1341			May-1997
1049	CHPG	[170846-74-9]	NC(C(O)=O)C1=CC(O)=CC=C1Cl	mGlu5 selective agonist	"A selective mGlu5 metabotropic glutamate receptor agonist, completely inactive at mGlu1a receptors expressed in CHO cells. Active in vivo. CHPG sodium salt (Cat. No. 3695) also available."	"Doherty et al (1997) (RS)-2-Chloro-5-hydroxyphenylglycine (CHPG) activates mGlu5, but not mGlu1, receptors expressed in CHO cells and potentiates NMDA responses in the hippocampus. Neuropharmacology 36 265. PMID:9144665. Salt et al (1999) Antagonism of the mGlu5 agonist 2-chloro-5-hydroxyphenylglycine by the novel selective mGlu5 antagonist 6-methyl-2-(phenylethynyl)-pyridine (MPEP) in the thalamus. Br.J.Pharmacol. 127 1057. PMID:10455248. Ugolini et al (1999) Potentiation of NMDA and AMPA responses by the specific mGluR5 agonist CHPG in spinal cord motoneurones. Neuropharmacology 38 1569. PMID:10530818. Bao et al (2001) Selective mGluR5 receptor antagonist or agonist provides neuroprotection in a rat model of focal cerebral ischaemia. Brain Res. 922 173. PMID:11743947."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1777	SQ1341			Sep-1997
1050	RS 102221 hydrochloride	[187397-18-8]	Cl.COC1=CC(OC)=C(NS(=O)(=O)C2=CC=C(C=C2)C(F)(F)F)C=C1C(=O)CCCCN1CCC2(CC1)NC(=O)NC2=O	Selective 5-HT2C antagonist	"Potent and selective 5-HT2C antagonist (pKi = 8.7). Displays ~ 100-fold selectivity over the 5-HT2A and 5-HT2B subtypes and is > 100-fold selective over other 5-HT receptors, _- and _-adrenergic and muscarinic ACh receptors."	"Weinhardt et al (1996) Some benzenesulphonamido-substituted valerophenones that are selective antagonists for the 5-HT2C receptor. Bioorg.Med.Chem.Lett. 6 2687. Bonhaus et al (1997) RS-102221: a novel high affinity and selective 5-HT2C receptor antagonist. Neuropharmacology 36 621. PMID:9225287. Bonhaus et al (1998) Absorption and brain penetration of a high affinity, highly selective 5-HT2C receptor antagonist, RS-102221. Ann.N.Y.Acad.Sci. 861 269. PMID:9928284."	Small Molecule	Sold with the permission of Roche Bioscience	http://www.tocris.com/dispprod.php?ItemId=2244	SQ1341			Dec-1997
1051	Zinterol hydrochloride	[37000-20-7]	OC1=C(NS(=O)(C)=O)C=C(C(O)CNC(C)(C)CC2=CC=CC=C2)C=C1.Cl	Selective _2 agonist	"Potent and selective _2-adrenoceptor agonist (pKB values are 8.3 and < 5.7 for _ 2 and _1 receptors respectively, as measured in human artery)."	Arvydas Skeberdis et al (1997) Beta-2 adrenergic activation of L-type Ca2+ current in cardiac myocytes. J.Pharmacol.Exp.Ther. 283 452. PMID:9353357. Kauman (1997) Four _-adrenoceptor subtypes in the mammalian heart. TiPS 18 70. PMID:9133774. Hutchinson et al (2006) Agonist effects of zinterol at the mouse and human _3-adrenoceptor. Naunyn Schmiedebergs Arch.Pharmacol. 373 158. PMID:16601951.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1606	SQ1070			Feb-2008
1052	A 61603 hydrobromide	[107756-30-9]	Br.CS(=O)(=O)NC1=C(O)C=CC2=C1CCCC2C1=NCCN1	_1A agonist	Potent _-adrenoceptor agonist that is at least 35-fold more potent at _1A than at _1B or _1D sites. Induces dose response increases in spontaneous Ca2+ transients in rat ventricular myocytes in vitro (EC50 = 6.9 nmol/L). Also available as part of the _1-Adrenoceptor Tocriset.	"Knepper et al (1995) A-61603, a potent _1-adrenergic receptor agonist, selective for the _1A receptor subtype. J.Pharmacol.Exp.Ther. 274 97. PMID:7616455. Meyer et al (1996) Synthesis and in vitro characterisation of N-[5-(4,5-dihydro-1H-imidazol-2-yl)-2-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl]methanesulfonamide and its enantiomers: a novel selective _1A receptor agonist. J.Med.Chem. 39 4116. PMID:8831777. Luo et al (2007) Receptor subtype involved in _1A-adrenergic receptor-mediated Ca2+ signaling in cardiomyocytes. Acta.Pharmacol.Sin. 28 968. PMID:17588332."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=2122	SQ1341			Mar-1999
1053	RJR 2403 oxalate	[220662-95-3]	O=C(O)C(O)=O.CNCC/C=C/C1=CC=CN=C1	_4_2 selective nicotinic agonist	"A neuronal nicotinic receptor agonist, showing high selectivity for the _4_2 subtype (Ki values are 26 and 36000 nM for _4_2 and _7 receptors respectively). Active in vivo."	"Bencherif et al (1996) RJR-2403: a nicotinic agonist with CNS selectivity I. In vitro characterization. J.Pharmacol.Exp.Ther. 279 1413. PMID:8968366. Lippiello et al (1996) RJR-2403: a nicotinic agonist with CNS selectivity II. In vivo characterization. J.Pharmacol.Exp.Ther. 279 1422. PMID:8968367. Damaj et al (1999) Antinociceptive and pharmacological effects of metanicotine, a selective nicotinic agonist. J.Pharmacol.Exp.Ther. 291 390. PMID:10490929."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1818				Jan-1998
1054	GR 55562 dihydrochloride	[159533-25-2]	Cl.Cl.CN(C)CCCC1=CC(=CC=C1O)C(=O)NC1=CC=C(C=C1)C1=CC=NC=C1	5-HT1B antagonist	A selective competitive 5-HT1B (5-HT1D_) silent antagonist with pKB values of 7.3 and 6.3 for human cloned 5-HT1B and 5-HT1D receptors respectively and only weak binding at a number of other 5-HT subtypes.	"Walsh et al (1995) The activity of 5-HT1D receptor ligands at cloned human 5-HT1D_ and 5-HT1D_ receptors. Eur.J.Pharmacol. 287 79. PMID:8666030. Connor et al (1995) Use of GR55562, a selective 5-HT1D antagonist, to investigate 5-HT1D receptor subtypes mediating cerebral vasoconstriction. Cephalalgia 15 (suppl. 14) 99. MacLean et al (1996) Evidence for 5-HT1-like receptor-mediated vasoconstriction in human pulmonary artery. Br.J.Pharmacol. 119 277. PMID:8886409."	Small Molecule	Sold with the permission of GlaxoSmithKline	http://www.tocris.com/dispprod.php?ItemId=1749	SQ1341			Jul-1998
1057	WIN 64338 hydrochloride	[163727-74-0]	O=C(NC5=CC=C(C[P+](CCCC)(CCCC)CCCC)C=C5)[C@H](CC3=CC=C(C=CC=C4)C4=C3)NC(NC2CCCCC2)=NC1CCCCC1.Cl.[Cl-]	Bradykinin B2 antagonist	"The first potent, non-peptide, competitive bradykinin B2 receptor antagonist. In organ bath studies, WIN 64338 inhibits [3H]-bradykinin binding on guinea pig trachea with nanomolar affinity but is not active in the rabbit aorta (the classical bradykinin B1 preparation)."	"Marceau et al (1994) Effects of peptide and nonpeptide antagonists of bradykinin B2 receptors on the venoconstrictor action of bradykinin. J.Pharmacol.Exp.Ther. 269 1136. PMID:8014858. Scherrer et al (1995) Effects of WIN 64338, a nonpeptide bradykinin B2 receptor antagonist, on guinea-pig trachea. Br.J.Pharmacol. 115 1127. PMID:7582533. Hu et al (2004) Action of bradykinin in the submucosal plexus of guinea pig small intestine. J.Pharmacol.Exp.Ther. 309 320. PMID:14718600."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1750				Jan-1998
1059	BW 723C86 hydrochloride	[160521-72-2]	Cl.CC(N)CC1=CNC2=CC=C(OCC3=CC=CS3)C=C12	5-HT2B agonist	Selective 5-HT2B receptor agonist.	"Kennett et al (1997) BW 723C86, a 5-HT2B receptor agonist, causes hyperphagia and reduced grooming in rats. Neuropharmacology 36 233. PMID:9144661. Duxon et al (1997) Activation of 5-HT2B receptors in the medial amygdala causes anxiolysis in the social interaction test in the rat. Neuropharmacology 36 601. PMID:9225285. Kennett et al (1998) Anxiolytic-like actions of BW 723C86 in the rat Vogel conflict test are 5-HT2B receptor mediated. Neuropharmacology 37 1603. PMID:9886683. Niebert et al (2011) Expression and function of serotonin 2A and 2B receptors in the mammalian respiratory network. PLoS One 6 e21395. PMID:21789169."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1751	SQ1341			Jan-1998
1060	(S)-(-)-Pindolol	[26328-11-0]	CC(C)NC[C@H](O)COC1=C2C=CNC2=CC=C1	_3 partial agonist. More active enantiomer of pindolol (Cat. No. 0994)	"5-HT1A/1B receptor antagonist, with roughly equal affinity for each subtype. A partial agonist at mouse and human _3-adrenoceptors. More active enantiomer of pindolol (Cat. No. 0994)."	Walter et al (1984) Stimulant and blocking effects of optical isomers of pindolol on the sinoatrial node and trachea of guinea pig. Role of _-adrenoceptor subtypes in the dissociation between blockade and stimulation. Naunyn Schmiedebergs Arch.Pharmacol. 327 159. PMID:6092972. Kalkman (1989) _-Adrenoceptor blockade in rats enhances the ambulation induced by 5-HT1A receptor agonists. Eur.J.Pharmacol. 173 121. PMID:2576226. Corradetti et al (1998) Antagonist properties of (-)-pindolol and WAY 100635 at somatodendritic and postsynaptic 5-HT1A receptors in the rat brain. Br.J.Pharmacol. 123 449. PMID:9504386.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1752	SQ1533			Feb-1998
1061	(-)-Quinpirole hydrochloride	[85798-08-9]	Cl.[H][C@]12CCCN(CCC)[C@]1([H])CC1=CNN=C1C2	Selective D2-like agonist	"Selective dopamine D2 receptor agonist (Ki values are 4.8, ~24, ~30 and 1900 nM at D2, D3, D4 and D1 receptors respectively)."	Seeman and Van Tol (1994) Dopamine receptor pharmacology. Trends Pharmacol.Sci. 15 264. PMID:7940991. Levant et al (1996) Modulation of [3H]quinpirole binding in brain by monoamine oxidase inhibitors: evidence for a potential novel binding site. J.Pharmacol.Exp.Ther. 278 145. PMID:8764345. Sullivan et al (1998) Effects of quinpirole on central dopamine systems in sensitized and non-sensitized rats. Neuroscience 83 781. PMID:9483561.	Small Molecule	Sold with the permission of Eli Lilly and Company	http://www.tocris.com/dispprod.php?ItemId=1039	SQ1533			Jul-1997
1062	2-Methylthioadenosine triphosphate tetrasodium salt	[100020-57-3]	NC1=C2C(N([C@@H]3O[C@H](COP(OP(OP([O-])([O-])=O)([O-])=O)([O-])=O)[C@@H](O)[C@H]3O)C=N2)=NC(SC)=N1.[Na+].[Na+].[Na+].[Na+]	P2 purinergic agonist	P2 purinoceptor agonist.	Cusack et al (1982) Specific but non-competitive inhibition by 2-alkylthioanalogues of adenosine 5'-monophosphate and adenosine 5'-triphosphate of human platelet aggregation induced by adenosine 5'-diphosphate. Br.J.Pharmacol. 75 397. PMID:7186826. Burnstock et al (1983) Studies on the stereoselectivity of the P2-purinoreceptor. Br.J.Pharmacol. 79 907. PMID:6317121. McMurray et al (1998) Purinoceptor subtypes mediating contraction and relaxation of marmoset urinary bladder smooth muscle. Br.J.Pharmacol. 123 1579. PMID:9605564. Khakh et al (2001) International Union of Pharmacology. XXIV. Current status of the nomenclature and properties of P2X receptors and their subunits. Pharmacol.Rev. 53 107. PMID:11171941.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=2215	SQ1341			Jul-1997
1063	CGS 21680 hydrochloride	[124431-80-7]	NC1=NC(NCCC4=CC=C(CCC(O)=O)C=C4)=NC2=C1N=CN2[C@@H]3O[C@H]([C@](NCC)=O)[C@@H](O)[C@H]3O.Cl	A2A agonist	A2A adenosine receptor agonist (Ki = 27 nM). Has affinity for A1 and A3 adenosine receptors but can be used to distinguish A2A- and A2B-mediated effects.	"Phillis et al (1990) The selective adenosine A2 receptor agonist, CGS 21680, is a potent depressant of cerebral cortical neuronal activity. Brain Res. 509 328. PMID:2322828. Nekooeian and Tabrizchi (1998) Effects of CGS 21680, a selective A2A adenosine receptor agonist, on cardiac output and vascular resistance in acute heart failure in the anaesthetized rat. Br.J.Pharmacol. 123 1666. PMID:9605574. Klot (2000) Adenosine receptors and their ligands. Naunyn Schmiedebergs Arch.Pharmacol. 362 382. PMID:11111832."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=2216	SQ1533			Jul-1997
1064	Methysergide maleate	[129-49-7]	OC(=O)\C=C/C(O)=O.[H][C@@]12CC3=CN(C)C4=CC=CC(=C34)C1=C[C@H](CN2C)C(=O)N[C@@H](CC)CO	5-HT1/5-HT2 antagonist	Mixed 5-HT1/5-HT2 receptor antagonist.	Merck Index 12 6217. Hoyer et al (1994) VII. International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (serotonin). Pharmacol.Rev. 46 157. PMID:7938165.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=2214	SQ1533			Jul-1997
1065	PD 168077 maleate	[630117-19-0]	OC(=O)\C=C/C(O)=O.CC1=CC(=CC=C1)C(=O)NCN1CCN(CC1)C1=C(C=CC=C1)C#N	"High affinity, selective D4 agonist"	A potent D4 dopamine receptor agonist (Ki = 8.7 nM) with > 400-fold selectivity over D2 and > 300-fold selectivity versus D3 subtypes respectively. Induces synaptic translocation of CaMK II to postsynaptic sites in cultured prefrontal cortical neurons. Centrally active in vivo.	"Glase et al (1997) Substituted [(4-phenylpiperazinyl)methyl]benzamides: selective dopamine D4 agonists. J.Med.Chem. 40 1771. PMID:9191952. Clifford and Waddington (2000) Topographically based search for an ""Ethogram"" among a series of novel D4 dopamine receptor agonists and antagonists. Neuropsychopharmacology 22 538. PMID:10731629. Gu et al (2006) Activation of dopamine D4 receptors induces synaptic translocation of Ca2+/calmodulin-dependent protein kinase II in cultured prefrontal cortical neurons. Mol.Pharmacol. 69 813. PMID:16365279."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1778	SQ1341			Sep-1997
1066	IB-MECA	[152918-18-8]	IC1=CC=CC(CNC2=NC=NC3=C2N=CN3[C@@H]4O[C@H]([C@@](NC)=O)[C@@H](O)[C@H]4O)=C1	A3 selective agonist	"Potent and selective A3 adenosine receptor agonist (Ki values are 1.1, 54 and 56 nM for A3, A1 and A2A receptors respectively). Cardioprotective, reduces infarct size upon reperfusion in rats."	Gallo-Rodriguez et al (1994) Structure-activity relationships of N6-benzyladenosine-5'-uronamides as A3-selective adenosine agonists. J.Med.Chem. 37 636. PMID:8126704. Klotz (2000) Adenosine receptors and their ligands. Naunyn Schmiedebergs Arch.Pharmacol. 362 382. PMID:11111832. Park et al (2006) N6-(3-iodobenzyl)-adenosine-5'-N-methylcarboxamide confers cardioprotection at reperfusion by inhibiting mitochondrial permeability transition pore opening via glycogen synthase kinase 3_. J.Pharmacol.Exp.Ther. 318 124. PMID:16611852.	Small Molecule	"Sold with the permission of the NIH, US Patent 08/091,109"	http://www.tocris.com/dispprod.php?ItemId=2217	SQ1070			Jul-1997
1067	Oxotremorine M	[3854-04-4]	O=C1N(CC#CC[N+](C)(C)C)CCC1.[I-]	Muscarinic agonist	Muscarinic receptor agonist.	"Birdsall et al (1978) The binding of agonists to brain muscarinic receptors. Mol.Pharmacol. 14 723. PMID:714021. Kukkonen et al (1996) Functional properties of muscarinic receptor subtypes Hm1, Hm3 and Hm5 expressed in Sf9 cells using the baculovirus expression system. J.Pharmacol.Exp.Ther. 279 593. PMID:8930161."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1775	SQ1341			Aug-1997
1070	Zolantidine dimaleate	[104076-39-3]	OC(=O)\C=C/C(O)=O.OC(=O)\C=C/C(O)=O.C(CNC1=NC2=C(S1)C=CC=C2)COC1=CC(CN2CCCCC2)=CC=C1	"Potent, centrally active H2 antagonist"	"A potent, selective and brain penetrating H2 receptor antagonist."	Calcutt et al (1988) Zolantidine (SK&F 95282) is a potent selective brain penetrating histamine H2-receptor antagonist. Br.J.Pharmacol. 93 69. PMID:2894879. Coruzzi et al (1994) Activity of the new histamine H2-receptor antagonist zolantidine at cardiac and gastric H2 receptors. Pharmacology 48 69. PMID:7907797. Coruzzi et al (1996) Cardiac and gastric effects of histamine H2 receptor antagonists: no evidence for a correlation between lipophilicity and receptor affinity. Br.J.Pharmacol. 118 1813. PMID:8842448.	Small Molecule	Sold with the permission of GlaxoSmithKline	http://www.tocris.com/dispprod.php?ItemId=1856	SQ1533			Jan-1998
1071	Pirenzepine dihydrochloride	[29868-97-1]	O=C1C3=C(C=CC=C3)N(C(CN4CCN(CC4)C)=O)C2=C(C=CC=N2)N1.Cl.Cl	Selective M1 muscarinic antagonist	M1 muscarinic receptor selective antagonist. Inverse agonist activity reported.	Hammer et al (1980) Pirenzepine distinguishes between different subclasses of muscarinic receptors. Nature 283 90. PMID:7350532. Doods et al (1994) Pharmacological profile of selective muscarinic receptor antagonists on guinea-pig ileal smooth muscle. Eur.J.Pharmacol. 253 275. PMID:8200421. Eglen et al (1996) Muscarinic receptor subtypes and smooth muscle function. Pharmacol.Rev. 48 531. PMID:8981565. Daeffler et al (1999) Inverse agonist activity of pirenzepine at M2 muscarinic acetylcholine receptors. Br.J.Pharmacol. 126 1246. PMID:10205015.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1061	SQ1533			Jan-1998
1072	AGN 192403 hydrochloride	[1021868-90-5]	Cl.CC(C)C1C(C2CC1CC2)N	I1 selective ligand	"I1 imidazoline binding site selective ligand with a potency at I1 comparable to moxonidine, but devoid of affinity for adrenoceptors and the I2 binding site. Interestingly, in animal models, this compound causes none of the physiological responses associated with the I1 binding site."	"Munk et al (1996) Synthesis and pharmacologic evaluation of 2-endo-amino-3-exo-isopropylbicyclo[2.2.1]heptane: a potent imidazoline1 receptor specific agent. J.Med.Chem. 39 1193. PMID:8632424. Raasch et al (2002) Agmatine, an endogenous ligand at imidazoline binding sites, does not antagonize the clonidine-mediated blood pressure reaction. Br.J.Pharmacol. 135 663. PMID:11834614. Mukaddam-Daher et al (2006) Receptors involved in moxonidine-stimulated strial natriuretic peptide released from isolated normotensive rat hearts. Eur.J.Pharmacol. 541 73. PMID:16774751."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1881	SQ1341			Jan-1998
1073	(RS)-APICA	[170847-18-4]	NC2(C(O)=O)CCC1=CC(P(O)(O)=O)=CC=C12	Selective group II antagonist	Rigidified analog of MPPG (Cat. No. 0853); selective group II metabotropic glutamate receptor antagonist (IC50 = 30 _M) with no significant effect on group I and III mGlu receptors at concentrations up to 1 mM. Increases extracellular glutamate concentrations and possesses unusual inverse agonist-like action.	"Ma et al (1997) Synthesis and biological activity of cyclic analogues of MPPG and MCPG as metabotropic glutamate receptor antagonists. Bioorg.Med.Chem.Lett. 7 1195. Krenz et al (2000) Group I, II and III mGluR compounds affect rhythm generation in the gastric circuit of the crustacean stomatogastric ganglion. J.Neurophysiol. 83 1188. PMID:10712449. Xi et al (2002) Group II metabotropic glutamate receptors modulate extracellular glutamate in the nucleus accumbens. J.Pharmacol.Exp.Ther. 300 162. PMID:11752112."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1882	SQ1341			Feb-1998
1074	(RS)-AMPA hydrobromide	[171259-81-7]	Br.CC1=C(CC(N)C(O)=O)C(O)=NO1	Selective AMPA agonist. More water soluble form of (RS)-AMPA (Cat. No. 0169)	More water soluble hydrobromide salt of (RS)-AMPA (Cat. No. 0169).	"Krogsgaard-Larsen et al (1980) New class of glutamate agonist structurally related to ibotenic acid. Nature 284 64. PMID:6101908. Honore et al (1982) The binding of 3H-AMPA, a structural analogue of glutamic acid, to rat brain membranes. J.Neurochem. 38 173. PMID:6125564."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1062				Jan-1998
1075	Nifedipine	[21829-25-4]	COC(=O)C1=C(C)NC(C)=C(C1C1=CC=CC=C1[N+]([O-])=O)C(=O)OC	Ca2+ channel blocker (L-type)	L-type calcium channel blocker.	Merck Index 12 6617. Stork and Cocks (1994) Pharmacological reactivity of human epicardial coronary arteries: phasic and tonic responses to vasoconstrictor agents differentiated by nifedipine. Br.J.Pharmacol. 113 1093. PMID:7889259.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1932	SQ1533			Jan-1998
1076	Ouabain	[630-60-4]	O[C@@]12[C@@]3([H])[C@]([C@]([C@H](O)C[C@@H](O[C@@H]6O[C@@H](C)[C@H](O)[C@@H](O)[C@H]6O)C4)(CO)[C@]4(O)CC3)([H])[C@H](O)C[C@@](C)1[C@@H]([C@@](CO5)=CC5=O)CC2	Na+/K+ ATPase inhibitor	"Selective Na+, K+-ATPase inhibitor."	"Merck Index 12 7031. Croyle et al (1997) Extensive random mutagenesis analysis of the Na/K+ ATPase alpha subunit identifies known and previously unidentified amino acid residues that alter ouabain sensitivity-implications for ouabain binding. Eur.J.Biochem. 248 488. PMID:9346307. Hosoi et al (1997) Isoform-specific up-regulation by ouabain of Na+, K+-ATPase in cultured rat astrocytes. J.Neurochem. 69 2189. PMID:9349566. Marjorie et al (1997) Ouabain improves cardiac function in vivo in rats with heart failure after chronic but not acute treatment. Naunyn Schmiedebergs Arch.Pharmacol. 356 203. PMID:9272726."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1931	SQ1533			Jan-1998
1077	(-)-Lobeline hydrochloride	[134-63-4]	O[C@H]([C@]2=CC=CC=C2)C[C@@H]1CCC[C@H](CC(C3=CC=CC=C3)=O)N1C.Cl	Nicotinic partial agonist	"High affinity, partial agonist with a Ki value of 4.4 nM in rat brain."	"Merck Index 12 5580. Damaj et al (1997) Pharmacology of lobeline, a nicotinic receptor ligand. J.Pharmacol.Exp.Ther. 282 410. PMID:9223582. Farook et al (2009) Lobeline, a nicotinic partial agonist attenuates alcohol consumption and preference in male C57BL/6J mice. Physiol.Behav. 97 503. PMID:PMID: 19268674."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1884	SQ1070			Jan-1998
1079	(+)-SK&F 10047 hydrochloride	[133005-41-1]	OC1=CC=C2C([C@](CC3)(C)[C@@H](C)C(N3CC=C)C2)=C1.Cl	_1 selective agonist	Prototypical _1 receptor agonist. Behaviorally active in animal models of memory and stress.	"Walker et al (1990) Sigma receptors: biology and function. Pharmacol.Rev. 42 355. PMID:1964225. Matsuno et al (1995) Involvement of _1 receptor in (+)-N-allylnormetazocine-stimulated hippocampal cholinergic functions in rats. Brain Res. 690 200. PMID:8535837. Kamei et al (1996) (+)-SKF-10,047 and dextromethorphan ameliorate conditioned fear stress via dopaminergic systems linked to phenytoin-regulated _1 sites. Eur.J.Pharmacol. 309 149. PMID:8874133."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1933	SQ1341			Jan-1998
1080	(R)-(+)-8-Hydroxy-DPAT hydrobromide	[78095-19-9]	Br.CCCN(CCC)[C@@H]1CCC2=CC=CC(O)=C2C1	Selective 5-HT1A agonist. Enantiomer of 8-Hydroxy-DPAT hydrobromide (Cat. No. 0529)	Full 5-HT1A serotonin receptor agonist; more active enantiomer. Reduces hippocampal 5-HT levels following systemic administration in rats in vivo. More active enantiomer of 8-Hydroxy-DPAT hydrobromide (Cat. No. 0529). 7-Hydroxy-DPAT hydrobromide (Cat. No. 0706) also available.	"Bjork et al (1989) Resolved N,N-dialkylated 2-amino-8-hydroxytetralins: stereoselective interactions with 5-HT1A receptors in the brain. J.Med.Chem. 32 779. PMID:2522991. Corrfield et al (1991) Intrinsic activity of enantiomers of 8-hydroxy-2-(di-n-propylamino)tetralin and its analogues at 5-hydroxytryptamine1A receptors that are negatively coupled to adenylate cyclase. Mol.Pharmacol. 39 780. PMID:1828859. Yoshitake and Kehr (2004) Differential effects of (R)-, (R, S)- and (S)-8-hydroxy-2-(di-n-propylamino)tetralin on hippocampal serotonin release and induction of hypothermia in awake rats. Life Sci. 74 2865. PMID:15050424."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1063	SQ1341			Aug-1998
1081	SKF 89976A hydrochloride	[85375-15-1]	Cl[H].OC(=O)C1CCCN(CC\C=C(\C2=CC=CC=C2)C2=CC=CC=C2)C1	Potent GABA uptake inhibitor. Penetrates blood brain barrier	"A potent GABA uptake inhibitor, selective for GAT-1 (IC50 values are 0.13, 550, 944 and 7210 _M for hGAT-1, rGAT-2, hGAT-3 and hBGT-1 respectively). Inhibits transport current competitively (Ki = 7 _M) and transmitter-gated current non-competitively (Ki = 0.03 nM). Able to pass the blood-brain barrier after systemic administration and is active in vivo."	Ali et al (1985) Orally active and potent inhibitors of _-aminobutyric acid. J.Med.Chem. 28 653. PMID:2985785. Murali Dha (1996) On the bioactive conformation of the GABA uptake inhibitor SK&F 89976-A. Bioorg.Med.Chem.Lett. 6 1535. Krause and Schwarz (2005) Identification and selective inhibition of the channel mode of the neuronal GABA transporter 1. Mol.Pharmacol. 68 1728. PMID:16150932.	Small Molecule	Sold with the permission of GlaxoSmithKline	http://www.tocris.com/dispprod.php?ItemId=1930	SQ1533			Mar-1998
1082	CFM-2	[178616-26-7]	COC1=CC2=C(C=C1OC)C(=NNC(=O)C2)C1=CC=C(N)C=C1	Non-competitive AMPA antagonist	"Novel, selective non-competitive AMPA antagonist. Highly potent, long-acting anticonvulsant."	"Chimirri et al (1997) 1-Aryl-3,5-dihydro-4H-2,3-benzodiazepin-4-ones: novel AMPA receptor antagonists. J.Med.Chem. 40 1258. PMID:9111300. De Sarro et al (1999) Effects of some AMPA receptor antagonists on the development of tolerance in epilepsy-prone rats and in pentylenetetrazole kindled rats. Eur.J.Pharmacol. 368 149. PMID:10193651. De Sarro et al (1999) Anticonvulsant activity and plasma level of 2,3-benzodiazepin-4-ones (CFMs) in genetically epilepsy-prone rats. Pharmacol.Biochem.Behav. 63 621. PMID:10462191."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1934	SQ1341			Jan-1998
1088	CGP 54626 hydrochloride	[149184-21-4]	OP(CC1CCCCC1)(C[C@@H](O)CN[C@@H](C)C2=CC(Cl)=C(Cl)C=C2)=O.Cl	"Potent, selective GABAB antagonist"	"A potent, selective GABAB receptor antagonist (IC50 = 4 nM)."	"Brugger et al (1993) The action of new potent GABAB receptor antagonists in the hemisected spinal cord preparation of the rat. Eur.J.Pharmacol. 235 153. PMID:8390938. Froestl et al (1996) Potent, orally active GABAB receptor antagonists. Pharmacol.Rev.Comm. 8 127. Kaupmann et al (1998) GABAB-receptor subtypes assemble into functional heteromeric complexes. Nature 396 683. PMID:9872317."	Small Molecule	Sold with the permission of Novartis Pharma AG	http://www.tocris.com/dispprod.php?ItemId=1109	SQ1341			Sep-1999
1089	"8-Bromo-cGMP, sodium salt"	[51116-01-9]	[Na+].[H][C@@]12COP([O-])(=O)O[C@@]1([H])[C@@H](O)[C@@H](O2)N1C(Br)=NC2=C1NC(N)=NC2=O	cGMP analog; activates PKG	Membrane permeable cGMP analog that activates protein kinase G (PKG). 4.3-fold more potent than cGMP in activating PKG1_ and promotes relaxation of tracheal and vascular smooth muscle tissue in vitro.	"Ignarro et al (1974) Stimulation of phagocytic release of neutral protease from human neutrophils by cholinergic amines and cyclic 3',5'-guanosine monophosphate. J.Immunol. 112 210. PMID:4359834. Buchan et al (1991) Modulation of agonist-induced calcium mobilisation in bovine aortic endothelial cells by phorbol myristate acetate and cyclic AMP but not cyclic GMP. Br.J.Pharmacol. 104 361. PMID:1665733. Sekhar et al (1992) Relaxation of pig coronary arteries by new and potent cGMP analogs that selectively activate type 1_, compared with type 1_, cGMP-dependent protein kinase. Mol.Pharmacol. 42 103. PMID:1321950."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1988	SQ1341			Jun-1998
1091	BU 226 hydrochloride	[1186195-56-1]	Cl.C1CN=C(N1)C1=CC2=CC=CC=C2C=N1	"Potent, highly selective I2 ligand"	A high affinity ligand for I2 imidazoline sites (Ki = 2.7 nM) with very high selectivity (> 2000-fold) over _2-adrenoceptors (Ki = 6700 nM).	Lione et al (1997) BU226: A selective ligand for rat brain imidazoline I2 sites. Soc.Neurosci.Abstr. 23 695.28. Hudson et al (1999) Novel selective compounds for the investigation of imidazoline receptors. Ann.N.Y.Acad.Sci. 881 81. PMID:10415900.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1987	SQ1341			Jan-1998
1093	Pirfenidone	[53179-13-8]	CC1=CN(C(=O)C=C1)C1=CC=CC=C1	Antifibrotic agent; regulates cytokine levels in vivo	"Antifibrotic agent, effective in models of pulmonary and lung fibrosis. Inhibits collagen production and fibroblast proliferation. Regulates cytokine levels following oral administration in vivo. Potent scavenger of free radicals and inhibitor of lipid peroxidation."	"Kehrer and Margolin (1997) Pirfenidone diminishes cyclophosphamide-induced lung fibrosis in mice. Toxicol.Lett. 90 125. PMID:9067480. Iyer et al (1999) Effects of pirfenidone on procollagen gene expression at the transcriptional level in bleomycin hamster model of lung fibrosis. J.Pharmacol.Exp.Ther. 289 211. PMID:10087006. Oku et al (2002) Pirfenidone suppresses tumor necrosis factor-_, enhances interleukin-10 and protects mice from endotoxic shock. Eur.J.Pharmacol. 446 167. PMID:12098599. Mei et al (2005) Protection of pirfenidone against an early phase of oleic acid-induced acute lung injury in rats. J.Pharmacol.Exp.Ther. 313 379. PMID:15608079."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=2327	SQ1533			Feb-1998
1095	(R)-(-)-Deprenyl hydrochloride	[14611-52-0]	C#CCN(C)[C@H](C)CC1=CC=CC=C1.Cl	MAO-B inhibitor	Selective inhibitor of monoamine oxidase B (MAO-B).	"Merck Index 12 8569. Gerlach et al (1992) The molecular pharmacology of L-deprenyl. Eur.J.Pharmacol. 226 97. PMID:1639115. Kotake et al (1998) Deprenyl decreases an endogenous parkinsonism-inducing compound, 1-benzyl-1,2,3,4-tetrahydroisoquinoline in mice: in vivo and in vitro studies. Brain Res. 787 341. PMID:9518683. Mercuri et al (1998) Modification of levodopa responses by deprenyl (selegiline): an electrophysiological and behavioural study in the rat relevant to Parkinson's disease. Ann.Neurol. 43 613. PMID:9585355. Kaseda et al (1999) Effect of selegeline on dopamine concentration in the striatum of a primate. Brain Res. 815 44. PMID:9974121."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=2329	SQ1533			Mar-1998
1097	Taxol	[33069-62-4]	O=C2[C@@]3(C)C([C@@]4(OC(C)=O)[C@H](OC4)C[C@@H]3O)[C@H](OC(C7=CC=CC=C7)=O)[C@@]1(O)[C@](C)(C)C([C@H]2OC(C)=O)=C(C)[C@@H](OC([C@H](O)[C@H]([C@]5=CC=CC=C5)NC(C6=CC=CC=C6)=O)=O)C1	Promotes assembly and inhibits disassembly of microtubules	"Antitumor agent; promotes and stabilizes tubulin polymerization, causing cell cycle arrest. Induces autocatalytic activation of caspase-10 in CCRF-HSB-2 cells, triggering apoptosis."	Merck Index 12 7117. McGuire et al (1989) Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann.Intern.Med. 111 273. PMID:2569287. Rowinsky et al (1990) Taxol: a novel investigational antimicrotubule agent. J.Natl.Cancer Inst. 82 1247. PMID:1973737. Rao et al (1999) Characterization of the taxol binding site on the microtubule. J.Biol.Chem. 274 37990. PMID:10608867. Park et al (2004) Taxol induces caspase-10-dependent apoptosis. J.Biol.Chem. 279 51057. PMID:15452117.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=2336	SQ1533			Mar-1998
1098	Tranilast	[53902-12-8]	COC1=CC=C(\C=C\C(=O)NC2=CC=CC=C2C(O)=O)C=C1OC	Antiallergic; inhibits inflammatory mediator release from mast cells	"Antiallergic via inhibition of chemical mediator release from mast cells. Shown to be an effective inhibitor of angiogenesis. Demonstrated to antagonize the effects of angiotensin II on human arteries, possibly by an interaction at the level of the AT1 receptor. Inhibits TRPV2-mediated responses; binds to A_40 monomers and increases A_40 fibrillation."	"Hishikawa et al (1996) Tranilast restores cytokine-induced nitric oxide production against platelet derived growth factor in vascular smooth muscle cells. J.Cardiovasc.Pharmacol. 28 200. PMID:8856474. Isaji et al (1997) Tranilast inhibits the proliferation, chemotaxis and tube formation of human microvascular endothelial cells in vitro and angiogenesis in vivo. Br.J.Pharmacol. 122 1061. PMID:9401770. Jin et al (1998) Tranilast, an anti-allergic drug, possesses antagonistic potency to angiotensin II. Eur.J.Pharmacol. 361 199. PMID:9865509. Hisanaga et al (2009) Regulation of calcium-permeable TRPV2 channel by insulin in pancreatic beta-cells. Diabetes. 58 174. PMID:18984736. Connors et al (2013) Tranilast binds to A_ monomers and promotes A_ fibrillation. Biochemistry. PMID:23679559."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=2331	SQ1533			Mar-1998
1099	Forskolin	[66575-29-9]	C=C[C@](C3)(C)O[C@]2(C)[C@@H](OC(C)=O)[C@@H](O)[C@@]1([H])C(C)(C)CC[C@H](O)[C@@](C)1[C@](O)2C3=O	Adenylyl cyclase activator	"Cell-permeable activator of adenylyl cyclase. Hypotensive and vasodilatory agent. Induces neuronal differentiation in stem cells and in several neuroblastoma. Used to reprogram mouse embryonic fibroblasts to induced pluripotent stem cells in combination with three other small molecules (Cat. Nos. 3742, 4423 and 4703). Also available as part of the PKA Tocriset."	Awad et al (1983) Interactions of forskolin and adenylate cyclase. J.Biol.Chem. 258 2960. PMID:6681815. Seamon et al (1983) Structure-activity relationships for activation of adenylate cyclase by the diterpene forskolin and its derivatives. J.Med.Chem. 26 436. PMID:6681845. Laurenza et al (1989) Forskolin: a specific stimulator of adenylyl cyclase or a diterpene with multiple sites of action? TiPS 10 442. PMID:2692256. Kim et al (2005) cAMP induces neuronal differentiation of mesenchymal stem cells via activation of extracellular signal-regulated kinase/MAPK. Neuroreport 16 1357. PMID:16056139. Hou et al (2013) Pluripotent stem cells induced from mouse somatic cells by small-molecule compounds. 341 651. PMID:23868920.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=2337	SQ1533			Mar-1998
1100	Camptothecin	[7689-03-4]	O=C4C5=C([C@](CC)(O)C(OC5)=O)C=C3C2=NC1=CC=CC=C1C=C2CN34	DNA topoisomerase inhibitor	Cytotoxic plant alkaloid with antitumor properties; prototypic DNA topoisomerase I inhibitor. Induces single strand DNA breaks and protein-DNA crosslinks.	Merck Index 12 1783. Hsiang et al (1985) Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J.Biol.Chem. 260 14873. PMID:2997227. Liu (1989) DNA topoisomerase poisons as antitumour drugs. Annu.Rev.Biochem 58 351. PMID:2549853. Pantazis et al (1993) Camptothecin derivatives induce regression of human ovarian carcinomas grown in nude mice and distinguish between non-tumorigenic and tumorigenic cells in vitro. Int.J.Cancer 53 863. PMID:8449612.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=2334	SQ1533			May-1998
1101	Cyclosporin A	[59865-13-3]	OC(C(CC=CC)C)C1C(=O)NC(C(=O)N(C)CC(N(C)C(CC(C)C)C(NC(C(=O)N(C)C(CC(C)C)C(NC(C)C(=O)NC(C)C(N(C)C(C(N(C)C(C(N(C)C(C(C)C)C(=O)N1C)=O)CC(C)C)=O)CC(C)C)=O)=O)C(C)C)=O)=O)CC	Calcineurin inhibitor	Immunosuppressant; inhibits phosphatase activity of calcineurin (IC50 = 5 nM). Also inhibits formation and opening of the mitochondrial permeability transition pore (MPTP).	Fruman et al (1992) Calcineurin phosphatase activity in T lymphocytes is inhibited by FK 506 and cyclosporin A. Proc.Natl.Acad.Sci.U.S.A. 89 3686. PMID:1373887. Brookemeier and Pfeiffer (1995) Inhibition of the mitochondrial permeability transition pore by cyclosporin A during long time frame experiments: relationship between pore opening and the activity of mitochondrial phospholipases. Biochemistry 34 16440. PMID:8845372. Nakata et al (1998) Evidence that cyclosporin A and dexamethasone inhibit allergic airway inflammation via suppression of interleukin-5 synthesis by T cells. Br.J.Pharmacol. 124 1425. PMID:9723954. Yan et al (2009) Cyclosporin-A potently induces highly cardiogenic progenitors from embryonic stem cells. BiochemsBiophys.Res.Commun. 379 115. PMID:19094963.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=2335	SQ1533			Mar-1998
1102	Procaterol hydrochloride	[62929-91-3]	O=C1C=CC2=C(C(O)=CC=C2[C@@]([H])(O)[C@@](NC(C)C)(CC)[H])N1.Cl	Potent _2 agonist	Specific and very potent _2 agonist.	"Yoshizaki et al (1976) Sympathomimetic amines having a carbostyril nucleus. J.Med.Chem. 19 1138. PMID:10441. Yoshizaki et al (1977) Isomers of erythro-5-(1-hydroxy-2-isoproylaminobutyl)-8-hydroxycarbostyril, a new bronchodilator. J.Med.Chem. 20 1103. PMID:894683. Kotsonis and Majewski (1994) Facilitation by procaterol, a _-adrenoceptor agonist, of noradrenaline release in the pithed rat independently of angiotensin II formation. Br.J.Pharmacol. 113 781. PMID:7858867. Lakhlani et al (1994) Pharmacological characterization and anatomical localization of prejunctional _-adrenoceptors in the rat kidney. Br.J.Pharmacol. 111 1296. PMID:8032617."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=2332	SQ1533			Mar-1998
1103	Ketoconazole	[65277-42-1]	ClC1=CC(Cl)=[C@]([C@]3(OC[C@@](COC4=CC=C(N5CCN(C(C)=O)CC5)C=C4)([H])O3)CN2C=CN=C2)C=C1	Cytochrome P450c17 inhibitor	Antifungal agent; potent inhibitor of cytochrome P450c17.	Merck Index 12 5313. Ayub and Levell (1989) Inhibition of human adrenal steroidogenic enzymes in vitro by imidazole drugs including ketoconazole. J.Steroid Biochem. 32 515. PMID:2724954. Kuhn-Velten et al (1992) Ketoconazole inhibition of the bifunctional cytochrome P450c17 does not affect androgen formation from the endogenous lyase substrate. Biochem.Pharmacol. 44 2371. PMID:1472102. Dumaine et al (1998) Blockade of HERG and Kv1.5 by ketoconazole. J.Pharmacol.Exp.Ther. 286 727. PMID:9694927.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=2333	SQ1533			Mar-1998
1104	2-Cl-IB-MECA	[163042-96-4]	O[C@@H]1[C@@H]([C@](NC)=O)O[C@@H](N(C=N4)C2=C4C(NCC3=CC(I)=CC=C3)=NC(Cl)=N2)[C@@H]1O	Highly selective A3 agonist	High affinity and extremely selective A3 adenosine receptor agonist (Ki = 0.33 nM). Displays 2500- and 1400-fold selectivity over A1 and A2A receptors respectively. Exhibits high selectivity over the Na+-independent adenosine transporter.	Kim et al (1994) 2-Substitution of N6-benzyladenosine-5'-uronamides enhances selectivity for A3 adenosine receptors. J.Med.Chem. 37 3614. PMID:7932588. Schaick et al (1996) Hemodynamic effects of histamine release elicited by the selective adenosine A3 receptor agonist 2-Cl-IB-MECA in conscious rats. Eur.J.Pharmacol. 308 311. PMID:8858305. Jacobson (1998) Adenosine A3 receptors: novel ligands and paradoxical effects. TiPS 19 184. PMID:9652191.	Small Molecule	"Sold with the permission of the NIH, US Patent 08/091,109"	http://www.tocris.com/dispprod.php?ItemId=1163	SQ1070			Nov-1999
1105	AF-DX 116	[102394-31-0]	CCN(CC)CC1CCCCN1CC(=O)N1C2=C(C=CC=C2)C(=O)NC2=CC=CN=C12	Selective M2 antagonist	"Selective M2 muscarinic receptor antagonist. Ki values are 64, 417, 786, 211 and 5130 nM for human recombinant M2, M1, M3, M4 and M5 muscarinic receptors, respectively."	"Hammer et al (1986) Binding profile of a novel cardioselective muscarinic receptor antagonist, AF-DX 116, to membranes of peripheral tissues and brain in the rat. Life Sci. 38 1653. PMID:3754610. Billard et al (1995) Identification of the primary muscarinic autoreceptor subtype in rat striatum as M2 through a correlation of in vivo microdialysis and in vitro receptor binding data. J.Pharmacol.Exp.Ther. 273 273. PMID:7714776. Eglen et al (1996) Muscarinic receptor subtypes and smooth muscle function. Pharmacol.Rev. 48 531. PMID:8981565. Mansfield et al (2005) Muscarinic receptor subtypes in human bladder detrusor and mucosa, studied by radioligand binding and quantitative competitive RT-PCR: changes in ageing. Br.J.Pharmacol. 114 1089. PMID:15723094."	Small Molecule	Sold with the permission of Boehringer Ingelheim GmbH	http://www.tocris.com/dispprod.php?ItemId=2135	SQ1533			Mar-1998
1107	ATPA	[140158-50-5]	CC(C)(C)C1=C(CC(N)C(O)=O)C(O)=NO1	"Selective, potent GluR5 agonist"	"A selective and potent GluR5 kainate receptor agonist (Ki = 4.3 nM), inactive at GluR6 (Ki > 1 mM) and only weakly active at AMPA receptors (GluR1-4) and the kainate receptors KA-2 and GluR7 (Ki values of 6 - 14 _M). Also available as part of the Kainate Receptor Tocriset."	"Clarke et al (1997) A hippocampal GluR5 kainate receptor regulating inhibitory synaptic transmission. Nature 389 599. PMID:9335499. Matzen et al (1997) AMPA receptor agonists: synthesis, protolytic properties, and pharmacology of 3-isothiazole bioisasteres of glutamic acid. J.Med.Chem. 40 520. PMID:9046343. Moldrich et al (1999) Excitotoxic injury profiles of low-affinity kainate receptor agonists in neuronal cultures. Eur.J.Pharmacol. 378 R1. PMID:10478637."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=2137	SQ1341			Nov-1998
1109	GR 103691	[162408-66-4]	COC1=CC=CC=C1N1CCN(CCCCNC(=O)C2=CC=C(C=C2)C2=CC=C(C=C2)C(C)=O)CC1	Highly selective D3 antagonist	"A potent and selective dopamine D3 receptor antagonist, with a Ki value of 0.3 nM  and > 100- fold selectivity over D2 and D4 sites."	"Murray et al (1995) A novel series of arylpiperazines with high affinity and selectivity for the dopamine D3 receptor. Bioorg.Med.Chem.Lett. 5 219. Hurley et al (1996) Dopamine D3 receptors are not involved in the induction of c-fos mRNA by neuroleptic drugs: comparison of the dopamine D3 receptor antagonist GR 103691 with the typical and atypical neuroleptics. Eur.J.Pharmacol. 318 283. PMID:9016916. Audinot et al (1998) A comparative in vitro and in vivo pharmacological characterization of the novel dopamine D3 receptor antagonists (+)-S 14297, nafadotride, GR 103,691 and U 99194. J.Pharmacol.Exp.Ther. 287 187. PMID:9765337."	Small Molecule	Sold with the permission of GlaxoSmithKline	http://www.tocris.com/dispprod.php?ItemId=2153	SQ1533			Aug-1998
1110	Genistein	[446-72-0]	OC1=CC=C(C=C1)C1=COC2=C(C(O)=CC(O)=C2)C1=O	EGFR kinase inhibitor. Also estrogen and PPAR_ ligand	Phytoestrogen with a wide range of biological actions. Inhibits protein tyrosine kinases including epidermal growth factor receptor kinase. Also binds to PPAR_ and estrogen receptors and acts as an agonist at GPR30. Also available as part of the MAPK Cascade Inhibitor Tocriset.	"Merck Index 12 4395. Akiyama et al (1987) Genistein, a specific inhibitor of tyrosine-specific protein kinases. J.Biol.Chem. 262 5592. PMID:3106339. Linassier et al (1990) Mechanisms of action in NIH-3T3 cells of genistein, an inhibitor of EGF receptor tyrosine kinase activity. Biochem.Pharmacol. 39 187. PMID:2153378. Migita et al (1994) Prevention of anti-CD3 monoclonal antibody-induced thymic apoptosis by protein tyrosine kinase inhibitors. J.Immunol. 153 3457. PMID:7523495. Dang et al (2003) Peroxisome proliferator-activated receptor _ (PPAR_) as a molecular target for the soy phytoestrogen genistein. J.Biol.Chem. 278 962. PMID:12421816."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=2152	SQ1533			May-1998
1111	ACPT-I	[194918-76-8]	N[C@]1([C@](O)=O)C[C@@H]([C@](O)=O)[C@@H]([C@@](O)=O)C1	Group III mGlu agonist	Agonist for group III mGlu receptors (EC50 values are 7.2 and 8.2 _M for mGlu4a and mGlu8 respectively). Anticonvulsant in mice.	"Acher et al (1997) Synthesis and pharmacological characterization of aminocyclopentanetricarboxylic acids: new tools to discriminate between metabotropic glutamate receptor subtypes. J.Med.Chem. 40 3119. PMID:9301676. De Colle et al (2000) Pharmacological characterization of the rat metabotropic glutamate receptor 8a revealed strong similarities and slight differences with the type 4a receptor. Eur.J.Pharmacol. 394 17. PMID:10771029. Chapman et al (2001) Anticonvulsant activity of a mGlu4_ receptor selective agonist, (1S,3R,4S)-1-aminocyclopentane-1,2,4-tricarboxylic acid. Eur.J.Pharmacol. 424 107. PMID:11476756."	Small Molecule	Sold with the permission of the CNRS	http://www.tocris.com/dispprod.php?ItemId=1165	SQ1341			Dec-1998
1112	ACPT-II	[195209-04-2]	N[C@]1([C@@](O)=O)C[C@H]([C@](O)=O)[C@H]([C@@](O)=O)C1	Competitive mGlu receptor antagonist	"Competitive metabotropic receptor antagonist (KB values are 115, 88 and 77 _M at mGlu1a, mGlu2 and mGlu4a respectively)."	Acher et al (1997) Synthesis and pharmacological characterization of aminocyclopentanetricarboxylic acids: new tools to discriminate between metabotropic glutamate receptor subtypes. J.Med.Chem. 40 3119. PMID:9301676. Bessis et al (2002) Closure of the venus flytrap model of mGlu8 receptor and the activation process: Insights from mutations converting antagonists into agonists. Proc.Natl.Acad.Sci.U.S.A. 99 11097. PMID:12151600.	Small Molecule	Sold with the permission of the CNRS	http://www.tocris.com/dispprod.php?ItemId=2167	SQ1341			Nov-1998
1114	CGP 37157	[75450-34-9]	ClC1=CC=C2NC(=O)CSC(C3=CC=CC=C3Cl)C2=C1	Antagonist of mitochondrial Na+/Ca2+ exchange	Selective antagonist of the mitochondrial Na+-Ca2+ exchanger (IC50 = 0.4 _M).	Cox et al (1993) Selectivity of inhibition of Na+-Ca2+ exchange of heart mitochondria by benzothiazepine CGP-37157. J.Cardiovasc.Pharmacol. 21 595. PMID:7681905. Cox and Matlib (1993) Modulation of intramitochondrial free Ca2+ concentration by antagonists of Na+-Ca2+ exchange. TiPS 14 408. PMID:8296399. White and Reynolds (1997) Mitochondria accumulate Ca2+ following intense glutamate stimulation of cultured rat forebrain neurones. J.Physiol. 498 31. PMID:9023766. Baron and Thayer (1997) CGP37157 modulates mitochondrial Ca2+ homeostasis in cultured rat dorsal root ganglion neurons. Eur.J.Pharmacol. 340 295. PMID:9537826.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=2169	SQ1341			Mar-1999
1115	AM 281	[202463-68-1]	CC1=C(N(N=C1C(=O)NN1CCOCC1)C1=C(Cl)C=C(Cl)C=C1)C1=CC=C(I)C=C1	"Potent, selective CB1 antagonist/inverse agonist"	"Potent, selective CB1 cannabinoid receptor antagonist/inverse agonist (Ki values are 12 and 4200 nM for CB1 and CB2 receptors respectively). Increases locomotor activity following systemic administration in vivo. Analog of SR141716A (Ki = 14 nM)."	"Gifford et al (1997) Effect of the cannabinoid receptor SPECT agent, AM 281, on hippocampal acetylcholine release from rat brain slices. Neurosci.Lett. 238 84. PMID:9464661. Gatley et al (1998) Imaging the brain marijuana receptor: development of a radioligand that binds to cannabinoid CB1 receptors in vivo. J.Neurochem. 70 417. PMID:9422389. Lan et al (1999) Design and synthesis of the CB1 selective cannabinoid antagonist AM281: a potential human SPECT ligand. AAPS Pharmsci. 1 E4. PMID:11741201. Cosenza et al (2000) Locomotor activity and occupancy of brain cannabinoid CB1 receptors by the antagonist/inverse agonist AM281. Synapse 38 477. PMID:11044895."	Small Molecule	Sold with the permission of the University of Connecticut	http://www.tocris.com/dispprod.php?ItemId=1179	SQ1341			Sep-1998
1116	AM 404	[198022-70-7]	CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)NC1=CC=C(O)C=C1	Anandamide transport inhibitor	Competitive and selective inhibitor of carrier-mediated anandamide transport (IC50 = 1 _M). Does not activate CB1 receptors or inhibit anandamide hydrolysis but has been shown to activate native and cloned vanilloid receptors (pEC50 = 7.4). Active in vivo. Also available in water soluble emulsion (Cat. No. 1685).	"Beltramo et al (1997) Functional role of high-affinity anandamide transport, as revealed by selective inhibition. Science 277 1094. PMID:9262477. Calignano et al (1997) Potentiation of anandamide hypotension by the transport inhibitor, AM 404. Eur.J.Pharmacol. 337 R1. PMID:9389389. Piomelli et al (1999) Structural determinants for recognition and translocation by the anandamide transporter. Proc.Natl.Acad.Sci.U.S.A. 96 5802. PMID:10318965. Zygmunt et al (2000) The anandamide transport inhibitor AM404 activates vanilloid receptors. Eur.J.Pharmacol. 396 39. PMID:10822052."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=2199	SQ1070			Jul-1998
1117	AM 251	[183232-66-8]	CC1=C(N(N=C1C(=O)NN1CCCCC1)C1=C(Cl)C=C(Cl)C=C1)C1=CC=C(I)C=C1	Potent CB1 antagonist; also GPR55 agonist	"Potent CB1 receptor antagonist (IC50 = 8 nM, Ki = 7.49 nM) that displays 306-fold selectivity over CB2 receptors. Also potent GPR55 agonist (EC50 = 39 nM). Also available as part of the Cannabinoid CB1 Receptor Tocriset; and in a fluorescent form (Cat. No. 2540)."	"Gatley et al (1996) 125I-labeled AM 251: a radioiodinated ligand which binds in vivo to mouse brain cannabinoid CB1 receptors. Eur.J.Pharmacol. 307 331. PMID:8836622. Gatley et al (1997) Binding of the non-classical cannabinoid CP 55,940, and the diarylpyrazole AM251 to rodent brain cannabinoid receptors. Life Sci. 61 191. PMID:9335234. Lan et al (1999) Structure-activity relationships of pyrazole derivatives as cannabinoid receptor antagonists. J.Med.Chem. 42 769. PMID:10052983. Pertwee (2005) Inverse agonism and neutral antagonism at cannabinoid CB1 receptors. Life Sci. 76 1307. PMID:15670612. Ryberg et al (2007) The orphan receptor GPR55 is a novel cannabinoid receptor. Br.J.Pharmacol. 152 1092. PMID:17876302."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=2200				Oct-1998
1120	AM 630	[164178-33-0]	COC1=CC=C(C=C1)C(=O)C1=C(C)N(CCN2CCOCC2)C2=CC(I)=CC=C12	CB2 selective antagonist/inverse agonist	CB2 antagonist/inverse agonist (Ki = 31.2 nM) that displays 165-fold selectivity over CB1 receptors. Behaves as a weak partial/inverse agonist at CB1 receptors.	"Hosohata et al (1997) AM630 is a competitive cannabinoid receptor antagonist in the guinea pig brain. Life Sci. 61 PL115. PMID:9284087. Hosohata et al (1997) AM630 antagonism of cannabinoid-stimulated [35S]GTP_S binding in the mouse brain. Eur.J.Pharmacol. 321 R1. PMID:9083796. Landsman et al (1998) AM630 is an inverse agonist at the human cannabinoid CB1 receptor. Life Sci. 62 PL109. PMID:9496703. Ross et al (1999) Agonist-inverse agonist characterization at CB1 and CB2 cannabinoid receptors of L759633, L759656 and AM630. Br.J.Pharmacol. 126 665. PMID:10188977."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=2218	SQ1533			Jul-1998
1122	Telenzepine dihydrochloride	[147416-96-4]	Cl.Cl.CN1CCN(CC(=O)N2C3=C(C)SC=C3C(=O)NC3=C2C=CC=C3)CC1	"Potent, selective M1 antagonist"	Selective high affinity muscarinic M1 receptor antagonist (Ki = 0.94 nM). Inhibits gastric acid secretion.	"Eltze et al (1985) Pharmacological evidence for selective inhibition of gastric acid secretion by telenzepine, a new antimuscarinic drug. Eur.J.Pharmacol. 112 211. PMID:4029260. Galvan et al (1989) Interaction of telenzepine with muscarinic receptors in mammalian sympathetic ganglia. Eur.J.Pharmacol. 167 1. PMID:2776837. Christofi et al (1991) Neuropharmacology of the muscarinic antagonist telenzepine in myenteric ganglia of the guinea-pig small intestine. Eur.J.Pharmacol. 195 333. PMID:1868879."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=2233	SQ1533			Aug-1998
1123	(S)-(+)-Niguldipine hydrochloride	[113145-69-0]	O=C(OC)C1=C(C)NC(C)=C(C(OCCCN3CCC(C4=CC=CC=C4)(C5=CC=CC=C5)CC3)=O)[C@H]1[C@]2=CC=CC([N+]([O-])=O)=C2.Cl	"_1 antagonist, L-type Ca2+ channel blocker"	L-type Ca2+ channel blocker and _1A-adrenoceptor antagonist; more active enantiomer. (R)-(-)-Niguldipine hydrochloride (Cat. No. 1124) also available.	Boer et al (1989) (+)-Niguldipine binds with very high affinity to Ca2+ channels and to a subtype of alpha1-adrenoceptor. Eur.J.Pharmacol. 172 131. PMID:2548881. Graziadei et al (1989) Stereoselective binding of niguldipine enantiomers to alpha1A-adrenoceptors labeled with [3H]5-methyl-urapidil. Eur.J.Pharmacol. 172 329. PMID:2555206. Hollt et al (1992) Stereoisomers of calcium antagonists which differ markedly in their potencies as calcium blockers are equally effective in modulating drug transport by P-glycoprotein. Biochem.Pharmacol. 43 2601. PMID:1352973. Wetzel et al (1995) Discovery of alpha1a-adrenergic receptor antagonists based on the L-type Ca2+ channel antagonist niguldipine. J.Med.Chem. 38 1579. PMID:7752182.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=2219	SQ1533			Aug-1998
1124	(R)-(-)-Niguldipine hydrochloride	[113145-70-3]	O=C(OC)C1=C(C)NC(C)=C(C(OCCCN3CCC(C4=CC=CC=C4)(C5=CC=CC=C5)CC3)=O)[C@@H]1[C@]2=CC=CC([N+]([O-])=O)=C2.Cl	"_1 antagonist, L-type Ca2+ channel blocker. Less active enantiomer of Niguldipine hydrochloride (Cat. No. 1123)"	L-type Ca2+ channel blocker and _1A-adrenoceptor antagonist; less active enantiomer. (S)-(+)-Niguldipine hydrochloride (Cat. No. 1123) also available.	Boer et al (1989) (+)-Niguldipine binds with very high affinity to Ca2+ channels and to a subtype of alpha1-adrenoceptor. Eur.J.Pharmacol. 172 131. PMID:2548881. Graziadei et al (1989) Stereoselective binding of niguldipine enantiomers to alpha1A-adrenoceptors labeled with [3H]5-methyl-urapidil. Eur.J.Pharmacol. 172 329. PMID:2555206. Hollt et al (1992) Stereoisomers of calcium antagonists which differ markedly in their potencies as calcium blockers are equally effective in modulating drug transport by P-glycoprotein. Biochem.Pharmacol. 43 2601. PMID:1352973. Wetzel et al (1995) Discovery of alpha1a-adrenergic receptor antagonists based on the L-type Ca2+ channel antagonist niguldipine. J.Med.Chem. 38 1579. PMID:7752182.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=2220	SQ1533			Aug-1998
1125	Quercetin	[117-39-5]	OC1=CC(O)=C2C(OC(=C(O)C2=O)C2=CC=C(O)C(O)=C2)=C1	Non-selective PI 3-kinase inhibitor	"Antitumor agent; induces apoptosis and inhibits synthesis of heat shock proteins. Inhibits many enzyme systems including tyrosine protein kinase, phospholipase A2, phosphodiesterases, mitochondrial ATPase, PI 3-kinase and protein kinase C. Can also activate Ca2+ and K+ channels and behaves as an agonist at estrogen (GPR30) receptors."	Merck Index 12 8216. Graziani et al (1983) The effect of quercetin on the phosphorylation activity of the Rous sarcoma virus transforming gene product in vitro and in vivo. J.Biochem. 135 583. PMID:6311542. Levy et al (1984) Tyrosine protein kinase activity in the DMBA-induced rat mammary tumor: inhibition by quercetin. Biochem.Biophys.Res.Commun. 123 1227. PMID:6091650. Wei et al (1994) Induction of apoptosis by quercetin: involvement of heat shock protein. Cancer Res. 54 4952. PMID:8069862. Cermak et al (2002) The flavonol quercetin activates basolateral K+ channels in rat distal colon epithelium. Br.J.Pharmacol. 135 1183. PMID:11877325. Saponara et al (2002) Quercetin as a novel activator of L-type Ca2+ channels in rat tail artery smooth muscle cells. Br.J.Pharmacol. 135 1819. PMID:11934824.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1304	SQ1533			Jul-1998
1126	Dexamethasone	[50-02-2]	O=C1C=CC2(C)C(CC[C@]3([H])[C@@](F)2[C@@H](O)C[C@@]4(C)[C@]([H])3C[C@@H](C)[C@@](O)4C(CO)=O)=C1	Anti-inflammatory glucocorticoid	Glucocorticoid; anti-inflammatory. Reduces levels of activated NF-_B in immature dendritic cells (DCs) and inhibits differentiation into mature DCs. Induces differentiation of human mesenchymal stem cells (MSCs). Also induces autophagy in acute lymphoblastic leukemia (ALL) cell lines.	Merck Index 12 2986. Teixeira et al (1996) Effects of dexamethasone and cyclosporin A on the accumulation of eosinophils in acute cutaneous inflammation in the guinea-pig. Br.J.Pharmacol. 118 317. PMID:8735633. Matasic et al (1999) Dexamethasone inhibits dendritic cell maturation by redirecting differentiation of a subset of cells. J.Leukoc.Biol. 66 909. PMID:10614771. Laane et al (2009) Cell death induced by dexamethasone in lymphoid leukemia is mediated through initiation of autophagy. Cell Death Differ. 16 1018. PMID:19390558. Sittichokechaiwut et al (2010) Short bouts of mechanical loading are as effective as dexamethasone at inducing matrix production by human bone marrow mesenchymal stem cell. Eur.Cell Mater. 20 45. PMID:20648425.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1090	SQ1533			Jul-1998
1127	Yohimbine hydrochloride	[65-19-0]	[H][C@]12C4=C(C(C=CC=C5)=C5N4)CCN1C[C@@]3([H])[C@]([C@@H]([C@@](OC)=O)[C@@H](O)CC3)([H])C2.Cl	Selective _2 antagonist	"_2-adrenoceptor antagonist (pKi values are 8.52, 8.00 and 9.17 for human _2A, _2B and _2C receptors respectively). Diastereomer Rauwolscine hydrochloride (Cat. No. 0891) also available."	"Doxey et al (1984) Comparison of the _-adrenoceptor antagonist profiles of idazoxan (RX 781094), yohimbine, rauwolscine and corynanthine. Naunyn Schmiedebergs Arch.Pharmacol. 325 136. PMID:6144048. Goldberg and Robertson (1987) Yohimbine: a pharmacological probe for study of the _2-adrenoceptor. Pharmacol.Rev. 35 143. Redfern and Williams (1995) A re-evaluation of the role of _2-adrenoceptors in the anxiogenic effects of yohimbine, using the selective antagonist delequamine in the rat. Br.J.Pharmacol. 116 2081. PMID:8640349. Lalchandani et al (2002) Yohimbine dimers exhibiting selectivity for the human _2c-adrenoceptor subtype. J.Pharmacol.Exp.Ther. 303 979. PMID:12438517."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1181	SQ1533			Jul-1998
1129	BRL 54443	[57477-39-1]	CN1CCC(CC1)C1=CNC2=CC=C(O)C=C12	Potent 5-ht1E/F agonist	"A potent 5-ht1E/1F receptor agonist (pEC50 values are 8.5 and 8.6 respectively). Displays > 30-fold selectivity over other 5-HT and dopamine receptors (pKi values are 8.7. 8.9, 7.2, 6.9, 7.2, 5.9, 7.0, 6.5, < 6, < 6, 6.3 and 6.2 for human 5-HT1E, 1F, 1A, 1B, 1D, 2A, 2B, 2C, 4, 7, D2 and D3 receptors respectively). Induces 5-HT2A receptor-mediated mouse aortic contraction in vitro (pEC50 = 6.52). Active in vivo."	"Brown et al (1998) BRL 54443, a potent agonist with selectivity for human cloned 5-HT1E and 5-HT1F receptors. Br.J.Pharmacol. 123 233P. Lightowler et al (1998) Effect of BRL 54443 (3-(1-methylpiperidin-4-yl)-1H-indol-5-ol), a 5-HT1E/1F receptor agonist, on general behaviour and maximal electroshock seizure threshold in the rat. Br.J.Pharmacol. 123 237P. McKune and Watt (2001) Characterization of the serotonin receptor mediating contraction in the mouse thoracic aorta and signal pathway coupling. J.Pharmacol.Exp.Ther. 297 88. PMID:11259531."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1989	SQ1070			Oct-1998
1130	LY 294002 hydrochloride	[934389-88-5]	Cl.O=C1C=C(OC2=C1C=CC=C2C1=CC=CC=C1)N1CCOCC1	Selective PI 3-kinase inhibitor	"A highly selective inhibitor of phosphatidylinositol 3-kinase (IC50 values are 0.31, 0.73, 1.06 and 6.60 _M for PI 3-K_, PI 3-K_, PI 3-K_ and PI 3-K_ respectively). Inhibits proliferation and induces apoptosis in human colon cancer cells in vitro and in vivo. Suppresses proliferation of mESCs. Inhibits autophagic sequestration in rat hepatocytes. Negative control LY 303511 (Cat. No. 2418) also available."	"Vlahos et al (1994) A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY 294002). J.Biol.Chem. 269 5241. PMID:8106507. Blommaart et al (1997) The phosphatidylinositol 3-kinase inhibitors wortmannin and LY294002 inhibit autophagy in isolated rat hepatocytes. Eur.J.Biochem. 243 240. PMID:9030745. Chasserot-Golaz et al (1998) Possible involvement of phosphatidyl-3-kinase in regulated exocytosis: studies in chromaffin cells with inhibitor LY 294002. J.Neurochem. 70 2347. PMID:9603199. Lianguzova et al (2007) Phosphoinositide 3-kinase inhibitor LY294002 but not serum withdrawal suppresses proliferation of murine embryonic stem cells. Cell Biol.Int. 31 330. PMID:17321171."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=2022	SQ1533			Jan-1999
1131	KU14R	[189224-48-4]	CCC1(CC2=CC=CC=C2O1)C1=NC=CN1	Antagonist of pancreatic imidazoline receptor	Antagonist of the atypical imidazoline binding site (putative I3 receptor) of pancreatic _-cells. Selectively blocks efaroxan-induced insulin secretion in vitro and in vivo.	"Chan et al (1997) The putative endogenous imidazoline receptor ligand, clonidine-displacing substance, is a potent insulin secretagogue in rat and human islets of Langerhans. Br.J.Pharmacol. 120 926. PMID:9138700. Chan et al (1997) Clotrimazole and efaroxan stimulate insulin secretion by different mechanisms in rat pancreatic islets. Naunyn Schmiedebergs Arch.Pharmacol. 356 763. PMID:9453462. Mayer and Taberner (2002) Effects of the imidazoline ligands efaroxan and KU14R on blood glucose in the mouse. Eur.J.Pharmacol. 454 95. PMID:12409010."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1091				Sep-1998
1132	Harmane	[486-84-0]	CC1=NC=CC2=C1NC1=C2C=CC=C1	Putative endogenous imidazoline ligand. Also MAO inhibitor	Proposed as the endogenous ligand for imidazoline binding sites. Binds to I1-sites in rat kidney (IC50 = 31 nM) and I2-sites (Ki = 49 nM). Produces dose-dependent hypotension in vivo that is reversed by efaroxan (Cat. No. 0792). Potent inhibitor of monoamine oxidase A and B (IC50 values are 0.5 and 5 _M respectively).	"Merck Index 12 4646. Glover et al (1982) _-Carbolines as selective monoamine oxidase inhibitors: in vivo implications. J.Neural Transm. 54 209. PMID:7130973. Ernsberger et al (1999) The I1-imidazoline receptor and its cellular signalling pathways. Ann.N.Y.Acad.Sci. 881 35. PMID:10415895. Hudson et al (1999) Harmane, norharmane and tetrahydro _-carboline have high affinity for rat imidazoline binding sites. Br.J.Pharmacol. 126 2P. Musgrave and Badoer (2000) Harmane produces hypotension following microinjection into the RVLM: possible role of I1-imidazoline receptors. Br.J.Pharmacol. 129 1057. PMID:10725251."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=2101				Oct-1998
1133	BRL 44408 maleate	[681806-46-2]	OC(=O)\C=C/C(O)=O.CC1N(CC2=NCCN2)CC2=C1C=CC=C2	Selective _2A antagonist	Selective _2A-adrenoceptor antagonist (Ki = 1.7 nM and 144.5 nM at _2A and _2B-adrenergic receptors respectively). Increases hippocampal noradrenalin release following systemic administration. Also available as part of the _2-Adrenoceptor Tocriset.	Young et al (1989) Novel _2-adrenoceptor antagonists show selectivity for _2A- and _2B-adrenoceptor subtypes. Eur.J.Pharmacol. 168 381. PMID:2573535. Kiss et al (1995) Subtype-specificity of the presynaptic _2-adrenoceptors modulating hippocampal norepinephrine release in rat. Brain Res. 674 238. PMID:7796102. Gavin et al (1997) _2C-adrenoceptors mediate contractile responses to noradrenaline in the human saphenous vein. Naunyn Schmiedebergs Arch.Pharmacol. 355 406. PMID:9089673. Callado et al (1999) _2A-But not _2B/C-adrenoceptors modulate noradrenaline release in rat locus coeruleus: voltammetric data. Eur.J.Pharmacol. 366 35. PMID:10064149.	Small Molecule	Sold with the permission of GlaxoSmithKline	http://www.tocris.com/dispprod.php?ItemId=2023	SQ1070			Nov-1999
1134	CGP 12177 hydrochloride	[64208-32-8]	Cl.CC(C)(C)NCC(O)COC1=CC=CC2=C1NC(=O)N2	_3 partial agonist. _1/_2 antagonist.	"Partial agonist at _3-adrenoceptors. _1- and _2-adrenoceptor antagonist (Ki values are 0.9, 4 and 88 nM for _1, _2 and _3 receptors respectively)."	Staehelin et al (1983) CGP-12177. A hydrophilic beta-adrenergic receptor radioligand reveals high affinity binding of agonists to intact cells. J.Biol.Chem. 258 3496. PMID:6131886. Strosberg and Pietri-Rouxel (1996) Function and regulation of the _3-adrenoceptor. TiPS 17 373. PMID:8979772. Galitzky et al (1998) On the presence of a putative fourth _-adrenoceptor in human adipose tissue. TiPS 19 164. PMID:9652187. Preitner et al (1998) Metabolic response to various _-adrenoceptor agonists in _3-adrenoceptor knockout mice: evidence for a new _-adrenergic receptor in brown adipose tissue. Br.J.Pharmacol. 124 1684. PMID:9756384.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1092	SQ1341			Nov-1998
1135	Spermine NONOate	[136587-13-8]	NCCCN(N(O)N=O)CCCCNCCCN	Slow NO releasing agent	"A stable complex of nitric oxide and spermine used to generate a controlled release of nitric oxide in solution (EC50 = 6.2 _M for relaxation of rabbit aorta, and t_ =39 min at 37C, pH 7.4, aqueous solution)."	Maragos et al (1991) Complexes of NO with nucleophiles as agents for the controlled biological release of nitric oxide. Vasorelaxant effects. J.Med.Chem. 34 3242. PMID:1956043. Ramamurthi and Lewis (1997) Measurement and modeling of nitric oxide release rates for nitric oxide donors. Chem.Res.Toxicol. 10 408. PMID:9114977. Homer and Wanstall (1998) In vitro comparison of two NONOates (novel nitric oxide donors) on rat pulmonary arteries. Eur.J.Pharmacol. 356 49. PMID:9761423. Ferrero et al (1999) Comparative effects of several nitric oxide donors on intracellular cyclic GMP levels in bovine chromaffin cells: correlation with nitric oxide production. Br.J.Pharmacol. 127 779. PMID:10401570.	Small Molecule	"Sold with the permission of the NIH, US Patent 5,155,137"	http://www.tocris.com/dispprod.php?ItemId=2044				Jan-1999
1139	L-NIL hydrochloride	[150403-89-7]	N=C(NCCCC[C@@H](C(O)=O)N)C.Cl	Selective iNOS inhibitor	A selective inhibitor of inducible nitric oxide synthase (IC50 = 3.3 _M).	Moore et al (1994) L-N6-(1-Iminoethyl)lysine: a selective inhibitor of inducible nitric oxide synthase. J.Med.Chem. 37 3886. PMID:7525961. Connor et al (1995) Suppression of adjuvant-induced arthritis by selective inhibition of inducible nitric oxide synthase. Eur.J.Pharmacol. 273 15. PMID:7537678.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=2045				Sep-1998
1140	"8-Bromo-cAMP, sodium salt"	[76939-46-3]	[Na+].[H][C@@]12COP([O-])(=O)O[C@@]1([H])[C@@H](O)[C@@H](O2)N1C(Br)=NC2=C1N=CN=C2N	Cell-permeable cAMP analog	Cell-permeable cAMP analog; activator of protein kinase A. Also available as part of the PKA Tocriset.	"Hei et al (1991) Lack of correlation between activation of cyclic AMP-dependent protein kinase and inhibition of contraction of rat vas deferens by cyclic AMP analogs. Mol.Pharmacol. 39 233. PMID:1847496. Carranza et al (1998) Protein kinase A induces recruitment of active Na+,K+-ATPase units to the plasma membrane of rat proximal convoluted tubule cells. J.Physiol. 511 235. PMID:9679177. Chow et al (1998) Functional modulation of P2X2 receptors by cyclic AMP-dependent protein kinase. J.Neurochem. 70 2606. PMID:9603227. Wang et al (2011) A cyclic AMP analog, 8-Br-cAMP, enhances the induction of pluripotency in human fibroblast cells. Stem Cell Rev. 7 331. PMID:21120637."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1176	SQ1341			Sep-1998
1141	"Dibutyryl-cAMP, sodium salt"	[16980-89-5]	[Na+].[H][C@@]12COP([O-])(=O)O[C@@]1([H])[C@@H](OC(=O)CCC)[C@@H](O2)N1C=NC2=C1N=CN=C2NC(=O)CCC	Cell-permeable cAMP analog	Cell-permeable analog of cAMP; activates cAMP-dependent protein kinases.	"Hei et al (1991) Lack of correlation between activation of cyclic AMP-dependent protein kinase and inhibition of contraction of rat vas deferens by cyclic AMP analogs Mol.Pharmacol. 39 233. PMID:1847496. Imamura et al (1998) Differential expression of dystrophin isoforms and utrophin during dibutyryl-cAMP-induced morphological differentiation of rat brain astrocytes. Proc.Natl.Acad.Sci.U.S.A. 95 6139. PMID:96006931. Carranza et al (1998) Protein kinase A induces recruitment of active Na+,K+-ATPase units to the plasma membrane of rat proximal convoluted tubule cells. J.Physiol. 511 235. PMID:9679177."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1110	SQ1070			Sep-1998
1142	Oxymetazoline hydrochloride	[2315-02-8]	Cl.CC1=C(CC2=NCCN2)C(C)=C(O)C(=C1)C(C)(C)C	_1A agonist	Partial _2A adrenoceptor agonist and _1A agonist. Agonist/antagonist activity at 5-HT receptors.	"Schoeffter et al (1991) Interaction of the _-adrenoceptor agonist oxymetazoline with serotonin 5-HT1A, 5-HT1B, 5-HT1C and 5-HT1D receptors. Eur.J.Pharmacol. 196 213. PMID:1678720. Horie et al (1995) Selectivity of the imidazoline _-adrenoceptor agonists (oxymetazoline and cirazoline) for human cloned _1-adrenoceptor subtypes. Br.J.Pharmacol. 116 1611. PMID:8564227. Bayorh et al (1997) Cardiovascular effects of oxymetazoline and UK14,304 in conscious and pithed rats. Clin.Exp.Hypertens. 19 445. PMID:9140707."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=2121	SQ1533			Nov-1998
1144	U0126	[109511-58-2]	N\C(SC1=CC=CC=C1N)=C(C#N)/C(C#N)=C(\N)SC1=CC=CC=C1N	"Potent, selective inhibitor of MEK1 and 2"	"Potent and selective non-competitive inhibitor of MAP kinase kinase. Inhibits MEK-1 and MEK-2 (IC50 values of 0.07 and 0.06 _M respectively) with little or no effect on the activities of PKC, Abl, Raf, MEKK, ERK, JNK, MKK-3, MKK-4/SEK, MKK-6, Cdk2 or Cdk4. Centrally active following systemic administration in vivo. Also available as part of the MAPK Cascade Inhibitor Tocriset and MAPK Inhibitor Tocriset. Negative control U0124 (Cat. No. 1868) also available."	"Duncia et al (1998) MEK inhibitors: the chemistry and biological activity of U0126, its analogs, and cyclization products. Bioorg.Med.Chem.Lett. 8 2839. PMID:9873633. Favata et al (1998) Identification of a novel inhibitor of mitogen-activated protein kinase kinase. J.Biol.Chem. 273 18623. PMID:9660836. Davies et al (2000) Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem.J. 351 95. PMID:10998351. Namura et al (2001) Intravenous administraton of MEK inhibitor U0126 affords brain protection against forebrain ischemia and focal cerebral ischemia. Proc.Natl.Acad.Sci.U.S.A. 98 11569. PMID:11504919."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=2119	SQ1533			Jan-1999
1145	"L-733,060 hydrochloride"	[148687-76-7]	Cl[H].FC(F)(F)C1=CC(=CC(CO[C@H]2CCCN[C@H]2C2=CC=CC=C2)=C1)C(F)(F)F	Potent NK1 antagonist	"A potent antagonist of human tachykinin NK1 receptors (Ki values are 0.08, 0.2 and 93.13 nM for gerbil, human and rat receptors respectively). Produces anxiolytic-like effects in the gerbil elevated plus-maze. Exhibits antitumor activity in vitro. Orally bioavailable and brain penetrant."	"Seabrook et al (1996) L-733,060, a novel tachykinin NK1 receptor antagonist; effects in [Ca2+]i mobilisation, cardiovascular and dural extravasation assays. Eur.J.Pharmacol. 317 129. PMID:8982729. Kramer et al (1998) Distinct mechanism for antidepressant blockade of central substance P receptors. Science 281 1640. PMID:9733503. Varty et al (2002) The gerbil elevated plus-maze II: anxiolytic-like effects of selective neurokinin NK1 receptor antagonists. Neuropsychopharmacology 27 371. PMID:12225694. Muoz et al (2008) NK-1 receptor antagonists induce apoptosis and counteract substance P-related mitogenesis in human laryngeal cancer cell line HEp-2. Invest New Drugs 26 111. PMID:17906845."	Small Molecule	"Sold with the permission of Merck, Sharpe and Dohme Ltd."	http://www.tocris.com/dispprod.php?ItemId=1301	SQ1341			Dec-1999
1146	MDL 28170	[88191-84-8]	O=C(N[C@@H]([C@H](C)C)C(NC(CC2=CC=CC=C2)C([H])=O)=O)OCC1=CC=CC=C1	"Potent, selective calpain and cathepsin B inhibitor"	"Potent, selective inhibitor of calpain and cathepsin B (Ki values are 10 and 25 nM respectively) that does not inhibit trypsin-like serine proteases. Rapidly penetrates the blood-brain barrier following systemic administration and displays neuroprotective effects in vivo."	Mehdi (1991) Cell-penetrating inhibitor of calpain. TiBS 16 150. PMID:1877091. Chen et al (1997) Neuronal recovery after moderate hypoxia is improved by the calpain inhibitor MDL 28170. Brain Res. 769 188. PMID:9374290. Li et al (1998) Postischemic treatment with a calpain inhibitor MDL 28170 ameliorates brain damage in a gerbil model of global ischemia. Neurosci.Lett. 247 17. PMID:9637399.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1111	SQ1070			Nov-2008
1147	SKF 96365 hydrochloride	[130495-35-1]	Cl.COC1=CC=C(CCCOC(CN2C=CN=C2)C2=CC=C(OC)C=C2)C=C1	TRPC channel blocker; also inhibits store-operated Ca2+ entry	"Store-operated Ca2+ entry (SOCE) inhibitor that inhibits STIM1. Also blocks TRPC channels, voltage-gated Ca2+ channels and potassium channels."	"Merritt et al (1990) SK&F96365, a novel inhibitor of receptor-mediated calcium entry. Biochem.J. 271 515. PMID:2173565. Varnai et al (2009) STIM and Orai: the long-awaited constituents of store-operated calcium entry. TiPS 30 118. PMID:19187978. Singh et al (2010) The transient receptor potential channel antagonist SKF96365 is a potent blocker of low-voltage-activated T-type calcium channels. Br.J.Pharmacol. 160 1464. PMID:20590636."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=2141	SQ1341			Aug-1999
1148	Siguazodan	[115344-47-3]	CN\C(NC#N)=N/C1=CC=C(C=C1)C1=NNC(=O)CC1C	PDE3 inhibitor	"Phosphodiesterase inhibitor, selective for PDE3 (IC50 = 117 nM)."	Tang et al (1994) Photoaffinity labelling of cyclic GMP-inhibited phosphodiesterase (PDE III) in human and rat platelets and rat tissues: effects of phosphodiesterase inhibitors. Eur.J.Pharmacol. 268 105. PMID:7925608. Christensen and Torphy (1994) Isozyme-selective phosphodiesterase inhibitors as antiasthmatic agents. Annu.Rep.Med.Chem. 29 185. Freitag et al (1998) Phosphodiesterase inhibitors suppress _2-adrenoceptor-mediated 5-hydroxytryptamine release from trachea of newborn rabbits. Eur.J.Pharmacol. 354 67. PMID:9726632.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=2142	SQ1533			Nov-1999
1199	NF 279	[202983-32-2]	[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[O-]S(=O)(=O)C1=CC2=C(C(NC(=O)C3=CC=C(NC(=O)C4=CC=C(NC(=O)NC5=CC=C(C=C5)C(=O)NC5=CC=C(C=C5)C(=O)NC5=C6C(C=C(C=C6S([O-])(=O)=O)S([O-])(=O)=O)=C(C=C5)S([O-])(=O)=O)C=C4)C=C3)=CC=C2S([O-])(=O)=O)C(=C1)S([O-])(=O)=O	Potent and selective P2X1 antagonist	"A potent and selective P2X1 antagonist (IC50 = 19 nM). Displays good selectivity over P2X2,(IC50 = 0.76 _M), P2X3 (IC50 = 1.62_M), P2X4 (IC50 > 300 _M), P2Y receptors and ecto-nucleotidases."	Damer et al (1998) NF279: a novel potent and selective antagonist of P2X receptor-mediated responses. Eur.J.Pharmacol. 350 R5. PMID:9683026. Klapperstuck et al (2000) Antagonism by the suramin analogue NF 279 on human P2X1 and P2X7 receptors. Eur.J.Pharmacol. 387 245. PMID:10650169. Rettinger et al (2000) The suramin analogue NF279 is a novel and potent antagonist selective for the P2X1 receptor. Neuropharmacology 39 2044. PMID:10963748.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1730				Jan-1999
1200	N_-Propyl-L-arginine hydrochloride	[137361-05-8]	N=C(NCCC[C@H](N)C(O)=O)NCCC	Highly selective inhibitor of nNOS	Highly selective and potent inhibitor of nNOS (Ki = 57 nM). Displays 3158-fold and 149-fold selectivity over iNOS and eNOS respectively. Hypotensive in vivo.	Zhang et al (1997) Potent and selective inhibition of neuronal nitric oxide synthase by N_-propyl-L-arginine. J.Med.Chem. 40 3869. PMID:9397167. Kakoki et al (2001) The influence of nitric oxide synthase 1 on blood flow and interstitial nitric oxide in the kidney. Am.J.Physiol.Regul.Integr.Comp.Physiol. 281 R91. PMID:11404282.	Small Molecule	Sold under license.	http://www.tocris.com/dispprod.php?ItemId=1767				Nov-1999
1202	SB 203580	[152121-47-6]	CS(=O)C1=CC=C(C=C1)C1=NC(=C(N1)C1=CC=NC=C1)C1=CC=C(F)C=C1	Selective inhibitor of p38 MAPK	"Selective inhibitor of p38 mitogen-activated protein kinase (IC50 values are 50 and 500 nM for SAPK2a/p38 and SAPK2b/p38_2 respectively). Displays 100-500-fold selectivity over LCK, GSK-3_ and PKB_. Shown to inhibit interleukin-2-induced T cell proliferation, cyclooxygenase-1 and -2, and thromboxane synthase. Enhances clonal growth of skin epithelial progenitor cells; stimulates neural stem cell (NSC) proliferation. Part of the MAPK Cascade Inhibitor Tocriset and MAPK Inhibitor Tocriset. Water-soluble salt SB 203580 hydrochloride (Cat. No. 1402) also available."	Saklatvala et al (1996) Role for p38 mitogen-activated protein kinase in platelet aggregation caused by collagen on a thromboxane analogue. J.Biol.Chem. 271 6586. PMID:8636072. Borsch-Haubold et al (1998) Direct inhibition of cyclooxygenase-1 and -2 by the kinase inhibitors SB 203580 and PD 98059. J.Biol.Chem. 273 28766. PMID:9786874. Davies et al (2000) Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem.J. 351 95. PMID:10998351. Sato et al (2008) Inhibitors of p38 mitogen-activated protein kinase enhance proliferation of mouse neural stem cells. J.Neurosci.Res. 86 2179. PMID:18338804.	Small Molecule	Sold with the permission of GlaxoSmithKline	http://www.tocris.com/dispprod.php?ItemId=1187	SQ1533			Feb-1999
1203	MRS 2219	[14141-47-0]	OC1=C(C)N=CC(CO2)=C1COP2(O)=O	Potentiates P2X1-mediated responses	A selective potentiator of ATP-evoked responses at rat P2X1 receptors (EC50 = 5.9 _M).	Jacobson et al (1998) A pyridoxine cyclic phosphate and its 6-azoaryl derivative selectively potentiate and antagonise activation of P2X1 receptors. J.Med.Chem. 41 2201. PMID:9632352.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1772	SQ1341			Apr-2003
1205	SR 57227 hydrochloride	[77145-61-0]	Cl.NC1CCN(CC1)C1=NC(Cl)=CC=C1	"Potent, selective 5-HT3 agonist"	"A high affinity, selective 5-HT3 receptor agonist, active in vivo and CNS penetrant."	Bachy et al (1993) SR 57227A: a potent and selective agonist at central and peripheral 5-HT3 receptors in vitro and in vivo. Eur.J.Pharmacol. 237 299. PMID:7689975. Edwards et al (1996) 5-HT3-like receptors in the rat medial prefrontal cortex: further pharmacological characterization. Brain Res. 733 21. PMID:8891244.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1770	SQ1533			Apr-1999
1206	SC 19220	[19395-87-0]	CC(=O)NNC(=O)N1CC2=C(OC3=CC=C(Cl)C=C13)C=CC=C2	Selective EP1 receptor antagonist	Selective EP1 receptor antagonist (IC50 = 6.7 _M for inhibition of [3H]-PGE2 binding to EP1 transfected COS cells).	Sanner (1972) Dibenzoxazepine hydrazides as prostaglandin antagonists. Intra-Science Chem.Rept. 6 1. Funk et al (1993) Cloning and expression of a cDNA for the human prostaglandin E receptor EP1 subtype. J.Biol.Chem. 268 26767. PMID:8253813. Botella et al (1995) Receptor subtypes involved in dual effects induced by prostaglandin E2 in circular smooth muscle from dog colon. J.Pharmacol.Exp.Ther. 273 1008. PMID:7791070.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1769	SQ1341			Nov-1999
1207	BRL 15572 hydrochloride	[1173022-77-9]	Cl.OC(CN1CCN(CC1)C1=CC=CC(Cl)=C1)C(C1=CC=CC=C1)C1=CC=CC=C1	Selective h5-HT1D antagonist	"A selective h5-HT1D antagonist, displaying 60-fold selectivity over h5-HT1B, and exhibiting little or no affinity for a range of other receptor types."	Hagan et al (1997) Stimulation of 5-HT1B receptors causes hypothermia in the rat. Eur.J.Pharmacol. 331 169. PMID:9274976. Price et al (1997) SB-216641 and BRL-15572 - compounds to pharmacologically discriminate h5-HT1B and h5-HT1D receptors. Naunyn Schmiedebergs Arch.Pharmacol. 356 312. PMID:9303567. Schlicker et al (1997) Effects of selective h5-HT1B (SB-216641) and h5-HT1D (BRL-15572) receptor ligands on guinea-pig and human 5-HT auto- and heteroreceptors. Naunyn Schmiedebergs Arch.Pharmacol. 356 321. PMID:9303568. Saxena et al (1998) 5-HT1-like receptors: a time to bid goodbye. TiPS 19 311. PMID:9745358.	Small Molecule	Sold with the permission of GlaxoSmithKline	http://www.tocris.com/dispprod.php?ItemId=2078	SQ1533			May-1999
1208	"(2R,4R)-APDC"	[169209-63-6]	N[C@]1([C@](O)=O)C[C@H]([C@](O)=O)NC1	Highly selective group II agonist	"A highly selective and relatively potent group II metabotropic glutamate receptor agonist. EC50 values are 0.4, 0.4, > 100, > 100, > 300 and > 300 _M for human mGlu2, mGlu3, mGlu1, mGlu5, mGlu4 and mGlu7 receptors respectively. Centrally active following systemic administration in vivo. Also available as part of the Group II mGlu Receptor Tocriset."	"Schoepp et al (1995) Selective inhibition of forskolin-stimulated cyclic AMP formation in rat hippocampus by a novel mGluR agonist, 2R,4R-4-aminopyrrolidine-2,4-dicarboxylate. Neuropharmacology 34 843. PMID:8532165. Monn et al (1996) Synthesis of the four isomers of 4-aminopyrrolidine-2,4-dicarboxylate: identification of a potent, highly selective, and systemically active agonist for metabotropic glutamate receptors negatively coupled to adenylate cyclase. J.Med.Chem. 39 2990. PMID:8709133. Schoepp et al (1999) Pharmacological agents acting at subtypes of metabotropic glutamate receptors. Neuropharmacology 38 1431. PMID:10530808."	Small Molecule	Sold with the permission of Eli Lilly and Company	http://www.tocris.com/dispprod.php?ItemId=1321	SQ1341			Oct-1999
1209	LY 341495	[201943-63-7]	[H][C@]4([C@@H]([C@](O)=O)C4)[C@](N)(C(O)=O)CC2C3=C(C=CC=C3)OC1=CC=CC=C12	"Highly potent, selective group II antagonist"	"Highly potent and selective group II metabotropic glutamate receptor antagonist (Ki/IC50 values are 2.3, 1.3, 173, 990, 6800, 8200 and 22000 nM for human mGlu2, mGlu3, mGlu8 , mGlu7a, mGlu1a, mGlu5a and mGlu4a receptors respectively). Readily brain penetrant and active in vivo. Disodium salt (Cat. No. 4062) also available. Also available as part of the Group II mGlu Receptor Tocriset, Group III mGlu Receptor Tocriset and Mixed mGlu Receptor Tocriset."	"Fitzjohn et al (1998) The potent mGlu receptor antagonist LY341495 identifies roles for both cloned and novel mGlu receptors in hippocampal synaptic plasticity. Neuropharmacology 37 1445. PMID:9886667. Kingston et al (1998) LY341495 is a nanomolar potent and selective antagonist of group II metabotropic glutamate receptors. Neuropharmacology 37 1. PMID:9680254. Ornstein et al (1998) 2-Substituted (2SR)-2-amino-2-((1SR,2SR)-2-carboxycycloprop-1-yl) glycines as potent and selective antagonists of group II metabotropic glutamate receptors. 2. Effects of aromatic substitution, pharmacological characterization, and bioavailability. J.Med.Chem. 41 358. PMID:9464367. Johnson et al (1999) [3H]-LY341495 as a novel antagonist radioligand for group II metabotropic glutamate receptors: characterization of binding to membranes of mGlu receptor subtype expressing cells. Neuropharmacology 38 1519. PMID:10530814."	Small Molecule	Sold with the permission of Eli Lilly and Company	http://www.tocris.com/dispprod.php?ItemId=1322	SQ1341			Nov-1999
1210	FR 139317	[142375-60-8]	O=C([C@H](CC(C)C)NC(N1CCCCCC1)=O)N[C@@H]([C@@](N[C@H](CC2=NC=CC=C2)C(O)=O)=O)CC(C3=CC=CC=C34)=CN4C	"Highly potent, selective ETA antagonist"	A highly potent and selective ETA endothelin receptor antagonist (Ki values are 1 nM and 7.3 _M at ETA and ETB subtypes respectively). Active in vivo.	"Aramori et al (1993) Subtype selectivity of a novel endothelin antagonist, FR139317, for the two endothelin receptors in transfected Chinese hamster ovary cells. Mol.Pharmacol. 43 127. PMID:8429819. Sogabe et al (1993) Pharmacological profile of FR139317, a novel, potent endothelin ETA receptor antagonist. J.Pharmacol.Exp.Ther. 264 1040. PMID:8450448. Rubanyi and Polokoff (1994) Endothelins: molecular biology, biochemistry, pharmacology, physiology, and pathophysiology. Pharmacol.Rev. 46 325. PMID:7831383. Palacios et al (2002) Role of endothelin ETA- and ETB-receptors in haemodynamic compensation following haemorrhage in anaesthetized rats. Br.J.Pharmacol. 135 876. PMID:11861314."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1326	SQ1341			Aug-2000
1211	ZD 7155 hydrochloride	[146709-78-6]	Cl.CCC1=CC2=C(CCC(=O)N2CC2=CC=C(C=C2)C2=CC=CC=C2C2=NN=NN2)C(CC)=N1	Selective non-peptide AT1 antagonist	"A potent and selective competitive antagonist for the angiotensin II type 1 (AT1) receptor. Displaces [125I]-angiotensin II binding with an IC50 value of 3.8 nM in guinea pig adrenal gland membranes. Orally active, and is more potent and longer-acting than the prototype AT1 antagonist, losartan."	"Oldham et al (1993) Zeneca ZD7155: a novel, potent and orally-effective angiotensin II receptor antagonist. Br.J.Pharmacol. 109 P136. Junggren et al (1996) Comparative cardiovascular effects of the angiotensin II type 1 receptor antagonists ZD 7155 and losartan in the rat. J.Pharm.Pharmacol. 48 829. PMID:8887734. Veelken et al (1998) Endogenous angiotensin II and the reflex response to stimulation of cardiopulmonary serotonin 5HT3 receptors. Br.J.Pharmacol. 125 1761. PMID:9886768."	Small Molecule	Sold with the permission of AstraZeneca UK Ltd.	http://www.tocris.com/dispprod.php?ItemId=1327	SQ1341			Mar-2000
1212	MPEP hydrochloride	[219911-35-0]	Cl.CC1=CC=CC(=N1)C#CC1=CC=CC=C1	mGlu5 antagonist and positive allosteric modulator at mGlu4	Potent and highly selective non-competitive antagonist at the mGlu5 receptor subtype (IC50 = 36 nM) and a positive allosteric modulator at mGlu4 receptors. Centrally active following systemic administration in vivo. Reverses mechanical hyperalgesia in the inflamed rat hind paw. Also available as part of the Group I mGlu Receptor Tocriset.	"Gasparini et al (1999) 2-Methyl-6-(phenylethynyl)-pyridine (MPEP), a potent, selective and systemically active mGlu5 receptor antagonist. Neuropharmacology 38 1493. PMID:10530811. Salt et al (1999) Antagonism of the mGlu5 agonist 2-chloro-5-hydroxyphenylglycine by the novel selective mGlu5 antagonist 6-methyl-2-(phenylethynyl)-pyridine (MPEP) in the thalamus. Br.J.Pharmacol. 127 1057. PMID:10455248. Bowes et al (1999) Anti-hyperalgesic effects of the novel metabotropic glutamate receptor 5 antagonist, methylphenylethynylpyridine, in rat models of inflammatory pain. Br.J.Pharmacol. 126 250P. Mathiesen et al (2003) Positive allosteric modulation of the human metabotropic glutamate receptor 4 (hmGluR4) by SIB-1893 and MPEP. Br.J.Pharmacol. 138 1026. PMID:12684257."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1328	SQ1533			Feb-1999
1213	PD 98059	[167869-21-8]	COC1=C(N)C(=CC=C1)C1=CC(=O)C2=CC=CC=C2O1	MEK inhibitor	"Inhibitor of mitogen-activated protein kinase kinase (MKK / MEK). Acts by binding to the inactivated form of MEK, thereby preventing its phosphorylation by cRAF or MEK kinase (IC50 = 2-7 _M). Inhibits cell growth and proliferation in acute myelogenous leukemia (AML) cell lines; causes G1 arrest by blocking p53-dependent p21 induction. Enhances embryonic stem cell self-renewal. Also available as part of the MAPK Cascade Inhibitor Tocriset and MAPK Inhibitor Tocriset."	Alessi et al (1995) PD 98059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase in vitro and in vivo. J.Biol.Chem. 270 27489. PMID:7499206. Dudley et al (1995) A synthetic inhibitor of the mitogen-activated protein kinase cascade. Proc.Natl.Acad.Sci.U.S.A. 92 7686. PMID:7644477. Tsang et al (1998) Effects of mitogen-activated protein kinase kinase inhibitor PD 98059 on antigen challenge of guinea-pig airways in vitro. Br.J.Pharmacol. 125 61. PMID:9776345. Qi et al (2004) BMP4 supports self-renewal of embryonic stem cells by inhibiting mitogen-activated protein kinase pathways. Proc.Natl.Acad.Sci.USA 101 6027. PMID:15075392. Kojima et al (2007) Mitogen-activated protein kinase kinase inhibition enhances nuclear proapoptotic function of p53 in acute myelogenous leukemia cells. 67 3210. PMID:17409429.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1356	SQ1533			Apr-1999
1214	SIB 1893	[6266-99-5]	CC1=NC(\C=C\C2=CC=CC=C2)=CC=C1	mGlu5 antagonist and positive allosteric modulator at mGlu4	"A highly selective non-competitive antagonist for the metabotropic glutamate mGlu5 receptor subtype; displays an IC50 value of 0.3 _M  at hmGlu5, compared with > 100 _M at hmGlu1b, hmGlu2, hmGlu6, hmGlu7 and hmGlu8. Centrally active upon systemic administration in vivo. Positive allosteric modulator at mGlu4 receptors."	"Varney et al (1999) SIB-1757 and SIB-1893: selective, noncompetitive antagonists of metabotropic glutamate receptor type 5. J.Pharmacol.Exp.Ther. 290 170. PMID:10381773. Chapman et al (2000) Anticonvulsant activity of two metabotropic glutamate group I antagonists selective for the mGlu5 receptor: 2-methyl-6-(phenylethynyl)-pyridine (MPEP), and (E)-6-methyl-2-styryl-pyridine (SIB 1893). Neuropharmacology 39 1567. PMID:10854901. Mathiesen et al (2003) Positive allosteric modulation of the human metabotropic glutamate receptor 4 (hmGluR4) by SIB-1893 and MPEP. Br.J.Pharmacol. 138 1026. PMID:12684257."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1263	SQ1341			Feb-1999
1215	SIB 1757	[31993-01-8]	CC1=NC(\N=N\C2=CC=CC=C2)=C(O)C=C1	Highly selective mGlu5 antagonist	"A highly selective antagonist for the mGlu5 metabotropic glutamate receptor subtype; displays an IC50 value of 0.4 _M at hmGlu5 compared with > 30 _M at hmGlu1b, hmGlu2, hmGlu4, hmGlu6, hmGlu7 and hmGlu8."	"Varney et al (1999) SIB-1757 and SIB-1893: selective, noncompetitive antagonists of metabotropic glutamate receptor type 5. J.Pharmacol.Exp.Ther. 290 170. PMID:10381773. Varney et al (1999) Characterisation of SIB-1757 and SIB-1893: highly selective antagonists at metabotropic glutamate receptor subtype 5. Br.J.Pharmacol. 126 248P."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1357				Feb-1999
1217	MRS 1220	[183721-15-5]	ClC1=CC=C2N=C(NC(=O)CC3=CC=CC=C3)N3N=C(N=C3C2=C1)C1=CC=CO1	"Highly potent, selective hA3 antagonist"	"A potent and highly selective antagonist at the human A3 adenosine receptor (Ki values are 0.65, 305, and 52 nM at hA3, rA1 and rA2A respectively. Displays an IC50 value > 1 _M for inhibition of binding to rat A3 receptors)."	Kim et al (1996) Derivatives of the triazoloquinazoline adenosine antagonist (CGS 15943) are selective for the human A3 receptor subtype. J.Med.Chem. 39 4142. PMID:8863790. Jacobson et al (1997) Pharmacological characterization of novel A3 adenosine receptor selective antagonists. Neuropharmacology 36 1157. PMID:9364471. Kim et al (1998) Derivatives of the triazoloquinazoline adenosine antagonist (CGS 15943) having high potency at the human A2B and A3 receptor subtypes. J.Med.Chem. 41 2835. PMID:9667972.	Small Molecule	"Sold with the permission of the NIH, US Patent 60/029,855"	http://www.tocris.com/dispprod.php?ItemId=1358	SQ1341			Sep-1999
1218	DH 97	[220339-00-4]	CCCCC(=O)NCCC1=C(CC2=CC=CC=C2)NC2=CC=CC=C12	MT2 receptor antagonist	"A relatively potent MT2 melatonin receptor antagonist (pKi value = 8.03), displaying 89- and 229-fold selectivity over MT1 and GPR50 (melatonin-related orphan receptor) respectively."	Teh and Sugden (1998) Comparison of the relationships of melatonin receptor agonists and antagonists; lengthening the N-acyl side chain has differing effects on potency on Xenopus melanophores. Naunyn Schmiedebergs Arch.Pharmacol. 358 522. PMID:9840420. Ting et al (1999) Molecular and pharmacological evidence for MT1 melatonin receptor subtype in the tail artery of juvenile Wistar rats. Br.J.Pharmacol. 127 987. PMID:10433507.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1361	SQ1341			Feb-1999
1219	IDRA 21	[22503-72-6]	CC1NC2=C(C=C(Cl)C=C2)S(=O)(=O)N1	Inhibits AMPA receptor desensitization	Inhibits AMPA receptor desensitization and enhances cognition by a related mechanism. More able to cross the blood-brain barrier than cyclothiazide (Cat. No. 0713).	"Thompson et al (1995) 7-Chloro-3-methyl-3,4-dihydro-2H-1,2,4-benzothiadiazine S,S-dioxide (IDRA 21), a congener of aniracetam, potently abates pharmacologically induced cognitive impairments in patas monkeys. Proc.Natl.Acad.Sci.U.S.A. 92 7667. PMID:7644474. Zivkovic et al (1995) 7-Chloro-3-methyl-3,4-dihydro-2H-1,2,4-benzothiadiazine S,S-dioxide (IDRA 21): a benzothiadiazine derivative that enhances cognition by attenuating DL-_-amino-2,3-dihydro-5-methyl-3-oxo-4-isoxazolepropanoic acid (AMPA) receptor desensitization. J.Pharmacol.Exp.Ther. 272 300. PMID:7815345. Impagnatiello et al (1997) 7-Chloro-3-methyl-3,4-dihydro-2H-1,2,4-benzothiadiazine S,S-dioxide: a partial modulator of AMPA receptor desensitization devoid of neurotoxicity. Proc.Natl.Acad.Sci.U.S.A. 94 7053. PMID:9192690."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1364	SQ1341			Apr-1999
1220	(RS)-PPG	[120667-15-4]	NC(C(O)=O)C1=CC=C(P(O)(O)=O)C=C1	"Potent, selective mGlu8 agonist"	"A potent and selective group III metabotropic glutamate receptor agonist, with approximately 25-fold preference for hmGlu8; anticonvulsant and neuroprotective in vivo. Also available as part of the Group III mGlu Receptor Tocriset."	"Bigge et al (1989) Exploration of phenyl-spaced 2-amino-(5,9)-phosphonoalkanoic acids as competitive N-methyl-D-aspartic acid antagonists. J.Med.Chem. 32 1580. PMID:2544728. Flor et al (1998) Neuroprotection in vitro and in vivo by (R,S)-PPG, a potent and selective group III metabotropic glutamate receptor agonist. Soc.Neurosci.Abstr. 24 431.11. Gasparini et al (1999) (R,S)-4-Phosphonophenylglycine, a potent and selective group III metabotropic glutamate receptor agonist, is anticonvulsive and neuroprotective in vivo. J.Pharmacol.Exp.Ther. 289 1678. PMID:10336568."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1411				Feb-1999
1221	SB 224289 hydrochloride	[180084-26-8]	O=C(C5=CC=C(C6=CC=C(C7=NOC(C)=N7)C=C6C)C=C5)N2C1=CC3=C(OCC43CCN(CC4)C)C=C1CC2.Cl	Selective 5-HT1B antagonist	"Selective 5-HT1B receptor antagonist (pKi = 8.2). Displays > 60-fold selectivity over 5-HT1D, 5-HT1A, 5-HT1E, 5-HT1F, 5-HT2A and 5-HT2C receptors in radioligand binding and functional assays. Centrally active following oral administration in vivo."	"Hagan et al (1997) Stimulation of 5-HT1B receptors causes hypothermia in the guinea-pig. Eur.J.Pharmacol. 331 169. PMID:9274976. Roberts et al (1998) Differential effects of 5-HT1B/1D receptor antagonists in dorsal and median raphe innervated brain regions. Eur.J.Pharmacol. 346 175. PMID:9652357. Selkirk et al (1998) SB-224289 - a novel selective (human) 5-HT1B receptor antagonist with negative intrinsic activity. Br.J.Pharmacol. 125 202. PMID:9776361. Gaster et al (1998) The selective 5-HT1B receptor inverse agonist 1'-methyl-5-[[2'-methyl-4'-(5-methyl-1,2,4-oxadiazol-3-yl)biphenyl-4-yl]carbonyl]-2,3,6,7-tetrahydrospiro[furo[2,3-f]indole-3,4'-piperidine (SB-224289) potently blocks terminal 5-HT autoreceptor function both in vitro and in vivo. J.Med.Chem. 41 1218. PMID:9548813."	Small Molecule	Sold with the permission of GlaxoSmithKline	http://www.tocris.com/dispprod.php?ItemId=1412	SQ1533			Sep-2002
1222	DMPQ dihydrochloride	[1123491-15-5]	COC1=CC(OC)=C2C(N=CC(C3=CC=NC=C3)=C2)=C1.Cl.Cl	"Potent, selective inhibitor of PDGFR_"	"A potent and selective inhibitor of human vascular _-type platelet derived growth factor receptor tyrosine kinase (PDGFR_) (IC50 = 80 nM). Displays > 100-fold selectivity over EGFR tyrosine kinase, erbB2, p56, protein kinase A and protein kinase C."	"Dolle et al (1994) 5,7-Dimethoxy-3-(4-pyridinyl)quinoline is a potent and selective inhibitor of human vascular _-type platelet-derived growth factor receptor tyrosine kinase J.Med.Chem. 37 2627. PMID:8064792."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1413	SQ1341			Jul-1999
1223	DL-TBOA	[205309-81-5]	[H][C@@](OCC1=CC=CC=C1)(C(O)=O)[C@@]([H])(C(O)=O)N.[H][C@](OCC2=CC=CC=C2)(C(O)=O)[C@]([H])(C(O)=O)N	Selective non-transportable inhibitor of EAATs	"A competitive, non-transportable blocker of excitatory amino acid transporters (IC50 values are 70, 6, and 6 _M for EAAT1, EAAT2 and EAAT3 respectively). Also inhibits EAAT4 and EAAT5 (Ki values are 4.4 and 3.2 _M respectively). Displays high selectivity for EAATs over ionotropic and metabotropic glutamate receptors. Also available as part of the Excitatory Amino Acid Transporter Inhibitor Tocriset."	"Shimamoto et al (1998) DL-threo-_-benzyloxyaspartate, a potent blocker of excitatory amino acid transporters. Mol.Pharmacol. 53 195. PMID:9463476. Jabaudon et al (1999) Inhibition of uptake unmasks rapid extracellular turnover of glutamate of nonvesicular origin. Proc.Natl.Acad.Sci.U.S.A. 96 8733. PMID:10411944. Shimamoto et al (2000) Syntheses of optically pure _-hydroxyaspartate derivatives as glutamate transporter blockers. Bioorg.Med.Chem.Lett. 10 2407. PMID:11078189. Shigeri et al (2001) Effects of threo-_-hydroxyaspartate derivatives on excitatory amino acid transporters (EAAT4 and EAAT5). J.Neurochem. 79 297. PMID:11677257."	Small Molecule	Sold for research purposes under license from Suntory Ltd.	http://www.tocris.com/dispprod.php?ItemId=1414	SQ1341			Oct-2000
1224	2-APB	[524-95-8]	NCCOB(C1=CC=CC=C1)C1=CC=CC=C1	IP3 receptor antagonist. Also TRP channel modulator	"A functional and membrane permeable D-myo-inositol 1,4,5-trisphosphate (IP3) receptor antagonist (IC50 = 42 _M). Stimulates store-operated calcium (SOC) release at low concentrations (< 10 _M) and inhibits it at higher concentrations (up to 50 _M). Increases STIM-Orai channel conductance and limits ion selectivity. Modulator of TRP channels; blocks TRPC1, TRPC3, TRPC5, TRPC6, TRPV6, TRPM3, TRPM7, TRPM8 and TRPP2 and at higher concentrations stimulates TRPV1, TRPV2 and TRPV3. Also blocks specific gap channel subtypes."	"Maruyama et al (1997) 2APB, 2-aminoethoxydiphenyl borate, a membrane-penetrable modulator of Ins(1,4,5)P3-induced Ca2+ release. J.Biochem. 122 498. PMID:9348075. Xu et al (2005) Block of TRPC5 channels by 2-aminoethoxydiphenyl borate: a differential, extracellular and voltafe-dependent effect. Br.J.Pharmacol. 145 405. PMID:15806115. Bai et al (2006) Block of specific gap junction channel subtypes by 2-aminoethoxydiphenyl borate (2-APB). J.Pharmacol.Exp.Ther. 319 1452. PMID:16985167. Togashi et al (2008) Inhibition of the transient receptor potential cation channel TRPM2 by 2-aminoethoxydiphenyl borate (2-APB). Br.J.Pharmacol. 153 1324. PMID:18204483. Varnai et al (2009) STIM and Orai: the long-awaited constituents of store-operated calcium entry. TiPs 30 118. PMID:19187978."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1427				Nov-1999
1225	TCPOBOP	[76150-91-9]	ClC(C=N3)=CC(Cl)=C3OC(C=C2)=CC=C2OC1=NC=C(Cl)C=C1Cl	Constitutive androstane receptor agonist	"Agonist of the constitutive androstane receptor (CAR) (EC50 = 20 nM). Induces activity of ER1 cytochrome P450 isozymes, NADPH-cytochrome c reductase, microsomal epoxide hydrolase and glutathione S transferase. Potent mitogen; induces liver cell proliferation in mice."	"Poland et al (1980) 1,4-Bis[2-(3,5-dichloropyridyloxy)]benzene, a potent phenobarbital-like inducer of microsomal monooxygenase activity. Mol.Pharmacol. 18 571. PMID:7464820. Ledda-Columbano et al (1998) In vivo hepatocyte proliferation is inducible through a TNF and IL-6-independent pathway. Oncogene 17 1039. PMID:9747883. Tzameli et al (2000) The xenobiotic compound 1,4-bis[2-(3,5-dichloropyridyloxy)]benzene is an agonist ligand for the nuclear receptor CAR. Mol.Cell.Biol. 20 2951. PMID:10757780."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=2205	SQ1341			Jan-2013
1226	Etoposide	[33419-42-0]	COC1=CC(=CC(OC)=C1O)[C@H]1[C@@H]2C(COC2=O)C(OC2OC3COC(C)OC3C(O)C2O)C2=CC3=C(OCO3)C=C12	Topoisomerase II inhibitor	Topoisomerase II inhibitor (IC50 = 59.2 _M).	"Terada et al (1993) Antitumor agents.3.Synthesis and biological activity of 4_-alkyl derivatives containing hydroxy, amino, and amido groups of 4'-O-demethyl-4-desoxypodophyllotoxin as antitumor agents. J.Med.Chem. 36 1689. PMID:8389875. Burden et al (1996) Toposiomerase II.etoposide interactions direct the formation of drug-induced enzyme-DNA cleavage complexes. J.Biol.Chem. 271 29238. PMID:8910583. Hande et al (1998) Etoposide: four decades of development of a topoisomerase II inhibitor. Eur.J.Cancer 34 1514. PMID:9893622."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=2051	SQ1533			May-1999
1227	Apigenin	[520-36-5]	OC1=CC=C(C=C1)C1=CC(=O)C2=C(O1)C=C(O)C=C2O	Protein kinase inhibitor	"Protein kinase inhibitor. Suppresses tumor-promoting effects of TPA and exhibits antiproliferative activity in human breast cancer cells (IC50 values are 59.44 and 31.15 _M at 24 and 72 hrs respectively). Activates both the intrinsic and extrinsic apoptotic pathways and displays anti-inflammatory, hypotensive, antispasmodic and antioxidant properties in vivo."	Sato et al (1994) Apigenin induces morphological differentiation and G2-M arrest in rat neuronal cells. Biochem.Biophys.Res.Commun. 204 578. PMID:7980517. Kuo and Yang (1995) Reversion of v-H-ras-transformed NIH3T3 cells by apigenin through inhibiting mitogen activated protein kinase and its downstream oncogenes. Biochem.Biophys.Res.Commun. 212 767. PMID:7626110. Lin et al (1997) Suppression of protein kinase C and nuclear oncogene expression as possible molecular mechanisms of cancer chemoprevention by apigenin and curcumin. J.Cell.Biochem.Suppl. 28-29 39. PMID:9589348. Choi et al (2009) Apigen induces apoptosis through a mitochondria/caspase-pathway in human breast cancer MDA-MB-453 cells. J.Clin.Biochem.Nutr. 44 260. PMID:19430615. Jin et al (2009) Apigenin protects endothelium-dependent relaxation of rat aorta against oxidative stress. Eur.J.Pharmacol. 616 200. PMID:19549516.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=2052	SQ1533			May-1999
1228	Nocodazole	[31430-18-9]	COC(=O)NC1=NC2=CC(=CC=C2N1)C(=O)C1=CC=CS1	Microtubule inhibitor	Microtubule inhibitor; inhibits mitosis. Also inhibits autophagosome-lysosome fusion.	Vasquez et al (1997) Nanomolar concentrations of nocodazole alter microtubule dynamic instability in vivo and in vitro. Mol.Biol.Cell 8 973. PMID:9201709. Mikhailov and Gundersen` (1998) Relationship between microtubule dynamics and lamellipodium formation revealed by direct imaging of microtubules in cells treated with nocodazole or taxol. Cell.Motil.Cytoskeleton 41 325. PMID:9858157. Webb et al (2004) Microtubule disruption inhibits autophagosome-lysosome fusion: implications for studying the roles of aggresomes in polyglutamine diseases. Int.J.Biochem.Cell Biol. 36 2541. PMID:15325591. Mizushima et al (2010) Methods in mammalian autophagy research. Cell 140 313. PMID:20144757.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=2053	SQ1533			May-1999
1229	Actinomycin D	[50-76-0]	CC(C)C1NC(=O)C(NC(=O)C2=CC=C(C)C3=C2N=C2C(O3)=C(C)C(=O)C(N)=C2C(=O)NC2C(C)OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C3CCCN3C(=O)C(NC2=O)C(C)C)C(C)OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C1=O	Inhibits RNA polymerase	Anti-neoplastic antibiotic. Inhibits RNA polymerase and is a potent inducer of apoptosis.	"Aktipis et al (1981) A kinetic study on the mechanism of inhibition of RNA synthesis catalyzed by DNA-dependent RNA polymerase. Differences in inhibition by ethidium bromide, 3,8-diamino-6-ethylphenanthridinium bromide and actinomycin D. Biochim.Biophys.Acta 655 278. PMID:7025910. Glynn et al (1992) Apoptosis induced by actinomycin D, camptothecin or aphidicolin can occur in all phases of the cell cycle. Biochem.Soc.Trans. 20 84S. PMID:1634006. Jeeninga et al (1998) The mechanism of actinomycin D-mediated inhibition of HIV-1 reverse transcription. Nucleic Acids Res. 26 5472. PMID:9826774."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=2054	SQ1533			May-1999
1230	Methotrexate	[59-05-2]	O=C(N[C@H]([C@](O)=O)CCC(O)=O)C(C=C3)=CC=C3N(CC2=NC1=C(N)N=C(N)N=C1N=C2)C	Cytotoxic agent	"Cytotoxic agent. Inhibits thymidylate synthetase and de novo purine synthesis. Potent folic acid antagonist; inhibits dihydrofolate reductase. Also inhibits Ras carboxyl methylation in DKOB8 cells, leading to decreased p44 and Akt activation."	Jolivet et al (1983) The pharmacology and clinical use of methotrexate. N.Engl.J.Med. 309 1094. PMID:6353235. Allegra et al (1987) Evidence for direct inhibition of de novo protein synthesis in human MCF-7 breast cells as a principal mode of metabolic inhibition by methotrexate. J.Biol.Chem. 262 13520. PMID:2443493. Chu et al (1990) Mechanism of thymidylate synthase inhibition by methotrexate in human neoplastic cell lines and normal human myeloid progenitor cells. J.Biol.Chem. 265 8470. PMID:2341391. Winter-Vann et al (2003) Targeting Ras signaling through inhibition of carboxyl methylation: an unexpected property of methotrexate. Proc.Natl.Acad.Sci.U.S.A. 100 6529. PMID:12750467.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1365	SQ1533			May-1999
1231	Brefeldin A	[20350-15-6]	[H][C@]1(C)CCC\C=C\C2C[C@H](O)C[C@H]2[C@H](O)\C=C\C(=O)O1	Disrupts protein translocation to Golgi	Reversible inhibitor of protein translocation from the endoplasmic reticulum (ER) to the Golgi apparatus. Blocks binding of ADP-ribosylation factor to the Golgi apparatus and inhibits GDP-GTP exchange. Can be used to induce autophagy in mammalian cells.	Ktistakis et al (1992) Action of brefeldin A blocked by activation of a pertussis-toxin-sensitive G protein. Nature 356 344. PMID:1549178. Tsai et al (1994) Identification of a brefeldin A-insensitive guanine nucleotide-exchange protein for ADP-ribosylation factor in bovine brain. Proc.Natl.Acad.Sci.U.S.A. 91 3063. PMID:8159707. Morinaga et al (1996) Isolation of a brefeldin A-inhibited guanine nucleotide-exchange protein for ADP ribosylation factor (ARF)1 and ARF3 that contains a Sec7-like domain. Proc.Natl.Acad.Sci.U.S.A. 93 12856. PMID:8917509. Ding et al (2007) Differential effects of endoplasmic reticulum stress-induced autophagy on cell survival. J.Biol.Chem. 282 4702. PMID:17135238.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=2180	SQ1533			May-1999
1232	Wortmannin	[19545-26-7]	O=C(C4=CO5)O[C@H](COC)[C@@]1(C)C4=C5C(C2=C1[C@H](OC(C)=O)C[C@@]3(C)C2CCC3=O)=O	"Potent, irreversible inhibitor of PI 3-kinase. Also inhibitor of PLK1"	"Potent, selective, cell-permeable and irreversible inhibitor of phosphatidylinositol 3-kinase (PI 3-kinase) (IC50 = 2 - 4 nM). Also potently inhibits polo-like kinase 1 (PLK1) (IC50 = 5.8 nM)."	"Arcaro and Wymann (1993) Wortmannin is a potent phophatidylinositol 3-kinase inhibitor: the role of phosphatidylinositol 3,4,5-trisphosphate in neutrophil responses. Biochem.J. 296 297. PMID:8257416. Powis et al (1994) Wortmannin, a potent and selective inhibitor of phosphatidylinositol-3-kinase. Cancer Res. 54 2419. PMID:8162590. Schultz et al (1995) In vitro and in vivo antitumor activity of the phosphatidylinositol-3-kinase inhibitor wortmannin. Anticancer Res. 15 1135. PMID:7653991. Liu et al (2005) Wortmannin, a widely used phosphoinositide 3-kinase inhibitor, also potently inhibits mammalian polo-like kinase. Chem.Biol. 12 99. PMID:15664519."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=2181	SQ1533			Jun-1999
1233	Cytochalasin D	[22144-77-0]	C=C([C@H]4C)[C@@H](O)[C@]([C@@]1([C@H](OC(C)=O)/C=C/[C@@](O)3C)[C@]4([H])[C@@H](CC2=CC=CC=C2)N[C@]1=O)([H])/C=C/C[C@H](C)C3=O	Disrupts actin filament function	"Potent disruptor of actin filament function. Alters tight junction permeability. Unlike cytochalasin B, does not inhibit monosaccharide transport across the plasma membrane."	Carlier et al (1986) Interaction of cytochalasin D with actin filaments in the presence of ADP and ATP. J.Biol.Chem. 261 2041. PMID:3944126. Stevenson and Begg (1994) Concentration-dependent effects of cytochalasin D on tight junctions and actin filaments in MDCK epithelial cells. J.Cell Sci. 107 367. PMID:8006058. Abedi and Zachary (1998) Cytochalasin D stimulation of tyrosine phosphorylation and phosphotyrosine-associated kinase activity in vascular smooth muscle cells. Biochem.Biophys.Res.Commun. 245 646. PMID:9588169.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=2182	SQ1070			Jun-1999
1234	"A23187, free acid"	[52665-69-7]	[H][C@@]1([C@H](C)C(C5=CC=CN5)=O)[C@H](C)C[C@@H](C)[C@@]2(O[C@H](CC3=NC(C(C(O)=O)=C(NC)C=C4)=C4O3)[C@H](C)CC2)O1	Calcium ionophore	Calcium ionophore that induces Ca2+-dependent cell death by increasing intracellular calcium concentration. Promotes intracelllular ROS generation and platelet particle formation (fragmentation) in vitro and in vivo. Can be used to induce autophagy in mammalian cells.	"Kajitani et al (2007) Mechanism of A23187-induced apoptosis in HL-60 cells: dependency on mitochondrial permeability transition but not NADPH oxidase. Biosci.Biotechnol.Bichem. 71 2701. PMID:7535265. Nardi et al (2007) Platelet particle formation by anti-GPIIIa49-66 Ab, Ca2+ ionophore A23187, and phorbol myristate acetate is induced by reactive oxygen species and inhibited by dexamethasone blockade of platelet phospholipase A2, 12-lipoxygenase, and NADPH oxidase. Blood 110 1989. PMID:17545506. Ding et al (2007) Differential effects of endoplasmic reticulum stress-induced autophagy on cell survival. J.Biol.Chem. 282 4702. PMID:17135238. Sakanashi et al (2009) Zn2+, derived from cell preparation, partly attenuates Ca2+-dependent cell death induced by A23187, calcium ionophore, in rat thymocytes. Toxicol.In Vitro 23 338. PMID:19124067."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=2184	SQ1070			Jun-1999
1235	Cyclopiazonic acid	[18172-33-3]	OC([C@](N4C(C)5C)([H])[C@]1([H])[C@@]5([H])CC3=C2C1=CNC2=CC=C3)=C(C(C)=O)C4=O	Inhibitor of SERCA ATPase	"Cell-permeable, reversible inhibitor of sarcoplasmic reticulum Ca2+-ATPase."	"Plenge-Tellechea et al (1997) On the inhibition mechanism of sarcoplasmic or endoplasmic reticulum Ca2+-ATPases by cyclopiazonic acid. J.Biol.Chem. 272 2794. PMID:9006919. Soler et al (1998) Cyclopiazonic acid effect on Ca2+-dependent conformational states of the sarcoplasmic reticulum ATPase. Implication for the enzyme turnover. Biochemistry 37 4266. PMID:9521749. Takemoto et al (1998) Comparison of contractions produced by carbachol, thapsigargin and cyclopiazonic acid in the guinea-pig tracheal muscle. Br.J.Pharmacol. 124 1449. PMID:9723957."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=2183	SQ1070			Jun-1999
1236	BHQ	[88-58-4]	CC(C)(C)C1=CC(O)=C(C=C1O)C(C)(C)C	Inhibitor of SERCA ATPase	A selective inhibitor of endoplasmic reticulum Ca2+-ATPase.	"Hassessian et al (1994) Blockade of the inward rectifier potassium current by the Ca2+-ATPase inhibitor 2',5'-di(tert-butyl)-1,4-benzohydroquinone (BHQ). Br.J.Pharmacol. 112 1118. PMID:7952872. Jan et al (1999) Mechanism of rise and decay of 2,5-di-tert-butylhydroquinone-induced Ca2+ signals in Madin Darby canine kidney cells. Eur.J.Pharmacol. 365 111. PMID:9988129. Dettbarn and Palade (1999) Effects of three sarcoplasmic/endoplasmic Ca++ pump inhibitors on release channels and intracellular stores. J.Pharmacol.Exp.Ther. 285 739. PMID:9580621. Fusi et al (1999) 2,5-Di-t-butyl-1,4 benzohydroquinone induces endothelium-dependent relaxation of rat thoracic aorta. Eur.J.Pharmacol. 366 181. PMID:10082199."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=2206	SQ1070			Jun-1999
1237	LY 367385	[198419-91-9]	N[C@H](C(O)=O)C1=C(C)C=C(C(O)=O)C=C1	Selective mGlu1a antagonist	"A selective mGlu1a receptor antagonist, with an IC50 value of 8.8 _M for blockade of quisqualate-induced phosphoinositide hydrolysis vs. > 100 _M for mGlu5a, and negligible action on group II and III receptors. Also available as part of the Group I mGlu Receptor Tocriset."	"Clark et al (1997) (+)-2-Methyl-4-carboxyphenylglycine (LY 367385) selectively antagonises metabotropic glutamate mGluR1 receptors. Bioorg.Med.Chem.Lett. 7 2777. Salt and Turner (1998) Reduction of sensory and metabotropic glutamate receptor responses in the thalamus by the novel metabotropic glutamate receptor-1-selective antagonist S-2-methyl-4-carboxy-phenylglycine. Neuroscience 85 655. PMID:9639261. Bruno et al (1999) Neuroprotective activity of the potent and selective mGlu1a metabotropic glutamate receptor antagonist, (+)-2-methyl-4 carboxyphenylglycine (LY367385): comparison with LY357366, a broader spectrum antagonist with equal affinity for mGlu1a and mGlu5 receptors. Neuropharmacology 38 199. PMID:10218860. Chapman et al (1999) Anticonvulsant actions of LY 367385 ((+)-methyl-4-carboxyphenylglycine), and AIDA ((RS)-1-aminoindan-1,5-dicarboxylic acid). Eur.J.Pharmacol. 368 17. PMID:10096765."	Small Molecule	Sold with the permission of Eli Lilly and Company	http://www.tocris.com/dispprod.php?ItemId=2207	SQ1341			Oct-1999
1238	CCMQ	[132623-44-0]	OC(=O)CC1=C(N=C2C=CC=CC2=C1)C(O)=O	Used to characterize NR2B-containing NMDA receptors	For use in conjunction with [3H]-homoquinolinic acid to characterize NR2B-containing NMDA receptors; selectively inhibits [3H]-homoquinolinic acid binding to non-NMDA sensitive sites.	Brown et al (1998) [3H]-Homoquinolinate binds to a subpopulation of NMDA receptors and to a novel binding site. J.Neurochem. 71 1464. PMID:9751179.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=2208	SQ1341			Jun-1999
1240	NF 023	[104869-31-0]	[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[O-]S(=O)(=O)C1=CC2=C(C=CC(NC(=O)C3=CC=CC(NC(=O)NC4=CC(=CC=C4)C(=O)NC4=C5C(C=C(C=C5S([O-])(=O)=O)S([O-])(=O)=O)=C(C=C4)S([O-])(=O)=O)=C3)=C2C(=C1)S([O-])(=O)=O)S([O-])(=O)=O	"Selective, competitive P2X1 antagonist"	"A subtype-selective, competitive and reversible P2X1 receptor antagonist. Displays IC50 values of 0.21, 28.9, > 50 and > 100 _M for human P2X1, P2X3, P2X2, and P2X4-mediated responses respectively. Selective over adrenoceptors, histamine and P2Y receptors. Also selectively inhibits the _-subunit of Go/i (EC50 ~300 nM)."	Van Rhee et al (1994) Novel competitive antagonists for P2 purinoceptors. Eur.J.Pharmacol. 268 1. PMID:7925607. Freissmuth et al (1996) Suramin analogues as subtype-selective G protein inhibitors. Mol.Pharmacol. 49 602. PMID:8609887. Soto et al (1999) Antagonistic properties of the suramin analogue NF023 at heterologously expressed P2X receptors. Neuropharmacology 38 141. PMID:10193905. Sneddon et al (2000) The effect of P2 receptor antagonists and ATPase inhibition on sympathetic purinergic neurotransmission in the guinea-pig isolated vas deferens. Br.J.Pharmacol. 129 1089. PMID:10725256.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1379				Jun-2000
1241	CGS 19755	[110347-85-8]	O=P(C[C@@H]1C[C@H]([C@](O)=O)NCC1)(O)O	"Potent, competitive NMDA antagonist"	"Potent, competitive NMDA receptor antagonist. Anticonvulsant and neuroprotective. Also available as part of the Mixed NMDA Receptor Tocriset."	"Lehmann et al (1988) CGS 19755, a selective and competitive N-methyl-D-aspartate-type excitatory amino acid receptor antagonist. J.Pharmacol.Exp.Ther. 246 65. PMID:2899170. Bennett et al (1989) Behavioral pharmacological profile of CGS 19755, a competitive antagonist at N-methyl-D-aspartate receptors. J.Pharmacol.Exp.Ther. 250 454. PMID:2547931. Perez-Pinzon et al (1995) Correlation of CGS 19755 neuroprotection against in vivo excitotoxicity and focal cerebral ischemia. J.Cereb.Blood Flow Metab. 15 865. PMID:7673380."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=2229	SQ1070			Feb-2001
1242	SB 216641 hydrochloride	[193611-67-5]	Cl.COC1=C(OCCN(C)C)C=C(NC(=O)C2=CC=C(C=C2)C2=CC=C(C=C2C)C2=NOC(C)=N2)C=C1	Selective h5-HT1B antagonist	A selective h5-HT1B antagonist with approximately 25-fold selectivity over h5-HT1D and little or no affinity for a range of other receptor types.	Hagan et al (1997) Stimulation of 5-HT1B receptors causes hypothermia in the guinea pig. Eur.J.Pharmacol. 331 169. PMID:9274976. Price et al (1997) SB-216641 and BRL-15572 - compounds to pharmacologically discriminate h5-HT1B and h5-HT1D receptors. Naunyn Schmiedebergs Arch.Pharmacol. 356 312. PMID:930567. Schlicker et al (1997) Effects of selective h5-HT1B (SB-216641) and 5-HT1D (BRL-15572) receptor ligands on guinea pig and human 5-HT auto- and heteroreceptors. Naunyn Schmiedebergs Arch.Pharmacol. 356 321. PMID:9303568.	Small Molecule	Sold with the permission of GlaxoSmithKline	http://www.tocris.com/dispprod.php?ItemId=2230	SQ1341			Jul-1999
1243	(+)-PD 128907 hydrochloride	[300576-59-4]	CCCN3[C@@H]2COC1=CC=C(O)C=C1[C@H]2OCC3.Cl	D3 agonist (D3  D2 > D4)	Potent D3 dopamine receptor agonist (Ki = 2.3 nM). Displays 18 - 200-fold selectivity over other dopamine receptor subtypes.	"Pugsley et al (1995) Neurochemical and functional characterization of the preferentially selective dopamine D3 agonist PD 128907. J.Pharmacol.Exp.Ther. 275 1355. PMID:8531103. Bristow et al (1996) The behavioural and neurochemical profile of the putative dopamine D3 receptor agonist, (+)-PD 128907, in the rat. Neuropharmacology 35 285. PMID:8783203. Witkin et al (1998) Atypical antipsychotic-like effects of the dopamine D3 receptor agonist (+)-PD 128907. Eur.J.Pharmacol. 347 R1. PMID:9741997."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=2231	SQ1533			Jul-1999
1244	KB-R7943 mesylate	[182004-65-5]	CS(O)(=O)=O.NC(=N)SCCC1=CC=C(OCC2=CC=C(C=C2)[N+]([O-])=O)C=C1	Na+/Ca2+ exchange inhibitor (reverse mode)	"Potent, selective inhibitor of the reverse mode of the Na+/Ca2+ exchanger (IC50 = 0.7 _M). Also inhibits the mitochondrial Ca2+ uniporter (MCU; IC50 = 5.5 _M). Does not affect Na+-dependent transport systems or ionotropic glutamate receptors."	"Hoyt et al (1998) Reverse Na+/Ca2+ exchange contributes to glutamate-induced intracellular Ca2+ concentration increases in cultured rat forebrain neurons. Mol.Pharmacol. 53 742. PMID:9547366. Schrder et al (1999) The novel Na+/Ca2+ exchange inhibitor KB-R7943 protects CA1 neurons in rat hippocampal slices against hypoxia/hypoglycemic injury. Neuropharmacology 38 319. PMID:10218875. Watano et al (1999) Effect of +/Ca2+ exchange inhibitor, KB-R7943 on ouabain-induced arrhythmias in guinea-pigs. Br.J.Pharmacol. 127 1846. PMID:10482915. Santo-Domingo et al (2007) The plasma membrane +/Ca2+ exchange inhibitor KB-R7943 is also a potent inhibitor of the mitochondrial Ca2+ uniporter. Br.J.Pharmacol. 151 647. PMID:17471180."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1380				Oct-1999
1245	CGP 35348	[123690-79-9]	NCCCP(C(OCC)OCC)(O)=O	"Brain penetrant, selective GABAB antagonist"	"Selective, brain penetrant GABAB receptor antagonist (IC50 = 34 _M as measured in rat cortical membranes). Has higher affinity for postsynaptic versus presynaptic receptors."	Olpe et al (1990) CGP 35348: a centrally active blocker of GABAB receptors. Eur.J.Pharmacol. 187 27. PMID:2176979. Hao et al (1994) Intrathecal _-aminobutyric acidB (GABAB) receptor antagonist CGP 35348 induces hypersensitisation to mechanical stimuli in the rat. Neurosci.Lett. 182 299. PMID:7715832. Sutor and Luhmann (1998) Involvement of GABAB receptors in convulsant-induced epileptiform activity in rat neocortex in vitro. Eur.J.Neurosci. 10 3417. PMID:9824455. Staubli et al (1999) GABAB receptor antagonism: facilitatory effects on memory parallel those on LTP induced by TBS but not HFS. J.Neurosci. 19 4609. PMID:10341258.	Small Molecule	Sold with the permission of Novartis Pharma AG	http://www.tocris.com/dispprod.php?ItemId=2259				Sep-1999
1246	CGP 52432	[139667-74-6]	ClC1=CC=C(CNCCCP(C(OCC)OCC)(O)=O)C=C1Cl	"Potent, selective GABAB antagonist"	"Potent, selective GABAB receptor antagonist (IC50 = 85 nM)."	"Lanza et al (1993) CGP 52432: a novel potent and selective GABAB autoreceptor antagonist in rat cerebral cortex. Eur.J.Pharmacol. 237 191. PMID:8103461. Froestl et al (1996) Potent, orally active GABAB receptor antagonists. Pharmacol.Rev.Comm. 8 127. Bonanno et al (1998) GABAB receptors as potential targets for drugs able to prevent excessive excitatory amino acid transmission in the spinal cord. Eur.J.Pharmacol. 362 143. PMID:9874164. Libri et al (1998) Blockade of GABAB receptors facilitates muscarinic agonist-induced epileptiform activity in immature rat piriform cortex in vitro. Naunyn Schmiedebergs Arch.Pharmacol. 358 168. PMID:9750001."	Small Molecule	Sold with the permission of Novartis Pharma AG	http://www.tocris.com/dispprod.php?ItemId=2260	SQ1341			Sep-1999
1247	CGP 46381	[123691-14-5]	NCCCP(CC1CCCCC1)(O)=O	"Brain penetrant, selective GABAB antagonist"	"Brain penetrant, selective GABAB receptor antagonist (IC50 = 4.9 _M)."	"Lingenhoehl and Olpe (1993) Blockade of the late inhibitory postsynaptic potential in vivo by the GABAB antagonist CGP 46381. Pharmacol.Comm. 3 49. Froestl et al (1996) Potent, orally active GABAB receptor antagonists. Pharmacol.Rev.Comm. 8 127. Curtis and Lacey (1998) Prolonged GABAB receptor-mediated synaptic inhibition in the cat spinal cord: an in vivo study. Exp.Brain Res. 121 319. PMID:9746138. Staubli et al (1999) GABAB receptor antagonism: facilitatory effects on memory parallel those on LTP induced by TBS but not HFS. J.Neurosci. 19 4609. PMID:10341258."	Small Molecule	Sold with the permission of Novartis Pharma AG	http://www.tocris.com/dispprod.php?ItemId=2261	SQ1341			Sep-1999
1248	CGP 55845 hydrochloride	[149184-22-5]	O[C@H](CP(CC2=CC=CC=C2)(O)=O)CN[C@@H](C)C1=CC=C(Cl)C(Cl)=C1	"Potent, selective GABAB antagonist"	"Potent, selective GABAB receptor antagonist (IC50 = 5 nM) that prevents agonist binding (pKi = 8.35) and inhibits GABA and glutamate release (pEC50 values are 8.08 and 7.85 respectively). Inhibits GABAB responses to baclofen (IC50 = 130 nM in an isoproterenol assay) and potentiates the hypoglycemic response to glucose in vitro."	"Waldmeier et al (1994) GABA and glutamate release affected by GABAB receptor antagonists with similar potency: no evidence for pharmacologically different presynaptic receptors. Br.J.Pharmacol. 113 1515. PMID:7889310. Cunninghan and Enna (1996) Evidence for pharmacologically distinct GABAB receptors associated with cAMP production in rat brain. Brain Res. 720 220. PMID:8782915. Froestl et al (1996) Potent, orally active GABAB receptor antagonists. Pharmacol.Rev.Comm. 8 127. Deisz (1999) The GABAB antagonist CGP 55845A reduces presynaptic GABA1 actions in neurons of the rat in vitro. Neuroscience 93 1241. PMID:10501448. Zhang et al (2007) Neurotransmitter mechanisms mediating low-glucose signalling in cocultures and fresh tissue slices of rat carotid body. J.Physiol. 578 735. PMID:17124268. Salah and Perkins (2008) Effects of subtype-selective group I mGluR antagonists on synchronous activity induced by 4-aminopyridine/CGP 55845 in adult guinea pig hippocampal slices. Neuropharmacology 55 47. PMID:18538357."	Small Molecule	Sold with the permission of Novartis Pharma AG	http://www.tocris.com/dispprod.php?ItemId=2262	SQ1341			Sep-1999
1249	CY 208-243	[100999-26-6]	[H][C@]4([C@@]([H])3C5=C(C=CC=C5)CN4C)CC1=CNC2=C1C3=CC=C2	Selective D1-like agonist	"Centrally active dopamine D1 receptor agonist, selective over D2 receptor sites. Stimulates adenylate cyclase in rat striatal homogenates with an EC50 of 125 nM. Unlike SKF 38393 (Cat. No. 0922), it exerts antiParkinsonian activity in animal models."	"Markstein et al (1988) Pharmacologic properties of CY 208-243, a novel D1 agonist. Progress in Catecholamine Research. Part B. Centra 59-64. Temlett et al (1989) Antiparkinsonian activity of CY 208-243, a partial D-1 dopamine receptor agonist, in MPTP-treated marmosets and patients with Parkinson's disease. Mov.Disord. 4 261. PMID:2571082. Andersen and Jansen (1990) Dopamine receptor agonists: selectivity and dopamine D1 receptor efficacy. Eur.J.Pharmacol. 188 335. PMID:1973652."	Small Molecule	Sold with the permission of Novartis Pharma AG	http://www.tocris.com/dispprod.php?ItemId=1381	SQ1341			Sep-1999
1250	SDZ 220-581	[174575-17-8]	OC([C@@H](N)CC1=CC(C2=CC=CC=C2Cl)=CC(CP(O)(O)=O)=C1)=O	Competitive NMDA antagonist	Competitive NMDA receptor antagonist (pKi = 7.7). Centrally active following oral administration (ED50 < 3.2 mg/kg for protection against MES-induced seizures).	"Urwyler et al (1996) Biphenyl-derivatives of 2-amino-7-phosphono-heptanoic acid, a novel class of potent competitive N-methyl-D-aspartate receptor antagonists - I. Pharmacological characterization in vitro. Neuropharmacology 35 643. PMID:8887974. Urwyler et al (1996) Biphenyl-derivatives of 2-amino-7-phosphono-heptanoic acid, a novel class of potent competitive N-methyl-D-aspartate receptor antagonists - II. Pharmacological characterization in vivo. Neuropharmacology 35 655. PMID:8887975. Bakshi et al (1999) Disruption of prepulse inhibition and increases in locomotor activity by competitive N-methyl-D-aspartate receptor antagonists in rats. J.Pharmacol.Exp.Ther. 288 643. PMID:9918570."	Small Molecule	Sold with the permission of Novartis Pharma AG	http://www.tocris.com/dispprod.php?ItemId=2288	SQ1341			Sep-1999
1251	SDZ 220-040	[174575-40-7]	OC([C@@H](N)CC1=CC(C2=CC=C(Cl)C=C2Cl)=CC(CP(O)(O)=O)=C1O)=O	"Potent, competitive NMDA antagonist"	Potent competitive antagonist at the NMDA receptor (pKi = 8.5). Selective over a range of other receptor sites.	"Urwyler et al (1996) Biphenyl-derivatives of 2-amino-7-phosphono-heptanoic acid, a novel class of potent competitive N-methyl-D-aspartate receptor antagonists - I. Pharmacological characterization in vitro. Neuropharmacology 35 643. PMID:8887974. Urwyler et al (1996) Biphenyl-derivatives of 2-amino-7-phosphono-heptanoic acid, a novel class of potent competitive N-methyl-D-aspartate receptor antagonists - II. Pharmacological characterization in vivo. Neuropharmacology 35 655. PMID:8887975."	Small Molecule	Sold with the permission of Novartis Pharma AG	http://www.tocris.com/dispprod.php?ItemId=2289				Oct-1999
1253	(S)-WAY 100135 dihydrochloride	[149007-54-5]	O=C(NC(C)(C)C)[C@@]([C@]3=CC=CC=C3)([H])CN(CC2)CCN2C1=C(OC)C=CC=C1.Cl.Cl	"Potent, selective 5-HT1A antagonist"	"Potent, selective 5-HT1A receptor antagonist (IC50 = 15 nM). Selective over 5-HT1B, 1C, 2,_1, _2 and D2 receptors (IC50 > 1000 nM). Centrally active on systemic administration."	"Cliffe et al (1993) (S)-N-tert-Butyl-3(4-(2-methoxyphenyl)-piperazin-1-yl)-2-phenylpropanamide [(S)-WAY-100135]: a selective antagonist at presynaptic and postsynaptic 5-HT1A receptors. J.Med.Chem. 36 1509. PMID:8496920. Fletcher et al (1993) WAY100135: a novel, selective antagonist at presynaptic and postsynaptic 5-HT1A receptors. Eur.J.Pharmacol. 237 283. PMID:8365456. Fletcher et al (1993) Silent 5-HT1A receptor antagonists: utility as research tools and therapeutic agents. Trends Pharmacol.Sci. 14 41. PMID:8122313. Rodgers and Cole (1994) Anxiolytic-like effect of (S)-WAY 100135, a 5-HT1A receptor antagonist, in the murine elevated plus-maze test. Eur.J.Pharmacol. 261 321. PMID:7813555."	Small Molecule	"Sold with the permission of Wyeth-Ayerst Research, US Patent 4,988,814"	http://www.tocris.com/dispprod.php?ItemId=2291	SQ1341			Jul-2000
1254	Y-27632 dihydrochloride	[129830-38-2]	N[C@H](C)[C@@]1([H])CC[C@H]([C@](NC2=CC=NC=C2)=O)CC1.Cl.Cl	Selective p160ROCK inhibitor	"Selective inhibitor of the Rho-associated protein kinase p160ROCK. Ki values are 0.14, 26, 25 and > 250 _M for p160ROCK, PKC, cAMP-dependent protein kinase and myosin light-chain kinase respectively. Also inhibits the protein kinase C-related protein kinase, PRK2 (IC50 = 600 nM). Smooth muscle relaxant and orally active in vivo. Increases survival rate of human embryonic stem (hES) cells undergoing cryopreservation."	Uehata et al (1997) Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase. Nature 389 990. PMID:9353125. Iizuk (1999) A major role for the Rho-associated coiled coil forming protein kinase in G-protein-mediated Ca2+ sensitization through inhibition of myosin phosphatase in rabbit trachea. Br.J.Pharmacol. 128 925. PMID:10556927. Narumiya et al (2000) Use and properties of ROCK-specific inhibitor Y-27632. Methods Enzymol. 325 273. PMID:11036610. Davies et al (2000) Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem.J. 351 95. PMID:10998351. Ichikawa et al (2011) Freeze-thawing single human embryonic stem cells induce e-cadherin and actin filament network disruption via g13 signaling. Cryo Letters. 32 516. PMID:22227712.	Small Molecule	Sold under license from Mitsubishi Tanabe Pharma Corporation.	http://www.tocris.com/dispprod.php?ItemId=1382	SQ1533			Jan-2001
1255	SDZ SER 082 fumarate	[1417343-80-6]	C(\C=C\C(O[H])=O)(O[H])=O.[H][C@@]23[C@@](CCN(C3)C)([H])CN(CC4)C1=C4C=CC=C12	Selective 5-HT2B/2C antagonist	Selective 5-HT2B/2C receptor antagonist with low affinity for 5-HT1A receptors. Inhibits [3H]-mesulergine binding to 5-HT2C receptors with a pKD of 7.8. Inhibits 5-HT2B mediated responses in the rat fundus (pKB = 7.34).	"Nozulak et al (1995) (+)-cis 4,5,7a,8,9,10,11,11a-Octahydro-7H-10-methylindolo[1,7-bc][2,6]-naphthyridine: a 5-HT2C/2B receptor antagonist with low 5-HT2A receptor affinity. J.Med.Chem. 38 28. PMID:7837236. Mora et al (1997) Role of 5-HT2A and 5-HT2C receptor subtypes in the two types of fear generated by the elevated T-maze. Pharmacol.Biochem.Behav. 58 1051. PMID:9408213. Kalkman et al (1998) Cataleptogenic effect of subtype selective 5-HT receptor antagonists in the rat. Eur.J.Pharmacol. 343 201. PMID:9570468."	Small Molecule	Sold with the permission of Novartis Pharma AG	http://www.tocris.com/dispprod.php?ItemId=2322				Nov-1999
1256	Vinblastine sulfate	[143-67-9]	OS(O)(=O)=O.[H][C@@]23N(C)C1=CC(OC)=[C@]([C@@]7([C@](OC)=O)C[C@H]6C[C@@](O)(CC)CN(CCC8=C7NC9=C8C=CC=C9)C6)C=C1[C@@]52[C@](N(CC5)CC=C4)([H])[C@]4(CC)[C@@H](OC(C)=O)[C@]([C@](OC)=O)3O	Disrupts microtubules	Anticancer agent; microtubule disrupter. Induces apoptosis in cultured hepatocytes and human lymphoma cells. Shown to inhibit autophagosome maturation.	"Jordan et al (1985) Comparison of the effects of vinblastine, vincristine, vindesine, and vinepidine on microtubule dynamics and cell proliferation in vitro. Cancer Res. 45 2741. PMID:3986806. Tsukidate et al (1993) Microtubule antagonists activate programmed cell death (apoptosis) in cultured rat hepatocytes. Am.J.Pathol. 143 918. PMID:8362985. Rai and Wolf (1998) Localization of critical histidyl residues required for vinblastine-induced tubulin polymerization and for microtubulin assembly. J.Biol.Chem. 273 31131. PMID:9813016. Veldhoen et al (2012) The chemotherapeutic agent paclitaxel inhibits autophagy through two distinct mechanisms that regulate apoptosis. Oncogene 32 736. PMID:22430212."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=2323	SQ1533			Oct-1999
1257	Vincristine sulfate	[2068-78-2]	OS(O)(=O)=O.[H][C@@]23N(C=O)C1=CC(OC)=[C@]([C@@]7([C@](OC)=O)C[C@H]6C[C@@](O)(CC)CN(CCC8=C7NC9=C8C=CC=C9)C6)C=C1[C@@]52[C@](N(CC5)CC=C4)([H])[C@]4(CC)[C@@H](OC(C)=O)[C@]([C@](OC)=O)3O	Disrupts microtubules	Anticancer agent; microtubule disrupter. Induces apoptosis in human lymphoma cells.	"Jordan et al (1985) Comparison of the effects of vinblastine, vincristine, vindesine, and vinepidine on microtubule dynamics and cell proliferation in vitro. Cancer Res. 45 2741. PMID:3986806. Takano et al (1993) Apoptosis induced by microtubule disrupting drugs in cultured human lymphoma cells. Inhibitory effects of phorbol ester and zinc sulphate. Pathol.Res.Pract. 189 197. PMID:8321748. Wang et al (1999) The effect of antimicrotubule agents on signal transduction pathways of apoptosis. Cancer Chemother.Pharmacol. 44 355. PMID:10501907."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=2324	SQ1533			Nov-1999
1258	1-Deoxynojirimycin	[19130-96-2]	OC[C@H]1NC[C@H](O)[C@@H](O)[C@@H]1O	Glucosidase I and II inhibitor	Inhibitor of glucosidase I (Ki = 2.1 mM) and II (Ki = 7 mM).	Fuhrmann et al (1985) Inhibitors of oligosaccharide processing. Biochim.Biophys.Acta 825 95. PMID:3159432. Bause et al (1989) Purification and characterization of trimming glucosidase I from pig liver. Eur.J.Biochem. 183 661. PMID:2673780. Hentges and Bause (1997) Affinity purification and characterization of glucosidase II from pig liver. Biol.Chem. 378 1031. PMID:9348113.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=2080				Nov-1999
1259	1-Deoxymannojirimycin hydrochloride	[73465-43-7]	Cl[H].OC[C@H]1NC[C@@H](O)[C@@H](O)[C@@H]1O	_-Mannosidase I inhibitor	Selective inhibitor of _-mannosidase I.	Bischoff and Kornfeld (1984) The effect of 1-deoxymannojirimycin on rat liver _-mannosidases. Biochem.Biophys.Res.Commun. 125 324. PMID:6239623. Fuhrmann et al (1984) Novel mannosidase inhibitor blocking conversion of high mannose to complex oligosaccharides. Nature 307 755. PMID:6230538. Bischoff et al (1986) The use of 1-deoxymannojirimycin to evaluate the role of various _-mannosidases in oligosaccharide processing in intact cells. J.Biol.Chem. 261 4766. PMID:2937779.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=2081	SQ1070			Nov-1999
1260	Ivermectin	[70288-86-7]	O[C@H]1[C@H](C)O[C@](O[C@H]2[C@@H](O[C@](O[C@H](/C(C)=C/C[C@@]4([H])O[C@@]7(CC[C@H](C)[C@@]([H])([C@]([H])(C)C)O7)C[C@@H]6C4)[C@@H](C)/C=C/C=C3/[C@]5(O)[C@]([C@H](O)C(C)=CC5C(O6)=O)([H])OC3)([H])C[C@@H]2OC)C)([H])C[C@@H]1OC.O[C@H]8[C@H](C)O[C@](O[C@H]9[C@@H](O[C@](O[C@H](/C(C)=C/C[C@@]%11([H])O[C@@]%14(CC[C@H](C)[C@@]([H])([C@]([H])(C)CC)O%14)C[C@@H]%13C%11)[C@@H](C)/C=C/C=C%10/[C@]%12(O)[C@]([C@H](O)C(C)=CC%12C(O%13)=O)([H])OC%10)([H])C[C@@H]9OC)C)([H])C[C@@H]8OC	Allosteric modulator of _7 nicotinic receptors	Positive allosteric modulator of the _7 neuronal nicotinic acetylcholine receptor and the purinergic P2X4 receptor. Antihelmintic. Also modulates glutamate- and GABA-activated chloride channels. Potentiates glycine-gated currents at low concentrations (30 nM).	"Merck Index 12 5264. Krause et al (1998) Ivermectin: a positive allosteric effector of the _7 neuronal nicotinic acetylcholine receptor. Mol.Pharmacol. 53 283. PMID:9463487. Khakh et al (1999) Allosteric control of gating and kinetics at P2X4 receptor channels. J.Neurosci. 19 7289. PMID:10460235. Adelsberger et al (2000) Activation of rat recombinant _1_2_2S GABAA receptor by the insecticide ivermectin. Eur.J.Pharmacol. 394 163. PMID:10771281. Shan et al (2001) Ivermectin, an unconventional agonist of the glycine receptor chloride channel. J.Biol.Chem. 276 12556. PMID:11278873."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=2010	SQ1070			Nov-1999
1261	EHNA hydrochloride	[81408-49-3]	O[C@]([H])(C)[C@@](CCCCCC)([H])N(C=N2)C1=C2C(N)=NC=N1.Cl	Adenosine deaminase inhibitor	Selective inhibitor of cGMP-stimulated phosphodiesterase (PDE2) (IC50 = 0.8 - 4 mM). Also a potent inhibitor of adenosine deaminase. Suppresses spontaneous differentiation of human ESCs in feeder-free conditions. Also prevents directed neuronal differentiation.	Bessodes et al (1982) Effect of chirality in erythro-9-(2-hydroxy-3-nonyl) adenine (EHNA) on adenosine deaminase inhibition. Biochem.Pharmacol. 31 879. PMID:7082355. Podzuweit et al (1995) Isozyme selective inhibition of cGMP-stimulated cyclic nucleotide phosphodiesterases by erythro-9-(2-hydroxy-3-nonyl)adenine. Cell.Signal. 7 733. PMID:8519602. Michie et al (1996) Rapid regulation of PDE-2 and PDE-4 cyclic AMP phosphodiesterase activity following ligation of the T-cell antigen receptor on thymocytes: analysis using the selective inhibitors erythro-9-(2-hydroxy-3-nonyl)-adenine (EHNA) and rolipram. Cell.Signal. 8 97. PMID:8730511.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1408	SQ1341			Nov-1999
1262	SR 95531 hydrobromide	[104104-50-9]	Br.COC1=CC=C(C=C1)C1=NN(CCCC(O)=O)C(=N)C=C1	"Selective, competitive GABAA receptor antagonist"	"Selective, competitive GABAA receptor antagonist. Displaces [3H]-GABA from rat brain membranes with a Ki of 150 nM. Unlike bicuculline, selectively antagonizes GABA-induced Cl- currents with little action on pentobarbitone-induced currents. Also acts as a low affinity glycine receptor antagonist."	Heaulme et al (1986) Biochemical characterization of the interaction of three pyridazinyl-GABA derivatives with the GABAA receptor site. Brain Res. 384 224. PMID:3022866. Uchida et al (1996) The differential antagonism by bicuculline and SR95531 of pentobarbitone-induced currents in cultured hippocampal neurons. Eur.J.Pharmacol. 307 89. PMID:8831109. Beato et al (2007) The kinetics of inhibition of rat recombinant heterotrimeric _1_ glycine receptors by the low affinity antagonist SR-95531. J.Physiol. 580 171. PMID:17218350.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=2011	SQ1341			Apr-2000
1263	GR 144053 trihydrochloride	[1215333-48-4]	Cl.Cl.Cl.NC(=N)C1=CC=C(C=C1)N1CCN(CC1)C1CCN(CC(O)=O)CC1	Glycoprotein IIb/IIIa (integrin _IIb_3) receptor antagonist. Antithrombotic	A potent and selective platelet fibrinogen receptor glycoprotein IIb/IIIa (GpIIb/IIIa) antagonist (IC50 = 37 nM). Orally active and highly effective at inhibiting thrombus formation in vivo.	"Eldred et al (1994) Orally active non-peptide fibrinogen receptor (GpIIb/IIIa) antagonists: identification of 4-[4-[4-(aminoiminomethyl)phenyl]-1-piperazinyl]-1-piperidineacetic acid as a long-acting, broad spectrum antithrombotic agent. J.Med.Chem. 37 3882. PMID:7966149. Matsuno et al (1997) GR 144053, a fibrinogen receptor antagonist, enhances the suppression of neointima formation by losartan, an angiotensin II receptor antagonist, in the injured carotid artery of hamster. Br.J.Pharmacol. 122 1099. PMID:9480031. Matsuno et al (1999) Comparative antiplatelet effects of aspirin, vapiprost and GR 144053, a GPIIb/IIIa antagonist with special reference to the role of platelet microaggregates. Br.J.Pharmacol. 127 1129. PMID:10455258."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=2012	SQ1341			Jul-2002
1264	SB 202190	[152121-30-7]	OC1=CC=C(C=C1)C1=NC(=C(N1)C1=CC=NC=C1)C1=CC=C(F)C=C1	"Potent, selective inhibitor of p38 MAPK"	"A highly selective, potent and cell-permeable inhibitor of p38 MAP kinase. Binds within the ATP pocket of the active kinase (Kd = 38 nM, as measured in recombinant human p38), and selectively inhibits the p38_ and _ isoforms (IC50 = 50 and 100 nM at SAPK2a/p38 and SAPK2b/p38_2 respectively). Also available as part of the MAPK Inhibitor Tocriset."	Jiang et al (1996) Characterization of the structure and function of a new mitogen-activated protein kinase (p38_). J.Biol.Chem. 271 17920. PMID:8663524. Nemoto et al (1998) Induction of apoptosis by SB 202190 through inhibition of p38_ mitogen-activated protein kinase. J.Biol.Chem. 273 16415. PMID:9632706. Frantz et al (1998) The activation of p38 mitogen-activated protein kinase determines the efficiency of ATP competition for pyridinylimidazole inhibitor binding. Biochemistry 37 13846. PMID:9753474. Davies et al (2000) Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem.J. 351 95. PMID:10998351.	Small Molecule	Sold with the permission of GlaxoSmithKline	http://www.tocris.com/dispprod.php?ItemId=2013	SQ1533			Mar-2000
1265	D-CPP-ene	[117414-74-1]	O=P(/C=C/CN1C[C@H]([C@](O)=O)NCC1)(O)O	"Potent, competitive NMDA antagonist"	Potent and competitive NMDA antagonist (Ki = 40 nM). Centrally active following systemic administration.	"Aebischer et al (1989) Synthesis and NMDA antagonistic properties of the enantiomers of 4-(3-phosphonopropyl)piperazine-2-carboxylic acid (CPP) and of the unsaturated analogue (E)-4-(3-phosphono-2-enyl)piperazine-2-carboxylic acid (CPP-ene). Helv.Chim.Acta 72 1043. Lowe et al (1990) D-CPP-ene (SDZ EAA 494), a potent and competitive N-methyl-D-aspartate (NMDA) antagonist: effect on spontaneous activity and NMDA-induced depolarizations in the rat neocortical slice preparation, compared with other CPP derivatives and MK-801. Neurosci.Lett. 113 315. PMID:2166255. Potschka et al (1999) Effects of the NMDA receptor antagonist D-CPPene on extracellular levels of dopamine and dopamine and serotonin metabolites in striatum of kindled and non-kindled rats. Eur.J.Pharmacol. 374 175. PMID:10422758."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1443	SQ1070			Dec-2005
1267	Pifithrin-_ hydrobromide	[63208-82-2]	Br.CC1=CC=C(C=C1)C(=O)CN1C(=N)SC2=C1CCCC2	p53 inhibitor. Also aryl hydrocarbon receptor agonist	"Inhibitor of p53; reversibly blocks p53-dependent transcriptional activation and apoptosis. Protects against neuronal death in models of stroke and neurodegenerative disorders. Active in vivo; protects mice from the side-effects of cancer therapy associated with p53 induction. Supresses self-renewal of embryonic stem cells. Also aryl hydrocarbon receptor (AHR) agonist, causes upregulation of AHR target gene CYP1A1 (EC50 = 1.1 _M). Cyclic analog available (Cat. No. 3843)."	"Komarov et al (1999) A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy. Science 285 1733. PMID:10481009. Komarova and Gudkov (2000) Suppression of p53: a new approach to overcome side effects of antitumor therapy. Biochemistry 65 41. PMID:10702639. Culmsee et al (2001) A synthetic inhibitor of p53 protects neurons against death induced by ischemic and excitotoxic insults, and amyloid _-peptide. J.Neurochem. 77 220. PMID:11279278. Hoagland et al (2005) The p53 inhibitor pifithrin-_ is a potent agonist of the aryl hydrocarbon receptor. J.Pharmacol.Exp.Ther. 314 603. PMID:15843497. Abdelalim and Tooyama (2012) The p53 inhibitor, pifithrin-_, suppresses self-renewal of embryonic stem cells. Biochem.Biophys.Res.Comm. 420 605. PMID:22445757."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1445	SQ1341			Feb-2000
1268	U 73122	[112648-68-7]	[H][C@]23[C@@]([C@]([H])(CC[C@@H]4NCCCCCCN5C(C=CC5=O)=O)[C@]4(C)CC3)([H])CCC1=CC(OC)=CC=C12	Phospholipase C inhibitor	Phospholipase C inhibitor. Inhibits agonist-induced platelet aggregation with IC50 values of 1-5 _M. Potently inhibits human polymorphonuclear neutrophil adhesion on biological surfaces (IC50 < 50 nM) and exhibits antinociceptive activity in vivo. Negative control U 73343 (Cat. No. 4133) also available.	Bleasdale et al (1990) Selective inhibition of receptor-coupled phospholipase C-dependent processes in human platelets and polymorphonuclear neutrophils. J.Pharmacol.Exp.Ther. 255 756. PMID:2147038. Smith et al (1996) U-73122: a potent inhibitor of human polymorphonuclear neutrophil adhesion on biological surfaces and adhesion-related effector functions. J.Pharmacol.Exp.Ther. 278 320. PMID:8764366. Shi et al (2008) Phospholipase C_3 in mouse and human dorsal root ganglia and spinal cord is a possible target for treatment of neuropathic pain. Proc.Natl.Acad.Sci.U.S.A. 105 20004. PMID:19066214.	Small Molecule	Sold with the permission of Pharmacia	http://www.tocris.com/dispprod.php?ItemId=1428	SQ1533			Jan-2001
1269	PD 150606	[179528-45-1]	IC1=CC=C(/C=C(C(O)=O)\S)C=C1	Cell permeable calpain inhibitor	"Selective, cell-permeable non-peptide calpain inhibitor (Ki values for _ and m-calpains are 0.21 and 0.37 _M respectively). Targets the calcium binding sites of calpain. Demonstrates high specificity for calpains relative to other proteases, and is a non-competitive inhibitor with respect to the substrate."	Wang et al (1996) An alpha-mercaptoacrylic acid derivative is a selective nonpeptide cell-permeable calpain inhibitor and is neuroprotective. Proc.Natl.Acad.Sci.U.S.A. 93 6687. PMID:8692879. Waters et al (1997) Calpains mediate calcium chloride influx during the late phase of cell injury. J.Pharmacol.Exp.Ther. 283 1177. PMID:9399991. Squier et al (1999) Calpain and calpastatin regulate neutrophil apoptosis. J.Cell Physiol. 178 311. PMID:9989777.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1484				Jun-2011
1271	RJR 2429 dihydrochloride	[1021418-53-0]	C1(C2N3CCC(CC3)C2)=CC=CN=C1.Cl.Cl	Nicotinic receptor agonist	Potent nAChR agonist that displays selectivity for _4_2 (Ki = 1 nM) and _1___ subtypes (EC50 values are 297 and 55 nM respectively). Induces dopamine release from striatal neurons (EC50 = 2 nM) and inhibits ion flux in thalamic neurons (IC50 = 154 nM). Also putative _3_4 agonist that potentiates catecholamine release.	"Bencherif et al (1998) The heterocyclic substituted pyridine derivative ()-2-(3-pyridinyl)-1-azabicyclo[2.2.2]octane (RJR-2429): a selective ligand at nicotinic acetylcholine receptors. J.Pharmacol.Exp.Ther. 284 886. PMID:9495846. Yokotani et al (2002) Characterization of functional nicotinic acetylcholine receptors involved in catecholamine release from isolated rat adrenal gland. Eur.J.Pharmacol. 446 83. PMID:12098588. Bhatti et al (2008) Synthesis of 2-(pyridin-3-yl)-1-azabicyclo[3.2.2]nonane, 2-(pyridin-3-yl)-1-azabicyclo[2.2.2]octane, and 2-(pyridin-3-yl)-1-azabicyclo[3.2.1]octane, a class of potent nicotinic acetylcholine receptor-ligands. J.Org.Chem. 73 3497. PMID:18363376."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1485	SQ1341			Nov-2008
1274	GR 159897	[158848-32-9]	FC1=CC=C2C(C(CCN3CCC(C[S@@+]([O-])C4=CC=CC=C4)(OC)CC3)=CN2)=C1	"Non-peptide, potent NK2 antagonist"	"A potent, selective, non-peptide, orally active neurokinin NK2 receptor antagonist. Competes for binding of [3H]GR100679 to hNK2-transfected CHO cells with a pKi of 9.5. Inhibits NK2 receptor-mediated contraction of guinea pig trachea with a pA2 of 8.7. Anxiolytic in vivo."	"Cooper et al (1994) GR 159897 and related analogues as highly potent, orally active non-peptide neurokinin NK2 receptor antagonists. Bioorg.Med.Chem.Lett. 4 1951. Beresford et al (1995) GR 159897, a potent non-peptide antagonist at tachykinin NK2 receptors. Eur.J.Pharmacol. 272 241. PMID:7713168. Walsh et al (1995) The anxiolytic-like activity of GR 159897, a non-peptide NK2 receptor antagonist, in rodent and primate models of anxiety. Psychopharmacology 121 186. PMID:8545524."	Small Molecule	Sold with the permission of GlaxoSmithKline	http://www.tocris.com/dispprod.php?ItemId=1488	SQ1533			Dec-2002
1276	AG 1478 hydrochloride	[170449-18-0]	ClC1=CC(NC2=NC=NC3=C2C=C(OC)C(OC)=C3)=CC=C1.Cl	Highly potent EGFR-kinase inhibitor	Potent and selective inhibitor of epidermal growth factor receptor kinase (IC50 values 3 nM for EGFR and > 100 _M for ErbB2 and PDGFR). Inhibits proliferation of NCI-H2170 NSCLC cells in vitro (IC50 = 1 _M).	"Levitzki and Gazit (1995) Tyrosine kinase inhibition: an approach to drug development. Science 267 1782. PMID:7892601. Han et al (1996) Tyrphostin AG 1478 preferentially inhibits human glioma cells expressing truncated rather than wild-type epidermal growth factor receptors. Cancer Res. 56 3859. PMID:8752145. Eguchi et al (1998) Calcium-dependent epidermal growth factor receptor transactivation mediates the angiotensin II-induced mitogen-activated protein kinase activation in vascular smooth muscle cells. J.Biol.Chem. 273 8890. PMID:9535870. Puri and Salgia (2008) Synergism of EGFR and c-Met pathways, cross-talk and inhibition, in non-small cell lung cancer. J.Carcinog. 7 9. PMID:19240370."	Small Molecule	Sold with the permission of AstraZeneca UK Ltd.	http://www.tocris.com/dispprod.php?ItemId=2236	SQ1533			Oct-2000
1282	GNTI dihydrochloride	[351183-88-5]	OC3=CC=C2CC([C@@]5(O)[C@@]4(CC8)C2=C3O[C@H]4C(NC7=C6C=C(NC=N)C=C7)=C6C5)N8CC1CC1.Cl.Cl	"Potent, selective _ antagonist"	"Highly potent _ opioid receptor antagonist (Ki = 0.18 nM for human cloned _ receptors expressed in CHO cells). Displays 208- and 799-fold selectivity over _ and _ receptors respectively. Reduces feeding behavior in rats with a much higher potency (300-30,000-fold) and a shorter duration of action than nor-binaltorphimine (Cat.No. 0347)."	"Jones et al (1998) Mutational evidence for a common _ antagonist binding pocket in the wild type _ and mutant _[K303E] opioid receptors. J.Med.Chem. 41 4911. PMID:9836606. Jones and Portoghese (2000) 5'-Guanidinonaltrindole, a highly selective and potent _-opioid receptor antagonist. Eur.J.Pharmacol. 396 49. PMID:10822054. Jewett et al (2001) The kappa-opioid antagonist GNTI reduces U50,488-, DAMGO-, and deprivation-induced feeding, but not butorphanol- and neuropeptide Y-induced feeding in rats. Brain Res. 909 75. PMID:11478923."	Small Molecule	Not for sale in the USA.	http://www.tocris.com/dispprod.php?ItemId=1495				Apr-2001
1283	ARL 67156 trisodium salt	[1021868-83-6]	O[C@H]3[C@H](O)[C@@H](O[C@@H]3COP(OP(C(Br)(Br)P(O)(O[Na])=O)(O[Na])=O)(O[Na])=O)N1C=NC2=C1N=CN=C2N(CC)CC	Ecto-ATPase inhibitor	A selective ecto-ATPase inhibitor (pIC50 = 4.62 and 5.1 in human blood and rat vas deferens respectively).	"Crack et al (1995) Pharmacological and biochemical analysis of FPL 67156, a novel, selective inhibitor of ecto-ATPase. Br.J.Pharmacol. 114 475. PMID:7533620. Kennedy et al (1997) Release of soluble nucleotidases: a novel mechanism for neurotransmitter inactivation? TiPS 18 263. PMID:9277128. Westfall et al (1997) The ecto-ATPase inhibitor ARL 67156 enhances parasympathetic neurotransmission in the guinea pig urinary bladder. Eur.J.Pharmacol. 329 169. PMID:9226410. Levesque et al (2007) Specificity of the ecto-ATPase inhibitor ARL 67156 on human and mouse ecotnucleotidases. Br.J.Pharmacol. 152 141. PMID:17603550."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1508	SQ1341			Sep-2001
1284	Olomoucine	[101622-51-9]	CN1C=NC2=C(NCC3=CC=CC=C3)N=C(NCCO)N=C12	Cyclin-dependent kinase inhibitor	"Cyclin-dependent kinase inhibitor that competes for the ATP binding site of the kinase. Selectively inhibits cdc2/cyclin B (IC50 = 7 _M), cdk2/cyclin A (IC50 = 7 _M), cdk2/cyclin E (IC50 = 7 _M), cdk/p35 kinase (IC50 = 3 _M)  and ERK1/MAP kinase (IC50 = 25 _M). Arrests human fibroblasts in the G1 phase."	"Vesely et al (1994) Inhibition of cyclin-dependent kinases by purine analogues. Eur.J.Biochem. 224 771. PMID:7925396. Abraham et al (1995) Cellular effects of olomoucine, an inhibitor of cyclin-dependent kinases. Biol.Cell 83 105. PMID:7549905. Alessi et al (1998) The cyclin-dependent kinase inhibitors olomoucine and roscovitine arrest human fibroblasts in G1 phase by specific inhibition of CDK2 kinase activity. Exp.Cell.Res. 245 8. PMID:9828096."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1569	SQ1070			Apr-2000
1285	Staurosporine	[62996-74-1]	O=C(NC6)C1=C6C4=C3C2=C1C8=C(C=CC=C8)N2[C@](C[C@@H](NC)[C@H]7OC)([H])O[C@]7(C)N3C5=CC=CC=C45	Non-selective protein kinase inhibitor	"Broad spectrum protein kinase inhibitor. Enzymes inhibited include protein kinase C (IC50 = 3 nM), protein kinase A (IC50 = 7 nM), p60v-src tyrosine protein kinase (IC50 = 6 nM) and CaM kinase II (IC50 = 20 nM)."	"Tamaoki et al (1986) Staurosporine, a potent inhibitor of phospholipid/Ca2+ dependent protein kinase. Biochem.Biophys.Res.Commun. 135 397. PMID:3457562. Ruegg and Burgess (1989) Staurosporine, K-252 and UCN-01: potent but nonspecific inhibitors of protein kinases. TiPS 10 218. PMID:2672462. Yanagihara et al (1991) Staurosporine: an effective inhibitor for Ca2+/calmodulin-dependent protein kinase II. J.Neurochem. 56 294. PMID:1846174."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1570	SQ1070			May-2000
1286	LY 231617	[141545-89-3]	CC(C)(C)C1=C(O)C(C(C)(C)C)=CC(CNCC)=C1.Cl	Antioxidant; neuroprotective in vitro and in vivo	Antioxidant; protects against ischemia-induced neuronal damage in rat models of global and focal cerebral ischemia. Neuroprotective in vitro and in vivo.	Clemens et al (1993) The antioxidant LY 231617 reduces global ischemic neuronal injury in rats. Stroke 24 716. PMID:8488528. O'Neill et al (1997) Neuroprotective effects of the antioxidant LY 231617 and NO synthase inhibitors in global ischaemia. Brain Res. 760 170. PMID:9237532. Fuson et al (1999) Characterization of LY 231617 protection against hydrogen peroxide toxicity. J.Neurochem. 72 1154. PMID:10037488.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1571	SQ1341			May-2014
1290	Anisomycin	[22862-76-6]	O[C@H]1CN[C@H](CC2=CC=C(OC)C=C2)[C@@H]1OC(C)=O	Activates JNK/SAPK/p38 MAP kinase	"Protein synthesis inhibitor (blocks translation). Potent activator of stress-activated protein kinases (JNK/SAPK) and p38 MAP kinase. Acts as a potent signaling agonist to selectively elicit homologous desensitization of immediate early gene induction (c-fos, fosB, c-jun, junB and junD)."	Cano et al (1994) Anisomycin-activated protein kinases p45 and p55 but not mitogen-activated protein kinases ERK-1 and -2 are implicated in the induction of c-fos and c-jun. Mol.Cell.Biol. 14 7352. PMID:7935449. Kyriakis et al (1994) The stress-activated protein kinase subfamily of c-Jun kinases. Nature 369 156. PMID:8177321. Sanchez et al (1994) Role of SAPK/ERK kinase-1 in the stress-activated pathway regulating transcription factor c-Jun. Nature 372 794. PMID:7997269. Hazzalin et al (1998) Anisomycin selectively desensitizes signalling components involved in stress kinase activation and fos and jun induction. Mol.Cell.Biol. 18 1844. PMID:9528756. Croons et al (2009) The protein synthesis inhibitor anisomycin induces macrophage apoptosis in rabbit atherosclerotic plaques through p38 mitogen-activated protein kinase. J.Pharmacol.Exp.Ther. 329 856. PMID:19286921.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1607	SQ1070			Apr-2000
1292	Rapamycin	[53123-88-9]	O=C([C@H](C)\C=C([C@@H](O)[C@@H](OC)C([C@@H]4C)=O)/C)C[C@]([C@H](C)C[C@H]2C[C@@H](OC)[C@H](O)CC2)([H])OC([C@@]1([H])N(C(C([C@@]3(O)[C@H](C)CC[C@](C[C@@H](/C(C)=C/C=C/C=C/[C@H](C4)C)OC)([H])O3)=O)=O)CCCC1)=O	mTOR inhibitor; immunosuppressant	Antifungal and immunosuppressant. Specific inhibitor of mTOR (mammalian target of Rapamycin). Complexes with FKBP-12 and binds mTOR inhibiting its activity. Inhibits interleukin-2-induced phosphorylation and activation of p70 S6 kinase. Induces autophagy in yeast and mammalian cell lines.	"Kuo et al (1992) Rapamycin selectively inhibits interleukin-2 activation of p70 S6 kinase. Nature 358 70. PMID:1614535. Huang et al (2003) Rapamycins: mechanism of action and cellular resistance. Cancer Biol.Ther. 2 221. PMID:12878853. Kobayashi et al (2007) Rapamycin, a specific inhibitor of the mammalian target of rapamycin, suppresses lymphangiogenesis and lymphatic metastasis. Cancer Sci. 98 726. PMID:17425689. Fleming et al (2011) Chemical modulators of autophagy as biological probes and potential therapeutics. 7 9. PMID:21164513."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=2234	SQ1533			May-2000
1293	_-Lapachone	[4707-32-8]	O=C(C(C3=C2OC(C)(C)CC3)=O)C1=C2C=CC=C1	DNA topoisomerase I inhibitor	"DNA topoisomerase I inhibitor. Exhibits a different inhibitory mechanism to camptothecin (Cat. No. 1100). Induces apoptosis in a variety of cell lines, including prostate cancer and promyelocytic leukemia cells; blocks the cell cycle in G0/G1. Also has effects on DNA topoisomerase II, NF-_B, AP-1, and JNK."	"Li et al (1993) Beta-Lapachone, a novel topoisomerase I inhibitor with a mode of action different from camptothecin. J.Biol.Chem. 268 22463. PMID:8226754. Wuerzberger et al (1998) Induction of apoptosis in MCF-7:WS8 breast cancer cells by _-Lapachone. Cancer Res. 58 1876. PMID:9581828. Manna et al (1999) Suppression of tumor necrosis factor-activated nuclear transcription factor-_B, activator protein-1, c-Jun N-terminal kinase, and apoptosis by _ lapachone. Biochem.Pharmacol. 57 763. PMID:10075082. Shiah et al (1999) Activation of c-Jun NH2-terminal kinase and subsequent CPP32/Yama during topoisomerase inhibitor _-lapachone-induced apoptosis through an oxidation-dependent pathway Cancer Res. 59 391. PMID:9927052."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1182	SQ1533			May-2012
1295	Loreclezole hydrochloride	[117857-45-1]	Cl[H].Cl\C(=C/N1C=NC=N1)C1=C(Cl)C=C(Cl)C=C1	Subtype-selective GABAA receptor modulator	"Subtype-selective GABAA receptor modulator. Acts as a positive allosteric modulator of _2 or _3-subunit containing receptors. Also acts as a negative modulator at a novel regulatory site, enhancing GABAA receptor sensitization. Inhibits homomeric _1 GABAC receptors."	Donnelly and Macdonald (1996) Loreclezole enhances apparent desensitisation of recombinant GABAA receptor currents. Neuropharmacology 35 1233. PMID:9014138. Fisher et al (2000) Loreclezole inhibition of recombinant _1_1_2L GABAA receptor single channel currents. Neuropharmacology 39 235. PMID:10670419. Thomet et al (2000) Loreclezole as a simple functional marker for homomeric _ type GABAC receptors. Eur.J.Pharmacol. 408 R1. PMID:11080529. Smith et al (2004) Compounds exhibiting selective efficacy for different _ subunits of human recombinant _-aminobutyric acidA receptors. J.Pharmacol.Exp.Ther. 311 601. PMID:15210837.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=2253	SQ1533			Feb-2002
1296	CI 966 hydrochloride	[110283-66-4]	Cl.OC(=O)C1=CCCN(CCOC(C2=CC=C(C=C2)C(F)(F)F)C2=CC=C(C=C2)C(F)(F)F)C1	Selective inhibitor of GAT-1	Selective inhibitor of the GABA transporter GAT-1 (IC50 values are 0.26 and 1.2 _M at cloned human and rat GAT-1 respectively). Displays over 200-fold selectivity over GAT-2 and GAT-3. Centrally active upon systemic administration in vivo. Anticonvulsive and neuroprotective.	"Ebert et al (1990) Systemic CI-966, a new gamma-aminobutyric acid uptake blocker, enhances gamma-aminobutyric acid action in CA1 pyramidal layer in situ. Can.J.Physiol.Pharmacol. 68 1194. PMID:2276082. Radulovic et al (1993) Pharmacokinetics, mass balance, and induction potential of novel GABA uptake inhibitor, CI-966 HCl, in laboratory animals. Pharm.Res. 10 1442. PMID:8272405. Borden et al (1994) Tiagabine, SK&F 89976-A, CI-966, and NNC-711 are selective for the cloned GABA transporter GAT-1. Eur.J.Pharmacol. 269 219. PMID:7851497."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=2254	SQ1341			Dec-2000
1300	LFM-A13	[62004-35-7]	C\C(O)=C(/C#N)C(=O)NC1=C(Br)C=CC(Br)=C1	"Potent, selective BTK inhibitor"	"Potent and selective inhibitor of Bruton's tyrosine kinase (BTK). Inhibits recombinant BTK with an IC50 value of 2.5 _M and has no activity on other protein kinases ( including JAK1, JAK3, HCK, EGFR kinase and insulin receptor kinase) at concentrations of up to 278 _M."	"Mahajan et al (1999) Rational design and synthesis of a novel anti-leukemic agent targeting Bruton's tyrosine kinase (BTK), LFM-A13 [_-cyano-_-hydroxy-_-methyl-N-(2,5-dibromophenyl)propenamide]. J.Biol.Chem. 274 9587. PMID:10092645. Vassilev et al (1999) Bruton's tyrosine kinase as an inhibitor of the Fas/CD95 death-inducing signaling complex. J.Biol.Chem. 274 1646. PMID:9880544. Crosby and Pool (2002) Interaction of Bruton's tyrosine kinase and protein kinase C_ in platelets. J.Biol.Chem. 277 9958. PMID:11788586."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=2296	SQ1533			Apr-2001
1302	"(S)-3,4-DCPG"	[201730-11-2]	N[C@]([H])(C(O)=O)C1=CC(C(O)=O)=C(C(O)=O)C=C1	"Potent, selective mGlu8a agonist"	"Potent, selective mGlu8a agonist (EC50 = 31 nM). Displays > 100-fold selectivity over mGlu1-7 and displays little or no activity at NMDA and kainate receptors. Increases c-Fos expression in stress-related brain areas following systemic administration in mice in vivo. Also potent anticonvulsant in mice in vivo. Caged (S)-3,4-DCPG (Cat. No. 3330), (RS)-3,4-DCPG (Cat. No. 1394) and (R)-3,4-DCPG (Cat. No. 1395) also available."	"Thomas et al (1997) Dicarboxyphenylglycines antagonize AMPA- but not kainate-induced depolarizations in neonatal rat motoneurones. Eur.J.Pharmacol. 338 111. PMID:9455991. Thomas et al (2001) (S)-3,4-DCPG, a potent and selective mGlu8a receptor agonist activates metabotropic glutamate receptors on primary afferent terminals in the neonatal rat spinal cord. Neuropharmacology 40 311. PMID:11166323. Moldrich et al (2001) Anticonvulsant activity of 3,4-dicarboxyphenylglycines in DBA/2 mice. Neuropharmacology 40 732. PMID:11311902. Linden et al (2003) Systemic administration of the potent mGlu8 receptor agonist (S)-3,4-DCPG induces c-Fos in stress-related brain regions in wild-type, but not mGlu8 receptor knockout mice. Neuropharmacology 45 473. PMID:12907308."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=2294	SQ1341			Oct-2001
1304	BW-B 70C	[134470-38-5]	CC(\C=C\C1=CC(OC2=CC=C(F)C=C2)=CC=C1)N(O)C(N)=O	5-Lipoxygenase inhibitor	"Potent, selective inhibitor of 5-lipoxygenase. Long half-life and high oral bioavailability in vivo."	"Salmon et al (1990) Inhibition of 5-lipoxygenase: development of hydroxamic acids and hydroxyureas as potential therapeutic agents. Adv.Prost.Throm.Leuk.Res. 21 109. PMID:1847758. Payne et al (1991) Hydroxamic acids and hydroxyureas as novel, selective 5-lipoxygenase inhibitors for possible use in asthma. Agents Actions Suppl. 34 189. PMID:1793063. Yeadon et al (1993) Effect of BW B70C, a novel inhibitor of arachidonic acid 5-lipoxygenase, on allergen-induced bronchoconstriction and late-phase lung eosinophil accumulation in sensitised guinea-pigs. Agents Actions 38 8. PMID:8480540."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1946				Jan-2001
1305	Monastrol	[254753-54-3]	CCOC(=O)C1=C(C)NC(=S)NC1C1=CC(O)=CC=C1	Selective inhibitor of mitotic kinesin Eg5	"Potent, cell-permeable, small molecule mitosis inhibitor that does not interact with tubulin. Arrests cells in mitosis and specifically inhibits the motility of the mitotic kinesin Eg5, a motor protein required for mitotic spindle formation and maintenance (IC50 = 14 _M)."	"Mayer et al (1999) Small molecule inhibitor of mitotic spindle bipolarity identified in a phenotype-based screen. Science 286 971. PMID:10542155. Kapoor et al (2000) Probing spindle assembly mechanisms with monastrol, a small molecule inhibitor of the mitotic kinesin, Eg5. J.Cell Biol. 150 975. PMID:10973989."	Small Molecule	Sold with the permission of Harvard University	http://www.tocris.com/dispprod.php?ItemId=1911	SQ1533			Apr-2000
1307	Ciglitazone	[74772-77-3]	CC1(COC2=CC=C(CC3SC(=O)NC3=O)C=C2)CCCCC1	Selective PPAR_ agonist	"Selective agonist at PPAR_ (peroxisome proliferator-activated receptor _). Activates PPAR_ with an EC50 value of 3 _M in vitro, and is at least 33-fold selective over PPAR_ and _. Antihyperglycemic in vivo."	Willson et al (1996) The structure-activity relationship between peroxisome proliferator receptor _ agonism and the antihyperglycemic activity of thiazolidinediones. J.Med.Chem. 39 665. PMID:8576907. Xin et al (1999) Peroxisome proliferator-activated receptor _ ligands are potent inhibitors of angiogenesis in vitro and in vivo. J.Biol.Chem. 274 9116. PMID:10085162. Jh (1999) Thiazolidinediones - the new insulin enhancers. Clin.Exp.Hypertens. 21 157. PMID:10052651.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1912	SQ1533			Mar-2001
1309	PPNDS	[1021868-77-8]	[Na+].[Na+].[Na+].[Na+].CC1=C(O)C(C=O)=C(COP([O-])([O-])=O)C(N=NC2=CC3=C(C=C(C=C3C(=C2)S([O-])(=O)=O)[N+]([O-])=O)S([O-])(=O)=O)=N1	"Potent, selective P2X1 antagonist"	"Potent and selective P2X1 receptor antagonist (pKB = 7.43 in rat vas deferens). Up to 52-fold selective over P2Y1 receptors, and selective over ecto-nucleotidase, _1A-adrenoceptors, A1, A2B, H1 and M3 receptors."	Lambrecht et al (2000) The novel pyridoxal-5'-phosphate derivative PPNDS potently antagonizes activation of P2X1 receptors. Eur.J.Pharmacol. 387 R19. PMID:10650184.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1199				May-2000
1310	UCL 1684	[199934-16-2]	C12=CC=CC=C1C(NCC4=CC=C(CNC5=CC=[N+]7C6=C5C=CC=C6)C=C4)=CC=[N+]2CC3=CC=CC(C7)=C3.[Br-].[Br-]	Highly potent blocker of KCa2	"Highly potent, non-peptidic blocker of the apamin-sensitive Ca2+-activated K+ channel (KCa2.1) (IC50 = 3 nM in rat sympathetic neurons). Blocks hKCa2.1 and rKCa2.2 channels expressed in HEK 293 cells with IC50 values of 762 and 364 pM respectively."	"Campos Rosa et al (2000) Synthesis, molecular modeling, and pharmacological testing of bis-quinolinium cyclophanes: potent, non-peptidic blockers of the apamin-sensitive Ca2+-activated K+ channel. J.Med.Chem. 43 420. PMID:10669569. Malik-Hall et al (2000) Compounds that block intermediate-conductance (IKCa) and small-conductance (SKCa) calcium-activated potassium channels. Br.J.Pharmacol. 129 1431. PMID:10742299. Strobaek et al (2000) Pharmacological characterization of small-conductance Ca2+-activated K+ channels stably expressed in HEK 293 cells. Br.J.Pharmacol. 129 991. PMID:10696100."	Small Molecule	"Sold with the permission of University College, London"	http://www.tocris.com/dispprod.php?ItemId=1928				May-2004
1311	MK 886	[118414-82-7]	ClC(C=C3)=CC=C3CN(C(CC(C)(C(O)=O)C)=C2SC(C)(C)C)C1=C2C=C(C(C)C)C=C1	Inhibitor of 5-lipoxygenase-activating protein (FLAP)	"An inhibitor of leukotriene biosynthesis (IC50 = 3 nM in human polymorphonuclear leukocytes). Acts by inhibiting 5-lipoxygenase-activating protein (FLAP) (IC50 = 30 nM for inhibition of [125I]-L-691,678 photoaffinity labelling). Also moderately potent PPAR_ antagonist (IC50 = 0.5-1 _M). Orally active in vivo."	"Gillard et al (1989) L-663,536 (MK-886) (3-[1-(4-chlorobenzyl)-3-t-butyl-thio-5-isopropylindol-2-yl]-2,2-dimethylpropanoic acid), a novel, orally active leukotriene biosynthesis inhibitor. Can.J.Physiol.Pharmacol. 67 456. PMID:2548691. Dixon et al (1990) Requirement of a 5-lipoxygenase-activating protein for leukotriene synthesis. Nature 343 282. PMID:2300173. Mancini et al (1992) 5-Lipoxygenase-activating protein is the target of a novel hybrid of two classes of leukotriene biosynthesis inhibitors. Mol.Pharmacol. 41 267. PMID:1538707. Kehrer et al (2001) Inhibition of peroxisome-proliferator-activated receptor (PPAR)_ by MK886. Biochem.J. 356 899. PMID:11389700."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1945	SQ1533			Jul-2003
1312	WY 14643	[50892-23-4]	CC1=C(C)C(NC2=CC(Cl)=NC(SCC(O)=O)=N2)=CC=C1	Selective PPAR_ agonist	"Selective PPAR_ agonist (EC50 values are 0.63, 32 and > 100 _M at PPAR_, PPAR_ and PPAR_ respectively). Negatively inhibits NF-_B transcriptional activity and decreases the inflammatory response in vitro and in vivo."	"Forman et al (1997) Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors _ and _. Proc.Natl.Acad.Sci.U.S.A. 94 4312. PMID:9113986. Willson et al (2000) The PPARs: from orphan receptors to drug discovery. J.Med.Chem. 43 527. PMID:10691680. Bishop-Bailey (2000) Peroxisome proliferator-activated receptors in the cardiovascular system. Br.J.Pharmacol. 129 823. PMID:10696077."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1994	SQ1533			Nov-2000
1317	CP 94253 hydrochloride	[845861-39-4]	Cl.CCCOC1=CC=C2NC=C(C2=N1)C1=CCNCC1	"Potent, selective 5-HT1B agonist"	"Potent, selective 5-HT1B agonist (Ki values are 89, 2, 860, 49 and 1,600 nM for 5-HT1A, 5-HT1B, 5-HT1C, 5-HT1D and 5-HT2 receptors respectively). Centrally active upon systemic administration in vivo."	"Koe et al (1992) Biochemical and behavioral studies of the 5-HT1B receptor agonist, CP-94,253. Drug Dev.Res. 26 241. Fish et al (1999) Aggression heightened by alcohol or social instigation in mice: reduction by the 5-HT(1B) receptor agonist CP-94,253. Psychopharmacology 146 391. PMID:10550489. Knobelman et al (2000) Regulation of extracellular concentrations of 5-hydroxytryptamine (5-HT) in mouse striatum by 5-HT1A and 5-HT1B receptors. J.Pharmacol.Exp.Ther. 292 1111. PMID:10688630."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1976	SQ1341			Feb-2002
1321	ZM 336372	[208260-29-1]	CN(C)C1=CC(=CC=C1)C(=O)NC1=CC=C(C)C(NC(=O)C2=CC=C(O)C=C2)=C1	"Potent, selective c-Raf inhibitor"	"Potent, selective inhibitor of c-Raf in vitro (IC50 = 70 nM for inhibition of human c-Raf). Shows 10-fold selectivity over B-Raf. Also inhibits SAPK2/p38 (IC50 = 2 _M). Selective over 17 other protein kinases including PKA, PKC, p42 MAPK, CDK1 and SAPK1/JNK (up to 50 _M). Also available as part of the MAPK Cascade Inhibitor Tocriset."	Hall-Jackson et al (1999) Paradoxical activation of Raf by a novel Raf inhibitor. Chem.Biol. 6 559. PMID:10421767. Wartenberg et al (2001) Down-regulation of intrinsic p-glycoprotein expression in multicellular prostate tumor spheroids by reactive oxygen species. J.Biol.Chem. 276 17420. PMID:11279018.	Small Molecule	Sold with the permission of AstraZeneca Ltd	http://www.tocris.com/dispprod.php?ItemId=1992	SQ1533			Sep-2000
1322	GR 113808	[144625-51-4]	CN1C=C(C(=O)OCC2CCN(CCNS(C)(=O)=O)CC2)C2=CC=CC=C12	"Potent, selective 5-HT4 antagonist"	"Potent, selective 5-HT4 receptor antagonist (pKB = 9.43 in human colonic muscle, and Kd = 0.15 nM for binding to cloned human 5-HT4 receptors). Displays > 300-fold selectivity over 5-HT1A, 5-HT1B, 5-HT2A, 5-HT2C and 5-HT3 receptors."	"Gale et al (1994) GR113808: a novel, selective antagonist with high affinity at the 5-HT4 receptor. Br.J.Pharmacol. 111 332. PMID:8012715. Eglen et al (1995) Central 5-HT4 receptors. TiPS 16 391. PMID:8578609. Van den Wyngaert et al (1997) Cloning and expression of a human serotonin 5-HT4 receptor cDNA. J.Neurochem. 69 1810. PMID:9349523. Prins et al (2000) An improved in vitro bioassay for the study of 5-HT4 receptors in the human isolated large intestinal circular muscle. Br.J.Pharmacol. 129 1601. PMID:10780964."	Small Molecule	Sold with the permission of GlaxoSmithKline	http://www.tocris.com/dispprod.php?ItemId=2006	SQ1070			Nov-2001
1323	Butabindide oxalate	[185213-03-0]	O=C(O)C(O)=O.O=[C@]([C@@H](N)CC)N([C@H]([C@@](NCCCC)=O)C2)C1=C2C=CC=C1	CCK-inactivating serine protease inhibitor	"Potent, reversible, selective and competitive inhibitor of a CCK-inactivating serine protease (tripeptidyl peptidase II) (Ki = 7 nM). Active in vivo (ID50 = 1.1 and 6.8 mg/kg i.v. for inhibition of liver and brain enzyme respectively)."	"Rose et al (1996) Characterization and inhibition of a cholecystokinin-inactivating serine peptidase. Nature 380 403. PMID:8602240. Renn et al (1998) Characterization and cloning of tripeptidyl peptidase II from the fruit fly, Drosophila melanogaster. J.Biol.Chem. 273 19173. PMID:9668104. Ganellin et al (2000) Inhibitors of tripeptidyl peptidase II. 2. Generation of the first novel lead inhibitor of cholecystokinin-8-inactivating peptidase: a strategy for the design of peptidase inhibitors. J.Med.Chem. 43 664. PMID:10691692."	Small Molecule	Sold with the permission of INSERM and UCL	http://www.tocris.com/dispprod.php?ItemId=2007	SQ1341			Sep-2001
1324	RX 821002 hydrochloride	[109544-45-8]	Cl.COC1(COC2=CC=CC=C2O1)C1=NCCN1	"Potent, selective _2D antagonist"	"Potent, selective _2-adrenoceptor antagonist with very low affinity for imidazoline sites. Displays selectivity for the _2D over the _2A subtypes (pKd values are 9.7 and 8.2 respectively)."	O'Rourke et al (1994) Characterisation of [3H]RX 821002 binding to alpha-2 adrenergic receptor subtypes. J.Pharmacol.Exp.Ther. 268 1362. PMID:7908054. Erdbrugger et al (1995) Does [3H]2-methoxy-idazoxan (RX 821002) detect more alpha-2-adrenoceptor agonist high-affinity sites than [3H]rauwolscine? A comparison of nine tissues and cell lines. J.Pharmacol.Exp.Ther. 273 1287. PMID:7791100. Trendelenburg et al (1996) Antagonists that differentiate between _2A- and _2D-adrenoceptors. Naunyn Schmiedebergs Arch.Pharmacol. 353 245. PMID:8692278.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1281	SQ1341			Nov-2000
1325	RS 100329 hydrochloride	[1215654-26-4]	Cl.CC1=CNC(=O)N(CCCN2CCN(CC2)C2=C(OCC(F)(F)F)C=CC=C2)C1=O	"Potent, subtype-selective _1A antagonist"	Subtype-selective _1A-adrenoceptor antagonist (pKi = 9.6 for human cloned _1A receptors). Displays 126- and 50-fold selectivity over human _1B and _1D receptors respectively. Active in vivo.	"Shannon Kava et al (1998) _1L-Adrenoceptor mediation of smooth muscle contraction in rabbit bladder neck: a model for lower urinary tract tissues of man. Br.J.Pharmacol. 123 1359. PMID:9579731. Williams et al (1999) In vitro _1-adrenoceptor pharmacology of Ro 70-0004 and RS-100329, novel _1A-adrenoceptor selective antagonists. Br.J.Pharmacol. 127 252. PMID:10369480. Conley et al (2001) The role of _1-adrenoceptors and 5-HT1A receptors in the control of the micturition reflex in male anaesthetized rats. Br.J.Pharmacol. 133 61. PMID:11325795."	Small Molecule	Sold with the permission of Roche Bioscience	http://www.tocris.com/dispprod.php?ItemId=1993	SQ1341			Jan-2001
1326	BADGE	[1675-54-3]	CC(C)(C1=CC=C(OCC2CO2)C=C1)C1=CC=C(OCC2CO2)C=C1	PPAR_ antagonist	PPAR_ pure antagonist with micromolar affinity in 3T3-L1 and 3T3-F442A preadipocyte cells; selective over PPAR_ and PPAR_. Antagonizes the ability of rosiglitazone to stimulate transcriptional activity of PPAR_. Acts as a PPAR_ agonist in an ECV304 cell line. Also produces PPAR_-independent apoptosis of tumor cells via several mechanisms. Active in vivo.	"Bishop-Bailey et al (2000) Bisphenol A diglycidyl ether (BADGE) is a PPAR_ agonist in an ECV304 cell line. Br.J.Pharmacol. 131 651. PMID:11030710. Wright et al (2000) A synthetic antagonist for the peroxisome proliferator-activated receptor _ inhibits adipocyte differentiation. J.Biol.Chem. 275 1873. PMID:10636887. Fehlberg et al (2003) Bisphenol A diglycidyl ether-induced apoptosis involves Bax/Bid-dependent mitochondrial release of apoptosis-inducing factor (AIF), cytochrome c and Smac/DIABLO. Br.J.Pharmacol. 139 495. PMID:12788809. Cuzzocrea et al (2004) Rosiglitazone, a ligand of the peroxisome proliferator-activated receptor-_, reduces acute inflammation. Eur.J.Pharmacol. 483 79. PMID:14709329."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1294	SQ1070			Aug-2000
1327	"L-655,708"	[130477-52-0]	O=C(N3[C@]([H])2CCC3)C4=C(C=CC(OC)=C4)N1C2=C(C(OCC)=O)N=C1	Selective for _5-containing GABAA receptors	"Potent, selective inverse agonist for the benzodiazepine site of GABAA receptors containing the _5 subunit (Ki = 0.45 nM). Displays 50-100-fold selectivity over GABAA receptors containing _1, _2, _3 or _6 subunits in combination with _3 and _2. Enhances LTP in  a mouse hippocampal slice model and increases spatial learning, without displaying proconvulsant activity."	"Quirk et al (1996) [3H]L-655,708, a novel ligand selective for the benzodiazepine site of GABAA receptors which contain the _5 subunit. Neuropharmacology 35 1331. PMID:9014149. Sur et al (1998) Rat and human hippocampal _5 subunit-containing _-aminobutyric acidA receptors have _5_3_2 pharmacological characteristics. Mol.Pharmacol. 54 928. PMID:9804628. Atack et al (2006) L-655,708 enhances cognition in rats but is not proconvulsant at a dose selective for _5-containing GABAA receptors. Neuropharmacology 51 1023. PMID:17046030."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=2008	SQ1341			Nov-2000
1328	Flumazenil	[78755-81-4]	CCOC(=O)C1=C2CN(C)C(=O)C3=CC(F)=CC=C3N2C=N1	Benzodiazepine antagonist	"Benzodiazepine antagonist, non-selective for _1, _2, _3 or _5-containing GABAA receptors. Centrally active upon systemic administration in vivo."	Polc et al (1981) Electrophysiological studies on the specific benzodiazepine antagonist Ro 15-1788. Naunyn Schmiedebergs Arch.Pharmacol. 316 317. PMID:7196507. Atack et al (1999) Regional differences in the inhibition of mouse in vivo [3H]Ro 15-1788 binding reflect selectivity for _1 versus _2 and _3 subunit-containing GABAA receptors. Neuropsychopharmacology 20 255. PMID:10063485. Dobl (1999) New insights into the mechanism of action of hypnotics. J.Psychopharmacol. 13 S11. PMID:10667451.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=2339	SQ1533			Aug-2000
1330	Chelerythrine chloride	[3895-92-9]	C[N+](C3=C2C=CC4=C3C=C(OCO5)C5=C4)=CC1=C2C=CC(OC)=C1OC.[Cl-]	Cell-permeable protein kinase C inhibitor	"Cell-permeable inhibitor of protein kinase C (IC50 = 660 nM); competitive with respect to the phosphate acceptor and non-competitive with respect to ATP. Has a wide range of biological activities, including antiplatelet, anti-inflammatory, antibacterial and antitumor effects. Activates MAPK pathways, independent of PKC inhibition. Inhibits binding of BclXL to Bak (IC50 = 1.5 _M) or Bad proteins and stimulates apoptosis."	"Herbert et al (1990) Chelerythrine is a potent and specfic inhibitor of protein kinase C. Biochem.Biophys.Res.Commun. 172 993. PMID:2244923. Lee et al (1998) Angoline and chelerythrine, benzophenanthridine alkaloids that do not inhibit protein kinase C. J.Biol.Chem. 273 19829. PMID:9677417. Yu et al (2000) Activation of p38 and c-Jun N-terminal kinase pathways and induction of apoptosis by chelerythrine do not require inhibition of protein kinase C. J.Biol.Chem. 275 9612. PMID:10734112. Chan et al (2003) Identification of chelerythrine as an inhibitor of BclXL function. J.Biol.Chem. 278 20453. PMID:12702731."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=2342	SQ1533			Sep-2000
1343	JWH 133	[259869-55-1]	[H][C@]([C@]3([H])C(C)(C)O2)(CC(C)=CC3)C1=C2C=C(C(C)(C)CCC)C=C1	"Potent, selective CB2 agonist"	"Potent CB2 selective agonist (Ki = 3.4 nM). Approx. 200-fold selective over CB1 receptors. Active in vivo, reducing spasticity in a murine model of multiple sclerosis. Activity also enhances the release of IL-10 by LPS/IFN-_-stimulated macrophages and results in downregulation of the IL-12 subunit p40. Also available in water soluble emulsion (Cat. No. 1783)."	Huffman et al (1999) 3-(1'-Dimethylbutyl)-1-deoxy-_8-THC and related compounds: synthesis of selective ligands for the CB2 receptor. Bioorg.Med.Chem. 7 2905. PMID:10658595. Pertwee (1999) Pharmacology of cannabinoid receptor ligands. Curr.Med.Chem. 6 635. PMID:10469884. Baker et al (2000) Cannabinoids control spasticity and tremor in a multiple sclerosis model. Nature 404 84. PMID:10716447. Correa et al (2005) Activation of cannabinoid CB2 receptor negatively regulates IL-12p40 production in murine macrophages: role of IL-10 and ERK1/2 kinase signaling. Br.J.Pharmacol. 145 441. PMID:15821753.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=2344				Nov-2001
1345	AF-DX 384	[118290-26-9]	CCCN(CCC)CC1CCCCN1CCNC(=O)N1C2=C(C=CC=C2)C(=O)NC2=C1N=CC=C2	Potent M2/M4 antagonist	"Potent M2/M4 selective antagonist (pKi values are 8.22, 8.00, 7.51, 7.18 and 6.27 at human M2, M4, M1, M3 and M5 receptors respectively)."	Miller et al (1991) Binding of [3H]AF-DX 384 to cloned and native muscarinic receptors. J.Pharmacol.Exp.Ther. 259 601. PMID:1941609. Dopke et al (1995) AF-DX 384 binding in rabbit cingulate cortex: two site kinetics and section autoradiography. J.Pharmacol.Exp.Ther. 274 562. PMID:7616446. Grailhe et al (2009) Regional changes in the cholinergic system in mice lacking monoamine A. Brain Res.Bull. 78 283. PMID:19111597.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=2350	SQ1341			Aug-2003
1347	Nafadotride	[149649-22-9]	CCCCN1CCCC1CNC(=O)C1=C(OC)C2=CC=CC=C2C(=C1)C#N	"Highly potent, preferential D3 antagonist"	"Highly potent, competitive, preferential dopamine D3 receptor antagonist. Ki values are 0.52, 5, and 269 nM for human cloned D3, D2 and D4 receptors respectively. Centrally active upon systemic administration."	"Sautel et al (1995) Nafadotride, a potent preferential dopamine D3 receptor antagonist, activates locomotion in rodents. J.Pharmacol.Exp.Ther. 275 1239. PMID:8531087. Audinot et al (1998) A comparative in vitro and in vivo pharmacological characterization of the novel dopamine D3 receptor antagonists (+)-S 14297, nafadotride, GR 103,691 and U 99194. J.Pharmacol.Exp.Ther. 287 187. PMID:9765337. Richtand et al (2000) The dopamine D3 receptor antagonist nafadotride inhibits development of locomotor sensitization to amphetamine. Brain Res. 867 239. PMID:10837819."	Small Molecule	Sold with the permission of INSERM and BIOPROJET	http://www.tocris.com/dispprod.php?ItemId=2040	SQ1341			Jul-2003
1348	UB 165 fumarate	[200432-86-6]	[H]OC(=O)\C=C\C(=O)O[H].ClC1=CC=C(C=N1)C1=CCCC2CCC1N2	Subunit selective nAChR agonist	"Subtype-selective nicotinic agonist. Full agonist at _3_2- and very weak partial agonist at _4_2- containing nAChRs. Ki values are 0.27, 20 (IC50), 2790 and 990 nM for _4_2, _3, _7 and _1_1__ respectively."	Wright et al (1997) Synthesis of UB-165: a novel nicotinic ligand and anatoxin-a/epibatidine hybrid. Bioorg.Med.Chem.Lett. 7 2867. Sharples et al (2000) UB-165: a novel agonist with subtype selectivity implicates the _4_2 subtype in the modulation of dopamine release from rat striatal synaptosomes. J.Neurosci. 20 2783. PMID:10751429. Cao et al (2005) Different nicotinic acetylcholine receptor subtypes mediating striatal and prefrontal cortical [3H]dopamine release. Neuropharmacology 48 72. PMID:15617729.	Small Molecule	Sold with the permission of the University of Bristol	http://www.tocris.com/dispprod.php?ItemId=2056				Feb-2002
1349	(R)-(-)-Rolipram	[85416-75-7]	O=C1NC[C@@H](C2=CC(OC3CCCC3)=C(OC)C=C2)C1	PDE4 inhibitor. More active enantiomer of rolipram (Cat. No. 0905)	More active enantiomer of the PDE4 inhibitor rolipram (Cat. No. 0905); 2-10-fold more potent than the S-(+) enantiomer (Cat. No. 1350). Also available as part of the Phosphodiesterase Inhibitor Tocriset.	Schneider et al (1986) Stereospecific binding of the antidepressant rolipram to brain protein structures. Eur.J.Pharmacol. 127 105. PMID:3019721. Owens et al (1997) Human phosphodiesterase 4A: characterization of full-length and truncated enzymes expressed in COS cells. Biochem.J. 326 53. PMID:9337850. Ohsawa et al (1998) Inhibitory effects of rolipram on partially purified phosphodiesterase 4 from rat brains. Jpn.J.Pharmacol. 77 147. PMID:9681571.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=2358	SQ1533			Mar-2001
1350	(S)-(+)-Rolipram	[85416-73-5]	O=C1NC[C@H](C2=CC(OC3CCCC3)=C(OC)C=C2)C1	PDE4 inhibitor. Less active enantiomer of rolipram (Cat. No. 0905)	Less active enantiomer of the PDE4 inhibitor rolipram (Cat. No. 0905). (R)-(-)-Rolipram (Cat. No. 1349) also available.	Schneider et al (1986) Stereospecific binding of the antidepressant rolipram to brain protein structures. Eur.J.Pharmacol. 127 105. PMID:3019721. Owens et al (1997) Human phosphodiesterase 4A: characterization of full-length and truncated enzymes expressed in COS cells. Biochem.J. 326 53. PMID:9337850. Ohsawa et al (1998) Inhibitory effects of rolipram on partially purified phosphodiesterase 4 from rat brains. Jpn.J.Pharmacol. 77 147. PMID:9681571.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=2359	SQ1533			Apr-2001
1355	P1075	[60559-98-0]	CCC(C)(C)\N=C(/NC#N)NC1=CC=CN=C1	Potent Kir6 (KATP) channel opener	Potent Kir6 (KATP) channel opener (EC50 for relaxation of rat aorta = 7.5 nM). Binds to SUR2A and SUR2B with high affinity (Kd values are 17 and 3 nM respectively).	"Higdon et al (1997) Tissue and species variation in the vascular receptor binding of 3H-P1075, a potent KATP opener vasodilator. J.Pharmacol.Exp.Ther. 280 255. PMID:8996204. Gross et al (1999) Stoichiometry of potassium channel opener action. Mol.Pharmacol. 56 1370. PMID:10570067. Ashcroft and Gribble (2000) New windows on the mechanism of action of KATP channel openers. TiPS 21 439. PMID:11121575. Buckner et al (2000) Pharmacological and molecular analysis of ATP-sensitive K+ channels in the pig and human detrusor. Eur.J.Pharmacol. 400 287. PMID:10988346."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=2090	SQ1341			Sep-2001
1356	MG 624	[77257-42-2]	[I-].CC[N+](CC)(CC)CCOC1=CC=C(\C=C\C2=CC=CC=C2)C=C1	_7 neuronal nicotinic receptor antagonist	A selective antagonist for neuronal _7 subunit- containing nAChR subtypes. Inhibits _-Bgtx binding to chick _7 and _4_2 subtypes with Ki values of 106 nM and 84 _M respectively.	Gotti et al (1998) 4-Oxystilbene compounds are selective ligands for neuronal nicotinic abungarotoxin receptors. Br.J.Pharmacol. 124 1197. PMID:9720791. Maggi et al (1999) Selective effects of a 4-oxystilbene derivative on wild and mutant neuronal chick _7 nicotinic receptor. Br.J.Pharmacol. 126 285. PMID:10051147.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=2091	SQ1533			Feb-2002
1357	U 99194 maleate	[234757-41-6]	OC(=O)\C=C/C(O)=O.CCCN(CCC)C1CC2=C(C1)C=C(OC)C(OC)=C2	"Potent, selective D3 antagonist"	"Potent, selective D3 antagonist. Ki values are 160, 2281 and > 10000 nM for human cloned D3, D2 and D4 receptors respectively."	"Audinot et al (1998) A comparative in vitro and in vivo pharmacological characterization of the novel dopamine D3 receptor antagonists (+)-S 14297, nafadotride, GR 103,691 and U 99194. J.Pharmacol.Exp.Ther. 287 187. PMID:9765337. Clifford and Waddington (1998) Heterogeneity of behavioural profile between three putative selective D3 dopamine receptor antagonists using an ethologically based approach. Psychopharmacology 136 284. PMID:9566814. LaHoste et al (2000) Dopamine D1 receptors synergize with D2, but not D3 or D4, receptors in the striatum without the involvement of action potentials. J.Neurosci. 20 6666. PMID:10964971."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=2039	SQ1341			Oct-2000
1359	VUF 5574	[280570-45-8]	O=C(NC2=NC(C4=CC=CN=C4)=NC3=C2C=CC=C3)NC1=C(OC)C=CC=C1	"Potent, selective hA3 antagonist"	"Potent, selective, competitive antagonist for the human adenosine A3 receptor (Ki = 4 nM). Displays  2500-fold selectivity over A1 and A2A receptors."	Baraldi and Borea (2000) New potent and selective human adenosine A3 receptor antagonists. TiPS 21 456. PMID:11121831. van Muijlwijk-Koezen et al (2000) Isoquinoline and quinazoline urea analogues as antagonists for the human adenosine A3 receptor. J.Med.Chem. 43 2227. PMID:10841801.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=2274	SQ1341			Mar-2001
1361	PD 123319 ditrifluoroacetate	[130663-39-7]	O=C(C(C5=CC=CC=C5)C4=CC=CC=C4)N1[C@H]([C@](O)=O)CC(N(CC3=CC(C)=C(N(C)C)C=C3)C=N2)=C2C1.FC(F)(F)C(O)=O.FC(F)(F)C(O)=O	"Potent, selective non-peptide AT2 antagonist"	"Potent, selective, non-peptide angiotensin AT2 receptor antagonist. IC50 values are 34 and 210 nM in rat adrenal tissue and brain respectively."	Blankley et al (1991) Synthesis and structure-activity relationships of a novel series of non-peptide angiotensin II receptor binding inhibitors specific for the AT2 subtype. J.Med.Chem. 34 3248. PMID:1956044. Boulay et al (1992) Modulation of angiotensin II binding affinity by allosteric interaction of polyvinyl sulfate with an intracellular domain of the DuP-753-sensitive angiotensin II receptor of bovine adrenal glomerulosa. Mol.Pharmacol. 41 809. PMID:1569928. Tamura et al (2000) Induction of angiotensin II subtype 2 receptor-mediated blood pressure regulation in synthetic diet-fed rats. J.Hypertens. 18 1239. PMID:10994755.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1784	SQ1341			Sep-2002
1363	PD 81723	[132861-87-1]	CC1=C(C)C(C(=O)C2=CC(=CC=C2)C(F)(F)F)=C(N)S1	Allosteric potentiator of A1 receptors	"Allosteric potentiator at the adenosine A1 receptor; acts via agonist-dependent and -independent mechanisms. Enhances agonist affinity for, and increased t_ of dissociation from, the receptor. Also inhibits basal and forskolin-stimulated adenylyl cyclase (AC) activity in A1 receptors expressed in CHO cells, possibly via direct potentiation of constitutive receptor activity or by direct inhibition of AC. Active in vivo."	"Bruns et al (1990) Structure-activity relationships for enhancement of adenosine A1 receptor binding by 2-amino-3-benzoylthiophenes. Mol.Pharmacol. 38 950. PMID:2250667. Mizumura et al (1996) PD 81,723, an allosteric enhancer of the A1 adenosine receptor, lowers the threshold for ischemic preconditioning in dogs. Circ.Res. 79 415. PMID:8781475. Kollias-Baker et al (1997) Agonist-independent effect of an allosteric enhancer of the A1 adenosine receptor in CHO cells stably expressing the recombinant human A1 receptor. J.Pharmacol.Exp.Ther. 281 761. PMID:9152383. Musser et al (1999) Adenosine A1 receptor-dependent and -independent effects of the allosteric enhancer PD 81,723. J.Pharmacol.Exp.Ther. 288 446. PMID:9918544."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=2275	SQ1341			May-2003
1364	Colchicine	[64-86-8]	COC1=C(OC)C(OC)=C2C(CCC(NC(C)=O)C3=CC(=O)C(OC)=CC=C23)=C1	Inhibitor of tubulin	Plant-derived alkaloid that binds to tubulin and depolymerizes microtubules.	Hastie (1991) Interactions of colchicine with tubulin. Pharmacol.Ther. 51 377. PMID:1792241. Burns (1992) Analysis of the colchicine-binding site of _-tubulin. FEBS Lett. 297 205. PMID:1544399. Bai et al (1996) Identification of cysteine 354 of _-tubulin as part of the binding site for the A ring of colchicine. J.Biol.Chem. 271 12639. PMID:8647876.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=2106	SQ1533			Feb-2001
1366	ZM 449829	[4452-06-6]	C=CC(C2=CC1=CC=CC=C1C=C2)=O	"Potent, selective JAK3 inhibitor"	"Potent, selective inhibitor of Janus tyrosine kinase 3 (JAK3) which binds competitively to the JAK3 ATP site. pIC50 values are 6.8, 5.0, 4.7, and < 5.0 for JAK3, EGFR, JAK1 and CDK4 respectively. Inhibits STAT-5 phosphorylation and T cell proliferation."	Brown et al (2000) Naphthyl ketones: a new class of janus kinase 3 inhibitors Bioorg.Med.Chem.Lett. 10 575. PMID:10741557. Orange et al (2011) IL-2 induces a WAVE2-dependent pathway for actin reorganization that enables WASp-independent human NK cell function. J.Clin.Invest. 121 1535. PMID:21383498.	Small Molecule	Sold with the permission of AstraZeneca Ltd.	http://www.tocris.com/dispprod.php?ItemId=2107				Feb-2002
1367	ZM 39923 hydrochloride	[58753-54-1]	Cl.CC(C)N(CCC(=O)C1=CC=C2C=CC=CC2=C1)CC1=CC=CC=C1	"Potent, selective JAK3 inhibitor"	"Potent, selective inhibitor of Janus tyrosine kinase 3 (JAK3). pIC50 values are 7.1, 5.6, 4.4, and < 5.0 for JAK3, EGFR, JAK1 and CDK4 respectively. Breaks down in neutral buffer (t_ = 36 mins, pH 7.43, 25C) to form ZM 449829 (Cat. No. 1366)."	Brown et al (2000) Naphthyl ketones: a new class of janus kinase 3 inhibitors. Bioorg.Med.Chem.Lett. 10 575. PMID:10741557.	Small Molecule	Sold with the permission of AstraZeneca Ltd.	http://www.tocris.com/dispprod.php?ItemId=1344	SQ1341			Oct-2001
1368	Geldanamycin	[30562-34-6]	O=C1C(OC)=C(C[C@@H](C)C[C@H](OC)[C@H](O)[C@@H](C)/C=C(C)/[C@H](OC(N)=O)[C@@H](OC)/C=C/C=C(C)/C2=O)C(C(N2)=C1)=O	Selective Hsp90 inhibitor	"Selectively inhibits heat shock protein 90 (Hsp90). Binds to the ATP site of Hsp90 (Kd = 1.2 _M) and inhibits its chaperone activity. Consequently inhibits activities of oncogenic kinases (e.g. src, Raf), p53 and steroid receptors. Demonstrates anti-proliferative effects on breast cancer cells in a dose dependent manner."	Whitesell et al (1994) Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation. Proc.Natl.Acad.Sci.U.S.A. 91 8324. PMID:8078881. Cardenas et al (1998) Signal-transduction cascades as targets for therapeutic intervention by natural products. Trends Biotechnol. 16 427. PMID:9807840. Roe et al (1999) Structural basis for inhibition of the Hsp90 molecular chaperone by the antitumor antibiotics radicicol and geldanomycin. J.Med.Chem. 42 260. PMID:9925731. Lee et al (2012) Inhibition of heat shock protein (Hsp) 27 potentiates the suppressive effect of Hsp90 inhibitors in targeting breast cancer stem-like cells. Biochimie. 94 1382. PMID:22445681.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1345	SQ1533			Feb-2001
1369	UBP1112	[339526-74-8]	NC(C(O)=O)(C)C1=CC=C(P(O)(O)=O)C(C)=C1	Group III mGlu antagonist	"A selective group III mGlu receptor antagonist (apparent Kd values are 5.1 and 488 _M for group III and group II mGlu receptors respectively; IC50 > 1 mM for group I, NMDA, AMPA and kainate receptors)."	Conway et al (2001) Synthesis of phenylglycine derivatives as potent and selective antagonists of group III metabotropic glutamate receptors. Bioorg.Med.Chem.Lett. 11 777. PMID:11277518. Miller et al (2003) Phenylglycine derivatives as antagonists of group III metabotropic glutamate receptors expressed on neonatal rat primary afferent terminals. Br.J.Pharmacol. 139 1523. PMID:12922940.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1346	SQ1341			Jan-2002
1371	SB 200646 hydrochloride	[143797-62-0]	Cl.CN1C=CC2=CC(NC(=O)NC3=CN=CC=C3)=CC=C12	5-HT2C/2B antagonist	"5-HT2C/2B receptor antagonist, selective over 5-HT1A. Affinities are 7.4 (pA2), 6.9 (pKi) and 5.2 (pKi) for 5-HT2B, 2C and 2A respectively. Orally active in vivo."	"Forbes et al (1993) N-(1-Methyl-5-indolyl)-N'-(3-pyridyl)urea hydrochloride: the first selective 5-HT1C receptor antagonist. J.Med.Chem. 36 1104. PMID:8478907. Kennett et al (1994) In vivo properties of SB 200646A, a 5-HT2C/2B recepor antagonist. Br.J.Pharmacol. 111 797. PMID:7912626. Kennett et al (1995) Effect of SB 200646A, a 5-HT2C/5-HT2B receptor antagonist, in two conflict models of anxiety. Psychopharmacology (Berl.) 118 178. PMID:7617805."	Small Molecule	Sold under license	http://www.tocris.com/dispprod.php?ItemId=1765	SQ1341			Sep-2001
1372	SB 204741	[152239-46-8]	O=C(NC3=CC(C)=NS3)NC1=CC(C=CN2C)=C2C=C1	"Potent, selective 5-HT2B antagonist"	"Potent and selective 5-HT2B receptor antagonist (pA2 = 7.95). Displays  135-fold selectivity over 5-HT2C (pKi = 5.82), 5-HT2A (pKi < 5.2), 5-HT1A, 1D, 1E, 5-HT3 and 5-HT4 receptors."	"Bonhaus et al (1995) The pharmacology and distribution of human 5-hydroxytryptamine2B (5-HT2B) receptor gene products: comparison with 5-HT2A and 5-HT2C receptors. Br.J.Pharmacol. 115 622. PMID:7582481. Forbes et al (1995) N-(1-Methyl-5-indolyl)-N'-(3-methyl-5-isothiazolyl)urea: a novel, high-affinity 5-HT2B receptor antagonist. J.Med.Chem. 38 855. PMID:7699699. Glusa and Pertz (2000) Further evidence that 5-HT-induced relaxation of pig pulmonary artery is mediated by endothelial 5-HT2B receptors. Br.J.Pharmacol. 130 692. PMID:10821800. Ebrahimkhani et al (2011) Stimulating healthy tissue regeneration by targeting the 5-HT2B receptor in chronic liver disease. Nat.Med. 17 1668. PMID:22120177."	Small Molecule	Sold under license	http://www.tocris.com/dispprod.php?ItemId=1747	SQ1341			Jul-2001
1373	SB 204070	[148688-01-1]	ClC1=C(N)C(OCCO2)=C2C(C(OCC3CCN(CCCC)CC3)=O)=C1.Cl	Potent and selective 5-HT4 antagonist	"Potent and selective 5-HT4 receptor antagonist (pIC50 = 10.1). Displays >5000-fold selectivity for 5-HT4 over 5-HT1A, 5-HT1D, 5-HT1E, 5-HT2A, 5-HT2C, and 5-HT3 receptors. Exhibits anxiolytic activity upon systemic administration in vivo."	"Gaster et al (1993) (1-Butyl-4-piperidinyl)methyl 8-amino-7-chloro-1,4-benzodioxane-5-carboxylate hydrochloride: a highly potent and selective 5-HT4 antagonist derived from metoclopramide. J.Med.Chem. 36 4121. PMID:8258837. Bingham et al (1995) Antagonism by SB 204070 of 5-HT-evoked contractions in the dog stomach: an in-vivo model of 5-HT4 receptor function. J.Pharm.Pharmacol. 47 219. PMID:7602484. Prins et al (2000) An improved in vitro bioassay for the study of 5-HT4 receptors in the human isolated large intestine circular muscle. Br.J.Pharmacol. 129 1601. PMID:10780964."	Small Molecule	Sold for research purposes under agreement from GlaxoSmithKline.	http://www.tocris.com/dispprod.php?ItemId=1764	SQ1070			Feb-2012
1375	SB 228357	[181629-93-6]	COC1=C(C=C2N(CCC2=C1)C(=O)NC1=CC(F)=CC(=C1)C1=CC=CN=C1)C(F)(F)F	5-HT2C/2B antagonist/inverse agonist	"5-HT2C/2B receptor antagonist (pKi values are 7.0, 8.1 and 9.1 at 5-HT2A, 2B and 2C receptors respectively). Displays inverse agonism in a 5-HT-stimulated PI hydrolysis model of 5-HT2C receptor function. Orally active in vivo."	Reavill et al (1999) Attenuation of haloperidol-induced catalepsy by a 5-HT2C receptor antagonist. Br.J.Pharmacol. 126 572. PMID:10188965. Bromidge et al (2000) Biarylcarbamoylindolines are novel and selective 5-HT2C receptor inverse agonists: identification of 5-methyl-1-[[2-[(2-methyl-3-pyridyl)oxy]-5-pyridyl]carbamoyl]-6-trifluoromethylindoline (SB-243213) as a potential antidepressant/anxiolytic agent. J.Med.Chem. 43 1123. PMID:10737744.	Small Molecule	Sold under license	http://www.tocris.com/dispprod.php?ItemId=1782	SQ1341			Oct-2003
1376	SB 218795	[174635-53-1]	COC(=O)[C@H](NC(=O)C1=C2C=CC=CC2=NC(=C1)C1=CC=CC=C1)C1=CC=CC=C1	"Potent, selective non-peptide NK3 antagonist"	"Potent, selective and competitive non-peptide NK3 receptor antagonist (Ki = 13 nM at hNK3). Displays 90-fold and 7000-fold selectivity over hNK2 and hNK1 receptors respectively. Active in vivo, inhibiting agonist-induced pupillary constriction."	Giardina et al (1997) Discovery of a novel class of selective non-peptide antagonists for the human neurokinin-3 receptor. 1. Identification of the 4-quinolinecarboxamide framework. J.Med.Chem. 40 1794. PMID:9191956. Medhurst et al (1997) In vitro and in vivo characterization of NK3 receptors in the rabbit eye by use of selective non-peptide NK3 receptor antagonists. Br.J.Pharmacol. 122 469. PMID:9351503.	Small Molecule	Sold under license	http://www.tocris.com/dispprod.php?ItemId=1748	SQ1341			Jul-2001
1377	Cromakalim	[94470-67-4]	O=C1CCCN1[C@H]2[C@H](O)C(C)(C)OC3=C2C=C(C#N)C=C3.O=C4CCCN4[C@@H]5[C@@H](O)C(C)(C)OC6=C5C=C(C#N)C=C6	Kir6 (KATP) channel opener	"Prototypical Kir6 (KATP) channel opener. Relaxes rabbit isolated portal vein with an IC50 value of 21 nM . Potent, orally active and hypotensive in vivo."	"Escande et al (1988) The potassium channel opener cromakalim (BRL 34915) activates ATP-dependent K+ channels in isolated cardiac myocytes. Biochem.Biophys.Res.Commun. 154 620. PMID:2456760. Longman et al (1988) Cromakalim, a potassium channel activator: a comparison of its cardiovascular haemodynamic profile and tissue specificity with those of pinacidil and nicorandil. J.Cardiovasc.Pharmacol. 12 535. PMID:2468052. Wilson et al (1988) Comparative effects of K+ channel blockade on the vasorelaxant activity of cromakalim, pinacidil and nicorandil. Eur.J.Pharmacol. 152 331. PMID:2851450."	Small Molecule	Sold under license	http://www.tocris.com/dispprod.php?ItemId=1745	SQ1533			Jul-2001
1378	Levcromakalim	[94535-50-9]	O=C1CCCN1[C@H]2[C@H](O)C(C)(C)OC3=C2C=C(C#N)C=C3	Kir6 (KATP) channel opener; active enantiomer of cromakalim (Cat. No. 1377)	Active enantiomer of the prototypical Kir6 (KATP) channel opener cromakalim (Cat. No. 1377). Hypotensive and airways relaxant. IC50 = 490 nM in guinea pig trachea.	"Buckle et al (1991) Synthesis and smooth muscle relaxant activity of a new series of potassium channel activators: 3-amido-1,1-dimethylindan-2-ols. J.Med.Chem. 34 919. PMID:2002472. Noack et al (1992) Potassium channel modulation in rat portal vein by ATP depletion: a comparison with the effects of levcromakalim (BRL 38227). Br.J.Pharmacol. 107 945. PMID:1467843. Taylor et al (1992) The inhibitory effects of cromakalim and its active enantiomer BRL 38227 against various agonists in guinea pig and human airways. J.Pharmacol.Exp.Ther. 261 429. PMID:1578358."	Small Molecule	Sold under license	http://www.tocris.com/dispprod.php?ItemId=1746	SQ1533			Jul-2001
1379	SB 221284	[196965-14-7]	CSC1=C(C=C2N(CCC2=C1)C(=O)NC1=CC=CN=C1)C(F)(F)F	"Potent, selective 5-HT2C/2B antagonist"	"Potent, selective 5-HT2C/2B receptor antagonist. pKi values are 6.4, 7.9 and 8.6 for 5-HT2A, 2B and 2C receptors respectively. Centrally active upon systemic administration in vivo."	"Bromidge et al (1998) Novel and selective 5-HT2C/2B receptor antagonists as potential anxiolytic agents: synthesis, quantitative structure-activity relationships, and molecular modeling of substituted 1-(3-pyridylcarbamoyl)indolines. J.Med.Chem. 41 1598. PMID:9572885. Hutson et al (2000) Activation of mesolimbic dopamine function by phencyclidine is enhanced by 5-HT2C/2B receptor antagonists: neurochemical and behavioural studies. Neuropharmacology 39 2318. PMID:10974315. Bristow et al (2000) Evidence for accelerated desensitisation of 5-HT2C receptors following combined treatment with fluoxetine and the 5-HT1A receptor antagonist, WAY 100,635, in the rat. Neuropharmacology 39 1222. PMID:10760364."	Small Molecule	Sold under license	http://www.tocris.com/dispprod.php?ItemId=1783	SQ1341			Jul-2003
1380	PMPA (NAALADase inhibitor)	[173039-10-6]	OC(=O)CCC(CP(=O)(O)O)C(O)=O	GCP II inhibitor	Highly potent and selective inhibitor of  glutamate carboxypeptidase 2 (GCP II/N-acetylated _-linked dipeptidase/NAALADase) with a Ki value of 275 pM. Neuroprotective; protects against glutamate-mediated motor neuron degeneration and reduces volume of injury following middle cerebral artery occlusion (MCAO).	"Jackson et al (1996) Design, synthesis, and biological activity of a potent inhibitor of the neuropeptidase N-acetylated _-linked acidic dipeptidase. J.Med.Chem. 39 619. PMID:8558536. Slusher et al (1999) Selective inhibition of NAALADase, which converts NAAG to glutamate, reduces ischemic brain injury. Nat.Med. 5 1396. PMID:10581082. Thomas et al (2003) NAALADase inhibition protects motor neurons against chronic glutamate toxicity. Eur.J.Pharmacol. 471 177. PMID:12826236. Rahn et al (2012) Inhibition of glutamate carboxypeptidase II (GCPII) activity as a treatment for cognitive impairment in multiple sclerosis. Proc.Natl.Acad.Sci.U S A (Epub ahead of print]. PMID:23169655."	Small Molecule	Sold with the permission of AstraZeneca Ltd.	http://www.tocris.com/dispprod.php?ItemId=1717	SQ1341			Jan-2007
1381	GW 5074	[220904-83-6]	OC1=C(Br)C=C(\C=C2/C(=O)NC3=CC=C(I)C=C23)C=C1Br	"Potent, selective c-Raf1 kinase inhibitor"	"Potent, selective and cell-permeable c-Raf1 kinase inhibitor (IC50 = 9 nM). Displays  100-fold selectivity for raf kinase over CDK1, CDK2, c-src, ERK2, MEK, p38, Tie2, VEGFR2 and c-fm."	Lackey et al (2000) The discovery of potent cRaf1 kinase inhibitors. Bioorg.Med.Chem.Lett. 10 223. PMID:10698440. Varga et al (2002) Involvement of Raf-1 in chronic delta-opioid receptor agonist-mediated adenylyl cyclase superactivation. Eur.J.Pharmacol. 451 101. PMID:12223234. Breslin et al (2003) VEGF increases endothelial permeability by separate signaling pathways involving ERK-1/2 and nitric oxide. Am.J.Physiol.Heart Circ.Physiol. 284 H92. PMID:12388327. Chen et al (2008) Inhibition of ATF-3 expression by B-Raf mediates the neuroprotective action of GW5074. J.Neurochem. 105 1300. PMID:18194435.	Small Molecule	Sold for research purposes under agreement from Glaxo Wellcome Inc and Glaxo Group Ltd.	http://www.tocris.com/dispprod.php?ItemId=1718	SQ1533			Jul-2001
1382	"L-152,804"	[6508-43-6]	CC1(C)CC(=O)C(C2C3=C(OC4=C2C(=O)CC(C)(C)C4)C=CC=C3)C(=O)C1	"Potent, selective non-peptide NPY Y5 receptor antagonist"	"Potent, selective non-peptide neuropeptide Y Y5 receptor antagonist (Ki = 26 nM for hY5). Displays > 300-fold selectivity over hY1, hY2, and hY4 receptors. Causes weight loss in diet-induced obese mice by modulating food intake and energy expenditure. Centrally active upon oral administration in vivo."	"Kanatani et al (2000) L-152,804: orally active and selective neuropeptide Y Y5 receptor antagonist. Biochem.Biophys.Res.Commun. 272 169. PMID:10872822. Schroeder et al (2005) The neuropeptide-Y Y5 receptor antagonist L-152,804 decreases alcohol self-administration in inbred alcohol-preferring (iP) rats. Alcohol 36 179. PMID:16377459. Mashiko et al (2007) A pair-feeding study reveals that a Y5 antagonist causes weight loss in diet-induced obese mice by modulating food intake and energy expenditure. Mol.Pharmacol. 71 602. PMID:17105869."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1396				Feb-2002
1383	BML-190	[2854-32-2]	COC1=CC=C2N(C(=O)C3=CC=C(Cl)C=C3)C(C)=C(CC(=O)N3CCOCC3)C2=C1	"Potent, selective CB2 ligand"	Potent and selective CB2 receptor ligand (Ki values are 435 nM and > 2 _M for CB2 and CB1 respectively).	Gallant et al (1996) New class of potent ligands for the human peripheral cannabinoid receptor. Bioorg.Med.Chem.Lett. 6 2263. Melck et al (2000) Suppression of nerve growth factor Trk receptors and prolactin receptors by endocannabinoids leads to inhibition of human breast and prostate cancer cell proliferation. Endocrinology 141 118. PMID:10614630.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1762				Feb-2002
1384	McN-A 343	[55-45-8]	ClC1=CC=CC(NC(OCC#CC[N+](C)(C)C)=O)=C1.[Cl-]	Selective M1 muscarinic agonist	Selective muscarinic M1 receptor agonist. Selectivity for M1 over other muscarinic receptor types appears to arise from a high efficacy at M1 receptors.	Micheletti and Schiavone (1990) Functional determination of McN-A-343 affinity for M1 muscarinic receptors. J.Pharmacol.Exp.Ther. 253 310. PMID:1691785. Eglen et al (1996) Muscarinic receptor subtypes and smooth muscle function. Pharmacol.Rev. 48 531. PMID:8981565. Davies et al (2001) Inhibition of field stimulation-induced contractions of rabbit vas deferens by muscarinic receptor agonists: selectivity of McN-A-343 for M1 receptors. J.Pharm.Pharmacol. 53 487. PMID:11341365.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1876	SQ1070			May-2007
1385	MRS 1334	[192053-05-7]	CCOC(=O)C1=C(C)NC(C2=CC=CC=C2)=C(C1C#CC1=CC=CC=C1)C(=O)OCC1=CC=C(C=C1)N(=O)=O	"Potent, highly selective hA3 antagonist"	"Potent and highly selective antagonist for the human adenosine A3 receptor. Ki values are 2.69 nM at hA3, and > 100 _M at rat A1 and rat A2A receptors."	"Li et al (1998) Structure-activity relationships and molecular modeling of 3,5-diacyl-2,4-dialkylpyridine derivatives as selective A3 adenosine receptor antagonists. J.Med.Chem. 41 3186. PMID:9703464. Baraldi and Borea (2000) New potent and selective human adenosine A3 receptor antagonists. TiPS 21 456. PMID:11121831."	Small Molecule	"Sold with the permission of the NIH, US Patent 60/029,855"	http://www.tocris.com/dispprod.php?ItemId=1785	SQ1341			Jun-2003
1390	(-)-Cytisine	[485-35-8]	O=C2N1C[C@@]([H])(C3)CNC[C@@]([H])3C1=CC=C2	"Potent, selective neuronal nicotinic agonist"	"A potent, selective agonist at neuronal nicotinic receptors. Acts as a partial agonist at _2-containing nicotinic receptors."	"Reavill et al (1990) Behavioural and pharmacokinetic studies on nicotine, cytisine and lobeline. Neuropharmacology 29 619. PMID:2385332. Happe et al (1994) Localization of nicotinic cholinergic receptors in rat brain: autoradiographic studies with [3H]cytisine. Neuroscience 62 929. PMID:7870314. Papke et al (1994) Partial agonist properties of cytisine on neuronal nicotinic receptors containing the _2 subunit. Mol.Pharmacol. 45 142. PMID:8302273."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1800	SQ1533			May-2001
1391	NF 449	[627034-85-9]	[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[O-]S(=O)(=O)C1=CC=C(NC(=O)C2=CC(=CC(NC(=O)NC3=CC(=CC(=C3)C(=O)NC3=CC=C(C=C3S([O-])(=O)=O)S([O-])(=O)=O)C(=O)NC3=CC=C(C=C3S([O-])(=O)=O)S([O-])(=O)=O)=C2)C(=O)NC2=CC=C(C=C2S([O-])(=O)=O)S([O-])(=O)=O)C(=C1)S([O-])(=O)=O	Highly selective P2X1 antagonist	"Potent purinergic receptor antagonist that displays high selectivity for P2X1 (IC50 values are 0.28, 0.69, 120, 1820, 47000 and > 300000 nM for rP2X1, rP2X1+5, rP2X2+3, rP2X3, rP2X2 and P2X4 receptors respectively). Provides antithrombotic protection in vivo. Also acts as a Gs_-selective antagonist."	"Hohenegger et al (1998) Gs_-selective G protein antagonists. Proc.Natl.Acad.Sci.U.S.A. 95 346. PMID:9419378. Rettinger et al (2005) Profiling at recombinant homomeric and heteromeric rat P2X receptors identifies the suramin analogue NF449 as a highly potent P2X1 receptor antagonist. Neuropharmacology. 48 461. PMID:15721178. Hechler et al (2005) Inhibition of platelet functions and thrombosis through selective or non-selective inhibition of the platelet P2 receptors with increasing doses of NF449 [4,4',4"",4'""-(carbonylbis(imino-5,1,3-benzenetriylbis-(carbonylimino)))tetrakis-benzene-1,3-disulfonic acid octasodium salt]. J.Pharmacol.Exp.Ther. 314 232. PMID:15792995. Fleming et al (2011) Chemical modulators of autophagy as biological probes and potential therapeutics. Nat.Chem.Biol. 7 9. PMID:21164513."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1801				May-2002
1393	SB 222200	[174635-69-9]	O=C(C2=C(C)C(C4=CC=CC=C4)=NC3=CC=CC=C23)N[C@@H](CC)C1=CC=CC=C1	"Potent, selective non-peptide NK3 antagonist. Brain penetrant"	"Potent and selective non-peptide NK3 receptor antagonist (Ki values are 4.4, > 100,000 and 250 nM for human NK3, NK1 and NK2 receptors respectively). Antihypertensive in vivo. Brain penetrant."	"Medhurst et al (1997) In vitro and in vivo characterization of NK3 receptors in the rabbit eye by use of selective non-peptide NK3 receptor antagonists. Br.J.Pharmacol. 122 469. PMID:9351503. Sarau et al (2000) Nonpeptide tachykinin receptor antagonists. II. Pharmacological and pharmacokinetic profile of SB-222200, a central nervous system penetrant, potent and selective NK-3 receptor antagonist. J.Pharmacol.Exp.Ther. 295 373. PMID:10992004. De Brito Gariepy and Couture (2010) Blockade of tachykinin NK3 receptor reverses hypertension through a dopaminergic mechanism in the ventral tegmental area of spontaneously hypertensive rats. Br.J.Pharmacol. 161 1868. PMID:20804497."	Small Molecule	Sold under license	http://www.tocris.com/dispprod.php?ItemId=1398	SQ1341			Oct-2001
1394	"(RS)-3,4-DCPG"	[176796-64-8]	NC(C(O)=O)C1=CC=C(C(O)=O)C(=C1)C(O)=O	"Potent systemically active anticonvulsant. Racemate of (R)-3,4,-DCPG (Cat. No. 1395)"	"Systemically active anticonvulsant that is 30-100-fold more potent in vivo than the separate enantiomers (S)-3,4-DCPG (Cat. No. 1302) or (R)-3,4,-DCPG (Cat. No. 1395)."	"Thomas et al (1997) Dicarboxyphenylglycines antagonize AMPA- but not kainate-induced depolarizations in neonatal rat motoneurones. Eur.J.Pharmacol. 338 111. PMID:9455991. Thomas et al (1998) Pharmacological differentiation of kainate receptors on neonatal rat spinal motoneurones and dorsal roots. Neuropharmacology 37 1223. PMID:9849660. Moldrich et al (2001) Anticonvulsant activity of 3,4-dicarboxyphenylglycines in DBA/2 mice. Neuropharmacology 40 732. PMID:11311902."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1828				Jul-2001
1395	"(R)-3,4-DCPG"	[201730-10-1]	N[C@@]([H])(C(O)=O)C1=CC(C(O)=O)=C(C(O)=O)C=C1	AMPA antagonist/weak NMDA antagonist	"AMPA receptor antagonist with weak activity at NMDA receptors and little activity at kainate receptors. (RS)-3,4-DCPG (Cat. No. 1394) and (S)-3,4-DCPG (Cat. No. 1302) also available."	"Thomas et al (1997) Dicarboxyphenylglycines antagonize AMPA- but not kainate-induced depolarizations in neonatal rat motoneurones. Eur.J.Pharmacol. 338 111. PMID:9455991. Moldrich et al (2001) Anticonvulsant activity of 3,4-dicarboxyphenylglycines in DBA/2 mice. Neuropharmacology 40 732. PMID:11311902."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1897	SQ1341			Oct-2001
1396	Fenretinide	[65646-68-6]	CC(/C=C/C1=C(C)CCCC1(C)C)=C\C=C\C(C)=C\C(=O)NC1=CC=C(O)C=C1	Synthetic retinoid; antiproliferative and antioxidant	"Synthetic retinoid agonist. Antiproliferative, antioxidant and anticancer agent with a long half-life in vivo. Apoptotic effects appear to be mediated by a mechanism distinct from that of 'classical' retinoids."	"Ulukaya and Wood (1999) Fenretinide and its relation to cancer. Cancer Treat.Rev. 25 229. PMID:10448131. Le Doze et al (2000) Pharmacokinetics of all-trans retinoic acid, 13-cis retinoic acid, and fenretinide in plasma and brain of rat. Drug Metab.Dispos. 28 205. PMID:10640519. Takahashi (2000) Antioxidant properties of N-(4-hydroxyphenyl)retinamide (fenretinide). Biol.Pharm.Bull. 23 222. PMID:10706389."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1474	SQ1533			Mar-2004
1397	PP 1	[172889-26-8]	CC1=CC=C(C=C1)C1=NN(C2=NC=NC(N)=C12)C(C)(C)C	"Potent, selective Src family kinase inhibitor"	"Potent inhibitor of Src-family tyrosine kinases. Inhibits p56lck and p59fynT (IC50 values are 5 and 6 nM respectively). Displays > 8000-fold selectivity over ZAP-70 and JAK2. Also moderately inhibits p38, CSK, PDGF receptors, RET-derived oncoproteins, c-Kit and Bcr-Abl."	"Hanke et al (1996) Discovery of a novel, potent, and src family-selective tyrosine kinase inhibitor. J.Biol.Chem. 271 695. PMID:8557675. Liu et al (1999) Structural basis for selective inhibition of Src family kinases by PP1. Chem.Biol. 6 671. PMID:10467133. Carlomagno et al (2002) The kinase inhibitor PP1 blocks tumorigenesis induced by RET oncogenes. Cancer Res. 62 1077. PMID:11861385. Bain et al (2003) The specificities of protein kinase inhibitors: an update. Biochem.J. 371 199. PMID:12534346. Tatton et al (2003) The src-selective kinase inhibitor PP1 also inhibits Kit and Bcr-Abl tyrosine kinases. J.Biol.Chem. 278 4847. PMID:12475982."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1459	SQ1341			Aug-2001
1398	Kenpaullone	[142273-20-9]	BrC1=CC=C2NC3=C(CC(=O)NC4=CC=CC=C34)C2=C1	Potent cyclin-dependent kinase inhibitor. Also inhibits GSK-3	"Potent inhibitor of CDK1/cyclin B and GSK-3_ (IC50 values are 0.4 and 0.23 _M respectively). Also inhibits CDK2/cyclin A, CDK2/cyclin E and CDK5/cyclin/p35 (IC50 values are 0.68, 7.5 and 0.85 _M respectively). Selective over c-src (IC50 = 15 _M), casein kinase 2 (IC50 = 20 _M), ERK1 (IC50 = 20 _M), ERK2 (IC50 = 9 _M) and a range of other protein kinases (IC50 values > 35 _M). Generates induced pluripotent stem cells (iPSCs) from somatic cells when used in combination with reprogramming factors; can replace Klf4."	"Schultz et al (1999) Paullones, a series of cyclin-dependent kinase inhibitors: synthesis, evaluation of CDK1/cyclin B inhibition, and in vitro antitumor activity. J.Med.Chem. 42 2909. PMID:10425100. Zaharevitz et al (1999) Discovery and initial characterization of the paullones, a novel class of small-molecule inhibitors of cyclin-dependent kinases. Cancer Res. 59 2566. PMID:10363974. Buolamwini (2000) Cell cycle targets in novel anticancer drug discovery. Curr.Pharm.Des. 6 379. PMID:10788588. Lyssiotis et al (2009) Reprogramming of murine fibroblasts to induced pluripotent stem cells with chemical complementation of Klf4. Proc.Natl.Acad.Sci.U.S.A. 106 8912. PMID:19447925 ."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1877	SQ1341			Feb-2002
1399	CP 339818 hydrochloride	[478341-55-8]	CCCCC\N=C2C1=CC=CC=C1N(CC3=CC=CC=C3)C=C/2.Cl	"Non-peptide, potent KV1.3 channel blocker"	"Potent, non-peptide KV1.3 channel antagonist that preferentially binds to the C-type inactivated state of the channel (IC50 ~ 200 nM) . Inhibits KV1.4 with an IC50 of ~ 300 nM. Selective over KV1.1, KV1.2, KV1.5, KV1.6, KV3.1-4, and KV4.2."	Nguyen et al (1996) Novel nonpeptide agents potently block the C-type inactivated conformation of Kv1.3 and suppress T cell activation. Mol.Pharmacol. 50 1672. PMID:8967992. Jager et al (1998) Regulation of mammalian Shaker-related K+ channels: evidence for non-conducting closed and non-conducting inactivated. J.Physiol. 506 291. PMID:9490854.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1896	SQ1341			Aug-2001
1400	SCH 202676 hydrobromide	[265980-25-4]	C\N=C1SN(C3=CC=CC=C3)C(C2=CC=CC=C2)=N/1.Br	Inhibitor of ligand binding to G-protein-coupled receptors	"Sulphydryl-reactive compound that inhibits agonist and antagonist binding to G-protein-coupled receptors. Inhibits a variety of GPCRs including adenosine, opioid, muscarinic, adrenergic and dopaminergic receptors (IC50 values are 0.1-1.8 _M)."	Fawzi et al (2001) SCH-202676: an allosteric modulator of both agonist and antagonist binding to G protein-coupled receptors. Mol.Pharmacol. 59 30. PMID:11125021. Gao et al (2004) Effects of the allosteric modulator SCH-202676 on adenosine and P2Y receptors. Life Sci. 74 3173. PMID:15081581. Lewandowicz et al (2006) The 'allosteric modulator' SCH-202676 disrupts G protein-coupled receptor function via sulphydryl-sensitive mechanisms. Br.J.Pharmacol. 147 422. PMID:16402041.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1860				Feb-2002
1401	NU 1025	[90417-38-2]	CC1=NC2=C(O)C=CC=C2C(=O)N1	Potent PARP inhibitor	"Novel, potent inhibitor of poly(ADP-ribose) polymerase (PARP). Ki and IC50 values are 48 and 400 nM respectively."	Bowman et al (1998) Potentiation of anti-cancer agent cytotoxicity by the potent poly(ADP-ribose) polymerase inhibitors NU1025 and NU1064. Br.J.Cancer. 78 1269. PMID:9823965. Griffin et al (1998) Resistance-modifying agents. 5. Synthesis and biological properties of quinazolinone inhibitors of the DNA repair enzyme poly(ADP-ribose) polymerase (PARP). J.Med.Chem. 41 5247. PMID:9857092. Delaney et al (2000) Potentiation of temozolomide and topotecan growth inhibition and cytotoxicity by novel poly(adenosine diphosphoribose) polymerase inhibitors in a panel of human tumor cell lines. Clin.Cancer.Res. 6 2860. PMID:10914735.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1859	SQ1341			Jul-2003
1402	SB 203580 hydrochloride	[869185-85-3]	Cl.CS(=O)C1=CC=C(C=C1)C1=NC(=C(N1)C1=CC=NC=C1)C1=CC=C(F)C=C1	Selective inhibitor of p38 MAPK; water-soluble	"Water-soluble salt of SB 203580 (Cat. No. 1202). Selective inhibitor of p38 mitogen-activated protein kinase (IC50 values are 50 and 500 nM for SAPK2a/p38 and SAPK2b/p38_2 respectively). Displays 100-500-fold selectivity over LCK, GSK3_ and PKB_. Shown to inhibit interleukin-2-induced T cell proliferation, cyclooxygenase-1 and -2, and thromboxane synthase."	Cuenda et al (1995) SB 203580 is a specific inhibitor of a MAP kinase homologue which is stimulated by cellular stresses and interleukin-1. FEBS Lett. 364 229. PMID:7750577. Saklatvala et al (1996) Role for p38 mitogen-activated protein kinase in platelet aggregation caused by collagen on a thromboxane analogue. J.Biol.Chem. 271 6586. PMID:8636072. Borsch-Haubold et al (1998) Direct inhibition of cyclooxygenase-1 and -2 by the kinase inhibitors SB 203580 and PD 98059. J.Biol.Chem. 273 28766. PMID:9786874. Davies et al (2000) Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem.J. 351 95. PMID:10998351.	Small Molecule	Sold with the permission of GlaxoSmithKline	http://www.tocris.com/dispprod.php?ItemId=1830	SQ1533			May-2001
1403	FPL 64176	[120934-96-5]	COC(=O)C1=C(C)NC(C)=C1C(=O)C1=CC=CC=C1CC1=CC=CC=C1	Potent activator of Ca2+ channels (L-type)	Potent activator of L-type Ca2+ channels (EC50 = 16 nM). 40-fold more potent than Bay K 8644 (Cat. No. 1544) as a positive inotrope in guinea pig atria.	"Zheng et al (1991) Pharmacological, radioligand binding, and electrophysiological characteristics of FPL 64176, a novel nondihydropyridine Ca2+ channel activator, in cardiac and vascular preparations. Mol.Pharmacol. 40 734. PMID:1719369. Baxter et al (1993) Discovery and synthesis of methyl 2,5-dimethyl-4-[2-(phenylmethyl)benzoyl]-1H-pyrrole-3-carboxylate (FPL 64176) and analogues: the first examples of a new class of calcium channel activator. J.Med.Chem. 36 2739. PMID:7692047. Rampe et al (1993) Comparison of the in vitro and in vivo cardiovascular effects of two structurally distinct Ca++ channel activators, BAY K 8644 and FPL 64176. J.Pharmacol.Exp.Ther. 265 1125. PMID:7685384."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1844	SQ1070			Oct-2003
1405	(-)-Terreic acid	[121-40-4]	CC1=C(O)C(=O)[C@@H]2O[C@@H]2C1=O	Selective inhibitor of BTK	"Selective inhibitor of Bruton's tyrosine kinase (BTK). Inhibits the interaction between PKCbII and BTK (IC50 ~ 30 mM) and the catalytic activity of BTK but does not affect the activity of PKC. Has little effect on the activities of Lyn, Syk, PKA, casein kinase I, ERK1, ERK2 and p38 kinases."	"Yamamoto et al (1980) Studies on terreic acid. Jpn.J.Antibiot. 33 320. PMID:7190624. Subramanian et al (1982) In vivo and in vitro studies on the binding nature of terreic acid with macromolecules such as protein and nucleic acids. Toxicol.Lett. 10 249. PMID:7080093. Kawakami et al (1999) Terreic acid, a quinone epoxide inhibitor of Bruton's tyrosine kinase. Proc.Natl.Acad.Sci.U.S.A. 96 2227. PMID:10051623."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1879				Sep-2002
1407	PP 2	[172889-27-9]	CC(C)(C)N1N=C(C2=C(N)N=CN=C12)C1=CC=C(Cl)C=C1	"Potent, selective Src family kinase inhibitor"	Selective inhibitor of Src-family tyrosine kinases. Inhibits p56lck and p59fynT (IC50 values are 4 and 5 nM respectively). Displays > 10000-fold selectivity over ZAP-70 and JAK2. Moderately inhibits CSK (IC50 = 0.73 _M). Negative control PP 3 (Cat. No. 2794) also available.	"Hanke et al (1996) Discovery of a novel, potent, and Src family-selective tyrosine kinase inhibitor. J.Biol.Chem. 271 695. PMID:8557675. Lawrence and Niu (1998) Protein kinase inhibitors: the tyrosine-specific protein kinases. Pharmacol.Ther. 77 81. PMID:9578319. Sanna et al (2000) A role for Src kinase in spontaneous epileptiform activity in the CA3 region of the hippocampus. Proc.Natl.Acad.Sci.U.S.A. 97 8653. PMID:10890901. Bain et al (2003) The specificities of protein kinase inhibitors: an update. Biochem.J. 371 199. PMID:12534346."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1845	SQ1341			Aug-2001
1408	YM 022	[145084-28-2]	CC1=CC(NC(=O)NC2N=C(C3=CC=CC=C3)C3=CC=CC=C3N(CC(=O)C3=C(C)C=CC=C3)C2=O)=CC=C1	"Highly potent, selective non-peptide CCK2 antagonist"	Extremely potent and highly selective non-peptide CCK2 silent antagonist (Ki values are 68 pM and 63 nM at CCK2 and CCK1 receptors respectively). Acts in vivo to potently inhibit gastrin-induced gastric acid secretion and histidine decarboxylase activation with a long duration of action.	"Nishida et al (1994) Pharmacological profile of (R)-1-[2,3-dihydro-1-(2'-methylphenacyl)-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-3-(3-methylphenyl)urea (YM022), a new potent and selective gastrin/cholecystokinin-B receptor antagonist, in vitro and in vivo. J.Pharmacol.Exp.Ther. 269 725. PMID:7910212. Beinborn et al (1998) Small synthetic ligands of the cholecystokinin-B/gastrin receptor can mimic the function of endogenous peptide hormones. Yale J.Biol.Med. 71 337. PMID:10461364. Kitano et al (2000) Long-lasting cholecystokinin2 receptor blockade after a single subcutaneous injection of YF476 or YM022. Br.J.Pharmacol. 130 699. PMID:10821801."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1461	SQ1070			Feb-2003
1409	CGP 39551	[127910-32-1]	NC(C(OCC)=O)/C=C(C)/CP(O)(O)=O	"Potent, selective and competitive NMDA antagonist"	"Potent, selective and competitive NMDA antagonist (Ki = 310 nM for inhibition of [3H]-CPP binding in rat brain). Centrally active upon oral administration in vivo."	"Fagg et al (1990) CGP 37849 and CGP 39551: novel and potent competitive N-methyl-D-asparate receptor antagonists with oral activity. Br.J.Pharmacol. 99 791. PMID:1972895. Loscher and Honack (1991) Anticonvulsant and behavioural effects of two novel competitive N-methyl-D-aspartic acid receptor antagonists, CGP 37849 and CGP 39551, in the kindling model of epilepsy. Comparison with MK-801 and carbamazepine. J.Pharmacol.Exp.Ther. 256 432. PMID:1671593. D'Hooge et al (1999) Effects of competitive NMDA receptor antagonists on excitatory amino-acid-evoked currents in mouse spinal cord. Fundam.Clin.Pharmacol. 13 67. PMID:10027090."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1878				May-2002
1410	SDM25N hydrochloride	[342884-71-3]	O[C@@]24[C@]3([C@@H]7C(N6)=C(C5=C6C=CC=C5)C4)C1=C(O7)C(O)=CC=C1CC2N(CC(C)=C)CC3.Cl	"Potent, selective non-peptide _ antagonist"	"Potent and highly selective non-peptide _ receptor antagonist (Ki values are 4.7, 3800 and 7900 nM for _, _ and _ receptors respectively). More selective than naltrindole (Cat. No. 0740)."	"McLamore et al (2001) Effect of N-alkyl and N-alkenyl substituents in noroxymorphindole, 17-substituted-6,7-dehydro-4,5_-epoxy-3,14-dihydroxy-6,7:2 ',3 '-indolomorphinans, on opioid receptor affinity, selectivity, and efficacy. J.Med.Chem. 44 1471. PMID:11311071."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=2024	SQ1341			Jan-2002
1412	Chromanol 293B	[163163-23-3]	O[C@H]1[C@H](N(C)S(=O)(CC)=O)C2=C(C=CC(C#N)=C2)OC(C)1C.O[C@@H]3[C@@H](N(C)S(=O)(CC)=O)C4=C(C=CC(C#N)=C4)OC(C)3C	IKs blocker. Also blocks ICFTR	"Blocker of the slow delayed rectifier K+ current (IKs) (IC50 = 1-10 _M). Also blocks the CFTR chloride current (ICFTR) (IC50 = 19 _M). (-)-[3R,4S]-Chromanol 293B (Cat. No. 1475) also available."	"Fujisawa et al (2000) Time-dependent block of the slowly activating delayed rectifier K+ current by chromanol 293B in guinea-pig ventricular cells. Br.J.Pharmacol. 129 1007. PMID:10696102. Sun et al (2001) Chromanol 293B inhibits slowly activating delayed rectifier and transient outward currents in canine left ventricular myocytes. J.Cardiovasc.Electrophysiol. 12 472. PMID:11332571. Bachmann et al (2001) Chromanol 293B, a blocker of the slow delayed rectifier K+ current (IKS), inhibits the CFTR Cl- current. Naunyn Schmiedebergs Arch.Pharmacol. 363 590. PMID:11414653."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=2073				Jan-2002
1413	NAS-181	[1217474-40-2]	CS(=O)(O)=O.CS(=O)(O)=O.N1(CC2=CC3=C(C(OC[C@H]4CNCCO4)=CC=C3)OC2)CCOCC1	Selective r5-HT1B antagonist. Active in vivo	"Potent, selective antagonist at the rat 5-HT1B receptor (Ki = 47 nM). Increases synthesis and metabolism of 5-HT in the brain following systemic administration and improves passive avoidance retention performance in vivo. Increases subthalamic nucleus-triggered complex EPSCs and burst firing in SNr GABA neurons"	"Berg et al (1998) (R)-(+)-2-[[[3-Morpholinomethyl)-2H-chromen-8-yl]oxy]methyl]morpholine methanesulfonate: a new selective rat 5-hydroxytryptamine1B receptor antagonist. J.Med.Chem. 41 1934. PMID:9599242. Stenfors et al (2000) Enhanced 5-HT metabolism and synthesis rate by the new selective r5-HT1B receptor antagonist, NAS-181 in the rat brain. Neuropharmacology 39 553. PMID:10728876. Eriksson et al (2008) Blockade of 5-HT1B receptors facilitates contextual aversive learning in mice by disinhibition of cholinergic and glutamatergic neurotransmission. Neuropharmacology 54 1041. PMID:18394658. Ding et al (2013) Presynaptic serotonergic gating of the subthalamonigral glutamatergic projection. J.Neurosci. 33 4875. PMID:23486958."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=2072	SQ1341			Aug-2003
1414	Scopolamine hydrobromide	[114-49-8]	O=C([C@@H]([C@]3=CC=CC=C3)CO)O[C@H]1C[C@H]4[C@H](O2)[C@H]2[C@H](N4C)C1.Br	Non-selective muscarinic antagonist	Non-selective muscarinic antagonist. Widely used clinically to treat motion sickness.	"Parkes (1965) An examination of central actions characteristic of scopolamine: comparison of central and peripheral activity in scopolamine, atropine and some synthetic basic esters. Psychopharmacologia 7 1. PMID:5830966. Nakao et al (1999) Cerebral blood flow responses to somatosensory stimulation are unaffected by scopolamine in unanesthetized rat. J.Pharmacol.Exp.Ther. 290 929. PMID:10411611. Jones and Shannon (2000) Effects of scopolamine in comparison with apomorphine and phencyclidine on prepulse inhibition in rats. Eur.J.Pharmacol. 391 105. PMID:10720641."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=2074	SQ1533			Jul-2001
1415	1400W dihydrochloride	[214358-33-5]	Cl.Cl.CC(=N)NCC1=CC=CC(CN)=C1	"Potent, highly selective iNOS inhibitor"	"Slow, tight binding, potent and highly selective inhibitor of inducible nitric oxide synthase (Kd = 7 nM). Selective over nNOS and eNOS (Ki values are 2 and 50 _M respectively). Cell-permeable and active in vivo."	"Garvey et al (1997) 1400W is a slow, tight binding, and highly selective inhibitor of inducible nitric-oxide synthase in vitro and in vivo. J.Biol.Chem. 272 4959. PMID:9030556. Thomsen et al (1997) Selective inhibition of inducible nitric oxide inhibits tumor growth in vivo: studies with 1400W, a novel inhibitor. Cancer Res. 57 3300. PMID:9242464. Parmentier et al (1999) Selective inhibition of inducible nitric oxide synthase prevents ischaemic brain injury. Br.J.Pharmacol. 127 546. PMID:10385257."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1475				Feb-2002
1416	Homoharringtonine	[26833-87-4]	O=C([C@](CCCC(O)(C)C)(O)CC(OC)=O)O[C@@H]1C(OC)=C[C@@](N(CCC5)CCC2=CC4=C(OCO4)C=C23)5[C@]31[H]	Inhibitor of protein synthesis. Antileukemic agent	Inhibitor of protein synthesis. Blocks elongation phase of translation by binding to the 60-S ribosome subunit. Antileukemic.	"Fresno et al (1977) Inhibition of translation in eukaryotic systems by harringtonine. Eur.J.Biochem. 72 323. PMID:319998. Zhou et al (1995) Homoharringtonine: an effective new natural product in cancer chemotherapy. Bull.Cancer 82 987. PMID:8745664. Cai et al (2001) Apoptotic response to homoharringtonine in human wt p53 leukemic cells is independent of reactive oxygen species generation and implicates Bax translocation, mitochondrial cytochrome c release and caspase activation. Leukemia 15 567. PMID:11368358."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1476	SQ1533			Jul-2001
1417	Daidzein	[486-66-8]	OC1=CC=C(C=C1)C1=COC2=CC(O)=CC=C2C1=O	Arrests cell cycle in G1 phase	Analog of the phytoestrogen genistein (Cat. No. 1110). Blocks G1 phase cell cycle progression. Agonist at estrogen receptors.	Jing et al (1993) Differentiation of promyelocytic leukemia cells HL-60 induced by daidzein in vitro and in vivo. Anticancer Res. 13 1049. PMID:8352524. Higashi and Ogawara (1994) Daidzein inhibits insulin- or insulin-like growth factor-1-mediated signaling in cell cycle progression of Swiss 3T3 cells. Biochim.Biophys.Acta 1221 29. PMID:8130274. Casanova et al (1999) Development effects of dietary phytoestrogens in Sprague Dawley rats and interactions of genistein and daidzein with rat estrogen receptors _ and _ in vitro. Toxicol.Sci. 51 236. PMID:10543025.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1551	SQ1533			Jan-2002
1418	Resveratrol	[501-36-0]	OC1=CC=C(C=C1)\C=C\C1=CC(O)=CC(O)=C1	Cyclooxygenase inhibitor	"A phytoestrogen with antitumor, antioxidant, antiplatelet, anti-inflammatory and antifungal effects. Inhibits cytochrome P450 1A1 (IC50 = 23 _M) and displays mixed agonist/antagonist actions at ER_ and ER_ estrogen receptors. Converted into the anticancer agent piceatannol (Cat. No. 1554) by cytochrome P450 1B1."	Kimura et al (1985) Effects of stilbenes on arachidonate metabolism in leukocytes. Biochim.Biophys.Acta 834 275. PMID:3922423. Chun et al (1999) Resveratrol is a selective human cytochrome P450 1A1 inhibitor. Biochem.Biophys.Res.Commun. 262 20. PMID:10448061. Fremont (2000) Biological effects of resveratrol. Life Sci. 66 663. PMID:10680575. Bowers et al (2000) Resveratrol acts as a mixed agonist/antagonist for estrogen receptors _ and _. Endocrinology 141 3657. PMID:11014220. Baur and Sinclair (2006) Therapeutic potential of resveratrol: the in vivo evidence. Nat.Rev.Drug Discov. 5 493. PMID:16732220. Baptista et al (2013) Regulation of histone H2A.Z exprsesion is mediated by sirtuin 1 in prostate cancer. Oncotarget 4 1673. PMID:24127549.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1552	SQ1533			Sep-2001
1419	Naloxone benzoylhydrazone	[119630-94-3]	O[C@@]23[C@@]([C@]5([H])/C(CC3)=N/NC(C6=CC=CC=C6)=O)(CC4)C1=C(O5)C(O)=CC=C1C[C@H]2N4CC=C	"Full _ agonist, partial _ and _ agonist and antagonizes agonist-induced activation of NOP"	"Mixed opioid receptor agonist/antagonist. Acts as a potent and full agonist at _, a partial agonist at _ and _ opioid receptors (pEC50 values are 9.45, 8.74 and 8.61 in a cAMP assay, 9.70, 8.59 and 8.49 in a [35S]GTP_S binding assay respectively). Fails to exert agonist effects at NOP receptors and antagonizes agonist-induced NOP activation. Stimulates _-, _- and _-mediated analgesia and blocks NOP-induced supraspinal nociception."	Gistrak et al (1989) Pharmacological actions of a novel mixed opiate agonist/antagonist: naloxone benzoylhydrazone J.Pharmacol.Exp.Ther. 251 469. PMID:2553921. Olianas et al (2006) Agonist activity of naloxone benzoylhydrazone at recombinant and native opioid receptors. Br.J.Pharmacol. 147 360. PMID:16402046. Connor and Kitchen (2006) Has the sun set on _3-opioid receptors? Br.J.Pharmacol 147 349. PMID:16402044.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1553	SQ1341			Nov-2005
1422	DCEBIO	[60563-36-2]	CCN1C(=O)NC2=C1C=C(Cl)C(Cl)=C2	Activates Cl- conductance and hKCa3.1 channels	Stimulates Cl- secretion via the activation of hKCa3.1 (IK1) potassium channels and an apical Cl- conductance carried by the CFTR channel. More potent than its analog 1-EBIO (Cat. No. 1041).	Singh et al (2001) Benzimidazolone activators of chloride secretion: potential therapeutics for cystic fibrosis and chronic obstructive pulmonary disease. J.Pharmacol.Exp.Ther. 296 600. PMID:11160649. Hamilton and Kiessling et al (2006) DCEBIO stimulates Cl- secretion in the mouse jejunum. Am.J.Physiol.Cell Physiol. 290 152. PMID:16135545.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1206				Nov-2001
1425	(S)-(+)-Dimethindene maleate	[136152-65-3]	C[C@H](C3=NC=CC=C3)C2=C(CCN(C)C)CC1=CC=CC=C12.OC(=O)\C=C/C(O)=O	M2-selective antagonist	"Enantiomer that is a subtype-selective M2 muscarinic receptor antagonist (pKi values are 7.08, 7.78, 6.70 and 7.00 for M1, M2, M3 and M4 receptors respectively). Also H1 histamine receptor antagonist (pKi = 7.48)."	Pfaff et al (1995) The (S)-(+)-enantiomer of dimethindene: a novel M2-selective muscarinic receptor antagonist. Eur.J.Pharmacol. 286 229. PMID:8608784. Lambrecht et al (1999) Neuronal soma-dendritic and prejunctional M1-M4 receptors in gastrointestinal and genitourinary smooth muscle. Life Sci. 64 403. PMID:10069503.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1209	SQ1533			Jun-2002
1426	PPT	[263717-53-9]	CCCC1=C(N(N=C1C1=CC=C(O)C=C1)C1=CC=C(O)C=C1)C1=CC=C(O)C=C1	Subtype-selective ER_ agonist	"Potent, subtype-selective estrogen receptor agonist (EC50 ~ 200 pM); displays 410-fold selectivity for ER_ over ER_. Prevents ovariectomy-induced weight gain and loss of bone mineral density, and induces gene expression in the hypothalamus following systemic administration in vivo."	"Kraichely et al (2000) Conformational changes and coactivator recruitment by novel ligands for estrogen receptor-_ and estrogen receptor-_: correlations with biological character and distinct differences among SRC coactivator family members. Endocrinology 141 3534. PMID:11014206. Stauffer et al (2000) Pyrazole ligands: structure-affinity/activity relationships and estrogen receptor-_-selective agonists. J.Med.Chem. 43 4934. PMID:11150164. Harris et al (2002) Characterization of the biological roles of the estrogen receptors, ER_ and ER_, in estrogen target tissues in vivo through the use of an ER_-selective ligand. Endocrinology 143 4172. PMID:12399409."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1208	SQ1341			Jan-2002
1427	Citalopram hydrobromide	[59729-32-7]	Br.CN(C)CCCC1(OCC2=C1C=CC(=C2)C#N)C1=CC=C(F)C=C1	Highly potent and selective 5-HT uptake inhibitor	"Highly selective and potent 5-HT uptake inhibitor with no effect on noradrenalin or dopamine uptake (IC50 values are 1.8, 8800 and 41000 nM respectively). Has negligible activity at a wide range of receptors. Also available as part of the Serotonin Uptake Inhibitor Tocriset."	"Hyttel (1982) Citalopram - pharmacological profile of a specific serotonin uptake inhibitor with antidepressant activity. Prog.Drug Metabolism. Eds. Bridges, J. W. & Ch 6 277. Auerbach and Hjorth (1995) Effect of chronic administration of the selective serotonin (5-HT) uptake inhibitor citalopram on extracellular 5-HT and apparent autoreceptor sensitivity in rat forebrain in vivo. Naunyn Schmiedebergs Arch.Pharmacol. 352 597. PMID:9053730. Mateo et al (2000) Inhibition of 5-hydroxytryptamine reuptake by the antidepressant citalopram in the locus coeruleus modulates the rat brain noradrenergic transmission in vivo. Neuropharmacology 39 2036. PMID:10963747."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1211	SQ1533			Jan-2002
1430	DuP 697	[88149-94-4]	CS(=O)(=O)C1=CC=C(C=C1)C1=C(SC(Br)=C1)C1=CC=C(F)C=C1	Cyclooxygenase-2 (COX-2) inhibitor	Potent and selective inhibitor of cyclooxygenase-2 (IC50 values are 10 and 800 nM for COX-2 and COX-1 respectively). Inhibits prostaglandin synthesis and is anti-inflammatory in vivo. Orally active.	"Gans et al (1990) Anti-inflammatory and safety profile of DuP 697, a novel orally effective prostaglandin synthesis inhibitor. J.Pharmacol.Exp.Ther. 254 180. PMID:2366180. Gierse et al (1995) Expression and selective inhibition of the constitutive and inducible forms of human cyclo-oxygenase. Biochem.J. 305 479. PMID:7832763. Rossoni et al (2002) Inhibition of cyclo-oxygenase-2 exacerbates ischaemia-induced acute myocardial dysfunction in the rabbit. Br.J.Pharmacol. 135 1540. PMID:11906968."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1101	SQ1341			Jul-2002
1435	SQ 22536	[17318-31-9]	NC1=C2N=CN(C3CCCO3)C2=NC=N1	Adenylyl cyclase inhibitor	Inhibitor of adenylyl cyclase (IC50 = 1.4 _M). Inhibits PGE1-stimulated increases in cAMP levels in intact human platelets.	Harris et al (1979) Inhibition of adenylate cyclase in human blood platelets by 9-substituted adenine derivatives. J.Cyclic Nucleotide Res. 5 125. PMID:221552. Fabbri et al (1991) Inhibition of adenylate cyclase of catfish and rat hepatocyte membranes by 9-(tetrahydro-2-furyl)adenine (SQ 22536). J.Enzyme Inhib. 5 87. PMID:1669444. Hourani et al (2001) Role of cyclic nucleotides in vasodilations of the rat thoracic aorta induced by adenosine analogues. Br.J.Pharmacol. 133 833. PMID:11454656.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1217	SQ1341			Aug-2007
1436	MDL 12330A hydrochloride	[40297-09-4]	C1(/N[C@@H]2[C@H]([C@]3=CC=CC=C3)CCC2)=N\CCCCCCCCCCC1.Cl	Adenylyl cyclase inhibitor; also cyclic nucleotide PDE inhibitor	"Inhibitor of adenylyl cyclase. Also inhibits cAMP and cGMP phosphodiesterases, and blocks slow extracellular and store-operated Ca2+ entry into cells."	"Guellaen et al (1977) RMI 12330 A, an inhibitor of adenylate cyclase in rat liver. Biochim.Biophys.Acta 484 465. PMID:911855. Hunt and Evans (1980) RMI 12330A, an inhibitor of cyclic nucleotide phosphodiesterases and adenylate cyclase in kidney preparations. Biochim.Biophys.Acta 613 499. PMID:6256001. van Rossum et al (2000) Ca2+ entry mediated by store depletion, S-nitrosylation, and TRP3 channels. Comparison of coupling and function. J.Biol.Chem. 275 28562. PMID:10878007."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1216				Mar-2011
1437	D609	[83373-60-8]	S=C(S[K])OC1CC2C3CCCC3C1C2	Selective PC-PLC inhibitor	Selective competitive phosphatidyl choline-specific phospholipase C (PC-PLC) inhibitor (Ki = 6.4 _M); antiviral and antitumor agent. Suppresses LPS- and IFN_-induced NO production (IC50 = 20 mg/ml) and blocks oxidative glutamate toxicity in nerve cells. Antioxidant in vivo.	"Tschiakowsky et al (1994) Induction of nitric oxide synthase activity in phagocytic cells inhibited by tricyclodecan-9-yl-xanthogenate (D609). Br.J.Pharmacol. 113 664. PMID:7532078. Amtmann (1996) The antiviral, antitumoural xanthate D609 is a competitive inhibitor of phosphatidylcholine-specific phospholipase C. Drugs Exp.Clin.Res. 22 287. PMID:9034754. Li et al (1998) Phosphatidylcholine-specific phospholipase C regulates glutamate-induced nerve cell death. Proc.Natl.Acad.Sci.U.S.A. 95 7748. PMID:9636222. Zhou et al (2001) D609 inhibits ionizing radiation-induced oxidative damage by acting as a potent antioxidant. J.Pharmacol.Exp.Ther. 298 103. PMID:11408530."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1215				Aug-2003
1440	BMY 14802 hydrochloride	[105565-55-7]	Cl.OC(CCCN1CCN(CC1)C1=NC=C(F)C=N1)C1=CC=C(F)C=C1	Sigma antagonist. Antipsychotic agent	Potent sigma receptor antagonist (IC50 = 112 nM) with modest to weak affinity for 5-HT1A and _1 receptors. Antipsychotic following oral administration and acts via indirect modulation of central dopaminergic systems.	Yevich et al (1992) Synthesis and biological characterization of _-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazinebutanol and analogues as potential atypical antipsychotic agents. J.Med.Chem. 35 4516. PMID:1361578. Zhang et al (1993) Further characterization of the effects of BMY 14802 on dopamine neuronal activity. Synapse 15 276. PMID:7908761. Taylor et al (1993) A role for sigma binding in the antipsychotic profile of BMY 14802? NIDA Res.Monogr. 133 125. PMID:8232511.	Small Molecule	Sold with the permission of Bristol-Myers Squibb Company	http://www.tocris.com/dispprod.php?ItemId=1083	SQ1341			Jan-2003
1441	BMS 182874 hydrochloride	[1215703-04-0]	Cl.CN(C)C1=C2C=CC=C(C2=CC=C1)S(=O)(=O)NC1=C(C)C(C)=NO1	"Highly selective, orally active non-peptide ETA antagonist"	"Potent, selective and competitive non-peptide endothelin ETA receptor antagonist (Ki = 48 nM). Displays > 1000-fold selectivity over ETB receptors. Inhibits ET-1-induced pressor response following oral or intravenous administration in vivo. Inhibits ET-1-induced longitudinal muscle contraction in the mouse colon in vitro."	"Stein et al (1994) The discovery of sulfonamide endothelin antagonists and the development of the orally active ETA antagonist 5-(Dimethylamino)-N-(3,4-dimethyl-5-isoazolyl)-1-naphthalenesulfonamide. J.Med.Chem. 37 329. PMID:8308857. Webb et al (1995) BMS-182874 is a selective, nonpeptide endothelin ETA receptor antagonist. J.Pharmacol.Exp.Ther. 272 1124. PMID:7891325. Khan et al (2006) Pharmacological characterization of endothelin receptors-mediated contraction in the mouse isolated proximal and distal colon. Br.J.Pharmacol. 147 607. PMID:16432510."	Small Molecule	"Sold with the permission of Bristol-Myers Squibb Company, subject to U.S. Patent No. 5,378,715 and other US and foreign patents"	http://www.tocris.com/dispprod.php?ItemId=1219	SQ1341			Dec-2001
1442	BMY 45778	[152575-66-1]	OC(=O)COC1=CC(=CC=C1)C1=C(N=CO1)C1=NC(=C(O1)C1=CC=CC=C1)C1=CC=CC=C1	Non-prostanoid prostacyclin IP receptor partial agonist	Non-prostanoid prostacyclin mimetic that acts as a partial agonist at IP1 prostacyclin receptors. Potently inhibits platelet aggregation in vitro (IC50 = 27-35 nM).	"Meanwell et al (1993) Nonprostanoid prostacyclin mimetics. 5. Structure-activity relationships associated with [3-[4-(4,5-diphenyl-2-oxazolyl)-5-oxazolyl]phenoxy]acetic acid. 36 3884. PMID:7504734. Seiler et al (1997) [3-[4-(4,5-Diphenyl-2-oxazolyl)-5-oxazolyl]phenoxy]acetic acid (BMY 45778) is a potent non-prostanoid prostacyclin partial agonist: effects on platelet aggregation, adenylyl cyclase, cAMP levels, protein kinase, and iloprost binding. Prostaglandins 53 21. PMID:9068064. Rudd et al (2000) Non-prostanoid prostacyclin mimetics as neuronal stimulants in the rat: comparison of vagus nerve and NANC innervation of the colon. Br.J.Pharmacol. 129 782. PMID:10683203."	Small Molecule	Sold with the permission of Bristol-Myers Squibb Company	http://www.tocris.com/dispprod.php?ItemId=1082	SQ1341			Jul-2003
1447	SKF 81297 hydrobromide	[67287-39-2]	Br.OC1=C(O)C(Cl)=C2CCNCC(C3=CC=CC=C3)C2=C1	D1 agonist	Dopamine D1-like receptor agonist. Centrally active following systemic administration in vivo.	"Arnt et al (1988) Relative dopamine D1 and D2 receptor affinity and efficacy determine whether dopamine agonists induce hyperactivity or oral stereotypy in rats. Pharmacol.Toxicol. 62 121. PMID:3259694. Peacock et al (1990) The effects of dopamine D1 and D2 receptor agonists and antagonists in monkeys withdrawn from long-term neuroleptic treatment. Eur.J.Pharmacol. 186 49. PMID:1980891. Reavill et al (1993) Pharmacological characterization of the discriminative stimulus properties of the dopamine D1 agonist, SKF 81297. Behav.Pharmacol. 4 135. PMID:11224180."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1099				Sep-2003
1448	Formoterol hemifumarate	[43229-80-7]	[H]OC(=O)\C=C\C(=O)O[H].COC1=CC=C(C=C1)C[C@H](C)NC[C@@H](O)C1=CC(NC([H])=O)=C(O)C=C1.COC1=CC=C(C=C1)C[C@H](C)NC[C@@H](O)C1=CC(NC([H])=O)=C(O)C=C1	Potent and selective _2 agonist	"Potent, selective and long-acting _2-adrenoceptor agonist. Displays 330-fold selectivity for _2 over _1 receptors (pKd values are 8.12 and 5.58 respectively). Potently relaxes guinea pig trachea (pD2 = 9.29), and is longer-acting and 100-fold more potent than salbutamol."	"Decker et al (1982) Effects of N-aralkyl substitution of _-agonists on _- and _-adrenoceptor subtypes: pharmacological studies and binding assays. J.Pharm.Pharmacol. 34 107. PMID:6121868. Anderson (1993) Formoterol: pharmacology, molecular basis of agonism, and mechanism of long duration of a highly potent and selective _2-adrenoceptor agonist bronchodilator. Life Sci. 52 2145. PMID:8099696. Naline et al (1994) Relaxant effects and durations of action of formoterol and salmeterol on the isolated human bronchus. Eur.Respir.J. 7 914. PMID:7914176."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1029	SQ1070			Aug-2001
1453	Clemastine fumarate	[14976-57-9]	[H]OC(=O)\C=C\C(=O)O[H].CN1CCC[C@@H]1CCO[C@](C)(C1=CC=CC=C1)C1=CC=C(Cl)C=C1	H1 antagonist	H1-receptor antagonist. Clinically-used antihistamine.	"Hartmann et al (1981) Modulation of histamine-induced bronchoconstriction with inhaled, oral, and intravenous clemastine in normal and asthmatic subjects. Thorax 36 737. PMID:7330790. Dorsch et al (1982) Histamine1-histamine2 antagonism: effect of combined clemastine and cimetidine pretreatment on allergen and histamine-induced reactions of the guinea pig lung in vivo and in vitro. Agents Actions 12 113. PMID:6177209. Nair and Schwartz (1983) Effect of histamine and histamine antagonists on natural and antibody-dependent cellular cytotoxicity of human lymphocytes in vitro. Cell.Immunol. 81 45. PMID:6225527."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1030	SQ1533			Sep-2001
1454	GYKI 52466 dihydrochloride	[102771-26-6]	Cl.CC1=NN=C(C2=CC=C(N)C=C2)C2=C(C1)C=C1OCOC1=C2	Selective non-competitive AMPA antagonist	"Selective non-competitive AMPA receptor antagonist (IC50 values are 10-20, ~ 450 and >> 50 _M for AMPA- , kainate- and NMDA-induced responses respectively). Skeletal muscle relaxant and orally-active anticonvulsant. Has anti-proliferative effects in transformed cells. Also available as part of the AMPA Receptor Tocriset. Also available as part of the Kainate Receptor Tocriset."	"Tarnawa et al (1989) Electrophysiological studies with a 2,3-benzodiazepine muscle relaxant: GYKI 52466. Eur.J.Pharmacol. 167 193. PMID:2574112. Donevan and Rogawsk (1993) GYKI 52466, a 2,3-benzodiazepine, is a highly selective, non-competitive antagonist of AMPA/kainate receptor responses. Neuron 10 51. PMID:7678966. Paternain et al (1995) Selective antagonism of AMPA receptors unmasks kainate receptor-mediated responses in hippocampal neurons. Neuron 14 185. PMID:7826635. Rzeski et al (2001) Glutamate antagonists limit tumor growth. Proc.Natl.Acad.Sci.USA 98 6372. PMID:11331750. Szabados et al (2001) Comparison of anticonvulsive and acute neuroprotective activity of three 2,3-benzodiazepine compounds, GYKI 52466, GYKI 53405, and GYKI 53655. Brain Res.Bull. 55 387. PMID:11489346."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1046	SQ1533			Nov-2001
1459	SU 4312	[5812-07-7]	CN(C)C1=CC=C(C=C1)\C=C1/C(=O)NC2=CC=CC=C12	Potent inhibitor of VEGFR tyrosine kinase	Potent and selective inhibitor of VEGFR and PDGFR tyrosine kinases (IC50 values are 0.8 and 19.4 _M respectively). Selective over EGFR and c-Src tyrosine kinases.	Sun et al (1998) Synthesis and biological evaluations of 3-substituted indol-2-ones: a novel class of tyrosine kinase inhibitors that exhibit selectivity toward particular receptor tyrosine kinases. J.Med.Chem. 41 2588. PMID:9651163. Zaman et al (1998) Tyrosine kinase activity of purified recombinant cytoplasmic domain of platelet-derived growth factor _-receptor (_-PDGFR) and discovery of a novel inhibitor of receptor tyrosine kinases. Biochem.Pharmacol. 57 57. PMID:9920285. Kendall et al (1999) Vascular endothelial growth factor receptor KDR tyrosine kinase activity is increased by autophosphorylation of two activation loop tyrosine residues. J.Biol.Chem. 274 6453. PMID:10037737.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1048	SQ1341			Sep-2001
1460	PACOCF3	[141022-99-3]	FC(F)(F)C(CCCCCCCCCCCCCCC)=O	Phospholipase A2 inhibitor	Phospholipase A2 inhibitor. Can also alter Ca2+ signaling in renal tubular cells.	Ackermann et al (1995) Inhibition of macrophage Ca2+-independent phospholipase A2 by bromoenol lactone and trifluoromethyl ketones. J.Biol.Chem. 270 445. PMID:7814408. Lio et al (1996) Irreversible inhibition of Ca2+-independent phospholipase A2 by methyl arachidonyl fluorophosphonate. Biochim.Biophys.Acta 1302 55. PMID:8695655. Jan et al (2000) Dual action of palmitoyl trifluoromethyl ketone (PACOCF3) on Ca2+ signaling: activation of extracellular Ca2+ influx and alteration of ATP- and bradykinin-induced Ca2+ responses in Madin Darby canine kidney cells. Arch.Toxicol. 74 447. PMID:11097381.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1081				Nov-2001
1461	Linomide	[84088-42-6]	CN(C(=O)C1=C(O)C2=CC=CC=C2N(C)C1=O)C1=CC=CC=C1	Immunomodulator with antiangiogenic properties	Immunomodulator with stimulatory and antitumor properties. Inhibits in vivo apoptosis of T cells and inhibits angiogenesis in rats in vivo.	Ichikawa et al (1992) The antitumor effects of the quinoline-3-carboxamide linomide on Dunning R-3327 rat prostatic cancers. Cancer Res. 52 3022. PMID:1591718. Vukanovic et al (1993) Antiangiogenic effects of the quinoline-3-carboxamide linomide. Cancer Res. 53 1833. PMID:7682157. Gonzalo et al (1994) Linomide inhibits programmed cell death of peripheral T cells in vivo. Eur.J.Immunol. 24 48. PMID:8020570.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1134	SQ1533			Feb-2002
1467	Daunorubicin hydrochloride	[23541-50-6]	NC1CC(O[C@H]2C[C@@]([C@@](C)=O)(O)CC3=C2C(O)=C5C(C(C4=CC=CC(OC)=C4C5=O)=O)=C3O)OC(C)C1O.Cl	RNA synthesis inhibitor	Anticancer agent that is clinically used to treat nonlymphocytic leukemia. Inhibits RNA and DNA synthesis and causes DNA fragmentation in vivo. Reduces tau mRNA levels in vitro.	"Aubel-Sadron and Londos-Gagliardi (1984) Daunorubicin and doxorubicin, anthracycline antibiotics, a physicochemical and biological review. Biochimie 66 333. PMID:6380596. Gewirtz (1999) A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem.Pharmacol. 57 727. PMID:10075079. Laurent and Jaffrezou (2001) Signaling pathways activated by daunorubicin. Blood 98 913. PMID:11493433. Dickey et al (2006) Pharmacologic reductions of total tau levels; implications for the role of microtubule dynamics in regulating tau expression. Mol.Neurodegen. 1 6. PMID:16930453."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1103	SQ1533			Oct-2001
1469	CGP 37849	[127910-31-0]	NC(C(O)=O)/C=C(C)/CP(O)(O)=O	Potent and selective NMDA antagonist	"Potent, selective and competitive NMDA receptor antagonist (Ki = 35 nM). Anticonvulsive following oral administration in vivo."	"Fagg et al (1990) CGP 37849 and CGP 39551: novel and potent competitive N-methyl-D-asparate receptor antagonists with oral activity. Br.J.Pharmacol. 99 791. PMID:1972895. Pozza et al (1990) Electrophysiological characterization of a novel potent and orally active NMDA receptor antagonist: CGP 37849 and its ethylester CGP 39551. Eur.J.Pharmacol. 182 91. PMID:1976098. Loscher and Honack (1991) Anticonvulsant and behavioural effects of two novel competitive N-methyl-D-aspartic acid receptor antagonists, CGP 37849 and CGP 39551, in the kindling model of epilepsy. Comparison with MK-801 and carbamazepine. J.Pharmacol.Exp.Ther. 256 432. PMID:1671593."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1119				Mar-2002
1470	Flecainide acetate	[54143-56-5]	CC(O)=O.FC(F)(F)COC1=CC=C(OCC(F)(F)F)C(=C1)C(=O)NCC1CCCCN1	Cardiac Na+ channel blocker. Antiarrhythmic	Open Na+ channel blocker that inhibits fast Na+ current in cardiac muscle in a use- and concentration-dependent manner. Orally-active class Ic antiarrhythmic agent.	"Banitt et al (1977) Antiarrhythmics. 2. Synthesis and antiarrhythmic activity of N-(piperidylalkyl)trifluoroethoxybenzamides. J.Med.Chem. 20 821. PMID:874956. Singh et al (1984) The electrophysiology and pharmacology of verapamil, flecainide, and amiodarone: correlations with clinical effects and antiarrhythmic actions. Ann.N.Y.Acad.Sci. 17 251. PMID:6395762. Rouet and Ducouret (1994) Use-and concentration-dependent effects of flecainide in guinea pig right ventricular muscle. J.Cardiovasc.Pharmacol. 24 177. PMID:7526048."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1133	SQ1533			Jan-2002
1471	Etomidate	[33125-97-2]	O=C(OCC)C1=CN=CN1[C@@H]([C@@]2=CC=CC=C2)C	GABA mimetic and GABA modulatory agent	"General anesthetic with GABA modulatory and GABA-mimetic actions; selectively interacts with _2- and _3-subunit containing GABAA receptors. Short acting and potent hypnotic, with low toxicity."	Giese et al (1983) Etomidate: a new intravenous anesthetic induction agent. Pharmacother. 3 251. PMID:6359080. Belelli et al (1997) The interaction of the general anesthetic etomidate with the _-aminobutyric acid type A receptor is influenced by a single amino acid. Proc.Natl.Acad.Sci.U.S.A. 94 11031. PMID:9380754. Moody et al (1998) Distinct structural requirements for the direct and indirect actions of the anaesthetic etomidate at GABAA receptors. Toxicol.Lett. 100-101 209. PMID:10049144.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1120	SQ1533			Nov-2001
1472	Suramin hexasodium salt	[129-46-4]	[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].CC1=CC=C(C=C1NC(=O)C1=CC=CC(NC(=O)NC2=CC=CC(=C2)C(=O)NC2=C(C)C=CC(=C2)C(=O)NC2=C3C(C=C(C=C3S([O-])(=O)=O)S([O-])(=O)=O)=C(C=C2)S([O-])(=O)=O)=C1)C(=O)NC1=C2C(C=C(C=C2S([O-])(=O)=O)S([O-])(=O)=O)=C(C=C1)S([O-])(=O)=O	Non-selective P2 antagonist	Non-selective P2 purinergic antagonist. Also blocks calmodulin binding to recognition sites and G protein coupling to G protein-coupled receptors. Increases open probability of ryanodine receptor (RyR) channels. Anticancer and antiviral agent.	Voogd et al (1993) Recent research on the biological activity of suramin. Pharmacol.Rev. 45 177. PMID:8396782. Beindl et al (1996) Inhibition of receptor/G protein coupling by suramin analogues. Mol.Pharmacol. 50 415. PMID:8700151. Charlton et al (1996) PPADS and suramin as antagonists at cloned P2Y- and P2U-purinoceptors. Br.J.Pharmacol. 118 704. PMID:8762097. Klinger et al (2001) Suramin and the suramin analogue NF307 discriminate among calmodulin-binding sites. Biochem.J. 355 827. PMID:11311147. Hill et al (2004) Functional regulation of the cardiac ryanodine receptor by suramin and calmodulin involves multiple binding sites. Mol.Pharmacol. 65 1258. PMID:15102954.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1224	SQ1533			Sep-2002
1475	"(-)-[3R,4S]-Chromanol 293B"	[163163-24-4]	CCS(=O)(=O)N(C)[C@@H]1[C@@H](O)C(C)(C)OC2=C1C=C(C=C2)C#N	IKs blocker. Enantiomer of Chromanol 293B (Cat. No. 1412)	"Enantiomer that selectively inhibits the slow component of delayed rectifier K+ current (IKs). Block is use-dependent and 7-fold more potent than the (+)-(3S,4R) enantiomer (IC50 values are 1.36 and 9.6 _M respectively). Has negligible inhibitory action at KV11.1 (hERG) channels (IC50 > 30 _M). Racemate Chromanol 293B (Cat. No. 1412) also available."	Yang et al (2000) Stereoselective interactions of the enantiomers of chromanol 293B with human voltage-gated potassium channels. J.Pharmacol.Exp.Ther. 294 955. PMID:10945846. Lerche et al (2001) Molecular impact of MinK on the enantiospecific block of IKs by chromanols. Br.J.Pharmacol. 131 1503. PMID:11139424. Seebohm et al (2001) A kinetic study on the stereospecific inhibition of KCNQ1 and IKs by the chromanol 293B. Br.J.Pharmacol. 134 1647. PMID:11739240.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1228	SQ1341			Feb-2002
1477	GR 127935 hydrochloride	[148642-42-6]	Cl.COC1=C(C=C(NC(=O)C2=CC=C(C=C2)C2=CC=C(C=C2C)C2=NOC(C)=N2)C=C1)N1CCN(C)CC1	"Potent, selective 5-HT1B/1D antagonist"	"Potent and selective 5-HT1B/1D receptor antagonist (pKi values are 8.5 for both guinea pig 5-HT1D and rat 5-HT1B receptors). Displays > 100-fold selectivity over 5HT1A, 5-HT2A, 5-HT2C receptors and other receptor types. Centrally active following oral administration."	"Clitherow et al (1994) Evolution of a novel series of [(N,N-dimethylamino)propyl]- and piperazinylbenzalides as the first selective 5-HT1D antagonists. J.Med.Chem. 37 2253. PMID:8057272. De Vries et al (1996) Blockade of porcine carotid vascular response to sumatriptan by GR 127935, a selective 5-HT1D receptor antagonist. Br.J.Pharmacol. 118 85. PMID:8733580. Knobelman et al (2001) Genetic regulation of extracellular serotonin by 5-hydroxytryptamine1A and 5-hydroxytryptamine1B autoreceptors in different brain regions of the mouse. J.Pharmacol.Exp.Ther. 298 1083. PMID:11504805."	Small Molecule	Sold under license	http://www.tocris.com/dispprod.php?ItemId=1231	SQ1070			Apr-2002
1478	Proglumide sodium salt	[99247-33-3]	[Na+].CCCN(CCC)C(=O)C(CCC([O-])=O)NC(=O)C1=CC=CC=C1	Non-selective CCK antagonist; orally active	Non-selective cholecystokinin (CCK) antagonist. Inhibits CCK-stimulated amylase secretion and prevents CCK-induced 2-deoxyglucose uptake in mouse pancreatic acini. Blocks growth of HT29 colon carcinoma cells in response to gastrin 17 treatment. Orally active.	"Hahne et al (1981) Proglumide and benzotript: members of a different class of cholecystokinin receptor antagonists. Proc.Natl.Acad.Sci.U.S.A. 78 6304. PMID:6171817. Iwamoto et al (1984) In vitro and in vivo effect of proglumide on cholecystokinin-stimulated amylase release in mouse pancreatic acini. Gastroenterol.Jpn. 19 53. PMID:6202584. Mauss et al (1994) Effects of gastrin, proglumide, loxiglumide and L-365,260 on growth of human colon carcinoma cells. Anticancer Res. 14 215. PMID:8166452."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1232	SQ1533			Jun-2012
1479	Mifepristone	[84371-65-3]	[H][C@@]23CCC1=CC(CCC1=C2[C@@H]([C@]5=CC=C(N(C)C)C=C5)C[C@@]4(C)[C@]([H])3CC[C@@](C#CC)4O)=O	Progesterone and glucocorticoid antagonist	Selective antagonist at progesterone (PR) and glucocorticoid (GR) receptors in vitro and in vivo. Is a silent antagonist at PR and has a higher affinity than progesterone. Has higher affinity for GR than dexamethasone.	Schrieber et al (1983) Binding of the anti-progestin RU 486 to rat ovary steroid receptors. Contraception 28 77. PMID:6627946. Gagne et al (1985) RU 38486: a potent antiglucocorticoid in vitro and in vivo. J.Steroid Biochem. 23 247. PMID:2864478. Mao et al (1992) Molecular mechanism of RU 486 action: a review. Mol.Cell.Biochem. 109 1. PMID:1614417.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1235	SQ1533			Apr-2002
1480	FIT	[85951-63-9]	CCC(=O)N(C1CCN(CCC2=CC=C(C=C2)N=C=S)CC1)C1=CC=CC=C1	Irreversible _ agonist	Selective and irreversible _-opioid agonist (EC50 = 8 nM); acts by alkylating the receptor.	"Rice et al (1983) Irreversible ligands with high selectivity toward _ or _ opiate receptors. Science 220 314. PMID:6132444. Rothman et al (1985) Evidence that the delta-selective alkylating agent, fit, alters the mu-noncompetitive opiate delta binding site. Neuropeptides 6 227. PMID:2991807. Schoffelmeer et al (1988) _-, _- and _-opioid receptor-mediated inhibition of neurotransmitter release and adenylate cyclase activity in rat brain slices: studies with fentanyl isothiocyanate. Eur.J.Pharmacol. 154 169. PMID:2906610."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1234				Mar-2002
1483	GR 89696 fumarate	[126766-32-3]	[H]OC(=O)\C=C\C(=O)O[H].COC(=O)N1CCN(C(CN2CCCC2)C1)C(=O)CC1=CC=C(Cl)C(Cl)=C1	Subtype-selective _ opioid agonist	Highly potent and selective _-opioid agonist (IC50 = 0.04 nM) that may be selective for the putative _2 receptor. Anti-nociceptive and neuroprotective in vivo.	"Birch et al (1991) Neuroprotective actions of GR89696, a highly potent and selective _-opioid receptor agonist. Br.J.Pharmacol. 103 1819. PMID:1657267. Naylor et al (1993) A potent new class of _-receptor agonist: 4-substituted 1-(arylacetyl)-2-[(dialkylamino)methyl]piperazines. J.Med.Chem. 36 2075. PMID:8393489. Butelman et al (2001) GR89,696: a potent _-opioid agonist with subtype selectivity in rhesus monkeys. J.Pharmacol.Exp.Ther. 298 1049. PMID:11504802."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=1237	SQ1341			Oct-2002
1484	Oleylethanolamide	[111-58-0]	CCCCCCCC\C=C/CCCCCCCC(=O)NCCO	GPR55 agonist; also PPAR_ agonist	"Lipid mediator and analog of anandamide (Cat. No. 1339) that is involved in peripheral regulation of feeding. Selective GPR55 agonist (EC50 values are 0.44, >30 and >30 _M at GPR55, CB1 and CB2 respectively) and PPAR_ agonist (EC50 = 120 nM). Induces satiety through activation of PPAR_ and is also a ceramidase inhibitor. Also endogenous agonist at the GPR119 receptor."	"Coroneos et al (1995) Differential regulation of sphingomyelinase and ceramidase activities by growth factors and cytokines. J.Biol.Chem. 270 23305. PMID:7559485. de Fonseca et al (2001) An anorexic lipid mediator regulated by feeding. Nature 414 209. PMID:11700558. Calignano et al (2001) Antinociceptive activity of the endogenous fatty acid amide, palmitylethanolamide. Eur.J.Pharmacol. 419 191. PMID:11426841. Fu et al (2003) Oleylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR-_. Nature 425 90. PMID:12955147. Ryberg et al (2007) The orphan receptor GPR55 is a novel cannabinoid receptor. Br.J.Pharmacol. 152 1092. PMID:17876302."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=22735	SQ1070			Mar-2002
1490	MNI-caged-L-glutamate	[295325-62-1]	O=C(CC[C@H](N)C(O)=O)N2C1=C([N+]([O-])=O)C=CC(OC)=C1CC2	Stable photoreleaser of L-glutamate	"MNI-caged glutamate that rapidly and efficiently releases glutamate (Cat. No. 0218) when photolysed (300 - 380 nm excitation). Water-soluble, highly resistant to hydrolysis, stable at neutral pH, and pharmacologically inactive at neuronal glutamate receptors (up to mM concentrations). 2.5-fold more efficient at releasing L-glutamate than NI-caged L-glutamate."	"Papageorgiou and Corrie (2000) Effects of aromatic substitutions on the photocleavage of 1-acyl-7-nitroindolines. Tetrahedron 56 8197. Canepari et al (2001) Photochemical and pharmacological evaluation of 7-nitroindolinyl- and 4-methoxy-7-nitroindolinyl-amino acids as novel, fast caged neurotransmitters. J.Neurosci.Methods 112 29. PMID:11640955. Matsuzaki et al (2001) Dendritic spine geometry is critical for AMPA receptor expression in hippocampal CA1 pyramidal neurons. Nat.Neurosci. 4 1086. PMID:11687814. Maier et al (2005) Comparative analysis of inhibitory effects of caged ligands for the NMDA receptor. J.Neurosci.Methods 142 1. PMID:15652611. Palma-Cerda et al (2012) New caged neurotransmitter analogs selective for glutamate receptor sub-types based on methoxynitroindoline and nitrophenylethoxycarbonyl caging groups. Neuropharmacology. 63 624. PMID:22609535."	Small Molecule	Sold under license from the Medical Research Council	http://www.tocris.com/dispprod.php?ItemId=22603	SQ1341			Sep-2002
1493	CGP 78608 hydrochloride	[1135278-54-4]	O=C2C(NC1=CC(Br)=CC(CN[C@@H]([P@](O)(O)=O)C)=C1N2)=O.Cl	"Potent, selective glycine-site NMDA antagonist"	Potent and selective NMDA antagonist that acts through the glycine site (IC50 = 5 nM). Displays > 500-fold selectivity over kainate and AMPA receptors (IC50 values are 2.7 and 3 _M respectively). Anticonvulsant in vivo following systemic administration. Also available as part of the NMDA Receptor - Glycine Site Tocriset.	"John et al (1994) Synthesis and characterisation of [125I]-N-(N-benzylpiperidin-4-yl)-4-iodobenzamide, a new _ receptor radiopharmaceutical: high affinity binding to MCF-7 breast tumor cells. J.Med.Chem. 37 1737. PMID:8021913. Whittemore et al (1997) Antagonistm of N-methyl-D-aspartate receptors by _ site ligands: potency, subtype-selectivity and mechanisms of inhibition. J.Pharmacol.Exp.Ther. 282 326. PMID:9223571. Auberson et al (1999) N-phosphonoalkyl-5-aminomethylquinoxaline-2,3-diones: in vivo active AMPA and NMDA(glycine) antagonists. Bioorg.Med.Chem.Lett. 9 249. PMID:10021939. Ametamey et al (2000) Synthesis, radiolabelling and biological characterization of (D)-7-iodo-N-(1-phosphonoethyl)l-5-aminomethylquinoxaline-2,3-dione, a glycine-binding site antagonist of NMDA receptors. Bioorg.Med.Chem.Lett. 10 75. PMID:10636248."	Small Molecule	Sold with the permission of Novartis Pharma AG	http://www.tocris.com/dispprod.php?ItemId=23476				Mar-2002
1494	DPN	[1428-67-7]	OC1=CC=C(CC(C#N)C2=CC=C(O)C=C2)C=C1	Highly potent ER_ agonist	"Highly potent estrogen ER_ receptor agonist with a 70-fold selectivity over ER_ (EC50 values are 0.85 and 66 nM respectively). Relaxes mesenteric arteries in vitro. Shown to regulate expression of GluR1, GluR2 and GluR3 in rat hippocampus."	Meyers et al (2001) Estrogen receptor-_ potency-selective ligands: structure-activity relationship studies of diarylpropionitriles and their acetylene and polar analogues. J.Med.Chem. 44 4230. PMID:11708925. Montgomery et al (2003) Acute effects of oestrogen receptor subtype-specific agonists on vascular contractility. Br.J.Pharmacol. 139 1249. PMID:12890703. Harrington et al (2003) Activities of estrogen receptor alpha- and beta-selective ligands at diverse estrogen responsive gene sites mediating transactivation or transrepression. Mol.Cell.Endocrinol. 206 13. PMID:12943986. Waters et al (2009) Estrogen receptor alpha and beta specific agonists regulate expression of synaptic proteins in rat hippocampus. Brain Res. 1290 1. PMID:19596275.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=23895				Mar-2002
1495	Combretastatin A4	[117048-59-6]	OC1=CC(\C=C/C2=CC(OC)=C(OC)C(OC)=C2)=CC=C1OC	Antiangiogenic	"Antitumor, antiangiogenic and antimetastatic agent, in vitro and in vivo. Inhibits tubulin polymerization."	"Dorr et al (1996) Antitumor activity of combretastatin-A4 phosphate, a natural product tubulin inhibitor. Invest.New Drugs 14 131. PMID:8913833. Griggs et al (2001) Potent anti-metastatic activity of combretastatin-A4. Int.J.Oncol. 19 821. PMID:11562761. Lin et al (2007) Combretastatin A4-induced differential cytotoxicity and reduced metastatic ability by inhibition of AKT function in human gastric cancer cells. J.Pharmacol.Exp.Ther. 323 365. PMID:17646428."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=23990	SQ1533			Feb-2008
1496	SP 600125	[129-56-6]	O=C1C2=C3C(NN=C3C3=CC=CC=C13)=CC=C2	Selective JNK inhibitor	"Selective inhibitor of c-Jun N-terminal kinase (JNK). Competitively and reversibly inhibits JNK1, 2 and 3 (IC50 = 40 - 90 nM) with negligible activity at ERK2, p38_ and a range of enzymes (IC50 > 10 _M). Active in vivo. Shown to have reduced selectivity over other protein kinases under certain conditions. Protects renal tubular epithelial cells against ischemia/reperfusion-induced apoptosis. Prevents BMP9-induced osteogenic differentiation of MSCs. Also available as part of the MAPK Inhibitor Tocriset."	"Bennett et al (2001) SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase. Proc.Natl.Acad.Sci.U.S.A. 98 13681. PMID:11717429. Schnabl et al (2001) TAK1/JNK and p38 have opposite effects on rat hepatic stellate cells. Hepatology 34 953. PMID:11679966. Wang et al (2007) SP600125, a selective JNK inhibitor, protects ischemic renal injury via suppressing the extrinsic pathways of apoptosis. Life Sci. 80 2067. PMID:17459422. Zhao et al (2013) Activation of JNKs is essential for BMP9-induced osteogenic differentiation of mesenchymal stem cells. BMB Rep. 46 422. PMID:23977991."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=23929	SQ1533			Mar-2002
1497	Rimcazole dihydrochloride	[75859-03-9]	C[C@H](N[C@H](C)C4)CN4CCCN1C3=C(C=CC=C3)C2=C1C=CC=C2.Cl.Cl	_2 antagonist. Also DAT inhibitor	Antagonist at _ receptors (IC50 values are 1480 and 386 nM at _1 and _2 receptors respectively). Also binds to the dopamine transporter (IC50 = 57.6 nM) and inhibits dopamine uptake. Reduces the stimulatory effects of cocaine in vivo.	"Ferris et al (1986) Evidence that the potential antipsychotic agent rimcazole (BW 234U) is a specific, competitive antagonist of sigma sites in brain. Life Sci. 38 2329. PMID:2873494. Husbands et al (1997) Isothiocyanate derivatives of 9-[3-(cis-3,5-dimethyl-1-piperazinyl)propyl]-carbazole (Rimcazole): irreversible ligands for the dopamine transporter. J.Med.Chem. 40 4340. PMID:9435903. Matsumoto et al (2001) Rimcazole analogs attenuate the convulsive effects of cocaine: correlation with binding to sigma receptors rather than dopamine transporters. Neuropharmacology 41 878. PMID:11684152."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=23991	SQ1533			Dec-2002
1499	CL 316243 disodium salt	[151126-84-0]	[Na+].[Na+].C[C@H](CC1=CC=C2OC(OC2=C1)(C([O-])=O)C([O-])=O)NC[C@H](O)C1=CC=CC(Cl)=C1	Highly selective _3 agonist	"Potent and highly selective _3-adrenoceptor agonist (EC50 = 3 nM); > 10000-fold selective over _1 and _2 receptors. Increases brown adipose tissue thermogenesis and metabolic rate, and decreases blood insulin and glucose levels following oral administration in vivo."	"Bloom et al (1992) Disodium(R,R)-5-[2-[[2-(3-chlorophenyl)-2-hydroxyethyl]-amino]propyl]-1,3-benzodioxole-2,2-dicarboxylate (CL 316,243). A potent _-adrenergic agonist virtually specific for _3 receptors. A promising antidiabetic and antiobesity agent. J.Med.Chem. 35 3081. PMID:1354264. Yoshida et al (1994) Anti-obesity and anti-diabetic effects of CL 316,243, a highly specific _3-adrenoceptor agonist, in yellow KK mice. Life Sci. 54 491. PMID:8309351. Woods et al (2001) Efficacy of the _3-adrenergic receptor agonist CL-316243 on experimental bladder hyperflexia and detrusor instability in the rat. J.Urol. 166 1142. PMID:11490313."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=5213	SQ1341			Mar-2004
1504	Milrinone	[78415-72-2]	CC1=C(C=C(C#N)C(=O)N1)C1=CC=NC=C1	PDE3 inhibitor	Potent cAMP phosphodiesterase inhibitor (IC50 = 56 nM for inhibition of PDE III). Has inotropic and vasodilator effects following oral or intravenous administration in vivo. Also available as part of the Phosphodiesterase Inhibitor Tocriset.	"Alousi et al (1983) Characterization of the cardiotonic effects of milrinone, a new and potent cardiac bipyridine, on isolated tissues from several animal species. J.Cardiovasc.Pharmacol. 5 804. PMID:6195468. Shahid et al (1991) The presence of five cyclic nucleotide phosphodiesterase isoenzyme activities in bovine tracheal smooth muscle and the functional effects of selective inhibitors. Br.J.Pharmacol. 104 471. PMID:1665737. Tang et al (1994) Photoaffinity labelling of cyclic GMP-inhibited phosphodiesterase (PDE III) in human and rat platelets and rat tissues: effects of phosphodiesterase inhibitors. Eur.J.Pharmacol. 268 105. PMID:7925608."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=26803	SQ1533			Jun-2002
1505	Mycophenolic acid	[24280-93-1]	COC1=C(C)C2=C(C(=O)OC2)C(O)=C1C\C=C(/C)CCC(O)=O	Inosine monophosphatase dehydrogenase inhibitor	"Immunosuppressive agent with antiviral and antitumor effects in vitro and in vivo. Potently inhibits inosine monophosphate dehydrogenase, thus inhibiting de novo GTP synthesis leading to decreased RNA and DNA synthesis. Reversibly inhibits proliferation of T and B lymphocytes and antibody formation."	"Eugui et al (1991) Lymphocyte-selective cytostatic and immunosuppressive effects of mycophenolic acid in vitro: role of deoxyguanosine nucleotide depeletion. Scand.J.Immunol. 33 161. PMID:1826793. Allison et al (1993) Mechanisms of action of mycophenolic acid. Ann.N.Y.Acad.Sci. 696 63. PMID:7906496. Senda et al (1995) Mycophenolic acid, an inhibitor of IMP dehydrogenase that is also an immunosuppressive agent, suppresses the cytokine-induced nitric oxide production in mouse and rat vascular endothelial cells. Transplantation 60 1143. PMID:7482723. Zadina et al (1997) A potent and selective endogenous agonist for the _-opiate receptor. Nature 386 499. PMID:9087409. Chapman et al (1997) Distinct inhibitory effects of spinal endomorphin-1 and endomorphin-2 on evoked dorsal horn neuronal responses in the rat. Br.J.Pharmacol. 122 1537. PMID:9422796. Goldberg et al (1998) Pharmacological characterization of endomorphin-1 and endomorphin-2 in mouse brain. J.Pharmacol.Exp.Ther. 286 1007. PMID:9694962."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=27442	SQ1533			Apr-2002
1506	Terazosin hydrochloride	[63074-08-8]	Cl.COC1=C(OC)C=C2C(N)=NC(=NC2=C1)N1CCN(CC1)C(=O)C1CCCO1	_1 and _2B antagonist (_1 > _2B). Orally active	"_1- and _2B-adrenoceptor antagonist (Ki values are 3.3, 0.7, 1.1, 7.7, 1510 and 78.2 nM for _1A, _1B, _1D, _2B, _2A and _2C receptors respectively). Antihypertensive following oral or intravenous administration in vivo."	Kyncl (1986) Pharmacology of terazosin. Am.J.Med. 80 12. PMID:2872801. Maruyama et al (1994) Comparison of displacemental potencies of terazosin enantiomers for _1-adrenoceptor subtypes. Biol.Pharm.Bull. 17 1126. PMID:7820122. Hancock et al (1995) Actions of terazosin and its enantiomers at subtypes of _1- and _2-adrenoceptors in vitro. J.Recept.Signal Transduct.Res. 15 863. PMID:8673721.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=27453	SQ1533			Jul-2002
1507	FR 122047 hydrochloride	[130717-51-0]	Cl.COC1=CC=C(C=C1)C1=C(N=C(S1)C(=O)N1CCN(C)CC1)C1=CC=C(OC)C=C1	Cyclooxygenase (COX-1) inhibitor	"Selective cyclooxygenase-1 (COX-1) inhibitor (IC50 values are 0.028 and 65 _M for COX-1 and COX-2 respectively). Antiplatelet, analgesic and anti-inflammatory following oral administration in vivo."	"Dohi et al (1993) The anti-platelet actions of FR122047, a novel cyclooxygenase inhibitor. Eur.J.Pharmacol. 243 179. PMID:8276067. Tanaka et al (1994) Antiplatelet agents based on cyclooxygenase inhibition without ulcerogenesis. Evaluation and synthesis of 4,5-bis(4-methoxyphenyl)-2-substituted-thiazoles. J.Med.Chem. 37 1189. PMID:8164261. Ochi et al (2000) The analgesic effect profile of FR122047, a selective cyclo-oxygenase-1 inhibitor, in chemical nociceptive models. Eur.J.Pharmacol. 391 49. PMID:10720634. Ochi and Goto (2002) Differential effect of FR122047, a selective cyclo-oxygenase-1 inhibitor, in rat chronic models of arthritis. Br.J.Pharmacol. 135 782. PMID:11834626."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=28492	SQ1341			Aug-2002
1508	GW 9662	[22978-25-2]	[O-][N+](=O)C1=CC(C(=O)NC2=CC=CC=C2)=C(Cl)C=C1	Selective PPAR_ antagonist	"Selective PPAR_ antagonist (IC50 values are 3.3, 32 and 2000 nM for PPAR_, PPAR_ and PPAR_ respectively). Blocks the inhibition of osteoclast formation induced by IL-4 in the low micromolar range (1-2 _M), therefore is more potent than BADGE (Cat. No. 1326). Anticancer, inhibits growth of human mammary tumor cell lines."	"Bendixen et al (2001) IL-4 inhibits osteoclast formation through a direct action on osteoclast precursors via peroxisome proliferator-activated receptor _1. Proc.Natl.Acad.Sci.U.S.A. 98 2443. PMID:11226258. Leesnitzer et al (2002) Functional consequences of cysteine modification in the ligand binding sites of peroxisone proliferator activated receptors by GW9662. Biochemistry 41 6640. PMID:12022867. Seargent et al (2004) GW9662, a potent antaognist of PPAR_, inhibits growth of breast tumour cells and promotes the anticancer effects of the PPAR_ agonist rosiglitazone, independently of PPAR_ activation. Br.J.Pharmacol. 143 933. PMID:15533890."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=28566	SQ1341			May-2002
1509	TMS	[24144-92-1]	COC1=CC(OC)=C(\C=C\C2=CC(OC)=CC(OC)=C2)C=C1	Cytochrome P450 1B1 inhibitor	"Potent, selective and competitive inhibitor of cytochrome P450 1B1, an enzyme overexpressed in certain tumors (IC50 = 6 nM). 50- and 520-fold selective over P450 1A1 and 1A2 respectively. Inhibits cancer cell growth in vitro."	"Chun et al (2001) A new selective and potent inhibitor of human cytochrome P450 1B1 and its application to antimutagenesis. Cancer Res. 61 8164. PMID:11719446. Nam et al (2001) Resveratrol analog, 3,5,2',4'-tetramethoxy-trans-stilbene, potentiates the inhibition of cell growth and induces apoptosis in human cancer cells. Arch.Pharm.Res. 24 441. PMID:11693548. Kim et al (2002) Design, synthesis, and discovery of novel trans-stilbene analogues as potent and selective human cytochrome P450 1B1 inhibitors. J.Med.Chem. 45 160. PMID:11754588."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=28567				May-2002
1510	Ozagrel hydrochloride	[74003-18-2]	Cl[H].OC(=O)\C=C\C1=CC=C(CN2C=CN=C2)C=C1	Selective thromboxane A2 synthetase inhibitor	"Potent and selective inhibitor of thromboxane (TXA2) synthetase (IC50 = 4 nM). Does not inhibit prostacyclin (PGI2) synthetase, cyclooxygenase or PGE2 isomerase (IC50 > 1 mM). Inhibits platelet aggregation in vitro and arachidonate-induced arterial contraction in vivo."	Naito et al (1983) Effects of thromboxane synthetase inhibitors on aggregation of rabbit platelets. Eur.J.Pharmacol. 91 41. PMID:6413227. Hiraku et al (1986) Pharmacological studies on the TXA2 synthetase inhibitor (E)-3-[p-(1H-imidazol-1ylmethyl)phenyl]-2-propenoic acid (OKY-046). Jpn.J.Pharmacol. 41 393. PMID:3093741. Shinagawa et al (2000) Participation of thromboxane A2 in the cough response in guinea-pigs: antitussive effect of ozagrel. Br.J.Pharmacol. 131 266. PMID:10991919.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=28565	SQ1533			Sep-2002
1511	SR 59230A hydrochloride	[1135278-41-9]	O[C@@H](CN[C@H]2CCCC3=C2C=CC=C3)COC1=C(CC)C=CC=C1.Cl	Potent and selective _3 antagonist	"Potent and selective _3 adrenoceptor antagonist (IC50 values are 40, 408 and 648 nM for _3, _1 and _2 receptors respectively). Orally active in vivo. Also available as part of the _-Adrenoceptor Antagonist Tocriset."	"Manara et al (1995) Aryloxypropanolaminotetralins are the first selective antagonists for atypical (_3) _-adrenoceptors. Pharmacol.Comm. 6 253. Manara et al (1996) Functional identification of rat atypical _-adrenoceptors by the first _3-selective antagonists, aryloxypropanolaminotetralins. Br.J.Pharmacol. 117 435. PMID:8821531. Mizuno et al (2002) Stimulation of _3-adrenoceptors causes phosphorylation of p38 mitogen-activated protein kinase via a stimulatory G protein-dependent pathway in 3T3-L1 adipocytes. Br.J.Pharmacol. 135 951. PMID:11861323."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=28705	SQ1341			Jun-2002
1512	SB 205384	[160296-13-9]	CC#CCOC(=O)C1=C(C)N=C2SC3=C(CCC(O)C3)C2=C1N	GABAA receptor modulator; slows current decay	"GABAA receptor modulator; slows current decay. Potentiates _6, _3 and _5-subunit-containing receptors (EC50 values are 280, 695 and 730 nM respectively). Displays little effect on receptors containing _1 or _2 subunits."	"Meadows et al (1997) Effect of SB-205384 on the decay of GABA-activated chloride currents in granule cells cultured from rat cerebellum. Br.J.Pharmacol. 121 1334. PMID:9257911. Meadows et al (1998) SB-205384: a GABAA receptor modulator with novel mechanism of action that shows subunit selectivity. Br.J.Pharmacol. 123 1253. PMID:9559912. Hutcheon et al (2000) Developmental change in GABAA receptor desensitization kinetics and its role in synapse function in rat cortical neurons. J.Physiol. 522 3. PMID:10618148. Heidelberg et al (2013) SB-205384 is a positive allosteric modulator of recombinant GABAA receptors containing rat _3, _5, or _6 subunit subtypes coexpressed with _3 and _2 Subunits. J.Pharmacol.Exp.Ther. 347 235. PMID:23902941."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=28782	SQ1341			Dec-2002
1513	CGP 7930	[57717-80-3]	CC(C)(CO)CC1=CC(=C(O)C(=C1)C(C)(C)C)C(C)(C)C	Positive modulator at GABAB receptors	Positive allosteric modulator of GABAB receptors. Increases the potency and efficacy of GABA at both native and recombinant GABAB receptors (EC50 values are 5.37 and 4.60_M respectively) and enhances the inhibitory effect of the agonist L-baclofen in cultured cortical neurons. Reduces operant self-administration of ethanol in alcohol-preferring rats following i.p. administration.	"Urwyler et al (2001) Positive allosteric modulation of native and recombinant _-aminobutyric acidB receptors by 2,6-di-tert-butyl-4-(3-hydroxy-2,2-dimethyl-propyl)-phenol (CGP7930) and its aldehyde analog CGP13501. Mol.Pharmacol. 60 963. PMID:11641424. Chen et al (2006) Differential modulation by the GABAB receptor allosteric potentiator 2,6-Di-tert-butyl-4-(3-hydroxy-2,2-dimethylpropyl)-phenol (CGP7930) of synaptic transmission in the rat hippocampal CA1 area. J.Pharmacol.Exp.Ther. 317 1170. PMID:16507713. Liang et al (2006) The GABAB receptor allosteric modulator CGP7930, like baclofen, reduces operant self-administration of ethanol in alcohol-preferring rats. Neuropharmacology 50 632. PMID:16406445."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=34268	SQ1341			May-2002
1514	CGP 13501	[56189-68-5]	CC(C)(C)C1=CC(CC(C)(C)C=O)=CC(=C1O)C(C)(C)C	Positive modulator at GABAB receptors	"Positive allosteric modulator of GABAB receptors, potentiating the effects of GABA at this receptor type."	"Urwyler et al (2001) Positive allosteric modulation of native and recombinant _-aminobutyric acidB receptors by 2,6-di-tert-butyl-4-(3-hydroxy-2,2-dimethyl-propyl)-phenol (CGP7930) and its aldehyde analog CGP13501. Mol.Pharmacol. 60 963. PMID:11641424."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=34269				Apr-2002
1515	17-AAG	[75747-14-7]	O=C1C(NCC=C)=C(C[C@@H](C)C[C@H](OC)[C@H](O)[C@@H](C)/C=C(C)/[C@H](OC(N)=O)[C@@H](OC)/C=C/C=C(C)/C2=O)C(C(N2)=C1)=O	Selective Hsp90 inhibitor	"Inhibitor of heat shock protein 90 (Hsp90) chaperone activity, and an analog of geldanamycin (Cat. No. 1368). Subsequently inhibits the activity of oncogenic proteins such as p185erbB-2 (IC50 = 31 nM), N-ras, Ki-ras and c-Akt. Antitumor in vivo. Also protects neuroprogenitor cells against stress-induced apoptosis at low concentrations (10 nM) in vitro."	Schnur et al (1995) Inhibition of the oncogene product p185erbB-2 in vitro and in vivo by geldanamycin and dihydrogeldanamycin derivatives. J.Med.Chem. 38 3806. PMID:7562911. Yang et al (2001) Disruption of the EF-2 kinase/Hsp90 protein complex: a possible mechanism to inhibit glioblastoma by geldanamycin. Cancer Res. 61 4010. PMID:11358819. Hostein et al (2001) Inhibition of signal transduction by the Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin results in cytostasis and apoptosis. Cancer Res. 61 4003. PMID:11358818. Wang et al (2011) Protection of murine neural progenitor cells by the Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin in the low nanomolar concentration range. J.Neurochem. 117 703. PMID:21395580.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=34270	SQ1533			Jul-2002
1516	SDZ 21009	[39731-05-0]	CC(C)OC(=O)C1=CC2=C(OCC(O)CNC(C)(C)C)C=CC=C2N1	_-adrenoceptor antagonist. Also 5-HT1A/1B antagonist	_-adrenoceptor and 5-HT1A/1B receptor antagonist. pKB/pA2 values are 8.3 and 8.0 for 5-HT1A and 5-HT1B receptors respectively. Centrally active following systemic administration in vivo.	Engel et al (1986) Identity of inhibitory presynaptic 5-hydroxytryptamine (5-HT) autoreceptors in the rat brain cortex with 5-HT1B binding sites. Naunyn-Schmied.Arch.Pharmacol. 332 1. Chojnacka-Wojcik and Przegalinski (1991) Evidence for the involvement of 5-HT1A receptors in the anticonflict effect of ipsapirone in rats. Neuropharmacology 30 703. PMID:1681448. Hoyer et al (1994) VII International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (serotonin). Pharmacol.Rev. 46 157. PMID:7938165.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=34271	SQ1533			Jul-2004
1518	5-Iodo-A-85380 dihydrochloride	[1217837-17-6]	IC1=CN=CC(OC[C@@H]2CCN2)=C1.Cl.Cl	High affinity _4_2 and _6_2 subtype-selective agonist	"A highly potent and subtype-selective agonist for the _4_2 and _6_2 nicotinic acetylcholine receptors. Activates _-CTx-MII-sensitive and -insensitive components of [3H]dopamine release from rat striatal synaptosomes, corresponding to _6_2 and _4_2 (EC50 values are 12.7 and ~35 nM respectively). ~5000- , 25000- and 140000-fold selective over _3_4, _7 and muscle nAChR receptors respectively. Precursor (Cat. No. 1527) also available."	"Koren et al (1998) 2-, 5-, and 6-Halo-3-(2(S)-azetidinylmethoxy)pyridines: synthesis, affinity for nicotinic acetylcholine receptors, and molecular modeling. J.Med.Chem. 41 3690. PMID:9733494. Mukhin et al (2000) 5-Iodo-A-85380, an _4_2 subtype-selective ligand for nicotinic acetylcholine receptors. Mol.Pharmacol. 57 642. PMID:10692507. Mogg et al (2004) Functional responses and subunit composition of presynaptic nicotinic receptor subtypes explored using the novel agonist 5-iodo-A-85380. Neuropharmacology 47 848. PMID:15527819."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=35238	SQ1070			Oct-2002
1519	Quinelorane hydrochloride	[97548-97-5]	[H][C@]23[C@@](CCCN3CCC)([H])CC1=NC(N)=NC=C1C2.Cl.Cl	D2 and D3 agonist	Dopamine D2 and D3 receptor agonist; Ki values are 5.7 and 3.4 nM respectively.	"Foreman et al (1989) Preclinical studies on quinelorane, a potent and highly selective D2-dopaminergic agonist. J.Pharmacol.Exp.Ther. 250 227. PMID:2526214. Eaton et al (1994) Effects of the selective dopaminergic D2 agonist quinelorane on the activity of dopaminergic and noradrenergic neurons projecting to the diencephalon of the rat. J.Pharmacol.Exp.Ther. 268 645. PMID:7906734. Flietstra and Levant (1998) Comparison of D2 and D3 dopamine receptor affinity of dopaminergic compounds in the rat brain. Life Sci. 62 1825. PMID:9600324."	Small Molecule	Sold with the permission of Eli Lilly and Company	http://www.tocris.com/dispprod.php?ItemId=35563				Sep-2007
1521	LY 233053	[125546-04-5]	O=[C@@]([C@@H]1C[C@H](CC2=NN=NN2)CCN1)O.O=C([C@H]3C[C@@H](CC4=NN=NN4)CCN3)O	Competitive NMDA receptor antagonist	Competitive NMDA receptor antagonist (IC50 = 7 nM) that displays no affinity for AMPA or kainate receptors at a concentration of 10 _M. Inhibits NMDA-induced neuronal degeneration and protects from NMDA-induced convulsions in neonatal rats.	"Schoepp et al (1990) Pharmacological characterization of LY233053: a structurally novel tetrazole-substituted competitive N-methyl-D-aspartic acid antagonist with a short duration of action. J.Pharmacol.Exp.Ther. 255 1301. PMID:2148188. Madden et al (1992) Efficacy of LY233053, a competitive glutamate antagonist, in experimental central nervous system ischemia. J.Neurosurg. 76 106. PMID:1727148. Madden et al (1993) Delayed therapy of experimental ischemia with competitive N-methyl-D-aspartate antagonists in rabbits. Stroke 24 1068. PMID:8322381."	Small Molecule	Sold with the permission of Eli Lilly and Company	http://www.tocris.com/dispprod.php?ItemId=36256	SQ1341			Oct-2007
1523	LY 215840	[137328-52-0]	CC(C)N2C1=C(C(C[C@]4([H])[C@@]([H])3C[C@@H]([C@@](N[C@@H]5[C@H](O)CCC5)=O)CN4C)=C2)C3=CC=C1	5-HT2/5-HT7 antagonist	5-HT2/5-HT7 receptor antagonist. Reduces stimulatory effect of serotonin on aldosterone secretion; also reduces 5-HT-induced cAMP formation (pKB = 8.26).	"Cushing et al (1996) LY215840, a high-affinity 5-HT7 receptor ligand, blocks serotonin-induced relaxation in canine coronary artery. J.Pharmacol.Exp.Ther. 277 1560. PMID:8667223. Lenglet et al (2002) Activation of 5-HT7 receptor in rat glomerulosa cells is associated with an increase in adenylyl cyclase activity and calcium influx through T-type calcium channels. Endocrinology 143 1748. PMID:11956157. Louiset et al (2006) Expression of serotonin7 receptor and coupling of ectopic receptors to protein kinase A and ionic currents in adrenocorticotropin-independent macronodular adrenal hyperplasia causing Cushing's syndrome. J.Clin.Endocrinol.Metab. 91 4578. PMID:16954157."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=36258	SQ1070			Jan-2011
1524	LY 288513	[147523-65-7]	BrC1=CC=C(NC(=O)N2NC(=O)[C@H]([C@@H]2C2=CC=CC=C2)C2=CC=CC=C2)C=C1	Selective CCK2 antagonist	"Selective CCK2 receptor antagonist (IC50 values are 16 and > 30,000 nM for CCK2 and CCK1 respectively). Displays anxiolytic and antipsychotic properties in vivo."	"Rasmussen et al (1992) Electrophysiological effects of diphenylpyrazolidinone cholecystokinin-B and cholecystokinin-A antagonists on midbrain dopamine neurons. J.Pharmacol.Exp.Ther. 264 480. Rasmussen (1994) CCK, schizophrenia, and anxiety. CCK-B antagonists inhibit the activity of brain dopamine neurons. Ann.N.Y.Acad.Sci. 713 300. PMID:8185172. Helton et al (1996) Central nervous system characterization of the new cholecystokininB antagonist LY288513. Pharmacol.Biochem.Behav. 53 493. PMID:8866946."	Small Molecule	Sold with the permission of Eli Lilly and Company	http://www.tocris.com/dispprod.php?ItemId=36259	SQ1341			Jun-2007
1526	Mevastatin	[73573-88-3]	[H][C@@]12C(C=C[C@H](C)[C@@]([H])2CC[C@@]3([H])OC(C[C@]([H])(O)C3)=O)=CCC[C@@H]1OC([C@@H](C)CC)=O	HMG-CoA reductase inhibitor	"Inhibitor of HMG-CoA reductase; decreases cholesterol biosynthesis, in vitro and in vivo. Induces apoptosis, arrests cancer cells in G1 phase and downregulates cdk 2, 4, and 6, cyclin D1 and E1, p21 and p27."	"Cohen et al (1984) Effects of compactin, mevalonate and low-density lipoprotein on 3-hydroxy-3-methylglutaryl-coenzyme A reductase activity and low-density lipoprotein-receptor activity in the human hepatoma cell line Hep G2. Biochem.J. 222 35. PMID:6089762. Wachtershauser et al (2001) HMG-CoA reductase inhibitor mevastatin enhances the growth inhibitory effect of butyrate in the colorectal carcinoma cell line Caco-2. Carcinogenesis 22 1061. PMID:11408350. Amin-Hanjani et al (2001) Mevastatin, an HMG-CoA reductase inhibitor, reduces stroke damage and upregulates endothelial nitric oxide synthase in mice. Stroke 32 980. PMID:11283400."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=37488	SQ1070			Jul-2002
1529	SNC 162	[178803-51-5]	[H][C@@](C2=CC=CC=C2)(N3C[C@@H](C)N(CC=C)C[C@@H]3C)C1=CC=C(C(N(CC)CC)=O)C=C1	"Potent, selective non-peptide _ agonist"	Potent and selective non-peptide _-opioid receptor agonist (Ki = 0.63 nM). Displays > 8000-fold selectivity over _-opioid receptors and is centrally active following systemic administration in vivo.	"Knapp et al (1996) Structure-activity relationships for SNC80 and related compounds at cloned human delta and mu opioid receptors. J.Pharmacol.Exp.Ther. 277 1284. PMID:8667189. Calderon et al (1997) Probes for narcotic receptor mediated phenomena. 23. Synthesis, opioid receptor binding, and bioassay of the highly selective _ agonist (+)-4-[(_R)-_-((2S,5R)-4-allyl-2,5-dimethyl-1-piperazinyl)-3-methoxybenzyl]-N,N-diethylbenzamide (SNC 80) and related novel nonpeptide _ opioid receptor ligands. J.Med.Chem. 40 695. PMID:9057856. Negus et al (1998) Behavioral effects of the delta-selective opioid agonist SNC80 and related compounds in rhesus monkeys. J.Pharmacol.Exp.Ther. 286 362. PMID:9655881."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=37812	SQ1341			Sep-2002
1530	Lovastatin	[75330-75-5]	[H][C@]12[C@H](C[C@@H](C)C=C1C=C[C@H](C)[C@@H]2CC[C@@H]1C[C@@H](O)CC(=O)O1)OC(=O)[C@@H](C)CC	HMG-CoA reductase inhibitor	"Potent, competitive inhibitor of HMG-CoA reductase (Ki = 0.6 nM) therefore decreases cholesterol biosynthesis, in vitro and in vivo. Decreases CDK2, 4, 6 and cyclin E levels and induces G1 arrest and apoptosis in tumor cell lines in vitro."	"Alberts et al (1980) Mevinolin: a highly potent competitive inhibitor of hydroxymethylglutaryl-coenzyme A reductase and a cholesterol-lowering agent. Proc.Natl.Acad.Sci.U.S.A. 77 3957. PMID:6933445. Alberts (1988) Discovery, biochemistry and biology of lovastatin. Am.J.Cardiol. 62 10J. PMID:3055919. Park et al (1999) Lovastatin-induced inhibition of HL-60 cell proliferation via cell cycle arrest and apoptosis. Anticancer Res. 19 3133. PMID:10652602."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=38097	SQ1533			Oct-2002
1531	Icilin	[36945-98-9]	OC1=C(C=CC=C1)N1CC=C(NC1=O)C1=CC=CC(=C1)[N+]([O-])=O	Activates a novel cold receptor. Cooling agent	"Cooling agent that activates the novel cold receptors TRPM8 (CMR1) and TRPA1 (ANKTM1/TRPN1), members of the TRP ion channel family. Induces currents in CMR1-expressing HEK 293 cells (EC50 = 0.36 _M) more potently than menthol or low temperatures. Produces ""wet shakes"" in vivo."	"Wei et al (1983) AG-3-5: a chemical producing sensations of cold. J.Pharm.Pharmacol. 35 110. PMID:6131976. McKemy et al (2002) Identification of a cold receptor reveals a general role for TRP channels in thermosensation. Nature 416 52. PMID:11882888. Story et al (2003) ANKTM1, a TRP-like channel expressed in nociceptive neurons, is activated by cold temperatures. Cell 112 819. PMID:12654248. Behrendt et al (2004) Characterization of the mouse cold-menthol receptor TRPM8 and vanilloid receptor type-1 VR1 using a fluorometric imaging plate reader (FLIPR) assay. Br.J.Pharmacol. 141 737. PMID:14757700."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=38283				Jul-2002
1534	A 68930 hydrochloride	[130465-39-3]	OC1=C(O)C=CC2=C1C[C@@H]([C@]3=CC=CC=C3)O[C@H]2CN.Cl	"Potent, selective D1-like agonist"	Potent and selective D1-like dopamine receptor agonist (EC50 values are 2.1 and 3910 nM for D1-like and D2-like receptors respectively). Centrally active following systemic administration in vivo.	"Kebabian et al (1990) A68930: a potent and specific agonist for the D-1 dopamine receptor. Am.J.Hypertens. 3 40S. PMID:2143387. Quaglia et al (1990) (1R,3S)-1-(Aminomethyl)-3,4-dihydro-5,6-dihydroxy-3-phenyl-1H-2-benzopyran: a potent and selective D1 agonist. J.Med.Chem. 33 2948. PMID:1977907. Deveney and Waddingto (1997) Psychopharmacological distinction between novel full-efficacy ""D1-like"" dopamine receptor agonists. Pharmacol.Biochem.Behav. 58 551. PMID:9300618."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=38649	SQ1070			Sep-2002
1540	DCPIB	[82749-70-0]	CCCCC1(CC2=C(C1=O)C(Cl)=C(Cl)C(OCCCC(O)=O)=C2)C1CCCC1	"Selective blocker of VSAC/ICl, swell. Inhibits glucose-stimulated insulin release"	"Potent, selective blocker of the volume-sensitive anion channel (VSAC) in rat pancreatic _-cells (IC50 ~ 2 _M) and ICl,swell in various cardiovascular tissues (IC50 = 4.1 _M in CPAE cells); blockade is voltage-independent. Displays minimal inhibition of other Cl- and K+ currents (< 10% inhibition at 10 _M). Inhibits glucose-stimulated insulin secretion in intact _-cells via VSAC inhibition and indirect KATP channel activation. Reverses cell swelling-induced action potential duration shortening in atrial myocytes and inhibits astroglial swelling in vitro."	"Bourke et al (1981) Adenosine-stimulated astroglial swelling in cat cerebral cortex in vivo with total inhibition by a non-diuretic acylaryloxyacid derivative. J.Neurosurg. 55 364. PMID:6267227. Decher et al (2001) DCPIB is a novel selective blocker of ICl,swell and prevents swelling-induced shortening of guinea-pig atrial action potential duration. Br.J.Pharmacol. 134 1467. PMID:11724753. Best et al (2004) Inhibition of glucose-induced electrical activity in rat pancreatic _-cells by DCPIB, a selective inhibitor of volume-sensitive anion currents. Eur.J.Pharmacol. 489 13. PMID:15063150."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=40972	SQ1341			Apr-2005
1541	HA14-1	[65673-63-4]	CCOC(=O)C(C#N)C1C2=C(OC(N)=C1C(=O)OCC)C=CC(Br)=C2	Bcl-2 inhibitor. Induces apoptosis	Cell-permeable inhibitor of Bcl-2 protein (IC50 ~ 9 _M); acts by binding to the surface pocket. Disrupts Bax/Bcl-2 interaction and induces apoptosis of tumor cells. Also binds to the antiapoptotic Blc-2 proteins Bcl-XL and Bcl-w.	"Wang et al (2000) Structure-based discovery of an organic compound that binds Bcl-2 protein and induces apoptosis of tumor cells. Proc.Natl.Acad.Sci.U.S.A. 97 7124. PMID:10860979. Milella et al (2002) Synergistic induction of apoptosis by simultaneous disruption of the Bcl-2 and MEK/MAPK pathways in acute myelogenous leukemia. Blood 99 3461. PMID:11964319. Doshi et al (2006) Structure-activity relationship studies of ethyl 2-amino-6-bromo-4-(1-cyano-2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate (HA 14-1), an antagonist for antiapoptotic Bcl-2 proteins to overcome drug resistance in cancer. J.Med.Chem. 49 7731. PMID:17181155."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=40985	SQ1533			Oct-2002
1542	Splitomicin	[5690-03-9]	O=C1CCC2=C(O1)C=CC1=CC=CC=C21	Sir2p inhibitor	"Inhibitor of Sir2p (IC50 = 60 _M), an NAD+-dependent Sir2 family deacetylase required for chromatin-dependent silencing in yeast."	Bedalov et al (2001) Identification of a small molecule inhibitor of Sir2p. Proc.Natl.Acad.Sci.U.S.A. 98 15113. PMID:11752457.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=40988	SQ1341			Sep-2002
1543	(S)-CPW 399	[389888-02-2]	O=C1NC(C2=C(CCC2)N1C[C@H](N)C(O)=O)=O	Subtype-selective weakly desensitizing AMPA agonist	"Novel subtype-selective and weakly desensitizing AMPA receptor partial agonist (Ki values are 44, 109, 223, 1890 and 2090 nM at GluR5, GluR1, GluR2, GluR3 and GluR4 receptors respectively). Exhibits potent agonist activity at GluR1 and GluR2 subunit-containing AMPA receptors (EC50 values are 24.9 and 13.9 _M respectively) and is excitotoxic in vitro."	"Campiani et al (2001) Characterization of the 1H-cyclopentapyrimidine-2,4(1H,3H)-dione derivative (S)-CPW399 as a novel, potent and subtype-selective AMPA receptor full agonist with partial desensitization properties. J.Med.Chem. 44 4501. PMID:11741469. Sinclair et al (2003) Inherent desensitisation-preventing properties of a novel subtype-selective AMPA receptor agonist, (S)-CPW 399, as a possible explanation for its excitotoxic action in cultured cerebellar granule cells. Neurochem.Int. 42 499. PMID:12547649. Butini et al (2008) 1H-Cyclopentapyrimidine-2,4(1H,3H)-dione-related ionotropic glutamate receptor ligands. Structure-activity relationships and identification of potent and selective iGluR5 modulators. J.Med.Chem. 51 6614. PMID:18811139."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=41172	SQ1341			Feb-2003
1544	()-Bay K 8644	[71145-03-4]	COC(=O)C1=C(C)NC(C)=C(C1C1=CC=CC=C1C(F)(F)F)[N+]([O-])=O	Ca2+-channel activator (L-type)	"L-type Ca2+-channel activator (EC50 = 17.3 nM). Has positive inotropic, vasoconstrictive and behavioral effects in vivo. Separate enantiomers (R)-(+)-Bay K 8644 and (S)-(-)-Bay K 8644 also available (Cat. Nos. 1545 and 1546 respectively). In combination with BIX-01294 (Cat. No. 3364), helps generate induced pluripotent stem cells (iPSCs) from mouse embryonic fibroblasts (MEFs). Inhibits autophagy."	Greenberg et al (1984) Calcium channel 'agonist' BAY K 8644 inhibits calcium antagonist binding to brain and PC12 cell membranes. Brain Res. 305 365. PMID:6204725. Bourson et al (1989) Central and peripheral effects of the dihydropyridine calcium channel activator BAY K 8644 in the rat. Eur.J.Pharmacol. 160 339. PMID:2469593. Shi et al (2008) Induction of pluripotent stem cells from mouse embryonic fibroblasts by Oct4 and Klf4 with small-molecule compounds. Cell Stem Cell 3 568. PMID:18983970. Sarkar et al (2009) Rapamycin and mTOR-independent autophagy inducers ameliorate toxicity of polyglutamine-expanded huntingtin and related proteinopathies. Cell Death Differ. 16 46. PMID:18636076.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=5180	SQ1341			Oct-2002
1545	(R)-(+)-Bay K 8644	[98791-67-4]	O=C(OC)C1=C(C)NC(C)=C([N+]([O-])=O)[C@@H]1[C@]2=CC=CC=C2C(F)(F)F	Ca2+-channel blocker (L-type)	L-type Ca2+-channel blocker with negative inotropic and vasodilatatory effects in vivo. Enantiomer showing opposite effects to the racemate ()-Bay K 8644 (Cat. No. 1544) and (S)-(-)- enantiomer (Cat. No. 1546).	"Franckowiak et al (1985) The optical isomers of the 1,4-dihydropyridine BAY K 8644 show opposite effects on Ca channels. Eur.J.Pharmacol. 114 223. PMID:2412855. O'Neill and Bolger (1988) Enantiomer selectivity and the development of tolerance to the behavioral effects of the calcium channel activator BAY K 8644. Brain Res.Bull. 21 865. PMID:2465070. Ravens and Schopper (1990) Opposite cardiac actions of the enantiomers of Bay K 8644 at different membrane potentials in guinea-pig papillary muscles. Naunyn Schmiedebergs Arch.Pharmacol. 341 232. PMID:1692975. Shi et al (2008) Induction of pluripotent stem cells from mouse embryonic fibroblasts by Oct4 and Klf4 with small-molecule compounds. Cell Stem Cell. 3 568. PMID:18983970."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=41309	SQ1341			Feb-2003
1546	(S)-(-)-Bay K 8644	[98625-26-4]	O=C(OC)C1=C(C)NC(C)=C([N+]([O-])=O)[C@H]1[C@]2=CC=CC=C2C(F)(F)F	Ca2+-channel activator (L-type)	"L-type Ca2+-channel activator with positive inotropic, vasoconstrictive and behavioral effects in vivo. Enantiomer of ()-Bay K 8644 (Cat. No. 1544)."	"Franckowiak et al (1985) The optical isomers of the 1,4-dihydropyridine BAY K 8644 show opposite effects on Ca channels. Eur.J.Pharmacol. 114 223. PMID:2412855. O'Neill and Bolger (1988) Enantiomer selectivity and the development of tolerance to the behavioral effects of the calcium channel activator BAY K 8644. Brain Res.Bull. 21 865. PMID:2465070. Ravens and Schopper (1990) Opposite cardiac actions of the enantiomers of Bay K 8644 at different membrane potentials in guinea-pig papillary muscles. Naunyn Schmiedebergs Arch.Pharmacol. 341 232. PMID:1692975."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=41310	SQ1341			Feb-2003
1547	NSC 95397	[93718-83-3]	OCCSC1=C(SCCO)C(=O)C2=CC=CC=C2C1=O	Selective Cdc25 dual specificity phosphatase inhibitor	"Potent and selective irreversible inhibitor of Cdc25 dual specificity phosphatases (Ki values are 32, 96 and 40 nM for inhibition of Cdc25A, -B and -C respectively). Displays 125 - 180-fold selectivity over VH1-related dual-specificity phosphatase and protein tyrosine phosphatase 1b. Inhibits carcinoma cell growth and blocks G2/M phase transition in vitro."	Lazo et al (2002) Identification of a potent and selective pharmacophore for Cdc25 dual specificity phosphatase inhibitors. Mol.Pharmacol. 61 720. PMID:11901209. Han et al (2004) NAD(P)H:Quinone oxidoreductase-1-dependent and -independent cytotoxicity of potent quinone Cdc25 phosphatase inhibitors. J.Pharmacol.Exp.Ther. 309 64. PMID:14718602. Melchheier et al (2005) Quinone-induced Cdc25A inhibition causes ERK-dependent connexin phosphorylation. Biochem.Biophys.Res.Commun. 327 1016. PMID:15652497.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=41894				Sep-2002
1548	Cantharidin	[56-25-7]	O=C(O2)[C@]1(C)[C@H](O3)CC[C@H]3[C@@](C)1C2=O	Protein phosphatase 1 and 2A inhibitor	Natural toxin inhibitor of protein phosphatases 1 and 2A (Ki values are 1.1 and 0.19 _M respectively); similar to okadaic acid (Cat. No. 1136). Displays > 500-fold selectivity over PP2B.	"Honkanen (1993) Cantharidin, another natural toxin that inhibits the activity of serine/threonine protein phosphatases types 1 and 2A. FEBS Lett. 330 283. PMID:8397101. Eldridge and Casida (1995) Cantharidin effects on protein phosphatases and the phosphorylation state of phosphoproteins in mice. Toxicol.Appl.Pharmacol. 130 95. PMID:7839375. Knapp et al (1999) The protein phosphatase inhibitor cantharidin alters vascular endothelial cell permeability. J.Pharmacol.Exp.Ther. 289 1480. PMID:10336542."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=5197	SQ1533			Dec-2002
1549	CD 437	[125316-60-1]	OC(=O)C1=CC=C2C=C(C=CC2=C1)C1=CC=C(O)C(=C1)C12CC3CC(CC(C3)C1)C2	RAR_-selective agonist	Synthetic retinoid that is an RAR_-selective agonist. Displays RAR_-dependent and -independent effects on differentiation and apoptosis.	"Zhao and Spanjaard (2003) The apoptotic action of the retinoid CD437/AHPN: diverse effects, common basis. J.Biomed.Sci. 10 44. PMID:12566985. Wang et al (2011) Rapid and efficient reprogramming of somatic cells to induced pluripotent stem cells by retinoic acid receptor gamma and liver receptor homolog 1. Proc.Natl.Acad.Sci U.S.A. 108 18283. PMID:21990348."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=42810	SQ1533			Feb-2006
1550	SC 560	[188817-13-2]	COC1=CC=C(C=C1)N1N=C(C=C1C1=CC=C(Cl)C=C1)C(F)(F)F	Cyclooxygenase (COX-1) inhibitor	"Highly selective cyclooxygenase-1 (COX-1) inhibitor (IC50 values are 0.009 and 6.3 _M for COX-1 and COX-2 respectively). Inhibits COX-1-derived platelet thromboxane B2, gastric PGE2 and dermal PDE2 production. Significantly reduces ovarian surface epithelial tumor growth in vivo. Orally active."	Smith et al (1998) Pharmacological analysis of cyclooxygenase-1 in inflammation. Proc Natl Acad Sci U S A 95 13313. PMID:9789085. Daikoku et al (2005) Cyclooxygenase-1 is a potential target for prevention and treatment of ovarian epithelial cancer. Cancer Res. 65 3735. PMID:15867369. Takeuchi et al (2005) COX inhibition and NSAID-induced gastric damage - roles in various pathogenic events. Curr.Top.Med.Chem. 5 475. PMID:15974942.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=42829	SQ1341			Sep-2006
1551	STO-609 acetate	[1173022-21-3]	CC(O)=O.OC(=O)C1=C2C=CC=C3C(=O)N4C5=CC=CC=C5N=C4C(C=C1)=C23	Selective CaM kinase kinase inhibitor	"Selective, cell-permeable inhibitor of Ca2+-calmodulin-dependent protein kinase kinase (Ki values are 80 and 15 ng/ml for inhibition of CaM-KK_ and CaM-KK_ respectively); competes for the ATP-binding site. Displays > 80-fold selectivity over CaMK1, CaMK2, CaMK4, MLCK, PKC, PKA and p42 MAPK."	"Tokumitsu et al (2002) STO-609, a specific inhibitor of the Ca2+/calmodulin-dependent protein kinase kinase. J.Biol.Chem. 277 15813. PMID:11867640."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=42855	SQ1341			Nov-2002
1554	Piceatannol	[10083-24-6]	OC1=CC(\C=C\C2=CC(O)=C(O)C=C2)=CC(O)=C1	Inhibits TNF-induced NF-_B activation	"Anti-inflammatory, immunomodulatory and antiproliferative agent. Inhibits p56lck and syk protein tyrosine kinases and inhibits TNF-induced NF-_B activation and gene expression. Synthesis results from conversion of resveratrol (Cat. No. 1418) by cytochrome P450 1B1."	"Geahlen and McLaughlin (1989) Piceatannol (3,4,3',5'-tetrahydroxy-trans-stilbene) is a naturally occurring protein-tyrosine kinase inhibitor. Biochem.Biophys.Res.Commun. 165 241. PMID:2590224. Oliver et al (1994) Inhibition of mast cell FceR1-mediated signalling and effector function by the syk-selective inhibitor, piceatannol. J.Biol.Chem. 269 29697. PMID:7961959. Potter et al (2002) The cancer preventative agent resveratrol is converted to the anticancer agent piceatannol by the cytochrome P450 enzyme CYP1B1. Br.J.Cancer 86 774. PMID:11875742. Ashikawa et al (2002) Piceatannol inhibits TNF-induced NF-kB activation and NF-kB-mediated gene expression through suppression of IkBa kinase and p65 phosphorylation. J.Immunol. 169 6490. PMID:12444159."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=43353	SQ1533			Nov-2003
1555	AG 825	[149092-50-2]	COC1=CC(\C=C(/C#N)C(N)=O)=CC(CSC2=NC3=C(S2)C=CC=C3)=C1O	Selective ErbB2 inhibitor	Selective ErbB2 inhibitor (IC50 values are 0.15 and 19 _M at ErbB2 and ErbB1 respectively). Preferentially triggers p38 MAP kinase-dependent apoptosis in androgen-independent prostate cancer cells.	Gazit et al (1993) Tyrphostins. 3. Structure-activity relationship studies of _-substituted benzylidenemalononitrile 5-S-aryltyrphostins. J.Med.Chem. 36 3556. PMID:7902440. Osherov et al (1993) Selective inhibition of the epidermal growth factor and HER2/Neu receptors by tyrphostins. J.Biol.Chem. 268 11134. PMID:8098709. Murillo et al (2001) Tyrphostin AG825 triggers p38 mitogen-activated protein kinase-dependent apoptosis in androgen-independent prostate cancer cells C4 and C4-21. Cancer Res. 61 7408. PMID:11606371.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=44145	SQ1341			Dec-2002
1558	Tracazolate hydrochloride	[1135210-68-2]	Cl.CCCCNC1=C2C=NN(CC)C2=NC(C)=C1C(=O)OCC	Subtype-selective GABAA allosteric modulator	Subtype-selective GABAA receptor modulator. Can potentiate or inhibit recombinant GABAA function depending on subunit combination. Enhances native GABAA receptor function and is anxiolytic following systemic administration in vivo.	"Meiners and Salama (1982) Enhancement of benzodiazepine and GABA binding by the novel anxiolytic, tracazolate. Eur.J.Pharmacol. 78 315. PMID:6121710. Patel and Malick (1982) Pharmacological properties of tracazolate: a new non-benzodiazepine anxiolytic agent. Eur.J.Pharmacol. 78 323. PMID:6121711. Thompson et al (2002) Tracazolate reveals a novel type of allosteric interaction with recombinant _-aminobutyric acidA receptors. Mol.Pharmacol. 61 861. PMID:11901225."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=44570	SQ1533			Oct-2002
1559	Roxindole hydrochloride	[108050-82-4]	OC(C=C4)=CC1=C4NC=C1CCCCN2CCC(C3=CC=CC=C3)=CC2.Cl	"Dopamine D2 autoreceptor agonist. Also has affinity for D3, D4, 5-HT1A receptors and the 5-HT transporter"	"Dopamine D2 autoreceptor agonist, with affinity for D3, D4 and 5-HT1 receptors (pKi values are 8.55, 8.93, 8.23, 9.42, 6.00 and 7.05 for human D2, D3, D4, 5-HT1A, 5-HT1B and 5-HT1D receptors). Inhibits 5-HT uptake and is antidepressant in vivo."	"Seyfried et al (1989) Biochemical and functional studies on EMD 49980: a potent, selectively presynaptic D-2 dopamine agonist with actions on serotonin systems. Eur.J.Pharmacol. 160 31. PMID:2565817. Bartoszyk et al (1996) Roxindole: psychopharmacological profile of a dopamine D2 autoreceptor agonist. J.Pharmacol.Exp.Ther. 276 41. PMID:8558454. Newman-Tancredi et al (1999) Actions of roxindole at recombinant human dopamine D2, D3 and D4 and serotonin 5-HT1A, 5-HT1B and 5-HT1D receptors. Naunyn Schmiedebergs Arch.Pharmacol. 359 447. PMID:10431754."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=44571	SQ1533			Mar-2003
1561	(S)-SNAP 5114	[157604-55-2]	O=[C@]([C@@H]1CN(CCOC(C3=CC=C(OC)C=C3)(C4=CC=C(OC)C=C4)C2=CC=C(OC)C=C2)CCC1)O	GABA uptake inhibitor	"GABA transport inhibitor, showing selectivity for GAT-3 and GAT-2 (IC50 values are 5, 21 and 388 _M for hGAT-3, rGAT-2 and hGAT-1 respectively). Increases thalamic GABA levels and is an anticonvulsant following systemic administration in vivo."	Borden et al (1994) Cloning of the human homologue of the GABA transporter GAT-3 and identification of a novel inhibitor with selectivity for this site. Receptors Channels 2 207. PMID:7874447. Borden (1996) GABA transporter heterogeneity: pharmacology and cellular localization. Neurochem.Int. 29 335. PMID:8939442. Dalby (2000) GABA-level increasing and anticonvulsant effects of three different GABA uptake inhibitors. Neuropharmacology 39 2399. PMID:10974324.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=44850	SQ1341			Mar-2003
1579	HEMADO	[403842-38-6]	O[C@@H]1[C@@H](CO)O[C@@H](N(C=N3)C2=C3C(NC)=NC(C#CCCCC)=N2)[C@@H]1O	High affinity selective A3 agonist	"High affinity and selective adenosine A3 receptor agonist (Ki values are 1.1, 327, 1230 and > 30,000 nM for human A3, A1, A2A and A2B receptors respectively)."	Volpini et al (2002) N6-Alkyl-2-alkynyl derivatives of adenosine as potent and selective agonists at the human adenosine A3 receptor and a starting point for searching A2B ligands J.Med.Chem. 45 3271. PMID:12109910. Klotz et al (2006) [3H]HEMADO- a novel tritated agonist selective for the human adenosine A3-receptor. Eur.J.Pharmacol. 556 14. PMID:17126322.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=48837	SQ1341			Feb-2003
1580	Purvalanol A	[212844-53-6]	ClC1=CC=CC(NC2=C3C(N(C(C)C)C=N3)=NC(N[C@H]([C@@H](C)C)CO)=N2)=C1	Cyclin-dependent kinase inhibitor	"Cyclin-dependent kinase inhibitor. IC50 values are 4, 70, 35, 850 and 75 nM for cdc2/cyclin B, cdk2/cyclin A, cdk2/cyclin E, cdk4/cyclin D1 and cdk5-p35 respectively. Reversibly arrests synchronised cells in G1 and G2, and inhibits cell proliferation and cell death."	"Gray et al (1998) Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors. Science 281 533. PMID:9677190. Gray et al (1999) ATP-site directed inhibitors of cyclin-dependent kinases. Curr.Med.Chem. 6 859. PMID:10495356. Villerbu et al (2002) Cellular effects of purvalanol A: a specific inhibitor of cyclin-dependent kinase activities. Int.J.Cancer 97 761. PMID:11857351. Bain et al (2003) The specificities of protein kinase inhibitors: an update. Biochem.J. 371 199. PMID:12534346."	Small Molecule	Sold under license from the Regents of the University of California	http://www.tocris.com/dispprod.php?ItemId=5395	SQ1533			Mar-2003
1581	Purvalanol B	[212844-54-7]	CC(C)[C@H](CO)NC1=NC(NC2=CC(Cl)=C(C=C2)C(O)=O)=C2N=CN(C(C)C)C2=N1	Cyclin-dependent kinase inhibitor	"Cyclin-dependent kinase inhibitor. IC50 values are 6, 6, 9, > 10,000, and 6 nM for cdc2/cyclin B, cdk2/cyclin A, cdk2/cyclin E, cdk4/cyclin D1 and cdk5-p35 respectively. Selective over a range of other protein kinases (IC50 > 10,000 nM). Shown to have antiproliferative properties, mediated by p42/p44 MAPK."	"Gray et al (1998) Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors. Science 281 533. PMID:9677190. Gray et al (1999) ATP-site directed inhibitors of cyclin-dependent kinases. Curr.Med.Chem. 6 859. PMID:10495356. Knockaert et al (2002) p42/p44 MAPKs are intracellular targets of the CDK inhibitor purvalanol. Oncogene 21 6413. PMID:12226745."	Small Molecule	Sold under license from the Regents of the University of California	http://www.tocris.com/dispprod.php?ItemId=49227	SQ1533			Apr-2003
1584	MRS 1706	[264622-53-9]	O=C(C(NC(C3=CC=C(OCC(NC4=CC=C(C(C)=O)C=C4)=O)C=C3)=N2)=C2N1CCC)N(CCC)C1=O	Potent and selective A2B inverse agonist	"Potent and selective adenosine A2B receptor inverse agonist (Ki values are 1.39, 157, 112 and 230 nM for human A2B, A1, A2A and A3 receptors respectively)."	"Kim et al (2000) Anilide derivatives of an 8-phenylxanthine carboxylic congener are highly potent and selective antagonists at human A2B adenosine receptors. J.Med.Chem. 43 1165. PMID:10737749. Kiec-Kononowicz et al (2001) New developments in A1 and A2 adenosine receptor antagonists. Pure Appl.Chem. 73 1411. Li et al (2007) ZM241385, DPCPX, MRS1706 are inverse agonists with different relative intrinsic efficacies on constitutively active mutants of the human adenosine A2B receptor. J.Pharmacol.Exp.Ther. 320 637. PMID:17077318."	Small Molecule	"Manufactured and sold under license from Adenosine Therapeutics, LLC"	http://www.tocris.com/dispprod.php?ItemId=51619	SQ1341			Dec-2002
1586	SKF 83566 hydrobromide	[108179-91-5]	Br.CN1CCC2=CC(Br)=C(O)C=C2C(C1)C1=CC=CC=C1	"Potent, selective D1-like antagonist"	Potent and selective D1-like dopamine receptor antagonist (Ki~ 0.56 nM for D1; KB = 2 _M for D2). Also antagonist at the vascular 5-HT2 receptor (Ki = 11 nM). Displays selective inhibition of adenylyl cyclase 2 (AC2); inactive against AC1 or AC5. Centrally active following systemic administration in vivo.	"Ohlstein and Berkowitz (1985) SCH 23390 and SK&F 83566 are antagonists at vascular dopamine and serotonin receptors. Eur.J.Pharmacol. 108 205. PMID:3884345. Meyer et al (1993) Effects of dopamine D1 antagonists SCH23390 and SK&F83566 on locomotor activities in rats. Pharmacol.Biochem.Behav. 44 429. PMID:8446676. Fritts et al (1998) Locomotor stereotypy produced by dexbenzetimide and scopolamine is reduced by SKF 83566, not sulpiride. Pharmacol.Biochem.Behav. 60 639. PMID:9678647. Conley et al (2013) Development of a high-throughput screening paradigm for the discovery of small-molecule modulators of adenylyl cyclase: identification of an adenylyl cyclase 2 inhibitor. J.Pharmacol.Exp.Ther. 347 276. PMID:24008337."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=40539	SQ1070			Mar-2003
1587	Ro 32-0432 hydrochloride	[151342-35-7]	O=C(N1)C(C2=C6N(CC[C@H](CN(C)C)C6)C3=CC=CC=C23)=C(C(C5=C4C=CC=C5)=CN4C)C1=O.Cl	"Potent, orally active PKC inhibitor"	"Selective cell-permeable protein kinase C inhibitor. Displays slight selectivity for conventional PKC isoforms over Ca2+ and atypical PKC isoforms; binding affinities for rat isoforms are 9, 28, 31, 37 and 108 nM for PKC's _, __, ___, _ and _ respectively. Orally available and prevents T cell chronic inflammation in vivo."	"Wilkinson et al (1993) Isoenzyme specificity of bisindolylmaleimides, selective inhibitors of protein kinase C. Biochem.J. 294 335. PMID:8373348. Birchall et al (1994) Ro 32-0432, a selective and orally active inhibitor of protein kinase C prevents T-cell activation. J.Pharmacol.Exp.Ther. 268 922. PMID:8114006."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=52466	SQ1341			Apr-2007
1588	Indatraline hydrochloride	[96850-13-4]	ClC(C=C3)=C(Cl)C=[C@@]3[C@H]2C1=CC=CC=C1[C@H](NC)C2.Cl	Potent 5-HT uptake inhibitor; also inhibits dopamine and noradrenalin uptake	"Potent monoamine uptake inhibitor. Inhibits transporters for 5-HT (SERT), dopamine (DAT) and noradrenalin (NET) (Ki values are 0.42, 1.7 and 5.8 nM respectively). Centrally active following systemic administration in vivo."	"Hyttel and Larsen (1985) Neurochemical profile of Lu 19-005, a potent inhibitor of uptake of dopamine, noradrenaline and serotonin. J.Neurochem. 44 1615. PMID:2580950. Negus et al (1999) Effects of the long-acting monoamine reuptake inhibitor indatraline on cocaine self-administration in rhesus monkeys. J.Pharmacol.Exp.Ther. 291 60. PMID:10490887. Gu et al (2000) Design, synthesis, and monoamine transporter binding site affinities of methoxy derivatives of indatraline. J.Med.Chem. 43 4868. PMID:11123996."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=52479	SQ1070			May-2003
1591	NBI 27914 hydrochloride	[1215766-76-9]	Cl.CCCN(CC1CC1)C1=C(Cl)C(NC2=C(Cl)C=C(Cl)C=C2Cl)=NC(C)=N1	Selective non-peptide CRF1 antagonist	"Selective, non-peptide corticotropin-releasing factor1 (CRF1) receptor antagonist (Ki = 1.7 nM); has no activity at CRF2 receptors. Blocks behavioral seizures in vivo."	"Chen et al (1996) Design and synthesis of a series of non-peptide high-affinity human corticotropin-releasing factor1 receptor antagonists. J.Med.Chem. 39 4358. PMID:8893829. Baram et al (1997) The CRF1 receptor mediates the excitatory actions of corticotropin releasing factor (CRF) in the developing rat brain: in vivo evidence using a novel, selective, non-peptide CRF receptor antagonist. Brain Res. 770 89. PMID:9372207. McCarthy et al (1999) Recent advances with the CRF1 receptor: design of small molecule inhibitors, receptor subtypes and clinical indications. Curr.Pharm.Des. 5 289. PMID:10213797."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=5359	SQ1341			Nov-2002
1592	SCH 79797 dihydrochloride	[1216720-69-2]	Cl.Cl.CC(C)C1=CC=C(CN2C=CC3=C2C=CC2=NC(NC4CC4)=NC(N)=C32)C=C1	"Potent, selective non-peptide PAR1 antagonist"	"Potent, selective non-peptide PAR1 receptor antagonist (IC50 = 70 nM). Inhibits haTRAP-induced- but not _-thrombin-, ADP- or collagen-induced human platelet aggregation. Also selectively blocks PAR1 agonist- or thrombin-induced increases in cytosolic Ca2+ in vascular smooth muscle cells."	"Ahn et al (1999) Structure-activity relationships of pyrroloquinazolines as thrombin receptor antagonists. Bioorg.Med.Chem.Lett. 9 2073. PMID:10450984. Ahn et al (2000) Inhibition of cellular action of thrombin by N3-cyclopropyl-7-{[4-(1-methylethyl)phenyl]methyl}-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine (SCH 79797), a nonpeptide thrombin receptor antagonist. Biochem.Pharmacol. 60 1425. PMID:11020444. Lidington et al (2005) A role for proteinase-activated receptor 2 and PKC-_ in thrombin-mediated induction of decay-accelerating factor on human endothelial cells. Am.J.Physiol.Cell Physiol. 289 C1437. PMID:16079188."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=52973	SQ1533			Feb-2003
1594	Ro 25-6981 maleate	[1312991-76-6]	OC(=O)\C=C/C(O)=O.C[C@@H](CN1CCC(CC2=CC=CC=C2)CC1)[C@@H](O)C1=CC=C(O)C=C1	Subtype-selective NR2B antagonist	Potent and selective activity-dependent blocker of NMDA receptors containing the NR2B subunit. IC50 values are 0.009 and 52 _M for cloned receptor subunit combinations NR1C/NR2B and NR1C/NR2A respectively. Displays neuroprotectant effects in vivo and in vitro.	"Fischer et al (1997) Ro 25-6981, a highly potent and selective blocker of N-Methyl-D-aspartate receptors containing the NR2B subunit. Characterization in vitro. J.Pharmacol.Exp.Ther. 283 1285. PMID:9400004. Lynch et al (2001) Pharmacological characterization of interactions of RO 25-6981 with the NR2B (_2) subunit. Eur.J.Pharmacol. 416 185. PMID:11290368. Kosowski and Liljequist (2004) The NR2B- selective N-methyl-D-aspartate receptor antagonist Ro 25-6981 [()-(R*,S*)-_-(4-hydroxyphenyl)-_-methyl-4-(phenylmethyl)-1-piperidine propanol] potentiates the effect of nicotine on locomotor activity and dopamine release in the nucleus accumbens. J.Pharmacol.Exp.Ther. 311 560. PMID:15256539."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=53008	SQ1341			Feb-2003
1603	NKH 477	[138605-00-2]	O=C(CCN(C)C)O[C@H]2[C@@]1([H])C(C)(C)CC[C@H](O)[C@@](C)1[C@]3(O)[C@@](O[C@](C=C)(C)CC3=O)(C)[C@H]2OC(C)=O.Cl	Water-soluble adenylyl cyclase activator	Water-soluble analog of forskolin (Cat. No. 1099) that is a potent activator of adenylyl cyclase; shows some selectivity for cardiac (type V) adenylyl cyclase. Stimulates bronchodilation (EC50 = 32.6 nM) and is an orally active potent positive chronotrope and hypotensive agent in vivo. Also available as part of the PKA Tocriset.	"Hosono et al (1992) Cardiovascular and adenylate cyclase stimulant properties of NKH477, a novel water-soluble forskolin derivative. J.Cardiovasc.Pharmacol. 19 625. PMID:1380607. Satake et al (1998) Relaxant effects of NKH477, a new water-soluble forskolin derivative, on guinea-pig tracheal smooth muscle: the role of Ca2+-activated K+ channels. Br.J.Pharmacol. 123 753. PMID:9517396. Toya et al (1998) Forskolin derivatives with increased selectivity for cardiac adenylyl cyclase. J.Mol.Cell.Cardiol. 30 97. PMID:9500868."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=53767	SQ1070			Feb-2003
1610	Rottlerin	[82-08-6]	CC(=O)C1=C(O)C(CC2=C(O)C(C(=O)\C=C\C3=CC=CC=C3)=C3OC(C)(C)C=CC3=C2O)=C(O)C(C)=C1O	Reported PKC_ inhibitor	"Originally reported to inhibit PKC isoforms. Also reported to inhibit CAM kinase III. However, recently shown to inhibit a wide range of protein kinases, and most potently to inhibit PRAK and MAPKAP-K2 (IC50 values are 1.9 and 5 _M respectively). Also shown to act as a direct mitochondrial uncoupler. Thought to stimulate autophagy by targeting upstream mTORC1 control pathways."	"Gschwendt et al (1994) Rottlerin, a novel protein kinase inhibitor. Biochem.Biophys.Res.Commun. 199 93. PMID:8123051. Davies et al (2000) Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem.J. 351 95. PMID:10998351. Zhang et al (2007) Neuroprotective effect of protein kinase C_ inhibitor rottlerin in cell culture and animal models of Parkinson's disease. J.Pharmacol.Exp.Ther. 322 913. PMID:17565007. Balgi et al (2009) Screen for chemical modulators of autophagy reveals novel therapeutic inhibitors of mTORC1 signaling. PLoS One 4 e7124. PMID:19771169."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=54209	SQ1070			Nov-2002
1611	Lamotrigine	[84057-84-1]	NC1=NC(N)=C(N=N1)C1=CC=CC(Cl)=C1Cl	Inhibits glutamate release. Anticonvulsant	"Anticonvulsant. Inhibits glutamate release, possibly through inhibition of Na+, K+ and Ca2+ currents. Also blocks heterologously expressed and native _4_2 nAChRs with a similar affinity to Na+ channels. Water-soluble salt available (lamotrigine isethionate, Cat. No. 2289)."	Leach et al (1991) Neurochemical and behavioral aspects of lamotrigine. Epilepsia 32 S4. PMID:1685439. Zona and Avoli (1997) Lamotrigine reduces voltage-gated sodium currents in rat central neurons in culture. Epilepsia 38 522. PMID:9184596. Grunze et al (1998) Modulation of calcium and potassium currents by lamotrigine. Neuropsychobiology 38 131. PMID:9778600. Zheng et al (2010) The anticonvulsive drug lamotrigine blocks neuronal _4_2 nicotinic acetylcholine receptors. J.Pharmacol.Exp.Ther. 335 401. PMID:20688974.	Small Molecule	Sold for research purposes under agreement from GlaxoSmithKline	http://www.tocris.com/dispprod.php?ItemId=40545	SQ1533			Nov-2002
1612	SB 269970 hydrochloride	[261901-57-9]	OC1=CC(S(N2[C@@H](CCN3CCC(C)CC3)CCC2)(=O)=O)=CC=C1.Cl	Potent and selective 5-HT7 antagonist; brain penetrant	"Potent and selective 5-HT7 receptor antagonist (pKi values are 8.9, 7.2 and 6.0 for 5-HT7A, 5-HT5A and 5-HT1B and < 6.0 for 5-HT1A, 5-HT1D, 5-HT1E, 5-HT1F, 5-HT2A, 5-HT2B, 5-HT2C, 5-HT4 and 5-HT6 receptors respectively). Brain penetrant in vivo."	"Hagan et al (2000) Characterization of SB-269970-A, a selective 5-HT7 receptor antagonist. Br.J.Pharmacol. 130 539. PMID:10821781. Lovell et al (2000) A novel, potent, and selective 5-HT7 antagonist: (R)-3-(2-(2-(4-methylpiperidin-1-yl)-ethyl)pyrrolidine-1-sulfonyl)phenol (SB-269970) J.Med.Chem. 43 342. PMID:10669560. Kogan et al (2002) DR4004, a putative 5-HT7 receptor antagonist, also has functional activity at the dopamine receptor. Eur.J.Pharmacol. 449 105. PMID:12163113."	Small Molecule	Sold for research purposes under agreement from GlaxoSmithKline.	http://www.tocris.com/dispprod.php?ItemId=5435	SQ1341			Jan-2003
1614	SB 431542	[301836-41-9]	NC(=O)C1=CC=C(C=C1)C1=NC(=C(N1)C1=CC=CC=N1)C1=CC2=C(OCO2)C=C1	"Potent, selective inhibitor of TGF-_RI, ALK4 and ALK7"	"Potent and selective inhibitor of the transforming growth factor-_ (TGF-_) type I receptor activin receptor-like kinase ALK5 (IC50 = 94 nM), and its relatives ALK4 and ALK7. Suppresses TGF-_-induced proliferation of human osteosarcoma cells. Stimulates proliferation, differentiation and sheet formation of ESC-derived endothelial cells."	"Inman et al (2002) SB-431542 is a potent and specific inhibitor of transforming growth factor-_ superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7. Mol.Pharmacol. 62 65. PMID:12065756. Laping et al (2002) Inhibition of transforming growth factor (TGF)-_1-induced extracellular matrix with a novel inhibitor of the TGF-_ type I receptor kinase activity: SB-431542. Mol.Pharmacol. 62 58. PMID:12065755. Matsuyama et al (2003) SB-431542 and Gleevec inhibit transforming growth factor-_-induced proliferation of human osteosarcoma cells. Cancer Res. 63 7791. PMID:14633705. Watabe et al (2003) TGF-beta receptor kinase inhibitor enhances growth and integrity of embryonic stem cell-derived endothelial cells. J.Cell Biol. 163 163. PMID:14676305."	Small Molecule	Sold for research purposes under agreement from GlaxoSmithKline	http://www.tocris.com/dispprod.php?ItemId=54518	SQ1533			Sep-2003
1615	SB 366791	[472981-92-3]	COC1=CC=CC(NC(=O)\C=C\C2=CC=C(Cl)C=C2)=C1	"Potent, selective, competitive TRPV1 antagonist"	"Potent, selective and competitive vanilloid TRPV1 receptor antagonist (pA2 = 7.71 at hVR1); antagonizes hTRPV1 receptors activated by agonists, noxious heat, but not protons. Displays selectivity over a wide range of receptors and systems including CB1 and CB2 receptors, voltage-gated Ca2+ channels and the hyperpolarization-activated current (Ih). Also available as part of the Vanilloid TRPV1 Receptor Tocriset."	"Fowler et al (2003) Inhibition of C6 glioma cell proliferation by anandamide, 1-arachidonylglycerol, and by a water soluble phosphate ester of anandamide: variability in response and involvement of arachidonic acid. Biochem.Pharmacol. 66 757. PMID:12948856. Gunthorpe et al (2004) Identification and characterisation of SB-366791, a potent and selective vanilloid receptor (VR1/TRPV1) antagonist. Neuropharmacology 46 133. PMID:14654105. Gavva et al (2005) Proton activation does not alter antagonist interaction with the capsaicin-binding pocket of TRPV1. Mol.Pharmacol. 68 1524. PMID:16135784."	Small Molecule	Sold for research purposes under agreement from GlaxoSmithKline	http://www.tocris.com/dispprod.php?ItemId=54519	SQ1341			Nov-2002
1616	SB 216763	[280744-09-4]	CN1C=C(C2=CC=CC=C12)C1=C(C(=O)NC1=O)C1=C(Cl)C=C(Cl)C=C1	"Potent, selective GSK-3 inhibitor"	"Potent and selective, ATP-competitive glycogen synthase kinase-3 (GSK-3) inhibitor (IC50 = 34.3 nM for GSK-3_). Equally effective at inhibiting human GSK-3_ and GSK-3_. Exhibits minimal activity against 24 other protein kinases (IC50 >10 _M). Stimulates glycogen synthesis in liver cells, and induces _-catenin-dependent gene transcription. Neuroprotective; also reduces pulmonary inflammation and fibrosis in a mouse model. Shown to maintain mouse embryonic stem cells in a pluripotent state."	"Coghlan et al (2000) Selective small molecule inhibitors of glycogen synthase kinase-3 modulate glycogen metabolism and gene transcription. Chem.Biol. 7 793. PMID:11033082. Cross et al (2001) Selective small-molecule inhibitors of glycogen synthase kinase-3 activity protect primary neurones from death. J.Neurochem. 77 94. PMID:11279265. Liang and Chuang (2006) Regulation and function of glycogen synthase kinase-3 isoforms in neuronal survival. J.Biol.Chem. 282 3904. PMID:17148450. Gurrieri et al (2010) 3-(2,4-dichlorophenyl)-4-(1-methyl-1H-indol-3-yl)-1H-pyrrole-2,5-dione (SB216763), a glycogen synthase kinase-3 inhibitor, displays therapeutic properties in a mouse model of pulmonary inflammation and fibrosis. J.Pharmacol.Exp.Ther. 332 785. PMID:19959748. Kirby et al (2012) Glycogen synthase kinase 3 (GSK3) inhibitor, SB-216763, promotes pluripotency in mouse embryonic stem cells. PLoS One 7 e39329. PMID:22745733."	Small Molecule	Sold for research purposes under agreement from GlaxoSmithKline	http://www.tocris.com/dispprod.php?ItemId=40544	SQ1341			Dec-2002
1617	SB 415286	[264218-23-7]	OC1=C(Cl)C=C(NC2=C(C(=O)NC2=O)C2=C(C=CC=C2)[N+]([O-])=O)C=C1	"Potent, selective GSK-3 inhibitor"	"Potent and selective glycogen synthase kinase-3 (GSK-3) inhibitor (Ki = 31 nM for GSK-3_); competes with ATP. Has minimal activity against 24 other protein kinases (IC50 > 10 _ M). Stimulates glycogen synthesis, gene transcription and is neuroprotective."	Coghlan et al (2000) Selective small molecule inhibitors of glycogen synthase kinase-3 modulate glycogen metabolism and gene transcription. Chem.Biol. 7 793. PMID:11033082. Cross et al (2001) Selective small-molecule inhibitors of glycogen synthase kinase-3 activity protect primary neurones from death. J.Neurochem. 77 94. PMID:11279265. Liang and Chuang (2006) Regulation and function of glycogen synthase kinase-3 isoforms in neuronal survival. J.Biol.Chem. 282 3904. PMID:17148450.	Small Molecule	Sold for research purposes under agreement from GlaxoSmithKline	http://www.tocris.com/dispprod.php?ItemId=40543	SQ1533			Jan-2003
1620	Alprostadil	[745-65-3]	CCCCC[C@H](O)/C=C/[C@@H]1[C@H](C(C[C@H]1O)=O)CCCCCCC(O)=O	Prostaglandin. Vasodilator and antiplatelet agent in vivo	"Prostaglandin with some selectivity for EP3 and EP4 receptors (Ki values are 1.1, 2.1, 36, 10  and 33 nM for mouse EP3, EP4, EP1, EP2 and IP receptors respectively). Inhibits platelet aggregation and is a vasodilator in vivo."	"Whittle et al (1985) Specificity between the anti-aggregatory actions of prostacyclin, prostaglandin E1 and D2 on platelets. Adv.Exp.Med.Biol. 192 109. PMID:2871707. Kirtland (1988) Prostaglandin E1: a review. Prostaglandins Leukot.Essent.Fatty Acids 32 165. PMID:2901111. Kiriyama et al (1997) Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells. Br.J.Pharmacol. 122 217. PMID:9313928."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=55294	SQ1533			Oct-2002
1621	Streptozocin	[18883-66-4]	O[C@H]1[C@H](O)[C@@H](CO)OC(O)[C@@H]1NC(N(C)N=O)=O	DNA alkylator; antitumor and induces diabetes	Antibiotic and antitumor agent. Alkylates DNA and induces diabetes mellitus via reduction of nicotinamide adenine dinucleotide in pancreatic _-cells in vivo.	"Bennett and Pegg (1981) Alkylation of DNA in rat tissues following administration of streptozotocin. Cancer Res. 41 2786. PMID:6454479. Weis (1982) Steptozotocin: A review of its pharmacology, efficacy and toxicity. Cancer Treat. Rep. 66 427. PMID:6277485."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=56023	SQ1533			Dec-2002
1622	Remacemide hydrochloride	[111686-79-4]	Cl.CC(CC1=CC=CC=C1)(NC(=O)CN)C1=CC=CC=C1	NMDA antagonist; blocks ion channel and allosteric modulatory site	Non-competitive NMDA receptor antagonist; blocks ion channel and allosteric modulatory site (IC50 = 8 - 68 mM). Anticonvulsant in vivo and metabolizes to a more potent desglycine analog. Weakly blocks voltage-dependent Na+ channels (IC50 = 161 mM).	Palmer et al (1995) Neuroprotective properties of the uncompetitive NMDA receptor antagonist remacemide hydrochloride. Ann.N.Y.Acad.Sci. 765 236. PMID:7486610. Subramaniam et al (1996) Block of the N-methyl-D-aspartate receptor by remacemide and its des-glycine metabolite. J.Pharmacol.Exp.Ther. 276 161. PMID:8558426. Santangeli et al (2002) Na+ channel effects of remacemide and desglycinyl-remacemide in rat cortical synaptosomes. Eur.J.Pharmacol. 438 63. PMID:11906711.	Small Molecule	Sold with the permission of AstraZeneca UK Ltd.	http://www.tocris.com/dispprod.php?ItemId=56447	SQ1533			Jan-2003
1625	DFB	[15332-10-2]	FC1=CC(=CC=C1)\C=N\N=C\C1=CC=CC(F)=C1	Allosteric potentiator at mGlu5	"Novel allosteric potentiator of the metabotropic glutamate receptor mGlu5. Devoid of agonist activity itself, but potentiates (3 - 6-fold) the action of agonists at mGlu5 without any effect at other mGlu subtypes (EC50 for potentiation = 2 - 5.3 _M)."	"Williams et al (2002) DFB, an allosteric potentiator of mGluR5 4th International Meeting on Metabotropic Glutamat. O'Brien et al (2003) A family of highly selective allosteric modulators of the metabotropic glutamate receptor subtype 5. Mol.Pharmacol. 64 731. PMID:12920211. Zhang et al (2005) Allosteric potentiators of metabotropic glutamate receptor subtype 5 have differential effects on different signaling pathways in cortical astrocytes. J.Pharmacol.Exp.Ther. 315 1212. PMID:16135701."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=56665	SQ1341			Jan-2003
1634	Y-29794 oxalate	[146794-84-5]	O=C(C2=CC=CS2)C1=CC=C(C(C)C)N=C1SCCCCCCCCN(C)C.O=C(C(=O)O)O	Prolyl endopeptidase inhibitor	"Inhibitor of prolyl endopeptidase, a serine peptidase that may be implicated in the biosynthesis of amyloid _-peptide. Potently inhibits rat brain prolyl endopeptidase (Ki = 0.95 nM) in vitro, and prevents amyloid _-peptide deposition in vivo. Orally active and brain penetrant."	"Nakajima et al (1992) Y-29794 - a non-peptide prolyl endopeptidase inhibitor that can penetrate into the brain. Neurosci.Lett. 141 156. PMID:1436628. Kato et al (1997) Prevention of amyloid-like deposition by a selective prolyl endopeptidase inhibitor, Y-29794, in senescence-accelerated mouse. J.Pharmacol.Exp.Ther. 283 328. PMID:9336340."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=56823	SQ1341			Sep-2003
1635	RP 67580	[135911-02-3]	[H][C@@]13[C@@](CN(C(CC4=C(OC)C=CC=C4)=N)C3)([H])C(CCC(C5=CC=CC=C5)1C2=CC=CC=C2)=O	Potent and selective NK1 antagonist	"Potent and selective tachykinin NK1 receptor antagonist (Ki values are 2.9 nM and > 10 _M for rat NK1, and rat NK2 and NK3 receptors respectively). Displays higher affinity at rat and mouse than human receptors. Antinociceptive in vivo, possibly partly via inhibition of calcium channels."	"Garret et al (1991) Pharmacological properties of a potent and selective nonpeptide substance P antagonist. Proc.Natl.Acad.Sci.U.S.A. 88 10208. PMID:1719549. Fong et al (1992) Molecular basis for the species selectivity of the neurokinin-1 receptor antagonists CP-96,345 and RP67580. J.Biol.Chem. 267 25668. PMID:1281470. Beaujouan et al (1993) Higher potency of RP 67580, in the mouse and the rat compared with other nonpeptide and peptide tachykinin NK1 antagonists. Br.J.Pharmacol. 108 793. PMID:7682138. Rupniak et al (1993) Antinociceptive activity of NK1 receptor antagonists: non-specific effects of racemic RP67580. Br.J.Pharmacol. 110 1607. PMID:8306108."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=56826	SQ1070			May-2003
1636	IEM 1460	[121034-89-7]	[Br-].Br.C[N+](C)(C)CCCCCNCC12CC3CC(C1)CC(C2)C3	Open-channel blocker of AMPA currents; selective for non-GluR2-containing receptors	"Voltage-dependent open-channel blocker of AMPA receptors. Displays selectivity between subtypes, blocking GluR2 subunit-lacking (Ca2+-permeable) receptors more potently than GluR2-containing receptors (IC50 values are 2.6 and 1102 _M respectively). Selectively blocks fast spiking interneron but not medium spiny projection neuron in mouse striatum. Also blocks NMDA receptor-mediated currents. Anticonvulsant in vivo."	"Buldakova et al (1999) Characterization of AMPA receptor populations in rat brain cells by the use of subunit-specific open channel blocking drug, IEM-1460. Brain Res. 846 52. PMID:10536213. Schlesinger et al (2005) Two mechanisms of action of the adamantane derivative IEM-1460 at human AMPA-type glutamate receptors. Br.J.Pharmacol. 145 656. PMID:15834439. Gittis et al (2012) Selective inhibition of striatal fast-spiking interneurons causes dyskinesias. J.Neurosci. 31 15727. PMID:22049415."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=56829	SQ1341			Aug-2003
1637	Argatroban	[74863-84-6]	O=C(N1[C@@H]([C@@](O)=O)C[C@H](C)CC1)[C@@H](NS(C2=CC=CC3=C2NCC(C)C3)(=O)=O)CCCNC(N)=N	Potent thrombin inhibitor	Potent inhibitor of thrombin mediated fibrinogen cleavage (Ki = 19 nM). Competitive inhibitor of thrombin-induced platelet activation and clotting. Shown to exhibit antithrombotic activity in animal models.	"Kikumoto et al (1984) Selective inhibition of thrombin by (2R,4R)-4-methyl-1-[N2-[(3-methyl-1,2,3,4-tetrahydro-8-quinolinyl++ +) sulfonyl]-1-arginyl)]-2-piperidinecarboxylic acid. Biochemistry 23 85. PMID:6691968. Fitzgerald and Fitzgerald (1989) Role of thrombin and thromboxane A2 in reocclusion following coronary thrombolysis with tissue-type plasminogen activator. Proc.Natl.Acad.Sci.USA 86 7585. Jang et al (1990) Prevention of platelet-rich arterial thrombosis by selective thrombin inhibition. Circulation 81 219. PMID:2297828."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=56865	SQ1070			Jun-2010
1638	U 18666A	[3039-71-2]	[H][C@@]23CC=C1C[C@@H](OCCN(CC)CC)CC[C@@](C)1[C@]([H])2CC[C@@]4(C)[C@]([H])3CCC4=O.Cl	Inhibitor of Hedgehog (Hh) signaling. Also inhibits cholesterol synthesis	"Inhibitor of cholesterol synthesis and cellular transport, and weak inhibitor of hedgehog (Hh) signaling. Reduces serum sterol levels in rats in vivo."	Cenedella et al (1980) Concentration-dependent effects of AY-9944 and U18666A on sterol synthesis in brain. Biochem.Pharmacol. 29 2751. PMID:6159896. Liscum and Faust (1989) The intracellular transport of low density lipoprotein-derived cholesterol is inhibited in Chinese hamster ovary cells cultured with 3-_-[2-(diethylamino)ethoxy]androst-5-en-17-one. J.Biol.Chem. 264 11796. PMID:2745416. Incardona et al (2000) Cyclopamine inhibition of sonic hedgehog signal transduction is not mediated through effects on cholesterol transport. Dev.Biol. 224 440. PMID:10926779.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=57015	SQ1341			Mar-2003
1639	AY 9944 dihydrochloride	[366-93-8]	ClC(C=CC=C3)=C3CNC[C@H]1CC[C@H](CNCC2=C(Cl)C=CC=C2)CC1.Cl.Cl	Inhibitor of Hedgehog (Hh) signaling. Inhibits _7-dehydrocholesterol reductase	"Inhibitor of hedgehog (Hh) signaling, possibly via several mechanisms. Inhibits _7-dehydrocholesterol reductase (IC50 = 13 nM), thus reduces cholesterol biosynthesis, and also inhibits cholesterol esterification. May also directly block the cellular response to Hh proteins. Teratogenic in vivo."	Kraml et al (1964) Inhibition of the conversion of 7-dehydrocholesterol to cholesterol by AY-9944. Biochem.Biophys.Res.Commun. 15 455. PMID:4283982. Moebius et al (1998) Molecular cloning and expression of the human _7-sterol reductase. Proc.Natl.Acad.Sci.U.S.A. 95 1899. PMID:9465114. Cooper et al (1998) Teratogen-mediated inhibition of target tissue response to Shh signaling. Science 280 1603. PMID:9616123. Incardona and Eaton (2000) Cholesterol in signal transduction. Curr.Opin.Cell Biol. 12 193. PMID:10712926.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=57054	SQ1341			Mar-2003
1641	OLDA	[105955-11-1]	CCCCCCCC\C=C/CCCCCCCC(=O)NCCC1=CC=C(O)C(O)=C1	"Potent, selective endogenous TRPV1 agonist"	Potent endogenous vanilloid TRPV1 (VR1) receptor agonist (EC50 = 36 nM at hVR1) with low affinity for rCB1 receptors (Ki = 1.6 _M). Potently induces VR1-mediated thermal hyperalgesia in rats in vivo.	"Chu et al (2003) N-Oleoyldopamine, a novel endogenous capsaicin-like lipid that produces hyperalgesia. J.Biol.Chem. 278 13633. PMID:12569099. Butelman et al (2004) Anitallodynic effects of loperamide and fentanyl against topical capsaicin-induced allodynia in unanesthetized primates. J.Pharmacol.Exp.Ther. 311 155. PMID:15152028."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=58402	SQ1341			Dec-2002
1643	D-64131	[74588-78-6]	COC1=CC=C2NC(=CC2=C1)C(=O)C1=CC=CC=C1	Inhibitor of tubulin polymerization. Antitumor in vivo	Novel inhibitor of tubulin polymerization; cytotoxic and inhibits tumor cell proliferation in vitro (IC50 = 74 nM). Prevents growth of tumor models in mice following oral administration in vivo.	"Mahboobi et al (2001) Synthetic 2-aroylindole derivatives as a new class of potent tubulin-inhibitory, antimitotic agents. J.Med.Chem. 44 4535. PMID:11741473. Beckers et al (2002) 2-aroylindoles, a novel class of potent, orally active small molecule tubulin inhibitors. Cancer Res. 62 3113. PMID:12036922."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=59009				Mar-2003
1644	Mesulergine hydrochloride	[72786-12-0]	CN2C1=CC=CC([C@]4([H])[C@@](N(C)C[C@@H](NS(=O)(N(C)C)=O)C4)([H])C3)=C1C3=C2.Cl	5-HT2A and 5-HT2C antagonist. Also dopamine receptor partial agonist	5-HT2A and 2C receptor antagonist (pA2 values are 9.1 for each receptor) and D2-like dopamine receptor partial agonist (Ki = 8 nM). Displays antiprolactin and antiparkinsonian effects in vivo.	"Markstei (1983) Mesulergine and its 1,20-N,N-bidemethylated metabolite interact directly with D1- and D2-receptors. Eur.J.Pharmacol. 95 101. PMID:6230246. Marko (1984) Dopamine agonistic potency of two novel prolactin release-inhibiting ergolines. Eur.J.Pharmacol. 101 263. PMID:6468500. Hoyer et al (1994) VII. International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (serotonin). Pharmacol.Rev. 46 157. PMID:7938165."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=59146	SQ1533			Nov-2010
1646	Lonidamine	[50264-69-2]	OC(=O)C1=NN(CC2=C(Cl)C=C(Cl)C=C2)C2=CC=CC=C12	Mitochondrial hexokinase inhibitor	Anticancer and antispermatogenic agent in vitro and in vivo. Inhibits cellular energy metabolism in some cells via inhibition of mitochondrial hexokinase. Also blocks CFTR Cl- channels in vitro.	"Lobl et al (1981) Effects of lonidamine (AF 1890) and its analogues on follicle-stimulating hormone, luteinizing hormone, testosterone and rat androgen binding protein concentrations in the rat and rhesus monkey. Chemotherapy 27 61. PMID:6793318. De Martino et al (1984) Effects of lonidamine on murine and human tumor cells in vitro. A morphological and biochemical study. Oncology 41 15. PMID:6717891. Teiche (1994) Lonidamine: in vitro/in vivo correlations. Eur.J.Cancer 30A 1411. PMID:7833093. Gong et al (2002) Mechanism of lonidamine inhibition of the CFTR chloride channel. Br.J.Pharmacol. 137 928. PMID:12411425."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=59413	SQ1533			May-2003
1655	O-2050		OC1=CC(CC#CCCCNS(=O)(C)=O)=CC3=[C@@]1[C@@H]2CC(C)=CC[C@H]2[C@@](C)(C)O3	Putative CB1 silent antagonist; displays mixed activity at CB receptors	"Originally defined as a high affinity cannabinoid CB1 receptor silent antagonist. Acts as a partial agonist in inhibiting forksolin-induced cyclic AMP stimulation (EC50 = 40.4 nM). Decreases food intake and stimulates locomotor activity in rodents. Antagonizes effects of CP55,940 (Cat. No. 0949) in vitro."	"Martin et al (2002) Agonists and silent antagonists in a series of cannabinoid sulfonamides. Symposium on the Cannabinoids, International Canna. Gardner and Mallet (2006) Suppression of feeding, drinking, and locomotion by a putative cannabinoid receptor 'silent antagonist.' Eur.J.Pharmacol. 530 103. PMID:16380113. Wiley et al (2011) Structural and pharmacological analysis of O-2050, a putative neutral cannabinoid CB1 receptor antagonist. Eur.J.Pharmacol. 651 96. PMID:21114999."	Small Molecule	Sold under license from VCU-IPF	http://www.tocris.com/dispprod.php?ItemId=60065	SQ1341			Aug-2004
1657	Ginkgolide B	[15291-77-7]	O=C1[C@@H](C)[C@@]2(O)[C@@]([C@H](O)C34[C@]52O[C@@]6([H])[C@]([C@@H](O)C(O6)=O)3[C@H]([C@](C)(C)C)C[C@H]4O[C@]5=O)([H])O1	PAF receptor antagonist	Platelet-activating factor (PAF) receptor antagonist (Ki = 1.3 _M). Inhibits neutrophil degranulation and superoxide production in vitro and inhibits bronchoconstriction and is neuroprotective following oral administration in vivo.	Desquand et al (1986) Interference of BN 52021 (ginkgolide B) with the bronchopulmonary effects of PAF-acether in the guinea-pig. Eur.J.Pharmacol. 127 83. PMID:3019727. Foldes-Filep et al (1987) Inhibition by BN 52021 (ginkgolide B) of the binding of [3H]-platelet-activating factor to human neutrophil granulocytes. Biochem.Biophys.Res.Commun. 148 1412. PMID:2825685. Maclennan et al (2002) The CNS effects of Ginkgo biloba extracts and ginkgolide B. Prog.Neurobiol. 67 235. PMID:12169298.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=61611	SQ1533			Mar-2003
1658	GR 125487 sulfamate	[859502-43-5]	NS(O)(=O)=O.COC1=C(C(=O)OCC2CCN(CCNS(C)(=O)=O)CC2)C2=CC(F)=CC=C2N1	"Potent, selective 5-HT4 antagonist; active in vivo"	Potent and selective 5-HT4 receptor antagonist (Ki = 0.19 nM for porcine 5-HT4). Centrally active following systemic administration in vivo.	"Schiavi et al (1994) Identification of serotonin 5-HT4 recognition sites in the porcine caudate nucleus by radioligand binding. Neuropharmacology 33 543. PMID:7984293. Galeotti et al (1998) Role of 5-HT4 receptors in the mouse passive avoidance test. J.Pharmacol.Exp.Ther. 286 1115. PMID:9732367. Horikoshi et al (2001) Possible involvement of 5-HT4 receptors, in addition to 5-HT3 receptors, in the emesis induced by high-dose cisplatin in Suncus murinus. Jpn.J.Pharmacol. 85 70. PMID:11243577."	Small Molecule	Sold for research purposes under agreement from GlaxoSmithKline	http://www.tocris.com/dispprod.php?ItemId=40535	SQ1341			Jan-2003
1659	Fenoldopam hydrochloride	[181217-39-0]	Cl.OC1=CC=C(C=C1)C1CNCCC2=C(Cl)C(O)=C(O)C=C12	Selective D1-like partial agonist	Selective D1-like dopamine receptor partial agonist (EC50 = 57 nM). Vasodilator in vivo and does not readily cross the blood-brain barrier. Also _2-adrenoceptor antagonist in vitro (Ki = 15 - 25 nM).	"Hahn et al (1982) Characterization of the peripheral and central effects of SK&F 82526, a novel dopamine receptor agonist. J.Pharmacol.Exp.Ther. 223 305. PMID:6127401. Sibley et al (1982) Interactions of novel dopaminergic ligands with D-1 and D-2 dopamine receptors. Life Sci. 31 637. PMID:6127585. Nichols et al (1990) The pharmacology of fenoldopam. Am.J.Hypertens. 3 116S. PMID:1974439."	Small Molecule	Sold for research purposes under agreement from GlaxoSmithKline	http://www.tocris.com/dispprod.php?ItemId=40540	SQ1533			Feb-2003
1661	SB 206553 hydrochloride	[1197334-04-5]	Cl.CN1C=CC2=CC3=C(CCN3C(=O)NC3=CC=CN=C3)C=C12	"Potent, selective 5-HT2C/5-HT2B antagonist. Orally active"	"Potent and selective 5-HT2B/5-HT2C receptor antagonist (rat 5-HT2B pA2 = 8.89, human 5-HT2C pKi = 7.92). Displays > 80-fold selectivity over all other 5-HT receptor subtypes and a variety of other receptors (pKi < 6). Centrally active following oral administration in vivo."	"Forbes et al (1995) 5-Methyl-1-(3-pyridylcarbamoyl)-1,2,3,5-tetrahydropyrrolo[2,3-f]indole: a novel 5-HT2C/5-HT2B receptor antagonist with improved affinity, selectivity and oral activity. J.Med.Chem. 38 2524. PMID:7629791. Kennett et al (1996) In vitro and in vivo profile of SB 206553, a potent 5-HT2C/5-HT2B receptor antagonist with anxiolytic-like properties. Br.J.Pharmacol. 117 427. PMID:8821530. Porras et al (2002) 5-HT2A and 5-HT2C/2B receptor subtypes modulate dopamine release induced in vivo by amphetamine and morphine in both the rat nucleus accumbens and striatum. Neuropsychopharmacology 26 311. PMID:11850146."	Small Molecule	Sold for research purposes under agreement from GlaxoSmithKline	http://www.tocris.com/dispprod.php?ItemId=40531	SQ1533			May-2003
1662	SKF 77434 hydrobromide	[300561-58-4]	Br.OC1=CC2=C(C=C1O)C(CN(CC=C)CC2)C1=CC=CC=C1	Selective D1-like partial agonist	Selective dopamine D1-like receptor partial agonist (IC50 values are 19.7 and 2425 nM for binding to D1-like and D2-like receptors respectively). Centrally active following systemic administration in vivo.	"Briggs et al (1991) Activation of the 5-HT1C receptor expressed in Xenopus oocytes by the benzazepines SCH 23390 and SKF 38393. Br.J.Pharmacol. 104 1038. PMID:1687364. Neumeyer et al (1992) Stereoisomeric probes for the D1 dopamine receptor: synthesis and characterization of R-(+) and S-(-) enantiomers of 3-allyl-7,8-dihydroxy-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine and its 6-bromo analogue. J.Med.Chem. 35 1466. PMID:1533424. Meyer and Schults (1993) Dopamine D1 receptor family agonists, SK&F38393, SK&F77434, and SK&F82958, differentially affect locomotor activities in rats. Pharmacol.Biochem.Behav. 46 269. PMID:7903456."	Small Molecule	Sold for research purposes under agreement from GlaxoSmithKline	http://www.tocris.com/dispprod.php?ItemId=40530				Mar-2003
1663	BW 373U86	[155836-50-3]	O=C(N(CC)CC)C1=CC=C([C@@]([H])(N3C[C@@H](C)N(CC=C)C[C@@H]3C)C2=CC(O)=CC=C2)C=C1	"Potent, selective non-peptide _ agonist"	"Potent, selective non-peptide _-opioid receptor agonist. Ki values are 1.8, 15 and 34 nM for _, _ and _ receptors respectively. Centrally active following systemic administration in vivo."	"Chang et al (1993) A novel, potent and selective nonpeptidic delta opioid receptor agonist BW373U86. J.Pharmacol.Exp.Ther. 267 852. PMID:8246159. Dykstra et al (1993) A novel delta opioid agonist, BW373U86, in squirrel monkeys responding under a schedule of shock titration. J.Pharmacol.Exp.Ther. 267 875. PMID:8246162. Broom et al (2002) Comparison of receptor mechanisms and efficacy requirements for _-agonist-induced convulsive activity and antinociception in mice. J.Pharmacol.Exp.Ther. 303 723. PMID:12388657."	Small Molecule	Sold for research purposes under agreement from GlaxoSmithKline	http://www.tocris.com/dispprod.php?ItemId=40491	SQ1341			May-2003
1664	GW 1929 hydrochloride	[1217466-21-1]	Cl.CN(CCOC1=CC=C(CC(NC2=CC=CC=C2C(=O)C2=CC=CC=C2)C(O)=O)C=C1)C1=NC=CC=C1	Selective PPAR_ agonist. Orally active	"Highly selective orally active peroxisome proliferator-activated receptor (PPAR)_ agonist (pEC50 values are 8.05, < 4 and < 4 for human PPAR_, PPAR_ and PPAR_ receptors respectively). Decreases glucose, fatty acid and triglyceride levels following oral administration in vivo."	Brown et al (1999) A novel N-aryl tyrosine activator of peroxisome proliferator-activated receptor-_ reverses the diabetic phenotype of the Zucker diabetic fatty rat. Diabetes 48 1415. PMID:10389847. Nugent et al (2001) Potentiation of glucose uptake in 3T3-L1 adipocytes by PPAR_ agonists is maintained in cells expressing a PPAR_ dominant-negative mutant: evidence for selectivity in the downstream responses to PPAR_ activation. Mol.Endocrinol. 15 1729. PMID:11579205. Way et al (2001) Adipose tissue resistin expression is severely suppressed in obesity and stimulated by peroxisome proliferator-activated receptor _ agonists. J.Biol.Chem. 276 25651. PMID:11373275.	Small Molecule	Sold for research purposes under agreement from GlaxoSmithKline	http://www.tocris.com/dispprod.php?ItemId=61688	SQ1070			Nov-2003
1671	PD 102807	[23062-91-1]	CCOC(=O)C1=C(C)NC2=CC=C3OC4N(CCC5=CC(OC)=CC=C45)CC3=C12	Selective M4 antagonist	"Selective M4 muscarinic receptor antagonist. IC50 values are 91, 6559, 3441, 950 and 7412 nM for human M4, M1, M2, M3, and M5 receptors respectively."	Augelli-Szafran et al (1998) Identification and characterization of m4 selective muscarinic antagonists. Bioorg.Med.Chem.Lett. 8 1991. PMID:9873472. Kitaichi et al (1999) A novel muscarinic M4 receptor antagonist provides further evidence of an autoreceptor role for the muscarinic M2 receptor sub-type. Eur.J.Pharmacol. 383 53. PMID:10556681. Bohme et al (2002) Synthesis and pharmacology of benzoxazines as highly selective antagonists at M4 muscarinic receptors. J.Med.Chem. 45 3094. PMID:12086495.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=61839	SQ1341			Apr-2003
1672	"RU 28318, potassium salt"	[76676-34-1]	[K+].[H][C@@]12CC[C@@](O)(CCC([O-])=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])[C@H](CCC)CC2=CC(=O)CC[C@]12C	"Potent, selective mineralocorticoid receptor antagonist"	"Potent and selective antagonist for the mineralocorticoid receptor (MR). Inhibits aldosterone production and secretion, and selectively decreases ex-vivo MR binding in the hippocampus of adrenalectomised rats. Also decreases blood pressure in female rats following central administration in vivo."	"Perroteau et al (1984) The effect of the antimineralocorticoid RU 28318 on aldosterone biosythesis in vitro. J.Steroid Biochem. 20 853. PMID:6323881. Kim et al (1998) Evaluation of RU28318 and RU40555 as selective mineralocorticoid receptor and glucocorticoid receptor antagonists, respectively: receptor measures and functional studies. J.Steroid Biochem.Mol.Biol. 67 213. PMID:9879980. Rahmouni et al (1999) Cardiovascular and renal effects of central administration of a mineralocorticoid receptor antagonist in concious female rats. Eur.J.Pharmacol. 385 199. PMID:10607876."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=61861	SQ1070			Jun-2003
1673	Cl-HIBO	[909400-43-7]	ClC1=C(CC(C(O)=O)N)ON=C1O	Subtype-selective AMPA agonist (GluR1 and GluR2)	"Subtype-selective and strongly desensitising AMPA receptor agonist; selective for GluR1 and GluR2 subunit-containing receptors (EC50 values are 4.7, 1.7, 2700 and 1300 _M for rat recombinant homomeric GluR1, 2, 3 and 4 receptors respectively)."	"Kristensen et al (2002) Pharmacological characterization of 4-chlorohomoibotenic acid: a GluR1 and -2 subtype-selective agonist. Soc.Neurosci.Abstr. 540.7. Bjerrum et al (2003) Design, synthesis, and pharmacology of a highly subtype-selective GluR1/2 agonist, (RS-2-amino-3-(4-chloro-3-hydroxy-5-isoxazolyl)propionic acid (Cl-HIBO). J.Med.Chem. 46 2246. PMID:12747796."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=62090	SQ1341			May-2003
1674	LE 300	[274694-98-3]	CN1CCC2=C(CC3=CC=CC=C3CC1)NC1=CC=CC=C21	Potent and selective dopamine D1 antagonist	Potent and selective dopamine D1 receptor antagonist (Ki values are 0.08 - 1.9 nM and 6 - 45 nM for D1 and D2 receptors respectively). Also displays moderate affinity for the 5-HT2A receptor (Ki = 20 nM). Active in vivo.	"Witt et al (2000) 7-Methyl-6,7,8,9,14,15-hexahydro-5H-benz[d]indolo[2,3-g]azecine: a new heterocyclic system and a new lead compound for dopamine receptor antagonists. J.Med.Chem. 43 2079. PMID:10821720. El-Subbagh et al (2002) Dopamine/serotonin receptor ligands: Part IV [1]: Synthesis and pharmacology of novel 3-benzazecines and 3-benzazonines as potential 5-HT2A and dopamine receptor ligands. Arch.Pharm. (Weinheim). 9 443. PMID:12447918. Kassack et al (2002) Pharmacological characterization of the benz[d]indolo[2,3-g]azecine LE300, a novel type of a nanomolar dopamine receptor antagonist. Naunyn Schmiedebergs Arch.Pharmacol. 366 543. PMID:12444495."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=62091	SQ1341			Jun-2003
1675	YM 90709	[163769-88-8]	COC1=CC2=C(C=C1OC)C1=CC3=NC4=CC=CC=C4N=C3N1C(C)(C)C2	Interleukin-5 receptor antagonist	"Novel, selective inhibitor of interleukin-5 (IL-5) (IC50 = 0.45 - 1 mM). Inhibits IL-5-prolonged eosinophil survival and IL-5-induced tyrosine phosphorylation of JAK2 without inhibiting GM-CSF-mediated effects. Inhibits antigen-induced eosinophil and lymphocyte recruitment in rat airways in vivo, without affecting peripheral blood or bone marrow leukocytes."	"Morokata et al (2002) Characterization of YM-90709 as a novel antagonist which inhibits the binding of interleukin-5 to interleukin-5 receptor. Int.Immunopharmacol. 2 1693. PMID:12469943. Morokata et al (2004) Effect of a novel interleukin-5 receptor antagonist, YM-90709 (2,3-dimethoxy-6,6-dimethyl-5,6-dihydrobenzo[7,8]indolizino[2,3-b]quinoxaline), on antigen-induced airway inflammation in BN rats. Int.Immunopharmacol. 4 873. PMID:15182727. Morokata et al (2005) Effect of a novel interleukin-5 receptor antagonist, YM-90709, on antigen-induced eosinophil infiltration into the airway of BDF1 mice. Immunol.Lett. 98 161. PMID:15790522."	Small Molecule	Sold with the permission of Astellas Pharma Inc.	http://www.tocris.com/dispprod.php?ItemId=62645	SQ1341			May-2003
1676	T 0156 hydrochloride	[324572-93-2]	Cl.COC(=O)C1=C(C2=CC(OC)=C(OC)C(OC)=C2)C2=CC=NC(OCC3=NC=CC=N3)=C2C(=O)N1CC1=CC=NC(C)=C1	"Highly potent, selective PDE5 inhibitor"	"Potent and selective inhibitor of phosphodiesterase type 5 (PDE5); more selective than sildenafil (IC50 values are 0.23, 56 and > 63000 nM for T 0156 and 3.6, 29 and > 270 nM for sildenafil at PDE5, PDE6 and PDEs 1 - 4 respectively). Selective over 30 other enzymes and receptors (IC50 > 10 mM) and potentiates electrical field stimulation-induced relaxation of isolated rabbit corpus cavernosum. Active in vivo."	"Mochida et al (2002) Enzymological and pharmacological profile of T-0156, a potent and selective phosphodiesterase type 5 inhibitor. Eur.J.Pharmacol. 456 91. PMID:12450574. Mochida et al (2004) T-0156, a novel phosphodiesterase type 5 inhibitor, and sildenafil have different pharmacological effects on penile tumescence and electroretinogram in dogs. Eur.J.Pharmacol. 485 283. PMID:14757152."	Small Molecule	Sold with the permission of Tanabe Seiyaku Co. Ltd.	http://www.tocris.com/dispprod.php?ItemId=62724	SQ1341			Feb-2003
1677	GW 7647	[265129-71-3]	CC(C)(SC1=CC=C(CCN(CCCCC2CCCCC2)C(=O)NC2CCCCC2)C=C1)C(O)=O	"Highly selective, potent PPAR_ agonist. Orally active"	"Potent and highly selective PPAR_ agonist (EC50 values are 6, 1100 and 6200 nM for human PPAR_, PPAR_ and PPAR_ receptors respectively). Modulates oleate metabolism and mitochondrial enzyme gene expression in mature myotubules in vitro. Has lipid-lowering effects following oral administration in vivo. Reduces NO production in macrophages; exhibits anti-inflammatory properties."	Brown et al (2001) Identification of a subtype selective human PPAR_ agonist through parallel-array synthesis. Bioorg.Med.Chem.Lett. 11 1225. PMID:11354382. Cunard et al (2002) Regulation of cytokine expression by ligands of peroxisome proliferator activated receptors. J.Immunol. 168 2795. PMID:11884448. Muoio et al (2002) Peroxisome proliferator-activated receptor-_ regulates fatty acid utilization in primary human skeletal muscle cells. Diabetes 51 901. PMID:11916905. Paukkeri et al (2007) PPARalpha agonists inhibit nitric oxide production by enhancing iNOS degradation in LPS-treated macrophages. Br.J.Pharmacol. 152 1081. PMID:17891158.	Small Molecule	Sold for research purposes under agreement from GlaxoSmithKline	http://www.tocris.com/dispprod.php?ItemId=62731	SQ1533			Jan-2003
1682	PIT	[56583-49-4]	CC1=CC=C(C=C1)S(O)(=O)=O.[O-][N+]1=C(C(=O)C2=CC=CC=C12)C1=CC=CC=N1	P2Y ligand; displays mixed antagonism/potentiation	Purinergic P2Y receptor ligand. Displays irreversible antagonism at P2Y receptors in some smooth muscles but potentiates responses to ATP in other systems (chick brain recombinant P2Y1 receptor and sympathetic/purinergic nerve stimulation).	"Spedding et al (1975) Antagonism of adenosine 5'-triphosphate-induced relaxation by 2-2'-pyridylisatogen in the taenia of guinea-pig caecum. Br.J.Pharmacol. 53 575. PMID:1148500. King et al (1996) Potentiation by 2,2'-pyridylisatogen tosylate of ATP-responses at a recombinant P2Y1 purinoceptor. Br.J.Pharmacol. 117 1111. PMID:8882604. Ren and Burnstock (1997) Prominent sympathetic purinergic vasoconstriction in the rabbit splenic artery: potentiation by 2.2'-pyridylisatogen tosylate. Br.J.Pharmacol. 120 530. PMID:9031760."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=5389	SQ1341			Mar-2003
1690	SCH 28080	[76081-98-6]	CC1=C(CC#N)N2C=CC=C(OCC3=CC=CC=C3)C2=N1	"H+,K+-ATPase inhibitor"	"Potent inhibitor of H+,K+-ATPase (IC50 = 20 nM); binds to the K+ recognition site and is competitive with respect to K+. Inhibits gastric acid secretion in vitro and in vivo."	"Long et al (1983) Gastric antisecretory and cytoprotective activities of SCH 28080. J.Pharmacol.Exp.Ther. 226 114. PMID:6864535. Scott et al (1987) Studies on the mechanism of action of the gastric microsomal (H+K+)-ATPase inhibitors SCH 32651 and SCH 28080. Biochem.Pharmacol. 36 97. PMID:3026407. Vagin et al (2002) SCH 28080, a K+-competitive inhibitor of the gastric H,K-ATPase, binds near the M5-6 luminal loop, preventing K+ access to the ion binding domain. Biochemistry 41 12755. PMID:12379118."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=64754	SQ1341			May-2003
1691	NECA	[35920-39-9]	O[C@@H]1[C@@H]([C@](NCC)=O)O[C@@H](N2C=NC3=C2N=CN=C3N)[C@@H]1O	High affinity adenosine receptor agonist	"High affinity adenosine receptor agonist (Ki values are 6.2, 14, and 20 nM for human A3, A1 and A2A receptors respectively; EC50 = 2.4 _M for human A2B). Inhibits platelet aggregation and is centrally active in vivo."	Cusack and Hourani (1981) 5'-N-ethylcarboxamidoadenosine: a potent inhibitor of human platelet aggregation. Br.J.Pharmacol. 72 443. PMID:7260485. Klotz (2000) Adenosine receptors and their ligands. Naunyn Schmiedebergs Arch.Pharmacol. 362 382. PMID:11111832. Knapp et al (2001) Adenosine agonists CGS21680 and NECA inhibit the initiation of cocaine self-administration. Pharmacol.Biochem.Behav. 68 797. PMID:11526979.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=64844	SQ1341			Mar-2003
1692	Cilostazol	[73963-72-1]	O=C1CCC2=CC(OCCCCC3=NN=NN3C3CCCCC3)=CC=C2N1	PDE3A inhibitor. Also adenosine uptake inhibitor	"Potent phosphodiesterase III A (PDE3A) inhibitor (IC50 = 0.2 _M) and inhibitor of adenosine uptake. Has antimitogenic, antithrombotic, vasodilatory and cardiotonic properties in vivo. Also affects lipid levels in vivo."	"Shintani et al (1985) General pharmacological properties of cilostazol, a new antithrombotic drug. Part I: effects on the central nervous system. Arzneimittelforschung 35 1157. PMID:4074429. Shintani et al (1985) General pharmacological properties of cilostazol, a new antithrombotic drug. Part II: effects on the peripheral organs. Arzneimittelforschung 35 1163. PMID:3000392. Schror (2002) The pharmacology of cilostazol. Diabetes Obes.Metab. 4 S14. PMID:12180353."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=64847	SQ1533			Mar-2003
1693	Enoximone	[77671-31-9]	CC(NC(N2)=O)=C2C(C1=CC=C(SC)C=C1)=O	PDE3 inhibitor	Inhibitor of type III phosphodiesterase (PDE3). Increases intracellular cyclic AMP (cAMP) concentrations and enhances myocardial contractility. Also induces concentration-dependent vasodilation in vitro.	"Vroom et al (1996) Effect of phosphodiesterase inhibitors on human arteries in vitro. Br.J.Anaesth. 76 122. PMID:8672353. Pacher and Stanek (1999) Ambulatory vasodilator therapy in heart failure: systematic review of the literature and personal observational experience. Eur.J.Heart Fail. 1 263. PMID:10935673. Jung et al (2005) Pharmacological effects of ATI22-107 [2-(2-{2-[2-chloro-4-(6-oxo-1,4,5,6-tetrahydro-pyridazin-3-yl)-phenoxy]-acetylamino}-ethoxymethyl)-4-(2-chloro-phenyl)-6-methyl-1,4-dihydro-pyridine-3,5-dicarboxylic acid dimethyl ester)], a novel dual pharmacophore, on myocyte calcium cycling and contractility. J.Pharmacol.Exp.Ther. 312 517. PMID:15550574."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=64854	SQ1533			Jun-2010
1694	Ibudilast	[50847-11-5]	CC(C)C(=O)C1=C2C=CC=CN2N=C1C(C)C	PDE inhibitor (non-selective)	"Phosphodiesterase inhibitor (IC50 values are 53, 35, 48, 12 and 10 _M for PDE Ia, II, III, IV and V respectively). Inhibits platelet aggregation and is an orally-active cerebral vasodilator, bronchodilator and antiallergic agent."	Nishino et al (1983) KC-404: a potential anti-allergic agent with antagonistic action against slow reacting substance of anaphylaxis. Jpn.J.Pharmacol. 33 267. PMID:6193303. Souness et al (1994) Possible role of cyclic AMP phosphodiesterases in the actions of ibudilast on eosinophil thromboxane generation and airways smooth muscle tone. Br.J.Pharmacol. 111 1081. PMID:8032594. Kishi et al (2001) Ibudilast: a non-selective PDE inhibitor with multiple actions on blood cells and the vascular wall. Cardiovasc.Drug Rev. 19 215. PMID:11607039.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=64856	SQ1533			Oct-2003
1695	Cisapride	[81098-60-4]	CO[C@H]1CN(CCCOC2=CC=C(F)C=C2)CC[C@H]1NC(=O)C1=C(OC)C=C(N)C(Cl)=C1	5-HT4 agonist; stimulates intestinal ACh release	"5-HT4 receptor agonist and gastrokinetic agent. Stimulates intestinal acetylcholine release, possibly via 5-HT4 receptor-dependent and -independent mechanisms, leading to increased intestinal motility."	"Schuurkes et al (1985) Motor-stimulating properties of cisapride on isolated gastrointestinal preparations of the guinea pig. J.Pharmacol.Exp.Ther. 234 775. PMID:3897516. Taniyama et al (1991) Cisapride stimulates motility of the intestine via the 5-hydroxytryptamine receptors. J.Pharmacol.Exp.Ther. 258 1098. PMID:1890614. Briejer et al (1993) Cisapride and a structural analogue, R 76,186, are 5-hydroxytryptamine4 (5-HT4) receptor agonists on the guinea-pig colon ascendens. Naunyn Schmiedebergs Arch.Pharmacol. 347 464. PMID:8321323."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=64865	SQ1533			Jun-2003
1697	Noscapine hydrochloride	[912-60-7]	O=C2C1=C(OC)C(OC)=CC=C1[C@]([C@]3([H])N(CCC4=C3C(OC)=C5C(OCO5)=C4)C)([H])O2.Cl	Tubulin inhibitor; induces apoptosis	"Opioid alkaloid with several actions. Binds to tubulin, arrests cells in mitosis and induces apoptosis. Antagonist at bradykinin receptors (pA2 = 6.68), inhibits carbachol-stimulated phosphoinositol turnover and enhances forskolin-stimulated cAMP increases in CNS tissues. Modulates IKK activation, suppressing the NF-_B signaling pathway. Blocks proliferation of human leukemia and multiple myeloma cells. Exhibits anti-inflammatory activity."	"Mourey et al (1992) [3H]Noscapine binding sites in brain: relationship to indoleamines and the phosphoinositide and adenylyl cyclase messenger systems. Mol.Pharmacol. 42 619. PMID:1331753. Mahmoudian and Mojaverian (2001) Effect of noscapine, the antitussive opioid alkaloid, on bradykinin-induced smooth muscle contraction in the isolated ileum of the guinea-pig. Acta Physiol.Hung. 88 231. PMID:12162581. Landen et al (2002) Noscapine alters microtubule dynamics in living cells and inhibits the progression of melanoma. Cancer Res. 62 4109. PMID:12124349. Sung et al (2010) Noscapine, a benzylisoquinoline alkaloid, sensitizes leukemic cells to chemotherapeutic agents and cytokines by modulating the NF-_B signaling pathway. Cancer Res. 70 3259. PMID:20354190."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=64869	SQ1533			Feb-2003
1698	"L-655,240"	[103253-15-2]	CC1=C(CC(C)(C)C(O)=O)N(CC2=CC=C(Cl)C=C2)C2=CC=C(F)C=C12	"Potent, selective thromboxane A2/prostaglandin endoperoxide antagonist"	Potent and selective thromboxane A2/prostaglandin endoperoxide receptor antagonist. pA2 values are 8 - 8.4 in guinea pig smooth muscle; IC50 = 7 nM for inhibition of human platelet aggregation. Orally active in vivo.	"Hall et al (1987) Pharmacology of L-655,240 (3-[1-(4-chlorobenzyl)-5-fluoro-3-methyl-indol-2-yl]2,2-dimethylpropanoic acid); a potent, selective thomboxane / prostaglandin endoperoxide antagonist. Eur.J.Pharmacol. 135 193. PMID:3582493. Wainright and Parratt (1988) The effects of L655,240, a selective thromboxane and prostaglandin endoperoxide antagonist, on ischemia- and reperfusion-induced cardiac arrhythmias. J.Cardiovasc.Pharmacol. 12 264. PMID:2464097. Ogletree and Allen (1992) Interspecies differences in thromboxane receptors: studies with thromboxane receptor antagonists in rat and guinea pig smooth muscles. J.Pharmacol.Exp.Ther. 260 789. PMID:1531361."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=65306	SQ1341			Jun-2003
1699	CGS 15943	[104615-18-1]	NC1=NC2=CC=C(Cl)C=C2C2=NC(=NN12)C1=CC=CO1	Potent adenosine receptor antagonist	"Potent adenosine receptor antagonist (Ki values are 3.5, 4.2, 16 and 51 nM for human A1, A2A, A2B and A3 receptors respectively). Orally active in vivo."	"Ghai et al (1987) Pharmacological characterization of CGS 15943A: a novel nonxanthine adenosine antagonist. J.Pharmacol.Exp.Ther. 242 784. PMID:3656113. Williams et al (1987) Biochemical characterization of the triazoloquinazoline CGS 15943, a novel, non-xanthine adenosine antagonist. J.Pharmacol.Exp.Ther. 241 415. PMID:2883298. Klotz (2000) Adenosine receptors and their ligands. Naunyn Schmiedebergs Arch.Pharmacol. 362 382. PMID:11111832."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=65307	SQ1341			Mar-2003
1700	BIIE 0246	[246146-55-4]	O=C(C4=C3C=CC=C4)NC1=CC=CC=C1C3N(CC2)CCN2C(CC5(CCCC5)CC(N[C@@H](CCCNC(N)=N)C(NCCN6C(N(C7=CC=CC=C7)N(C8=CC=CC=C8)C6=O)=O)=O)=O)=O	"Potent, selective non-peptide NPY Y2 receptor antagonist"	"Potent, selective and competitive non-peptide antagonist for the neuropeptide Y Y2 receptor (IC50 = 15 nM). Displays > 650-fold selectivity over Y1, Y4 and Y5 receptors. Active in vivo."	"Doods et al (1999) BIIE0246: a selective and high affinity neuropeptide Y Y2 receptor antagonist. Eur.J.Pharmacol. 384 R3. PMID:10611450. Dumont et al (2000) BIIE0246, a potent and highly selective non-peptide neuropeptide Y Y2 receptor antagonist. Br.J.Pharmacol. 129 1075. PMID:10725255. Malmstrom (2001) Vascular pharmacology of BIIE0246, the first selective non-peptide neuropeptide Y Y2 receptor antagonist, in vivo. Br.J.Pharmacol. 133 1073. PMID:11487518."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=65309	SQ1070			Nov-2004
1701	A 77636 hydrochloride	[145307-34-2]	NC[C@@H]2O[C@H]([C@]35CC(CC(C5)C4)CC4C3)CC1=C(O)C(O)=CC=C12.Cl	"Potent, selective D1-like agonist. Orally active"	Potent and selective dopamine D1-like receptor agonist (pEC50 values are 8.97 and < 5 for D1-like and D2-like receptors respectively). Displays anti-Parkinsonian activity following oral administration in vivo.	Kebabian et al (1992) A-77636: a potent and selective dopamine D1 receptor agonist with antiparkinsonian activity in marmosets. Eur.J.Pharmacol. 229 203. PMID:1362704. Acquas et al (1994) The potent and selective dopamine D1 receptor agonist A-77636 increases cortical and hippocampal acetylcholine release in the rat. Eur.J.Pharmacol. 260 85. PMID:7957630. Lewis et al (1998) Homologous desensitization of the D1A dopamine receptor: efficacy in causing desensitization dissociates from both receptor occupancy and functional potency. J.Pharmacol.Exp.Ther. 286 345. PMID:9655879.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=65401	SQ1341			Mar-2003
1702	N6-Cyclopentyladenosine	[41552-82-3]	O[C@@H]1[C@@H](CO)O[C@@H](N(C=N4)C2=C4C(NC3CCCC3)=NC=N2)[C@@H]1O	"Potent, selective A1 agonist"	"Potent and selective adenosine A1 receptor agonist (Ki values are 2.3, 790 and 43 nM for human A1, A2A and A3 receptors respectively; EC50 = 18600 nM for hA2B). Centrally active following systemic administration in vivo."	Coffin and Spealman (1987) Behavioral and cardiovascular effects of analogs of adenosine in Cynomolgus monkeys. J.Pharmacol.Exp.Ther. 241 76. PMID:3572798. Van der Graaf et al (1997) Mechanism-based pharmacokinetic-pharmacodynamic modeling of the effects of N6-cyclopentyladenosine analogs on heart rate in rat: estimation of in vivo operational affinity and efficacy at adenosine A1 receptors. J.Pharmacol.Exp.Ther. 283 809. PMID:9353402. Klotz (2000) Adenosine receptors and their ligands. Naunyn Schmiedebergs Arch.Pharmacol. 362 382. PMID:11111832.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=65402	SQ1341			Mar-2003
1705	2-Chloro-N6-cyclopentyladenosine	[37739-05-2]	O[C@@H]1[C@@H](CO)O[C@@H](N(C=N4)C2=C4C(NC3CCCC3)=NC(Cl)=N2)[C@@H]1O	"Potent, selective A1 agonist"	"Potent and selective adenosine A1 receptor agonist (Ki values are 0.8, 2300 and 42 nM for human A1, A2A and A3 receptors respectively; EC50 = 18800 nM for hA2B). Centrally active following systemic administration in vivo."	"Lohse et al (1988) 2-Chloro-N6-cyclopentyladenosine: a highly selective agonist at A1 adenosine receptors. Naunyn Schmiedebergs Arch.Pharmacol. 337 687. PMID:3216901. Concas et al (1993) Anticonvulsant doses of 2-chloro-N6-cyclopentyladenosine, an adenosine A1 receptor agonist, reduce GABAergic transmission in different areas of the mouse brain. J.Pharmacol.Exp.Ther. 267 844. PMID:8246158. Monopoli et al (1994) Pharmacology of the highly selective A1 adenosine receptor agonist 2-chloro-N6-cyclopentyladenosine. Arzneimittelforschung 44 1305. PMID:7848348. Klotz (2000) Adenosine receptors and their ligands. Naunyn Schmiedebergs Arch.Pharmacol. 362 382. PMID:11111832."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=65813	SQ1341			Apr-2003
1706	Acetaminophen	[103-90-2]	CC(=O)NC1=CC=C(O)C=C1	Cyclooxygenase inhibitor; may be selective for COX-3	"Cyclooxygenase inhibitor; may be selective for COX-3 (IC50 values are 460, > 1000 and > 1000 _M for canine COX-3, and murine COX-1 and COX-2 respectively). Widely used analgesic and antipyretic agent."	"Riendeau et al (1997) Comparison of the cyclooxygenase-1 inhibitory properties of nonsteroidal anti-inflammatory drugs (NSAIDS) and selective COX-2 inhibitors, using sensitive microsomal and platelet assays. Can.J.Physiol.Pharmacol. 75 1088. PMID:9365818. Chong et al (2001) Effect of acetaminophen on atherosclerosis. Ann.Pharmacother. 35 1476. PMID:11724102. Chandrasekharan et al (2002) COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression. Proc.Natl.Acad.Sci.U.S.A. 99 13926. PMID:12242329."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=66105	SQ1533			Mar-2003
1707	Sulindac	[38194-50-2]	FC1=CC=C(/C(C(C)=C3CC(O)=O)=C\C2=CC=C(S(C)=O)C=C2)C3=C1	Cyclooxygenase inhibitor (following metabolism to sulindac sulfide)	"Prodrug. Metabolizes to sulindac sulfide, a cyclooxgenase inhibitor that represses ras signaling, and sulindac sulfone, an antitumor agent, following oral administration in vivo. Widely used anti-inflammatory agent."	"Shen and Winter (1977) Chemical and biological studies on indomethacin, sulindac and their analogs. Adv.Drug Res. 12 90. PMID:343530. Taylor et al (2000) Sulindac sulfone inhibits K-ras-dependent cyclooxygenase-2 expression in human colon cancer cells. Cancer Res. 60 6607. PMID:11118042. Haanen (2001) Sulindac and its derivatives: a novel class of anticancer agents. Curr.Opin.Investig.Drugs 2 677. PMID:11569947."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=66123	SQ1533			Apr-2003
1708	Indomethacin	[53-86-1]	COC1=CC=C2N(C(=O)C3=CC=C(Cl)C=C3)C(C)=C(CC(O)=O)C2=C1	Cyclooxygenase inhibitor (COX-1 > COX-2)	Cyclooxgenase (COX) inhibitor; displays selectivity for COX-1 (IC50 values are 230 and 630 nM for human COX-1 and COX-2 respectively). Widely used anti-inflammatory agent.	"Walters and Willoughby (1965) Indomethacin, a new anti-inflammatory drug: its potential use as a laboratory tool. J.Pathol.Bacteriol. 90 641. PMID:5849618. Shen and Winter (1977) Chemical and biological studies on indomethacin, sulindac and their analogs. Adv.Drug Res. 12 90. PMID:343530. Palomer et al (2002) Identification of novel cyclooxygenase-2 selective inhibitors using pharmacophore models. J.Med.Chem. 45 1402. PMID:11906281."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=66126	SQ1533			Feb-2003
1709	CL 218872	[66548-69-4]	CC1=NN=C2C=CC(=NN12)C1=CC(=CC=C1)C(F)(F)F	Benzodiazepine agonist	"Benzodiazepine agonist displaying selectivity for _1 subunit-containing GABAA receptors (Ki values are 130, 1820, 1530, > 10000, 490 and > 10000 nM for _1, _2, _3, _4, _5 and _6-subunit containing receptors respectively). Orally active anxiolytic and anticonvulsant in vivo."	Lippa et al (1979) Benzodiazepine receptors: cellular and behavioral characteristics. Pharmacol.Biochem.Behav. 10 831. PMID:40258. Squires et al (1979) Some properties of brain specific benzodiazepine receptors: new evidence for multiple receptors. Pharmacol.Biochem.Behav. 10 825. PMID:40257. Sieghart (1995) Structure and pharmacology of _-aminobutyric acidA receptor subtypes. Pharmacol.Rev. 47 181. PMID:7568326.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=66391	SQ1341			Mar-2004
1710	CV 1808	[53296-10-9]	O[C@@H]1[C@@H](CO)O[C@@H](N(C=N3)C2=C3C(N)=NC(NC4=CC=CC=C4)=N2)[C@@H]1O	Non-selective adenosine A2 receptor agonist	"Adenosine A2 receptor agonist. Coronary vasodilator, antihypertensive and antipsychotic following systemic administration in vivo."	Marumoto et al (1975) Synthesis and coronary vasodilating activity of 2-substituted adenosines. Chem.Pharm.Bull. 23 759. PMID:1182861. Abiru et al (1991) The antihypertensive effect of 2-alkynyladenosines and the selective affinity for adenosine A2 receptors. Eur.J.Pharmacol. 196 69. PMID:1874281. Martin et al (1993) Adenosine agonists reduce conditioned avoidance responding in the rat. Pharmacol.Biochem.Behav. 45 951. PMID:8105493.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=66396	SQ1070			Jul-2003
1742	R-96544 hydrochloride	[167144-80-1]	Cl[H].COC1=CC=CC(CCC2=C(OCC[C@@H]3C[C@@H](O)CN3C)C=CC=C2)=C1	"Potent, selective 5-HT2A antagonist"	"Potent, selective 5-HT2 receptor antagonist; displays some selectivity for 5-HT2A receptors (Ki = 1.6 nM). IC50 values are 2.2, 310, 2400, 3700, > 5000 and > 5000 nM for 5-HT2, _1-adrenergic, D2 dopamine, 5-HT1, 5-HT3 and _-adrenergic receptors respectively. Inhibits 5-HT-induced platelet aggregation and pressor responses in vivo."	"Tanaka et al (2000) [2-(_-Phenylalkyl)phenoxy]alkylamines III: Synthesis and selective serotonin-2 receptor binding. Chem.Pharm.Bull. 48 1729. PMID:11086903. Ogawa et al (2002) Pharmacological profiles of R-96544, the active form of a novel 5-HT2A receptor antagonist R-102444. Eur.J.Pharmacol. 457 107. PMID:12464356. Ogawa et al (2005) Effects of R-102444 and its active metabolite R-96544, selective 5-HT2A receptor antagonists, on experimental acute and chronic pancreatitis: additional evidence for possible involvement of 5-HT2A receptors in the development of experimental pancreatitis. Eur.J.Pharmacol. 521 156. PMID:16183055."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=68264	SQ1341			May-2004
1743	Bay 11-7085	[196309-76-9]	CC(C)(C)C1=CC=C(C=C1)S(=O)(=O)\C=C\C#N	Irreversible inhibitor of TNF-_-induced I_B_ phosphorylation	Irreversible inhibitor of TNF-_-stimulated I_B_ phosphorylation (IC50 ~ 10 _M); leads to decreased NF-_B and subsequent decreased expression of adhesion molecules. Also reversibly activates MAP kinases and stimulates apoptosis. Anti-inflammatory in vivo.	"Pierce et al (1997) Novel inhibitors of cytokine-induced IkBa phosphorylation and endothelial cell adhesion molecule expression show anti-inflammatory effects in vivo. J.Biol.Chem. 272 21096. PMID:9261113. Hu et al (2001) An I_B_ inhibitor causes leukemia cell death through a p38 MAP kinase-dependent, NF-_B-independent mechanism. Cancer Res. 61 6290. PMID:11507084. Scaife et al (2002) Nuclear factor _B inhibitors induce adhesion-dependent colon cancer apoptosis: implications for metastasis. Cancer Res. 62 6870. PMID:12460901."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=68355				Oct-2003
1744	Bay 11-7821	[19542-67-7]	CC1=CC=C(C=C1)S(=O)(=O)\C=C\C#N	E2 ubiquitin (Ub) conjugating enzymes inhibitor	E2 ubiquitin (Ub) conjugating enzyme inhibitor. Inhibits the conjugation of Ub to a range of E2 enzymes. Inhibits E2 enzyme mediated I_B_ phosphorylation and indirectly decreases NF-_b activity. Also reversibly activates MAPK signaling. Induces apoptosis of leukemic T cell and B-cell lymphoma cell lines.	Pierce et al (1997) Novel inhibitors of cytokine-induced I_B_ phosphorylation and endothelial cell adhesion molecule expression show anti-inflammatory effects in vivo. J.Biol.Chem. 272 21096. PMID:9261113. Mori et al (2002) Bay 11-7082 inhibits transcription factor NF-_B and induces apoptosis of HTLV-I-infected T-cell lines and primary adult T-cell leukemia cells. Blood 100 1828. PMID:12176906. Strickson et al (2013) The anti-inflammatory drug BAY 11-7082 suppresses the MyD88-dependent signalling network by targeting the ubiquitin system. Biochem.J. 451 427. PMID:23441730.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=68418				Aug-2003
1746	Nemonapride	[75272-39-8]	O=C(C3=C(OC)C=C(NC)C(Cl)=C3)N[C@@H]1CCN(CC2=CC=CC=C2)[C@@H]1C.O=C(C6=C(OC)C=C(NC)C(Cl)=C6)N[C@H]4CCN(CC5=CC=CC=C5)[C@H]4C	Highly potent D2-like antagonist. Also 5-HT1A agonist	Highly potent dopamine D2-like receptor antagonist; selective over D1-like receptors (Ki values are 0.1 and 740 nM for D2-like and D1-like receptors respectively). Also potent 5-HT1A receptor agonist (IC50 = 34 nM) and has affinity for sigma receptors.	"Terai et al (1983) Selective binding of YM-09151-2, a new potent neuroleptic, to D2-dopaminergic receptors. Jpn.J.Pharmacol. 33 749. PMID:6138453. Ujike et al (1996) [3H]YM-09151-2 (nemonapride), a potent radioligand for both sigma1 and sigma2 receptor subtypes. Neuroreport 7 1057. PMID:8804051. Assie et al (1997) 5-HT1A receptor agonist properties of the antipsychotic, nemonapride: comparison with bromerguride and clozapine. Eur.J.Pharmacol. 334 141. PMID:9369342."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=69797	SQ1070			May-2004
1747	Isoproterenol hydrochloride	[51-30-9]	Cl.CC(C)NCC(O)C1=CC(O)=C(O)C=C1	Standard selective _ agonist	"Standard selective _-adrenoceptor agonist; vasorelaxant and bronchodilator. Activation of _2 receptors activates downstream PKA and ERK, and may stimulate NO-mediated endothelium-dependent smooth muscle relaxation. Active in vivo. Also available as part of the _-Adrenoceptor Agonist Tocriset and Mixed Adrenergic Tocriset."	Lotti et al (1982) Characterization of the adrenoreceptor activities of isoprenaline in the field stimulated rat vas deferens: selective supersensitivity to beta 2-mediated responses following reserpine treatment. J.Auton.Pharmacol. 2 169. PMID:6292228. Schmitt and Stork (2000) _2-adrenergic receptor activates extracellular signal-regulated kinases (ERKs) via the small G protein Rap1 and the serine/threonine kinase B-Raf. J.Biol.Chem. 275 25342. PMID:10840035. Akimoto et al (2002) Nitric oxide (NO) primarily accounts for endothelium-dependent component of _-adrenoceptor-activated smooth muscle relaxation of mouse aorta in response to isoprenaline. J.Smooth Muscle Res. 38 87. PMID:12596888.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=69801	SQ1533			May-2003
1748	MG 132	[133407-82-6]	[H]C(C)C[C@H](NC(=O)OCC1=CC=CC=C1)C(=O)NC(CC(C)C)C(=O)N[C@@H](CC(C)C)C(C)=O	Proteasome and calpain inhibitor. Inhibits NF-_B activation	Potent cell-permeable inhibitor of proteasome (IC50 = 100 nM) and calpain (IC50 = 1.2 _M). Inhibits TNF-_-induced NF-_B activation and I_B_ degradation. Induces neurite outgrowth in PC12 cells and has anticancer properties in vitro.	"Palombella et al (1994) The ubiquitin-proteasome pathway is required for processing the NF-_B1 precursor protein and the activation of NF-_B. Cell 78 773. PMID:8087845. Tsubuki et al (1996) Differential inhibition of calpain and proteasome activities by peptidyl aldehydes of di-Leucine and tri-Leucine. J.Biochem. 119 572. PMID:8830056. Banerjee and Liefshitz (2001) Potential of the proteasome inhibitor MG-132 as an anticancer agent, alone and in combination. Anticancer Res. 21 3941. PMID:11911275."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=69832	SQ1341			Sep-2003
1749	HexylHIBO	[334887-43-3]	OC1=NOC(CC(C(O)=O)N)=C1CCCCCC	Group I mGlu antagonist	Group I mGlu receptor antagonist (Ki values are 140 and 110 _M at mGlu1a and mGlu5a receptors respectively). Decreases sEPSCs in rat pyramidal neurons in vitro.	Madsen et al (2001) Synthesis and pharmacology of 3-isoxazolol amino acids as selective antagonists at group I metabotropic glutamic acid receptors. J.Med.Chem. 44 1051. PMID:11297452. Bandrowski et al (2003) Baseline glutamate levels affect group I and II mGluRs in layer V pyramidal neurons of rat sensorimotor cortex. J.Neurophysiol. 89 1308. PMID:12626613.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=70093	SQ1341			Oct-2003
1750	(S)-HexylHIBO	[334887-48-8]	OC1=NOC(C[C@@H](C(O)=O)N)=C1CCCCCC	Group I mGlu antagonist	Group I mGlu receptor antagonist (Kb values are 30 and 61 _M at mGlu1a and mGlu5a receptors respectively). Enantiomer of hexylHIBO (Cat. No. 1749).	Madsen et al (2001) Synthesis and pharmacology of 3-isoxazolol amino acids as selective antagonists at group I metabotropic glutamic acid receptors J.Med.Chem. 44 1051. PMID:11297452.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=70094	SQ1341			Mar-2004
1757	ALX 5407 hydrochloride	[200006-08-2]	FC(C=C2)=CC=C2[C@@H](CCN(CC(O)=O)C)OC1=CC=C(C3=CC=CC=C3)C=C1.Cl	Selective non-transportable GlyT1 inhibitor	Selective non-transportable inhibitor of the glycine transporter GlyT1 (IC50 values are 3 nM and > 100 _M for human GlyT1c and GlyT2 respectively). Displays no activity at the inhibitory glycine receptor or glycine site of the NMDA receptor (IC50 > 100 mM).	"Atkinson et al (2001) ALX 5407: a potent, selective inhibitor of the hGlyT1 glycine transporter. Mol.Pharmacol. 60 1414. PMID:11723250. Aubrey and Vandenber (2001) N[3-(4'-fluorophenyl)-3-(4'-phenylphenoxy)propyl]sarcosine (NFPS) is a selective persistent inhibitor of glycine transport. Br.J.Pharmacol. 134 1429. PMID:11724748. Herdon et al (2001) Pharmacological assessment of the role of the glycine transporter GlyT-1 in mediating high-affinity glycine uptake by rat cerebral cortex and cerebellum synaptosomes. Neuropharmacology 41 88. PMID:11445189."	Small Molecule	Sold with the permission of NPS Pharmaceuticals Inc. Strictly for in vitro use only	http://www.tocris.com/dispprod.php?ItemId=71180	SQ1341			May-2004
1758	PETCM	[10129-56-3]	OC(CC1=CC=NC=C1)C(Cl)(Cl)Cl	Activator of caspase-3	"Caspase-3 activator. Acts via inhibition of the oncoprotein ProT, therefore stimulates apoptosome formation and subsequent caspase-3 activation in a cytochrome c-dependent manner."	Jiang et al (2003) Distinctive roles of PHAP proteins and prothymosin-_ in a death regulatory pathway. Science 299 223. PMID:12522243. Nguyen and Wells (2003) Direct activation of the apoptosis machinery as a mechanism to target cancer cells. Proc.Natl.Acad.Sci.U.S.A. 100 7533. PMID:12808146.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=71192	SQ1341			Jul-2003
1759	Nilutamide	[63612-50-0]	CC1(C)NC(=O)N(C1=O)C1=CC=C(C(=C1)C(F)(F)F)N(=O)=O	Androgen receptor antagonist. Orally active	Non-steroidal and silent antiandrogen. Binds to androgen receptors and also inhibits androgen biosynthesis in vitro. In rats in vivo it inhibits androgen-induced prostate weight increase and inhibits negative androgen-dependent gonadotropin feedback leading to an increase in luteinising hormone and testosterone. Orally active.	"Raynaud et al (1979) Action of a non-steroid anti-androgen, RU 23908, in peripheral and central tissues. J.Steroid Biochem. 11 93. PMID:385986. Raynaud et al (1984) The pure antiandrogen RU 23908 (Anandron), a candidate of choice for the combined antihormonal treatment of prostatic cancer. The Prostate 5 299. PMID:6374639. Raynaud et al (1985) Pharmacology and clinical studies with RU 23908 (Anandron). Prog.Clin.Biol.Res. 185A 99. PMID:4034583. Ayub and Levell (1987) Inhibition of rat testicular 17-_-hydroxylase and 17,20-lyase activities by anti-androgens (flutamide, hydroxyflutamide, RU23908, cyproterone acetate) in vitro. J.Steroid Biochem. 28 43. PMID:2956461."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=71437	SQ1533			May-2003
1760	()-Blebbistatin	[674289-55-5]	CC1=CC=C2N=C3N(CCC3(O)C(=O)C2=C1)C1=CC=CC=C1	Selective inhibitor of myosin II ATPase activity	"Selective inhibitor of myosin II ATPase activity; inhibits contraction of the cleavage furrow without disrupting mitosis or contractile ring assembly. Rapidly and reversibly blocks cell blebbing, and disrupts directed cell migration and cytokinesis in vertebrate cells."	"Straight et al (2002) Dissecting cytokinesis with small molecules. Amer.Soc.Cell Biol.Abstr. 2515. Straight et al (2003) Dissecting temporal and spatial control of cytokinesis with a myosin II inhibitor. Science 299 1743. PMID:12637748. Limouze et al (2004) Specificity of blebbistatin, an inhibitor of myosin II. J.Muscle Res.Cell Motil. 25 337. PMID:15548862. Walker et al (2010) Non-muscle myosin II regulates survival threshold of pluripotent stem cells. Nat.Commun. 1 71. PMID:20842192."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=62895	SQ1533			Jun-2003
1761	Baicalein	[491-67-8]	OC1=C(O)C(O)=C2C(=O)C=C(OC2=C1)C1=CC=CC=C1	5- and 12-Lipoxygenase inhibitor	"Inhibitor of 5- and platelet 12-lipoxygenases (IC50 values are 9.5 and 0.12 _M respectively). Also inhibits Raf-mediated MEK-1 phosphorylation in C6 rat glioma cells and induces G1 and G2 cell cycle arrest by decreasing cdk1, cdk2, cyclin D2 and cyclin A expression. Inhibits production of inflammatory cytokines by inhibiting NF-_B activation."	Sekiya and Okuda (1982) Selective inhibition of platelet lipoxygenase by baicalein. Biochem.Biophys.Res.Commun. 105 1090. PMID:6807310. Hsu et al (2001) Baicalein induces a dual growth arrest by modulating multiple cell cycle regulatory molecules. Eur.J.Pharmacol. 425 165. PMID:11513834. Nakahata et al (2003) Baicalein inhibits Raf-1-mediated phosphorylation of MEK-1 in C6 rat glioma cells. Eur.J.Pharmacol. 461 1. PMID:12568909. Hsieh et al (2007) Baicalein inhibits IL-1_- and TNF_-induced inflammatory cytokine production from human mast cells via regulation of the NF-_B pathway. Clin.Mol.Allergy 26 5. PMID:18039391.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=72317	SQ1533			Sep-2003
1762	Acifran	[72420-38-3]	CC1(OC(=CC1=O)C(O)=O)C1=CC=CC=C1	Hypolipidemic agent; agonist for the GPR109A (HM74A) and GPR109B receptors	"Hypolipidemic agent. Exhibits higher potency than nicotinic acid and clofibrate. Full and potent agonist at the human orphan GPCR HM74A/GPR109A and GPR109B (EC50 values are 1.3 and 4.2 _M respectively). Reduces serum triglycerides and circulating LDL-cholesterol in vivo, without affecting liver weight or liver enzymes."	"Cayen et al (1982) Evaluation of the lipid-lowering activity of AY-25,712 in rats. Atherosclerosis 45 267. PMID:6818976. Jirkovsky and Cayen (1982) Hypolipidemic 4,5-dihydro-4-oxo-5,5-disubstituted-2-furancarboxylic acids. J.Med.Chem. 25 1154. PMID:7143351. Wise et al (2003) Molecular identification of high and low affinity receptors for nicotinic acid. J.Biol.Chem. 278 9869. PMID:12522134. Jung et al (2007) Analogues of acrifan: agonists of the high and low affinity niacin receptors, GPR109a and GPR109b. J.Med.Chem. 50 1445. PMID:17358052."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=72422	SQ1533			Oct-2003
1765	UBP 282	[544697-47-4]	O=C(C=CN1C[C@H](N)C(O)=O)N(CC2=CC=C(C(O)=O)C=C2)C1=O	AMPA/kainate antagonist; distinguishes between motoneuron and dorsal root kainate receptors	"AMPA and kainate receptor antagonist. Inhibits AMPA receptor-, but not kainate receptor-mediated currents on spinal neonatal motoneurons yet antagonizes kainate-induced responses on dorsal root C-fibres."	More et al (2002) The novel antagonist 3-CBW discriminates between kainate receptors expressed on neonatal rat motoneurones and those on dorsal root C-fibres. Br.J.Pharmacol. 137 1125. PMID:12429586. More et al (2003) Structural requirements for novel willardiine derivatives acting as AMPA and kainate receptor antagonists. Br.J.Pharmacol. 138 1093. PMID:12684265.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=72973	SQ1341			Feb-2004
1766	UBP 301	[569371-10-4]	O=C(C(I)=CN1C[C@H](N)C(O)=O)N(CC2=CC=C(C(O)=O)C=C2)C1=O	Kainate receptor antagonist	Potent kainate receptor antagonist (apparent Kd = 5.94 _M). Displays ~ 30-fold selectivity over AMPA receptors.	More et al (2003) Structural requirements for novel willardiine derivatives acting as AMPA and kainate receptor antagonists. Br.J.Pharmacol. 138 1093. PMID:12684265.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=72974	SQ1341			Mar-2004
1767	Zimelidine dihydrochloride	[60525-15-7]	Cl[H].Cl[H].CN(C)C\C=C(\C1=CC=C(Br)C=C1)C1=CC=CN=C1	Selective 5-HT uptake inhibitor	"5-HT re-uptake inhibitor; selective over noradrenalin and dopamine uptake (IC50 values are 0.33, 8.2 and 12 _M respectively). Modulates nociception and induces hyperglycemia in vivo, and is an orally active antidepressant."	Ogren et al (1981) The pharmacology of zimelidine: a 5-HT selective reuptake inhibitor. Acta Psychiatr.Scand.Suppl. 290 127. PMID:6452789. Fasmer et al (1987) Changes in nociception after acute and chronic administration of zimelidine: different effects in the formalin test and substance P behavioural assay. Neuropharmacology 26 309. PMID:2438584. Sugimoto et al (1999) Involvement of serotonin in zimelidine-induced hyperglycemia in mice. Biol.Pharm.Bull. 22 1240. PMID:10598036.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=73677	SQ1533			Mar-2004
1769	Flurbiprofen	[5104-49-4]	CC(C(O)=O)C1=CC=C(C(F)=C1)C1=CC=CC=C1	Cyclooxygenase inhibitor	"Potent inhibitor of cyclooxygenase (IC50 values are 0.1 and 0.4 _M for inhibition of human COX-1 and COX-2 respectively). Analgesic, anti-inflammatory and antipyretic in vivo. Inhibits tumor cell growth in vitro and in vivo. Regulates prostate stem cell antigen through activation of Akt kinase. Also inhibits fibroblast proliferation in vitro."	"Glenn et al (1973) The pharmacology of 2-(2-fluoro-4-biphenylyl)propionic acid (flurbiprofen). A potent non-steroidal anti-inflammatory drug. Agents Actions 3 210. PMID:4776365. Gierse et al (1995) Expression and selective inhibition of the constitutive and inducible forms of human cyclo-oxygenase. Biochem.J. 305 479. PMID:7832763. Hoferova et al (2002) The effect of nonsteroidal antiinflammatory drugs ibuprofen, flurbiprofen, and diclofenac on in vitro and in vivo growth of mouse fibrosarcoma. Cancer Invest. 20 490. PMID:12094544. Zemskova et al (2006) Gene expression profiling in R-flurbiprofen-treated prostate cancer: R-Flurbiprofen regulates prostate stem cell antigen through activation of AKT kinase. Biochem.Pharmacol. 72 1257. PMID:16949054."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=73704	SQ1533			Jun-2003
1770	Deguelin	[522-17-8]	O=C(C(C=CC5=C4C=CC(C)(C)O5)=C4O3)[C@@]([C@@]3([H])CO2)([H])C1=C2C=C(OC)C(OC)=C1	Anticancer and antiviral agent; chemopreventive and pro-apoptotic	Anticancer and antiviral agent; chemopreventive and pro-apoptotic. Inhibits phorbol ester-induced ornithine decarboxylase and NADH:ubiquinone oxidoreductase activities (IC50 values are 11 and 6.9 nM respectively). Inhibits PI 3-kinase and reduces pAkt levels in pre-malignant and malignant human bronchial epithelial cells. Active in vivo.	"Takatsuki et al (1969) Antiviral and antitumor antibiotics. XX. Effects of rotenone, deguelin, and related compounds on animal and plant viruses. Appl.Microbiol. 18 660. PMID:4312925. Udeani et al (1997) Cancer chemopreventive activity mediated by deguelin, a naturally occurring rotenoid. Cancer Res. 57 3424. PMID:9270008. Fang and Casida (1998) Anticancer action of cube insecticide: correlation for rotenoid constituents between inhibition of NADH:ubiquinone oxidoreductase and induced ornithine decarboxylase activities. Proc.Natl.Acad.Sci.U.S.A. 95 3380. PMID:9520374. Chun et al (2003) Effects of deguelin on the phosphatidylinositol 3-kinase/Akt pathway and apoptosis in premalignant human bronchial epithelial cells. J.Natl.Cancer Inst. 95 291. PMID:12591985."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=73964	SQ1533			Jul-2004
1771	S 14506 hydrochloride	[286369-38-8]	Cl.COC1=CC2=C(C=CC=C2C=C1)N1CCN(CCNC(=O)C2=CC=C(F)C=C2)CC1	Highly potent 5-HT1A agonist; displays unique binding mechanism	"Highly potent selective 5-HT1A receptor full agonist (pKi values are 9.0, 6.6, 7.5, 6.6 and < 6.0 for 5-HT1A, 5-HT1B, 5-HT1C, 5-HT2 and 5-HT3 receptors respectively). Possibly binds between the agonist binding site and the G protein interaction switch site, affecting the activation mechanism, and may display positive cooperativity. Anxiolytic following central administration in vivo."	"Colpaert et al (1992) S 14506: a novel, potent, high-efficacy 5-HT1A agonist and potential anxiolytic agent. Drug Dev.Res. 26 21. Lima et al (1997) Atypical in vitro and in vivo binding of [3H]S-14506 to brain 5-HT1A receptors. J.Neural Transm. 104 1059. PMID:9503258. Milligan et al (2001) S 14506: novel receptor coupling at 5-HT1A receptors. Neuropharmacology 40 334. PMID:11166326."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=74074	SQ1341			Jun-2003
1772	Urapidil hydrochloride	[64887-14-5]	Cl.COC1=CC=CC=C1N1CCN(CCCNC2=CC(=O)N(C)C(=O)N2C)CC1	_1 antagonist. Also 5-HT1A receptor agonist	_1-adrenoceptor antagonist and 5-HT1A receptor agonist (pIC50 values are 6.13 and 6.4 respectively). Clinically used hypotensive agent.	Gross et al (1987) Urapidil and some analogues with hypotensive properties show high affinities for 5-hydroxytryptamine (5-HT) binding sites of the 5-HT1A subtype and for _1-adrenoceptor binding sites. Naunyn Schmiedebergs Arch.Pharmacol. 336 597. PMID:2832770. Kolassa et al (1989) Involvement of brain 5-HT1A receptors in the hypotensive response to urapidil. Am.J.Cardiol. 64 7D. PMID:2569265. van Zwieten PA (1989) Pharmacologic profile of urapidil. Am.J.Cardiol. 64 1D. PMID:2569262.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=75113	SQ1533			May-2003
1777	Arctigenin	[7770-78-7]	OC(C=C3)=C(OC)C=C3C[C@@H](C(OC2)=O)[C@H]2CC1=CC(OC)=C(OC)C=C1	Potent MEK1 inhibitor. Also inhibits I_B_ phosphorylation	"Antioxidant, anti-inflammatory, antiproliferative and antiviral agent. Inhibits LPS-induced iNOS expression via inhibition of I_B_ phosphorylation and p65 nuclear translocation (IC50 = 10 nM). Inhibits HIV-1 replication in vitro. Also potently inhibits MKK1 (MEK1) (IC50 = 0.5 nM) and provides neuroprotection by binding to kainate receptors."	"Schroder et al (1990) Differential in vitro anti-HIV activity of natural lignans. Z.Naturforsch.C. 45 1215. PMID:1965681. Cho et al (2002) Potent inhibition of lipopolysaccharide-inducible nitric oxide synthase expression by dibenzylbutyrolactone lignans through inhibition of I-_B_ phosphorylation and of p65 nuclear translocation. Int.Immunopharmacol. 2 105. PMID:11789661. Jang et al (2002) Arctigenin protects cultured cortical neurons from glutamate-induced neurodegeneration by binding to kainate receptor. J.Neurosci.Res. 68 233. PMID:11948668. Cho et al (2003) Arctigenin, a potent inhibitor of MKK1, inhibits lipopolysaccharide (LPS)-inducible nitric oxide synthase expression through inhibition of I-_B_ phosphorylation and of p65 nuclear translocation. Exp.Biol.Abstr. 152.2."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=75119	SQ1070			Sep-2003
1778	Ro 106-9920	[62645-28-7]	O=S(C1=CC=CC=C1)C1=NN2N=NN=C2C=C1	Inhibitor of NF-_B activation	"Inhibitor of NF-_B activation, possibly via selective inhibition of LPS- and TNF-_-induced I_B_ ubiquitination (IC50 = 3 _M). Blocks subsequent production of TNF-_, IL-1_ and IL-6. Inhibits mucin production in an in vitro model of COPD, and is anti-inflammatory following oral administration in vivo. Also weakly inhibits EGFR, 5-lipoxygenase and iNOS."	Conalty et al (1976) Anticancer agents. XII. Pyridazine and benzodiazine derivatives. Proc.R.Ir.Acad.B. 76 151. PMID:967871. Swinney et al (2002) A small molecule ubiquitination inhibitor blocks NF-_B-dependent cytokine expression in cells and rats. J.Biol.Chem. 277 23573. PMID:11950839. Baginski et al (2002) Glucocorticoid modulation of MUC5AC secretion in H292 cells. Am.Soc.Cell Biol.Abstr. 765.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=75352	SQ1341			Aug-2003
1779	NNC 711	[145645-62-1]	O=C(C1=CCCN(CCO/N=C(C3=CC=CC=C3)/C2=CC=CC=C2)C1)O.Cl	Selective inhibitor of GAT-1	"Potent and selective inhibitor of GABA uptake by GAT-1 (IC50 values are 0.04, 171, 1700 and 622 _M for hGAT-1, rGAT-2, hGAT-3 and hBGT-1 respectively). Anticonvulsant following systemic administration in vivo. Also exhibits cognition-enhancing activity."	"Suzdak et al (1992) NNC-711, a novel potent and selective _-aminobutyric acid uptake inhibitor: pharmacological characterization. Eur.J.Pharmacol. 224 189. PMID:1468507. Borden et al (1994) Tiagabine, SK&F 89976-A, CI-966, and NNC-711 are selective for the cloned GABA transporter GAT-1. Eur.J.Pharmacol. 269 219. PMID:7851497. O'Connell et al (2001) Anti-ischemic and cognition-enhancing properties of NNC-711, a _-aminobutyric acid reuptake inhibitor. Eur.J.Pharmacol. 424 37. PMID:11470258."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=75475	SQ1070			Jun-2003
1780	NNC 63-0532	[250685-44-0]	COC(=O)CN1CN(C2=CC=CC=C2)C2(CCN(CC3=CC=C4C=CC=CC4=C3)CC2)C1=O	Potent non-peptide NOP agonist; brain penetrant	"Potent non-peptide agonist for the NOP receptor (EC50 = 305 nM, Ki = 7.3 nM); ~ 12-fold selective over other receptors. Centrally active following systemic administration in vivo."	"Thomsen and Hohlweg (2000) (8-Naphthalen-1-ylmethyl-4-oxo-1-phenyl-1,3,8-triaza-spiro[4.5]-dec-3-yl)-acetic acid methyl ester (NNC 63-0532) is a novel potent nociceptin receptor agonist. Br.J.Pharmacol. 131 903. PMID:11053209."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=75482	SQ1341			Jun-2003
1794	Ro 26-4550 trifluoroacetate	[1217448-66-2]	FC(F)(F)C(O)=O.NC(N1CCC[C@H](CC(N[C@H](C(OC)=O)CC2=CC=C(C#CC3=CC=CC=C3)C=C2)=O)C1)=N	Competitive inhibitor of IL-2/ IL-2R_ receptor interaction	Competitive reversible inhibitor of interleukin-2 (IL-2) binding to its receptor (IC50 = 3 _M for inhibition of IL-2 interaction with IL-2R _-subunit). Appears to compete with IL-2R_ for its binding site on IL-2.	Tilley et al (1997) Identification of a small molecule inhibitor of the IL-2/IL-2R_ receptor interaction which binds to IL-2. J.Am.Chem.Soc. 119 7589. Braisted et al (2003) Discovery of a potent small molecule IL-2 inhibitor through fragment assembly. J.Am.Chem.Soc. 125 3714. PMID:12656598.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=77408	SQ1341			Aug-2005
1795	Zacopride hydrochloride	[101303-98-4]	Cl.COC1=C(C=C(Cl)C(N)=C1)C(=O)NC1CN2CCC1CC2	Highly potent 5-HT3 receptor antagonist. Also 5-HT4 agonist	Highly potent 5-HT3 receptor antagonist (Ki = 0.38 nM) and 5-HT4 receptor agonist (Ki = 373 nM). Antiemetic and anxiolytic following systemic administration in vivo.	"Costall et al (1988) Zacopride: anxiolytic profile in rodent and primate models of anxiety. J.Pharm.Pharmacol. 40 302. PMID:2900320. Cohen et al (1989) Comparison of the 5-HT3 receptor antagonist properties of ICS 205-930, GR38032F and zacopride. J.Pharmacol.Exp.Ther. 248 197. PMID:2521513. Kii and Ito (1997) Effects of 5-HT4-receptor agonists, cisapride, mosapride citrate, and zacopride, on cardiac action potentials in guinea pig isolated papillary muscles. J.Cardiovasc.Pharmacol. 29 670. PMID:9213211. Nagakura et al (1999) Pharmacological properties of a novel gastrointestinal prokinetic benzamide selective for human 5-HT4 receptor versus human 5-HT3 receptor. Pharmacol.Res. 39 375. PMID:10328995."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=77409	SQ1533			Jul-2003
1797	OMDM-2	[616884-63-0]	CCCCCCCC\C=C/CCCCCCCC(=O)N[C@@H](CO)CC1=CC=C(O)C=C1	Potent inhibitor of anandamide uptake	Metabolically stable inhibitor of anandamide cellular uptake (Ki = 3 _M). Displays relatively low affinity for CB1 and CB2 receptors (Ki values are 5.1 and > 10 _M) and for vanilloid VR1 receptors (EC50 = 10 _M). Has minimal activity against FAAH (Ki > 50 _M). Active in vivo.	Ortar et al (2003) Novel selective and metabolically stable inhibitors of anandamide cellular uptake. Biochem.Pharmacol. 35 1473. PMID:12732359. de Lago et al (2004) In vivo pharmacological actions of two novel inhibitors of anandamide cellular uptake. Eur.J.Pharmacol. 484 249. PMID:14744610.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=77413	SQ1341			Sep-2003
1798	Gabexate mesylate	[56974-61-9]	CS(O)(=O)=O.CCOC(=O)C1=CC=C(OC(=O)CCCCCNC(N)=N)C=C1	"Serine protease inhibitor; inhibits thrombin, trypsin, kallikrein and plasmin"	"Serine protease inhibitor; inhibits trypsin, plasmin, plasma kallikrein and thrombin (IC50 values are 9.4, 30, 41 and 110 _M respectively). Antithrombotic in vitro and in vivo. Also inhibits LPS-induced TNF-_ production, probably by inhibiting NF-_B and AP-1 activation."	"Tamura et al (1977) Synthetic inhibitors of trypsin, plasmin, kallikrein, thrombin, C1r and C1 esterase. Biochim.Biophys.Acta 484 417. PMID:143965. Ohno et al (1980) FOY: [Ethyl p-(6-guanidinohexanoyloxy) benzoate] methanesulfonate as a serine proteinase inhibitor. I. Inhibition of thrombin and factor Xa in vitro. Thromb.Res. 19 579. PMID:6449757. Ohno et al (1981) FOY: [Ethyl p-(6-guanidinohexanoyloxy) benzoate] methanesulfonate as a serine proteinase inhibitor. II. In vivo effect on coagulo-fibrinolytic system in comparison with heparin or aprotinin. Thromb.Res. 24 445. PMID:6178174. Yuksel et al (2003) Gabexate mesilate, a synthetic protease inhibitor, inhibits lipopolysaccharide-induced tumor necrosis factor-_ production by inhibiting activation of both nuclear factor-_B and activator protein-1 in human monocytes. J.Pharmacol.Exp.Ther. 305 298. PMID:12649382."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=77651	SQ1533			Aug-2003
1801	WAY 161503 hydrochloride	[276695-22-8]	Cl.ClC1=CC2=C(C=C1Cl)N1CCNCC1C(=O)N2	"Potent, selective 5-HT2C agonist"	Potent and selective 5-HT2C receptor agonist (Ki = 4 nM; EC50 = 12 nM). Antidepressant following systemic administration in vivo.	"Cryan and Lucki (2000) Antidepressant-like behavioral effects mediated by 5-hydroxytryptamine2C receptors. J.Pharmacol.Exp.Ther. 295 1120. PMID:11082448. Welmaker et al (2000) Synthesis and 5-hydroxytryptamine (5-HT) activity of 2,3,4,4a-tetrahydro-1H-pyrazino[1,2-a]quinoxalin-5-(6H)ones and 2,3,4,4a,5,6-hexahydro-1H-pyrazino[1,2-a]quinoxalines. Bioorg.Med.Chem.Lett. 10 1991. PMID:10987434. Jensen et al (2013) Design, synthesis, and pharmacological characterization of N- and O-substituted 5,6,7,8-tetrahydro-4H-isoxazolo[4,5-d]azepin-3-ol analogues: novel 5-HT2A/5-HT2C receptor agonists with pro-cognitive properties. J.Med.Chem. 56 1211. PMID:23301527."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=77675	SQ1341			Sep-2003
1803	ITE	[448906-42-1]	COC(=O)C1=CSC(=N1)C(=O)C1=CNC2=CC=CC=C12	Endogenous agonist for the transcription factor aryl hydrocarbon receptor	Endogenous agonist for the transcription factor aryl hydrocarbon receptor (AHR); Ki = 3 nM for binding to murine AHR. Transactivates DRE-containing reporter gene constructs in Hepa1c1c7 cells ~ 5-fold more potently than _-naphthoflavone. Active in vivo.	Song et al (2002) A ligand for the aryl hydrocarbon receptor isolated from lung. Proc.Natl.Acad.Sci.U.S.A. 99 14694. PMID:12409613. Henry et al (2006) A potential endogenous ligand for the aryl hydrocarbon receptor has potent agonist activity in vitro and in vivo. Arch.Biochem.Biophys. 450 67. PMID:16545771.	Small Molecule	"Sold under license, US Patent Application 2002183524"	http://www.tocris.com/dispprod.php?ItemId=77799	SQ1341			Sep-2003
1804	SR 2640 hydrochloride	[146662-42-2]	Cl.OC(=O)C1=CC=CC=C1NC1=CC(OCC2=CC=C3C=CC=CC3=N2)=CC=C1	"Potent, selective LTD4 /LTE4 receptor antagonist"	Potent and selective competitive leukotriene D4 and E4 receptor antagonist. Inhibits LTD4- but not histamine-induced guinea pig ileum and trachea contraction (pA2 = 8.7). Also inhibits LTD4-attenuation of human PMN chemotaxis. Orally active in vivo.	"Ahnfelt-Ronne et al (1988) A novel leukotriene D4/E4 antagonist, SR2640 (2-[3-(2-quinolylmethoxy)phenylamino]benzoic acid). Eur.J.Pharmacol. 155 117. PMID:2854067. Thomsen and Ahnfelt-Ronne (1989) Inhibition by the LTD4 antagonist, SR2640, of effects of LTD4 on canine polymorphonuclear leukocyte functions. Biochem.Pharmacol. 38 2291. PMID:2546563. Bouchelouche et al (1990) LTD4 increases cytosolic free calcium and inositol phosphates in human neutrophils: inhibition by the novel LTD4 receptor antagonist, SR2640, and possible relation to modulation of chemotaxis. Agents Actions 29 299. PMID:2160189."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=77880	SQ1341			Sep-2003
1806	SR 33805 oxalate	[121346-33-6]	O=C(O)C(O)=O.O=S(C2=C(C(C)C)C1=CC=CC=C1N2C)(C3=CC=C(OCCCN(C)CCC4=CC=C(OC)C(OC)=C4)C=C3)=O	Ca2+ channel blocker; binds allosterically to distinct site on L-type channels	"Potent Ca2+ channel antagonist; binds allosterically to the a1-subunit of L-type Ca2+ channels (Kd = 20 pM), at a site distinct from other types of blocker. Shows some selectivity for vascular smooth muscle, inducing vasorelaxation without producing inotropic or chronotropic effects. Inhibits PDGF-stimulated smooth muscle cell proliferation."	"Chatelain et al (1993) In vitro characterization of a novel Ca2+ entry blocker: SR 33805. Eur.J.Pharmacol. 246 181. PMID:8223943. Romey and Lazdunski (1994) Effects of a new class of calcium antagonists, SR33557 (fantofarone) and SR33805, on neuronal voltage-activated Ca++ channels. J.Pharmacol.Exp.Ther. 271 1348. PMID:7996445. Magnier-Gaubil et al (1996) Smooth muscle cell cycle and proliferation. Relationship between calcium influx and sarco-endoplasmic reticulum Ca2+ATPase regulation. J.Biol.Chem. 271 27788. PMID:8910375."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=77893	SQ1341			Feb-2004
1807	2-Methoxyestradiol	[362-07-2]	OC1=C(OC)C=C2C(CC[C@]3([H])[C@@]([H])2CC[C@@]4(C)[C@]([H])3CC[C@@H]4O)=C1	Apoptotic and antiangiogenic agent	"Apoptotic, antiproliferative and antiangiogenic agent, in vitro and in vivo; acts via an estrogen receptor-independent mechanism. Induces p53-induced apoptosis via two pathways: activation of p38 and NF-_B; and activation of JNK and AP-1 leading to Bcl-2 phosphorylation. Also upregulates death receptor 5 and binds to tubulin, inhibiting its assembly."	"D'Amato et al (1994) 2-Methoxyestradiol, an endogenous mammalian metabolite, inhibits tubulin polymerization by interacting at the colchicine site. Proc.Natl.Acad.Sci.U.S.A. 91 3964. PMID:8171020. LaVallee et al (2002) 2-Methoxyestradiol inhibits proliferation and induces apoptosis independently of estrogen receptors _ and _. Cancer Res. 62 3691. PMID:12097276. LaVallee et al (2003) 2-Methoxyestradiol up-regulates death receptor 5 and induces apoptosis through activation of the extrinsic pathway. Cancer Res. 63 468. PMID:12543804. Shimada et al (2003) Roles of p38 and c-jun NH2-terminal kinase-mediated pathways in 2-methoxyestradiol-induced p53 induction and apoptosis. Carcinogenesis 24 1067. PMID:12807754."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=78389	SQ1533			Jul-2003
1808	E-4031 dihydrochloride	[113559-13-0]	Cl.Cl.CC1=CC=CC(CCN2CCC(CC2)C(=O)C2=CC=C(NS(C)(=O)=O)C=C2)=N1	KV11.1 (hERG) channel blocker; inhibits rapid delayed rectifier K+ current (IKr)	"Selective blocker of KV11.1 (hERG) channels; inhibits the rapid delayed-rectifier K+ current (IKr). Reversibly prolongs action potential duration in guinea pig papillary muscle and isolated ventricular myocytes, without affecting Na+ or Ca2+ inward currents. Class III antiarrhythmic agent."	Wettwer et al (1991) Effects of the new class III antiarrhythmic drug E-4031 on myocardial contractility and electrophysiological parameters. J.Cardiovasc.Pharmacol. 17 480. PMID:1711611. Verheijck et al (1995) Effects of the delayed rectifier current blockade by E-4031 on impulse generation in single sinoatrial nodal myocytes of the rabbit. Circ.Res. 76 607. PMID:7895335. Ficker et al (2002) The binding site for channel blockers that rescue misprocessed human long QT syndrome type 2 ether-a-gogo-related gene (HERG) mutations. J.Biol.Chem. 277 4989. PMID:11741928.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=78404	SQ1341			Jan-2005
1809	Altanserin hydrochloride	[1135280-78-2]	Cl.FC1=CC=C(C=C1)C(=O)C1CCN(CCN2C(=S)NC3=CC=CC=C3C2=O)CC1	5-HT2A receptor antagonist	"Potent and selective 5-HT2A receptor antagonist (Ki values are 0.13, 4.55, 40, 62 and 1570 nM at 5-HT2A, _1, 5-HT2C, D2 and 5-HT1A respectively). Centrally active following systemic administration in vivo."	Sietnick (1985) Involvement of 5-HT2 receptors in the LSD- and L-5-HTP-induced suppression of lordotic behavior in the female rat. J.Neural Transm. 61 65. PMID:3872342. Koenig et al (1987) Stimulation of corticosterone and _-endorphin secretion in the rat by selective 5-HT receptor subtype activation. Eur.J.Pharmacol. 137 1. PMID:2956114. Kennett et al (1994) Evidence that 5-HT2C receptor antagonists are anxiolytic in the rat Geller-Seifter model of anxiety. Psychopharmacology 114 90. PMID:7846211. Herth et al (2009) Synthesis and in vitro affinities of various MDL 100907 derivatives as potential 18F-radioligands for 5-HT2A receptor imaging with PET. Bioorg.Med.Chem. 17 2989. PMID:19329329.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=78546	SQ1533			Oct-2003
1810	Raclopride	[84225-95-6]	ClC1=C(OC)C(C(NC[C@H]2N(CC)CCC2)=O)=C(O)C(Cl)=C1	"Potent, selective D2/D3 antagonist"	"Selective and potent dopamine D2/D3 receptor antagonist (Ki values are 1.8, 3.5, 2400 and 18000 nM for D2, D3, D4 and D1 receptors respectively). Centrally active following systemic administration in vivo."	"Ogren et al (1986) The selective dopamine D2 receptor antagonist raclopride discriminates between dopamine-mediated motor functions. Psychopharmacology 90 287. PMID:2947255. Hall et al (1989) Animal pharmacology of raclopride, a selective dopamine D2 antagonist. Psychopharmacol.Ser. 7 123. PMID:2687851. Seeman and Van Tol (1994) Dopamine receptor pharmacology. TiPS 15 264. PMID:7940991."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=78551	SQ1533			Nov-2003
1813	Indirubin-3'-oxime	[160807-49-8]	O\N=C1C2=CC=CC=C2NC/1=C1\C(=O)NC2=C1C=CC=C2	GSK-3_ inhibitor. Also inhibits other protein kinases	"Protein kinase inhibitor; inhibits cyclin-dependent kinases (IC50 = 0.18 - 3.33 _M) and GSK-3_ (IC50 = 0.19 _M). Inhibits CDK5- and GSK-3_-mediated tau phosphorylation, a process over-active in Alzheimer disease states. Also inhibits AMPK, LCK and SGK. Induces cell cycle arrest and inhibits cell proliferation."	"Hoessel et al (1999) Indirubin, the active constituent of a Chinese antileukaemia medicine, inhibits cyclin-dependent kinases. Nat.Cell.Biol. 1 60. PMID:10559866. Leclerc et al (2001) Indirubins inhibit glycogen synthase kinase-3_ and CDK5/p25, two protein kinases involved in abnormal tau phosphorylation in Alzheimer's disease. J.Biol.Chem. 276 251. PMID:11013232. Bain et al (2003) The specificities of protein kinase inhibitors: an update. Biochem.J. 371 199. PMID:12534346."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=78575				Sep-2003
1814	N-ArachidonylGABA	[128201-89-8]	CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)NCCCC(O)=O	Inhibits pain in vivo	Arachidonyl amino acid; first isolated from bovine brain. Inhibits pain in vivo.	"Huang et al (2001) Identification of a new class of molecules, the arachidonyl amino acids, and characterization of one member that inhibits pain. J.Biol.Chem. 276 42639. PMID:11518719. El Fangour et al (2003) Hemisynthesis and preliminary evaluation of novel endocannabinoid analogues. Bioorg.Med.Chem.Lett. 13 1977. PMID:12781177."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=78924				Jun-2004
1815	Palmitoylisopropylamide	[189939-61-5]	CCCCCCCCCCCCCCCC(NC(C)C)=O	Inhibitor of FAAH	Inhibitor of fatty acid amide hydrolase (FAAH); pIC50 = 4.89 for inhibition of [3H]-anandamide metabolism. Displays little binding to CB1 and CB2 receptors (IC50 > 100 _M) and very weakly blocks anandamide uptake (IC50 ~ 100 _M). Inhibits proliferation of C6 glioma cells.	Jonsson et al (2001) Effects of homologues and analogues of palmitoylethanolamide upon the inactivation of the endocannabinoid anandamide. Br.J.Pharmacol. 133 1263. PMID:11498512. Jonsson et al (2003) AM404 and VDM 11 non-specifically inhibit C6 glioma cell proliferation at concentrations used to block the cellular accumulation of the endocannabinoid anandamide. Arch.Toxicol. 77 201. PMID:12698235.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=78931				Aug-2003
1816	ICI 63197	[27277-00-5]	CCCN1C2=NC(N)=NN2C=C(C)C1=O	PDE4 inhibitor	Potent phosphodiesterase (PDE) 4 inhibitor (IC50 = 35 nM for inhibition of [3H]-rolipram binding to rat brain). Antidepressant following systemic administration in vivo.	"Wachtel (1983) Potential antidepressant activity of rolipram and other selective cyclic adenosine 3',5'-monophosphate phosphodiesterase inhibitors. Neuropharmacology 22 267. PMID:6302550. Kaulen et al (1989) Autoradiographic mapping of a selective cyclic adenosine monophosphate phosphodiesterase in rat brain with the antidepressant [3H]rolipram. Brain Res. 503 229. PMID:2557965. Zhao et al (2003) Inhibitor binding to type 4 phosphodiesterase (PDE4) assessed using [3H]piclamilast and [3H]rolipram J.Pharmacol.Exp.Ther. 305 565. PMID:12704225."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=78955	SQ1341			Aug-2003
1819	Demethylasterriquinone B1	[78860-34-1]	CC(C)=CCC1=C2NC=C(C2=CC=C1)C1=C(O)C(=O)C(C2=C(NC3=CC=CC=C23)C(C)(C)C=C)=C(O)C1=O	Selective insulin RTK activator	"Selective insulin receptor (IR) activator/mimetic (EC50 values are 3 - 6 _M for IRTK and 100 _M for IGF1R and EGFR). Increases IR _ subunit tyrosine phosphorylation and downstream activation of PI 3-kinase and Akt, but not ERK. Induces glucose uptake in adipocytes and skeletal muscle in vitro, without enhancing vascular proliferation. Binds GAPDH."	"Weber et al (2000) A novel insulin mimetic without a proliferative effect on vascular smooth muscle cells. J.Vasc.Surg. 32 1118. PMID:11107083. Salituro et al (2001) Discovery of a small molecule insulin receptor activator. Recent Prog.Horm.Res. 56 107. PMID:11237209. Webster et al (2003) Signaling effects of demethylasterriquinone B1, a selective insulin receptor modulator. Chembiochem 4 379. PMID:12740809. Kim et al (2007) Glyceraldehyde 3-phosphate dehydrogenase is a cellular target of the insulin mimic demethylasterriquinone B1. J.Med.Chem. 50 3423. PMID:17595071."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=78972	SQ1341			Oct-2003
1820	(+)-Clopidogrel hydrogen sulfate	[120202-66-6]	OS(O)(=O)=O.COC(=O)[C@@H](N1CCC2=C(C1)C=CS2)C1=CC=CC=C1Cl	Selective P2Y12 antagonist	"Selective, high affinity P2Y12 receptor antagonist. Inhibits ADP-induced platelet aggregation and displays antithrombotic activity. Active enantiomer of ()-clopidogrel hydrochloride (Cat. No. 2490)."	"Reist et al (2000) Very low chiral inversion of clopidogrel in rats: a pharmacokinetic and mechanistic investigation. Drug Metab.Disp. 28 1405. Savi et al (2001) P2Y12, a new platelet ADP receptor, target of clopidogrel. Biochem.Biophys.Res.Comm. 283 379. Savi and Herbert (2005) Clopidogrel and ticlopidine: P2Y12 adenosine diphosphate-receptor antagonists for the prevention of atherothrombosis. Semin.Thromb.Haemostas. 31 174. Kugelgen (2006) Pharmacological profiles of cloned mammalian P2Y-receptor subtypes. Pharmacol.Ther. 110 415. PMID:16257449."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=78974	SQ1533			Jan-2011
1821	YM 976	[191219-80-4]	CCN1C(=O)N=C(C2=CC=CC(Cl)=C2)C2=C1N=C(CC)C=C2	PDE4 inhibitor	"Orally active PDE4 inhibitor (IC50 = 2.2 nM). Low emetogenic activity, suggested to be due to poor brain penetration."	"Aoki et al (2000) A novel phosphodiesterase type 4 inhibitor, YM976 (4-(3-chlorophenyl)-1,7-diethylpyrido[2,3-d]pyrimidin-2(1H)-one), with little emetogenic activity. J.Pharmacol.Exp.Ther. 295 255. PMID:10991987. Aoki et al (2001) Studies on mechanisms of low emetogenicity of YM976, a novel phosphodiesterase type 4 inhibitor. J.Pharmacol.Exp.Ther. 298 1142. PMID:11504812. Moriuchi et al (2003) Relaxant effect of YM976, a novel phosphodiesterase 4 inhibitor, on bovine tracheal smooth muscle. Eur.J.Pharmacol. 470 57. PMID:12787831."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=79452	SQ1341			Feb-2004
1838	IRL-2500	[169545-27-1]	O=C([C@@H](CC4=CC=C(C5=CC=CC=C5)C=C4)N(C)C(C3=CC(C)=CC(C)=C3)=O)N[C@H]([C@@](O)=O)CC1=CNC2=C1C=CC=C2	Potent ETB antagonist	Potent endothelin receptor antagonist; shows some selectivity for ETB receptors (IC50 values are 1.3 and 94 nM for ETB and ETA receptors respectively). Inhibits ETB receptor-mediated blood pressure increase and renal vascular resistance in rats in vivo.	"Balwierczak et al (1995) Characterization of a potent and selective endothelin-B receptor antagonist, IRL 2500. J.Cardiovasc.Pharmacol. 26 S393. PMID:8587424. Webb et al (1995) Effects of the ETB-selective antagonist IRL 2500 in conscious spontaneously hypertensive and Wistar-Kyoto rats. J.Cardiovasc.Pharmacol. 26 S389. PMID:8587423. Leung et al (2002) Use of A-192621 and IRL-2500 to unmask the mesenteric and renal vasodilator role of endothelin ETB receptors. J.Cardiovasc.Pharmacol. 39 533. PMID:11904527."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=80169	SQ1341			Nov-2003
1842	RHC 80267	[83654-05-1]	O=C(NCCCCCCNC(O/N=C2\CCCCC2)=O)O/N=C1CCCCC/1	Diacylglycerol lipase inhibitor	Inhibitor of diacylglycerol lipase (IC50 values are 1.1 and 4 _M in rat cardiac myocytes and canine platelets respectively). Weakly inhibits phospholipases C and A2. Potentiates acetylcholine evoked relaxation in mesenteric arteries by the inhibition of cholinesterase activity (IC50 = 4 _M).	"Sutherland and Amin (1982) Relative activities of rat and dog platelet phospholipase A2 and diglyceride lipase. J.Biol.Chem. 257 14006. PMID:7142192. Suzuki et al (2002) Effects of RHC-80267, an inhibitor of diacylglycerol lipase, on excitation of circular smooth muscle of the guinea-pig gastric antrum. J.Smooth Muscle Res. 38 153. PMID:12713022. Ghisdal et al (2005) The diacylglycerol lipase inhibitor RHC-80267 potentiates the relaxation to acetylcholine in rat mesenteric artery by anti-cholinesterase action. Eur.J.Pharmacol. 517 97. PMID:15958263."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=80188				Sep-2006
1847	Eticlopride hydrochloride	[97612-24-3]	O=C(C2=C(OC)C(Cl)=CC(CC)=C2O)NC[C@@H]1CCCN1CC.Cl	Selective D2/D3 antagonist	Selective dopamine D2/D3 receptor antagonist (Ki values are 0.50 and 0.16 nM respectively). Antipsychotic.	"Hall et al (1985) Some in vitro receptor binding properties of [3H]eticlopride, a novel substituted benzamide, selective for dopamine-D2 receptors in the rat brain. Eur.J.Pharmacol. 111 191. PMID:4018125. Giuliani and Ferrari (1997) Involvement of dopamine receptors in the antipsychotic profile of (-) eticlopride. Physiol.Behav. 61 563. PMID:9108576. Claytor et al (2006) The effects of eticlopride and the selective D3-antagonist PNU 99194-A on food- and cocaine-maintained responding in rhesus monkeys. Pharmacol.Biochem.Behav. 83 456. PMID:16631246."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=80396	SQ1533			Sep-2006
1849	EMD 66684	[1216884-39-7]	Cl.CCCCC1=NC2=C(N1CC1=CC=C(C=C1)C1=C(C=CC=C1)C1=NN=NN1)C(=O)N(CC(=O)N(C)C)C=C2	"Potent, selective non-peptide AT1 antagonist"	Highly potent and very selective non-peptide angiotensin AT1 receptor antagonist (IC50 values are 0.7 and > 10000 nM for AT1 and AT2 receptors respectively). Potently inhibits angiotensin II-induced contractions in isolated rabbit aorta (IC50 = 0.2 nM) and reduces blood pressure in hypertensive rats.	"Mederski et al (1994) Non-peptide angiotensin II receptor antagonists: synthesis and biological activity of a series of novel 4,5-dihydro-4-oxo-3H-imidazo[4,5-c]pyridine derivatives. J.Med.Chem. 37 1632. PMID:8201597. Mederski et al (1995) 4,5-Dihydro-4-oxo-3H-imidazo[4,5-c]pyridines: potent arylacetic acid-derived AT1 antagonists with improved affinity for the AT2 receptor. Bioorg.Med.Chem.Lett. 5 2665."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=80444	SQ1341			Jul-2006
1850	Exo1	[461681-88-9]	COC(=O)C1=CC=CC=C1NC(=O)C1=CC=C(F)C=C1	Inhibits Golgi-ER traffic; blocks exocytosis	"Reversible inhibitor of vesicular trafficking between endoplasmic reticulum and Golgi apparatus. Modifies Golgi ADP-ribosylation factor (ARF)1 GTPase activity and inhibits exocytosis (IC50 ~ 20 mM). Has similar, but not identical, action to brefeldin A (Cat. No. 1231)."	Feng et al (2003) Exo1: A new chemical inhibitor of the exocytic pathway. Proc.Natl.Acad.Sci.U.S.A. 100 6469. PMID:12738886.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=80445	SQ1341			May-2004
1852	(S)-(-)-Blebbistatin	[856925-71-8]	O=C2[C@@]3(O)C(N(C4=CC=CC=C4)CC3)=NC1=CC=C(C)C=C12	Selective inhibitor of myosin II ATPase activity. Active enantiomer of ()-blebbistatin (Cat. No. 1760)	"Selective inhibitor of myosin II ATPase activity (IC50 ~0.5 - 5 _M); active enantiomer of ()-blebbistatin (Cat. No. 1760). Inhibits contraction of the cleavage furrow without disrupting mitosis or contractile ring assembly. Rapidly and reversibly blocks cell blebbing, and disrupts directed cell migration and cytokinesis in vertebrate cells."	"Straight et al (2002) Dissecting cytokinesis with small molecules. Amer.Soc.Cell Biol.Abstr. 2515. Straight et al (2003) Dissecting temporal and spatial control of cytokinesis with a myosin II inhibitor. Science 299 1743. PMID:12637748. Limouze et al (2004) Specificity of blebbistatin, an inhibitor of myosin II. J.Muscle Res.Cell Motil. 25 337. PMID:15548862."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=80965	SQ1533			Jan-2005
1853	(R)-(+)-Blebbistatin	[1177356-70-5]	O=C2[C@]3(O)C(N(C4=CC=CC=C4)CC3)=NC1=CC=C(C)C=C12	Selective inhibitor of myosin II ATPase activity. Inactive enantiomer of ()-blebbistatin (Cat. No. 1760)	"Inactive enantiomer of the selective inhibitor of myosin II, ()-blebbistatin (Cat. No. 1760)."	"Straight et al (2002) Dissecting cytokinesis with small molecules. Amer.Soc.Cell Biol.Abstr. 2515. Straight et al (2003) Dissecting temporal and spatial control of cytokinesis with a myosin II inhibitor. Science 299 1743. PMID:12637748. Limouze et al (2004) Specificity of blebbistatin, an inhibitor of myosin II. J.Muscle Res.Cell Motil. 25 337. PMID:15548862."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=80968	SQ1533			Jan-2005
1854	Ro 60-0175 fumarate	[169675-09-6]	O=C(O)/C=C/C(O)=O.FC1=C(Cl)C=C(N(C[C@H](C)N)C=C2)C2=C1	"Potent, selective 5-HT2C agonist"	"Potent, selective 5-HT2 receptor agonist; shows selectivity for the 5-HT2C subtype (pKi values are 9, 7.5, 5.4, 5.2 and 5.6 for human 5-HT2C, 2A, 1A, 6 and 7 receptors respectively). Centrally active following oral or systemic administration in vivo."	"Martin et al (1998) 5-HT2C receptor agonists: pharmacological characteristics and therapeutic potential. J.Pharmacol.Exp.Ther. 286 913. PMID:9694950. Kennett et al (2000) Effects of Ro 60 0175, a 5-HT2C receptor agonist, in three animal models of anxiety. Eur.J.Pharmacol. 387 197. PMID:10650160. Damjanoska et al (2003) Neuroendocrine evidence that (S)-2-(chloro-5-fluoro-indol-l-yl)-1-methylethylamine fumarate (Ro 60-0175) is not a selective 5-hydroxytryptamine2C receptor agonist. J.Pharmacol.Exp.Ther. 304 1209. PMID:12604698. Jensen et al (2013) Design, synthesis, and pharmacological characterization of N- and O-substituted 5,6,7,8-tetrahydro-4H-isoxazolo[4,5-d]azepin-3-ol analogues: novel 5-HT2A/5-HT2C receptor agonists with pro-cognitive properties. J.Med.Chem. 56 1211. PMID:23301527."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=81239	SQ1341			Nov-2003
1856	"L-165,041"	[79558-09-1]	CCCC1=C(O)C(CC=O)=CC=C1OCCCOC1=CC=C(OCC(O)=O)C=C1	Potent PPAR_ agonist	"Potent PPAR_ agonist (Ki = 6 nM); displays > 100-fold selectivity for both mouse and human PPAR_ receptors over other subtypes. Raises plasma cholesterol levels in vivo, in insulin-resistant db/db mice. Neuroprotective in models of cerebral infarction and Parkinson's disease."	Berger et al (1999) Novel peroxisome proliferator-activated receptor (PPAR)_ and PPAR_ ligands produce distinct biological effects. J.Biol.Chem. 274 6718. PMID:10037770. Leibowitz et al (2000) Activation of PPAR_ alters lipid metabolism in db/db mice. FEBS Lett. 473 333. PMID:10818235. Iwashita et al (2007) Neuroprotective efficacy of the peroxisome proliferator-activated receptor _-selective agonists in vitro and in vivo. J.Pharmacol.Exp.Ther. 320 1087. PMID:17167170.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=81251	SQ1341			Oct-2003
1858	Impentamine dihydrobromide	[149629-70-9]	Br.Br.NCCCCCC1=CN=CN1	Selective H3 antagonist	"Potent and highly selective histamine H3 receptor antagonist (pA2 = 8.4); displays > 30000-fold selectivity over H1 and H2 receptors. Can act as a partial agonist in SK-N-MC cells expressing human H3 receptors. Produces antinociception, possibly via a non-H1, -H2 or -H3 receptor-mediated mechanism, following central administration in vivo."	"Vollinga et al (1995) Homologs of histamine as histamine H3 receptor antagonists: a new potent and selective H3 antagonist, 4(5)-(5-aminopentyl)-1H-imidazole. J.Med.Chem. 38 266. PMID:7830269. Hough et al (1999) Antinociceptive activity of impentamine, a histamine congener, after CNS administration. Life Sci. 64 PL79. PMID:10072195. Wieland et al (2001) Constitutive activity of histamine H3 receptors stably expressed in SK-N-MC cells: display of agonism and inverse agonism by H3 antagonists. J.Pharmacol.Exp.Ther. 299 908. PMID:11714875."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=81252	SQ1341			Jul-2006
1862	PRIMA-1	[5608-24-2]	O=C1C(CO)(CO)N2CCC1CC2	Restores mutant p53 activity; induces apoptosis	Selectively restores mutant p53 activity in tumor cells via activation of Bax and PUMA. Induces apoptosis and inhibits growth of human tumors with mutant p53.	Bykov et al (2002) Restoration of the tumour suppressor function to mutant p53 by a low-molecular-weight compound. Nat.Med. 8 282. PMID:11875500. Bykov et al (2002) Mutant p53-dependent growth suppression distinguishes PRIMA-1 from known anticancer drugs: a statistical analysis of information in the National Cancer Institute database. Carcinogenesis 23 2011. PMID:12507923. Wang et al (2007) PRIMA-1 induces apoptosis by inhibiting JNK signalling but promoting the activation of Bax. Biochem.Biophys.Res.Commun. 352 203. PMID:17113036.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=82390	SQ1341			Oct-2003
1866	MRS 1845	[544478-19-5]	O=C(OCC)C1=C(C)N(CC#C)C(C)=C(C(OC)=O)C1C2=CC([N+]([O-])=O)=CC=C2	Potent SOC inhibitor; blocks capacitative Ca2+ entry	Potent blocker of store-operated Ca2+ channels; inhibits capacitative Ca2+ influx in HL-60 cells (IC50 = 1.7 mM).	Harper et al (2003) Dihydropyridines as inhibitors of capacitative calcium entry in leukemic HL-60 cells. Biochem.Pharmacol. 65 329. PMID:12527326. Szikra et al (2008) Depletion of calcium stores regulates calcium influx and signal transmission in rod photoreceptors. J.Physiol. 586 4859. PMID:18755743. Szikra et al (2009) Calcium homeostasis and cone signaling are regulated by interactions between calcium stores and plasma membrane ion channels. PLoS ONE 4 e6723. PMID:19696927.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=82695	SQ1341			Oct-2003
1867	NSC 663284	[383907-43-5]	ClC1=C(NCCN2CCOCC2)C(=O)C2=NC=CC=C2C1=O	"Potent, selective Cdc25 phosphatase inhibitor"	"Potent, selective inhibitor of Cdc25 dual specificity phosphatases (Ki values are 29, 95 and 89 nM for human Cdc25A, Cdc25B2 and Cdc25C respectively); > 20- and > 450-fold selective over VHR and PTP1B phosphatases respectively. Arrests cells at both G1 and G2/M phase and blocks cdk2 and cdk1 activation. Blocks proliferation of a range of human tumor cell lines (IC50 = 0.2 - 35 _M)."	"Lazo et al (2001) Discovery and biological evaluation of a new family of potent inhibitors of the dual specificity protein phosphatase Cdc25. J.Med.Chem. 44 4042. PMID:11708908. Pu et al (2002) Dual G1 and G2 phase inhibition by a novel, selective Cdc25 inhibitor 7-chloro-6-(2-morpholin-4-ylethylamino)-quinoline-5,8-dione. J.Biol.Chem. 277 46877. PMID:12356752. Brisson et al (2005) Redox regulation of cdc25B by cell-active Quinolinediones. Mol.Pharmacol. 68 1810. PMID:16155209."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=83018	SQ1533			Aug-2005
1868	U0124	[108923-79-1]	N/C(SC)=C(\C(C#N)=C(SC)/N)/C#N	Inactive analog of U0126 (Cat. No. 1144)	Inactive analog of U0126 (Cat. No. 1144). Used as a negative control. Does not inhibit MEK at concentrations up to 100 _M.	"Favata et al (1998) Identification of a novel inhibitor of mitogen-activated protein kinase kinase. J.Biol.Chem. 273 18623. PMID:9660836. Fitzgerald (2000) Regulation of voltage-dependent calcium channels in rat sensory neurones involves a Ras-mitogen-activated protein kinase pathway. J.Physiol. 527 433. PMID:10990531. Sekar et al (2001) Concerted transcriptional activation of the low density lipoprotein receptor gene by insulin and luteinizing hormone in cultured porcine granulosa-luteal cells: possible convergence of protein kinase A, phosphatidylinositol 3-kinase, and mitogen-activated protein kinase signaling pathways. Endocrinology 142 2921. PMID:11416012."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=83019				Jan-2005
1869	Ipsapirone	[95847-70-4]	O=C1N(CCCCN2CCN(CC2)C2=NC=CC=N2)S(=O)(=O)C2=CC=CC=C12	Selective 5-HT1A agonist	Selective 5-HT1A receptor agonist (Ki = 10 nM). Anxiolytic in vivo.	"Traber et al (1984) Brain serotonin receptors as a target for the putative anxiolytic TVX Q 7821. Brain Res.Bull. 12 741. PMID:6541079. Glaser and Traber (1985) Binding of the putative anxiolytic TVX Q 7821 to hippocampal 5-hydroxytryptamine (5-HT) recognition sites. Naunyn-Schmied.Arch.Pharmacol. 329 211. Maj et al (1987) Central action of ipsapirone, a new anxiolytic drug, on serotoninergic, noradrenergic and dopaminergic functions. J.Neural.Transm. 70 1. PMID:2889795."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=83024	SQ1533			Feb-2004
1870	BTS	[1576-37-0]	CC1=CC=C(C=C1)S(=O)(=O)NCC1=CC=CC=C1	Selective inhibitor of skeletal muscle myosin II ATPase activity	Selective inhibitor of the ATPase activity of skeletal muscle myosin II subfragment 1 (S1) (IC50 ~ 5 mM). Reversibly blocks gliding motility and suppresses force and twitch production in fast skeletal muscle.	Cheung et al (2001) A small-molecule inhibitor of skeletal muscle myosin II. Nat.Cell.Biol. 4 83. PMID:11744924. Ramachandran et al (2003) Skeletal muscle myosin cross-bridge cycling is necessary for myofibrillogenesis. Cell Motil.Cytoskeleton 55 61. PMID:12673599. Shaw et al (2003) Mechanism of inhibition of skeletal muscle actomyosin by N-benzyl-p-toluenesulfonamide. Biochemistry 42 6128. PMID:12755615.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=83025	SQ1341			Nov-2003
1937	NSC 693868	[40254-90-8]	NC1=NN=C2NC3=CC=CC=C3N=C12	Cdk inhibitor. Also inhibits GSK-3	"Inhibitor of cyclin-dependent kinases (cdks) and glycogen synthase kinase-3 (GSK-3). IC50 values are 0.6, 0.4 and 1 _M for cdk1/cyclin B, cdk5/p25 and GSK-3 respectively."	"Monge et al (1995) 3-Amino-2-quinoxalinecarbonitrile. New fused quinoxalines with potential cytotoxic activity. J.Heterocycl.Chem. 31 1135. Ortega et al (2002) Pyrazolo[3,4-b]quinoxalines. A new class of cyclin-dependent kinases inhibitors. Bioorg.Med.Chem.Lett. 10 2177. PMID:11983514."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=83574				Sep-2003
1941	m-3M3FBS	[200933-14-8]	CC1=CC(C)=C(C(C)=C1)S(=O)(=O)NC1=CC=CC(=C1)C(F)(F)F	Phospholipase C activator	"Activator of phospholipase C (PLC). Stimulates superoxide generation, Ca2+ release and inositol phosphate formation in a variety of cell types. Also inhibits growth of the leukemic cell lines U937 and THP-1. Inactive control o-3M3FBS (Cat. No. 1942) available."	"Bae et al (2003) Identification of a compound that directly stimulates phospholipase C activity. Mol.Pharmacol. 63 1043. PMID:12695532. Krjukova et al (2004) Phospholipase C activator m-3M3FBS affects Ca2+ homeostasis independently of phospholipase C activation. Br.J.Pharmacol. 143 3. PMID:15302681. Lee et al (2005) The novel phospholipase C activator, m-3M3FBS, induces monocytic leukemia cell apoptosis. Cancer Lett. 222 227. PMID:15863272."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=83638	SQ1341			Oct-2003
1942	o-3M3FBS	[313981-55-4]	CC1=CC(C)=C(C(C)=C1)S(=O)(=O)NC1=C(C=CC=C1)C(F)(F)F	Inactive analog of m-3M3FBS (Cat. No. 1941)	Inactive analog of m-3M3FBS (Cat. No. 1941). Used as a negative control.	Bae et al (2003) Identification of a compound that directly stimulates phospholipase C activity. Mol.Pharmacol. 63 1043. PMID:12695532.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=83639				Oct-2003
1944	Loratidine	[79794-75-5]	CCOC(=O)N1CC\C(CC1)=C1/C2=NC=CC=C2CCC2=C1C=CC(Cl)=C2	Peripheral H1 antagonist; antiallergic agent	Peripheral histamine H1 receptor antagonist (Ki = 35 nM); devoid of central effects. Orally active antiallergic agent.	"Barnett et al (1984) Evaluation of the CNS properties of SCH 29851, a potential non-sedating antihistamine. Agents Actions 14 590. PMID:6236679. Ahn and Barnett (1986) Selective displacement of [3H]mepyramine from peripheral vs. central nervous system receptors by loratadine, a non-sedating antihistamine. Eur.J.Pharmacol. 127 153. PMID:2875889. Kreutner et al (1987) Antiallergic activity of loratidine, a non-sedating antihistamine. Allergy 42 57. PMID:2436504."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=84958	SQ1533			Oct-2003
1949	"L-670,596"	[121083-05-4]	CS(=O)(=O)C1=CC=C(CN2C3=C(CCCC3CC(O)=O)C3=CC(F)=CC(F)=C23)C=C1	"Potent, selective thromboxane A2/prostaglandin endoperoxide antagonist"	Potent and selective thromboxane A2/prostaglandin endoperoxide receptor antagonist (IC50 = 5.5 nM). Inhibits U-44069-induced contractions of guinea pig trachea (pA2 = 9.0) and human platelet aggregation in vitro (IC50 = 6.5 nM). Also prevents thromboxane-mediated endothelial cell death. Orally active in vivo.	"Ford-Hutchinson et al (1989) The pharmacology of L-670,596, a potent and selective thromboxane/prostaglandin endoperoxide receptor antagonist. Can.J.Physiol.Pharmacol. 67 989. PMID:2598135. Girard et al (1989) Tetrahydrocarbazol-1-acetic acids: new class of thromboxane receptor antagonists. Prog.Clin.Biol.Res. 301 585. PMID:2529558. Beauchamp et al (2001) Role of thromboxane in retinal microvascular degeneration in oxygen-induced retinopathy. J.Appl.Physiol. 90 2279. PMID:11356793."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=85157	SQ1341			Jul-2004
1952	DCB	[6971-97-7]	ClC1=CC(=CC=C1)\N=C\N=C\C1=CC(Cl)=CC=C1	Allosteric modulator at mGlu5	"Allosteric ligand for the metabotropic glutamate receptor mGlu5; displays neutral modulation. Does not affect agonist-stimulated mGlu5 responses, but blocks regulation of the receptor by other allosteric modulators such as DFB (Cat. No. 1625) and DMeOB (Cat. No. 1953)."	O'Brien et al (2003) A family of highly selective allosteric modulators of the metabotropic glutamate receptor subtype 5. Mol.Pharmacol. 64 731. PMID:12920211.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=85553				Feb-2004
1953	DMeOB	[40252-74-2]	COC1=CC(=CC=C1)\N=C\N=C\C1=CC(OC)=CC=C1	Negative allosteric modulator at mGlu5	Negative allosteric modulator of the metabotropic glutamate receptor mGlu5; displays reversible non-competitive inhibition of mGlu5-mediated responses (IC50 = 3 _M).	O'Brien et al (2003) A family of highly selective allosteric modulators of the metabotropic glutamate receptor subtype 5 Mol.Pharmacol. 64 731. PMID:12920211.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=85560				Feb-2004
1955	Ritanserin	[87051-43-2]	O=C1N3C(SC=C3)=NC(C)=C1CCN4CC/C(CC4)=C(C5=CC=C(F)C=C5)/C2=CC=C(F)C=C2	Potent 5-HT2 antagonist	Potent and long-acting 5-HT2 receptor antagonist (Ki = 0.39 nM). Anxiolytic in vivo.	"Janssen (1985) Pharmacology of potent and selective S2-serotonergic antagonists. J.Cardiovasc.Pharmacol. 7 S2. PMID:2412048. Leysen et al (1985) Receptor-binding properties in vitro and in vivo of ritanserin. Mol.Pharmacol. 27 600. PMID:2860558. Watanabe et al (1992) Syntheses and 5-HT2 antagonist activity of bicyclic 1,2,4-triazol-3(2H)-one and 1,3,5-triazine-2,4(3H)-dione derivatives. J.Med.Chem. 35 189. PMID:1732528."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=5399	SQ1533			Apr-2005
1956	Bestatin	[58970-76-6]	CC(C)C[C@H](NC(=O)[C@@H](O)[C@H](N)CC1=CC=CC=C1)C(O)=O	Aminopeptidase inhibitor	Aminopeptidase inhibitor (Ki = 0.001 - 90 mM); inhibits enkephalin metabolism and leukotriene A4 hydrolase. Inhibits tumor cell proliferation.	"Umezawa et al (1976) Bestatin, an inhibitor of aminopeptidase B, produced by actinomycetes. J.Antibiot. 29 97. PMID:931798. Imamura and Kimura (2000) Effect of ubenimex (Bestatin) on the cell growth and phenotype of HL-60 and HL-60R cell lines: up- and down-regulation of CD13/aminopeptidase N. Leuk.Lymphoma 37 663. PMID:11042531. Scornik and Botbol (2001) Bestatin as an experimental tool in mammals. Curr.Drug Metab. 2 67. PMID:11465152."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=87433	SQ1533			Oct-2003
1957	GR 79236	[124555-18-6]	O[C@@H](CCC4)[C@H]4NC1=NC=NC2=C1N=CN2[C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O	A1 agonist	Adenosine A1 receptor agonist (Ki = 3.1 nM). Anticonvulsive in mice following systemic administration in vivo.	Gurden et al (1993) Functional characterization of three adenosine receptor types. Br.J.Pharmacol. 109 693. PMID:8358566. Merkel et al (1995) Cardiovascular and antilipolytic effects of the adenosine agonist GR 79236. Pharmacology 51 224. PMID:8577816. Knutsen et al (1999) N-Substituted adenosines as novel neuroprotective A1 agonists with diminished hypotensive effects. J.Med.Chem. 42 3463. PMID:10479279.	Small Molecule	Sold for research purposes under agreement from GlaxoSmithKline	http://www.tocris.com/dispprod.php?ItemId=87264	SQ1341			Dec-2003
1960	SB 334867	[792173-99-0]	CC1=NC2=CC=C(NC(=O)NC3=CC=NC4=CC=CN=C34)C=C2O1	Selective non-peptide OX1 antagonist	Selective non-peptide orexin OX1 receptor antagonist. pKb values are 7.2 and < 5 for inhibition of intracellular Ca2+ release in CHO cells expressing human OX1 and OX2 receptors respectively. Blocks orexin-A induced grooming and feeding following systemic administration in vivo.	"Haynes et al (2000) A selective orexin-1 receptor antagonist reduces food consumption in male and female rats. Regul.Pept. 96 45. PMID:11102651. Porter et al (2001) 1,3-Biarylureas as selective non-peptide antagonists of the orexin-1 receptor. Bioorg.Med.Chem.Lett. 11 1907. PMID:11459658. Smart et al (2001) SB-334867-A: the first selective orexin-1 receptor antagonist. Br.J.Pharmacol. 132 1179. PMID:11250867. Duxon et al (2001) Evidence that orexin-A-evoked grooming in the rat is mediated by orexin-1 (OX1) receptors, with downstream 5-HT2C receptor involvement. Psychopharmacology 153 203. PMID:11205420."	Small Molecule	Sold for research purposes under agreement from GlaxoSmithKline	http://www.tocris.com/dispprod.php?ItemId=87255	SQ1341			May-2004
1961	SB 258585 hydrochloride	[1216468-02-8]	Cl.COC1=CC=C(NS(=O)(=O)C2=CC=C(I)C=C2)C=C1N1CCN(C)CC1	"Potent, selective 5-HT6 antagonist"	Potent and selective 5-HT6 receptor antagonist (pKi = 8.6); displays > 160-fold selectivity over other 5-HT receptor subtypes.	"Bromidge et al (1999) 5-Chloro-N-(4-methoxy-3-piperazin-1-yl-phenyl)-3-methyl-2-benzothiophenesulfonamide (SB-271046): a potent, selective, and orally bioavailable 5-HT6 receptor antagonist. J.Med.Chem. 42 202. PMID:9925723. Hirst et al (2000) Characterization of [125I]-SB-258585 binding to human recombinant and native 5-HT6 receptors in rat, pig and human brain tissue. Br.J.Pharmacol. 130 1597. PMID:10928963. East et al (2002) 5-HT6 receptor binding sites in schizophrenia and following antipsychotic drug administration: autoradiographic studies with [125I]SB-258585. Synapse 45 191. PMID:12112397."	Small Molecule	Sold for research purposes under agreement from GlaxoSmithKline	http://www.tocris.com/dispprod.php?ItemId=87278	SQ1341			Nov-2003
1962	SB 239063	[193551-21-2]	O[C@@H]1CC[C@@H](N2C=NC(C4=CC=C(F)C=C4)=C2C3=CC=NC(OC)=N3)CC1	"Potent, selective p38 MAPK inhibitor; orally active"	"Potent and selective p38 MAP kinase inhibitor (IC50 = 44 nM for p38_). Displays > 220-fold selectivity over ERK, JNK1 and other kinases; ~ 3-fold more selective than SB 203580 (Cat. Nos. 1202 and 1402). Reduces inflammatory cytokine production and is neuroprotective following oral administration in vivo."	"Underwood et al (2000) SB 239063, a potent p38 MAP kinase inhibitor, reduces inflammatory cytokine production, airways eosinophil infiltration, and persistence. J.Pharmacol.Exp.Ther. 293 281. PMID:10734180. Barone et al (2001) SB 239063, a second-generation p38 mitogen-activated protein kinase inhibitor, reduces brain injury and neurological deficits in cerebral focal ischemia. J.Pharmacol.Exp.Ther. 296 312. PMID:11160612. Legos et al (2002) The selective p38 inhibitor SB-239063 protects primary neurons from mild to moderate excitotoxic injury. Eur.J.Pharmacol. 447 37. PMID:12106800."	Small Molecule	Sold for research purposes under agreement from GlaxoSmithKline	http://www.tocris.com/dispprod.php?ItemId=5426	SQ1533			Dec-2003
1963	SB 408124	[288150-92-5]	CN(C)C1=CC=C(NC(=O)NC2=CC(C)=NC3=C(F)C=C(F)C=C23)C=C1	Selective non-peptide OX1 antagonist	Selective non-peptide orexin OX1 receptor antagonist (Kb values are 21.7 and 1405 nM for human OX1 and OX2 receptors respectively). Blocks orexin-A induced grooming following oral administration in vivo.	"Porter (2001) Advances in novel 7-TM receptors: non-peptide orexin-1 antagonists. Royal Society of Chemistry Meeting.. Langmead et al (2004) Characterisation of the binding of [3H]-SB-674042, a novel nonpeptide antagonist, to the human orexin-1 receptor. Br.J.Pharmacol. 141 340. PMID:14691055."	Small Molecule	Sold for research purposes under agreement from GlaxoSmithKline	http://www.tocris.com/dispprod.php?ItemId=87290	SQ1533			Feb-2004
1964	Gossypol	[303-45-7]	CC(C)C1=C(O)C(O)=C(C=O)C2=C(O)C(=C(C)C=C12)C1=C(O)C2=C(C=O)C(O)=C(O)C(C(C)C)=C2C=C1C	Proapoptotic; downregulates Bcl-2 and Bcl-XL	Lipophilic agent derived from cottonseed. Exhibits multiple biological effects including antifertility and anticancer activity. Proapoptotic; downregulates Bcl-2 and Bcl-XL. R-enantiomer available (Cat. No. 3367).	Vander Jagt et al (2000) Gosspyol: prototype of inhibitors targeted to dinucleotide folds. Curr.Med.Chem. 7 479. PMID:10702620. Coutinh (2002) Gossypol: a contraceptive for men. Contraception 65 259. PMID:12020773. Zhang et al (2003) Molecular mechanism of gossypol-induced cell growth inhibition and cell death of HT-29 human colon carcinoma cells. Biochem.Pharmacol. 66 93. PMID:12818369.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=87803	SQ1533			Oct-2003
1965	Simvastatin	[79902-63-9]	[H][C@@]12C(C=C[C@H](C)[C@@H]2CC[C@@H]3C[C@@H](O)CC(O3)=O)=C[C@H](C)C[C@@H]1OC(C(C)(C)CC)=O	HMG-CoA reductase inhibitor	"HMG-CoA reductase inhibitor; decreases levels of low density lipoprotein. Has multiple biological effects including bone formation stimulation, inhibition of smooth muscle cell proliferation and migration, and anticancer and anti-inflammatory activity."	White (1999) Pharmacological effects of HMG CoA reductase inhibitors other than lipoprotein modulation. J.Clin.Pharmacol. 39 111. PMID:11563401. Garrett et al (2001) Statins and bone formation. Curr.Pharm.Des. 7 715. PMID:11405194. Reinoso et al (2002) Preclinical pharmacokinetics of statins. Methods Find.Exp.Clin.Pharmacol. 24 593. PMID:12616706. Kaushal et al (2003) Potential anticancer effects of statins: fact or fiction? Endothelium 10 49. PMID:12699077.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=88098	SQ1533			Oct-2003
1967	Ranitidine hydrochloride	[66357-59-3]	Cl[H].CN\C(NCCSCC1=CC=C(CN(C)C)O1)=C\N(=O)=O	Selective H2 antagonist	"Potent, selective and competitive histamine H2 receptor antagonist (pA2 = 6.95 - 7.2). Inhibits gastric acid secretion induced by histamine, pentagastrin, bethanecol and food in vivo. Also inhibits aspirin-induced gastric lesions."	"Daly et al (1981) Some in vitro and in vivo actions of the new histamine H2-receptor antagonist, ranitidine. Br.J.Pharmacol. 72 49. PMID:6112034. Daly et al (1981) Antagonism of vasodepressor and gastric secretory responses to histamine by the H2-receptor antagonists, ranitidine and cimetidine, in the anaesthetized dog. Br.J.Pharmacol. 72 55. PMID:6112035. Brittain and Daly (1981) A review of the animal pharmacology of ranitidine - a new, selective histamine H2-antagonist. Scand.J.Gastroenterol.Suppl. 69 1."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=88773	SQ1533			Dec-2003
1969	SL 327	[305350-87-2]	N\C(SC1=CC=C(N)C=C1)=C(\C#N)C1=CC=CC=C1C(F)(F)F	Selective inhibitor of MEK1 and MEK2; brain penetrant	"Selective inhibitor of MEK1 and MEK2 (IC50 values are 0.18 and 0.22 _M respectively); blocks hippocampal LTP in vitro. Brain penetrant in vivo, blocking fear conditioning and learning in rats, and producing neuroprotection in mice, following systemic administration."	Atkins et al (1998) The MAPK cascade is required for mammalian associative learning. Nature Neurosci. 1 602. Davis et al (2000) The MAPK/ERK cascade targets both Elk-1 and cAMP response element-binding protein to control long-term potentiation-dependent gene expression in the dentate gyrus in vivo. J.Neurosci. 20 4563. PMID:10844026. Scherle et al (2000) Regulation of cyclooxygenase-2 induction in the mouse uterus during decidualization. An event of early pregnancy. J.Biol.Chem. 275 37086. PMID:10969080. Wang et al (2003) Significant neuroprotection against ischemic brain injury by inhibition of the MEK1 protein kinase in mice: exploration of potential mechanism associated with apoptosis. J.Pharmacol.Exp.Ther. 304 172. PMID:12490588.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=89322	SQ1533			Feb-2004
1970	Norketamine hydrochloride	[79499-59-5]	Cl.NC1(CCCCC1=O)C1=C(Cl)C=CC=C1	"Potent, non-competitive NMDA antagonist"	Major metabolite of ketamine that is a potent non-competitive NMDA receptor antagonist (Ki = 3.6 _M for displacement of [3H]-MK 801 in rat brain). Antinociceptive and anesthetic in vivo.	"Leung et al (1986) Comparative pharmacology in the rat of ketamine and its two principal metabolites, norketamine and (Z)-6-hydroxynorketamine. J.Med.Chem. 29 2396. PMID:3783598. Ebert et al (1997) Norketamine, the main metabolite of ketamine, is a non-competitive NMDA receptor antagonist in the rat cortex and spinal cord. Eur.J.Pharmacol. 333 99. PMID:9311667. Shimoyama et al (1999) Oral ketamine is antinociceptive in the rat formalin test: role of the metabolite, norketamine. Pain 81 85. PMID:10353496."	Small Molecule	Sold for research purposes under agreement from Pfizer Inc.	http://www.tocris.com/dispprod.php?ItemId=89699	SQ1341			Jun-2004
1971	(+)-Anabasine hydrochloride	[53912-89-3]	[C@]1([C@H]2NCCCC2)=CC=CN=C1.Cl	Neuronal nicotinic receptor partial agonist	"High affinity neuronal nicotinic ACh receptor partial agonist (Ki values are 0.058, 0.26 and 7.2 _M for rat _7, rat _4_2 and fish skeletal muscle nAChRs respectively). Also stimulates Ca2+-dependent catecholamine release from rat adrenomedullary cells in vitro."	Kem et al (1997) Anabaseine is a potent agonist on muscle and neuronal alpha-bungarotoxin-sensitive nicotinic receptors. J.Pharmacol.Exp.Ther. 283 979. PMID:9399967. Parker et al (1998) Neuronal nicotinic receptor _2 and _4 subunits confer large differences in agonist binding affinity. Mol.Pharmacol. 54 1132. PMID:9855644. Lu et al (1999) Desensitization of nicotinic agonist-induced [3H]_-aminobutyric acid release from mouse brain synaptosomes is produced by subactivating concentrations of agonists. J.Pharmacol.Exp.Ther. 291 1127. PMID:10565833. Hong et al (2007) Effect of anabasine on catecholamine secreation from the perfused rat adrenal medulla. J.Cardiol. 50 351. PMID:18186309.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=89702				Sep-2004
1972	Tianeptine sodium salt	[30123-17-2]	[Na+].CN1C2=CC=CC=C2C(NCCCCCCC([O-])=O)C2=CC=C(Cl)C=C2S1(=O)=O	Selective facilitator of 5-HT uptake; antidepressant	"Selective facilitator of 5-HT uptake in vitro and in vivo. Has no affinity for a wide range of receptors, including 5-HT and dopamine (IC50 > 10 _M) and has no effect on noradrenalin or dopamine uptake. Antidepressant, analgesic and neuroprotective following systemic administration in vivo."	"Mennini et al (1987) Tianeptine, a selective enhancer of serotonin uptake in rat brain. Naunyn-Schmied.Arch.Pharmacol. 336 478. Kato and Weitsch (1988) Neurochemical profile of tianeptine, a new antidepressant drug. Clin.Neuropharmacol. 11 S43. PMID:3052825. Uzbay et al (1999) Analgesic effect of tianeptine in mice. Life Sci. 64 1313. PMID:10227587. Plaisant et al (2003) Neuroprotective properties of tianeptine: interactions with cytokines. Neuropharmacology 44 801. PMID:12681378."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=89705	SQ1070			May-2007
1974	SANT-1	[304909-07-7]	CC1=NN(C(C)=C1\C=N\N1CCN(CC2=CC=CC=C2)CC1)C1=CC=CC=C1	Inhibitor of hedgehog (Hh) signaling; antagonizes smoothened activity	"Potent, cell-permeable inhibitor of Sonic hedgehog (Shh) signaling; high affinity antagonist of smoothened activity (KD = 1.2 nM). Inhibits smoothened agonist effects with an IC50 of 20 nM (in Shh-LIGHT2 cells)."	Chen et al (2002) Small molecule modulation of smoothened activity. Proc.Natl.Acad.Sci.USA. 99 1407.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=89793	SQ1341			Jun-2005
1975	6-Iodonordihydrocapsaicin	[859171-97-4]	CCCCCCCCC(=O)NCC1=CC(OC)=C(O)C=C1I	"Potent, competitive vanilloid receptor antagonist"	"Potent competitive vanilloid TRPV1 (VR1) receptor antagonist (IC50 = 10 nM). Inhibits capsaicin-induced [Ca2+]i increase in rat DRG neurons, and guinea pig bladder and trachea contractions in vitro."	Appendino et al (2003) Halogenation of a capsaicin analogue leads to novel vanilloid TRPV1 receptor antagonists. Br.J.Pharmacol. 139 1417. PMID:12922928.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=89884	SQ1341			Feb-2004
1979	"L-803,087 trifluoroacetate"	[217480-26-7]	FC(F)(F)C(O)=O.NC(NCCC[C@@H]([C@@](OC)=O)NC(CCCC1=C(C3=CC=CC=C3)NC2=C1C=C(F)C=C2F)=O)=N	Potent and selective sst4 agonist	"Potent and selective somatostatin sst4 receptor agonist. Ki values are 0.7, 199, 4720, 1280 and 3880 nM for cloned human sst4, sst1, sst2, sst3 and sst5 receptors respectively. Facilitates AMPA-mediated hippocampal synaptic responses in vitro and increases kainate-induced seizures in mice in vivo."	Rohrer et al (1998) Rapid identification of subtype-selective agonists of the somatostatin receptor through combinatorial chemistry. Science 282 737. PMID:9784130. Rohrer and Schaeffer (2000) Identification and characterization of subtype selective somatostatin receptor agonists. J.Physiol.Paris 94 211. PMID:11087999. Moneta et al (2002) Somatostatin receptor subtypes 2 and 4 affect seizure susceptibility and hippocampal excitatory neurotransmission in mice. Eur.J.Neurosci. 16 843. PMID:12372020.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=89912	SQ1341			Aug-2006
1980	"L-817,818"	[217480-27-8]	O=C(CC1=C(C4=CC=C(C=CC=C5)C5=C4)NC2=C1C=CC3=C2C=CC=C3)N[C@@H]([C@](OC[C@@H](N)C)=O)CCCCN	Potent and selective sst5 agonist	"Potent and selective somatostatin sst5 receptor agonist. Ki values are 0.4, 3.3, 52, 64 and 82 nM for cloned human sst5, sst1, sst2, sst3 and sst4 receptors respectively. Inhibits growth hormone release from rat pituitary cells (EC50 = 3.1 nM) and insulin release from mouse pancreatic islets (EC50 = 0.3 nM) in vitro."	Rohrer et al (1998) Rapid identification of subtype-selective agonists of the somatostatin receptor through combinatorial chemistry. Science 282 737. PMID:9784130. Rohrer and Schaeffer (2000) Identification and characterization of subtype selective somatostatin receptor agonists. J.Physiol.Paris 94 211. PMID:11087999. Strowski et al (2000) Somatostatin inhibits insulin and glucagon secretion via two receptor subtypes: An in vitro study of pancreatic islets from somatostatin receptor 2 knockout mice. Endocrinology 141 111. PMID:10614629.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=89913	SQ1341			Aug-2007
1982	Reboxetine mesylate	[98769-84-7]	[H][C@]2(OCCNC2)[C@@H]([C@]3=CC=CC=C3)OC1=C(OCC)C=CC=C1.[H][C@@]5(OCCNC5)[C@H]([C@]6=CC=CC=C6)OC4=C(OCC)C=CC=C4.CS(=O)(O)=O.CS(=O)(O)=O	"Potent, selective noradrenalin uptake inhibitor; orally active"	"Potent and selective inhibitor of noradrenalin uptake (Ki values are 1.1, 129 and > 10000 nM for rat NET, SERT and DAT respectively). Displays > 1000-fold selectivity over _-adrenoceptors, 5-HT, dopamine and muscarinic ACh receptors. Orally active antidepressant."	"Sacchetti et al (1999) Studies on the acute and chronic effects of reboxetine on extracellular noradrenaline and other monoamines in the rat brain. Br.J.Pharmacol. 128 1332. PMID:10578149. Wong et al (2000) Reboxetine: a pharmacologically potent, selective, and specific norepinephrine reuptake inhibitor. Biol.Psychiatry. 47 818. PMID:10812041. Millan et al (2001) S33005, a novel ligand at both serotonin and norepinephrine transporters: I Receptor binding, electrophysiological, and neurochemical profile in comparison with venlafaxine, reboxetine, citalopram, and clomipramine. J.Pharmacol.Exp.Ther. 298 565. PMID:11454918. Owen and Whitton (2003) Reboxetine modulates norepinephrine efflux in the frontal cortex of the freely moving rat: the involvement of _2 and 5-HT1A receptors. Neurosci.Lett. 348 171. PMID:12932821."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=90132	SQ1533			Jul-2004
1985	PNU 142633	[187665-65-2]	O=C(NC)C3=CC(CCO2)=C(C=C3)[C@@H]2CCN1CCN(C4=CC=C(C(N)=O)C=C4)CC1	Highly selective 5-HT1D agonist	"Very selective, high affinity 5-HT1D receptor agonist (Ki values are 6 and > 18000 nM at human 5-HT1D and 5-HT1B receptors respectively). Inhibits sympathetically-induced tachycardic responses and blocks neurogenic plasma protein extravasation in vivo."	Roon et al (1999) Bovine isolated middle cerebral artery contractions to antimigraine drugs. Naunyn-Schmied.Arch.Pharmacol. 360 591. McCall et al (2002) Preclinical studies characterizing the anti-migraine and cardiovascular effects of the selective 5-HT1D receptor agonist PNU-142633. Cephalalgia 22 799. PMID:12485205. Sanchez-Lopez et al (2003) Pharmacological profile of the 5-HT-induced inhibition of cardioaccelerator sympathetic outflow in pithed rats: correlation with 5-HT1 and putative 5-ht5A/5B receptors. Br.J.Pharmacol. 140 725. PMID:14504136.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=90707	SQ1341			Apr-2008
1990	"(R,R)-THC"	[138090-06-9]	OC3=CC=C(C(C[C@H]4CC)=C3)C2=C4C1=CC=C(O)C=C1C[C@H]2CC	Potent subtype-selective ligand; ER_ agonist/ER_ antagonist	"Non-steroidal, selective estrogen receptor ligand; agonist at ER_ receptor (Ki = 9.0 nM) and antagonist at ER_ receptor (Ki = 3.6 nM)."	Sun et al (1999) Novel ligands that function as selective estrogens or antiestrogens for estrogen receptor-_ or estrogen receptor-_. Endocrinology 140 800. PMID:9927308. Kraichely et al (2000) Conformational changes and coactivator recruitment by novel ligands for estrogen receptor-_ and estrogen receptor-_: correlations with biological character and distinct differences among SRC coactivator family members. Endocrinology 141 3534. PMID:11014206.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=90875	SQ1341			Apr-2006
1991	MPP dihydrochloride	[911295-24-4]	OC(C=C4)=CC=C4N1C(C(C=C3)=CC=C3OCCN2CCCCC2)=C(C)C(C5=CC=C(O)C=C5)=N1.Cl.Cl	Highly selective ER_ antagonist	"Selective, high affinity silent antagonist at ER_ receptors. Displays > 200-fold selectivity for ER_ over ER_. Ki values are 2.7 and 1800 nM at ER_ and ER_ receptors respectively."	Sun et al (2002) Antagonists selective for estrogen receptor _. Endocrinol. 143 941. Harrington et al (2003) Activities of estrogen receptor alpha- and beta-selective ligands at diverse responsive gene sites mediating transactivation or transrepression. Mol.Cell.Endocrinol. 206 13. PMID:12943986.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=90908	SQ1341			Mar-2004
1992	Nomifensine	[32795-47-4]	NC1=CC=CC2=C1C[N+]([H])(C)CC2C3=CC=CC=C3.O=C(O)\C=C/C([O-])=O	Potent noradrenalin and dopamine uptake inhibitor. Antidepressant	"Potent inhibitor of noradrenalin and dopamine uptake (Ki values are 4.7, 26 and 4000 nM for inhibition of noradrenalin, dopamine and 5-HT uptake respectively, in rat brain). Increases central dopamine levels in rats following systemic administration. Displays antidepressant activity."	Tuomisto (1977) Nomifensine and its derivatives as possible tools for studying amine uptake. Eur.J.Pharmacol. 42 101. PMID:844493. Nakachi et al (1995) Effects of various dopamine uptake inhibitors on striatal extracellular dopamine levels and behaviours in rats. Eur.J.Pharmacol. 281 195. PMID:7589207. Katz et al (2010) Effects of acute and sustained administration of the catecholamine reuptake inhibitor nomifensine on the firing activity of monoaminergic neurons. J.Psychopharmacol. 24 1223. PMID:19939862.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=90909	SQ1533			Nov-2013
1994	ZK 93423 hydrochloride	[1216574-52-5]	Cl.CCOC(=O)C1=C(COC)C2=C(NC3=C2C=C(OCC2=CC=CC=C2)C=C3)C=N1	Potent benzodiazepine agonist	"Potent benzodiazepine receptor agonist (IC50 = 1 nM). Non-selective between _1-, _2-, _3- and _5-subunit containing GABAA receptors (Ki values are 4.1, 4.2, 6 and 4.5 nM for inhibition of [3H]Ro15-1788 binding to human recombinant _1_3_2, _2_3_2, _3_3_2 and _5_3_2 receptors respectively). Anxiolytic following systemic administration in vivo."	Stephens et al (1984) Discriminative stimulus properties of _-carbolines characterized as agonists and inverse agonists at central benzodiazepine receptors. Psychopharmacology 83 233. PMID:6089245. File and Baldwin (1987) Effects of _-carbolines in animal models of anxiety. Brain Res.Bull. 19 293. PMID:3315125. Cox et al (1998) Synthesis and evaluation of analogues of the partial agonist 6-(propyloxy)-4-(methoxymethyl)-_-carboline-3-carboxylic acid ethyl ester (6-PBC) and the full agonist 6-(benzyloxy)-4-(methoxymethyl)-_-carboline-3-carboxylic acid ethyl ester (ZK 93423) at wild type and recombinant GABAA receptors. J.Med.Chem. 41 2537. PMID:9651158.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=91161	SQ1341			Aug-2006
1995	Ro 19-4603	[99632-94-7]	CN1CC2=C(N=CN2C2=C(SC=C2)C1=O)C(=O)OC(C)(C)C	Benzodiazepine inverse agonist	Benzodiazepine inverse agonist. Binds with high affinity to both diazepam-sensitive (DS) and diazepam-insensitive (DI) GABAA receptors (Ki values are ~ 0.2 and ~ 2.6 nM for DS and DI receptors respectively). Antagonizes effects of ethanol on locomotor behavior and suppresses ethanol intake in alcohol-preferring rats.	Wong and Skolnick (1992) High affinity ligands for 'diazepam-insensitive' benzodiazepine receptors. Eur.J.Pharmacol. 225 63. PMID:1311690. June et al (1995) Effects of the benzodiazepine inverse agonist RO19-4603 on the maintenance of tolerance to a single dose of ethanol. J.Pharmacol.Exp.Ther. 274 1105. PMID:7562476. June et al (1998) The novel benzodiazepine inverse agonist RO19-4603 antagonises ethanol motivated behaviours: neuropharmacological studies. Brain Res. 784 256. PMID:9518641.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=91164	SQ1341			Sep-2004
1996	ZK 93426 hydrochloride	[1216792-30-1]	Cl.CCOC(=O)C1=C(C)C2=C(NC3=C2C(OC(C)C)=CC=C3)C=N1	"Potent, competitive benzodiazepine antagonist"	"Potent, selective and competitive benzodiazepine receptor antagonist (IC50 values are 0.4 and 0.7 nM for inhibition of [3H]-flunitrazepam binding to rat cerebellum and hippocampus respectively). Similar in vivo profile to flumazenil (Ro 15-1788, Cat No. 1328); produces anxiogenic effects in some behavioral tests and anxiolytic effects in others. Orally active."	Jensen et al (1984) Evaluation of the _-carboline ZK 93 426 as a benzodiazepine receptor antagonist. Psychopharmacology 83 249. PMID:6089247. Corda et al (1987) Enhancement of _-aminobutyric acid binding by the anxiolytic _-carbolines ZK 93423 and ZK 91296. J.Neurochem. 48 1355. PMID:2881979. File and Baldwin (1987) Effects of _-carbolines in animal models of anxiety. Brain Res.Bull. 19 293. PMID:3315125.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=91165	SQ1341			Jun-2006
1997	Ro 15-4513	[91917-65-6]	CCOC(=O)C1=C2CN(C)C(=O)C3=C(C=CC(=C3)N=[N+]=[N-])N2C=N1	Benzodiazepine partial inverse agonist	"High affinity benzodiazepine ligand. Ki values are 3.1 and 5.3 nM for diazepam-insensitive (DI) and diazepam-sensitive (DS) benzodiazepine receptors respectively. Acts as partial inverse agonist at recombinant DS _1-, _2-, _3- and _5-GABAA receptors. Displays partial agonism at DI _4- and _6-GABAA receptors. Antagonizes several behavioral and neurochemical effects of ethanol. Proconvulsant and anxiogenic."	Suzdak et al (1986) A selective imidazobenzodiazepine antagonist of ethanol in the rat. Science 234 1243. PMID:3022383. Wong and Skolnick (1992) High affinity ligands for 'diazepam-insensitive' benzodiazepine receptors. Eur.J.Pharmacol. 225 63. PMID:1311690. Knoflach et al (1996) Pharmacological modulation of the diazepam-insensitive recombinant gamma-aminobutyric acidA receptors alpha 4 beta 2 gamma 2 and alpha 6 beta 2 gamma 2. Mol.Pharmacol. 50 1253. PMID:8913357.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=91166	SQ1070			Feb-2005
1999	Linopirdine dihydrochloride	[113168-57-3]	Cl.Cl.O=C1N(C2=CC=CC=C2C1(CC1=CC=NC=C1)CC1=CC=NC=C1)C1=CC=CC=C1	KV7 (KCNQ) channel blocker	Blocker of KV7 (KCNQ) voltage-gated potassium channels; blocks KV7.1+7.3 (KCNQ2+3) / M-currents (IC50 = 4 - 7 _M) and KV7.1 (KCNQ1) homomeric channels (IC50 = 8.9 _M). Augments hippocampal ACh release and is a cognitive enhancer following oral administration in vivo.	"Schnee and Brown (1998) Selectivity of linopirdine (DuP 966), a neurotransmitter release enhancer, in blocking voltage-dependent and calcium-activated potassium currents in hippocampal neurons. J.Pharmacol.Exp.Ther. 286 709. PMID:9694925. Wang et al (1998) KCNQ2 and KCNQ3 potassium channel subunits: molecular correlates of the M-channel. Science 282 1890. PMID:9836639. Zaczek et al (1998) Two new potent neurotransmitter release enhancers, 10,10-bis(4-pyridinylmethyl)-9(10H)-anthracenone and 10,10-bis(2-fluoro-4-pyridinylmethyl)-9(10H)-anthracenone: comparison to linopirdine. J.Pharmacol.Exp.Ther. 285 724. PMID:9580619."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=91172	SQ1533			Feb-2004
2000	XE 991 dihydrochloride	[122955-13-9]	Cl.Cl.O=C1C2=C(C=CC=C2)C(CC2=CC=NC=C2)(CC2=CC=NC=C2)C2=C1C=CC=C2	"Potent, selective KV7 (KCNQ) channel blocker; blocks M-currents"	Potent and selective blocker of KV7 (KCNQ) voltage-gated potassium channels. Blocks KV7.2+7.3 (KCNQ2+3) / M-currents (IC50 = 0.6 - 0.98 _M) and KV7.1 (KCNQ1) homomeric channels (IC50 = 0.75 _M) but is less potent against KV7.1/minK channels (IC50 = 11.1 _M). Augments hippocampal ACh release and is a cognitive enhancer following oral administration in vivo.	"Wang et al (1998) KCNQ2 and KCNQ3 potassium channel subunits: molecular correlates of the M-channel. Science 282 1890. PMID:9836639. Zaczek et al (1998) Two new potent neurotransmitter release enhancers, 10,10-bis(4-pyridinylmethyl)-9(10H)-anthracenone and 10,10-bis(2-fluoro-4-pyridinylmethyl)-9(10H)-anthracenone: comparison to linopirdine. J.Pharmacol.Exp.Ther. 285 724. PMID:9580619. Wang et al (2000) Molecular basis for differential sensitivity of KCNQ and IKs channels to the cognitive enhancer XE991. Mol.Pharmacol. 57 1218. PMID:10825393. Passmore et al (2003) KCNQ/M currents in sensory neurons: significance for pain therapy. J.Neurosci. 23 7227. PMID:12904483."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=5482	SQ1341			Feb-2004
2001	GS 39783	[39069-52-8]	CSC1=NC(NC2CCCC2)=C(C(NC2CCCC2)=N1)[N+]([O-])=O	Positive modulator at GABAB receptors	"Novel positive allosteric modulator of GABAB receptor function. Potentiates the effects of GABA on [35S]GTP_S binding at recombinant and native GABAB receptors (EC50 values are 2.1 and 3.1_M respectively). Decreases cocaine self-administration, blocks the rewarding properties of nicotine and produces anxiolytic-like activity without the side effects associated with baclofen or benzodiazepines."	"Urwyler et al (2003) N,N'-Dicyclopentyl-2-methylsulfanyl-5-nitro-pyrimidine-4,6-diamine (GS39783) and structurally related compounds: novel allosteric enhancers of _-aminobutyric acidB receptor function. J.Pharmacol.Exp.Ther. 307 322. PMID:12954816. Cryan et al (2004) Behavioral characterization of the novel GABAB receptor-positive modulator GS39783 (N,N'-dicyclopentyl-2-methylsulfanyl-5-nitro-pyrimidine-4,6-diamine: anxiolytic-like activity without side effects associated with baclofen or benzodiazepines. J.Pharmacol.Exp.Ther. 310 952. PMID:15113848. Mombereau et al (2007) GABAB receptor-positive modulation-induced blockade of the rewarding effects of nicotine is associated with a reduction in nucleus accumbens _FosB accumulation. J.Pharmacol.Exp.Ther. 321 172. PMID:17215447."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=93120	SQ1341			May-2004
2002	Ro 31-8220 mesylate	[138489-18-6]	CS(O)(=O)=O.CN1C=C(C2=CC=CC=C12)C1=C(C(=O)NC1=O)C1=CN(CCCSC(N)=N)C2=CC=CC=C12	Protein kinase inhibitor	"Protein kinase C inhibitor, with activity at other protein kinases (IC50 values are 33, 3, 8, 15 and 38 nM for PKC_, MAPKAP-K1b, MSK1, GSK3_ and S6K1 respectively). Activates JNK and glycogen synthase, and inhibits MAPK and ERK2, in rat adipocytes and L6 myotubes. Also inhibits voltage-dependent Na+ channels in the micromolar range."	"Davis et al (1989) Potent, selective inhibitors of protein kinase C. FEBS Lett. 259 61. PMID:2532156. Standaert et al (1999) RO 31-8220 activates c-Jun N-terminal kinase and glycogen synthase in rat adipocytes and L6 myotubes. Comparison to actions of insulin. Endocrinology 150 2145. Lingameneni et al (2000) Inhibition of voltage-dependent sodium channels by Ro 31-8220, a 'specific' protein kinase C inhibitor. FEBS Lett. 473 265. PMID:10812087. Davies et al (2000) Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem.J. 351 95. PMID:10998351."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=93121	SQ1070			Aug-2005
2004	Isradipine	[75695-93-1]	COC(=O)C1=C(C)NC(C)=C(C1C1=CC=CC2=NON=C12)C(=O)OC(C)C	Ca2+ channel blocker (L-type)	"Potent and selective L-type voltage-gated Ca2+ channel blocker. EC50 and pA2 values are 1.4 nM and 10.3 for relaxation of depolarization- and Ca2+-induced contractions of rabbit aorta respectively; EC25 = 0.45 nM for reduction in rate of spontaneously beating guinea pig right atria. Long-acting antihypertensive agent in vivo, exerting primary effects on vascular tissue with secondary negative chronotropic action."	"Hof et al (1984) PN 200-110, a new calcium antagonist: electrophysiological, inotropic, and chronotropic effects on guinea pig myocardial tissue and effects on contraction and calcium uptake of rabbit aorta. J.Cardiovasc.Pharmacol. 6 399. PMID:6202964. Wada et al (1985) Separation of the coronary vasodilator from the cardiac effects of PN 200-110, a new dihydropyridine calcium antagonist, in the dog heart. J.Cardiovasc.Pharmacol. 7 190. PMID:2580142. Ruegg and Hof (1990) Pharmacology of the calcium antagonist isradipine. Drugs 40 3."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=40282	SQ1533			Feb-2004
2005	Ro 04-5595 hydrochloride	[64047-73-0]	Cl.COC1=CC2=C(C=C1O)C(CCC1=CC=C(Cl)C=C1)N(C)CC2	Selective NR2B antagonist	Selective antagonist for NR2B-containing NMDA receptors (Ki = 31 nM).	"Mutel et al (1998) In vitro binding properties in rat brain of [3H] Ro 25-6981, a potent and selective antagonist of NMDA receptors containing NR2B subunits. J.Neurochem. 70 214."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=93381	SQ1341			Feb-2006
2006	Paxilline	[57186-25-1]	[H][C@@]4([C@](C)3[C@]5(C)[C@@](C([C@]6([H])CC5)=CC([C@@H]([C@](O)(C)C)O6)=O)(O)CC4)CC2=C3NC1=CC=CC=C12	SERCA ATPase blocker. Also potent BKCa channel blocker	"Potent blocker of high-conductance Ca2+-activated K+ (BKCa, KCa1.1) channels. Binds to the _-subunit of BKCa (Ki = 1.9 nM for block of currents in _-subunit-expressing oocytes) and enhances binding of charybdotoxin to BKCa channels in vascular smooth muscle. Also inhibits sarco/endoplasmic reticulum Ca2+-ATPase (IC50 = 5 - 50 _M)."	Knaus et al (1994) Tremorgenic indole alkaloids potently inhibit smooth muscle high-conductance calcium-activated potassium channels. Biochemistry 33 5819. PMID:7514038. Sanchez and McManus (1996) Paxilline inhibition of the alpha-subunit of the high-conductance calcium-activated potassium channel. Neuropharmacology 35 963. PMID:8938726. Bilmen et al (2002) The mechanism of inhibition of the sarco/endoplasmic reticulum Ca2+ ATPase by paxilline. Arch.Biochem.Biophys. 406 55. PMID:12234490.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=93414	SQ1070			Feb-2004
2007	Fluticasone propionate	[80474-14-2]	O=C1C=C[C@@]2(C)C([C@@H](F)C[C@]3([H])[C@@](F)2[C@@H](O)C[C@@]4(C)[C@]([H])3C[C@@H](C)[C@](C(SCF)=O)4OC(CC)=O)=C1	Selective high affinity glucocorticoid agonist	"High affinity, selective glucocorticoid receptor agonist (Kd = 0.5 nM). Potently stimulates glucocorticoid receptor-mediated transactivation of gene expression and enhances human eosinophil apoptosis (EC50 = 3.7 nM) in vitro. Inhibits mast cell accumulation in nasal mucosa following topical administration. Lipophilic anti-inflammatory agent with low oral bioavailability. Also potentiates KV1 channels (EC50 = 37 nM)."	"Johnson (1995) The anti-inflammatory profile of fluticasone propionate. Allergy 50 11. PMID:7604948. Smith and Kreutner (1998) In vitro glucocorticoid receptor binding and transcriptional activation by topically active glucocorticoids. Arzneim.-Forsch. 48 956. Zhang et al (2000) Enhancement of human eosinophil apoptosis by fluticasone propionate, budesonide, and beclomethasone. Eur.J.Pharmacol. 406 325. PMID:11040338. Pan et al (2012) Potentiation of the Kv1 family K+ channel by cortisone analogues. ACS Chem.Biol. 7 1641. PMID:22803826."	Small Molecule	Sold for research purposes under agreement from GlaxoSmithKline	http://www.tocris.com/dispprod.php?ItemId=93860	SQ1533			Feb-2004
2008	SKF 86002 dihydrochloride	[116339-68-5]	Cl.Cl.FC1=CC=C(C=C1)C1=C(N2CCSC2=N1)C1=CC=NC=C1	p38 MAPK inhibitor; anti-inflammatory agent	Inhibitor of p38 MAP kinase (IC50 = 0.1 - 1 _M). Potently inhibits LPS-induced IL-1 and TNF-_ production in human monocytes (IC50 = 1 _M). Also inhibits 5-lipoxygenase- and cyclooxygenase-mediated arachidonic acid metabolism in RBL-1 cells (IC50 values are 10 and 100 _M respectively). Anti-inflammatory following oral administration in vivo.	Griswold et al (1987) SK&F 86002: a structurally novel anti-inflammatory agent that inhibits lipoxygenase- and cyclooxygenase-mediated metabolism of arachidonic acid. Biochem.Pharmacol. 36 3463. PMID:2823821. Lee et al (1994) A protein kinase involved in the regulaton of inflammatory cytokine biosynthesis. Nature 372 739. PMID:7997261. Nick et al (1997) Common and distinct intracellular signaling pathways in human neutrophils utilized by platelet activating factor and FMLP. J.Clin.Invest. 99 975. PMID:9062356.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=93894	SQ1341			Apr-2005
2009	PSB 1115	[152529-79-8]	O=C(NC2=C1NC(C3=CC=C(S(=O)(O)=O)C=C3)=N2)N(CCC)C1=O	Selective human A2B receptor antagonist; water-soluble	"Highly selective, water-soluble, human A2B adenosine receptor antagonist. Ki values are 53.4, > 10000 and > 10000 nM at human A2B, A1 and A3 receptors respectively. Also selective versus rat A1 and A2A receptors (Ki values are 2200 and 24000 nM respectively). Produces potent analgesic effects in vivo."	"Muller et al (1998) 8-(Sulfostyryl)xanthines: water-soluble A2A-selective adenosine receptor antagonists. Bioorg.Med.Chem. 6 707. PMID:9681137. Hayallah et al (2002) 1,8-Disubstituted xanthine derivatives: synthesis of potent A2B-selective adenosine receptor antagonists. J.Med.Chem. 45 1500. PMID:11906291. Abo-Salem et al (2004) Antinociceptive effects of novel A2B adenosine receptor antagonists. J.Pharmacol.Exp.Ther. 308 358. PMID:14563788. Yan and Muller (2004) Preparation, properties, reactions, and adenosine receptor affinities of sulfophenylxanthine nitrophenyl esters: toward the development of sulfonic acid prodrugs with peroral bioavailability. J.Med.Chem. 47 1031. PMID:14761205."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=93895	SQ1341			May-2004
2010	PSB 10 hydrochloride	[591771-91-4]	CC[C@H](C3)N=C1N3C(N(C)C2=C1NC(C4=C(Cl)C(Cl)=CC(Cl)=C4)=N2)=O.Cl	"Potent, highly selective hA3 receptor antagonist/inverse agonist"	"Potent and highly selective antagonist for the human adenosine A3 receptor, with low affinity for the rat A3 receptor (Ki values are 0.44 and > 17000 nM respectively). Displays > 3800-fold selectivity over human A1, A2A and A2B receptors (Ki values are 4.1, 3.3 and 30 _M respectively) and > 1800-fold selectivity over rat A1 and A2A receptors. Acts as an inverse agonist in the [35S]GTP_S binding assay in hA3-CHO cells (IC50 = 4 nM). Produces thermal hyperalgesia in mice in vivo."	"Muller (2003) Medicinal chemistry of adenosine A3 receptor ligands. Curr.Top.Med.Chem. 3 445. PMID:12570761. Ozola et al (2003) 2-Phenylimidazo[2,1-i]purin-5-ones: structure-activity relationships and characterization of potent and selective inverse agonists at human A3 adenosine receptors. Bioorg.Med.Chem. 11 347. PMID:12517430. Abo-Salem et al (2004) Antinociceptive effects of novel A2B adenosine receptor antagonists. J.Pharmacol.Exp.Ther. 308 358. PMID:14563788."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=93896	SQ1341			Aug-2005
2011	Tomoxetine hydrochloride	[82248-59-7]	Cl[H].CNCC[C@@H](OC1=C(C)C=CC=C1)C1=CC=CC=C1	"Potent, selective noradrenalin re-uptake inhibitor"	"Potent and selective noradrenalin re-uptake inhibitor (Ki values are 5, 77 and 1451 nM for inhibition of radioligand binding to human NET, SERT and DAT respectively). Displays minimal affinity for a range of other neurotransmitter receptors and transporters (Ki > 1 _M). Antidepressant."	Wong et al (1982) A new inhibitor of norepinephrine uptake devoid of affinity for receptors in rat brain. J.Pharmacol.Exp.Ther. 222 61. PMID:6123593. Bymaster et al (2002) Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology 27 699. PMID:12431845.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=93926	SQ1533			Aug-2004
2012	PSB 11 hydrochloride	[453591-58-7]	Cl[H].CC[C@@H]1CN2C(=N1)C1=C(N=C(N1)C1=CC=CC=C1)N(C)C2=O	"Potent, selective hA3 receptor antagonist/inverse agonist"	"Potent and selective antagonist for the human adenosine A3 receptor, with low affinity for the rat A3 receptor (Ki values are 2.3 and > 10000 nM respectively). Displays > 1000-fold selectivity over human A1 and A2A receptors (Ki values are 4.1 and 3.3 _M respectively) and > 180-fold selectivity over rat A1, rat A2A and mouse A2B receptors. Acts as an inverse agonist in the [35S]GTP_S binding assay in hA3-CHO cells (IC50 = 36 nM)."	"Muller et al (2002) Imidazo[2,1-i]purin-5-ones and related tricyclic water-soluble purine derivatives: potent A2A- and A3-adenosine receptor antagonists. J.Med.Chem. 45 3440. PMID:12139454. Muller (2003) Medicinal chemistry of adenosine A3 receptor ligands. Curr.Top.Med.Chem. 3 445. PMID:12570761. Ozola et al (2003) 2-Phenylimidazo[2,1-i]purin-5-ones: structure-activity relationships and characterization of potent and selective inverse agonists at human A3 adenosine receptors. Bioorg.Med.Chem. 11 347. PMID:12517430."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=93933	SQ1341			Jan-2005
2013	Guggulsterone	[95975-55-6]	[H][C@@]12CC(=O)C(=CC)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C	Broad spectrum steroid receptor ligand. Antagonizes FXR and displays hypolipidemic activity	"Broad spectrum steroid receptor ligand; binds with high affinity to mineralocorticoid receptors (Ki = 39 nM) and lower affinity to progesterone, androgen and glucocorticoid receptors (Ki values are 201, 240 and 224 nM respectively). Functions primarily as an antagonist of these receptors, with the exception of the progesterone receptor where it displays partial agonist effects. Also exerts hypolipidemic activity, likely via antagonism of the receptor for bile acids (farnesoid X receptor; FXR)."	Owsley and Chiang (2003) Guggulsterone antagonizes farnesoid X receptor induction of bile salt export pump but activates pregnane X receptor to inhibit cholesterol 7_-hydroxylase gene. Biochem.Biophys.Res.Comm. 304 191. Burris et al (2005) The hypolipidemic natural product guggulsterone is a promiscuous steroid receptor ligand. Mol.Pharmacol. 67 948. PMID:15602004. Meyer et al (2005) Is antagonism of E/Z-guggulsterone at the farnesoid X receptor mediated by a noncanonical binding site? A molecular modeling study. J.Med.Chem. 48 6948. PMID:16250653.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=93935	SQ1070			Apr-2006
2018	Mirtazapine	[85650-52-8]	CN1CCN2C(C1)C1=CC=CC=C1CC1=C2N=CC=C1	"Potent 5-HT2 antagonist. Also 5-HT3, H1 and _2-antagonist. Antidepressant"	"Antidepressant agent; potent 5-HT2, 5-HT3 and histamine H1 receptor antagonist and moderately potent _2-adrenoceptor antagonist (pKi values are 8.05, ~ 8.1, 9.3 and 6.95 respectively). Enhances noradrenalin (NA) release in rat brain via inhibition of _2-adrenergic autoreceptors and displays only weak affinity for monoamine transporters (pKi values are 5.6, < 5 and < 5.1 for inhibition of NA, dopamine and 5-HT uptake respectively). Increases hippocampal NA and 5-HT levels in rats following systemic administration in vivo."	"de Boer et al (1988) Neurochemical and autonomic pharmacological profiles of the 6-aza-analogue of mianserin, ORG 3770 and its enantiomers. Neuropharmacology 27 399. PMID:3419539. Kooyman et al (1994) Interaction between enantiomers of mianserin and ORG3770 at 5-HT3 receptors in cultured mouse neuroblastoma cells. Neuropharmacology 33 501. PMID:7984289. de Boer et al (1996) Differences in modulation of noradrenergic and serotonergic transmission by the alpha-2 adrenoceptor antagonists, mirtazepine, mianserin and idazoxan. J.Pharmacol.Exp.Ther. 277 852. PMID:8627567."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=95394	SQ1533			Aug-2004
2019	PSB 36	[524944-72-7]	CCCCN1C(=O)N(CCCO)C2=C(NC(=N2)C23CC4CC2CC(C3)C4)C1=O	Potent and selective A1 antagonist	"Potent and selective A1 adenosine receptor antagonist. Displays binding affinities of 0.12, 187, 552, 6500 and 2300 nM for rA1, hA2B, rA2A, rA3 and hA3 receptors respectively. Demonstrates greater selectivity than DPCPX (Cat. No. 0439)."	"Abo-Salem et al (2004) Antinociceptive effects of novel A2B adenosine receptor antagonists. J.Pharmacol.Exp.Ther 308 358. PMID:14563788. Weyler et al (2006) Improving potency, selectivity, and water solubility of adenosine A1 receptor antagonists: xanthines modified at position 3 and related pyrimido[1,2,3-cd]purinediones. Chem.Med.Chem. 1 891."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=95401	SQ1341			Mar-2006
2020	Ch 55	[110368-33-7]	CC(C)(C)C1=CC(=CC(=C1)C(=O)\C=C\C1=CC=C(C=C1)C(O)=O)C(C)(C)C	Potent RAR agonist	Highly potent synthetic retinoid that has high affinity for RAR-_ and RAR-_ receptors and low affinity for cellular retinoic acid binding protein (CRABP). Inhibits rabbit tracheal epithelial cell differentiation by inhibiting transglutaminase and increasing cholesterol sulfate (EC50 values are 0.02 and 0.03 nM respectively). Induces differentiation of embryonic carcinoma F9 and melanoma S91 cells (EC50 values are 0.26 and 0.5 nM respectively) and inhibits the induction of ornithine decarboxylase activity in 3T6 fibroblasts (EC50 = 1 nM).	Jetten et al (1987) New benzoic acid derivatives with retinoid activity: lack of direct correlation between biological activity and binding to cellular retinoic acid binding protein. Cancer Res. 47 3523. PMID:2884032. Sato et al (1988) Functional studies of newly sythesized benzoic acid derivatives: identification of highly potent retinoid-like activity. J.Cell.Physiol. 135 179. PMID:2836439. Hashimoto et al (1990) Expression of retinoic acid receptor genes and the ligand-binding selectivity of retinoic acid receptors (RAR's). Biochem.Biophys.Res.Comm. 166 1300.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=99202	SQ1341			Sep-2004
2021	LE 135	[155877-83-1]	CN1C2=C(C=C3C(=C2)C(C)(C)CCC3(C)C)N=C(C2=CC=C(C=C2)C(O)=O)C2=C1C=CC=C2	Selective RAR_ antagonist	Retinoic acid antagonist; displays moderate selectivity for RAR_ over RAR_ (Ki values are 0.22 and 1.4 _M respectively). Highly selective over RAR_ and RXR_. Inhibits human HL-60 leukemia cell differentiation induced by Am80 (IC50 = 150 nM).	Eyrolles et al (1994) Retinobenzoic acids. 6. Retinoid antagonists with heterocyclic ring. J.Med.Chem. 37 1508. PMID:8182710. Umemiya et al (1997) Regulation of retinoidal actions by diazepinylbenzoic acids. Retinoid synergists which activate the RXR-RAR heterodimers. J.Med.Chem. 40 4222. PMID:9435893. Li et al (1999) Identification of a novel class of retinoic acid receptor _-selective retinoid antagonists and their inhibitory effects on AP-1 activity and retinoic acid-induced apoptosis in human breast cancer cells. J.Biol.Chem. 274 15360. PMID:10336422.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=99208	SQ1341			Dec-2004
2022	SR 202	[76541-72-5]	COP(=O)(OC)OC(C1=CC=C(Cl)C=C1)P(=O)(OC)OC	Selective PPAR_ antagonist; antidiabetic and antiobesity agent	"Selective PPAR_ antagonist; antidiabetic and antiobesity agent. Attenuates troglitazone-induced PPAR_ transcriptional activity (IC50 = 140 _M) without affecting ligand-stimulated PPAR_, PPAR_ or FXR transcriptional activity. Inhibits PPAR_-dependent adipocyte differentiation and growth in vitro and in vivo. Improves insulin sensitivity in diabetic ob/ob mice and increases HDL levels in rats in vivo."	Nguyen et al (1987) gem-Diphosphonate and gem-phosphonate-phosphate compounds with specific high density lipoprotein inducing activity. J.Med.Chem. 30 1426. PMID:3612689. Rieusset et al (2002) A new selective peroxisome proliferator-activated receptor _ antagonist with antiobesity and antidiabetic activity. Mol.Endocrinol. 16 2628. PMID:12403851. Doggrell (2003) Do peroxisome proliferation receptor-_ antagonists have clinical potential as combined antiobesity and antidiabetic drugs? Expert.Opin.Invest.Drugs 12 713.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=99402	SQ1533			Jan-2005
2025	Cinalukast	[128312-51-6]	CCC(CC)(CC(=O)NC1=CC(\C=C\C2=NC(=CS2)C2CCC2)=CC=C1)C(O)=O	"Potent, selective CysLT1 (LTD4) antagonist; orally active"	"Potent, selective CysLT1 (LTD4) leukotriene receptor antagonist (IC50 = 6.4 nM). Inhibits LTD4-induced bronchoconstriction in guinea pigs when administered intravenously, orally or by aerosol."	"O'Donnell (1991) Ro 24-5913: a potent, specific, orally active LTD4 antagonist. Ann.N.Y.Acad.Sci. 629 413. PMID:1659286. O'Donnell et al (1991) Pharmacologic actions of Ro 24-5913, a novel antagonist of leukotriene D4. J.Pharmacol.Exp.Ther. 259 751. PMID:1658310."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=99811	SQ1533			Dec-2004
2033	Pentostatin	[53910-25-1]	O[C@@H]1[C@@H](CO)O[C@@H](N2C(N=CNC[C@H]3O)=C3N=C2)C1	Adenosine deaminase inhibitor	Irreversible inhibitor of adenosine deaminase (Ki = 2.5 pM). Anticancer agent.	Klohs and Kraker (1992) Pentostatin: future directions. Pharmacol.Rev. 44 459. PMID:1480666. Nabhan et al (2004) Purine nucleoside analogues and combination therapies in B-cell chronic lymphocytic leukemia: dawn of a new era. Leukemia Res. 28 429.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=100409	SQ1070			Feb-2008
2034	ROS 234 dioxalate	[184576-87-2]	O=C(O)C(O)=O.O=C(O)C(O)=O.C1(CCCNC2=NC3=C(C=CC=C3)N2)=CNC=N1	Potent H3 antagonist	Potent H3 antagonist (pKB at guinea-pig ileum H3-receptor = 9.46). Limited blood brain barrier permeability (ED50 = 19.12 mg/kg i.p.).	"Ballabeni et al (2002) CNS access of selected H3-antagonists: ex vivo binding study in rats. Inflamm.Res. 51 (Suppl 1) S55. PMID:12013409. Mor et al (2004) Synthesis, biological activity, QSAR and QSPR study of 2-aminobenzimidazole derivatives as potent H3-antagonists. Bioorg.Med.Chem.Lett. 12 663."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=100223	SQ1341			Aug-2007
2037	SDZ 205-557 hydrochloride	[1197334-02-3]	Cl.CCN(CC)CCOC(=O)C1=CC(Cl)=C(N)C=C1OC	5-HT4/5-HT3 receptor antagonist	5-HT3/5-HT4 receptor antagonist.	"Buchheit et al (1992) SDZ 205-557, a selective, surmountable antagonist for 5-HT4 receptors in the isolated guinea pig ileum. Naunyn-Schmied.Arch.Pharmacol. 345 387. Eglen et al (1993) The action of SDZ 205,557 at 5-hydroxytryptamine (5-HT3 and 5-HT4) receptors. Br.J.Pharmacol. 108 376. PMID:8448587. McMahon and Cunningham (1999) Antagonism of 5-hydroxytryptamine(4) receptors attenuates hyperactivity induced by cocaine: putative role for 5-hydroxytryptamine(4) receptors in the nucleus accumbens shell. J.Pharmacol.Exp.Ther. 291 300. PMID:10490917."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=100658	SQ1341			Nov-2005
2039	CI 898 trihydrochloride	[82952-64-5]	NC1=NC(N)=NC(C=C3)=C1C(C)=C3CNC2=CC(OC)=C(OC)C(OC)=C2.Cl.Cl.Cl	Dihydrofolate reductase inhibitor	"Potent lipophilic inhibitor of dihydrofolate reductase (DHFR) that displays antineoplastic and antiprotozoal properties. Inhibits protozoal, bacterial and human DHFR with IC50 values of 1.4, 6.1 and 3.2 nM respectively. Affects G1/S phase cell cycle progression."	Hook et al (1986) Cell cycle effects of trimetrexate (CI-898). Cancer Chemother.Pharmacol. 16 116. PMID:2936525. Allegra et al (1987) Potent in vitro and in vivo antitoxoplasma activity of the lipid-soluble antifolate trimetrexate. J.Clin.Invest. 79 478. PMID:2948969. Chan and Anderson (2006) Towards species-specific antifolates. Curr.Med.Chem. 13 377. PMID:16475929.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=100815	SQ1533			Nov-2006
2072	Aminopurvalanol A	[220792-57-4]	ClC1=CC(N)=CC(NC2=C3C(N(C(C)C)C=N3)=NC(N[C@H]([C@@H](C)C)CO)=N2)=C1	Cyclin-dependent kinase inhibitor	"Cell-permeable cyclin-dependent kinase inhibitor. IC50 values are 0.033, 0.033, 0.028 and 0.020 _M for cdk1/cyclin B, cdk2/cyclin A, cdk2/cyclin E, and cdk5/p35 respectively. Inhibits ERK1 (IC50 = 12.0 _M) and ERK2 (IC50 = 3.1 _M) and is 3000-fold selective over a range of other protein kinases (IC50 > 100 _M). Arrests cell cycle at G2/M boundary (IC50 = 1.25 _M), and induces apoptosis at concentrations > 10 _M."	"Chang et al (1999) Synthesis and application of functionally diverse 2,6,9-trisubstituted purine libraries as CDK inhibitors. Chem.Biol. 6 361. PMID:10375538. Rosiana et al (1999) A cyclin-dependent kinase inhibitor inducing cancer cell differentiation: biochemical identification using Xenopus egg extracts. Proc.Natl.Acad.Sci.USA 96 4797. Knockaert et al (2000) Intracellular targets of cyclin-dependent kinase inhibitors: identification by affinity chromatography using immobilised inhibitors. Chem.Biol. 7 411. PMID:10873834."	Small Molecule	Sold under license from the Regents of the University of California	http://www.tocris.com/dispprod.php?ItemId=102615	SQ1341			Jun-2004
2073	(R)-(-)-Apomorphine hydrochloride	[314-19-2]	OC1=C2C(C[C@]4([H])C3=C2C=CC=C3CCN4C)=CC=C1O.Cl	Dopamine agonist; non-subtype-selective	"Prototypical dopamine agonist (pKi values are 6.43, 7.08, 7.59, 8.36 and 7.83 for human recombinant D1, D2L, D3, D4 and D5 receptors respectively). Produces biphasic effects on locomotor activity, and displays anti-Parkinsonian and neuroprotective actions following systemic administration in vivo."	Liu et al (1996) Low doses of apomorphine suppress operant motor performance in rats. Pharmacol.Biochem.Behav. 53 335. PMID:8808141. Grunblatt et al (1999) Apomorphine protects against MPTP-induced neurotoxicity in mice. Mov.Disord. 14 612. PMID:10435498. Millan et al (2002) Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes. J.Pharmacol.Exp.Ther. 303 791. PMID:12388666.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=103280	SQ1533			Apr-2004
2074	SKF 83959 hydrobromide	[67287-95-0]	Br.CN1CCC2=C(C=C(O)C(O)=C2Cl)C(C1)C1=CC(C)=CC=C1	D1-like partial agonist	"Dopamine D1-like receptor partial agonist (Ki values are 1.18, 7.56, 920 and 399 nM for rat D1, D5, D2 and D3 receptors respectively). May act as an antagonist in vivo, producing anti-Parkinsonian effects and antagonizing the behavioral effects of cocaine. Shown to potentiate agonist binding of the _1 receptor."	Platt et al (2000) Dissociation of cocaine-antagonist properties and motoric effects of the D1 receptor partial agonists SKF 83959 and SKF 77434. J.Pharmacol.Exp.Ther. 293 1017. PMID:10869406. Cools et al (2002) SKF 83959 is an antagonist of dopamine D1-like receptors in the prefrontal cortex and nucleus accumbens: a key to its antiparkinsonian effect in animals? Neuropharmacology 42 237. PMID:11804620. Neumeyer et al (2003) Receptor affinities of dopamine D1 receptor-selective novel phenylbenzazepines. Eur.J.Pharmacol. 474 137. PMID:12921854. Guo et al (2013) SKF83959 is a potent allosteric modulator of sigma-1 receptor. Mol.Pharmacol. 83 577. PMID:23295385.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=103281	SQ1341			Apr-2004
2075	SKF 83822 hydrobromide	[74115-10-9]	ClC1=C(O)C(O)=CC2=C1CCN(CC=C)CC2C3=CC=CC(C)=C3.Br	Selective D1-like agonist	"High affinity, selective dopamine D1-like receptor agonist. Ki values are 3.2, 3.1, 186, 66, 335, 1167, 1251 and 1385 nM at recombinant D1, D5, D2, D3, D4, 5-HT2A, _1A and _1B receptors respectively. Stimulates adenylyl cyclase (EC50 = 65 nM) but not phosphoinositide hydrolysis. Induces extreme arousal and hyperlocomotion following subcutaneous administration in monkeys."	Undie et al (1994) Evidence for a distinct D1-like dopamine receptor that couples to activation of phosphoinositide metabolism in brain. J.Neurochem. 62 2045. PMID:7908949. Peacock and Gerlach (2001) Aberrant behavioural effects of a dopamine D1 receptor antagonist and agonist in monkeys: evidence of uncharted dopamine D1 receptor actions. Biol.Psychiatry 50 501. PMID:11600103. O'Sullivan et al (2004) SK&F 83822 distinguishes adenylyl cyclase from phospholipase C-coupled D1-like receptors: behavioural topography. Eur.J.Pharmacol. 486 273. PMID:14985049.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=103282	SQ1341			Feb-2005
2076	Y-26763	[127408-31-5]	CC(=O)N(O)[C@H]1[C@H](O)C(C)(C)OC2=C1C=C(C=C2)C#N	Kir6 (KATP) channel opener	Kir6 (KATP) channel opener and active metabolite of Y-27152 (Cat. No. 2077). Relaxes contracted rat aortic rings (IC50 = 0.027 mM) and inhibits glucose-induced insulin secretion in isolated human pancreatic _-cells in vitro. Produces hypotension in spontaneously hypertensive rats and displays cardioprotective properties in dogs following systemic administration in vivo.	"Nakajima et al (1992) Y-27152, a long-acting K+ channel opener with less tachycardia: antihypertensive effects in hypertensive rats and dogs in conscious state. J.Pharmacol.Exp.Ther. 261 730. PMID:1578381. Fukunari et al (1997) Y-26763 protects the canine heart from a stunning injury through opening of the KATP channels Eur.J.Pharmacol. 323 197. PMID:9128839. Cosgrove et al (2004) Y-26763: ATP-sensitive K+ channel activation and the inhibition of insulin release from human pancreatic _-cells Eur.J.Pharmacol. 486 133. PMID:14975702."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=103301	SQ1070			Feb-2005
2077	Y-27152	[127408-30-4]	CC(=O)N(OCC1=CC=CC=C1)[C@H]1[C@H](O)C(C)(C)OC2=C1C=C(C=C2)C#N	Prodrug of Kir6 (KATP) channel opener Y-26763 (Cat. No. 2076); orally active in vivo	"Prodrug of the Kir6 (KATP) channel opener Y-26763 (Cat. No. 2076). Inactive in vitro; fails to modify tension in contracted aortic rings at concentrations up to 1 mM. Produces long-lasting antihypertensive effects in vivo, with minimal tachycardia following oral administration in hypertensive animals."	"Nakajima et al (1992) Y-27152, a long-acting K+ channel opener with less tachycardia: antihypertensive effects in hypertensive rats and dogs in conscious state. J.Pharmacol.Exp.Ther. 261 730. PMID:1578381. Fukunari et al (1997) Y-26763 protects the canine heart from a stunning injury through opening of the KATP channels. Eur.J.Pharmacol. 323 197. PMID:9128839."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=103302	SQ1341			Jan-2005
2078	UBP 296	[745055-86-1]	NC(CN1C=CC(=O)N(CC2=C(C=CC=C2)C(O)=O)C1=O)C(O)=O	"Selective, potent kainate antagonist; selective for GluR5-containing receptors"	Selective GluR5-subunit containing kainate receptor antagonist (apparent KD = 1.09 _M). Displays ~ 90-fold selectivity over AMPA receptors and recombinant human GluR6- and KA2-containing kainate receptors. Has little or no action at NMDA or group I mGlu receptors. Selectively blocks kainate receptor-mediated LTP induction in rat hippocampal mossy fibers. Active enantiomer UBP 302 (Cat. No. 2079) available.	"More et al (2004) Characterisation of UBP296: a novel, potent and selective kainate receptor antagonist. Neuropharmacology 47 46. PMID:15165833. Dolman et al (2005) Synthesis and pharmacology of willardiine derivatives acting as antagonists of kainate receptors. J.Med.Chem. 48 7867. PMID:16302825."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=103552	SQ1341			Jul-2004
2079	UBP 302	[745055-91-8]	O=C(C=CN(C[C@H](N)C(O)=O)C2=O)N2CC1=CC=CC=C1C(O)=O	Potent and selective kainate antagonist; active enantiomer of UBP 296 (Cat. No. 2078)	"Potent and selective GLUK5 (GluR5)-subunit containing kainate receptor antagonist (apparent KD = 402 nM); active enantiomer of UBP 296 (Cat. No. 2078). Displays ~ 260-fold selectivity over AMPA receptors, ~ 90-fold selectivity over recombinant human GLUK6- and GLUK2-containing kainate receptors and has little or no action at NMDA or group I mGlu receptors. Selectively blocks kainate receptor-mediated LTP induction in rat hippocampal mossy fibers. Also protects against soman-induced seizures and neuronal degeneration for up to 30 days when administered one hour after soman exposure."	"More et al (2004) Characterisation of UBP296: a novel, potent and selective kainate receptor antagonist. Neuropharmacology 47 46. PMID:15165833. Dolman et al (2005) Synthesis and pharmacology of willardiine derivatives acting as antagonists of kainate receptors. J.Med.Chem. 48 7867. PMID:16302825. Apland et al (2014) The Limitations of Diazepam as a Treatment for Nerve Agent-Induced Seizures and Neuropathology in Rats: Comparison with UBP302. J.Pharmacol.Exp.Ther. 351 359. PMID:25157087."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=103553	SQ1341			Aug-2004
2085	Galnon	[475115-35-6]	CC1=CC(=O)OC2=C1C=CC(NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC1CCCCC1)NC(=O)OCC1C3=CC=CC=C3C3=C1C=CC=C3)=C2	Non-selective galanin receptor agonist	Novel non-peptide galanin GAL1 and GAL2 receptor agonist (Ki values are 11.7 and 34.1 _M respectively). Stimulates insulin release in isolated pancreatic islets from normal and diabetic rats. Systemically active in vivo; displays anticonvulsant activity following i.p. administration in mice. Central and peripheral administration also transiently inhibits food intake in rats and mice.	"Saar et al (2002) Anticonvulsant activity of a nonpeptide galanin receptor agonist Proc.Natl.Acad.Sci.USA 99 7136. PMID:12011470. Abramov et al (2004) Regulation of feeding by galnon. Neuropeptides 38 55. PMID:15003717. Lu et al (2005) A role for galanin in antidepressant actions with a focus on the dorsal raphe nucleus. Proc.Natl.Acad.Sci. 102 874. PMID:15647369. Quynh et al (2005) Effects of galnon, a non-peptide galanin-receptor agonist, on insulin release from rat pancreatic islets. Biochem.Biophys.Res.Comm. 328 213. PMID:15670772."	Peptide		http://www.tocris.com/dispprod.php?ItemId=104011	SQ1341			Jun-2005
2086	GTP 14564	[34823-86-4]	N1N=C(C2=C1C1=C(O2)C=CC=C1)C1=CC=CC=C1	Class III receptor tyrosine kinase (RTK) inhibitor	"Potent, selective inhibitor of class III receptor tyrosine kinases (IC50 values are 0.3 _M for c-Fms, c-Kit, FLT3 and ITD-FLT3 and 1 _M for PDGFR_). Displays no activity against ERK1, ERK2, EGFR, MEK1, HER2, Src, Abl, PKC, PKA and Akt (IC50 > 10 _M). Inhibits FL-dependent proliferation in BaF/ITD-FLT3 cells more potently than BaF/wt-FLT3 cells; anti-leukemic."	"Murata et al (2003) Selective cytotoxic mechanism of GTP-14564, a novel tyrosine kinase inhibitor in leukemia cells expressing a constitutively active Fms-like tyrosine kinase 3 (FLT3). J.Biol.Chem. 278 32892. PMID:12815052. Yao et al (2005) Human leukemias with mutated FLT3 kinase are synergistically sensitive to FLT3 and Hsp90 inhibitors: the key role of the STAT5 signal transduction pathway. Leukemia 19 1605. PMID:16034464."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=104019	SQ1341			Sep-2006
2088	DMNB	[20357-25-9]	COC1=C(OC)C=C(C(C=O)=C1)[N+]([O-])=O	DNA-PK inhibitor	"Inhibitor of DNA-dependent protein kinase (DNA-PK) (IC50 = 15 _M), an enzyme involved in the non-homologous end-joining (NHEJ) pathway of double-stranded DNA break (DSB) repair in human cells. Displays 100-fold higher potency than its analog vanillin and does not affect PKC activity. Produces lethal effects on cisplatin-treated D5037 cells upon continuous exposure."	Durant and Karran (2003) Vanillins - a novel family of DNA-PK inhibitors. Nucleic Acids Res. 31 5501. PMID:14500812.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=104030				Sep-2004
2089	RS 102895 hydrochloride	[1173022-16-6]	Cl.FC(F)(F)C1=CC=C(CCN2CCC3(CC2)OC(=O)NC2=CC=CC=C32)C=C1	CCR2b chemokine receptor antagonist	"CCR2-selective chemokine receptor antagonist (IC50 values are 0.36 and 17.8 _M for inhibition of human recombinant CCR2b and CCR1 receptors respectively). Blocks MCP-1-stimulated calcium influx and chemotaxis with IC50 values of 32 nM and 1.7 _M respectively. Also inhibits _1A, _1D and 5-HT1A receptors."	"Clark et al (1983) Synthesis and antihypertensive activity of 4'-substituted spiro[4H-3,1-benzoxazine-4,4'piperidin]-2(1H)-ones. J.Med.Chem. 26 657. PMID:6842505. Mirzadegan et al (2000) Identification of the binding site for a novel class of CCR2b chemokine receptor antagonists. J.Biol.Chem. 275 25562. PMID:10770925."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=104317	SQ1341			Aug-2005
2095	PNU 37883 hydrochloride	[57568-80-6]	C1(CC3C2)CC2(/N=C(N5CCOCC5)/NC4CCCCC4)CC(C3)C1.Cl	Vascular Kir6 (KATP) channel blocker	Novel antagonist selective for the vascular form of Kir6 (KATP) channel; inhibits Kir6 currents in isolated mesenteric artery smooth muscle cells (Kd = 65 nM) but not in cardiac or skeletal myocytes. Inhibits blood vessel relaxation and hypotension induced by pinacidil in vivo. Displays weak diuretic effects.	"Humphrey and Ludens (1998) KATP-blocking diuretic PNU-37883A reduces plasma renin activity in dogs. J.Cardiovasc.Pharmacol. 31 894. PMID:9641474. Cui et al (2003) Different molecular sites of action for the KATP channel inhibitors, PNU-99963 and PNU-37883A. Br.J.Pharmacol. 139 122. PMID:12746230. Kovalev et al (2004) Molecular analysis of the subtype-selective inhibition of cloned KATP channels by PNU-37883A. Br.J.Pharmacol. 141 867. PMID:14757705."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=106669	SQ1341			Jun-2005
2096	DAU 5884 hydrochloride	[131780-48-8]	Cl.CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)N1CC2=C(NC1=O)C=CC=C2	M3 receptor antagonist	"Selective muscarinic M3 receptor antagonist. In bovine tracheal smooth muscle, inhibits methacholine-dependent effects on cell proliferation and muscle contractility."	Doods et al (1993) Characterization of muscarinic receptors in guinea-pig uterus. Eur.J.Pharmacol. 250 223. PMID:8112383. Roffel et al (1993) Cholinergic contraction of the guinea pig lung strip is mediated by muscarinic M2-like receptors. Eur.J.Pharmacol. 250 267. PMID:8112384. Gosens et al (2003) Muscarinic M3-receptors mediate cholinergic synergism of mitogenesis in airway smooth muscle. Am.J.Respir.Cell Mol.Biol. 28 257. PMID:12540494. Gosens et al (2004) Muscarinic M3 receptor-dependent regulation of airway smooth muscle contractile phenotype. Br.J.Pharmacol. 141 943. PMID:14993104.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=107360	SQ1341			Jul-2005
2097	SKI II	[312636-16-1]	OC1=CC=C(NC2=NC(=CS2)C2=CC=C(Cl)C=C2)C=C1	Selective non-lipid inhibitor of sphingosine kinase	"Selective non-lipid inhibitor of sphingosine kinase (IC50 = 0.5 _M); does not act at ATP-binding site. Displays no inhibition of ERK2, PI 3-kinase, or PKC_ at concentrations up to 60 _M. Reduces levels of sphingosine-1-phosphate in MDA-MB-231 breast cancer cells. Induces apoptosis and inhibits proliferation in several other tumor cell lines in vitro (IC50 = 0.9 - 4.6 _M)."	French et al (2003) Discovery and evaluation of inhibitors of human sphingosine kinase. Cancer Res. 63 5862. French et al (2006) Antitumor activity of sphingosine kinase inhibitors. J.Pharmacol.Exp.Ther. 318 596. PMID:16632640.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=107361	SQ1341			Jun-2005
2098	Apoptosis Activator 2	[79183-19-0]	ClC1=CC=C(CN2C(=O)C(=O)C3=CC=CC=C23)C=C1Cl	Promotes apoptosome formation and activates caspase-9/caspase-3 pathway. Selectively induces tumor cell apoptosis	"Apoptosis activator; promotes the cytochrome c-dependent oligomerization of Apaf-1 into the mature apoptosome. Increases procaspase-9 processing and subsequent caspase-3 activation. Induces apoptosis in tumor cells (IC50 = 4 - 9 _M for leukemia cells) with weak or no effect on normal cell lines or those defective/deficient in Apaf-1, caspase-9 or caspase-3 activity (IC50 > 40 _M)."	Nguyen and Wells (2003) Direct activation of the apoptosis machinery as a mechanism to target cancer cells. Proc.Natl.Acad.Sci.USA 100 7533. Alavian et al (2009) Elevtaed p75NTR expression causes death of engrailed-deficient midbrain dopaminergic neurons by Erk1/2 suppression. Neural Dev. 4 11. PMID:19291307. Jayaraman and Pike (2009) Progesterone attenuates oestrogen neuroprotection via downregulation of oestrogen receptor expression in cultured neurones. J.Neuroendocrinol. 21 77. PMID:19094096.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=107750				Jun-2004
2132	Amisulpride	[71675-85-9]	CCN1CCCC1CNC(=O)C1=C(OC)C=C(N)C(=C1)S(=O)(=O)CC	Selective D2/D3 receptor antagonist; atypical antipsychotic agent	"Potent, selective dopamine D2 and D3 receptor antagonist. Ki values are 2.8 and 3.2 nM respectively for human D2 and D3 and > 1000 nM for human D1, D4 and D5 receptors. Shows selectivity for presynaptic dopamine autoreceptors at low doses and blocks postsynaptic D2/D3 receptors at higher doses. Preferentially interacts with limbic D2-like receptors in vivo. Atypical antipsychotic/antischizophrenic agent with limited extrapyrimidal side effects and a profile distinct from that of haloperidol and remoxipride."	"Perrault et al (1997) Psychopharmacological profile of amisulpride: an antipsychotic drug with presynaptic D2/D3 dopamine receptor antagonist activity and limbic selectivity. J.Pharmacol.Exp.Ther. 280 73. PMID:8996184. Schoemaker et al (1997) Neurochemical characteristics of amisulpride, an atypical dopamine D2/D3 receptor antagonist with both presynaptic and limbic selectivity. J.Pharmacol.Exp.Ther. 280 83. PMID:8996185. Moller (2003) Amisulpride: limbic specificity and the mechanism of antipsychotic atypicality. Prog.Neuro-Psychopharm.Biol.Psychiat. 27 1101."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=108700	SQ1070			May-2005
2137	"2,3-DCPE hydrochloride"	[1009555-55-8]	Cl.OCCNCCCOC1=C(Cl)C(Cl)=CC=C1	Selectively induces cancer cell apoptosis	Selectively induces apoptosis and downregulates Bcl-XL protein expression in various human cancer cells versus normal cells in vitro. IC50 values are 0.89 and 12.6 _M for LoVo human colon cancer cell line and normal human fibroblasts respectively. Induces p21 expression and S-phase arrest in cancer cells via ERK-mediated pathways.	"Wu et al (2004) Induction of apoptosis and down-regulation of Bcl-XL in cancer cells by a novel small molecule, 2[[3-(2,3-Dichlorophenoxy)propyl]amino]ethanol. Cancer Res. 64 1110. PMID:14871845. Zhu et al (2004) Induction of S-phase arrest and p21 overexpression by a small molecule 2[[3-(2,3-dichlorophenoxy)propyl]amino]ethanol in correlation with activation of ERK. Oncogene 23 4984. PMID:15122344."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=109182	SQ1341			Aug-2004
2139	Leelamine hydrochloride	[16496-99-4]	NC[C@]1(C)CCC[C@@]3(C)[C@]([H])1CCC2=CC(C(C)C)=CC=C23.Cl	CB1 agonist	CB1 agonist. Displaces binding of [3H]-SR141716A with an IC50 value of 2.86 _M.		Small Molecule		http://www.tocris.com/dispprod.php?ItemId=109462	SQ1070			Dec-2004
2141	Paroxetine maleate	[64006-44-6]	OC(=O)\C=C/C(O)=O.FC1=CC=C(C=C1)[C@@H]1CCNC[C@H]1COC1=CC2=C(OCO2)C=C1	Highly potent and selective 5-HT uptake inhibitor	"Highly potent and selective 5-HT uptake inhibitor that binds with high affinity to the serotonin transporter (Ki = 0.05 nM). Ki values are 1.1, 350 and 1100 nM for inhibition of [3H]-5-HT, [3H]-l-NA and [3H]-DA uptake respectively. Displays minimal affinity for _1-, _2- or _-adrenoceptors, 5-HT2A, 5-HT1A, D2 or H1 receptors at concentrations below 1000 nM, however displays weak affinity for muscarinic ACh receptors (Ki = 42 nM). Antidepressant and anxiolytic in vivo."	"Thomas et al (1987) Biochemical effects of the antidepressant paroxetine, a specific 5-hydroxytryptamine uptake inhibitor. Psychopharmacology 93 193. PMID:2962217. Owens et al (1997) Neurotransmitter receptor and transporter binding profile of antidepressants and their metabolites. J.Pharmacol.Exp.Ther. 283 1305. PMID:9400006. Bourin et al (2001) Paroxetine: a review. CNS Drug Rev. 7 25. PMID:11420571. Fujishiro et al (2002) Comparison of the anticholinergic effects of the serotonergic antidepressants, paroxetine, fluvoxamine and clomipramine. Eur.J.Pharmacol. 454 183. PMID:12421645."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=110486	SQ1533			Jul-2004
2143	SCS	[3232-36-8]	OC1=CC=CC=C1\C=N\NC(=O)C1=CC=CC=C1O	Selective GABAA receptor antagonist; _1-subunit-selective	"Potent and selective partial inhibitor of _1-containing GABAA receptors (IC50 values are 4.5, 5.3 and 7.9 nM at _2_1_1_, _2_1_1 and _2_1_2s GABAA receptors respectively). May bind allosterically to a novel site on GABAA receptor."	"Thompson et al (2004) Salicylidene salicylhydrazide, a selective inhibitor of _1-containing GABAA receptors. Br.J.Pharmacol. 142 97. PMID:15100159."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=110663				Jun-2004
2146	MRS 2578	[711019-86-2]	S=C(NCCCCNC(NC2=CC(N=C=S)=CC=C2)=S)NC1=CC(N=C=S)=CC=C1	Selective P2Y6 antagonist	"Selective antagonist of P2Y6 nucleotide receptors; IC50 values are 37 and 98 nM at human and rat P2Y6 receptors respectively. Displays no activity at P2Y1, P2Y2, P2Y4 and P2Y11 receptors (IC50 > 10 _M). Inhibits agonist-induced cardiomyocyte contraction and UDP-induced phagocytosis."	"Mamedova et al (2004) Diisothiocyanate derivatives as potent, insurmountable antagonists of P2Y6 nucleotide receptors. Biochem.Pharmacol. 67 1763. PMID:15081875. Koizumi et al (2007) UDP acting at P2Y6 receptors is a mediator of microglial phagocytosis. Nature 446 1091. PMID:17410128. Kukulski et al (2007) Extracellular nucleotides mediate LPS-induced neutrophil migration in vitro and in vivo. J.Leukoc.Biol. 81 1269. PMID:17322022."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=111728				Oct-2005
2147	Nicorandil	[65141-46-0]	[O-][N+](=O)OCCNC(=O)C1=CC=CN=C1	Kir6 (KATP) channel opener and NO donor	"Kir6 (KATP) channel opener and NO donor; antianginal agent. Preferentially activates SUR2B- versus SUR2A-containing Kir6 channels (EC50 values are 10 and > 500 _M respectively) and causes 1.6-fold increase in cardiac eNOS expression. Displays coronary and peripheral vasodilatory properties, reduces both pre- and after-load, and increases coronary blood flow. Also displays cardioprotective effects, possibly through ischemic preconditioning."	Shindo et al (1998) SUR2 subtype (A and B)-dependent differential activation of the cloned ATP-sensitive K+ channels by pinacidil and nicorandil. Br.J.Pharmacol. 124 985. PMID:9692785. Horinaka et al (2001) Nicorandil enhances cardiac endothelial nitric oxide synthase expression via activation of adenosine triphosphate-sensitive K channel in rat. J.Cardiovasc.Pharmacol. 38 200. PMID:11483869. Gomma et al (2001) Potassium channel openers in myocardial ischaemia: therapeutic potential of nicorandil. Drugs 61 1705. PMID:11693460.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=111729	SQ1533			Oct-2004
2148	()-McN 5652	[96795-89-0]	[H][C@]23C1=CC=CC=C1[C@@H]([C@]4=CC=C(SC)C=C4)CN2CCC3	"Potent, orally active 5-HT uptake inhibitor. Also inhibits noradrenalin and dopamine uptake in vitro"	"Potent, high affinity serotonin re-uptake inhibitor; selective in vivo. Displays moderate selectivity over noradrenalin and dopamine re-uptake in vitro (Ki values are 0.68, 2.9 and 36.8 nM for inhibition of serotonin, noradrenalin and dopamine uptake respectively in rat brain synaptosomes). Potently potentiates 5-HT-induced effects in vivo following oral administration. Biological activity resides predominantly in the (+)-enantiomer."	Shank et al (1988) McN-5652: a highly potent inhibitor of serotonin uptake. J.Pharmacol.Exp.Ther. 247 1032. PMID:2905001. Maryanoff et al (1990) Pyrroloisoquinoline antidepressants. 3. A focus on serotonin. J.Med.Chem. 33 2793. PMID:2213832. Smith et al (1991) Effects of pyrroloisoquinoline enantiomers ((+)- and (-)-McN-5652-Z) on behavioral and pharmacological serotonergic mechanisms in rats. Eur.J.Pharmacol. 196 85. PMID:1831423.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=111733	SQ1070			Sep-2006
2150	nTZDpa	[118414-59-8]	OC(=O)C1=C(SC2=CC=CC=C2)C2=CC(Cl)=CC=C2N1CC1=CC=C(Cl)C=C1	"Potent, selective PPAR_ partial agonist"	"Potent, selective non-thiazolidinedione PPAR_ partial agonist (EC50 = 57 nM); produces ~25% maximum efficacy. Antagonizes full agonist activity by ~60% (IC50 ~ 285 nM). Displays no activity at PPAR_ or PPAR_ receptors. Produces altered receptor conformation, and regulates adipocyte development and gene expression, in a differential manner to full PPAR_ agonists. Modulates metabolism and insulin sensitivity without causing cardiac hypertrophy in mice in vivo."	Berger et al (2003) Distinct properties and advantages of a novel peroxisome proliferator-activated protein _ selective modulator. Mol.Endocrinol. 17 662. PMID:12554792.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=112621	SQ1341			Jan-2005
2151	API-2	[35943-35-2]	O[C@@H]1[C@@H](CO)O[C@@H](N2C3=C(C4=NC=N3)C(C(N)=NN4C)=C2)[C@@H]1O	Selective inhibitor of Akt/PKB signaling. Antitumor and antiviral	"Selective inhibitor of Akt (protein kinase B) signaling; displays minimal inhibition of PKC, PKA, SGK and p38 pathways. Inhibits phosphorylation and activation of downstream targets of Akt including Bad, GSK-3_ and AFX. Induces apoptosis and growth arrest in vitro, preferentially in human cancer cells with elevated levels of Akt. Potently and selectively inhibits growth of Akt-overexpressing tumors in mice. Inhibits DNA synthesis and displays antiviral activity against HIV-1 and -2."	"Wotring et al (1990) Dual mechanisms of inhibition of DNA synthesis by triciribine. Cancer Res. 50 4891. PMID:2379153. Ptak et al (1998) Phosphorylation of triciribine is necessary for activity against HIV type 1. AIDS Res.Hum.Retroviruses. 14 1315. PMID:9788672. Yang et al (2004) Akt/protein kinase B signaling inhibitor-2, a selective small molecule inhibitor of Akt signaling with antitumour activity in cancer cells overexpressing Akt. Cancer Res. 64 4394. PMID:15231645."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=113600	SQ1533			Apr-2005
2152	NSC 625987	[141992-47-4]	COC1=C2NC3=CC=CC=C3C(=S)C2=C(OC)C=C1	Cyclin-dependent kinase 4 (cdk4) inhibitor	"Cyclin-dependent kinase (cdk) 4 inhibitor (IC50 = 0.2 _M at cdk4/cyclin D1). Displays > 500-fold selectivity over cdk2 (IC50 > 100 _M for cdc2/cyclin A, cdk2/cyclin A and cdk2/cyclin E)."	Kubo et al (1999) The p16 status of tumor cell lines identifies small molecule inhibitors specific for cyclin-dependent kinase 4. Clin.Cancer Res. 5 4279. PMID:10632371. McInnes et al (2004) Structural determinants of CDK4 inhibition and design of selective ATP competitive inhibitors. Chem.Biol. 11 525. PMID:15123247.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=113603				Jan-2005
2154	ZD 2079	[178600-17-4]	Cl[H].O[C@@H](CNCCOC1=CC=C(CC(O)=O)C=C1)C1=CC=CC=C1	_3-adrenoceptor agonist	_3-adrenoceptor agonist. Relaxes rat mesenteric artery and isolated aorta in vitro. Inhibits ob gene expression and circulating leptin levels in lean mice in vivo.	"Trayhurn et al (1996) Rapid inhibition of ob gene expression and circulating leptin levels in lean mice by the _3-adrenoceptor agonists BRL 35135A and ZD2079. Biochem.Biophys.Res.Comm. 228 605. Brawley et al (2000) Role of endothelium/nitric oxide in atypical _-adrenoceptor-mediated relaxation in rat isolated aorta. Eur.J.Pharmacol. 398 285. PMID:10854841. Kozlowska et al (2003) Atypical _-adrenoceptors, different from _3-adrenoceptors, relax the rat isolated mesenteric artery. Br.J.Pharmacol. 140 3. PMID:12967929."	Small Molecule	Sold with the permission of AstraZeneca UK Ltd.	http://www.tocris.com/dispprod.php?ItemId=113640	SQ1533			Aug-2004
2155	NTNCB hydrochloride	[191931-56-3]	O=S(NC[C@@H](CC3)CC[C@H]3CNCC2CCC1=CC=CC=C1C2)(C4=C([N+]([O-])=O)C=CC=C4)=O.Cl	Potent and selective non-peptidic NPY Y5 antagonist	"Selective, non-peptide competitive NPY Y5 antagonist. Ki values are 8.0 and 16032 nM at human recombinant Y5 and Y1 receptors respectively. Potently antagonizes NPY inhibition of forskolin-stimulated cAMP. Displays some affinity for cloned human D2 and _2C receptors (Ki values are 63 and 100 nM respectively)."	Islam et al (2002) Discovery of potent and selective small molecule NPY Y5 receptor antagonists. Bioorg.Med.Chem.Lett. 12 1767. PMID:12067557.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=113643	SQ1341			Apr-2005
2156	Embelin	[550-24-3]	OC=1C(=O)C(CCCCCCCCCCC)=C(C(=O)C1)O	Inhibitor of X-linked inhibitor of apoptosis (XIAP); cell-permeable and antitumor	"Cell-permeable, non-peptide inhibitor of X-linked inhibitor of apoptosis (XIAP) (IC50 = 4.1 _M in competition binding assay with Smac peptide); binds to the BIR3 domain, preventing XIAP interaction with caspase-9 and Smac. Inhibits cell growth, induces apoptosis and activates caspase-9 in prostate cancer cells (IC50 4 - 6 _M), but has a weaker effect on normal prostate cells (IC50 = 19 - 20 _M). Overcomes the protective effect of XIAP on apoptosis in XIAP-transfected Jurkat cells. Anti-tumor, analgesic and anti-inflammatory in vivo."	"Chitra et al (1994) Antitumor, anti-inflammatory and analgesic property of embelin, a plant product. Chemotherapy 40 109. PMID:7510605. Nikolovska-Coleska et al (2004) Discovery of embelin as a cell-permeable, small-molecular weight inhibitor of XIAP through structure-based computational screening of a traditional herbal medicine three-dimensional structure database. J.Med.Chem. 47 2430. PMID:15115387. Modak et al (2013) Probing p300/CBP associated factor (PCAF)-dependent pathways with a small molecule inhibitor. ACS Chem.Biol. 8 1311. PMID:23570531."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=113659	SQ1533			Aug-2004
2160	Bax channel blocker	[329349-20-4]	Cl.Cl.OC(CN1C2=C(C=C(Br)C=C2)C2=C1C=CC(Br)=C2)CN1CCNCC1	Inhibits Bax-mediated mitochondrial cytochrome c release	Potent inhibitor of Bax-mediated mitochondrial cytochrome c release (IC50 = 0.52 _M). Suggested to inhibit Bax channel formation/activity.	"Bombrun et al (2003) 3,6-Dibromocarbazole piperazine derivatives of 2-propanol as first inhibitors of cytochrome c release via Bax channel modulation. J.Med.Chem. 46 21."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=113685	SQ1341			Oct-2004
2161	NSC 23766	[1177865-17-6]	Cl.Cl.Cl.CCN(CC)CCCC(C)NC1=NC(C)=CC(NC2=CC=C3N=C(C)C=C(N)C3=C2)=N1	Selective inhibitor of Rac1-GEF interaction; antioncogenic	Selective inhibitor of Rac1-GEF interaction. Prevents Rac1 activation by Rac-specific guanine nucleotide exchange factors (GEFs) TrioN and Tiam1 (IC50 ~ 50 _M) without affecting Cdc42 or RhoA activation. Inhibits Rac1-mediated cell functions and is reported to reverse tumor cell phenotyes in prostate cancer cells.	Gao et al (2004) Rational design and characterization of a Rac GTPase-specific small molecule inhibitor. Proc.Natl.Acad.Sci.USA 101 7618.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=113686	SQ1533			Jul-2005
2162	INCA-6	[3519-82-2]	O=C1C=CC(=O)C2=C1C1C3=C(C=CC=C3)C2C2=C1C=CC=C2	Inhibitor of calcineurin-substrate association	Inhibitor of interaction between calcineurin and its substrate nuclear factor of activated T cells (NFAT); blocks at the substrate recognition site but not at the catalytic site (Kd = 0.8 mM). Inhibits NFAT dephosphorylation and nuclear import. Also prevents induction of cytokine mRNAs that are downstream targets of NFAT.	Roehrl et al (2004) Selective inhibition of calcineurin-NFAT signaling by blocking protein-protein interaction with small organic molecules. Proc.Natl.Acad.Sci.USA 101 7554.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=113687	SQ1341			Feb-2005
2172	AZ 10417808	[331645-84-2]	[O-][N+](=O)C1=CC2=C(N=C(NC3=CC(Cl)=C(Cl)C=C3)NC2=O)C(=C1)C(=O)NCC=C	Selective non-peptide caspase-3 inhibitor	"Selective non-peptide inhibitor of caspase-3 (Ki = 247 nM); displays > 40-fold selectivity over caspases 1, 2, 6, 7 and 8 (Ki > 10 _M). Completely blocks staurosporine-induced intracellular DEVDase activity in SH-SY5Y cells (IC50 = 14.9 _M)."	Scott et al (2003) Novel small molecule inhibitors of caspase-3 block cellular and biochemical features of apoptosis. J.Pharmacol.Exp.Ther. 304 433. PMID:12490620.	Small Molecule	Sold with the permission of AstraZeneca UK Ltd.	http://www.tocris.com/dispprod.php?ItemId=114100	SQ1341			Mar-2005
2173	WAY 629 hydrochloride	[57756-44-2]	Cl.C1CCC2=C(C1)N1CCNCC3=C1C2=CC=C3	Selective 5-HT2C agonist	"Selective 5-HT2C agonist. Ki values are 56, 2350, 1575 and 815 nM for human recombinant 5-HT2C, 5-HT2A, 5-HT6 and 5-HT7 receptors respectively. Stimulates intracellular Ca2+ mobilization in CHO cells expressing human 5-HT2C receptors (EC50 = 72 nM). Reduces food intake in rats."	"Sabb et al (2004) Cycloalkyl[b][1,4]benzodiazepinoindoles are agonists at the human 5-HT2C receptor. Bioorg.Med.Chem.Lett. 14 2603. PMID:15109661. Dunlop et al (2004) Identification of cycloalkyl[b][1,4]benzodiazepinoindoles as novel 5-HT2C receptor agonists. Fund.Clin.Pharmacol. 18 (Suppl.1) 145."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=114872	SQ1341			Dec-2004
2174	Hispidulin	[1447-88-7]	OC1=CC2=C(C(C=C(C3=CC=C(O)C=C3)O2)=O)C(O)=C1OC	Partial positive allosteric modulator at the benzodiazepine receptor	"Partial positive allosteric modulator at the benzodiazepine receptor (IC50 = 1.3 _M for inhibition of flumazenil binding); natural sage flavone. Stimulates GABA-induced chloride currents in Xenopus oocytes expressing _1-, _2-, _3-, _5- or _6-_2 _2S GABAA receptors. Brain penetrant; oral administration reduces seizures in a gerbil model of epilepsy. Also has antifungal, antiproliferative, antioxidant and antithrombotic properties."	"Bourdillat et al (1988) Hispidulin, a natural flavone, inhibits human platelet aggregation by increasing cAMP levels. Eur.J.Pharmacol. 147 1. PMID:2836213. Kavvadias et al (2003) Constituents of sage (Salvia officinalis) with in vitro affinity to human brain benzodiazepine receptor. Planta Med. 69 113. PMID:12624814. Kavvadias et al (2004) The flavone hispidulin, a benzodiazepine receptor ligand with positive allosteric properties, traverses the blood-brain barrier and exhibits anticonvulsive effects. Br.J.Pharmacol. 142 811. PMID:15231642."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=114873	SQ1341			Sep-2006
2175	Tetrabenazine	[58-46-8]	O=C3[C@@H](CC(C)C)CN2CCC1=CC(OC)=C(OC)C=C1[C@@]([H])2C3	Potent inhibitor of vesicular monoamine transport	"Potent inhibitor of vesicular monoamine uptake; depletes stores of dopamine, serotonin and noradrenalin. Binds with high affinity (IC50= 3.2 nM) to vesicular monoamine transporter (VMAT) in chromaffin granule membranes and displays higher affinity for VMAT2 than VMAT1. Also reported to block dopamine receptors. Causes behavioral depression; inhibits locomotor activity and produces hypothermia upon systemic administration in rats and mice."	"Reches et al (1983) Tetrabenazine, an amine-depleting drug, also blocks dopamine receptors in rat brain. J.Pharmacol.Exp.Ther 225 515. PMID:6864517. Scherman et al (1983) Characterisation of the monoamine carrier of chromaffin granule membrane by binding of [2-3H]dihydrotetrabenazine. Proc.Natl.Acad.Sci.USA 80 584. Pettibone et al (1984) Tetrabenazine-induced depletion of brain monoamines: characterisation and interaction with selected antidepressants. Eur.J.Pharmacol. 102 425. PMID:6489435. Peter et al (1996) Chimeric vesicular monoamine transporters identify structural domains that influence substrate affinity and sensitivity to tetrabenazine. J.Biol.Chem. 271 2979. PMID:8621690."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=5461	SQ1533			Mar-2005
2176	BVT 948	[39674-97-0]	CC1(C)C(=O)N=C2C1=C(O)C(=O)C1=CC=CC=C21	Non-competitive protein tyrosine phosphatase inhibitor; enhances insulin signaling	"Non-competitive, cell-permeable inhibitor of protein tyrosine phosphatases (PTPs) (IC50 = 0.09 - 1.7 _M); displays irreversible inhibition through catalysis of the hydrogen peroxide-dependent oxidation of PTP. Enhances insulin signaling in vitro and insulin tolerance in ob/ob mice in vivo. Also inhibits several cytochrome P450 isoforms (IC50 < 10 _M)."	"Liljebris et al (2004) Oxidation of protein tyrosine phosphatases as a pharmaceutical mechanism of action: a study using 4-hydroxy-3,3-dimethyl-2H-benzo[g]indole-2,5(3H)-dione. J.Pharmacol.Exp.Ther. 309 711. PMID:14747616."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=117008	SQ1341			Jan-2005
2183	ZK 164015	[177583-70-9]	CCCCCS(=O)(=O)CCCCCCCCCCN1C2=CC=C(O)C=C2C(C)=C1C1=CC=C(O)C=C1	Potent estrogen receptor antagonist	Potent estrogen receptor silent antagonist. Inhibits 17_-estradiol stimulation of luciferase activity (IC50 = 0.025 _M); potently inhibits the growth of estrogen-sensitive human MCF-7 breast cancer cells in vitro (IC50 ~ 1 nM).	"Biberger and von Angerer (1996) 2-Phenylindoles with sulfur containing side chains. Estrogen receptor affinity, antiestrogenic potency, and antitumour activity. J.Steroid Biochem.Molec.Biol. 58 31. Liu et al (1999) The anti-estrogen hydroxytamoxifen is a potent antagonist in a novel yeast system. Biol.Chem. 380 1341. PMID:10614829. Walter et al (2004) Synthesis and biological evaluation of stilbene-based pure estrogen antagonists. Bioorg.Med.Chem.Lett. 14 4659. PMID:15324884."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=117166	SQ1341			Nov-2004
2184	SN-6	[415697-08-4]	CCOC(=O)C1CSC(CC2=CC=C(OCC3=CC=C(C=C3)[N+]([O-])=O)C=C2)N1	Selective Na+/Ca2+ exchange inhibitor (reverse mode)	"Selective Na+/Ca2+-exchange (NCX) inhibitor; displays some selectivity for NCX1. IC50 values are 2.9, 16 and 8.6 _M for inhibition of intracellular Na+-dependent 45Ca2+ uptake by cells expressing NCX1, NCX2 and NCX3 respectively. Has some affinity for mACh receptors (IC50 = 18 _M) but minimal activity against NCKX2 and various receptors and ion channels (IC50 > 30 _M). Preferentially blocks Ca2+ influx mode and is more selective for NCX isoforms than KB-R7943 (Cat. No. 1244). Anti-ischemic; potently protects against hypoxia-induced renal tubular cell damage (IC50 = 0.63 _M)."	"Iwamoto et al (2004) The exchanger inhibitory peptide region-dependent inhibition of Na+/Ca2+ exchange by SN-6 [2-[4-(4-nitrobenzyloxy)benzyl]thiazolidine-4-carboxylic acid ethyl ester], a novel benzyloxyphenyl derivative. Mol.Pharmacol. 66 45. PMID:15213295. Iwamoto (2004) Forefront of Na+/Ca2+ exchanger studies: molecular pharmacology of N+/Ca2+ exchange inhibitors. J.Pharmacol.Sci. 96 27. PMID:15359084."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=117167	SQ1341			Nov-2004
2185	NSC 146109 hydrochloride	[59474-01-0]	N=C(N)SCC1=C(C=CC=C3)C3=C(C)C2=C1C=CC=C2.Cl	"Cell-permeable, genotype-selective antitumor agent; activates p53-dependent transcription"	"Cell-permeable, genotype-selective antitumor agent that activates p53-dependent transcription. Increases levels of endogenous p53 in tumor cells and protects p53 from Mdm2-mediated degradation. Displays some selectivity for tumor cells vs. normal cells in an MTT cell viability assay."	Dolma et al (2003) Identification of genotype-selective antitumor agents using synthetic lethal chemical screening in engineered human tumor cells. Cancer Cell 3 285. PMID:12676586. Berkson et al (2005) Pilot screening programme for small molecule activators of p53. Int.J.Cancer 115 701. PMID:15729694.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=119693				Mar-2005
2186	CMPD-1	[41179-33-3]	OC1=CC=C(NC(=O)CCCC2=CC=C(C=C2)C2=CC=CC=C2F)C=C1	Non-ATP-competitive p38_ inhibitor	"Non-ATP-competitive, selective inhibitor of p38_-mediated MK2a (mitogen-activated protein kinase-activated protein kinase 2a) phosphorylation (apparent Ki = 330 nM). Does not inhibit p38_-mediated phosphorylation of the two other known p38 substrates, MBP and ATF-2."	Davidson et al (2004) Discovery and characterisation of a substrate selective p38_ inhibitor. Biochemistry 43 11658. PMID:15362850.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=119694	SQ1341			Aug-2005
2187	NS 3763	[70553-45-6]	O=C(C2=CC=CC=C2)NC1=CC(NC(C3=CC=CC=C3)=O)=C(C(O)=O)C=C1C(O)=O	Selective non-competitive kainate antagonist; selective for GLUK5	Selective non-competitive kainate receptor antagonist; displays selectivity for GLUK5 subunit-containing receptors (IC50 values are 1.6 and > 30 _M for homomeric GLUK5 and GLUK6 receptors respectively). Has minimal activity at AMPA and NMDA receptors (IC50> 30 _M).	"Christensen et al (2004) In vitro characterization of 5-carboxyl-2,4-di-benzamido-benzoic acid (NS3763), a noncompetitive antagonist of GLUK5 receptors. J.Pharmacol.Exp.Ther. 309 1003. PMID:14985418."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=119850				Mar-2005
2188	Ro 0437626	[134362-79-1]	O[C@@H](C1CC1)[C@H](O)[C@H](CC2CCCCC2)NC([C@@H](CC3=CSC=N3)NC(C(N4)=NC5=C4C=CC=C5)=O)=O	Selective P2X1 antagonist	"Selective P2X1 purinergic receptor antagonist (IC50 = 3 _M) that displays > 30-fold selectivity over P2X2, P2X3 and P2X2/3 receptors (IC50 > 100 _M)."	King et al (2004) Investigation of the effects of P2 purinoceptor ligands on the micturition reflex in female urethane-anaesthetized rats. Br.J.Pharmacol. 142 519. PMID:15148261. Jaime-Figueroa et al (2005) Discovery and synthesis of a novel and selective drug-like P2X1 antagonist. Bioorg.Med.Chem.Lett. 15 3292. PMID:15927468. Ford et al (2006) Purinoceptors as therapeutic targets for lower urinary tract dysfunction. Br.J.Pharmacol. 147 S132. PMID:16465177.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=120462	SQ1341			Dec-2008
2190	SR 27897	[136381-85-6]	OC(=O)CN1C(=CC2=CC=CC=C12)C(=O)NC1=NC(=CS1)C1=CC=CC=C1Cl	Potent and selective CCK1 antagonist	"Potent, non-peptide CCK1 receptor antagonist that displays > 33-fold selectivity over CCK2 receptors (EC50 values are 6 and 200 nM respectively). Causes an increase in plasma leptin levels and increases food intake in rats in vivo."	Gully et al (1993) Peripheral biological activity of SR 27897: a new potent non-peptide antagonist of CCKA receptors. Eur.J.Pharmacol. 23 232. Gouldson et al (1999) Contrasting roles of Leu356 in the human CCK1 receptor for antagonist SR 27897 and agonist SR 146131 binding. Eur.J.Pharmacol. 383 339. PMID:10594328. Cano et al (2003) Regulation of leptin distribution between plasma and cerebrospinal fluid by cholecystokinin receptors. Br.J.Pharmacol. 140 647. PMID:14534148.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=121459	SQ1533			Mar-2007
2191	S-Trityl-L-cysteine	[2799-07-7]	N[C@@H](C(O)=O)CSC(C2=CC=CC=C2)(C3=CC=CC=C3)C1=CC=CC=C1	"Potent, selective inhibitor of mitotic kinesin Eg5"	"Potent, cell-permeable, selective inhibitor of mitotic kinesin Eg5, a protein required for establishing and maintaining a bipolar spindle. Inhibits basal ATPase activity (IC50 = 1 mM) and microtubule-activated ATPase activity of Eg5 (IC50 = 140 nM). Induces mitotic arrest in HeLa cells with an IC50 of 700 nM. Displays antitumor activity."	"DeBonis et al (2004) In vitro screening for inhibitors of the human mitotic kinesin Eg5 with antimitotic and antitumour activities. Mol.Cancer Ther. 3 1079. PMID:15367702. Brier et al (2004) Identification of the protein binding region of S-trityl-L-cysteine, a new potent inhibitor of mitotic kinesin Eg5. Biochemistry 43 13072. PMID:15476401."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=121537	SQ1533			Nov-2004
2192	4-HQN	[491-36-1]	OC1=C2C=CC=CC2=NC=N1	PARP inhibitor	"Inhibitor of poly(ADP-ribose) polymerase (PARP) (IC50 = 9.5 _M); displays mixed inhibition with respect to NAD+. Protective against ischemia-reperfusion induced ROS production, and subsequent mitochondrial and cell damage in rat heart. Anti-inflammatory in LPS-induced endotoxic mice in vivo; decreases NF-_B and AP-1 activation."	"Banasik et al (1992) Specific inhibitors of poly(ADP-ribose) synthetase and mono(ADP-ribosyl)transferase. J.Biol.Chem. 267 1569. PMID:1530940. Halmosi et al (2001) Effect of poly(ADP-ribose) polymerase inhibitors on the ischemia-reperfusion-induced oxidative cell damage and mitochondrial metabolism in Langendorff heart perfusion system. Mol.Pharmacol. 59 1497. PMID:11353811. Veres et al (2004) Regulation of kinase cascades and transcription factors by a poly(ADP-ribose) polymerase-1 inhibitor, 4-hydroxyquinazoline, in lipopolysaccharide-induced inflammation in mice. J.Pharmacol.Exp.Ther. 310 247. PMID:14999056."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=121538				Dec-2004
2193	Carmoxirole hydrochloride	[115092-85-8]	Cl.OC(=O)C1=CC=C2NC=C(CCCCN3CCC(=CC3)C3=CC=CC=C3)C2=C1	"Selective, peripherally acting D2-like agonist"	"Selective, peripherally acting dopamine D2 receptor agonist. Modulates noradrenalin release and sympathetic activation. Displays antihypertensive properties in vivo."	"Hasse et al (1991) Neurochemical profile of EMD 45609 (carmoxirole), a dopamine DA2-receptor agonist. Naunyn-Schmied.Arch.Pharmacol. 343 588. Haeusler et al (1992) Pharmacological basis for antihypertensive therapy with a novel dopamine agonist Eur.Heart J. 13 129. PMID:1356783. Rump et al (1993) Dopamine receptor modulation of noradrenaline release by carmoxirole in human cortical kidney slices. Eur.J.Clin.Pharmacol. 44 S47. PMID:8097997."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=121708	SQ1533			Jul-2005
2194	R 59-022	[93076-89-2]	CC1=C(CCN2CC\C(CC2)=C(/C2=CC=CC=C2)C2=CC=C(F)C=C2)C(=O)N2C=CSC2=N1	Diacylglycerol kinase inhibitor; increases PKC activity	Diacylglycerol (DAG) kinase inhibitor (IC50 = 2.8 _M); increases protein kinase C activity. Potentiates thrombin-induced platelet aggregation and induces neutrophil chemotaxis. Inhibits U46619-induced contractions in mouse aorta and porcine coronary artery.	"de Chaffoy de Courcelles et al (1985) R 59 022, a diacylglycerol kinase inhibitor. Its effect on diacylglycerol and thrombin-induced C kinase activation in the intact platelet. J.Biol.Chem. 260 15762. PMID:2999135. Nunn and Watson (1987) A diacylglyerol kinase inhibitor, R59022, potentiates secretion by and aggregation of thrombin-stimulated human platelets. Biochem.J. 243 809. PMID:2821994. Boonen et al (1993) Neutrophil chemotaxis induced by the diacylglycerol kinase inhibitor R59022. Biochim.Biophys.Acta 1178 97. PMID:8392381. Nobe et al (2004) Novel diacylglycerol kinase inhibitor selectively suppressed an U46619-induced enhancement of mouse portal vein contraction under high glucose conditions. Br.J.Pharmacol. 143 166. PMID:15289283."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=121709	SQ1070			Feb-2005
2195	Eliprodil	[119431-25-3]	OC(CN1CCC(CC2=CC=C(F)C=C2)CC1)C1=CC=C(Cl)C=C1	Non-competitive NR2B-selective NMDA antagonist	"Non-competitive NMDA receptor antagonist that acts at the polyamine modulatory site. Selective for NR2B- over NR2A- and NR2C-containing receptors (IC50 values are 1, > 100 and > 100 _M respectively). Also _1 ligand (Ki = 0.013 _M). Antagonizes neuronal voltage-gated Ca2+ channels and selectively inhibits the rapid component of the delayed rectifier K+ current (IKr). Neuroprotective."	"Bath et al (1996) The effects of ifenprodil and eliprodil on voltage-dependent Ca2+ channels and in gerbil global cerebral ischaemia. Eur.J.Pharmacol. 299 103. PMID:8901012. Whittemore et al (1997) Antagonism of N-methyl-D-aspartate receptors by _ site ligands: potency, subtype-selectivity and mechanisms of inhibition. J.Pharmacol.Exp.Ther. 282 326. PMID:9223571. Lengyel et al (2004) Effect of a neuroprotective drug, eliprodil on cardiac repolarisation: importance of the decreased repolarisation reserve in the development of proarrhythmic risk. Br.J.Pharmacol. 143 152. PMID:15302678."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=5238	SQ1533			Mar-2005
2196	3-MATIDA	[518357-51-2]	CC1=C(SC(=C1)C(O)=O)C(N)C(O)=O	"Potent, selective mGlu1 antagonist"	"Potent metabotropic glutamate mGlu1 receptor antagonist (IC50 = 6.3 _M at rat mGlu1a). Displays  40-fold selectivity over other receptors: mGlu5, mGlu2, mGlu4a (IC50 > 300 _M), NMDA and AMPA (IC50 = 250 _M). Neuroprotective in cultured murine cortical cells and rat hippocampal slice cultures in vitro. Reduces the volume of ischemia-induced brain infarcts in rats following systemic administration in vivo."	Moroni et al (2002) The novel and systemically active metabotropic glutamate 1 (mGlu1) receptor antagonist 3-MATIDA reduces post-ischemic neuronal death. Neuropharmacology 42 741. PMID:12015200. Cozzi et al (2002) Metabotropic glutamate 1 (mGlu1) receptor antagonists enhance GABAergic neurotransmission: a mechanism for the attenuation of post-ischemic injury and epileptiform activity? Neuropharmacology 43 119. PMID:12213266. Constantino et al (2004) Stereoselective synthesis and preliminary evaluation of (+)- and (-)-3-methyl-5-carboxy-thien-2-yl-glycine (3-MATIDA): identification of (+)-3-MATIDA as a novel mGluR1 competitive antagonist. Il Farmaco 59 93. PMID:14871500.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=122762				Mar-2005
2197	"L-755,507"	[159182-43-1]	O=S(C1=CC=C(NC(NCCCCCC)=O)C=C1)(NC2=CC=C(CCNC[C@H](O)COC3=CC=C(O)C=C3)C=C2)=O	Very potent and selective _3 partial agonist	"Potent _3-adrenergic receptor partial agonist > 1000-fold selective over _1- and _2-adrenoceptors (EC50 values are 0.43, 580 and > 10000 nM for activation of cloned human _3-, _1- and _2-adrenoceptors respectively). Stimulates lipolysis in rhesus adipocytes in vitro (EC50 = 3.9 nM). Enhances CRISPR-mediated homology-directed repair (HDR) efficiency in human induced pluripotent stem cells (iPSCs)."	"Parmee et al (1998) Discovery of L-755,507: a subnanomolar human _3 adrenergic receptor agonist. Bioorg.Med.Chem.Lett. 8 1107. PMID:9871717. Fisher et al (1998) A selective human _3 adrenergic receptor agonist increases metabolic rate in rhesus monkeys. J.Clin.Invest. 101 2387. PMID:9616210. Yu et al (2015) Small Molecules Enhance CRISPR Genome Editing in Pluripotent Stem Cells. Cell Stem Cell 16 142. PMID:25658371."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=123646	SQ1341			Jul-2005
2198	Mibefradil dihydrochloride	[116666-63-8]	Cl.Cl.COCC(=O)O[C@]1(CCN(C)CCCC2=NC3=C(N2)C=CC=C3)CCC2=C(C=CC(F)=C2)[C@@H]1C(C)C	Ca2+ channel blocker (T-type)	Ca2+ channel blocker with moderate selectivity for T-type Ca2+ channels displaying IC50 values of 2.7 _M and 18.6 _M for T-type and L-type channels respectively. Antihypertensive agent.	"Osterrieder and Holck (1989) In vitro pharmacologic profile of Ro 40-5967, a novel Ca2+ channel blocker with potent vasodilator but weak inotropic action. J.Cardiovasc.Pharmacol. 13 754. PMID:2472524. Veniant et al (1991) Hemodynamic profile of Ro 40-5967 in conscious rats: comparison with diltiazem, verapamil, and amlodipine. J.Cardiovasc.Pharmacol. 18 (Suppl 10 ) S55. PMID:1725005. Mehrke et al (1994) The Ca(++)-channel blocker Ro 40-5967 blocks differently T-type and L-type Ca++ channels. J.Pharmacol.Exp.Ther. 271 1483. PMID:7996461."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=5346	SQ1533			Jun-2006
2199	CGP 71683 hydrochloride	[192322-50-2]	NC1=NC(NC[C@H]3CC[C@H](CNS(=O)(C4=CC=CC5=C4C=CC=C5)=O)CC3)=NC2=C1C=CC=C2.Cl	Highly selective and potent non-peptide NPY Y5 receptor antagonist	"Extremely selective, non-peptide NPY Y5 receptor antagonist. Displays > 1000-fold selectivity over Y1, Y2 and Y4 receptors; IC50 values are 1.4, 2765, 7187 and 5637 nM at cloned rat Y5, Y1, Y2 and Y4 receptors respectively. Potently inhibits NPY-induced food intake following i.p. administration in diabetic, free-feeding and fasted rats."	Criscione et al (1998) Food intake in free-feeding and energy-deprived lean rats is mediated by the neuropeptide Y5 receptor. J.Clin.Invest. 102 2136. PMID:9854049. Dumont et al (2000) Potent and selective tools to investigate neuropeptide Y receptors in the central and peripheral nervous systems: BIB03304 (Y1) and CGP71683A (Y5). Can.J.Physiol.Pharmacol. 78 116. PMID:10737674. Lecklin et al (2002) Receptor subtypes Y1 and Y5 mediate neuropeptide Y induced feeding in the guinea-pig. Br.J.Pharmacol. 135 2029. PMID:11959807.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=5204	SQ1070			May-2005
2200	PD 160170	[181468-88-2]	CC(C)C1=CC=CC=C1S(=O)(=O)C1=CC(N)=C2N=CC=CC2=C1[N+]([O-])=O	Selective non-peptide NPY Y1 receptor antagonist	"Potent, selective non-peptidic neuropeptide Y1 receptor antagonist (Ki = 48 nM); selective over Y2 and Y5 receptors (Ki > 10 _M). Antagonizes NPY-mediated inhibition of cAMP accumulation in SK-N-MC cells (IC50 = 8.2 nM)."	Wright et al (1996) 8-Amino-6-(arylsulphonyl)-5-nitroquinolines: novel nonpeptide neuropeptide Y1 receptor antagonists. Bioorg.Med.Chem.Lett. 6 1809. Wielgosz-Collin et al (2002) 8-Amino-5-nitro-6-phenoxyquinolines:potential non-peptidic neuropeptide Y receptor ligands. J.Enz.Inhib.Med.Chem. 17 449.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=123699	SQ1341			Jul-2005
2201	PNU 22394 hydrochloride	[15923-42-9]	Cl.CN1C2=C(CCNCC2)C2=CC=CC=C12	5-HT2C agonist and 5-HT2A/2B partial agonist	"Potent 5-HT2C agonist and partial 5-HT2A/5-HT2B agonist. Non-selective between 5-HT2 receptor subtypes (Ki values are 18, 18 and 66 nM for human recombinant 5-HT2C, 5-HT2A and 5-HT2B receptors respectively). Reduces food intake in rats following subcutaneous administration and displays anorexigenic effects in humans."	". McCall et al (2001) PNU-22394, a 5-HT2C receptor agonist, reduces feeding in rodents and produces weight loss in humans. Soc.Neurosci.Abstr. 27 309. Jensen et al (2013) Design, synthesis and pharmacological characterization of N- and O-substituted 5,6,7,8-tetrahydro-4H-isoxazolo[4,5-d]azepin-3-ol analogues: novel 5-HT2A/5-HT2C receptor agonists with pro-cognitive properties. J.Med.Chem. 56 1211."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=123700	SQ1341			Feb-2005
2202	Zatebradine hydrochloride	[91940-87-3]	Cl.COC1=CC=C(CCN(C)CCCN2CCC3=C(CC2=O)C=C(OC)C(OC)=C3)C=C1OC	Bradycardic agent; blocks If pacemaker current	Bradycardic agent that produces use-dependent inhibition of hyperpolarization-activated current If (HCN channel) in sinoatrial node cells (EC50 = 480 nM) and Purkinje fibres. Displays negative chronotropic activity in isolated guinea pig atria (EC50 of 13.4 _M).	"Van Bogaert et al (1990) Use- and frequency-dependent blockade by UL-FS 49 of the if pacemaker current in sheep cardiac Purkinje fibres. Eur.J.Pharmacol. 187 241. PMID:2272362. Goethals et al (1993) Use-dependent block of the pacemaker current I(f) in rabbit sinoatrial node cells by zatebradine (UL-FS 49). On the mode of action of sinus node inhibitors. Circulation 88 2389. PMID:8222132. Romanelli et al (2005) Design, synthesis and preliminary biological evaluation of zatebradine analogues as potential blockers of the hyperpolarization-activated current. Bioorg.Med.Chem. 13 1211. PMID:15670930."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=124201	SQ1533			May-2005
2203	PALDA	[136181-87-8]	CCCCCCCCCCCCCCCC(=O)NCCC1=CC(O)=C(O)C=C1	Endogenous lipid; potentiates effects of endovanilloids at TRPV1 receptors	"Endogenous fatty acid dopamide that displays 'entourage' effects on endovanilloids NADA and anandamide. Inactive at TRPV1 and CB1 receptors (at concentrations up to 5 _M) and does not inhibit AMT or FAAH (IC50 > 25 _M). However, potentiates TRPV1-mediated effects of NADA; lowers EC50 from ~ 90 to ~ 30 nM."	"Chu et al (2003) N-Oleoyldopamine, a novel endogenous capsaicin-like lipid that produces hyperalgesia. J.Biol.Chem. 278 13633. PMID:12569099. De Petrocellis et al (2004) Actions of two naturally occurring saturated N-acyldopamines on transient receptor potential vanilloid 1 (TRPV1) channels. Br.J.Pharmacol. 143 251. PMID:15289293."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=124202	SQ1341			Oct-2005
2204	STEARDA	[105955-10-0]	O=C(NCCC1=CC=C(O)C(O)=C1)CCCCCCCCCCCCCCCCC	"Endogenous lipid, active in vivo. Enhances effects of endovanilloids at TRPV1 receptors"	"Endogenous fatty acid dopamide that displays 'entourage' effects on endovanilloids NADA and anandamide. Inactive at TRPV1 and CB1 receptors (at concentrations up to 5 _M) and does not inhibit AMT or FAAH (IC50 > 25 _M). However, potentiates TRPV1-mediated effects of NADA in vitro and in vivo; enhances effects on intracellular Ca2+ (EC50 lowered 3-fold) and nociception. Also inhibits arachidonate 5-lipoxygenase (IC50 = 16 nM)."	"Chu et al (2003) N-Oleoyldopamine, a novel endogenous capsaicin-like lipid that produces hyperalgesia. J.Biol.Chem. 278 13633. PMID:12569099. De Petrocellis et al (2004) Actions of two naturally occurring saturated N-acyldopamines on transient receptor potential vanilloid 1 (TRPV1) channels. Br.J.Pharmacol. 143 251. PMID:15289293."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=124203	SQ1341			Oct-2005
2206	2-Palmitoylglycerol	[23470-00-0]	OCC(CO)OC(CCCCCCCCCCCCCCC)=O	Endogenous lipid; enhances activity of 2-arachidonylglycerol (Cat. No. 1298)	"Endogenous fatty acid glycerol ester that enhances activity of 2-arachidonylglycerol (Cat. No. 1298). Does not bind to CB1 or CB2 cannabinoid receptors, but potentiates the apparent binding of 2-AG and increases its ability to inhibit adenylyl cyclase. Enhances in vivo cannabinoid effects of 2-AG following combined administration with 2-linoleoylglycerol."	"Ben-Shabat et al (1998) An entourage effect: inactive endogenous fatty acid glycerol esters enhance 2-arachidonyl-glycerol cannabinoid activity. Eur.J.Pharmacol. 353 23. PMID:9721036. Gallily et al (2000) 2-Arachidonylglycerol, an endogenous cannabinoid, inhibits tumor necrosis factor-_ production in murine macrophages, and in mice. Eur.J.Pharmacol. 406 R5. PMID:11011050. Walker et al (2002) Endocannabinoids and related fatty acid derivatives in pain modulation. Chem.Phys.Lipids 121 159. PMID:12505698."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=124205	SQ1070			May-2005
2208	LY 255283	[117690-79-6]	CCC1=C(OCCCCCC(C)(C)C2=NN=NN2)C=C(O)C(=C1)C(C)=O	"Selective, competitive BLT2 receptor antagonist"	"Selective, competitive antagonist of BLT2 receptors (IC50 values are ~ 1 and > 10 _M at human recombinant BLT2 and BLT1 receptors respectively). Inhibits LTB4-induced contraction of lung parenchyma (pA2 = 7.2), and reduces LTB4-mediated airway obstruction in guinea pigs following i.v. and oral administration. ."	"Herron et al (1992) Leukotriene B4 receptor antagonists: the LY255283 series of hydroxyacetophenones. J.Med.Chem. 35 1818. PMID:1316967. Silbaugh et al (1992) Pulmonary actions of LY255283, a leukotriene B4 receptor antagonist. Eur.J.Pharmacol. 223 57. PMID:1335877. Yokomizo et al (2001) Hydroxyeicosanoids bind to and activate the low affinity leukotriene B4 receptor, BLT2. J.Biol.Chem. 276 12454. PMID:11278893."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=40407	SQ1070			Jun-2005
2211	Carcinine ditrifluoroacetate	[56897-53-1]	NCCC(NCCC1=CN=CN1)=O	Highly selective H3 antagonist	"Highly selective H3 receptor antagonist (Ki values are 0.30, 365 and 3621 _M for H3, H2 and H1 receptors respectively). Acts as a natural antioxidant with hydroxyl radical scavenging and lipid peroxidase activities."	Babizhayev et al (1994) L-Carnosine (_-alanyl-L-histidine) and carcinine (_-alanylhistamine) act as natural antioxidants with hydroxyl-radical-scavenging and lipid-peroxidase activities. Biochem.J. 304 509. PMID:7998987. Chen et al (2004) Pharmacological effects of carcinine on histaminergic neurons in the brain. Br.J.Pharmacol. 143 573. PMID:15466447.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=124245	SQ1070			Oct-2009
2213	N20C hydrochloride	[1177583-87-7]	Cl.NC(=O)CNCCC(C1=CC=CC=C1)C1=CC=CC=C1	Non-competitive NMDA receptor open-channel blocker	"Selective, non-competitive NMDA receptor antagonist (IC50 = 5 _M); binds to the receptor-associated ion channel and prevents glutamate-induced Ca2+ influx. Displays neuroprotective activity in vivo. Brain-penetrant."	Planells-Cases et al (2002) A novel N-methyl-D-aspartate receptor open channel blocker with in vivo neuroprotectant activity. J.Pharmacol.Exp.Ther. 302 163. PMID:12065713.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=124256	SQ1341			Jan-2005
2214	ABT 724 trihydrochloride	[587870-77-7]	Cl.Cl.Cl.C(N1CCN(CC1)C1=NC=CC=C1)C1=NC2=CC=CC=C2N1	"Potent, selective D4 partial agonist; proerectile"	Potent dopamine D4 receptor partial agonist (EC50 = 12.4 nM; 61% efficacy vs. dopamine). Has no agonist activity at D2 receptors (EC50 > 10 _M). Selective in rats in vivo; produces penile erection following i.c.v. administration; increases intracavernosal pressure and potentiates the proerectile effects of sildenafil following s.c. administration. Displays minimal side effects.	"Stewart et al (2004) Dopamine D4 ligands and models of receptor activation: 2-(4-pyridin-2-ylpiperazin-1-ylmethyl)-1H-benzimidazole and related heteroarylmethylarylpiperazines exhibit a substituent effect responsible for additional efficacy tuning. J.Med.Chem. 47 2348. PMID:15084133. Cowart et al (2004) Discovery of 2-(4-pyridin-2-ylpiperazin-1-ylmethyl)-1H-benzimidazole (ABT-724), a dopaminergic agent with a novel mode of action for the potential treatment of erectile dysfunction. J.Med.Chem. 47 3853. PMID:15239663. Brioni et al (2004) Activation of dopamine D4 receptors by ABT-724 induces penile erection in rats. Proc.Natl.Acad.Sci.USA 101 6758."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=124748	SQ1070			Jan-2005
2217	()-HIP-A	[227619-64-9]	OC1=NO[C@@]2([H])[C@@]([H])1[C@H]([C@@](O)=O)NC2.OC3=NO[C@]4([H])[C@]([H])3[C@@H](C(O)=O)NC4	"Potent, non-competitive EAAT inhibitor"	"Potent, non-competitive excitatory amino acid transporter (EAAT) blocker. Preferentially inhibits glutamate-induced [3H]D-aspartate release (IC50 = 1.6 _M) rather than [3H]L-glutamate uptake (IC50 = 18 _M). Moderately selective; displays no affinity for NMDA and metabotropic glutamate receptors, and low affinity for AMPA and kainate receptors (IC50 values are 43 and 8 _M respectively).  ."	"Conti et al (1999) Synthesis and enantiopharmacology of new AMPA-kainate receptor agonists. J.Med.Chem. 42 4099. PMID:10514280. Conti et al (1999) Synthesis of new bicyclic analogues of glutamic acid. Tetrahedron 55 5623. Funicello et al (2004) Dissociation of [3H]glutamate uptake from glutamate-induced [3H]D-Aspartate release by 3-hydroxy-4,5,6,6a-tetrahydro-3aH-pyrrolo[3,4-d]isoxazole-4-carboxylic acid and 3-hydroxy-4,5,6,6a-tetrahydro-3aH-pyrrolo[3,4-d]isoxazole-6-carboxylic acid, two conformationally constrained aspartate and glutamate analogs. Mol.Pharmacol. 66 522. PMID:15322243."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=125757	SQ1341			Jul-2005
2218	()-HIP-B	[227619-65-0]	OC1=NO[C@@]2([H])[C@@]([H])1CN[C@@H]2[C@@](O)=O.OC3=NO[C@]4([H])[C@]([H])3CN[C@H]4C(O)=O	"Potent, non-competitive EAAT inhibitor"	"Potent, non-competitive excitatory amino acid transporter (EAAT) blocker. Preferentially inhibits glutamate-induced [3H]D-aspartate release (IC50 = 1.2 _M) rather than [3H]L-glutamate uptake (IC50 = 16.9 _M). Moderately selective; displays no affinity for NMDA and metabotropic glutamate receptors, and low affinity for AMPA and kainate receptors (IC50 values are 35 and 45 _M respectively)."	"Conti et al (1999) Synthesis and enantiopharmacology of new AMPA-kainate receptor agonists. J.Med.Chem. 42 4099. PMID:10514280. Conti et al (1999) Synthesis of new bicyclic analogues of glutamic acid. Tetrahedron 55 5623. Funicello et al (2004) Dissociation of [3H]glutamate uptake from glutamate-induced [3H]D-Aspartate release by 3-hydroxy-4,5,6,6a-tetrahydro-3aH-pyrrolo[3,4-d]isoxazole-4-carboxylic acid and 3-hydroxy-4,5,6,6a-tetrahydro-3aH-pyrrolo[3,4-d]isoxazole-6-carboxylic acid, two conformationally constrained aspartate and glutamate analogs. Mol.Pharmacol. 66 522. PMID:15322243."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=125758	SQ1341			Jul-2005
2226	Flutax 1	[191930-58-2]	O=C2[C@@]3(C)C([C@@]4(OC(C)=O)[C@H](OC4)C[C@@H]3OC([C@H](C)NC(C7=CC=C(C8=C(C=C%10)C(OC9=C8C=CC(O)=C9)=CC%10=O)C(C(O)=O)=C7)=O)=O)[C@H](OC(C6=CC=CC=C6)=O)[C@@]1(O)[C@](C)(C)C([C@H]2OC(C)=O)=C(C)[C@@H](OC([C@H](O)[C@H]([C@]5=CC=CC=C5)NC(C%11=CC=CC=C%11)=O)=O)C1	Fluorescent taxol derivative	A fluorescent taxol derivative that binds to the taxol microtubule binding site with high affinity (Ka ~ 107M-1). Useful for direct imaging of the microtubule cytoskeleton. Excitation maximum ~ 495 nm; emission maximum ~ 520 nm.	Evangelio et al (1998) Fluorescent taxoids as probes of the microtubule cytoskeleton. Cell Motil.Cytoskel. 39 73. Diaz et al (2000) Molecular recognition of taxol by microtubules. Kinetics and thermodynamics of binding of fluorescent taxol derivatives to an exposed site. J.Biol.Chem. 275 26265. PMID:10818101. Diaz et al (2003) Fast kinetics of taxol binding to microtubules. J.Biol.Chem. 278 8407. PMID:12496245.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=127647	SQ1341			Dec-2005
2227	CI 976	[114289-47-3]	CCCCCCCCCCC(C)(C)C(=O)NC1=C(OC)C=C(OC)C=C1OC	Acyl-CoA:cholesterol acyltransferase (ACAT) inhibitor	Selective acyl-coenzyme A:cholesterol acyltransferase (ACAT) inhibitor (IC50 = 0.073 _M). Lowers non-high density lipoprotein (HDL)-cholesterol and increases HDL-cholesterol concentrations in rats with pre-established dyslipidemia. Orally active. Also inhibits Golgi-associated LPL acyltransferase (LPAT) activity (IC50 = 15 _M).	Sliskovic and White (1991) Therapeutic potential of ACAT inhibitors as lipid lowering and anti-atherosclerotic agents. TiPS. 12 194. Krause et al (1993) In vivo evidence that the lipid-regulating activity of ACAT inhibitor CI-976 in rats is due to inhibition of both intestinal and liver ACAT. J.Lipid Res. 34 279. PMID:8429262. Drecktrah et al (2003) Inhibition of a Golgi complex lysophospholipid acyltransferase induces membrane tubule formation and retrograde trafficking. Mol.Biol.Cell 14 3549.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=127648	SQ1341			Apr-2005
2228	Leflunomide	[75706-12-6]	CC1=C(C=NO1)C(=O)NC1=CC=C(C=C1)C(F)(F)F	Dihydroorotate dehydrogenase inhibitor	"Inhibitor of dihydroorotate dehydrogenase (IC50 = 2.5 _M). Inhibits de novo pyrimidine synthesis in human T cells in vitro; also inhibits lymphocyte proliferation. Exhibits efficacy in several animal models of autoimmune disease, arthritis and graft rejection. Active metabolite, teriflunomide (A77 1726, Cat. No. 5069), also available."	"Greene et al (1995) Inhibition of dihydroorotate dehydrogenase by the immunosuppressive agent leflunomide. Biochem.Pharmacol. 50 861. PMID:7575649. Cherwinski et al (1995) The immunosuppressant leflunomide inhibits lymphocyte proliferation by inhibiting pyrimidine biosynthesis. J.Pharmacol.Exp.Ther. 275 1043. PMID:7473131. Brazelton and Morris (1996) Molecular mechanisms of action of new xenobiotic immunosuppressive drugs: tacrolimus (FK506), sirolimus (rapamycin), mycophenolate mofetil and leflunomide. Curr.Opin.Immunol. 8 710. PMID:8902398."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=5299	SQ1533			Mar-2005
2229	GW 0742	[317318-84-6]	CC1=C(CSC2=CC(C)=C(OCC(O)=O)C=C2)SC(=N1)C1=CC(F)=C(C=C1)C(F)(F)F	"Highly selective, potent PPAR_ agonist"	"Potent and highly selective PPAR_ agonist. EC50 values are 0.001, 1.1 and 2 _M for transactivation of human PPAR_, -_, and -_ receptors respectively. Neuroprotective in rat cerebellar granule neuronal cultures after brief (12-hour) exposure but exhibits inherent toxicity after prolonged (48-hour) incubation. Increases rate of fatty acid oxidation and protects against ischemia/reperfusion injury in neonatal and adult cardiomyocytes."	Sznaidman et al (2003) Novel selective small molecule agonists for peroxisome proliferator-activated receptor _ (PPAR_) - Synthesis and biological activity. Bioorg.Med.Chem.Lett. 13 1517. PMID:12699745. Smith et al (2004) Effect of the peroxisome proliferator-activated receptor _ activator GW0742 in rat cultured cerebellar granule neurons. J.Neurosci.Res. 77 240. PMID:15211590. Yue et al (2008) In vivo activation of peroxisome proliferator-activayed receptor-_ protects the heart from ischemia/reperfusion injury in Zucker fatty rats. J.Pharm.Exp.Ther. 325 466.	Small Molecule	Sold for research purposes under agreement from GlaxoSmithKline	http://www.tocris.com/dispprod.php?ItemId=128231	SQ1533			Jan-2005
2237	BRL 50481	[433695-36-4]	CN(C)S(=O)(=O)C1=C(C)C=CC(=C1)[N+]([O-])=O	Selective PDE7 inhibitor	"Selective, substrate-competitive inhibitor of phosphodiesterase (PDE) 7 (Ki = 180 nM). Displays > 200-fold selectivity over PDE1B, PDE1C, PDE2, PDE3, PDE4A4 and PDE5."	"Smith et al (2004) Discovery of BRL 50481 [3-(N,N-dimethylsulfonamido)-4-methyl-nitrobenzene], a selective inhibitor of phosphodiesterase 7: in vitro studies in human monocytes, lung macrophages, and CD8+ T-lymphocytes. Mol.Pharmacol. 66 1679. PMID:15371556."	Small Molecule	Sold with the permission of GlaxoSmithKline	http://www.tocris.com/dispprod.php?ItemId=129551				Apr-2005
2238	GW 441756	[504433-23-2]	CN1C=C(C=C2C(=O)NC3=CC=CN=C23)C2=C1C=CC=C2	"Potent, selective TrkA inhibitor"	"Potent, selective inhibitor of the NGF receptor tyrosine kinase A (TrkA) (IC50 = 2 nM). Displays > 100-fold selectivity over a range of other kinases."	Wood et al (2004) Discovery and in vitro evaluation of potent TrkA kinase inhibitors: oxindole and aza-oxindoles. Bioorg.Med.Chem.Lett. 14 953. PMID:15013000.	Small Molecule	Sold for research purposes under agreement from GlaxoSmithKline.	http://www.tocris.com/dispprod.php?ItemId=129573	SQ1533			Jun-2005
2239	GW 583340 dihydrochloride	[1173023-85-2]	Cl.Cl.CS(=O)(=O)CCNCC1=NC(=CS1)C1=CC=C2N=CN=C(NC3=CC=C(OCC4=CC=CC(F)=C4)C(Cl)=C3)C2=C1	Potent dual EGFR/ErbB2 inhibitor; orally active	"Potent dual EGFR/ErbB2 tyrosine kinase inhibitor (IC50 values are 0.01 and 0.014 _M respectively). Selectively inhibits growth of human tumor cells overexpressing EGFR and ErbB2 (IC50 values are 0.11 _M for inhibition of HN5, N87 and BT474 tumor cell lines vs. > 30 _M for inhibition of non-tumor cell line HFF). Inhibits tumor growth in vivo by ~ 80% in a murine xenograft model following oral administration."	Gaul et al (2003) Discovery and biological evaluation of potent dual ErbB-2/EGFR tyrosine kinase inhibitors: 6-thiazolylquinazolines. Bioorg.Med.Chem.Lett. 13 637. PMID:12639547.	Small Molecule	Sold for research purposes under agreement from GlaxoSmithKline.	http://www.tocris.com/dispprod.php?ItemId=129574	SQ1341			Jun-2005
2241	DMAB-anabaseine dihydrochloride	[154149-38-9]	CN(C)C1=CC=C(/C=C2/C(C3=CN=CC=C3)=NCCC2)C=C1.Cl.Cl	Partial agonist at _7-containing receptors and antagonist at _4_2 neuronal nicotinic receptors	Partial agonist at _7-containing neuronal nicotinic receptors and antagonist at _4_2 and other nicotinic receptors. Displays specific cognition-enhancing effects; improves long-term memory in rats.	Arendash et al (1995) Improved learning and memory in aged rats with chronic administration of the nicotinic receptor agonist GTS-21. Brain Res. 674 252. PMID:7796104. Kem et al (1997) Anabaseine is a potent agonist on muscle and neuronal alpha-bungarotoxin-sensitive nicotinic receptors. J.Pharmacol.Exp.Ther. 283 979. PMID:9399967. Stevens et al (1998) Selective alpha7-nicotinic agonists normalize inhibition of auditory response in DBA mice. Psychopharmacology 136 320. PMID:9600576.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=129870				May-2005
2242	Octopamine hydrochloride	[770-05-8]	Cl.NCC(O)C1=CC=C(O)C=C1	Invertebrate biogenic amine: activates _3 adrenoceptors	"Invertebrate biogenic amine neurotransmitter, related to noradrenalin, that is an adrenoceptor agonist. Stimulates lipolysis in mammalian adipocytes via activation of _3 receptors. Has dual effect on glucose transport in adipocytes: inhibits transport via _3 receptor activation but stimulates transport when oxidized by MAO. Also activates human _2A receptors, inhibiting subsequent cAMP production."	Airriess et al (1997) Selective inhibition of adenylyl cyclase by octopamine via a human cloned _2A-adrenoceptor. Br.J.Pharmacol. 122 191. PMID:9313925. Roeder (1999) Octopamine in invertebrates. Prog.Neurobiol. 59 533. PMID:10515667. Carpene et al (1999) Selective activation of _3-adrenoceptors by octopamine: comparative studies in mammalian fat cells. Naunyn-Schmied.Arch.Pharmacol. 359 310. Visentin et al (2001) Dual action of octopamine on glucose transport into adipocytes: inhibition via _3-adrenoceptor activation and stimulation via oxidation by amine oxidases. J.Pharmacol.Exp.Ther. 299 96. PMID:11561068.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=130116	SQ1533			Mar-2005
2251	Cisplatin	[15663-27-1]	N.N.[Cl-].[Cl-].[Pt++]	Potent pro-apoptotic anticancer agent; activates caspase-3	"Potent anticancer agent that blocks DNA synthesis. Induces apoptosis via p53-dependent and -independent mechanisms. Inhibits X-linked inhibitor of apoptosis protein (XIAP) expression and activates caspase-3. In certain glioma cell lines, sensitizes cells to TNF-_-induced apoptosis."	"Seki et al (2000) Cisplatin (CDDP) specifically induces apoptosis via sequential activation of caspase-8, -3 and -6 in osteosarcoma. Cancer Chemother.Pharmacol. 45 199. PMID:10663637. Duan et al (2004) Impairment of both apoptotic and cytoprotective signalings in glioma cells resistant to the combined use of cisplatin and tumor necrosis factor _. Clin.Cancer Res. 10 234. PMID:14734475. Nomura et al (2004) Cisplatin inhibits the expression of X-linked inhibitor of apoptosis protein in human LNCaP cells. Urol.Oncology 22 453."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=131992				Apr-2005
2252	Doxorubicin hydrochloride	[25316-40-9]	OC1=C(C[C@]([C@](CO)=O)(O)C[C@@H]4O[C@@]5([H])C[C@H](N)[C@H](O)[C@H](C)O5)C4=C(O)C3=C1C(C2=CC=CC(OC)=C2C3=O)=O.Cl	Antitumor antibiotic agent. Inhibits DNA topoisomerase II	Antitumor antibiotic agent that inhibits DNA topoisomerase II. DNA intercalator that inhibits nucleic acid synthesis and induces apoptosis. Reduces intracellular tau levels.	Skladanowski and Konopa (1993) Adriamycin and daunomycin induce programmed cell death (apoptosis) in tumour cells. Biochem.Pharmacol. 46 357. PMID:8347161. Patel et al (1997) Identification of yeast DNA topoisomerase II mutants resistant to the antitumor drug doxorubicin: implications for the mechanisms of doxorubicin action and cyotoxicity. Mol.Pharmacol. 52 658. PMID:9380029. Gewirtz (1999) A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem.Pharmacol. 57 727. PMID:10075079. Dickey et al (2006) Pharmacologic reductions of total tau levels; implications for the role of microtubule dynamics in regulating tau expression. Mol.Neurodegen. 1 6. PMID:16930453.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=131997	SQ1533			May-2005
2254	ACDPP hydrochloride	[37804-11-8]	Cl.CN(C)C1=C(Cl)N=C(C(=O)NC2=CN=CC=C2)C(N)=N1	Selective mGlu5 receptor antagonist	Antagonist at the mGlu5 receptor (Ki = 295 nM). Inhibits human mGlu5 receptor-mediated calcium flux with an IC50 of 134 nM.	Bonnefous et al (2005) Dipyridyl amides: potent metabotropic glutamate subtype 5 (mGlu5) receptor antagonists. Bioorg.Med.Chem.Lett. 15 1197. PMID:15686941. Wang et al (2008) Roles of calcium-stimulated adenylyl cyclase and calmodulin-dependent protein kinase IV in the regulation of FMRP by group I metabotropic glutamate receptors. J.Neurosci. 28 4385. PMID:18434517.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=132007	SQ1341			Jun-2005
2255	CGS 9343B	[109826-27-9]	OC(=O)\C=C/C(O)=O.CC1(CN2CCC(CC2)N2C(=O)NC3=C2C=CC=C3)OCC2=C(C=CC=C2)N2C=CC=C12	Calmodulin antagonist	"Calmodulin antagonist; inhibits calmodulin-stimulated cAMP phosphodiesterase activity with an IC50 of 3.3 nM. Also prevents estrogen-induced transcription activation by ER, reversibly blocks voltage-activated Na+, Ca2+ and K+ currents in PC12 cells and inhibits nAChR."	"Norman et al (1987) CGS 9343B, a novel, potent, and selective inhibitor of Calmodulin activity. Mol.Pharmacol. 31 535. PMID:3033469. Neuhaus and Reber (1992) Inhibition of membrane currents and rises of intracellular Ca2+ in PC12 cells by CGS 9343B, a calmodulin inhibitor. Eur.J.Pharmacol. 226 183. PMID:1379190. Li et al (2003) Calmodulin regulates the transcriptional activity of estrogen receptors. J.Biol.Chem. 278 1195. PMID:12419798."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=132008	SQ1533			Aug-2006
2261	"L-692,585"	[145455-35-2]	C[C@@H](O)CNC(C)(C)CC(=O)N[C@@H]1CCC2=CC=CC=C2N(CC2=CC=C(C=C2)C2=CC=CC=C2C2=NNN=N2)C1=O	"Potent, non-peptide ghrelin receptor agonist"	"Highly potent, non-peptide ghrelin receptor (GHS-R1a) agonist (Ki = 0.8 nM). Increases plasma GH levels in vivo and is 2- to 2.5-fold more potent than GHRP-6."	"Jacks et al (1994) Effects of acute and repeated intravenous administration of L-692,585, a novel non-peptidyl growth hormone secretagogue, on plasma growth hormone, IGF-1, ACTH, cortisol, prolactin, insulin, and thyroxine levels in beagles. J.Endocrinol. 143 399. PMID:7830002. Smith et al (1999) Peptidomimetic regulation of growth hormone secretion. Endocrine Rev. 18 621. Glavaski-Joksimovic et al (2002) Mechanism of action of the growth hormone secretagogue, L-692,585, on isolated porcine somatotropes. J.Endocrinol. 175 625. PMID:12475374."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=132015	SQ1341			Oct-2006
2266	DY131	[95167-41-2]	CCN(CC)C1=CC=C(C=C1)\C=N\NC(=O)C1=CC=C(O)C=C1	Agonist selective for estrogen-related receptors ERR_ and ERR_	"Novel selective agonist at estrogen-related receptors ERR_ and ERR_. Displays minimal activity at ERR_, ER_ and ER_ at concentrations up to 30 _M."	Yu and Forman (2005) Identification of an agonist ligand for estrogen-related receptors ERR_/_. Bioorg.Med.Chem.Lett. 15 1311. PMID:15713377.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=132020				Mar-2005
2268	NNC 55-0396 dihydrochloride	[357400-13-6]	FC1=CC(CC[C@@](CCN(C)CCCC3=NC(C=CC=C5)=C5N3)(OC(C4CC4)=O)[C@H]2[C@H](C)C)=C2C=C1.Cl.Cl	Highly selective Ca2+ channel blocker (T-type)	Highly selective T-type calcium channel blocker. Displays IC50 values of 6.8 and > 100 _M for inhibition of Cav3.1 T-type channels and HVA currents respectively in INS-1 cells.	"Huang et al (2004) NNC 55-0396 [(1S,2S)-2-(2-(N-[(3-benzimidazol-2-yl)propyl]-N-methylamino)ethyl)-6-fluoro-1,2,3,4-tetrahydro-1-isopropyl-2-naphtyl cyclopropanecarboxylate dihydrochloride]: A new selective inhibitor of T-type calcium channels. J.Pharmacol.Exp.Ther. 309 193. PMID:14718587. Chen et al (2010) CaV3.2 T-type Ca2+ channel-dependent activation of ERK in paraventricular thalamus modulates acid-induced chronic muscle pain. J.Neurosci. 30 10360. PMID:20685979."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=132066	SQ1341			Jun-2006
2270	SCH 58261	[160098-96-4]	NC1=NC2=C(C=NN2CCC2=CC=CC=C2)C2=NC(=NN12)C1=CC=CO1	"Potent, highly selective A2A antagonist"	"Potent and selective A2A adenosine receptor competitive antagonist (Ki = 1.3 nM). Displays 323-, 53- and 100-fold selectivity over A1, A2B and A3 receptors, respectively."	"Zocchi et al (1996) Binding of the radioligand [3H]-SCH 58261, a new non-xanthine A2A adenosine receptor antagonist, to rat striatal membranes. J.Pharmacol.Exp.Ther. 276 398. PMID:8632302. Belardinelli et al (1997) The A2A adenosine receptor mediates coronary vasodilation. J.Pharmacol.Exp.Ther. 284 1066. Bastia et al (2002) Effects of A1 and A2A adenosine receptor ligands in mouse acute models of pain. Neurosci.Lett. 328 241. PMID:12147316."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=132243	SQ1341			Aug-2005
2272	Ro 08-2750	[37854-59-4]	CN1C2=CC(C=O)=C(C)C=C2N=C2C(=O)NC(=O)N=C12	Inhibits NGF binding to p75NTR and TrkA	"Non-peptide inhibitor of NGF that binds the NGF dimer (KD ~ 1 _M) possibly causing a conformational change. Selectively inhibits binding of NGF to p75NTR at submicromolar concentrations, and to both p75NTR and TrkA at concentrations > 5 _M. Prevents NGF-induced apoptosis in SK-N-MC cells."	Niederhauser et al (2000) NGF ligand alters NGF signaling via p75NTR and TrkA. J.Neurosci.Res. 61 263. PMID:10900073. Arkin and Wells (2004) Small-molecule inhibitors of protein-protein interactions: progressing towards the dream. Nat.Rev.Drug Discov. 3 301. PMID:15060526.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=132740	SQ1341			Aug-2006
2273	PMPA (NMDA antagonist)	[113919-36-1]	OP(CN1CC(C(O)=O)NCC1)(O)=O	Competitive NMDA antagonist	"Competitive NMDA receptor antagonist. Displays Ki values of 0.84, 2.74, 3.53 and 4.16 _M at NR2A, NR2B, NR2C and NR2D subunit-containing receptors respectively. Selective over AMPA receptors."	Harris and Davies (1992) Cortically evoked excitatory synaptic transmission in the cat red nucleus is antagonised by D-AP5 but not by D-AP7. Brain Res. 594 176. PMID:1361408. Feng et al (2005) The effect of competitive antagonist chain length on NMDA receptor subunit selectivity. Neuropharmacology 48 354. PMID:15721167.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=132749	SQ1341			Apr-2006
2274	PPPA	[113190-92-4]	O=P(CCC[C@@H]1C[C@H]([C@](O)=O)NCC1)(O)O.O=C([C@H]2NCC[C@@H](CCCP(O)(O)=O)C2)O	Competitive NR2A antagonist	"Competitive NMDA receptor antagonist that displays moderate selectivity for NR2A-containing receptors (Ki values are 0.13, 0.47, 1.10 and 3.86 _M for NR2A, NR2B, NR2C and NR2D subunits respectively)."	Benveniste and Mayer (1992) Effect of extracellular pH on the potency of N-methyl-D-aspartic acid receptor competitive antagonists. Mol.Pharmacol. 42 679. PMID:1435743. Feng et al (2005) The effect of competitive antagonist chain length on NMDA receptor subunit selectivity. Neuropharmacology 48 354. PMID:15721167. Kinarsky et al (2005) Identification of subunit- and antagonist-specific amino acid residues in the N-methyl-D-aspartate receptor glutamate-binding pocket. J.Pharmacol.Exp.Ther. 313 1066. PMID:15743930.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=132750	SQ1341			Nov-2006
2275	TBB	[17374-26-4]	BrC1=C2NN=NC2=C(Br)C(Br)=C1Br	Selective cell-permeable CK2 inhibitor	"A cell-permeable, selective inhibitor of casein kinase-2 (CK2) (IC50 = 0.9 and 1.6 _M for rat liver and human recombinant CK2 respectively). Exhibits modest discrimination between CK2 subunits, with Ki values ranging from 80 nM to 210 nM. Acts in an ATP/GTP-competitive manner and displays one to two orders of magnitude selectivity over a panel of 33 protein kinases."	"Sarno et al (2001) Selectivity of 4,5,6,7-tetrabromobenzotriazole, an ATP site-directed inhibitor of protein kinase CK2 ('casein kinase-2'). FEBS Lett. 496 44. PMID:11343704. Pagano et al (2004) Optimization of protein kinase CK2 inhibitors derived from 4,5,6,7-tetrabromobenzimidazole. J.Med.Chem. 47 6239. PMID:15566294. Zien et al (2005) Tetrabromobenzotriazole (TBBt) and tetrabromobenzimidazole (TBBz) as selective inhibitors of protein kinase CK2: evaluation of their effects on cells and different molecular forms of human CK2. Biochim.Biophys.Acta. 1754 271. PMID:16203192."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=132972				Oct-2005
2276	FPL 55712	[40785-97-5]	CCCC1=C(O)C(=CC=C1OCC(O)COC1=CC=C2C(=O)C=C(OC2=C1CCC)C(O)=O)C(C)=O	Leukotriene receptor antagonist	"Leukotriene receptor antagonist; inhibits contraction of guinea pig trachealis induced by leukotrienes C4, D4, E4 and F4."	"Jones et al (1983) Pharmacological study of the effects of leukotrienes C4, D4, E4 & F4 on guinea pig trachealis: interaction with FPL-55712. Prostaglandins 26 833. PMID:6322240. O'Donnell and Welto (1984) Pharmacologic properties of FPL 55712 administered by aerosol. Agents Actions 14 43. PMID:6322547. Folkerts et al (1995) Leukotrienes mediate tracheal hyperresponsiveness after nitric oxide synthesis inhibition. Eur.J.Pharmacol. 285 R1. PMID:8566126."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=133065	SQ1341			Jun-2006
2280	Raloxifene hydrochloride	[82640-04-8]	Cl.OC1=CC=C(C=C1)C1=C(C(=O)C2=CC=C(OCCN3CCCCC3)C=C2)C2=CC=C(O)C=C2S1	Selective estrogen receptor modulator (SERM)	"Selective estrogen receptor modulator (SERM) that binds to ER_ and ER_, and tissue-dependently activates or blocks estrogen-induced transcription. Acts as an antiestrogen in breast and uterine tissue, but displays estrogen agonist activity in bone. In D12 rat hypothalamic cells, inhibits progesterone receptor induction by estrogen with an IC50 of 1 nM."	"Fitzpatrick et al (1999) Effect of estrogen agonists and antagonists on induction of progesterone receptor in a rat hypothalamic cell line. Endocrinology 140 3928. PMID:10465261. Bryant (2001) Mechanism of action and preclinical profile of raloxifene, a selective estrogen receptor modulator. Rev.Endocr.Metab.Disord. 2 129. PMID:11704975. Hibner et al (2004) Effects of raloxifene hydrochloride on endometrial cancer cells in vitro. Gynecologic Oncol. 93 642."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=5397	SQ1533			Jun-2005
2281	2'-MeCCPA	[205171-12-6]	O[C@@H]1[C@@H](CO)O[C@@H](N2C=NC3=C2N=C(Cl)N=C3NC4CCCC4)[C@@](C)1O	Very selective and potent A1 receptor agonist	"Potent and highly selective agonist at A1 adenosine receptors (Ki values are 3.3, 9580, 37600 and 1150 nM for human recombinant A1, A2A, A2B and A3 receptors respectively). Acts as a full agonist; inhibits forskolin-stimulated adenylyl cyclase activity in rat cortical membranes with an IC50 value of 13.1 nM."	"Franchetti et al (1998) 2'-C-Methyl analogues of selective adenosine receptor agonists: synthesis and binding studies. J.Med.Chem. 41 1708. PMID:9572897. Cappellacci et al (2005) Synthesis, biological evaluation, and molecular modeling of ribose-modified adenosine analogues as adenosine receptor agonists. J.Med.Chem. 48 1550. PMID:15743197."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=137074	SQ1341			Feb-2006
2282	Moxonidine hydrochloride	[75536-04-8]	Cl.COC1=NC(C)=NC(Cl)=C1NC1=NCCN1	I1 receptor and _2-adrenoceptor agonist (I1 > _2)	Mixed I1 imidazoline receptor and _2-adrenergic agonist; displays 40-fold higher affinity for I1 receptors versus _2-adrenoceptors. Centrally acting antihypertensive agent.	Schafer et al (2002) Presynaptic effects of moxonidine in isolated buffer perfused rat hearts: role of imidazoline-1 receptors and _2-adrenoceptors. J.Pharmacol.Exp.Ther. 303 1163. PMID:12438540. El-Ayoubi et al (2004) Imidazoline receptors but not a2-adrenoceptors are regulated in spontaneously hypertensive rat heart by chronic moxonidine treatment. J.Pharmacol.Exp.Ther. 310 446. PMID:15075383. Chan et al (2005) Imidazoline receptors associated with noradrenergic terminals in the rostral ventrolateral medulla mediate the hypotensive responses of moxonidine but not clonidine. Neuroscience 132 991. PMID:15857704.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=137154	SQ1533			Jun-2005
2284	SEW 2871	[256414-75-2]	FC(F)(F)C1=C(C=C(S1)C1=NC(=NO1)C1=CC(=CC=C1)C(F)(F)F)C1=CC=CC=C1	"Cell-permeable, selective S1P1 receptor agonist"	"Novel, potent and selective sphingosine-1-phosphate 1 (S1P1) receptor agonist. Activates S1P1 receptor with an EC50 of 13 nM, but does not activate S1P2, S1P3, S1P4 or S1P5 receptors at concentrations up to 10 _M. Cell-permeable and active in vivo."	"Hale et al (2004) A rational utilization of high-throughput screening affords selective, orally bioavailable 1-benzyl-3-carboxyazetidine sphingosine-1-phosphate-1 receptor agonists. J.Med.Chem. 47 6662. PMID:15615513. Sanna et al (2004) Sphingosine 1-phosphate (S1P) receptor subtypes S1P1 and S1P3, respectively, regulate lymphocyte recirculation and heart rate. J.Biol.Chem. 279 13839. PMID:14732717. Bolick et al (2005) Sphingosine-1-phosphate prevents tumor necrosis factor-_-mediated monocyte adhesion to aortic endothelium in mice. Arterioscler.Thromb.Vasc.Biol. 25 976. PMID:15761190."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=137192	SQ1341			Jun-2005
2288	O-1918	[536697-79-7]	COC1=CC(C)=CC(OC)=C1[C@@H]1C=C(C)CC[C@H]1C(C)=C	Silent antagonist for putative abnormal-CBD (Cat. No. 1297) receptor	"Selective, silent antagonist of a putative endothelial anandamide receptor distinct from CB1 or CB2 receptors. Inhibits vasodilation and cell migration induced by abnormal-cannabidiol (abn-CBD; Cat. No. 1297)."	"Offertler et al (2003) Selective ligands and cellular effectors of a G protein-coupled endothelial cannabinoid receptor. Mol.Pharmacol. 63 699. PMID:12606780. Mo et al (2004) Atypical cannabinoid stimulates endothelial cell migration via a Gi/Go coupled receptor distinct from CB1, CB2 or EDG-1. Eur.J.Pharmacol. 489 21. PMID:15063151. Hoi and Hiley (2006) Vasorelaxant effects of oleamide in rat small mesenteric artery indicate action at a novel cannabinoid receptor. Br.J.Pharmacol. 147 560. PMID:16415907."	Small Molecule	"Sold under license from the NIH, US patent 60/312,674"	http://www.tocris.com/dispprod.php?ItemId=137580	SQ1341			Jan-2007
2289	Lamotrigine isethionate	[113170-86-8]	OCCS(O)(=O)=O.NC1=NC(N)=C(N=N1)C1=CC=CC(Cl)=C1Cl	Inhibits glutamate release. Water-soluble salt of lamotrigine (Cat. No. 1611)	"Water-soluble salt of lamotrigine (Cat. No. 1611). Displays anticonvulsant effects and inhibits glutamate release, possibly through inhibition of Na+, K+ and Ca2+ currents."	Leach et al (1991) Neurochemical and behavioral aspects of lamotrigine. Epilepsia 32 S4. PMID:1685439. Smith and Meldrum (1995) Cardioprotective effect of lamotrigine after focal ischemia in rats. Stroke 26 117. PMID:7839380. Zona and Avoli (1997) Lamotrigine reduces voltage-gated sodium currents in rat central neurons in culture. Epilepsia 38 522. PMID:9184596. Grunze et al (1998) Modulation of calcium and potassium currents by lamotrigine. Neuropsychobiology 38 131. PMID:9778600.	Small Molecule	Sold for research purposes under agreement from GlaxoSmithKline	http://www.tocris.com/dispprod.php?ItemId=137860	SQ1533			Jun-2005
2291	"1,2,3,4,5,6-Hexabromocyclohexane"	[1837-91-8]	BrC1C(C(C(C(C1Br)Br)Br)Br)Br	Inhibits JAK2 autophosphorylation	"Potently and directly inhibits JAK2 tyrosine kinase autophosphorylation, specifically inhibiting ligand-dependent JAK2 activation. A 16-hour treatment with 1 _M of compound reduces JAK2 tyrosine autophosphorylation levels to ~ 50% while 50 _M elimates nearly all JAK2 activity. Non-cytotoxic at 100 _M."	"Sandberg et al (2005) Identification of 1,2,3,4,5,6-Hexabromocyclohexane as a small molecule inhibitor of Jak2 tyrosine kinase autophosphorylation. J.Med.Chem. 48 2526. PMID:15801842."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=138031				Dec-2005
2292	AQ-RA 741	[123548-16-3]	CCN(CC)CCCCC1CCN(CC(=O)N2C3=CC=CC=C3C(=O)NC3=C2N=CC=C3)CC1	"Selective, high affinity M2 antagonist"	"High affinity, selective muscarinic M2 receptor antagonist (pKi values are 8.3, 7.7 and 6.82 for M2, M1 and M3 receptors, respectively). Displays cardioselectivity in vivo, over intestinal, tracheal and bladder muscarinic receptors; inhibits vagally and agonist-induced bradycardia."	"Doods et al (1991) Cardioselectivity of AQ-RA 741, a novel tricyclic antimuscarinic drug. Eur.J.Pharmacol. 192 147. PMID:2040358. Dorje et al (1991) Antagonist binding profiles of five cloned human muscarinic receptor subtypes. J.Pharmacol.Exp.Ther. 256 727. PMID:1994002. Doods et al (1994) Pharmacological profile of selective muscarinic receptor antagonists on guinea-pig ileal smooth muscle. Eur.J.Pharmacol. 253 275. PMID:8200421."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=138087	SQ1341			Sep-2005
2293	Zebularine	[3690-10-6]	O[C@@H]1[C@@H](CO)O[C@@H](N2C(N=CC=C2)=O)[C@@H]1O	DNA methyltransferase and cytidine deaminase inhibitor	Orally active DNA methyltransferase inhibitor. Inhibits tumor cell proliferation (IC50 = 120 _M) and re-activates silenced genes in T24 bladder carcinoma cells. Inhibits cytidine deaminase (Ki ~ 2 _M); induces differentiation of mesenchymal stem cells into cardiomyocytes.	"Laliberte et al (1992) Potent inhibitors for the deamination of cytosine arabinoside and 5-aza-2'-deoxycytidine by human cytidine deaminase. Cancer Chemother.Pharmacol. 30 7. PMID:1375134. Ben-Kasus et al (2005) Metabolic activation of zebularine, a novel DNA methylation inhibitor, in human bladder carcinoma cells. Biochem.Pharmacol. 70 121. PMID:15885659. Naeem et al (2012) DNA methylation inhibitors, 5-azacytidine and zebularine potentiate the trans-differentiation of rat bone marrow mesenchymal stem cells into cardiomyocytes. Cardiovasc.Ther. [Epub ahead of print]."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=138088	SQ1341			Sep-2006
2294	Cordycepin	[73-03-0]	NC1=NC=NC2=C1N=CN2[C@@H]3O[C@H](CO)C[C@H]3O	RNA synthesis inhibitor	"Nucleoside analog that acts as an anticancer and antifungal agent. Can be converted to 3'-deoxyadenosine triphosphate (3'-dATP), which inhibits ATP-dependent DNA synthesis. Inhibits growth of various tumor cells in vitro."	Gumport and Edelhei et al (1976) The synthesis of 3'-dATP and its use as an inhibitor of ATP-dependent DNA synthesis in toluene-treated Escherichia coli. Biochemistry 15 2804. PMID:779831. Sugar and McCaffrey (1998) Antifungal activity of 3'-deoxyadenosine (cordycepin). Antimicrob.Agents Chemother. 42 1424. PMID:9624488. Kodama et al (2000) Antileukemic activity and mechanism of action of cordycepin against terminal deoxynucleotidyl transferase-positive (TdT+) leukemic cells. Biochem.Pharmacol. 59 273. PMID:10609556.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=138093	SQ1533			Jun-2005
2295	()-Cloprostenol sodium salt	[55028-72-3]	[Na+].O[C@@H](COC1=CC(Cl)=CC=C1)\C=C\[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC([O-])=O	Water-soluble PGF2_ analog and potent FP receptor agonist	Water-soluble prostaglandin F2_ (PGF2_) analog; acts as a potent FP receptor agonist (EC50 = 0.84 nM). Potently inhibits differentiation of adipocyte precursor cells. Luteolytic agent in vivo.	Dukes et al (1974) Potent luteolytic agents related to prostaglandin F2_. Nature 250 330. PMID:4853720. Griffin et al (1998) Pharmacological characterization of an FP prostaglandin receptor on rat vascular smooth muscle cells (A7r5) coupled to phosphoinositide turnover and intracellular calcium mobilization. J.Pharmacol.Exp.Ther. 286 411. PMID:9655886. Serrero and Lepak (2002) Prostaglandin F2_ receptor (FP receptor) agonists are potent adipose differentiation inhibitors for primary culture of adipocyte precursors in defined medium. Biochem.Biophys.Res.Comm. 233 200.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=138103	SQ1070			Jul-2005
2296	Prostaglandin E2	[363-24-6]	CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O	Major endogenous prostanoid	"Endogenous prostaglandin and primary product of arachidonic acid/cyclooxygenase pathway. Binds with high affinity to EP1, EP2, EP3 and EP4 receptors (Kd values range between ~ 1 - 10 nM). Influences a wide range of processes including inflammation, smooth muscle relaxation, fertility and gastric mucosal integrity. Regulates vertebrate hematopoietic stem cell (HSC) homeostasis."	"Coleman et al (1994) Classification of prostanoid receptors: properties, distribution, and structure of the receptors and their subtypes. Pharmacol.Rev. 46 205. PMID:7938166. Hata and Breyer (2004) Pharmacology and signaling of prostaglandin receptors: multiple roles in inflammation and immune modulation. Pharm.Ther. 103 147. North et al (2007) Prostaglandin E2 regulates vertebrate haematopoietic stem cell homeostasis. Nature. 447 1007. PMID:17581586."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=138104	SQ1533			Dec-2005
2299	SCH 39166 hydrobromide	[1227675-51-5]	Br.CN1CCC2=C(C=C(O)C(Cl)=C2)[C@@H]2[C@@H]1CCC1=CC=CC=C21	High affinity D1/D5 receptor antagonist	"High affinity dopamine D1/D5 receptor antagonist; displays Ki values of 1.2, 2, 980, 5520, 80 and 731 nM for binding to D1, D5, D2, D4, 5-HT and _2a receptors, respectively."	"McQuade et al (1991) In vivo binding of SCH 39166: a D-1 selective antagonist. J.Pharmacol.Exp.Ther. 257 42. PMID:1826927. Terry and Katz (1994) A comparison of the effects of the D1 receptor antagonists SCH 23390 and SCH 39166 on suppression of feeding behaviour by the D1 agonist SKF38393. Psychopharmacology 113 328. PMID:7862841. Wu et al (2005) Dopamine D1/D5 receptor antagonists with improved pharmacokinetics: design, synthesis, and biological evaluation of phenol bioisosteric analogues of benzazepine D1/D5 antagonists. J.Med.Chem. 48 680. PMID:15689153."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=5446	SQ1533			Sep-2005
2301	T 0070907	[313516-66-4]	[O-][N+](=O)C1=CC=C(Cl)C(=C1)C(=O)NC1=CC=NC=C1	Highly potent and selective PPAR_ antagonist	Potent and selective PPAR_ antagonist (IC50 = 1 nM). Displays > 800-fold selectivity for PPAR_ over PPAR_ and PPAR_. Blocks transcriptional activity of PPAR_ in vitro and inhibits rosiglitazone-induced adipogenesis.	"Lee et al (2002) T0070907, a selective ligand for peroxisome proliferator-activated receptor _, functions as an antagonist of biochemical and cellular activities. J.Biol.Chem. 277 19649. PMID:11877444. Rockwell and Kaminski (2004) A cyclooxygenase metabolite of anandamide causes inhibition of interleukin-2 secretion in murine splenocytes. J.Pharmacol.Exp.Ther. 311 683. PMID:15284281. Schaefer et al (2005) Peroxisome proliferator-activated receptor _ inhibition prevents adhesion to the extracellular matrix and induces anoikis in hepatocellular carcinoma cells. Cancer Res. 65 2251. PMID:15781638."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=138569	SQ1341			Jul-2005
2302	Sanguinarine chloride	[5578-73-4]	C[N+]1=CC4=C(C=CC5=C4OCO5)C3=C1C2=CC(OCO6)=C6C=C2C=C3.[Cl-]	Inhibitor of protein phosphatase 2C (PP2C)	"Inhibitor of protein phosphatase 2C (PP2C), selective over PP1, PP2A and PP2B in vitro. Also inhibits mitogen-activated protein kinase phosphatase-1 (MKP-1) (IC50 = 10 _M). Plant alkaloid that exhibits anti-inflammatory and antioxidant activity. Blocks cell cycle in the G1 phase; inhibits cell growth in human prostate carcinoma cells."	"Adhami et al (2004) Sanguinarine causes cell cycle blockade and apoptosis of human prostate carcinoma cells via modulation of cyclin kinase inhibitor-cyclin-cyclin-dependent kinase machinery. Mol.Cell Ther. 3 934. Vogt et al (2005) The benzo[c]phenanthridine alkaloid, sanguinarine, is a selective, cell-active inhibitor ofm mitogen-activated protein kinase phosphatase-1. J.Biol.Chem. 280 19078. PMID:15753082. Aburai et al (2010) Sanguinarine as a potent and specific inhibitor of protein phosphatase 2C in vitro and induces apoptosis via phosphorylation of p38 in HL60 cells. Biosci.Biotechnol.Biochem. 74 548. PMID:20208361."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=138595	SQ1533			Feb-2011
2303	PNU 282987	[123464-89-1]	O=C(C2=CC=C(Cl)C=C2)N[C@@H]1C3CCN(CC3)C1	Selective _7 nAChR agonist	"Highly selective _7 nAChR agonist (Ki = 26 nM) displaying negligible blockade of _1_1__ and _3_4 nAChRs (IC50  60 _M). Found to be inactive against a panel of 32 receptors at 1 _M, except 5-HT3 receptors (Ki = 930 nM)."	Bodnar et al (2005) Discovery and structure-activity relationship of quinuclidine benzamides as agonists of _7 nicotinic acetylcholine receptors. J.Med.Chem. 48 905. PMID:15715459. Hajs et al (2005) The selective _7 nicotinic acetylcholine receptor agonist PNU-282987 [N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-4-chlorobenzamide hydrochloride] enhances GABAergic synaptic activity in brain slices and restores auditory gating deficits in anesthetized rats. J.Pharmacol.Exp.Ther. 312 1213. PMID:15523001.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=138608	SQ1533			Aug-2005
2304	Devazepide	[103420-77-5]	CN1C2=CC=CC=C2C(=N[C@H](NC(=O)C2=CC3=C(N2)C=CC=C3)C1=O)C1=CC=CC=C1	"Selective, orally active CCK1 receptor antagonist"	"Potent, orally active CCK1 (CCK-A) receptor antagonist that displays appetite-stimulant effects. Blocks the anorectic response to CCK-8 and increases food intake in rats following systemic and i.c.v administration."	Ebenezer (2002) Effects of intracerebroventricular administration of the CCK1 receptor antagonist devazepide on food intake in rats. Eur.J.Pharmacol. 441 79. PMID:12007923. Reidelberger et al (2003) Effects of peripheral CCK receptor blockade on food intake in rats. Am.J.Physiol.Reg.Integr.Comp.Physiol. 285 R429. Ritter (2004) Increased food intake and CCK receptor antagonists: beyond abdominal vagal afferents. Am.J.Physiol.Reg.Integr.Comp.Physiol. 286 R991.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=138733	SQ1533			Apr-2006
2308	Tabimorelin hemifumarate	[242143-80-2]	[H]OC(=O)\C=C\C(=O)O[H].CNC(=O)[C@@H](CC1=CC=CC=C1)N(C)C(=O)[C@@H](CC1=CC2=CC=CC=C2C=C1)N(C)C(=O)\C=C\CC(C)(C)N.CNC(=O)[C@@H](CC1=CC=CC=C1)N(C)C(=O)[C@@H](CC1=CC2=CC=CC=C2C=C1)N(C)C(=O)\C=C\CC(C)(C)N	"Potent, orally active ghrelin receptor agonist"	"Potent, orally active ghrelin receptor (GHS-R1a) agonist (Ki = 50 nM at human recombinant GHS-R1a). Stimulates GH release from rat pituitary cells with an EC50 value of 2.7 nM. Induces hyperphagia and adiposity in lean rats, but not in leptin signaling-deficient ZDF rats."	"Hansen et al (1999) Pharmacological characterisation of a new oral GH secretagogue, NN703. Eur.J.Endocrinol. 141 180. PMID:10427162. Holm et al (2004) Adipogenic and orexigenic effects of the ghrelin-receptor ligand tabimorelin are diminished in leptin-signalling-deficient ZDF rats. Eur.J.Pharmacol. 150 893."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=139029	SQ1070			Feb-2006
2309	SR 142948	[184162-64-9]	COC1=CC=CC(OC)=C1C1=CC(=NN1C1=C(C=C(C=C1)C(=O)N(C)CCCN(C)C)C(C)C)C(=O)NC1(C2CC3CC(C2)CC1C3)C(O)=O	Highly potent NT receptor antagonist	Potent non-peptide neurotensin (NT) receptor antagonist that binds with high affinity (IC50 = 0.32 - 3.96 nM; Ki < 10 nM). Attenuates amphetamine-induced hyperactivity and is orally active in vivo.	"Gully et al (1997) Biochemical and pharmacological activities of SR 142948A, a new potent neurotensin receptor antagonist. J.Pharmacol.Exp.Ther. 280 802. PMID:9023294. Quere et al (1998) X-ray structural characterization of SR 142948, a novel potent synthetic neurotensin receptor antagonist. Bioorg.Med.Chem.Lett. 8 653. PMID:9871577. Marie-Claire et al (2008) Effects of the selective neurotensin antagonist SR 142948A on 3,4-methylenedioxymethamphetamine-induced behaviours in mice. Neuropharmacology 54 1107. PMID:18410947."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=139209	SQ1341			Jun-2006
2310	SR 49059	[150375-75-0]	O=S(C1=CC(OC)=C(OC)C=C1)(N2[C@@H]([C@@](N5CCC[C@H]5[C@@](N)=O)=O)[C@](C4=CC=CC=C4Cl)(O)C3=C2C=CC(Cl)=C3)=O	"Selective, orally active vasopressin V1A receptor antagonist"	Potent and selective non-peptide vasopressin V1A receptor antagonist; devoid of agonist activity. Displays high affinity and efficacy at both rat (Ki = 1.6 nM) and human (Ki = 1.1 - 6.3 nM) V1A receptors. Potently antagonizes arginine vasopressin-induced effects in vitro (IC50 = 3.7 nM for inhibition of human platelet aggregation) and is orally active in vivo.	"Serradeil-Le Gal et al (1993) Biochemical and pharmacological properties of SR 49059, a new, potent, nonpeptide antagonist of rat and human vasopressin V1a receptors. J.Clin.Invest. 92 224. PMID:8392086. Serradeil-Le Gal et al (1994) Binding of [3H]SR 49059, a potent nonpeptide vasopressin V1a antagonist, to rat and human liver membranes. Biochem.Biophys.Res.Comm. 199 353. Tahtaoui et al (2003) Identification of the binding sites of the SR 49059 nonpeptide antagonist into the V1a vasopressin receptor using sulfydryl-reactive ligands and cysteine mutants as chemical sensors. J.Biol.Chem. 278 40010. PMID:12869559."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=139316	SQ1070			Mar-2006
2311	"L-168,049"	[191034-25-0]	CCCOC1=C(C=C(Br)C=C1)C1=C(NC(=C1)C1=CC=C(Cl)C=C1)C1=CC=NC=C1	"Potent, orally active human glucagon receptor antagonist"	"Very potent and selective, non-competitive antagonist of the human glucagon receptor (hGR). Binds with high affinity to human GR (IC50 = 3.7 nM), and moderate affinity to murine and canine GRs (IC50 values are 63 and 60 nM respectively). In contrast, displays poor affinity for rat, guinea pig, and rabbit glucagon receptors (IC50 > 1 _M). In functional studies, inhibits glucagon-stimulated cAMP synthesis in CHO cells expressing hGR (IC50 = 41 nM), and in murine liver membranes. Orally active in vivo."	"Cascieri et al (1999) Characterization of a novel, non-peptidyl antagonist of the human glucagon receptor. J.Biol.Chem. 274 8694. PMID:10085108. de Laszlo et al (1999) Potent, orally absorbed glucagon receptor antagonists. Bioorg.Med.Chem.Lett. 9 641. PMID:10201821. Dallas-Yang et al (2001) Detection of glucagon-dependent GTPgS binding in high-throughput format. Anal.Biochem. 301 156."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=139345	SQ1341			Sep-2005
2312	DNQX disodium salt	[1312992-24-7]	[Na+].[Na+].[O-]C1=C([O-])N=C2C=C(C(=CC2=N1)[N+]([O-])=O)[N+]([O-])=O	Selective non-NMDA antagonist. Water-soluble salt of DNQX (Cat. No. 0189)	Water-soluble form of DNQX (Cat. No. 0189). Selective non-NMDA receptor antagonist.	Honore et al (1988) Quinoxalinediones: potent competitive non-NMDA glutamate receptor antagonists. Science 241 701. PMID:2899909. Watkins et al (1990) Structure-activity relationships in the development of excitatory amino acid receptor agonists and competitive antagonists. TiPS 11 25. PMID:2155495.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=139622				Jul-2005
2313	QX 314 chloride	[5369-03-9]	[Cl-].CC[N+](CC)(CC)CC(=O)NC1=C(C)C=CC=C1C	Na+ channel blocker	"Membrane impermeable quaternary derivative of lidocaine, a blocker of voltage-activated Na+ channels."	Stichartz et al (1973) The inhibition of sodium currents in myelinated nerve by quaternary derivatives of lidocaine. J.Gen.Physiol. 62 37. PMID:4541340. Alreja and Aghajanian (1994) QX-314 blocks the potassium but not the sodium dependent components of the opiate response in locus coeruleus neurons. Brain Res. 639 320. PMID:8205485. Perkins and Wong (1995) Intracellular QX-314 blocks the hyperpolarization activated inward current Iq in hippocampal CA1 pyramidal cells. J.Neurophysiol. 72 911.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=139623	SQ1341			Aug-2005
2314	LOE 908 hydrochloride	[143482-60-4]	Cl.COC1=CC=C(CCN(CCC2=C(OC)C(OC)=C(OC)C=C2)C(=O)C(C2=CC=CC=C2)C2=NCCC3=CC(OC)=C(OC)C=C23)C(OC)=C1OC	Broad spectrum cation channel blocker; neuroprotective	"Broad spectrum cation channel blocker. Inhibits several cation channels including store-operated calcium channels (SOCs), voltage-operated calcium channels (VOCs), non-selective cation channels (NSCCs), AMPA, NMDA, Na+ and K+ channels. Neuroprotective; reduces cortical infarct size and improves neurological outcome following middle cerebral artery occlusion."	Krause et al (1998) LOE 908 blocks delayed rectifier type potassium channels in PC12 cells and cortical neurons in culture. Biochem.Biophys.Res.Comm. 244 659. PMID:9535721. Tatlisumak et al (2000) Broad-spectrum cation channel inhibition by LOE 908 MS reduces infarct volume in vivo and postmortem in focal cerebral ischemia in the rat. J.Neurol.Sci. 178 107. PMID:11018702. Christensen et al (2005) The broad-spectrum cation channel blocker pinokalant (LOE 908 MS) reduces brain infarct volume in rats: a temperature-controlled histological study. Basic Clin.Pharmacol.Toxicol. 96 316. PMID:15755315.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=139624	SQ1533			Nov-2006
2315	Immethridine dihydrobromide	[699020-93-4]	Br.Br.C(C1=CN=CN1)C1=CC=NC=C1	"Potent H3 agonist, highly selective over H4"	Potent and highly selective histamine H3 receptor agonist (pEC50 = 9.74) that displays 300-fold selectivity over the H4 receptor (pKi values are 9.07 and 6.61 respectively). Does not bind to H1 or H2 receptors at concentrations up to 10 _M. .	"Kitbunnadaj et al (2004) Identification of 4-(1H-imidazol-4(5)-ylmethyl)pyridine (immethridine) as a novel, potent, and highly selective histamine H3 receptor agonist. J.Med.Chem. 47 2414. PMID:15115383."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=139775	SQ1341			Feb-2006
2316	AMG 9810	[545395-94-6]	CC(C)(C)C1=CC=C(C=C1)\C=C\C(=O)NC1=CC=C2OCCOC2=C1	"Potent and selective, competitive antagonist of TRPV1"	"Potent and selective, competitive vanilloid TRPV1 receptor antagonist (IC50 = 17 nM). Inhibits capsaicin-, proton-, heat- and endogenous ligand-induced activation of human and rat recombinant TRPV1 receptors. Displays antihyperalgesic properties in a rat model of inflammatory pain."	"Doherty et al (2005) Discovery of potent, orally available vanilloid receptor-1 antagonists. Structure-activity relationship of N-aryl cinnamides. J.Med.Chem. 48 71. PMID:15634002. Gavva et al (2005) AMG 9810 [(E)-3-(4-t-Butylphenyl)-N-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)acrylamide], a novel vanilloid receptor 1 (TRPV1) antagonist with antihyperalgesic properties. J.Pharmacol.Exp.Ther. 313 474. PMID:15615864."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=139782	SQ1070			Jul-2005
2318	Pravastatin sodium salt	[81131-70-6]	[Na+].[H][C@@](O)(CC[C@H]1[C@@H](C)C=CC2=C[C@@H](O)C[C@H](OC(=O)[C@@H](C)CC)[C@]12[H])C[C@@H](O)CC([O-])=O	HMG-CoA reductase inhibitor	"Water-soluble, competitive inhibitor of 3-hydroxy-3-methyl coenzyme A (HMG-CoA) reductase. Potently blocks cholesterol synthesis in vivo (Ki~ 1 nM) and displays cardioprotective properties."	Hamelin and Turgeon (1998) Hydrophilicity/lipophilicity: relevance for the pharmacology and clinical effects of HMG-CoA reductase inhibitors. TiPS 19 26. PMID:9509899.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=140287	SQ1533			Aug-2005
2322	BTS 54-505 hydrochloride	[84484-78-6]	Cl.CC(C)CC(N)C1(CCC1)C1=CC=C(Cl)C=C1	Potent SNRI; active metabolite of sibutramine (Cat. No. 2290)	"Potently active primary amine metabolite of sibutramine (Cat. No. 2290), exhibits a similar pharmacological profile to the parent compound. Inhibits serotonin and noradrenalin reuptake more potently than sibutramine in vitro. Reduces food intake in rodents following i.c.v. administration and increases energy expenditure via thermogenesis in vivo."	"Luscombe et al (1989) The contribution of metabolites to the rapid and potent down-regulation of rat cortical beta-adrenoceptors by the putative antidepressant sibutramine hydrochloride. Neuropharmacology 28 129. PMID:2541365. Gundlah et al (1997) In vivo criteria to differentiate monoamine reuptake inhibitors from releasing agents: sibutramine is a reuptake inhibitor. J.Pharmacol.Exp.Ther. 283 581. PMID:9353373. Liu et al (2002) Mechanism of the thermogenic effect of Metabolite 2 (BTS 54 505), a major pharmacologically active metabolite of the novel anti-obesity drug, sibutramine. Int.J.Obes.Relat.Metab.Disord. 26 1245. PMID:12187403."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=140813	SQ1070			Feb-2006
2324	Necrostatin-1	[4311-88-0]	CN1C(=S)NC(CC2=CNC3=CC=CC=C23)C1=O	RIPK1 inhibitor; inhibits necroptosis	"ATP-competitive, allosteric inhibitor of receptor-interacting protein kinase 1 (RIPK1) (EC50 = 182 nM). Blocks non-apoptotic cell death via inhibition of a specific cellular pathway, necroptosis, which leads to necrosis (EC50 = 494 nM). Reduces ischemic brain injury in a mouse model of stroke."	Degterev et al (2005) Chemical inhibitor of nonapoptotic cell death with therapeutic potential for ischemic brain injury. Nat.Chem.Biol. 1 112. PMID:16408008. Degterev et al (2008) Identification of RIP1 kinase as a specific cellular target of necrostatins. Nat.Chem.Biol. 4 313. PMID:18408713. Linkermann et al (2012) Rip1 (receptor-interacting protein kinase 1) mediates necroptosis and contributes to renal ischemia/reperfusion injury. 81 751. PMID:22237751.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=141558	SQ1533			Oct-2005
2329	Ro 10-5824 dihydrochloride	[189744-94-3]	Cl.Cl.CC1=NC=C(CN2CCC(=CC2)C2=CC=CC=C2)C(N)=N1	Selective D4 receptor partial agonist	"Selective dopamine D4 receptor partial agonist (EC50 = 205 nM) that binds with high affinity (Ki = 5.2 nM). Displays 250-fold selectivity over D3 receptors and > 1000-fold selectivity over D2, D1 and D5 receptors."	Powell et al (2003) RO-10-5824 is a selective dopamine D4 receptor agonist that increases novel object exploration in C57 mice. Neuropharmacology 44 473. PMID:12646284.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=141942	SQ1341			Dec-2005
2330	DMP 543	[160588-45-4]	FC1=CC(CC2(CC3=CC(F)=NC=C3)C3=CC=CC=C3C(=O)C3=C2C=CC=C3)=CC=N1	K+ channel blocker and potent ACh release enhancer	"K+ channel blocker and acetylcholine release stimulator. Potently enhances K+-stimulated [3H]-ACh release from rat hippocampal slices (EC50 = 700 nM), and also increases release of dopamine and glutamate (EC50 values are 0.25 and 0.22 _M, respectively). Orally active in vivo; increases ACh levels in rats (with a minimum effective dose of 1 mg/kg) and exerts a long duration of action. More potent than linopirdine (Cat. No. 1999) both in vitro and in vivo."	"Zaczek et al (1998) Two new potent neurotransmitter release enhancers, 10,10-Bis(4-pyridinylmethyl)-9(10H)-anthracenone and 10,10-Bis(2-fluoro-4-pyridinylmethyl)-9(10H)-anthracenone: comparison to linopirdine. J.Pharmacol.Exp.Ther. 285 724. PMID:9580619. Earl et al (1998) 2-Fluoro-4-pyridinylmethyl analogues of linopirdine as orally active acetylcholine release-enhancing agents with good efficacy and duration of action. J.Med.Chem. 41 4615. PMID:9804701."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=141995	SQ1341			Sep-2005
2332	(+)-Igmesine hydrochloride	[130152-35-1]	CN(C(CC)(C3=CC=CC=C3)C/C=C/C2=CC=CC=C2)CC1CC1.Cl	Selective _1 ligand; antidepressant	"Selective _1 receptor ligand (KD = 19.1 nM), with little or no activity at _2 receptors (IC50 > 1000 nM). Inhibits the NMDA-induced increase in cGMP in a concentration-dependent manner (IC50 value is approximately 100 nM). Weak inhibitor of brain 5-HT uptake in vitro. Exhibits neuroprotective and antidepressant effects."	"O'Neill et al (1995) The sigma receptor ligand JO 1784 (igmesine hydrochloride) is neuroprotective in the gerbil model of global cerebral ischaemia. Eur.J.Pharmacol. 283 217. PMID:7498313. Akunne et al (2001) Neuropharmacological profile of a selective sigma ligand, igmesine: a potential antidepressant. Neuropharmacology 41 138. PMID:11445194."	Small Molecule	Sold for research purposes under agreement from Pfizer Inc.	http://www.tocris.com/dispprod.php?ItemId=142442	SQ1070			Nov-2011
2333	JNJ 16259685	[409345-29-5]	O=[C@@]([C@@H]4CC[C@H](OC)CC4)C(C=C3)=CC1=C3N=C(OCCC2)C2=C1	"Extremely potent, mGlu1-selective non-competitive antagonist"	"Sub-nanomolar potent, non-competitive mGlu1 antagonist (Ki = 0.34 nM). Inhibits glutamate-induced Ca2+ response at the human mGlu1 receptor with an IC50 value of 0.55 nM. Selective over mGlu5 (> 400-fold) and displays no activity at mGlu2, mGlu3, mGlu4, mGlu6, AMPA or NMDA receptors (IC50 > 10 _M). Centrally active following systemic administration."	"Lavreysen et al (2004) JNJ16259685, a highly potent, selective and systemically active mGlu1 receptor antagonist. Neuropharmacology 47 961. PMID:15555631. Mabire et al (2005) Synthesis, structure-activity relationship, and receptor pharmacology of a new series of quinoline derivatives acting as selective, noncompetitive mGlu1 antagonists. J.Med.Chem. 48 2134. PMID:15771457. Steckler et al (2005) Metabotropic glutamate receptor 1 blockade impairs acquisition and retention in a spatial water maze task. Behav.Brain Res. 164 52. PMID:16043241. Xie et al (2010) Effects of mGluR1 antagonism in the dorsal hippocampus on drug context-induced reinstatement of cocaine-seeking behavior in rats. Psychopharmacology (Berl). 208 1. PMID:19847405."	Small Molecule	"Sold under license from Johnson & Johnson Pharmaceutical Research & Development, a division of Janssen Pharmaceutica NV"	http://www.tocris.com/dispprod.php?ItemId=142504	SQ1533			Nov-2005
2337	Trequinsin hydrochloride	[78416-81-6]	Cl.COC1=C(OC)C=C2C(CCN3C(=O)N(C)C(\C=C23)=N\C2=C(C)C=C(C)C=C2C)=C1	Extremely potent inhibitor of PDE3	Extremely potent inhibitor of cGMP-inhibited phosphodiesterase (PDE3; IC50 = 250 pM). Potently inhibits arachidonic acid-induced aggregation of human platelets (IC50 = 50 pM). Orally active antihypertensive agent; reduces systemic blood pressure in both normotensive and hypertensive animal models.	"Ruppert and Weithmann (1982) HL 725, an extremely potent inhibitor of platelet phosphodiesterase and induced platelet aggregation in vitro. Life Sci. 31 2037. PMID:6294426. Lal et al (1984) Trequinsin, a potent new antihypertensive vasodilator in the series of 2-(arylimino)-3-alkyl-9,10-dimethoxy-3,4,6,7-tetrahydro-2H-pyrimido[6,1-a]isoquinolin-4-ones. J.Med.Chem. 27 1470. PMID:6492077. Agarwal et al (1987) Role of plasma adenosine in the antiplatelet action of HL 725, a potent inhibitor of cAMP phosphodiesterase: species differences. Thromb.Res. 47 191. PMID:2821650."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=142512	SQ1533			Nov-2005
2338	MK 571	[115104-28-4]	ClC1=CC=C(C=CC(/C=C/C3=CC(C(SCCC(O)=O)SCCC(N(C)C)=O)=CC=C3)=N2)C2=C1	Potent CysLT1 (LTD4) inverse agonist. Also MRP inhibitor	Potent CysLT1 (LTD4) leukotriene receptor inverse agonist (EC50 = 1.3 nM). Antagonizes LTD4-induced contractions of guinea pig trachea and ileum (pA2 values are 9.4 and 10.5 respectively). Also inhibitor of multidrug resistance protein-1 (MRP1) mediated transport; in vitro augments the effects of cytotoxic agents on malignant cells.	"Vellenga et al (1999) Interleukin-6 production by activated human monocytic cells is enhanced by MK-571, a specific inhibitor of the multi-drug resistance protein-1. Br.J.Pharmacol. 127 441. PMID:10385244. Blain and Sirois (2000) Involvement of LTD4 in allergic pulmonary inflammation in mice: modulation by cysLT1 antagonist MK-571. Prost.Leuko.Essent.Fatty Acids 62 361. Dupre et al (2004) Inverse agonist activity of selected ligands of the cysteinyl-leukotriene receptor 1. J.Pharmacol.Exp.Ther. 309 102. PMID:14718577."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=5348				Nov-2007
2339	WEB 2086	[105219-56-5]	CC1=NN=C2CN=C(C3=C(SC(CCC(=O)N4CCOCC4)=C3)N12)C1=CC=CC=C1Cl	Potent PAF receptor antagonist	"Potent, selective platelet-activating factor (PAF) receptor antagonist (Ki = 16.3 nM). Displays anti-inflammatory, antiangiogenic and anticancer activity. Inhibits growth and proliferation of MCF-7 breast cancer cells."	"Dent et al (1989) Characterization of PAF receptors on human neutrophils using the specific antagonist, WEB 2086. FEBS Lett. 244 365. PMID:2537761. Sariahmetoglu et al (1998) Effects of WEB 2086 on the protective role of preconditioning against arrhythmias in rats. Pharmacol.Res. 38 173. PMID:9782066. Cellai et al (2006) Growth inhibition and differentiation of human breast cancer cells by the PAFR antagonist WEB-2086. Br.J.Cancer 94 1637. PMID:16721373."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=142945	SQ1533			Dec-2005
2341	A 80426 mesylate	[152148-64-6]	COC1=C2C([C@H](CN(CCC3=CC(OC=C4)=C4C=C3)C)CCC2)=CC=C1.CS(=O)(O)=O	High affinity _2 antagonist. Also 5-HT uptake inhibitor	High affinity _2-adrenoceptor antagonist and selective 5-HT uptake inhibitor (Ki values are 2.01 and 3.77 nM respectively). Displays low affinity at a variety of structurally homologous GPCRs.	"Meyer et al (1995) Synthesis and pharmacological characterisation of A-80426: a putative novel antidepressant combining _-2 antagonism with 5-HT uptake inhibition. Bioorg.Med.Chem.Letts. 5 2287. Giardina et al (1995) A-80426, a potent and selective _2-adrenoceptor antagonist with serotonin uptake-blocking activity and putative antidepressant-like effects: II. Pharmacology profile. Drug Devel.Res. 35 246."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=143048	SQ1341			May-2008
2342	4-Methylhistamine dihydrochloride	[36376-47-3]	Cl.Cl.CC1=C(CCN)NC=N1	"Selective, high affinity H4 agonist"	"Potent, high affinity H4 receptor agonist (Ki = 7 nM) that displays > 100-fold selectivity over other human histamine receptor subtypes."	"Lim et al (2005) Evaluation of histamine H1-, H2-, and H3-receptor ligands at the human histamine H4 receptor: identification of 4-methylhistamine as the first potent and selective H4 receptor agonist. J.Pharmacol.Exp.Ther. 314 1310. PMID:15947036. Gbahou et al (2006) Compared pharmacology of human histamine H3 and H4 receptors: structure-activity relationships of histamine derivatives. Br.J.Pharmacol 147 74."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=143690				Oct-2005
2344	CGH 2466 dihydrochloride	[1177618-54-0]	Cl.Cl.NC1=NC(=C(S1)C1=CC=NC=C1)C1=CC(Cl)=C(Cl)C=C1	"A1, A2B and A3 antagonist and inhibitor of p38 MAPK and PDE4"	"Adenosine A1, A2B and A3 receptor antagonist (IC50 values are 19, 21, and 80 nM respectively). Also inhibits p38 MAPK (IC50 = 187 - 400 nM) and phosphodiesterase type 4D (IC50 = 22 nM). Displays potent anti-inflammatory effects in vitro and in vivo. Potentially useful for asthma and chronic obstructive pulmonary disease (COPD) research."	"Trifilieff et al (2005) CGH2466, a combined adenosine receptor antagonist, p38 mitogen-activated protein kinase and phosphodiesterase type 4 inhibitor with potent in vitro and in vivo anti-inflammatory activities. Br.J.Pharmacol. 144 1002. PMID:15685201."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=143720	SQ1341			Dec-2005
2345	ZK 200775	[161605-73-8]	OP(O)(=O)CN1C(=O)C(=O)NC2=CC(=C(C=C12)N1CCOCC1)C(F)(F)F	Competitive AMPA/kainate antagonist	"Competitive AMPA/kainate antagonist. In rat cortical membranes, displays high affinity for [3H]-AMPA (Ki = 120 nM) and [3H]-CNQX (Ki = 32 nM) binding sites and low affinity for kainate and NMDA channel-associated binding sites (IC50 values range from 2.5 to 11 _M). Inhibits currents induced by AMPA, kainate and NMDA with IC50 values of 21 nM, 27 nM, and > 1 _M respectively. Displays anxiolytic, anticonvulsant and muscle relaxant activity in vivo."	"Turski et al (1998) ZK200775: a phosphonate quinoxalinedione AMPA antagonist for neuroprotection in stroke and trauman Proc.Natl.Acad.Sci.USA. 95 10960. Kosowski et al (2004) Nicotine-induced dopamine release in the nucleus accumbens is inhibited by the novel AMPA antagonist ZK200775 and the NMDA antagonist CGP39551n Pychopharmacology 175 114. Elger et al (2005) Novel _-amino-3-hydroxy-5-methyl-4-isoxazole propionate (AMPA) receptor antagonists of 2,3-benzodiazepine type: chemical synthesis, in vitro characterization, and in vivo prevention of acute neurodegeneration. J.Med.Chem. 48 4618. PMID:15999999. Sobolevsky (2009) X-ray structure, symmetry and mechanism of an AMPA-subtype glutamate receptor. Nature 462 745. PMID:19946266."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=143731	SQ1533			Apr-2006
2347	Salubrinal	[405060-95-9]	S=C(NC(NC(/C=C/C3=CC=CC=C3)=O)C(Cl)(Cl)Cl)NC1=C2C(C=CC=N2)=CC=C1	Selective inhibitor of eIF2_ dephosphorylation	"Cell-permeable, selective inhibitor of cellular phosphatase complexes that dephosphorylate eukaryotic translation initiation factor 2 subunit _ (eIF2_). Protects cells from endoplasmic reticulum stress-induced apoptosis (EC50 ~ 15 _M)."	Boyce et al (2005) A selective inhibitor of eIF2_ dephosphorylation protects cells from ER stress. Science 307 935. PMID:15705855. Long et al (2005) Structure-activity relationship studies of salubrinal lead to its active biotinylated derivative. Bioorg.Med.Chem.Lett. 15 3849. PMID:16002288.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=143907				May-2006
2348	Gavestinel	[153436-38-5]	[Na+].[O-]C(=O)C1=C(\C=C\C(=O)NC2=CC=CC=C2)C2=C(N1)C=C(Cl)C=C2Cl	Potent and selective glycine site antagonist; orally available and active in vivo	"Highly potent and selective non-competitive antagonist acting at the strychnine-insensitive glycine binding site of the NMDA receptor-channel complex (Kd = 0.8 nM). Displays > 1000-fold selectivity over NMDA, AMPA and kainate binding sites. Orally bioavailable and active in vivo."	"Di Fabio et al (1997) Substituted indole-2-carboxylates as in vivo potent antagonists acting at the strychnine-insensitive glycine binding site. J.Med.Chem. 40 841. PMID:9083472. Mugnaini et al (2000) Receptor binding characteristics of the novel NMDA receptor glycine site antagonist [3H]GV150526A in rat cerebral cortical membranes. Eur.J.Pharmacol. 391 233. PMID:10729363. Kajbaf et al (2003) Pharmacokinetics, metabolism and excretion of the glycine antagonist GV150526A in rat and dog. Xenobiotica. 33 415. PMID:12745876."	Small Molecule	Sold with the permission of GlaxoSmithKline	http://www.tocris.com/dispprod.php?ItemId=144171	SQ1533			Dec-2005
2349	Dihydro-_-erythroidine hydrobromide	[29734-68-7]	O=C1CC2=C(CCN4[C@]32C(CC4)=CC[C@H](OC)C3)CO1.Br	Antagonist for neuronal _4-containing nicotinic receptors	Competitive nicotinic acetylcholine receptor antagonist with moderate selectivity for the neuronal _4 receptor subunit (IC50 values are 0.19 and 0.37 _M for _4_4 and _4_2 receptors respectively). Antagonizes behavioral effects of nicotine in vivo.	"Williams and Robinson (1984) Binding of the nicotinic cholinergic antagonist, dihydro-#946;-erythroidine, to rat brain tissue. J.Neurosci. 4 2906. PMID:6502210. Damaj et al (1995) In vivo pharmacological effects of dihydro-#946;-erythroidine, a nicotinic antagonist, in mice. Psychopharmacology 117 67. PMID:7724704. Harvey et al (1996) Multiple determinants of dihydro-#946;-erythroidine sensitivity on rat neuronal nicotinic receptor #945; subunits. J.Neurochem. 67 1953. PMID:8863500."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=144245	SQ1341			Jun-2006
2372	ABT 702 dihydrochloride	[1188890-28-9]	Cl.Cl.NC1=NC=NC2=NC(=CC(C3=CC(Br)=CC=C3)=C12)C1=CN=C(C=C1)N1CCOCC1	Adenosine kinase inhibitor; orally active	"Potent non-nucleoside adenosine kinase inhibitor (IC50 = 1.7 nM), selective over other sites of adenosine interaction (A1, A2A and A3 receptors, adenosine transporter and adenosine deaminase). Displays oral activity in animal models of pain and inflammation."	"Jarvis et al (2000) ABT-702 (4-amino-5-(3-bromophenyl)-7-(6-morpholino-pyridin-3-yl)pyrido[2, 3-d]pyrimidine), a novel orally effective adenosine kinase inhibitor with analgesic and anti-inflammatory properties: I In vitro characterization and acute antinociceptive effects in the mouse. J.Pharmacol.Exp.Ther. 295 1156. PMID:11082453. Kowaluk et al (2000) ABT-702 (4-amino-5-(3-bromophenyl)-7-(6-morpholino-pyridin- 3-yl)pyrido[2,3-d]pyrimidine), a novel orally effective adenosine kinase inhibitor with analgesic and anti-inflammatory properties II. In vivo characterization in the rat. J.Pharmacol.Exp.Ther. 295 1165. PMID:11082454. Lee et al (2001) Discovery of 4-amino-5-(3-bromophenyl)-7-(6-morpholino-pyridin-3-yl)pyrido[2,3-d]pyrimidine, an orally active, non-nucleoside adenosine kinase inhibitor. J.Med.Chem. 44 2133. PMID:11405650."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=144415	SQ1533			Feb-2006
2373	T 0901317	[293754-55-9]	OC(C1=CC=C(C=C1)N(CC(F)(F)F)S(=O)(=O)C1=CC=CC=C1)(C(F)(F)F)C(F)(F)F	Potent liver X receptor (LXR) agonist; also CAR inverse agonist	"Potent, high affinity liver X receptor (LXR) agonist (EC50 ~ 50 nM, Kd values are 7 and 22 nM for LXR-_ and LXR-_ respectively). Upregulates expression of the ABCA1 gene associated with cholesterol efflux regulation and HDL metabolism. Decreases amyloid-_ production in primary neurons in vitro. Displays an EC50 of ~ 5 _M for activation of bile acid farnesoid X receptors (FXRs); 10-fold more potent than natural FXR ligand chenodeoxycholic acid. Also exhibits inverse agonist activity at constitutive androstane receptors (CAR)."	"Repa et al (2000) Regulation of absorption and ABC1-mediated efflux of cholesterol by RXR heterodimers. Science 289 1524. PMID:10968783. Houck et al (2004) T0901317 is a dual LXR/FXR agonist. Mol.Gen.Metab. 83 184. Koldamova et al (2005) The liver X receptor ligand T0901317 decreases amyloid _ production in vitro and in a mouse model of Alzheimer's disease. J.Biol.Chem. 280 4079. PMID:15557325. Mitro et al (2007) The nuclear receptor LXR is a glucose sensor. Nature Lett. 445 219. Kanno et al (2013) T0901317, a potent LXR agonist, is an inverse agonist of CAR. J.Toxicol.Sci. 38 309. PMID:23665929."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=144452	SQ1341			Apr-2006
2374	GW 405833	[180002-83-9]	COC1=CC=C2N(C(=O)C3=C(Cl)C(Cl)=CC=C3)C(C)=C(CCN3CCOCC3)C2=C1	"Selective, high affinity CB2 receptor partial agonist"	Potent and selective CB2 receptor partial agonist (EC50 = 0.65 nM; maximum inhibition = 44.6%). Binds with high affinity to both human and rat CB2 receptors and displays ~ 1200-fold selectivity over CB1 (Ki values are 3.92 and 4772 nM for human recombinant CB2 and CB1 receptors respectively). Produces potent antihyperalgesic effects in several rodent models of pain.	"Clayton et al (2002) CB1 and CB2 cannabinoid receptors are implicated in inflammatory pain. Pain 96 253. PMID:11972997. Valenzano et al (2005) Pharmacological and pharmacokinetic characterization of the cannabinoid receptor 2 agonist, GW405833, utilizing rodent models of acute and chronic pain, anxiety, ataxia and catalepsy. Neuropharmacology 48 658. PMID:15814101."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=144481	SQ1341			Feb-2006
2382	EMD 386088 hydrochloride	[1171123-46-8]	Cl.CC1=C(C2=CC(Cl)=CC=C2N1)C1=CCNCC1	Potent 5-HT6 agonist	"Potent 5-HT6 receptor agonist (EC50 = 1.0 nM) that displays selectivity over other 5-HT receptors (IC50 values are 7.4, 110, 180, 240, 450, 620, 660 and 3000 nM for 5-HT6, 5-HT1D, 5-HT1B, 5-HT2A, 5-HT2C, 5-HT4, 5-HT1A and 5-HT7 receptors respectively). Shows moderate affinity at 5-HT3 receptors (IC50 = 34 nM)."	"Mattsson et al (2005) 2-Alkyl-3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indoles as novel 5-HT6 receptor agonists. Bioorg.Med.Chem.Lett. 15 4230. PMID:16055331."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=144639	SQ1341			Sep-2006
2385	AMN 082 dihydrochloride	[97075-46-2]	Cl.Cl.C(CNC(C1=CC=CC=C1)C1=CC=CC=C1)NC(C1=CC=CC=C1)C1=CC=CC=C1	The first selective mGlu7 agonist	The first selective mGlu7 agonist. Potently inhibits cAMP accumulation and stimulates GTP_S binding in recombinant cells and on membranes expressing mGlu7 (EC50 = 64 - 290 nM). Selective over other mGluR subtypes and selected ionotropic glutamate receptors up to 10 _M. Acts via a novel allosteric site and is orally active and brain penetrant. Reduces haloperidol-induced catalepsy in rats.	"Flor et al (2005) AMN082, the first selective mGluR7 agonist: activation of receptor signaling via an allosteric site in the transmembrane domain modulates stress parameters in vivo. Neuropharmacology 49 (Suppl. 1) 244. Mitsukawa et al (2005) A selective metabotropic glutamate receptor 7 agonist: Activation of receptor signaling via an allosteric site modulates stress parameters in vivo. Proc.Natl.Acad.Sci.USA 102 18712. Greco et al (2010) Metabotropic glutamate 7 receptor subtype modulates motor symptoms in rodent models of Parkinson's disease. J.Pharmacol.Exp.Ther. 332 1064. PMID:19940105."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=145226	SQ1341			Oct-2005
2386	Fenobam	[57653-26-6]	CN1CC(=O)N=C1NC(=O)NC1=CC(Cl)=CC=C1	Potent and selective mGlu5 antagonist	Potent and selective non-competitive mGlu5 antagonist that displays inverse agonist properties; blocks mGlu5 constitutive activity in vitro (IC50 = 87 nM). Acts at an allosteric modulatory site shared with MPEP and binds the mGlu5 receptor with Kd values of 54 and 31 nM for rat and human receptors respectively. Displays anxiolytic activity following oral administration in vivo; also exhibits analgesic properties.	"Porter et al (2005) Fenobam: a clinically validated nonbenzodiazepine anxiolytic is a potent, selective, and noncompetitive mGlu5 receptor antagonist with inverse agonist activity. J.Pharmacol.Exp.Ther. 315 711. PMID:16040814. Porter et al (2005) Description of a clinically validated anxiolytic with mGlu5 antagonist properties. Neuropharmacology 49 (Suppl. 1) 267. Montana et al (2009) The metabotropic glutamate receptor subtype 5 antagonist fenobam is analgesic and has improved in vivo selectivity compared with the prototypical antagonist 2-methyl-6-(phenylethynyl)-pyridine. J.Pharmacol.Exp.Ther. 330 834. PMID:19515968."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=145229	SQ1533			Nov-2005
2387	LY 320135	[176977-56-3]	COC1=CC=C(C=C1)C1=C(C(=O)C2=CC=C(C=C2)C#N)C2=CC=C(OC)C=C2O1	Selective CB1 receptor antagonist/inverse agonist	Potent CB1 receptor antagonist/inverse agonist (Ki = 141 nM) with greater than 70-fold selectivity over CB2 receptors (Ki > 10 _M). Structurally dissimilar from SR 141716A and AM 251. Shows weak binding to both 5-HT2 (Ki = 6.4 _M) and muscarinic receptors (Ki = 2.1 _M).	"Felder et al (1998) LY320135, a novel cannabinoid CB1 receptor antagonist, unmasks coupling of the CB1 receptor to stimulation of cAMP accumulation. J.Pharmacol.Exp.Ther. 284 291. PMID:9435190. Holland et al (1999) Cannabinoid CB1 receptors fail to cause relaxation, but couple via Gi/Go to the inhibition of adenylyl cyclase in carotid artery smooth muscle. Br.J.Pharmacol. 128 597. PMID:10516638. Pertwee (2005) Inverse agonism and neutral antagonism at cannabinoid CB1 receptors. Life Sci. 76 1307. PMID:15670612."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=5316	SQ1533			Feb-2006
2390	LY 456236 hydrochloride	[338736-46-2]	Cl.COC1=CC=C(NC2=C3C=C(OC)C=CC3=NC=N2)C=C1	Selective mGlu1 antagonist	Selective mGlu1 receptor antagonist (IC50 values are 143 nM and > 10 _M for mGlu1 and mGlu5 receptors respectively). Reduces hyperalgesic behavior induced by formalin in both mouse and rat with ED50 values of 28 and 16.3 mg/kg respectively.	"Shannon et al (2005) Anticonvulsant effects of LY456236, a selective mGlu1 receptor antagonist. Neuropharmacology 49 (Suppl. 1) 188. PMID:16011839. Bertorelli et al (2005) Selective blockade of metabotropic glutamate subtype mGluR1 receptors induce anti-nociceptive effects. Neuropharmacology 49 (Suppl. 1) 231."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=145310	SQ1341			Mar-2006
2392	JTE 013	[547756-93-4]	CC(C)C1=C2C(C)=NN(C)C2=NC(NNC(=O)NC2=CC(Cl)=NC(Cl)=C2)=C1	S1P2 receptor antagonist	"Sphingosine-1-phosphate (S1P) receptor antagonist, highly selective for S1P2 (EDG-5). Inhibits S1P binding to human S1P2 receptors with an IC50 value of 17.6 nM. At concentrations up to 10 _M, displays 4.2% inhibition of S1P3 and does not antagonize S1P1. Enhances S1P-induced angiogenesis in vivo."	Ohmori et al (2003) Spingosine 1-phosphate induces contraction of coronary artery smooth muscle cells via S1P2. Cardiovasc.Res. 58 170. PMID:12667959. Parrill et al (2004) Sphingosine 1-phosphate and lysophosphatidic acid receptors: agonist and antagonist binding and progress toward development of receptor-specific ligands. Semin.Cell.Dev.Biol. 15 467. PMID:15271292. Inoki et al (2006) Negative regulation of endothelial morphogenesis and angiogenesis by S1P2 receptor. Biochem.Biophys.Res.Comm. 346 293.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=147290				Mar-2006
2394	SDZ NKT 343	[180046-99-5]	O=C(NC3=C([N+]([O-])=O)C=CC=C3)N1[C@H]([C@@](N[C@H]([C@@](N(C)CC4=CC=CC=C4)=O)CC2=CC=C(C=CC=C5)C5=C2)=O)CCC1	"Highly selective, human NK1 antagonist"	Highly selective human tachykinin NK1 receptor antagonist (IC50 values are 0.62 and 451 nM for human and rat receptors respectively) that displays > 130-fold selectivity over human NK2 and NK3 receptors. Potently antagonizes SP-induced Ca2+ efflux in vitro and inhibits mechanical hyperalgesia in vivo.	"Walpole et al (1998) Comparative, general pharmacology of SDZ NKT 343, a novel, selective NK1 receptor antagonist. Br.J.Pharmacol. 124 83. PMID:9630347. Walpole et al (1998) 2-Nitrophenylcarbamoyl-(S)-prolyl-(S)-3-(2-naphthyl)alanyl-N-benzyl-N-methylamide (SDZ NKT 343), a potent human NK1 tachykinin receptor antagonist with good oral analgesic activity in chronic pain models. J.Med.Chem. 41 3159. PMID:9703462. Campbell et al (1998) Selective neurokinin-1 receptor antagonists are anti-hyperalgesic in a model of neuropathic pain in the guinea-pig. Neuroscience. 87 527. PMID:9758219."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=147429	SQ1341			Apr-2006
2395	Sertraline hydrochloride	[79559-97-0]	ClC(C(Cl)=C3)=CC=[C@@]3[C@H]2C1=CC=CC=C1[C@@H](NC)CC2.Cl	5-HT re-uptake inhibitor	"Potent, orally active selective serotonin re-uptake inhibitor (SSRI); antidepressant."	"Koe et al (1983) Sertraline, 1S,4S-N-methyl-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthylamine, a new uptake inhibitor with selectivity for serotonin. J.Pharmacol.Exp.Ther. 226 686. PMID:6310078. Heym and Koe (1988) Pharmacology of sertraline: a review. J.Clin.Psychiatry 49 40. PMID:3045112. Doogan and Caillard (1988) Sertraline: a new antidepressant. J.Clin.Psychiatry. 49 46."	Small Molecule	Sold for research purposes under agreement from Pfizer Inc.	http://www.tocris.com/dispprod.php?ItemId=147644	SQ1533			Nov-2005
2396	Glimepiride	[93479-97-1]	O=C1C(CC)=C(C)CN1C(NCCC2=CC=C(S(NC(N[C@H]3CC[C@H](C)CC3)=O)(=O)=O)C=C2)=O	Kir6 (KATP) channel blocker	Potent Kir6 (KATP) channel blocker and anti-diabetic agent. Inhibits pinacidil-activated cardiac Kir6 channels with an IC50 of 6.8 nM.	Lawrence et al (2002) Effect of metabolic inhibition on glimepiride block of native and cloned cardiac sacrolemmal KATP channels. Br.J.Pharmacol. 136 746. PMID:12086984.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=147651	SQ1070			Feb-2006
2397	Eplerenone	[107724-20-9]	O=C1CC[C@@]2(C)C(C[C@@H]([C@](OC)=O)[C@]3([H])[C@@](O6)2[C@H]6C[C@@]4(C)[C@]([H])3CC[C@@]54OC(CC5)=O)=C1	Selective mineralocorticoid receptor antagonist	"Selective mineralocorticoid (aldosterone) receptor antagonist (IC50 = 360 nM). Displays > 27-fold selectivity over androgen, progesterone and estrogen receptors (IC50 > 10 _M). Orally active antihypertensive in vivo."	"De Gasparo et al (1987) Three new epoxy-spirolactone derivatives: characterization in vivo and in vitro. J.Pharmacol.Exp.Ther. 240 650. PMID:2949071. McMahon and Cunningham (2001) Recent studies with eplerenone, a novel selective aldosterone receptor antagonist. Curr.Opin.Pharmacol. 1 190. PMID:11714095."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=147722	SQ1533			Apr-2006
2398	SNAP 5089	[157066-77-8]	CC1=C(C(OC)=O)C(C2=CC=C([N+]([O-])=O)C=C2)C(C(NCCCN3CCC(C4=CC=CC=C4)(C5=CC=CC=C5)CC3)=O)=C(C)N1.Cl	Subtype-selective _1A antagonist	"Subtype-selective _1A-adrenoceptor antagonist that displays > 600-fold selectivity over other adrenoceptors (Kivalues are 0.35, 220, 370, 540, 800 and 1200 nM for _1A, _1B, _2C, _1D, _2B and _2A subtypes respectively and 540 nM for L-type Ca2+ channels). Inhibits noradrenalin-induced contractions in rabbit vascular and lower urinary tissues."	"Wetzel et al (1995) Discovery of _1a-adrenergic receptor antagonists based on the L-type Ca2+ channel antagonist niguldipine. J.Med.Chem. 38 1579. PMID:7752182. Leonardi et al (1997) Pharmacological characterization of the uroselective alpha-1 antagonist Rec 15-2739 (SB 216469): role of the alpha-1L adrenoceptor in tissue selectivity, Part I. J.Pharmacol.Exp.Ther. 281 1272. PMID:9190863. Kava et al (1998) _1L-adrenceptor mediation of smooth muscle contraction in rabbit bladder neck: a model for lower urinary tract tissues of man. Br.J.Pharmacol. 123 1359. PMID:9579731."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=5449	SQ1341			Sep-2007
2400	FK 888	[138449-07-7]	O=C(N3[C@H]([C@](N[C@@H](CC5=CC(C=CC=C6)=C6C=C5)C(N(C)CC4=CC=CC=C4)=O)=O)C[C@@H](O)C3)C2=CN(C)C1=CC=CC=C12	High affinity NK1 receptor antagonist	"Selective, high affinity tachykinin NK1 receptor antagonist (Ki = 0.69 nM) that displays 320-fold selectivity for human over rat NK1 receptors. Inhibits substance P-induced contraction of isolated guinea pig trachea (IC50 = 32 nM) and inhibits substance P-induced airway constriction in vivo following i.v. and oral administration."	"Fujii et al (1992) Pharmacological profile of a high affinity dipeptide NK1 receptor antagonist. Br.J.Pharmacol. 107 785. PMID:1282073. Murai et al (1993) Effects of an NK1 receptor antagonist, FK888, on constriction and plasma extravasation induced in guinea pig airway by neurokinins and capsaicin. Eur.J.Pharmacol. 236 7. PMID:7686493. Aramori et al (1994) Subtype- and species-selectivity of a tachykinin receptor antagonist, FK888, for cloned rat and human tachykinin receptors. Eur.J.Pharmacol. 269 277. PMID:7531648."	Small Molecule	Sold with the permission of Astellas Pharma Inc.	http://www.tocris.com/dispprod.php?ItemId=148223	SQ1341			Jun-2006
2402	MRS 2211		[Na+].[Na+].CC1=C(O)C(C=O)=C(COP([O-])([O-])=O)C(\N=N\C2=C(Cl)C=CC(=C2)[N+]([O-])=O)=N1	Competitive P2Y13 antagonist	Competitive P2Y13 receptor antagonist (pIC50 = 5.97) that displays > 20-fold selectivity over P2Y1 and P2Y12 receptors.	Kim et al (2005) Synthesis of pyridoxal phosphate derivatives with antagonist activity at the P2Y13 receptor. Biochem.Pharmacol. 70 266. PMID:15913566. Kugelgen (2006) Pharmacological profiles of cloned mammalian P2Y-receptor subtypes. Pharmacol.Ther. 110 415. PMID:16257449.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=148265				Jul-2007
2403	MRS 3777 hemioxalate	[1186195-57-2]	OC(=O)C(O)=O.C1CCC(CC1)NC1=C2N=CNC2=NC(OC2=CC=CC=C2)=N1.C1CCC(CC1)NC1=C2N=CNC2=NC(OC2=CC=CC=C2)=N1	"High affinity, selective A3 antagonist"	"High affinity adenosine A3 receptor antagonist (Ki = 47 nM) that displays > 200-fold selectivity versus A1, A2A and A2B receptors."	"Perreira et al (2005) ""Reversine"" and its 2-substituted adenine derivatives as potent and selective A3 adenosine receptor antagonists. J.Med.Chem. 48 4910. PMID:16033270. Jacobson and Gao (2006) Adenosine receptors as therapeutic targets. Nat.Rev.Drug Discov. 5 247. PMID:16518376. Moro et al (2006) Progress in the pursuit of therapeutic adenosine receptor antagonists. Med.Res.Rev. 26 131. PMID:16380972."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=148280	SQ1341			Nov-2006
2404	Ambroxol hydrochloride	[23828-92-4]	NC1=C(Br)C=C(Br)C=C1CN[C@H]2CC[C@H](O)CC2.Cl	Na+ channel blocker	"Sodium channel blocker and mucolytic agent with antioxidant, anti-viral and anti-inflammatory properties. Inhibits tetrodotoxin (TTX)-resistant channels more potently than TTX-sensitive subtypes (IC50 values for tonic block are 35.2 and 111.5 _M respectively). Inhibits release of histamine, leukotrienes and cytokines from human leukocytes and mast cells."	"Gillissen et al (1997) Antioxidant function of ambroxol in mononuclear and polymorphonuclear cells in vitro. Lung 175 235. PMID:9195551. Gibbs et al (1999) Ambroxol inhibits the release of histamine, leukotrienes and cytokines from human leukocytes and mast cells. Inflamm.Res. 48 86. PMID:10202994. Weiser and Wilson (2002) Inhibition of tetrodotoxin (TTX)-resistant and TTX-sensitive neuronal Na+ channels by the secretolytic ambroxol. Mol.Pharmacol. 62 433. PMID:12181417."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=148323	SQ1070			Feb-2006
2408	Ro 90-7501	[293762-45-5]	NC1=CC=C(C=C1)C1=NC2=CC=C(C=C2N1)C1=NC2=CC=C(N)C=C2N1	Inhibitor of A_42 fibril formation	Inhibitor of amyloid _42 (A_42) fibril assembly; reduces A_42-induced toxicity (EC50 = 2 _M).	Bohrmann et al (2000) Self-assembly of beta-amyloid 42 is retarded by small molecular ligands at the stage of structural intermediates. J.Struct.Biol. 130 232. PMID:10940228.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=148391				Jun-2006
2409	Conessine	[546-06-5]	[H][C@@]23CC=C1C[C@@H](N(C)C)CC[C@@](C)1[C@]([H])2CC[C@@]45[C@]([H])3CC[C@@]([H])4[C@H](C)N(C)C5	Potent and selective H3 receptor antagonist	Potent and selective histamine H3 receptor antagonist (pKi values are 7.61 and 8.27 at rat and human H3 receptors respectively). A steroidal alkaloid that displays in vitro antiplasmodial activity (IC50 = 1.04 _M). Also has high affinity for _2C adrenoceptors (pKi = 7.98).	"Zirihi et al (2005) Isolation, characterization and antiplasmodial activity of steroidal alkaloids from Funtumia elastica (Preuss) Stapf. Bioorg.Med.Chem.Lett. 15 2637. PMID:15863333. Witte et al (2005) Discovery of a novel natural product of unique chemical structure as a potent and selective histamine H3 receptor (H3R) antagonist. Soc.Neurosci.Abstr. 491 19. Zhao et al (2008) The alkaloid conessine and analogues as potent histamine H3 receptor antagonists. J.Med.Chem. 51 5423. PMID:18683917."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=148486	SQ1533			Feb-2006
2410	"L-371,257"	[162042-44-6]	CC(N(CC3)CCC3OC(C=C2)=CC(OC)=C2C(N1CCC(N4C(OCC5=C4C=CC=C5)=O)CC1)=O)=O	Potent and selective oxytocin receptor antagonist	"Potent, high affinity human oxytocin (OT) receptor antagonist (Ki = 4.6 nM) that displays > 800-fold selectivity over human arginine vasopressin receptors V1a and V2. Antagonizes oxytocin-induced contractions in isolated rat uterine tissue (pA2 = 8.44) and in anesthetised rats following intravenous and intraduodenal administration. Orally active."	"Williams et al (1995) 1-{1-[4-[N-acetyl-4-piperidinyl)oxy]-2-methoxybenzoyl]piperidin-4-yl}-4H-3,1-benzoxazin-2(1H)-one (L-371,257): a new, orally bioavailable, non-peptide oxytocin antagonist. J.Med.Chem. 38 4634. PMID:7473590. Tahara et al (1999) Comparison of vasopressin binding sites in human uterine and vascular smooth muscle cells. Eur.J.Pharmacol. 378 137. PMID:10478574. Tahara et al (2000) Pharmacologic characterization of the oxytocin receptor in human uterine smooth muscle cells. Br.J.Pharmacol. 129 131. PMID:10694212."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=148521	SQ1341			Sep-2006
2412	BIBO 3304 trifluoroacetate	[191868-14-1]	O=C([C@H](NC(C(C3=CC=CC=C3)C2=CC=CC=C2)=O)CCCNC(N)=N)NCC1=CC=C(CNC(N)=O)C=C1	Highly selective NPY Y1 receptor antagonist	"High affinity NPY Y1 receptor antagonist (IC50 values are 0.38 and 0.72 nM at human and rat receptors respectively) that displays > 2600-fold selectivity over Y2, Y4 and Y5 receptors. Inhibits NPY- and fasting-induced feeding in vivo following central administration. Also antagonizes anxiolytic-like effects of NPY."	Wieland et al (1998) Subtype selectivity of the novel nonpeptide neuropeptide Y Y1 receptor antagonist BIBO 3304 and its effect on feeding in rodents. Br.J.Pharmacol. 125 549. PMID:9806339. Sajdyk et al (1999) Amygdalar neuropeptide Y Y1 receptors mediate the anxiolytic-like actions of neuropeptide Y in the social interaction test. Eur.J.Pharmacol. 368 143. PMID:10193650. Lecklin et al (2002) Receptor subtypes Y1 and Y5 mediate neuropeptide Y induced feeding in the guinea-pig. Br.J.Pharmacol. 135 2029. PMID:11959807.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=5186	SQ1070			Nov-2008
2414	H 1152 dihydrochloride	[871543-07-6]	CC1=CN=CC2=C1C(S(N3CCCNC[C@@H]3C)(=O)=O)=CC=C2.Cl.Cl	Selective Rho-kinase (ROCK) inhibitor	"Rho-kinase (ROCK) inhibitor that displays high selectivity over other protein kinases (IC50 values are 0.012, 0.180, 0.360, 0.745, 3.03, 5.68 and 28.3 _M for ROCKII, CAMKII, PKG, Aurora A, PKA, PKC and MLCK respectively). Inhibits sulprostone-induced contractions in guinea pig aorta (IC50 = 190 nM) and displays proerectile effects in rats. Glycyl derivative available (Cat. No. 2485)."	Shum et al (2003) Involvement of Rho-kinase in contraction of guinea-pig aorta induced by prostanoid EP3 receptor agonist. Br.J.Pharmacol. 139 1449. PMID:12922932. Teixeira et al (2005) Proerectile effects of the rho-kinase inhibitor (S)-(+)-2-methyl-1-[(4-methyl-5-isoquinolinyl)sulfonyl]homopiperazine (H-1152) in the rat penis. J.Pharmacol.Exp.Ther. 315 155. PMID:15976017. Tamura et al (2005) Development of specific Rho-kinase inhibitors and their clinical application. Biochim.Biophys.Acta 1754 245. PMID:16213195.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=85249	SQ1341			Jan-2007
2415	HA 1100 hydrochloride	[155558-32-0]	Cl.OC1=NC=CC2=C(C=CC=C12)S(=O)(=O)N1CCCNCC1	"Cell-permeable, selective Rho-kinase inhibitor"	Cell-permeable active metabolite of Fasudil (HA 1077; Cat. No. 0541). Produces ATP-competitive and reversible inhibition of Rho-kinase and is ~ 100-fold selective over a range of other protein kinases. Inhibits neutrophil migration and produces potent vasodilatory effects in vivo.	"Arai et al (1993) Inhibition by the protein kinase inhibitor HA1077 of the activation of NADPH oxidase in human neutrophils. Biochem.Pharmacol. 46 1487. PMID:8240400. Shimokawa et al (1999) Rho-kinase-mediated pathway induces enhanced myosin light chain phosphorylations in a swine model of coronary artery spasm. Cardiovasc.Res. 43 1029. PMID:10615430. Utsunomiya et al (2001) Antianginal effects of hydroxyfasudil, a Rho-kinase inhibitor, in a canine model of effort angina. Br.J.Pharmacol. 134 1724. PMID:11739249."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=149078	SQ1341			May-2006
2416	BIBX 1382 dihydrochloride	[1216920-18-1]	Cl.Cl.CN1CCC(CC1)NC1=NC=C2N=CN=C(NC3=CC(Cl)=C(F)C=C3)C2=N1	Highly selective EGFR-kinase inhibitor	"Potent, selective inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase (IC50 = 3 nM). Displays > 1000-fold lower potency against ErbB2 (IC50 = 3.4 _M) and a range of other related tyrosine kinases (IC50 > 10 _M). Oral administration inhibits growth of established human xenografts in athymic mice."	"Dittrich et al (2002) Phase I and pharmacokinetic study of BIBX1382 BS, an epidermal growth factor receptor (EGFR) inhibitor, given in a continuous daily oral administration. Eur.J.Cancer 38 1072. PMID:12008195. Solca et al (2004) Inhibition of epidermal growth factor receptor activity by two pyrimidopyrimidine derivatives. J.Pharmacol.Exp.Ther. 311 502. PMID:15199094."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=149452	SQ1533			May-2006
2417	BIBU 1361 dihydrochloride	[793726-84-8]	Cl.Cl.CCN(CC)CC1CCN(CC1)C1=NC=C2N=CN=C(NC3=CC(Cl)=C(F)C=C3)C2=N1	Selective inhibitor of EGFR-kinase	Potent inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase (IC50 = 3 nM). Displays ~ 100-fold lower potency against ErbB2 (IC50 = 290 nM) and is selective over a range of other related tyrosine kinases (IC50 > 10 _M). Blocks downstream EGFR signaling events such as MAPKK/MAPK activation. Oral administration inhibits growth of established human xenografts in athymic mice.	Solca et al (2004) Inhibition of epidermal growth factor receptor activity by two pyrimidopyrimidine derivatives. J.Pharmacol.Exp.Ther. 311 502. PMID:15199094.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=149465	SQ1341			Jul-2006
2418	LY 303511	[154447-38-8]	O=C1C=C(OC2=C(C=CC=C12)C1=CC=CC=C1)N1CCNCC1	Negative control of LY 294002 (Cat. No. 1130)	"Negative control compound with respect to LY 294002 (Cat. No. 1130) PI 3-kinase inhibitory activity. Blocks voltage-gated potassium (Kv) channels (IC50 = 64.6 _M) and inhibits IL-1_-stimulated NF-_B activation, attenuating MCP-1 expression. Antiproliferative. Also inhibits the BET bromodomain proteins BRD2, BRD3 and BRD4."	El-kholy et al (2003) The phosphatidylinositol 3-kinase inhibitor LY294002 potently blocks KV currents via a direct mechanism. FASEB J. 17 720. PMID:12586735. Choi et al (2004) LY294002 inhibits monocyte chemoattractant protein-1 expression through a phosphatidylinositol 3-kinase-independent mechanism. FEBS Letters. 559 141. PMID:14960322. Kristof et al (2005) LY303511 (2-Piperazinyl-8-phenyl-4H-1-benzopyran-4-one) acts via phosphatidylinositol 3-kinase-independent pathways to inhibit cell proliferation via mammalian target rapamycin (mTOR)- and non-mTOR-dependent mechanisms. J.Pharmacol.Exp.Ther. 314 1134. PMID:15923340.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=149466	SQ1341			Oct-2006
2419	GT 2016	[152241-24-2]	O=C(CCCCC3CCCCC3)N(CC2)CCC2C1=CN=CN1	Selective H3 antagonist	High affinity H3 receptor antagonist (Ki = 43.8 nM). Displays selectivity against H1 and H2 receptors (IC50 >10 _M). Increases the release of histamine in the cerebral cortex. Displays no activity at histamine methyltransferase in vitro at concentrations up to 3 _M. Brain penetrant.	"Tedford et al (1995) Pharmacological characterization of GT-2016, a non-thiourea-containing histamine H3 receptor antagonist: in vitro and in vivo studies. J.Pharmacol.Exp.Ther. 275 598. PMID:7473144. Tedford et al (1999) Development of trans-2-[1H-imidazol-4-yl] cyclopropane derivatives as new high-affinity histamine H3 receptor ligands. J.Pharmacol.Exp.Ther. 289 1160. PMID:10215700. Yates et al (1999) Identification and pharmacological characterization of a series of new 1H-4-substituted-imidazoyl histamine H3 receptor ligands. J.Pharmacol.Exp.Ther. 289 1151. PMID:10215699."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=149471	SQ1070			Jul-2011
2421	Scriptaid	[287383-59-9]	ONC(=O)CCCCCN1C(=O)C2=CC=CC3=CC=CC(C1=O)=C23	Histone deacetylase inhibitor	Novel histone deacetylase inhibitor. Produces > 100-fold increase in histone acetylation and displays relatively low toxicity.	Su et al (2000) A novel histone deacetylase inhibitor identified by high-throughput transcriptional screening of a compound library. Cancer Res. 60 3137. PMID:10866300.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=149481	SQ1341			Apr-2006
2429	Fexofenadine hydrochloride	[153439-40-8]	Cl.CC(C)(C(O)=O)C1=CC=C(C=C1)C(O)CCCN1CCC(CC1)C(O)(C1=CC=CC=C1)C1=CC=CC=C1	H1 receptor antagonist; non-sedating antiallergic agent	Selective histamine H1 receptor antagonist (pKi = 8.1). Active metabolite of terfenadine that displays non-sedating antiallergic effects.	Markham and Wagstaff (1998) Fexofenadine. Drugs 55 269. PMID:9506246. Sakairi et al (2005) Effects of fexofenadine hydrochloride in a guinea pig model of antigen-induced rhinitis. Pharmacology 75 76. PMID:16037679. Gillard and Chatelaine (2006) Changes in pH differently affect the binding properties of histamine H1 receptor antagonists. Eur.J.Pharmacol. 530 205. PMID:16388798.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=149570	SQ1533			Feb-2006
2432	Anagrelide hydrochloride	[58579-51-4]	ClC1=C(CN(C3)C(N2)=NC3=O)C2=CC=C1Cl.Cl	Potent PDE3 inhibitor	Potent type III phosphodiesterase (PDE3) inhibitor (IC50 = 36 nM). Inhibits platelet aggregation and produces potent thrombocytopenic effects via inhibition of megakaryocyte maturation.	Gillespie (1988) Anagrelide: a potent and selective inhibitor of platelet cyclic AMP phosphodiesterase enzyme activity. Biochem.Pharmacol. 37 2866. PMID:2456068. Mazur et al (1992) Analysis of the mechanism of anagrelide-induced thrombocytopenia in humans. Blood 79 1931. PMID:1562721. Wang et al (2005) Comparison of the biological activities of anagrelide and its major metabolites in haematopoietic cell cultures. Br.J.Pharmacol. 146 324. PMID:16041400.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=150810	SQ1533			May-2006
2433	"L-759,633"	[174627-50-0]	CCCCCCC(C)(C)C(C=C3OC)=CC2=[C@@]3[C@H]1[C@H]([C@@](C)(C)O2)CC=C(C)C1	"High affinity, selective CB2 agonist"	"High affinity, selective CB2 receptor agonist (Ki values are 6.4 and 1043 nM for CB2 and CB1 receptors respectively). Potently inhibits forskolin-stimulated cAMP production via CB2 receptors expressed in CHO cells (EC50 = 8.1 nM)."	"Ross et al (1999) Agonist-inverse agonist characterization at CB1 and CB2 cannabinoid receptors of L759633, L759656 and AM630. Br.J.Pharmacol. 126 665. PMID:10188977. Huffman et al (1999) 3-(1',1'-dimethylbutyl)-1-deoxy-D8-THC and related compounds: synthesis of selective ligands for the CB2 receptor. Bioorg.Med.Chem. 7 2905. PMID:10658595. Huffman (2000) The search for selective ligands for the CB2 receptor. Curr.Pharmaceut.Des. 6 1323."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=150819				Sep-2006
2435	CCT 018159	[171009-07-7]	CCC1=C(O)C=C(O)C(=C1)C1=NNC(C)=C1C1=CC2=C(OCCO2)C=C1	Hsp90 inhibitor	Novel inhibitor of heat shock protein 90 (Hsp90) ATPase activity (IC50 = 5.7 _M) that displays selectivity over human Hsp72 and topoisomerase II. Inhibits proliferation of HCT116 human colon tumor cells and produces upregulation of Hsp70 and downregulation of c-Raf and cdk4. More soluble than 17-AAG (Cat. No. 1515) and is independent of NQO1/DT-diaphorase and P-glycoprotein expression.	"Cheung et al (2005) The identification, synthesis, protein crystal structure and in vitro biochemical evaluation of a new 3,4-diarylpyrazole class of Hsp90 inhibitors. Bioorg.Med.Chem.Lett. 15 3338. PMID:15955698. Dymock et al (2005) Novel, potent small-molecule inhibitors of the molecular chaperone Hsp90 discovered through structure-based design. J.Med.Chem. 48 4212. PMID:15974572. Sharp et al (2007) In vitro biological characterization of a novel, synthetic diaryl pyrazole resorcinol class of heat shock protein 90 inhibitors. Cancer Res. 67 2206. PMID:17332351."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=151522	SQ1533			Nov-2006
2436	AC 55649	[59662-49-6]	CCCCCCCCC1=CC=C(C=C1)C1=CC=C(C=C1)C(O)=O	Selective RAR_2 agonist	"Potent, isoform-selective RAR_2 receptor agonist (pEC50 values are 6.9, 5.7 and 5.6 at RAR_2, RAR_1 and RAR_ respectively) that displays 100-fold selectivity versus other retinoid receptors. Inhibits proliferation of the breast cancer cell line MCF-7."	"Lund et al (2005) Discovery of a potent, orally available, and isoform-selective retinoic acid _2 receptor agonist. J.Med.Chem. 48 7517. PMID:16302793. Lund et al (2009) Design, synthesis, and structure-activity analysis of isoform selective retinoic acid receptor ligands. J.Med.Chem. 52 1540. PMID:19239230."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=151567	SQ1341			Aug-2006
2438	TMPH hydrochloride	[849461-91-2]	CC1(C)NC(C)(C)CC(OC(CCCCCC)=O)C1.Cl	Neuronal nicotinic receptor antagonist	"Potent non-competitive antagonist of neuronal nicotinic ACh receptors (nAChRs). Produces long-lasting inhibition of neuronal nAChRs formed by the combination of the most abundant _ and _ subunits (i.e. _3, _4 and _2, _4 respectively). Displays little inhibition of muscle-type (_1_1__) or _7 receptors."	"Papke et al (2005) The effects of subunit composition on the inhibition of nicotinic receptors by the amphipathic blocker 2,2,6,6-tetramethylpiperidin-4-yl heptanoate. Mol.Pharmacol. 67 1977. PMID:15761116."	Small Molecule	Sold under license from the University of Florida Research Foundation Inc.	http://www.tocris.com/dispprod.php?ItemId=152259	SQ1341			Mar-2006
2440	NNC 26-9100	[199522-35-5]	ClC1=C(Cl)C=C(CN(CCCNC(=S)NCCCC2=CNC=N2)C2=CC=C(Br)C=N2)C=C1	Selective sst4 agonist	Somatostatin sst4 receptor agonist that displays > 100-fold selectivity over sst2 receptors (Ki values are 6 and 621 nM for sst4 and sst2 receptors respectively). Potently inhibits forskolin-induced cAMP accumulation (EC50 = 26 nM).	Liu et al (1998) Nonpeptide somatostatin agonists with sst4 selectivity: synthesis and structure-activity relationships of thioureas. J.Med.Chem. 41 4693. PMID:9822540. Liu et al (1999) 2-pyridylthioureas: novel nonpeptide somatostatin agonists with SST4 selectivity. Curr.Pharm.Des. 5 255. PMID:10101224.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=152300	SQ1341			Sep-2006
2441	JNJ 10191584 maleate	[869497-75-6]	O=C(O)/C=C\C(O)=O.ClC(C=C3)=CC2=C3N=C(N2)C(N1CCN(C)CC1)=O	Selective H4 receptor antagonist; orally active	Highly selective histamine H4 receptor silent antagonist; binds with high affinity to the human H4 receptor (Ki = 26 nM). > 540-fold selective over the H3 receptor (Ki = 14.1 _M). Inhibits mast cell and eosinophil chemotaxis in vitro with IC50 values of 138 and 530 nM respectively. Orally active in vivo.	"Terzioglu et al (2004) Synthesis and structure-activity relationships of indole and benzimidazole piperazines as histamine H4 receptor antagonists. Bioorg.Med.Chem.Lett. 14 5251. PMID:15454206. Venable et al (2005) Preparation and biological evaluation of indole, benzimidazole, and thienopyrrole piperazine carboxamides: potent human histamine H4 antagonists. J.Med.Chem. 48 8289. PMID:16366610. Varga et al (2005) Inhibitory effects of histamine H4 receptor antagonists on experimental colitis in the rat. Eur.J.Pharmacol. 522 130. PMID:16213481."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=152342	SQ1341			Mar-2006
2442	CGP 53353	[145915-60-2]	FC1=CC=C(NC2=CC3=C(C=C2NC2=CC=C(F)C=C2)C(=O)NC3=O)C=C1	Selective inhibitor of PKC_II	Selective inhibitor of PKC_II (IC50 values are 0.41 and 3.8 _M for PKC_II and PKC_I respectively). Also inhibits prionogenic Sup35 fibrillization (IC50 ~ 3.4 _M) and inhibits de novo A_42 assembly in vitro.	"Kouroedov et al (2004) Selective inhibition of protein kinase C_2 prevents acute effects of high glucose on vascular cell adhesion molecule-1 expression in human endothelial cells. Circulation 110 91. PMID:15210597. Wang et al (2008) Direct and selective elimination of specific prions and amyloids by 4,5-dianilinophthalimide and analogs. Proc.Natl.Acad.Sci.USA 105 7159."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=152351	SQ1341			Mar-2006
2443	RITA	[213261-59-7]	OCC1=CC=C(S1)C1=CC=C(O1)C1=CC=C(CO)S1	MDM2-p53 interaction inhibitor	Anti-tumor agent that binds wild-type p53 (Kd = 1.5 nM) preventing p53-MDM2 (HDM2) interaction. Induces p53 accumulation and stimulates apoptosis in tumor cell lines expressing wild-type p53 in vitro and in vivo. Inhibits HPV-E6-mediated proteasomal degradation. Suppresses expression of cervical carcinoma HeLa xenografts in vivo.	"Rivera et al (1999) Selective toxicity of the tricyclic thiophene NSC 652287 in renal carcinoma cell lines: differential accumulation and metabolism. Biochem.Pharmacol. 57 1283. PMID:10230772. Issaeva et al (2004) Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumours. Nature Med. 10 1321. Espinoza-Fonseca (2005) Targeting MDM2 by the small molecule RITA: towards the development of new multi-target drugs against cancer. Theor.Biol.Med.Mod. 2 38. Zhao et al (2010) Rescue of p53 function by small-molecule RITA in cervical carcinoma by blocking E6-mediated degradation. Cancer Res. 70 3372. PMID:20395210."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=152372	SQ1533			Aug-2006
2444	"(1R,1'S,3'R/1R,1'R,3'S)-L-054,264"	[208706-12-1]	NC[C@H]1CCC[C@@H](CNC([C@H](NC(N4CCC5(C(C=CC=C6)=C6C=C5)CC4)=O)CC2=CNC3=C2C=CC=C3)=O)C1	Potent and selective sst2 agonist	"Potent and selective somatostatin sst2 receptor agonist (Ki values are 4, 537, 2480, 3614 and 5017 nM for cloned human sst2, sst1, sst4, sst3 and sst5 receptors respectively)."	"Yang et al (1998) Spiro[1H-indene-1,4'-piperidine] derivatives as potent and selective non-peptide human somatostatin receptor subtype 2 (sst2) agonists. J.Med.Chem. 41 2175. PMID:9632348."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=152419	SQ1341			Nov-2007
2446	AS 101	[106566-58-9]	[Cl-].[Cl-].[Cl-].[Te+4].[O-]CC[O-].[H][N+]([H])([H])[H]	"Immunomodulator; inhibits IL-10 synthesis and potentiates IL-1_, IL-2 and TNF-_ release"	"Immunomodulator; inhibits IL-10 synthesis and potentiates IL-1_, IL-2 and TNF-_ release."	Kalechman et al (2004) Inhibition of interleukin-10 by the immunomodulator AS101 reduces mesangial cell proliferation in experimental mesangioproliferative glomerulonephritis. J.Biol.Chem. 279 24724. PMID:15001575.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=152719				Mar-2006
2447	Desmethyl-YM 298198	[1177767-57-5]	Cl.CC1=C(SC2=NC3=CC=C(N)C=C3N12)C(=O)NC1CCCCC1	Derivative of mGlu1 antagonist YM 298198 (Cat. No. 2448)	Derivative of the mGlu1-selective antagonist YM 298198 (Cat. No. 2448).	"Kohara et al (2005) Radioligand binding properties and pharmacological characterization of 6-Amino-N-cyclohexyl-N,3-dimethyl-thiazolo[3,2-a]-benzimidazole-2-carboxamide (YM-298198), a high-affinity, selective and noncompetitive antagonist of metabotropic glutamate receptor type 1. J.Pharmacol.Exp.Ther. 315 163. PMID:15976016."	Small Molecule	Sold with the permission of Astellas Pharma Inc.	http://www.tocris.com/dispprod.php?ItemId=152728	SQ1341			Mar-2006
2448	YM 298198 hydrochloride	[1216398-09-2]	Cl.CN(C1CCCCC1)C(=O)C1=C(C)N2C(S1)=NC1=CC=C(N)C=C21	"Highly potent, selective non-competitive mGlu1 antagonist"	"Non-competitive antagonist with high affinity and selectivity for mGlu1 receptors (Ki = 19 nM); inactive at other mGlu receptor subtypes (mGlu2-7), ionotropic receptors and glutamate transporters (IC50 > 10 _M). Inhibits glutamate-induced IP production more potently than CPCCOEt (IC50 values are 16 nM and 6.3 _M respectively), and is orally active in vivo, demonstrating an antinociceptive effect in hyperalgesic mice. Desmethyl derivative (Cat. No. 2447) also available."	"Kohara et al (2005) Radioligand binding properties and pharmacological characterization of 6-Amino-N-cyclohexyl-N,3-dimethyl-thiazolo[3,2-a]-benzimidazole-2-carboxamide (YM-298198), a high-affinity, selective and noncompetitive antagonist of metabotropic glutamate receptor type 1. J.Pharmacol.Exp.Ther. 315 163. PMID:15976016. Emery et al (2010) The protective signaling of metabotropic glutamate receptor 1 is mediated by sustained, _-arrestin-1-dependent ERK phosphorylation. J.Biol.Chem. 285 26041. PMID:20566651."	Small Molecule	Sold with the permission of Astellas Pharma Inc.	http://www.tocris.com/dispprod.php?ItemId=152729	SQ1341			Apr-2006
2450	NF 157	[104869-26-3]	[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[O-]OOSC1=C2C(NC(=O)C3=CC(NC(=O)C4=CC(NC(=O)NC5=CC(=CC=C5)C(=O)NC5=CC(=CC=C5F)C(=O)NC5=CC=C(C6=CC(=CC(=C56)S([O-])(=O)=O)S([O-])(=O)=O)S([O-])(=O)=O)=CC=C4)=C(F)C=C3)=CC=C(C2=CC(=C1)S([O-])(=O)=O)S([O-])(=O)=O	Selective P2Y11/P2X1 antagonist	"Purinergic receptor antagonist that potently inhibits P2Y11 receptor activity (IC50 = 463 nM). Displays selectivity for P2Y11 and P2X1 receptors over P2Y1, P2Y2 , P2X2, P2X3, P2X4 and P2X7 receptors. Inhibits NAD+-induced activation of human granulocytes."	Ullmann et al (2005) Synthesis and structure-activity relationships of suramin-derived P2Y11 receptor antagonists with nanomolar potency. J.Med.Chem. 48 7040. PMID:16250663. Moreschi et al (2006) Extracellular NAD+ is an agonist of the human P2Y11 purinergic receptor in human granulocytes. J.Biol.Chem. 281 31419. PMID:16926152.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=152787				Nov-2006
2451	LY 344864 hydrochloride	[1217756-94-9]	Cl[H].CN(C)[C@@H]1CCC2=C(C1)C1=CC(NC(=O)C3=CC=C(F)C=C3)=CC=C1N2	"Potent, selective 5-HT1F agonist"	"Potent, selective 5-HT1F receptor agonist (EC50 = 3 nM). Displays > 80-fold selectivity over other 5-HT receptors (Ki values are 0.006, 0.53, 0.55, 0.56, 1.42, 1.70, 3.50, 3.94 and 4.85 _M for 5-HT1F, 5-HT1A, 5-HT1B, 5-HT1D, 5-HT1E, 5-HT2B, 5-HT2C, 5-HT2A and 5-HT7 receptors respectively). Inhibits neurogenic dural inflammation in vivo following i.v. and oral administration."	"Lee et al (1997) Characterization of LY344864 as a pharmacological tool to study 5-HT1F receptors: binding affinities, brain penetration and activity in the neurogenic dural inflammation model of migraine. Life Science 61 2117. Ramadan et al (2003) 5-HT1F receptor agonists in acute migraine treatment: a hypothesis. Cephalalgia 23 776. PMID:14510923. Goadsby and Classey (2003) Evidence for serotonin (5-HT)1B, 5-HT1D and 5-HT1F receptor inhibitory effects on trigeminal neurons with craniovascular input. Neuroscience 122 491. PMID:14614913."	Small Molecule	Sold under license from Eli Lilly and Company	http://www.tocris.com/dispprod.php?ItemId=5325	SQ1341			Feb-2007
2452	LY 2183240	[874902-19-9]	CN(C)C(=O)N1N=NN=C1CC1=CC=C(C=C1)C1=CC=CC=C1	"Novel, potent anandamide uptake inhibitor; inhibits FAAH"	"Novel and highly potent blocker of anandamide uptake (IC50 = 270 pM). Inhibits fatty acid amide hydrolase (FAAH) activity (IC50 = 12.4 nM). Following i.p. administration in rats, increases brain anandamide concentration and exerts antinociceptive effects in formalin model of pain."	Moore et al (2005) Identification of a high-affinity binding site involved in the transport of endocannabinoids. Proc.Natl.Acad.Sci.USA 102 17852. Dickason-Chesterfield et al (2006) Pharmacological characterization of endocannabinoid transport and fatty acid amide hydrolase inhibitors. Cell Mol.Neurobiol. 26 407. PMID:16736384. Alexander and Cravat (2006) The putative endocannabinoid transport blocker LY2183240 is a potent inhibitor of FAAH and several other brain serine hydrolases. J.Am.Chem.Soc. 128 9699. PMID:16866524.	Small Molecule	Sold under license from Eli Lilly and Company	http://www.tocris.com/dispprod.php?ItemId=153259	SQ1341			May-2006
2453	LY 379268	[191471-52-0]	[H][C@]12[C@]([C@H]2[C@@](O)=O)([H])[C@](N)([C@](O)=O)CO1	Highly selective group II mGlu agonist	Highly selective group II mGlu receptor agonist (EC50 values are 2.69 and 4.48 nM for hmGlu2 and hmGlu3 respectively) that displays > 80-fold selectivity over group I and group III receptors. Provides protection against NMDA-mediated cell death in vitro and offers almost complete protection against CA1 hippocampal damage following global ischemia in gerbils. Orally and systemically active. Caged LY 379268 is also available (Cat. No. 3332).	"Bond et al (1999) LY379268, a potent and selective group II metabotropic glutamate receptor agonist, is neuroprotective in gerbil global, but not focal cerebral ischaemia. Neurosci.Lett. 273 191. PMID:10515191. Bond et al (2000) Neuroprotective effects of LY379268, a selective mGlu2/3 receptor agonist: investigations into possible mechanisms of action in vivo. J.Pharmacol.Exp.Ther. 294 800. PMID:10945827. Collado et al (2002) (2S,1'S,2'S,3'R)-2-(2'-carboxy-3'-methylcyclopropyl) glycine is a potent and selective metabotropic group 2 agonist with anxiolytic properties. J.Med.Chem. 45 3619. PMID:12166935."	Small Molecule	Sold under license from Eli Lilly and Company	http://www.tocris.com/dispprod.php?ItemId=5330	SQ1341			Oct-2006
2456	Co 101244 hydrochloride	[193356-17-1]	Cl.CC1=CC=C(CC2(O)CCN(CCOC3=CC=C(O)C=C3)CC2)C=C1	Highly selective NR2B antagonist	"Novel, potent and selective antagonist of NR2B-containing NMDA receptors (IC50 values are 0.043, > 100 and > 100 _M for NR1A/2B, NR1A/2A and NR1A/2C subunit combinations respectively). Displays neuroprotective effects in vivo and in vitro."	"Zhou et al (1999) 4-Hydroxy-1-[2-(4-hydroxyphenoxy)ethyl]-4-(4-methylbenzyl)piperidine: a novel, potent, and selective NR1/2B NMDA receptor antagonist. J.Med.Chem. 42 2993. PMID:10425109. Gill et al (2002) Pharmacological characterization of Ro 63-1908 (1-[2-(4-hydroxy-phenoxy)-ethyl]-4-(4-methyl-benzyl)-piperidin-4-ol), a novel subtype-selective N-methyl-D-aspartate antagonist. J.Pharmacol.Exp.Ther. 302 940. PMID:12183650. Higgins et al (2003) Evaluation of the NR2B-selective NMDA receptor antagonist Ro 63-1908 on rodent behaviour: evidence for an involvement of NR2B NMDA receptors in response inhibition. Neuropharmacology 44 324. PMID:12604092."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=5215	SQ1070			May-2006
2457	Arcyriaflavin A	[118458-54-1]	O=C1NC(=O)C2=C1C1=C(NC3=CC=CC=C13)C1=C2C2=C(N1)C=CC=C2	Potent cdk4/cyclin D1 and CaM Kinase II inhibitor. Antiviral agent (anti-HCMV)	Potent inhibitor of cdk4/cyclin D1 (IC50 = 59 nM). Also active against CaM kinase II (IC50 = 25 nM) but displays selectivity over several other kinases in vitro (IC50 values for inhibition of PKA and PKC are > 2 and > 100 _M respectively). Inhibits human cytomegalovirus (HCMV) replication in vitro (IC50 = 200 nM).	"Slater et al (1999) Indolocarbazoles: potent, selective inhibitors of human cytomegalovirus replication. Bioorg.Med.Chem. 7 1067. PMID:10428375. Zhu et al (2003) Synthesis of quinolinyl/isoquinolinyl[a]pyrrolo [3,4-c] carbazoles as cyclin D1/CDK4 inhibitors. Bioorg.Med.Chem.Lett. 13 1231. PMID:12657252. Sanchez-Martinez et al (2003) Aryl[a]pyrrolo[3,4-c]carbazoles as selective cyclin D1-CDK4 inhibitors. Bioorg.Med.Chem.Lett. 13 3835. PMID:14552791."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=154014	SQ1341			Jun-2006
2458	ZM 447439	[331771-20-1]	COC1=CC2=C(NC3=CC=C(NC(=O)C4=CC=CC=C4)C=C3)N=CN=C2C=C1OCCCN1CCOCC1	Inhibits Aurora kinase B	"Novel, selective ATP-competitive inhibitor of Aurora B kinase in vitro (IC50 values are 50, 250 and 1000 nM for Aurora B, C and A kinases respectively). Selective over a range of other kinases including cdk1 and PLK1 (IC50 > 10 _M). Inhibits cell division and displays selective toxicity towards proliferating tumor cells versus non-dividing cells."	"Ditchfield et al (2003) Aurora B couples chromosome alignment with anaphase by targeting BubR1, Mad2, and Cenp-E to kinetochores. J.Cell Biol. 161 267. PMID:12719470. Jung et al (2006) Discovery of novel and potent thiazoloquinazolines as selective Aurora A and B kinase inhibitors. J.Med.Chem. 49 955. PMID:16451062. Girdler et al (2006) Validating Aurora B as an anti-cancer drug target. J.Cell Sci. 119 3664. PMID:16912073."	Small Molecule	Sold with the permission of AstraZeneca UK Ltd.	http://www.tocris.com/dispprod.php?ItemId=154252	SQ1533			Jun-2006
2459	Tropisetron hydrochloride	[105826-92-4]	O=C(O[C@@H]3C[C@@H]4CC[C@@H](N4C)C3)C2=CNC1=CC=CC=C12.O=C(O[C@@H]7C[C@H]8CC[C@H](N8C)C7)C6=CNC5=CC=CC=C56.Cl.Cl	Potent 5-HT3 receptor antagonist; also partial agonist of _7 nAChR	"Potent, orally active 5-HT3 receptor antagonist. Antiemetic. Also partial agonist of _7 nAChR."	"Seynaeve et al (1991) 5-HT3 receptor antagonists, a new approach in emesis: a review of ondansetron, granisetron and tropisetron. Anticancer Drugs 2 343. PMID:1665723. Middlemiss and Tricklebank (1992) Centrally active 5-HT receptor agonists and antagonists. Neurosci.Biobehav.Rev. 16 75. PMID:1553108. Mhatre et al (2004) 5-HT3 antagonist ICS 205-930 enhances naltrexone's effects on ethanol intake. Eur.J.Pharmacol. 491 149. PMID:15140631. Papke et al (2004) Activity of _7-selective agonists at nicotinic and serotonin 5HT3 receptors expressed in Xenopus oocytes. Bioorg.Med.Chem.Lett. 14 1849. PMID:15050614."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=69695	SQ1533			Jun-2006
2460	Lazabemide hydrochloride	[103878-83-7]	Cl.NCCNC(=O)C1=NC=C(Cl)C=C1	Selective MAO-B inhibitor	"Selective, reversible monoamine oxidase B (MAO-B) inhibitor (IC50 values are 0.03 and > 100 _M for MAO-B and MAO-A respectively). Inhibits monoamine uptake at high concentrations (IC50 values are 86, 123 and > 500 _M for noradrenalin, serotonin and dopamine uptake respectively)."	"Saura et al (1992) Quantitative enzyme radioautography with 3H-Ro 41-1049 and 3H-Ro 19-6327 in vitro: localization and abundance of MAO-A and MAO-B in rat CNS, peripheral organs, and human brain. J.Neurosci. 12 1977. PMID:1578281. Bondiolotti et al (1995) In vitro effects on monoamine uptake and release by the reversible monoamine oxidase-B inhibitors lazabemide and N-(2-aminoethyl)-p-chlorobenzamide: a comparison with L-deprenyl. Biochem.Pharmacol. 50 97. PMID:7605351. Guimaraes and Soares-da-Silva (1998) The activity of MAO A and B in rat renal cells and tubules. Life Sci. 62 727. PMID:9489509."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=55945	SQ1533			Jan-2007
2463	SCH 442416	[316173-57-6]	COC1=CC=C(CCCN2N=CC3=C2N=C(N)N2N=C(N=C32)C2=CC=CO2)C=C1	"Very selective, high affinity A2A antagonist"	Selective adenosine A2A receptor antagonist; binds to human and rat A2A receptors with high affinity (Ki values are 0.048 and 0.5 nM respectively). Displays > 23000-fold selectivity for hA2A over hA1 in vitro with minimal affinity for hA2B and hA3 receptors (IC50 > 10 _M). Blocks the cytoprotective effect of A2A agonist CGS-21680 (Cat.No. 1063).	"Todde et al (2000) Design, radiosynthesis, and biodistribution of a new potent and selective ligand for in vivo imaging of the adenosine A2A receptor system using positron emission tomography. J.Med.Chem. 43 4359. PMID:11087559. Zheng et al (2007) Protective roles of adenosine A1, A2, and A3 receptors in skeletal muscle ischemia and reperfusion injury. Am.J.Physiol.Heart Circ.Physiol. 293 3685."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=154337	SQ1341			Jul-2006
2465	SDZ WAG 994	[130714-47-5]	O[C@@H]1[C@@H](CO)O[C@@H](N(C=N4)C2=C4C(NC3CCCCC3)=NC=N2)[C@@H]1OC	"Potent, selective A1 agonist"	"Potent and selective A1 adenosine receptor agonist (Ki values are 23, > 10000 and 25000 nM for A1, A2A and A2B receptors respectively). Causes a sustained fall in blood pressure and heart rate in spontaneous hypertensive rats and inhibits adenosine deaminase-stimulated lipolysis in rat adipocytes (Ki = 8 nM)."	"Wagner et al (1995) General pharmacology of SDZ WAG 994, a potent selective and orally active adenosine A1 receptor agonist. Drug Dev.Res. 34 276. Ishikawa et al (1998) Hypoglycemic and hypotensive effects of 6-cyclohexyl-2'-O-methyl-adenosine, an adenosine A1 receptor agonist, in spontaneous hypertensive rat complicated with hyperglycemia. Diabetes Res.Clin.Pract. 39 3. PMID:9597368. Jacobson and Gao (2006) Adenosine receptors as therapeutic targets. Nat.Rev.Drug Discov. 5 247. PMID:16518376."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=154424	SQ1070			Mar-2007
2466	"UK 14,304 tartrate"	[70359-46-5]	O=C(O)C(O)C(O)C(O)=O.BrC2=C(NC3=NCCN3)C=CC1=NC=CN=C12	"_2 agonist. Water-soluble form of UK 14,304 (Cat. No. 0425)"	"Water-soluble form of UK 14,304 (Cat. No. 0425). Full _2 adrenergic agonist. Centrally active following systemic administration in vivo."	"Cambridge (1981) UK-14,304, a potent and selective alpha2-gonist for the characterisation of alpha-adrenoceptor subtypes. Eur.J.Pharmacol. 72 413. PMID:6115759. Andorn et al (1988) Specific [3H]UK-14,304 binding in human cortex occurs at multiple high affinity states with _2-adrenergic selectivity and different affinities for GTP. Life Sci. 43 1805. PMID:2904634. Macdonald et al (1997) Gene targeting - homing in on _2-adrenoceptor-subtype function. TiPS 18 211. PMID:9227000. Chopin et al (1999) Effects of alpha-2 adrenoceptor agonists and antagonists on circling behavior in rats with unilateral 6-hydroxydopamine lesions of the nigrostriatal pathway. J.Pharmacol.Exp.Ther. 288 798. PMID:9918591."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=154425	SQ1533			May-2006
2467	CGS 20625	[111205-55-1]	COC1=CC=C(C=C1)N1N=C2C(=CNC3=C2CCCCC3)C1=O	Selective central benzodiazepine receptor partial agonist	"Selective, partial agonist for the benzodiazepine binding site of the GABAA receptor. Potently inhibits [3H]-flunitrazepam binding to central benzodiazepine receptors (IC50 = 1.3 nM) and displays weak affinity for peripheral benzodiazepine (IC50 = 0.68 - 2.25 _M) and GABA binding sites (IC50 > 10000 _M). Displays anxiolytic activity in vivo following oral administration. ."	"Bennett (1987) Pharmacology of the pyrazolo-type compounds: agonist, antagonist and inverse agonist actions. Physiol.Behav. 41 241. PMID:2893398. Williams et al (1989) CGS 20625, a novel pyrazolopyridine anxiolytic. J.Pharmacol.Exp.Ther. 248 89. PMID:2563294. Jarvis et al (1990) CGS 20625, a novel pyrazolopyridine with selective anxiolytic activity. Prog.Clin.Biol.Res. 361 477. PMID:1981266."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=154449	SQ1341			Jun-2006
2469	IBC 293	[306935-41-1]	CC(C)N1N=NC2=CC(=CC=C12)C(O)=O	Selective agonist for the GPR109B (HM74) receptor. Antilipolytic	"Highly selective agonist for GPR109B (HM74), human orphan G-protein-coupled receptor expressed in adipocytes. Selective for GPR109B over niacin receptor GPR109A (HM74A); EC50 values are 400 nM and > 1 _M respectively. Inhibits isoproterenol-stimulated lipolysis in vitro in isolated human adipocytes."	Semple et al (2006) 1-Alkyl-benzotriazole-5-carboxylic acids are highly selective agonists of the human orphan G-protein-coupled receptor GPR109b. J.Med.Chem. 49 1227. PMID:16480258.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=154938	SQ1341			May-2006
2470	Nimesulide	[51803-78-2]	CS(=O)(=O)NC1=C(OC2=CC=CC=C2)C=C(C=C1)[N+]([O-])=O	Cyclooxygenase-2 (COX-2) inhibitor	"Selective, orally active cyclooxygenase-2 (COX-2) inhibitor. Produces potent analgesic, anti-inflammatory and antipyretic activities in vivo. Reported to produce fewer gastrointestinal side effects than standard NSAIDs.  ."	Famaey (1997) In vitro and in vivo pharmacological evidence of selective cyclooxygenase-2 inhibition by nimesulide: an overview. Inflamm.Res. 46 437. PMID:9427063. Cullen et al (1998) Selective cyclooxygenase-2 inhibition by nimesulide in man. J.Pharmacol.Exp.Ther. 287 578. PMID:9808683.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=154943	SQ1070			May-2006
2471	ER 27319 maleate	[1204480-26-1]	OC(=O)\C=C/C(O)=O.CC1=C(C)C2=C(C=C1)C(=O)C1=CC=CC=C1N2CCCN	Selective Syk kinase inhibitor	"Selective inhibitor of Syk kinase. Inhibits tyrosine phosphorylation of Syk initiated by the engagement of Fc_RI in rat and human mast cells. Results in the abrogation of degranulation, TNF-_ production (IC50 = 10 _M) and other related signaling events."	"Moriya et al (1997) ER-27319, an acridone-related compound, inhibits release of antigen-induced allergic mediators from mast cells by selective inhibition of Fce receptor I-mediated activation of Syk. Proc.Natl.Acad.Sci.USA 94 12539. Luskova and Draber (2004) Modulation of the Fc_ receptor I signaling by tyrosine kinase inhibitors: search for therapeutic targets of inflammatory and allergy diseases. Curr.Pharm.Des. 10 1727. PMID:15180535."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=154944				Jul-2006
2473	GW 4064	[278779-30-9]	CC(C)C1=C(COC2=CC(Cl)=C(\C=C\C3=CC=CC(=C3)C(O)=O)C=C2)C(=NO1)C1=C(Cl)C=CC=C1Cl	Selective farnesoid X receptor (FXR) agonist	"Selective, non-steroidal farnesoid X receptor (FXR) agonist (EC50 = 15 nM). Displays no activity at other nuclear receptors at concentrations up to 1 _M. Improves hyperglycaemia and hyperlipidemia in diabetic db/db mice. Shown to suppress autophagy in nutrient-deprived mouse hepatocytes."	Maloney et al (2000) Identification of a chemical tool for the orphan nuclear receptor FXR. J.Med.Chem. 43 2971. PMID:10956205. Cariou et al (2006) The farnesoid X receptor modulates adiposity and peripheral insulin sensitivity in mice. J.Biol.Chem. 281 11039. PMID:16446356. Zhang et al (2006) Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice. Proc.Natl.Acad.Sci.USA 103 1006. Lee et al (2014) Nutrient-sensing nuclear receptors coordinate autophagy. Nature 516 112. PMID:25383539.	Small Molecule	Sold for research purposes under agreement from GlaxoSmithKline	http://www.tocris.com/dispprod.php?ItemId=155940	SQ1533			Feb-2007
2474	GW 3965 hydrochloride	[405911-17-3]	Cl.OC(=O)CC1=CC=CC(OCCCN(CC(C2=CC=CC=C2)C2=CC=CC=C2)CC2=C(Cl)C(=CC=C2)C(F)(F)F)=C1	Orally active liver X receptor (LXR) agonist	"Selective, orally active non-steroidal agonist for the liver X receptor (LXR). In cell-based reporter gene assays, acts as a full agonist of hLXR_ and hLXR_ (EC50 values are 190 and 30 nM respectively). Reduces angiotensin II-mediated increases in blood pressure; up-regulates ABCA1 gene expression and raises circulating HDL levels. Displays potent antiatherogenic activity in mouse models of atherosclerosis."	"Collins et al (2002) Identification of a nonsteroidal liver X receptor agonist through parallel array synthesis of tertiary amines. J.Med.Chem. 45 1963. PMID:11985463. Joseph et al (2002) Synthetic LXR ligand inhibits the development of atherosclerosis in mice Proc.Natl.Acad.Sci.USA 99 7604. Leik et al (2007) GW3965, a synthetic liver X receptor (LXR) agonist, reduces angiotensin II-mediated pressor responses in Sprague-Dawley rats. Br.J.Pharmacol. 151 450. PMID:17420776."	Small Molecule	Sold for research purposes under agreement from GlaxoSmithKline	http://www.tocris.com/dispprod.php?ItemId=155941	SQ1533			May-2006
2475	ZM 323881 hydrochloride	[193000-39-4]	Cl.CC1=C(O)C=C(NC2=C3C=CC(OCC4=CC=CC=C4)=CC3=NC=N2)C(F)=C1	"Potent, selective inhibitor of VEGFR-2"	"Potent and selective inhibitor of human vascular endothelial growth factor receptor 2 (VEGFR-2/KDR) activity. Selectively inhibits VEGFR-2 (IC50 = 2 nM) over VEGFR-1 and a range of other receptor tyrosine kinases such as PDGFR_, FGFR1, EGFR and erbB2 (IC50 > 50 _M). Inhibits VEGF-A-induced endothelial cell proliferation in vitro (IC50 = 8 nM)."	"Whittles et al (2002) ZM323881, a novel inhibitor of vascular endothelial growth factor-receptor-2 tyrosine kinase activity. Microcirculation 9 513. PMID:12483548. Endo et al (2003) Selective inhibition of vascular endothelial growth factor receptor-2 (VEGFR-2) identifies a central role for VEGFR-2 in human aortic endothelial cell responses to VEGF. J.Recept.Signal Transduct.Res. 23 239. PMID:14626450."	Small Molecule	Sold with the permission of AstraZeneca UK Ltd.	http://www.tocris.com/dispprod.php?ItemId=156230				Jul-2006
2476	SR 11302	[160162-42-5]	CC(\C=C\C=C(\C=C\C1=C(C)CCCC1(C)C)C1=CC=C(C)C=C1)=C/C(O)=O	Inhibitor of AP-1 transcription factor; antitumor agent	"Inhibitor of activator protein-1 (AP-1) transcription factor activity that displays antitumor effects in vivo. Does not activate transcription from the retinoic acid response element (RARE) and displays no activity at retinoic acid receptors (EC50 > 1 _M for RAR_, RAR_, RAR_ and RXR_)."	"Fanjul et al (1994) A new class of retinoids with selective inhibition of AP-1 inhibits proliferation. Nature 372 107. PMID:7969403. Huang et al (1997) Blocking activator protein-1 activity, but not activating retinoic acid response element, is required for the antitumor promotion effect of retinoic acid. Proc.Natl.Acad.Sci.USA 94 5826. Shiohara et al (1999) Effects of novel RAR- and RXR-selective retinoids on myeloid leukemic proliferation and differentiation in vitro. Blood 93 2057. PMID:10068679."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=156281				Nov-2006
2477	Proxyfan oxalate	[177708-09-7]	OC(=O)C(O)=O.C(COCC1=CC=CC=C1)CC1=CN=CN1	High affinity H3 ligand	"High affinity histamine H3 receptor ligand (pKi = 8.62) that acts as a protean agonist at recombinant and native receptors. In functional studies, activity ranges from full agonist to inverse agonist depending on system used. Displays partial agonist effects on cAMP inhibition and MAPK activity, neutral antagonist activity on histamine release and partial inverse agonism of [3H]-arachidonic acid release."	Gbahou et al (2003) Protean agonism at histamine H3 receptors in vitro and in vivo. Proc.Natl.Acad.Sci.USA 100 11086. Baldi et al (2005) The H3 receptor protean agonist proxyfan enhances the expression of fear memory in the rat. Neuropharmacology 48 246. PMID:15695163. Krueger et al (2005) G protein-dependent pharmacology of histamine H3 receptor ligands: evidence for heterogeneous active state receptor conformations. J.Pharmacol.Exp.Ther 314 271. PMID:15821027.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=156407	SQ1341			Oct-2006
2478	2-Pyridylethylamine dihydrochloride	[3343-39-3]	Cl.Cl.NCCC1=NC=CC=C1	H1 receptor agonist	Histamine H1 receptor agonist that produces vasoconstriction in vivo.	Martinez-Mir et al (1992) Effect of histamine and histamine analogues on human isolated myometrial strips. Br.J.Pharmacol. 107 528. PMID:1358393. Arai and Chiba (1999) Endothelium-dependent vasodilation mechanisms by histamine in simian but not in canine femoral arterial branches. J.Auton.Pharmacol. 19 267. PMID:10759332.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=156434				Jun-2006
2479	JTE 907	[282089-49-0]	CCCCCOC1=C2NC(=O)C(=CC2=CC=C1OC)C(=O)NCC1=CC2=C(OCO2)C=C1	Selective CB2 receptor antagonist/inverse agonist	"Highly selective cannabinoid CB2 receptor inverse agonist. Binds with high affinity to rat, mouse and human CB2 receptors (Ki values are 0.38, 1.55 and 35.9 nM respectively). Produces anti-inflammatory effects in vivo."	"Iwamura et al (2001) In vitro and in vivo pharmacological characterization of JTE-907, a novel selective ligand for cannabinoid CB2 receptor. J.Pharmacol.Exp.Ther. 296 420. PMID:11160626. Ueda et al (2005) Involvement of cannabinoid CB2 receptor-mediated response and efficacy of cannabinoid CB2 receptor inverse agonist, JTE 907, in cutaneous inflammation in mice. Eur.J.Pharmacol. 520 164. PMID:16153638. Maekawa et al (2006) The cannabinoid CB2 receptor inverse agonist JTE-907 suppresses spontaneous itch-associated responses of NC mice, a model of atopic dermatitis. Eur.J.Pharmacol. 542 179. PMID:16824511."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=156543	SQ1341			Jun-2006
2481	JTC 801	[244218-51-7]	Cl.CCC1=CC=C(OCC2=CC=CC=C2C(=O)NC2=CC3=C(N)C=C(C)N=C3C=C2)C=C1	Selective NOP antagonist	"High affinity, selective NOP receptor antagonist (Ki = 8.2 nM). Displays approximately 12.5-, 129- and 1055-fold selectivity over human _-, _- and _-opioid receptors respectively. Exhibits anti-nociceptive effects in acute pain models in vivo. Orally active."	"Shinkai et al (2000) 4-Aminoquinolines: novel nociceptin antagonists with analgesic activity. J.Med.Chem 43 4667. PMID:11101358. Yamada et al (2002) Pharmacological profiles of a novel opioid receptor-like1 (ORL1) receptor antagonist, JTC-801. Br.J.Pharmacol. 135 323. PMID:11815367. Tamai et al (2005) Anti-allodynic and anti-hyperalgesic effects of nociceptin receptor antagonist, JTC-801, in rats after spinal nerve injury and inflammation. Eur.J.Pharmacol. 510 223. PMID:15763246."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=156738	SQ1533			Sep-2006
2483	Costunolide	[553-21-9]	C/C1=C\[C@@H](OC([C@]2=C)=O)[C@H]2CC/C(C)=C/CC1	Inhibitor of human telomerase activity	"Inhibitor of human telomerase activity (IC50 = 65 _M in MCF-7 breast cancer cells). Suppresses proliferation and induces apoptosis in a variety of human tumor cell lines. Selectively blocks endothelial cell proliferation induced by VEGF. Inhibits expression of iNOS and IL-1_ and disrupts NF-_B activation. Displays anti-inflammatory, antifungal and antiviral properties."	"Park et al (1996) Syringin 4-O-_-glucoside, a new phenylpropanoid glycoside, and costunolide, a nitric oxide synthase inhibitor, from the stem bark of Magnolia sieboldi. J.Nat.Prod. 59 1128. PMID:8988596. Jeong et al (2002) Costunolide, a sesquiterpene lactone from Saussurea lappa, inhibits the VEGFR KDR/Flk-1 signaling pathway. Cancer Lett. 187 129. PMID:12359360. Choi et al (2005) Inhibitory effects of costunolide on the telomerase activity in human breast carcinoma cells. Cancer Lett. 227 153. PMID:16112418."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=157176	SQ1533			Jul-2006
2484	()-AC 7954 hydrochloride	[477313-09-0]	Cl.CN(C)CCC1(CC2=CC=CC=C2C(=O)O1)C1=CC=C(Cl)C=C1	Non-peptide UT receptor agonist	"Highly selective, non-peptide urotensin-II (UT) receptor agonist that displays potent activity at human and rat UT receptors (pEC50 values are 6.5 and 6.7 respectively)."	Croston et al (2002) Discovery of the first nonpeptide agonist of the GPR14/urotensin-II receptor: 3-(4-chlorophenyl)-3-(2-(dimethylamino)ethyl)isochroman-1-one (AC-7954). J.Med.Chem. 45 4950. PMID:12408704. Lavecchia et al (2005) Architecture of the human urotensin II receptor: comparison of the binding domains of peptide and non-peptide urotensin II agonists. J.Med.Chem. 48 2480. PMID:15801838. Lehmann et al (2006) Novel potent and efficacious nonpeptidic urotensin II receptor agonists. J.Med.Chem. 49 2232. PMID:16570919.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=157220	SQ1341			Dec-2006
2485	Glycyl-H 1152 dihydrochloride	[913844-45-8]	CC1=CN=CC2=C1C(S(N3CCCN(C(CN)=O)C[C@@H]3C)(=O)=O)=CC=C2.Cl.Cl	Selective Rho-kinase (ROCK) inhibitor. More selective analog of H 1152 dihydrochloride (Cat. No. 2414)	"Glycyl analog of the Rho-kinase inhibitor H 1152 dihydrochloride (Cat. No. 2414) that displays improved ROCKII selectivity. IC50 values are 0.0118, 2.35, 2.57, 3.26, > 10 and >10 _M for ROCKII, Aurora A, CAMKII, PKG, PKA and PKC respectively."	Tamura et al (2005) Development of specific Rho-kinase inhibitors and their clinical application. Biochim.Biophys.Acta 1754 245. PMID:16213195.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=157263	SQ1533			Mar-2007
2489	C 75	[191282-48-1]	C=C([C@@H]([C@](O)=O)[C@H](CCCCCCCC)O1)C1=O.C=C([C@H](C(O)=O)[C@@H](CCCCCCCC)O2)C2=O	Potent fatty acid synthase inhibitor; proapoptotic	Synthetic inhibitor of fatty acid synthase (FASN); inhibits fatty acid synthesis in vitro and in vivo. Displays anorectic effects. Induces apoptosis in MCF-7 xenografts and exhibits anti-tumor activity.	"Kuhajda et al (2000) Synthesis and antitumor activity of an inhibitor of fatty acid synthase. Proc.Natl.Acad.Sci. 97 3450. Zhou et al (2003) Fatty acid synthase inhibition triggers apoptosis during S phase in human cancer cells. Cancer Res. 63 7330. PMID:14612531. Takahashi et al (2004) The anorexigenic fatty acid synthase inhibitor, C45, is a nonspecific neuronal activator. Endocrinology 145 184. PMID:14512433. Thupari et al (2004) Chronic C75 treatment of diet-induced obese mice increases fat oxidation and reduces food intake to reduce adipose mass. Am.J.Physiol.Endocrinol.Metab. 287 97."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=157480	SQ1533			Aug-2010
2490	()-Clopidogrel hydrochloride	[130209-90-4]	Cl.COC(=O)C(N1CCC2=C(C1)C=CS2)C1=C(Cl)C=CC=C1	Selective P2Y12 antagonist	"Selective, high affinity P2Y12 receptor antagonist (pKi = 6.9 for hP2Y12 receptor). Inhibits ADP-induced platelet aggregation; potent antithrombotic agent. Requires bioactivation, unlike PSB 0739 (Cat. No. 3983). (+)-Clopidogrel hydrogen sulfate (Cat. No. 1820) also available."	"Savi et al (2001) P2Y12, a new platelet ADP receptor, target of clopidogrel. Biochem.Biophys.Res.Comm. 283 379. Savi and Herbert (2005) Clopidogrel and ticlopidine: P2Y12 adenosine diphosphate-receptor antagonists for the prevention of atherothrombosis. Semin.Thromb.Haemostas. 31 174. Kugelgen (2006) Pharmacological profiles of cloned mammalian P2Y-receptor subtypes. Pharmacol.Ther. 110 415. PMID:16257449."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=157921	SQ1533			Aug-2006
2491	Xaliproden hydrochloride	[90494-79-4]	Cl.FC(F)(F)C1=CC(=CC=C1)C1=CCN(CCC2=CC=C3C=CC=CC3=C2)CC1	"Orally active, high affinity 5-HT1A agonist"	"Orally active, full agonist at 5-HT1A receptors. Binds rat 5-HT1A with high affinity (Ki = 2.0 nM) and is > 300-fold selective over other 5-HT receptor subtypes (IC50 > 650 nM). Increases motoneuron survival and promotes effects of NGF on neurite outgrowth in vitro. Displays neurotrophic activity in several neurodegenerative models in vivo. ."	"Fournier et al (1993) Protective effects of SR 57746A in central and peripheral models of neurodegenerative disorders in rodents and primates. Neuroscience 55 629. PMID:8413926. Bachy et al (1993) Biochemical and electrophysiological properties of SR 57746A, a new, potent 5-HT1A receptor agonist. Fund.Clin.Pharmacol. 7 487. Duong et al (1999) Effect of the nonpeptide neurotrophic compound SR 57746A on the phenotypic survival of purified mouse motoneurons. Br.J.Pharmacol. 128 1385. PMID:10602316."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=157980	SQ1533			Jul-2006
2492	MNITMT	[177653-76-8]	CN1C=NN=C1SC1=C(N=CN1C)[N+]([O-])=O	"Novel, non-toxic immunosuppressive agent"	"Novel, non-toxic immunosuppressive agent. Inhibits human mixed lymphocyte reaction in vitro (ED50 = 2.7 _M) and prolongs skin graft survival in mice. Produces a 98.1% reduction in antibody response following oral administration in rabbits."	Crawford et al (1996) Rational design of novel immunosuppressive drugs: analogues of azathioprine lacking the 6-mercaptopurine substituent retain or have enhanced immunosuppressive effects. J.Med.Chem. 39 2690. PMID:8709098. Al-Safi et al (2003) Comparison of the effects of azathioprine and its novel non-mercaptopurine analog on antibody response in rabbits. Pol.J.Pharmacol. 55 239. PMID:12926553.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=158001	SQ1341			Jul-2006
2493	VUF 5681 dihydrobromide	[639089-06-8]	Br.Br.C(CC1CCNCC1)CC1=CNC=N1	Potent H3 receptor silent antagonist	Potent histamine H3 receptor silent antagonist (pKi = 8.35).	"Kitbunnadaj et al (2004) Identification of 4-(1H-imidazol-4(5)-ylmethyl)pyridine (immethridine) as a novel, potent, and highly selective histamine H3 receptor agonist. J.Med.Chem. 47 2414. PMID:15115383. Leurs et al (2005) The histamine H3 receptor: from gene cloning to H3 receptor drugs. Nat.Rev.Drug Discov. 4 107. PMID:15665857. Moreno-Delgado et al (2006) Constitutive activity of H3 autoreceptors modulates histamine synthesis in rat brain through the cAMP/PKA pathway. Neuropharmacology 51 517. PMID:16769092."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=158051	SQ1341			Aug-2006
2494	VUF 8430 dihydrobromide	[100130-32-3]	Br.Br.NC(SCCNC(N)=N)=N	"Potent, high affinity H4 agonist"	"High affinity (pKi = 7.5), potent histamine H4 receptor full agonist (pEC50 = 7.3). Displays moderate affinity for H3 receptors (pKi = 6.0) and weak partial agonist activity at H2 receptors."	Sterk et al (1986) The influence of guanidio and isothiourea groups in histaminergic compounds on H2-activity. Agents Actions 18 137. PMID:2942013. Lim et al (2006) Discovery of S-(2-guanidylethyl)-isothiourea (VUF 8430) as a potent nonimidazole histamine H4 receptor agonist. J.Med.Chem. 49 6650. PMID:17154494. Lim et al (2008) Phenylalanine 169 in the second extracellular loop of the human histamine H4 receptor is responsible for the difference in agonist binding between human and mouse H4 receptors. J.Pharmacol.Exp.Ther. 327 88. PMID:18635748.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=158052				Aug-2006
2495	Melperone hydrochloride	[1622-79-3]	Cl.CC1CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1	5-HT2A/D2 receptor antagonist; neuroleptic	Atypical neuroleptic; 5-HT2A/D2 receptor antagonist (Ki values are 120 and 180 nM respectively). Causes an increase in dopamine levels in the medial prefrontal cortex (mPFC) and nucleus accumbens and an increase in ACh in the mPFC. Also binds adrenergic _1 and _2 receptors (Ki values are 180 and 150 nM respectively).	"Seeman et al (1997) Atypical neuroleptics have low affinity for dopamine D2 receptors or are selective for D4 receptors. Neuropsychopharmacology. 16 93. PMID:9015795. Ichikawa et al (2002) Atypical antipsychotic drugs, quetiapine, iloperidone, and melperone, preferentially increase dopamine and acetylcholine release in rat medial prefrontal cortex: role of 5-HT1A receptor agonism. Brain Res. 956 349. PMID:12445705. Uhr et al (2005) P-glycoprotein is a factor in the uptake of dextromethorphan, but not of melperone, into mouse brain: evidence for an overlap in substrate specificity between P-gp and CYP2D6. J.Psychopharmacol. 18 509."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=158202	SQ1533			Mar-2007
2496	DR 2313	[284028-90-6]	CC1=NC(=O)C2=C(N1)CCSC2	PARP-1 and PARP-2 inhibitor	Competitive inhibitor of poly(ADP-ribose) polymerase (PARP) (IC50 values are 0.20 and 0.24 _M for PARP-1 and PARP-2 respectively). Neuroprotective; reduces neuronal cell death in models of cerebral ischemia in vivo and in vitro. Brain penetrant.	"Nakajima et al (2005) A newly synthesized poly(ADP-ribose) polymerase inhibitor, DR2313 [2-Methyl-3,5,7,8-tetrahydrothiopyrano[4,3-d]-pyrimidine-4-one]: pharmacological profiles, neuroprotective effects, and therapeutic time window in cerebral ischemia in rats. J.Pharmacol.Exp.Ther. 312 472. PMID:15466246. Jagtap and Szabo (2005) Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors. Nat.Rev.Drug Discov. 4 421. PMID:15864271."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=158207	SQ1341			Jul-2006
2498	PNU 120596	[501925-31-1]	COC1=CC(OC)=C(Cl)C=C1NC(=O)NC1=NOC(C)=C1	Positive allosteric modulator of _7 nAChR; active in vivo	"Positive allosteric modulator of _7 neuronal nicotinic acetylcholine receptors (EC50 = 216 nM), with no detectable effect on _4_2, _3_4 and _9_10 receptors. Active in vivo following systemic administration. Neuroprotective in an in vivo model of transient focal cerebral ischemia."	Hurst et al (2005) A novel positive allosteric modulator of the _7 neuronal nicotinic acetylcholine receptor: in vitro and in vivo characterization. J.Neurosci. 25 4396. PMID:15858066. Timmermann et al (2007) An allosteric modulator of the _7 nicotinic acetylcholine receptor possessing cognition-enhancing properties in vivo. J.Pharmacol.Exp.Ther. 323 294. PMID:17625074. Kalappa et al (2013) A positive allosteric modulator of _7 nAChRs augments neuroprotective effects of endogenous nicotinic agonists in cerebral ischemia. Br.J.Pharmacol. [Epub ahead of print]. PMID:23713819.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=158269	SQ1533			Jul-2006
2499	ZM 306416 hydrochloride	[196603-47-1]	Cl.COC1=C(OC)C=C2C(NC3=CC=C(Cl)C=C3F)=NC=NC2=C1	Inhibitor of VEGF receptor tyrosine kinase	Inhibitor of vascular endothelial growth factor (VEGF) receptor tyrosine kinase. Inhibits activity of KDR and FLT VEGF receptors (IC50 values are 100 nM and 2 _M respectively) and displays > 3-fold selectivity over FGFR-1. Orally active in vivo.	Hennequin et al (1999) Design and structure-activity relationship of a new class of potent VEGF receptor tyrosine kinase inhibitors. J.Med.Chem. 42 5369. PMID:10639280.	Small Molecule	Sold with the permission of AstraZeneca UK Ltd.	http://www.tocris.com/dispprod.php?ItemId=158591				Jul-2006
2500	Bay 59-3074	[406205-74-1]	FC(F)(F)CCCS(=O)(=O)OC1=CC(OC2=CC=CC(=C2C#N)C(F)(F)F)=CC=C1	CB1/CB2 receptor partial agonist	Novel CB1/CB2 receptor partial agonist (Ki values are 48.3 and 45.5 nM at human CB1 and CB2 receptors respectively). Orally active CB1 agonist in vivo. Displays anti-hyperalgesic and antiallodynic properties in rat models of chronic neuropathic and inflammatory pain.	"De Vry et al (2004) 3-[2-Cyano-3-(trifluoromethyl)phenoxy]phenyl-4,4,4-trifluoro-1-butanesulfonate (BAY 59-3074): a novel cannabinoid CB1/CB2 receptor partial agonist with antihyperalgesic and antiallodynic effects. J.Pharmacol.Exp.Ther. 310 620. PMID:15140913. De Vry et al (2004) Discriminative stimulus effects of the structurally novel cannabinoid CB1/CB2 receptor partial agonist BAY 59-3074 in the rat. Eur J Pharmacol. 505 127. PMID:15556145."	Small Molecule	Sold for research purposes under agreement from Bayer	http://www.tocris.com/dispprod.php?ItemId=158711	SQ1070			Sep-2006
2501	Bay 36-7620	[232605-26-4]	C=C1C[C@@]2([H])[C@@](C(OC2)=O)(CC3=CC(C=CC=C4)=C4C=C3)C1	Non-competitive mGlu1 antagonist with inverse agonist activity	Selective mGlu1 receptor non-competitive antagonist (IC50 = 0.16 _M) with inverse agonist activity. Impairs classical conditioning and associated synaptic plasticity in hippocampal neurons. Exhibits neuroprotective and anticonvulsive effects in vivo following systemic administration.	Carroll et al (2001) BAY36-7620: a potent non-competitive mGlu1 receptor antagonist with inverse agonist activity. Mol.Pharmacol. 59 965. PMID:11306677. De Vry et al (2001) Neuroprotective and behavioural effects of the selective metabotropic glutamate mGlu1 receptor antagonist BAY 36-7620. Eur.J.Pharmacol. 428 203. PMID:11675037. Gil-Sanz et al (2007) Involvement of the mGluR1 receptor in hippocampal synaptic plasticity and associative learning in behaving mice. Cereb.Cortex 18 1653. PMID:18024992.	Small Molecule	Sold for research purposes under agreement from Bayer	http://www.tocris.com/dispprod.php?ItemId=5179	SQ1070			Jan-2010
2503	(-)-Bicuculline methiodide	[40709-69-1]	[H][C@](C(C=CC6=C5OCO6)=C5C(O4)=O)4[C@]2([H])C1=CC3=C(OCO3)C=C1CC[N+](C)2C.[I-]	Water-soluble GABAA antagonist	"Methiodide form of classical GABAA receptor antagonist (+)-bicuculline (Cat. No. 0130). More water-soluble and stable. Non-GABA receptor-mediated actions reported, including actions on calcium-dependent potassium channels."	Olsen et al (1976) Studies on the neuropharmacological activity of bicuculline and related compounds. Brain Res. 102 283. PMID:1247886. Seutin and Johnson (1999) Recent advances in the pharmacology of quaternary salts of bicuculline. TiPS 20 268. PMID:10390643. Chan et al (2006) Blockade of GABA(A) receptors in the ventromedial hypothalamus further stimulates glucagon and sympathoadrenal but not the hypothalamo-pituitary-adrenal response to hypoglycemia. Diabetes 55 1080. PMID:16567532. Kurt et al (2006) Differential effects of iontophoretic in vivo application of the GABAA-antagonists bicuculline and gabazine in sensory cortex. Hear.Res. 212 224. PMID:16442250.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=159237	SQ1341			Jul-2006
2504	Irsogladine maleate	[84504-69-8]	OC(=O)\C=C/C(O)=O.NC1=NC(=NC(N)=N1)C1=CC(Cl)=CC=C1Cl	PDE4 inhibitor; antiulcer agent	Phosphodiesterase 4 (PDE4) inhibitor that displays gastroprotective properties. Prevents gastric mucosal injury induced by monochloramine and ischemia-reperfusion. Activates gap-junctional intercellular communication improving gastric mucosal barrier function. Inhibits superoxide production in human neutrophils and inhibits in vitro and in vivo angiogenesis.	"Nozaki et al (2004) Inhibition of breast cancer regrowth and pulmonary metastasis in nude mice by anti-gastric ulcer agent, irsogladine. Breast Cancer Res.Treat. 83 195. PMID:14758089. Kyoi et al (2004) Phosphodiesterase type IV inhibitors prevent ischemia-reperfusion-induced gastric injury in rats. J.Pharmacol.Sci. 95 321. PMID:15272207. Kyoi et al (2004) Irsogladine, an anti-ulcer drug, suppresses superoxide production by inhibiting phosphodiesterase type 4 in human neutrophils. Life Sci. 76 71. PMID:15501481."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=159296	SQ1533			Sep-2006
2505	Nonactin	[6833-84-7]	[H][C@]3(CC[C@@](C[C@@H](C)OC([C@H](C)[C@@]4([H])CC[C@](C[C@H](C)OC([C@H]5C)=O)([H])O4)=O)([H])O3)[C@H](C)C(O[C@@H](C)C[C@@]1([H])O[C@]([C@@H](C)C(O[C@H](C)C[C@]2([H])O[C@@]5([H])CC2)=O)([H])CC1)=O	Monovalent cation ionophore	Monovalent cation ionophore that displays selectivity for K+ and NH4+ (K+ = NH4+ > Na+ > Mg2+ > Li+ >> Ca2+ for nonactin-EVA sensor). Induces cation transport across artificial membranes. Also inhibits P-glycoprotein-mediated efflux of chemotherapeutic agents in multiple-drug resistant cancer cells. Antibiotic.	Borrel et al (1994) Mobile ionophores are a novel class of P-glycoprotein inhibitors. The effects of ionophores on 4'O-tetrahydropyranyl-adriamycin incorporation in K562 drug-resistant cells. Eur.J.Biochem. 223 125. PMID:7518390. Woo et al (1999) Nonactin biosynthesis: the product of nonS catalyzes the formation of the furan ring of nonactic acid. Antimicrob.Agents Chemother. 43 1662. PMID:10390219. Garcia et al (2003) Determination of potassium ions in pharmaceutical samples by FIA using a potentiometric electrode based on ionophore nonactin occluded in EVA membrane. J.Pharm.Biomed.Anal. 31 11. PMID:12560044.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=159307	SQ1341			Sep-2006
2506	SSR 69071	[344930-95-6]	COC1=CC(C(C)C)=C2C(=O)N(COC3=CC(=O)N4C=CC=C(OCCN5CCCCC5)C4=N3)S(=O)(=O)C2=C1	"Potent, orally active human leukocyte elastase inhibitor"	"High affinity, potent inhibitor of human leukocyte elastase (HLE) (IC50 = 3.9 nM). Displays species-selectivity (Ki values are 0.017, 1.70, 3.01, 58 and > 100 nM  for human, mouse, rat, rabbit and porcine elastase respectively). Inhibits HLE-induced lung hemorrhage in mice (ID50 = 2.8 mg/kg) and reduces infarct size in an in vivo acute model of coronary ischemia-reperfusion injury. Orally active."	"Bidouard et al (2003) SSR69071, an elastase inhibitor, reduces myocardial infarct size following ischemia-reperfusion injury. Eur.J.Pharmacol. 461 49. PMID:12568915. Varga et al (2003) A novel orally active inhibitor of HLE. Eur.J.Med.Chem. 38 421. PMID:12750030. Kapui et al (2003) Biochemical and pharmacological characterization of 2-(9-(2-Piperidinoethoxy)-4-oxo-4H-pyrido[1,2-_]pyrimidin-2-yloxymethyl)-4-(1-methylethyl)-6-methoxy-1,2-benzisothiazol-3(2H)-one-1,1-dioxide (SSR69071), a novel, orally active elastase inhibitor. J.Pharmacol.Exp.Ther. 305 451. PMID:12606659."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=159308	SQ1533			Nov-2006
2507	J 104129 fumarate	[257603-40-0]	[H]OC(=O)\C=C\C(=O)O[H].C\C(C)=C\CCN1CCC(CC1)NC(=O)[C@@](O)(C1CCCC1)C1=CC=CC=C1	"Potent, selective M3 antagonist"	"Potent M3 muscarinic receptor antagonist that displays ~ 120-fold selectivity over M2 receptors (Ki values are 4.2, 19 and 490 nM for human M3, M1 and M2 receptors respectively). Exhibits > 250-fold bronchial selectivity; inhibits ACh-induced bronchoconstriction but not ACh-induced bradycardia (KB values are 3.3 and 170 nM for rat trachea M3 and rat right atria M2 receptors respectively)."	"Mitsuya et al (1999) J-104129, a novel muscarinic M3 receptor antagonist with high selectivity for M3 over M2 receptors. Bioorg.Med.Chem. 7 2555. PMID:10632066. Mitsuya et al (1999) Stereoselective synthesis of a new muscarinic M3 receptor antagonist, J-104129. Bioorrg.Med.Chem.Lett. 9 2037. Mitsuya et al (2000) Discovery of a muscarinic M3 receptor antagonist with high selectivity for M3 over M2 receptors among 2-[(1S,3S)-3-sulfonylaminocyclopentyl]phenylacetamide derivatives. Bioorg.Med.Chem. 8 825. PMID:10819171."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=159327	SQ1341			May-2007
2508	Trap 101	[1216621-00-9]	Cl.CCN1C(=O)N(C2=CC=CC=C12)C1=C(CO)CN(CC2CCCCCCC2)CC1	Potent and selective NOP antagonist; active in vivo	"Potent and selective nociceptin/orphanin FQ (NOP) receptor antagonist (pA2 = 7.75). Displays selectivity for NOP receptors over classical opioid receptors (pKi values are 8.65, 6.60, 6.14 and < 5 for NOP, _-, _-, and _-opioid receptors respectively). Attenuates motor deficits in a rat model of Parkinson's Disease. Active in vivo."	Trapella et al (2006) Identification of an achiral analogue of J-113397 as potent nociceptin/orphanin FQ receptor antagonist. Bioorg.Med.Chem. 14 692. PMID:16202610. Marti et al (2008) The novel nociceptin/orphanin FQ receptor antagonist Trap-101 alleviates experimental parkinsonism through inhibition of the nigro-thalamic pathway: positive interaction with L-DOPA. J.Neurochem. 107 1683. PMID:19014386.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=159329	SQ1341			Jul-2007
2509	Cardamonin	[19309-14-9]	OC1=CC(O)=C(C(/C=C/C2=CC=CC=C2)=O)C(OC)=C1	Inhibitor of NF-_B activation; anti-inflammatory	"Chalone analog that display anti-inflammatory activity. Inhibits NO and PGE2 production from LPS- and IFN-_-induced RAW cells and inhibits TXB2 production via the COX-1 and COX-2 pathways. Inhibits NF-_B activation via inhibition of I_B_ degradation and phosphorylation, I_B kinase activation and NF-_B nuclear translocation."	"Lee et al (2006) Blockade of nuclear factor-_B signaling pathway and anti-inflammatory activity of Cardamomin, a chalcone analog from Alpina conchigera. J.Pharmacol.Exp.Ther. 316 271. PMID:16183703. Ahmad et al (2006) Cardamonin, inhibits pro-inflammatory mediators in activated RAW 264.7 cells and whole blood. Eur.J.Pharmacol. 538 188. PMID:16650843. Israf et al (2007) Cardamonin inhibits COX and iNOS expression via inhibition of p65NF-_B nuclear translocation and I_-B phosphorylation in RAW 264.7 macrophage cells. Mol.Immunol. 44 673. PMID:16777230."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=159394				Mar-2010
2510	Talniflumate	[66898-62-2]	FC(F)(F)C1=CC(NC2=NC=CC=C2C(=O)OC2OC(=O)C3=CC=CC=C23)=CC=C1	CaCC blocker and Cl-/HCO3- exchange inhibitor	Calcium-activated chloride channel (CaCC) (hCLCA1/mCLCA3) blocker; reduces mucin synthesis and release in cell culture and animal models. Possesses anti-inflammatory actions via inhibition of cyclooxygenases and inhibits Cl-/HCO3- exchanger activity. Increases survival in a cystic fibrosis mouse model of distal intestinal obstructive syndrome.	Sanchez et al (1982) Action of a non-steroidal anti-inflammatory drug on gastric mucosa of rats. J.Appl.Toxicol. 2 42. Knight (2004) Talniflumate (Genaera). Curr.Opin.Invest.Drugs 5 557. Walker et al (2006) Talniflumate increases survival in a cystic fibrosis mouse model of distal intestinal obstructuve syndrome. J.Pharmacol.Exp.Ther. 317 275. PMID:16354791.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=159450	SQ1533			Sep-2006
2512	CGS 35066	[261619-50-5]	O=C([C@@H](NCP(O)(O)=O)CC1=CC3=C(C2=CC=CC=C2O3)C=C1)O	Endothelin-converting enzyme (ECE) inhibitor	Potent endothelin-converting enzyme (ECE) inhibitor that displays > 100-fold selectivity over neutral endopeptidase 24.11 (IC50 values are 22 and 2300 nM respectively). Blocks the hypertensive effects induced by big ET-1 in vitro and reduces the magnitude of cerebral vasospasm following subarachnoid hemorrhage (SAH).	"De Lombaert et al (2000) Potent and selective non-peptidic inhibitors of endothelin-converting enzyme-1 with sustained duration of action. J.Med.Chem. 43 488. PMID:10669576. Trapani et al (2000) Pharmacological properties of CGS 35066, a potent and selective endothelin-converting enzyme inhibitor, in conscious rats. J.Cardiovasc.Pharmacol. 36 (5 Suppl. 1) S40. PMID:11078331. Kwan et al (2002) Attenuation of SAH-induced cerebral vasospasm by a selective ECE inhibitor. Neuropharmacol.Neurotoxicol. 13 197."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=159558	SQ1341			Feb-2007
2513	Acyclovir	[59277-89-3]	NC1=NC(=O)C2=C(N1)N(COCCO)C=N2	Inhibits viral DNA polymerase; antiherpetic agent	"Antiviral agent, active against herpes simplex viruses HSV-1 and HSV-2 (EC50 values are 0.85 and 0.86 _M respectively). Interferes with viral DNA polymerization through competitive inhibition with guanosine triphosphate. Induces apoptosis in cells transfected with HSV-TK (suicidal gene therapy)."	"Elion et al (1977) Selectivity of action of an antiherpetic agent, 9-(2-hydroxyethoxymethyl)guanine. Proc.Natl.Acad.Sci.USA. 74 5716. Hayashi et al (2006) The role of a HSV thymidine kinase stimulating substance, scopadulciol, in improving the efficacy of cancer gene therapy. J.Gene.Med. 8 1056. PMID:16779868. Suzuki et al (2006) Synergistic antiviral activity of acyclovir and vidarabine against herpes simplex virus types 1 and 2 and varicella-zoster virus. Antiviral Res. 72 157. PMID:16797734."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=159716	SQ1533			Aug-2006
2514	"L-161,982"	[147776-06-5]	CCCCC1=NN(C(=O)N1CC1=CC=C(C=C1)C1=C(C=CC=C1)S(=O)(=O)NC(=O)C1=C(C)C=CS1)C1=C(C=CC=C1)C(F)(F)F	Selective EP4 receptor antagonist	"EP4 receptor antagonist that is selective over all other members of the prostanoid receptor family (Ki values are 0.024, 0.71, 1.90, 5.10, 5.63, 6.74, 19 and 23 _M for human EP4, TP, EP3, DP, FP, IP, EP1 and EP2 receptors respectively). Suppresses PGE2-induced bone formation in rats and prevents the nociceptive response induced by misoprostol in formalin-injected mice."	Machwate et al (2001) Prostaglandin receptor EP4 mediates the bone anabolic effects of PGE2. Mol.Pharmacol. 60 36. PMID:11408598. Oliva et al (2006) Role of periaqueductal grey prostaglandin receptors in formalin-induced hyperalgesia. Eur.J.Pharmacol. 530 40. PMID:16360148. Balzary et al (2006) Lipopolysaccharide induces epithelium- and prostaglandin E2-dependent relaxation of mouse isolated trachea through activation of cyclooxygenase (COX)-1 and COX-2. J.Pharmacol.Exp.Ther. 317 806. PMID:16464966.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=159902	SQ1341			Mar-2007
2517	RS 504393	[300816-15-3]	CC1=C(CCN2CCC3(CC2)OC(=O)NC2=C3C=C(C)C=C2)N=C(O1)C1=CC=CC=C1	Highly selective CCR2 chemokine receptor antagonist	Extremely selective CCR2 chemokine receptor antagonist (IC50 values are 98 nM and > 100 _M for inhibition of human recombinant CCR2b and CCR1 receptors respectively). Inhibits MCP-1 chemotaxis (IC50 = 330 nM) and ischemia-reperfusion injury in kidneys.	Mirzadegan et al (2000) Identification of the binding site for a novel class of CCR2b chemokine receptor antagonists. J.Biol.Chem. 275 25562. PMID:10770925. Furuichi et al (2003) CCR2 signaling contributes to ischemia-reperfusion injury in kidney. J.Am.Soc.Nephrol. 14 2503. PMID:14514728. Kitagawa et al (2004) Blockade of CCR2 ameliorates progressive fibrosis in kidney. Am.J.Pathol. 165 237. PMID:15215179.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=160040				Nov-2006
2518	TC 1698 dihydrochloride	[787587-06-8]	C1(C2N3CCC(CC3)CC2)=CC=CN=C1.Cl.Cl	_7-selective agonist	Selective nicotinic _7 receptor agonist (EC50 = 440 nM). Also displays weak partial agonist/antagonist activity at _-subunit-containing receptors. Neuroprotective.	"Marrero et al (2004) The neuroprotective effect of 2-(3-Pyridyl)-1-azabicyclo[3.2.2]nonane (TC-1698), a novel _7 ligand, is prevented through angiotensin II activation of a tyrosine phosphatase. J.Pharmacol.Exp.Ther. 309 16. PMID:14722323. Papke et al (2005) Rhesus monkey _7 nicotinic acetylcholine receptors: comparisons to human _7 receptors expressed in Xenopus oocytes. Eur.J.Pharmacol. 524 11. PMID:16266703."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=160085	SQ1341			Sep-2008
2519	T 98475	[199119-18-1]	CC(C)OC(=O)C1=CN(CC2=C(F)C=CC=C2F)C2=C(C(CN(C)CC3=CC=CC=C3)=C(S2)C2=CC=C(NC(=O)C(C)C)C=C2)C1=O	GnRH receptor antagonist	"Potent, orally active and non-peptide gonadotropin-releasing hormone (GnRH, LHRH) receptor antagonist (IC50 values are 0.2, 4.0 and 60 nM for human, monkey and rat GnRH receptors respectively). Inhibits LH release in vitro (IC50 = 100 nM) and reduces plasma LH concentration in castrated male cynomolgus monkeys."	"Cho et al (1998) Discovery of a novel, potent, and orally active nonpeptide antagonist of the human luteinizing hormone-releasing hormone (LHRH) receptor. J.Med.Chem. 41 4190. PMID:9784092. Sasaki et al (2003) Discovery of a thieno[2,3-d]pyrimidine-2,4-dione bearing a p-methoxyureidophenyl moiety at the 6-position: a highly potent and orally bioavailable non-peptide antagonist for the human luteinizing hormone-releasing hormone receptor. J.Med.Chem. 46 113. PMID:12502365. Imada et al (2006) Design, synthesis, and structure-activity relationships of thieno[2,3-b]pyridin-4-one derivatives as a novel class of potent, orally active, non-peptide luteinizing hormone-releasing hormone receptor antagonists. J.Med.Chem. 49 3809. PMID:16789738."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=160086	SQ1341			Jul-2007
2520	PD 166793	[199850-67-4]	BrC1=CC=C(C2=CC=C(S(N[C@@H]([C@H](C)C)C(O)=O)(=O)=O)C=C2)C=C1	Broad spectrum MMP inhibitor	"Broad spectrum MMP inhibitor. Displays high affinity for MMP-2, -3 and -13 (IC50 values are 4, 7 and 8 nM respectively) and exhibits > 750-fold selectivity over MMP-1, -7 and -9. Attenuates left ventricular remodelling and dysfunction in rat model of heart failure."	"O'Brien et al (2000) Structure-activity relationships and pharmacokinetic analysis for a series of potent, systemically available Biphenylsulfonamide matrix metalloproteinase inhibitors. J.Med.Chem. 43 156. PMID:10649971. Peterson et al (2001) Matrix metalloproteinase inhibition attenuates left ventricular remodeling and dysfunction in a rat model of progressive heart failure. Circulation 103 2303. PMID:11342481. Chancey et al (2002) Effects of matrix metalloproteinase inhibition on ventricular remodeling due to volume overload. Circulation 105 1983. PMID:11997287."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=160089	SQ1341			Nov-2007
2521	NSC 3852	[3565-26-2]	OC1=C2N=CC=CC2=C(C=C1)N=O	Histone deacetylase inhibitor	Histone deacetylase inhibitor. Causes cell differentiation and antiproliferative activity in MCF-7 human breast cancer cells in vitro and displays antitumor activity in vivo.	Martirosyan et al (2004) Differentiation-inducing quinolines as experimental breast cancer agents in the MCF-7 human breast cancer cell model. Biochem.Pharmacol. 68 1729. PMID:15450938. Martirosyan et al (2006) Actions of a histone deacetylase inhibitor NSC3852 (5-nitroso-8-quinolinol) link reactive oxygen species to cell differentiation and apoptosis in MCF-7 human mammary tumor cells. J.Pharmacol.Exp.Ther. 317 546. PMID:16497787.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=160092				Nov-2006
2522	YM 26734	[144337-18-8]	OC1=C(C2CC(C4=CC=C(O)C=C4)OC3=C2C=CC(O)=C3)C(O)=C(C(CCCCCCCCCCC)=O)C(O)=C1C(CCCCCCCCCCC)=O	Secretory phospholipase A2 (sPLA2) inhibitor	"Competitive inhibitor of secretory phospholipase A2 (sPLA2) that exhibits a broad inhibitory profile to several sPLA2s (IC50 values are 0.2, 1, 1, 1 and 3 _M for sPLA2-X, -IIA, -IID, -V and -IIE respectively). Displays minimal activity at sPLA2-IIF and no activity at cytosolic PLA2, cyclooxygenase and lipoxygenase. Ameliorates local inflammatory responses in TPA-induced mouse ear edema."	"Miyake et al (1993) Suppression of inflammatory responses to 12-O-tetradecanoyl-phorbol-13-acetate and carregeenin by YM-26734, a selective inhibitor of extracellular group II phospholipase A2. Br.J.Pharmacol. 110 447. PMID:8220906. Miyake et al (1994) Exogenous group II phospholipase A2 prostaglandin E2 production in mouse peritoneal macrophages. Eur.J.Pharmacol. 253 155. PMID:8013541. Hamaguchi et al (2003) Induction of distinct sets of secretory phospholipase A2 in rodents during inflammation. Biochim.Biophys.Acta 1635 37. PMID:14642775."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=160164				Jan-2009
2524	A 205804	[251992-66-2]	CC1=CC=C(SC2=C3C=C(SC3=CN=C2)C(N)=O)C=C1	Selective inhibitor of E-selectin and ICAM-1 expression	"Selective inhibitor of E-selectin and ICAM-1 expression (IC50 values are 20, 25 and > 1000 nM for TNF-_-induced E-selectin, ICAM-1 and VCAM-1 expression respectively). Effective inhibitor of cell-cell adhesion in an in vitro flow experiment."	"Stewart et al (2001) Discovery of inhibitors of cell adhesion molecule expression in human endothelial cells. 1. Selective inhibition of ICAM-1 and E-selectin expression. J.Med.Chem. 44 988. PMID:11300880. Zhu et al (2001) Selective inhibition of ICAM-1 and E-selectin expression in human endothelial cells. 2. Aryl modifications of 4-(aryloxy)thieno[2,3-c]pyridines with fine-tuning at C-2 carbamides. J.Med.Chem. 44 3469. PMID:11585452. Zhu et al (2002) Synthesis and mode of action of 125I- and 3H-labeled thieno[2,3-c]pyridine antagonists of cell adhesion molecule expression. J.Org.Chem. 67 943. PMID:11856042."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=160288	SQ1070			Dec-2006
2530	PPDA	[684283-16-7]	O=C(C2=CC=C3C(C=CC4=C3C=CC=C4)=C2)N1[C@@H]([C@](O)=O)[C@@H]([C@](O)=O)NCC1.O=C(C6=CC=C7C(C=CC8=C7C=CC=C8)=C6)N5[C@H](C(O)=O)[C@H](C(O)=O)NCC5	Subtype-selective NR2C/NR2D antagonist	"Subtype-selective NMDA receptor antagonist that preferentially binds to NR2C/NR2D-containing receptors (Ki values are 0.096, 0.125, 0.31 and 0.55 _M for NR2C, NR2D, NR2B and NR2A subunits respectively)."	"Feng et al (2004) Structure-activity analysis of a novel NR2C/NR2D-preferring NMDA receptor antagonist: 1-(phenanthrene-2-carbonyl)piperazine-2,3-dicarboxylic acid. Br.J.Pharmacol. 141 508. PMID:14718249. Morley et al (2005) Synthesis and pharmacology of N1-substituted piperazine-2,3-dicarboxylic acid derivatives acting as NMDA receptor antagonists. J.Med.Chem. 48 2627. PMID:15801853. Kinarsky et al (2005) Identification of subunit- and antagonist-specific amino acid residues in the N-methyl-D-aspartate receptor glutamate-binding pocket. J.Pharmacol.Exp.Ther. 313 1066. PMID:15743930."	Small Molecule	Sold under license from UNeMed Corporation.	http://www.tocris.com/dispprod.php?ItemId=160375	SQ1341			Nov-2006
2531	Ganaxolone	[38398-32-2]	O[C@]1(C)CC[C@@]2(C)[C@](CC[C@]3([H])[C@@]([H])2CC[C@@]4(C)[C@]([H])3CC[C@@H]4[C@](C)=O)([H])C1	"Potent, positive allosteric modulator of GABAA receptors"	"Potent positive allosteric modulator of GABAA receptors. Enhances GABA-evoked chloride currents in Xenopus oocytes expressing GABAA receptors (EC50 values are 94, 122 and 213 nM for _2_1_2L, _3_1_2L and _1_1_2L receptors respectively). Exerts anticonvulsive effects in a broad range of animal seizure models."	"Carter et al (1997) Characterization of the anticonvulsive properties of ganaxolone (CCD 1044; 3_-hydroxy-3_-methyl-5_-pregnan-20-one), a selective, high affinity, steroid modulator of the _-aminobutyric acidA receptor. J.Pharmacol.Exp.Ther. 280 1284. PMID:9067315. Lyden et al (2000) Effect of ganaxolone in a rodent model of cerebral hematoma. Stroke 31 169. PMID:10625734. Ungard et al (2000) Modification of behavioral effects of drugs in mice by neuroactive steroids. Psychopharmacology 148 336. PMID:10928304."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=160401	SQ1533			Nov-2006
2532	TFB-TBOA	[480439-73-4]	OC([C@@H](N)[C@H](OCC1=CC=CC(NC(C2=CC=C(C(F)(F)F)C=C2)=O)=C1)C(O)=O)=O	High affinity EAAT1 and EAAT2 blocker	"Potent and selective glial glutamate transporter EAAT1 and EAAT2 inhibitor (IC50 values are 17, 22 and 300 nM for EAAT2, EAAT1 and EAAT3 respectively). Has no effect on EAAT4 and EAAT5, or a wide range of neuronal receptors and transporters. Attenuates glutamate-stimulated intracellular Na+ elevation in astrocytes in vitro (IC50 = 43 nM). Induces severe convulsions in vivo."	"Tsukada et al (2005) Effects of a novel glutamate transporter blocker, (2S, 3S)-3-{3-[4-(trifluoromethyl)benzoylamino]benzyloxy}aspartate (TFB-TBOA), on activities of hippocampal neurons. Neuropharmacology 48 479. PMID:15755476. Shimamoto and Shigeri (2006) Elucidation of glutamate transporter functions using selective inhibitors. CNS Agents Med.Chem. 6 59. Bozzo and Chatton (2010) Inhibitory effects of (2S, 3S)-3-[3-[4-(trifluoromethyl)benzoylamino]benzyloxy]aspartate (TFB-TBOA) on the astrocytic sodium responses to glutamate. Brain Res. 1316 (27). PMID:20026319. Magi et al (2012) Physical and functional interaction of NCX1 and EAAC1 transporters leading to glutamate-enhanced ATP production in brain mitochondria. PLoS One 7 e34015. PMID:22479505."	Small Molecule	Sold for research purposes under license from Suntory Ltd.	http://www.tocris.com/dispprod.php?ItemId=160458	SQ1341			Feb-2008
2533	DPO-1	[43077-30-1]	C[C@@H]1CC[C@@H]([C@@H](C)C)[C@@H]([P@@](C2=CC=CC=C2)(C3=CC=CC=C3)=O)C1	Blocker of KV1.5 channel and IKur current	"Blocker of IKur ultrarapid delayed rectifier potassium current and KV1.5 channels (IC50 = 0.31 _M for rKV1.5). Displays selectivity for inhibition of IKur over Ito (8-fold), IK1, IKr and IKs (20-fold) in native myocytes and selectivity for rat recombinant KV1.5 over KV3.1 (~ 15-fold). Increases action potential duration in atrial but not ventricular myocytes and prevents atrial arrhythmia."	"Stump et al (2005) In vivo antiarrhythmic and cardiac electrophysiologic effects of a novel diphenylphosphine oxide IKur blocker (2-isopropyl-5-methylcyclohexyl) diphenylphosphine oxide. J.Pharmacol.Exp.Ther. 315 1362. PMID:16157659. Regan et al (2006) In vivo cardiac electrophysiologic effects of a novel diphenylphosphine oxide IKur blocker, (2-isopropyl-5-methylcyclohexyl) diphenylphosphine oxide, in rat and nonhuman primate. J.Pharmacol.Exp.Ther. 316 727. PMID:16243963. Lagrutta et al (2006) Novel, potent inhibitors of human Kv1.5 K+ channels and ultrarapid activating delayed rectifier potassium current. J.Pharmacol.Exp.Ther. 317 1054. PMID:16522807."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=160533	SQ1341			Dec-2006
2534	LP 44	[824958-12-5]	O=C(CCCCCN3CCN(C4=C(SC)C=CC=C4)CC3)NC1CCCC2=C1C=CC=C2.Cl	High affinity 5-HT7 agonist	High affinity 5-HT7 receptor agonist (Ki = 0.22 nM) that displays selectivity over 5-HT1A and 5-HT2A receptors (200- and > 1000-fold respectively). Induces relaxation of substance P-stimulated guinea pig ileum (EC50 = 2.56 _M).	"Leopoldo et al (2004) Structure-affinity relationship study on N-(1,2,3,4-tetrahydronaphthalen-1-yl)-4-aryl-1-piperazinealkylamides, a new class of 5-hydroxytryptamine7 receptor agents. J.Med.Chem. 47 6616. PMID:15588097."	Small Molecule	Sold under license from the University of Bari	http://www.tocris.com/dispprod.php?ItemId=160731	SQ1341			Oct-2006
2536	Domperidone	[57808-66-9]	ClC1=CC=C2N(C3CCN(CCCN4C(=O)NC5=C4C=CC=C5)CC3)C(=O)NC2=C1	Peripheral D2-like antagonist	Peripheral dopamine D2-like receptor antagonist that does not readily cross the blood brain barrier. Displays gastroprokinetic and antiemetic properties; increases the frequency and duration of antral and duodenal contractions and protects from apomorphine-induced emesis (ED50 values are 0.003 and 0.03 mg/kg for i.v. and oral administration respectively).	"Neimegeers et al (1980) The antiemetic effects of domperidone, a novel potent gastrokinetic. Arch.Int.Pharmacodyn.Ther. 244 130. PMID:7416883. Prakash and Wagstaff (1998) Domperidone. A review of its use in diabetic gastropathy. Drugs 56 429. PMID:9777316. Osinski et al (2005) Dopamine D2, but not D4, receptor agonists are emetogenic in ferrets. Pharmacol.Biochem.Behav. 81 211. PMID:15894081."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=160733	SQ1533			Oct-2006
2538	L-BMAA hydrochloride	[16012-55-8]	N[C@@H](CNC)C(O)=O.Cl	Neurotoxic amino acid	Neurotoxic glutamate agonist originally isolated from Cycas circinalis. Implicated in the pathogenesis of amyotrophic lateral sclerosis-Parkinsonism-dementia complex of Guam (Guam ALS-PD).	Vega et al (1968) The preparation of L- and D-_-amino-_<-methylaminopropionic acids and the identification of the compound isolated from Cycas circinalis as the L-isomer. Phytochemistry 7 1885. Weiss et al (1989) Neurotoxicity of _-N-methylamino-L-alanine (BMAA) and _-N-oxalylamino-L-alanine (BOAA) on cultured cortical neurons. Brain Res. 497 64. PMID:2551452.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=160777				Aug-2006
2539	IKK 16	[1186195-62-9]	Cl.O=C(N1CCC(CC1)N1CCCC1)C1=CC=C(NC2=NC=CC(=N2)C2=CC3=CC=CC=C3S2)C=C1	Selective inhibitor of IKK	"Selective inhibitor of I_B kinase (IKK) (IC50 values are 40, 70 and 200 nM for IKK_, IKK complex and IKK_ respectively). Inhibits TNF-_-stimulated I_B degradation and expression of adhesion molecules E-selectin, ICAM and VCAM (IC50 values are 1.0, 0.5, 0.3 and 0.3 _M respectively). Inhibits LPS-induced TNF-_ release in vivo and neutrophil extravasion in thioglycollate-induced peritonitis."	Waelchli et al (2006) Design and preparation of 2-benzoamido-pyrimidines as inhibitors of IKK. Bioorg.Med.Chem.Lett. 16 108. PMID:16236504.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=160784	SQ1533			Jun-2007
2542	Ki 8751	[228559-41-9]	COC1=C(OC)C=C2C(OC3=CC=C(NC(=O)NC4=CC=C(F)C=C4F)C(F)=C3)=CC=NC2=C1	"Potent, selective VEGFR-2 inhibitor"	"Potent, selective inhibitor of VEGFR-2 tyrosine kinase (IC50 = 0.9 nM). Displays some inhibitory activity towards c-Kit, PDGFR_ and FGFR-2 (IC50 values range from 40 to 170 nM) but is highly selective over other receptor tyrosine kinases (IC50 > 10000 nM for FGFR-2, EGFR and HGFR). Inhibits VEGF-stimulated proliferation of human umbilical vein endothelial cells (HUVEC) and inhibits tumor growth in vivo; antiangiogenic."	"Kubo et al (2005) Novel potent orally active selective VEGFR-2 tyrosine kinase inhibitors: synthesis, structure-activity relationships, and antitumour activities of N-phenyl-N'-{4-(4-quinolyloxy)phenyl}ureas. J.Med.Chem. 48 1359. PMID:15743179."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=160833	SQ1533			Mar-2007
2545	Lofepramine	[23047-25-8]	CN(CCCN1C2=CC=CC=C2CCC2=CC=CC=C12)CC(=O)C1=CC=C(Cl)C=C1	5-HT and noradrenalin re-uptake inhibitor (SNRI)	Serotonin and noradrenalin re-uptake inhibitor (SNRI) that is metabolized to desipramine. Produces inhibition of liver tryptophan pyrollase activity in vitro and displays antidepressant properties in vivo.	"Leonard (1987) A comparison of the pharmacological properties of the novel tricyclic antidepressant lofepramine with its major metabolite, desipramine: a review. Int.Clin.Psychopharmacol. 2 281. PMID:2891742. Badawy et al (1991) The effects of lofepramine and desmethylimipramine on tryptophan metabolism and disposition in the rat Biochem.Pharmacol. 42 921. PMID:1867646. Kelly and Leonard (1999) An investigation of the antidepressant properties of lofepramine and its desmethylated metabolites in the forced swim and olfactory bulbectomized rat models of depression. Eur.Neuropsychopharmacol. 9 101. PMID:10082234."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=161411	SQ1533			Nov-2006
2547	6-Hydroxydopamine hydrobromide	[636-00-0]	NCCC1=CC(O)=C(O)C=C1O.Br	Selective catecholaminergic neurotoxin	"Selective catecholaminergic neurotoxin. Depletes brain catecholamine levels via uptake and accumulation by a transport mechanism specific to these neurons. Causes almost complete destruction of nigral dopaminergic neurons and their striatal terminals when injected into the substantia nigra of rats, producing an animal model of Parkinson's disease."	Breese and Traylor (1970) Effect of 6-hydroxydopamine on brain norepinephrine and dopamine: evidence for selective degeneration of catecholamine neurons. J.Pharmacol.Exp.Ther. 174 413. PMID:5456173. Soto-Otero et al (2000) Autoxidation and neurotoxicity of 6-hydroxydopamine in the presence of some antioxidants: potential implication in relation to the pathogenesis of Parkinson's disease. J.Neurochem. 74 1605. PMID:10737618. Fujita et al (2006) Cell-permeable cAMP analog suppresses 6-hydroxydopamine-induced apoptosis in PC12 cells through the activation of the Akt pathway. Brain Res. 1113 10. PMID:16945353.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=162005	SQ1533			Oct-2006
2548	NF 110	[111150-22-2]	[Na+].[Na+].[Na+].[Na+].[O-]S(=O)(=O)C1=CC=C(NC(=O)C2=CC(=CC(NC(=O)NC3=CC(=CC(=C3)C(=O)NC3=CC=C(C=C3)S([O-])(=O)=O)C(=O)NC3=CC=C(C=C3)S([O-])(=O)=O)=C2)C(=O)NC2=CC=C(C=C2)S([O-])(=O)=O)C=C1	Potent P2X3 antagonist	"High affinity P2X3 receptor antagonist (Ki values are 36, 82 and 4144 nM for P2X3, P2X1 and P2X2 recombinant receptors respectively). Shows no activity at P2Y1, P2Y2 and P2Y11 receptors (IC50 > 10 _M). Potently inhibits _,_-meATP-evoked desensitizing currents in rat DRG neurons (IC50 = 527 nM). Shows antitumor activity against several tumor types."	"Dhar et al (2000) Antitumour activity of suramin analogues in human tumour cell lines and primary cultures of tumour cells from patients. Eur.J.Cancer 36 803. PMID:10762755. Kassack et al (2004) Structure-activity relationships of analogues of NF449 confirm NF449 as the most potent and selective known P2X1 receptor antagonist. Eur.J.Med.Chem. 39 345. PMID:15072843. Hausmann et al (2006) The suramin analog 4,4',4'',4'''-(Carbonylbis(imino-5,1,3-benzenetriylbis (carbonylimino)))tetra-kis-benzenesulfonic acid (NF110) potently blocks P2X3 receptors: subtype selectivity is determined by location of sulfonic acid groups. Mol.Pharmacol. 69 2058. PMID:16551782."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=162464				Oct-2006
2550	SUN-B 8155	[345893-91-6]	O=C1C=C(C)C(/C(C)=N/C2=C(N)C=CC=C2)=C(O)N1O	Non-peptide calcitonin (CT) receptor agonist	Non-peptide calcitonin (CT) receptor agonist that fully stimulates cAMP production in CHO/hCTR cells (EC50 = 21 _M). Causes a significant reduction in serum calcium concentrations in vivo following i.p. administration.	Katayama et al (2001) Discovery of a non-peptide small molecule that selectively mimics the biological actions of calcitonin. Biochim.Biophys.Acta 1526 183. PMID:11325540.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=162513	SQ1341			Mar-2007
2554	CD 1530	[107430-66-0]	OC(=O)C1=CC=C(C=C1)C1=CC=C2C=C(C(O)=CC2=C1)C12CC3CC(CC(C3)C1)C2	Potent and selective RAR_ agonist	"Potent and selective RAR_ receptor agonist (Ki values are 150, 1500 and 2750 nM for RAR_, RAR_ and RAR_ receptors respectively). Activates transcriptional activity (AC50 = 1.8 nM)."	Thacher et al (2000) Therapeutic applications for ligands of retinoid receptors. Curr.Pharmaceut.Des. 6 25.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=162835	SQ1341			Jan-2007
2555	GYKI 53655 hydrochloride	[143692-48-2]	CC(N(C(NC)=O)N=C3C4=CC=C(N)C=C4)CC1=C3C=C(OCO2)C2=C1.Cl	Non-competitive AMPA receptor antagonist	Non-competitive AMPA and kainate receptor antagonist. Analog of GYKI 52466 (Cat. No. 1454). Prolongs the survival time after MgCl2- induced global cerebral ischemia. Exhibits anticonvulsant activity. Also blocks GluK3 homomeric receptors (IC50 = 63 _M) and GluK2b(R)/GluK3 heteroreceptors (IC50 = 32 _M) at high concentrations.	"Paternain et al (1995) Selective antagonism of AMPA receptors unmasks kainate receptor-mediated responses in hippocampal neurons. Neuron 14 185. PMID:7826635. Szabados et al (2001) Comparison of anticonvulsive and acute neuroprotective activity of three 2,3-benzodiazepine compounds, GYKI 52466, GYKI 53405, and GYKI 53655. Brain Res.Bull. 55 387. PMID:11489346. Perrais et al (2009) Antagonism of recombinant and native GluK3-containing kainate receptors. Neuropharmacology 56 131. PMID:18761361."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=5264	SQ1533			Mar-2011
2556	PNU 109291	[187665-60-7]	O=C(NC)C3=CC(CCO2)=C(C=C3)[C@@H]2CCN1CCN(C4=CC=C(OC)C=C4)CC1	Potent and selective 5-HT1D agonist	"Potent and selective 5-HT1D receptor agonist that displays > 600-fold selectivity over 5-HT1A and 5-HT2A receptors and no activity at 5-HT1B, 5-HT1E, 5-HT2B, 5-HT2C, 5-HT6 and 5-HT7 receptors. Reduces dural plasma extravasation evoked by trigeminal ganglion stimulation."	"Ennis et al (1998) Isochroman-6-carboxamides as highly selective 5-HT1D agonists: potential new treatment for migraine without cardiovascular side effects. J.Med.Chem. 41 2180. PMID:9632349. Cutrer et al (1999) Effects of PNU-109,291, a selective 5-HT1D receptor agonist, on electrically induced dural plasma extravasation and capsaicin-evoked c-fos immunoreactivity within trigeminal nucleus caudalis. Neuropharmacology 38 1043. PMID:10428423. Bhattacharya et al (2004) 5-Hydroxytryptamine1B receptor-mediated contraction of rabbit saphenous vein and basilar artery: role of vascular endothelium. J.Pharmacol.Exp.Ther. 309 825. PMID:14724223."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=163485	SQ1341			May-2008
2558	10-DEBC hydrochloride	[925681-41-0]	Cl.CCN(CC)CCCCN1C2=CC=CC=C2OC2=C1C=C(Cl)C=C2	Selective Akt/PKB inhibitor	"Selective inhibitor of Akt/PKB. Inhibits IGF-1-stimulated phosphorylation and activation of Akt (complete inhibition at 2.5 _M), suppressing downstream activation of mTOR, p70 S6 kinase and S6 ribosomal protein. Shows no activity at PDK1, SGK1 or PI 3-kinase. Inhibits cell growth (IC50 ~ 2-6 _M) and induces apoptosis in rhabdomyosarcoma cells."	Thimmaiah et al (1992) Synthesis and chemical characterization of N-substituted phenoxazines directed toward reversing vinca alkaloid resistance in multidrug-resistant cancer cells. J.Med.Chem. 35 3358. PMID:1527786. Thimmaiah et al (2005) Identification of N10-substituted phenoxazines as potent and specific inhibitors of Akt signaling. J.Biol.Chem. 36 31924.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=163597	SQ1341			Nov-2006
2559	TPCA-1	[507475-17-4]	NC(=O)NC1=C(C=C(S1)C1=CC=C(F)C=C1)C(N)=O	"Potent, selective inhibitor of IKK_"	"Potent, selective inhibitor of I_B kinase (IKK) _ (IC50 = 17.9 nM) that displays > 22-fold selectivity over IKK_ and > 550-fold selectivity over other kinases and enzymes. Inhibits production of pro-inflammatory cytokines in vitro and in vivo and inhibits NF-_B nuclear localization. Reduces the severity and onset of collagen-induced arthritis; anti-inflammatory."	"Podolin et al (2005) Attenuation of murine collagen-induced arthritis by a novel, potent, selective small molecule inhibitor of I_B kinase 2, TPCA-1 (2-[aminocarbonyl)amino]-5-(4-fluorophenyl)-3-thiophenecarboxamide), occurs via reduction of proinflammatory cytokines and antigen-induced T cell proliferation. J.Pharmacol.Exp.Ther. 312 373. PMID:15316093. Birrell et al (2005) IK-B kinase-2 inhibitor blocks inflammation in human airway smooth muscle and a rat model of asthma. Am.J.Respir.Crit.Care Med. 172 962. PMID:16002568. Birrell et al (2006) I_B kinase-2-independent and-dependent inflammation in airway disease models: relevance of IKK-2 inhibition to the clinic. Mol.Pharmacol. 69 1791. PMID:16517756."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=163598	SQ1533			Mar-2007
2560	SB 218078	[135897-06-2]	O=C1NC(=O)C2=C1C1=C3N(C4CCC(O4)N4C5=C(C=CC=C5)C2=C34)C2=CC=CC=C12	Inhibitor of checkpoint kinase 1 (Chk1)	"Inhibitor of checkpoint kinase 1 (Chk1) that displays selectivity over other protein kinases (IC50 values are 15, 250 and 1000 nM for Chk1, cdc2 and PKC respectively). Abrogates G2 cell cycle arrest caused by _-irradiation and topoisomerase I inhibition. Potentiates cytotoxicity of DNA-damaging drugs, enhancing the efficacy of some chemotherapeutics."	Jackson et al (2000) An indolocarbazole inhibitor of human checkpoint kinase (Chk1) abrogates cell cycle arrest caused by DNA damage. Cancer Res. 60 566. PMID:10676638. Kawabe (2004) G2 checkpoint abrogators as anticancer drugs. Mol.Cancer Ther. 3 513. PMID:15078995. Chen et al (2006) Checkpoint kinase 1-mediated phosphorylation of cdc25C and bad proteins are involved in antitumor effects of loratadine-induced G2/M phase cell-cycle arrest and apoptosis. Mol.Carcinogenesis 45 461.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=163617	SQ1341			Jun-2007
2561	Calmidazolium chloride	[57265-65-3]	[Cl-].ClC1=CC=C(C=C1)C(N1C=C[N+](CC(OCC2=CC=C(Cl)C=C2Cl)C2=CC=C(Cl)C=C2Cl)=C1)C1=CC=C(Cl)C=C1	Calmodulin antagonist	"Calmodulin antagonist. Inhibits calmodulin-dependent phosphodiesterase and Ca2+-transporting ATPase with IC50 values of 0.15 and 0.35 _M respectively. Also causes elevation of intracellular calcium in HL-60 cells, independent of calmodulin inhibition."	Gietzen (1983) Comparison of the calmodulin antagonists compound 48/80 and calmidazolium. Biochem.J. 216 611. PMID:6141789. Harper and Daly (2000) Effect of calmidazolium analogs on calcium influx in HL-60 cells. Biochem.Pharmacol. 60 317. PMID:10856426. Peppiatt et al (2004) Calmidazolium and arachidonate activate a calcium entry pathway that is distinct from store-operated calcium influx in HeLa cells. Biochem.J. 381 929. PMID:15130089.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=163735	SQ1533			Jan-2007
2562	PB 28 dihydrochloride	[172907-03-8]	O=C1C=C(C)C(/C(C)=N/C2=C(N)C=CC=C2)=C(O)N1O	High affinity _2 agonist	High affinity _2 receptor agonist (Ki values are 0.8 and 15.2 nM for _2 and _1 receptors respectively) that displays minimal affinity at other receptors. Inhibits electrically evoked twitch in guinea pig bladder and ileum (EC50 values are 2.62 and 3.96 _M respectively). Displays antiproliferative and cytotoxic effects in SK-N-SH neuroblastoma and C6 glioma cells.	Berardi et al (1996) New _ and 5-HT1A receptor ligands: _-(tetralin-1-yl)-n-alkylamine derivatives. J.Med.Chem. 39 176. PMID:8568804. Colabufo et al (2003) A new method for evaluating _2 ligand activity in the isolated guinea-pig bladder. Naunyn-Schmied.Arch.Pharmacol. 368 106. Colabufo et al (2004) Antiproliferative and cytotoxic effects of some _2 agonists and _1 antagonists in tumour cell lines. Naunyn-Schmied.Arch.Pharmacol. 370 106.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=163773	SQ1341			Jan-2007
2563	Fexaramine	[574013-66-4]	O=C(C3CCCCC3)N(CC2=CC=C(C4=CC=C(N(C)C)C=C4)C=C2)C1=CC(/C=C/C(OC)=O)=CC=C1	"Potent, selective farnesoid X receptor (FXR) agonist"	"Potent, selective farnesoid X receptor agonist (EC50 = 25 nM). Displays no activity at hRXR_, hPPAR_, hPPAR_, hPPAR_, mPXR, hPXR, hLXR_, hTR_, hRAR_, mCAR, mERR_ and hVDR receptors."	"Nicolaou et al (2003) Discovery and optimization of non-steroidal FXR agonists from natural product-like libraries. Org.Biomol.Chem. 1 908. PMID:12929628. Downes et al (2003) A chemical, genetic, and structural analysis of the nuclear bile acid receptor FXR. Mol.Cell 11 1079. PMID:12718892. Pellicciari et al (2006) Back door modulation of the farnesoid X receptor: design, synthesis, and biological evaluation of a series of side chain modified chenodeoxycholic acid derivatives. J.Med.Chem. 49 4208. PMID:16821780."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=163774	SQ1341			Jan-2007
2564	AM 114	[856849-35-9]	O=C(/C(CN(C)C3)=C/C2=CC=C(B(O)O)C=C2)/C3=C/C1=CC=C(B(O)O)C=C1	20S proteasome inhibitor	Inhibitor of the chymotrypsin-like activity of the 20S proteasome (IC50 ~ 1 _M). Displays anticancer activity; inhibits cell growth in human colon cancer HCT116 p53+/+ cells (IC50 = 1.49 _M).	Achanta et al (2005) Preferential killing of cancer cells with wild-type p53 by boronic chalcones. Proc.Am.Assoc.Cancer Res.Abstr. 46 6162. Achanta et al (2006) A boronic-chalcone derivative exhibits potent anticancer activity through inhibition of the proteasome. Mol.Pharmacol. 70 426. PMID:16636137.	Small Molecule	Sold with the permission of Johns Hopkins University	http://www.tocris.com/dispprod.php?ItemId=163938				Jan-2007
2565	ZK 756326	[874911-96-3]	OCCOCCN(CC3)CCN3CC1=CC=CC(OC2=CC=CC=C2)=C1.Cl.Cl	"Selective, non-peptide CCR8 agonist"	"Selective, non-peptide CCR8 chemokine receptor agonist (IC50 values are 1.8 and 2.6 _M for human and mouse receptors respectively). Displays no activity at CCR4, CXCR3, CXCR4 and CCR5 and shows > 28-fold selectivity over 26 other GPCRs (less selective at _2A and 5-HT receptors). Induces chemotaxis and inhibits Env-mediated (HIV) cell-cell fusion."	"Haskell et al (2006) Identification and characterization of a potent, selective nonpeptide agonist of the CC chemokine receptor CCR8. Mol.Pharmacol. 69 309. PMID:16221874."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=163949				Nov-2006
2571	Amlodipine besylate	[111470-99-6]	OS(=O)(=O)C1=CC=CC=C1.CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC	Ca2+ channel blocker (L-type)	L-type calcium channel blocker that displays antihypertensive properties. Inhibits Ca2+-induced contractions in depolarized rat aorta (IC50 = 1.9 nM) and displays vasoprotective effects in cardiovascular disease. Inhibits proliferation of human vascular smooth muscle cells and epidermoid carcinoma A431 cells (IC50 = 25 _M).	Burges et al (1987) Calcium channel blocking properties of amlodipine in vascular smooth muscle and cardiac muscle in vitro: evidence for voltage modulation of vascular dihydropyridine receptors. J.Cardiovasc.Pharmacol. 9 110. PMID:2434785. Yoshida et al (2003) Antiproliferative effect of Ca2+ channel blockers on human epidermoid carcinoma A431 cells. Eur.J.Pharmacol. 472 23. PMID:12860469. Toba et al (2005) Calcium channel blockades exhibit anti-inflammatory and antioxidative effects by augmentation of endothelial nitric oxide synthase and the inhibition of angiotensin converting enzyme in the NG-nitro-L-arginine methyl ester-induced hypertensive rat aorta: vasoprotective effects beyond the blood pressure-lowering effects of amlodipine and manidipine. Hypertens.Res. 28 689. PMID:16392774.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=163956	SQ1070			Nov-2006
2573	PSB 069	[78510-31-3]	[Na+].NC1=C2C(=O)C3=CC=CC=C3C(=O)C2=C(NC2=CC=C(Cl)C=C2)C=C1S([O-])(=O)=O	Non-selective NTPDase inhibitor	"Non-selective nucleoside triphosphate diphosphohydrolase (NTPDase) inhibitor. Reported to inhibit rat NTPDases 1, 2 and 3 with similar potencies."	Baqi et al (2009) Structure activity relationships of antraquinone derivatives derived from bromaminic acid as inhibitors of ectonucleoside triphosphate diphosphohydrolases(E-NTPDases). Purinerg.Sig. 5 91.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=164447				Mar-2007
2574	PSB 06126	[1052089-16-3]	[Na+].NC1=C2C(=O)C3=CC=CC=C3C(=O)C2=C(NC2=C3C=CC=CC3=CC=C2)C=C1S([O-])(=O)=O	NTPDase 3 inhibitor	Nucleoside triphosphate diphosphohydrolase 3 (NTPDase 3) inhibitor. Reported to inhibit rat NTPDase 3 at low micromolar concentrations and display selectivity over NTPDase 1 and NTPDase 2.	Baqi et al (2009) Structure activity relationships of antraquinone derivatives derived from bromaminic acid as inhibitors of ectonucleoside triphosphate diphosphohydrolases(E-NTPDases). Purinerg.Sig. 5 91.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=164448				Mar-2007
2577	Cetirizine dihydrochloride	[83881-52-1]	Cl.Cl.OC(=O)COCCN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=C(Cl)C=C1	Selective H1 antagonist	"Histamine H1 receptor antagonist that displays selectivity over other receptors at concentrations up to 10 _M. A non-sedating antihistamine that inhibits histamine release and eosinophil chemotaxis during secondary phase allergic response. Inhibits activation of eosinophils, neutrophils and monocytes in vivo."	"Campoli-Richards et al (1990) Cetirizine. A review of its pharmacological properties and clinical potential in allergic rhinitis, pollen-induced asthma, and chronic urticaria. Drugs 40 762. PMID:1981354. Snowman and Snyder (1990) Cetirizine: actions on neurotransmitter receptors. J.Allergy.Clin.Immunol. 86 1025. PMID:1979798. Walsh et al (1991) Effects of cetirizine on human eosinophil and neutrophil activation in vitro. Int.Arch.Allergy Appl.Immunol. 95 158. PMID:1682275."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=164501	SQ1533			Nov-2006
2578	Benazepril hydrochloride	[86541-74-4]	O=[C@@](OCC)[C@H](CCC3=CC=CC=C3)N[C@H]1CCC2=C(C=CC=C2)N(CC(O)=O)C1=O.Cl	Angiotensin-converting enzyme (ACE) inhibitor	Non-peptide angiotensin-converting enzyme (ACE) inhibitor. Reduces blood pressure and myocardial hypertrophy in spontaneous hypertensive rats.	"Takemori et al (1991) Effect of benazepril hydrochloride on cardiac hypertrophy in spontaneous hypertensive rats. Arzneim.-Forsch. 41 612. Ishibashi et al (1991) Hemodynamic effects of benazepril, an angiotensin-converting enzyme inhibitor, as studied in conscious normotensive dogs. Cardiovas.Drugs Ther. 5 635. Yamamoto et al (1991) General pharmacology of the novel angiotensin converting enzyme inhibitor benazepril hydrochloride. Effects on cardiovascular, visceral and renal functions and on hemodynamics. Arzneim.-Forsch. 41 913."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=164504	SQ1533			Nov-2006
2579	Zamifenacin fumarate	[127308-98-9]	C1(CCN3C[C@H](OC(C5=CC=CC=C5)C4=CC=CC=C4)CCC3)=CC=C(OCO2)C2=C1.C(\C=C\C(O[H])=O)(O[H])=O	Selective M3 antagonist	"Selective M3 muscarinic receptor antagonist (pKi values are 8.52, 7.93, 7.90 and 7.78 for M3, M2, M1 and M4 receptors respectively). Displays higher affinity at ileal M3 receptors (pKi = 9.3) compared to oesophageal and tracheal M3 receptors (pKi values are 8.8 and 8.2 respectively). Inhibits gastrointestinal motility in vivo in the absence of cardiovascular effects."	Wallis (1995) Pre-clinical and clinical pharmacology of selective muscarinic M3 receptor antagonists. Life Sci. 56 861. PMID:10188786. Watson et al (1995) Characterization of the interaction of zamifenacin at muscarinic receptors in vitro. Eur.J.Pharmacol. 285 135. PMID:8566131. Choppin (2002) Muscarinic receptors in isolated urinary bladder smooth muscle from different mouse strains. Br.J.Pharmacol. 137 522. PMID:12359634.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=164505	SQ1533			Feb-2007
2580	Tenidap	[120210-48-2]	O=C2N(C(N)=O)C1=CC=C(Cl)C=C1/C2=C(O)\C3=CC=CS3	"NSAID, cyclooxygenase (COX-1) inhibitor. Also opener of KIR2.3"	"NSAID that preferentially inhibits COX-1 (IC50 values are < 0.03, 1.2 and > 30 _M for COX-1, COX-2 and 5-lipoxygenase respectively). Inhibits formation of pro-inflammatory arachidonic acid metabolites in isolated human peripheral polymorphonuclear leukocytes. Opener of inward rectifying hKir2.3 channel (EC50 = 402 nM)."	"Moilanen et al (1988) CP-66,248, a new anti-inflammatory agent, is a potent inhibitor of leukotriene B4 and prostanoid synthesis in human polymorphonuclear leucocytes in vitro. Eicosanoids 1 35. PMID:2856170. Kirchner et al (1997) Evaluation of the antiinflammatory activity of a dual cyclooxygenase-2 selective/5-lipoxygenase inhibitor, RWJ 63556, in a canine model of inflammation. J.Pharmacol.Exp.Ther. 282 1094. PMID:9262379. Liu et al (2002) Tenidap, a novel anti-inflammatory agent, is an opener of the inwardly rectifying K+ channel hKir2.3. Eur.J.Pharmacol. 435 153. PMID:11821021."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=164506	SQ1533			Jan-2007
2581	PAC 1	[315183-21-2]	O=C(N/N=C/C3=CC=CC(CC=C)=C3O)CN(CC2)CCN2CC1=CC=CC=C1	Activator of procaspase-3; pro-apoptotic	Procaspase-activating compound; activates procaspase-3 to produce caspase-3 (EC50 = 0.22 _M). Also activates procaspase-7 in a less efficient manner (EC50 = 4.5 _M). Pro-apoptotic; induces apoptosis in both cancerous and non-cancerous cells dependent on procaspase-3 concentration (IC50 values are 0.003 - 1.41 and 5.02 - 9.98 _M respectively).	Putt et al (2006) Small-molecule activation of procaspase-3 to caspase-3 as a personalized anticancer strategy. Nat.Chem.Biol. 2 543. PMID:16936720. Peterson et al (2009) Procaspase-3 activation as an anti-cancer strategy: structure-activity relationship of procaspase-activating compound 1 (PAC-1) and its cellular co-localization with caspase-3. J.Med.Chem. 52 5721. PMID:19708658.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=164545	SQ1533			Dec-2006
2582	Lansoprazole	[103577-45-3]	CC1=C(OCC(F)(F)F)C=CN=C1CS(=O)C1=NC2=CC=CC=C2N1	"H+,K+-ATPase inhibitor"	"H+,K+-ATPase inhibitor (IC50 = 6.3 _M) that displays antisecretory and antiulcer activity. Inhibits gastric acid secretion (IC50 = 0.09 _M for histamine-induced acid formation) and reduces gastric lesion formation induced by a variety of ulcerative stimuli. Antibacterial against Helicobacter pylori in vitro. Also blocks swelling-dependent chloride channel (ICIswell) in NIH3T3 fibroblasts. More potent than omeprazole (Cat. No. 2583)."	"Satoh et al (1989) Antisecretory and antiulcer activities of a novel proton pump inhibitor AG-1749 in dogs and rats. J.Pharmacol.Exp.Ther. 248 806. PMID:2537418. Schmarda et al (2000) The gastric H,K-ATPase blocker lansoprazole is an inhibitor of chloride channels. Br.J.Pharmacol. 129 598. PMID:10711360. Matheson and Jarvis (2001) Lansoprazole. Drugs 61 1801. PMID:11693467."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=165986	SQ1533			Dec-2006
2583	Omeprazole	[73590-58-6]	COC1=CC=C2N=C(NC2=C1)S(=O)CC1=C(C)C(OC)=C(C)C=N1	"H+,K+-ATPase inhibitor"	"H+,K+-ATPase inhibitor (IC50 = 5.8 _M) that displays antisecretory and antiulcer activity. Inhibits gastric acid secretion (IC50 = 0.16 _M for histamine-induced acid formation) and reduces gastric lesion formation induced by a variety of ulcerative stimuli. Antibacteral against Helicobacter pylori in vitro. Also inhibits CYP2C19, CYP2C9 and CYP3A (Ki values are 3.1, 40.1 and 84.4 _M respectively) and blocks swelling-dependent chloride channels (ICIswell)."	"Satoh et al (1989) Antisecretory and anitulcer activities of a novel proton pump inhibitor AG-1749 in dogs and rats. J.Pharmacol.Exp.Ther. 248 806. PMID:2537418. Richardson et al (1998) Proton pump inhibitors. Drugs 56 307. PMID:9777309. Schmarda et al (2000) The gastric H,K-ATPase blocker lansoprazole is an inhibitor of chloride channels. Br.J.Pharmacol. 129 598. PMID:10711360."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=5369	SQ1533			Dec-2006
2586	CFM 1571 hydrochloride	[1215548-30-3]	Cl.COC1=CC=C(NC(=O)C2=CC(OCCCN(C)C)=NN2CC2=CC=CC=C2)C=C1	Soluble guanylyl cyclase (sGC) activator	"Soluble guanylyl cyclase (sGC) activator (EC50 = 5.49 _M). Does not activate adenylyl cyclase, shows no significant inhibition of phosphodiesterases and displays minimal inhibition of iNOS (25%) and nNOS (17%). Inhibits collagen-stimulated platelet aggregation in vitro (IC50 = 2.84 _M)."	"Selwood et al (2001) Synthesis and biological evaluation of novel pyrazoles and indazoles as activators of the nitric oxide receptor, soluble guanylate cyclase. J.Med.Chem. 44 78. PMID:11141091. Evgenov et al (2006) NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential. Nat.Rev.Drug Discov. 5 755. PMID:16955067."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=166344	SQ1070			Mar-2007
2591	TCS 359	[301305-73-7]	COC1=CC=C(C=C1OC)C(=O)NC1=C(C(N)=O)C2=C(CCCC2)S1	Potent FLT3 inhibitor	"Potent inhibitor of FLT3 receptor tyrosine kinase (IC50 = 42 nM) that displays selectivity over a range of other kinases. Exhibits antiproliferative effects on MV4-11 cells, a human acute myelogenous leukemia cell line expressing a constitutively active mutant FLT3 (IC50 = 340 nM)."	Patch et al (2006) Identification of 2-acylaminothiophene-3-carboxamides as potent inhibitors of FLT3. Bioorg.Med.Chem.Lett. 16 3282. PMID:16580199.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=166844	SQ1341			Apr-2007
2592	TCB-2	[912342-28-0]	Br.COC1=C2C(CN)CC2=C(OC)C(Br)=C1	"Potent, high affinity 5-HT2A agonist"	High affinity 5-HT2A receptor agonist (Ki values are 0.73 and 0.75 nM for rat and human receptors respectively). Potently stimulates IP3 accumulation in NIH3T3 cells stably expressing rat 5-HT2A receptors (EC50 = 36 nM). Induces head twitches and hypothermia in mice following i.p. adminitration.	McLean et al (2006) 1-Aminomethylbenzocycloalkanes: conformationally restricted hallucinogenic phenethylamine analogues as functionally selective 5-HT2A receptor agonists. J.Med.Chem. 49 5794. PMID:16970404. Fox et al (2010) The serotonin 5-HT2A receptor agonist TCB-2: a behavioral and neurophysiological analysis. Psychopharmacology 212 13. PMID:19823806. Niebert et al (2011) Expression and function of serotonin 2A and 2B receptors in the mammalian respiratory network. PLoS One 6 e21395. PMID:21789169.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=166910	SQ1341			Mar-2007
2595	J 113863	[353791-85-2]	ClC1=CC=C(OC(C=CC(Cl)=C3)=C3C2C(N[C@@H]4CC[N@@+](C/C5=C/CCCCCC5)(CC)CC4)=O)C2=C1.ClC6=CC=C(OC(C=CC(Cl)=C8)=C8C7C(N[C@H]9CC[N@+](C/C%10=C/CCCCCC%10)(CC)CC9)=O)C7=C6.[I-].[I-]	Potent CCR1 chemokine receptor antagonist	"Potent chemokine receptor 1 (CCR1) antagonist (IC50 values are 0.9 and 5.8 nM for human and mouse CCR1 receptors respectively). Also displays high selectivity for human but not mouse CCR3 receptors (IC50 values are 0.58 and 460 nM respectively). Improves paw inflammation, joint damage and dramatically reduces cell infiltration into joints in collagen-induced arthritis in mice. Isomer of UCB 35625 (Cat. No. 2757)."	"Naya et al (2001) Design, synthesis, and discovery of a novel CCR1 antagonist. J.Med.Chem. 44 1429. PMID:11311066. Amat et al (2006) Pharmacological blockade of CCR1 ameliorates murine arthritis and alters cytokine networks in vivo. Br.J.Pharmacol. 149 666. PMID:17016504."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=166922	SQ1341			Oct-2007
2596	Mexiletine hydrochloride	[5370-01-4]	Cl.CC(N)COC1=C(C)C=CC=C1C	Na+ channel blocker; antiarrhythmic agent	"Use-dependent sodium channel blocker (IC50 values are 75.3 and 23.6 _M for tonic and use-dependent block respectively). Class Ib antiarrhythmic, neuroprotective and antimyotonic agent."	Franchini et al (2003) Optically active mexiletine analogues as stereoselective blockers of voltage-gated Na+ channels. J.Med.Chem. 46 5238. PMID:14613326. Ates et al (2006) Neuroprotective effect of mexiletine in the central nervous system of diabetic rats. Mol.Cell.Biochem. 286 125. PMID:16541198. Bellis et al (2006) Evaluation of the pharmacological activity of the major mexiletine metabolites on skeletal muscle sodium currents. Br.J.Pharmacol. 149 300. PMID:16921388.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=167463	SQ1533			Dec-2006
2598	()-J 113397	[217461-40-0]	CCN1C4=C(C=CC=C4)N([C@@H]2CCN(CC3CCCCCCC3)C[C@H]2CO)C1=O.CCN5C8=C(C=CC=C8)N([C@H]6CCN(CC7CCCCCCC7)C[C@@H]6CO)C5=O	Potent and selective NOP antagonist	"Potent and selective NOP receptor antagonist (IC50 values are 2.3, 1400, 2200 and > 10000 nM for NOP, _, _ and _-opioid receptors respectively). Inhibits nociceptin/orphanin FQ-induced hyperalgesia in the mouse tail-flick test."	"Kawamoto et al (1999) Discovery of the first potent and selective small molecule opioid receptor-like (ORL1) antagonist: 1-[(3R,4R)-1-cyclooctylmethyl-3-hydroxymethyl-4-piperidyl]-3-ethyl-1,3-dihydro-2H-benzimidazol-2-one (J-113397). J.Med.Chem. 42 5061. PMID:10602690. Ozaki et al (2000) In vitro and in vivo pharmacological characterization of J-113397, a potent and selective non-peptidyl ORL1 receptor antagonist. Eur.J.Pharmacol. 402 45. PMID:10940356. Marti et al (2007) The nociceptin/orphanin FQ receptor antagonist J-113397 and L-DOPA additively attenuate experimental Parkinsonism through overinhibition of nigrothalamic pathway. J.Neurosci. 27 1297. PMID:17287504."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=167523	SQ1533			Oct-2007
2599	OSU 6162 hydrochloride	[156907-84-5]	CCCN(C2)CCC[C@@]2([H])C1=CC=CC(S(=O)(C)=O)=C1.Cl	Dopamine stabilizer	Dopamine stabilizer; lacks high affinity for various neuroreceptors in vitro (Ki values are 447 and 1305 nM for D2 and D3 receptors respectively and > 1 _M for other targets). Exhibits high D2 receptor occupancy in vivo; highly active on dopamine synthesis and turnover. Induces stabilizing effects on psychomotor function in behavioral tests without inducing hypolocomotion or catalepsy.	"Nichols et al (2002) PNU-96391A (OSU6162) antagonizes the development of behavioural sensitization induced by dopamine agonists in a rat model for Parkinson's disease. Neuropharmacology 43 817. PMID:12384167. Rung et al (2005) The dopaminergic stabilizers (-)-OSU6162 and ACR16 reverse (+)-MK-801-induced social withdrawal in rats. Prog.Neuro-Psychopharm.Biol.Psychiat. 29 833. Natesan et al (2006) The dopamine stabilizers (S)-(-)-(3-methanesulfonyl-phenyl)-1-propyl-piperidine [(-)-OSU6162] and 4-(3-methanesulfonyl-phenyl)-1-propyl-piperidine (ACR16) show high in vivo D2 receptor occupancy, antipsychotic-like efficacy, and low potential for motor side effects in the rat. J.Pharmacol.Exp.Ther. 318 810. PMID:16648369."	Small Molecule	Sold for research purposes under agreement from Pfizer Inc.	http://www.tocris.com/dispprod.php?ItemId=167534	SQ1341			Jun-2007
2600	Clofarabine	[123318-82-1]	O[C@@H]1[C@@H](CO)O[C@@H](N(C=N3)C2=C3C(N)=NC(Cl)=N2)[C@H]1F	Deoxycytidine kinase (dCK) substrate	"Deoxycytidine kinase (dCK) substrate. Phosphorylated to form clofarabine triphosphate, which competes with dATP for DNA polymerase-_ and -_ and potently inhibits ribonucleotide reductase (IC50 = 65 nM). Induces apoptosis by directly altering mitochondrial transmembrane potential. Demonstrates growth inhibition and cytotoxic activity in a variety of leukemias and solid tumors."	Parker et al (1991) Effects of 2-chloro-9-(2-deoxy-2-fluoro-_-D-arabinofuranosyl) adenine on K562 cellular metabolism and the inhibition of human ribonucleotide reductase and DNA polymerases by its 5'-triphosphate. Cancer Res. 51 2386. PMID:1707752. Carson et al (1992) Oral antilymphocyte activity and induction of apoptosis by 2-chloro-2'-arabino-fluoro-2'-deoxyadenosine. Proc.Natl.Acad.Sci.USA 89 2970. Bonate et al (2006) Discovery and development of clofarabine: a nucleoside analogue for treating cancer. Nat.Rev.Drug Discov. 5 855. PMID:17016426.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=167574	SQ1533			Dec-2006
2601	Cyprodime hydrochloride	[118111-54-9]	O=C3C[C@]24C1=C(OC)C=CC=C1C[C@@H](N(CC5CC5)CC4)[C@@](OC)2CC3.Cl	Selective _ antagonist	"Selective _-opioid receptor antagonist (Ki values are 5.4, 244.6 and 2187 nM for _-, _- and _-opioid receptors respectively). Reduces levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease."	Schmidhammer et al (1995) Synthesis and biological evaluation of 14-alkoxymorphinans. 11. 3-hydroxycyprodime and analogues: opioid antagonist profile in comparison to cyprodime. J.Med.Chem. 38 3071. PMID:7636870. Marki et al (1999) _-opioid receptor specific antagonist cyprodime: characterization by in vitro radioligand and [35S]GTP_s binding assays. Eur.J.Pharmacol. 383 209. PMID:10585536. Henry et al (2001) _- and _-opioid receptor antagonists reduce levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease. Exp.Neurol. 171 139. PMID:11520128.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=167598	SQ1533			Aug-2007
2602	PD 176252	[204067-01-6]	O=C(NC3=CC=C([N+]([O-])=O)C=C3)N[C@@](C)(CC5=CNC4=CC=CC=C45)C(NCC1(C2=CC=C(OC)C=N2)CCCCC1)=O	GRP (BB2) and NMB (BB1) receptor antagonist	"Non-peptide gastrin-releasing peptide receptor (GRP-R, BB2) and neuromedin B receptor (NMB-R, BB1) antagonist (Ki values are 0.17 and 1.0 nM for BB1 and BB2 respectively). Inhibits proliferation of rat C6 glioma cells (IC50 = 2 _M) and inhibits NCI-H1299 xenograft proliferation in nude mice (IC50 = 5 _M)."	"Ashwood et al (1998) PD 176252 - the first high affinity non-peptide gastrin-releasing peptide (BB2) receptor antagonist Bioorg.Med.Chem.Lett. 8 2589. PMID:9873586. Moody et al (2000) Nonpeptide neuromedin B receptor antagonists inhibit the proliferation of C6 cells Eur.J.Pharmacol. 409 133. PMID:11104826. Moody et al (2003) Nonpeptide gastrin releasing peptide receptor antagonists inhibit the proliferation of lung cancer cells Eur.J.Pharmacol. 474 21. PMID:12909192. Schepetkin et al (2011) Gastrin-releasing peptide/neuromedin B receptor antagonists pD176252, PD168368, and related analogs are potent agonists of human formyl-peptide receptors. Mol.Pharmacol. 79 77. PMID:20943772."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=83319	SQ1341			Nov-2007
2604	Milameline hydrochloride	[139886-04-7]	CN1CC(/C=N/OC)=CCC1.Cl	Muscarinic receptor agonist	"Muscarinic receptor agonist that displays roughly equal affinity at all receptor subtypes (Ki values are 2.3, 2.4, 3.6, 3.8 and 4.3 _M for hM1, hM2, hM3, hM4 and hM5 receptors respectively). Cognitive enhancer; reverses spatial memory deficits in rats."	"Sedman et al (1995) Preclinical and phase I clinical characterization of CI-979/RU35926, a novel muscarinic agonist for the treatment of Alzheimer's disease. Life Sci. 56 877. PMID:10188788. Wood et al (1999) Functional comparison of muscarinic partial agonists at muscarinic receptor subtypes hM1, hM2, hM3, hM4 and hM5 using microphysiometry. Br.J.Pharmacol. 126 1620. PMID:10323594. Schwarz et al (1999) Milameline (CI-979/RU35926): a muscarinic receptor agonist with cognition-activating properties: biochemical and in vivo characterization. J.Pharmacol.Exp.Ther. 291 812. PMID:10525104."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=5163				Aug-2008
2605	PD 198306	[212631-61-3]	CC1=C(NC2=C(C=C(F)C(F)=C2F)C(=O)NOCC2CC2)C=CC(I)=C1	Selective inhibitor of MEK1/2	"Potent inhibitor of MEK1/2. Inhibits isolated enzyme at a concentration of 8 nM and inhibits MEK activity in synovial fibroblasts at concentrations of 30 - 100 nM. Highly selective for MEK; IC50 values are > 1, > 4, > 4 and > 10 _M for ERK, c-Src, cdks and PI 3-kinase _ respectively. Antihyperalgesic; blocks static allodynia in the streptozocin model of neuropathic pain following i.t. administration."	Ciruela et al (2003) Identification of MEK1 as a novel target for the treatment of neuropathic pain. Br.J.Pharmacol. 138 751. PMID:12642375. Pelletier et al (2003) In vivo selective inhibition of mitogen-activated protein kinase kinase 1/2 in rabbit experimental osteoarthritis is associated with a reduction in the development of structural changes. Arthrit.Rheumat. 48 1582.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=5161	SQ1341			Jun-2007
2606	PD 144418 oxalate	[154130-99-1]	CCCN1CC(C2=CC(C3=CC=C(C)C=C3)=NO2)=CCC1	"High affinity, selective _1 ligand"	"High affinity, selective _1 ligand (Ki values are 0.08 and 1377 nM for _1 and _2 respectively). Displays no significant activity at a wide range of other receptors, ion channels and enzymes. Antagonizes mescaline-induced scratching in mice following i.p. administration. Also attenuates cocaine-induced hyperactivity in mice."	"Akunne et al (1997) The pharmacology of the novel and selective sigma ligand, PD 144418. Neuropharmacology 36 51. PMID:9144641. Lever et al (2014) Relationship between cerebral sigma-1 receptor occupancy and attenuation of cocaine's motor stimulatory effects in mice by PD144418. J.Pharmacol.Exp.Ther. 351 153. PMID:25100754."	Small Molecule	Sold for research purposes under agreement from Pfizer Inc.	http://www.tocris.com/dispprod.php?ItemId=81933	SQ1341			Apr-2008
2607	CI 988	[130332-27-3]	C[C@](NC(OC5C3CC(CC5C6)CC6C3)=O)(C(NC[C@@H]([C@]4=CC=CC=C4)NC(CCC(O)=O)=O)=O)CC2=CNC1=CC=CC=C12	Potent and selective CCK2 antagonist	Potent and selective CCK2 (CCK-B) receptor antagonist that displays ~ 1600-fold selectivity over CCK1 receptors (IC50 values are 1.7 and 2717 nM for CCK2 and CCK1 respectively). Has negligible affinity at a range of other binding sites (IC50 > 10 _M). Exhibits anxiolytic activity following oral administration.	Hughes et al (1990) Development of a class of selective cholecystokinin type B receptor antagonists having potent anxiolytic activity. Proc.Natl.Acad.Sci.USA 87 6728. Moody et al (2001) CI-988 inhibits growth of small cell lung cancer cells. J.Pharmacol.Exp.Ther. 299 1154. PMID:11714907. Andre et al (2005) Involvement of cholecystokininergic systems in anxiety-induced hyperalgesia in male rats: behavioral and biochemical studies. J.Neurosci. 25 7896. PMID:16135746.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=5164	SQ1533			Dec-2007
2608	PD 135158	[130285-87-9]	C[C@](NC(OC3C4(C)CCC(C(C)4C)C3)=O)(C(NC[C@@H]([C@]5=CC=CC=C5)NC(CCC(O)=O)=O)=O)CC2=CNC1=CC=CC=C12	Potent and selective CCK2 antagonist	"Potent and selective, nonpeptide CCK2 receptor antagonist (IC50 values are 2.8 and 1232 nM for CCK2 and CCK1 respectively) that displays negligible affinity at GABAA, benzodiazepine, substance P, neurotensin, opioid, bradykinin and 5-HT3 receptors (IC50 > 10 _M). Exhibits anxiolytic activity in elevated plus maze and social interaction tests and increases food intake in rats."	Hughes et al (1990) Development of a class of selective cholecystokinin type B receptor antagonists having potent anxiolytic activity. Proc.Natl.Acad.Sci.USA 87 6728. Dorre and Smith (1998) CholecystokininB receptor antagonist increases food intake in rats. Physiol.Behav. 65 11. PMID:9811359. Tsutsumi et al (1999) Suppression of conditioned fear by administration of CCKB receptor antagonist PD135158. Neuropeptides 33 483. PMID:10657528.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=40533	SQ1341			Dec-2007
2609	Ryuvidine	[265312-55-8]	CC1=NC2=C(S1)C(=O)C=C(NC1=CC=C(C)C=C1)C2=O	Cyclin-dependent kinase 4 (CDK4) inhibitor; also SETD8 inhibitor	Inhibitor of SETD8 protein lysine methyltransferase (PKMT) (IC50 = 0.5 _M); suppresses H4K20 monomethylation in vitro. Also inhibits cyclin-dependent kinase (CDK) 4 (IC50 = 6.0 _M at CDK4/cyclin D1). Induces S phase accumulation in HEK293T cells. Cytotoxic against a range of human cancer cells.	"Ryu et al (2000) 5-Arylamino-2-methyl-4,7-dioxobenzothiazoles as inhibitors of cyclin-dependent kinase 4 and cytotoxic agents. Bioorg.Med.Chem.Lett. 10 461. PMID:10743948. Blum et al (2014) Small-molecule inhibitors of SETD8 with cellular activity. ASC.Chem.Biol. [Epub ahead of print]. PMID:25137013."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=5165	SQ1341			May-2007
2611	IMD 0354	[978-62-1]	OC1=C(C=C(Cl)C=C1)C(=O)NC1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F	Inhibitor of IKK_	Inhibitor of I_B kinase-_ (IKK_) that blocks NF-_B nuclear translocation. Attenuates myocardial ischemia/reperfusion injury by decreasing expression of adhesion molecules ICAM-1 and P-selectin and inhibiting cytokine and chemokine production in cardiomyocytes. Induces G0/G1 cell cycle arrest and apoptosis in HMC-1 and breast cancer cells.	"Onai et al (2004) Inhibition of I_B phosphorylation in cardiomyocytes attenuates myocardial ischemia/reperfusion injury. Cardiovasc.Res. 63 51. PMID:15194461. Tanaka et al (2005) A novel NF-_B inhibitor, IMD-0354, supresses neoplastic proliferation of human mast cells with constitutively activated c-kit receptors. Hematopoiesis 105 2324. Tanaka et al (2006) A new I_B kinase _ inhibitor prevents human breast cancer progression through negative regulation of cell cycle transition. Cancer Res. 66 419. PMID:16397257."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=5166	SQ1533			Mar-2007
2613	NSC 87877	[56990-57-9]	OC2=C(/N=N/C3=CC=C(C=C(S(=O)(O)=O)C=C4)C4=C3)C=C(S(=O)(O)=O)C1=CC=CN=C12	Potent inhibitor of shp2 and shp1 PTP	"Potent inhibitor of shp2 and shp1 protein tyrosine phosphatases (PTP) (IC50 values are 0.318, 0.355, 1.691, 7.745, 65.617, 84.473 and 150.930 _M for shp2, shp1, PTP1B, HePTP, DEP1, CD45 and LAR respectively). Inhibits EGF-induced Erk1/2 activation in HEK293 cells and significantly reduces MDA-MB-468 cell viability/proliferation."	"Chen et al (2006) Discovery of a novel shp2 protein tyrosine phosphatase inhibitor. Mol.Pharmacol. 70 562. PMID:16717135. Zhao et al (2007) Regulation of ACh receptor clustering by the tyrosine phosphatase Shp2. Dev.Neurobiol. 67 1789. PMID:17659592. Redonde et al (2007) hTRPC1-associated _-actinin, and not hTRPC1 itself, is tyrosine phosphorylated during human platelet activation. J.Thromb.Haemost. 5 2476. PMID:17892531."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=5168	SQ1341			Jan-2008
2615	PD 158780	[171179-06-9]	CNC1=NC=C2N=CN=C(NC3=CC=CC(Br)=C3)C2=C1	Potent ErbB receptor family inhibitor	"Potent inhibitor of ErbB receptor family tyrosine kinases (IC50 values are 0.008, 49 and 52 nM for EGFR, ErbB2 and ErbB2/ErbB4 respectively) that does not inhibit FGF or PDGF-mediated tyrosine phosphorylation. Induces G1 cell cycle arrest in MCF10A cells and is antiproliferative in A431 human epidermal carcinoma cells."	"Fry et al (1997) Biochemical and antiproliferative properties of 4-[ar(alk)ylmino]pyridopyrimidines, a new chemical class of potent and specific epidermal growth factor receptor tyrosine kinase inhibitor. Biochem.Pharmacol. 54 877. PMID:9354588. Sun et al (1999) Growth inhibition of nasopharyngeal carcinoma cells by EGF receptor tyrosine kinase inhibitors. Anticancer Res. 19 919. PMID:10368634. Gonzales et al (2005) G1 cell cycle arrest due to inhibition of erbB family receptor tyrosine kinases does not require the retinoblastoma protein. Exp.Cell Res. 303 56. PMID:15572027."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=167884	SQ1341			Apr-2007
2617	AG 879	[148741-30-4]	CC(C)(C)C1=CC(/C=C(C#N)/C(N)=S)=CC(C(C)(C)C)=C1O	TrkA inhibitor	Inhibitor of the tyrosine kinase activity of nerve growth factor (NGF) TrkA. Decreases cellular proliferation in human muscular sarcoma cell lines. Also inhibits ErbB2 and VEGFR-2 (IC50 values are approximately 1 _M for both).	"He et al (2004) The Tyr-kinase inhibitor AG879, that blocks the ETK-PAK1 interaction, suppresses the RAS-induced PAK1 activation and malignant transformation. Cancer Biol.Ther. 3 96. PMID:14726663. Rende et al (2006) Role of nerve growth factor and its receptors in non-nervous cancer growth: efficacy of a tyrosine kinase inhibitor (AG879) and neutralizing antibodies antityrosine kinase receptor A and antinerve growth factor: an in-vitro and in-vivo study. Anticancer Drugs 17 929. PMID:16940803."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=5173				Feb-2011
2621	ARP 100	[704888-90-4]	O=S(C1=CC=C(C2=CC=CC=C2)C=C1)(N(OC(C)C)CC(NO)=O)=O	Selective inhibitor of MMP-2	"Selective inhibitor of MMP-2 (IC50 = 12 nM); displays selectivity over MMP-9, MMP-3, MMP-1 and MMP-7 (IC50 values are 200, 4500, > 50000 and > 50000 nM respectively). Exhibits anti-invasive properties in HT1080 fibrosarcoma cells."	"Rossello et al (2004) New N-arylsulfonyl-N-alkoxyaminoacetohydroxamic acids as selective inhibitors of gelatinase A (MMP-2). Bioorg.Med.Chem. 12 2441. PMID:15080939. Tuccinardi et al (2006) Amber force field implementation, molecular modelling study, synthesis and MMP-1/MMP-2 inhibition profile of (R)- and (S)-N-hydroxy-2-(N-isopropoxybiphenyl-4-ylsulfonamido)-3 methylbutanamides. Bioorg.Med.Chem. 14 4260. PMID:16483784."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=5175	SQ1341			Feb-2007
2622	ARP 101	[849773-63-3]	O=S(C1=CC=C(C2=CC=CC=C2)C=C1)(N(OC(C)C)[C@H]([C@@H](C)C)C(NO)=O)=O	Inhibitor of MMP-2	Selective inhibitor of MMP-2 that displays ~ 600-fold selectivity over MMP-1 (IC50 values are 0.81 and 486 nM respectively).	"Tuccinardi et al (2006) Amber force field implementation, molecular modelling study, synthesis and MMP-1/MMP-2 inhibition profile of (R)- and (S)-N-hydroxy-2-(N-isopropoxybiphenyl-4-ylsulfonamido)-3 methylbutanamides. Bioorg.Med.Chem. 14 4260. PMID:16483784."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=5178	SQ1341			Apr-2007
2623	Oxaliplatin	[61825-94-3]	[Pt++].[O-]C(=O)C([O-])=O.[H][C@@]1(N)CCCC[C@@]1([H])N	DNA cross-linking antitumor agent	Antitumor agent that forms platinum-DNA adducts. Causes intra- and interstrand DNA crosslinks blocking DNA replication and transcription. Displays higher cytotoxicity and lower nephrotoxicity than analog cisplatin (Cat. No. 2251) and shows antitumor activity in cell lines with acquired cisplatin resistance.	Culy et al (2000) Oxaliplatin. A review of its pharmacological properties and clinical efficacy in metastatic colorectal cancer and its potential in other malignancies. Drugs 60 895. PMID:11085200. Raymond et al (2002) Cellular and molecular pharmacology of oxaliplatin. Mol.Cancer Ther. 1 227. PMID:12467217. Mani et al (2002) Oxaliplatin: a review of evolving concepts. Cancer Invest. 20 246. PMID:11901545.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=83008				Jan-2007
2624	Decitabine	[2353-33-5]	O[C@@H]1[C@@H](CO)O[C@@H](N2C=NC(N)=NC2=O)C1	DNA methyltransferase inhibitor	Cytosine analog that once incorporated into DNA acts as a suicide substrate for DNA methyltransferase. Inhibits DNA methyltransferase and results in DNA hypomethylation and activation of silent genes. Chemotherapeutic agent; suppresses growth of human tumor cell lines. Demethylates differentiation-related genes; reverses embryonic stem cell differentiation.	Jackson-Grusby et al (1997) Mutagenicity of 5-aza-2'-deoxycytidine is mediated by the mammalian DNA methyltransferase. Proc.Natl.Acad.Sci.USA 94 4681. Bender et al (1998) Inhibition of DNA methylation by 5-aza-2'-deoxycytidine supresses the growth of human tumour cell lines. Cancer Res. 58 95. PMID:9426064. Momparler (2005) Pharmacology of 5-aza-2'-deoxycytidine (decitabine). Semin.Hematol. 42 (Suppl 2) S9. PMID:16015507.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=88417	SQ1533			Aug-2007
2625	Zonisamide	[68291-97-4]	NS(=O)(=O)CC1=NOC2=CC=CC=C12	Blocks voltage-sensitive Na+ and Ca2+ channels (T-type)	"Antiepileptic that possesses a broad spectrum anticonvulsant and mechanistic profile. Blocks voltage-sensitive Na+ and T-type Ca2+ channels, stimulates BKCa channels, modulates GABA, glutamate and monoamine neurotransmission, inhibits lipid peroxidation and scavenges hydroxyl and nitric oxide free radicals. Displays neuroprotective and antiParkinsonian activity."	"Tokumaru et al (2000) In vivo evaluation of hippocampal anti-oxidant ability of zonisamide in rats. Neurochem.Res. 25 1107. PMID:11055748. Sobieszek et al (2003) Zonisamide: a new antiepileptic drug. Pol.J.Pharmacol. 55 683. PMID:14704463. Gluck et al (2004) Novel dopamine releasing response of an anti-convulsant agent with possible anti-Parkinson's activity. J.Neural Transm. 111 713. PMID:15168218. Huang et al (2007) Activation by Zonisamide, a newer antiepileptic drug, of large-conductance calcium-activated potassium channel in differentiated hippocampal neuron-derived H19-7 cells. J.Pharmacol.Exp.Ther. 321 98. PMID:17255467."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=5181	SQ1533			Jan-2007
2626	Carboplatin	[41575-94-4]	O=C(C21CCC2)O[Pt-2]([NH3+])([NH3+])OC1=O	DNA cross-linking antitumor agent	Antitumor agent that forms platinum-DNA adducts. Causes intra- and interstrand DNA crosslinks blocking DNA replication and transcription. Enhances radiation-induced single-strand DNA breakage and displays lower nephrotoxicity than analog cisplatin (Cat. No. 2251).	"Yang et al (1995) Carboplatin enhances the production and persistence of radiation-induced DNA single-strand breaks. Radiation Res. 143 302. Natarajan et al (1999) Increased DNA-binding activity of cis-1,1-cyclobutanedicarboxylatodiammineplatinum (II) (carboplatin) in the presence of nucleophiles and human breast cancer MCF-7 cell cytoplasmic extracts: activation theory revisited. Biochem.Pharmacol. 58 1625. PMID:10535754. Thomas et al (2006) High accumulation of platinum-DNA adducts in strial marginal cells of the cochlea is an early event in cisplatin but not carboplatin ototoxicity. Mol.Pharmacol. 70 23. PMID:16569706."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=5202				Jan-2007
2628	ONO 4817	[223472-31-9]	O=C(N[C@H](COCOCC)C[C@H](C)C(NO)=O)C1=CC=C(OC2=CC=CC=C2)C=C1	Broad spectrum MMP inhibitor	"Broad spectrum MMP inhibitor; Ki values are 0.45, 0.73, 1.1, 1.1, 2.1, 42 and 2500 nM for MMP-12, MMP-2, MMP-8, MMP-13, MMP-9, MMP-3 and MMP-7 respectively and IC50 = 1600 nM for MMP-1). Displays no activity at other proteases up to a concentration of 100 _M. Exhibits antiangiogenic and anti-invasive properties on lung metastasis of murine renal cell carcinoma."	"Yamada et al (2000) ONO-4817, an orally active matrix metalloproteinase inhibitor, prevents lipopolysaccharide-induced proteoglycan release from the joint cartilage in guinea pigs. Inflamm.Res. 49 144. PMID:10858013. Muraishi et al (2001) Effect of a matrix metalloproteinase inhibitor (ONO-4817) on lung metastasis of murine renal cell carcinoma. Anticancer Res. 21 3845. PMID:11911256. Medina and Radomski (2006) Role of matrix metalloproteinases in intestinal inflammation. J.Pharmacol.Exp.Ther. 318 933. PMID:16644899."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=5183	SQ1341			Nov-2007
2629	Cilnidipine	[132203-70-4]	COCCOC(=O)C1=C(C)NC(C)=C(C1C1=CC=CC(=C1)[N+]([O-])=O)C(=O)OCC=CC1=CC=CC=C1	Ca2+ channel blocker (dual L/N-type)	"Dual L- and N-type calcium channel blocker that displays antihypertensive, sympatholytic and neuroprotective activity. Lowers mean blood pressure and reduces the size of cerebral infarction in the rat model of focal brain ischemia."	Murai et al (2000) Preferential inhibition of L- and N-type calcium channels in the rat hippocampal neurons by cilnidipine. Brain Res. 854 6. PMID:10784100. Takahara et al (2004) Neuroprotective effects of a dual L/N-type Ca2+ channel blocker cilnidipine in the rat focal brain ischemia model. Biol.Pharm.Bull. 27 1388. PMID:15340224. Nap et al (2004) The evaluation of the N-type channel blocking properties of cilnidipine and other voltage-dependent calcium antagonists. Fund.Clin.Pharmacol. 18 309.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=5184	SQ1533			Jan-2007
2631	Marimastat	[154039-60-8]	O=C(NO)[C@@H](O)[C@H]([C@](N[C@@H]([C@](C)(C)C)C(NC)=O)=O)CC(C)C	Broad spectrum MMP inhibitor	"Broad spectrum inhibitor of MMPs (IC50 values are 3, 5, 6, 9 and 13 nM for MMP-9, MMP-1, MMP-2, MMP-14 and MMP-7 respectively). Inhibits peritoneal dissemination of human gastric cancer cells in vivo through inhibition of tumor angiogenesis."	Rasmussen and McCann (1997) Matrix metalloproteinase inhibition as a novel anticancer strategy: a review with special focus on batimastat and marimastat. Pharmacol.Ther. 75 69. PMID:9364582. Wada et al (2003) Reduced angiogenesis in peritoneal dissemination of gastric cancer through gelatinase inhibition. Clin.Exp.Metastasis 20 431. PMID:14524532. Bjornland et al (2005) Matrix metalloproteinases participate in osteosarcoma invasion. J.Surg.Res. 127 151. PMID:16083752.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=5207	SQ1070			Jun-2007
2632	CL 82198 hydrochloride	[1188890-36-9]	Cl.O=C(NCCCCN1CCOCC1)C1=CC2=CC=CC=C2O1	Selective inhibitor of MMP-13	"Selective inhibitor of MMP-13 (89% inhibition at 10 _g/mL) that displays no activity at MMP-1, MMP-9 or TACE. Inhibits in vitro invasion by the human pituitary adenoma cell line HP75."	"Chen et al (2000) Structure-based design of a novel, potent, and selective inhibitor for MMP-13 utilizing NMR spectroscopy and computer-aided molecular design. J.Am.Chem.Soc. 122 9648. Borg et al (2003) IL1 alpha, IL6 and MMP13 are required for invasion by the human pituitary cell line HP75. Endocrine Abstr. 5 122."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=5223	SQ1533			May-2007
2633	WAY 170523	[307002-73-9]	CC1=CC(C(=O)NO)=C(N(CC2=CC=CC=C2)S(=O)(=O)C2=CC=C(OCCNC(=O)C3=CC4=CC=CC=C4O3)C=C2)C(C)=C1	Potent and selective inhibitor of MMP-13	"Potent and selective inhibitor of MMP-13 (IC50 values are 17, 945, > 1000 and > 10000 nM for MMP-13, MMP-9, TACE and MMP-1 respectively)."	"Chen et al (2000) Structure-based design of a novel, potent, and selective inhibitor for MMP-13 utilizing NMR spectroscopy and computer-aided molecular design. J.Am.Chem.Soc. 122 9648. Jaffr et al (2012) -adrenergic receptor stimulation transactivates protease-activated receptor 1 via matrix metalloproteinase 13 in cardiac cells. Circulation 125 2993. PMID:22610965."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=5198	SQ1341			Jun-2007
2634	DAPT	[208255-80-5]	CC(C)(C)OC([C@H]([C@]2=CC=CC=C2)NC([C@H](C)NC(CC1=CC(F)=CC(F)=C1)=O)=O)=O	_-secretase inhibitor	"Inhibitor of _-secretase; causes a reduction in A_40 and A_42 levels in human primary neuronal cultures (IC50 values are 115 and 200 nM for total A_ and A_42 respectively) and in brain extract, cerebrospinal fluid and plasma in vivo. Does not effect APP_ and APP_ levels. Blocks Notch signaling in hybrid human-mouse fetal thymus organ culture (FTOC). Activity causes neural cells to commit to neuronal differentiation."	"Dovey et al (2001) Functional gamma-secretase inhibitors reduce beta-amyloid peptide levels in brain. J.Neurochem. 76 173. PMID:11145990. De Smedt et al (2005) Different thresholds of notch signaling bias human precursor cells towards B-, NK-, monocytic/dendritic, or T-cell lineage in thymus microenvironment. Blood 106 3498. PMID:16030192. Crawford and Roelink (2007) The notch response inhibitor DAPT enhances neuronal differentiation in embryonic stem cell-derived embryoid bodies independently of sonic hedgehog signaling. Dev.Dyn. 236 886. PMID:17295317."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=5199	SQ1533			Mar-2007
2635	NGB 2904	[189061-11-8]	Cl.ClC1=C(Cl)C(=CC=C1)N1CCN(CCCCNC(=O)C2=CC=C3C(CC4=CC=CC=C34)=C2)CC1	Potent and selective D3 antagonist	"Potent and selective dopamine D3 receptor antagonist (Ki values are 1.4, 217, 223, 642, > 5000, > 10000 and > 10000 nM for D3, D2, 5-HT2, _1, D4, D1 and D5 receptors respectively). Potently antagonizes quinpirole-stimulated mitogenesis (IC50 = 6.8 nM). Attenuates cocaine's rewarding effects and inhibits relapse to drug-seeking behavior."	Yuan et al (1998) NGB 2904 and NGB 2849: two highly selective dopamine D3 receptor antagonists. Bioorg.Med.Chem.Lett. 8 2715. PMID:9873609. Xi et al (2006) The novel dopamine D3 receptor antagonist NGB 2904 inhibits cocaine's rewarding effects and cocaine-induced reinstatement of drug-seeking behavior in rats. Neuropsychopharmacology 31 1393. PMID:16205781. Pritchard et al (2007) The dopamine D3 receptor antagonist NGB 2904 increases spontaneous and amphetamine-stimulated locomotion. Pharmacol.Biochem.Behav. 86 718. PMID:17408730.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=5205	SQ1341			Jun-2007
2636	Ivachtin	[745046-84-8]	CC(=O)OCCN1C(=O)C2=C(C)N=C3C=CC(=CC3=C2C1=O)S(=O)(=O)N1CCOCC1	Potent caspase-3 inhibitor	"Potent, reversible inhibitor of caspase-3 (IC50 = 23 nM) that displays moderate selectivity over other caspases. Exhibits antiapoptotic activity in human Jurkat T cells treated with staurosporine; exhibits a higher level of protection than Z-VAD-FMK (Cat. No. 2163)."	"Kravchenko et al (2005) Synthesis and structure-activity relationship of 4-substituted 2-(2-acetyloxyethyl)-8-(morpholine-4-sulfonyl)pyrrolo[3,4-c]quinoline-1,3-diones as potent caspase-3 inhibitors. J.Med.Chem. 48 3680. PMID:15916416."	Small Molecule	"Sold with the permission of ChemDiv, Inc."	http://www.tocris.com/dispprod.php?ItemId=5210	SQ1533			Jul-2007
2638	ST 91	[4749-61-5]	CCC2=C(C(CC)=CC=C2)/N=C1NCCN/1.Cl	"_2 agonist, putative _2C agonist"	_2-adrenoceptor agonist that does not cross the blood brain barrier. Displays ~ 120-fold selectivity for _2 receptors over _1 receptors and acts predominantly at non-_2A-adrenoceptors which may be of the _2C subtype. Antinociceptive; increases tail-flick latencies in Sasco and Harlan rats.	"Takano and Yaksh (1992) Characterization of the pharmacology of intrathecally administered alpha-2 agonists and antagonists in rats. J.Pharmacol.Exp.Ther. 261 764. PMID:1349648. Celly et al (1999) Cardiopulmonary effects of the _2-adrenoceptor agonists medetomidine and ST-91 in anesthetized sheep. J.Pharmacol.Exp.Ther. 289 712. PMID:10215644. Graham et al (2000) Synergistic interactions between two _2-adrenoceptor agonists, dexmedetomidine and ST-91, in two substrains of Sprague-Dawley rats. Pain 85 135. PMID:10692612."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=85017	SQ1070			Jun-2007
2639	CGK 733	[905973-89-9]	[O-][N+](=O)C1=CC(NC(=S)NC(NC(=O)C(C2=CC=CC=C2)C2=CC=CC=C2)C(Cl)(Cl)Cl)=CC=C1F	Induces apoptosis in prematurely senescent cells	Originally defined as a selective inhibitor of ATR and ATM kinases. Induces cell death in prematurely senescent breast cancer cells. Decreases p21CIP1 levels in premature senescent MCF-7 and HCT-116 cells; also exhibits antiproliferative activity in a range of cancer cell lines. Blocks camptothecin-induced p53 phosphorylation and protects cells from camptothecin-induced apoptosis.	Crescenzi et al (2008) Ataxia telangiectasia mutated and p21CIP1 modulate cell survival of drug-induced senescent tumor cells: Implications for chemotherapy. Clin.Cancer Res. 14 1877. PMID:18347191. Won et al (2008) Retraction: small molecule-based reversible reprogramming of cellular lifespan. Nat.Chem.Biol. 4 431. PMID:18560433. Bhattacharya et al (2009) Role of polyamines in p53-dependent apoptosis of intestinal epithelial cells. Cell Signal. 21 509. PMID:19136059. Alao and Sunnerhagen (2009) The ATM and ATR inhibitors CGK733 and caffeine suppress cyclin D1 levels and inhibit cell proliferation. Radiat.Oncol. 10 4. PMID:19903334.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=5203				May-2007
2640	"L-703,664 succinate"	[144776-01-2]	O=S1(N(CCN1C)CC2=CC=C(NC=C3CCN(C)C)C3=C2)=O.O=C(CCC(O)=O)O	Selective 5-HT1D receptor agonist	"5-HT1D receptor agonist that displays selectivity over other 5-HT receptor subtypes (pIC50 values are 7.2, 6.1, < 5.0 and < 5.0 for 5-HT1D, 5-HT1A, 5-HT2A and 5-HT3 respectively) and other receptors (pIC50 < 5.0 for adenosine, adrenergic, excitatory amino acids, dopamine, histamine, muscarinic, nicotinic and opiate receptors)."	"Castro et al (1994) Synthesis and biological activity of 3-[2-(dimethylamino)ethyl]-5-[(1,1-dioxo-5-methyl-1,2,5-thiadiazolidin-2-yl)-methyl]-1H-indole and analogues: agonists for the 5-HT1D receptor. J.Med.Chem. 37 3023. PMID:7932524."	Small Molecule	"Sold with the permission of Merck, Sharpe and Dohme Ltd."	http://www.tocris.com/dispprod.php?ItemId=84027	SQ1341			Dec-2008
2641	"L-368,899 hydrochloride"	[160312-62-9]	CC(C=CC=C2)=C2N1CCN(S(CC34CCC(C(C)4C)C[C@@H]3NC([C@@H](N)CCS(C)(=O)=O)=O)(=O)=O)CC1.Cl	"Potent, non-peptide oxytocin receptor antagonist"	"Potent, non-peptide and orally active oxytocin receptor antagonist (IC50 = 8.9 nM) that displays > 40-fold selectivity over vasopressin V1a and V2 receptors (IC50 values are 370 and 570 nM respectively). Antagonizes oxytocin-induced uterine contractions in vitro and in vivo."	"Williams et al (1994) 1-(((7,7-dimethyl-2(S)-(2(S)-amino-4-(methylsulfonyl)butyramido)bicyclo[2.2.1]-heptan-1(S)-yl)methyl)sulfonyl)-4-(2-methylphenyl)piperazine (L-368,899): an orally bioavailable, non-peptide oxytocin antagonist with potential utility for managing preterm labor. J.Med.Chem. 37 565. PMID:8126695. Mann et al (2003) Attenuation of PGE2_ release in ewes infused with the oxytocin antagonist L-368,899. Domest.Anim.Endocrinol. 25 255. PMID:14550509. Quattropani et al (2005) Discovery and development of a new class of potent, selective, orally active oxytocin receptor antagonist. J.Med.Chem. 48 7882. PMID:16302826. Borthwick (2010) Oral oxytocin antagonists. J.Med.Chem. 53 6525. PMID:20550119."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=5221	SQ1341			Apr-2007
2642	Co 102862	[181144-66-1]	NC(=O)N\N=C\C1=CC=C(OC2=CC=C(F)C=C2)C=C1	State-dependent of voltage-gated sodium channels	"Broad spectrum, state-dependent blocker of voltage-gated sodium channels. Displays ~ 80-fold higher affinity for inactivated Na+ channels compared to channels in the resting state. Anticonvulsant; displays activity in rodent models of tonic/clonic and partial-complex seizures."	"Ilyin et al (2005) V102862 (Co 102862): a potent, broad-spectrum state-dependent blocker of mammalian voltage-gated sodium channels. Br.J.Pharmacol. 144 801. PMID:15778702. Ilyin et al (2006) Pharmacology of 2-[4-(4-chloro-2-fluorophenoxy)phenyl]-pyrimidine-4-carboxamide: a potent, broad-spectrum state-dependent sodium channel blocker for treating pain states. J.Pharmacol.Exp.Ther. 318 1083. PMID:16728593."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=5255				Feb-2007
2645	Fananserin	[127625-29-0]	FC1=CC=C(C=C1)N1CCN(CCCN2C3=C4C(=CC=CC4=CC=C3)S2(=O)=O)CC1	5-HT2A antagonist. Also D4 antagonist	"5-HT2A receptor antagonist that also displays high affinity at D4 receptors (Ki values are 0.26, 2.93, 25, 38, 70 and 726 nM for 5-HT2A, D4, H1, _1, 5-HT1A and D2 receptors respectively). Inhibits inositol phosphate formation evoked by 5-HT in vitro (IC50 = 7.76 nM) and antagonizes mescaline-induced head twitches in vivo."	"Malleron et al (1991) Naphthosultam derivatives: a new class of potent and selective 5-HT2 antagonists. J.Med.Chem. 34 2477. PMID:1908521. Doble et al (1992) Pharmacological characterization of RP 62203, a novel 5-hydroxytryptamine 5-HT2 receptor antagonist. Br.J.Pharmacol. 105 27. PMID:1596688. Heuillet et al (1996) The naphtosultam derivative RP 62203 (fananserin) has high affinity for the dopamine D4 receptor. Eur.J.Pharmacol. 314 229. PMID:8957240."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=5247	SQ1533			Mar-2007
2646	HDS 029	[881001-19-0]	FC(C=C3)=C(Cl)C=C3NC1=NC=NC2=C1C=C(NC(C#CC)=O)N=C2	Potent inhibitor of the ErbB receptor family	"Potent inhibitor of the ErbB receptor family (IC50 values are 0.3, 0.5 and 1.1 nM for ErbB1 (EGFR), ErbB4 and ErbB2 respectively). Inhibits EGF-induced erbB1 autophosphorylation in NIH3T3 cells and heregulin-stimulated ErbB autophosphorylation in MDA-MB-453 human breast carcinoma cells (IC50 values are 2.5 and 24 nM respectively)."	"Klutchko et al (2006) Tyrosine kinase inhibitors. 19. 6-alkynamides of 4-anilinoquinazolines and 4-aniliopyrido[3,4-d]pyrimidines as irreversible inhibitors of the erbB family of tyrosine kinase receptors. J.Med.Chem. 49 1475. PMID:16480284."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=5232	SQ1341			Jul-2007
2647	NSC 632839 hydrochloride	[157654-67-6]	O=C(/C(CNC3)=C/C2=CC=C(C)C=C2)/C3=C/C1=CC=C(C)C=C1.Cl	Inhibitor of ubiquitin isopeptidase activity	Inhibitor of ubiquitin isopeptidase activity that displays no effect on the proteolytic activity of the proteasome. Induces apoptosis via a Bcl-2-dependent and apoptosome-independent pathway of caspase activation (IC50 values are 15.65 and 16.23 _M in E1A and E1A/C9CN cells respectively).	Aleo et al (2006) Identification of new compounds that trigger apoptosome-independent caspase activation and apoptosis. Cancer Res. 66 9235. PMID:16982768.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=63116				Apr-2007
2649	GW 9508	[885101-89-3]	OC(=O)CCC1=CC=C(NCC2=CC=CC(OC3=CC=CC=C3)=C2)C=C1	Potent and selective FFA1 (GPR40) agonist	"Potent and selective agonist for the free fatty acid receptor FFA1 (GPR40) (pEC50 values are 7.32, < 4.3 and < 4.3 for FFA1, FFA2 and FFA3 receptors respectively). Inactive against a range of other GPCRs, kinases, proteases, integrins and PPARs. Potentiates glucose-stimulated insulin secretion in MIN6 cells (pEC50 = 6.14)."	Garrido et al (2006) Synthesis and activity of small molecule GPR40 agonists. Bioorg.Med.Chem.Lett. 16 1840. PMID:16439116. Briscoe et al (2006) Pharmacological regulation of insulin secretion in MIN6 cells through fatty acid receptor GPR40: identification of agonist and antagonist small molecules. Br.J.Pharmacol. 148 619. PMID:16702987. Zhao and Chen (2008) Activation of ATP-sensitive potassium channels in rat pancreatic _-cells by linoleic acid through both intracellular metabolites and membrane receptor signalling pathway. J.Endocrinol. 198 533. PMID:18550787.	Small Molecule	Sold with the permission of GlaxoSmithKline	http://www.tocris.com/dispprod.php?ItemId=80537	SQ1533			Apr-2007
2650	SB 590885	[405554-55-4]	CN(C)CCOC(C=C4)=CC=C4C1=NC(C3=CC=C(C(CC5)=NO)C5=C3)=C(C2=CC=NC=C2)N1	Potent B-Raf inhibitor	Potent B-Raf inhibitor (Kd = 0.3 nM). Selective for B-Raf against 46 other kinases (Ki app values are 0.16 and 1.72 nM for B-Raf and c-Raf respectively). Decreases anchorage-independent growth of melanoma cell lines. Inhibits ERK phosphorylation and proliferation in tumor cells expressing B-RafV600E.	King et al (2006) Demonstration of a genetic therapeutic index for tumors expressing oncogenic BRAF by the kinase inhibitor SB-590885. Cancer Res. 66 11100. PMID:17145850. Takle et al (2006) The identification of potent and selective imidazole-based inhibitors of B-Raf kinase. Bioorg.Med.Chem.Lett. 16 378. PMID:16260133.	Small Molecule	Sold for research purposes under agreement from GlaxoSmithKline.	http://www.tocris.com/dispprod.php?ItemId=5214	SQ1533			Aug-2011
2651	AEG 3482	[63735-71-7]	NS(=O)(=O)C1=NN2C=C(N=C2S1)C1=CC=CC=C1	Inhibitor of JNK signaling	"Inhibitor of c-jun N-terminal kinase (JNK) signaling. Binds Hsp90 and facilitates HSF1 release, induces expression of Hsp70, which in turn blocks JNK activation and JNK-dependent apoptosis. Antiapoptotic; inhibits NGF withdrawal-induced death in SCG neurons (EC50 = 20 _M)."	Gallo (2006) Targeting HSP90 to halt neurodegeneration. Chem.Biol. 13 115. PMID:16492558. Salehi et al (2006) AEG3482 is an antiapoptotic compound that inhibits Jun kinase activity and cell death through induced expression of heat shock protein 70. Chem.Biol. 13 213. PMID:16492569.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=141692	SQ1070			May-2007
2652	WAY 213613	[868359-05-1]	FC1=C(F)C=C(OC2=CC=C(NC(C[C@H](N)C(O)=O)=O)C=C2)C(Br)=C1	"Potent, non-substrate EAAT2 inhibitor"	"Potent, non-substrate inhibitor of EAAT2 (GLT-1) that displays > 44-fold selectivity over EAAT1 and EAAT3 (IC50 values are 85, 3787 and 5004 nM for EAAT2, EAAT3 and EAAT1 respectively). Exhibits no activity towards ionotropic and metabotropic glutamate receptors."	"Dunlop et al (2005) Characterization of novel aryl-ether, biaryl, and fluorene aspartic acid and diaminopropionic acid analogs as potent inhibitors of the high-affinity glutamate transporter EAAT2. Mol.Pharmacol. 68 974. PMID:16014807. Beart and Shea (2007) Transporters for L-glutamate: an update on their molecular pharmacology and pathological involvement. Br.J.Pharmacol. 150 5. PMID:17088867."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=5244	SQ1341			May-2007
2653	Pifithrin-_	[64984-31-2]	NS(=O)(=O)C#CC1=CC=CC=C1	Inhibitor of p53-mitochondrial binding	Inhibits p53 binding to mitochondria by reducing its affinity for antiapoptotic proteins Bcl-2 and Bcl-XL. Displays no effect on the transactivational or cell cycle checkpoint control function of p53. Potentially increases reprogramming efficiency of human somatic cells to induced pluripotent stem cells (iPSCs) by silencing p53. Reduces cell death induced by _-radiation in vitro and protects mice from doses of radiation that cause lethal hematopoietic syndrome. Selectively inhibits heat shock protein 70 (HSP70) activity.	Strom et al (2006) Small-molecule inhibitor of p53 binding to mitochondria protects mice from gamma radiation. Nat.Chem.Biol. 2 474. PMID:16862141. Leu et al (2009) A small molecule inhibitor of inducible heat shock protein 70 (HSP70). Mol.Cell 36 15. PMID:19818706. Kawamura et al (2009) Linking the p53 tumor suppressor pathway to somatic cell reprogramming. Nature 460 1140. PMID:19668186. Steele et al (2009) 2-phenylacetylenesulfonamide (PAS) induces p53-independent apoptotic killing of B-chronic lymphocytic leukemia (CLL) cells. Blood 114 1217. PMID:19515722.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=5217	SQ1341			Apr-2007
2654	Compound W	[173550-33-9]	OC(=O)C1=CC(OC2=CC=C(C=C2)[N+]([O-])=O)=CC(OC2=CC=C(C=C2)[N+]([O-])=O)=C1	_-secretase inhibitor	Inhibitor of _-secretase; causes a decrease in the released levels of A_42 and notch-1 A_-like peptide 25 (N_25).	Okochi et al (2006) Secretion of the notch-1 A_-like peptide during notch signaling. J.Biol.Chem. 281 7890. PMID:16434391.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=5187				Feb-2007
2655	Naproxen sodium	[26159-34-2]	[Na+].COC1=CC=C2C=C(C=CC2=C1)[C@H](C)C([O-])=O	Cyclooxygenase inhibitor	"Non-selective cyclooxygenase (COX) inhibitor that displays anti-inflammatory, antipyretic and analgesic effects. Has a neuroprotective role against colchicine-induced cognitive impairment and oxidative stress."	Sutton (1996) Naproxen sodium. J.Am.Pharm.Assoc. (Wash) NS36 633. PMID:8952250. Dhir et al (2006) Protective effect of naproxen (non-selective COX-inhibitor) or rofecoxib (selective COX-2 inhibitor) on immobilization stress-induced behavioral and biochemical alterations in mice. Eur.J.Pharmacol. 535 192. PMID:16522321. Kumar et al (2006) Differential effects of cyclooxygenase inhibitors on intracerebroventricular colchicine-induced dysfunction and oxidative stress in rats. Eur.J.Pharmacol. 551 58. PMID:17027965.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=5220	SQ1533			Feb-2007
2657	JX 401	[349087-34-9]	COC1=C(C=CC(SC)=C1)C(=O)N1CCC(CC2=CC=CC=C2)CC1	"Potent, reversible p38_ inhibitor"	"Potent, reversible inhibitor of p38_ that displays no activity on the p38_ isoform (IC50 values are 32 nM and > 10 _M respectively). Inhibits the differentiation of myoblasts to myotubes in mammalian cells in culture."	"Friedmann et al (2006) JX401, a p38_ inhibitor containing a 4-benzylpiperidine motif, identified via a novel screening system in yeast. Mol.Pharmacol. 70 1395. PMID:16847144."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=5188	SQ1341			Mar-2007
2658	Bucindolol	[71119-11-4]	CC(NCC(O)COC3=C(C#N)C=CC=C3)(C)CC1=CNC2=C1C=CC=C2	_1 and _2 antagonist	"Non-selective _-adrenoceptor antagonist with additional _1-adrenoceptor blocking activity. Ki values are 1.61, 1.20 and 68.9 nM for _1-, _2- and _1-adrenoceptors respectively. Also acts as a weak 5-HT2A/2B antagonist. Displays vasodilatory and antihypertensive actions."	Marwood and Stokes (1985) Bucindolol has serotonin and alpha-adrenoceptor blocking properties. J.Cardiovasc.Pharmacol. 7 (Suppl. 7) S67. Watts et al (2000) Interaction of the [beta] adrenergic receptor antagonist bucindolol with serotonergic receptors. J.Cardiovasc.Pharmacol. 35 29. PMID:10630730. Ponicke et al (2002) Differential effects of bucindolol and carvedilol on noradrenaline-induced hypertrophic response in ventricular cardiomyocytes of adult rats. J.Pharmacol.Exp.Ther. 301 71. PMID:11907159.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=5189	SQ1533			Apr-2007
2660	"L-364,373"	[103342-82-1]	CN(C1=CC=CC=C1C(C5=CC=CC=C5F)=N[C@@H]2CC3=CNC4=C3C=CC=C4)C2=O	"KV7.1 channel activator, activates IKs"	Activator of KV7.1 (KCNQ1) channels. Activates the cardiac IKs current that decreases action potential duration (APD) in cardiac myocytes.	"Salata et al (1998) A novel benzodiazepine that activates cardiac slow delayed rectifier K+ currents. Am.Soc.Pharmacol.Exp.Ther. 53 220. Seebohm et al (2003) Pharmacological activation of normal and arrhythmia-associated mutant KCNQ1 potassium channels. Circ.Res. 93 941. PMID:14576198. Jow et al (2006) Rb+ efflux through functional activation of cardiac KCNQ1/minK channels by the benzodiazepine R-L3 (L-364,373). Assay Drug Dev.Technol. 4 443. PMID:16945016. Chadha et al (2012) Pharmacological dissection of K(V)7.1 channels in systemic and pulmonary arteries. Br.J.Pharmacol. 166 1377. PMID:22251082."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=5190	SQ1341			Feb-2008
2661	UCL 2077	[918311-87-2]	C(NC(C1=CC=CC=C1)(C1=CC=CC=C1)C1=CC=CC=C1)C1=CN=CC=C1	Slow afterhyperpolarization (sAHP) channel blocker	Slow afterhyperpolarization (sAHP) channel blocker; reduces sAHP in hippocampal slice preparations. Displays no effect on Ca2+ currents or the time course of sAHP/sIAHP. Rescues memory retrieval in dopamine _-hydroxylase knockout mice.	Shah et al (2006) Enhancement of hippocampal pyramidal cell excitability by the novel selective slow-afterhyperpolarization channel blocker 3-(triphenylmethylaminomethyl)pyridine (UCL2077). Mol.Pharmacol. 70 1494. PMID:16877678. Zhang et al (2013) The slow afterhyperpolarization: a target of _1-adrenergic signaling in hippocampus-dependent memory retrieval. J.Neurosci. 33 5006. PMID:23486971.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=5191	SQ1341			Apr-2007
2662	PHTPP	[805239-56-9]	OC1=CC=C(C=C1)C1=C2N=C(C=C(N2N=C1C1=CC=CC=C1)C(F)(F)F)C(F)(F)F	Selective ER_ antagonist	"Selective estrogen ER_ receptor antagonist that displays 36-fold selectivity over ER_. Exhibits full antagonism at ER_ in a cotransfection assay in human endometrial cancer cells (HEC-1), with minimal effects on ER_."	"Compton et al (2004) Pyrazolo[1,5-a]pyrimidines: estrogen receptor ligands possessing estrogen receptor _ antagonist activity. J.Med.Chem. 47 5872. PMID:15537344. Compton et al (2005) Erratum. J.Med.Chem. 48 2724."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=5192	SQ1341			May-2007
2663	CB 65	[913534-05-1]	ClC1=CC=C2C(N(CCN3CCOCC3)C=C(C(NC4CCCCC4)=O)C2=O)=C1	"High affinity, selective CB2 agonist"	High affinity and selective CB2 receptor agonist; Ki values are 3.3 and > 1000 nM for CB2 and CB1 receptors respectively.	"Manera et al (2006) Design, synthesis, and biological evaluation of new 1,8-naphthyridin-4(1H)-on-3-carboxamide and quinolin-4(1H)-on-3-carboxamide derivatives as CB2 selective agonists. J.Med.Chem. 49 5947. PMID:17004710."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=5193	SQ1341			May-2007
2664	Cabergoline	[81409-90-7]	CC2=C(C(C[C@]3([H])[C@@]([H])2C[C@@H]([C@@](N(C(NCC)=O)CCCN(C)C)=O)CN3CC=C)=CN1)/C/1=C	Selective D2-like agonist	"Selective D2-like dopamine receptor agonist (Ki values are 0.7, 1.5, 9.0 and 165 nM for D2, D3, D4 and D5 receptors respectively) that also displays high affinity for several serotonin receptor subtypes (Ki = 1.2 - 20.0 nM for 5-HT1A, 5-HT1D, 5-HT2A and 5-HT2B). Inhibits secretion of prolactin and growth hormone and reverses levodopa-induced dyskinesias in Parkinsonian monkeys."	"Eguchi et al (1995) Effect of cabergoline, a dopamine agonist, on estrogen-induced rat pituitary tumors:in vitro culture studies. Endocr.J. 42 413. PMID:7670571. Hadj Tahar et al (2000) Sustained cabergoline treatment reverses levodopa-induced dyskinesias in parkinsonian monkeys. Cin.Neuropharmacol. 23 195. Kvernmo et al (2006) A review of the receptor-binding and pharmacokinetic properties of dopamine agonists. Clin.Ther. 28 1065. PMID:16982285."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=66103	SQ1341			May-2007
2665	BMS 191011	[202821-81-6]	OC1=CC=C(Cl)C=C1CN1N=C(OC1=O)C1=CC=C(C=C1)C(F)(F)F	Potent BKCa (KCa1.1) channel opener	"Potent BKCa channel opener (large-conductance Ca2+-activated potassium channel, KCa1.1). Neuroprotectant in two distinct animal models of stroke (MCAO in the SHR rat and a normotensive model of focal stroke)."	"Hewawasam et al (2003) Synthesis of water-soluble prodrugs of BMS-191011: a Maxi-K channel opener targeted for post-stroke neuroprotection. Bioorg.Med.Chem.Letts. 13 1695. Romine et al (2007) 3-[(5-chloro-2-hydroxyphenyl)methyl]-5-[4-trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one, BMS-191011: opener of large-conductance Ca2+-activated potassium (Maki-K) channels, identification, solubility, and SAR. J.Med.Chem. 50 528. PMID:17266205."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=5194	SQ1070			Jul-2007
2666	JP 1302 dihydrochloride	[1259314-65-2]	CN(CC5)CCN5C(C=C4)=CC=C4NC2=C3C(C=CC=C3)=NC1=CC=CC=C12.Cl.Cl	Potent and selective _2C antagonist	"_2C-adrenoceptor antagonist that displays ~ 50-fold selectivity over other _2-adrenoceptor subtypes (Ki values are 28, 1470, 1700 and 3150 nM for human _2C, _2B, _2D and _2A subtypes respectively). Potently antagonizes adrenalin-stimulated 35GTP_S binding in vitro (KB = 16 nM) and produces antidepressant and antipsychotic-like effects in vivo."	Tricklebank (2007) JP-1302: a new tool to shed light on the roles of _2C-adrenoceptors in brain. Br.J.Pharmacol. 150 381. PMID:17220912. Sallinen et al (2007) Pharmacological characterization and CNS effects of a novel highly selective _2C-adrenoceptor antagonist JP-1302. Br.J.Pharmacol. 150 391. PMID:17220913.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=68366	SQ1341			Mar-2007
2668	Artemisinin	[63968-64-9]	O=C1O[C@]([H])(O[C@@](OO4)(C)CC3)[C@]24[C@](CC[C@@H](C)[C@]32[H])([H])[C@H]1C	Antimalarial; inhibits P-type ATPase (PfATP6) of P.falciparum	"Antimalarial agent; interacts with heme to produce carbon-centred free radicals, causes protein alkylation and damages parasite microorganelles and membranes. Also selectively inhibits the P-type ATPase (PfATP6) of Plasmodium falciparum (Ki ~ 150 nM). Displays antiangiogenic effects in mouse embryonic stem cell-derived embryoid bodies."	Balint (2001) Artemisinin and its derivatives. An important new class of antimalarial agents. Pharmacol.Ther. 90 261. PMID:11578659. Eckstein-Ludwig et al (2003) Artemisinins target the SERCA of Plasmodium falciparum. Nature 424 957. PMID:12931192. Wartenberg et al (2003) The antimalarial agent artemisinin exerts antiangiogenic effects in mouse embryonic stem cell-derived embryoid bodies. Lab.Invest. 83 1647. PMID:14615418.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=85199	SQ1533			Mar-2007
2669	TC 1	[362512-81-0]	OC12C3C4C5C3C(C3C5CC4C13)N2CCC1=CC(F)=CC=C1	High affinity _1 ligand	"High affinity _1 receptor ligand that displays selectivity over _2 receptors (Ki values are 10 and 370 nM respectively). Exhibits low affinity for dopamine (DAT), serotonin (SERT) and noradrenalin (NET) transporters (Ki > 10 _M) and low affinity for dopamine D2 receptors (Ki = 1226 nM). Attenuates cocaine-induced locomotor activity in mice."	Liu et al (2007) Trishomocubanes: novel _ ligands modulate cocaine-induced behavioural effects. Eur.J.Pharmacol. 555 37. PMID:17113074.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=73102	SQ1341			Jul-2007
2671	Budesonide	[51333-22-3]	O=C1C=C[C@@]2(C)C(CC[C@]3([H])[C@@]([H])2[C@@H](O)C[C@@]4(C)[C@]([H])3C[C@@H]5[C@](C(CO)=O)4OC(CCC)O5)=C1	Synthetic glucocorticoid; anti-inflammatory and chemopreventive	Synthetic anti-inflammatory glucocorticoid that displays chemopreventive activity. Prevents formation of lung adenomas and adenocarcinomas in mice following inhalation or oral administration. Reverses DNA hypomethylation and modulates expression of cancer related genes.	Spencer et al (1995) Budesonide. A review of its pharmacological properties and therapeutic efficacy in inflammatory bowel disease. Drugs 50 854. PMID:8586030. Pereira et al (2006) Modulation by budesonide of DNA methylation and mRNA expression in mouse lung tumors. Int.J.Cancer 120 1150. Wattenberg et al (2007) Chemoprevention of pulmonary carcinogenesis by aerosolized budesonide in female A/J mice. Cancer Res. 57 5489.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=5200	SQ1533			Apr-2007
2672	Taltirelin	[103300-74-9]	CN(C(C[C@@H]([C@@](N[C@@H](CC3=CNC=N3)C(N2[C@H]([C@](N)=O)CCC2)=O)=O)N1)=O)C1=O	Synthetic thyrotropin-releasing hormone analog	Synthetic thyrotropin-releasing hormone (TRH) analog. Displays ~ 30 - 100-fold more potent CNS activity and ~ 50-fold weaker endocrine activity than TRH. Antinociceptive and neuroprotective.	"Suzuki et al (1990) Synthesis and central nervous system actions of thyrotropin-releasing hormone analogues containing a dihydroorotic acid moiety. J.Med.Chem. 33 2130. PMID:2115588. Urayama et al (2002) Neuroprotective effect and brain receptor binding of taltirelin, a novel thyrotropin-releasing hormone (TRH) analogue, in transient forebrain ischemia of C57BL/6J mice. Life Sci. 72 601. PMID:12467901. Tanabe et al (2007) The synthetic TRH analogue taltirelin exerts modality-specific antinociceptive effects via distinct descending monoaminergic systems. Br.J.Pharmacol. 150 403. PMID:17220907."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=5201	SQ1533			Jan-2008
2673	Acarbose	[56180-94-0]	C[C@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@H](O[C@@H]3[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]3O)[C@H](O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1N[C@H]1C=C(CO)[C@@H](O)[C@H](O)[C@H]1O	Glucosidase _ inhibitor (intestinal)	Inhibitor of intestinal _-glucosidase (IC50 = 11 nM). Antidiabetic; inhibits the hydrolysis of complex carbohydrates.	Krause et al (1982) Inhibition of disaccharide digestion in rat intestine by the alpha-glucosidase inhibitor acarbose (BAY g 5421). Digestion 23 232. PMID:6754513. Balfour and McTavish (1993) Acarbose: an update of its pharmacology and therapeutic use in diabetes mellitus. Drugs 46 1025. PMID:7510610. Oki et al (2000) Evaluation of alpha-glucosidase inhibition by using an immobilized assay system. Biol.Pharm.Bull. 23 1084. PMID:10993209.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=148224	SQ1533			May-2007
2675	ZJ 43	[723331-20-2]	CC(C[C@@]([H])(C(O)=O)NC(N[C@@]([H])(CCC(O)=O)C(O)=O)=O)C	"Glutamate carboxypeptidase II and III (NAALADase, NAAG peptidase) inhibitor"	Potent inhibitor of glutamate carboxypeptidase II and III (GCP II and III/NAAG peptidase/NAALADase) (Ki values are 0.8 and 23 nM respectively) that inhibits the hydrolysis of NAAG (IC50 = 2.4 nM) . Does not directly interact with NMDA or metabotropic glutamate receptors. Reduces neuronal degeneration in a rat model of  traumatic brain injury (TBI) and reduces locomotor activity in the PCP-model of schizophrenia.	Olszewski et al (2004) NAAG peptidase inhibition reduces locomotor activity and some stereotypes in the PCP model of schizophrenia via group II mGluR. J.Neurochem. 89 876. PMID:15140187. Zhou et al (2005) NAAG peptidase inhibitors and their potential for diagnosis and therapy. Nat.Rev.Drug Discov. 4 1015. PMID:16341066. Yamamoto et al (2007) Local administration of N-acetylaspartylglutamate (NAAG) peptidase inhibitors is analgesic in peripheral pain in rats. Eur.J.Neurosci. 25 147. PMID:17241276.	Small Molecule	"Sold with the permission of Acenta Discovery, Inc."	http://www.tocris.com/dispprod.php?ItemId=5206	SQ1341			May-2007
2676	Y 134	[849662-80-2]	CC(C)N1CCN(CC1)C1=CC=C(C=C1)C(=O)C1=C(SC2=CC(O)=CC=C12)C1=CC=C(O)C=C1	"Selective estrogen receptor modulator (SERM), selective for ER_"	"Selective estrogen receptor modulator (SERM) that displays selectivity for ER_ over ER_ (Ki values are 0.09 and 11.31 nM respectively) and no cross-reactivity with mineralocorticoid, glucocorticoid, androgen and progesterone receptors. Acts as an agonist in the bone and antagonist in reproductive tissue. Suppresses estrogen-stimulated proliferation of ER-positive human breast cancer MCF-7 and T47D cells."	Yang et al (2005) Benzothiophenes containing a piperazine side chain as selective ligands for the estrogen receptor _ and their bioactivities in vivo. Bioorg.Med.Chem.Lett. 15 1505. PMID:15713417. Ning et al (2007) Biological activities of a novel selective oestrogen receptor modulator derived from raloxifene (Y134). Br.J.Pharmacol. 150 19. PMID:17115070.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=78754	SQ1341			Jun-2007
2677	JLK 6	[62252-26-0]	COC1=C(Cl)C2=CC=C(N)C=C2C(=O)O1	Inhibitor of _-secretase-mediated _APP processing	"Inhibitor of _-secretase that selectively inhibits _APP cleavage without affecting other _-secretase-mediated pathways. Prevents recovery of A_40 and A_42 from HEK293 cell overexpressing wild-type or Swedish-mutated _APP (IC50 ~ 30 _M) but displays no effect on Notch cleavage and Notch-mediated intracellular signaling. Displays no activity on BACE1, BACE2, _-secretase, the proteosome or GSK3_."	Petit et al (2001) New protease inhibitors prevent _-secretase-mediated production of A_40/42 without affecting Notch cleavage. Nat.Cell.Biol. 3 507. PMID:11331880. Petit et al (2003) JLK isocoumarin inhibitors: selective _-secretase inhibitors that do not interfere with Notch pathway in vitro or in vivo. J.Neurosci.Res. 74 370. PMID:14598313. Hellstrom et al (2007) DII4 signalling through Notch1 regulates formation of tip cells during angiogenesis. Nature 445 776. PMID:17259973.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=5231	SQ1341			May-2007
2678	GP 2a	[919077-81-9]	CC1=CC=C2C(CC3=C2N(N=C3C(=O)NC2CCCCC2)C2=CC=C(Cl)C=C2Cl)=C1	Selective CB2 agonist	Selective CB2 receptor agonist; Ki values are 7.6 and 900 nM for CB2 and CB1 receptors respectively. Increases P-ERK1/2 expression in HL-60 cells in vitro.	"Murineddu et al (2006) Tricyclic pyrazoles. 4. Synthesis and biological evaluation of analogues of the robust and selective CB2 cannabinoid ligand 1-(2',4'-dichlorophenyl)-6-methyl-N-piperidin-1-yl-1,4-dihydroindeno[1,2-c]pyrazole-3-carboxamide. J.Med.Chem. 49 7502. PMID:17149879."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=5209	SQ1341			Jun-2007
2681	17-PA	[694438-95-4]	O=C1C=C[C@@]2(C)C(CC[C@]3([H])[C@@]([H])2[C@@H](O)C[C@@]4(C)[C@]([H])3C[C@@H]5[C@](C(CO)=O)4OC(CCC)O5)=C1	Antagonist of neurosteroid potentiation and direct gating of GABAA	"Selective antagonist of neurosteroid potentiation and direct gating of GABAA receptors. Selectively reduces the effects of 5_-reduced steroids compared to 5_-reduced steroids and displays no effect on potentiation evoked by barbiturates and benzodiazepines. Attenuates 3_,5_-THP-induced loss of righting reflex and total sleep time following i.c.v administration in rats."	"Mennerick et al (2004) Selective antagonism of 5_-reduced neurosteroid effects at GABAA receptors. Mol.Pharmacol. 65 1191. PMID:15102947. Akk et al (2007) Ethanol modulates the interaction of the endogenous neurosteroid allopregnanolone with the _1_2_2L GABAA receptor. Mol.Pharmacol. 71 461. PMID:17105870. Kelley et al (2007) Antagonism of neurosteroid modulaton of native _-aminobutyric acid receptors by (3_,5_)-17-phenylandrost-16-en-3-ol. Eur.J.Pharmacol. 572 94. PMID:17658511."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=5222	SQ1533			Sep-2007
2682	Sodium 4-Phenylbutyrate	[1716-12-7]	[Na+].[O-]C(=O)CCCC1=CC=CC=C1	Histone deacetylase inhibitor	"Histone deacetylase inhibitor that displays anticancer activity. Inhibits cell proliferation, invasion and migration and induces apoptosis in glioma cells. Also inhibits protein isoprenylation, depletes plasma glutamine, increases production of fetal hemoglobin through transcriptional activation of the _-globin gene and affects hPPAR_ activation."	"Engelhard et al (1998) Inhibitory effects of phenylbutyrate on the proliferation, morphology, migration and invasiveness of malignant glioma cells. J.Neuro-Oncol. 37 97. Appelskog et al (2004) Histone deacetylase inhibitor 4-phenylbutyrate suppresses GADPH mRNA expression in glioma cells. Int.J.Oncol. 24 1419. PMID:15138583. Ammerpohl et al (2007) Complementary effects of HDAC inhibitor 4-PB on gap junction communication and cellular export mechanisms support restoration of chemosensitivity of PDAC cells. Br.J.Cancer 96 73. PMID:17164759. Khan et al (2011) HDAC inhibitor 4-phenylbutyrate preserves immature phenotype of human embryonic midbrain stem cells: implications for the involvement of DNA methyltransferase. Int.J.Mol.Med. 28 977. PMID:21894430."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=5218	SQ1533			Mar-2007
2684	SN 38	[86639-52-3]	OC1=CC=C(N=C(C(N3C4)=CC([C@](CC)(O)C(OC5)=O)=C5C3=O)C4=C2CC)C2=C1	DNA topoisomerase I inhibitor; antitumor	"Active metabolite of CPT-11 (Cat. No. 2688) that inhibits DNA topoisomerase I (IC50 values are 0.74 and 1.9 _M in P388 and Ehrlich cells respectively). Inhibits DNA and RNA synthesis (IC50 values are 0.077 and 1.3 _M respectively) but does not affect protein synthesis. Displays potent antitumor activity against a range of human tumor cell lines (IC50 values are 3.3, 13, 19 and 22 nM for HCT-116, BEL-7402, HL60 and HELA cells respectively)."	"Kawato et al (1991) Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. Cancer Res. 51 4187. PMID:1651156. Gao et al (2005) Synthesis and antitumor activity of the hexacyclic camptothecin derivatives. Bioorg.Med.Chem.Lett. 15 3233. PMID:15913996. Koizumi et al (2006) Novel SN-38-incorporating ploymeric micelles, NK012, eradicate vascular endothelial growth factor-secreting bulky tumors. Cancer Res. 66 10048. PMID:17047068."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=56263	SQ1533			Jun-2007
2685	Carvedilol	[72956-09-3]	COC1=C(OCCNCC(O)COC2=CC=CC3=C2C2=C(N3)C=CC=C2)C=CC=C1	_-adrenoceptor and _1-adrenoceptor antagonist	"Potent _-adrenoceptor and _1-adrenoceptor antagonist (Ki values are 0.81, 0.96 and 2.2 nM for _1-, _2- and _1-adrenoceptors respectively) that displays antihypertensive and peripheral vasodilatory activity. Blocks cardiac inward-rectifier K+ (KIR) channels, voltage-dependent Ca2+ channels and exhibits antioxidant properties at higher concentrations."	"Ohlstein et al (1993) Carvedilol, a cardiovascular drug, prevents vascular smooth muscle cell proliferation, migration, and neointimal formation following vascular injury. Proc.Natl.Acad.Sci.USA. 90 6189. Ponicke et al (2002) Differential effects of bucindolol and carvedilol on noradrenaline-induced hypertonic response in ventricular cardiomyocytes of adult rats. J.Pharmacol.Exp.Ther. 301 71. PMID:11907159. Kikuta et al (2006) Carvedilol blocks cardiac KATP and KG but not IK1 channels by acting at the bundle-crossing region. Eur.J.Pharmacol. 529 47. PMID:16325804."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=5225	SQ1533			Apr-2007
2687	Pentylenetetrazole	[54-95-5]	C1CCN2N=NN=C2CC1	CNS stimulant	CNS stimulant that induces kindling in vivo. Causes alterations in excitatory and inhibitory neurotransmitter systems.	Rocha et al (1996) Pentylenetetrazol-induced kindling: early involvement of excitatory and inhibitory systems. Epilepsy Res. 26 105. PMID:8985692. Walsh et al (1999) Acute pentylenetetrazol injection reduces rat GABAA receptor mRNA levels and GABA stimulation of benzodiazepine binding with no effect on benzodiazepine binding site density. J.Pharmacol.Exp.Ther. 289 1626. PMID:10336561. Dhir et al (2006) Effect of cyclooxygenase inhibitors on pentylenetetrazol (PTZ)-induced convulsions: possible mechanism of action. Prog.Neuro-Psychopharm.Biol.Psychiat. 30 1478.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=149059	SQ1070			Apr-2007
2688	CPT 11	[100286-90-6]	CCC2=C4C(C(N3C4)=CC([C@](CC)(O)C(OC5)=O)=C5C3=O)=NC1=CC=C(OC(N6CCC(N7CCCCC7)CC6)=O)C=C12.Cl	DNA topoisomerase I inhibitor; antitumor	"Inhibitor of DNA topoisomerase I that displays antitumor activity against a range of tumor types. Active metabolite available (SN 38, Cat. No. 2684)."	"Kawato et al (1993) Inhibitory activity of camptothecin derivatives against acetylcholinesterase in dogs and their binding activity to acetylcholine receptors in rats. J.Pharm.Pharmacol. 45 444. PMID:8099964. Vassal et al (1996) Therapeutic activity of CPT-11, a DNA topoisomerase I inhibitor against peripheral primitive neuroectodermal tumour and neuroblastoma xenografts. Br.J.Cancer. 74 537. PMID:8761367. Morton et al (2005) Activation and antitumour activity of CPT-11 in plasma esterase-deficient mice. Can.Chemother.Pharmacol. 56 629."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=149024	SQ1533			Apr-2007
2691	Moexipril hydrochloride	[82586-52-5]	O=C([C@@H](N[C@H]([C@@](OCC)=O)CCC3=CC=CC=C3)C)N2CC1=CC(OC)=C(OC)C=C1C[C@H]2[C@@](O)=O.Cl	Angiotensin-converting enzyme (ACE) inhibitor	Angiotensin-converting enzyme (ACE) inhibitor that is hydrolyzed in the liver to the active metabolite moexiprilat (IC50 values are 2.1 and 2700 nM for moexiprilat and moexipril respectively). Antihypertensive; decreases mean blood pressure in the spontaneous hypertensive rat (SHR). Also blocks degradation of bradykinin into inactive metabolites.	"Edling et al (1995) Moexipril, a new angiotensin-converting enzyme (ACE) inhibitor: pharmacological characterization and comparison with enalapril. J.Pharmacol.Exp.Ther. 275 854. PMID:7473177. Friehe and Ney (1997) Pharmacological and toxicological studies of the new angiotensin converting enzyme inhibitor moexipril hydrochloride. Arzneim.-Forsch. 47 132. Chrysant and Chrysant (2004) Pharmacological and clinical profile of moexipril: a concise review. J.Clin.Pharmacol. 44 827. PMID:15286086."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=5230	SQ1533			May-2007
2693	PHA 665752	[477575-56-7]	ClC1=C(CS(C2=CC(/C(C(N4)=O)=C/C3=C(C)C(C(N5CCC[C@@H]5CN6CCCC6)=O)=C(C)N3)=C4C=C2)(=O)=O)C(Cl)=CC=C1	Potent and selective MET inhibitor	"Potent, selective and ATP-competitive inhibitor of MET kinase (IC50 values are 9, 68, 200, 1400, 3000, 3800 and 6000 nM for MET, Ron, Flk-1, c-abl, FGFR1, EGFR and c-src respectively and > 10000 nM for IGF-IR, PDGFR, AURORA2, PKA, PKB_, p38_, MK2 and MK3). Antitumor agent; inhibits tumorigenicity and angiogenesis in mouse lung cancer xenografts."	"Christensen et al (2003) A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in vitro and exhibits cytoreductive antitumour activity in vivo. Cancer Res. 63 7345. PMID:14612533. Smolen et al (2006) Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752. Proc.Natl.Acad.Sci.USA 103 2316. Puri et al (2007) A selective small molecule inhibitor of c-Met, PHA665752, inhibits tumorigenicity and angiogenesis in mouse lung cancer xenografts. Cancer Res. 67 3529. PMID:17440059. Tu et al (2010) Efficacy of c-Met inhibitor for advanced prostate cancer. BMC Cancer 10 556. PMID:20946682."	Small Molecule	Sold for research purposes under agreement from Pfizer Inc.	http://www.tocris.com/dispprod.php?ItemId=88278	SQ1070			Jul-2007
2694	PD 407824	[622864-54-4]	OC1=CC2=C(NC3=C2C2=C(C(=O)NC2=O)C(=C3)C2=CC=CC=C2)C=C1	Selective inhibitor of Chk1 and Wee1	"Selective inhibitor of checkpoint kinases Chk1 and Wee1 (IC50 values are 47 and 97 nM respectively). Displays selectivity over a range of other protein kinases; IC50 values are 3.4, 3.75, > 5, > 50, > 50 and > 50 _M for PKC, CDK4, other CDKs, c-Src, PDGFR and FGFR respectively."	"Squire et al (2005) Structure and inhibition of the human cell cycle checkpoint kinase, Wee1A kinase: an atypical tyrosine kinase with a key role in CDK1 regulation. Structure 13 541. PMID:15837193. Palmer et al (2006) 4-Phenylpyrrolo[3,4-c]carbazole-1,3(2H,6H)-dione inhibitors of the checkpoint kinase Wee1. Structure-activity relationships for chromophore modification and phenylring substitutions. J.Med.Chem. 49 4896. PMID:16884302."	Small Molecule	Sold for research purposes under agreement from Pfizer Inc.	http://www.tocris.com/dispprod.php?ItemId=52977	SQ1341			Apr-2007
2700	Calcipotriol	[112965-21-6]	[H][C@@]12[C@]([C@]([C@@H](/C=C/[C@@H](O)C4CC4)C)([H])CC2)(C)CCC/C1=C\C=C3/C([C@@H](O)C[C@H](O)C3)=C	Vitamin D3 analog	"Vitamin D3 analog that displays minimal effects on calcium homeostasis. Regulates cell differentiation and proliferation; exhibits antiproliferative activity against human HL-60, HL60/MX2, MCF-7, T47D, SCC-25 and mouse WEHI-3 cancer cell lines."	"Binderu (1993) Comparison of calcipotriol with selected metabolites and analogues of vitamin D3: effects on cell growth regulation in vitro and calcium metabolism in vivo. Pharmacol.Toxicol. 72 240. PMID:8396769. Knutson et al (1997) Pharmacokinetics and systemic effect on calcium homeostasis of 1_,24-dihydroxyvitamin D2 in rats. Biochem.Pharmacol. 53 829. PMID:9113104. Wietrzyk et al (2007) Antitumor properties of diastereomeric and geometric analogs of vitamin D3. Anticancer Drugs 18 447. PMID:17351397."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=5480	SQ1533			Jun-2007
2701	YM 90K hydrochloride	[154164-30-4]	O=C(N2)C(NC1=C2C=C(N3C=NC=C3)C([N+]([O-])=O)=C1)=O.Cl	Selective AMPA antagonist	"Selective AMPA receptor antagonist (Ki values are 84, 2200 and > 37000 nM for AMPA, kainate and NMDA receptors respectively). Neuroprotective; delays neuronal death in a global ischemia model and cerebral infarction in a focal ischemia model following postischemic administration."	"Ohmori et al (1994) 6-(1H-imidazol-1-yl)-7-nitro-2,3(1H,4H)-quinoxalinedione hydrochloride (YM90K) and related compounds: structure-activity relationships for the AMPA-type non-NMDA receptor. J.Med.Chem. 37 467. PMID:8120865. Umemura et al (1997) Neuroprotective effect of a novel AMPA receptor antagonist, YM90K, in rat focal cerebral ischaemia. Brain Res. 773 61. PMID:9409705. Nakano et al (2001) A potent AMPA/kainate receptor antagonist, YM90K, attenuates the loss of N-acetylaspartate in the hippocampal CA1 area after transient unilateral forebrain ischemia in gerbils. Life Sci. 69 1983. PMID:11589513."	Small Molecule	Sold with the permission of Astellas Pharma Inc.	http://www.tocris.com/dispprod.php?ItemId=5237				Jul-2007
2705	Liarozole hydrochloride	[145858-50-0]	ClC1=CC(C(N4C=CN=C4)C2=CC=C(N=CN3)C3=C2)=CC=C1.Cl	Blocks retinoic acid metabolism	"Cytochrome P450 inhibitor. Inhibits several cytochrome P450 enzymes including aromatase (CYP19) and retinoic acid 4-hydroxylase (CYP26). Blocks retinoic acid metabolism (retinoic acid metabolism blocking agent, RAMBA). Displays antitumor activity against androgen-dependent and independent rat prostate carcinomas."	"Van Wauwe et al (1992) Liarozole, an inhibitor of retinoic acid metabolism, exerts retinoid-mimetic effects in vivo. J.Pharmacol.Exp.Ther. 261 773. PMID:1374473. Njar et al (2006) Retinoic acid metabolism blocking agents (RAMBAs) for treatment of cancer and dermatological diseases. Bioorg.Med.Chem. 14 4323. PMID:16530416. Goss et al (2007) Effects of liarozole fumarate (R85246) in combination with tamoxifen on N-methyl-N-nitrosourea (MNU)-induced mammary carcinoma and uterus in the rat model. BMC Cancer 7 26. PMID:17266767."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=5242	SQ1533			Oct-2007
2706	Temozolomide	[85622-93-1]	CN1N=NC2=C(N=CN2C1=O)C(N)=O	DNA-methylating antitumor agent	"DNA methylating, chemotherapeutic agent. Displays antitumor activity against a board spectrum of tumors, including leukemias, lymphomas and solid tumors (IC50 = 5.0 _M for cytotoxicity against mouse TLX5 lymphoma cells). Induces autophagy in malignant glioma cells. Exhibits enhanced activity when used in combination with CHC (Cat No. 5029)."	"Plowman et al (1994) Preclinical antitumor activity of temozolomide in mice: efficacy against human brain tumor xenografts and synergism with 1,3-bis(2-chloroethyl)-1-nitrosourea. Cancer Res. 54 3793. PMID:8033099. Clark et al (1995) Antitumor imidazotetraazines. 32. Synthesis of novel imidazotetrazinones and related bicyclic heterocycles to probe the mode of action of the antitumor drug temozolomide. J.Med.Chem. 38 1493. PMID:7739008. Bodell et al (2003) Formation of DNA adducts and induction of lacI mutations in big blue rat-2 cells treated with temozolomide: implications for the treatment of low-grade adult and pediatric tumors. Cancer Epidemiol.Biomarkers Prevent. 12 545. Kanzawa et al (2004) Role of autophagy in temozolomide-induced cytotoxicity for malignant glioma cells. Cell Death Differ. 11 448. PMID:14713959."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=5243	SQ1533			May-2007
2707	BIBP 3226 trifluoroacetate	[1068148-47-9]	OC1=CC=C(CNC([C@H](NC(C(C3=CC=CC=C3)C2=CC=CC=C2)=O)CCCNC(N)=N)=O)C=C1.FC(F)(C(O)=O)F	Mixed NPY Y1 and NPFF receptor antagonist	"Mixed non-peptide neuropeptide Y Y1 (NPY Y1) and neuropeptide FF (NPFF) receptor antagonist (Ki values are 1.1, 79, 108, > 1000, > 1000 and >1000 for rNPY Y1, hNPFF2, rNPFF, rNPY Y2, rNPY Y4 and rNPY Y5 respectively). Produces an anxiogenic-like effect in rats following i.c.v. administration."	"Kask et al (1996) Anxiogenic-like effect of the neuropeptide Y Y1 receptor antagonist BIBP3226: antagonism with diazepam. Eur.J.Pharmacol. 317 R3. PMID:8997632. Mollereau et al (2001) Agonist and antagonist activities on human NPFF2 receptors of the NPY ligands GR231118 and BIBP3226. Br.J.Pharmacol. 133 1. PMID:11325787. Fang et al (2006) In vivo inhibition of neuropeptide FF agonism by BIBP3226, an NPY Y1 receptor antagonist. Peptides 27 2207. PMID:16762456."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=5245	SQ1341			Feb-2008
2709	Cilastatin sodium	[81129-83-1]	[Na+].N[C@H](CSCCCC\C=C(/NC(=O)[C@H]1CC1(C)C)C(O)=O)C([O-])=O	Dipeptidase inhibitor	"Dipeptidase inhibitor (LTDase, leukotriene D4 hydrolase, dehydropeptidase I) that displays a Ki value of 0.11 _M. Inhibits metabolism of LTD4 to LTE4 and the hydrolysis of _-lactam antibiotics. Nephroprotective; reduces toxic accumulation of cyclosporin A in kidney proximal tubule epithelial cells."	Graham et al (1987) Inhibition of the mammalian _-lactamase renal dipeptidase (dehydropeptidase-I) by (Z)-2-(acylamino)-3-substituted-propenoic acids. J.Med.Chem. 30 1074. PMID:3495664. White et al (1999) A continuous fluorometric assay for leukotriene D4 hydrolase. Anal.Biochem. 268 245. PMID:10075814. Perez et al (2004) Inhibition of brush border dipeptidase with cilastatin reduces toxic accumulation of cyclosporin A in kidney proximal tubule epithelial cells. Nephrol.Dial.Transplant. 19 2445. PMID:15252165.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=85200	SQ1070			Jun-2007
2710	OGT 2115	[853929-59-6]	O=C(/C=C/C4=CC=C(Br)C=C4)NC(C(F)=C3)=CC=C3C2=NC1=CC(CC(O)=O)=CC=C1O2	Antiangiogenic. Heparanase inhibitor	Heparanase inhibitor (IC50 = 0.4 _M) that displays no major inhibition of human cytochrome P450 isoenzymes (IC50 > 30 _M). Exhibits antiangiogenic properties in vitro (IC50 = 1 _M).	"Courtney et al (2005) Furanyl-1,3-thiazol-2-yl and benzoxazol-5-yl acetic acid derivates: novel classes of heparanase inhibitor. Bioorg.Med.Chem.Letts. 15 2295. McKenzie (2007) Heparanase: a target for drug discovery in cancer and inflammation. Br.J.Pharmacol. 151 1. PMID:17339837."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=61604	SQ1070			Apr-2009
2718	LY 364947	[396129-53-6]	N1C=C(C(=N1)C1=CC=CC=N1)C1=CC=NC2=CC=CC=C12	Selective inhibitor of TGF-_RI	"Selective inhibitor of TGF-_ type-I receptor (TGF-_ RI, TGFR-I, T_R-I, ALK-5) (IC50 values are 59, 400 and 1400 nM for TGR-_ RI, TGF-_ RII and MLK-7K respectively). Inhibits TGF-_-dependent luciferase production in mink lung cells (p3TP lux) and growth in mouse fibroblasts (NIH 3T3) (IC50 values are 47 and 89 nM respectively). Suppresses invasion of MDA-MB-231 breast cancer cells in a matrigel invasion assay."	Sawyer et al (2003) Synthesis and activity of new aryl- and heteroaryl-substituted pyrazole inhibitors of the transforming growth factor-_ type I receptor kinase domain. J.Med.Chem. 46 3953. PMID:12954047. Li et al (2006) Dihydropyrrolopyrazole transforming growth factor-_ type I receptor kinase domain inhibitors: a novel benzimidazole series with selectivity versus transforming growth factor-_ type II receptor kinase and mixed lineage kinase 7. J.Med.Chem. 49 2138. PMID:16539403. Shiou et al (2006) Smad4-dependent regulation of urokinase plasminogen activator secretion and RNA stability associated with invasiveness by autocrine and paracrine transforming growth factor-_. J.Biol.Chem. 281 33971. PMID:16959768.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=80564				Jul-2007
2719	RWJ 21757	[121288-39-9]	O[C@@H]1[C@@H](CO)O[C@@H](N(C(N3CC=C)=O)C2=C3C(NC(N)=N2)=O)[C@@H]1O	Toll-like receptor 7 (TLR7) agonist	Toll-like receptor 7 (TLR7) agonist; induces immune cell activation and increases cytokine production. Displays antitumor and antiviral activity in various animal models.	"Goodman et al (1994) Loxoribine induces chronic lymphocytic leukemia B cells to traverse the cell cycle. Blood 84 3457. PMID:7949100. Heil et al (2003) The toll-like receptor 7 (TLR7)-specific stimulus loxoribine uncovers a strong relationship within the TLR7, 8 and 9 subfamily. Eur.J.Immunol. 33 2987. PMID:14579267. Lee et al (2003) Molecular basis for the immunostimulatory activity of guanine nucleoside analogs: activation of toll-like receptor 7. Proc.Natl.Acad.Sci.USA 100 6646."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=40256	SQ1533			Sep-2007
2724	SB 265610	[211096-49-0]	O=C(NC3=C(Br)C=CC=C3)NC1=CC=C(C#N)C2=C1NN=N2	Potent CXCR2 antagonist	Potent CXCR2 antagonist that inhibits CINC-1-mediated but not C5a-mediated Ca2+ mobilization (IC50 values are 3.4 and 6800 nM respectively). Inhibits CINC-induced chemotaxis and attenuates neutrophil accumulation in inflammatory lung injury in vivo.	Auten et al (2001) Nonpeptide CXCR2 antagonist prevents neutrophil accumulation in hyperoxia-exposed newborn rats. J.Pharmacol.Exp.Ther. 299 90. PMID:11561067. Milatovic et al (2003) Impaired healing of nitrogen mustard wounds in CXCR2 null mice. Wound Repair Regen. 11 213. PMID:12753603.	Small Molecule	Sold for research purposes under agreement from GlaxoSmithKline	http://www.tocris.com/dispprod.php?ItemId=175799	SQ1533			Oct-2007
2725	SB 225002	[182498-32-4]	OC1=CC(=CC=C1NC(=O)NC1=CC=CC=C1Br)[N+]([O-])=O	Potent and selective CXCR2 antagonist	Potent and selective CXCR2 chemokine receptor antagonist (IC50 = 22 nM) that displays > 150-fold selectivity over CXCR1 receptors. Causes inhibition of IL-8 and GRO_-mediated calcium mobilization in HL60 cells (IC50 values are 8 and 10 nM respectively). Prevents IL-8-induced neutrophil chemotaxis in vitro and sequestration in vivo. Inhibits HIV replication in lymphocytes and macrophages.	"White et al (1998) Identification of a potent, selective non-peptide CXCR2 antagonist that inhibits interleukin-8-induced neutrophil migration. J.Biol.Chem. 273 10095. PMID:9553055. Lane et al (2001) Interleukin-8 stimulates human immunodeficiency virus type 1 replication and is a potential new target for antiretroviral therapy. J.Virol. 75 8195. PMID:11483765. Catusse et al (2003) Characterization of the molecular interactions of interleukin-8 (CXCL8), growth related oncogen a (CXCL1) and a non-peptide antagonist (SB 225002) with the human CXCR2. Biochem.Pharmacol. 65 813. PMID:12628493."	Small Molecule	Sold for research purposes under agreement from GlaxoSmithKline	http://www.tocris.com/dispprod.php?ItemId=5420	SQ1341			Jul-2007
2726	SB 258719 hydrochloride	[1217674-10-6]	O=S(C1=CC(C)=CC=C1)(N(C)[C@H](C)CCN2CCC(C)CC2)=O.Cl	Selective 5-HT7 antagonist	Selective 5-HT7 receptor antagonist that displays > 100-fold selectivity over a range of other receptors. Reverses the hypothermic effect of 5-CT in mice following i.p. administration.	"Forbes et al (1998) (R)-3,N-dimethyl-N-[1-methyl-3-(4-methyl-piperidin-1-yl)propyl]benzenesulfonamide: the first selective 5-HT7 receptor antagonist. J.Med.Chem. 41 655. PMID:9513592. Thomas et al (1998) Functional characterisation of the human cloned 5-HT7 receptor (long form); antagonist profile of SB-258719. Br.J.Pharmacol. 124 1300. PMID:9720804. Guscott et al (2003) The hypothermic effect of 5-CT in mice is mediated through the 5-HT7receptor. Neuropharmacology 44 1031. PMID:12763096."	Small Molecule	Sold for research purposes under agreement from GlaxoSmithKline	http://www.tocris.com/dispprod.php?ItemId=5432	SQ1341			Dec-2007
2727	Zoniporide dihydrochloride	[241799-10-0]	O=C(/N=C(N)/N)C(C=N3)=C(C4CC4)N3C1=C2C(N=CC=C2)=CC=C1.Cl.Cl	Selective NHE1 inhibitor	"Sodium-hydrogen exchanger isoform 1 (NHE1) inhibitor that displays selectivity over other NHE isoforms (Ki values are 14, 2200 and 220000 nM for human NHE1, human NHE2 and rat NHE3 respectively). Inhibits NHE1 dependent 22Na+ uptake in vitro (IC50 = 14 nM) and provides cardioprotection from myocardial ischemic injury in vivo (EC50 = 0.25 nM)."	"Knight et al (2001) A novel sodium-hydrogen exchanger isoform-1 inhibitor, zoniporide, reduces ischemic myocardial injury in vitro and in vivo. J.Pharmacol.Exp.Ther. 297 254. PMID:11259552. Marala et al (2002) Zoniporide: a potent and highly selective inhibitor of human Na+/H+ exchanger-1. Eur.J.Pharmacol. 451 37. PMID:12223226. Clements-Jewery et al (2004) Cardioprotective efficacy of zoniporide, a potent and selective inhibitor of Na+/H+ exchanger isoform-1, in an experimental model of cardiopulmonary bypass. Br.J.Pharmacol. 142 57. PMID:15037516."	Small Molecule	Sold for research purposes under agreement from Pfizer Inc	http://www.tocris.com/dispprod.php?ItemId=76736	SQ1070			Nov-2007
2728	ACET	[936095-50-0]	O=C(C(C)=CN1C[C@@H](C(O)=O)N)N(CC2=C(C(O)=O)SC(C3=CC=CC=C3)=C2)C1=O	Potent antagonist of GluR5-containing kainate receptors	"Potent and selective GluR5-containing kainate receptor antagonist (IC50 = 7 nM) that displays selectivity over GluR6-containing kainate, NMDA, AMPA and group I mGlu receptors. Reversibly blocks induction of NMDA receptor-independent long term potentiation (LTP) in vitro at nanomolar concentrations."	Dolman et al (2007) Synthesis and pharmacological characterisation of N3-substituted willardiine derivatives: role of the substituent at the 5-position of the uracil ring in the development of highly potent and selective GLUK5 kainate receptor antagonists. J.Med.Chem. 50 1558. PMID:17348638. Dargan et al (2009) ACET is a highly potent and specific kainate receptor antagonist: Characterisation and effects on hippocampal mossy fibre function. Neuropharmacology 56 121. PMID:18789344.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=40541	SQ1341			Aug-2008
2729	CP 80633	[135637-46-6]	O=C(NC4)NCC4C1=CC(O[C@H]2C[C@@H]3CC[C@H]2C3)=C(OC)C=C1	Selective PDE4 inhibitor	"Selective inhibitor of phosphodiesterase type 4 (IC50 values are 1.9, > 100, > 100, > 100 and > 100 _M for human lung PDE4, lung PDE1, lung PDE2, heart PDE3 and platelet PDE-V respectively) that displays no significant PDE4 isozyme selectivity. Inhibits hydrolysis of cAMP in isolated human peripheral blood monocytes, eosinophils and T cells.  Displays anti-inflammatory and bronchodilatory effects in vivo."	"Turner et al (1996) The in vivo pharmacology of CP-80,633, a selective inhibitor of phosphodiesterase 4. J.Pharmacol.Exp.Ther. 278 1349. PMID:8819522. Cohan et al (1996) In vitro pharmacology of the novel phosphodiesterase type 4 inhibitor, CP-80633. J.Pharmacol.Exp.Ther. 278 1356. PMID:8819523. Cheng et al (1997) The phosphodiesterase type 4 (PDE4) inhibitor CP-80,633 elevates plasma cyclic AMP levels and decreases tumor necrosis factor-_ (TNF_) production in mice: effect of adrenalectomy. J.Pharmacol.Exp.Ther. 280 621. PMID:9023272."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=5341	SQ1070			Jun-2008
2730	AG 045572	[263847-55-8]	CC(CCC(C)2C)(C)C1=C2C=C(C)C(CC3=CC=C(C(NC4=C(OC)C=C(OC)C=C4OC)=O)O3)=C1	Selective GnRH receptor antagonist	"Selective gonadotropin-releasing hormone (GnRH) receptor antagonist (Ki values are 2.2, 3.8 and 6.0 nM for mouse, rat and human receptors respectively). Suppresses testosterone and luteinising hormone (LH) levels in vivo."	"Iatsimirskaia et al (2002) Effect of testosterone suppression on the pharmacokinetics of a potent GnRH receptor antagonist. Pharm.Res. 19 202. PMID:11883648. Anderes et al (2003) Biological characterization of a novel, orally active small molecule gonadotropin-releasing hormone (GnRH) antagonist using castrated and intact rats. J.Pharmacol.Exp.Ther. 305 688. PMID:12606616."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=5284	SQ1341			Oct-2007
2731	CGP 57380	[522629-08-9]	NC1=C2C(NC3=CC=C(F)C=C3)=NNC2=NC=N1	Selective inhibitor of Mnk1	"Inhibitor of MAP-kinase interacting kinase-1 (Mnk1, MKNK1) (IC50 = 2.2 _M) that displays selectivity over p38, JNK1, ERK1, ERK2, PKC and c-src family kinases. Blocks phosphorylation of eIF4E in cellular assays (IC50 = 3 _M) and inhibits LPS-induced TNF_ expression in macrophages."	Knauf et al (2001) Negative regulation of protein translation by mitogen-activated protein kinase-interacting kinases 1 and 2. Mol.Cell.Biol. 21 5500. PMID:11463832. Ishida et al (2003) Mnk1 is required for angiotensin II-induced protein synthesis in vascular smooth muscle cells. Circ.Res. 93 1218. PMID:14605021. Andersson and Sundler (2006) Posttranscriptional regulation of TNF_ expression via eukaryotic initiation factor 4E (eIF4E) phosphorylation in mouse macrophages. Cytokine 33 52. PMID:16431125.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=40542	SQ1341			Jul-2007
2732	BAY-u 3405	[116649-85-5]	FC(C=C4)=CC=C4S(N[C@@H](C3)CCC2=C3C1=CC=CC=C1N2CCC(O)=O)(=O)=O	Dual TP/DP2 (CRTH2) receptor antagonist	"Potent dual antagonist of TP/DP2 (CRTH2) prostanoid receptors (Ki values are 4.3, 4.5 and > 10000 nM for hDP2, hTP and hDP1 receptors respectively). Suppresses PGD2-induced migration of human eosinophils (IC50 = 170 nM)."	"Sundstrom et al (2003) Interactions among three classes of mediators explain antigen-induced bronchoconstriction in the isolated perfused and ventilated guinea pig lung. J.Pharmacol.Exp.Ther. 307 408. PMID:12954791. Ishizuka et al (2004) Ramatroban (BAY u3405): a novel dual antagonist of TXA2 receptor and CRTh2, a newly identified prostaglandin D2 receptor. Cardiovasc.Drug Rev. 22 71. PMID:15179446. Ulven and Kostenis (2005) Minor structural modifications convert the dual TP/CRTH2 antagonist ramatroban into a highly selective and potent CRTH2 antagonist. J.Med.Chem. 48 897. PMID:15715457."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=40538	SQ1533			Oct-2008
2733	U 90042	[134516-99-7]	ClC1=CC=C4C(C2=NCCN2C(N4C=N5)=C5C3=NOC(C6CC6)=N3)=C1	GABAA receptor ligand	"GABAA receptor ligand that binds with comparable affinities to three receptor subtypes: _1_2_2, _3_2_2 and _6_2_2 (Ki values are 7.8, 9.5 and 11.0 nM respectively). Potentiates GABA-induced chloride currents in _6_2_2 receptors. Sedative/hypnotic compound."	"Tang et al (1995) U-90042, a sedative/hypnotic compound that interacts differentially with the GABAA receptor subtypes. J.Pharmacol.Exp.Ther. 275 761. PMID:7473164."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=5489	SQ1341			Jun-2008
2734	U 89843A	[157013-85-9]	CC2=CC1=C(N3CCCC3)N=C(N4CCCC4)N=C1N2C.Cl	Positive allosteric modulator of GABAA receptors	"Positive allosteric modulator of GABAA receptors. Enhances GABA-induced Cl- currents in the _1_2_2, _3_2_2 and _6_2_2 subtypes. Causes sedation in vivo following i.v. administration without losing ""righting reflex"". Also displays antioxidant activity."	"Bundy et al (1995) Synthesis of novel 2,4-diaminopyrrolo-[2,3-d]pyrimidines with antioxidant, neuroprotective, and antiasthma activity. J.Med.Chem. 38 4161. PMID:7473542. Haesook et al (1995) U-89843A is a novel allosteric modulator of _-aminobutyric acidA receptors. J.Pharmacol.Exp.Ther. 275 1390. PMID:8531107. Rohn et al (1996) Inhibition of Ca2+-pump ATPase and the Na+/K+-pump ATPase by iron-generated free radicals. Biochem.Pharmacol. 51 471. PMID:8619892."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=5462	SQ1341			Jan-2008
2735	PNU 96415E	[170856-41-4]	FC(C=C4)=CC=C4N(CC3)CCN3CCC2C1=CC=CC=C1CCO2.Cl.Cl	D4 and 5-HT2A antagonist; antipsychotic	"Antipsychotic agent. Displays high affinity for dopamine D4 and serotonergic 5-HT2A receptors and relatively weak affinity at D2 receptors (Ki values are 3.0, 5.8, 134, 181, 199, 240, 411 and > 678 nM for D4, 5-HT2A, 5-HT1A, _1, D2, D3, D1, _2 and muscarinic receptors respectively). Inhibits exploratory locomotor activity and antagonizes d-amphetamine-induced locomotor stimulation in rats."	"Tang et al (1997) PNU-96415E, a potential antipsychotic agent with clozapine-like pharmacological properties. J.Pharmacol.Exp.Ther. 281 440. PMID:9103528. Goudie et al (1998) Discriminative stimulus properties of the atypical neuroleptic clozapine in rats: tests with subtype selective receptor ligands. Behav.Pharmacol. 9 699. PMID:9890260."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=5356	SQ1341			Oct-2007
2736	Sazetidine A dihydrochloride	[1197329-42-2]	OCCCCC#CC1=CN=CC(OC[C@H]2NCC2)=C1.Cl.Cl	_4_2 receptor ligand; may act as an agonist or a desensitizer	"Subtype-selective _4_2 nicotinic acetylcholine receptor ligand (Ki values are 0.26 and 54 nM at _4_2 and _3_4 receptors respectively). May act as a silent desensitizer or as an agonist, depending on subunit stoichiometry (EC50 = 1.1 nM for nAChR-stimulated dopamine release). Exhibits analgesic activity in vivo and significantly reduces nicotine self-administration in an experimental rat model."	"Xiao et al (2006) Sazetidine-A, a novel ligand that desensitizes _4_2 nicotinic acetylcholine receptors without activating them. Mol.Pharmacol. 70 1454. PMID:16857741. Cucchiaro et al (2008) Analgesic effects of Sazetidine-A, a new nicotinic cholinergic drug. Anesthesiology 109 512. PMID:18719450. Zwart et al (2008) Sazetidine-A is a potent and selective agonist at native recombinant _4_2 nicotinic acetylcholine receptors. Mol.Pharmacol. 73 1843. Levin et al (2010) Sazetidine-A, a selective _4_2 nicotinic receptor desensitizing agent and partial agonist, reduces nicotine self-administration in rats. J.Pharmacol.Exp.Ther. 332 933. PMID:20007754."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=5259	SQ1341			Feb-2008
2737	TC 2559 difumarate	[212332-35-9]	CCOC1=CN=CC(/C=C/CCNC)=C1.O=C(O)/C=C/C(O)=O.O=C(O)/C=C/C(O)=O	Selective partial agonist at _4_2 receptors	"Subtype-selective partial agonist for _4_2 nicotinic acetylcholine receptors (EC50 values are 0.18, 12.5, 14.0, > 30, > 100 and > 100 _M for _4_2, _4_4, _2_4, _3_4, _3_2 and _7 receptor subtypes respectively). Displays selectivity for (_4)2(_2)3 receptor stoichiometry and enhanced CNS-PNS selectivity ratio. Attenuates scopolamine-induced cognitive deficits in a step-through passive avoidance task."	"Bencherif et al (2000) TC-2559: a novel orally active ligand selective at neuronal acetylcholine receptors. Eur.J.Pharmacol. 409 45. PMID:11099699. Chen et al (2003) The nicotinic _4_2 receptor selective agonist, TC-2559, increases dopamine neuronal activity in the ventral tegmental area of rat midbrain slices. Neuropharmacology 45 334. PMID:12871651. Zwart et al (2006) 5-I A-85380 and TC-2559 differentially activate heterologously expressed _4_2 nicotinic receptors. Eur.J.Pharmacol. 539 10. PMID:16674940."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=5260				Sep-2007
2738	Org 20599	[156685-94-8]	O=[C@](CCl)[C@H]4CC[C@@]3([H])[C@]2([H])CC[C@@]1([H])C[C@H](O)[C@@H](N5CCOCC5)C[C@@](C)1[C@]([H])2CC[C@@]34C	Positive allosteric modulator and direct agonist of GABAA receptors	Positive allosteric modulator and at higher concentrations direct agonist of GABAA receptors (EC50 = 1.1 _M). Also displays positive modulation of glycine receptors (EC50 = 22.9 _M). Anesthetic steroid; induces hypnosis and loss of righting reflexes in mice.	Hill-Venning et al (1996) The anaesthetic action and modulaton of GABAA receptor activity by the novel water-soluble aminosteroid Org 20599. Neuropharmacology 35 1209. PMID:9014136. Visser et al (2002) Neuroactive steroids differ in potency but not in intrinsic efficacy at the GABAA receptor in vivo. J.Pharmacol.Exp.Ther. 303 616. PMID:12388643. Weir et al (2004) The interaction of anaesthetic steroids with recombinant glycine and GABAA receptors. Br.J.Anaesth. 92 704. PMID:15033889.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=5261	SQ1341			Mar-2008
2742	Reserpine	[50-55-5]	[H][C@@](N4CC3)(C[C@@]([C@H]([C@@](OC)=O)[C@@H](OC)[C@H](OC(C6=CC(OC)=C(OC)C(OC)=C6)=O)C5)([H])[C@@]5([H])C4)C2=C3C1=C(N2)C=C(OC)C=C1	Inhibitor of vesicular monoamine transport	Binds the vesicular monoamine transporter (VMAT2) and inhibits transport of biogenic amines into adrenal chromaffin granules and synaptic vesicles. Causes depletion of biogenic amine stores. Antihypertensive and antipsychotic.	"Schuldiner et al (1993) Reserpine binding to a vesicular amine transporter expressed in chinese hamster ovary fibroblasts. J.Biol.Chem. 268 29. PMID:8416935. Heslop and Curzon (1999) Effect of reserpine on behavioural responses to agonists at 5-HT1A, 5-HT1B, 5-HT2A, and 5-HT2C receptor subtypes. Neuropharmacology 38 883. PMID:10465692. Metzger et al (2002) Inhibitory effect of reserpine on dopamine transporter function. Eur.J.Pharmacol. 456 39. PMID:12450567."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=66533	SQ1533			Jul-2007
2743	Caffeic acid phenethyl ester	[104594-70-9]	OC1=C(O)C=C(/C=C/C(OCCC2=CC=CC=C2)=O)C=C1	Specific inhibitor of NF-_B activation	"Antioxidant, antimitogenic, anticarcinogenic, anti-inflammatory and antiviral. Specifically inhibits NF-_B activation and inhibits the growth of transformed cells. Also suppresses lipid peroxidation and inhibits ornithine decarboxylase, protein tyrosine kinase and lipoxygenase activities."	"Sud'ina et al (1993) Caffeic acid phenethyl ester as a lipoxygenase inhibitor with antioxidant properties. FEBS Lett. 329 21. PMID:7689063. Natarajan et al (1996) Caffeic acid phenethyl ester is a potent and specific inhibitor of activation of nuclear transcription factor NF-_B. Proc.Natl.Acad.Sci.USA 93 9090. Fitzpatrick et al (2001) Caffeic acid phenethyl ester, an inhibitor of nuclear factor-_B, attenuates bacterial peptidoglycan polysaccharide-induced colitis in rats. J.Pharmacol.Exp.Ther. 299 915. PMID:11714876."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=5362				Jul-2007
2745	U 93631	[152273-12-6]	CC(C)(C)OC(=O)C1=C2N(C=N1)C1=CC=CC=C1NC2(C)C	GABAA receptor antagonist	GABAA receptor antagonist that binds the picrotoxin site and stabilizes the inactive form of the channel via allosteric interaction. Accelerates the decay of GABA-induced Cl- currents with little effect on peak amplitude. Also inhibits 5-HT3A receptors via a similar mechanism.	"Dillon et al (1993) U-93631 causes rapid decay of _-aminobutyric acid-induced chloride currents in recombinant rat _-aminobutyric acid type A receptors. Mol.Pharmacol. 44 860. PMID:8232235. Dillon et al (1995) [4-Dimethyl-3-t-butylcarboxyl-4,5-dihydro (1,5-a) quinoxaline] is a novel ligand to the picrotoxin site on GABAA receptors, and decreases single-channel open probability. J.Pharmacol.Exp.Ther. 272 597. PMID:7531762. Das et al (2003) The GABAA receptor antagonist picrotoxin inhibits 5-hydroxytryptamine type 3A receptors. Neuropharmacology 44 431. PMID:12646280."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=5347	SQ1341			Oct-2007
2746	Amperozide hydrochloride	[86725-37-3]	FC1=CC=C(C(C3=CC=C(F)C=C3)CCCN2CCN(C(NCC)=O)CC2)C=C1.Cl	Atypical antipsychotic; high affinity 5-HT2 ligand	Atypical antipsychotic that displays high affinity for 5-HT2 receptors (Ki = 26 nM) and low affinity for D2 receptors. Supresses ethanol drinking in genetically ethanol-preferring rats.	"Haskins et al (1987) Biochemical and electrophysical studies of the psychotropic compound, amperozide. Brain Res.Bull. 19 465. PMID:2825928. Meltzer et al (1992) Effect of amperozide on rat cortical 5-HT2 and striatal and limbic dopamine D2 receptor occupancy: implications for antipsychotic action. Eur.J.Pharmacol. 216 67. PMID:1388121. Myers et al (1993) 5-HT2 receptor blockade by amperozide suppresses ethanol drinking in genetically preferring rats. Pharmacol.Biochem.Behav. 45 741. PMID:8332634."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=5297	SQ1533			Oct-2007
2747	NNC 05-2090 hydrochloride	[184845-18-9]	Cl.COC1=C(C=CC=C1)C1(O)CCN(CCCN2C3=C(C=CC=C3)C3=C2C=CC=C3)CC1	GABA uptake inhibitor; moderately BGT-1 selective	"GABA uptake inhibitor that displays moderate selectivity for BGT-1 (mGAT-2) transporters (Ki values are 1.4, 15, 19 and 41 _M for hBGT-1, hGAT-3, hGAT-1 and hGAT-2 respectively). Anticonvulsive; inhibits sound-induced tonic and clonic convulsions in DBA/2 mice. Also displays affinity at _1- and D2-receptors (IC50 values are 266 and 1632 nM respectively)."	"Thomsen et al (1997) 1-(3-(9H-carbazol-9-yl)-1-propyl)-4-(2-methoxyphenyl)-4-piperidinol, a novel subtype selective inhibitor of the mouse type II GABA-transporter. Br.J.Pharmacol. 120 983. PMID:9134205. Dalby et al (1997) Anticonvulsive properties of two GABA uptake inhibitors NNC 05-2045 and NNC 05-2090, not acting preferentially on GAT-1. Epilepsy Res. 28 51. PMID:9255599."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=5268	SQ1341			Sep-2007
2748	KF 38789	[257292-29-8]	COC1=CC=C(C2CC(=NCCS2)C2=C(O)C=C(C)OC2=O)C(OC)=C1	Selective inhibitor of P-selectin-mediated cell adhesion	Selective inhibitor of P-selectin-mediated cell adhesion (IC50 = 1.97 _M) that displays no effects on L-selectin- and E-selectin-mediated adhesion. Blocks P-selectin-mediated binding in vitro and leukocyte accumulation in vivo.	"Haggerty et al (2000) Dissecting cellular processes using small molecules: identification of colchicine-like, taxol-like and other small moleculaes that perturb mitosis. Chem.Biol. 7 275. PMID:10780927. Ohta et al (2001) Inhibition of P-selectin specific cell adhesion by a low molecular weight, non-carbohydrate compound, KF38779. Inflamm.Res. 50 544. PMID:11766994. Kaila et al (2007) Synthesis and biological evaluation of quinoline salicylic acids as P-selectin antagonists. J.Med.Chem. 50 21. PMID:17201408."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=52750	SQ1341			Jul-2007
2749	Dexmedetomidine hydrochloride	[145108-58-3]	C[C@H](C2=CN=CN2)C1=C(C)C(C)=CC=C1.Cl	"Potent, highly selective _2 agonist. Active isomer of medetomidine (Cat. No. 2023)"	"Active isomer of medetomidine (Cat.No. 5160), a potent, highly selective _2-adrenoceptor agonist (Ki values are 1.08 and 1750 nM for _2- and _1-adrenoceptors respectively). Displays greater selectivity over _1-adrenoceptors than clonidine and UK 14,304 (1620-, 220- and 300-fold respectively). Active in vivo; displays hypotensive, bradycardic, sedative, anxiolytic, hypothermic and analgesic effects."	"Virtanen et al (1988) Characterization of the selectivity, specificity and potency of medetomidine as an _2-adrenoceptor agonist. Eur.J.Pharmacol. 150 9. PMID:2900154. Scheinin et al (1989) Medetomidine - a novel _2-adrenoceptor agonist: a review of its pharmacodynamic effects. Prog.Neuro-Psychopharm.Biol.Psychiat. 13 635. Fisher et al (1991) Antinociceptive properties of intrathecal dexmedetomidine in rats. Eur.J.Pharmacol. 192 221. PMID:1674472."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=44138	SQ1070			May-2008
2752	MRS 1754	[264622-58-4]	CCCN1C2=C(NC(=N2)C2=CC=C(OCC(=O)NC3=CC=C(C=C3)C#N)C=C2)C(=O)N(CCC)C1=O	Selective A2B antagonist	"Selective adenosine A2B receptor antagonist (Ki values are 1.97, 16.8, 403, 503, 570 and 612 nM for hA2B, rA1, hA1, hA2A, hA3 and rA2A receptors respectively)."	"Kim et al (2000) Anilide derivatives of an 8-phenylxanthine carboxylic congener are highly potent and selective antagonists at human A2B adenosine receptors. J.Med.Chem. 43 1165. PMID:10737749. Ji et al (2001) [3H]MRS 1754, a selective antagonist radioligand for A2B adenosine receptors. Biochem.Pharmacol. 61 657. PMID:11266650. Nemeth et al (2007) Adenosine receptor activation ameliorates type I diabetes. FASEB J. 21 2380."	Small Molecule	Sold with the permission of the University of Virginia Patent Foundation	http://www.tocris.com/dispprod.php?ItemId=5392	SQ1341			Sep-2007
2753	A 350619 hydrochloride	[1217201-17-6]	O=C(NCCCCN(C)C)/C=C/C1=C(SC2=CC=C(Cl)C=C2)C=CC=C1.Cl	Soluble guanylyl cyclase (sGC) activator	Activator of soluble guanylyl cyclase (sGC). Activates basal sGC and synergistically activates sGC in the presence of NO. Relaxes cavernosum smooth muscle in vitro and induces penile erections in rats. Induces a sustained increase in skin blood flow in vivo.	Miller et al (2003) A-350619: a novel activator of soluble guanylyl cyclase. Life Sci. 72 1015. PMID:12495780. Evgenov et al (2006) NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential. Nat.Rev.Drug Discov. 5 755. PMID:16955067. Kotzki et al (2013) Anodal iontophoresis of a soluble guanylate cyclase stimulator induces a sustained increase in skin blood flow in rats. J.Pharmacol.Exp.Ther. 346 424. PMID:23838678.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=59518				Nov-2007
2754	TCS 401	[243966-09-8]	O=C(C(O)=O)NC2=C(C(O)=O)C1=C(S2)CNCC1.Cl	Selective inhibitor of PTP1B	"Selective inhibitor of protein-tyrosine phosphatase 1B (PTP1B) (Ki values are 0.29, 59, 560, 1100, > 2000, > 2000 and > 2000 _M for PTP1B, CD45 D1D2, PTP_, PTP_ D1, SHP-1, PTP_ D1 and LAR D1D2 respectively)."	"Iversen et al (2000) Structure-based design of a low molecular weight, nonphosphorus, nonpeptide, and highly selective inhibitor of protein-tyrosine phosphatase 1B. J.Biol.Chem. 275 10300. PMID:10744717. Andersen et al (2002) Discovery and SAR of a novel selective and orally bioavailable nonpeptide classical competitive inhibitor class of protein-tyrosine phosphatase 1B. J.Med.Chem. 45 4443. PMID:12238924."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=5272	SQ1341			Oct-2007
2755	DCA	[2156-56-1]	[Na+].[O-]C(=O)C(Cl)Cl	Mitochondrial pyruvate dehydrogenase kinase (PDK) inhibitor	Inhibitor of mitochondrial pyruvate dehydrogenase kinase (PDK). Shifts pyruvate metabolism from glycolysis and lactate production to glucose oxidation in the mitochondria. Induces mitochondrial-dependent apoptosis and reverses the inhibition/downregulation of KV1.5 channels in cancer but not normal cells. Decreases tumor growth in vitro and in vivo.	Stacpoole (1989) The pharmacology of dichloroacetate. Metabolism Clin.Exp. 38 1124. Bowker-kinley et al (1998) Evidence for existence of tissue-specific regulation of the mammalian pyruvate dehydrogenase complex. Biochem.J. 329 191. PMID:9405293. Bonnet et al (2007) A mitochondria-K+ channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth. Cancer Cell 11 37. PMID:17222789.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=5275	SQ1533			Jul-2007
2757	UCB 35625		ClC1=CC=C(OC(C=CC(Cl)=C3)=C3C2C(N[C@H]4CC[N@@+](C/C5=C/CCCCCC5)(CC)CC4)=O)C2=C1.ClC6=CC=C(OC(C=CC(Cl)=C8)=C8C7C(N[C@@H]9CC[N@+](C/C%10=C/CCCCCC%10)(CC)CC9)=O)C7=C6.[I-].[I-]	Potent CCR1 and CCR3 antagonist	Potent chemokine CCR1 and CCR3 receptor antagonist. Inhibits MIP-1_-induced chemotaxis in CCR1 transfectants and eotaxin-induced chemotaxis in CCR3 transfectants (IC50 values are 9.57 and 93.8 nM respectively). Antagonizes CCR3-mediated entry of HIV-1 isolate 89.6 into NP-2 cells (IC50 = 57 nM). Isomer of J 113863 (Cat. No. 2595).	"Sabroe et al (2000) A small molecule antagonist of chemokine receptors CCR1 and CCR3. J.Biol.Chem. 275 25985. PMID:10854442. Lopes de Mendonca et al (2005) Site-directed mutagenesis of CC chemokine receptor 1 reveals the mechanism of action of UCB 35625, a small molecule chemokine receptor antagonist. J.Biol.Chem. 280 4808. PMID:15548526."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=78399	SQ1341			Oct-2007
2758	B-HT 933 dihydrochloride	[36067-72-8]	CCN1CCC(OC(N)=N2)=C2CC1.Cl.Cl	Selective _2 agonist	Selective _2-adrenoceptor agonist. Exhibits greater than 300-fold selectivity for the _2-adrenoceptor over the _1-adrenoceptor.	"Kobinger and Pichler (1977) Pharmacological characterization of B-HT 933 (2-amino-6-ethyl-4,5,7,8-tetrahydro-6H-oxazolo-[5,4-d]-azepindihydrochloride) as a hypotensive agent of the ""clonidine-type"". Naunyn-Schmied.Arch.Pharmacol. 300 39. Bill et al (1989) The thermogenic actions of _2-adrenoceptor agonists in reserpinized mice are mediated via a central postsynaptic _2-adrenoceptor mechanism. Br.J.Pharmacol. 96 133. PMID:2564288. Parkinson and Hughes (1995) The mechanism of action of _2-adrenoceptors in human isolated subcutaneous resistance arteries. Br.J.Pharmacol. 115 1463. PMID:8564206."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=5464	SQ1533			Feb-2011
2759	B-HT 920	[36085-73-1]	Cl.Cl.NC1=NC2=C(CCN(CC=C)CC2)S1	D2 receptor agonist. Also _2 agonist and 5-HT3 antagonist	"Dopamine D2 receptor agonist, _2-adrenoceptor agonist and 5-HT3 receptor antagonist. Displays antiParkinsonian activity."	"Robertson et al (1993) In vivo comparisons of the effects of quinpirole and the putative presynaptic dopaminergic agonists B-HT 920 and SND 919 on striatal dopamine and acetylcholine release. J.Pharmacol.Exp.Ther. 264 1344. PMID:8095550. Nishio et al (1996) 5-HT3 receptor blocking properties of the antiParkinsonian agent, talipexole. Gen.Pharmacol. 27 779. PMID:8842679. Ricci and Taira (1999) Adrenoceptor involvement in the cardiovascular responses to B-HT 920 in sinoaortic denervated rats. Gen.Pharmacol. 32 29. PMID:9888250. Maina and Mathews (2010) A functional fast scan cyclic voltammetry assay to characterize dopamine D2 and D3 autoreceptors in the mouse striatum. ACS Chem.Neurosci. 1 450. PMID:20567609."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=5360	SQ1533			Aug-2007
2760	"L-748,337"	[244192-94-7]	O[C@H](COC2=CC=CC(CNC(C)=O)=C2)CNCCC1=CC=C(NS(=O)(C3=CC=CC=C3)=O)C=C1	Selective _3 antagonist	"Competitive _3-adrenoceptor antagonist that displays selectivity over _1 and _2 receptors (Ki values are 4.0, 204 and 390 nM for _3-, _2- and _1-adrenoceptors respectively). Inhibits cAMP accumulation in response to isoproterenol (IC50 = 6 nM). Reduces iNOS expression, attenuates nitric oxide-induced cell proliferation and induces apoptosis in a melanoma cell line."	Candelore et al (1999) Potent and selective human _3-adrenergic receptor antagonist. J.Pharmacol.Exp.Ther. 290 649. PMID:10411574. Neidhold et al (2007) The function of _- and _-adrenoceptors of the saphenous artery in caveolin-1 knockout and wild-type mice. Br.J.Pharmacol. 150 261. PMID:17179950. Dal Monte et al (2014) _3-adrenergic receptor activity modulates melanoma cell proliferation and survival through nitric oxide signaling. Naunyn Schmiedebergs Arch.Pharmacol. 387 533. PMID:24599317.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=5468	SQ1341			May-2008
2761	DFMO	[68278-23-9]	NC(C(F)F)(C(O)=O)CCCN.Cl	Ornithine decarboxylase inhibitor	"Irreversible inhibitor of ornithine decarboxylase (ODC) that inhibits polyamine biosynthesis. Displays antiapoptotic, antiangiogenic and antiparasitic activity. Induces re-expression of aberrantly silenced tumor suppressor genes when used in combination with oligoamine analogs."	"Carrillo et al (2000) Sensitivity of Trypanosomatid protozoa to DFMO and metabolic turnover of ornithine decarboxylase. Biochem.Biophys.Res.Comm. 279 663. Raul (2007) Revival of 2-(difluoromethyl)ornithine (DFMO), an inhibitor of polyamine biosynthesis, as a cancer chemopreventative agent. Biochem.Soc.Trans. 35 353. PMID:17371277. Wu et al (2012) Oligoamine analogues in combination with 2-difluoromethylornithine synergistically induce re-expression of aberrantly silenced tumour-suppressor genes. Biochem.J. 442 693. PMID:22132744."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=5363	SQ1533			Oct-2007
2764	GP 1a	[511532-96-0]	CC1=CC2=C(C=C1)C1=C(C2)C(=NN1C1=CC=C(Cl)C=C1Cl)C(=O)NN1CCCCC1	Highly selective CB2 agonist	Highly selective CB2 receptor agonist; Ki values are 0.037 and 363 nM for CB2 and CB1 receptors respectively. Increases P-ERK1/2 expression in HL-60 cells in vitro.	"Murineddu et al (2006) Tricyclic pyrazoles. 4. Synthesis and biological evaluation of analogues of the robust and selective CB2 cannabinoid ligand 1-(2',4'-dichlorophenyl)-6-methyl-N-piperidin-1-yl-1,4-dihydroindeno[1,2-c]pyrazole-3-carboxamide. J.Med.Chem. 49 7502. PMID:17149879. Tschop et al (2009) The cannabinoid receptor 2 is critical for the host response to sepsis. J.Immunol. 183 499. PMID:19525393."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=5469	SQ1341			Aug-2007
2766	Naspm trihydrochloride	[1049731-36-3]	O=C(NCCCNCCCCNCCCN)CC2=CC=CC1=CC=CC=C12.Cl.Cl.Cl	Ca2+-permeable AMPA receptor antagonist	Selective antagonist of Ca2+-permeable AMPA receptors; blocks AMPA receptors lacking the GluR2 subunit. Protects hippocampal neurons against global ischemia-induced cell death.	"Tsubokawa et al (1995) Effects of spider toxin and its analogue on glutamate-activated currents in the hippocampal CA1 neuron after ischaemia. J.Neurophysiol. 74 218. PMID:7472325. Koike et al (1997) Blocking effect of 1-naphthyl acetyl spermine on Ca2+-permeable AMPA receptors in cultured rat hippocampal neurons. Neurosci.Res. 29 27. PMID:9293490. Noh et al (2005) Blockade of calcium-permeable AMPA receptors protects hippocampal neurons against global ischemia-induced death. Proc.Natl.Acad.Sci.USA 102 12230. Nilsen and England (2007) A subtype-selective, use-dependent inhibitor of native AMPA receptors. J.Am.Chem.Soc. 129 4902. PMID:17391037."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=5274				Oct-2010
2767	"L-365,260"	[118101-09-0]	O=C1[C@H](NC(NC4=CC=CC(C)=C4)=O)N=C(C3=CC=CC=C3)C2=C(C=CC=C2)N1C	Selective CCK2 antagonist	"Selective cholecystokinin receptor 2 (CCK2) antagonist (IC50 values are 2 and 280 nM at CCK2 and CCK1 receptors respectively) that is inactive at a range of other receptors including opiate, muscarinic acetylcholine, _- and _ adrenergic, histamine, angiotensin and bradykinin receptors."	"Kees et al (1989) Benzodiazepine gastrin and brain cholecystokinin receptor ligands: L-365,260. J.Med.Chem. 32 13. PMID:2909725. Lotti and Chang (1989) A new potent and selective non-peptide gastrin antagonist and brain cholecystokinin receptor (CCK-B) ligand: L-365,260. Eur.J.Pharmacol. 162 273. PMID:2721567. Chung et al (2009) Cholecystokinin action on layer 6b neurons in somatosensory cortex. Brain Res. 1282 10. PMID:19497313."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=5276	SQ1070			Nov-2009
2768	PQ 401	[196868-63-0]	O=C(NC3=C(OC)C=CC(Cl)=C3)NC2=CC(C)=NC1=CC=CC=C12	IGF1R inhibitor	Insulin-like growth factor receptor (IGF1R) inhibitor. Suppresses IGF-stimulated IGF-IR autophosphorylation with an IC50 value of 12 _M. Inhibits growth of MCF-7 breast cancer cells in vitro and in vivo.	Anderson et al (2006) Parallel synthesis of diarylureas and their evaluation as inhibitors of insulin-like growth factor receptor. J.Comb.Chem. 8 784. PMID:16961415. Gable et al (2006) Diarylureas are small-molecule inhibitors of insulin-like growth factor I receptor signaling and breast cancer cell growth. Mol.Cancer 5 1079. Sivakumar et al (2009) Autocrine loop for IGF-I receptor signaling in SLUG-mediated epithelial-mesenchymal transition. 34 329. PMID:19148466.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=83713	SQ1070			Nov-2007
2769	BX 513 hydrochloride	[1216540-18-9]	ClC1=CC=C(C2(O)CCN(CCCC(C4=CC=CC=C4)(C#N)C3=CC=CC=C3)CC2)C=C1.Cl	Selective CCR1 antagonist	"Selective CCR1 receptor antagonist (Ki values are 0.04, > 10, > 10 and > 10 nM for CCR1, CCR5, CXCR2 and CXCR4 receptors respectively). Inhibits MIP-1_-induced intracellular calcium mobilization (IC50 = 2.5 _M). Also a full inverse agonist at US28, a  HCMV-encoded chemokine receptor."	Hesselgesser et al (1998) Identification and characterisation of small molecule functional antagonists of the CCR1 chemokine receptor. J.Biol.Chem. 273 15687. PMID:9624164. Ng et al (1999) Discovery of a novel non-peptide CCR1 receptor antagonists. J.Med.Chem. 42 4680. PMID:10579830. Casarosa et al (2003) Identification of the first nonpeptidergic inverse agonist for a constitutively active viral-encoded G-protein-coupled receptor. J.Biol.Chem. 278 5172. PMID:12456673.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=5277	SQ1341			Nov-2007
2770	Philanthotoxin 74	[1227301-51-0]	OC1=CC=C(C[C@H](NC(CCC)=O)C(NCCCCCCCNCCCCN)=O)C=C1.Cl.Cl	GluR1 and GluR3 AMPA receptor antagonist	AMPA receptor antagonist. Non-selective homomeric GluR3 and GluR1 receptor antagonist (IC50 values are 263 and 296 nM respectively). Inhibits homomeric GluR3 and GluR1 with a 100-fold greater potency than heteromeric GluR1/2 and GluR2/3 receptors.	"Nilsen and England (2007) A subtype-selective, use-dependent inhibitor of native AMPA receptors. J.Am.Chem.Soc. 129 4902. PMID:17391037. Poulsen et al (2013) Evaluation of PhTX-74 as subtype-selective inhibitor of GluA2-containing AMPA receptors. Mol.Pharmacol. 85 261. PMID:24220009."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=5278	SQ1341			Nov-2007
2771	M 344	[251456-60-7]	O=C(NCCCCCCC(NO)=O)C1=CC=C(N(C)C)C=C1	Histone deacetylase inhibitor	Histone deacetylase inhibitor (IC50 = 100 nM). Induces terminal cell differentiation and causes an increase in hyperacetylated histone H4. Antiproliferative agent; suppresses the growth of human endometrial and ovarian cancer cells by inducing cell cycle arrest and apoptosis.	"Jung et al (1999) Amide analogues of trichostatin A as inhibitors of histone deacetylase and inducers of terminal cell differentiation. J.Med.Chem. 42 4669. PMID:10579829. Takai et al (2006) M344 is a novel synthesized histone deacetylase inhibitor that induces growth inhibition, cell cycle arrest, and apoptosis in human endometrial cancer and ovarian cancer cells. Gynecol.Oncol. 101 108. PMID:16263156. Riessland et al (2006) The benzamide M344, a novel histone deacetylase inhibitor, significantly increases SMN2 RNA/protein levels in spinal muscular atrophy cells. Hum.Genet. 120 101. PMID:16724231."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=5282	SQ1533			Oct-2007
2773	Sumanirole maleate	[179386-44-8]	O=C3N2C1=C(N3)C=CC=C1C[C@@H](NC)C2.O=C(/C=C\C(O)=O)O	D2-selective agonist	"High affinity D2 receptor agonist (EC50 values are between 17 and 75 nM in cell-based assays). Displays >200-fold selectivity for the D2 receptor against other dopamine receptor subtypes (Ki values are 9.0, 1940, >2190 and >7140 for D2, D3, D4 and D1 receptors respectively). Exhibits antiParkinsonian activity similar to ropinirole (Cat. No. 3680)."	"McCall et al (2005) Sumanirole, a highly dopamine D2-selective receptor agonist: in vitro and in vivo pharmacological characterization and efficacy in animal models of Parkinson's disease. J.Pharmacol.Exp.Ther. 314 1248. PMID:15980060. Stephenson et al (2005) The effects of a selective dopamine D2 receptor agonist on behavioral and pathological outcome in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated squirrel monkeys. J.Pharmacol.Exp.Ther. 314 1257. PMID:15980058."	Small Molecule	Sold for research purposes under agreement from Pfizer Inc.	http://www.tocris.com/dispprod.php?ItemId=55279	SQ1533			Apr-2011
2775	Probucol	[23288-49-5]	CC(SC2=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C2)(C)SC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1	"Antioxidant, anti-inflammatory and hypocholesterolemic agent"	"Antioxidant, anti-inflammatory and hypocholesterolemic agent. Inhibits atherogenesis in genetically hypercholesterolemic rabbits (Watanabe) and attenuates ischemia/reperfusion-induced cardiomyocyte apoptosis."	"Ku et al (1990) Ex vivo lipopolysaccharide-induced interleukin-1 secretion from murine peritoneal macrophages inhibited by probucol, a hypocholesterolemic agent with antioxidant properties. FASEB J. 4 1645. PMID:2318380. Ruixing et al (2006) Pretreatment with probucol attenuates cardiomyocyte apoptosis in a rabbit model of ischemia/reperfusion. Scand.J.Clin.Lab.Invest. 66 549. PMID:17101546. Wu et al (2007) Probucol [4,4'-[(1-methylethylidene)bis(thio)]bis-[2,6-bis(1,1-dimethylethyl)phenol]] inhibits compensatory remodeling and promotes lumen loss associated with atherosclerosis in apolipoprotein E-deficient mice. J.Pharmacol.Exp.Ther. 321 477. PMID:17293560."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=58060	SQ1533			Aug-2007
2776	FK 3311	[116686-15-8]	FC1=CC(F)=CC=C1OC2=C(NS(=O)(C)=O)C=CC(C(C)=O)=C2	Cyclooxygenase-2 (COX-2) inhibitor	Cyclooxygenase-2 (COX-2) inhibitor. Inhibits zymosan-induced prostaglandin E2 production by rat peritoneal neutrophils in vitro and adjuvant-induced arthritis in vivo. Anti-inflammatory.	"Tsuji et al (1992) Studies on antiinflammatory agents. I. Synthesis and pharmacological properties of 2'-phenoxy-methanesulfonanilide derivatives. Chem.Pharm.Bull. 40 2399. PMID:1446362. Nakamura et al (1993) Studies on antiinflammatory agents. III. Synthesis and pharmacological properties of metabolites of 4'-acetyl-2'-(2,4-difluorophenoxy)methanesulfonanilide (FK3311). Chem.Pharm.Bull. 41 (2050). Otani et al (2007) Effects of the COX-2 inhibitor FK3311 on ischemia-reperfusion injury in the rat lung. J.Invest.Surg. 20 175. PMID:17613692."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=64004	SQ1341			Jul-2008
2777	Nefazodone hydrochloride	[82752-99-6]	Cl.CCC1=NN(CCCN2CCN(CC2)C2=CC(Cl)=CC=C2)C(=O)N1CCOC1=CC=CC=C1	5-HT2A antagonist and 5-HT uptake inhibitor. Antidepressant	Serotonin 5-HT2A receptor antagonist (Ki = 5.8 nM) and inhibitor of serotonin and noradrenalin uptake (IC50 values are 290 and 300 nM respectively). Displays no activity at 5-HT1B and 5-HT1D receptors. Active in models predictive of antidepressant potential.	"Eison et al (1990) Nefazodone: preclinical pharmacology of a new antidepressant. Psychopharmacol.Bull. 26 311. PMID:2274630. Davis et al (1997) Nefazodone. A review of its pharmacology and clinical efficacy in the management of major depression. Drugs 53 608. PMID:9098663. Pullar et al (2000) LY367265, an inhibitor of the 5-hydroxytryptamine transporter and 5-hydroxytryptamine2A receptor antagonist: a comparison with the antidepressant, nefazodone. Eur.J.Pharmacol. 407 39. PMID:11050288."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=5343	SQ1533			Aug-2007
2778	Antalarmin hydrochloride	[220953-69-5]	CC1=C(C)N(C3=C(C)C=C(C)C=C3C)C2=C1C(N(CC)CCCC)=NC(C)=N2.Cl	CRF1 antagonist	Non-peptide corticotropin-releasing hormone receptor 1 (CRF1) antagonist (Ki = 1 nM). Suppresses CRF-induced ACTH secretion. Blocks CRF- and novelty-induced anxiety-like behavior in animal models of anxiety.	"Webster et al (1996) In vivo and in vitro characterization of antalarmin, a nonpeptide corticotropin-releasing hormone (CRH) receptor antagonist: suppression of pituitary ACTH release and peripheral inflammation. Endocrinology 137 5747. PMID:8940412. Zorrilla et al (2002) Effects of antalarmin, a CRF type 1 receptor antagonist, on anxiety-like behavior and motor activation in the rat. Brain Res. 952 188. PMID:12376179. Specio et al (2008) CRF1 receptor antagonists attenuate ascalated cocaine self-administration in rats. Psychopharmacol. 196 473."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=5283	SQ1341			Feb-2008
2779	CP 154526	[257639-98-8]	CC1=CN(C3=C(C)C=C(C)C=C3C)C2=C1C(N(CC)CCCC)=NC(C)=N2.Cl	"Selective, non-peptide CRF1 antagonist"	"Selective, non-peptide CRF1 receptor antagonist (Ki values are 2.7 and > 10000 nM for CRF1 and CRF2 receptors respectively). Blocks CRF-induced adenylate cyclase activation (Ki = 3.7 nM) and attenuates activation of the HPA axis by CRF. Displays anxiolytic-like activity in the rat elevated plus-maze test; brain penetrant."	"Lundkist et al (1996) A non peptidic corticotropin releasing factor receptor antagonist attenuates fever and exhibits anxiolytic activity. Eur.J.Pharmacol. 309 195. PMID:8874139. Schulz et al (1996) CP-154,526: a potent and selective nonpeptide antagonist of corticotropin releasing factor receptors. Proc.Natl.Acad.Sci.USA 93 10477. Hodgson et al (2007) Comparison of the V1b antagonist, SSR149415, and the CRF1 antagonist, CP-154,526, in rodent models of anxiety and depression. Pharmacol.Biochem.Behav. 86 431. PMID:17291571."	Small Molecule	Sold for research purposes under agreement from Pfizer Inc.	http://www.tocris.com/dispprod.php?ItemId=90696	SQ1341			Nov-2007
2780	EX 527	[49843-98-3]	ClC1=CC=C(NC3=C2CCCC3C(N)=O)C2=C1	Selective SIRT1 inhibitor	"Selective inhibitor of SIRT1 that does not inhibit histone deacetylase (HDAC) or other sirtuin deacetylase family members (IC50 values are 98, 19600, 48700, > 100000 and > 100000 nM for SIRT1, SIRT2, SIRT3, HDAC and NADase respectively). Enhances p53 acetylation in response to DNA damaging agents."	Napper et al (2005) Discovery of indoles as potent and selective inhibitors of the deacetylase SIRT1. J.Med.Chem. 48 8045. PMID:16335928. Solomon et al (2006) Inhibition of SIRT1 catalytic activity increases p53 acetylation but does not alter cell survival following DNA damage. Mol.Cell.Biol. 26 28. PMID:16354677. Zhao et al (2013) The 2.5  crystal structure of the SIRT1 catalytic domain bound to nicotinamide adenine dinucleotide (NAD+) and an indole (EX527 analogue) reveals a novel mechanism of histone deacetylase inhibition. J.Med.Chem. 56 963. PMID:23311358.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=85010	SQ1533			Oct-2007
2782	TCS 46b	[302799-86-6]	O=C2NC1=CC=C(C#CCN3CCC(CC4=CC=CC=C4)CC3)C=C1N2	"Orally active, subtype-selective NR1A/NR2B antagonist"	"Orally active, subtype-selective NR1A/NR2B NMDA receptor antagonist (IC50 values are 5.3, 35000 and > 100000 nM for NR1A/2B, NR1A/2A and NR1A/2C receptor subtypes respectively). Potentiates the effect of L-DOPA in 6-OHDA-lesioned rats following oral administration."	"Wright et al (2000) Subtype-selective N-methyl-D-aspartate receptor antagonists: synthesis and biological evaluation of 1-(heteroarylalkynyl)-4-benzylpiperidines. J.Med.Chem. 43 3408. PMID:10978188. Roger et al (2003) Synthesis, radiosynthesis and in vivo evaluation of 5-[3-(4-benzylpiperidin-1-yl)prop-1-ynyl]-1,3-dihydrobenzoimidazol-2-[11C]one, as a potent NR1A/2B subtype selective NMDA PET radiotracer. Bioorg.Med.Chem. 11 5401. PMID:14642584."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=58061	SQ1341			Dec-2007
2783	DPPI 1c hydrochloride	[866396-70-5]	O=C(CNC2(CO)CCCC2)N1[C@@H](C#N)CC[C@H]1C#N.Cl	Dipeptidyl peptidase IV (DPP-IV) inhibitor	Inhibitor of dipeptidyl peptidase IV (DPP-IV) (IC50 = 104 nM) that displays selectivity over enzymes with DPP-like activity (IC50 > 30 _M). Increases plasma GLP-1 levels and improves glucose tolerance in diabetic mice following oral glucose challenge.	"Wright et al (2006) cis-2-5-dicyanopyrrolidine inhibitors of dipeptidyl peptidase IV: synthesis and in vitro, in vivo, and X-ray crystallographic characterization. J.Med.Chem. 49 3068. PMID:16722626."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=5301	SQ1341			Nov-2007
2784	Acipimox	[51037-30-0]	CC1=CN=C(C(O)=O)C=[N+]1[O-]	Antilipolytic agent	"Antilipolytic agent; lowers plasma free fatty acid (FFA), triglyceride (TG), glucose and insulin levels and increases leptin levels."	Lovisolo et al (1981) Pharmacological proflie of a new antilipolytic agent: 5-methyl-pyrazine-2-carboxylic acid 4-oxide (acipimox) II - Antilipolytic and blood lipid lowering activitiy Pharmacol.Res.Comms. 13 163. Christie et al (1996) Mechanism of anti-lipolytic action of acipimox in isolated rat adipocytes. Diabetol. 39 45. Wang-Fisher et al (2002) Acipimox stimulates leptin production from isolated rat adipocytes. J.Endocrinol. 174 267. PMID:12176665.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=5285	SQ1533			Oct-2007
2787	BAPTA AM	[126150-97-8]	O=C(OCOC(C)=O)CN(CC(OCOC(C)=O)=O)C1=CC=CC=C1OCCOC2=CC=CC=C2N(CC(OCOC(C)=O)=O)CC(OCOC(C)=O)=O	Cell-permeable Ca2+ chelator	"Selective calcium chelator that is the cell-permeable analog of BAPTA (Cat. No. 2786). Blocks hKv1.5, hKV11.1 (hERG) and hKv1.3 channels (Ki values are 1.23, 1.30 and 1.45 _M respectively). Displays antithrombotic activity in vitro."	Raspe et al (1989) Enhanced release of prostacyclin from quin 2-loaded endothelial cells. Eur.J.Pharmacol. 163 345. PMID:2498111. Heilporn et al (1994) Synthesis of BAPTA-AM analogues capable of enhancing the vascuar production of prostacyclin. Bull.Soc.Chim.Belg. 103 309. Tang et al (2007) The membrane permeable calcium chelaotr BAPTA-AM directly blocks human ether a-go-go-related gene potassium channels stably expressed in HEK 293 cells. Biochem.Pharmacol. 74 1596. PMID:17826747.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=5296				Dec-2008
2789	NFPS	[405225-21-0]	FC1=CC=C(C(OC2=CC=C(C3=CC=CC=C3)C=C2)CCN(C)CC(O)=O)C=C1	Selective non-transportable GlyT1 inhibitor	"Selective, non-transportable inhibitor of GlyT1 which displays no activity on GlyT2 or the transport of proline, GABA or glutamate (IC50 values are 2.8, 9.8 and  56000 nM for hGlyT1, rGlyT1 and rGlyT2 respectively). Enhances the amplitude of the NMDA component of glutamatergic EPSCs."	Bergeron et al (1998) Modulation of N-methyl-D-aspartate receptor function by glycine transport. Proc.Natl.Acad.Sci.USA 95 15730. Harsing Jr. et al (2003) The glycine transporter-1 inhibitors NFPS and Org 24461: a pharmacological study. Pharmacol.Biochem.Behav. 74 881. Mallorga et al (2003) Pharmacology and expression analysis of glycine transporter GlyT1 with [3H]-(N-[3-(4'-fluorophenyl)-3-(4'phenylphenoxy)propyl])sarcosine. Neuropharmacology 45 585. PMID:12941372.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=5292	SQ1341			Jun-2008
2790	K 579	[440100-64-1]	O=C(CNC2(C)CCN(C3=NC=CC=N3)CC2)N1CCC[C@H]1C#N	Dipeptidyl peptidase IV (DPP-IV) inhibitor	"Dipeptidyl peptidase IV inhibitor. Inhibits rat, canine, human and monkey enzymes with IC50 values of 3, 5, 8, and 8 nM respectively. Long-acting hypoglycemic agent; attenuates glucose excursion following glucose loading in Zucker fatty rats."	"Takasaki et al (2004) K579, a slow-binding inhibitor of dipeptidyl peptidase IV, is a long-acting hypoglycemic agent. Eur.J.Pharmacol. 486 335. PMID:14985056. Takasaki et al (2004) Effects of combination treatment with dipeptidyl peptidase IV inhibitor and sulfonylurea on glucose levels in rats. J.Pharmacol.Sci. 95 291. PMID:15215655. Takasaki et al (2004) Involvement of the active metabolites in the inhibitory activity of K579 on rat plasma dipeptidyl peptidase IV. Eur.J.Pharmacol. 505 237. PMID:15556158."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=75987	SQ1341			Apr-2008
2791	SC 51322	[146032-79-3]	O=C(NNC(CCSCC4=CC=CO4)=O)N3CC1=CC=CC=C1OC2=CC=C(Cl)C=C23	Potent EP1 receptor antagonist	Potent EP1 prostanoid receptor antagonist (Ki = 13.8 nM). Displays analgesic properties in vivo.	"Hallinan et al (1994) 8-chlorodibenz[b,f][1,4]oxazepine-10(11H)-carboxylic acid,2-[3-[2-(furanylmethyl)thio]-1-oxopropyl]hydrazide (SC-51322): A potent PGE2 antagonist and analgesic. Bioorg.Med.Chem.Lett. 4 509. Durocher et al (2000) A reporter gene assay for high-throughput screening of G-protein-coupled receptors stably or transiently expressed in HEK293 EBNA cells grown in suspension culture Anal.Biochem. 284 316. PMID:10964415."	Small Molecule	Sold for research purposes under agreement from Pfizer Inc.	http://www.tocris.com/dispprod.php?ItemId=5317	SQ1070			May-2010
2793	Caffeine	[58-08-2]	O=C1C2=C(N=CN2C)N(C)C(N1C)=O	A1 and A2B antagonist. CNS stimulant	Central nervous system stimulant. Antagonist at A1 and A2A adenosine receptors and inhibitor of cyclic nucleotide phosphodiesterases. Mobilizes calcium from intracellular stores and inhibits benzodiazepine binding to GABA receptors.	"Nehlig et al (1992) Caffeine and the central nervous system: mechanisms of action, biochemical, metabolic and psychostimulant effects. Brain Res.Brain Res.Rev. 17 139. PMID:1356551. Fisone et al (2004) Caffeine as a psychomotor stimulant: mechanism of action. Cell.Mol.Life Sci. 61 857. PMID:15095008. Chen et al (2008) Caffeine blocks disruption of blood brain barrier in a rabbit model of Alzheimer's disease. J.Neuroinflammation 5 12. PMID:18387175."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=5286	SQ1533			Aug-2007
2794	PP 3	[5334-30-5]	NC1=NC=NC2=C1C=NN2C3=CC=CC=C3	Negative control for PP 2 (Cat. No. 1407)	Negative control for the Src kinase inhibitor PP 2 (Cat. No. 1407). Inhibits EGFR kinase (IC50 = 2.7 _M).	"Traxler et al (1997) Use of a pharmacophore model for the design of EGF-R tyrosine kinase inhibitors: 4-(phenylamino)pyrazolo[3,4-d]pyrimidines. J.Med.Chem. 40 3601. PMID:9357527. Hou et al (2007) PP2, a potent inhibitor of Src family kinases, protects against hippocampal CA1 pyramidal cell death after transient global brain ischemia. Neurosci.Letts. 420 235."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=5302	SQ1341			Sep-2007
2795	Theophylline	[58-55-9]	O=C1C2=C(N=CN2)N(C)C(N1C)=O	Adenosine receptor antagonist; bronchodilator	"Bronchodilator, anti-inflammatory and immunomodulator. Antagonizes adenosine receptors and is a weak non-selective inhibitor of phosphodiesterases (PDEs)."	"Coward et al (1998) Asthma, adenosine, mast cells and theophylline. Clin.Exp.Allery 28 (Suppl. 3) 42. Page (1999) Recent advances in our understanding of the use of theophylline in the treatment of asthma. J.Clin.Pharmacol. 39 237. PMID:10073321. Barnes (2003) Theophylline. New perspectives for an old drug. Am.J.Respir.Care Med. 167 813."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=5333	SQ1533			Sep-2007
2796	(S)-(+)-Ibuprofen	[51146-56-6]	CC(C)CC1=CC=C([C@H](C)C(O)=O)C=C1	Cyclooxygenase inhibitor (COX-1 > COX-2)	Non-steroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase 1 and cyclooxygenase 2 (IC50 values are 12 and 80 _M respectively). Active isomer of ibuprofen.	Kato et al (2001) Cyclooxygenase-1 and cyclooxygenase-2 selectivity of non-steroidal anti-inflammatory drugs: investigation using human peripheral monocytes. J.Pharm.Pharmacol. 53 1679. PMID:11804398.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=5300	SQ1533			Sep-2007
2798	Stattic	[19983-44-9]	O=S2(C1=CC([N+]([O-])=O)=CC=C1C=C2)=O	Selective STAT3 inhibitor	"Small molecule inhibitor of STAT3. Inhibits binding of tyrosine-phosphorylated peptide motifs to STAT3 SH2 domain and inhibits STAT3 activation, dimerization and nuclear translocation. Displays selectivity over STAT1, STAT5, c-Myc/Max, Jun/Jun and Lck. Induces apoptosis in STAT3-dependent cancer cell lines."	Schust et al (2006) Stattic: a small-molecule inhibitor of STAT3 activation and dimerization. Chem.Biol. 13 1235. PMID:17114005.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=5288	SQ1341			Sep-2007
2806	Alprenolol hydrochloride	[13707-88-5]	C=CCC1=CC=CC=C1OCC(O)CNC(C)C.Cl	_ antagonist	_-adrenoceptor (_2 > _1 > _3) and 5-HT1A receptor antagonist.	"Blue et al (1990) Antagonist characterization of atypical beta adrenoceptors in guinea pig ileum: blockade by alprenolol and dihydroalprenolol. J.Pharmacol.Exp.Ther. 252 1034. PMID:1969469. Bjorvatin et al (1992) The 5-HT1A antagonist (-)-alprenolol fails to modify sleep or zimeldine-induced sleep-waking effects in rats. Pharmacol.Biochem.Behav. 42 49. PMID:1388278. Baker (2005) The selectivity of _-adrenoceptor antagonists at the human _1, _2 and _3 adrenoceptors. Br.J.Pharmacol. 144 317. PMID:15655528."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=5337	SQ1533			Sep-2007
2809	Acetylcholine chloride	[60-31-1]	CC(OCC[N+](C)(C)C)=O.[Cl-]	Endogenous neurotransmitter	Endogenous neurotransmitter. Acts at nicotinic and muscarinic acetylcholine receptors.	"Wessler et al (1999) The cholinergic 'pitfall': acetylcholine, a universal cell molecule in biological systems, including humans. Clin.Exp.Pharmacol.Physiol. 26 198. PMID:10081614."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=5332	SQ1533			Sep-2007
2810	Carbamoylcholine chloride	[51-83-2]	NC(OCC[N+](C)(C)C)=O.[Cl-]	Cholinergic receptor agonist	Cholinergic receptor agonist that is resistant to the action of cholinesterases. Blocks apoptosis in cerebellar granule neurons.	Yan et al (1995) Activation of muscarinic cholinergic receptors blocks apoptosis of cultured cerebellar granule neurons. Mol.Pharmacol. 47 248. PMID:7870032.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=5329	SQ1533			Oct-2007
2814	PI 828	[942289-87-4]	O=C2C=C(N3CCOCC3)OC1=C(C4=CC=C(N)C=C4)C=CC=C12	"PI 3-kinase inhibitor, more potent than LY 294002 (Cat. No. 1130)"	"PI 3-Kinase inhibitor (IC50 values are 0.098, 0.183, 0.227 and 1.967 _M for p110_, p110_, p110_ and p110_ respectively) that displays higher potency than LY 294002 (Cat No. 1130). Can be immobilized onto a solid phase."	Gharbi et al (2007) Exploring the specificity of the PI3K family inhibitor LY294002. Biochem.J. 404 15. PMID:17302559.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=167608	SQ1341			Jun-2008
2815	"Valproic acid, sodium salt"	[1069-66-5]	[Na+].CCCC(CCC)C([O-])=O	Histone deacetylase inhibitor	"Histone deacetylase inhibitor (IC50 = 400 _M) that exhibits anticancer, anti-inflammatory and neuroprotective effects. Displays anticonvulsive activity via an increase in GABA levels and decreases A_ production in animal models of Alzheimer's disease. Also attenuates NMDA-mediated excitation, blocks voltage-gated Na+ channels and modulates firing of neurons. Enables induction of pluripotent stem cells from somatic cells by Oct4 and Sox2. Can induce autophagy by inhibiting inositol synthesis."	"Phiel et al (2001) Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J.Biol.Chem. 276 36734. PMID:11473107. Kostrouchova et al (2007) Valproic acid, a molecular lead to multiple regulatory pathways. Folia Biologica 53 37. PMID:17448293. Kim et al (2007) Histone deacetylase inhibitors exhibit anti-inflammatory and neuroprotective effects in a rat permanent ischemic model of stroke: multiple mechanisms of action. J.Pharmacol.Exp.Ther. 321 892. PMID:17371805. Qing et al (2008) Valproic acid inhibits A_ production, neuritic plaque formation, and behavioural defects in Alzheimer's disease mouse models. J.Exp.Med. 205 2781. PMID:18955571. Huangfu et al (2008) Induction of pluripotent stem cells from primary human fibroblasts with only Oct4 and Sox2. Nat.Biotechnol. 26 1269. PMID:18849973."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=5320				Sep-2007
2820	(+)-Tubocurarine chloride	[57-94-3]	OC1=C(OC)C=C3C([C@@H]7[N+](C)(C)CC3)=C1OC(C=C5)=CC=C5C[C@H](N(C)CC4)C2=C4C=C(OC)C(OC6=C(O)C=CC(C7)=C6)=C2.[Cl-].Cl	Nicotinic receptor antagonist	"Competitive, non-selective nicotinic acetylcholine receptor antagonist; causes skeletal muscle relaxation. Also a 5-HT3 and GABAA receptor antagonist."	Pederson and Cohen (1990) d-Tucocurarine binding sites are located at _-_ and _-_ subunit interfaces of the nicotinic acetylcholine receptor. Proc.Natl.Acad.Sci.USA 87 2785. Peters et al (1990) Antagonism of 5-HT3 receptor mediated currents in murine N1E-115 neuroblastoma cells by (+)-tubocurarine. Neurosci.Letts. 110 107. Wotring and Yoon (1995) The inhibitory effects of nicotinic antagonists on currents elicited by GABA in rat hippocampal neurons. Neurosci. 67 293.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=5306	SQ1533			Nov-2007
2823	_-Estradiol	[57-91-0]	[H][C@@]23CCC1=CC(O)=CC=C1[C@]([H])2CC[C@@]4(C)[C@]([H])3CC[C@H]4O	Endogenous estrogen receptor agonist	Endogenous estrogen receptor ligand (Ki values are 0.2 and 1.2 nM for ER_ and ER_ receptors respectively). _-Estradiol (Cat. No. 2824) also available.	"Kuiper et al (1997) Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors _ and _. Endocrinology 138 863. PMID:9048584. Toran-Allerand et al (2002) ER-X: a novel, plasma membrane-associated, putative estrogen receptor that is regulated during development and after ischemic brain injury. J.Neurosci. 22 8391. PMID:12351713."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=5321	SQ1533			Oct-2007
2824	_-Estradiol	[50-28-2]	[H][C@@]23CCC1=CC(O)=CC=C1[C@]([H])2CC[C@@]4(C)[C@]([H])3CC[C@@H]4O	Endogenous ER agonist	Endogenous estrogen receptor (ER) agonist (Ki values are 0.12 and 0.13 nM for ER_ and ER_ respectively). Also high affinity ligand at membrane estrogen GPR30 receptors. _-Estradiol (Cat. No. 2823) also available.	Kuiper et al (1997) Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors _ and _. Endocrinology 138 863. PMID:9048584. Thomas et al (2005) Identity of an estrogen membrane receptor coupled to a G protein in human breast cancer cells. Endocrinology 146 624. PMID:15539556.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=5326	SQ1533			Sep-2007
2826	FPR A14	[329691-12-5]	O=C(N/N=C\C3=CC=C(OCC4=CC=CC=C4)C(OC)=C3)C1=CC(OCO2)=C2C=C1	FPR agonist	Formyl peptide receptor (FPR) agonist that potently activates neutrophils in vitro (EC50 values are 42 and 630 nM for neutrophil chemotaxis and Ca2+ mobilization respectively).	Schepetkin et al (2007) High-throughput screening for small molecule activators of neutrophils: Identification of novel N-formyl peptide receptor agonists. Mol.Pharmacol. 71 1061. PMID:17229869.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=5318	SQ1070			Apr-2010
2827	TCS JNK 5a	[312917-14-9]	O=C(C3=CC=CC4=C3C=CC=C4)NC2=C(C#N)C1=C(S2)CCCC1	Selective inhibitor of JNK2 and JNK3	"Selective inhibitor of JNK2 and JNK3 (pIC50 values are 6.7, 6.5, <5.0 and <4.8 for JNK3, JNK2, JNK1 and p38_ respectively). Displays no significant activity at a range of other protein kinases including EGFR, ErbB2, cdk2, PLK-1 and Src (pIC50 < 5.0)."	"Angell et al (2007) N-(3-cyano-4,5,6,7-tetrahydro-1-benzothien-2-yl)amides as potent, selective, inhibitors of JNK2 and JNK3. Bioorg.Med.Chem.Letts. 17 1296."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=124261	SQ1533			Feb-2009
2828	NU 7026	[154447-35-5]	O=C2C1=CC=C3C(C=CC=C3)=C1OC(N4CCOCC4)=C2	Selective DNA-PK inhibitor	"ATP-competitive inhibitor of DNA-dependent protein kinase (DNA-PK). Displays selectivity over other PIKK family enzymes (IC50 values are 0.23, 13.0, > 100 and > 100 _M for DNA-PK, PI3K, ATM and ATR respectively). Radiosensitizes both proliferating and quiescent mouse embryonic fibroblast cells to IR and inhibits DSB repair."	"Veuger et al (2003) Radiosensitization and DNA repair inhibition by the combined use of novel inhibitors of DNA-dependent protein kinase and poly(ADP-ribose) polymerase-I. Cancer Res. 63 6008. PMID:14522929. Hollick et al (2003) 2,6-disubstituted pyran-4-one and thiopyran-4-one inhibitors of DNA-dependent protein kinase (DNA-PK). Bioorg.Med.Chem.Letts. 13 3083. Amrein et al (2007) Chlorambucil cytotoxicity in malignant B lymphocytes is synergistically increased by 2-(morpholin-4-yl)-benzo[h]chomen-4-one (NU7026)-mediated inhibition of DNA double-strand break repair via inhibition of DNA-dependent protein kinase. J.Pharmacol.Exp.Ther. 321 848. PMID:17351105."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=5212	SQ1341			Feb-2008
2830	PD 118057	[313674-97-4]	ClC(C(Cl)=C3)=CC=C3CCC(C=C2)=CC=C2NC1=C(C(O)=O)C=CC=C1	Selective KV11.1 (hERG) channel activator	"Human ether-a-go-go (hERG) KV11.1 potassium channel activator. Displays no major effect on INa, ICa/L, IK1 and IKs currents. Causes resting membrane hyperpolarization and decreases action potential duration in rat myocytes in vitro."	Zhou et al (2005) Novel potent human ether-a-go-go-related gene (hERG) potassium channel enhancers and their in vitro antiarrhythmic activity. Mol.Pharmacol. 68 876. PMID:15976038. Yeung and Greenwood (2007) Pharmacological and biophysical isolation of K+ currents encoded by ether-a-go-go-related genes in murine hepatic portal vein smooth muscle cells. Am.J.Physiol.Cell.Physiol. 292 C468. PMID:16870833. Duff (2008) hERG: The long and short of it. Heart Rhythm 5 591. PMID:18362028.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=5323	SQ1070			Nov-2010
2831	Bupropion hydrochloride	[31677-93-7]	ClC1=CC=CC(C(C(C)NC(C)(C)C)=O)=C1.Cl	Non-selective inhibitor of dopamine and noradrenalin transporters	"Non-selective inhibitor of dopamine and noradrenalin transporters (Ki values are 1.4, 2.8 and 45 _M for NET, DAT and SERT transporters respectively). Also inhibits neuronal nicotinic acetylcholine receptors. Displays antidepressant activity and augments nicotine self-administration at low doses in vivo."	"Slemmer et al (2000) Bupropion is a nicotinic antagonist. J.Pharmacol.Exp.Ther. 295 321. PMID:10991997. Torres et al (2003) Plasma membrane monoamine transporters: structure regulation and function. Nat.Rev.Neurosci. 4 13. PMID:12511858. Dwoskin et al (2006) Review of the pharmacology and clinical profile of bupropion, antidepressant and tobacco use cessation agent. CNS Drug Rev. 12 178. PMID:17227286."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=85370	SQ1533			Jan-2008
2835	Progesterone	[57-83-0]	O=C1CC[C@@]2(C)C(CC[C@]3([H])[C@@]([H])2CC[C@@]4(C)[C@]([H])3CC[C@@H]4[C@@](C)=O)=C1	Endogenous progesterone receptor agonist	Endogenous progesterone receptor (PR) agonist (EC50 = 0.5 nM).	Dong et al (2004) Characterization of a new class of selective nonsteroidal progesterone receptor agonist. Steroids 69 201. PMID:15072922. Jerry (2007) Roles of estrogen and progesterone in breast cancer prevention. Breast Cancer Res. 9 102. PMID:17381827.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=5328	SQ1533			Sep-2007
2838	(R)-(-)-Phenylephrine hydrochloride	[61-76-7]	OC1=CC=CC([C@@H](O)CNC)=C1.Cl	_1 agonist	"_1-adrenoceptor agonist; pKi values are 5.86, 4.87 and 4.70 for _1D, _1B and _1A receptors respectively."	Minneman et al (1994) Selectivity of agonists for cloned _1-adrenergic receptor subtypes. Mol.Pharmacol. 46 929. PMID:7969082. Ford et al (1997) Pharmacological pleiotropism of the human recombinant _1A-adrenoceptor: implications for _1-adrenoceptor classification. Br.J.Pharmacol. 121 1127. PMID:9249248. Morton et al (2007) _1A-adrenoceptors mediate contractions to phenylephrine in rabbit penile arteries. Br.J.Pharmacol. 150 112. PMID:17115072.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=5315	SQ1533			Oct-2007
2839	Levetiracetam	[102767-28-2]	O=C1N([C@@H](CC)C(N)=O)CCC1	Antiepileptic; binds SV2A	Antiepileptic that displays distinctive properties from conventional antiepileptic drugs. Displays potent seizure protection in animal models of chronic epilepsy but lacks activity in acute seizure models. Binds synaptic vesicle protein 2A (SV2A) and inhibits Na+-dependent Cl-/HCO3- exchange.	Lynch et al (2004) The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proct.Natl.Acad.Sci. USA 101 9861. Smedt et al (2007) Levetiracetam: the profile of a novel anticonvulsant drug - part I: preclinical data. CNS Drug Rev. 13 43. PMID:17461889. Ueda et al (2007) Effect of levetiracetam on molecular regulation of hippocampal glutamate and GABA transporters in rats with chronic seizures induced by amygdalar FeCl3 injection. Brain Res. 1151 55. PMID:17408599.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=5331	SQ1533			Sep-2007
2840	AICAR	[2627-69-2]	O[C@@H]1[C@@H](CO)O[C@@H](N2C=NC(C(N)=O)=C2N)[C@@H]1O	AMPK activator	"Cell-permeable, allosteric activator of AMP-activated protein kinase (AMPK). Augments proliferation, differentiation and mineralization of osteoblastic MC3T3-EI cells and attenuates psychosine-induced expression of proinflammatory cytokines and iNOS in astrocytes. Promotes osteogenic differentiation of hAMSCs and BM-MSCs in vitro."	"Giri et al (2004) 5-Aminoimidazole-4-carboxamide-1-_-4-ribofuranoside inhibits proinflammatory response in glial cells: a possible role of AMP-activated protein kinase. J.Neurosci. 24 479. PMID:14724246. Kanazawa et al (2007) Adiponectin and AMP kinase activator stimulate proliferation, differentiation and mineralization of osteoblastic MC3T3-EI cells. BMC Cell Biol. 8 51. PMID:18047638. Giri et al (2008) The role of AMPK in psychosine mediated effects on oligodendrocytes and astrocytes: Implication for Krabbe disease. J.Neurochem. 105 1820. PMID:18248608. Wu et al (2011) AICAR, a small chemical molecule, primes osteogenic differentiation of adult mesenchymal stem cells. Int.J.Artif.Organs. 34 1128. PMID:22198598."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=5334	SQ1533			May-2008
2841	Curcumin	[458-37-7]	O=C(CC(/C=C/C2=CC=C(O)C(OC)=C2)=O)/C=C/C1=CC(OC)=C(O)C=C1	"Antitumor, anti-inflammatory and antioxidant"	"Antitumor, anti-inflammatory and antioxidant agent. Downregulates expression of reactive-oxygen-generating enzymes (cyclooxygenase, lipoxygenase, iNOS), TNF_, IL-1, IL-6, PKC, EGFR, NF-_B, I_B kinase and more. Upregulates expression of PPAR_, p53, Nrf2. Also displays antimicrobial, antidiabetic neuro- and cardioprotective properties in vivo."	"Kuttan et al (2007) Antitumour, anti-invasion, and antimetastatic effects of curcumin. Adv.Exp.Med.Biol. 595 173. PMID:17569210. Cole et al (2007) Neuroprotective effects of curcumin. Adv.Exp.Med.Biol. 595 197. PMID:17569212. Lin (2007) Molecular targets of curcumin. Adv.Exp.Med.Biol. 595 227. PMID:17569214. Miriyala et al (2007) Cardioprotective effects of curcumin. Adv.Exp.Med.Biol. 595 359. PMID:17569220. Aggarwal and Sung (2009) Pharmacological basis for the role of curcumin in chronic diseases: an age-old spice with modern targets. TiPS 30 85. PMID:19110321."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=152298	SQ1533			Sep-2007
2843	Mecamylamine hydrochloride	[826-39-1]	CC1(C)C2CCC(C2)C(NC)1C.Cl	Non-competitive nicotinic receptor antagonist	Non-competitive nicotinic acetylcholine receptor antagonist. Displays antidepressant-like effects in mice.	Rabenstein et al (2006) The nicotinic antagonist mecamylamine has antidepressant-like effects in wild-type but not _2- or _7-nicotinic acetylcholine receptor subunit knockout mice. Psychopharmacol. 189 395. Ostroumov et al (2007) Modeling study of mecamylamine block of muscle type acetylcholine receptors. Eur.Biophys.J. 37 393. PMID:17938901.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=5339	SQ1533			Oct-2007
2844	Mosapride citrate	[112885-42-4]	O=C(O)C(O)(CC(O)=O)CC(O)=O.ClC1=C(N)C=C(OCC)C(C(NCC2OCCN(CC3=CC=C(F)C=C3)C2)=O)=C1	5-HT4 agonist and 5-HT3 antagonist	"5-HT4 receptor agonist and 5-HT3 receptor antagonist. Displays no activity at D2, _1, _2, 5-HT1 and 5-HT2 receptors. Gastroprokinetic agent; increases gastric emptying in rats and stimulates gastric motor actvity in conscious dogs."	"Yoshida et al (1989) AS-4370, a novel gastrokinetic agent free of dopamine D2 receptor antagonist properties. Arch.Int.Pharmacodyn.Ther. 300 51. PMID:2533479. Yoshida et al (1993) Pharmacological effects of the new gastroprokinetic agent mosapride citrate and its metabolites in experimental animals. Arzneim.-Forsch. 43 1078. Mine et al (1997) Comparison of effect of mosapride citrate and existing 5-HT4 receptor agonists on gastrointestinal motility in vivo and in vitro. J.Pharmacol.Exp.Ther. 283 1000. PMID:9399969."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=5342	SQ1533			Oct-2007
2845	IBMX	[28822-58-4]	O=C1C2=C(N=CN2)N(CC(C)C)C(N1C)=O	PDE inhibitor (non-selective)	"Phosphodiesterase inhibitor (IC50 values are 13, 18, 19, 32 and 50 _M for PDE4, PDE3, PDE1, PDE5 and PDE2 respectively). Suppresses _-adrenoceptor-mediated 5-HT release from neuroendocrine epithelial cells (IC50 = 1.3 _M). Facilitates differentiation of neural progenitor cells in vitro."	Freitag et al (1998) Phosphodiesterase inhibitors suppress _2-adrenoceptor-mediated 5-hydroxytryptamine release from tracheae of newborn rabbits. Eur.J.Pharmacol. 354 67. PMID:9726632. Lepski et al (2013) cAMP promotes the differentiation of neural progenitor cells in vitro via modulation of voltage-gated calcium channels. Front.Cell Neurosci. 7 155. PMID:24065885.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=5345	SQ1070			Oct-2007
2849	SecinH3	[853625-60-2]	O=C(CSC5=CC=CC=C5)NC(C=C4)=CC=C4N1C(C2=CC(OCO3)=C3C=C2)=NC(OC)=N1	Sec7-specific GEF inhibitor (cytohesins)	"Sec7-specific GEF inhibitor that displays selectivity for small GEFs of the cytohesin family (IC50 values are 2.4, 5.4, 5.4, 5.6, 5.6, 65 and > 100 _M for hCyh2, hCyh1, mCyh3, hCyh3, drosophila steppke, yGea2-S7 and hEFA6-S7 respectively). Inhibits insulin signaling via inhibition of insulin receptor substrate protein (IRS) phosphorylation."	Hafner et al (2006) Inhibition of cytohesins by secinH3 leads to hepatic insulin resistance. Nature 444 941. PMID:17167487. Fuss et al (2006) The cytohesin Steppke is essential for insulin signalling in Drosophila. Nature 444 945. PMID:17167488.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=5352	SQ1533			Mar-2008
2850	PD 146176	[4079-26-9]	C12=CC=CC=C1C3=C(C(C=CC=C4)=C4SC3)N2	Selective 15-lipoxygenase inhibitor	"Specific, non-competitve 15-lipoxygenase (15-LOX) inhibitor (Ki = 197nM) that has no demonstrable effect on 5-LOX, 12-LOX, COX-1 or COX-2 (IC50 = 0.54 _M for 15-LOX in rabbit reticulocytes). Lacks non-specific antioxidant properties and prevents atherogenesis via regulation of monocyte-macrophage enrichment in vivo."	Sendobry et al (1997) Attenuation of diet-induced atherosclerosis in rabbits with a highly selective 15-lipoxygenase inhibitor lacking significant antioxidant properties. Br.J.Pharmacol. 120 1199. PMID:9105693. Bocan et al (1998) A specific 15-lipoxygenase inhibitor limits the progression and monocyte-macrophage enrichment of hypercholesterolemia-induced atherosclerosis in the rabbit. Atherosclerosis 136 203. PMID:9543090. Sordillo et al (2005) Enhanced 15-HPETE production during oxidant stress induces apoptosis of endothelial cells. Prostaglandins Other Lipid Mediat. 76 19. PMID:15967159.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=54821				Apr-2009
2851	Nefiracetam	[77191-36-7]	O=C(NC2=C(C)C=CC=C2C)CN1C(CCC1)=O	Cognitive enhancer	"Cognitive enhancer that displays various pharmacological effects. Activates L/N-type calcium channels, cholinergic, monoaminergic and GABAergic systems. Displays potent neuroprotective action in the retinal ischemia-reperfusion model in vivo."	"Narahashi et al (2004) Mechanisms of action of cognitive enhancers on neuroreceptors. Biol.Pharm.Bull. 27 1701. PMID:15516710. Ueda et al (2004) The cognitive-enhancer nefiracetam inhibits both necrosis and apoptosis in retinal ischemic models in vitro and in vivo. J.Pharmacol.Exp.Ther. 309 200. PMID:14718588. Kitano et al (2005) Effects of nefiracetam, a novel pyrrolidone-type nootropic agent, on the amygdala-kindled seizures in rats. Epilepsia 46 1561. PMID:16190926."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=5375	SQ1533			Nov-2007
2852	Adapalene	[106685-40-9]	COC1=CC=C(C3=CC=C(C=C(C(O)=O)C=C4)C4=C3)C=C1C25CC(C6)CC(CC6C5)C2	RAR_ and RAR_ agonist	"Retinoic acid analog that is a RAR_ and RAR_ agonist (AC50 values are 2.2, 9.3, 22 and > 1000 nM for RAR_, RAR_, RAR_ and RXR_ receptors respectively). Inhibits proliferation and induces apoptosis in colorectal cancer cell in vitro. Displays comedolytic activity."	Shroot et al (1997) Pharmacology and chemistry of adapalene. J.Am.Acad.Dermatol. 36 S96. PMID:9204085. Millikan (2000) Adapalene: an update on newer comparative studies between the various retinoids. Int.J.Dermatol. 39 784. PMID:11095202. Ocker et al (2003) The synthetic retinoid adapalene inhibits proliferation and induces apoptosis in colorectal cancer cells in vitro. Int.J.Cancer 107 453. PMID:14506747.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=5353	SQ1533			Nov-2007
2853	Biperiden hydrochloride	[1235-82-1]	OC(CCN3CCCCC3)(C4=CC=CC=C4)C1CC2C=CC1C2.Cl	Muscarinic receptor antagonist; some selectivity for M1	"Muscarinic receptor antagonist that displays some selectivity for the M1 subtype (Ki values are 0.48, 2.4, 3.9, 6.3 and 6.3 nM for M1, M4, M3, M2 and M5 receptors respectively). Alleviates extrapyramidal symptoms associated with antipsychotic drugs. Displays antiparkinsonian activity."	Bolden et al (1992) Antagonism by antimuscarinic and neuroleptic compounds at the five cloned human muscarinic cholinergic receptors expressed in chinese hamster ovary cells. J.Pharmacol.Exp.Ther. 260 576. PMID:1346637. Sudo et al (1999) Muscarinic receptor occupancy by biperiden in living human brain. Life Sci. 64 PL99. PMID:10069534. Brocks (1999) Anticholinergic drugs used in Parkinson's disease: an overlooked class of drugs from a pharmacokinetic perspective. J.Pharm.Pharmaceut.Sci. 2 39.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=5354	SQ1533			Mar-2009
2854	Tandospirone hydrochloride	[99095-10-0]	[H][C@]13[C@](C(N(CCCCN4CCN(C5=NC=CC=N5)CC4)C3=O)=O)([H])[C@@H]2CC[C@H]1C2.Cl	Selective 5-HT1A partial agonist	"5-HT1A receptor partial agonist (Ki = 27 nM) that displays selectivity over 5-HT2, 5-HT1C, _1, _2, D1 and D2 receptors (Ki values ranging from 1300 - 41000 nM). Inactive at 5-HT uptake sites, 5-HT1B, _-adrenergic, muscarinic and benzodiazepine receptors. Displays anxiolytic activity."	"Hamik et al (1990) Analysis of tandospirone (SM-3997) interactions with neurotransmitter receptor binding sites. Biol.Psychiatry 28 99. PMID:1974152. Pollard et al (1992) Effects of tandospirone in three behavioral tests for anxiolytics. Eur.J.Pharmacol. 221 297. PMID:1358655. Matsubara et al (2006) Tandospirone, a 5-HT1A agonist, ameliorates movement disorder via non-dopaminergic systems in rats with unilateral 6-hydroxydopamine-generated lesions. Brain Res. 1112 126. PMID:16884702."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=132039	SQ1533			Jul-2008
2855	B2	[115687-05-3]	O=C(C4=CC=C(Cl)C=C4)N(CC3)CCN3C1=C(C=CC=N2)C2=C([N+]([O-])=O)C=C1	Promotes inclusion formation in Huntington's and Parkinson's diseases	Promotes inclusion formation in cellular models of Huntington's disease and Parkinson's disease. Prevents mutant huntingtin-mediated proteasome dysfunction and reduces _-synuclein-mediated toxicity.	Bodner et al (2006) Pharmacological promotion of inclusion formation: a therapeutic approach for Huntington's and Parksinson's diseases. Proc.Natl.Acad.Sci.USA 103 4246.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=5374	SQ1341			Sep-2008
2864	Metformin hydrochloride	[1115-70-4]	NC(NC(N(C)C)=N)=N.Cl	Activator of LKB1/AMPK; antidiabetic agent	Antidiabetic agent; lowers plasma glucose levels and improves insulin sensitivity. Inhibits hepatic gluconeogenesis via activation of the LKB1/AMPK pathway. Displays antiproliferative effects in cancer cell lines. Activates the aPKC-CBP pathway in neural precursors to promote neurogenesis.	Shaw et al (2005) The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science 310 1642. PMID:16308421. Towler and Hardie (2007) AMP-activated protein kinase in metabolic control and insulin signalling. Circ.Res. 100 328. PMID:17307971. Wang et al (2012) Metformin activates an atypical PKC-CBP pathway to promote neurogenesis and enhance spatial memory formation. Cell Stem Cell 11 23. PMID:22770240. Hirsch et al (2013) Metformin inhibits the inflammatory response associated with cellular transformation and cancer stem cell growth. Proc.Natl.Acad.Sci.USA 110 972. PMID:23277563.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=5367	SQ1533			Nov-2007
2865	Risperidone	[106266-06-2]	FC1=CC2=C(C(C3CCN(CCC4=C(C)N=C(CCCC5)N5C4=O)CC3)=NO2)C=C1	5-HT2A antagonist	Atypical antipsychotic agent that displays 5-HT2A receptor antagonism. Also displays high affinity at D2 receptors (Ki values are 0.4 and 3.13 nM for 5-HT2A and D2 receptors respectively).	"Leysen et al (1988) Biochemical profile of risperidone, a new antipsychotic. J.Pharmacol.Exp.Ther. 247 661. PMID:2460616. Leysen et al (1994) Risperidone: a novel antipsychotic with balanced serotonin-dopamine antagonism, receptor occupancy profile, and pharmacologic activity. J.Clin.Psychiatry 55 (Suppl.) 5. PMID:7520908. Stathis et al (1996) Risperidone: a novel antipsychotic with many ""atypical"" properties. Psychopharmacol. 127 181."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=69670	SQ1533			Oct-2007
2866	BYK 191023 dihydrochloride	[1216722-25-6]	COC1=CC(CCC2=NC(N=CC=C3)=C3N2)=NC=C1.Cl.Cl	Potent and selective inhibitor of iNOS	"Potent and selective inhibitor of inducible nitric oxide synthase (iNOS) (IC50 values are 86, 17000, 162000 nM for iNOS, nNOS and eNOS respectively). Acts in an NADPH- and time-dependent manner. Active in vivo, reverses pathological hypotension in the rodent endotoxin model."	"Lehner et al (2006) In vivo characterisation of the novel imidazopyridine BYK191023 2-[2-(4-methoxy-pyridin-2-yl)-ethyl]-3H-imidazo[4,5-b]pyridine, a potent and highly selective inhibitor of inducible nitric-oxide synthase. J.Pharmacol.Exp.Ther. 317 181. PMID:16368897. Strub et al (2006) The novel imidazopyridine 2-[2-(4-methoxy-pyridin-2-yl)-ethyl]-3H-imidazo[4,5-b]pyridine (BYK191023) is a highly selective inhibitor of the inducible nitric-oxide synthase. Mol.Pharmacol. 68 328. Tiso et al (2008) BYK191023 (2-[2-(4-methoxy-pyridin-2-yl)-ethyl]-3H-imidazo[4,5-b]pyridine) is an NADPH- and time-dependent irreversible inhibitor of inducible nitric-oxide synthase. Mol.Pharmacol. 72 1244."	Small Molecule	Sold with the permission of Nycomed	http://www.tocris.com/dispprod.php?ItemId=172123	SQ1341			Jul-2008
2867	Flupirtine maleate	[75507-68-5]	NC1=C(NC(OCC)=O)C=CC(NCC2=CC=C(F)C=C2)=N1	KV7 channel activator	"Non-opioid analgesic with muscle relaxant properties. Activates KV7 potassium channels, indirectly antagonizes NMDA receptors and modulates GABAA receptors. Exhibits neuroprotective actions in a model of cerebral ischemia in mice and reduces apoptosis and necrosis induced by noxious stimuli."	"Osborne et al (1998) Flupirtine, a nonopioid centrally acting analgesic, acts as an NMDA antagonist. Gen.Pharmacol. 30 255. PMID:9510072. Azad et al (2004) The potassium channel modulator flupirtine shifts the frequency-response function of hippocampal synapses to favour LTD in mice. Neurosci.Lett. 370 186. PMID:15488320. Yeung et al (2007) Molecular expression and pharmacological identification of a role for Kv7 channels in murine vascular reactivity. Br.J.Pharmacol. 151 758. PMID:17519950. Klinger (2012) Concomitant facilitation of GABAA receptors and KV7 channels by the non-opioid analgesic flupirtine. Br.J.Pharmacol. 166 1631. PMID:22188423."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=72011	SQ1533			Dec-2007
2870	BMS 299897	[290315-45-6]	FC1=CC=[C@@]([C@H](N(C3=CC(F)=CC=C3F)S(C2=CC=C(Cl)C=C2)(=O)=O)C)C(CCCC(O)=O)=C1	Potent _-secretase inhibitor	"Orally active, potent _-secretase inhibitor (IC50 = 12 nM). Inhibits A_40 and A_42 formation in vitro (IC50 values are 7.4 and 7.9 nM respectively) and reduces A_ in the brain, plasma and cerebrospinal fluid in vivo. Exhibits no Notch toxicity. Brain penetrant."	"Barten et al (2005) Dynamics of _-Amyloid reductions in brain, cerebrospinal fluid, and plasma of _-amyloid precursor protein transgenic mice treated with a _-secretase inhibitor. J.Pharmacol.Exp.Ther. 312 635. PMID:15452193. Anderson et al (2005) Reductions in _-amyloid concentrations in vivo by the _-secretase inhibitors BMS-289948 and BMS-299897. Biochem.Pharmacol. 69 689. PMID:15670587. Goldstein et al (2007) Ex vivo occupancy of the _-secretase inhibitors correlates with brain _-amyloid peptide reduction in Tg2576 mice. J.Pharmacol.Exp.Ther. 323 102. PMID:17640949."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=5371	SQ1070			Aug-2010
2874	Luteolin	[491-70-3]	O=C(C=C(C3=CC(O)=C(O)C=C3)O2)C1=C2C=C(O)C=C1O	"Anti-inflammatory, antioxidant and free radical scavenger"	"Anti-inflammatory, antioxidant and free radical scavenger. Inhibits LPS-induced TNF-_, IL-6 and inducible nitric oxide production and blocks NF-_B and AP-1 activation. Also inhibits TNF-_ -induced COX-2 expression. Antiproliferative and chemopreventative; inhibits proliferation of Lewis lung carcinoma cells in vivo."	"Ju et al (2007) A critical role of luteolin-induced reactive oxygen species in blockage of tumour necrosis factor-activated nuclear factor-_B pathway and sensitization of apoptosis in lung cancer cells. Mol.Pharmacol. 71 1381. PMID:17296806. Chen et al (2007) Luteolin suppresses inflammation-associated gene expression by blocking NF-_B and AP-1 activation pathway in mouse alveolar macrophage. Life Sci. 81 1602. PMID:17977562. Kim et al (2007) Caspase activation and extracellular signal-regulated kinase/Akt inhibition were involved in luteolin-induced apoptosis in Lewis lung carcinoma cells. Ann.N.Y.Acad.Sci. 1090 597. Kim et al (2011) Luteolin, a novel natural inhibitor of tumor progression locus 2 serine/ threonine kinase, inhibits tumor necrosis factor-_-induced cyclooxygenase-2 expression in JB6 mouse epidermis cells. J.Pharm.Exp.Ther. 338 1013."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=5373	SQ1533			Nov-2007
2875	Homovanillic acid	[306-08-1]	OC1=C(OC)C=C(CC(O)=O)C=C1	Fluorimetric reagent	Fluorimetric reagent and major catecholamine metabolite. Used for fluorimetric determination of oxidative enzymes including glucose oxidase.	Marcelis et al (2006) Evidence that brain tissue volumes are associated with HVA reactivity to metabolite stress in schizophrenia. Schizo.Res. 86 45.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=5376				Oct-2007
2877	MNS	[1485-00-3]	O=[N+](/C=C/C1=CC(OCO2)=C2C=C1)[O-]	Selective inhibitor of Src and Syk	"Selective inhibitor of Src and Syk tyrosine kinases. Displays antiaggregative activity via inhibition of GPIIb/IIIa activation (IC50 = 12.7 _M for thrombin-induced platelet aggregation). Exhibits no effects on Ca2+-dependent enzymes, PKC or arachidonic acid metabolism."	"Wang et al (2006) Prevention of platelet glycoprotein IIb/IIIa activation by 3,4-methylenedioxy-_-nitrostyrene, a novel tyrosine kinase inhibitor. Mol.Pharmacol. 70 1380. PMID:16837624. Wang et al (2007) Synthesis and pharmacological evaluation of novel _-nitrostyrene derivatives as tyrosine kinase inhibitors with potent antiplatelet activity. Biochem.Pharmacol. 74 601. PMID:17601492."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=154297				Oct-2007
2891	Ondansetron hydrochloride	[99614-01-4]	CN1C3=C(C=CC=C3)C2=C1CCC(CN4C(C)=NC=C4)C2=O.Cl	Selective 5-HT3 antagonist	Selective 5-HT3 receptor antagonist (Ki = 6.16 nM). Antiemetic; prevents emesis induced by cytotoxic drugs and radiation.	"Youssefyeh et al (1992) Development of high-affinity 5-HT3 receptor antagonists. 1. Initial structure-activity relationship of novel benzamides. J.Med.Chem. 35 895. PMID:1312602. Ye et al (2001) Ondansetron: a selective 5-HT3 receptor antagonist and its applications in CNS-related disorders. CNS Drug Rev. 7 199. PMID:11474424. Ginawi et al (2005) Ondansetron, a selective antagonist, antagonizes methamphetamine-induced anorexia in mice. Pharmacol.Res. 51 255. PMID:15661576."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=5385	SQ1533			Nov-2007
2892	threo Ifenprodil hemitartrate	[1312991-83-5]	OC(C=C3)=CC=C3[C@H](O)[C@H](C)N2CCC(CC2)CC1=CC=CC=C1.OC(C=C6)=CC=C6[C@H](O)[C@H](C)N5CCC(CC5)CC4=CC=CC=C4.OC(C=C9)=CC=C9[C@@H](O)[C@@H](C)N8CCC(CC8)CC7=CC=CC=C7.OC(C=C%12)=CC=C%12[C@@H](O)[C@@H](C)N%11CCC(CC%11)CC%10=CC=CC=C%10.O=C(O)C(O)C(O)C(O)=O.O=C(O)C(O)C(O)C(O)=O	NR2B-selective NMDA antagonist; also _ agonist	Potent _ receptor agonist (Ki values are 59.1 and 2 nM for _1 and _2 receptors respectively) and NR2B subunit-selective NMDA receptor antagonist (IC50 values are 0.22 and 324.8 _M at NR2B and NR2A respectively). Displays ~8-fold reduced affinity at _-adrenoceptors compared to Ifenprodil (Cat.No. 0545). Inhibits the hERG potassium channel (IC50 = 88 nM) and exhibits antiarrhythmic activity in vivo.	"Hashimoto and London (1995) Interactions of erythro-ifenprodil, threo-ifenprodil and erythro-iodoifenprodil, and eliprodil with subtypes of _ receptors. Eur.J.Pharmacol. 273 307. PMID:7737340. Avenet et al (1996) Antagonist properties of the stereoisomers of ifenprodil at NR1A/NR2A and NR1A/NR2B subtypes of the NMDA receptor expressed in Xenopus oocytes. Eur.J.Pharmacol. 296 209. PMID:8838458. Monassier et al (2007) _2-receptor ligand-mediated inhibition of inwardly rectifying K+channels in the heart. J.Pharmacol.Exp.Ther. 322 341. PMID:17460149."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=5387	SQ1533			Nov-2009
2893	CP 96345	[132746-60-2]	COC(C=CC=C3)=C3CN[C@H]1C(CC4)CCN4[C@H]1[C@H](C5=CC=CC=C5)C2=CC=CC=C2	Potent and selective NK1 antagonist	Potent and selective non-peptide NK1 receptor antagonist. Attenuates substance P-induced salivary response and inhibits neurogenic inflammation in vivo.	"Snider et al (1991) A potent nonpeptide antagonist of the substance P (NK1) receptor. Science 251 435. PMID:1703323. Lembeck et al (1992) The non-peptide tachykinin antagonist, CP-96,345, is a potent inhibitor of neurogenic inflammation. Br.J.Pharmacol. 105 527. PMID:1378337. Bang et al (2003) Neurokinin-1 receptor antagonists CP-96,345 and L-733,060 protect mice from cytokine-mediated liver injury. J.Pharmacol.Exp.Ther. 305 31. PMID:12649350."	Small Molecule	Sold for research purposes under agreement from Pfizer Inc.	http://www.tocris.com/dispprod.php?ItemId=124227	SQ1070			Feb-2010
2895	SC 58125	[162054-19-5]	FC(C=C3)=CC=C3C1=CC(C(F)(F)F)=NN1C2=CC=C(S(=O)(C)=O)C=C2	Selective cyclooxygenase-2 (COX-2) inhibitor	"Selective cyclooxygenase 2 (COX-2) inhibitor (IC50 values are 0.04 and >100 _M for COX-2 and COX-1 respectively). Anti-inflammatory; blocks edema and hyperalgesia in vivo following an inflammatory insult, without causing gastric mucosal damage. Also displays antitumor activity."	Seibert et al (1994) Pharmacological and biochemical demonstration of the role of cyclooxygenase 2 in inflammation and pain. Proc.Natl.Acad.Sci.USA 91 12013. Gierse et al (1996) A single amino acid difference between cyclooxygenase-1 (COX-1) and -2 (COX-2) reverses the selectivity of COX-2 specific inhibitors. J.Biol.Chem. 271 15810. PMID:8663121. Williams et al (2001) A cyclooxygenase-2 inhibitor (SC-58125) blocks growth of established colon cancer xenografts. Neoplasia 3 428. PMID:11687954.	Small Molecule	Sold for research purposes under agreement from Pfizer Inc.	http://www.tocris.com/dispprod.php?ItemId=143704	SQ1070			Jan-2009
2896	HC 030031	[349085-38-7]	O=C1C2=C(N=CN2CC(NC3=CC=C(C(C)C)C=C3)=O)N(C)C(N1C)=O	Selective TRPA1 blocker	"Selective TRPA1 channel blocker that antagonizes AITC- and formalin-evoked calcium influx (IC50 values are 6.2 and 5.3 _M respectively). Does not block currents mediated by TRPV1, TRPV3, TRPV4, hERG or NaV1.2 channels. Inhibits AITC- and formalin-induced flinching in vivo."	McNamara et al (2007) TRPA1 mediates formalin-induced pain. Proc.Natl.Acad.Sci.USA 104 13525. Taylor-Clark et al (2008) Prostaglandin-induced activation of nociceptive neurons via direct interactions with TRPA1. Mol.Pharmacol. 73 274. PMID:18000030.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=157284	SQ1341			Jun-2008
2897	Dynasore	[304448-55-3]	O=C(N/N=C/C3=CC(O)=C(O)C=C3)C2=CC1=CC=CC=C1C=C2O	Non-competitive dynamin inhibitor	"Non-competitive inhibitor of dynamin 1, dynamin 2 and mitochondrial dynamin (Drp1) GTPase activity. Does not inhibit other small GTPases. Blocks endocytic pathways dependent on dynamin and inhibits cell spreading and migration of BSC1 cells."	"Thompson and McNiven (2006) Discovery of a new 'dynasore'. Nat.Chem.Biol. 2 355. PMID:16783339. Macia et al (2006) Dynasore, a cell-permeable inhibitor of Dynamin. Develop.Cell 10 839. Newton et al (2006) Inhibition of dynamin completely blocks compensatory synaptic vesicle endocytosis. Proc.Natl.Acad.Sci.USA 103 17955."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=122658				Feb-2008
2900	UK 370106	[230961-21-4]	CC(C=C(CCC[C@@H](C(N[C@@H]([C@@](C)(C)C)C(N[C@H](COC)C3=CC=CC=C3)=O)=O)CC(O)=O)C=C2)=C2C1=CC=CC=C1	Highly selective MMP-3 and MMP-12 inhibitor	"Highly selective MMP-3 and MMP-12 inhibitor (IC50 values are 0.023, 0.042, 1.75, 2.3, 5.8, 30.4, 34.2 and 66.9 _M at MMP 3, 12, 8, 13, 7, 9, 2 and 14 respectively.) Inhibits fibronectin cleavage (IC50 = 320 nM) and has little effect on keratinocyte migration in vitro. Substantially inhibits MMP-3 in an ex vivo model of chronic dermal ulcers."	"Fray et al (2003) A potent, selective inhibitor of matrix metalloproteinase-3 for the topical treatment of chronic duodenal ulcers. J.Med.Chem. 46 3514. PMID:12877590. Whitlock et al (2007) A novel series of highly selective inhibitors of MMP-3. Bioorg.Med.Chem.Letts. 17 6750. Matthews et al (2008) Formulation, stability and thermal analysis of lypophilised wound healing wafers containing an insoluble MMP-3 inhibitor and a non-ionic surfactant. Int.J.Pharmaceutics 356 110."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=112622	SQ1070			Mar-2009
2901	SB 242084	[1215566-78-1]	O=C(N3C(C=C(Cl)C(C)=C4)=C4CC3)NC(C=C2)=CN=C2OC1=CC=CN=C1C.Cl.Cl	Selective 5-HT2C antagonist; brain penetrant	"5-HT2C receptor antagonist that displays 158- and 100-fold selectivity over 5-HT2A and 5-HT2B receptors respectively. Also displays selectivity over a range of other 5-HT, dopamine and adrenergic receptors. Brain penetrant; exerts anxiolytic-like activity."	"Bromidge et al (1997) 6-Chloro-5-methyl-1-[[(2-methyl-3-pyridyl)oxy]-5-pyridyl]carbamoyl]-indoline (SB-242084): the first selective and brain penetrant 5-HT2C receptor antagonist. J.Med.Chem. 40 3494. PMID:9357513. Kennet et al (1997) SB 242084, a selective and brain penetrant 5-HT2C receptor antagonist. Neuropharmacology 36 609. PMID:9225286. Dalton et al (2006) Serotonin 1B and 2C receptor interactions in the modulation of feeding behaviour in the mouse. Psychopharmacology 185 45. PMID:16470405."	Small Molecule	Sold with the permission of GlaxoSmithKline	http://www.tocris.com/dispprod.php?ItemId=5427	SQ1341			Feb-2008
2902	D 4476	[301836-43-1]	O=C(N)C4=CC=C(C=C4)C1=NC(C2=CC(OCCO5)=C5C=C2)=C(C3=NC=CC=C3)N1	Selective CK1 inhibitor. Also inhibits TGF-_RI	Selective inhibitor of casein kinase 1 (CK1) and TGF-_ type-I receptor (ALK5) that displays > 20-fold selectivity over SAPK2/p38 and a much greater selectivity over all other protein kinases tested. Suppresses site-specific phosphorylation and nuclear exclusion of FOXO1a.	"Callahan et al (2002) Identification of novel inhibitors of the transforming growth factor _1 (TGF-_1) type I receptor (ALK5). J.Med.Chem. 45 999. PMID:11855979. Rena et al (2004) D4476, a cell-permeant inhibitor of CK1, suppresses the site-specific phosphorylation and nuclear exclusion of FOXO1a. EMBO Rep. 5 60. PMID:14710188. Bain et al (2007) The selectivity of protein kinase inhibitors: a further update. Biochem.J. 408 297. PMID:17850214."	Small Molecule	Sold with the permission of GlaxoSmithKline	http://www.tocris.com/dispprod.php?ItemId=5415	SQ1533			Apr-2008
2903	Granisetron hydrochloride	[107007-99-8]	O=C(C3=NN(C)C4=C3C=CC=C4)NC1CC(N2C)CCCC2C1.Cl	5-HT3 antagonist	5-HT3 receptor antagonist that possesses potent antiemetic activity.	Sanger and Nelson (1989) Selective and functional 5-hydroxytryptamine3 receptor antagonism by BRL 43694 (granisetron). Eur.J.Pharmacol. 159 113. PMID:2540014. Plosker and Goa (1991) Granisetron. A review of its pharmacological properties and therapeutic use as an antiemetic. Drugs 42 805. PMID:1723376. Martin et al (1998) Anti-emetic effect of Ondansetron and Granisetron after exposure to mixed neutron and gamma irradiation. Rad.Res. 149 631.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=78401	SQ1533			Dec-2007
2905	TB 21007	[207306-50-1]	O=C2C1=C(SCCO)SC(C3=NC=CS3)=C1CC(C)(C)C2	_5-selective GABAA inverse agonist	"GABAA receptor inverse agonist selective for the _5-subtype (Ki values are 1.6, 16, 20 and 20 nM for _5, _2, _1 and _3 subtypes respectively). Brain penetrant; enhances cognitive performance in rats in the delayed matching-to-place morris water maze test following i.p. administration."	"Chambers et al (2003) Identification of a novel, selective GABA5 _5 receptor inverse agonist which enhances cognition. J.Med.Chem. 46 2227. PMID:12747794."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=5396	SQ1341			Apr-2008
2906	TRO 19622	[22033-87-0]	[H][C@@]23CCC1=CC(CC[C@@](C)1[C@]([H])2CC[C@@]4(C)[C@]([H])3CC[C@@]([H])4[C@@H](CCCC(C)C)C)=NO	Binds voltage-dependent anion channel (VDAC)	"Neuroprotective and neuroregenerative compound. Rescues motor neurons from axotomy-induced cell death and promotes nerve regeneration following sciatic nerve crush in vivo. Binds directly to two components of the mitochondrial permeability pore, the voltage-dependent anion channel (VDAC) and translocator protein; thought to inhibit MPTP opening."	"Bordet et al (2007) Identification and characterization of cholest-4-en-3-one, oxime (TRO19622), a novel drug candidate for amyotrophic lateral sclerosis. J.Pharmacol.Exp.Ther. 322 709. PMID:17496168."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=5400	SQ1070			Jan-2008
2907	SU 9516	[377090-84-1]	O=C2NC1=CC=C(OC)C=C1/C2=C/C3=CNC=N3	Potent cdk2 inhibitor	"Potent, selective cdk2 inhibitor (IC50 values are 0.022, 0.04, 0.2, >10, >10, 18 and >100 _M for cdk2, cdk1, cdk4, PKC, p38, PDGFR and EGFR respectively). Inhibits pRb phosphorylation causing enhanced pRB/E2F complex formation and induces G1 and G2-M cell cycle arrest. Transcriptionally downregulates Mcl-1 and has antiproliferative, cytostatic and pro-apoptotic effects in vitro."	"Lane et al (2001) A novel cdk2-selective inhibitor, SU9516, induces apoptosis in colon carcinoma cells. Cancer Res. 61 6170. PMID:11507069. Yu et al (2002) SU9516, a cyclin-dependent kinase 2 inhibitor, promotes accumulation of high molecular weight E2F complexes in human colon carcinoma cells. Biochem.Pharmacol. 64 1091. PMID:12234612. Gao et al (2006) The three-substituted indolinone cyclin-dependent kinase 2 inhibitor 3-[1-(3H-Imidazol-4-yl)-meth-(Z)-ylidene]-5-methoxy-1,3-dihydro-indol-2-one (SU9516) kills human leukemia cells via down-regulation of Mcl-1 through a transcriptional mechanism. Mol.Pharmacol. 70 645. PMID:16672643."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=5401	SQ1341			Nov-2008
2908	EO 1428	[321351-00-2]	CC1=CC=CC=C1C(C2=CC=C(NC3=C(N)C=C(Br)C=C3)C=C2Cl)=O	Selective inhibitor of p38_ and p38_2	"Selective inhibitor of p38_ and p38_2 that displays no activity at p38_, p38_, ERK1/2 and JNK1. Inhibits production of inflammatory cytokines including IL-8, TNF-_, IL-6, IL-1_ and IL-10 (IC50 values are 4, 5, 17, 30 and 74 nM respectively). Displays anti-inflammatory activity in murine models of acute and chronic dermatitis."	Ottosen et al (2003) Synthesis and structure-activity relationship of aminobenzophenones. A novel class of p38 MAP kinase inhibitors with high antiinflammatory activity. J.Med.Chem. 46 5651. PMID:14667219.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=5402	SQ1533			Jul-2008
2910	H 89 dihydrochloride	[130964-39-5]	O=S(C2=CC=CC1=CN=CC=C12)(NCCNC/C=C/C3=CC=C(Br)C=C3)=O.Cl.Cl	Protein kinase A inhibitor	"Protein kinase A inhibitor that also inhibits several other kinases (IC50 values are 80, 120, 135, 270, 2600 and 2800 nM for S6K1, MSK1, PKA, ROCKII, PKB_ and MAPKAP-K1b)."	Vitolo et al (2002) Amyloid _-peptide inhibition of the PKA/CREB pathway and long-term potentiation: reversibility by drugs that enhance cAMP signaling. Proct.Natl.Acad.Sci.USA 99 13217. Lochner and Moolman (2006) The many faces of H89: a review. Cardiovasc.Drug Rev. 24 261. PMID:17214602. Yamada et al (2006) Involvement of cAMP response element-binding protein activation in salivary secretion. Pathobiology 73 1. PMID:16785762.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=5403	SQ1533			Nov-2007
2911	Ro 04-6790	[202466-68-0]	NC1=CC=C(S(NC2=NC(NC)=NC(NC)=C2)(=O)=O)C=C1	Potent and selective 5-HT6 antagonist	Potent and selective 5-HT6 receptor antagonist (pKi values are 7.26 and 7.35 at rat and human 5-HT6 receptors respectively). Displays no affinity at a range of other receptors (IC50 > 10 _M). Induces stretching behavior in rats in vivo.	"Sleight et al (1998) Characterization of Ro 04-6790 and Ro 63-2563: potent and selective antagonists at human and rat 5-HT6 receptors. Br.J.Pharmacol. 124 556. PMID:9647481. Bentley et al (1999) Investigation of stretching behaviour induced by the selective 5-HT6 receptor antagonist, Ro 04-6790, in rats. Br.J.Pharmacol. 126 1537. PMID:10323584. Fone (2008) An update on the role of the 5-hydroxytryptamine6 receptor in cognitive function. Neuropharmacology 55 1015. PMID:18655798."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=5404	SQ1341			Nov-2008
2913	Ro 64-5229	[246852-46-0]	ClC1=CC=CC(Cl)=C1/C(OC3CCCCCC3)=C/N2N=CN=C2	"Selective, non-competitive mGlu2 antagonist"	"Selective, non-competitive mGlu2 antagonist. Inhibits GTP_35S binding to mGlu2-containing membranes (IC50 = 0.11 _M)."	"Kolczewski et al (1999) Synthesis of heterocyclic enol ethers and their use as a group 2 metabotropic glutamate receptor antagonists. Bioorg.Med.Chem.Lett. 9 2173. PMID:10465539. Brauner-Osbourne et al (2007) Structure, pharmacology and therapeutic prospects of family C G-protein coupled receptors. Curr.Drug Targets. 8 169. PMID:17266540."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=76565	SQ1070			Nov-2010
2916	Ro 32-3555	[190648-49-8]	O=[C@@](N3CCCCC3)[C@H](CC1CCCC1)[C@@H]([C@](NO)=O)CN2C(N(C)C(C)(C)C2=O)=O	"Potent, collagenase-selective MMP inhibitor"	"Potent, collagenase-selective MMP inhibitor (Ki values are 3.0, 3.4, 4.4, 59, 154 and 527 nM for MMP-1, MMP-13, MMP-8, MMP-9, MMP-2 and MMP-3 respectively). Inhibits cartilage breakdown in vitro and in vivo and displays antiarthritic activity. Orally active."	"Lewis et al (1997) Ro 32-3555, an orally active collagenase inhibitor, prevents cartilage breakdown in vitro and in vivo. Br.J.Pharmacol. 121 540. PMID:9179398. Broadhurst et al (1997) Design and synthesis of the cartilage protective agent (CPA, Ro32-3555). Bioorg.Med.Chem.Letts. 7 2299. Brewster et al (1998) Ro 32-3555, an orally active collagenase selective inhibitor, prevents structural damage in the SRT/ORT mouse model of osteoarthritis. Arthrit.Rheumat. 41 1639."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=5407	SQ1070			Jan-2010
2917	Venlafaxine hydrochloride	[99300-78-4]	OC2(CCCCC2)C(CN(C)C)C1=CC=C(OC)C=C1.Cl	Dual serotonin/noradrenalin re-uptake inhibitor	Dual serotonin/noradrenalin re-uptake inhibitor that displays ~ 30-fold higher affinity for SERT than NET (Ki values are 82 and 2480 nM respectively). Antidepressant; increases swimming and climbing behavior in the forced-swim test in rats.	"Bymaster et al (2001) Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors. Neuropsychopharmacol. 25 871. Magalas et al (2005) The serotonin/noradrenaline reuptake inhibitor venlafaxine attenuates acquistion, but not maintenance, of intravenous self-administration of heroin in rats. Eur.J.Pharmacol. 528 103. PMID:16325805. Gould et al (2006) A comparison of the chronic treatment effects of venlafaxine and other antidepressants on serotonin and norepinephrine transporters. Biol.Psychiatry 59 408. PMID:16140280."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=104898	SQ1533			Nov-2007
2918	Veratridine	[71-62-5]	O=C(C8=CC=C(OC)C(OC)=C8)O[C@H]1CC[C@@]2(C)[C@@]3([H])[C@@](O)1O[C@@]42[C@@]([C@@](C[C@H](O)[C@@]6(O)[C@]([H])5CN7[C@](CC[C@H](C)C7)([H])[C@@](O)6C)(O)[C@@]5(O)C4)([H])CC3	Voltage-gated Na+ channel opener	Voltage-gated Na+ channel opener; increases intracellular Ca2+ with no effect on the Na+/Ca2+ exchanger. Steroid-derived alkaloid neurotoxin. Increases membrane Na+ permeability and depolarizes excitable tissues.	"McKinney et al (1986) Purification, solubility and pKa of veratridine. Anal.Biochem. 153 33. PMID:3963380. Maroto et al (1994) Effects of Ca2+ channel antagonists on chromaffin cell death and cytosolic Ca2+ oscillations induced by veratridine. Eur.J.Pharmacol. 270 331. PMID:7805782. Fekete et al (2009) Mechanism of the persistant sodium current activator veratridine-evoked Ca2+ elevation: implication for epilepsy. J.Neurochem. 111 745. PMID:19719824."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=5475	SQ1070			Oct-2010
2921	MTEP hydrochloride	[1186195-60-7]	CC1=NC(C#CC2=CN=CC=C2)=CS1.Cl	"Potent, selective mGlu5 antagonist"	"Potent, selective and non-competitive mGlu5 antagonist (IC50 = 5 nM in Ca2+-flux assay; Ki= 16 nM). Displays anxiolytic activity in vivo and is orally active."	"Brodkin et al (2002) Reduced stress-induced hyperthermia in mGluR5 knockout mice. Eur.J.Neurosci. 16 2241. PMID:12473093. Cosford et al (2003) 3-[(2-Methyl-1,3-thiazol-4-yl)ethynyl]- pyridine: A potent and highly selective metabotropic glutamate subtype 5 receptor antagonist with anxiolytic activity. J.Med.Chem. 46 204. PMID:12519057. Roppe et al (2004) 5-[(2-Methyl-1,3-thiazol-4-yl)ethynyl]-2,3'-bipyridine: a highly potent, orally active metabotropic glutamate subtype 5 (mGlu5) receptor antagonist with anxiolytic activity. Bioorg.Med.Chem.Lett. 14 3993. PMID:15225713. Klodzinska et al (2004) Anxiolytic-like effects of MTEP, a potent and selective mGlu5 receptor agonist does not involve GABAA signaling. Neuropharmacology 47 342. PMID:15275823. Bradbury et al (2005) Metabotropic glutamate receptor mGlu5 is a mediator of appetite and energy balance in rats and mice. J.Pharmacol.Exp.Ther. 313 395. PMID:15590770."	Small Molecule	"Manufactured and sold under license from Merck & Co., Inc. for use solely for preclinical research purposes (ie: not for administration to or other use in humans)"	http://www.tocris.com/dispprod.php?ItemId=5408	SQ1070			Apr-2009
2924	NBMPR	[38048-32-7]	OC[C@H]1O[C@@H](N2C=NC3=C2N=CN=C3SCC4=CC=C([N+]([O-])=O)C=C4)[C@H](O)[C@@H]1O	Equilibrative nucleoside transporter 1 (ENT1) inhibitor	Equilibrative nucleoside transporter 1 (ENT1) inhibitor (Ki values are 0.4 and 2800 nM for hENT1 and hENT2 respectively).	"Ward et al (2000) Kinetic and pharmacological properties of cloned human equilibrative nucleoside transporters, ENT1 and ENT2, stably expressed in nucleoside transporter-deficient PK15 cells. J.Biol.Chem. 275 8375. PMID:10722669. Tsujie et al (2007) Human equilibrative nucleoside transporter 1, as a predictor of 5-fluorouracil resistance in human pancreatic cancer. Anticancer Res. 27 2241. PMID:17695509. Lin and Buolamwini (2007) Synthesis and flow cytometric evaluation, and identification of highly potent dipyridamole analogues as equilibrative nucleoside transporter 1 inhibitors. J.Med.Chem. 50 3906. PMID:17636949."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=5411	SQ1341			Jan-2008
2925	LP 12 hydrochloride	[1185136-22-4]	O=C(CCCCCN3CCN(C4=C(C5=CC=CC=C5)C=CC=C4)CC3)NC2CCCC1=CC=CC=C12.Cl	5-HT7 agonist	"5-HT7 receptor agonist displaying selectivity over D2, 5-HT1A and 5-HT2A receptors (Ki values are 0.22, 7.3, 52.7 and 326 nM respectively). Induces relaxation of substance P-induced contractions in guinea pig ileum (EC50 = 1.77 _M)."	"Leopoldo et al (2007) Structure-activity relationship study on N-(1,2,3,4-tetrahydronaphthalen-1-yl)-4-aryl-1-piperazinehexanamides, a class of 5-HT7 receptor agents. J.Med.Chem. 50 4214. PMID:17649988."	Small Molecule	Sold under license from the University of Bari	http://www.tocris.com/dispprod.php?ItemId=150067	SQ1341			Feb-2008
2926	FPA 124	[902779-59-3]	Cl[Cu]Cl.NC(=S)N\N=C\C1=COC2=C(C=CC=C2)C1=O	Akt/PKB inhibitor	Akt/PKB inhibitor (IC50 = 100 nM) that interacts with the PH and kinase domains. Inhibits cell proliferation in various cancer cell lines in vitro and decreases NF-_B activity and tumor load in vivo.	"Barve et al (2006) Synthesis, molecular characterization, and biological activity of novel synthetic derivatives of chromen-4-one in human cancer cells. J.Med.Chem. 49 3800. PMID:16789737."	Small Molecule	Sold under license from Wayne State University	http://www.tocris.com/dispprod.php?ItemId=5433				Apr-2008
2927	WS 3	[39711-79-0]	CC1CC(C(NCC)=O)C(C(C)C)CC1	TRPM8 agonist; cooling agent	Cooling agent that is an agonist at TRPM8 receptors (EC50 = 3.7 _M).	Behrendt et al (2004) Characterization of the mouse cold-menthol receptor TRPM8 and vanilloid receptor type-1 VR1 using a fluorometric imaging plate reader (FLIPR) assay. Br.J.Pharmacol. 141 737. PMID:14757700. Bodding (2007) TRP proteins and cancer. Cell Signal. 19 617. PMID:17029734. Rovner (2007) Better than mint. C&EN 85 95.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=84877	SQ1070			Nov-2007
2928	CB 13	[432047-72-8]	O=C(C3=CC=CC4=C3C=CC=C4)C2=CC=C(OCCCCC)C1=CC=CC=C12	Potent dual CB1/CB2 agonist	"Potent, orally active CB1/CB2 receptor agonist with limited brain penetration (EC50 values are 6.1 and 27.9 nM for CB1 and CB2 receptors respectively). Displays antihyperalgesic activity in a rat model of neuropathic pain with no CNS side effects."	"Dziadulewicz et al (2007) Naphthalen-1-yl-(4-pentyloxynaphthalen-1-yl)methanone: a potent, orally bioavailable human CB1/CB2 dual agonist with antihyperalgesic properties and restricted central nervous system penetration. J.Med.Chem. 50 3851. PMID:17630726. Cluny et al (2010) Naphthalen-1-yl-(4-pentyloxynaphthalen-1-yl)methanone (SAB378), a peripherally restricted cannabinoid CB1/CB2 receptor agonist, inhibits gastrointestinal motility but has no effect on experimental colitis in mice. J.Pharmacol.Exp.Ther. 334 973. PMID:20571060."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=144640	SQ1341			Oct-2008
2929	PEPA	[141286-78-4]	FC1=CC(SCCNS(C2=CC=CC=C2)(=O)=O)=CC(F)=C1OCC(N)=O	Allosteric potentiator of AMPA receptor desensitization	Novel allosteric potentiator of AMPA receptor desensitization. Slows the rate of onset of desensitization and potentiates steady-state equilibrium currents induced by glutamate with subunit (GluR3/4 > GluR1) and splice variant (flop > flip) selectivity. Ameliorates post-ischemic memory impairment in rats following i.v. administration.	"Sekiguchi et al (1997) A novel allosteric potentiator of AMPA receptors: 4-[2-(phenylsulfonylamino)ethylthio]-2,6-difluoro-phenoxyacetamide. J.Neurosci. 17 5760. PMID:9221774. Sekiguchi et al (2001) The AMPA receptor allosteric potentiator PEPA ameliorates post-ischemic memory impairment. Neuroreport 12 2974. Sekiguchi et al (2002) A desensitization-selective potentiator of AMPA-type glutamate receptors. Br.J.Pharmacol. 136 1033. PMID:12145103."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=100226	SQ1341			Feb-2008
2930	PI 103 hydrochloride	[371935-79-4]	OC1=CC(C(N=C4N5CCOCC5)=NC3=C4OC2=NC=CC=C23)=CC=C1.Cl	"Inhibitor of PI 3-kinase, mTOR and DNA-PK"	"Inhibitor of DNA-PK, PI 3-kinase (p110_) and mTOR (IC50 values are 2, 8, 20, 26, 48, 83, 88, 150, 850, 920, ~ 1000 and 2300 nM for DNA-PK, p110_, mTORC1, PI 3-KC2_, p110_, mTORC2, p110_, p110_, ATR, ATM, PI 3-KC2_ and hsVPS34 respectively). Inhibits growth of human tumor xenografts in mice in vivo. Induces autophagosome formation in glioma cells."	Fan et al (2006) A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma. Cancer cell 9 341. PMID:16697955. Knight et al (2006) A pharmacological map of the PI3-K family defines a role for p110_ in insulin signaling. Cell 125 733. PMID:16647110. Raynaud et al (2007) Pharmacologic characterization of a potent inhibitor of class I phosphatidylinositol 3-kinase. Cancer Res. 67 5840. PMID:17575152. Fan et al (2010) Akt and autophagy cooperate to promote survival of drug-resistant glioma. Sci.Signal. 3 ra81. PMID:21062993.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=5490	SQ1533			Mar-2008
2932	CP 465022 hydrochloride	[199655-36-2]	O=C2N(C3=CC=CC=C3Cl)C(/C=C/C4=NC(CN(CC)CC)=CC=C4)=NC1=CC=C(F)C=C12.Cl	"Selective, non-competitive AMPA antagonist"	"Selective, non-competitive AMPA antagonist (IC50 = 25 nM in rat cortical neurons) that displays potent anticonvulsant activity. Also significantly blocks the persistent component of Nav1.6 channel activity. Brain penetrant and orally active."	"Lazaro et al (2002) Functional characterization of CP-465,022, a selective, noncompetitive AMPA receptor antagonist. Neuropharmacology 42 143. PMID:11804610. Menniti et al (2003) CP-465,022, a selective noncompetitive AMPA receptor antagonist, blocks AMPA receptors but is not neuroprotective in vivo. Stroke 34 171. PMID:12511770. Welch et al (2008) Traditional AMPA receptor antagonists partially block Nav1.6-mediated persistent current. Neuropharmacology 55 1165. PMID:18687344."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=166781	SQ1070			May-2009
2936	NSC 66811	[6964-62-1]	CC2=NC1=C(O)C(C(NC4=CC=CC=C4)C3=CC=CC=C3)=CC=C1C=C2	MDM2 antagonist. Disrupts MDM2-p53 interaction	"Potent MDM2 inhibitor (Ki = 120 nM) which disrupts MDM2-p53 interaction and activates p53 function. Induces p21, p53 and MDM2 accumulation in human colon cancer cells in vitro."	"Lu et al (2006) Discovery of a nanomolar inhibitor of the human murine double minute 2 (MDM2)-p53 interaction through an integrated, virtual database screening strategy. J.Med.Chem. 49 3759. PMID:16789731. Shangary and Shaomeng (2009) Small-molecule inhibitors of the MDM2-p53 protein-protein interaction to reactivate p53 function: a novel approach for cancer therapy. Ann.Rev.Pharmacol.Toxicol. 49 223."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=5481	SQ1070			Nov-2009
2937	Atipamezole hydrochloride	[104075-48-1]	CCC2(C3=CN=CN3)CC1=CC=CC=C1C2.Cl	Selective _2 antagonist	"Selective _2-adrenergic receptor antagonist (Ki values are 1.1, 1.0, 0.89, 1300 and 6500 nM for _2A, _2B, _2C, _1A and _1B receptors respectively). Brain penetrant."	"Virtanen et al (1989) Highly selective and specific antagonism of central and peripheral alpha 2-adrenoceptors by atipamezole. Arch.Int.Pharmacodyn.Ther. 297 190. PMID:2567152. Puurunen et al (2001) An _2-adrenergic antagonist, atipamezole, facilitates behavioral recovery after focal cerebral ischemia in rats. Neuropharmacology 40 597. PMID:11249969. Jurgens et al (2007) _2A adrenergic receptor activation inhibits epileptiform activity in the rat hippocampal CA3 region. Mol.Pharmacol. 71 1572. PMID:17341653."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=5428	SQ1533			Mar-2010
2939	A 83-01	[909910-43-6]	S=C(NC5=CC=CC=C5)N(N=C3C4=NC(C)=CC=C4)C=C3C2=CC=NC1=CC=CC=C12	"Selective inhibitor of TGF-_RI, ALK4 and ALK7"	"Potent inhibitor of TGF-_ type I receptor ALK5 kinase, type I activin/nodal receptor ALK4 and type I nodal receptor ALK7 (IC50 values are 12, 45 and 7.5 nM respectively). Blocks phosphorylation of Smad2 and inhibits TGF-_-induced epithelial-to-mesenchymal transition. Only weakly inhibits ALK-1, -2, -3, -6 and MAPK activity. More potent than SB 431542 (Cat.No. 1614). Inhibits differentiation of rat induced pluripotent stem cells (riPSCs) and increases clonal expansion efficiency. Helps maintain homogeneity and long-term in vitro self-renewal of human iPSCs."	Tojo et al (2005) The ALK5 inhibitor A-83-01 inhibits smad signaling and epithelial-to-mesenchymal transition by transforming growth factor-_. Cancer.Sci. 96 791. PMID:16271073. Hoberg et al (2008) Attachment to laminin-111 facilitates transforming growth factor _-induced expression of matrix metalloproteinase-2 in synovial fibroblasts. Ann.Rheum.Dis. 66 446. Li et al (2009) Generation of rat and human induced pluripotent stem cells by combining genetic reprogramming and chemical inhibitors. Cell Stem Cell 4 16. PMID:19097958.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=5414	SQ1533			May-2008
2942	CI 1020	[162256-50-0]	O=C1C(C2=CC=C(OCO4)C4=C2)=C(CC3=CC(OC)=C(OC)C(OC)=C3)C(O)(C5=CC=C(OC)C=C5)O1	"Highly selective, orally active ETA antagonist"	"Highly selective, orally active, non-peptide endothelin-A receptor (ETA) antagonist (IC50 values are 0.3 and 480 nM for ETA and ETB receptors respectively). Antihypertensive; blocks ET-1-induced pressor responses following oral administration."	Doherty et al (1995) Discovery of a novel series of orally active non-peptide endothelin-A (ETA) receptor-selective antagonists. J.Med.Chem. 38 1259. PMID:7731010. Jones et al (1999) The effect of the endothelin ETA receptor antagonist CI-1020 on hypoxic pulmonary vasoconstriction. Eur.J.Pharmacol. 374 367. PMID:10422781. Coe et al (2002) The endothelin A receptor antagonists PD 156707 (CI-1020) and PD 180988 (CI-1034) reverse the hypoxic pulmonary vasoconstriction in ther perinatal lamb. J.Pharmacol.Exp.Ther. 302 672. PMID:12130731.	Small Molecule	Sold for research purposes under agreement from Pfizer Inc.	http://www.tocris.com/dispprod.php?ItemId=67978	SQ1341			Mar-2008
2946	TRAM 34	[289905-88-0]	ClC(C=CC=C4)=C4C(N2C=CC=N2)(C3=CC=CC=C3)C1=CC=CC=C1	Potent and highly selective KCa3.1 channel blocker	"Potent and highly selective blocker of intermediate conductance Ca2+-activated K+ channels (KCa3.1) (Kd = 20 nM). Exhibits 200-1500-fold selectivity over KV, BKCa, KCa2, Na+, CRAC and Cl- channels. Suppresses the reactivation of lymphocytes by mitogenic stimuli."	"Wulff et al (2000) Design of a potent and selective inhibitor of the intermediate-conductance Ca2+-activated K+ channel, IKCa1: a potential immunosuppressant. Proc.Natl.Acad.Sci. USA 97 8151. Schilling and Eder (2007) TRAM-34 inhibits nonselective cation channels. Pflugers Arch. 454 559. PMID:17318643. Wang et al (2007) An intermediate-conductance Ca2+-activated K+ channel mediates B lymphoma cell cycle progression induced by serum. Pflugers Arch. 454 945. PMID:17429684."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=5466	SQ1533			Feb-2008
2947	Methimepip dihydrobromide	[817636-54-7]	CN1CCC(CC2=CNC=N2)CC1.Br.Br	Extremely selective H3 agonist	"Extremely selective histamine H3 receptor agonist (pKi values are 9.0, 5.7, < 5.0 and < 5.0 for hH3, hH4, hH1 and hH2 receptors respectively). Potently inhibits EFS-evoked contractions of guinea pig ileum (pD2 = 8.26)."	Kitbunnadaj et al (2005) N-substituted piperidinyl alkyl imidazoles: discovery of methimepip as a potent and selective histamine H3 receptor agonist. J.Med.Chem. 48 2100. PMID:15771452.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=5479	SQ1341			Apr-2008
2952	CI 994	[112522-64-2]	O=C(NC2=C(N)C=CC=C2)C1=CC=C(NC(C)=O)C=C1	Class I histone deacetylase inhibitor; orally active	"Orally active class I histone deacetylase (HDAC) inhibitor (Ki values are 0.41, 0.75, >100 and >100 _M for HDAC1, HDAC3, HDAC6 and HDAC8 respectively). Mediates G1 cell cycle arrest, inhibits proliferation and induces apoptosis in vitro and in vivo. Increases neuroplasticity during memory extinction."	Kraker et al (2003) Modulation of histone acetylation by [4-(acetylamino)-N-(2-amino-phenyl) benamide] in HCT-8 colon carcinoma. Mol.Cancer Ther. 2 401. PMID:12700284. Beckers et al (2007) Distinct pharamacologcial properties of second generation HDAC inhibitors with the benzamide or hydroxamate head group. Int.J.Cancer 121 1138. PMID:17455259. Grff et al (2014) Epigenetic priming of memory updating during reconsolidation to attenuate remote fear memories. Cell 156 261. PMID:24439381.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=110225				Mar-2009
2953	CyPPA	[73029-73-9]	CC1=NC(N2N=C(C)C=C2C)=NC(NC3CCCCC3)=C1	Activator of KCa2.2 and KCa2.3 channels	Activator of small conductance Ca2+-activated K+ channels that displays selectivity for KCa2.2 (SK2) and KCa2.3 (SK3) channels (EC50 values are 5.6 and 14 _M for KCa2.3 and KCa2.2 respectively). Displays no activity at KCa2.1 (SK1) and KCa3.1 (IK) channels.	Hougaard et al (2007) Selective positive modulation of the SK3 and SK2 subtypes of small conductance Ca2+-activated K+ channels. Br.J.Pharmacol. 151 655. PMID:17486140.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=5477	SQ1341			Sep-2008
2954	PX 12	[141400-58-0]	CC(CC)SSC1=NC=CN1	Thioredoxin-1 inhibitor	"Thioredoxin-1 (Trx-1) inhibitor; irreversibly inactivates Trx-1 as a substrate for reduction by thioredoxin reductase (TR); competitively inhibits the reduction of Trx-1 by TR (Ki = 30.8 _M). Attenuates expression of HIF-1_, VEGF and iNOS (IC50 values are 7.2, 10.4 and 18.1 _M respectively). Exhibits antitumor activity; directly inhibits tubulin in vitro and decreases tumor microvessel density in vivo."	Kirkpatrick et al (1998) Mechanisms of inhibition of the thioredoxin growth factor system by antitumor 2-imidazolyl disulfides. Biochem.Pharmacol. 55 987. PMID:9605422. Welsh et al (2003) The thioredoxin redox inhibitors 1-methylpropyl 2-imidazolyl disulfide and pleurotin inhibit hypoxia-induced factor 1_ and vascular endothelial growth factor formation. Mol.Cancer.Ther. 2 235. PMID:12657718. Jordan et al (2005) The thioredoxin-1 inhibitor 1-methylpropyl 2-imidazolyl disulfide (PX-12) decreases vascular permeability in tumor xenografts monitored by dynamic contrast enhanced magnetic resonance imaging. Clin.Cancer Res. 11 529. PMID:15701837.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=5418	SQ1533			Jul-2010
2956	Picropodophyllotoxin	[477-47-4]	O=C3OC[C@]([C@@]([H])3[C@@H]4[C@]5=CC(OC)=C(OC)C(OC)=C5)([H])[C@@H](O)C1=C4C=C(OCO2)C2=C1	Selective IGF1R inhibitor	"Orally active insulin-like growth factor 1 receptor (IGF1R) inhibitor that exhibits no activity at the insulin receptor, FGFR, PDGFR or EGFR. Inhibits IGF1R autophosphorylation (IC50 ~ 1 nM), increases the fraction of cells in the G2/M phase and upregulates apoptosis. Exhibits antiproliferative effects in multiple cancer cell lines (IC50 = 0.05 - 15 _M), and has anticancer and antineovascularization activity in vivo."	"Girnita et al (2004) Cyclolignans as inhibitors of the insulin-like growth factor-1 receptor and malignant cell growth. Cancer Res. 64 236. PMID:14729630. Stromberg et al (2006) IGF-1 receptor tyrosine kinase inhibition by the cyclolignan PPP induces G2/M-phase accumulation and apoptosis in multiple myeloma cells. Blood 107 669. PMID:16166596. Economou et al (2008) Inhibition of VEGF secretion and experimental choroidal neovascularization by picropodophyllin (PPP), an inhibitor of the insulin-like growth factor-1 receptor. Invest.Ophthalmol.Vis.Sci. 49 2620. PMID:18515591."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=5421	SQ1533			Jun-2009
2957	Org 27569	[868273-06-7]	CCC2=C(C(NCCC3=CC=C(N4CCCCC4)C=C3)=O)NC1=CC=C(Cl)C=C12	Potent allosteric CB1 modulator	Potent CB1 receptor allosteric modulator (pEC50 = 8.24). Significantly increases binding of the CB1 agonist [3H]CP 55.940 (pKb = 5.67) and decreases binding of the CB1 inverse agonist [3H]SR 141716A (pKb = 5.95). Inhibits CB1 receptor antagonist efficacy in vitro (pKb = 7.57).	Price et al (2005) Allosteric modulation of the Cannabinoid CB1 receptor. Mol.Pharmacol. 68 1484. PMID:16113085. Ross (2007) Allosterism and the cannabinoid CB1 receptors: the shape of things to come. Trends Pharmacol.Sci. 28 567. PMID:18029031.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=5471	SQ1341			Oct-2008
2958	DSP-4	[40616-75-9]	BrC1=CC=CC=C1CN(CC)CCCl.Cl	Adrenergic neurotoxin	Adrenergic neurotoxin. Displays neurotoxic effects on both peripheral and central noradrenergic neurons.	Jaim-Etcheverry and Zieher (1980) DSP-4: a novel compound with neurotoxic effects on noradrenergic neurons of adult and developing rats. Brain Res. 188 513. PMID:7370771. Haidkind et al (2002) Denervation of the locus coeruleus projections by treatment with the selective neurotoxin DSP-4 [N(2-chloroethyl)-N-ethyl-2-bromobenzylamine] reduces dopamine release potential in the nucleus accumbens shell in conscious rats. Neurosci.Letts. 332 79. Kawamura et al (2005) Short and long term analysis of heart rate variations in spontaneous hypertensive rats: effect of DSP-4 administration. Biomed.Pharmacother. 59 S203. PMID:16275495.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=5422				Jan-2008
2959	Lercanidipine hydrochloride	[132866-11-6]	CC1=C(C(OC(C)(C)CN(C)CCC(C4=CC=CC=C4)C3=CC=CC=C3)=O)C(C2=CC=CC([N+]([O-])=O)=C2)C(C(OC)=O)=C(C)N1.Cl	Ca2+ channel blocker (L-type)	L-type Ca2+ channel blocker that displays higher vascular selectivity than felodipine (Cat. No. 2960). Causes peripheral vasodilation with only weak negative inotropic activity. Antihypertensive.	"Sironi et al (1996) Antihypertensive effects of lercanidipine in experimental hypertensive rats and dogs. Arzneim.Forsch. 46 152. Bang et al (2003) Lercanidipine. A review of its efficacy in the management of hypertension. Drugs 63 2449. PMID:14609358. Wirtz and Herzig (2004) Molecular mechanisms of vasoselectivity of the 1,4-dihydropyridine lercanidipine. Br.J.Pharmacol. 142 275. PMID:15155536."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=5423	SQ1533			Feb-2008
2960	Felodipine	[72509-76-3]	ClC1=C(Cl)C(C2C(C(OC)=O)=C(C)NC(C)=C2C(OCC)=O)=CC=C1	Ca2+ channel blocker (L-type)	"L-type Ca2+ channel blocker that is selective over N-, R-, P/Q- and T-type channels. Displays high vascular selectivity; lowers arterial blood pressure without altering cardiac contractility. Antihypertensive."	Ljung (1990) Vascular selectivity of felodipine: experimental pharmacology. J.Cardiovasc.Pharmacol. 15 S11. PMID:1693715. Furukawa et al (1999) Selectivities of dihydropyridine derivatives in blocking Ca2+ channel subtypes expressed in Xenopus oocytes. J.Pharmacol.Exp.Ther. 291 464. PMID:10525060. Furukawa et al (2005) Differential blocking action of dihydropyridine Ca2+ antagonists on a T-type Ca2+ channel (_1G) expressed in Xenopus oocytes. J.Cardiovasc.Pharmacol. 45 241. PMID:15725949.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=5424	SQ1533			Feb-2008
2961	Batimastat	[130370-60-4]	O=[C@]([C@H](CC(C)C)[C@@H]([C@](NO)=O)CSC2=CC=CS2)N[C@H](C(NC)=O)CC1=CC=CC=C1	"Potent, broad spectrum MMP inhibitor"	"Potent, broad spectrum MMP inhibitor (IC50 values are 3, 4, 4, 6 and 20 nM for MMP -1, -2, -9, -7 and -3 respectively). Exhibits antiproliferative, anti-invasive and antimetastatic activity in human ovarian carcinoma xenografts in vivo."	Davies et al (1993) A synthetic matrix metalloproteinase inhibitor decreases tumor burden and prolongs survival of mice bearing human ovarian carcinoma xenografts. Cancer Res. 53 2087. PMID:8347186. Wang et al (1994) Matrix metalloproteinase inhibitor BB-94 (Batimastat) inhibits human colon tumor growth and spread in a patient-like orthotopic model in nude mice. Cancer Res. 54 4726. PMID:8062271. Kohn and Liotta (1995) Molecular insights into cancer invasion: strategies for prevention and intervention. Cancer Res. 55 1856. PMID:7728753.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=5425	SQ1533			May-2009
2962	6'-GNTI dihydrochloride		OC1=CC=C2CC([C@@]3(O)[C@@]4(CC5)C2=C1O[C@H]4C(NC6=C7C=CC(NC(N)=N)=C6)=C7C3)N5CC8CC8.Cl.Cl	Selective _/_ opioid heterodimer receptor agonist	"Selective _/_-opioid heterodimer receptor agonist (EC50 = 39.8, 112.5 and > 1000 nM for _/_, _/_ and _/_ respectively) that has no effect on opioid receptor homodimers (EC50 > 1000 nM). Displays tissue-specific analgesic effects in vitro."	Sharma et al (2001) Transformation of a _-opoid receptor antagonist to a _-agonist by transfer of a guanidinium group from the 5' to 6' position of naltrindole. J.Med.Chem. 44 2073. PMID:11405645. Waldhoer et al (2005) A heterodimer-selective agonist shows in vivo relevance of G protein-coupled receptor dimers. Proc.Natl.Acad.Sci.USA 102 9050. Rozenfeld et al (2006) Heterodimers of G protein-coupled receptors as novel and distinct drug targets. Drug Discov.Today Ther.Strateg. 3 437. Rives et al (2012) 6'-guanidinonaltrindole (6'-GNTI) is a G protein-biased _-opioid receptor agonist that inhibits arrestin recruitment. J.Biol.Chem. 287 27050. PMID:22736766.	Small Molecule	Not for sale in the USA.	http://www.tocris.com/dispprod.php?ItemId=5429	SQ1341			Nov-2013
2963	MMPIP hydrochloride	[479077-02-6]	O=C1N(C)C(C3=CC=C(OC)C=C3)=CC2=C1C(C4=CC=NC=C4)=NO2.Cl	"Potent, allosteric mGlu7-selective antagonist"	"Potent allosteric mGlu7-selective receptor antagonist. Inhibits agonist-induced intracellular calcium mobilization and cAMP accumulation (IC50 values are 26 and 610 nM). Displays intrinsic activity; increases forskolin-induced cAMP accumulation in the absence of an agonist (IC50 = 15 nM), indicating inverse agonist activity."	Suzuki et al (2007) In vitro pharmacological characterization of novel isoxazolopyridone derivatives as allosteric metabotropic glutamate receptor 7 antagonists. J.Pharmacol.Exp.Ther. 323 147. PMID:17609420.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=5430	SQ1341			Mar-2008
2964	Doxazosin mesylate	[77883-43-3]	NC2=NC(N3CCN(C(C4COC(C=CC=C5)=C5O4)=O)CC3)=NC1=CC(OC)=C(OC)C=C12.CS(=O)(O)=O	_1 antagonist	"Selective _1-adrenoceptor antagonist (pKi values are 9.0, 8.5 and 8.4 for human _1B, _1A and _1D receptors respectively). Displays antihypertensive activity."	Alabaster and Davey (1986) The _1-adrenoceptor antagonist profile of doxazosin: preclinical pharmacology. Br.J.Clin.Pharmacol. 21 9S. PMID:2871857. Kenny et al (1996) Evaluation of the pharmacological selectivity profile of _1 adrenoceptor antagonists at prostatic _1 adrenoceptors: binding functional and in vivo studies. Br.J.Pharmacol. 118 871. PMID:8799556. Ma et al (2006) Chiral selective effects of doxazosin enantiomers on blood pressure and urinaruy bladder pressure in anesthetized rats. Acta Pharmacol.Sinica 27 1423.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=5431	SQ1533			Feb-2008
2966	CGP 3466B maleate	[200189-97-5]	O=C(O)/C=C\C(O)=O.CN(CC#C)CC2=CC1=CC=CC=C1OC3=C2C=CC=C3	GAPDH inhibitor. Neuroprotective	Orally active glyceraldehyde-3-phosphate dehydrogenase (GAPDH) inhibitor. Exhibits antiapoptotic activity via inhibition of GAPDH nuclear translocation and mitochondrial complex 1-dependent H2O2 release. Displays neuroprotective activity in vivo.	Sagot et al (2000) An orally active anti-apoptotic molecule (CGP 3466B) preserves mitochondria and enhances survival in an animal model of motoneuron disease. Br.J.Pharmacol. 131 721. PMID:11030721. Andringa et al (2003) TCH346 prevents motor symptoms and loss of striatal FDOPA uptake in bilaterally MPTP-treated primates. Neurobiol.Dis. 14 205. PMID:14572443. Zoccarato et al (2008) Clorgyline and other propargylamine derivatives as inhibitors of succinate-dependent H2O2 release at NADH:UBIQUINONE oxidoreductase (Complex I) in brain mitochondria. J.Bioenerg.Biomembr. 40 289. PMID:18763029.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=5434	SQ1533			May-2010
2967	Phenserine	[101246-66-6]	O=C(OC2=CC=C(N(C)[C@]4([H])[C@](C)3CCN4C)C3=C2)NC1=CC=CC=C1	Cholinesterase inhibitor	Physostigmine analog that inhibits acetylcholinesterase. Inhibits production of amyloid precursor protein (APP) and A_. Improves morris water maze performance of scopolamine-treated rats.	"Janas et al (2005) The cholinesterase inhibitor, phenserine, improves morris water maze performance of scopolamine-treated rats. Life Sci. 76 1073. PMID:15620572. Utsuki et al (2006) Identification of novel small molecule inhibitors of amyloid precursor protein synthesis as a route to lower Alzheimer's disease amyloid-_ peptide. J.Pharmacol.Exp.Ther. 318 855. PMID:16690718. Klein (2007) Phenserine. Expert Opin.Investig.Drugs 16 1087. PMID:17594192."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=5436	SQ1341			Apr-2008
2968	Spironolactone	[52-01-7]	O=C1CC[C@@]2(C)C(C[C@@H](SC(C)=O)[C@]3([H])[C@@]([H])2CC[C@@]4(C)[C@]([H])3CC[C@@]54OC(CC5)=O)=C1	Mineralocorticoid receptor antagonist	Competitive mineralocorticoid (aldosterone) receptor antagonist that exhibits antihypertensive activity in vivo. Also displays antiandrogen activity and inhibits steroid hormone biosynthesis.	Delyani et al (2000) Mineralocorticoid receptor antagonists: the evolution of utility and pharmacology. Kidney Int. 57 1408. PMID:10760075. Struthers et al (2008) A comparison of the aldosterone-blocking agents eplernone and spironolactone. Clin.Cardiol. 31 153. PMID:18404673. Ye et al (2009) Contrasting effects of eplerenone and spironolactone on adrenal cell steroidogenesis. Horm.Metab.Res. 41 35. PMID:18819053.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=5437	SQ1070			Feb-2008
2969	SR 12813	[126411-39-0]	OC1=C(C(C)(C)C)C=C(/C=C(P(OCC)(OCC)=O)/P(OCC)(OCC)=O)C=C1C(C)(C)C	Pregnane X receptor agonist	Pregnane X receptor (PXR) agonist (EC50 values are 200 and 700 nM for human and rabbit PXR respectively). Activates the farnesoid X receptor (FXR) at _M concentrations. Displays hypocholesterolaemic activity via enchanced degradation of HMG-CoA reductase.	"Berkhout et al (1996) The novel cholesterol-lowering drug SR-12813 inhibits cholesterol synthesis via an increased degradation of 3-hydroxy-3-methylglutaryl-coenzyme A reductase J.Biol.Chem. 271 14376. PMID:8662919. Jones et al (2000) The pregnane X receptor: a promiscuous xenobiotic receptor that has diverged during evolution. Mol.Pharmacol. 14 27. Lemaire et al (2007) Discovery of a highly active ligand of human pregnane X receptor: a case study from pharmacophore modeling and virtual screening to ""in vivo"" biological activity. Mol.Pharmacol. 72 572. PMID:17573484."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=5438	SQ1341			Oct-2008
2970	RU 26752	[76676-33-0]	O=C1CC[C@@]2(C)C(C[C@@H](CCC)[C@]3([H])[C@@]([H])2CC[C@@]4(C)[C@]([H])3CC[C@@]54OC(CC5)=O)=C1	Mineralocorticoid receptor antagonist	Mineralocorticoid receptor antagonist. Prevents aldosterone-induced hypertension in rats.	Lazar and Agarwal (1986) Evidence for an antagonist specific receptor that does not bind mineralocorticoid agonists. Biochem.Biophy.Res.Comms. 134 261. Kalimi et al (1990) Effects of antimineralocorticoid RU 26752 on steroid-induced hypertension in rats. Am.J.Physiol. 258 E737. PMID:2333987. Huyet et al (2007) Structural basis of spirolactone recognition by the mineralocorticoid receptor. Mol.Pharmacol. 72 563. PMID:17569793.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=5454				May-2008
2972	A 438079 hydrochloride	[899431-18-6]	ClC1=C(C2=NN=NN2CC3=CN=CC=C3)C=CC=C1Cl.Cl	Competitive P2X7 antagonist	Competitive P2X7 receptor antagonist (pIC50 = 6.9 for the inhibition of Ca2+ influx in the human recombinant P2X7 cell line). Devoid of activity at other P2 receptors (IC50 >> 10 _M). Possesses antinociceptive activity in models of neuropathic pain in vivo.	"Nelson et al (2006) Structure-activity relationship studies on a series of novel, substituted 1-benzyl-5-phenyltetrazole P2X7 antagonists. J.Med.Chem. 49 3659. PMID:16759108. Donnelly-Roberts and Jarvis (2007) Discovery of P2X7 receptor-selective antagonists offers new insights into P2X7 receptor function and indicates a role in chronic pain states. Br.J.Pharmacol. 151 571. PMID:17471177. McGaraughty et al (2007) P2X7-related modulation of pathological nociception in rats. Neuroscience 146 1817. PMID:17478048."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=5439	SQ1533			Feb-2008
2973	Piracetam	[7491-74-9]	O=C1CCCN1CC(N)=O	Nootropic; modulates Na+-flux at AMPA receptors	Nootropic that displays cognitive enhancing properties. Proposed to enhance neurotransmission via modulation of ion flux; potentiates Na+ influx through AMPA receptors. Facilitates efficiency of cholinergic neurotransmission at muscarinic receptors.	Vernon and Sorkin (1991) Piracetam. An overview of its pharmacological properties and a review of its therapeutic use in senile cognitive disorders. Drugs Aging. 1 17. PMID:1794001. Gouliaev and Senning (1994) Piracetam and other structurally related nootropics. Brain Res.Brain Res.Rev. 19 180. PMID:8061686. Winbald (2005) Piracetam: a review of pharmacological properties and clinical uses. CNS Drug Rev. 11 169. PMID:16007238.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=5440	SQ1533			Feb-2008
2974	CCG 2046	[13017-69-1]	CC1(CCC)C(C#N)(C#N)C(C#N)1C#N	Inhibitor of regulator of G-protein signaling 4 (RGS4)	Inhibitor of regulator of G-protein signaling 4 (RGS4). Reduces the RGS4-G_o protein-protein interaction signal.	Roman et al (2007) Identification of small-molecule inhibitors of RGS4 using a high-throughput flow cytometry protein interaction assay. Mol.Pharmacol. 71 169. PMID:17012620.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=88279				Jul-2008
2975	Sarcosine	[107-97-1]	OC(CNC)=O	GlyT1 inhibitor	Endogenous inhibitor of GlyT1 that displays antipsychotic activity. Potentiates the action of glycine on the NMDA glycine binding site.	"Tsai et al (2004) Glycine transporter I inhibitor, N-methylglycine (Sarcosine), added to antipsychotics for the treatment of schizophrenia. Biol.Psychiatry 55 452. PMID:15023571. Singh and Singh (2011) Meta-analysis of the efficacy of adjunctive NMDA receptor modulators in chronic schizophrenia. CNS Drugs. 25 859. PMID:21936588."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=5441				Feb-2008
2976	A 803467	[944261-79-4]	ClC(C=C2)=CC=C2C1=CC=C(C(NC3=CC(OC)=CC(OC)=C3)=O)O1	Selective NaV1.8 channel blocker	"Selective blocker of NaV1.8 channels (IC50 values are 8, 2450, 6740, 7340 and 7380 nM for hNaV1.8, hNaV1.3, hNaV1.7, hNaV1.5 and hNaV1.2 channels respectively). Shows no significant activity against TRPV1, P2X2/3, CaV2.2 and KCNQ2/3 channels. Antinociceptive; potently attenuates mechanical allodynia in two models of neuropathic pain following i.p. administration."	"Rush and Cummins (2007) Painful research: identification of a small-molecule inhibitor that selectively targets NaV1.8 sodium channels. Mol.Interv. 7 192. PMID:17827438. Jarvis et al (2007) A-803467, a potent and selective NaV1.8 sodium channel blocker, attenuates neuropathic and inflammatory pain in the rat. Proc.Natl.Acad.Sci. 104 8520. McGaraughty et al (2008) A selective NaV1.8 sodium channel blocker, A-803467 [5-(4-chlorophenyl-N-(3,5-dimethoxyphenyl)furan-2-carboxamide], attenuates spinal neuronal activity in neuropathic rats. J.Pharmacol.Exp.Ther. 324 1204. PMID:18089840. Kort et al (2008) Discovery and biological evaluation of 5-Aryl-2-furfuramides, potent and selective blockers of the Nav1.8 sodium channel with efficacy in models of neuropathic and inflammatory pain. J.Med.Chem. 51 407. PMID:18176998."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=5472	SQ1533			Apr-2008
2977	GW 843682X	[660868-91-7]	O=C(N)C(S3)=C(OCC4=CC=CC=C4C(F)(F)F)C=C3N2C1=CC(OC)=C(OC)C=C1N=C2	Selective inhibitor of PLK1 and PLK3	Selective inhibitor of polo-like kinase 1 (PLK1) and polo-like kinase 3 (PLK3) (IC50 values are 2.2 and 9.1 nM respectively). Displays > 100-fold selectivity over ~30 other kinases tested including cdk1 and cdk2. Inhibits proliferation of most tumor cells in vitro and is selective over normal diploid fibroblasts.	Lansing et al (2007) In vitro biological activity of a novel small-molecule inhibitor of polo-like kinase 1. Mol.Cancer Ther. 6 450. PMID:17267659.	Small Molecule	Sold for research purposes under agreement from GlaxoSmithKline	http://www.tocris.com/dispprod.php?ItemId=5442	SQ1533			Feb-2008
2978	PYR 41	[418805-02-4]	CCOC(=O)C1=CC=C(C=C1)N1NC(=O)C(=CC2=CC=C(O2)[N+]([O-])=O)C1=O	Ubiquitin-activating enzyme (E1) inhibitor	"Cell-permeable, irreversible ubiquitin-activating enzyme (E1) inhibitor (IC50 < 10 _M). Blocks ubiquitylation and prevents ubiquitin-mediated proteasomal degradation. Inhibits NF-_B activation, blocks degradation of p53, increases p21 levels and induces apoptosis in vitro. Also causes an increase in sumoylation of proteins."	"Yang et al (2007) Inhibitors of ubiquitin-activating enzyme (E1), a new class of potential cancer therapeutics. Cancer Res. 67 9472. PMID:17909057. Mi et al (2009) Cancer preventative isothiocyanates induce selective degradation of cellular _- and _-tubulins by proteasomes. J.Biol.Chem. 284 17039. PMID:19339240. Brahemi et al (2010) Homology modelling of human E1 ubiquitin activating enzyme. Lett.Drug Des.Discov. 7 57. PMID:20396627."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=5443	SQ1070			Jun-2011
2979	TCS PIM-1 1	[491871-58-0]	OC1=C(C2=CC(C3=CC=CC=C3)=C(C#N)C(N2)=O)C=C(Br)C=C1	"Selective, ATP-competitive Pim-1 kinase inhibitor"	"ATP-competitive Pim-1 kinase inhibitor that displays selectivity over Pim-2 and MEK1/2 (IC50 values are 50, > 20000 and > 20000 nM for Pim-1, Pim-2 and MEK1/2 respectively)."	Cheney et al (2007) Identification and structure-activity relationships of substituted pyridones as inhibitors of Pim-1 kinase. Bioorg.Med.Chem.Letts. 17 1679. PMID:17251021.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=5444	SQ1070			Jan-2009
2980	CX 546	[215923-54-9]	O=C(N3CCCCC3)C2=CC1=C(C=C2)OCCO1	AMPA receptor potentiator	"AMPA receptor potentiator. Binds specifically to the agonist bound non-desensitized receptor, most likely destabilizing the desensitized receptor conformation. Enhances cognitive function in rats."	Nagararjan et al (2001) Mechanism and impact of allosteric AMPA receptor modulation by the ampakine TM CX546. Neuropharmacology. 41 650. PMID:11640919. O'Neill et al (2004) AMPA receptor potentiators for the treatment of CNS disorders. Curr.Drug Targets CNS Neurol.Disord. 3 181. PMID:15180479. Shimazaki et al (2007) Blockade of the metabotropic glutamate 2/3 receptors enhances social memory via the AMPA receptor in rats. Eur.J.Pharmacol. 575 94. PMID:17727837.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=5445	SQ1070			May-2008
2981	BIBR 1532	[321674-73-1]	C/C(C2=CC1=CC=CC=C1C=C2)=C\C(NC3=C(C(O)=O)C=CC=C3)=O	Selective telomerase inhibitor	"Selective telomerase inhibitor (IC50 values are 93, > 100000 and > 100000 nM for human telomerase, human RNA polymerase I and human RNA polymerase II + III respectively). Causes telomere shortening in exponentially growing NCI-H460 lung carcinoma cells and eventual growth arrest."	Damm et al (2001) A highly selective telomerase inhibitor limiting human cell proliferation. EMBO J. 20 6958. PMID:11742973. Phatak and Burger (2007) Telomerase and its potential for therapeutic intervention. Br.J.Pharmacol. 152 1003. PMID:17603541. Rankin et al (2008) Telomerase inhibitors and 'T-oligo' as caner therapeutics: contrasting molecular mechanisms of cytotoxicity. Anticancer Drugs 19 329. PMID:18454043.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=5447	SQ1533			Sep-2008
2983	GM 6001	[142880-36-2]	O=C(NC)[C@@H](NC([C@@H](CC(NO)=O)CC(C)C)=O)CC2=CNC1=CC=CC=C12	Broad spectrum MMP inhibitor	Broad spectrum MMP inhibitor. Reduces infarct volume following middle cerebral artery occlusion in an ischemic mouse model. Also inhibits human skin fibroblast collagenase (Ki = 0.4 nM).	"Grobelny et al (1992) Inhibition of skin fibroblast collagenase, thermolysin, and Pseudomonas aeruginosa elastase by peptide hydroxamic acids. Biochemistry 31 7152. PMID:1322694. Chao et al (2007) Leptin stimulates endothelin-1 expression via extracellular signal-regulated kinase by epidermal growth factor receptor transactivation in rat aortic smooth muscle cells. Eur.J.Pharmacol. 573 49. PMID:17678888. Shichi et al (2011) Involvement of matrix metalloproteinase-mediated proteolysis of neural cell adhesion molecule in the development of cerebral ischemic neuronal damage. J.Pharmacol.Exp.Ther. 338 701. PMID:21602423."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=85444	SQ1070			Jul-2013
2986	YM 230888	[446257-23-4]	C1(NC4CCCCCC4)=C(C=C(CNC[C@H]3CCCO3)S2)C2=NC=N1	Selective mGlu1 antagonist	Selective mGlu1 antagonist (Ki = 13 nM). Inhibits mGlu1-mediated inositol phosphate production in rat cerebellar granule cells (IC50 = 13 nM). Displays antinociceptive and analgesic effects in vitro; exhibits no significant sedative effect on locomotor activity.	"Kohara et al (2007) Antinociceptive profile of a selective metabotropic glutamate receptor 1 antagonist YM-230888 in chronic pain rodent models. Eur.J.Pharmacol. 571 8. PMID:17597604. Satow et al (2008) Pharmacological effects of the metabotropic glutamate receptor 1 antagonist compared with those of the metabotropic glutamate receptor 5 antagonist and metabotropic glutamate receptor 2/3 agonist in rodents: detailed investigations with a selective allosteric metabotropic receptor 1 antagonist, FTIDC [4-[1-(2-Fluoropyridine-3-yl)-5-methyl-1H-1,2,3-triazol-4-yl]-N-isopropyl-N-methyl-3,6-dihydropyridine-1(2H)-carboxamide. J.Pharmacol.Exp.Ther. 326 577. PMID:18487514."	Small Molecule	Sold with the permission of Astellas Pharma Inc.	http://www.tocris.com/dispprod.php?ItemId=56259	SQ1070			Aug-2010
2988	VULM 1457	[228544-65-8]	O=C(NC3=C(C(C)C)C=CC=C3C(C)C)NC(C=C2)=CC=C2SC1=CC=C([N+]([O-])=O)C=C1	Acyl-CoA: cholesterol acyltransferase (ACAT) inhibitor	Acyl-CoA: cholesterol acyltransferase (ACAT) inhibitor. Decreases cholesterol levels in the plasma and liver of diabetic-hypercholesterolemic rats.	"Adameova et al (2006) Protective effect of simvastatin and VULM 1457 in ischaemic-reperfused myocardium of the diabetic-hypercholesterolemic rats. Pharmazie 61 807. PMID:17020164. Adameova et al (2007) The myocardial infarct size-limiting and antiarrhythmic effects of acyl-CoA: cholesterol acyltransferase inhibitor VULM 1457 protect the hearts of diabetic-hypercholesterolaemic rats against ischaemia/reperfusion injury both in vitro and in vivo. Eur.J.Pharmacol. 576 114. PMID:17764671. Vojtassakova et al (2007) Effect of VULM 1457, an ACAT inhibitor, on serum lipid levels and on real time red blood cell flow in diabetic and non-diabetic hamsters fed high cholesterol-lipid diet. Gen.Physiol.Biophys. 26 254. PMID:18281742."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=78400	SQ1341			May-2008
2989	Epoprostenol	[61849-14-7]	[Na+].CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)C[C@@H]2O\C(C[C@H]12)=C/CCCC([O-])=O	Endogenous IP receptor agonist	Endogenous prostanoid that is a potent agonist at IP prostanoid receptors. Inhibits platelet aggregation and induces vasodilation.	"Oliva and Nicosia (1987) PGI2-receptors and molecular mechanisms in platelets and vasculature: state of the art. Pharmacol.Res.Comm. 19 735. Kobzar et al (2001) Comparison of anti-aggregatory effects of PGI2, PGI3 and iloprost on human and rabbit platelets. Cell.Physiol.Biochem. 11 279. PMID:11684817."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=78398				Apr-2008
2993	RS 127445 hydrochloride	[199864-86-3]	FC1=C(C=CC=C2)C2=C(C3=CC(C(C)C)=NC(N)=N3)C=C1.Cl	"Selective, high affinity 5-HT2B antagonist"	High affinity 5-HT2B receptor antagonist (pKi = 9.5). Displays 1000-fold selectivity for 5-HT2B with good bioavailability.	"Bonhaus et al (1999) RS-127445: a selective, high affinity, orally bioavailable 5-HT2B receptor antagonist. Br.J.Pharmacol. 127 1075. PMID:10455251. Callebert et al (2006) Evidence for a control of plasma serotonin levels by 5-Hydroxytryptamine2B receptors in mice. J.Pharmacol.Exp.Ther. 317 724. PMID:16461587."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=5459				Aug-2008
2995	NS 1738	[501684-93-1]	O=C(NC2=CC(C(F)(F)F)=CC=C2Cl)NC1=C(O)C=CC(Cl)=C1	Positive allosteric modulator of _7 nAChR; active in vivo	"Selective positive allosteric modulator of _7 nicotinic acetylcholine receptors. Exhibits no substantial activity for _4_2, _3_3 and _1-containing receptors. Displays cognitive-enhancing properties in vivo."	Timmermann et al (2007) An allosteric modulator of the _7 nicotinic acetylcholine receptor possessing cognition-enhancing properties in vivo. J.Pharmacol.Exp.Ther. 323 294. PMID:17625074. Freitas et al (2013) The antinociceptive effects of nicotinic receptors _7-positive allosteric modulators in murine acute and tonic pain models. J.Pharmacol.Exp.Ther. 344 264. PMID:23115222.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=5463	SQ1341			Jul-2008
2999	RWJ 67657	[215303-72-3]	FC(C=C4)=CC=C4C(N=C(C#CCCO)N2CCCC3=CC=CC=C3)=C2C1=CC=NC=C1	"Potent, selective p38_ and p38_ inhibitor"	"Selective p38_ and p38_ inhibitor (IC50 values are 1 and 11 _M respectively) that displays no activity at p38_, p38_ and a range of other kinases. Potently inhibits TNF-_ and IL-1_ release (IC50 values are 3 and 11 nM respectively) and suppresses HIV-1 replication in T cells in vitro. Displays cardioprotective and anti-inflammatory activity in vivo. Orally active."	"Wadsworth et al (1999) RWJ 67657, a potent, orally active inhibitor of p38 mitogen-activated protein kinase. J.Pharm.Exp.Ther. 291 680. Muthumani et al (2004) Suppresssion of HIV-1 viral replication and cellular pathogenesis by a novel p38/JNK kinase inhibitor. AIDS 18 739. PMID:15075508. See et al (2004) p38 mitogen activated protein kinase inhibition improves cardiac function and attenuates left ventricular remodeling fowllowing myocardial infarction in the rat. J.Am.Coll.Cardiol. 44 1679. PMID:15489104."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=5467	SQ1533			Feb-2009
3000	Iressa	[184475-35-2]	FC(C=C3)=C(Cl)C=C3NC2=NC=NC1=CC(OC)=C(OCCCN4CCOCC4)C=C12	"Orally active, selective EGFR inhibitor"	"Orally active, selective inhibitor of EGFR tyrosine kinase (IC50 = 23 - 79 nM). Shows minimal activity against ErbB2, KDR, c-flt, PKC, MEK and ERK-2. Blocks EGFR autophosphorylation and inhibits tumor growth in mice bearing a range of human xenografts."	"Ciardiello et al (2000) Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin.Cancer Res. 6 2053. PMID:10815932. Baselga et al (2000) ZD1839 ('Iressa'), as an anticancer agent. Drugs 60 (Suppl. 1) 33. PMID:11129170. McKillop et al (2005) Tumor penetration of gefitinib (Iressa), an epidermal growth factor receptor tyrosine kinase inhibitor. Mol.Cancer Ther. 4 641. PMID:15827338."	Small Molecule	Sold for research purposes only under agreement from AstraZeneca	http://www.tocris.com/dispprod.php?ItemId=67981	SQ1533			Aug-2008
3002	Idebenone	[58186-27-9]	O=C(C(OC)=C1OC)C(CCCCCCCCCCO)=C(C)C1=O	Antioxidant and neuroprotective agent	Antioxidant and neuroprotective agent. Protects mitochondrial membranes against lipid peroxidation and blocks glutamate neurotoxicity in vitro and in vivo. Inhibits apoptosis of astrocytes via increased NGF production.	"Zs-Nagy (1990) Chemistry, toxicology, pharmacology and pharmacokinetics of idebenone: a review. Arch.Gerontol.Geriatr. 11 177. PMID:15374467. Civenni et al (1999) Inhibitory effect of the neuroprotective agent idebenone on arachidonic acid metabolism in astrocytes. Eur.J.Pharmacol. 370 161. PMID:10323265. Takuma et al (2000) CV-2619 protects cultured astrocytes against reperfusion injury via nerve growth factor production. Eur.J.Pharmacol. 406 333. PMID:11040339."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=56738	SQ1533			Feb-2008
3003	Coenzyme Q10	[303-98-0]	O=C(C(OC)=C1OC)C(C/C=C(C)/CC/C=C(C)/CC/C=C(C)/CC/C=C(C)/CC/C=C(C)/CC/C=C(C)/CC/C=C(C)/CC/C=C(C)/CC/C=C(C)/CC/C=C(C)/C)=C(C)C1=O	Antioxidant	Component of the mitochondrial transporter chain that behaves as a powerful antioxidant. Displays neuroprotective activity.	Shults (2003) Coenzyme Q10 in neurodegenerative diseases. Curr.Med.Chem. 10 1917. PMID:12871093. Young et al (2007) Coenzyme Q10: a review of its promise as a neuroprotectant. CNS Spectr. 12 62. PMID:17192765.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=5470	SQ1533			Mar-2008
3016	Miconazole nitrate	[22832-87-7]	ClC1=CC(Cl)=CC=C1COC(CN3C=CN=C3)C2=CC=C(Cl)C=C2Cl.O[N+]([O-])=O	Antifungal agent	Antifungal agent. Inhibits lanosterol demethylase and induces formation of reactive oxygen species.	Chang et al (2005) Effect of miconazole on intracellular Ca2+ levels and proliferation in human osteosarcoma cells. Life Sci. 76 2091. PMID:15826876.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=66496	SQ1533			Mar-2008
3017	1-Methylpsilocin	[1465-16-3]	OC1=C2C(N(C)C=C2CCN(C)C)=CC=C1	Potent and selective 5-HT2C agonist	Potent and selective 5-HT2C agonist (IC50 values are 12 and 633 nM for 5-HT2C and 5-HT2A receptors respectively). Displays high affinity for the 5-HT2B receptor (Ki = 38 nM) but acts as an inverse agonist. Active in vivo; inhibits scratching in a mouse model of OCD.	Sard et al (2005) SAR of psilocybin analogs: discovery of a selective 5-HT2C agonist. Bioorg.Med.Chem.Letts. 15 4559.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=189836	SQ1341			Jun-2008
3022	Edelfosine	[77286-66-9]	CO[C@@H](COP(OCC[N+](C)(C)C)([O-])=O)COCCCCCCCCCCCCCCCCCC	"Selective PI-PLC inhibitor, also PAF receptor agonist"	"Synthetic lysophospholipid analog that selectively inhibits phosphatidylinositol phospholipase C (IC50= 9.6 _M in fibroblasts and adenocarcinoma cells). Also acts as an agonist at platelet-activating factor (PAF) receptors. Antitumor lipid; selectively induces apoptosis in tumor cells, sparing normal cells."	Powis et al (1992) Selective inhibition of phosphatidylinositol phospholipase C by cytotoxic ether lipid analogues. Cancer Res. 52 2835. PMID:1316230. Aoki et al (1995) A radioreceptor binding assay for platelet-activating factor (PAF) using membranes from CHO cells expressing human PAF receptor. J.Immunol.Methods 186 225. PMID:7594622. Shimizu et al (2007) Roles of brain phosphatidylinositol-specific phospholipase C and diacylglycerol lipase in centrally administered histamine-induced adrenomedullary outflow in rats. Eur.J.Pharmacol. 571 138. PMID:17628524. Wong et al (2007) Phospholipase C and myosin light chain kinase inhibition define a common step in actin regulation during cytokinesis. BMC Cell Biol. 8 15. PMID:17509155.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=189845	SQ1070			Apr-2008
3023	CP 31398 dihydrochloride	[1217195-61-3]	COC(C=C3)=CC=C3/C=C/C2=NC1=CC=CC=C1C(NCCCN(C)C)=N2.Cl.Cl	p53-stabilizing agent	p53 stabilizing agent. Stabilizes the active conformation of p53 and promotes p53 activity in cancer cell lines with mutant or wild-type p53. Inhibits growth of small human tumor xenografts in vivo.	"Foster et al (1999) Pharmacological rescue of mutant p53 conformation and function. Science 286 2507. PMID:10617466. Wischhusen et al (2003) CP-31398, a novel p53-stabilizing agent, induces p53-dependent and p53-independent glioma cell death. Oncogene 22 8233. PMID:14614447. Demma et al (2004) CP-31398 restores DNA-binding activity to mutant p53 in vitro but does not affect p53 homologs p63 and p73. J.Biol.Chem. 279 45887. PMID:15308639."	Small Molecule	Sold for research purposes under agreement from Pfizer Inc.	http://www.tocris.com/dispprod.php?ItemId=189846	SQ1070			Nov-2008
3025	AA 2414	[112665-43-7]	O=C1C(C)=C(C)C(C(C(C2=CC=CC=C2)CCCCCC(O)=O)=C1C)=O	Thromboxane A2 (TP) receptor antagonist	Thromboxane A2 (TP) receptor antagonist. Antiasthmatic agent; inhibits platelet aggregation and bronchoconstriction induced by a TXA2 mimetic in guinea pigs.	"Ashida et al (1989) A novel anti-asthmatic quinone derivative, AA-2414 with a potent antagonistic activity against a variety of spasmogenic prostanoids. Prostaglandins 38 91. PMID:2748922. Kurokawa et al (1994) Antagonism of the human thromboxane A2 receptor by an anti-asthmatic agent AA-2414. Biol.Pharm.Bull. 17 383. PMID:8019502. Cui et al (2007) Leukotrienes and cyclooxygenase products mediate anaphylactic venoconstriction in ovalbumin sensitized rat livers. Eur.J.Pharmacol. 576 99. PMID:17706964."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=189883	SQ1533			Apr-2008
3026	ONO 1078	[103177-37-3]	O=C2C1=CC=CC(NC(C4=CC=C(OCCCCC5=CC=CC=C5)C=C4)=O)=C1OC(C3=NN=NN3)=C2	Selective CysLT1 antagonist	"Selective cysteinyl leukotriene receptor 1 (CysLT1) antagonist (IC50 values are ~ 4 - 7 and 3620 nM for CysLT1 and CysLT2 respectively). Inhibits contraction of airway smooth muscle, microvascular leakage into airways and eosinophil infiltration. Can decrease symptoms of bronchial asthma."	Lynch et al (1999) Characterization of the human leukotriene CysLT1 receptor. Nature 399 789. PMID:10391245. Heise et al (2000) Characterization of the human cysteinyl leukotriene 2 receptor. J.Biol.Chem. 275 30531. PMID:10851239. Suzuki et al (2003) Inhibition of human eosinophil activation by a cysteinyl leukotriene receptor antagonist (Pranlukast; ONO-1078). J.Asthma 40 395. PMID:12870835.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=189884	SQ1533			Jul-2008
3034	NSC 109555 ditosylate	[66748-43-4]	O=C(NC2=CC=C(/C(C)=N/NC(N)=N)C=C2)NC1=CC=C(/C(C)=N/NC(N)=N)C=C1.CC3=CC=C(S(=O)(O)=O)C=C3.CC4=CC=C(S(=O)(O)=O)C=C4	Selective Chk2 inhibitor	"Selective, reversible, ATP-competitive Chk2 inhibitor (IC50 = 0.2 _M) that displays no effect on a range of other kinases including Chk1 (IC50 > 10 _M). Inhibits histone H1 phosphorylation (IC50 = 0.24 _M) and attenuates mitochondrial ATP synthesis. Exhibits antiproliferative activity in a number of leukemias in vivo."	"Byczkowski et al (1981) Actions of bis(guanylhydrazones) on isolated rat liver mitochondria. Biochem.Pharmacol. 30 2851. PMID:6895596. Byczkowski et al (1982) Potentiation of the antimitochondrial and antiproliferative effects of bis(guanylhydrazones) by phenethylbiguanide. Cancer Res. 42 3592. PMID:6896674. Jobson et al (2007) Identification of a bis-guanylhydrazone [4,4'-diacetyldiphenylurea-bis(guanylhydrazone); NSC 109555] as a novel chemotype for inhibition of Chk2 kinase. Mol.Pharmacol. 72 876. PMID:17616632."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=190401				Mar-2009
3035	SD 1008	[960201-81-4]	O=C1C=C[C@@H]2[C@@H]([C@](OC)=O)[C@@H]([C@](OC)=O)[C@H]1N2CC3=CC=CC=C3.O=C4C=C[C@H]5[C@H](C(OC)=O)[C@H](C(OC)=O)[C@@H]4N5CC6=CC=CC=C6	JAK2/STAT3 signaling pathway inhibitor	"JAK2/STAT3 signaling pathway inhibitor. Inhibits activation of STAT3, JAK2 and Src. Induces apoptosis in cell lines expressing constitutively active tyrosine-phosphorylated STAT3."	"Duan et al (2007) 8-benzyl-4-oxo-8-azabicyclo[3.2.1]oct-2-ene-6,7-dicarboxylic acid (SD-1008), a novel Janus kinase 2 inhibitor, increases chemotherapy sensitivity in human ovarian cancer cells. Mol.Pharmacol. 72 1137. PMID:17675586."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=190404	SQ1070			Jul-2010
3037	SU 5416	[204005-46-9]	O=C2NC1=CC=CC=C1/C2=C/C3=C(C)C=C(C)N3	"VEGFR inhibitor. Also inhibits KIT, RET, MET and FLT3"	"Inhibitor of vascular endothelial growth factor receptor (VEGFR) that also inhibits other tyrosine kinases KIT, MET, FLT3 and RET. Displays no activity against EGFR, HER2, IGF1R and PDGFR. Inhibits tumor vascularization and growth of multiple tumor types."	"Fong et al (1999) SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularisation, and growth of multiple tumor types. Cancer Res. 59 99. PMID:9892193. Smolich et al (2001) The antiangiogenic protein kinase inhibitors SU5416 and SU6668 inhibit the SCF receptor (c-Kit) in a human myeloid leukemia cell line and in acute myeloid leukemia blasts. Blood 97 1413. PMID:11222388. Mologni et al (2006) Inhibition of RET tyrosine kinase by SU5416. J.Mol.Endocrinol. 37 199. PMID:17032739."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=190684	SQ1533			Sep-2008
3039	YM 750	[138046-43-2]	O=C(NC5=C(C)C=C(C)C=C5C)N(C4CCCCCC4)CC3=CC2=C(C=C3)C1=CC=CC=C1C2	Acyl-CoA:cholesterol acyltransferase (ACAT) inhibitor	Acyl-CoA:cholesterol acyltransferase (ACAT) inhibitor (IC50 = 0.18 _M). Exhibits hypocholesterolaemic and antiatherosclerotic activity in vivo.	"Nagata et al (1995) N-[2-[N'-pentyl-(6,6-dimethyl-2,4-heptadiynyl)amino]ethyl]-(2-methyl-1-naphthylthio)acetamide (FY-087). A new acyl coenzyme A: cholesterol acyltransferase (ACAT) inhibitor of diet-induced atherosclerosis formation in mice. Biochem.Pharmacol. 49 643. PMID:7887979. Kamiya et al (2000) Bioavailable acyl-CoA: cholesterol acyltransferase inhibitor with anti-peroxidative activity: synthesis and biological activity of novel indolinyl amide and urea derivatives. Chem.Pharm.Bull. 48 817. PMID:10866142. Miike et al (2008) Effects of an anti-oxidative ACAT inhibitor on apoptosis/necrosis and cholesterol accumulation under oxidative stress in THP-1 cell dervied foam cells. Life Sci. 82 79. PMID:18037448."	Small Molecule	Sold with the permission of Astellas Pharma Inc.	http://www.tocris.com/dispprod.php?ItemId=190686	SQ1070			Aug-2010
3040	WS 12	[68489-09-8]	C[C@H](C)[C@H]1[C@H]([C@@](NC2=CC=C(OC)C=C2)=O)C[C@H](C)CC1	TRPM8 agonist; cooling agent	Potent TRPM8 agonist that acts as a cooling agent (EC50 = 193 nM).	Beck et al (2007) Prospects for prostate cancer imaging and therapy using high-affinity TRPM8 activators. Cell Calcium 41 285. PMID:16949669. Bodding et al (2007) Characterisation of TRPM8 as a pharmacophore receptor. Cell Calcium 42 618. PMID:17517434.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=190687	SQ1341			Jun-2008
3041	CP 809101 hydrochloride	[1215721-40-6]	ClC1=CC(COC2=NC(N3CCNCC3)=CN=C2)=CC=C1.Cl	Potent and selective 5-HT2C agonist	"Potent and selective 5-HT2C receptor agonist (pEC50 values are 9.96, 7.19 and 6.81 for human 5-HT2C, 5-HT2B and 5-HT2A receptors respectively). Displays antipsychotic activity; suppresses condition avoidance responding (CAR) and inhibits PCP and amphetamine-stimulated hyperactivity in rats following subcutaneous administration."	"Siuciak et al (2007) CP-809,101, a selective 5-HT2C agonist, shows activity in animal models of antipsychotic activity. Neuropharmacology 52 279. PMID:16949622. Kalgutkar et al (2007) Genotoxicity of 2-(3-chlorobenzyloxy)-6-(piperazinyl)pyrazine, a novel 5-hydroxytryptamine2c receptor agonist for the treatment of obesity: role of metabolic activation. Drug Metab.Dispos. 35 848. PMID:17344339. Jensen et al (2013) Design, synthesis, and pharmacological characterization of N- and O-substituted 5,6,7,8-tetrahydro-4H-isoxazolo[4,5-d]azepin-3-ol analogues: novel 5-HT2A/5-HT2C receptor agonists with pro-cognitive properties. J.Med.Chem 56 1211. PMID:23301527."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=190760	SQ1070			Apr-2008
3043	AC 45594	[13037-86-0]	OC1=CC=C(OCCCCCCC)C=C1	SF-1 inverse agonist	"Selective inverse agonist at the orphan nuclear receptor steroidogenic factor-1 (SF-1) (IC50= 50 - 100 nM).  Displays no activity at estrogen, LRH-1, ROR, ERR or Nurr receptors. Inhibits SFRE-mediated transcription."	Del Tredici et al (2008) Identification of the first synthetic steroidogenic factor 1 inverse agonist.: pharmacological modulation of steroidogenic enymes. Mol.Pharmacol. 73 900. PMID:18055761.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=190959	SQ1341			Mar-2008
3044	PD 173074	[219580-11-7]	O=C(NC(C)(C)C)NC2=NC1=NC(NCCCCN(CC)CC)=NC=C1C=C2C3=CC(OC)=CC(OC)=C3	FGFR1 and -3 inhibitor	"Selective FGFR1 and FGFR3 inhibitor (IC50 values are 5, 21.5, ~100, 17600 and 19800 nM for FGFR3, FGFR1, VEGFR2, PDGFR and c-Src respectively, and > 50000 nM for EGFR, InsR, MEK and PKC). Inhibits VEGF- and FGF-induced angiogenesis in the mouse cornea model of angiogenesis. Inhibits proliferation and differentiation of oligodendrocyte progenitors. Suppresses cell proliferation in cell lines expressing mutated FGFR3 protein. Blocks tumor growth in H510 and H69 SCLC xenograft models."	"Bansal et al (2003) Specific inhibitor of FGF receptor signaling: FGF-2-mediated effects on proliferation, differentiation, and MAPK activation are inhibited by PD173074 in oligodendrocyte-lineage cells. J.Neurosci.Res. 74 486. PMID:14598292. Trudel et al (2004) Inhibition of fibroblast growth factor receptor 3 induces differentiation and apoptosis in t(4;14) myeloma. Neoplasia 103 3521. Pardo et al (2010) The fibroblast growth factor receptor inhibitor PD173074 blocks small cell lung cancer growth in vitro and in vivo. Cancer Res. 69 8645. Miyake et al (2010) 1-tert-butyl-3-[6-(3,5-dimethoxy-phenyl)-2-(4-diethylamino-butylamino)-pyrido[2,3-d]pyrimidin-7-yl]-urea (PD173074), a selective tyrosine kinase inhibitor of fibroblast growth factor receptor-3 (FGFR3), inhibits cell proliferation of bladder cancer carrying the FGFR3 gene mutation along with up-regulation of p27/Kip1 and G1/G0 arrest. J.Pharmacol.Exp.Ther. 332 795. PMID:19955487."	Small Molecule	Sold for research purposes under agreement from Pfizer Inc.	http://www.tocris.com/dispprod.php?ItemId=190969	SQ1533			Oct-2009
3046	Alphaxalone	[23930-19-0]	O=[C@](C)[C@H]3CC[C@@]([C@@](C)3C4)([H])[C@]2([H])CC[C@@]1([H])C[C@H](O)CC[C@@](C)1[C@]([H])2C4=O	Direct activator and potentiator of GABAA	"A neurosteroid anesthetic that directly activates and potentiates GABAA receptor-activated membrane current (IGABA). Efficacy but not potency is determined by the alpha subunit of the receptor (EC50 values are 1.4, 1.8, 2.1, 2.4 and 2.5 _M for _1_1_3, _1_1_1, _1_1, _2_1_2L and _1_1_2L isoforms respectively)."	Maitra et al (1999) Subunit dependent modulation of GABAA receptor function by neuroactive steroids. Brain Res. 819 75. PMID:10082863. Wegner et al (2007) Auto-modulation of neuroactive steroids on GABAA receptors: a novel pharmacological effect. Neuropharmacology. 52 672. PMID:17084864. Zecharia et al (2009) The involvement of hypothalamic sleep pathways in general anesthesia: Testing the hypothesis using the GABAA receptor _3N265M knock-in mouse. J.Neurosci. 29 2177. PMID:19228970.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=190987	SQ1533			May-2008
3050	Tamsulosin hydrochloride	[106463-17-6]	C[C@@H](NCCOC2=CC=CC=C2OCC)CC1=CC=C(OC)C(S(=O)(N)=O)=C1.Cl	Selective _1A antagonist	"Selective _1A-adrenoceptor antagonist (pKi values are 9.97, 9.64 and 8.86 for _1A, _1B and _1D subtypes respectively). Decreases resting maximal urethral pressure with negligable effect on mean arterial blood pressure in vivo."	Garcia-Sainz et al (1995) Alpha 1-adrenoceptor subtype selectivity of tamsulosin: studies using livers from different species. Eur.J.Pharmacol. 289 1. PMID:7781702. Taguchi et al (1997) Effects of tamsulosin metabolites at alpha-1 adrenoceptor subtypes. J.Pharmacol.Exp.Ther. 280 1. PMID:8996174. Ohtake et al (2005) Effects of tamsulosin on resting urethral pressure and arterial blood pressure in anaesthetized female dogs. J.Pharm.Pharmacol. 58 345.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=191269	SQ1533			May-2008
3052	RO-3	[1026582-88-6]	NC1=NC(N)=NC=C1CC2=C(C(C)C)C=C(OC)C(OC)=C2	Selective P2X3 and P2X2/3 antagonist	"Selective homomeric P2X3 and heteromeric P2X2/3 receptor antagonist (pIC50 values are 7.0 and 5.9 respectively) that exhibits no activity at P2X1, P2X2, P2X4, P2X5 and P2X7 receptors (IC50 > 10 _M). Attenuates nociceptive sensitivity in animal models of pain. Orally active and brain penetrant."	Ford et al (2006) Purinoceptors as therapeutic targets for lower urinary tract dysfunction. Br.J.Pharmacol. 147 S132. PMID:16465177. Gever et al (2006) Pharmacology of P2X channels. Eur.J.Physiol. 452 513. Donnelly-Roberts et al (2008) Painful purinergic receptors. J.Pharmacol.Exp.Ther. 324 409. PMID:18042830.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=191427	SQ1341			Dec-2008
3053	Mesopram	[189940-24-7]	O=C1O[C@@](C2=CC(OCCC)=C(OC)C=C2)(C)CN1	Orally active PDE4 inhibitor	"Orally active phosphodiesterase (PDE) 4 inhibitor. Inhibits Th1 cell proliferation and decreases production of IFN-_, TNF-_, IL-10 and iNOS in vitro. Triggers ovulation and exhibits efficacy against experimental autoimmune encephalomyelitis and murine colitis in vivo."	Dinter et al (2000) The type IV phosphodiesterase specific inhibitor mesopram inhibits experimental autoimmune encephalomyelitis in rodents. J.Neuroimmunol. 108 136. PMID:10900347. Loher et al (2003) The specific type-4 phosphodiesterase inhibitor mesopram alleviates experimental colitis in mice. J.Pharmacol.Exp.Ther. 305 549. PMID:12606674. McKenna et al (2005) Pharmacological inhibition of phosphodiesterase 4 triggers ovulation in follicle-stimulating hormone-primed rats. Endocrinology 146 208. PMID:15448112.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=191476	SQ1070			Aug-2009
3056	Pentoxifylline	[6493-05-6]	O=C(C(N(C)C=N2)=C2N1C)N(CCCCC(C)=O)C1=O	PDE inhibitor	Phosphodiesterase inhibitor that blocks production of TNF-_ and other cytokines. Displays antinociceptive activity.	Monshouwer et al (1996) Differential effect of pentoxifylline on lipopolysaccharide-induced downregulation of cytochrome P450. Biochem.Pharmacol. 52 1195. PMID:8937426. Vale et al (2004) Antihyperalgesic effect of pentoxifylline on experimental inflammatory pain. Br.J.Pharmacol. 143 833. PMID:15520047.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=191479	SQ1533			Mar-2008
3057	Lidocaine	[137-58-6]	O=C(CN(CC)CC)NC1=C(C)C=CC=C1C	Na+ channel blocker	Anasthetic and class Ib antiarrhythmic agent.  Blocks voltage-gated sodium channels in the inactivated state.	Sarraf et al (2003) Tedisamil and lidocaine enhance each other's antiarrhythmic activity against ischaemia-induced arrhythmias in rats. Br.J.Pharmacol. 139 1389. PMID:12922925.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=191480	SQ1533			Mar-2008
3058	Ellagic acid	[476-66-4]	OC1=C(O)C=C(C(C3=C2C=C(O)C(O)=C3O4)=C1OC2=O)C4=O	Selective inhibitor of CK2. Also inhibits glutathione S-transferase	"Selective, ATP-competitive inhibitor of casein kinase 2 (CK2) (IC50 values are 40, 2900, 3500, 4300 and 9400 nM for CK2, Lyn, PKA, Syk  and FGR respectively). Exhibits antioxidant, antitumor and anticarcinogenic activity and also inhibits glutathione S-transferase."	Cozza et al (2006) Identification of ellagic acid as potent inhibitor of protein kinase CK2: a successful example of a virtual screening application. J.Med.Chem. 49 2363. PMID:16610779. Han et al (2006) Antioxidant and apoptosis-inducing activities of ellagic acid. Anticancer Res. 26 3601. PMID:17094489. Hayeshi et al (2007) The inhibition of human glutathione S-transferases activity by plant polyphenolic compounds ellagic acid and curcumin. Food Chem.Toxicol. 45 286. PMID:17046132.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=191489	SQ1533			Apr-2008
3060	A 841720	[869802-58-4]	O=C(N(N4CCCCCC4)C=N3)C2=C3C1=C(N(C)C)C=CN=C1S2	Selective mGlu1 antagonist	"Potent, non-competitive mGlu1 receptor antagonist that displays 34-fold selectivity over mGlu5 (IC50 values are 10 and 342 nM respectively). Displays no significant activity at a range of other GPCRs, ion channels and transporters. Exhibits analgesic effects; decreases mechanical allodynia in models of neuropathic pain. Also impairs cognitive function."	"Zheng et al (2005) Structure-activity relationship of triazafluorenone derivatives as potent and selective mGluR1 antagonists. J.Med.Chem. 48 7374. PMID:16279797. El-Kouhen et al (2006) Blockade of mGluR1 receptor results in analgesia and disruption of motor and cognitive performances: effects of A-841720, a novel non-competitive mGluR1 receptor antagonist. Br.J.Pharmacol. 149 761. PMID:17016515. More et al (2007) Comparison of the mGluR1 antagonist A-841720 in rats models of pain and cognition. Behav.Pharmacol. 18 273. PMID:17551319."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=191699	SQ1070			Mar-2009
3062	NS 1643	[448895-37-2]	OC1=C(NC(NC2=C(O)C=CC(C(F)(F)F)=C2)=O)C=C(C(F)(F)F)C=C1	KV11.1 (hERG) channel activator; antiarrhythmic	Human ether-a-go-go related gene (hERG) KV11.1 channel activator (EC50 = 10.5 _M). Exhibits different molecular mechanisms of action at KV11.1 (hERG1) and KV11.2 (hERG2) channels. Displays antiarrhythmic activity in vitro.	"Hansen et al (2006) Activation of human ether-a-go-go related gene potassium channels by the diphenylurea 1,3-bis-(2-hydroxy-5-trifluoromethyl-phenyl)-urea (NS1643). Mol.Pharmacol. 69 266. PMID:16219910. Casis et al (2006) Mechanism of action of a novel human ether-a-go-ao related gene channel activator. Mol.Pharmacol. 69 658. PMID:16284303. Elmedyb et al (2007) Activation of ERG2 potassium channel by the diphenylurea NS1643. Neuropharmacology 53 283. PMID:17610913."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=191862	SQ1070			Jan-2009
3063	1-Naphthyl PP1	[221243-82-9]	NC1=NC=NC2=C1C(C3=C4C(C=CC=C4)=CC=C3)=NN2C(C)(C)C	Src family kinase inhibitor; also inhibits c-Abl	"Selective inhibitor of src family kinases v-Src and c-Fyn as well as the tyrosine kinase c-Abl. (IC50 values are 1.0, 0.6, 0.6, 18 and 22 _M for v-Src, c-Fyn, c-Abl, CDK2 and CAMK II respectively). Preferentially inhibits mutant over wild-type kinases (IC50 values are 1.5 vs 1000 nM for I338G v-src and v-src respectively)."	Bishop et al (1999) Generation of monospecific nanomolar tyrosine kinase inhibitors via a chemical genetic approach. J.Am.Chem.Soc. 121 627. Bishop et al (2000) A chemical switch for inhibitor-sensitive alleles of any protein kinase. Nature 407 395. PMID:11014197.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=191870	SQ1341			Apr-2008
3066	L 006235	[294623-49-7]	O=C(C2=CC=C(C3=CSC(N4CCN(C)CC4)=N3)C=C2)NC1(CCCCC1)C(NCC#N)=O	Potent cathepsin K inhibitor	"Potent, reversible cathepsin K inhibitor (IC50 = 0.25 nM) that displays > 4000-fold selectivity over cathepsins B, L and S. Displays reduced selectivity in cell-based assays possibly due to lysosomal accumulation. Reduces collagen breakdown and promotes bone deposition in vivo. Orally active and has intrinsic fluorescence."	"Palmer et al (2005) Design and synthesis of tri-ring P3 benamide-containing aminonitriles as potent, selective, orally effective inhibitors of cathepsin K. J.Med.Chem. 48 7520. PMID:16302794. Falgueyret et al (2005) Lysosomotropism of basic cathepsin K inhibitors contributes to increased cellular potencies against off-target cathepsins and reduced functional selectivity. J.Med.Chem. 48 7535. PMID:16302795. Desmarais et al (2008) Effects of cathepsin K inhibitors basicity on in vivo off-target activities. Mol.Pharmacol. 73 147. PMID:17940194."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=191873	SQ1070			Nov-2010
3067	Desipramine hydrochloride	[58-28-6]	CNCCCN2C1=CC=CC=C1CCC3=C2C=CC=C3.Cl	Selective inhibitor of noradrenalin transporters	"Tricyclic antidepressant that is a selective inhibitor of noradrenalin transporters (Ki values are 4, 61 and 78720 nM for NET, SERT and DAT transporters respectively)."	"Torres et al (2003) Plasma membrane monoamine transporters: structure, regulation and function. Nat.Rev.Neurosci. 4 13. PMID:12511858. Zhao et al (2008) Norepinephrine transporter regulation mediates the long-term behavioral effects of the antidepressant desipramine. Neuropsychopharmacol. 33 3190."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=191874	SQ1533			May-2008
3068	Tetraethylammonium chloride	[56-34-8]	CC[N+](CC)(CC)CC.[Cl-]	Non-selective K+ channel blocker	Non-selective K+ channel blocker.	Niu et al (2008) Vasorelaxant effect of taurine is diminished by tetraethylammonium in rat isolated arteries. Eur.J.Pharmacol. 580 169. PMID:17997400.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=191875	SQ1533			Apr-2008
3069	Acephate	[30560-19-1]	CC(NP(OC)(SC)=O)=O	Anticholinesterase insecticide	Anticholinesterase insecticide that produces cholinotoxicity. Displays weak inhibition of rat acetylcholinesterase (AChE) but potently inhibits cockroach AChE.	Singh (1990) Molecular properties and inhibition of acetylcholinesterase obtained from rat brain and cockroach ganglion. Toxicol.Ind.Health 6 551. Kumar (2004) Changes in rat brain regions serotoninergic system following acephate poisoning. Pest.Biochem.Physiol. 78 140.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=191876				May-2008
3070	Thioridazine hydrochloride	[130-61-0]	CN(CCCC4)C4CCN2C3=C(C=CC(SC)=C3)SC1=CC=CC=C12.Cl	Dopamine receptor antagonist; antipsychotic	"Dopamine receptor antagonist that displays antipsychotic activity. Exhibits anticancer activity in cervical, endometrial and breast cancer cells; triggers apoptosis by targeting the PI 3-K/Akt/mTOR/p70 S6K pathway. Induces G1 cell cycle arrest. Selective inducer of cancer stem cell (CSC) differentiation."	Merck Index 13 9435. Sachlos et al (2012) Identification of drugs including a dopamine receptor antagonist that selectively target cancer stem cells. Cell. May 23. Epub ahead of print. PMID:22632761. Kang et al (2012) Thioridazine induces apoptosis by targeting the PI3K/Akt/mTOR pathway in cervical and endometrial cancer cells. Apoptosis. Mar 30 Epub ahead of print. PMID:22460505.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=191877	SQ1533			May-2008
3071	Dextromethorphan hydrobromide	[6700-34-1]	[H][C@@]12[C@@H]4CC(C=CC(OC)=C3)=C3[C@@](CCN4C)1CCCC2.Br	NMDA receptor antagonist	"Non-competitive, low affinity NMDA receptor antagonist. Antitussive, anticonvulsive and neuroprotective agent."	Choi et al (1987) Dextrorophan and levorphanol selectively block N-methyl-D-aspartate receptor-mediated neurotoxicity on corticol neurons. J.Pharmacol.Exp.Ther. 242 713. PMID:3039122. Keller et al (2008) Dextromethorphan is protective against sensitized N-methyl-D-aspartate receptor-mediated excitotoxic brain damage in the developing mouse brain. Eur.J.Neurosci. 27 874. PMID:18279363.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=191878	SQ1533			Apr-2008
3072	Diphenhydramine hydrochloride	[147-24-0]	CN(CCOC(C2=CC=CC=C2)C1=CC=CC=C1)C.Cl	H1 receptor antagonist	H1 receptor antagonist. Antihistamine.	Khalia et al (1999) Block of potassium currents in guinea pig ventricular myocytes and lengthening of cardiac repolarization in man by the histamine H1 receptor antagonist diphenhydramide. J.Pharmacol.Exp.Ther. 288 858. PMID:9918600.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=191879	SQ1533			Apr-2008
3074	(+)-Muscarine iodide	[24570-49-8]	O[C@@H]1C[C@@H](C[N+](C)(C)C)O[C@H]1C.[I-]	Muscarinic receptor agonist	Muscarinic acetylcholine receptor agonist; mimics the activity of acetylcholine.	"Jin (2003) Muscarine, imidazole, oxazole and thiazole alkaloids. Nat.Prod.Rep. 20 584. PMID:14700201. Boukouvalas et al (2007) A concise asymmetric synthesis of (+)-muscarine from (S)-_-hydroxymethyl-_-butyrolactone. Tetrahedron Lett. 48 2971."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=192015				Aug-2011
3075	GSK 4716	[101574-65-6]	OC1=CC=C(C(N/N=C/C2=CC=C(C(C)C)C=C2)=O)C=C1	Selective ERR_ and ERR_ agonist	Selective agonist at estrogen-related receptors ERR_ and ERR_. Displays selectivity over ERR_ and the classical estrogen receptors.	Zuercher et al (2005) Identification and structure-activity relationship of phenolic acyl hydrazones as selective agonists for the estrogen-related orphan nuclear receptors ERR_ and ERR_. J.Med.Chem. 48 3107. PMID:15857113. Ariazi and Jordan (2006) Estrogen-related receptors as emerging targets in cancer and metabolic disorders. Curr.Top.Med.Chem. 6 203. PMID:16515477. Wang et al (2006) X-ray crystal structures of the estrogen-related receptor-gamma ligand binding domain in three functional states reveal the molecular basis of small molecule regulation. J.Biol.Chem. 281 37773. PMID:16990259.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=192091				May-2008
3077	LY 272015 hydrochloride	[172895-15-7]	CC1=CC=C(NC3=C2CCNC3CC4=CC=C(OC)C(OC)=C4)C2=C1.Cl	High affinity 5-HT2B antagonist; orally active	"High affinity 5-HT2B receptor antagonist that displays selectivity over 5-HT2A and 5-HT2C receptors (Ki values are 0.75, 21.63 and 28.7 nM for 5-HT2B, 5-HT2C and 5-HT2A receptors respectively). Orally active."	"Cohen et al (1996) LY272015, a potent, selective and orally active 5-HT2B receptor antagonist. J.Serotonin Res. 3 131. Sevoz-Couche et al (2000) In vivo modulation of vagal-identified dorsal medullary neurones by activation of different 5-Hydroxytryptamine2 receptors in rat. Br.J.Pharmacol. 131 1445. PMID:11090119. Niebert et al (2011) Expression and function of serotonin 2A and 2B receptors in the mammalian respiratory network. PLoS One 6 e21395. PMID:21789169."	Small Molecule	Sold under license from Eli Lilly and company	http://www.tocris.com/dispprod.php?ItemId=192173	SQ1341			Jul-2008
3078	LY 310762 hydrochloride	[192927-92-7]	CC(C1=CC=CC=C1N2CCN3CCC(C(C4=CC=C(F)C=C4)=O)CC3)(C)C2=O.Cl	5-HT1D-preferring antagonist	5-HT1D-preferring receptor antagonist (EC50 = 31 nM). Displays no activity on 5-HT transport.	Pullar et al (2004) The role of the 5-HT1D receptor as a presynaptic autoreceptor in the guinea pig. Eur.J.Pharmacol. 493 85. PMID:15189767.	Small Molecule	Sold under license from Eli Lilly and company	http://www.tocris.com/dispprod.php?ItemId=192174	SQ1533			Aug-2008
3079	LY 334370 hydrochloride	[199673-74-0]	O=C(C4=CC=C(F)C=C4)NC1=CC=C(NC=C2C3CCN(C)CC3)C2=C1.Cl	Selective 5-HT1F agonist	"Selective 5-HT1F receptor agonist (Ki values are 1.87, 16.4, > 100 (IC50), 176, 189, 281, 1280, 1530, 1550, > 3000 (IC50) and 3250 nM for 5-HT1F, 5-HT1A, 5-HT4, 5-HT1E, 5-HT1B, 5-HT1D, 5-HT2B, 5-HT2A, 5-HT7, 5-HT6 and 5-HT2C receptors respectively). Displays antimigraine effects."	"Dupuis et al (1998) G-protein activationat 5-HT1A receptors by the 5-ht1F ligand LY334370 in guinea-pig brain sections and recombinant cell lines. Br.J.Pharmacol. 124 283. PMID:9641544. Shepheard et al (1999) Possible antimigraine mechanisms of action of the 5-HT1F receptor agonist LY334370. Cephalalgia 19 851. PMID:10668103. Wainscott et al (2005) [H3]LY334370, a novel radioligand for the 5-HT1F receptor. I. In vitro characterization of binding properties. Naunyn-Schmied.Arch.Pharmacol. 371 169."	Small Molecule	Sold under license from Eli Lilly and company	http://www.tocris.com/dispprod.php?ItemId=192175	SQ1341			Sep-2008
3081	Nafamostat mesylate	[82956-11-4]	CS(=O)(O)=O.NC(C1=CC=C2C(C=CC(OC(C3=CC=C(NC(N)=N)C=C3)=O)=C2)=C1)=N.CS(=O)(O)=O	"Serine protease inhibitor, inhibits tryptase"	"Broad spectrum serine protease inhibitor. Displays selectivity for human tryptase when used at relatively low concentrations. Reduces eosinophil infiltration, mast cell activation and airway responsiveness in a murine model of asthma."	Mori et al (2003) Nafamostat mesilate is an extremely potent inhibitor of human tryptase. J.Pharmacol.Sci. 92 420. PMID:12939527. Sendo et al (2003) A potent tryptase inhibitor nafamostat mesilate dramatically suppressed pulmonary dysfunction induced in rats by a radiographic contrast medium. Br.J.Pharmacol. 138 959. PMID:12642398. Chen et al (2006) Serine protease inhibitors nafamostat mesilate and gabexate mesilate attenuate allergen-induced airway inflammation and eosinophilia in a murine model of asthma. J.Allergy Clin.Immunol. 118 105. PMID:16815145.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=192912	SQ1533			May-2008
3082	Tempol	[2226-96-2]	CC1(C)CC(O)CC(C)(C)N1[O]	Superoxide scavenger; antioxidant	"Superoxide scavenger that displays neuroprotective, anti-inflammatory and analgesic effects."	"Francis and Sehgal (2006) The superoxide scavenger TEMPOL induces urokinase receptor (uPAR) expression in human prostate cancer cells. Mol.Cancer 5 21. PMID:16756681. Khattab (2006) TEMPOL, a membrane-permeable radical scavenger, attenuates peroxynitrite- and superoxide anion-enhanced carrageenan-induced paw edema and hyperalgesia: a key role for superoxide anion. EurJ.Pharmacol. 548 167. Deng-Bryant et al (2008) Neuroprotective effect of tempol, a catalytic scavenger of peroxynitrite-derived free radicals, in a mouse traumatic brain injury model. J.Cereb.Blood Flow Metab. 28 1114. PMID:18319733."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=192913	SQ1533			May-2008
3083	DMCM hydrochloride	[1215833-62-7]	CCC1=C(C(OC)=O)N=CC3=C1C2=CC(OC)=C(OC)C=C2N3.Cl	Benzodiazepine inverse agonist	Benzodiazepine inverse agonist that displays anxiogenic and potent convulsant activity.	"Petersen (1983) DMCM: a potent convusive benzodiazepine receptor ligand. Eur.J.Pharmacol. 94 117. PMID:6317396. Sieve et al (2001) Pain and negative affect: evidence the inverse benzodiazepine agonist DMCM inhibits pain and learning in rats. Psychopharmacol. 153 180. Conto et al (2005) Behavioral differences between subgroups of rats with high and low threshold to clonic convulsions induced by DMCM, a benzodiazepine inverse agonist. Pharmacol.Biochem.Behav. 82 417. PMID:16297441."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=205179	SQ1070			Apr-2008
3084	Anacardic acid	[16611-84-0]	OC1=C(C(O)=O)C(CCCCCCCCCCCCCCC)=CC=C1	Noncompetitive PCAF/p300 HAT inhibitor	"Noncompetitive inhibitor of PCAF and p300 histone acetyltransferase (HAT) activity (IC50 values are ~5.0 and ~8.5 _M respectively). Inhibits NF-_B activation. Also reported to selectively activate Aurora kinase A-mediated phosphorylation of histone H3. Exhibits antitumor, antimicrobial and antioxidant activity."	"Balasubramanyam et al (2003) Small molecule modulators of histone acetyltransferase p300. J.Biol.Chem. 278 19134. PMID:12624111. Kishore et al (2008) Specific small molecule activator of aurora kinase A induces autophosphorylation in a cell-free system. J.Med.Chem. 51 792. PMID:18215015. Sung et al (2008) Anacardic acid (6-nonadecyl salicylic acid), an inhibitor of histone acetyltransferase, suppresses expression of nuclear factor-_B-regulated gene products involved in cell survival, proliferation, invasion, and inflammation through inhibition of the inhibitory subunit of nuclear factor-_B_ kinase, leading to potentiation of apoptosis. Blood 111 4880. PMID:18349320. Cui et al (2008) Histone acetyltransferase inhibitor anacardic acid causes changes in global gene expression during in vitro Plasmodium falciparum development. Eurkaryot.Cell 7 1200."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=205313	SQ1070			Feb-2012
3085	Ziprasidone hydrochloride	[138982-67-9]	O=C2CC1=CC(CCN3CCN(C4=NSC5=C4C=CC=C5)CC3)=C(Cl)C=C1N2.Cl	5-HT2A/D2 antagonist; atypical antipsychotic	"Atypical antipsychotic that displays combined serotonin and dopamine receptor antagonism. Displays high affinity at 5-HT2A receptors with a 5-HT2A/D2 affinity ratio greater than any other clinically available atypical antipsychotics (pKi values are 9.38, 8.88, 8.69, 8.47, 8.32, 8.14, 7.98, 7.49, 7.33 and 6.28 for 5-HT2A, 5-HT2C, 5-HT1D, 5-HT1A, D2, D3, _1, D4, H1 and D1 receptors respectively)."	"Seeger et al (1995) Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity. J.Pharmacol.Exp.Ther. 275 101. PMID:7562537. Schmidt et al (2001) Ziprasidone: a novel antipsychotic agent with a unique human receptor binding profile. Eur.J.Pharmacol. 425 197. PMID:11513838. Fell et al (2005) Investigation into the effects of the novel antipsychotic ziprasidone on weight gain and reproductive function in female rats. Behav.Brain Res. 160 338. PMID:15863230."	Small Molecule	Sold for research purposes under agreement from Pfizer Inc.	http://www.tocris.com/dispprod.php?ItemId=205316	SQ1533			Apr-2008
3086	"L-651,582"	[99519-84-3]	ClC1=CC=C(C(C2=C(Cl)C=C(CN3N=NC(C(N)=O)=C3N)C=C2Cl)=O)C=C1	Ca2+ channel blocker	"Orally active Ca2+ channel blocker; inhibits K+- and carbachol-stimulated Ca2+ influx (IC50 values are 500 and 935 nM respectively). Exhibits antiproliferative, antiangiogenic and antimetastatic activity in vivo and displays selectivity towards numerous mismatch repair-deficient tumor cell lines in vitro."	"Hupe et al (1991) The inhibition of receptor-mediated and voltage-dependent calcium entry by the antiproliferative L-651,582 J.Biol.Chem. 266 10136. PMID:1645340. Felder et al (1991) The antiproliferative and antimetastatic compound L651582 inhibits muscarinic acetylcholine receptor-stimulated calcium influx and arachidonic acid release. J.Pharm.Exp.Ther. 257 967. Yang et al (2008) Selective sensitivity to carboxyamidotriazole by human tumor cell lines with DNA mismatch repair deficiency. Int.J.Cancer. 123 258. PMID:18464258."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=205317	SQ1533			Feb-2009
3088	HU 308	[256934-39-1]	CCCCCCC(C)(C)C1=CC(OC)=C([C@]2([H])[C@H](C3)C(C)(C)[C@H]3C(CO)=C2)C(OC)=C1	Potent and selective CB2 agonist	"Potent and selective CB2 receptor agonist (Ki values are 22.7 nM and > 10 _M for CB2 and CB1 receptors respectively, EC50 = 5.57 nM). Displays antiallodynic activity in the rat hindpaw incision model of postoperative pain. Also neuroprotective and improves motor performance in a mouse model of Huntington's Disease."	"Hanus et al (1999) HU-308: a specific agonist for CB2, a peripheral cannabinoid receptor. Proc.Natl.Acad.Sci.USA 96 14228. PMID:10588688. LaBuda et al (2005) Cannabinoid CB2 receptor agonist activity in the hindpaw incision model of postoperative pain. Eur.J.Pharmacol. 527 172. PMID:16316653. Palazuelos et al (2009) Microglial CB2 cannabinoid receptors are neuroprotective in Huntington's disease excitotoxicity. Brain 132 3152. PMID:19805493."	Small Molecule	Sold under license from Hebrew University of Jerusalem	http://www.tocris.com/dispprod.php?ItemId=205396				Aug-2009
3089	CJ 033466	[519148-48-2]	ClC2=C(N)N1C(C(C(NCC3CCN(CC(C)C)CC3)=O)=C2)=NC(C)=C1	Selective 5-HT4 partial agonist	Potent and selective 5-HT4 partial agonist (EC50= 0.927 nM). Displays > 1000-fold selectivity for 5-HT4 over other 5-HT and D2 receptors. Exhibits gastroprokinetic effects in vivo following oral administration. Weakly blocks hERG (IC50 = 2.6 _M).	"Toga et al (2007) The 5-HT4 agonists cisapride, mosapride, and CJ-033466, a novel potent compound, exhibit different human ether-a-go-go-related gene (hERG)-blocking activities. J.Pharmacol.Sci. 105 207. PMID:17928736. Mikami et al (2008) 5-Amino-6-chloro-N-[(1-isobutylpiperidin-4-yl)methyl]-2-methylimidazo[1,2-_]pyridine-8-carboxamide (CJ-033,466), a novel and selective 5-hydroxytryptamine4 receptor partial agonist: pharmacological profile in vitro and gastroprokinetic effect in conscious dogs. J.Pharmacol.Exp.Ther. 325 190. PMID:18198343."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=205781	SQ1070			Oct-2008
3090	Gallein	[2103-64-2]	OC1=CC=C(C(C(C=CC=C5)=C5C(O4)=O)4C(C=CC(O)=C3O)=C3O2)C2=C1O	Inhibitor of __ signaling	Inhibitor of G protein __ subunit-dependent signaling. Blocks PI 3-kinase and Rac1 activation in HL60 cells and chemotaxis in HL60 differentiated cells.	Lehmann et al (2008) Small molecule disruption of G protein __ subunit signaling inhibits neutrophil chemotaxis and inflammation. Mol.Pharmacol. 73 410. PMID:18006643. Ukhanov et al (2011) Phosphoinositide 3-kinase-dependent antagonism in mammalian olfactory receptor neurons. J.Neurosci. 31 273. PMID:21209212.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=206147	SQ1341			May-2008
3091	FR 236924	[28399-31-7]	CCCCCC(C2)C2CC1C(CCCCCCCC(O)=O)C1	Selective PKC_ activator	Selective PKC_ activator that displays > 7-fold selectivity over other PKC isozymes. Stimulates glutamate release via presynaptic _7 nicotinic receptors on glutamatergic terminals in vitro and enhances cognition in vivo. Brain penetrant.	"Tanaka and Nishizaki (2003) The newly synthesized linoleic acid derivative FR236924 induces a long lasting facilitation of hippocampal neurotransmission by targeting nicotinic acetylcholine receptors. Bioorg.Med.Chem.Letts. 13 1037. Yamamoto et al (2005) The linoleic acid derivative FR236924 facilitates hippocampal synaptic transmission by enhancgng activity of presynaptic _7 acetylcholine receptors on the glutamatergic terminals. Neuroscience 130 207. PMID:15561436. Kanno et al (2006) The linoleic acid derivative DCP-LA selectively activates PKC-_, possibly binding to the phosphatidylserine binding site. J.Lipid Res. 47 1146. PMID:16520488."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=206186				Jul-2010
3092	PHA 543613 hydrochloride	[478149-53-0]	O=C(C2=NC=C(OC=C3)C3=C2)N[C@@H]1C4CCN(CC4)C1.Cl	Potent and selective _7 nAChR agonist	"Potent _7 nAChR agonist that displays selectivity over _3_4, _1_1__, _4_2 and 5-HT3 receptors. Positively influences sensory gating and memory in in vivo models of schizophrenia. Orally active and brain penetrant."	"Wishka et al (2006) Discovery of N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]furo[2,3-c]pyridine-5-carboxamide, an agonist of the _7 nicotinic acetylcholine receptor, for the potential treatment of cognitive deficits in schizophrenia; synthesis and structure-activity relationship. J.Med.Chem. 49 4425. PMID:16821801. Faghih et al (2008) Allosteric modulators of the _7 nicotinic acetylcholine receptor. J.Med.Chem. 51 701. PMID:18198823. Acker et al (2008) Discovery of N-[3R,5R)-1-azabicyclo[3.2.1]ocy-3-yl]furo-[2,3-c]pyridine-5-carboxamide as an agonist of the _7 nicotinic acetylcholine receptor: in vitro and in vivo activity. Bioorg.Med.Chem.Letts. 18 3611."	Small Molecule	Sold for research purposes under agreement from Pfizer Inc.	http://www.tocris.com/dispprod.php?ItemId=206500	SQ1070			Mar-2009
3093	Dorsomorphin dihydrochloride	[1219168-18-9]	C(C=N2)(C4=CC=C(OCCN5CCCCC5)C=C4)=CN1C2=C(C3=CC=NC=C3)C=N1.Cl.Cl	Potent and selective AMPK inhibitor	"Potent and selective inhibitor of AMP-activated protein kinase (AMPK) (Ki = 109 nM). Displays no significant activity on several structurally related kinases including ZAPK, SYK, PKC_, PKA and JAK3. Inhibits AMPK activation induced by AICAR (Cat. No. 2840) and metformin (Cat. No. 2864). Also inhibits bone morphogenetic protein (BMP) type I receptors (ALK2, ALK3 and ALK6). Promotes cardiomyogenesis in mouse embryonic stem cells (ESCs) in vitro. Shown to induce autophagy in cancer cell lines via a mechanism independent of AMPK inhibition."	"Zhou et al (2001) Role of AMP-activated protein kinase in mechanism of metformin action. J.Clin.Invest. 108 1167. PMID:11602624. Yu et al (2008) Dorsomorphin inhibits BMP signals required for embryogenesis and iron metabolism. Nat.Chem.Biol. 4 33. PMID:18026094. Hao et al (2008) Dorsomorphin, a selective small molecule inhibitor of BMP signaling, promotes cardiomyogenesis in embryonic stem cells. PLoS ONE 3 2904. PMID:18682835. Vucicevic et al (2011) Compound C induces protective autophagy in cancer cells through AMPK inhibition-independent blockade of Akt/mTOR pathway. Autophagy 7 40. PMID:20980833."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=206557	SQ1533			Sep-2008
3094	Flavopiridol hydrochloride	[131740-09-5]	CN(CC3)C[C@@H](O)[C@H]3[C@]1=C(OC(C4=CC=CC=C4Cl)=CC2=O)C2=C(O)C=C1O.Cl	Cyclin-dependent kinase inhibitor	Cyclin-dependent kinase (CDK) inhibitor that causes cell cycle arrest at G1 and G2 phase. Potently inhibits the growth of breast and lung cancer cell lines (IC50 = 25 - 160 nM) in vitro.	Kaur et al (1992) Growth inhibition with reversible cell cycle arrest of carcinoma cells by Flavone L86-8275. J.Natl.Cancer.Inst. 84 1736. PMID:1279187. Losiewicz et al (1994) Potent inhibition of Cdc2 kinase activity by the flavonoid L86-8275. Biochem.Biophys.Res.Comm. 201 589. Ambrosini et al (2008) The cyclin-dependent kinase inhibitor flavopiridol potentiates the effects of topoisomerase I poisons by suppressing Rad51 expression in a p53-dependent manner. Cancer Res. 68 2312. PMID:18381438.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=206558	SQ1533			Apr-2013
3096	Carbenoxolone disodium	[7421-40-1]	[Na+].[Na+].[H][C@@]12C[C@](C)(CC[C@]1(C)CC[C@]1(C)C2=CC(=O)[C@]2([H])[C@@]3(C)CC[C@H](OC(=O)CCC([O-])=O)C(C)(C)[C@]3([H])CC[C@@]12C)C([O-])=O	Gap junction blocker. Also inhibitor of 11 _-hydroxysteroid dehydrogenase	Glucocorticoid that inhibits 11_-hydroxysteroid dehydrogenase (11-HSD) and blocks gap junction communication.	Jellinck et al (1993) Differential inhibition of 11 beta-hydroxysteroid dehydrogenase by carbenoxolone in rat brain regions and peripheral tissues. J.Steroid Biochem.Mol.Biol. 46 209. PMID:8664169. Sagar and Larson (2006) Carbenoxolone inhibits junctional trasnfer and upregulates connexin43 expression by a protein kinase A-dependent pathway. J.Cell.Biochem. 98 1543. PMID:16552723.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=206754	SQ1533			May-2008
3099	GYKI 47261 dihydrochloride	[1217049-32-5]	ClC1=CC=C3C(C(C4=CC=C(N)C=C4)=NN2C(C3)=NC(C)=C2)=C1.Cl.Cl	Non-competitive AMPA antagonist	Non-competitive AMPA receptor antagonist (IC50 = 2.5 _M). Displays broad spectrum anticonvulsive activity and neuroprotective effects in vivo.	"Abraham et al (2000) New non competitive AMPA antagonists. Bioorg.Med.Chem. 8 2127. PMID:11003158. Solyo (2001) Research on new AMPA antagonists of 2,3-benzodiazepine type. Pharmazie 25 (Suppl. 1) S62. Bibbiani et al (2005) Combined blockade of AMPA and NMDA glutamate receptors reduces levodopa-induced motor complications in animal models of PD. Exp.Neurol. 196 422. PMID:16203001."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=206777	SQ1070			Oct-2008
3100	NBI 35965 hydrochloride	[603151-83-3]	CC[C@@H]3N(CC5CC5)C1=C2C(C(C4=CC=C(Cl)C=C4Cl)=NN2C3)=NC(C)=C1.Cl	Potent and selective CRF1 antagonist	Potent and selective corticotropin-releasing factor receptor 1 (CRF1) antagonist (Ki values are 4 and > 10000 nM at CRF1 and CRF2 respectively). Inhibits cAMP accumulation and adrenocorticotropic hormone (ACTH) production in vitro (pIC50 values are 7.1 and 6.9 respectively) and attenuates CRF and ACTH production in vivo. Orally active and brain penetrant with anxiolytic activity.	"Million et al (2003) A novel water-soluble selective CRF1 receptor antagonist, NBI 35965, blunts stress-induced visceral hyperalgesia and colonic motor function in rats. Brain Res. 985 32. PMID:12957366. Hoare et al (2003) Mechanism of corticotropin-releasing factor type I receptor regulation by non-peptide antagonists. Mol.Pharmacol. 63 751. PMID:12606786. Gross et al (2005) Design and synthesis of tricyclic corticotropin-releasing factor-1 antagonists. J.Med.Chem. 48 5780. PMID:16134945."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=206778	SQ1070			Apr-2011
3101	XRP44X	[729605-21-4]	CC1=NN(C2=CC=CC=C2)C(C(N3CCN(C4=CC(Cl)=CC=C4)CC3)=O)=C1	Ras-Net pathway inhibitor	"Ras-Net (Elk-3) pathway inhibitor (IC50 = 10 - 20 nM). Indirectly inhibits Net phosphorylation upstream of Erk1/2 activation. Mediates G2-M cell cycle arrest, suppresses growth of multiple cell types (IC50 ~ 2 nM), inhibits angiogenesis and acts as a microtubule depolymerizing agent in vitro."	Wasylyk et al (2008) Inhibition of the Ras-Net (Elk-3) pathway by a novel pyrazole that affects microtubules. Cancer Res. 68 1275. PMID:18316589.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=206779	SQ1533			Dec-2008
3104	PU H71	[873436-91-0]	IC1=CC4=C(OCO4)C=C1SC3=NC2=C(N)N=CN=C2N3CCCNC(C)C	Potent Hsp90 inhibitor	"Potent inhibitor of heat shock protein 90 (Hsp90) (IC50 = 51 nM in MDA-MB-468 cells). Also inhibits cell growth in a range of breast cancer cell lines (IC50 values are 17, 31, 65, 87 and 140 nM for SKBr3, MCF-7, MDA-MB-468, HCC-1806 and MDA-MB-231 cells respectively). Shown to inhibit cell proliferation and induce apoptosis in triple-negative breast cancer (TNBC) cells."	"He et al (2006) Identification of potent water soluble purine-scaffold inhibitors of the heat shock protein 90. J.Med.Chem. 49 381. PMID:16392823. Chan et al (2008) Molecular imaging of the efficacy of heat shock protein 90 inhibitors in living subjects. Cancer Res. 68 216. PMID:18172314. Caldas-Lopes et al (2009) Hsp90 inhibitor, PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer models. Proc.Natl.Acad.Sci.USA 106 8368. PMID:19416831."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=206850	SQ1070			May-2012
3107	SC 57461A	[423169-68-0]	CN(CCC(O)=O)CCCOC(C=C2)=CC=C2CC1=CC=CC=C1.Cl	Selective inhibitor of LTA4 hydrolase	"Potent and selective inhibitor of LTA4 hydrolase. Does not inhibit other enzymes of the arachidonic acid cascade including COX-1, COX-2, LTC4 synthase and 5-lipoxygenase. Potently inhibits LTB4 production in whole blood (IC50 = 49 nM). Orally active."	"Penning et al (2002) Synthesis of potent leukotriene A4 hydrolase inhibitors. Identification of 3-[methyl[3-[4-(phenylmethyl)phenoxy]propyl]amino]propanoic acid. J.Med.Chem. 45 3482. PMID:12139459. Askonas et al (2002) Pharmacological characterization of SC-57461A (3-[methyl[3-[4-(phenylmethyl)phenoxy]propyl]amino]propanoic acid HCl), a potent and selective inhibitor of leukotriene A4 hydrolase I: in vitro studies. J.Pharmacol.Exp.Ther. 300 577. PMID:11805219. Kachur et al (2002) Pharmacological characterization of SC-57461A (3-[methyl[3-[4-(phenylmethyl)phenoxy]propyl]amino]propanoic acid HCl), a potent and selective inhibitor of leukotriene A4 hydrolase II: in vivo studies. J.Pharmacol.Exp.Ther. 300 583. PMID:11805220."	Small Molecule	Sold for research purposes under agreement from Pfizer Inc.	http://www.tocris.com/dispprod.php?ItemId=207522	SQ1341			Sep-2008
3108	Bumetanide	[28395-03-1]	CCCCNC1=CC(C(O)=O)=CC(S(=O)(N)=O)=C1OC2=CC=CC=C2	Na+/2Cl-/K+ (NKCC) cotransporter inhibitor	Loop diuretic that inhibits the Na+/2Cl-/K+ (NKCC) cotransporter. More potent than furosemide (Cat. No. 3109).	O'Grady et al (1987) Characteristics and functions of Na-K-Cl cotransport in epithelial tissues. Am.J.Physiol. 253 C177. PMID:3303961. Isenring and Forbush (1997) Ion and bumetanide binding by the Na-K-Cl cotransporter. J.Biol.Chem. 272 24556. PMID:9305921. Morita et al (1999) Functional evidence for involvement of bumetanide-sensitive Na+K+2Cl- cotransport in the hepatoportal Na+ receptor of the sprague-dawley rat. Neurosci.Letts. 264 65.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=207535	SQ1070			Jul-2008
3109	Furosemide	[54-31-9]	ClC1=CC(NCC2=CC=CO2)=C(C(O)=O)C=C1S(=O)(N)=O	Na+/2Cl-/K+ (NKCC) cotransporter inhibitor. Also antagonizes GABAA	Loop diuretic that inhibits the Na+/2Cl-/K+ (NKCC) cotransporter. Also acts as a non-competitive antagonist at GABAA receptors with ~ 100-fold greater selectivity for _6-containing receptors than _1-containing receptors.	Thompson et al (1999) Residues in transmembrane domains I and II determine _-aminobutyric acid type AA receptor subtype-selective antagonism by furosemide. Mol.Pharmacol. 55 993. PMID:10347239. Gutschmidt et al (1999) Anticonvulsant actions of furosemide in vitro. Neuroscience 91 1471. PMID:10391452.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=207536	SQ1070			Jul-2008
3110	(-)-Cotinine	[486-56-6]	CN(C(CC2)=O)[C@@H]2[C@]1=CC=CN=C1	Major metabolite of nicotine	Major metabolite of nicotine. Shown to activate a subpopulation of _3/_6_2 nAChRs in monkey striatum. Displays cognition-enhancing effects in vivo; reduces amyloid _ (A_) aggregation and improves memory in an Alzheimer's disease mouse model.	"Buccafusco and Terry (2003) The potential role of cotinine in the cognitive and neuroprotective actions of nicotine. Life Sci. 72 2931. PMID:12706481. Terry et al (2005) Cotinine, a neuroactive metabolite of nicotine: potential for treating disorders of impaired cognition. CNS Drug Rev. 11 229. PMID:16389292. O'Leary et al (2008) Cotinine selectively activates a subpopulation of _3/_6_2 nicotinic receptors in monkey striatum. 325 646. PMID:18305015. Echeverria et al (2011) Cotinine reduces amyloid-_ aggregation and improves memory in Alzheimer's disease mice. J.Alzheimers Dis. 23 1. PMID:20930295."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=207559	SQ1533			Aug-2008
3111	UDP disodium salt	[27821-45-0]	[Na+].[Na+].O[C@H]1[C@@H](O)[C@@H](O[C@@H]1COP([O-])(=O)OP(O)([O-])=O)N1C=CC(=O)NC1=O	Endogenous ligand; competitive antagonist at P2Y14 receptors	Endogenous P2Y receptor agonist which preferentially activates P2Y6. Shown to be a competitive antagonist at P2Y14 receptors.	Ralevic and Burnstock (1998) Receptors for purines and pyrimidines. Pharmacol.Rev. 50 413. PMID:9755289. Fricks et al (2008) UDP is a competitive antagonist at the human P2Y14 receptor. J.Pharmacol.Exp.Ther. 325 588. PMID:18252808.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=207564	SQ1341			Jul-2008
3113	Etifoxine hydrochloride	[56776-32-0]	CCNC2=NC1=CC=C(Cl)C=C1C(C3=CC=CC=C3)(C)O2.Cl	Potentiator of GABAA receptors; anxiolytic	"Potentiator of GABAA receptor function in cultured neurons. Preferentially acts on _2 or _3 subunit-containing GABAA receptors. Exhibits anxiolytic activity in rodents and humans with no sedative, myorelaxant or mnesic side effects. Acts as a ligand of the translocator protein (TSPO); promotes axonal regeneration."	Hamon et al (2003) The modulatory effects of the anxiolytic etifoxine on GABAA receptors are mediated by the _ subunit. Neuropharmacology 45 293. PMID:12871647. Girard et al (2008) Etifoxine improves peripheral nerve regeneration and functional recovery. Proc.Natl.Acad.Sci. 105 20505.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=207711	SQ1070			Nov-2010
3114	Troglitazone	[97322-87-7]	CC1=C2C(CCC(COC3=CC=C(CC4C(NC(S4)=O)=O)C=C3)(C)O2)=C(C)C(O)=C1C	Selective PPAR_ agonist; antidiabetic agent	"Selective PPAR_ receptor agonist (EC50 values are 780 and 555 nM at murine and human PPAR_ receptors respectively). Displays no activity at PPAR_ or PPAR_ receptors. Antidiabetic agent; exerts potent glucose-lowering effects in insulin-resistant diabetic mice. Displays anti-invasive effect on human breast cancer cells; reduces migration, adhesion and spreading on fibronectin-coated plates. Also inhibits cell growth of hematopoietic cell lines. Inhibits lamellipodia formation and actin polymerization."	Lee and Olefsky (1995) Acute effects of troglitazone on in vivo insulin action in normal rats. Metabolism 44 1166. PMID:7666790. Fujimura et al (1998) Effects of troglitazone on the growth and differentiation of hematopoietic cell lines. Int.J.Oncol. 13 1263. PMID:9824642. Kodera et al (2000) Ligand type-specific interactions of peroxisome-proliferator-activated receptor _ with transcriptional coactivators. J.Biol.Chem. 275 33201. PMID:10944516. Willson et al (2000) The PPARs: from orphan receptors to drug discovery. J.Med.Chem. 43 527. PMID:10691680.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=207714	SQ1533			Sep-2008
3115	WHI-P 154	[211555-04-3]	OC(C=C3)=C(Br)C=C3NC2=NC=NC1=CC(OC)=C(OC)C=C12	JAK3 kinase inhibitor. Also inhibits EGFR	"JAK3 inhibitor (IC50 = 1.8 _M) that displays no activity at JAK1 or JAK2. Inhibits STAT1 activation, iNOS expression and NO production in macrophages in vitro. Also inhibits other common kinases including EGFR (IC50 = 4 nM), Src, Abl, VEGFR, MAPK and PI 3-K and induces apoptosis in human glioblastoma cell lines (IC50 = 158 _M). Induces differentiation of neural progenitor cells."	"Narla et al (1998) 4-(3'-bromo-4'hydroxylphenyl)-amino-6,7-dimethoxyquinazoline: a novel quinazoline derivative with potent cytotoxic activity against human glioblastoma cells. Clin.Cancer Res. 4 1405. PMID:9626456. Sareila et al (2008) Janus kinase 3 inhibitor WHI-P154 in macrophages activated by bacterial endotoxin: differential effects on the expression of iNOS, COX-2 and TNF-_. Int.Immunopharmacol. 8 100. PMID:18068105. Changelian et al (2008) The specificity of JAK3 kinase inhibitors. Blood 111 2155. PMID:18094329. Kim et al (2010) Differential regulation of proliferation and differentiation in neural precursor cells by the Jak pathway. Stem Cells. 28 1816. PMID:20979137."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=207720	SQ1070			Apr-2009
3116	Cyclapolin 9	[40533-25-3]	[O-][N+]2=C(C(N)=O)SC1=C([N+]([O-])=O)C=C(C(F)(F)F)C=C12	"Selective, ATP-competitive PLK1 inhibitor"	"Selective, ATP-competitive polo-like kinase 1 (PLK1) inhibitor (IC50 = 500 nM)."	McInnes et al (2006) Inhibitors of polo-like kinase reveal roles in spindle pole maintenance. Nature Chem.Biol. 2 608. Taylor et al (2008) Ligand discovery and virtual screening using the program LIDAEUS. Br.J.Pharmacol. 153 S55. PMID:18037921.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=207729				Mar-2009
3117	Miglustat hydrochloride	[210110-90-0]	CCCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO.Cl	_-glucosidase I and II inhibitor. Also inhibits ceramide-specific glycosyltransferases	Orally active _-glucosidase I and II and ceramide-specific glycosyltransferase inhibitor. Rescues trafficking-deficient F508del-CFTR in human airway epithelial cells via inhibition of ER _-glucosidases I and II. Also has broad spectrum antiviral activity.	Platt et al (1994) N-Butyldeoxynojirimycin is a novel inhibitor of glycolipid biosynthesis. J.Biol.Chem. 269 8362. PMID:8132559. Dwek et al (2002) Targeting glycosylation as a therapeutic approach. Nat.Rev.Drug Disc. 1 65. Noel et al (2008) Parallel improvements of sodium and chloride transport defects by miglustat (n-butyldeoxynojyrimicin) in cystic fibrosis epithelial cells. J.Pharamcol.Exp.Ther. 325 1016.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=207899	SQ1533			Dec-2008
3118	Ranolazine dihydrochloride	[95635-56-6]	COC1=CC=CC=C1OCC(CN2CCN(CC(NC3=C(C)C=CC=C3C)=O)CC2)O.Cl.Cl	"Antianginal, activates pyruvate dehydrogenase"	"Antianginal agent with antiarrhythmic properties that acts as a partial fatty acid oxidation inhibitor. Activates pyruvate dehydrogenase in ischemic myocytes to promote glucose oxidation, switching substrate utilization from fatty acids to glucose. Also shown to inhibit late INa and IKr currents."	"Zacharowski et al (2001) Ranolazine, a partial fatty acid oxidation inhibitor, reduces myocardial infarct size and cardiac troponin T release in the rat. Eur.J.Pharmacol. 418 105. PMID:11334871. Shryock and Belardinelli (2008) Inhibition of late sodium current to reduce electrical and mechanical dysfunction of ischaemic myocardium. Br.J.Pharmacol. 153 1128. PMID:18071302. Wang et al (2008) Antitorsadogenic effects of (+/-)-N-(2,6-dimethyl-phenyl)-4[2-hydroxy-3-(2-methoxyphenoxy)propyl]-1-piperazine (ranolazine) in anesthetized rabbits. J.Pharmacol.Exp.Ther. 325 875. PMID:18322148."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=207940	SQ1533			Jun-2008
3129	BMS CCR2 22	[445479-97-0]	O=C(N[C@@H]2CCCC[C@@H]2NC(CNC(C3=C(NC(NC(C)C)=O)C=CC(C(F)(F)F)=C3)=O)=O)C1=CC=C(SC)C=C1	"High affinity, potent CCR2 antagonist"	"High affinity CCR2 chemokine receptor antagonist (IC50 = 5.1 nM). Displays potent functional antagonism, IC50 values are 1 and 18 nM for chemotaxis and antagonism of calcium flux respectively. Selective over CCR3."	Cherney et al (2008) Discovery of disubstituted cyclohexanes as a new class of CC chemokine receptor 2 antagonists. J.Med.Chem. 51 721. PMID:18232650. You et al (2010) CCR2 receptor ligands inhibit Cav3.2 T-type calcium channels. Mol.Pharmacol. 77 211. PMID:19864434.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=208254	SQ1341			Oct-2008
3133	NE 100 hydrochloride	[149409-57-4]	CCCN(CCC)CCC1=CC=C(OC)C(OCCC2=CC=CC=C2)=C1.Cl	Selective _1 antagonist	"Potent and selective _1 receptor antagonist (Ki = 0.86 nM) that displays > 55-fold selectivity over _2 receptors and > 6000-fold selectivity over D1, D2, 5-HT1A, 5-HT2 and PCP receptors. Exhibits reversible binding (Kd = 1.2 nM) and displays antipsychotic activity in vivo. Orally active."	"Okuyama et al (1993) NE-100, a novel sigma receptor ligand: in vivo tests. Pharmacol.Letts. 53 PL285. Chaki et al (1994) NE-100, a novel potent _ ligand, preferentially binds to _1 binding sites in guinea pig brain. Eur.J.Pharmacol. 251 R1. PMID:8137864. Tanaka et al (1995) Characteristics of binding of [3H]NE-100, a novel sigma-receptor ligand, to guinea-pig brain membranes. Naunyn Schmied.Arch.Pharmacol. 351 244."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=209407				Sep-2009
3134	PHA 568487	[527680-57-5]	O=C(C3=CC=C(OCCO4)C4=C3)N[C@@H]1C2CCN(CC2)C1.O=C(/C=C/C(O)=O)O	_7-selective agonist	"Agonist of the _7 nicotinic acetylcholine receptor (Ki values are 44 and 2800 for _7 and 5-HT3 respectively, IC50 values are > 100 _M for _3_4 and _1_1__ respectively, and % inhibition is < 1 and 5% for _4_2 and hERG respectively). Orally active and brain penetrant."	"Walker et al (2006) Design, synthesis, structure-activity relationship, and in vivo activity of azabicyclic aryl amides as _7 nicotinic acetylcholine receptor agonists. Bioorg.Med.Chem. 14 8219. PMID:17011782."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=209437	SQ1341			Sep-2008
3135	NU 2058	[161058-83-9]	NC1=NC(OCC3CCCCC3)=C2C(NC=N2)=N1	Cdk1 and cdk2 inhibitor	Cyclin-dependent kinase (cdk) 1 and cdk2 inhibitor (Ki values are 5 and 12 _M respectively). Inhibits growth of human tumor cells in vitro (mean GI50 = 13 _M). Also inhibits DNA topoisomerase II ATPase activity (IC50 = 300 _M).	Arris et al (2000) Identification of novel purine and pyrimidine cyclin-dependent kinase inhibitors with distinct molecular interactions and tumor cell growth inhibition profiles. J.Med.Chem. 43 2797. PMID:10956187. Knockaert et al (2002) Pharmacological inhibitors of cyclin-dependent kinases. TiPS 23 417. PMID:12237154. Jensen et al (2005) Substituted purine analogues define a novel structural class of catalytic topoisomerase II inhibitors. Cancer Res. 65 7470. PMID:16103101.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=209459	SQ1070			Jan-2009
3136	2-Chloroadenosine	[146-77-0]	O[C@@H]1[C@@H](CO)O[C@@H](N3C2=NC(Cl)=NC(N)=C2N=C3)[C@@H]1O	Adenosine receptor agonist	"Metabolically stable analog of adenosine that behaves as an adenosine receptor agonist (Ki values are 300, 80 and 1900 nM for A1, A2A and A3 receptors respectively). Anticonvulsive in vivo."	Mathot et al (1996) Pharmacokinetic-haemodynamic relationships of 2-chloroadenosine at adenosine A1 and A2a receptors in vivo. Br.J.Pharmacol. 118 369. PMID:8735640. Pourgholami et al (1997) Intra-amygdala infusion of 2-chloroadenosine suppresses amygdala-kindled seizures. Brain Res. 775 37. PMID:9439826. Abdul-Ghani et al (1997) The protective effect of 2-chloroadenosine against the development of amygdala kindling and on amygdala-kindled seizures. Eur.J.Pharmacol. 326 7. PMID:9178649.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=209611	SQ1070			Jul-2008
3140	PHA 767491 hydrochloride	[942425-68-5]	O=C1NCCC2=C1C=C(C3=CC=NC=C3)N2.Cl	Dual cdc7/cdk9 inhibitor. Also inhibits MK2	"Potent, ATP-competitive dual cdc7/cdk9 inhibitor (IC50 values are 10 and 34 nM respectively) that prevents initiation of DNA replication. Inhibits cell proliferation in a variety of human cell lines (IC50 ~ 0.86 - 5.87 _M) and induces apoptosis in a p53-independent manner in vivo. Also inhibits mitogen-activated protein kinase-activated protein kinase-2 (MK2) (IC50 = 171 nM)."	"Anderson et al (2007) Pyrrolopyridine inhibitors of mitogen-activated protein kinase-activated protein kinase 2 (MK-2). J.Med.Chem. 50 2647. PMID:17480064. Jackson (2008) Stopping replication, at the beginning. Nature Chem.Biol. 4 331. Montagnoli et al (2008) A cdc7 kinase inhibitor restricts initiation of DNA replication and has antitumour activity. Nature Chem.Biol. 4 357."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=209792	SQ1533			Dec-2008
3141	VU 10010	[633283-39-3]	CC1=C2C(SC(C(NCC3=CC=C(Cl)C=C3)=O)=C2N)=NC(C)=C1	Selective allosteric potentiator of M4 receptors	Selective allosteric potentiator of M4 acetylcholine receptors (EC50 values are 33 and 0.7 nM for ACh in the absence and presence of VU10010 respectively). Binds to an allosteric site on the receptor increasing affinity for ACh and coupling to G-proteins.	Shirey et al (2008) An allosteric potentiator of M4 mAChR modulates hippocampal synaptic transmission. Nat.Chem.Biol. 4 42. PMID:18059262.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=209793	SQ1341			Aug-2008
3143	KM 11060	[774549-97-2]	ClC(C=C4)=CC=C4S(N(CC3)CCN3C1=CC=NC2=C1C=CC(Cl)=C2)(=O)=O	Corrects F508del-CFTR trafficking	Corrects F508del-CFTR trafficking; increases the amount of functional CFTR at the plasma membrane (~75%). Shown to inhibit PDE5 activity.	Robert et al (2008) Structural analog of Sildenafil identified as a novel corrector of the F508del-CFTR trafficking defect. Mol.Pharmacol. 73 478. PMID:17975008.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=210066	SQ1341			Aug-2008
3144	K 114	[872201-12-2]	OC(C=C3)=CC=C3/C=C/C1=CC(Br)=C(/C=C/C2=CC=C(O)C=C2)C=C1	Amyloid fibril-specific fluorescent dye	"Potent amyloid fibril-specific fluorescent dye (EC50 = 20 - 30 nM). Exhibits minimal fluorescence in aqueous buffers and fluoresces brightly in the presence of A_, _-synuclein and tau in situ. (Optimum wavelength = 550 nM)."	"Crystal et al (2003) A comparison of amyloid fibrillogenesis using the novel fluorescent compound K114. J.Neurochem. 86 1359. PMID:12950445. LeVine (2005) Mechanism of A_(1-40) fibril-induced fluorescence of (trans-trans)-1-bromo-2,5-bis(4-hydroxystyryl)benene (K114). Biochemistry 44 15937. PMID:16313197."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=210067				Jan-2009
3145	Talopram hydrochloride	[7013-41-4]	CC2(C)OC(C3=CC=CC=C3)(CCCNC)C1=CC=CC=C12.Cl	"Potent, selective inhibitor of noradrenalin transporters"	"Potent, selective inhibitor of the noradrenalin transporter (NET) (IC50 = 2.9 nM). Exhibits selectivity for NET against SERT (5-HT transporters) and DAT (dopamine transporters). Displays a similar structure but different pharmacological profile to citalopram (Cat. No. 1427)."	"Bogeso et al (1985) 3-phenyl-1-indanamines. Potential antidepressant activity and potent inhibition of dopamine, norepinephrine, and serotonin uptake. J.Med.Chem. 28 1817. PMID:2999402. Schou et al (2006) Synthesis and positron emission tomography evaluation of three norepinephrine transporter radioligands: [C-11]desipramine, [C-11]talopram and [C-11]talsupram. Mol.Imaging Biol. 8 1. Eildal et al (2008) From the selective serotonin transporter inhibitor citalopram to the selective norepinephrine transporter inhibitor talopram: synthesis and structure-activity relationship studies. J.Med.Chem. 51 3045. PMID:18429609."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=210200	SQ1070			Jan-2012
3185	"L-779,450"	[303727-31-3]	ClC(C(O)=C4)=CC=C4C(N=C(C3=CC=CC=C3)N2)=C2C1=CC=NC=C1	Potent Raf kinase inhibitor	"Potent, ATP-competitive Raf kinase inhibitor (IC50 = 10 nM) that displays > 7, > 30 and > 70-fold selectivity over p38_, GSK3_ and Lck respectively. Suppresses DNA synthesis and induces apoptosis in cells that proliferate in response to Raf-1 and A-Raf but not B-Raf."	"White (2003) Small-molecule inhibitors of signal transduction pathways in leukemia therapeutics: how to assess selectivity for malignant signals. Leukemia 17 1759. PMID:12970775. Shelton et al (2003) Differential effects of kinase cascade inhibitors on neoplastic and cytokine-mediated cell proliferation. Leukemia 17 1765. PMID:12970777. Takle et al (2006) Identification of potent and selective imidazole-based inhibitors of B-Raf kinase. Bioorg.Med.Chem.Letts. 16 378. Rring et al (2012) Distinct requirement for an intact dimer interface in wild-type, V600E and kinase-dead B-Raf signalling. EMBO J. 31 2629. PMID:22510884."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=210375	SQ1533			Aug-2009
3188	SB 699551	[864741-95-7]	O=C(CCC4CCCC4)N(CCN(C)C)CC(C=C2)=CC=C2C1=CC=C(CNCCC3=CC=CC=C3)C=C1.Cl.Cl	Selective 5-ht5a antagonist	"Selective 5-ht5a receptor antagonist (pKi values are 8.3, < 6.0, < 6.0, < 6.0, < 5.5 and < 5.5 for 5-ht5a, 5-HT1B/D, 5-HT2A, 5-HT2C, 5-HT1A and 5-HT7 receptors respectively)."	"Corbett et al (2005) Discovery of a potent and selective 5-ht5A receptor antagonist by high-throughput chemistry. Bioorg.Med.Chem.letts. 15 4014. Thomas et al (2006) SB-69951-A (3-cyclopentyl-N-[2-(dimethylamino)ethyl]-N-[(4'-{[(2-phenylethyl)amino]methyl}-4-biphenylyl)methyl]propanamide dihydrochloride), a novel 5-ht5A receptor-selective antagonist, enhances 5-HT neuronal function: evidence for an autoreceptor role for the 5-ht5A receptor in guinea pig brain. Neuropharmacology 51 566. PMID:16846620. Thomas (2006) 5-ht5A receptors as a therapeutic target. Pharmacol.Ther. 111 707. PMID:16516972."	Small Molecule	Sold for research purposes under agreement from GlaxoSmithKline	http://www.tocris.com/dispprod.php?ItemId=210401	SQ1341			Sep-2008
3189	SB 399885 hydrochloride	[402713-81-9]	ClC1=CC(Cl)=CC(NS(C2=CC(N3CCNCC3)=C(OC)C=C2)(=O)=O)=C1OC	Potent and selective 5-HT6 antagonist	"Potent, brain penetrant, orally active 5-HT6 antagonist. Displays > 200-fold selectivity for 5-HT6 over other 5-HT receptors (pKi values are 9.11, 8.81 and 9.02  for human recombinant, native rat and native human 5-HT6 receptors respectively)."	"Hirst et al (2006) SB-399885 is a potent, selective 5-HT6 receptor antagonist with cognitive enhancing properties in aged rat water maze and novel object recognition models. Eur.J.Pharm. 553 109. Wesolowska and Nikiforuk (2007) Effects of the brain-penetrant and selective 5-HT6 receptor antagonist SB-399885 in animal models of anxiety and depression. Neuropharmacology 52 1274. PMID:17320917. Foley et al (2008) The selective 5-HT6 receptor antagonists SB-271046 and SB-399885 potentiate NCAM PSA immunolabeling of dentate granule cells, but not neurogenesis, in the hippocampal formation of mature Wistar rats. Neuropharmacology 54 1166. PMID:18455201."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=210406	SQ1341			Sep-2008
3190	Mirin	[1198097-97-0]	OC(C=C1)=CC=C1/C=C2/C(NC(S2)=N)=O	MRN-ATM pathway inhibitor	Mre11-Rad50-Nbs1 (MRN)-ATM pathway inhibitor that blocks the 3' and 5' exonuclease activity associated with Mre11. Prevents ATM activation in response to double strand breaks (IC50 = 12 _M) and induces G2 cell cycle arrest. Also blocks homology-directed repair in vitro.	"Dupre et al (2008) A forward chemical genetic screen reveals an inhibitor of the Mre11-Rad50-Nbs1 complex. Nat.Chem.Biol. 4 119. PMID:18176557. Stivers (2008) Small molecule versus DNA repair mechanisms. Nat.Chem.Biol. 4 86. PMID:18202674. Garner et al (2009) Corrected structure of mirin, a small-molecule inhibitor of the Mre11-Rad50-Nbs1 complex. Nat.Chem.Biol. 5 129. PMID:19219009."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=210440				Apr-2009
3191	GANT 61	[500579-04-4]	CN(C1=CC=CC=C1CN2CCCN(CC4=C(N(C)C)C=CC=C4)C2C3=CC=NC=C3)C	GLI antagonist; inhibits Hedgehog (Hh) signaling	"GLI antagonist that inhibits GLI1 and GLI2-induced transcription (IC50 ~ 5 _M). Inhibits the hedgehog (Hh) signaling pathway downstream of SMO and SUFU causing GLI1 nuclear accumulation. Displays antiproliferative and antitumor activity in vivo. Inhibits the pluripotency factors Oct4, Sox-2, Nanog and c-Myc in pancreatic cancer stem cells."	Lauth et al (2007) Inhibition of GLI-mediated transcription and tumor cell growth by small molecule antagonists. Proc.Natl.Acad.Sci.USA 104 8455. PMID:17494766. Mazumdar et al (2011) Blocking Hedgehog survival signaling at the level of the GLI genes induces DNA damage and extensive cell death in human colon carcinoma cells. Cancer Res. 71 5904. PMID:21747117. Fu et al (2012) GANT-61 inhibits pancreatic cancer stem cell growth in vitro and in NOD/SCID/IL2R gamma null mice xenograft. Cancer Lett. 330 22. PMID:23200667.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=210479	SQ1533			Sep-2010
3193	Camostat mesylate	[59721-29-8]	O=C(C2=CC=C(NC(N)=N)C=C2)OC1=CC=C(CC(OCC(N(C)C)=O)=O)C=C1.CS(=O)(O)=O	Orally active protease inhibitor	"Orally active protease inhibitor. Known to inhibit trypsin and various inflammatory proteases including plasmin, kallikrein and thrombin. Suppresses pancreatitis-induced pain in rats following oral administration."	"Horiuchi et al (1990) Gabexate and camostat, synthetic proteinase inhibitors, as direct inducing factors of water and bicarbonate secretion in the isolated and blood-perfused dog pancreas. J.Pharmacol.Exp.Ther. 252 320. PMID:1688943. Ishikura et al (2007) The proteinase inhibitor camostat mesilate suppresses pancreatic pain in rodents. Life Sci. 80 1999. PMID:17433371."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=210525	SQ1533			Oct-2008
3194	BIO	[667463-62-9]	O/N=C(C1=CC=CC=C1N2)/C2=C3/C(NC4=C3C=CC(Br)=C4)=O	"Potent, selective GSK-3 inhibitor"	"Potent and selective, ATP-competitive glycogen synthase kinase-3 (GSK-3) inhibitor (IC50 values are 5, 83, 300, 320 and > 10 000 nM at GSK-3, CDK5/p25, CDK2/cyclin A, CDK1/cyclin B and other common kinases respectively). Maintains self-renewal and pluripotency in embryonic stem cells via activation of the Wnt signaling pathway in vitro; also promotes proliferation and dedifferentiation in cardiomyocytes. Negative control available (Cat. No. 3873)."	Meijer et al (2003) GSK-3-selective inhibitors derived from tyrian purple indirubins. Chem.Biol. 10 1255. PMID:14700633. Polychronopoulos et al (2004) Structural basis for the synthesis of indirubins as potent and selective inhibtors of glycogen synthase kinase-3 and cyclin dependent kinases. J.Med.Chem. 47 935. PMID:14761195. Tseng et al (2006) The GSK-3 inhibitor BIO promotes proliferation in mammalian cardiomyocytes. Chem.Biol. 13 957. PMID:16984885.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=210526	SQ1533			Jan-2009
3197	Polygodial	[6754-20-7]	[H][C@]12C(C)(C)CCC[C@@](C)1[C@@H](C=O)C(C=O)=CC2	TRPA1 channel activator; analgesic and antifungal	"TRPA1 channel activator (EC50 = 400 nM) that is selective against TRPV1, TRPV2, TRPV3, TRPV4 and TRPM8 channels. Acts as an analgesic via desensitization of sensory neurons. Also exhibits antifungal activity via inhibition of mitochondrial ATPase."	Lunde and Kubo (2000) Effect of polygodial on the mitochondrial ATPase of Saccharomyces cerevisiae. Antimicrob.Agents Chemother. 44 1943. PMID:10858359. Matsuda et al (2002) Protective effect of polygodial and related compounds on ethanol-induced gastric mucosal lesions in rats: structural requirements and mode of action. Bioorg.Med.Chem.Letts. 12 477. Escalera et al (2008) TRPA1 mediates the noxious effects of natural sesquiterpene deterrents. J.Biol.Chem. 283 24136. PMID:18550530.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=210730				Feb-2011
3198	PSB 603	[1092351-10-4]	O=C(NC2=C1NC(C3=CC=C(S(N4CCN(C5=CC=C(Cl)C=C5)CC4)(=O)=O)C=C3)=N2)N(CCC)C1=O	Highly selective A2B antagonist	"Adenosine A2B receptor antagonist that displays > 17000-fold selectivity over other adenosine receptors (Ki values are 0.553, > 10000, > 10000 and > 10000 nM for A2B, A1, A2A and A3 receptors respectively)."	Borrmann et al (2009) 1-alkyl-8-(piperazine-1-sulfonyl)phenylxanthines: development and characterization of adenosine A2B receptor antagonists and a new radioligand with subnanomolar affinity and subtype specificity. J.Med.Chem. 52 3994. PMID:19569717.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=210780	SQ1341			Sep-2008
3199	PSB 0788	[1027513-54-7]	O=C(NC2=C1NC(C3=CC=C(S(N4CCN(CC5=CC=C(Cl)C=C5)CC4)(=O)=O)C=C3)=N2)N(CCC)C1=O	Selective A2B antagonist	"Potent and selective adenosine A2B receptor antagonist (IC50 = 3.64 nM at human A2B receptors).  Displays > 100-fold selectivity over hA1, hA2A and hA3 receptors."	Borrmann et al (2009) 1-alkyl-8-(piperazine-1-sulfonyl)phenylxanthines: development and characterization of adenosine A2B receptor antagonists and a new radioligand with subnanomolar affinity and subtype specificity. J.Med.Chem. 52 3994. PMID:19569717.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=210782	SQ1341			Jul-2008
3200	XAC	[96865-92-8]	O=C1N(CCC)C(C(NC(C3=CC=C(OCC(NCCN)=O)C=C3)=N2)=C2N1CCC)=O.Cl	Adenosine receptor antagonist	Adenosine receptor antagonist (IC50 values are 1.8 and 114 nM at A1 and A2 receptors respectively). Attenuates adenosine-induced vasodilation and exhibits proconvulsant activity in vivo.	"Morgan et al (1989) Potent convulsant actions of the adenosine receptor antagonist, xanthine amine congener (XAC) Life Sci. 45 719. PMID:2779359. Sawmiller et al (1994) Effects of xanthine amine congener on hypoxic coronary resistance and venous and epicardial adenosine concentrations. Cardiovasc.Res. 28 604. PMID:8025903. Wei and Grisshammer (2002) Purification and characterization of the human adenosine A2A receptor functionally expressed in Escherichia coli. Eur.J.Biochem. 269 82. PMID:11784301."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=210793	SQ1070			Nov-2010
3201	Dimebon dihydrochloride	[97657-92-6]	CC(N=C4)=CC=C4CCN2C1=CC=C(C)C=C1C3=C2CCN(C)C3.Cl.Cl	Neuroprotectant; protects against _-amyloid neurotoxicity	"Non-selective antihistamine that displays cognitive enhancing abilities. Also displays high affinity for 5-HT (particularly 5-HT6 and 5-HT7), _-adrenergic, dopaminergic, AMPA and NMDA receptors, and L-type calcium channels. Does not inhibit acetylcholinesterase activity. Exhibits neuroprotective activity in cellular models of Alzheimer's and Huntington's disease and preserves cognitive function following administration to AF64A lesioned rats. Protects neurons against the neurotoxic action of _-amyloid fragment; shown to enhance autophagy in yeast and reduce intracellular A_42 levels."	Bachurin et al (2001) Antihistamine agent dimebon as a novel neuroprotector and a cognitive enhancer. Ann.N.Y.Acad.Sci. 939 425. PMID:11462798. Schaffhauser et al (2009) Dimebon is a 5-HT6 antagonist with acute cognitive enhancing activities. Biochem.Pharmacol. 78 1035. PMID:19549510. Okun et al (2009) From anti-allergic to anti-Alzheimer's: molecular pharmacology of dimebon. Curr.Alzheimer Res. 7 97. Giorgetti et al (2010) Cognition-enhancing properties of dimebon in a rat novel object recognition task are unlikely to be associated with acetylcholinesterase inhibition or N-methyl-D-aspartate receptor antagonism J.Pharm.Exp.Ther. 333 748. Bharadwaj et al (2012) Latrepirdine (Dimebon) enhances autophagy and reduces intracellular GFP-A_42 levels in yeast. J.Alzheimers Dis. 32 949. PMID:22903131.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=210798	SQ1533			Jan-2010
3203	Celastrol	[34157-83-0]	O=C2C(O)=C(C)C1=CC=C([C@](CC[C@]5(C)[C@]([H])4C[C@](C)([C@@](O)=O)CC5)(C)[C@@]4(C)CC3)[C@]3(C)C1=C2	Inhibits TNF-_-induced NF-_B activation	Antioxidant and anti-inflammatory agent. Potently inhibits lipid peroxidation in mitochondria and inhibits TNF-_-induced NF_B activation. Also shown to inhibit topoisomerase II activity in vitro (IC50 = 7.41 _M).	"Sassa et al (1990) The triterpene celastrol as a very potent inhibitor of lipid peroxidation in mitochondria. Biochem.Biophys.Res.Comms. 172 890. Nagase et al (2003) Apoptosis induction in HL-60 cells and inhibition of topoisomerase II by triterpene celastrol. Biosci.Biotechnol.Biochem. 67 1883. PMID:14519971. Sethi et al (2007) Celastrol, a novel triterpene, potentiates TNF-induced apoptosis and suppresses invasion of tumor cells by inhibiting NF-_B-regulated gene products and TAK1-mediated NF-_B activation. Blood 109 2727. PMID:17110449."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=210874	SQ1533			Sep-2008
3208	Swainsonine	[72741-87-8]	O[C@@H]2[C@H](O)CN1CCC[C@@H](O)[C@@]12[H]	Inhibitor of _-mannosidase II	Inhibitor of _-mannosidase II which inhibits glycoprotein processing. Displays anticancer and immune modulatory properties.	Tulsiani et al (1982) Swainsonine inhibits the biosynthesis of complex glycoproteins by inhibition of golgi mannosidase II. J.Biol.Chem. 257 7936. PMID:6806288. Olden et al (1991) The potential importance of swainsonine in therapy for cancers and immunology. Pharmacol.Ther. 50 285. PMID:1754603. Sun et al (2007) Inhibition of the growth of human gastric carcinoma in vivo and in vitro by swainsonine. Phytomedicine 14 353. PMID:17097281.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=210956	SQ1070			Sep-2008
3209	"_,_-Methyleneadenosine 5'-triphosphate trisodium salt"	[1343364-54-4]	O[C@@H]1[C@@H](COP(CP([O-])(OP([O-])(O)=O)=O)([O-])=O)O[C@@H](N3C2=NC=NC(N)=C2N=C3)[C@@H]1O.[Na+].[Na+].[Na+]	P2 agonist	P2-purinoceptor agonist. Also shown to inhibit adenylate cyclase (Ki = 0.5 mM).	"Krug et al (1973) _,_-Methylene-adenosine 5'-triphosphate. J.Biol.Chem. 248 1203. PMID:4686923. Burnstock and Kennedy (1985) Is there a basis for distinguishing two types of P2-purinoceptor? Gen.Pharmacol 16 433. PMID:2996968."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=5485	SQ1341			Sep-2008
3211	SB 525334	[356559-20-1]	CC1=NC(C4=C(NC(C(C)(C)C)=N4)C2=CC=C(N=CC=N3)C3=C2)=CC=C1	Selective inhibitor of TGF-_RI	"Selective inhibitor of transforming growth factor-_ receptor I (ALK5, TGF-_RI) (IC50 = 14.3 nM). Inhibits TGF-_1-induced smad2/3 nuclear localization and TGF-_RI-induced mRNA expression in kidney cells. Attenuates bleomycin-induced pulmonary fibrosis."	Grygielko et al (2005) Inhibition of gene markers of fibrosis with a novel inhibitor of transforming growth factor-_ type I receptor kinase in puromycin-induced nephritis. J.Pharmacol.Exp.Ther. 313 943. PMID:15769863. Higashiyama et al (2007) Inhibition of activin receptor-like kinase 5 attenuates bleomycin-induced pulmonary fibrosis Exp.Mol.Pathol. 83 39. PMID:17274978. Laping et al (2007) Tumor-specific efficacy of transforming growth factor-_RI inhibition in eker rats. Clin.Cancer Res. 13 3087. PMID:17505012.	Small Molecule	Sold with the permission of GlaxoSmithKline	http://www.tocris.com/dispprod.php?ItemId=211096	SQ1533			Dec-2008
3212	CP 376395 hydrochloride	[1013933-37-3]	CC1=CC(NC(CC)CC)=C(C)C(OC2=C(C)C=C(C)C=C2C)=N1.Cl	Potent and selective CRF1 antagonist	Potent and selective CRF1 receptor antagonist (Ki values are 12 and >10000 nM for CRF1 and CRF2 receptors respectively). Attenuates CRF-induced activation of the HPA axis in vivo following i.v. administration. Orally active.	Chen et al (2008) 2-Aryloxy-4-alkylaminopyridines: discovery of novel corticotropin-releasing factor 1 antagonists. J.Med.Chem. 51 1385. PMID:18288792. Hollenstein et al (2013) Structure of class B GPCR corticotropin-releasing factor receptor 1. Nature 499 438. PMID:23863939.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=211488	SQ1070			Nov-2008
3213	Methylene Blue	[61-73-4]	CN(C)C1=CC=C2C(SC(C3=N2)=C/C(C=C3)=[N+](C)/C)=C1.[Cl-]	Biological stain	Biological stain and redox indicator. Inhibits tau filament formation (IC50 = 1.9 _M). Also inhibits soluble guanylyl cyclase.	"Wischik et al (1996) Selective inhibition of Alzheimer disease-like tau aggregation by phenothiazines. Neurobiology 93 11213. Hwang et al (1998) Comparison of two soluble guanylyl cyclase inhibitors, methylene boue and ODQ, on sodium nitroprusside-induced relaxation in guinea-pig trachea. Br.J.Pharmacol. 125 1158. PMID:9863642. Taniguchi et al (2005) Inhibition of heparin-induced tau filament formation by phenothiazines, polyphenols, and porphyrins. J.Biol.Chem. 280 7614. PMID:15611092."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=211579	SQ1533			Aug-2008
3214	RETRA hydrochloride	[1173023-52-3]	OC1=CC(C(CSC2=NCCS2)=O)=CC=C1O.Cl	Antitumor agent; suppresses mutant p53-bearing cancer cells	Antitumor agent. Inhibits tumor cell growth in a mutant p53- and p73-dependent manner in vitro and in vivo (IC50 = 4 _M). Transcriptionally activates expression of p53-responsive genes and induces activation of effector caspases 3 and 7.	Kravchenko et al (2008) Small-molecule RETRA suppresses mutant p53-bearing cancer cells through a p73-dependent salvage pathway. Proc.Natl.Acad.Sci.USA 105 6302.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=211580				Nov-2008
3219	CGP 36216 hydrochloride	[123691-29-2]	O=P(CC)(CCCN)O.Cl	GABAB antagonist; displays activity at presynaptic receptors	Selective GABAB antagonist. Displays activity at presynaptic receptors; ineffective at GABAB postsynaptic receptors.	"Froestl et al (1995) Phosphinic acid analogues of GABA. 2. Selective, orally active GABAB antagonists. J.Med.Chem. 38 3313. PMID:7650685. Ong et al (2001) CGP 36216 is a selective antagonist at GABAB presynaptic receptors in rat brain. Eur.J.Pharmacol. 415 191. PMID:11274998."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=212484				Nov-2011
3221	bPiDDB	[525596-66-1]	CC1=C[N+](CCCCCCCCCCCC[N+]2=CC=CC(C)=C2)=CC=C1.[Br-].[Br-]	Orthosteric nAChR antagonist	"Orthosteric neuronal nicotinic acetylcholine receptor (nAChR) antagonist (IC50 values are 0.17, 0.25, 0.4, 4.8, 6.5, 8.2, 20 and 34 _M at _3_4, _1_1__, _3_4_3, _6_4_3, _7, _4_2, _3_2_3 and _6/3_2_3 receptors respectively). Attenuates nicotine-evoked dopamine release from the ventral tegmental area in vivo (IC50 = 0.2 nM) and reduces nicotine self-administration in rats. Brain penetrant."	"Ayers et al (2002) Bis-azaaromatic quaternary ammonium analogues: ligands for _4_2* and _7* subtypes of neuronal nicotinic receptors Bioorg.Med.Chem.Letts. 12 3067. Dwoskin et al (2008) N,N'alkane-diyl-bis-3-picoliniums as nicotinic receptor antagonists: Inhibition of nicotine-evoked dopamine release and hyperactivity. J.Pharmacol.Exp.Ther. 326 563. PMID:18460644. Rahman et al (2008) Region-specific effects of the N,N'-dodecane-1,12-diyl-bis-3-picolinium dibromide on nicotine-induced increase in extracellular dopamine in vivo. Br.J.Pharmacol. 153 792. PMID:18059317."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=212520				Jun-2011
3222	TCS JNK 6o	[894804-07-0]	CCOC1=NC(NC(=O)CC2=CC(OC)=CC=C2OC)=CC(N)=C1C#N	Selective JNK inhibitor	"ATP-competitive c-Jun N-terminal kinase (JNK) inhibitor (IC50 values are 2, 4 and 52 nM for JNK1, JNK2 and JNK3 respectively). Displays > 1000 fold selectivity over other kinases, including ERK2 and p38. Inhibits c-Jun phosphorylation (EC50 = 920 nM) and prevents collagen-induced platelet aggregation in vitro."	Szczepankiewicz et al (2006) Aminopyridine-based c-Jun N-terminal kinase inhibitors with cellular activity and minimal cross-kinase activity. J.Med.Chem. 49 3563. PMID:16759099. Kauskot et al (2007) Involvement of the mirogen-activated protein kinase c-Jun NH2-terminal kinase 1 in thrombus formation. J.Biol.Chem. 282 31990. PMID:17785464.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=212521				Mar-2011
3224	RU 58668	[151555-47-4]	OC1=CC=C2C(CC[C@]3([H])[C@@]([H])2[C@@H]([C@]5=CC=C(OCCCCCS(CCCC(F)(F)C(F)(F)F)(=O)=O)C=C5)C[C@@]4(C)[C@]([H])3CC[C@@H]4O)=C1	Pure antiestrogen	Pure antiestrogen that downregulates estrogen receptor expression (IC50 = 0.04 nM). Displays potent antiproliferative activity in vitro (IC50 = 0.035 - 0.09 nM in MCF-7 cells) and causes long term regression of tamoxifen-resistant MCF-7 xenografts in vivo.	Van de Velde et al (1996) RU 58668: Further in vitro and in vivo pharmacological data related to its antitumoral activity. J.Steroid Molec.Biol. 59 449. Muller et al (1998) Partial antagonism between steroidal and nonsteroidal antiestrogens in human breast cancer cell lines. Cancer Res. 58 263. PMID:9443403. Ameller et al (2004) Drug delivery systems for oestrogenic hormones and antagonists: the need for selective targeting in estradiol-dependent cancers. J.Steroid Molec.Biol. 92 1.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=212566	SQ1070			Jan-2010
3233	AGK 2	[304896-28-4]	O=C(/C(C#N)=C/C3=CC=C(C4=C(Cl)C=CC(Cl)=C4)O3)NC2=CC=CC1=NC=CC=C12	Selective SIRT2 inhibitor	Selective inhibitor of SIRT2 (IC50 = 3.5 _M). Displays no activity at SIRT1 and SIRT3 at concentrations up to 40 _M. Reduces _-synuclein-mediated toxicity in in vitro and in vivo models of Parkinson's disease.	Outeiro et al (2007) Sirtuin 2 inhibitors rescue _-synuclein-mediated toxicity in models of Parkinson's disease. Science 317 516. PMID:17588900.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=212617	SQ1070			Feb-2009
3235	CDPPB	[781652-57-1]	O=C(C4=CC(C#N)=CC=C4)NC1=CC(C3=CC=CC=C3)=NN1C2=CC=CC=C2	Positive allosteric modulator at mGlu5	"Brain penetrant, selective positive allosteric modulator at the mGlu5 receptor (EC50 values are 10 and 20 nM for human and rat receptors respectively). Antipsychotic; reverses amphetamine-induced locomotor activity and amphetamine-induced deficits in prepulse inhibition in rats."	"Lindsley et al (2004) Discovery of positive allosteric modulators for the metabotropic glutamate receptor subtype 5 from a series of N-(1,3-diphenyl-1H-pyrazol-5-yl)benzamides that potentiate receptor function in vivo. J.Med.Chem. 47 5825. PMID:15537338. Kinney et al (2005) A novel selective positive allosteric modulator of metabotropic glutamate receptor subtype 5 has in vivo activity and antipsychotic-like effects in rats behavioral models. J.Pharmacol.Exp.Ther. 313 199. PMID:15608073. Chen et al (2007) Interaction of novel positive allosteric modulators of metabotropic glutamate receptor 5 with the negative allosteric antagonist site is required for potentiation of receptor responses. Mol.Pharmacol. 71 1389. PMID:17303702."	Small Molecule	"Manufactured and sold under license from Merck & Co., Inc. for use solely for preclinical research purposes (ie: not for administration to or other use in humans)"	http://www.tocris.com/dispprod.php?ItemId=212729	SQ1070			Jan-2009
3238	TCS PrP Inhibitor 13	[34320-83-7]	O=C(C2)N(C3=CC=CC=C3)N=C2C1=CC=C([N+]([O-])=O)C=C1	Antiprion agent; potently inhibits PrP-res accumulation	Antiprion agent. Potently inhibits protease-resistant prion protein (PrP-res) accumulation in two types of prion-infected mouse neuroblastoma (N2a) cell lines (IC50 = 3 nM).	Kimata et al (2007) New series of antiprion compounds: pyrazolone derivatives have potent activity of inhibiting protease-resistant prion protein accumulation. J.Med.Chem. 50 5053. PMID:17850126.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=213205	SQ1341			Oct-2008
3239	PF 573228	[869288-64-2]	O=C(N3)CCC1=C3C=CC(NC2=NC(NCC4=CC=CC(S(=O)(C)=O)=C4)=C(C(F)(F)F)C=N2)=C1	Potent and selective FAK inhibitor	Potent and selective inhibitor of focal adhesion kinase (FAK) (IC50 = 4 nM). Displays 50 - 250-fold selectivity for FAK over other protein kinases. Blocks serum and fibronectin-directed migration and decreases focal adhesion turnover in vitro.	. Slack-Davis et al (2007) Cellular characterization of a novel focal adhesion kinase inhibitor. J.Biol.Chem. 282 14845. PMID:17395594. Kostourou et al (2013) FAK-heterozygous mice display enhanced tumour angiogenesis. Nat.Commun. 5 2020. PMID:23799510.	Small Molecule	Sold for research purposes under agreement from Pfizer Inc.	http://www.tocris.com/dispprod.php?ItemId=213493	SQ1341			Nov-2008
3240	SCH 221510	[322473-89-2]	OC1(C2=CC=CC=C2)CC3N(C(C5=CC=CC=C5C)C4=C(C)C=CC=C4)C(CC3)C1	Potent and selective NOP agonist	"Potent and selective nociceptin opioid receptor (NOP) agonist (EC50 values are 12, 693, 683 and 8071 nM, and Ki values are 0.3, 65, 131 and 2854 nM at NOP, _-, _- and _-opioid receptors respectively). Exhibits anxiolytic-like activity at doses that have no effect on overt behaviors such as locomotion in vivo. Orally active."	"Varty et al (2008) The anxiolytic-like effects of the novel, orally active nociceptin opioid receptor agonist 8-[bis(2-methylphenyl)methyl]-3-phenyl-8-azabicyclo[3.2.1]octan-3-ol (SCH 221510). J.Pharmacol.Exp.Ther. 326 672. PMID:18492950. Lambert (2008) The nociceptin/orphanin FQ receptor: a target with broad therapeutic potential. Nat.Rev.Drug Discov. 7 694. PMID:18670432. Yang et al (2009) Identification of 3-substituted N-benzhydryl-nortropane analogs as nociceptin receptor ligands for the management of cough and anxiety. Bioorg.Med.Chem.Lett. 19 2482. PMID:19332374."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=213539	SQ1070			Jul-2010
3241	Ko 143	[461054-93-3]	O=C(N[C@H]4CCC(OC(C)(C)C)=O)[C@]3([H])CC1=C([C@H](CC(C)C)N3C4=O)NC2=C1C=CC(OC)=C2	Potent and selective BCRP inhibitor	Potent and selective breast cancer resistance protein multidrug transporter (BCRP) inhibitor (EC90 = 26 nM). Displays > 200-fold selectivity over P-gp and MRP-1 transporters. Increases intracellular drug accumulation and reverses BCRP-mediated multidrug resistance.	"Loevezijn et al (2001) Inhibition of BCRP-mediated drug efflux by fumitremorgin-type indolyl diketopiperazines. Bioorg.Med.Chem.Letts. 11 29. Allen et al (2002) Potent and specific inhibition of breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C. Mol.Cancer Ther. 1 417. PMID:12477054. Allen et al (2003) Mouse breast cancer resistance protein (Bcrp1/Abcg2) mediates etoposide resistance and transport, but etoposide oral availability is limited primarily by P-glycoprotein. Cancer Res. 63 1339. PMID:12649196."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=213642	SQ1341			Nov-2008
3242	BMS 193885	[679839-66-8]	CC1=C(C(OC)=O)C(C2=CC(NC(NCCCN3CCC(C4=CC=CC(OC)=C4)CC3)=O)=CC=C2)C(C(OC)=O)=C(C)N1.C[C@H](O)C(O)=O	"Potent, competitive NPY Y1 receptor antagonist"	"Potent, competitive neuropeptide (NPY) Y1 antagonist (Ki = 3.3 nM, IC50 = 5.9 nM) that displays > 47, > 100, > 160, > 160 and > 160-fold selectivity over _1, _1, Y2, Y4 and Y5 receptors respectively. Reduces food intake and body weight via central Y1 inhibition and is brain penetrant."	"Poindexter et al (2002) Dihydropyridine neuropeptide Y Y1 receptor antagonists. Bioorg.Med.Chem.Letts. 12 379. Poindexter et al (2004) Dihydropyridine neuropeptide Y Y1 receptor antagonists 2: bioisosteric urea replacements Bioorg.Med.Chem. 12 507. PMID:14723969. Antal-Zimanyi et al (2008) Pharmacological characterization and appetite suppressive properties of BMS-193885, a novel and selective neuropeptide Y1 receptor antagonist Eur.J.Pharmacol. 590 224. PMID:18573246."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=213643	SQ1070			Sep-2009
3246	LY 354740	[176199-48-7]	N[C@]1([C@@](O)=O)[C@@]2([H])[C@@]([C@@H]2[C@](O)=O)([H])CC1	Potent and highly selective group II mGlu agonist	"Highly selective and potent agonist of group II mGlu receptors (EC50 values are 5.1 and 24.3 nM at mGlu2 and mGlu3 receptors respectively and > 100000 nM at mGlu4, mGlu7, mGlu1a and mGlu5a receptors). Displays antianxiety and antiaddictive activity in vivo. Orally and systemically active."	"Schoepp et al (1997) LY354740 is a potent and highly selective group II metabotropic glutamate receptor agonist in cell expressing human glutamate receptors. Neuropharmacology 36 1. PMID:9144636. Helton et al (1998) Anxiolytic and side-effect profile of LY354740: a potent, highly selective, orally active agonist for group II metabotropic glutamate receptors. J.Pharmacol.Exp.Ther. 284 651. PMID:9454811. Klodzinska et al (1999) Potential anti-anxiety, anti-addictive effects of LY 354740, a selective group II glutamate metabotropic receptors agonist in animal models. Neuropharmacology 38 1831. PMID:10608278."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=214157	SQ1070			Oct-2008
3248	VU 0155041	[1093757-42-6]	O=[C@](NC2=CC(Cl)=CC(Cl)=C2)[C@H]1CCCC[C@H]1[C@@](O)=O.O=[C@](NC4=CC(Cl)=CC(Cl)=C4)[C@@H]3CCCC[C@@H]3C(O)=O	"Potent, positive allosteric mGlu4 agonist"	"Potent, positive allosteric modulator/allosteric agonist at mGlu4 receptors (EC50 = 798 and 693 nM at human and rat mGlu4 receptors respectively). Active in in vivo models of Parkinson's disease following i.c.v. administration. Also available as sodium salt (Cat. No. 3311)."	"Niswender et al (2008) Discovery, characterization, and antiparkinsonian effect of novel positive allosteric modulators of metabotropic glutamate receptor 4. Mol.Pharmacol. 74 1345. PMID:18664603."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=214724	SQ1341			Dec-2008
3249	Z-Cyclopentyl-AP4	[103439-17-4]	[H][C@@]1(CC[C@@](N)(C1)C(O)=O)P(O)(O)=O.[H][C@]1(CC[C@](N)(C1)C(O)=O)P(O)(O)=O	Group III mGlu agonist (mGlu4 > mGlu8 > mGlu7)	Group III mGlu receptor agonist that exhibits higher potency at mGlu4 than mGlu8 (EC50 values are 49 and 124 _M respectively) with no activity at mGlu7. Selectively inhibits synaptic activity in the lateral perforant pathway (IC50 values are 130 and 1859 _M in the lateral and medial perforant pathways respectively). Conformationally restrained analog of L-AP4 (Cat No. 0103).	Crooks et al (1986) Cyclic analogues of 2-amino-4-phosphonobutanoic acid (APB) and their inhibition of hippocampal excitatory transmission and displacement of [3H]APB binding. J.Med.Chem. 29 1988. PMID:3020251. Ayala et al (2008) Group III mGluR regulation of synaptic transmission at the SC-CA1 synapse is developmentally regulated. Neuropharmacology 54 804. PMID:18255102. Jones et al (2008) Metabotropic glutamate receptors mGluR4 and mGluR8 regulate transmission in the lateral olfactory tract-piriform cortex synpase. Neuropharmacology 55 440. PMID:18625254.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=214734				Jun-2009
3250	"L-838,417"	[286456-42-6]	FC(C=CC(F)=C3)=C3C1=NN=C2N1N=C(OCC4=NC=NN4C)C(C(C)(C)C)=C2	Subtype-selective GABAA partial agonist	"Subtype-selective GABAA receptor partial agonist. Selectively binds to _1, _2, _3 and _5 subunits (Ki values are 0.79, 0.67, 0.67 and 2.25 nM respectively) but displays no efficacy at _1 (_1-sparing). Exhibits non-sedative anxiolytic, antinociceptive and anti-inflammatory activity in vivo."	McCabe et al (2004) Subtype-selective GABAergic drugs facilitate extinction of mouse operant behaviour. Neuropharmacology 46 171. PMID:14680756. McMahon and France (2006) Differential behavioural effects of low efficacy positive GABAA modulators in combination with benzodiazepines and a neuroactive steroid in rhesus monkeys. Br.J.Pharmacol. 147 260. PMID:16331290. Knabl et al (2008) Reversal of pathological pain through specific spinal GABAA receptor subtypes. Nature 451 330. PMID:18202657.	Small Molecule	"Manufactured and sold under license from Merck & Co., Inc. for use solely for preclinical research purposes (ie: not for administration to or other use in humans)"	http://www.tocris.com/dispprod.php?ItemId=214735	SQ1070			Feb-2009
3251	KC 12291 hydrochloride	[181936-98-1]	CN(CCCOC2=NSC(C3=CC=CC=C3)=N2)CCC1=CC=C(OC)C(OC)=C1.Cl	Orally active atypical Na+ channel blocker; cardioprotective	"Orally active atypical voltage-gated sodium channel blocker. Inhibits sustained sodium currents (INaL) and prevents diastolic contracture in isolated atria in vitro (IC50 values are 9.6 and 0.55 - 0.79 _M respectively). Displays anti-ischemic, bradycardic and cardioprotective activity in vivo."	Decking et al (1998) Cardioprotective actions of KC 12291. Naunyn-Schmied.Arch.Pharmacol. 358 547. Tamareille et al (2002) Anti-ischemic compound KC 12291 prevents diastolic contracture in isolated atria by blockade of voltage-gated sodium channels. J.Cardiovasc.Pharmacol. 40 346. PMID:12198320. John et al (2004) KC 12291: an atypical sodium channel blocker with myocardial antiischemic properties. Cardiovasc.Drug Rev. 22 17. PMID:14978516. Letienne et al (2006) Pharmacological characterisation of sodium channels in sinoatrial node pacemaking in the rat heart. Eur.J.Pharmacol. 530 243. PMID:16368090.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=214852	SQ1070			Jul-2009
3252	WWL 70	[947669-91-2]	O=C(N(C)CC2=CC(C4=CC=NC=C4)=CC=C2)OC1=CC=C(C3=CC=C(C(N)=O)C=C3)C=C1	Potent ABHD6 inhibitor	"Potent inhibitor of _/_-hydrolase domain 6 (ABHD6) (IC50 = 70 nM), an enzyme which catalyzes the hydrolysis of 2-arachidonylglycerol (Cat. No. 1298)."	Blankman et al (2007) A comprehensive profile of brain enzymes that hydrolyze the endocannabinoid 2-arachidonylglycerol. Chem.Biol. 14 1347. PMID:18096503. Li et al (2007) A functional proteomic strategy to discover inhibitors for uncharacterized hydrolases. J.Am.Chem.Soc. 129 9594. PMID:17629278.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=214910	SQ1070			Nov-2010
3253	Triptolide	[38748-32-2]	O=C1C2=C([C@@](C[C@H]5[C@]4(O5)[C@](O6)3[C@@H]6[C@H]7[C@](C(C)C)(O7)[C@H]4O)([H])[C@]3(C)CC2)CO1	"Inhibits RNAPII-mediated transcription; antitumor, anti-inflammatory and immunosuppressive"	Inhibits DNA-dependent ATPase activity of XBP and induces inhibition of RNA polymerase II (RNAPII)-mediated transcription (IC50 = 200 nM). Selective for RNAPII over RNAPI and RNAPIII. Blocks RNA synthesis in HeLa cells (IC50 = 62 nM); exhibits potent antiproliferative activity in 60 cancer cell lines (average IC50 = 12 nM) and induces apoptosis by blocking TNF-_-mediated c-IAP1 and c-IAP2 induction. Also displays immunosuppressive and anti-inflammatory activity.	"Qui et al (1999) Immunosuppressant PG490 (Triptolide) inhibits T-cell interleukin-2 expression at the level of purine-box/nuclear factor of activated T-cells and NF-_B transcriptional activation. J.Biol.Chem. 274 13443. PMID:10224109. Lee et al (1999) PG490 (Triptolide) cooperates with tumor necrosis factor-_ to induce apoptosis in tumor cells. J.Biol.Chem. 274 13451. PMID:10224110. Titov et al (2011) XPB, a subunit of TFIIH, is a target of the natural product triptolide. Nat.Chem.Biol. 7 182. PMID:21278739."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=214931	SQ1533			Oct-2008
3254	Ro 61-8048	[199666-03-0]	O=S(NC1=NC(C2=CC=CC([N+]([O-])=O)=C2)=CS1)(C3=CC=C(OC)C(OC)=C3)=O	Potent kynurenine 3-hydroxylase inhibitor	"Potent and competitive kynurenine 3-hydroxylase inhibitor (Ki = 4.8 nM, IC50 = 37 nM). Increases kynurenic acid levels to concentrations that antagonize the glycine site of NMDA receptors. Brain penetrant and exhibits antidystonic, anticonvulsant and neuroprotective activities."	Rover et al (1997) Synthesis and biochemical evaluation of N-(4-phenylthiazol-2-yl)benzenesulfonamides as high affinity inhibitors of kynurenine 3-hydroxylase. J.Med.Chem. 40 4378. PMID:9435907. Carpenedo et al (2002) Kynurenine 3-mono-oxygenase inhibitors attenuate post-ischaemic neuronal death in organotypic hippocampal slice cultures. J.Neurochem. 82 1465. PMID:12354294. Hamann et al (2008) Effects of kynurenine 3-hydroxylase inhibitor Ro 61-8048 after intrastriatal injections on the severity of dystonia in the dtsz mutant. Eur.J.Pharmacol. 586 156. PMID:18353306. Justinova et al (2013) Reducing cannabinoid abuse and preventing relapse by enhancing endogenous brain levels of kynurenic acid. Nat.Neurosci. 16 1652. PMID:24121737.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=214932	SQ1070			Mar-2009
3255	PJ 34 hydrochloride	[344458-15-7]	Cl.CN(C)CC(=O)NC1=CC2=C(NC(=O)C3=CC=CC=C23)C=C1	Potent PARP inhibitor	Potent inhibitor of poly(ADP-ribose) polymerase (PARP) (EC50 = 20 nM). ~1000-fold more potent than 3-Aminobenzamide (Cat. No. 0788). Protects primary neuronal cells from oxygen-glucose deprivation in vitro and reduces infarct size following focal cerebral ischemia in vivo. Displays protective effects against cisplatin-induced kidney injury. Also displays activity at Pim-1 and Pim-2 kinases at higher concentrations (IC50 values are 3.7 and 16 _M respectively).	"Abdelkarim et al (2001) Protective effects of PJ34, a novel, potent inhibitor of poly(ADP-ribose) polymerase (PARP) in in vitro and in vivo models of stroke. Int.J.Mol.Med. 7 255. PMID:11179503. Gambi et al (2008) Poly(ADPR)polymerase inhibition and apoptosis induction in cDDP-treated human carcinoma cell lines. Biochem.Pharmacol. 75 2356. PMID:18468580. Kim et al (2012) Poly(ADP-ribose) polymerase 1 activation is required for cisplatin nephrotoxicity. Kidney Int. 82 193. PMID:22437413. Antolin et al (2012) Identification of Pim kinases as novel targets for PJ34 with confounding effects in PARP biology. ACS Chem.Biol. 7 1962. PMID:23025350."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=214933	SQ1070			Sep-2009
3256	Metoprolol tartrate	[56392-17-7]	O=C(O)C(O)C(O)C(O)=O.OC(CNC(C)C)COC1=CC=C(CCOC)C=C1.OC(CNC(C)C)COC2=CC=C(CCOC)C=C2	Selective _1 antagonist	"Selective _1-adrenoceptor antagonist (Ki values are 47, 2960 and 10100 nM for _1, _2 and _3 adrenoceptors respectively). Inhibits spontaneous endothelin-1 production in vitro and displays antihypertensive and antianginal activity in vivo."	Garlichs et al (1999) Beta-blockers reduce the release and synthesis of endothelin-1 in human endothelial cells. Eur.J.Clin.Invest. 29 12. PMID:10092983. Hoffmann et al (2004) Comparative pharmacology of human _-adrenergic receptor subtypes - characterization of stably transfected receptors in CHO cells. Naunyn-Schmied.Arch.Pharmacol. 369 151. Dasbiswas et al (2008) S-metoprolol: The 2008 Clinical Review. J.Indian.Med.Assoc. 106 259. PMID:18828349.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=214934	SQ1533			Nov-2008
3257	5-Fluorouracil	[51-21-8]	O=C1C(F)=CNC(N1)=O	Inhibits RNA and DNA synthesis	"Anticancer agent. Metabolized to form fluorodeoxyuridine monophosphate (FdUMP), fluorodeoxyuridine triphosphate (FdUTP) and fluorouridine (FUTP). FdUMP inhibits thymidylate synthase, causing a reduction in dTMP synthesis. FUTP and FdUTP are misincorporated into RNA and DNA respectively."	"Ghoshal and Jacob (1997) An alternative molecular mechanism of action of 5-fluorouracil, a potent anticancer drug. Biochem.Pharmacol. 53 1569. PMID:9264308. Peters et al (2002) Induction of thymidylate synthase as a 5-fluorouracil resistance mechanism. Biochim.Biophys.Acta. 1587 194. PMID:12084461. Longley et al (2003) 5-Fluorouracil: mechanisms of action and clinical strategies. Nat.Rev.Cancer 3 330. PMID:12724731."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=214935	SQ1533			Oct-2008
3258	Mitomycin C	[50-07-7]	O=C(C(N)=C1C)C2=C(N(C[C@H]4[C@@H]3N4)[C@@]3(OC)[C@@H]2COC(N)=O)C1=O	DNA cross-linking antitumor agent	Antibiotic and antitumor agent. Covalently binds DNA forming intra- and interstrand crosslinks. Inhibits DNA synthesis.	Tomasz et al (1987) Isolation and structure of a covalent cross-link adduct between mitomycin C and DNA. Science 235 1204. PMID:3103215. Bizanek et al (1992) Isolation and structure of an intrastrand cross-link adduct of mitomycin C and DNA. Biochemistry 31 3084. PMID:1554696.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=214936	SQ1533			Oct-2008
3259	Gemcitabine hydrochloride	[122111-03-9]	O[C@@H]1[C@@H](CO)O[C@@H](N2C(N=C(N)C=C2)=O)[C@@H]1F.Cl	DNA synthesis inhibitor	Deoxycytidine analog that inhibits DNA synthesis. Metabolized to form gemcitabine triphosphate (dFdCTP) and gemcitabine diphosphate (dFdCDP). dFdCTD inhibits ribonucleotide reductase causing a reduction in cellular nucleotides. dFdCTP is incorporated in DNA resulting in DNA strand termination. Displays antitumor activity in vitro and in vivo.	"Hertel et al (1990) Evaluation of the antitumor activity of Gemcitabine (2',2'-Difluoro-2'-deoxycytidine). Cancer Res. 50 4417. PMID:2364394. Heinemann et al (1995) Gemcitabine: a modulator of intracellular nucleotide and deoxynucleotide metabolism. Semin.Oncol. 22 (Suppl. 11) 11. PMID:7481839. Plunkett et al (1995) Preclinical characteristics of gemcitabine. Anticancer Drugs 6 (Suppl. 6) 7. PMID:8718419."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=214937	SQ1070			Oct-2008
3260	Epirubicin hydrochloride	[56390-09-1]	O=C(C2=C1C(OC)=CC=C2)C3=C(C(O)=C([C@](OC5CC(N)C(O)C(C)O5)([H])C[C@@]([C@@](CO)=O)(O)C4)C4=C3O)C1=O.Cl	Inhibits DNA synthesis and function. Inhibits DNA topoisomerase II	Antibiotic antitumor agent. Inhibits the synthesis and function of DNA (IC50 = 62.7 _M in rat glioblastoma cell lines) and inhibits the relaxing property of topoisomerase II.	"Cersosimo et al (1986) Epirubicin: a review of pharmacology, clinical activity, and adverse effects of an adriamycin analogue. J.Clin.Oncol. 4 425. PMID:3005521. Spadari et al (1986) DNA polymerases and DNA topoisomerases as targets for the development of anticancer drugs. Anticancer Res. 6 935. PMID:3026237. Schott and Robert (1989) Comparative activity of anthracycline 13-dihydrometabolites against rat glioblastoma cells in culture. Biochem.Pharmacol. 38 4069. PMID:2597184."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=214938	SQ1533			Nov-2008
3262	JNJ 1661010	[681136-29-8]	O=C(NC3=CC=CC=C3)N1CCN(C2=NC(C4=CC=CC=C4)=NS2)CC1	"Selective, reversible FAAH inhibitor"	"Selective, reversible inhibitor of fatty acid amide hydrolase (FAAH) (IC50 = 12 nM). Brain penetrant and active in vivo."	Keith et al (2008) Thiadiazolopiperazinyl ureas as inhibitors of fatty acid amid hydrolase. Bioorg.Med.Chem.Lett. 18 4838. PMID:18693015.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=207717	SQ1341			Oct-2008
3263	SB 505124	[694433-59-5]	CC(C)(C)C1=NC(C2=CC(OCO4)=C4C=C2)=C(C3=NC(C)=CC=C3)N1	"Selective inhibitor of TGF-_RI, ALK4 and ALK7"	"Selective inhibitor of transforming growth factor-_ type I receptor (ALK5), ALK4 and ALK7 (IC50 values are 47 and 129 nM for ALK5 and ALK4 respectively). Selectively inhibits signaling from TGF-_ and activin; does not inhibit other ALK family members."	"Byfield et al (2004) SB-505124 is a selective inhibitor of transforming growth factor-_ type I receptors ALK4, ALK5, and ALK7. Mol.Pharmacol. 65 744. PMID:14978253. Hu et al (2005) Reactive oxygen species production via NADPH oxidase mediates TGF-_-induced cytoskeletal alterations in endothelial cells. Am.J.Physiol.Renal Physiol. 289 F816. PMID:16159901. Noma et al (2008) The essential role of fibroblasts in esophageal squamous cell carcinoma-induced angiogenesis. Gastroenterology 134 1981. PMID:18439605."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=215122				Oct-2011
3264	GW 788388	[452342-67-5]	O=C(NC5CCOCC5)C(C=C4)=CC=C4C1=CC(C2=CNN=C2C3=CC=CC=N3)=CC=N1	Potent and selective inhibitor of TGF-_RI	Potent inhibitor of transforming growth factor-_ type I receptor (ALK5) (IC50 values are 18 and 93 nM for ALK5 binding and for TGF-_ cellular assay respectively). Inhibits esophageal squamous cell carcinoma (ESCC)-induced neoangiogenesis. Orally active.	"Gellibert et al (2006) Discovery of 4-{4-[3-(pyridin-2-yl)-1H-pyrazol-4-yl]pyridin-2-yl}-N-(tetrahydro-2H- pyran-4-yl)benzamide (GW788388): a potent, selective, and orally active transforming growth factor-_ type I receptor inhibitor. J.Med.Chem. 49 2210. PMID:16570917. Noma et al (2008) The essential role of fibroblasts in esophageal squamous carcinoma-induced angiogenesis. Gastroenterology 134 1981. PMID:18439605. Tan et al (2010) Targeted inhibition of activin receptor-like kinase 5 signaling attenuates cardiac dysfunction following myocardial infarction. Am.J.Physiol.Heart Circ.Physiol. 298 H1415. PMID:20154262."	Small Molecule	Sold for research purposes under agreement from GlaxoSmithKline	http://www.tocris.com/dispprod.php?ItemId=215123	SQ1533			Feb-2012
3265	SB 452533	[459429-39-1]	CC1=CC(N(CC)CCNC(NC2=CC=CC=C2Br)=O)=CC=C1	Potent TRPV1 receptor antagonist	"Potent TRPV1 antagonist against capsaicin (pKb = 7.7), noxious heat and acid-mediated (pIC50 = 7.0) receptor activation (pKi = 6.22 at the recombinant hTRPV1 receptor). Exhibits analgesic properties."	"Rami et al (2004) Discovery of small molecule antagonists of TRPV1. Bioorg.Med.Chem.Lett. 14 3631. PMID:15203132. Weil et al (2005) Conservation of functional and pharmacological properties in the distantly related temperature sensors TRPV1 and TRPM8. Mol.Pharmacol. 68 518. PMID:15911692. Bianchi et al (2007) [3H]A-778317 [1-((R)-5-tert-Butyl-indan-1-yl)-3-isoquinolin-5-ylurea]: a novel, stereoselective, high-affinity antagonist is a useful radioligand for the human transient receptor potential vanilloid-1 (TRPV1) receptor. J.Pharmacol.Exp.Ther. 323 285. PMID:17660385."	Small Molecule	Sold for research purposes only under agreement from GlaxoSmithKline	http://www.tocris.com/dispprod.php?ItemId=215124				Mar-2011
3267	Thiostrepton	[1393-48-2]	C=C(C(NC(C(N)=O)=C)=O)NC(C1=CSC(C9=NC(C5=CSC(C(C(C)OC(C7=CC(C(C)O)=C(C=CC(NC(C(NC(C)C(NC(C(NC(C)C%10=O)=O)=C)=O)=O)C(CC)C)C8O)C8=N7)=O)N6)=N5)C(CC9)(N%10)C2=NC(C(NC(C(N/C(C3=NC(C(NC(C(O)(C)C(C)O)C4=NC(C6=O)=CS4)=O)CS3)=C/C)=O)C(C)O)=O)=CS2)=N1)=O	"Antibiotic, inhibits protein synthesis"	"Antibiotic that inhibits bacterial protein synthesis. Inhibits mRNA-tRNA translocation by GTPase elongation factor G (EF-G), EF-TU(GTP)-catalyzed aa-tRNA delivery and the activity of initiation factor 2 (IF-2). Antitumor agent; induces cell cycle arrest and apoptosis in breast cancer cells via downregulation of FOXM1 expression."	Rodnina et al (1999) Thiostrepton inhibits the turnover but not the GTPase of elongation factor G on the ribosome. Proc.Natl.Acad.Sci.USA 96 9586. Ruben et al (2007) Thiostrepton inhibition of tRNA delivery to the ribosome. RNA 13 2091. PMID:17951333. Kwok et al (2008) Thiostrepton selectively targets breast cancer cells through inhibition of forkhead box M1 expression. Mol.Cancer Ther. 7 2022. PMID:18645012.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=215190	SQ1070			Oct-2008
3268	Minocycline hydrochloride	[13614-98-7]	NC(C4=C(O)[C@@H](N(C)C)[C@@]3([H])[C@](C4=O)(O)C(O)=C2C(C1=C(O)C=CC(N(C)C)=C1C[C@]([H])2C3)=O)=O.Cl	Antibiotic. Displays neuroprotective effects	"Tetracycline antibiotic. Displays neuroprotective, antiapoptotic, anti-inflammatory and antimicrobial effects. Acts as a matrix metalloproteinase (MMP) inhibitor; attenuates disease severity in mouse models of multiple sclerosis. Orally active and brain penetrant."	"Tikka et al (2001) Minocycline, a tetracycline derivative, is neuroprotective against excitotoxicity by inhibiting activation and proliferation of microglia. J.Neurosci. 21 2580. PMID:11306611. Brundula et al (2002) Targeting leukocyte MMPs and transmigration: Minocycline as a potential therapy for multiple sclerosis. Brain 125 1297. PMID:12023318. Padi and Kulkarni (2008) Minocycline prevents the development of neuropathic pain, but not acute pain: possible anti-inflammatory and antioxidant mechanisms. Eur.J.Pharmacol. 601 79. PMID:18952075."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=215191	SQ1533			Sep-2010
3269	SD 208	[627536-09-8]	FC(C=CC(Cl)=C3)=C3C2=NC1=NC=CN=C1C(NC4=CC=NC=C4)=N2	Potent ATP-competitive TGF-_RI inhibitor	"Potent, orally active ATP-competitive transforming growth factor-_ receptor 1 (TGF-_RI) inhibitor (IC50 = 49 nM). Displays > 100-fold and > 17-fold selectivity over TGF-_RII and other common kinases respectively. Exhibits anti-inflammatory and antitumor activity."	"Uhl et al (2004) SD-208, a novel transforming growth factor _ feceptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogeneicity of murine and human glioma cells in vitro and in vivo. Cancer Res. 64 7954. PMID:15520202. Kapoun et al (2006) Transforming growth factor-_ receptor type I receptor (TGF_RI) kinase activity but not p38 activation is required for TGF_RI-induced myofibroblast differentiation and profibrotic gene expression. Mol.Pharmacol. 70 518. PMID:16707625. Leung et al (2006) Effect of transforming growth factor-_ receptor I kinase inhibitor 2,4-disubstituted pteridine (SD-208) in chronic allergic airway inflammation and remodeling. J.Pharmacol.Exp.Ther. 319 586. PMID:16888081."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=215192	SQ1533			Oct-2008
3270	GIT 27	[6501-72-0]	O=C(CC1CC(C2=CC=CC=C2)=NO1)O	Immunomodulator; reduces production of pro-inflammatory cytokines	"Orally active immunomodulatory agent that primarily targets macrophages. Inhibits TNF-_ secretion via interference of macrophage toll-like receptor (TLR) 4 and TLR 2/6 signaling pathway. Also reduces the secretion of pro-inflammatory cytokines IL1-_, IL-10 and IFN-_. Antidiabetogenic; prevents IL-_ and IFN-_-induced pancreatic islet cell death in vitro."	"Stosic-Grujicic et al (2007) A potent immunomodulatory compound (S,R)-3-phenyl-4,5-dihydro-5-isoxasoleacetic acid, prevents spontaneous and accelerated forms of autoimmune diabetes in NOD mice and inhibits the immunoinflammatory diabetes induced by multiple low doses of streptozotocin in CBA/H mice. J.Pharmacol.Exp.Ther. 320 1038. PMID:17148780. Stojanovic et al (2007) In vitro, ex vivo and in vivo immunopharmacological activities of the isoxazoline compound VGX-1027: Modulation of cytokine synthesis and prevention of both organ-specific and systemic autoimmune diseases in murine models. Clin.Immunol. 123 311. PMID:17449326. Mangano et al (2008) In vitro inhibition of enterobacteria-reactive CD4+CD25- T cells and suppression of immunoinflammatory colitis in mice by the novel immunomodulatory agent VGX-1027. Eur.J.Pharmacol. 586 313. PMID:18374912."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=215193	SQ1341			Jan-2009
3271	Compound 401	[168425-64-7]	O=C3N2C=CC1=CC=CC=C1C2=NC(N4CCOCC4)=C3	Selective DNA-PK and mTOR inhibitor	"Reversible and selective inhibitor of DNA-dependent protein kinase (DNA-PK) and mammalian target of rapamycin (mTOR) (IC50 values are 0.28 and 5.3 _M respectively). Displays little affinity for other commonly studied kinases including PI 3-K, ATM and ATR (IC50 values are all > 100 _M). Induces apoptosis in vitro."	"Griffen et al (2005) Selective benzopyranone and pyrimido[2,1-_]isoquinolin-4-one inhibitors of DNA-dependent protein kinase: synthesis, structure-activity studies and radiosensitization of a human tumor cell line in vitro. J.Med.Chem. 48 569. PMID:15658870. Ballo et al (2007) Inhibition of mammalian target of rapamycin signaling by 2-(morpholin-1-yl)oyrimido[2,1-_]isoquinolin-4-one. J.Biol.Chem. 282 24463. PMID:17562705."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=215220	SQ1341			Oct-2008
3272	()-LY 395756	[852679-66-4]	N[C@]1([C@](O)=O)[C@@]2([H])[C@@]([C@@H]2[C@](O)=O)([H])[C@H](C)C1	Mixed mGlu2 agonist/ mGlu3 antagonist	Selective metabotropic glutamate ligand for mGlu2 and mGlu3 receptors (Ki values are 0.165 _M and 0.302 _M respectively). Acts as an agonist at mGlu2 and antagonist at mGlu3. Analog of LY 354740 (Cat. No. 3246).	"Dominguez et al (2005) Methyl substitution of 2-aminobicyclo[3.1.0]hexane 2,6-dicarboxylate (LY354740) determines functional activity at metabotropic glutamate receptors: identification of a subtype selective mGlu2 receptor agonist. J.Med.Chem. 48 3605. PMID:15887967."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=215374	SQ1070			Sep-2010
3276	Mephenytoin	[50-12-4]	O=C1C(C2=CC=CC=C2)(CC)NC(N1C)=O	CYP2C19 substrate. Anticonvulsant	CYP2C19 substrate. Anticonvulsant.	Knabe and Wunn (1980) Racemic and optically active hydantoins from disubstituted cyanoacetic acids. Arch.Pharmacol. 313 53.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=215414	SQ1533			Oct-2008
3277	Pentamidine isethionate	[140-64-7]	NC(C1=CC=C(OCCCCCOC2=CC=C(C(N)=N)C=C2)C=C1)=N.OCCS(=O)(O)=O.OCCS(=O)(O)=O	Antimicrobial that antagonizes NMDA receptors	Antimicrobial. Neuroprotective; inhibits constitutive nitric oxide synthase in the brain and acts as a NMDA glutamate receptor antagonist.	"Reynolds and Aizeman (1992) Pentamidine is an N-methyl-D-aspartate receptor antagonist and is neuroprotective in vitro. J.Neurosci. 12 970. PMID:1532027. Kitamura et al (1995) Inhibition of constitutive nitric oxide synthase in the brain by pentamidine, a calmodulin antagonist. Eur.J.Pharmacol. 289 299. PMID:7542607."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=215442	SQ1533			Oct-2008
3278	YM 511	[148869-05-0]	BrC(C=C3)=CC=C3CN(N2C=NN=C2)C1=CC=C(C#N)C=C1	Potent aromatase (CYP19) inhibitor	"Orally active, potent aromatase (CYP19) inhibitor (IC50 values are 0.4 and 0.12 nM at rat ovary and human placenta cells respectively) that only weakly inhibits the synthesis of other steroid hormones. Reduces plasma estrogen levels into ranges induced by ovariectomy and inhibits testosterone-induced breast cancer cell growth in vitro (IC50 = 0.13 nM)."	"Kudoh et al (1995) The potent and selective inhibiton of estrogen production by non-steroidal aromatase inhibitor, YM511. J.Steroid Biochem.Molec.Biol. 54 265. Kudoh et al (1996) Inhibitory effect of a novel non-steroidal aromatase inhibitor, YM511 on the proliferation of MCF-7 human breast cancer cell. J.Steroid Biochem.Molec.Biol. 58 189. Okada et al (1996) Studies on aromatase inhibitors I. Synthesis and biological evaulation of 4-amino-4H-1,2,4-triaole derivatives. Chem.Pharm.Bull. 44 1871. PMID:8904814."	Small Molecule	(Sold with the permission of Astellas Pharma Inc.)	http://www.tocris.com/dispprod.php?ItemId=215461				Dec-2008
3281	Canrenone	[976-71-6]	O=C1CC[C@@]2(C)C(C=C[C@]3([H])[C@@]([H])2CC[C@@]4(C)[C@]([H])3CC[C@@]54OC(CC5)=O)=C1	Mineralocorticoid receptor antagonist	Mineralocorticoid receptor antagonist. Active metabolite of spironolactone (Cat. No. 2968).	Delyani et al (2000) Mineralocorticoid receptor antagonists: the evolution of utility and pharmacology. Kidney Int. 57 1408. PMID:10760075.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=215503	SQ1533			Oct-2008
3282	NAD 299 hydrochloride	[184674-99-5]	FC1=C2C(C[C@@H](N(C4CCC4)C3CCC3)CO2)=C(C(N)=O)C=C1.Cl	"Selective, high affinity 5-HT1A antagonist"	"Selective, high affinity 5-HT1A receptor antagonist (Ki = 0.6 nM in vitro). Enhances the action of selective 5-HT reuptake inhibitors and reverses citalopram-induced (Cat. No. 1427) inhibition of serotonergic cell firing."	"Johansson et al (1997) The pharmacological characterization of a novel selective 5-hydroxytryptamine-1A receptor antagonist, NAD-299. J.Pharamacol.Exp.Ther. 283 216. Larsson et al (1998) Differential regional antagonism of 8-OH-DPAT-induced decrease in serotonin synthesis by two 5-HT1A receptor antagonists. Eur.J.Pharmacol. 346 209. PMID:9652362. Arborelius et al (1999) The 5-HT1A receptor antagonist robalzotan completely reverses citalopram-induced inhibition of serotonergic cell firing. Eur.J.Pharmacol. 382 133. PMID:10528148."	Small Molecule	Sold for research purposes under agreement from AstraZeneca	http://www.tocris.com/dispprod.php?ItemId=215546	SQ1070			Jun-2010
3283	LY 487379 hydrochloride	[353229-59-1]	O=S(N(CC3=CC=CN=C3)C1=CC=C(OC2=CC=CC=C2OC)C=C1)(CC(F)(F)F)=O.Cl	Positive allosteric modulator selective for mGlu2	Positive allosteric modulator selective for mGlu2 receptors. Potentiates glutamate-stimulated [35S]GTP_S binding (EC50 values are 1.7 and > 10 _M for mGlu2 and mGlu3 receptors respectively). Devoid of any activity at mGlu5 and mGlu7 receptors. Promotes cognitive flexibility in a rat model.	"Johnson et al (2003) Discovery of allosteric potentiators for the metabotropic glutamate 2 receptor: synthesis and subtype selectivity of N-(4-(2-methoxyphenoxy)phenyl)-N-(2,2,-trifluoroethylsulfonyl)pyrid-3-ylmethyl-amine. J.Med.Chem. 46 3189. PMID:12852748. Schaffhauser et al (2003) Pharmacological characterization and identification of amino acids involved in the positive modulation of metabotropic glutamate receptor subtype 2. Mol.Pharmacol. 64 798. PMID:14500736. Poisik et al (2005) Metabotropic glutamate receptor 2 modulates excitatory synaptic transmission in the rat globus pallidus. Neuropharmacology 49 57. PMID:15993439. Nikiforuk et al (2010) Effects of a positive allosteric modulator of group II metabotropic glutamate receptors, LY487379, on cognitive flexibility and impulsive-like responding in rats. J.Pharmacol.Exp.Ther. 335 665. PMID:20739457."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=215560	SQ1341			Nov-2008
3284	Rec 15/2615 dihydrochloride	[173059-17-1]	NC2=NC(N3CCN(C(COC4=C(OC)C=CC=C4C(C)C)=O)CC3)=NC1=CC(OC)=C(OC)C=C12.Cl.Cl	Selective _1B antagonist	"Selective _1B-adrenoceptor antagonist (Ki values are 0.3, 1.9 and 2.6 nM at human _1B, _1A and _1D receptors respectively)."	"Testa et al (1997) Pharmacological characterization of the uroselective alpha-1 antagonist Rec 15/2739 (SB 216469): Role of the alpha-1L adrenoceptor in tissue selectivity, part II. J.Pharmacol.Exp.Ther. 281 1284. PMID:9190864. Bremner et al (2000) Ligand design for _1 adrenoceptor subtype selective antagonist. Bioorg.Med.Chem. 8 201. PMID:10968279. Morston et al (2007) _1A-adrenoceptors mediate contractions to phenylephrine in rabbit penile arteries. Br.J.Pharmacol. 150 112. PMID:17115072."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=215637	SQ1070			Feb-2009
3285	NPS ALX Compound 4a dihydrochloride	[299433-10-6]	O=S(N2C1=CC(N5CCN(CCC6)C6C5)=CC=C1C=C2)(C3=C(C=CC=C4)C4=CC=C3)=O.Cl.Cl	Potent and selective 5-HT6 antagonist	"Potent and competitive 5-HT6 antagonist (IC50 = 7.2 nM, Ki = 0.2 nM) that displays selectivity over other 5-HT and D2 receptors."	"Isaac et al (2000) 6-bicyclopiperazinyl-1-arylsulfonylindoles and 6-bicyclopiperidinyl-1-arylsulfonylindoles derivatives as novel, potent, and selective 5-HT6 receptor antagonists. Bioorg.Med.Chem.Letts. 10 1719."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=215684	SQ1070			Feb-2009
3286	Milnacipran hydrochloride	[101152-94-7]	NC[C@@H]1[C@@]([C@](N(CC)CC)=O)([C@]2=CC=CC=C2)C1.NC[C@H]3[C@]([C@](N(CC)CC)=O)([C@]4=CC=CC=C4)C3.Cl.Cl	5-HT and noradrenalin re-uptake inhibitor (SNRI)	Orally active 5-HT and noradrenalin re-uptake inhibitor (SNRI) (IC50 values are 203 and 100 nM respectively) that displays no affinity at a range of other receptors. Causes adaptive changes to _1-adrenergic and 5-HT2A serotonergic systems when administered repeatedly. Exhibits antidepressive and antinociceptive activities in vivo.	"Moret et al (1985) Biochemical profile of midalcipran (F 2207), 1-phenyl-1-diethyl-aminocarbonyl-2-aminomethyl-cyclopropane (z) hydrochloride, a potential fourth generation antidepressant drug. Neuropharmacology 24 1211. PMID:3005901. Maj et al (2000) Pharmacological effect of milnacipran, a new antidepressant, given repeatedly on the _1-adrenergic and serotonergic 5-HT2A systems. J.Neural.Transm. 107 1345. PMID:11145008. Suzuki et al (2008) Antiallodynic and antihyperalgesic effect of milnacipran in mice with spinal nerve ligation. Anesth.Analg. 106 1309. PMID:18349211."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=215685				Nov-2008
3287	Prochlorperazine dimaleate	[84-02-6]	O=C(O)/C=C\C(O)=O.ClC4=CC2=C(C=C4)SC1=CC=CC=C1N2CCCN3CCN(C)CC3.O=C(O)/C=C\C(O)=O	D2 receptor antagonist. Also 5-HT3 and nAChR antagonist	"D2 receptor antagonist. Also interacts with 5-HT3 and nAChR. Displays antipsychotic, antispasmodic, antiemetic and antinociceptive activity in vivo."	Lummis and Baker (1997) Radioligand binding and photoaffinity labeling studies show a direct interaction of phenothiazenes at 5-HT3 receptors. Neuropharmacology 36 665. PMID:9225292. Ghelardini et al (2004) Prochlorperazine induces central antinociception mediated by the muscarinic system. Pharmacol.Res. 50 351. PMID:15225680. Satoh et al (2005) The antipsychotic and antiemetic drug prochlorperazine delays the ventricular repolarization of the in situ canine heart. J.Pharm.Sci. 97 101.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=215878	SQ1533			Oct-2008
3288	Oxprenolol hydrochloride	[6452-73-9]	CC(C)NCC(O)COC1=CC=CC=C1OCC=C.Cl	Non-selective _ antagonist	Non-selective _-adrenergic antagonist.	Fujita et al (1998) Adrenergic agonists suppress the proliferation of microglia through _2-adrenergic receptor. Neuroscience Lett. 242 37.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=215889	SQ1533			Oct-2008
3291	PF 915275	[857290-04-1]	NC1=NC(NS(C(C=C3)=CC=C3C2=CC=C(C#N)C=C2)(=O)=O)=CC=C1	Potent and selective 11_-hydroxysteroid dehydrogenase inhibitor	Potent and selective 11_-hydroxysteroid dehydrogenase type 1 (11_HSD1) inhibitor (Ki = 2.3 nM) that displays little activity at 11_HSD2 (1.5% inhibition at 10 _M). Inhibits the conversion of prednisone to prednisolone in human hepatocytes in vitro (EC50 = 15 nM) and has antidiabetic activity in vivo. Orally active.	"Bhat et al (2008) Demonstration of proof of mechanism and pharmacokinetics and pharmacodynamic relationship with 4'-cyano-biphenyl-4-sulfonic acid (6-amino-pyridin-2-yl)-amide (PF-915275), an inhibitor of 11_-hydroxysteroid dehydrogenase type 1 in cynomolgus monkeys. J.Pharmacol.Exp.Ther. 324 299. PMID:17921190. Fotsch and Wang (2008) Blockade of glucocorticoid excess at the tissue level: inhibitors of 11_-hydroxysteroid dehydrogenase type 1 as a therapy for type 2 diabetes. J.Med.Chem. 51 4851. PMID:18652443. Courtney et al (2008) Modulation of 11_-hydroxysteroid dehydrogenase (11_HSD) activity biomarkers and pharmacokinetics of PF-00915275, a selective 11_HSD1 inhibitor. J.Clin.Endocrinol.Metab. 93 550. PMID:17986636."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=216036	SQ1070			Mar-2009
3292	Metyrapone	[54-36-4]	O=C(C2=CN=CC=C2)C(C)(C)C1=CC=CN=C1	11-_ hydroxylase inhibitor	Cytochrome P450 inhibitor. Blocks glucocorticoid synthesis via inhibition of steroid 11-_ hydroxylase (CYP11B1) activity (IC50 = 7.83 _M). Also inhibits CYP3A4 and cytochrome P450-mediated _/_-1 hydroxylase activity.	"Hays et al (1984) Structure-activity relationship study of the inhibition of adrenal cortical 11_-hydroxylase by new metyrapone analogues. J.Med.Chem. 27 15. PMID:6606707. Asakura and Shichi (1992) Cytochrome P450-mediated prostaglandin omega/omega-1 hydroxylase activities in porcine ciliary body epithelial cells. Exp.Eye Res. 55 377. PMID:1426070. Park et al (2005) Structural and dynamic basis of broad substrate specificity, catalytic mechanism and inhibition of cytochrome P450 3A4. J.Am.Chem.Soc. 127 13634. PMID:16190729."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=216080	SQ1533			Nov-2008
3293	Finasteride	[98319-26-7]	C[C@@]34[C@](CC[C@@H]4[C@@](NC(C)(C)C)=O)([H])[C@]2([H])CC[C@@]1([H])NC(C=C[C@@](C)1[C@]([H])2CC3)=O	Type II 5_-reductase inhibitor	Antiandrogen that inhibits type II 5_ reductase (IC50 = 65 nM). Suppresses the conversion of testosterone to dihydrotestosterone. Reduces prostatic dihydrotestosterone levels and prostate size in vivo. Orally active.	"Thigpen and Russell (1992) Four-amino acid segment in steroid 5_-reductase 1 confers sensitivity to finasteride, a competitive inhibitor. J.Biol.Chem. 267 8577. PMID:1314830. Gao et al (2004) Comparison of the pharmacological effects of a novel selective androgen receptor modulator, the 5_-reductase inhibitor finasteride, and the antiandrogen hydroxyflutamide in intact rats: new approach for benign prostate hyperplasia. Endocrinology 145 5420. PMID:15308613. Mukai et al (2008) Studies on neurosteroids XXV. Influence of a 5_-reductase inhibitor, finasteride, on rat brain neurosteroid levels and metabolism. Biol.Pharm.Bull. 31 1646. PMID:18758053."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=216081	SQ1533			Nov-2008
3294	SN 003	[197801-88-0]	CCC(COC)N2C1=CC(C)=NC(NC3=CC=C(OC)C=C3C)=C1N=N2	Potent and selective CRF1 antagonist	Reversible corticotropin releasing factor receptor 1 (CRF1) antagonist (Ki values are 3.4 and 7.9 nM at rat and human CRF1 respectively) that displays >1000-fold selectivity over CRF2 receptors. Suppresses CRF-induced ACTH release in vitro (IC50 = 241 nM) and is brain penetrant.	"Zhang et al (2003) Pharmacological characterization of a novel nonpeptide antagonist radioligand, ()-N-[2-Methyl-4-methoxyphenyl]-1-(1-(methoxymethyl) propyl)-6-methyl-1H-1,2,3-triazolo[4,5-c]pyridin-4-amine ([3H]SN003) for corticotropin-releasing factor1 receptors. J.Pharm.Exp.Ther. 305 57. Kumar et al (2006) Synthesis and in vivo evaluation of [11C]SN003 as a PET ligand for CRF1 receptors. Bioorg.Med.Chem. 14 4029. PMID:16529935. Sullivan et al (2007) PET imaging of CRF1 with [11C]R121920 and [11C]DMP696: Is the target of sufficient density? Nucl.Med.Biol 34 353. PMID:17499724."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=216556	SQ1070			Jan-2011
3295	RG 108	[48208-26-0]	O=C(C(C=CC=C4)=C4C3=O)N3[C@H](C(O)=O)CC2=CNC1=CC=CC=C12	Non-nucleoside DNA methyltransferase inhibitor	Non-nucleoside DNA methyltransferase inhibitor that blocks the enzyme active site. Inhibits DNA methylation in human cancer cell lines in vitro without detectable toxicity. Demethylates and reactivates epigenetically silenced tumor suppressor genes. Enhances the efficiency of induced pluripotent stem cell (iPS) generation.	Brueckner et al (2005) Epigenetic reactivation of tumor suppressor genes by a novel small-molecule inhibitor of DNA methyltransferase. Cancer Res. 65 6305. PMID:16024632. Stresemann et al (2006) Functional diversity of DNA methyltransferase inhibitors in human cancer cell lines. Cancer Res. 66 2794. PMID:16510601. Schirrmacher et al (2006) Synthesis and in vitro evaluation of biotinylated RG108: a high affinity compound for studying binding interactions with human DNA methyltransferases. Bioconjug.Chem. 17 261. PMID:16536454. Liang et al (2010) Butyrate promotes iPS cell generation. J.Biol.Chem. 285 25516. PMID:20554530.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=216684	SQ1533			May-2009
3296	AP 18	[55224-94-7]	ClC1=CC=C(/C=C(C)/C(C)=N/O)C=C1	Reversible TRPA1 channel blocker	Reversible TRPA1 channel blocker (IC50 values are 3.1 and 4.5 _M at human and mouse TRPA1 respectively). Blocks cinnameldehyde-induced but not capsaicin-induced nociception and reverses mechanical hyperalgesia in vivo. Also blocks TRPA1 pore dilation (IC50 = 10.3 _M for the inhibition of Yo-Pro uptake).	"Petrus et al (2007) A role of TRPA1 in mechanical hyperalgesia is revealed by pharmacological inhibition. Mol.Pain 3 40. PMID:18086313. Chen et al (2009) Pore dilation occurs in TRPA1 but not in TRPM8 channels. Mol.Pain 5 3. PMID:19159452. Taylor-Clark et al (2009) Nitrooleic acid, an endogenous product of nitrative stress, activates nociceptive sensory nerves via the direct activation of TRPA1. Mol.Pharmacol. 75 820. PMID:19171673."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=216745				Mar-2009
3297	SSR 146977 hydrochloride	[264618-38-4]	O=C(N(C)C)NC1(C4=CC=CC=C4)CCN(CCC[C@]3(CN(C(C5=CC=CC=C5)=O)CCC3)[C@]2=CC=C(Cl)C(Cl)=C2)CC1.Cl	Potent and selective NK3 antagonist	Potent and selective NK3 receptor antagonist (Ki values are 0.26 and 19.3 nM in CHO cells expressing the human NK3 and NK2 receptor respectively). Also inhibits senktide-induced inositol monophosphate formation and intracellular calcium mobilization (IC50 = 10 nM).	"Emonds-Alt et al (2002) Biochemical and pharmacological activities of SSR 146977, a new potent nonpeptide tachykinin NK3 receptor antagonist. Can.J.Physiol.Pharmacol. 80 482. PMID:12056557."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=217216	SQ1070			Feb-2011
3298	NGD 94-1	[178928-68-2]	C1(N2CCN(CC3=CN=C(C4=CC=CC=C4)N3)CC2)=NC=CC=N1	Selective D4 receptor ligand	"High affinity D4 receptor ligand; selective over D1, D2, D3 and D5 receptors. Displays antagonist activity at the human D4.2 receptor (Ki = 3.6 nM in transfected CHO cells) and exhibits agonist activity at the D4.4 receptor in HEK 293 cells."	"Tallman et al (1997) I. NGD 94-1: Identification of a novel, high affinity antagonist at the human dopamine D4 receptor. J.Pharmacol.Exp.Ther. 282 1011. PMID:9262370. Primus et al (1997) II. Localization and characterization of dopamine D4 binding sites in rat and human brain by use of the novel, D4 receptor-selective ligand [3H]NGD 94-1. J.Pharmacol.Exp.Ther. 282 1020. PMID:9262371. Gazi et al (1999) NGD 94-1 as an agonist at human recombinant dopamine D4.4 receptors expressed in HEK293 cells. Eur.J.Pharmacol. 372 R9. PMID:10395031."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=217217	SQ1070			Aug-2010
3299	AMD 3100 octahydrochloride	[155148-31-5]	C1(CN3CCCNCCNCCCNCC3)=CC=C(CN2CCCNCCNCCCNCC2)C=C1.Cl.Cl.Cl.Cl.Cl.Cl.Cl.Cl	Highly selective CXCR4 antagonist	Highly selective CXCR4 chemokine receptor antagonist (IC50 values are 0.02 - 0.13 and > 25 _M for CXCR4 and all other chemokine receptors respectively). Switches inflammatory responses from Th2 to Th1 type and reduces airway hyperresponsiveness in a mouse model of asthma. Potently inhibits HIV-1 and HIV-2 replication in vitro (EC50 = 4 - 35 nM) and mobilizes hematopoietic stem cells in vivo.	Bridger et al (1995) Synthesis and structure-activity relationships of phenylenebis(methylene)-linked bis-tetraazamacrocycles that inhibits HIV replication. Effects of macrocyclic ring size and substituents on the aromatic linker. J.Med.Chem. 38 366. PMID:7830280. Hatse et al (2002) Chemokine receptor inhibition by AMD3100 is strictly confined to CXCR4. FEBS Letts. 527 255. Hogaboam et al (2005) The therapeutic potential in targeting CCR5 and CXCR4 receptors in infectious and allergic pulmonary disease. Pharmacol.Ther. 107 314. PMID:16009428. Paganessi et al (2011) Effective mobilization of hematopoietic progenitor cells in G-CSF mobilization defective CD26-/- mice through AMD3100-induced disruption of the CXCL12-CXCR4 axis. Exp.Hematol. 39 384. PMID:21168468.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=217278				Feb-2009
3301	NU 6140	[444723-13-1]	O=C(N(CC)CC)C(C=C4)=CC=C4NC1=NC(NC=N2)=C2C(OCC3CCCCC3)=N1	Cyclin-dependent kinase 2 (cdk2) inhibitor	Cyclin-dependent kinase 2 (cdk2) inhibitor; induces cell-cycle arrest at the G2-M phase. 10- to 36-fold more selective for cdk2-cyclin A over other cdks (IC50 = 0.41 _M for cdk2-cyclin A). Potentiates the apoptotic effect of taxol (Cat. No. 1097) in HeLa cells; down-regulates the antiapoptotic protein survivin.	Pennati et al (2005) Potentiation of paclitaxel-induced apoptosis by the novel cyclin-dependent kinase inhibitor NU6140: a possible role for survivin down-regulation. Mol.Cancer.Ther. 4 1328. PMID:16170024.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=217282	SQ1070			Sep-2010
3302	CD 3254	[196961-43-0]	CC1(C)C2=C(C=C(C3=C(O)C=CC(/C=C/C(O)=O)=C3)C(C)=C2)C(C)(C)CC1	Potent and selective RXR_ agonist.	"Selective RXR_ agonist; exhibits no activity at RAR_, RAR_ or RAR_ receptors."	Pogenberg et al (2005) Characterization of the interaction between retinoic acid receptor/retinoid X receptor (RAR/RXR) heterodimers and transcriptional coactivators through structural and fluorescence anisotropy studies. J.Biol.Chem. 280 1625. PMID:15528208. Nahoum et al (2007) Modulators of the structural dynamics of the retinoid X receptor to reveal receptor function. Proc.Natl.Acad.Sci. 104 17323. le Maire et al (2009) Activation of RXR-PPAR heterodimers by organotin environmental endocrine disruptors. EMBO.Rep. 10 367. PMID:19270714.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=217283	SQ1070			Jul-2010
3303	UVI 3003	[847239-17-2]	CC1(C)C2=C(C=C(C3=C(O)C=CC(/C=C/C(O)=O)=C3)C(OCCCCC)=C2)C(C)(C)CC1	RXR antagonist	RXR antagonist; displays high RXR binding affinity. Does not affect the corepressor interaction capacity of the RAR_ subunit within the context of the RAR-RXR heterodimer.	"Nahoum et al (2007) Modulators of the stuctural dynamics of the retinoid X receptor to reveal receptor function. Proc.Natl.Acad.Sci. 104 17323. Le Maire et al (2009) Activation of RXR-PPAR heterodimers by organotin environmental endocrine disruptors. EMBO Rep. 10 367. PMID:19270714. Santin et al (2009) Modulating retinoid X receptor with a series of (E)-3-[4-Hydroxy-3-(3-alkoxy-5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)phenyl]acrylic acids and their 4-alkoxy isomers. J.Med.Chem. 52 3150. PMID:19408900."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=217284	SQ1070			Jul-2010
3304	SU 16f	[251356-45-3]	O=C2NC1=CC(C4=CC=CC=C4)=CC=C1/C2=C/C3=C(C)C(CCC(O)=O)=C(C)N3	Potent and selective PDGFR_ inhibitor	"Potent and selective platelet-derived growth factor receptor _ (PDGFR_) inhibitor (IC50 = 10 nM) that displays > 14-fold, > 229-fold and > 10000-fold selectivity over VEGFR2, FGFR1 and EGFR respectively. Inhibits proliferation of HUVEC and NIH3T3 cells in vitro (IC50 = 0.11 _M)."	"Sun et al (1999) Design, synthesis, and evaluations of substituted 3-[(3- or 4-carboxyethylpyrrol-2-yl)methylidenyl]indolin-2-ones as inhibitors of VEGF, FGF, and PDGF receptor tyrosine kinases. J.Med.Chem. 42 5120. PMID:10602697."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=217285	SQ1070			Mar-2009
3305	Alfuzosin hydrochloride	[81403-68-1]	NC2=NC(N(C)CCCNC(C3CCCO3)=O)=NC1=CC(OC)=C(OC)C=C12.Cl	Uroselective _1 antagonist	Functionally uro-selective _1 adrenoceptor antagonist that does not discriminate between _1 subtypes. Inhibits increases in intraurethral pressure caused by phenylephrine-induced contraction by 81% with minor cardiovascular effects. Also relaxes corpus cavernosum tissue (pIC50 = 7.64) in vitro.	"Palea and Barras (2003) Comparison of the relaxant effects of alfuzosin, phentolamine and sildenafil on rabbit isolated corpus cavernosum. BJU Int. 91 873. PMID:12780851. Lee (2003) Alfuzosin hydrocholride for the treatment of benign prostatic hyperplasia. Am.J.Health Syst.Pharm. 60 1426. PMID:12892027. Yamaguchi et al (2005) Effects of different alpha-1 adrenoceptor blockers on proximal urethral function using in vivo isovolumetric pressure changes. J.Smooth Muscle Res. 41 247. PMID:16428864."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=217286	SQ1533			Jan-2009
3306	8-(3-Chlorostyryl)caffeine	[147700-11-6]	ClC1=CC(/C=C/C(N3C)=NC2=C3C(N(C)C(N2C)=O)=O)=CC=C1	Selective A2A antagonist. Also MAO-B inhibitor	Selective adenosine A2A receptor antagonist and monoamine oxidase B (MAO-B) inhibitor (Ki values are 54 and 28200 nM at rat A2A and A1 receptors respectively and Ki ~ 100 nM at MAO-B). Potently protects against quinolinic acid-induced (Cat. No. 0225) neuronal damage and is neuroprotective in the MPTP model of Parkinson's disease.	"Chen et al (2002) 8-(3-Chlorostyryl)caffeine may attenuate MPTP neurotoxicity through dual actions on monoamine oxidase inhibition and A2A receptor antagonism. J.Biol.Chem. 277 36040. PMID:12130655. Behan and Stone (2002) Enhanced neuronal damage by co-administration of quinolinic acid and free radicals, and protection by adenosine A2A receptor antagonists. Br.J.Pharmacol. 135 1435. PMID:11906956. Vlok et al (2006) Inhibition of monoamine oxidase B by analogues of the adenosine A2A receptor antagonist (E)-8-(3-chlorostyryl)caffeine (CSC). Bioorg.Med.Chem. 14 3512. PMID:16442801."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=217350	SQ1070			Feb-2009
3307	PF 750	[959151-50-9]	O=C(NC4=CC=CC=C4)N(CC3)CCC3CC2=CC1=CC=CC=C1N=C2	Selective FAAH inhibitor	Irreversible fatty acid amide hydrolase (FAAH) inhibitor (IC50 = 16.2 nM) that displays no activity at a range of other serine hydrolases. Selectively inhibits FAAH within the central nervous system. Orally active.	Ahn et al (2007) Novel mechanistic class of fatty acid amide hydrolase inhibitors with remarkable selectivity. Biochemistry 46 13019. PMID:17949010. Mileni et al (2008) Structure-guided inhibitor design for human FAAH by interspecies active site conversion. Proc.Natl.Acad.Sci.USA 105 12820.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=218275	SQ1070			Aug-2009
3308	Zileuton	[111406-87-2]	CC(N(O)C(N)=O)C2=CC1=CC=CC=C1S2	Orally active 5-LOX inhibitor	"Orally active 5-lipoxygenase (5-LOX) inhibitor that inhibits LTB4 synthesis (IC50 values are 0.56, 2.3 and 2.6 _M in dog, rat and human blood respectively). Inhibits antigen-induced contraction of tracheal strips in vitro (IC50 = 6 _M) and exhibits antiasthmatic activity in vivo. Also weakly inhibits CYP1A2 (Ki = 66 - 98 _M)."	"McMillan et al (1992) Pre-clinical pharmacology of ICI D2138, a potent orally-active non-redox inhibitor of 5-lipoxygenase. Br.J.Pharmacol. 107 1042. PMID:1334748. Malo et al (1994) The 5-lipoxygenase inhibitory activity of zileuton in in vitro and in vivo models of antigen-induced airway anaphylaxis. Pulm.Pharmacol. 7 73. PMID:8081074. Lu et al (2003) Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor. Drug Metab.Dispos. 31 1352. PMID:14570767."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=218327	SQ1533			Jan-2009
3309	Fluvastatin sodium	[93957-55-2]	[Na+].[Na+].CC(C)N1C(\C=C\[C@H](O)C[C@H](O)CC([O-])=O)=C(C2=CC=C(F)C=C2)C2=C1C=CC=C2.CC(C)N1C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C(C2=CC=C(F)C=C2)C2=C1C=CC=C2	HMG-CoA reductase inhibitor	"Orally active, potent and competitive HMG-CoA reductase inhibitor (IC50 = 40 -100 nM at human liver microsomes). Inhibits vascular smooth muscle proliferation in vitro (IC50 = 70 nM) and exhibits antihypercholesterolemic and antioxidant activity in vivo."	"Dansette et al (2000) HMG-CoA reductase activity in human liver microsomes: comparative inhibition by statins. Exp.Toxicol.Pathol. 52 145. PMID:10965989. Yamamoto et al (2001) Antioxidative effects of fluvastatin, an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, on peroxidation of phospholipid liposomes. J.Pharm.Pharmacol. 53 227. PMID:11273020. Turner et al (2007) Comparison of the efficacies of five different statins on inhibition of human saphenous vein smooth muscle cell proliferation and invasion. J.Cardiovasc.Pharmacol. 50 458. PMID:18049315."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=218370	SQ1533			Jan-2009
3311	VU 0155041 sodium salt	[1259372-69-4]	[Na+].[Na+].[O-]C(=O)[C@H]1CCCC[C@H]1C(=O)NC1=CC(Cl)=CC(Cl)=C1.[O-]C(=O)[C@@H]1CCCC[C@@H]1C(=O)NC1=CC(Cl)=CC(Cl)=C1	"Potent, positive allosteric mGlu4 agonist. Sodium salt of VU 0155041 (Cat. No. 3248)"	"Potent, positive allosteric modulator/allosteric agonist at mGlu4 receptors (EC50 = 798 and 693 nM at human and rat mGlu4 receptors respectively). Active in in vivo models of Parkinson's disease following i.c.v. administration. Sodium salt of VU 0155041 (Cat. No. 3248)."	"Niswender et al (2008) Discovery, characterization, and antiparkinsonian effect of novel positive allosteric modulators of metabotropic glutamate receptor 4. Mol.Pharmacol. 74 1345. PMID:18664603."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=218538				Dec-2008
3313	rac BHFF	[123557-91-5]	CC(C)(C)C1=C2C(C(O)(C(F)(F)F)C(O2)=O)=CC(C(C)(C)C)=C1	"Potent, selective GABAB positive allosteric modulator"	Potent and selective GABAB receptor positive allosteric modulator that increases the potency and efficacy of GABA ( > 15-fold and > 149% respectively). Exhibits anxiolytic activity in vivo and is orally active.	"Malherbe et al (2008) Characterization of (R,S)-5,7-di-tert-butyl-3-hydroxy-3-trifluoromethyl-3H-benzofuran-2-one as a positive allosteric modulator of GABAB receptors. Br.J.Pharmacol. 154 797. PMID:18536733. Koek et al (2013) Discriminative stimulus effects of the GABAB receptor-positive modulator rac-BHFF: comparison with GABAB receptor agonists and drugs of abuse. J.Pharmacol.Exp.Ther. 344 553. PMID:23275067."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=218540	SQ1070			Jan-2009
3314	BI 78D3	[883065-90-5]	O=C1NN=C(SC3=NC=C([N+]([O-])=O)S3)N1C2=CC=C4C(OCCO4)=C2	"Selective, competitive JNK inhibitor"	Competitive c-Jun N-terminal kinase (JNK) inhibitor (IC50 = 280 nM) that displays > 100 fold selectivity over p38_ and no activity at mTOR and PI-3K. Inhibits JNK interacting protein 1 (JIP1)-JNK binding (IC50 = 500 nM) and prevents JNK substrate phosphorylation. Blocks JNK-dependent Con A-induced liver damage and restores insulin sensitivity in a mouse model of type II diabetes.	Stebbins et al (2008) Identification of a new JNK inhibitor targeting the JNK-JIP interaction site. Proc.Natl.Acad.Sci.USA 105 16809. Flight (2008) Getting rid of JNK. Nat.Rev.Drug Disc. 7 975. Haas and Writer (2008) Block JNK at the dock. SCiBX 1 1.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=218553	SQ1533			Jan-2009
3315	RS 25344 hydrochloride	[152815-28-6]	O=C(N(CC4=CC=NC=C4)C2=O)N(C3=CC([N+]([O-])=O)=CC=C3)C1=C2C=CC=N1.Cl	Potent PDE4 inhibitor	"Potent and selective phosphodiesterase (PDE) 4 inhibitor (IC50 values are 0.28, > 100, 160 and 330 nM at PDE4, PDE1, PDE2 and PDE3 respectively). Inhibits eosinophil chemotaxis and increases progressive motility of spermatozoa in vitro."	"Alvarez et al (1995) Activation and selective inhibition of a cyclic AMP-specific phosphodiesterase, PDE-4D3. Mol.Pharmacol. 48 616. PMID:7476886. Kaneko et al (1995) Elevated intracellular cyclic AMP inhibits chemotaxis in human eosinophils. Cell.Signal. 7 527. PMID:8562314. Bajpai et al (2006) AKAP3 selectively binds PDE4A isoforms in bovine spermatozoa. Biol.Reprod. 74 109. PMID:16177223."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=218554	SQ1070			Feb-2010
3316	PF 670462	[950912-80-8]	NC1=NC=CC(C2=C(C4=CC=C(F)C=C4)N=CN2C3CCCCC3)=N1.Cl.Cl	Potent and selective CK1_ and CK1_ inhibitor	Potent and selective casein kinase 1_ (CK1_) and CK1_ inhibitor (IC50 values are 7.7 and 14 nM respectively) that displays > 30-fold selectivity over 42 other common kinases. Inhibits PER protein nuclear translocation (EC50 = 290 nM) causing phase shifts in circadian rhythms and attenuates methamphetamine-stimulated locomotion in vivo.	Badura et al (2007) An inhibitor of casein kinase I_ induces phase delays in circadian rhythms under free-running and entrained conditions. J.Pharmacol.Exp.Ther. 322 730. PMID:17502429. Bryant et al (2009) A role for casein kinase 1 epsilon in the locomotor stimulant response to methamphetamine. Psychopharmacology 203 703. PMID:19050854. Sprose et al (2009) Inhibition of casein kinase I _/_ produces phase shifts in the circadian rhythms of Cynomolgus monkeys. Psychopharmacology 204 735. PMID:19277609.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=218698	SQ1070			Apr-2009
3317	AZ 11645373	[227088-94-0]	O=C(CSC4=O)N4C(COC2=CC=C(C3=CC=CC([N+]([O-])=O)=C3)C=C2)CCC1=CC=NC=C1	Potent and selective human P2X7 antagonist	"Potent and selective human P2X7 antagonist (KB values are 5 - 7 and > 10,000 nM at hP2X7 and rP2X7 respectively) that is completely without effect at all other P2X subtypes. Inhibits BzATP-mediated calcium influx and inhibits ATP-mediated IL-1_ release in vitro (KB values are 15 and 92 nM respectively)."	"Alcaraz et al (2003) Novel P2X7 receptor antagonists. Bioorg.Med.Chem.Letts. 13 4043. Stokes et al (2006) Characterization of a selective and potent antagonist of human P2X7 receptors, AZ11645373. Br.J.Pharmacol. 149 880. PMID:17031385. Michel et al (2009) Mechanism of action of species-selective P2X(7) receptor antagonists. Br.J.Pharmacol. 156 1312. PMID:19309360."	Small Molecule	Sold for research purposes under agreement from AstraZeneca	http://www.tocris.com/dispprod.php?ItemId=218780	SQ1533			Jul-2009
3318	SC 514	[354812-17-2]	NC1=C(C(N)=O)SC(C2=CSC=C2)=C1	IKK_ inhibitor; attenuates NF-_B-induced gene expression	"Orally active, ATP-competitive IKK_ inhibitor (IC50 = 3 - 12 _M) that displays > 10-fold selectivity over 28 other kinases including JNK, p38, MK2 and ERK. Attenuates NF-_B-induced gene expression of IL-6, IL-8 and COX-2 in synovial fibroblasts (IC50 values are 20, 20 and 8 _M respectively). Reduces iNOS induction and exhibits anti-inflammatory activity in vivo."	"Kishore et al (2003) A selective IKK-2 inhibitor blocks NF-_B-dependent gene expression in interleukin-1_-stimulated synovial fibroblasts. J.Biol.Chem. 278 32861. PMID:12813046. Baxter et al (2004) Hit-to-lead studies: the discovery of potent, orally active thiophenecarboxamide IKK-2 inhibitors. Bioorg.Med.Chem.Letts. 14 2817. Gomez et al (2005) Selective inhibition of kappa B kinase-_ aborgates induction of nitric oxide synthase in lipopolysaccharide-stimulated rat aortic smooth muscle cells. Br.J.Pharmacol. 146 217. PMID:15997236."	Small Molecule	Sold for research purposes under agreement from AstraZeneca	http://www.tocris.com/dispprod.php?ItemId=218781	SQ1070			Jan-2009
3319	ARL 17477 dihydrochloride	[866914-87-6]	ClC1=CC=CC(CNCCC2=CC=C(NC(C3=CC=CS3)=N)C=C2)=C1.Cl.Cl	Selective nNOS inhibitor	Selective neuronal nitrogen oxide synthase (nNOS) inhibitor (IC50 values are 1 and 17 _M for nNOS and endothelial NOS respectively). Reduces ischemic cell damage after middle cerebral artery (MCA) occlusion in rats. Displays a synergistic neuroprotective effect when combined with either an NMDA or AMPA receptor antagonist.	"Zhang et al (1996) ARL 17477, a potent and selective neuronal NOS inhibitor decreases infarct volume after transient middle cerebral artery occlusion in rats. J.Cereb.Flow Metab. 16 599. Hicks et al (1999) Synergistic neuroprotective effects by combining an NMDA or AMPA receptor antagonist with nitric oxide synthase inhibitors in global cerebral ischaemia. Eur.J.Pharmacol. 381 113. PMID:10554878. O'Neill et al (2000) ARL 17477, a selective nitric oxide synthase inhibitor, with neuroprotective effects in animal models of global and focal cerebral ischaemia. Brain Res. 871 234. PMID:10899290."	Small Molecule	Sold with the permission of AstraZeneca UK Ltd.	http://www.tocris.com/dispprod.php?ItemId=218788	SQ1070			May-2010
3322	ZD 9379		O=C2C3=C(C(NN(C4=C(C)C=C(OC)C=C4)C3=O)=O)NC1=CC(Cl)=CC=C12	Brain penetrant NMDA antagonist; acts at glycine site	NMDA receptor antagonist; acts at glycine site. Neuroprotective; reduces infarct size and frequency of spreading depressions in a rat model of ischemic stroke. Brain penetrant.	"Bare (1993) Pyridazino[4,5-b]quinolinediones: a series of novel glycine site NMDA antagonists with potent in vitro and in vivo properties. Abstracts of Papers of the ACS 205 79. Abstract.. Takano (1997) Glycine site antagonist attenuates infarct size in experimental focal ischemia. Postmortem and diffusion mapping studies. Stroke. 28 1255. PMID:9183359. Tatlisumak (2000) A glycine antagonist ZD9379 reduces number of spreading depressions and infarct size in rats with permanent middle cerebral artery occlusion. Acta.Neurochir.Suppl. 76 331. PMID:11450037."	Small Molecule	Sold for research purposes under agreement from AstraZeneca	http://www.tocris.com/dispprod.php?ItemId=218813				Mar-2014
3323	AZ 10606120 dihydrochloride	[607378-18-7]	O=C(NC4=C(C=CC(NCCNCCO)=N5)C5=CC=C4)CC1(C3)CC2CC(CC3C2)C1.Cl.Cl	Potent P2X7 receptor antagonist	"Potent P2X7 receptor antagonist (KD values are 1.4 and 19 nM at human and rat P2X7 receptors respectively). Binds in a positive cooperative manner to sites distinct from, but coupled to, the ATP binding site and acts as a negative allosteric modulator. Inhibits tumor growth and displays antiangiogenic effects in mice."	Michel et al (2007) Direct labelling of the human P2X7 receptor and identification of positive and negative cooperativity of binding. Br.J.Pharmacol. 151 103. PMID:17339830. Michel and Fonfria (2007) Agonist potency at P2X7 receptors is modulated by structurally diverse lipids. Br.J.Pharmacol. 152 523. PMID:17700717. Michel et al (2008) Negative and positive allosteric modulators of the P2X7 receptor. Br.J.Pharmacol. 153 737. PMID:18071294. Adinolfi et al (2012) Expression of P2X7 receptor increases in vivo tumor growth. Cancer Res. 72 2957. PMID:22505653.	Small Molecule	Sold for research purposes under agreement from AstraZeneca	http://www.tocris.com/dispprod.php?ItemId=218814	SQ1533			Apr-2009
3324	QS 11	[944328-88-5]	OC[C@H](CC6=CC=CC=C6)NC1=C2C(N(CC3=CC=C(C7=CC=CC=C7)C=C3)C=N2)=NC(OC4=CC=C(CCC5)C5=C4)=N1	ARFGAP1 inhibitor; modulates Wnt/_-catenin signaling	GTPase activating protein of ADP-ribosylation factor 1 (ARFGAP1) inhibitor. Modulates ARF-GTP levels and synergizes with the Wnt/_-catenin signaling pathway to upregulate _-catenin nuclear translocation. Also reduces in vitro migration of metastatic human breast cancer cells.	Zhang et al (2007) Small-molecule synergist of the Wnt/_-catenin signaling pathway. Proc.Natl.Acad.Sci.USA 104 7444. PMID:17460038. Emre et al (2007) A chemical approach to stem cell biology Curr.Opin.Chem.Biol. 11 252. PMID:17493865 .	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=218863	SQ1533			Sep-2010
3325	VU 1545	[890764-63-3]	O=C(C4=CC=C([N+]([O-])=O)C=C4)NC1=CC(C3=CC=CC=C3)=NN1C2=CC=CC=C2F	mGlu5 positive allosteric modulator	"Metabotropic glutamate receptor 5 (mGlu5) positive allosteric modulator (EC50 = 9.6 nM, Ki = 156 nM at rat mGlu5)."	"de Paulis et al (2006) Substituent effects of N-(1,3-diphenyl-1H-pyrazol-5-yl)benzamides on positive allosteric modulation of the metabotropic glutamate-5 receptor in rat cortical astrocytes. J.Med.Chem. 49 3332. PMID:16722652."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=218864	SQ1070			Jul-2009
3326	BGC 20-761	[17375-63-2]	CN(CCC2=C(C3=CC=CC=C3)NC1=CC=C(OC)C=C12)C	High affinity 5-HT6 antagonist	"Selective, high affinity 5-HT6 antagonist (Ki = 20 nM). Reverses the amnesic effects of scopolamine (Cat. No. 1414) and enhances memory consolidation in a rat model."	"Glennon et al (2000) 2-substituted tryptamines: agents with selectivity for 5-HT6 serotonin receptors. J.Med.Chem. 43 1011. PMID:10715164. Mitchell et al (2006) BGC20-761, a novel tryptamine analog, enhances memory consolidation and reverses scopolamine-induced memory deficit in social and visuospatial memory tasks through a 5-HT6 receptor-mediated mechanism. Neuropharmacology 50 412. PMID:16298400."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=218882	SQ1070			Jan-2011
3327	CID 755673	[521937-07-5]	OC1=CC2=C(OC3=C2CCCNC3=O)C=C1	Selective protein kinase D inhibitor	"Selective protein kinase D (PKD) inhibitor (IC50 values are 0.182, 0.280, 0.227, >10, 15.3, 20.3, 40.5 and >50 _M at PKD1, PKD2, PKD3, PKC, CAK, PLK1, CAMKII_ and Akt respectively). Blocks PKD-mediated protein transport and inhibits prostate cancer cell proliferation, migration and invasion in vitro."	Sharlow et al (2008) Potent and selective disruption of protein kinase D functionality by benzoxoloazepinolone. J.Biol.Chem. 283 33516. PMID:18829454.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=218914	SQ1070			Mar-2009
3328	Desformylflustrabromine hydrochloride	[951322-11-5]	CNCCC2=C(C(C)(C)C=C)NC1=CC(Br)=CC=C12.Cl	Positive allosteric modulator of _4_2	Positive allosteric modulator of _4_2 nicotinic acetylcholine receptors (nAChRs); selectively increases the ionic current through _4_2 in the presence of ACh. Displays 14.7-fold selectivity for _4_2 over homomeric (_7) receptors. Exhibits moderate cytotoxicity against HCT-116 cells.	Lysek et al (2002) Isolation and structure elucidation of deformylflustrabromine from the North Sea bryozoan Flustra foliacea. Z.Naturforsch. 57 11. Sala et al (2005) Potentiation of human _4_2 neuronal nicotinic receptors by a Flustra foliacea metabolite. Neurosci.Lett. 373 44. Kim et al (2007) Synthesis of desformylflustrabromine and its evaluation as an _4_2 and _7 nACh receptor modulator. Bioorg.Med.Chem.Lett. 17 4855. PMID:17604168. Weltzin and Schulte (2010) Pharmacological characterization of the allosteric modulator desformylflustrabromine and its interaction with _4_2 neuronal nicotinic acetylcholine receptor orthosteric ligands. J.Pharm.Exp.Ther. 334 917.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=218917	SQ1070			Aug-2010
3333	NDT 9513727	[439571-48-9]	CCCCN1C(C6=CC=CC=C6)=NC(C7=CC=CC=C7)=C1CN(CC3=CC(OCO5)=C5C=C3)CC2=CC=C(OCO4)C4=C2	"Potent, selective human C5a receptor antagonist"	Potent C5a receptor (C5aR) competitive antagonist (IC50 = 11.6 nM); selective for human C5aR (IC50 values for rat and mouse C5aR are > 10 _M). Exhibits inverse agonist pharmacokinetics. Blocks degranulation response in C5a-stimulated U937 cells (IC50 = 7.1 nM). Orally bioavailable.	"Brodbeck et al (2008) Identification and characterization of NDT 9513727 [N,N-bis(1,3-benzodioxol-5-ylmethyl)-1-butyl-2,4-diphenyl-1H-imidazole-5-methanamine], a novel, orally bioavailable C5a receptor inverse agonist. J.Pharmacol.Exp.Ther. 327 898. PMID:18753409."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=220443	SQ1341			May-2012
3335	SU 6668	[252916-29-3]	O=C2NC1=CC=CC=C1/C2=C/C3=C(C)C(CCC(O)=O)=C(C)N3	"PDGFR, VEGFR and FGFR inhibitor"	"ATP-competitive PDGFR, VEGF and FGFR inhibitor (IC50 values are 0.06, 2.43, 3.04 and > 100 _M at PDGFR_, VEGFR2, FGFR1 and EGFR respectively). Inhibits proliferation of HUVEC and NIH3T3 cells in vitro (IC50 values are 0.41, 9.3 and 16.5 _M for VEGF, FGF and PDGF-stimulated growth respectively) and induces > 75% growth inhibition against a broad range of tumor types in vivo. Exhibits antiangiogenic, anti-inflammatory, antimetastatic and proapoptotic activity and is orally active."	"Sun et al (1999) Design, synthesis, and evaluations of substituted 3-[(3- or 4-carboxyethylpyrrol-2-yl)methylidenyl]indolin-2-ones as inhibitors of VEGF, FGF, and PDGF receptor tyrosine kinases. J.Med.Chem. 42 5120. PMID:10602697. Laird et al (2000) SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors. Cancer Res. 60 4152. PMID:10945623. Yamamoto et al (2008) TSU68 prevents liver metastasis of colon cancer xenografts by modulating the premetastatic niche. Cancer Res. 68 9754. PMID:19047154."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=219395	SQ1533			Mar-2009
3336	A 769662	[844499-71-4]	OC(C1=C(N3)SC=C1C2=CC=C(C4=CC=CC=C4O)C=C2)=C(C#N)C3=O	Potent AMPK activator	"Potent, reversible AMP-activated protein kinase (AMPK) activator (EC50 = 0.8 _M) that displays selectivity towards _1 subunit-containing heterotrimers. Inhibits fatty acid synthesis (IC50 = 3.2 _M) and decreases plasma glucose and triglyceride levels in vivo. Also inhibits proliferation of mesenchymal stem cells, and impedes reprogramming of mouse embryonic fibroblasts to iPSCs."	"Cool et al (2006) Identification and characterization of a small molecule AMPK activator that treats key components of type 2 diabetes and the metabolic syndrome. Cell Met. 3 403. Sanders et al (2007) Defining the mechanism of activation of AMP-activated protein kinase by the small molecule A-769662, a member of the thienopyridone family. J.Biol.Chem. 282 32539. PMID:17728241. Scott et al (2008) Thienopyridone drugs are selective activators of AMP-activated protein kinase _1-containing complexes. Chem.Biol. 15 1220. PMID:19022182. Vazquez-Martin et al (2012) Activation of AMP-activated protein kinase (AMPK) provides a metabolic barrier to reprogramming somatic cells into stem cells. Cell Cycle 5 974. PMID:2233578. de Meester et al (2014) Role of AMP-activated protein kinase in regulating hypoxic survival and proliferation of mesenchymal stem cells. Cardiovasc.Res. 101 20. PMID:24104879."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=219396	SQ1533			Jul-2009
3341	JK 184	[315703-52-7]	CC2=C(C3=CSC(NC4=CC=C(OCC)C=C4)=N3)N1C=CC=CC1=N2	Alcohol dehydrogenase 7 inhibitor; inhibits downstream Hh signaling pathway	Potent downstream hedgehog (Hh) signaling inhibitor that prevents Gli-dependent transcriptional activity (IC50 = 30 nM). Exhibits antiproliferative activity in a range of cancer cell lines (GI50 = 3 - 21 nM) and in human xenografts in vivo. Inhibits alcohol dehydrogenase 7 (Adh7) (IC50 = 210 nM) and acts as a microtubule depolymerizing agent in vitro.	Lee et al (2007) A small-molecule antagonist of the hedgehog signaling pathway. Chembiochem. 8 1916. PMID:17886323. Cupido et al (2009) The imidazopyridine derivative JK184 reveals dual roles for microtubules in hedgehog signaling. Angew.Chem.Int.Ed.Engl. 48 2321. PMID:19222062.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=219403	SQ1533			Mar-2009
3342	"L-798,106"	[244101-02-8]	O=C(NS(C4=C(OC)C=CC(Br)=C4)(=O)=O)/C=C/C1=CC=CC=C1CC3=CC2=CC=CC=C2C=C3	Potent and highly selective EP3 antagonist	"Potent and highly selective prostanoid EP3 receptor antagonist (Ki values are 0.3, 916, > 5000 and > 5000 nM at EP3, EP4, EP1 and EP2 respectively). Attenuates sulprostone-induced inhibition of EFS-evoked twitch and contractile responses in vivo."	Juteau et al (2001) Structure-activity relationships of cinnamic acylsulfonamide analogues on human EP3 prostanoid receptor. Bioorg.Med.Chem. 9 1977. PMID:11504634. Clarke et al (2004) E-ring 8-isoprostanes inhibit ACh release from parasympathetic nerves innervating guinea-pig trachea through agonism of prostanoid receptors of the EP3-subtype. Br.J.Pharmacol. 141 600. PMID:14744812. Bassil et al (2008) Activation of prostaglandin EP receptors by lubiprostone in rat and human stomach and colon. Br.J.Pharmacol. 154 126. PMID:18332851.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=219404	SQ1070			Jul-2009
3343	Ro 8-4304 hydrochloride	[1312991-77-7]	NC(C1=CC=C(OCC(O)CN2CCC(C3=CC=C(F)C=C3)=CC2)C=C1)=O.Cl	Selective NR2B antagonist	NMDA receptor antagonist (IC50 = 0.4 _M) that displays > 100 fold selectivity for NR2B-containing receptors over NR2A-containing receptors. Exhibits an activity-dependent mechanism of NMDA antagonism and is competitive with respect to spermine (Cat. No. 0958).	"Kew et al (1998) State-dependent NMDA receptor antagonism by Ro 8-4304, a novel NR2B selective, non-competitive, voltage-independent antagonist. Br.J.Pharmacol. 123 463. PMID:9504387. Kew and Kemp (1998) An allosteric interaction between the NMDA receptor polyamine and ifenprodil sites in rat cultured cortical neurones. J.Physiol. 512 17. PMID:9729614."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=219405	SQ1070			Sep-2009
3344	SLV 320	[251945-92-3]	O[C@@H](CC4)CC[C@H]4NC1=C2C(NC=C2)=NC(C3=CC=CC=C3)=N1	Potent and selective A1 antagonist	"Potent and selective adenosine A1 receptor antagonist (Ki values are 1, 200, 398 and 3981 nM at human A1, A3, A2A and A2B receptors respectively). Suppresses cardiac fibrosis and attenuates albuminuria, without effect on blood pressure in animal models of chronic renal failure. Orally active."	Kalk et al (2007) The adenosine A1 receptor antagonist SLV320 reduces myocardial fibrosis in rats with 5/6 nephrectomy without effecting blood pressure. Br.J.Pharmacol. 151 1025. PMID:17558436.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=219406	SQ1070			Jul-2009
3346	ATC 0175 hydrochloride	[510733-97-8]	O=C(C4=CC(F)=C(F)C=C4)N[C@@H](CC3)CC[C@@H]3NC2=NC1=CC=CC=C1C(N(C)C)=N2.Cl	MCH1 antagonist; also 5-HT2B antagonist and 5-HT1A partial agonist	"Potent, selective and orally active melanin-concentrating hormone receptor 1 (MCH1) antagonist (IC50 values are 13.5 and > 10000 nM for MCH1 and MCH2 receptors respectively). Exhibits anxiolytic and antidepressant activity in rodents. Also displays affinity for 5-HT2B and 5-HT1A receptors (IC50 values are 9.66 and 16.9 nM respectively)."	Chaki et al (2005) Anxiolytic- and antidepressant-like profile of ATC0065 and ATC0175: nonpeptidic and orally active melanin-concentrating hormone receptor 1 antagonists. J.Pharmacol.Exp.Ther. 313 831. PMID:15677346. Chaki et al (2005) ATC0175: an orally active melanin-concentrating hormone receptor 1 antagonist for the potential treatment of depression and anxiety. CNS Drug Rev. 11 341. PMID:16614734.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=219784	SQ1070			May-2010
3347	SNAP 94847 hydrochloride	[487051-12-7]	CC1=CC=C(NC(C(C)C)=O)C=C1C(CC4)CCN4CC(C=C3)=CC=C3OC2=CC(F)=C(F)C=C2.Cl	Potent and selective MCH1 antagonist	"Potent melanin-concentrating hormone receptor 1 (MCH1) antagonist (Ki = 2.2 nM, KD = 530 pM) that displays > 80-fold and > 500-fold selectivity over _1A and D2 receptors respectively. Increases neurogenesis in the dentate gyrus and decreases food-reinforced operant responding in vivo. Exhibits anxiolytic activity and is orally active."	"Chen et al (2007) Synthesis and SAR investigations for novel melanin-concentrating hormone 1 receptor (MCH1) antagonists part 2: A hybrid strategy combining key features of HTS hits. J.Med.Chem. 50 3883. PMID:17668922. David et al (2007) Efficacy of the MCHR1 antagonist N-[3-(1-{[4-(3,4-difluorophenoxy)phenyl]methyl}(4-piperidyl))-4-methylphenyl]-2-methylpropanamide (SNAP 94847) in mouse models of anxiety and depression following acute and chronic administration is independent of hippocampal neurogenesis. J.Pharmacol.Exp.Ther. 321 237. PMID:17237257. Nair et al (2009) Effects of the MCH1 receptor antagonist SNAP 94847 on high-fat food-reinforced operant responding and reinstatement of food seeking in rats. Psychopharmacology 205 129. PMID:19340414."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=219785	SQ1070			Nov-2009
3349	Biocytin	[576-19-2]	O=C1N[C@@]2([H])[C@@](CS[C@H]2CCCCC(NCCCC[C@H](N)C(O)=O)=O)([H])N1	Versatile marker for neuroanatomical investigations	"Versatile marker used in anterograde, retrograde and intracellular neuroanatomical investigations and in biotinidase assays. Displays high solubility in aqueous solutions and has a low molecular weight facilitating injection using micropipettes. Can be incorporated with a variety of avidin and streptavidin conjugates for detection by light, fluorescence or electron microscope."	"Kobbert et al (2000) Current concepts in neuroanatomical tracing. Prog.Neurobiol. 62 327. PMID:10856608. Roth et al (2004) Morphology and axonal projection pattern of neurons in the telencephalon of the fire-bellied toad Bombina orientalis: an anterograde, retrograde and intracellular biocytin labelling study. J.Comp.Neurol. 478 35. PMID:15334648. MacNeil and Gaul (2008) Biocytin wide-field bipolar cells in rabbit retina selectively contact blue cones. J.Comp.Neurol. 506 6. PMID:17990268."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=219789				Feb-2009
3350	LY 393558	[271780-64-4]	CC(C)N2S(N(CCN3CC=C(C4=CNC5=C4C=CC(F)=C5)CC3)C1=CC=C(S(=O)(C)=O)C=C1C2)(=O)=O	Dual 5-HT1B/1D antagonist and 5-HT re-uptake inhibitor	Dual 5-HT1B/1D receptor antagonist (pKB values are 9.05 and 8.98 respectively) and 5-HT re-uptake inhibitor (pIC50 = 8.48). Potently antagonizes terminal autoreceptor activity in vitro and increases extracellular 5-HT levels above those evoked by fluoxetine (Cat. No. 0927) in vivo. Also acts as an antagonist at 5-HT2A and 5-HT2B receptors (pKi values are 7.29 and 7.35 respectively).	"Mitchell et al (2001) LY393558, a 5-hydroxytryptamine reuptake inhibitor and 5-HT1B/1D receptor antagonist: effects on extracellular levels of 5-hydroxytryptamine in the guinea pig and rat. Eur.J.Pharmacol. 432 19. PMID:11734183. Pullar et al (2001) In vitro activity of LY393558, an inhibitor of the 5-hydroxytryptamine transporter with 5-HT1B/1D/2 receptor antagonist properties. Eur.J.Pharmacol. 432 9. PMID:11734182. Morecroft et al (2005) Functional interactions between 5-hydroxytryptamine receptors and the serotonin transporter in pulmonary arteries. J.Pharmacol.Exp.Ther. 313 539. PMID:15659538."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=219986	SQ1070			Feb-2010
3351	NS 304	[475086-01-2]	CC(C)N(CCCCOCC(NS(C)(=O)=O)=O)C1=NC(C3=CC=CC=C3)=C(C2=CC=CC=C2)N=C1	Selective prostacyclin IP1 receptor agonist	"Selective prostacyclin IP1 receptor agonist (Ki values are 260 and 2100 nM and for human and rat IP receptors, and >10 _M for EP1-4, DP, FP, and TP receptors). Prodrug for the active form of MRE 26. Ameliorates vascular endothelial dysfunction and increases femoral skin blood flow in rats. Orally available."	"Kuwano et al (2007) 2-[4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy]-N-(methylsulfonyl)acetamide (NS-304), an orally available and long-acting prostacyclin receptor agonist prodrug. J.Pharmacol.Exp.Ther. 322 1181. PMID:17545310. Kuwano et al (2008) A long-acting and highly selective prostacyclin receptor agonist prodrug, 2-{4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}-N-(methylsulfonyl)acetamide (NS-304), ameliorates rat pulmonary hypertension with unique relaxant responses of its active form, {4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}acetic acid (MRE-269), on rat pulmonary artery. J.Pharmacol.Exp.Ther. 326 691. PMID:18552131. Morrison et al (2010) Selexipag: a selective prostacyclin receptor agonist that does not affect rat gastric function. J.Pharmacol.Exp.Ther. 335 249. PMID:20660124."	Small Molecule	Sold with the permission of Nippon Shinyaku Co.	http://www.tocris.com/dispprod.php?ItemId=219987	SQ1070			Oct-2013
3352	JNJ 28871063 hydrochloride	[944342-90-9]	NC1=C(/C=N/OCCN2CCOCC2)C(NC3=CC(Cl)=C(OCC4=CC=CC=C4)C=C3)=NC=N1.Cl	Potent ErbB receptor family inhibitor	"Potent and selective ErbB receptor family inhibitor (IC50 values are 21, 22 and 38 nM for ErbB4, EGFR and ErbB2 respectively). Displays potent growth inhibition of human cancer cell lines overexpressing ErbB2 in vitro (IC50 = 60 - 168 nM) and inhibits growth of human tumor xenografts in vivo. Brain penetrant and orally active."	"Contessa and Hamstra (2008) Revoking the privilege: targeting HER2 in the central nervous system. Mol.Pharmacol. 73 271. PMID:17981994. Emanuel et al (2008) Cellular and in vivo activity of JNJ-28871063, a nonquinazoline pan-ErbB kinase inhibitor that crosses the blood-brain barrier and displays efficacy against intracranial tumors. Mol.Pharmacol. 73 338. PMID:17975007. Guessous et al (2008) Signaling pathways in medulloblastoma. J.Cell.Phys. 217 577."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=220112	SQ1070			Jun-2009
3353	PSN 375963 hydrochloride	[388575-52-8]	CCCCC(CC3)CCC3C1=NC(C2=CC=NC=C2)=NO1.Cl	GPR119 receptor agonist	GPR119 receptor agonist (EC50 values are 8.4 and 7.9 _M at human and mouse receptors respectively). Displays similar potency to the endogenous ligand oleylethanolamide (OEA) (Cat. No. 1484).	Overton et al (2006) Deorphanization of a G protein-coupled receptor for oleoylethanolamide and its use in the discovery of small-molecule hypophagic agents. Cell Metab. 3 167. PMID:16517404. Ning et al (2008) Endogenous and synthetic agonists of GPR119 differ in signalling pathways and their effects on insulin secretion in MIN6c4 insulinoma cells. Br.J.Pharmacol. 155 1056. PMID:18724386.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=220113	SQ1070			Jun-2009
3354	PF 429242	[947303-87-9]	O=C(C2=CC=C(CN(CC)CC)C=C2)N(CCC3=CC=CC=C3OC)[C@@H]1CCNC1.Cl.Cl	Competitive inhibitor of SREBP site 1 protease	"Reversible, competitive inhibitor of sterol regulatory element-binding protein (SREBP) site 1 protease (IC50 = 0.175 _M). Selective for site 1 protease against a panel of serine proteases. Inhibits rate of cholesterol synthesis in CHO cells (IC50 = 0.53 _M). Also displays antiviral activity. Cell permeable."	Hay et al (2007) Aminopyrrolidineamide inhibitors of site-1 protease. Bioorg.Med.Chem.Lett. 17 4411. PMID:17583500. Hawkins et al (2008) Pharmacologic inhibition of site 1 protease activity inhibits sterol regulatory element-binding protein processing and reduces lipogenic enzyme gene expression and lipid synthesis in cultured cells and experimental animals. J.Pharmacol.Exp.Ther. 326 801. PMID:18577702. Urata et al (2011) Antiviral activity of a small-molecule inhibitor of arenavirus glycoprotein processing by the cellular site 1 protease. J.Virol. 85 795. PMID:21068251. Olmstead (2012) Human subtilase SKI-1/S1P is a master regulator of the HCV lifecycle and a potential host cell target for developing indirect-acting antiviral agents. PLoS.Pathog. 8 e1002468. PMID:22241994.	Small Molecule	Sold for research purposes under agreement from Pfizer Inc.	http://www.tocris.com/dispprod.php?ItemId=220431				Mar-2012
3355	PNU 177864 hydrochloride	[250266-51-4]	O=S(C1=CC=C(OC(F)(F)F)C=C1)(NC2=CC=C(CCNCCC)C=C2)=O.Cl	Highly selective D3 antagonist	Highly selective dopamine D3 receptor antagonist. Induces phospholipidosis and exhibits antischizophrenic activity in vivo.	Vonderfecht et al (2004) Myopathy related to administration of a cationic amphiphilic drug and the use of multidose drug distribution analysis to predict its occurrence. Toxicol.Pathol. 32 318. PMID:15204973. Rudmann et al (2004) Epididymal and systemic phospholipidosis in rats and dogs treated with dopamine D3 selective antagonist PNU-177864. Toxicol.Pathol. 32 326. PMID:15204974.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=220432	SQ1070			Jul-2009
3356	WR 1065	[14653-77-1]	NCCCNCCS.Cl.Cl	p53 activator. Also ROS scavenger	"Cell-permeable reactive oxygen species scavenger that activates p53 through a JNK-dependent signaling pathway. Activates p21waf-1 and MDM2, represses transcription of Myc and thymidine kinase, and inhibits DNA topoisomerase II_. Induces cell cycle arrest and exhibits cytoprotective activity towards normal cells but not cancer cells in vivo. Also exhibits broad spectrum antiviral activity in vitro."	North et al (2000) The cytoprotective aminothiol WR1065 activates p21waf-1 and down regulates cell cycle progression through a p53-dependent pathway. Oncogene 19 1206. PMID:10713709. Pluquet et al (2003) The cytoprotective aminothiol WR1065 activates p53 through a non-genotoxic signaling pathway involving c-Jun N-terminal kinase. J.Biol.Chem. 278 11879. PMID:12531896. Walker et al (2009) WR1065 mitigates AZT-ddl-induced mutagenesis and inhibits viral replication. Enviorn.Mol.Mutagen. 50 460.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=220433				Sep-2009
3357	Ellipticine	[519-23-3]	CC1=C4C(C=CN=C4)=C(C)C3=C1C2=C(N3)C=CC=C2	Antitumor and intercalating agent; inhibits DNA topoisomerase II	Naturally occurring plant alkaloid with antitumor activity. DNA intercalating agent; blocks DNA topoisomerase II activity. Prevents p53 phosphorylation in lung cancer cells.	Tewey et al (1984) Intercalative antitumor drugs interfere with the breakage-reunion reaction of mammalian DNA topoisomerase II. J.Biol.Chem. 259 9182. PMID:6086625. Ohashi et al (1995) Inhibition of p53 protein phosphorylation by 9-hydroxyellipticine: a possible anticancer mechanism. Jpn.J.Cancer Res. 86 819. PMID:7591958.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=220434	SQ1070			Mar-2012
3358	MG 101	[110044-82-1]	CCCC[C@H](NC([C@@H](N[C@@]([C@H](CC(C)C)NC(C)=O)=O)CC(C)C)=O)C=O	Calpain inhibitor; activates p53-dependent apoptosis	"Calpain inhibitor (IC50 = 0.09 _M) that activates p53-dependent apoptosis in tumor cell lines. Increases activated p53, p21 and caspase levels and promotes cell cycle arrest through inhibition of cyclin D degradation in vitro. Also attenuates ischemia/reperfusion injury in cardiomyocytes, hepatocytes and renal tubular cells through downregulation of iNOS and COX-2 expression."	Sherwood et al (1993) In vivo inhibition of cyclin B degradation and induction of cell-cycle arrest in mammalian cells by the neutral cysteine protease inhibitor N-acetylleucylleucylnorleucinal. Proc.Natl.Acad.Sci.USA 90 3353. Atencio et al (2000) Calpain inhibitor 1 activates p53-dependent apoptosis in tumor cell lines. Cell Growth Differ. 11 247. PMID:10845425. Chatterjee et al (2001) Calpain inhibitor-1 reduces renal ischemia/reperfusion injury in the rat. Kidney Int. 59 2073. PMID:11380809. Perrin et al (2002) In vitro antioxidant properties of calpain inhibitors: leupeptin and calpain inhibitor-1. Cell Mol.Biol. 48 OL267.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=157112				Mar-2009
3359	ATC 0065	[510732-84-0]	BrC(C=C4)=CC(OC(F)(F)F)=C4CCN[C@@H](CC3)CC[C@@H]3NC2=NC1=CC=CC=C1C(N(C)C)=N2.Cl.Cl	Potent and selective MCH1 antagonist	"Orally active, potent and selective melanin-concentrating hormone receptor 1 (MCH1) antagonist (IC50 = 15.7 nM) that displays > 96-fold selectivity over MCH2. Exhibits antidepressant and anxiolytic activity in vivo. Also displays affinity for 5-HT1A and 5-HT2B receptors (IC50 values are 62.9 and 266 nM respectively)."	Chaki et al (2005) Anxiolytic- and antidepressant-like profile of ATC0065 and ATC0175: Nonpeptide and orally active melanin-concentrating hormone receptor 1 antagonists. J.Pharmacol.Exp.Ther. 313 832. Dyck et al (2005) Small molecule melanin-concentrating hormone receptor 1 (MCH1R) antagonists as anxiolytic and antidepressive agents. Drug Dev.Res. 65 291. Kanuma et al (2006) Identification of 4-amino-2-cyclohexylaminoquinazolines as metabolically stable melanin-concentrating hormone receptor 1 antagonists. Bioorg.Med.Chem. 14 3307. PMID:16434202.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=220533	SQ1070			Jul-2010
3360	CGP 52411	[145915-58-8]	O=C2NC(C1=CC(NC4=CC=CC=C4)=C(NC3=CC=CC=C3)C=C12)=O	EGFR inhibitor. Also inhibits A_42 fibril formation	Selective inhibitor of the epidermal growth factor receptor (EGFR) (IC50 = 0.3 _M in vitro). Also inhibits and reverses the formation of A_42 fibers associated with Alzheimer's disease. Eliminates calcium influx potential when coincubated with amyloid _-peptide (1-42) (Cat.No. 1428); reduces neurotoxicity by blocking Ca2+ influx into neuronal cells.	"Buchdunger et al (1994) 4,5-dianilinophthalimide: a protein tyrosine kinase inhibitor with selectivity for the epidermal growth factor receptor signal transduction pathway and potent in vivo antitumor activity. Proc.Natl.Acad.Sci. 91 2334. Blanchard et al (2004) Efficient reversal of Alzheimer's disease fibril formation and elimination of neurotoxicity by a small molecule. Proc.Natl.Acad.Sci. 101 14326. Wang et al (2008) Direct and selective elimination of specific prions and amyloids by 4,5-dianilinophthalimide and analogs. Proc.Natl.Acad.Sci. 105 7159."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=220534				Oct-2010
3361	JNJ 17203212	[821768-06-3]	O=C(NC3=NC=C(C(F)(F)F)C=C3)N(CC2)CCN2C1=C(C(F)(F)F)C=CC=N1	"Reversible, competitive and potent TRPV1 antagonist"	"Reversible, competitive and potent TRPV1 antagonist (pKi values are 6.5, 7.1 and 7.3 at rat, guinea pig and human TRPV1 respectively). Inhibits capsaicin- and H+-induced channel activation (pIC50 values are 6.32 and 7.23 respectively) and exhibits antitussive and analgesic activity in vivo."	"Swanson et al (2005) Identification and biological evaluation of 4-(3-trifluoromethylpyridin-2-yl)piperazine-1-carboxylic acid (5-trifluoromethylpyridin-2-yl)amide, a high affinity TRPV1 (VR1) vanilloid receptor antagonist. J.Med.Chem. 48 1857. PMID:15771431. Ghilardi et al (2005) Selective blockade of the capsaicin receptor TRPV1 attenuates bone cancer pain. J.Neurosci. 25 3126. PMID:15788769. Bhattacharya et al (2007) Pharmacology and antitussive efficacy of 4-(3-trifluoromethyl-pyridin-2-yl)-piperazine-1-carboxylic acid (5-trifluoromethyl-pyridin-2-yl)-amide (JNJ17203212), a transient receptor potential vanilloid 1 antagonist in guinea pigs. J.Pharmacol.Exp.Ther. 323 665. PMID:17690251."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=220535	SQ1070			Mar-2009
3362	MIRA-1	[72835-26-8]	O=C(N1COC(CC)=O)C=CC1=O	Restores mutant p53 activity; proapoptotic	"Restores wild-type conformation, function and DNA binding activity to mutant p53. Induces p53 transcriptional transactivation of p21, MDM2 and PUMA, and promotes tumor cell death by apoptosis in a mutant p53-dependent manner in vitro (IC50 = 10_M)."	Bykov et al (2005) Reactivation of mutant p53 and induction of apoptosis in human tumor cells by maleimide analogs. J.Biol.Chem. 280 30384. PMID:15998635. Wiman (2006) Strategies for therapeutic targeting of the p53 pathway in cancer. Cell Death Differ. 13 921. PMID:16557267. Kumar et al (2007) p53 in breast cancer: mutation and countermeasures. Front.Biosci. 12 4168. PMID:17485365.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=220536				Jun-2009
3364	BIX 01294	[1392399-03-9]	CN(CCC3)CCN3C2=NC1=CC(OC)=C(OC)C=C1C(NC4CCN(CC5=CC=CC=C5)CC4)=N2.Cl.Cl.Cl	G9a-like protein and G9a histone lysine methyltransferase inhibitor	G9a-like protein and G9a histone lysine methyltransferase inhibitor (IC50 values are 0.7 and 1.7 _M respectively) that displays no activity at other histone methyltransferases up to 37 _M. Modulates H3K9me2 levels in mammalian cells and potentiates induction of pluripotent stem cells from somatic cells in vitro.	Kubicek et al (2007) Reversal of H3K9me2 by a small-molecule inhibitor for the G9a histone methyltransferase. Mol.Cell 25 473. PMID:17289593. Shi et al (2008) Induction of pluripotent stem cells from mouse embryonic fibroblasts by Oct4 and Klf4 with small-molecule compounds. Cell Stem Cell 3 568. PMID:18983970. Chang et al (2009) Structural basis for G9a-like protein lysine methyltransferase inhibition by BIX-01294. Nat.Struct.Mol.Biol. 16 312. PMID:19219047. Malmquist et al (2012) Small-molecule histone methyltransferase inhibitors display rapid antimalarial activity against all blood stage forms in Plasmodium falciparum. Proc.Natl.Acad.Sci.U S A 109 16708. PMID:23011794.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=220538	SQ1533			Oct-2009
3365	Tenovin-1	[380315-80-0]	CC(C)(C)C1=CC=C(C(NC(NC2=CC=C(NC(C)=O)C=C2)=S)=O)C=C1	Protects against MDM2-mediated p53 degradation	p53 activator that protects against MDM2-mediated p53 degradation. Elevates levels of p53 and p21CIP/WAF1 and induces expression from an endogenous p53-dependent promoter. Exhibits potent antiproliferative activity in vitro.	"Lain et al (2008) Discovery, in vivo activity, and mechanism of action of a small-molecule p53 activator. Cancer Cell 13 454. PMID:18455128."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=220539				Feb-2009
3366	WAY 200070	[440122-66-7]	BrC1=C2C(N=C(C3=CC=C(O)C=C3)O2)=CC(O)=C1	Selective ER_ agonist	Selective ER_ receptor agonist that displays 68-fold selectivity over ER_ (EC50 values are 2 and 155 nM for ER_ and ER_ respectively). Displays antianxiolytic and antidepressive effects in vivo.	"Malamas et al (2004) Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-_ ligands. J.Med.Chem. 47 5021. PMID:15456246. Hughes et al (2008) WAY-200070, a selective agonist of estrogen receptor beta as a potential novel anxiolytic/antidepressant agent. Neuropharmacology 54 1136. PMID:18423777. Clipperton et al (2008) Differential effects of estrogen receptor alpha and beta specific agonists on social learning of food preferences in female mice. Neuropsychopharmacology 33 2362. PMID:18004284."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=220540	SQ1070			Dec-2009
3367	AT 101	[90141-22-3]	OC1=C(C3=C(O)C(C(C=O)=C(O)C(O)=C4C(C)C)=C4C=C3C)C(C)=CC2=C1C(C=O)=C(O)C(O)=C2C(C)C	Downregulates Bcl-2 and Mcl-1; pro-apoptotic	"R-(-)-enantiomer of gossypol (Cat. No. 1964). Mimics the BH3 domains of Bcl-2, Bcl-XL and Mcl-1. Disrupts heterodimerization of Bcl-2 with proapoptotic family members. Induces apoptosis in vitro through activation of caspase-9; cytotoxic to multiple myeloma and drug-resistant cell lines. Delays onset of androgen-independent growth of VCaP prostate cancer xenografts in vivo."	Loberg et al (2007) In vivo evaluation of AT-101 (R-(-)-gossypol acetic acid) in androgen-independent growth of VCaP prostate cancer cells in combination with surgical castration. Neoplasia 9 1030. PMID:18084610. Kline et al (2008) R-(-)-gossypol (AT-101) activates programmed cell death in multiple myeloma cells. Exp.Hematol. 36 568. PMID:18346839. Balakrishnan et al (2009) AT-101 induces apoptosis in CLL B cells and overcomes stromal cell-mediated Mcl-1 induction and drug resistance. Blood 113 149. PMID:18836097.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=220541	SQ1533			Jun-2010
3368	SB 271046 hydrochloride	[209481-20-9]	CC2=C(S(NC3=CC=C(OC)C(N4CCNCC4)=C3)(=O)=O)SC1=CC=C(Cl)C=C12.Cl	"Selective, orally active 5-HT6 antagonist"	"Selective, orally active 5-HT6 antagonist (pKi values are 9.02-8.92, 6.55, 6.35, 6.27, 6.05, 5.95, 5.76, 5.73, 5.62, 5.55, 5.41, 5.39, 5.27 and < 4.99 at 5-HT6, 5-HT1D, 5-HT1A, D3, 5-HT1B, 5-HT1F, _1B, 5-HT2C, 5-HT2A, D2, 5-HT2B, 5-HT7, 5-HT4 and 5-HT1E respectively) and is > 200-fold selective over 55 other receptors, enzymes and ion channels. Increases extracellular glutamate and aspartate in the frontal cortex, and exhibits anticonvulsant activity (EC50 = 0.16 _M)."	"Bromidge et al (1999) 5-Chloro-N-(4-methoxy-3-piperazin-1-yl-phenyl)-3-methyl-2-benzothiophenesulfonamide (SB-271046): a potent, selective, and orally bioavailable 5-HT6 receptor antagonist. J.Med.Chem. 42 202. PMID:9925723. Dawson et al (2000) In vivo effects of the 5-HT6 antagonist SB-271046 on striatal and frontal cortex extracellular concentrations of noradrenaline, dopamine, 5-HT, glutamate and aspartate. Br.J.Pharmacol. 130 23. PMID:10780993. Routledge et al (2000) Characterization of SB-271046: a potent, selective and orally active 5-HT6 receptor antagonist. Br.J.Pharmacol. 130 1606. PMID:10928964. Marcos et al (2008) Effects of 5-HT6 receptor antagonism and cholinesterase inhibition in models of cognitive impairment in the rat. Br.J.Pharmacol. 155 434. PMID:18622410."	Small Molecule	Sold with the permission of GlaxoSmithKline	http://www.tocris.com/dispprod.php?ItemId=220544				Jul-2009
3369	AC 55541	[916170-19-9]	O=C2C1=CC=CC=C1C(C(NC(C3=CC=CC=C3)=O)C(N/N=C(C)/C4=CC=CC(Br)=C4)=O)=NN2	Potent and selective PAR2 agonist	"Potent and selective protease-activated receptor 2 (PAR2) agonist (pEC50 = 6.7) that displays no activity at other PAR subtypes or at over 30 other receptors involved in nociception and inflammation. Stimulates cell proliferation, PI hydrolysis and Ca2+ mobilization in vitro (pEC50 values are 6.7, 5.9 and 6.6 respectively) and exhibits pronociceptive activity in vivo."	Seitzberg et al (2008) Discovery of potent and selective small-molecule PAR-2 agonists. J.Med.Chem. 51 5490. PMID:18720984. Gardell et al (2008) Identification and characterization of novel small-molecule protease-activated receptor 2 agonists. J.Pharmacol.Exp.Ther. 327 799. PMID:18768780.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=220549	SQ1070			May-2009
3370	AC 264613	[1051487-82-1]	O=C1[C@@H]([C@](N/N=C(C)/C3=CC=CC(Br)=C3)=O)[C@H]([C@]2=CC=CC=C2)CN1	PAR2 receptor agonist	"Potent and selective protease-activated receptor 2 (PAR2) agonist (pEC50 = 7.5). Displays no activity at other PAR subtypes and exhibits no significant activity at over 30 other receptors implicated in nociception and inflammation. Stimulates PI hydrolysis, Ca2+ mobilization and cellular proliferation in vitro (pEC50 values are 6.9, 7.0 and 7.5 respectively)."	Gardell et al (2008) Identification and characterization of novel small-molecule protease-activated receptor 2 agonists. J.Pharmacol.Exp.Ther. 327 799. PMID:18768780. Seitzberg et al (2008) Discovery of potent and selective small-molecule PAR-2 agonists. J.Med.Chem. 51 5490. PMID:18720984.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=220650	SQ1070			Jul-2010
3371	TCS OX2 29	[372523-75-6]	C[C@@](C)(C)[C@H](NCC3=CC=NC=C3)C(N(C2)CCC1=C2C=C(OC)C(OC)=C1)=O.Cl	Potent and selective OX2 antagonist	"Potent and selective OX2 receptor antagonist (IC50 = 40 nM). Displays >250-fold selectivity for OX2 over OX1 and a range of receptors, ion channels and transporters. Inhibits orexin A induced IP3 accumulation and ERK1/2 phosphorylation in CHO cells transfected with the OX2 receptor."	"Hirose et al (2003) N-acyl 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline: The first orexin-2 receptor selective non-peptidic antagonist. Bioorg.Med.Chem.Lett. 13 4497. PMID:14643355. Mould et al (2014) Binding kinetics differentiates functional antagonism of orexin-2 receptor ligands. Br.J.Pharmacol. 171 351. PMID:23692283."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=220651	SQ1070			Mar-2009
3373	Valinomycin	[2001-95-8]	O=C([C@H](C)OC([C@@H]([C@@H](C)C)NC([C@H](OC([C@@H](NC([C@@H](O1)C)=O)[C@@H](C)C)=O)[C@@H](C)C)=O)=O)N[C@@H]([C@@H](C)C)C(O[C@H]([C@@H](C)C)C(N[C@@H](C(O[C@@H](C)C(N[C@@H]([C@H](C)C)C(O[C@H]([C@@H](C)C)C(N[C@H]([C@H](C)C)C1=O)=O)=O)=O)=O)[C@H](C)C)=O)=O	Selective K+ ionophore	"Selective K+ ionophore (K0.5 values are 48, 73, 75, 93 and 246 mM for K+, Rb+, Cs+, Na+ and Li+ respectively) that transports K+ across biological and artificial lipid membranes. Inhibits Ca2+-ATPase activity and induces apoptosis through mitochondrial membrane depolarization, caspase-3 activation and phosphatidylserine translocation in vitro."	"Davidson and Berman (1985) Interaction of valinomycin and monovalent cations with the (Ca2+,Mg2+)-ATPase of skeletal muscle sarcoplasmic reticulum. J.Biol.Chem. 260 7325. PMID:3158656. Abdalah et al (2006) Valinomycin-induced apoptosis in Chinese hamster ovary cells. Neurosci.Letts. 405 68. Rose and Jenkins (2007) The effects of the ionophore valinomycin on biomimetic solid supported lipid DPPTE/EPC membranes. Bioelectrochem. 70 387."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=220889	SQ1070			Feb-2009
3378	EIPA	[1154-25-2]	ClC1=C(N(C(C)C)CC)N=C(N)C(C(NC(N)=N)=O)=N1	Inhibits TRPP3-mediated currents; also inhibits the Na+/H+ exchanger (NHE)	TRPP3 channel inhibitor (IC50 = 10.5 _M). Inhibits the Na+/H+ exchanger (NHE). Derivative of amiloride (Cat. No. 0890).	Dai et al (2007) Inhibition of TRPP3 channel by amiloride and analogs. Mol.Pharmacol. 72 1576. PMID:17804601. Horinouchi et al (2008) Functional role of Na+/H+ exchanger in Ca2+ influx mediated via human endothelin type A receptor stably expressed in Chinese hamster ovary cells. J.Pharm.Sci. 107 456. PMID:18678984.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=220896				Apr-2013
3379	Phenamil	[1161-94-0]	NC1=C(Cl)N=C(C(NC(NC2=CC=CC=C2)=N)=O)C(N)=N1.CS(=O)(O)=O	Inhibits TRPP3-mediated currents; also inhibits epithelial Na+ channels	TRPP3 channel inhibitor (IC50 = 0.14 _M). Also inhibits epithelial Na+ channels (Kd = 0.4 nM for a high affinity site on the epithelial Na+ channel). Derivative of amiloride (Cat. No. 0890).	Barbry et al (1989) Biochemical identification of two types of phenamil binding sites associated with amiloride-sensitive Na+ channels. Biochemistry. 28 3744. PMID:2546581. Dai et al (2007) Inhibition of TRPP3 channel by amiloride and analogs. Mol.Pharmacol. 72 1576. PMID:17804601.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=220897				Feb-2013
3380	Benzamil	[161804-20-2]	NC1=C(Cl)N=C(C(NC(NCC2=CC=CC=C2)=N)=O)C(N)=N1.Cl	"NCX inhibitor, Deg/ENaC channel blocker; amiloride (Cat. No. 0890) derivative"	Na+/Ca2+ exhanger (NCX) inhibitor (IC50 ~ 100 nM); TRPP3 channel blocker (IC50 = 1.1 _M for inhibition of Ca2+-activated TRPP3 channel activity). Also non-selective Deg/ENaC family blocker; reduces mechanosensitivity of colonic afferents. More potent derivative of amiloride (Cat. No. 0890).	Fischer et al (2002) Characterization of a Na+-Ca2+ exchanger in podocytes. Nephrol.Dial.Transplant. 17 1742. PMID:12270979. Page et al (2007) Acid sensing ion channels 2 and 3 are required for inhibition of visceral nociceptors by benzamil. Pain 133 150. PMID:17467171. Dai et al (2007) Inhibition of TRPP3 channel by amiloride and analogs. Mol.Pharmacol. 72 1576. PMID:17804601.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=220898	SQ1533			Feb-2013
3381	AM 1172	[251908-92-6]	CCCCC\C=C/C\C=C/C/C=C\C/C=C\CCCCNC(C1=CC=C(O)C=C1)=O	Anandamide uptake inhibitor; also FAAH inhibitor and CB receptor partial agonist	"Metabolically stable anandamide uptake inhibitor (IC50 = 2.1 - 2.5 _M) and fatty acid amide hydrolase (FAAH) inhibitor (Ki = 3.18 _M). Inhibits N-arachidonylethanolamine (AEA) accumulation (IC50 = 24 _M) and hydrolysis (Ki = 3 _M), and inhibits N-palmitoylethanolamine (PEA) hydrolysis (IC50 = 36 _M) in cerebellar granule neurons. Also acts as a non-selective cannabinoid receptor partial agonist (EC50 values are 189 and 271 nM at CB2 and CB1 receptors respectively)."	Fegley et al (2004) Anandamide transport is independent of fatty-acid amide hydrolase activity and is blocked by the hydrolysis-resistant inhibitor AM1172. Proc.Natl.Acad.Sci.USA 101 8756. Kaczocha et al (2006) Anandamide uptake is consistent with rate-limited diffusion and is regulated by the degree of its hydrolysis by fatty acid amide hydrolase. J.Biol.Chem. 281 9066. PMID:16461355. Hillard et al (2007) Studies of anandamide accumulation inhibitors in cerebellar granule neurons. J.Mol.Neurosci. 33 18. PMID:17901541.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=220911	SQ1070			Nov-2009
3383	VU 152100	[409351-28-6]	CC1=C2C(SC(C(NCC3=CC=C(OC)C=C3)=O)=C2N)=NC(C)=C1	Positive allosteric modulator of M4 receptors	Selective positive allosteric modulator of M4 muscarinic acetylcholine receptors (mAChRs) (EC50 = 380 nM). Induces 21-fold shift in ACh potency at M4 receptor. Displays no activity at other mAChR subtypes.	Brady et al (2008) Centrally active allosteric potentiators of the M4 muscarinic acetylcholine receptor reverse amphetamine-induced hyperlocomotor activity in rats. J.Pharmacol.Exp.Ther. 327 941. PMID:18772318.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=220913	SQ1070			May-2010
3384	(Z)-Pugnac	[132489-69-1]	OC(C1NC(C)=O)C(O)C(CO)O/C1=N\OC(NC2=CC=CC=C2)=O	O-GlcNAcase and _-hexosaminidase inhibitor	O-GlcNAc-_-N-acetylglucosaminidase (O-GlcNAcase) and _-hexosaminidase inhibitor (Ki values are 46 and 36 nM respectively) that increases O-GlcNAc levels ~ 2-fold in HT29 cells. Z-linked isomer is more potent than the E isomer.	Dong and Hart (1994) Purification and characterization of an O-GlcNAc selective N-acetyl-_-D-glucosaminidase from rat spleen cytosol. J.Biol.Chem. 269 19321. PMID:8034696. Macauley et al (2005) O-GlcNAcase uses substrate-assisted catalysis. J.Biol.Chem. 280 25313. PMID:15795231. Perreira et al (2006) Inhibition of O-GlcNAcase by PUGNAc is dependent upon the oxime stereochemistry. Bioorg.Med.Chem. 14 837. PMID:16214344.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=220914				May-2009
3385	GW 791343 hydrochloride	[309712-55-8]	CC(C=C2)=C(NC(CNC3=CC=C(F)C(F)=C3)=O)C=C2CN1CCNCC1.Cl.Cl.Cl	P2X7 allosteric modulator	P2X7 allosteric modulator. Exhibits species-specific activity; acts as a negative allosteric modulator of human P2X7 (pIC50 = 6.9 - 7.2) and a positive allosteric modulator of rat P2X7.	Michel et al (2008) Negative and positive allosteric modulators of the P2X7 receptor. Br.J.Pharmacol. 153 737. PMID:18071294. Michel et al (2008) Identification of regions of the P2X7 receptor that contribute to human and rat species differences in antagonist effects. Br.J.Pharmacol. 155 738. PMID:18660826.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=220928	SQ1533			Jun-2009
3387	Gedunin	[2753-30-2]	O=C4[C@@H]6[C@]3(O6)[C@]2(C)[C@H](OC(C)=O)C[C@@]1([H])C(C)(C)C(C=C[C@@](C)1[C@]([H])2CC[C@](C)3[C@H]([C@]5=COC=C5)O4)=O	Hsp90 inhibitor; exhibits anticancer and antimalarial activity	"Naturally occurring Hsp90 inhibitor. Induces Hsp90-dependent client protein degradation and displays antiproliferative activity in vitro (IC50 values are 3.22, 8.84 and 16.8 _M in SKBr3, MCF-7 and CaCo-2 cancer cell lines respectively). Also exhibits antimalarial activity against P. falciparum (IC50 values are 0.14 and 3.1 _M in parasite development and [3H]-hypoxanthine uptake assays respectively)."	"Uddin et al (2007) Gedunin, a limonoid from Xylocarpus granatum, inhibits the growth of CaCo-2 colon cancer cell line in vitro. Phytother.Res. 21 757. PMID:17450509. Brandt et al (2008) Gedunin, a novel Hsp90 inhibitor: semisynthesis of derivatives and preliminary structure-activity relationships. J.Med.Chem. 51 6495. PMID:18816111. Lee et al (2008) Antimalarial activity of anthothecol derived from Khaya anthotheca (Meliaceae). Phytomedicine 15 533. PMID:17913482."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=220954				Jun-2009
3388	Anastrozole	[120511-73-1]	CC(C)(C#N)C1=CC(CN2C=NC=N2)=CC(C(C)(C)C#N)=C1	Potent aromatase (CYP19) inhibitor	Potent and highly selective aromatase (CYP19) inhibitor (IC50 = 15 nM) that has no discernible effect on adrenocorticoid hormone synthesis. Reduces plasma estrogen levels and exhibits antitumor activity in vivo. Orally active.	"Dukes et al (1996) The preclinical pharmacology of ""Arimidex"" (anastrozole; ZD1033)-a potent, selective aromatase inhibitor. J.Steroid Biochem.Mol.Biol. 58 439. PMID:8903429. Goss and Tye (1997) Anastrozole: a new selective nonsteroidal aromatase inhibitor. Oncology 11 1697. PMID:9394367. Buzda (2001) Anastrozole (ArimidexTM) - an aromatase inhibitor for the adjuvant setting? Br.J.Cancer 85 6. PMID:11900212."	Small Molecule	Sold for research purposes only under agreement from AstraZeneca	http://www.tocris.com/dispprod.php?ItemId=220997	SQ1533			Feb-2009
3389	Bicalutamide	[90357-06-5]	O=C(C(O)(C)CS(C2=CC=C(F)C=C2)(=O)=O)NC1=CC(C(F)(F)F)=C(C#N)C=C1	Non-steroidal androgen receptor antagonist	Orally active non-steroidal androgen receptor antagonist (IC50 = 190 nM). Displays peripheral selectivity and does not effect serum levels of LH and testosterone. Exhibits potent anticancer activity in vivo.	"Furr et al (1987) ICI 176,334: a novel non-steroidal, peripherally selective antiandrogen. J.Endocrinol. 113 R7. PMID:3625091. Tucker et al (1988) Nonsteroidal antiandrogens. Synthesis and structure-activity relationships of 3-substituted derivatives of 2-hydroxypropionanilides. J.Med.Chem. 31 954. PMID:3361581. Furr and Tucker (1996) The preclinical development of bicalutamide: pharmacodynamics and mechanism of action. Urology 47 13. PMID:8560673."	Small Molecule	Sold for research purposes only under agreement from AstraZeneca	http://www.tocris.com/dispprod.php?ItemId=220998	SQ1533			Feb-2009
3397	LY 2365109 hydrochloride	[868265-28-5]	CC(C)(C)C1=C(OCCN(C)CC(O)=O)C=CC(C2=CC(OCO3)=C3C=C2)=C1.Cl	Potent and selective GlyT1 inhibitor	"Potent and selective glycine transporter 1 (GlyT1) inhibitor (IC50 values are 15.8 and > 30 000 nM at GlyT1 and GlyT2 respectively). Induces a dose-dependent elevation in CSF levels of glycine, and enhances acetylcholine and dopamine release in the striatum and prefrontal cortex respectively. Produces profound locomotor and respiratory impairments at higher doses."	Perry et al (2008) Neurochemical and behavioral profiling of the selective GlyT1 inhibitors ALX5407 and LY2365109 indicate a preferential action in caudal vs cortical brain areas. Neuropharmacology 55 743. PMID:18602930.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=221337	SQ1070			Jun-2009
3401	Vinorelbine ditartrate	[125317-39-7]	[H][C@@]23N(C)C1=CC(OC)=[C@]([C@@](C7=C(C9)C(C=CC=C8)=C8N7)([C@](OC)=O)C[C@]6([H])C=C(CC)CN9C6)C=C1[C@@]52[C@](N(CC5)CC=C4)([H])[C@]4(CC)[C@@H](OC(C)=O)[C@]([C@](OC)=O)3O	Selective mitotic microtubule antagonist	Selective mitotic microtubule antagonist that exhibits > 20 fold selectivity over axonal microtubules. Inhibits proliferation of multiple human tumor cell lines (IC50 = 1.25 nM in HeLa cells) and blocks metaphase/anaphase transition by suppression of microtubule dynamics (IC50 = 3.8 nM). Reduces spindle length by 29% and inhibits microtubule polymerization at micromolar concentrations.	"Budman (1997) Vinorelbine (Navelbine): A third generation vinca alkaloid. Cancer Invest. 15 475. PMID:9316630. Ngan et al (2001) Mechanism of mitotic block and inhibition of cell proliferation by the semisynthetic vinca alkaloids vinorelbine and its newer derivative vinflunine. Mol.Pharmacol. 60 225. PMID:11408618. Okouneva et al (2003) The effects of vinflunine, vinorelbine, and vinblastine on centromere dynamics. Mol.Cancer Ther. 2 427. PMID:12748304."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=221640	SQ1533			Mar-2009
3404	S 32826	[1103672-43-0]	[Na+].[Na+].CCCCCCCCCCCCCC(=O)NC1=CC=C(CP([O-])([O-])=O)C=C1	Potent autotaxin inhibitor	"Inhibitor of autotaxin (IC50 = 9 nM). Displays similar inhibitory effects at all three autotaxin isoforms (_, _ and _). Exhibits no affinity for lysophosphatidic acid receptor 1 (LPA1) at concentrations up to 10 _M. Inhibits LPA release from adipocytes (IC50 = 90 nM)."	"Ferry et al (2008) S32826, a nanomolar inhibitor of autotaxin: discovery, synthesis and applications as a pharmacological tool. J.Pharmacol.Exp.Ther. 327 809. PMID:18755937. Gaetano et al (2009) Inhibition of autotaxin production or activity blocks lysophosphatiylcholine-induced migration of human breast cancer and melanoma cells. Mol.Carcinogenesis 48 801. Li et al (2011) Autotaxin is induced by TSA through HDAC3 and HDAC7 inhibition and antagonizes the TSA-induced cell apoptosis. Mol.Cancer 10 18. PMID:21314984."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=221738				Jun-2011
3409	BMS 453	[166977-43-1]	CC(CC=C3C4=CC=CC=C4)(C)C(C3=C2)=CC=C2/C=C/C1=CC=C(C(O)=O)C=C1	Synthetic retinoid and RAR_ agonist; also RAR_ and RAR_ antagonist	Synthetic retinoid. Retinoic acid receptor _ (RAR_) agonist in vivo; RAR_ and RAR_ antagonist in vitro. Inhibits breast cell proliferation by inducing active transforming growth factor _ (TGF_) and causes G1 arrest.	"Chen et al (1995) RAR-specific agonist/antagonists which dissociate transactivation and AP1 transrepression inhibit anchorage-independent cell proliferation. EMBO J. 14 1187. PMID:7720709. Yang et al (2001) The retinoic acid receptor antagonist, BMS543, inhibits normal breast cell growth by inducing active TGFB and causing cell cycle arrest. Oncogene 20 8025. PMID:11753686. Monteiro et al (2009) Commitment of mouse embryonic stem cells to the adipocyte lineage requires retinoic acid receptor beta and active GSK3. Stem Cells Dev. 18 457. PMID:18690793."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=222005	SQ1070			May-2010
3410	BMS 961	[185629-22-5]	CC1(C)C2=C(C=CC(C(O)C(NC3=CC=C(C(O)=O)C=C3F)=O)=C2)C(C)(C)CC1	Selective RAR_ agonist	Selective RAR_ agonist (EC50 values are 30 and 1000 nM at RAR_ and RAR_ respectively). Displays no activity at RAR_ receptors.	Taneja et al (1996) Cell-type and promoter-context dependent retinoic acid receptor (RAR) redundancies for RAR_2 and Hoxa-1 activation in F9 and P19 cells can be artefactually generated by gene knockouts. Proc.Natl.Acad.Sci.USA 93 6197. Abu-Abed et al (1998) Mouse P450RAI (CYP26) expression and retinoic acid-inducible retinoic acid metabolism in F9 cells are regulated by retinoic acid receptor _ and retinoid X receptor _. J.Biol.Chem. 273 2409. PMID:9442090. Klaholz et al (2000) Enantiomer discrimination illustrated by high-resolution crystal structures of the human nuclear receptor hRAR_. Proc.Natl.Acad.Sci. 97 6322.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=222006	SQ1070			Jun-2011
3411	SR 11237	[146670-40-8]	CC1(C)C2=C(C=CC(C4(OCCO4)C3=CC=C(C(O)=O)C=C3)=C2)C(C)(C)CC1	Pan RXR agonist	Pan retinoid X receptor (RXR) agonist that is devoid of any RAR activity.	Chiba et al (1997) Distinct retinoid X receptor-retinoic acid receptor heterodimers are differentially involved in the control of expression of retinoid target genes in F9 embryonal carcinoma cells. Mol.Cell.Biol. 17 3013. PMID:9154799. Benoit et al (1999) RAR-independent RXR signaling induces t(15;17) leukemia cell maturation. EMBO J. 18 7011. PMID:10601023. Zhou et al (2010) Retinoid X receptor agonists inhibit phorbol-12-myristate-13-acetate (PMA)-induced differentiation of monocytic THP-1 cells into macrophages. Mol.Cell.Biochem. 335 283. PMID:19784811.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=222007	SQ1070			Apr-2010
3412	(Z)-4-Hydroxytamoxifen	[68047-06-3]	CC\C(C3=CC=CC=C3)=C(C2=CC=C(OCCN(C)C)C=C2)/C1=CC=C(O)C=C1	Metabolite of tamoxifen (Cat. No. 0999)	Estrogen receptor antagonist. Tamoxifen (Cat. No. 0999) metabolite; exhibits greater potency than the parent compound. Chemotherapeutic agent.	"Jordan et al (1977) A monohydroxylated metabolite of tamoxifen with potent antioestrogenic activity. J.Endocrinology 75 305. PMID:591813. Yu and Forman (2003) Simple and efficient production of (Z)-4-hydroxytamoxifen, a potent estrogen receptor modulator. J.Org.Chem. 68 9489. PMID:14629178. Desta et al (2004) Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: Prominent roles for CYP3A and CYP2D6. J.Pharm.Exp.Ther. 310 1062. PMID:15159443."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=222008				Jul-2013
3413	YM 202074	[299900-84-8]	CN(CCOC)CC1=CC=C2C(N(C=C(C(N(C)C4CCCCC4)=O)S3)C3=N2)=C1.O=C(O)/C=C/C(O)=O.O=C(O)/C=C/C(O)=O.O=C(O)/C=C/C(O)=O.CN(CCOC)CC5=CC=C6C(N(C=C(C(N(C)C8CCCCC8)=O)S7)C7=N6)=C5	"High affinity, selective mGlu1 antagonist"	"High affinity, selective metabotropic glutamate receptor type 1 (mGlu1) antagonist. Binds an allosteric site of the rat mGlu1 receptor with a Ki of 4.8 nM. Inhibits mGlu1-mediated inositol phosphates production (IC50 = 8.6 nM in rat cerebellar granule cells). Neuroprotective in vivo."	Kohara et al (2008) Neuroprotective effects of the selective type 1 metabotropic glutamate receptor antagonist YM-202074 in rat stroke models. Brain Res. 1191 168. PMID:18164695. Ferraguti et al (2008) Metabotropic glutamate 1 receptor: current concepts and perspectives. Pharmacol.Rev. 60 536. PMID:19112153. Yanamoto et al (2010) Radiosynthesis and evaluation of [11C]YM-202074 as a PET ligand for imaging the metabotropic glutamate receptor type 1. Nucl.Med.Biol. 37 615. PMID:20610166.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=222011				Nov-2010
3414	FAK Inhibitor 14	[4506-66-5]	NC1=C(N)C=C(N)C(N)=C1.Cl.Cl.Cl.Cl	Selective FAK inhibitor	"Selective focal adhesion kinase (FAK) inhibitor that displays no significant activity at a range of other kinases including EGFR, PDGFR and IGF-RI. Prevents FAK autophosphorylation at Y397 (IC50 = 1 _M), promotes cell detachment and inhibits cell adhesion in vitro. Exhibits antiproliferative activity in a variety of human tumor cell lines in vitro and in breast cancer cells in vivo."	"Golubovskaya et al (2008) A small molecule inhibitor, 1,2,4,5-benzenetetraamine tetrahydrochloride, targeting the Y397 site of focal adhesion kinase decreases tumour growth. J.Med.Chem. 51 7405. PMID:18989950."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=222147				Mar-2009
3415	DMPO	[3317-61-1]	[O-][N+]1=CCCC(C)1C	Nitric oxide spin trap; measures oxygen-centered free radicals	"Water soluble nitric oxide spin trap; allows the measurement of oxygen-centered free radicals in biological systems at room temperature using electron spin resonance (ESR). Has a high reaction rate constant for superoxide and hydroxyl radicals, and distinguishes simultaneously among a variety of important biologically generated free radicals."	Togashi et al (2000) Analysis of hepatic oxidative stress status by electron spin resonance spectroscopy and imaging. Free Radic.Biol.Med. 28 846. PMID:10802214. Nohara et al (2009) The generation of lucigenin chemiluminescence from the reaction of guanidino compounds with phenylglyoxal under alkaline conditions and its application. Chem.Pharm.Bull. 57 700. PMID:19571414. Saito et al (2009) Comparison of superoxide detection abilities of newly developed spin traps in the living cells. Free Radic.Res. 43 668. PMID:19479584.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=222150				Jul-2009
3417	CP 99994 dihydrochloride	[145148-39-6]	COC(C=CC=C3)=C3CN[C@@H]1[C@H]([C@]2=CC=CC=C2)NCCC1.Cl.Cl	High affinity NK1 antagonist	High affinity NK1 antagonist (Ki = 0.145 nM in vitro). Also displays high ex vivo binding potency in gerbil striatum (IC50 = 36.8 nM). Attenuates endothelium-dependent contraction induced by substance P.	Shirahase et al (1995) Endothelium-dependent contraction in intrapulmonary arteries: mediation by endothelial NK1 receptors and TXA2. Br.J.Pharmacol. 115 1215. PMID:7582548. Duffy et al (2002) Correlation of neurokinin (NK) 1 receptor occupancy in gerbil striatum with behavioral effects of NK1 antagonists. J.Pharmacol.Exp.Ther. 301 536. PMID:11961054. Lindstrom et al (2007) Neurokinin 1 receptor antagonists: correlation between in vitro receptor interaction and in vivo efficacy. J.Pharmacol.Exp.Ther. 322 1286. PMID:17575073.	Small Molecule	Sold for research purposes under agreement from Pfizer Inc.	http://www.tocris.com/dispprod.php?ItemId=222233	SQ1070			Feb-2011
3427	Oncrasin 1	[75629-57-1]	O=CC2=CN(CC3=CC=C(Cl)C=C3)C1=CC=CC=C12	Induces abnormal nuclear aggregation of PKC_; proapoptotic	Proapoptotic agent that induces abnormal nuclear aggregation of PKC_ and suppresses RNA transcription. Exhibits antiproliferative effects against various human tumor cell lines with K-Ras mutations (IC50  3 _M) with minimal effects on normal epithelial cells and inhibits human xenograft growth by 75% in vivo.	"Guo et al (2007) Identification of a small molecule with synthetic lethality for k-Ras and protein kinase C iota. Cancer Res. 68 7403. Guo et al (2009) Interruption of RNA processing machinery by a small compound, 1-[(4-chlorophenyl)methyl]-1H-indole-3-carboxaldehyde (oncrasin-1). Mol.Cancer Ther. 8 441. PMID:19208825."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=222558				Mar-2009
3429	4-IPP	[41270-96-6]	IC1=NC=NC(C2=CC=CC=C2)=C1	Inhibitor of macrophage migration inhibitory factor (MIF); suicide substrate	Inhibitor of macrophage migration inhibitory factor (MIF). Acts as a suicide substrate to inactivate MIF catalytic and biological functions; inhibits MIF-associated liver enzyme activity in vivo. Also inhibits migration and anchorage independence of human lung adenocarcinoma cell lines in vitro.	"Winner et al (2008) A novel, macrophage migration inhibitory factor suicide substrate inhibits motility and growth of lung cancer cells. Cancer Res. 68 7253. PMID:18794110."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=222587				Jun-2010
3430	CFTRinh 172	[307510-92-5]	O=C(N(C3=CC=CC(C(F)(F)F)=C3)C(S2)=S)\C2=C/C1=CC=C(C(O)=O)C=C1	"Voltage-independent, selective CFTR chloride channel blocker"	"Voltage-independent, selective CFTR chloride channel blocker (Ki = 300 nM) that alters channel gating. Blocks intestinal fluid secretion induced by cholera toxin and Escherichia coli and suppresses cyst growth in animal models of polycystic kidney disease. Orally active. Inhibits mitochondrial respiration and increases reactive oxygen species (ROS) production independently of CFTR in several cell lines."	"Ma et al (2002) Thiazolidinone CFTR inhibitor identified by high-throughput screening blocks cholera toxin-induced intestinal fluid secretion. J.Clin.Invest. 110 1651. PMID:12464670. Taddei et al (2004) Altered channel gating mechanism for CFTR inhibition by a high-affinity thiazolidinone blocker. FEBS Lett. 558 52. PMID:14759515. Yang et al (2008) Small-molecule CFTR inhibitors slow cyst growth in polycystic kidney disease. J.Am.Soc.Nephrol. 19 1300. PMID:18385427. Rafferty et al (2009) Rescue of functional F508del cystic fibrosis transmembrane conductance regulator by vasoactive intestinal peptide in the human nasal epithelial cell line JME/CF15. J.Pharmacol.Exp.Ther. 331 2. PMID:19584307. Kelly et al (2010) Cystic fibrosis transmembrane regulator inhibitors CFTRinh-172 and GlyH-101 target mitochondrial functions, independently of chloride channel inhibition. J.Pharmaco.Exp.Ther. 333 60."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=222588				Apr-2009
3432	S 25585	[263849-50-9]	O=S(NC[C@H]1CC[C@H]([C@@](NNC(C3=CC=CC=C3)=O)=O)CC1)(C2=CC=C(C(F)(F)F)C=C2[N+]([O-])=O)=O	Potent and selective NPY Y5 receptor antagonist	"Potent neuropeptide Y (NPY) Y5 receptor antagonist (IC50 values are 5.4, > 1000, > 10 000 and > 10 000 nM at Y5, Y1, Y2 and Y4 receptors respectively) that displays no affinity for a wide range of other receptors. Does not produce a conditioned taste aversion, suppress sodium appetite or cause pica in rats. Significantly inhibits NPY-induced feeding but not through blockade of Y5 receptors."	Della-Zuana et al (2004) A potent and selective NPY Y5 antagonist reduces food intake but not through blockade of the NPY Y5 receptor. Int.J.Obes. 28 628. Beauverger et al (2005) Functional characterization of human neuropeptide Y receptor subtype 5 specific antagonists using a luciferase reporter gene assay. Cell.Signal. 17 489. PMID:15601626. Kamiji and Inui (2007) Neuropeptide Y receptor selective ligands in the treatment of obesity. 28 664.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=222590	SQ1070			Sep-2009
3433	GSK 0660	[1014691-61-2]	O=S(NC1=C(OC)C=C(NC3=CC=CC=C3)C=C1)(C2=C(C(OC)=O)SC=C2)=O	Selective PPAR_ antagonist	"Selective PPAR_ antagonist (IC50 values are 0.155, > 10 and  10 _M at PPAR_, PPAR_ and PPAR_ respectively). Exhibits inverse agonist effects when administered by itself."	Shearer et al (2008) Identification and characterization of a selective peroxisome proliferator-activated receptor _/_ (NR1C2) antagonist. Mol.Endocrinol. 22 523. PMID:17975020. Wang (2008) PPAR-_ in vascular pathophysiology. PPAR Res. 164163. PMID:19132133. Bishop-Bailey and Swales (2008) The role of PPARs in the endothelium: Implications for cancer therapy. PPAR Res. 904851.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=222591	SQ1070			Mar-2009
3439	NH 125	[278603-08-0]	CC1=[N+](CCCCCCCCCCCCCCCC)C=CN1CC2=CC=CC=C2.[I-]	CaM kinase III (eEF-2 kinase) inhibitor	"Eukaryotic elongation factor 2 (eEF-2) kinase (CaMK III) inhibitor (IC50 = 60 nM) that displays 125-fold, > 1300-fold and > 1500-fold selectivity over PKC, PKA and CaMK II respectively. Decreases the viability of a variety of cancer cell lines (IC50 values are 0.7 - 4.8 _M) and blocks G1/S cell cycle progression. Shown to induce eEF-2 phosphorylation in cancer cells. Also an effective antibacterial agent; inhibits histidine protein kinase in vitro (IC50 = 6.6 _M) and in vivo."	Yamamoto et al (2001) Antibacterial agents that inhibit histidine protein kinase YycG of Bacillus subtilis. Biosci.Biotechnol.Biochem. 65 2306. PMID:11758928. Arora et al (2003) Identification and characterization of an inhibitor of eukaryotic elongation factor 2 kinase against human cancer cell lines. Cancer Res. 63 6894. PMID:14583488. Arora et al (2004) P-glycoprotein mediates resistance to histidine kinase inhibitors. Mol.Pharmacol. 66 460. PMID:15322237. Chen (2011) 1-Benzyl-3-cetyl-2-methylimidazolium iodide (NH125) induces phosphorylation of eukaryotic elongation factor-2 (eEF2): a cautionary note on the anticancer mechanism of an eEF2 kinase inhibitor. J.Biol.Chem. 286 43951. PMID:22020937.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=222683				Jun-2009
3440	SID 7969543	[868224-64-0]	O=C2C1=CC=CC(OC(C)C(OCC)=O)=C1C=CN2CC(NC3=CC=C(OCCO4)C4=C3)=O	"Selective steroidogenic factor-1 (SF-1, NR5A1) inhibitor"	"Selective steroidogenic factor-1 (SF-1, NR5A1) inhibitor (IC50 values are 0.76, >33 and >33 _M at SF-1, ROR_ and VP16 respectively). Inhibits SF-1-dependent luciferase expression in HEK 293T cells in vitro (IC50 = 30 nM)."	"Roth et al (2008) Synthesis of small molecule inhibitors of the orphan nuclear receptor steroidogenic factor-1 (NR5A1) based on isoquinolinone scaffolds. Bioorg.med.Chem.Lett. 18 2628. PMID:18374567. Madoux et al (2008) Potent, selective and cell penetrant inhibitors of SF-1 by functional ultra-high-throughput screening. Mol.Pharmacol. 73 1776. PMID:18334597."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=222684	SQ1533			Apr-2009
3489	Astemizole	[68844-77-9]	FC(C=C5)=CC=C5CN2C1=CC=CC=C1N=C2NC3CCN(CCC4=CC=C(OC)C=C4)CC3	"Orally active, potent H1 antagonist. Also KV11.1 (hERG) channel blocker."	"Orally active, potent histamine H1 antagonist (IC50 = 4 nM) that displays 20-fold, > 250-fold and > 250-fold selectivity over 5-HT, dopamine and muscarinic acetylcholine receptors respectively. Exhibits antimalarial activity in multidrug resistant strains in vitro (IC50 = 227 - 734 nM). Also potent KV11.1 (hERG) channel blocker (IC50 = 0.9 nM) that displays cardiotoxicity in vivo."	"Laduron et al (1981) In vitro and in vivo binding characteristics of a new long-acting histamine H1 antagonist, astemizole. Mol.Pharmacol. 21 294. Cavalli et al (2002) Towards a pharmacophore for drugs inducing the long QT syndrome: Insights from a CoMFA study of hERG K+ channel blockers. J.Med.Chem. 45 3844. PMID:12190308. Chong et al (2006) A clinical drug library screen identifies astemizole as an antimalarial agent. Nat.Chem.Biol. 2 415. PMID:16816845."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=223129	SQ1533			Apr-2009
3495	Fludarabine	[21679-14-1]	O[C@@H]1[C@@H](CO)O[C@@H](N3C2=NC(F)=NC(N)=C2N=C3)[C@H]1O	Purine analog; inhibits DNA synthesis	"Purine analog that inhibits DNA synthesis. Exhibits antiproliferative activity (IC50 = 1.54 _M in RPMI cells) and triggers apoptosis through increasing Bax and decreasing Bid, XIAP and survivin expression. Displays anticancer activity against hematological malignancies in vivo."	Bellosillo et al (1999) In vitro evaluation of fludarabine in combination with cyclophosphamide and/or mitoxantrone in B-cell chronic lymphocytic leukemia. Blood 94 2836. PMID:10515887. Meng et al (2007) Antitumor activity of fludarabine against human multiple myeloma in vitro and in vivo. Eur.J.Haematol. 79 486. PMID:17976186. Torella et al (2007) Fludarabine prevents smooth muscle proliferation in vitro and neointimal hyperplasia in vivo through specific inhibition of STAT-1 activation. Am.J.Physiol.Heart Circ.Physiol. 292 H2935. PMID:17293493.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=223655	SQ1533			Apr-2009
3496	BX 471	[217645-70-0]	FC1=CC=C(CN2C[C@@H](C)N(C(COC3=CC=C(Cl)C=C3NC(N)=O)=O)CC2)C=C1	"Potent, selective CCR1 antagonist"	"Potent, selective non-peptide CCR1 antagonist (Ki = 1 nM for human CCR1). Exhibits 250-fold selectivity for CCR1 over CCR2, CCR5 and CXCR4. Inhibits MIP-_/CCL3-induced intracellular Ca2+ mobilization. Orally active; effectively reduces disease severity in a rat model of multiple sclerosis. Decreases renal fibrosis in a mouse model of obstructive nephropathy."	"Liang (2000) Identification and characterization of a potent, selective, and orally active antagonist of the CC chemokine receptor-1. J.Biol.Chem. 275 (25) 19000. PMID:10748002. Anders (2002) A chemokine receptor CCR-1 antagonist reduces renal fibrosis after unilateral ureter ligation. J.Clin.Invest. 109 (2) 251. PMID:11805137. Furuichi et al (2008) Chemokine receptor CCR1 regulates inflammatory cell infiltration after renal ischemia-reperfusion injury. J.Immunol. 181 8670. PMID:19050287."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=223750	SQ1070			Apr-2013
3499	ML 10302 hydrochloride	[186826-17-5]	ClC1=CC(C(OCCN2CCCCC2)=O)=C(OC)C=C1N.Cl	Potent and selective 5-HT4 partial agonist	Potent 5-HT4 partial agonist (EC50 = 4 nM) that displays > 680-fold selectivity over 5-HT3 receptors (Ki values are 1.07 and 730 nM respectively). Increases sAPP_ levels in the cortex in an animal model of Alzheimer's disease and exhibits progastrokinetic effects in vivo.	Yang et al (1997) New esters of 4-amino-5-chloro-2-methoxybenzoic acid as potent agonists and antagonists for 5-HT4 receptors. J.Med.Chem. 40 608. PMID:9046352. Ponti et al (2001) Intestinal motor stimulation by the 5-HT4 receptor agonist ML10302: differential involvement of tachykininergic pathways in the canine small bowel and colon. Neurogastroenterol.Mot. 13 543. Cachard-Chastel et al (2007) 5-HT4 receptor agonists increase sAPP_ levels in the cortex and hippocampus of male C57BL/6j mice. Br.J.Pharmacol. 150 883. PMID:17325649.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=223840	SQ1070			Apr-2009
3503	HLI 373	[502137-98-6]	CN2C1=CC=CC=C1C(NCCCN(C)C)=C3C2=NC(N(C)C3=O)=O.Cl.Cl	Hdm2 inhibitor; activates p53-dependent transcription	"Inhibitor of Hdm2 ubiquitin ligase (E3). Blocks Hdm2-mediated ubiquitylation and proteasomal degradation of p53; activates p53-dependent transcription. Induces apoptosis in several tumor cell lines that express wild-type p53 such as LOX-IMVI, A549, HT1080 and U2OS."	Kitagaki et al (2008) Targeting tumor cells expressing p53 with a water-soluble inhibitor of Hdm2. Mol.Cancer Ther. 7 2445. PMID:18723490. Yang et al (2009) Targeting the ubiquitin-proteasome system for cancer therapy. Cancer Sci. 100 24. PMID:19037995.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=224076	SQ1533			Aug-2010
3504	Risedronate	[115436-72-1]	OC(P(O)(O)=O)(P([O-])(O)=O)CC1=CC=CN=C1.[Na+]	Farnesyl diphosphate (FPP) synthase inhibitor	Orally active biphosphonate that inhibits farnesyl diphosphate (FPP) synthase. Exhibits antiproliferative and proapoptotic activity in numerous tumor cell lines and inhibits osteoclast-mediated bone reabsorption in vivo.	Coxon et al (2006) Recent advances in understanding the mechanism of action of bisphosphonates. Curr.Opin.Pharmacol. 6 307. PMID:16650801. Stressing et al (2007) Bisphosphonates in cancer therapy. Cancer Letts. 257 16. Fournier et al (2008) Lowering bone mineral affinity of bisphosphonates as a therapeutic stragey to optimize skeletal tumor growth inhibition in vivo. Cancer Res. 68 8945. PMID:18974139.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=224083	SQ1533			Apr-2009
3505	BMS 753	[215307-86-1]	O=C1C(C)(C)C2=C(C=CC(C(NC3=CC=C(C(O)=O)C=C3)=O)=C2)C(C)1C	RAR_-selective agonist	RAR_-selective agonist (Ki = 2 nM).	Taneja et al (1996) Cell-type and promoter-context dependent retinoic acid receptor (RAR) redundancies for RAR_2 and Hoxa-1 activation in F9 and P19 cells can be artefactually generated by gene knockouts. Proc.Natl.Acad.Sci.USA 93 6197. Dilworth et al (1999) Ligand-dependent activation of transcription in vitro by retinoid acid receptor _/retinoid X receptor _ heterodimers that mimics transactivation by retinoids in vivo. Proc.Natl.Acad.Sci.USA 96 1995. Gehin et al (1999) Structural basis for engineering of retinoic acid receptor isotype-selective agonists and antagonists. Chem.Biol. 6 519. PMID:10421757.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=224173	SQ1070			Feb-2011
3506	NVP DPP 728 dihydrochloride	[207556-62-5]	O=C(N2CCC[C@H]2C#N)CNCCNC1=NC=C(C#N)C=C1.Cl.Cl	"Potent, orally active dipeptidyl peptidase IV (DPP-IV) inhibitor"	"Potent, orally active dipeptidyl peptidase (DPP)-IV inhibitor (Ki = 11 nM, IC50 = 14 nM) that displays > 15 000-fold selectivity over DPP-II and a range of proline-cleaving proteases. Exhibits antidiabetic activity in vivo; improves glucose tolerance, increases glucagon-like peptide 1 (GLP-1) and insulin levels, augments insulin secretion and GLUT2 levels, and reduces (preserves) islet size."	"Hughes et al (1999) NVP-DPP728 (1-[[[2-[(5-cyanopyridin-2-yl)amino]ethyl]amino]acetyl]-2-cyano-(S)-pyrrolidine), a slow-binding inhibitor of dipeptidyl peptidase IV. Biochemistry 38 11597. PMID:10512614. Reimer et al (2002) Long-term inhibition of dipeptidyl peptidase IV improves glucose tolerance and preserves islet function in mice. Eur.J.Endocrinol. 146 717. PMID:11980629. Mitani et al (2002) Dipeptidyl peptidase IV inhibitor NVP-DPP728 ameliorates early insulin response and glucose tolerance in aged rats but not in aged Fischer 344 rats lacking its enzyme activity. Jpn.J.Pharmacol. 88 451. PMID:12046989."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=224199	SQ1070			Jul-2009
3507	AM 80	[94497-51-5]	O=C(C3=CC=C(C(O)=O)C=C3)NC(C=C2)=CC1=C2C(C)(C)CCC(C)1C	RAR_ agonist; anticancer	"Retinoic acid receptor _ (RAR_) agonist that induces differentiation (ED50 = 0.79 nM) and apoptosis of HL-60 cells in vitro. Exhibits antiproliferative effects against a variety of human tumor cells lines (mean values of 35, 40 and 60% growth inhibition at 0.1, 1 and 10 _M respectively) and displays anticancer activity against acute promyelocytic leukemia in vivo."	"Kagechika et al (1988) Retinobenzoic acids. 1. Structure-activity relationships of aromatic amides with retinoidal activity. J.Med.Chem. 31 2182. PMID:3184125. Jimi et al (2007) RAR_ is a regulatory factor for Am-80-induced cell growth inhibition of hematologic malignant cells. Int.J.Oncol. 31 397. PMID:17611697. Takenaga et al (2009) The effects of Am-80, a synthetic retinoid, on spinal cord injury-induced motor dysfunction in rats. Biol.Pharm.Bull. 32 225. PMID:19182380."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=224200	SQ1533			Apr-2009
3508	LG 101506	[331248-11-4]	CC(C)(C)C1=CC(/C(C)=C\C=C\C(C)=C\C(O)=O)=C(OCC(F)F)C(C(C)(C)C)=C1	Selective RXR modulator	"Selective RXR modulator (Ki values are 3, 9 and 11 for RXR_, RXR_ and RXR_ respectively). Displays poor binding affinity for RAR isoforms (Ki values are 2746, 3516 and >10,000 nM for RAR_, RAR_ and RAR_ respectively). Binding to RXR results in selective activation of RXR:PPAR_, RXR:PPAR_ and RXR:PPAR_ heterodimers."	"Michellys et al (2003) Novel (2E,4E,6Z)-7-(2-alkoxy-3,5-dialkylbenzene)-3-methylocta-2,4,6-trienoic acid retinoid X receptor modulators are active in models of type 2 diabetes. J.Med.Chem. 46 2683. PMID:12801232. Leibowitz et al (2006) Biological characterization of a heterodimer-selective retinoid X receptor modulator: potential benefits for the treatment of type 2 diabetes. Endocrinology 147 1044. PMID:16269450. Pinaire et al (2007) Therapeutic potential of retinoid X receptor modulators for the treatment of the metabolic syndrome. PPAR Res. 94156. PMID:17497022."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=224201				Apr-2011
3509	BMS 493	[215030-90-3]	CC1(C)CC=C(C#CC3=CC=CC=C3)C2=C1C=CC(/C=C/C4=CC=C(C(O)=O)C=C4)=C2	Pan-RAR inverse agonist	"Pan-retinoic acid receptor (pan-RAR) inverse agonist. Enhances nuclear corepressor (NCoR) interaction with RARs. Binding induces analogous conformational changes in all RAR types (RAR_, RAR_ and RAR_)."	Rinkevich et al (2007) Systemic bud induction and retinioic acid signaling underlie whole body regeneration in the urochordate Botrylloides leachi. PLoS Biology. 5 e71. PMID:17341137. Germain et al (2009) Differential action on coregulator interaction defines retinoid agonists and neutral antagonists. Chem.Biol. 16 479. PMID:19477412.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=224224				Dec-2010
3513	N2-Methyl-L-arginine	[2480-28-6]	NC(NCCC[C@H](NC)C(O)=O)=N	Lysosomal system c L-arginine uptake inhibitor	Selective L-arginine uptake inhibitor (Ki = 500 _M). Inhibits uptake of arginine by the lysosomal system c in human fibroblast in vitro.	Pisoni et al (1987) Important differences in cationic amino acid transport by lysosomal system c and system y+ of the human fibroblast. J.Biol.Chem. 262 15011. PMID:3499437.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=224270				Mar-2009
3517	Nebivolol hydrochloride	[152520-56-4]	FC(C=C4)=CC3=C4O[C@@](CC3)([H])[C@H](O)CNC[C@@H](O)[C@]2([H])CCC1=CC(F)=CC=C1O2.Cl	Highly selective _1-adrenoceptor antagonist	"Highly selective _1-adrenoceptor antagonist (Ki values are 0.88, 20, 44, 700, 1160, 2400 and 4000 nM at _1, 5-HT1A, _2, 5-HT2, _1, H1 and D2 receptors respectively). Induces vasodilation via a nitric oxide- and cGMP-dependent mechanism (EC50 = 11.36 _M in renal arteries) and displays antihypertensive activity in vivo. GRK/_ -arrestin biased agonist at the _2 adrenoceptor."	Pauwels et al (1988) The receptor binding profile of the new antihypertensive agent nebivolol and its stereoisomers compared with various _-adrenergic blockers. Mol.Pharmacol. 34 843. PMID:2462161. Georgescu et al (2008) Nebivolol induces a hyperpolarizing effect on smooth muscle cells in the mouse renal artery by activation of beta-2-adrenoceptors. Pharmacology 81 110. PMID:17952013. Erickson et al (2013) The -blocker Nebivolol Is a GRK/-arrestin biased agonist. PLoS One 8 e71980. PMID: 23977191.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=224752	SQ1533			May-2009
3518	S 24795	[304679-75-2]	BrC1=CC=C(C(CC2=[N+](C)C=CC=C2)=O)C=C1.[I-]	Partial agonist at _7 nAChR	Partial agonist of _7 nAChR. Improves mnemonic function in aged mice for the treatment of aging-related memory disturbances. Displays more efficient memory-enhancing effects than memantine (Cat. No. 0773) in Alzheimer's disease mouse models.	"Lagostena et al (2008) The partial _7 nicotine acetylcholine receptor agonist S 24795 enhances long-term potentiation at CA3-CA1 synapses in the adult mouse hippocampus. Neuropharmacology 54 676. PMID:18187166. Marighetto et al (2008) Comparative effects of the _7 nicotinic partial agonist, S 24795, and the cholinesterase inhibitor, donepezil, against aging-related deficits in declarative and working memory in mice. Psychopharmacology. 197 499. PMID:18265960. Beracochea et al (2008) Improvement of contextual memory by S 24795 in aged mice: comparison with memantine. Psychopharmacology 196 555. PMID:18034231."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=224753				Nov-2010
3521	Sirtinol	[410536-97-9]	O=C(NC(C)C3=CC=CC=C3)C1=CC=CC=C1/N=C/C2=C(C=CC=C4)C4=CC=C2O	Selective sirtuin family deacetylase inhibitor	"Cell-permeable, selective sirtuin deacetylase inhibitor (IC50 values are 38, 68 and 131 _M at SIRT2, Sir2p and SIRT1 respectively) that has no effect on HDAC1 activity. Significantly decreases growth and viability of PCa and HEK293T cells in vitro."	"Grozinger et al (2001) Identification of a class of small molecule inhibitors of the sirtuin family of NAD-dependent deacetylases by phenotypic screening. J.Biol.Chem. 276 38837. PMID:11483616. Mai et al (2005) Design, synthesis, and biological evaluation of sirtinol analogues as class III histone/protein deacetylase (sirtuin) inhibitors. J.Med.Chem. 48 7789. PMID:16302818. Kahyo et al (2008) A novel chalcone polyphenol inhibits the deacetylase activity of SIRT1 and cell growth in HEK293T cells. J.Pharmacol.Sci. 108 364. PMID:19008647. Jung-Hynes et al (2009) Role of sirtuin histone deacetylase SIRT1 in prostate cancer. A target for prostate cancer management via its inhibition? J.Biol.Chem. 284 3823. PMID:19075016."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=224760				May-2009
3523	FERb 033	[1111084-78-6]	OC1=C(/C=N/O)C=CC(C2=CC=C(O)C(F)=C2)=C1Cl	Potent and selective ER_ agonist	"Potent and selective ER_ receptor agonist (Ki = 7.1 nM, EC50 = 4.8 nM). Displays 62-fold selectivity over ER_."	Minutolo et al (2009) Structural evolutions of salicylaldoximes as selective agonists for estrogen receptor _. J.Med.Chem. 52 858. PMID:19128016.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=224053				Mar-2010
3527	SB 243213 dihydrochloride	[200940-23-4]	O=C(N3C(C=C(C(F)(F)F)C(C)=C4)=C4CC3)NC(C=C2)=CN=C2OC1=CC=CN=C1C.Cl.Cl	Selective 5-HT2C inverse agonist	"Selective 5-HT2C inverse agonist (pKb = 9.8). Displays selectivity over other 5-HT2 subtypes (pKi values are 6.8, 7.0 and 9.0 for 5-HT2A, 5-HT2B and 5-HT2C respectively); also exhibits >100-fold selectivity over 50 other receptors, ion channels and enzymes. Displays anxiolytic activity in rat models."	Bromidge et al (2000) Biarylcarbamoylindolines are novel and selective 5-HT2C receptor inverse agonists: identification of 5-methyl-1-[[2-[(2-methyl-3-pyridyl)oxy]- 5-pyridyl]carbamoyl]-6-trifluoromethylindoline (SB-243213) as a potential antidepressant/anxiolytic agent. J.Med.Chem. 43 1123. PMID:10737744. Wood et al (2001) SB-243213; a selective 5-HT2C receptor inverse agonist with improved anxiolytic profile: lack of tolderance and withdrawal anxiety. Neuropharmacology 41 186. PMID:11489455. Berg et al (2006) Differential effects of 5-methyl-1-[[2-[(2-methyl-3-pyridyl)oxyl]-5-pyridyl]carbamoyl]-6-trifluoromethylindone (SB 243213) on 5-hydroxytryptamine2C receptor-mediated responses. J.Pharmacol.Exp.Ther. 319 260. PMID:16807362.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=225026	SQ1070			Feb-2012
3528	SCIO 469 hydrochloride	[309913-83-5]	O=C(C(N(C)C)=O)C2=CN(C)C1=CC(Cl)=C(C(N3[C@H](C)CN(CC4=CC=C(F)C=C4)[C@@H](C)C3)=O)C=C12.Cl	Selective p38 MAPK inhibitor	"Selective, ATP-competitive p38 inhibitor (IC50 = 9 nM for p38_ in vitro). Displays approximately 10-fold selectivity for p38_ over p38_ and 2000-fold selectivity for p38_ over 20 other kinases. Reduces p38_ phosphorylation in multiple myeloma cells in vitro and in vivo; activity results in decreased tumor burden and angiogenesis in murine models of multiple myeloma. Also enhances bortezomib-induced cytotoxicity against multiple myeloma cells."	"Hideshima et al (2004) p38 MAPK inhibition enhances PS-341 (bortezomib)-induced cytotoxicity against multiple myeloma cells. Oncogene. 23 8766. PMID:15480425. Giafis et al (2006) Role of the p38 mitogen-activated protein kinase pathway in the generation of arsenic trioxide-dependent cellular responses. Cancer Res. 66 6763. PMID:16818652. Vanderkerken et al (2007) Inhibition of p38_ mitogen-activated protein kinase prevents the development of osteolytic bone disease, reduces tumor burden, and increases survival in murine models of multiple myeloma. Cancer Res. 67 4572. PMID:17495322."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=225230	SQ1533			Jan-2011
3529	PD 168568 dihydrochloride	[210688-56-5]	CC1=C(C)C=CC(N2CCN(CCC(N4)C3=CC=CC=C3C4=O)CC2)=C1.Cl.Cl	Potent and selective D4 antagonist	Potent and selective dopamine D4 receptor antagonist (Ki values are 8.8 and 1842 nM at D4 and D2 receptors respectively). Reverses amphetamine-stimulated locomotion in vivo and is orally active.	Belliotti et al (1998) Isoindolinone enantiomers having affinity for the dopamine D4 receptor. Bioorg.Med.Chem.Lett. 8 1499. PMID:9873377.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=225231	SQ1070			Aug-2009
3530	HQL 79	[162641-16-9]	C1(CCCN2CCC(OC(C4=CC=CC=C4)C3=CC=CC=C3)CC2)=NN=NN1	Human hematopoietic prostaglandin D synthase (H-PGDS) inhibitor	Orally active and specific inhibitor of human hematopoietic prostaglandin D synthase (H-PGDS) (IC50 = 6 _M). Antiallergic and anti-inflammatory; displays antiasthmatic activity and potent antihistaminic properties in vivo.	"Matsushita et al (1998) Pharmacological studies on the novel antiallergic drug HQL-79: II. Elucidation of mechanisms for antiallergic and antihistaminic effects. Jpn.J.Pharmacol. 78 11. PMID:9804057. Mohri et al (2006) Prostaglandin D2-mediated microglia/astrocyte interaction enhances astrogliosis and demyelination in twitcher. J.Neurosci. 26 4383. PMID:16624958. Aritake et al (2006) Structural and functional characterization of HQL-79, an orally selective inhibitor of human hematopoietic prostaglandin D synthase. J.Biol.Chem. 281 15277. PMID:16547010."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=225232				Jul-2010
3531	AT 56	[162640-98-4]	C2(C=CC=C3)=C3/C(C(C=CC=C4)=C4C=C2)=C1CCN(CCCCC5=NNN=N5)CC/1	L-PGDS inhibitor	"Orally active inhibitor of lipocalin-type prostaglandin D synthase (L-PGDS) (Ki = 75 _M, IC50 = 95 _M). Inhibits the production of PGD2 from PGH2 in vitro, with no effect on PGE2 or PGF2_ production."	"Irikura et al (2009) Biochemical, functional and pharmacological characterization of AT-56, an orally active and selective inhibitor of lipocalin-type prostaglandin D synthase. J.Biol.Chem. 284 7623. PMID:19131342."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=225233				Nov-2010
3532	endo-IWR 1	[1127442-82-3]	[H][C@]13[C@](C(N(C4=CC=C(C(NC5=CC=CC6=C5N=CC=C6)=O)C=C4)C3=O)=O)([H])[C@H]2C=C[C@@H]1C2.[H][C@@]79[C@@](C(N(C%10=CC=C(C(NC%11=CC=CC%12=C%11N=CC=C%12)=O)C=C%10)C9=O)=O)([H])[C@@H]8C=C[C@H]7C8	Axin stabilizer; promotes _-catenin phosphorylation	Inhibitor of Wnt signaling. Induces an increase in Axin2 protein levels; promotes _-catenin phosphorylation by stabilizing Axin-scaffolded destruction complexes. Negative control exo-IWR (Cat. No. 3947) available.	Chen et al (2008) Small molecule-mediated disruption of Wnt-dependent signaling in tissue regeneration and cancer. Nature Chem.Biol. 5 100. Lu et al (2009) Structure-activity relationship studies of small-molecule inhibitors of Wnt response. Bioorg.Med.Chem.Lett. 19 3825. PMID:19410457.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=225595				Jun-2010
3533	IWP 2	[686770-61-6]	O=C1C3=C(CCS3)N=C(SCC(NC4=NC(C=CC(C)=C5)=C5S4)=O)N1C2=CC=CC=C2	Inhibitor of Wnt processing and secretion; blocks _-catenin accumulation	"Inhibitor of Wnt processing and secretion. Inactivates Porcn, a membrane-bound O-acyltransferase (MBOAT), and selectively inhibits palmitoylation of Wnt. Blocks Wnt-dependent phosphorylation of Lrp6 receptor and Dvl2, and _-catenin accumulation. Suppresses self-renewal in R1 embryonic stem cells."	Chen et al (2009) Small molecule-mediated disruption of wnt-dependent signaling in tissue regeneration and cancer. Nature Chem.Biol. 5 100. PMID:19125156. ten Berge et al (2011) Embryonic stem cells require Wnt proteins to prevent differentiation to epiblast stem cells. Nat.Cell.Biol. 13 1070. PMID:21841791. Lian et al (2012) Robust cardiomyocyte differentiation from human pluripotent stem cells via temporal modulation of canonical Wnt signaling. Proc.Natl.Acad.Sci.U S A 109 E1848. PMID:22645348.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=225596				May-2010
3534	PNU 74654	[113906-27-7]	O=C(N/N=C/C2=CC=C(C)O2)C1=C(OC3=CC=CC=C3)C=CC=C1	_-catenin binder; inhibits Wnt signaling	Binds to _-catenin (KD = 450 nM). Inhibits the interaction between _-catenin and T cell factor 4 (Tcf4) and disrupts the Wnt signaling pathway.	Trosset et al (2006) Inhibition of protein-protein interactions: the discovery of druglike beta-catenin inhibitors by combining virtual and biophysical screening. Proteins 64 60. PMID:16568448. Wells and McClendon (2007) Reaching for high-hanging fruit in drug discovery at protein-protein interfaces. Nature 450 1001. PMID:18075579.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=225597	SQ1533			May-2010
3535	Sivelestat sodium salt	[150374-95-1]	[Na+].CC(C)(C)C(=O)OC1=CC=C(C=C1)S(=O)(=O)NC1=CC=CC=C1C(=O)NCC([O-])=O	Selective leukocyte elastase inhibitor	"Selective leukocyte elastase inhibitor (IC50 = 44 nM) that displays no activity at a range of other proteases. Inhibits NF-_B activation and LTB4-induced neutrophil transmigration in vitro. Significantly attenuates ischemia-induced spinal cord injury, decreases serum cytokine levels and reduces acute inflammatory lung injury in vivo."	"Kawabata et al (1991) ONO-5046, a novel inhibitor of human neutrophil elastase. Biochem.Biophys.Res.Commun. 177 814. PMID:2049103. Young et al (2007) Role of neutrophil elastase in LTB4-induced neutrophil transmigration in vivo assessed with a specific inhibitor and neutrophil elastase deficient mice. Br.J.Pharmacol. 151 628. PMID:17471175. Hagiwara et al (2009) Neutrophil elastase inhibitor (sivelestat) reduces the levels of inflammatory mediators by inhibiting NF-_B. Inflamm.Res. 58 198. PMID:19169649. Iwamoto et al (2009) Protective effect of sivelestat sodium hydrate (ONO-5046) on ischemic spinal cord injury. Interact.Cardiovasc.Thorac.Surg. 8 606. PMID:19289399."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=225598	SQ1070			May-2009
3540	Orlistat	[96829-58-2]	O=C1[C@@H](CCCCCC)[C@H](C[C@@H](O[C@]([C@H](CC(C)C)NC([H])=O)=O)CCCCCCCCCCC)O1	"Pancreatic, gastric and carboxylester lipase inhibitor; antiobesity and antihypercholesterolemic activity"	"Hypolipemic pancreatic, gastric and carboxylester lipase inhibitor. Exhibits no activity at phospholipase A2, liver esterase, trypsin and chymotrypsin. Inhibits the thioesterase domain of fatty acid synthase, leading to cell cycle arrest at the G1/S boundary in vitro. Prevents the absorption of approximately one third of fat from food and exhibits progastrokinetic, antiobesity and antihypercholesterolemic activity in vivo."	Hadvary et al (1991) The lipase inhibitor tetrahydrolipstatin binds covalently to the putative active site serine of pancreatic lipase. J.Biol.Chem. 266 2021. PMID:1899234. Kridel et al (2004) Orlistat is a novel inhibitor of fatty acid synthase with antitumor activity. Cancer Res. 64 2070. PMID:15026345. Enc et al (2008) Orlistat accelerates gastric emptying and attenuates GIP release in healthy subjects. Am.J.Physiol.Gastrointest.Liver Physiol. 296 G482. PMID:19109408.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=226659	SQ1533			May-2009
3541	BAY-X 1005	[128253-31-6]	O=[C@@]([C@H](C4CCCC4)C(C=C3)=CC=C3OCC2=NC1=CC=CC=C1C=C2)O	Orally active 5-lipoxygenase activating protein (FLAP) inhibitor	"5-lipoxygenase activating protein (FLAP) inhibitor. Inhibits the synthesis of leukotrienes B4 and C4 in animal models; inhibits synthesis of leukotriene B4 in A23187-stimulated leukocytes (IC50 values are 0.026, 0.039 and 0.22 _M for rat, mice and human leukocytes respectively). Displays anti-inflammatory activity. Orally active."	"Muller-Peddinghaus et al (1993) BAY X1005, a new inhibitor of leukotriene synthesis: in vivo inflammation pharmacology and pharmacokinetics. J.Pharmacol.Exp.Ther. 267 51. PMID:8229782. Fruchtmann et al (1993) In vitro pharmacology of BAY X1005, a new inhibitor of leukotriene synthesis. Agents Actions 38 188. PMID:8213345. Hatzelmann et al (1994) Mode of action of the leukotriene synthesis (FLAP) inhibitor BAY X 1005: implications for biological regulation of 5-lipoxygenase. Agents Actions 43 64. PMID:7741044."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=226660	SQ1533			Jun-2011
3542	CP 316819	[186392-43-8]	O=C(N[C@@H](CC3=CC=CC=C3)[C@H](C(N(OC)C)=O)O)C2=CC1=CC(Cl)=CC=C1N2	Selective glycogen phosphorylase inhibitor	Selective glycogen phosphorylase inhibitor [IC50 values are 0.017 and 0.034 _M against human skeletal muscle glycogen phosphorylase a (huSMGPa) and liver glycogen phosphorylase a (huLGPa) respectively]. Antihyperglycemic agent.	"Baker et al (2005) Glycogen phosphorylase inhibition in type 2 diabetes therapy: a systematic evaluation of metabolic and functional effects in rat skeletal muscle. Diabetes 54 2453. PMID:16046314. Freeman et al (2006) Sensitivity of glycogen phosphorylase isoforms to indole site inhibitors is markedly dependent on the activation site of the enzyme. Br.J.Pharmacol. 149 775. PMID:17016495. Suh et al (2007) Astrocyte glycogen sustains neuronal activity during hypoglycemia: studies with the glycogen phosphorylase inhibitor CP-316,819 ([R-R*,S*]-5-chloro-N-[2-hydroxy-3-(methoxymethylamino)-3-oxo-1-(phenylmethyl)propyl]-1H-indole-2-carboxamide). J.Pharmacol.Exp.Ther. 321 45. PMID:17251391."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=226661	SQ1070			Jan-2011
3543	Suplatast tosylate	[94055-76-2]	O=C(CC[S+](C)C)NC1=CC=C(OCC(O)COCC)C=C1.CC2=CC=C(S(=O)([O-])=O)C=C2	Th2 cytokine synthesis inhibitor; antiasthmatic	"Th2 cytokine inhibitor that attenuates IL-2, IL-5 and IL-13 production and has no effect on IFN-_ production. Acts as an immunoregulator that suppresses IgE production, eosinophil infiltration and histamine release. Exhibits antiasthmatic, anti-inflammatory and antifibrotic activity in vivo and is orally active."	Kurokawa et al (2001) Suppressive effects of anti-allergic agent suplatast tosilate (IPD-1151T) on the expression of co-stimulatory molecules on mouse splenocytes in vivo. Mediators Inflamm. 10 333. PMID:11817674. Hsu et al (2007) The effects of suplatast tosilate (IPD-1151T) on innate immunity and antigen-presenting cells. Transpl.Immunol. 18 108. PMID:18005853. Furonaka et al (2009) Suplatast tosilate prevents bleomycin-induced pulmonary fibrosis in mice. J.Pharmacol.Exp.Ther. 328 55. PMID:18832650.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=226662	SQ1533			Jun-2009
3544	KU 55933	[587871-26-9]	O=C1C=C(C3=CC=CC4=C3SC5=C(C=CC=C5)S4)OC(N2CCOCC2)=C1	Potent and selective ATM kinase inhibitor	"Potent, selective and competitive ATM kinase inhibitor (Ki = 2.2 nM, IC50 values are 13, 2500, 9300, 16600, > 100000 and > 100000 nM at ATM, DNA-PK, mTOR, PI 3-kinase, PI 4-K and ATR respectively). Decreases viability of MCF-7, A549 and HCT116 cells and decreases p21CIP1 levels in vitro. Acts as a radio- and chemosensitizer for the treatment of cancer."	Hickson et al (2004) Identification and characterization of a novel and specific inhibitor of the ataxia-telangiectasia mutated kinase ATM. Cancer Res. 64 9152. PMID:15604286. Eaton et al (2007) Ataxia-telangiectasia mutated kinase regulates ribonucleotide reductase and mitochondrial homeostasis. J.Clin.Invest. 117 2723. PMID:17786248. Crescenzi et al (2008) Ataxia telangiectasia mutated and p21CIP1 modulate cell survival of drug-induced senescent tumor cells: implications for chemotherapy. Clin.Cancer Res. 14 1877. PMID:18347191.	Small Molecule	Sold for research purposes only under agreement from KUDOS	http://www.tocris.com/dispprod.php?ItemId=226718	SQ1533			May-2009
3545	Histamine dihydrochloride	[56-92-8]	NCCC1=CNC=N1.Cl.Cl	Endogenous histamine receptor agonist	"Endogenous agonist at histamine receptors (H1-4). Released from mast cells and basophils and exhibits inflammatory, vasodilatory and bronchoconstrictory activity. Stimulates gastric acid secretion and acts as a neurotransmitter in vivo."	Hill et al (1997) International union of pharmacology. XIII. Classification of histamine receptors. Pharmacol.Rev. 49 253. PMID:9311023. Maintz and Novak (2007) Histamine and histamine intolerance. Am.J.Clin.Nutr. 85 1185. PMID:17490952. Thurmond et al (2008) The role of histamine H1 and H4 receptors in allergic inflammation: the search for new antihistamines. Nat.Rev.Drug Discov. 7 41. PMID:18172439.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=223841	SQ1533			Apr-2009
3547	Serotonin hydrochloride	[153-98-0]	NCCC2=CNC1=CC=C(O)C=C12.Cl	Endogenous 5-HT receptor agonist	"Endogenous agonist at 5-HT receptors and endogenous substrate for 5-HT transporters. Neurotransmitter that has roles in regulation of mood, emesis, sexuality, sleep and appetite in vivo. Caged serotonin is also available (Cat.No. 3991)."	Barnes and Sharp (1999) A review of central 5-HT receptors and their function. Neuropharmacology 38 1083. PMID:10462127.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=192177	SQ1070			Oct-2009
3548	Dopamine hydrochloride	[62-31-7]	NCCC1=CC(O)=C(O)C=C1.Cl	Endogenous agonist at dopamine D1-5 receptors	"Endogenous neurotransmitter that acts as an agonist at dopamine D1-5 receptors. Synthesized in the substantia nigra and ventral tegmental area, and is a precursor in noradrenalin and adrenalin biosynthesis. Caged dopamine is also available (Cat. No 3992)."	Rivonello et al (2007) Novel insights into dopamine receptor pharmacology. Eur.J.Endocrinol. 156 S13. PMID:17413183. Cools (2008) Role of dopamine in the motivational and cognitive control of behavior. Neuroscientist 14 381. PMID:18660464. Fitzgerald and Dinan (2008) Prolactin and dopamine: what is the connection? A review article. J.Psychopharmacol. 22 S12.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=223884				May-2009
3549	3-Bromocytisine	[207390-14-5]	O=C2N1C[C@@]([H])(C3)CNC[C@@]([H])3C1=CC=C2Br	"Potent agonist of _4_4, _4_2 and _7 nACh receptors"	"Potent agonist of _4_4, _4_2 and _7 nACh receptors (IC50 values are 0.28, 0.30 and 31.6 nM respectively). Displays different effects on high (HS) and low (LS) ACh sensitivity _4_2 nAChRs (EC50 values are 0.008 and 0.05 _M respectively)."	"Houlihan et al (2001) Activity of cytisine and its brominated isoteres on recombinant human _7, _4_2 and _4_4 nicotinic acetylcholine receptors. J.Neurochem. 78 1029. PMID:11553677. Moroni et al (2006) _4_2 nicotinic receptors with high and low acetylcholine sensitivity: pharmacology, stoichiometry, and sensitivity to long-term exposure to nicotine. Mol.Pharmacol. 70 755. PMID:16720757."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=226860	SQ1070			Apr-2011
3550	Melatonin	[73-31-4]	O=C(C)NCCC2=CNC1=CC=C(OC)C=C12	Endogenous hormone; agonist at MT1 and MT2	"Endogenous hormone that acts as an agonist at melatonin receptors MT1 and MT2. Exhibits a prominent role in the control of circadian rhythm, displays immunomodulatory activity and acts as a powerful antioxidant in vivo."	Bubenik (2008) Thirty four years since the discovery of gastrointestinal melatonin. J.Physiol.Pharmacol. 59 33. PMID:18812627. Fischer et al (2008) Melatonin as a major skin protectant: from free radical scavenging to DNA damage repair. Exp.Dermatol. 17 713. PMID:18643846. Cardinali et al (2009) Melatonin and melatonergic drugs on sleep: possible mechanisms of action. Int.J.Neurosci. 119 821. PMID:19326288.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=226861	SQ1533			May-2009
3551	INH1	[313553-47-8]	CC(C=C(C)C=C2)=C2C1=CSC(NC(C3=CC=CC=C3)=O)=N1.Cl	Hec1 inhibitor; causes arrest of mitosis	"Hec1 inhibitor. Binds Hec1, inhibiting its association with Nek2 and kinetochores. Causes arrest of mitosis and inhibits proliferation in breast cancer cell lines (GI50= 10 - 20 _M)."	Wu et al (2008) Small molecule targeting the Hec1/Nek2 mitotic pathway suppresses tumor cell growth in culture and in animal. Cancer Res. 68 8393. PMID:18922912.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=226844	SQ1070			May-2010
3552	PD 173212	[217171-01-2]	CC(C)(C)C1=CC=C(CN(C)[C@H](C(N[C@H]([C@](NC(C)(C)C)=O)CC2=CC=C(OCC3=CC=CC=C3)C=C2)=O)CC(C)C)C=C1	Potent N-type Ca2+ channel blocker	"Potent N-type voltage-gated calcium channel blocker (IC50 = 36 nM). Displays selectivity over K+, Na+ and L-type Ca2+ channels. Prevents tonic seizures in the audiogenic seizure model in vivo."	Hu et al (1999) Structure-activity relationships of N-methyl-N-aralkyl-peptidylamines as novel N-type calcium channel blockers. Bioorg.Med.Chem.Letts. 9 2151.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=227104	SQ1070			Aug-2009
3556	SER 601	[1048038-90-9]	O=C(C4=CN(CCCCC)C5=C(C=C(C(C)C)C=C5)C4=O)NC12CC(C3)CC(CC3C2)C1	"Potent, selective CB2 agonist"	Potent and selective CB2 receptor agonist (Ki values are 6.3 nM and 1.2 _M for CB2 and CB1 receptors respectively). Displays analgesic activity in the formalin test in mice.	"Pasquini et al (2008) Investigations on the 4-quinolone-3-carboxylic acid motif. 2. Synthesis and structure-activity relationship of potent and selective cannabinoid-2 receptor agonists endowed with analgesic activity in vivo. J.Med.Chem. 51 5075. PMID:18680276. Contartese (2012) A novel CB2 agonist, COR167, potently protects rat brain cortical slices against OGD and reperfusion injury. Pharmacol.Res. 66 555. PMID:23036353."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=227235	SQ1070			Feb-2010
3561	L189	[64232-83-3]	S=C1NC(N)=C(/N=C/C2=CC=CC=C2)C(N1)=O	"DNA ligase I, III and IV inhibitor"	"DNA ligase I, III and IV inhibitor (IC50 values are 5, 9 and 5 _M respectively) that blocks DNA binding (Ki = 5 _M for DNA ligase I). Preferentially inhibits step 2 of the ligation reaction, and inhibits base excision repair (BER) and non-homologous end joining (NHEJ). Specifically sensitizes cancer cells to DNA damage and increases the cytotoxicity of DNA-damaging agents."	Chen et al (2008) Rational design of human DNA ligase inhibitors that target cellular DNA replication and repair. Cancer Res. 68 3169. PMID:18451142.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=228321				Feb-2010
3562	LU AA33810	[304008-29-5]	O=S(NC[C@H](CC4)CC[C@@H]4NC1=NC(C2=CC=CC=C2SCC3)=C3S1)(C)=O	Potent NPY Y5 receptor antagonist	"Potent neuropeptide Y (NPY) Y5 receptor antagonist (Ki = 1.5 nM in vitro). Displays  3300-fold affinity for Y5 over Y1, Y2 and Y4 receptors. Also binds human 5-HT2B and 5-HT1A receptors (Ki values are 247 and 478 nM respectively). Exerts anxiolytic- and antidepressant-like effects in rat models of stress sensitivity."	"Walker et al (2009) The novel neuropeptide Y Y5 receptor antagonist Lu AA33810 [N-[[trans-4-[(4,5-dihydro[1]benzothiepino[5,4-d]thiazol-2-yl)amino]cyclohexyl]methyl]-methanesulfonamide] exerts anxiolytic- and antidepressant-like effects in rat models of stress anxiety. J.Pharmacol.Exp.Ther. 328 900. PMID:19098165."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=228823	SQ1070			May-2010
3565	ONO AE3 208	[402473-54-5]	O=C(C(C)C2=C(C=CC=C3)C3=C(F)C=C2)NC1=CC(C#N)=CC=C1CCCC(O)=O	High affinity and selective EP4 antagonist	"High affinity and selective EP4 receptor antagonist (Ki values are 1.3, 30, 790 and 2400 nM for EP4, EP3, FP and TP receptors respectively). Displays no affinity for EP1, EP2, DP or IP receptors (Ki >10 _M). Inhibits PGE2-induced IL-8 production in colonic epithelial caco-2 cells and attenuates PGE2 inhibition of natural killer T cell activation. Suppresses recovery from experimentally-induced colitis and stimulates CD4+ T cell proliferation in C57BL/6 mice. Also reduces metastasis of mammary tumor cells in a murine model of breast cancer. Orally active."	"Kabashima et al (2002) The prostaglandin receptor EP4 suppresses colitis, mucosal damage and CD4 cell activation in the gut. J.Clin.Invest. 109 883. PMID:11927615 . Ma et al (2006) Prostaglandin E receptor EP4 antagonism inhibits breast cancer metastasis. Cancer Res. 66 2923. PMID:16540639. Dey et al (2009) Prostaglandin E2 couples through EP4 prostanoid receptors to induce IL-8 production in human colonic epithelial cell lines. Br.J.Pharmacol 3 475. PMID:19175605. Deng et al (2013) Exosome-like nanoparticles from intestinal mucosal cells carry prostaglandin E2 and suppress activation of liver NKT cells. J.Immunol. 190 3579. PMID:23467936."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=228826				Sep-2014
3567	TC-S 7003	[847950-09-8]	O=C3N(C4=C(C)C=CC=C4C)C1=NC7=C(C=CC=C7)N1C2=NC(NC5=CC=C(N6CCN(C)CC6)C=C5)=NC=C23	Potent Lck inhibitor	"Potent inhibitor of lymphocyte specific kinase (Lck). IC50 values are 0.007, 0.021, 0.042 and 0.20 _M for Lck, Lyn, Src and Syk kinases respectively. Displays >1000-fold selectivity for Lck over MAPK, CDK and RSK family representatives. Inhibits T cell proliferation in vitro and inhibits arthritis in two in vivo models. Orally active."	"Martin et al (2008) Structure-based design of novel 2-amino-6-phenyl-pyrimido[5',4':5,6]pyrimido[1,2-a]benzimidazol-5(6H)-ones as potent and orally active inhibitors of lymphocyte specific kinase (Lck): synthesis, SAR, and in vivo anti-inflammatory activity. J.Med.Chem. 51 1637. PMID:18278858."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=228829	SQ1341			Dec-2013
3568	Bretazenil	[84379-13-5]	O=C(N4[C@]([H])3CCC4)C1=C(Br)C=CC=C1N2C3=C(C(OC(C)(C)C)=O)N=C2	Benzodiazepine partial agonist	Partial agonist at the GABAA benzodiazepine site (EC50 = 10 nM at _1_1_2 receptors). Displays anticonvulsive activity in vivo.	"Puia et al (1992) Molecular mechanisms of the partial allosteric modulatory effects of bretazenil at _-aminobutyric acid type A receptor. Proc.Natl.Acad.Sci. USA Neurobiology 89 3620. Rundfeldt et al (1995) Anticonvulsant tolerance and withdrawal characteristics of benzodiazepine receptor ligands in different seizure models in mice. Comparison of diazepam, bretazenil and abecarnil. J.Pharmacol.Exp.Ther. 275 693. PMID:7473156. Munro et al (2008) Comparison of the novel subtype-selective GABAA receptor-positive allosteric modulator NS11394 [3'-[5-(1-hydroxy-1-methyl-ethyl)-benzoimidazol-1-yl]-biphenyl-2-carbonitrile] with diazepam, zolpidem, bretazenil, and gaboxadol in rat models of inflammatory and neuropathic pain. J.Pharmacol.Exp.Ther. 327 969. PMID:18791060."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=228830	SQ1533			Dec-2009
3569	Xanomeline oxalate	[141064-23-5]	CCCCCCOC1=NSN=C1C2=CCCN(C)C2.OC(C(O)=O)=O	Functionally selective M1 agonist	"Functionally selective muscarinic M1 receptor agonist (EC50 values are 0.3, 5, 42, 52 and 92.5 nM at M1, M3, M5, M4 and M2 receptors respectively). Displays a complex pharmacological profile: reversible and wash-resistant binding, resulting in full agonist activity at M1; delayed wash-resistant partial agonist activity at M2; and delayed wash-resistant full agonist activity at M4. Exhibits antipsychotic activity, and improves cognitive deficits and behavioral disturbances in Alzheimer's disease and schizophrenia."	Stanhope et al (2001) The muscarinic receptor agonist xanomeline has an antipsychotic-like profile in the rat. J.Pharmacol.Exp.Ther. 299 782. Jakubik et al (2008) Importance and prospects for design of selective muscarinic agonists. Physiol.Res. 57 S39. PMID:18481916. Heinrich et al (2009) Pharmacological comparison of muscarinic ligands: historical versus more recent muscarinic M1-preferring receptor agonists. Eur.J.Pharmacol. 605 53. PMID:19168056.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=229419	SQ1070			Jun-2009
3570	Z-Guggulsterone	[39025-23-5]	O=C1CC[C@@]2(C)C(CC[C@]3([H])[C@@]([H])2CC[C@@]/4(C)[C@]([H])3CC(C4=C/C)=O)=C1	Broad spectrum steroid receptor ligand. More active isomer of guggulsterone (Cat. No. 2013)	"Broad spectrum steroid receptor ligand; mineralocorticoid, progesterone and glucocorticoid receptor antagonist (Ki values are 37, 224 and 252 nM respectively) and weak androgen receptor agonist (Ki = 315 nM). Induces apoptosis in prostate cancer cells and inhibits angiogenesis via suppression of the VEGF-VEGFR2-Akt signaling pathway. Exhibits antilipidemic activity via antagonism of the farnesoid X receptor (FXR) and displays antiseptic, antirheumatic and anti-inflammatory activity in vivo. More active isomer of guggulsterone (Cat. No. 2013)."	"Meyer et al (2005) Is antagonism of E/Z-guggulsterone at the farnesoid X receptor mediated by a noncanonical binding site? A molecular modeling study. J.Med.Chem. 48 6955. Singh et al (2007) Guggulsterone-induced apoptosis in human prostate cancer cells is caused by reactive oxygen intermediate-dependent activation of c-Jun NH2-terminal kinase. Cancer Res. 67 7439. PMID:17671214. Xiao and Singh (2008) z-Guggulsterone, a constituent of Ayurvedic medicinal plant Commiphora mukul, inhibits angiogenesis in vitro and in vivo. Mol.Cancer Ther. 7 171. PMID:18202020."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=229435	SQ1070			Jun-2009
3571	SB 657510	[474960-44-6]	BrC1=CC(OC)=C(OC)C=C1S(NC2=CC=C(Cl)C(O[C@H]3CN(C)CC3)=C2)(=O)=O	Selective urotensin-II (UT) receptor antagonist	"Selective urotensin-II (UT) receptor antagonist (Ki values are 61, 17, 30, 65 and 56 nM at human, monkey, cat, rat and mouse receptors respectively). Inhibits U-II-induced intracellular Ca2+ mobilization (IC50 = 180 nM) and antagonizes the contractile action of U-II in isolated mammalian arteries and aortae (EC50 = 50 - 189 nM)."	Douglas et al (2005) Nonpeptide urotensin-II receptor antagonists I: in vitro pharmacological characterization of SB-706375. Br.J.Pharmacol. 145 620. PMID:15852036. Behm et al (2008) Palosuran inhibits binding to primate UT receptors in cell membranes but demonstrates differential activity in intact cells and vascular tissues. Br.J.Pharmacol. 155 374. PMID:18587423.	Small Molecule	Sold with the permission of GlaxoSmithKline	http://www.tocris.com/dispprod.php?ItemId=229458	SQ1070			Feb-2010
3572	GSK 650394	[890842-28-1]	O=C(C(C(C5CCCC5)=C4)=CC=C4C2=CNC1=NC=C(C3=CC=CC=C3)C=C12)O	Serum- and glucocorticoid-regulated kinase (SGK) inhibitor	"Serum- and glucocorticoid-regulated kinase 1 (SGK1) inhibitor (IC50 values are 62 and 103 nM for SGK1 and SGK2 respectively). Displays >30-fold selectivity over Akt and other related kinases. Inhibits androgen-stimulated growth of LNCaP cells, a human prostate carcinoma cell line (IC50 ~ 1 _M)."	Sherk et al (2008) Development of a small-molecule serum- and glucocorticoid-regulated kinase-1 antagonist and its evaluation as a prostate cancer therapeutic. Cancer Res. 68 7475. PMID:18794135.	Small Molecule	Sold with the permission of GlaxoSmithKline	http://www.tocris.com/dispprod.php?ItemId=229467	SQ1533			Jul-2009
3573	SB 612111 hydrochloride	[371980-94-8]	CC1=CC=CC2=C1CC[C@H](CN3CCC(C4=C(Cl)C=CC=C4Cl)CC3)C[C@@H]2O.Cl	Selective NOP receptor antagonist	"Selective NOP receptor antagonist (Ki values are 0.33, 57.6, 160.5 and 2109 nM for NOP, _-, _- and _-receptors respectively). Antagonizes the pronociceptive action of nociceptin (Cat. No. 0910) in an acute pain model. Potentiates the action of morphine in morphine-tolerant animals and blocks hyperalgesia in an inflammatory pain model."	"Zaratin et al (2004) Modification of nociception and morphine tolerance by the selective opiate receptor-like orphan receptor antagonist (-)-cis-1-methyl-7-[[4-(2,6-dichlorophenyl)piperidin-1-yl]methyl]-6,7,8,9-tetrahydro-5H-benzocyclohepten-5-ol (SB-612111). J.Pharmacol.Exp.Ther. 308 454. PMID:14593080. Rizzi et al (2007) Pharmacological characterization of the nociceptin/orphanin FQ receptor antagonist SB-612111 [(-)-cis-1-methyl-7-[[4-(2,6-dichlorophenyl)piperidin-1-yl]methyl]-6,7,8,9-tetrahydro-5H-benzocyclohepten-5-ol]: in vivo studies. J.Pharmacol.Exp.Ther. 321 968. PMID:17329551. Spagnolo et al (2007) Pharmacological characterization of the nociceptin/orphanin FQ receptor antagonist SB-612111 [(-)-cis-1-Methyl-7-[[4-(2,6-dichlorophenyl)piperidin-1-yl]methyl]-6,7,8,9-tetrahydro-5H-benzocyclohepten-5-ol]: in vitro studies. J.Pharm.Exp.Ther. 106 961."	Small Molecule	Sold with the permission of GlaxoSmithKline	http://www.tocris.com/dispprod.php?ItemId=229474	SQ1533			Nov-2010
3575	VU 0155069	[1130067-06-9]	O=C(N[C@@H](C)CN3CCC(N5C4=C(NC5=O)C=C(Cl)C=C4)CC3)C(C=C2)=CC1=C2C=CC=C1.Cl	Potent and selective PLD1 inhibitor	Potent and selective phospholipase D1 (PLD1) inhibitor (IC50 values are 46 and 933 nM for PLD1 and PLD2 respectively). Inhibits migration of human and mouse breast cancer cell lines in transwell assays.	Scott et al (2009) Design of isoform-selective phospholipase D inhibitors that modulate cancer cell invasiveness. Nat.Chem.Biol. 5 108. PMID:19136975. Lewis et al (2009) Design and synthesis of isoform-selective phospholipase D (PLD) inhibitors. Part I: Impact of alternative halogenated privileged structures for PLD1 specificity. Bioorg.Med.Chem.Lett. 19 1916. PMID:19268584.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=229725	SQ1070			Apr-2010
3576	()-5'-Chloro-5'-deoxy-ENBA	[103626-26-2]	O[C@@H]1[C@H](O)[C@@H](CCl)O[C@H]1N(C=N3)C2=C3C(NC4C5CCC(C5)C4)=NC=N2	Highly selective A1 agonist	"Highly selective adenosine A1 receptor agonist (Ki values are 0.51, 1290, 1340 and 2740 nM at A1, A3, A2A and A2B receptors respectively). Reverses formaline-induced nocifensive behavior in mice; antinociceptive."	Trivedi et al (1989) N6-bicycloalkyladenosines with unusually high potency and selectivity for the adenosine A1 receptor. J.Med.Chem. 32 8. PMID:2909748. Franchetti et al (2009) N6-cycloalkyl- and N6-bicycloalkyl-C5'(C2')-modified adenosine derivatives as high-affinity and selective agonists at the human A1 adenosine receptor with antinociceptive effects in mice. J.Med.Chem. 52 2393. PMID:19317449.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=229728	SQ1070			Mar-2010
3577	G-1	[881639-98-1]	CC(C5=CC([C@@]4([H])[C@@]([H])3CC=C4)=C(C=C5)N[C@H]3[C@]1=CC(OCO2)=C2C=C1Br)=O	Potent and selective GPR30 agonist	"Potent and selective GPR30 receptor agonist (Ki = 11 nM, EC50 = 2 nM); displays no activity at ER_ and ER_ at concentrations up to 10 _M. Increases cytosolic Ca2+ and inhibits migration of SKBr3 cells and MCF-7 cells in response to chemoattractants (IC50 values are 0.7 and 1.6 nM respectively) in vitro. Blocks MCF-1 cell cycle progression at the G1 phase. Displays therapeutic effects in the mouse EAE model of multiple sclerosis."	Bologa et al (2006) Virtual and biomolecular screening converge on a selective agonist for GPR30. Nature Chem.Biol. 2 207. Albanito et al (2007) G protein-coupled receptor 30 (GPR30) mediates gene expression changes and growth response to 17_-estradiol and selective GPR30 ligand G-1 in ovarian cancer cells. Cancer Res. 67 1859. PMID:17308128. Blasko et al (2009) Beneficial role of the GPR30 agonist G-1 in an animal model of multiple sclerosis. J.Neuroimmunol. 214 67. PMID:19664827. Ariazi et al (2010) The G protein-coupled receptor GPR30 inhibits proliferation of estrogen receptor-positive breast cancer cells. Cancer Res. 70 1184. PMID:20086172.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=230007				Dec-2009
3578	AS 605240	[648450-29-7]	O=C(/C(S3)=C/C(C=C2)=CC1=C2N=CC=N1)NC3=O	Potent and selective PI 3-kinase _ (PI3-K_) inhibitor	Potent and selective inhibitor of PI 3-kinase _ (PI 3-K_) (IC50 = 8 nM). Displays 30-fold selectivity over PI 3-K_ and PI 3-K_ and 7.5-fold selectivity over PI 3-K_. Suppresses the progression of joint inflammation and damage in both lymphocyte-independent and lymphocyte-dependent mouse models of rheumatoid arthritis. Orally active and ATP-competitive.	Camps et al (2005) Blockade of PI3K_ suppresses joint inflammation and damage in mouse models of rheumatoid arthritis. Nature Med. 11 936. Wang et al (2009) Phosphoinositide 3-kinase _ inhibitor ameliorates concanavalin A-induced hepatic injury in mice. Biochem.Biophys.Res.Comm. 386 569. Peng et al (2010) Inhibition of phosphoinositide 3-kinase ameliorates dextran sodium sulfate-induced colitis in mice. J.Pharmacol.Exp.Ther. 332 46. PMID:19828878.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=230008	SQ1533			Mar-2010
3579	5-BDBD	[768404-03-1]	BrC1=CC(C(C3=C4C2=C(O3)C=CC=C2)=NCC(N4)=O)=CC=C1	Potent P2X4 receptor antagonist	Potent P2X4 receptor antagonist. Blocks P2X4-mediated currents in Chinese hamster ovary cells (IC50 = 0.50 _M).	Donnelly-Roberts et al (2008) Painful purinergic receptors. J.Pharmacol.Exp.Ther. 324 409. PMID:18042830. Casati et al (2011) Cell-autonomous regulation of hematopoietic stem cell cycling activity by ATP. Cell Death Differ. 18 396. PMID:20798687.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=230094	SQ1070			Apr-2010
3580	HKI 357	[848133-17-5]	O=C(/C=C/CN(C)C)NC1=C(OCC)C=C(N=CC(C#N)=C2NC3=CC=C(OCC4=CC=CC(F)=C4)C(Cl)=C3)C2=C1	Dual irreversible inhibitor of ErbB2 and EGFR	"Potent, irreversible inhibitor of ErbB2 (HER2) and EGFR (IC50 values are 33 and 34 nM respectively). Suppresses ligand-induced EGFR autophosphorylation and cell proliferation in NCI-H1975 cells containing L858R and T790M mutations. Circumvents mechanisms of resistance to Iressa (Cat. No. 3000) in non-small-cell lung cancer cells."	"Kwak et al (2005) Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. Proc.Natl.Acad.Sci.USA 102 7665. PMID:15897464. Tsou et al (2005) Optimization of 6,7-disubstituted-4-(arylamino)quinoline-3-carbonitriles as orally active, irreversible inhibitors of human epidermal growth factor receptor-2 kinase activity. J.Med.Chem. 48 1107. PMID:15715478. Schiffer et al (2007) Pharmacology and signaling properties of epidermal growth factor receptor isoforms studied by bioluminescence resonance energy transfer. Mol.Pharmacol. 71 508. PMID:16968809."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=230170	SQ1070			Jun-2013
3581	C 021 dihydrochloride	[864289-85-0]	COC1=C(OC)C=C(N=C(N4CCC(N5CCCCC5)CC4)N=C2NC3CCCCCC3)C2=C1.Cl.Cl	Potent CCR4 antagonist	Potent CCR4 chemokine receptor antagonist (IC50 values are 0.14 and 0.039 _M for inhibition of chemotaxis in human and mouse respectively).	Yokoyama et al (2009) Potent and orally bioavailable CCR4 antagonists: synthesis and structure-activity relationship study of 2-aminoquinazolines. Bioorg.Med.Chem. 17 64. PMID:19081254.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=230171	SQ1070			Feb-2010
3584	Golgicide A	[1139889-93-2]	FC4=CC([C@]3([H])[C@]([H])2CC=C3)=C(C(F)=C4)NC2C1=CN=CC=C1	"Potent, specific and reversible inhibitor of GBF1 ArfGEF"	"Potent, specific and reversible inhibitor of Golgi BFA resistance factor 1 (GBF1), an ArfGEF, that decreases Arf1 activation in vivo. Arrests secretion of soluble and membrane-associated proteins at the endoplasmic reticulum-Golgi intermediate compartment. Causes disassembly and dispersal of the Golgi and trans-Golgi network."	Saenz et al (2008) Golgicide A reveals essential roles for GBF1 in Golgi assembly and function. Nature Chem.Biol. 5 157.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=230204	SQ1070			May-2010
3585	Org 12962 hydrochloride	[210821-63-9]	ClC1=NC(N2CCNCC2)=CC=C1C(F)(F)F.Cl	Selective 5-HT2C agonist	"Selective 5-HT2C receptor agonist (pEC50 values are 7.01, 6.38 and 6.28 for 5-HT2C, 5-HT2A and 5-HT2B respectively). Displays antiaversive effects in a rat model of panic-like anxiety."	"Jenck et al (1998) Antiaversive effects of 5-HT2C receptor agonists and fluoxetine in a model of panic-like anxiety in rats. Eur.Neuropsychopharmacol. 8 161. PMID:9716307. Porter et al (1999) Functional characterization of agonists at recombinant human 5-HT2A, 5-HT2B and 5-HT2C receptors in CHO-K1 cells. Br.J.Pharmacol. 128 13. PMID:10498829. Halford et al (2005) Serotonin (5-HT) drugs: effects on appetite expression and use for the treatment of obesity. Curr.Drug Targets 6 201. PMID:15777190."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=230205	SQ1070			Nov-2009
3586	Sumatriptan succinate	[103628-48-4]	O=S(CC1=CC=C(NC=C2CCN(C)C)C2=C1)(NC)=O.O=C(CCC(O)=O)O	5-HT1A/1B/1D receptor agonist	"5-HT1 receptor agonist (Ki values are 17, 27 and 100 nM at 5-HT1D, 5-HT1B and 5-HT1A receptors respectively). Antimigraine agent."	Peroutka and McCarthy (1989) Sumatriptan (GR 43175) interacts selectivity with 5-HT1B and 5-HT1D binding sites. Eur.J.Pharmacol. 163 133. PMID:2545459. Peroutka (1990) Sumatriptan in acute migraine: pharmacology and review of world experience. Headache 30 554. PMID:2177047. Ottani et al (2004) Effect of sumatriptan in different models of pain in rats. Eur.J.Pharmacol. 497 181. PMID:15306203.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=230206	SQ1533			Jul-2009
3587	A 922500	[959122-11-3]	O=[C@]([C@@H]3CCC[C@H]3[C@@](O)=O)C(C=C2)=CC=C2C1=CC=C(NC(NC4=CC=CC=C4)=O)C=C1	Diacylglycerol acyltransferase 1 (DGAT-1) inhibitor	"Diacylglycerol acyltransferase 1 (DGAT-1) inhibitor (IC50 values are 7 and 24 nM at human and mouse DGAT-1 respectively) that is devoid of activity at DGAT-2, ACAT1 or ACAT2. Induces significant weight loss without altering food intake, and decreases liver and plasma triglyceride levels in vivo. Orally active."	Zhao et al (2008) Validation of diacyl glycerolacyltransferase I as a novel target of obesity and dyslipidemia using a potent and selective small molecule inhibitor. J.Med.Chem. 51 380. PMID:18183944. King et al (2009) Diacylglycerol acyltransferase 1 inhibition lowers serum triglycerides in the zucker fatty rat and the hyperlipidemic hamster. J.Pharmacol.Exp.Ther. 330 526. PMID:19478132. King et al (2010) In vivo efficacy of acyl CoA: diacylglycerol acyltransferase (DGAT) 1 inhibition in rodent models of postprandial hyperlipidemia. Eur.J.Pharmacol. 637 155. PMID:20385122.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=230326	SQ1533			Jul-2009
3588	Estropipate	[7280-37-7]	O=C4CC[C@@]3([H])[C@]2([H])CCC1=CC(OS(=O)(O)=O)=CC=C1[C@]([H])2CC[C@@]34C.C5NCCNC5	Estrogen receptor agonist and OATP1B1 inhibitor	Estrogen receptor agonist. Also inhibits organic anion transporting polypeptide 1B1 (OATP1B1) (IC50= 70 nM).	Williams et al (2004) Estrogen regulation of the cytochrome P450 3A subfamily in humans. J.Pharmacol.Exp.Ther. 311 728. PMID:15282264. Obaidat et al (2009) A cell-based high-throughput assay to identify inhibitors of organic anion transporting polypeptides 1B1 and 1B3. FASEB J. 23 748.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=230538	SQ1070			Sep-2009
3589	PIM-1 Inhibitor 2	[477845-12-8]	NC1=NC=CC(C3=CC2=C(C4=CC=C(Cl)C=C4)ON=C2C=C3)=N1	Pim-1 kinase inhibitor	Potent Pim-1 kinase inhibitor (Ki = 91 nM).	Pierce et al (2008) Docking study yields four novel inhibitors of the protooncogene Pim-1 kinase. J.Med.Chem. 51 1972. PMID:18290603.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=230541	SQ1533			Jul-2009
3590	Gambogic acid	[2752-65-0]	C/C(C)=C/CC[C@@](C=C2)(C)OC1=C2C(O)=C(C(C([C@]45O3)=C[C@H](C[C@@H]56)C([C@](OC(C)6C)4C/C=C(C(O)=O)/C)=O)=O)C3=C1C/C=C(C)/C	Apoptosis inducer. Activates caspases and inhibits Bcl-2 family proteins	"Natural product isolated from the Garcinia hanburyi tree. Induces apoptosis in several tumor cell lines including T47D cells. Activates caspases with an EC50 value of 0.78 - 1.64 _M and competitively inhibits antiapoptotic Bcl-2 family proteins (IC50 values are 1.47, 1.21, 2.02, 0.66, 1.06 and 0.79 _M for Bcl-XL, Bcl-2, Bcl-W, Bcl-B, Bfl-1 and Mcl-1 respectively). Also blocks Kir2.1 channels (EC50  100 nM)."	"Zhang et al (2004) Discovery, characterization and SAR of gambogic acid as a potent apoptosis inducer by a HTS assay. Bioorg.Med.Chem. 12 309. PMID:14723951. Zhai et al (2008) Gambogic acid is an antagonist of antiapoptotic Bcl-2 family proteins. Mol.Cancer Ther. 7 1639. PMID:18566235. Qi et al (2008) Anti-invasive effect of gambogic acid in MDA-MB-231 human breast carcinoma cells. Biochem.Cell Biol. 86 386. PMID:18923540. Zaks-Makhina et al (2009) Specific and slow inhibition of the Kir2.1 K+ channel by Gambogic acid. J.Biol.Chem. 284 15432. PMID:19366693."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=230542	SQ1070			Nov-2009
3591	VO-OHpic	[675848-25-6]	[O-][V]=O.OC(=O)C1=C(O)C=CC=N1.OC(=O)C1=C(O)C=CC=N1	Potent PTEN inhibitor	"Potent inhibitor of PTEN (phosphatase and tensin homolog) (IC50 = 35 nM). Displays selectivity for PTEN over cysteine-based phosphatases such as SopB, MTM, PTP_ and SAC (IC50 values are 588 nM, 4.03, 57.5 and >10 _M respectively). Increases PIP2 and PIP3 levels; also increases Akt translocation in NIH/3T3 fibroblasts."	Rosivatz et al (2006) A small-molecule inhibitor for phosphatase and tensin homologue deleted on chromosome 10 (PTEN). ACS Chem.Biol. 1 780. PMID:17240976.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=230563				Sep-2014
3595	CHR 2797	[238750-77-1]	O=C([C@H]([C@]2=CC=CC=C2)NC([C@@H]([C@@H](C(NO)=O)O)CC(C)C)=O)OC1CCCC1	Aminopeptidase inhibitor	"Aminopeptidase inhibitor (IC50 values are 100, 150, 220, > 1000, > 5000, > 10000 and > 30000 nM for LAP, PuSA, aminopeptidase N, aminopeptidase B, PILSAP, LTA4 hydrolase and MetAP2 respectively). Potently inhibits tumor cell proliferation in a variety of tumor cell lines in vitro and in vivo."	Krige et al (2008) CHR-2797: an anitproliferative aminopeptidase inhibitor that leads to amino acid deprivation in human leukemic cells. Cancer Res. 68 6669. PMID:18701491. Moore et al (2009) Aminopeptidase inhibition as a targeted treatment strategy in myeloma. Mol.Cancer Ther. 8 762. PMID:19372548.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=230685	SQ1533			Mar-2010
3596	Voglibose	[83480-29-9]	O[C@@H]1[C@](CO)(O)C[C@H](NC(CO)CO)[C@H](O)[C@H]1O	Orally active _-glucosidase inhibitor	"Orally active _-glucosidase inhibitor (IC50 values are 3.9 and 6.4 nM at sucrase and maltase respectively). Increases glucagon-like peptide 1 (GLP-1) secretion and decreases food consumption in ob/ob mice, and reduces plasma concentrations of glucose, triglycerides and insulin in Wistar fatty rats. Exhibits antidiabetic and antiobesity activity in vivo."	"Matsuo et al (1992) Effect of an intestinal disaccharidase inhibitor (AO-128) on obesity and diabetes. Am.J.Clin.Nutr. 55 314S. PMID:1728846. Matsui et al (2009) _-Glucosidase inhibition assay in an enzyme-immobilized amino-microplate. Anal.Sci. 25 559. PMID:19359799. Moritoh et al (2009) Chronic administration of voglibose, an _-glucosidase inhibitor, increases active glucagon-like peptide-1 levels by increasing its secretion and decreasing dipeptidyl peptidase-4 activity in ob/ob mice. J.Pharmacol.Exp.Ther. 329 669. PMID:19208898."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=230812	SQ1533			Jul-2009
3597	Indiplon	[325715-02-4]	CN(C(C)=O)C1=CC=CC(C3=CC=NC2=C(C(C4=CC=CS4)=O)C=NN23)=C1	Subtype-selective GABAA receptor positive allosteric modulator	"Potent GABAA receptor positive allosteric modulator that acts at the benzodiazepine site (Ki values are 1.2 and 1.7 nM in rat frontal cortex and cerebellum respectively). Displays ~ 10-fold selectivity for _1 subunit-containing receptors (EC50 values are 2.6, 24, 60 and 77 nM for _1_2_2, _2_2_2, _3_3_2 and _5_2_2 receptors respectively). Exhibits sedative, hypnotic, anxiolytic and anticonvulsant activity in vivo and is orally active."	"Sullivan et al (2004) Characterization of the interaction of indiplon, a novel pyrazolopyrimidine sedative-hypnotic, with the GABAA receptor. J.Pharmacol.Exp.Ther. 311 537. PMID:15256540. Foster et al (2004) In vivo pharmacological characterization of indiplon, a novel pyrazolopyrimidine sedative-hypnotic. J.Pharmacol.Exp.Ther. 311 547. PMID:15256538. Petroski et al (2006) Indiplon is a high-affinity positive allosteric modulator with selectivity for _1 subunit-containing GABAA receptors. J.Pharmacol.Exp.Ther. 317 369. PMID:16399882."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=230813	SQ1533			Jul-2009
3599	TAK 165	[366017-09-6]	FC(C(C=C2)=CC=C2/C=C/C1=NC(COC3=CC=C(CCCCN4C=CN=N4)C=C3)=CO1)(F)F	Potent and selective ErbB2 inhibitor	"Potent, irreversible human epithelial growth factor receptor 2 (ErbB2) inhibitor (IC50 = 6 nM) that displays > 4000-fold selectivity over EGFR, FGFR, PDGFR, JAK1 and Src. Exhibits potent antiproliferative effects in ErbB2-overexpressing cancer cell lines (IC50 = 5 nM in BT474 breast cancer cells) and significantly inhibits bladder, breast and prostate cancer xenograft growth in vivo."	"Sridhar et al (2003) Inhibitors of epidermal-growth-factor receptors: a review of clinical research with a focus on non-small-cell lung cancer. Lancet Oncol. 4 397. PMID:12850190. Nagasawa et al (2006) Novel HER2 selective tyrosine kinase inhibitor, TAK-165, inhibits bladder, kidney and androgen-independent prostate cancer in vitro and in vivo. Int.J.Urol. 13 585. Spector et al (2007) Small molecule HER-2 tyrosine kinase inhibitors. Breast Cancer Res. 9 205."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=230861	SQ1533			Jul-2009
3600	FIPI	[939055-18-2]	O=C(N2)N(C3CCN(CCNC(C4=CC5=C(C=CC(F)=C5)N4)=O)CC3)C1=C2C=CC=C1.Cl	Phospholipase D inhibitor	Potent phosholipase D (PLD) inhibitor (IC50 values are 20 and 25 nM for PLD2 and PLD1 respectively). Ameliorates PLD2-driven suppression of membrane ruffling and cell spreading. Orally available.	"Monovich et al (2007) Optimization of halopemide for phospholipase D2 inhibition. Bioorg.Med.Chem.Lett. 17 2310. PMID:17317170. Su et al (2009) 5-fluoro-2-indolyl des-chlorohalopemide (FIPI), a phospholipase D pharmacological inhibitor that alters cell spreading and inhibits chemotaxis. Mol.Pharmcol. 75 43."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=230862	SQ1070			Sep-2011
3601	CYM 5442 hydrochloride	[1094042-01-9]	OCCNC3CCC(C3=CC=C4)=C4C1=NOC(C2=CC(OCC)=C(OCC)C=C2)=N1.Cl	Selective S1P1 receptor agonist	Potent and selective S1P1 agonist in vitro (EC50 = 1.35 nM). Activates S1P1-mediated p42/p44 MAPK phosphorylation in CHO-K1 cells transfected with S1P1. Induces acute lymphopenia in mice. Brain penetrant.	Gonzalez-Cabrera et al (2008) Full pharmacological efficacy of a novel S1P1 agonist that does not require S1P-like headgroup interactions Mol.Pharmacol. 74 1308. PMID:18708635.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=230941	SQ1070			May-2010
3603	Kaempferol	[520-18-3]	O=C2C1=C(O)C=C(O)C=C1OC(C3=CC=C(O)C=C3)=C2O	Proapoptotic; downregulates PLK1 expression and activates mitochondrial Ca2+ uniporter	Naturally occurring flavonoid found in Gingko biloba and red wines that activates the mitochondrial Ca2+ uniporter (EC50 = 7 _M). Induces caspase-9-mediated apoptosis in a variety of cancer cell lines via downregulation of polo-like kinase 1 (PLK1) expression. Exhibits antioxidant activity and attenuates osteoclastic bone reabsorption in vitro. Also blocks EGF-induced histone H3Ser10 phosphorylation in mouse epidermal JB6 C141 cells.	Montero et al (2004) Direct activation of the mitochondrial calcium uniporter by natural plant flavonoids. Biochem.J. 384 19. PMID:15324303. Cho et al (2007) Ribosomal S6 kinase 2 is a key regulator in tumor promoter induced cell transformation. Cancer Res. 67 8104. PMID:17804722. Suh et al (2009) Kaempferol attenuates 2-deoxy-D-ribose-induced oxidative cell damage in MC3T3-E1 osteoblastic cells. Biol.Pharm.Bull. 32 746. PMID:19336918. Kang et al (2009) Downregulation of PLK-1 expression in kaempferol-induced apoptosis of MCF-7 cells. Eur.J.Pharmacol. 611 17. PMID:19356725. Vay et al (2009) Modulation of Ca2+ release and Ca2+ oscillations in HeLa cells and fibroblasts by mitochondrial Ca2+ uniporter stimulation. J.Physiol. 580 39.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=231432	SQ1533			Jun-2009
3605	(R)-CR8	[294646-77-8]	CC(C)N2C1=NC(N[C@H](CC)CO)=NC(NCC3=CC=C(C4=NC=CC=C4)C=C3)=C1N=C2.Cl.Cl.Cl	Dual cdk1/cdk5 inhibitor. Also inhibits CK1	Inhibitor of cyclin-dependent kinase (cdk) and casein kinase 1 (CK1) (IC50 values are 0.13 _M for cdk1/cyclin B and cdk5/p25; and 0.6 _M for CK1).	"Oumata et al (2008) Roscovitine-derived, dual-specificity inhibitors of cyclin-dependent kinases and casein kinases 1. J.Med.Chem. 51 5229. PMID:18698753."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=231659	SQ1070			Sep-2010
3606	BAG 956	[853910-02-8]	CC3=NC1=C(N3C4=CC=C(C(C)(C#N)C)C=C4)C2=C(C=CC(C#CC5=CN=CC=C5)=C2)N=C1	Dual PI 3-kinase and PDK1 inhibitor	"Dual PDK1 and class I PI 3-K inhibitor (IC50 values are 245, 56, 446, 35 and 117 nM for PDK1 and PI 3-K p110 -_, -_, -_, and -_ respectively). Inhibits cellular AKT phosphorylation at Thr308. Blocks cell proliferation, causing arrest in G1 phase of the cell cycle. Slows tumor progression in mouse xenograft models."	"Stauffer et al (2008) Imidazo[4,5-c]quinolines as inhibitors of the PI3K/PKB-pathway. Bioorg.Med.Chem.Lett. 18 1027. PMID:18248814. Weisberg et al (2008) Potentiation of antileukemic therapies by the dual PI3K/PDK-1 inhibitor, BAG956: effects on BCR-ABL- and mutant FLT3-expressing cells. Blood 111 3723. PMID:18184863. Marone et al (2009) Targeting melanoma with dual phosphoinositide 3-kinase/mammalian target of rapamycin inhibitors. Mol.Cancer Res. 7 601. PMID:19372588."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=231662	SQ1533			Mar-2010
3607	SU 3327	[40045-50-9]	NC2=NN=C(S2)SC1=NC=C([N+]([O-])=O)S1	Selective JNK inhibitor	Selective inhibitor of c-Jun N-terminal kinase (JNK) (IC50 = 0.7 _M). Inhibits the protein-protein interaction between JNK and JIP (IC50 = 239 nM). Displays selectivity over p38 MAPK and Akt. Restores insulin sensitivity in a mouse model of type-2 diabetes.	"De et al (2009) Design, synthesis and structure-activity relationship of substrate competitive, selective, and in vivo active triazole and thiadiazole inhibitors of the c-jun N-terminal kinase. J.Med.Chem. 52 1943. PMID:19271755."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=231683				Jan-2010
3609	Tizanidine hydrochloride	[64461-82-1]	ClC2=C(NC3=NCCN3)C1=NSN=C1C=C2.Cl	_2 agonist	_2-adrenergic receptor agonist. Antinociceptive upon epidural administration in rats (IC50 = 48 nM). Also binds to imidazoline receptor.	Asano et al (2000) Antinociception by epidural and systemic _2-adrenoceptor agonists and their binding affinity in rat spinal cord and brain. Anesth.Analg. 90 400. PMID:10648329. Piletz et al (2000) Autoradiographic comparison of [3H]-Clonidine binding to non-adrenergic sites and _2-adrenergic receptors in human brain. Neuropsychopharmacology 23 697. PMID:11063925.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=232039	SQ1533			Sep-2009
3610	(R)-DRF053 dihydrochloride	[1241675-76-2]	CC(C)N2C1=NC(N[C@H](CC)CO)=NC(NC3=CC(C4=NC=CC=C4)=CC=C3)=C1N=C2.Cl.Cl	Dual CK1/cdk inhibitor	"Potent, ATP-competitive inhibitor of cyclin-dependent kinase (cdk) and casein kinase 1 (CK1) (IC50 values are 220, 80 and 14 nM for cdk1/cyclin B, cdk5/p25 and CK1 respectively). Selective over GSK-3 __ (IC50= 4.1 _M). Also shown to inhibit amyloid-_ production in N2A-APP695 cells."	"Oumata et al (2008) Roscovitine-derived, dual-specificity inhibitors of cyclin-dependent kinases and casein kinases 1. J.Med.Chem. 51 522."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=232061	SQ1070			Feb-2010
3616	Rotenone	[83-79-4]	C=[C@](C)[C@@H](C5)OC4=C5C(O3)=C(C=C4)C([C@@]([C@@]3([H])CO2)([H])C1=C2C=C(OC)C(OC)=C1)=O	Inhibits complex I of the mitochondrial electron transport chain	Mitochondrial electron transport chain inhibitor (IC50 = 1.7 - 2.2 _M at complex I). Inhibits NADH oxidation by cardiac sarcoplasmic reticulum (IC50 = 3.4 nM). Commonly used pesticide and induces Parkinsonism in animal models. May also inhibit autophagy induction; blocks lysosomal degradation of autophagic vacuoles. Cell-permeable and brain penetrant.	"Cherednichenko et al (2004) NADH oxidase activity of rat cardiac sarcoplasmic reticulum regulates calcium-induced calcium release. Circ.Res. 94 478. PMID:14699012. Uversky (2004) Neurotoxicant-induced animal models of Parkinson's disease: understanding the role of rotenone, maneb and paraquat in neurodegeneration. Cell Tissue Res. 318 225. PMID:15258850. Gomez et al (2007) Pesticides and impairment of mitochondrial function in relation with the parkinsonian syndrome. Front.Biosci. 12 1079. PMID:17127363. Mader et al (2012) Rotenone inhibits autophagic flux prior to inducing cell death. ACS Chem.Neurosci. 3 1063. PMID:23259041."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=232134	SQ1533			Aug-2009
3617	SANT-2	[329196-48-7]	ClC1=CC=C(NC(C4=CC(OCC)=C(OCC)C(OCC)=C4)=O)C=C1C3=NC2=CC=CC=C2N3	Inhibitor of Hedgehog (Hh) signaling; antagonizes smoothened activity	Inhibitor of Sonic hedgehog (Shh) signaling; antagonizes smoothened receptor activity (KD = 12 nM). Displays allosteric binding characteristics similar to SANT-1 (Cat. No. 1974). Displaces smo-[3H]SAG-1.3 and -[3H]Cyclopamine binding (Ki values are 7.8 nM and 8.4 nM respectively).	Chen et al (2002) Small molecule modulation of smoothened activity. Proc.Natl.Acad.Sci. 99 14071. Rominger et al (2009) Evidence for allosteric interactions of antagonist binding to the smoothened receptor. J.Pharmacol.Exp.Ther. 329 995. PMID:19304771.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=232162	SQ1533			May-2010
3618	Acamprosate calcium	[77337-73-6]	CC(=O)NCCCS(=O)(=O)[O-].CC(=O)NCCCS(=O)(=O)[O-].[Ca+2]	GABA agonist and glutamatergic modulator	GABA receptor agonist and modulator of glutamatergic systems. Reduces alcohol consumption in animal models of alcohol addiction.	Spanagel et al (1996) Acamprosate and alcohol: I. Effects on alcohol intake following alcohol deprivation in the rat. Eur.J.Pharmacol. 305 39. PMID:8813529. Berton et al (1998) Acamprosate enhances N-methyl-D-aspartate receptor-mediated neurotransmission but inhibits presynaptic GABA(B) receptors in nucleus accumbens neurons. Alcohol Clin.Exp.Res. 22 183. PMID:9514305. Popp and Lovinger (2000) Interaction of acamprosate with ethanol and spermine on NMDA receptors in primary cultured neurons. Eur.J.Pharmacol. 394 221. PMID:10771287.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=232274				Mar-2010
3619	Tramiprosate	[3687-18-1]	NCCCS(=O)(O)=O	Targets soluble A_ to decrease amyloid plaque deposition. Also GABA analog	"Sulfated glycosaminoglycan (sGAG) mimetic that targets soluble amyloid _ (A_) and maintains A_ in a non-fibrillar form. Decreases A_42-induced neuronal death and inhibits amyloid deposition in vitro. Decreases brain amyloid plaque load by 30%, increases tau polymerization and is brain penetrant. Also a GABA analog that protects against the convulsant and cytotoxic activity of kainic acid in vivo."	"Fariello et al (1982) Homotaurine (3 aminopropanesulfonic acid; 3APS) protects from the convulsant and cytotoxic effect of systemically administered kainic acid. Neurology 32 241. PMID:7199633. Gervais et al (2007) Targeting soluble A_ peptide with tramiprosate for the treatment of brain amyloidosis. Neurobiol.Aging 28 537. PMID:16675063. Santa-Maria et al (2007) Tramiprosate, a drug of potential interest for the treatment of Alzheimer's disease, promotes an abnormal aggregation of tau. Mol.Neurodegen. 2 17."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=232275				Jul-2009
3620	Topiramate	[97240-79-4]	CC(O2)(C)O[C@H]1[C@@H]2[C@H](OC(C)(C)O3)[C@@]3(COS(N)(=O)=O)OC1	GluR5 antagonist; inhibits carbonic anhydrase (CA) II and IV	"Anticonvulsant. Antagonizes GluR5 kainate receptors (IC50 = 0.46 _M), acts as a positive allosteric modulator of GABAA receptor-mediated currents, inhibits Nav channels (IC50 = 48.9 _M) and inhibits L-type Ca2+ channels. Also inhibits carbonic anhydrase (CA) (Ki values are 0.1 and 0.2 _M at rat CA II and CA IV respectively), which lowers intracellular neuronal pH."	"Zona et al (1997) Topiramate attenuates voltage-gated sodium currents in rat cerebellar granule cells. Neurosci.Lett. 231 123. PMID:9300637. Dodgson et al (2000) Topiramate as an inhibitor of carbonic anhydrase isoenzymes. Epilepsia 41 S35. PMID:10768298. Gryder and Rogawski (2003) Selective antagonism of GluR5 kainate-receptor-mediated synaptic currents by topiramate in rat basolateral amygdala neurons. J.Neurosci. 23 7069. PMID:12904467. Kaminiski et al (2004) Topiramate selectively protects against seizures induced by ATPA, a GluR5 kainate receptor agonist. Neuropharmacology 46 1097. PMID:15111016."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=232342	SQ1070			Jul-2009
3621	UBP 310	[902464-46-4]	CC1=CN(C[C@@H](C(O)=O)N)C(N(CC2=C(C(O)=O)SC=C2)C1=O)=O	GLUK5 antagonist	"GLUK5 kainate receptor antagonist (IC50 = 130 nM); also blocks recombinant homomeric GLUK7 receptors. Displays 12,700-fold selectivity for GLUK5 over GLUK6. Exhibits no activity at mGlu group I or NMDA receptors at concentrations of up to 10 _M. Apparent KD value is 18  4 nM for depression of kainate responses on the dorsal root."	Mayer et al (2006) Crystal structures of the kainate receptor GluR5 ligand binding core dimer with novel GluR5-selective antagonists. J.Neurosci. 26 2852. PMID:16540562. Dolman et al (2007) Synthesis and pharmacological characterization of N3-substituted willardiine derivatives: Role of the substituent at the 5-position of the uracil ring in development of highly potent and selective GLUK5 kainate receptor antagonists. J.Med.Chem. 50 1558. PMID:17348638. Perrais et al (2009) Antagonism of recombinant and native GluK3-containing kainate receptors. Neuropharmacology 56 131. PMID:18761361.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=232365	SQ1070			Nov-2010
3622	IPA 3	[42521-82-4]	OC2=C(SSC3=C(O)C=CC4=C3C=CC=C4)C1=CC=CC=C1C=C2	Group I p21-activated kinase (PAK) inhibitor	Group I p21-activated kinase (PAK) inhibitor (IC50 = 2.5 _M at PAK1). Targets the autoregulatory mechanism and promotes the inactive conformation of PAKs. Inhibits PAK1-mediated signaling in vivo; potential anti-tumor agent. Negative control PIR 3.5 (Cat. No. 4212) available.	"Kumar et al (2006) p21-activated kinases in cancer. Nat.Rev.Cancer 6 459. PMID:16723992. Deacon et al (2008) An isoform-selective, small-molecule inhibitor targets the autoregulatory mechanism of p21-activated kinase. Chem.Biol. 15 322. PMID:18420139. Takahashi and Suzuki (2009) Membrane transport of WAVE2 and lamellipodia formation require Pak1 that mediates phosphorylation and recruitment of stathmin/op18 to Pak1-WAVE2-kinesin complex. Cell.Signal. 21 695. PMID:19162178. Viaud and Peterson (2009) An allosteric kinase inhibitor binds the p21-activated kinase (Pak) autoregulatory domain covalently. Mol.Cancer Ther. 8 2559. PMID:19723886."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=232389	SQ1533			Aug-2009
3624	Adenosine	[58-61-7]	O[C@@H]1[C@@H](CO)O[C@@H](N3C2=NC=NC(N)=C2N=C3)[C@@H]1O	Endogenous adenosine receptor agonist	Neurotransmitter that acts as the preferred endogenous agonist at all adenosine receptor subtypes.	Jacobson and Gao (2006) Adenosine receptors as therapeutic targets. Nat.Rev.Drug Discov. 5 247. PMID:16518376.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=223887	SQ1533			Jul-2009
3625	SID 26681509	[958772-66-2]	O=C(NNC(SCC(NC1=C(CC)C=CC=C1)=O)=O)[C@H](CC2=CNC3=C2C=CC=C3)NC(OC(C)(C)C)=O	Cathepsin L inhibitor	Potent and reversible human cathepsin L inhibitor (IC50 = 56 nM). Displays no inhibitory activity at cathepsin G. Antimalarial; inhibits leishmaniasis.	"Shah et al (2008) Kinetic characterization and molecular docking of a novel, potent and selective slow-binding inhibitor of human cathepsin L. Mol.Pharmacol. 74 34. PMID:18403718. Myers et al (2008) Identification and synthesis of a unique thiocarbazate cathepsin L inhibitor. Bioorg.Med.Chem.Lett. 18 210. PMID:18060772."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=232470	SQ1070			Apr-2011
3626	NPS 2143 hydrochloride	[324523-20-8]	CC(NC[C@@H](O)COC3=C(C#N)C(Cl)=CC=C3)(C)CC2=CC1=CC=CC=C1C=C2.Cl	Selective antagonist of the calcium-sensing receptor; orally active calcilytic agent	Selective Ca2+-sensing receptor antagonist. Blocks increases in cytoplasmic Ca2+ concentrations elicited by human Ca2+ receptors expressed in HEK293 cells (IC50 = 43 nM). Also stimulates parathyroid hormone secretion from bovine parathyroid cells (EC50 = 41 nM). Orally active calcilytic compound.	Nemeth et al (2001) Calcilytic compounds: potent and selective Ca2+ receptor antagonists that stimulate secretion of parathyroid hormone. J.Pharmacol.Exp.Ther. 299 323. PMID:11561095. Nemeth (2002) The search for calcium receptor antagonists (calcilytics). J.Mol.Endocrinol. 29 15. PMID:12200226. Huang and Breitwieser (2007) Rescue of calcium-sensing receptor mutants by allosteric modulators reveals a conformational checkpoint in receptor biogenesis. J.Biol.Chem. 282 9517. PMID:17284438.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=232703	SQ1533			Jan-2011
3627	LY 311727	[164083-84-5]	NC(CC2=C(CC)N(CC3=CC=CC=C3)C1=CC=C(OCCCP(O)(O)=O)C=C12)=O	Selective secreted phospholipase A2 (sPLA2) inhibitor	Selective secreted phospholipase A2 (sPLA2) inhibitor (IC50 values are <1 _M for group IIA and <50 _M for group V). Attenuates VEGF-mediated platelet-activating factor (PAF) synthesis in BAEC and HUVEC cells at a concentration of 100 _M.	Schevitz et al (1995) Structure-based design of the first potent and selective inhibitor of human non-pancreatic secretory phospholipase A2. Nat.Struct.Biol. 2 429. PMID:7664101. Bridonneau et al (1997) High-affinity aptamers selectively inhibit human nonpancreatic secretory phospholipase A2 (hnps-PLA2). J.Med.Chem 41 778. Bernatchez et al (2001) VEGF stimulation of endothelial cell PAF synthesis is mediated by group V 14 kDa secretory phospholipase A2. Br.J.Pharmacol. 134 197. PMID:11522612.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=232704	SQ1070			Jul-2010
3631	FK 506	[104987-11-3]	O[C@H]1[C@H](OC)C[C@H](/C=C(C)/[C@@H](O4)[C@H](C)[C@@H](O)CC([C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@@]2([H])O[C@](C(C(N3[C@@](C4=O)([H])CCCC3)=O)=O)(O)[C@H](C)C[C@@H]2OC)=O)CC1	Potent calcineurin inhibitor; immunosuppressant	"Potent calcineurin (protein phosphatase 2B) inhibitor that requires FK 506-binding protein 12 (FKBP12) for activity (IC50 = 3 nM). Inhibits secretion of IL-1, IL-2 (IC50 = 1 nM), IL-3, IL-4, IL-6 (IC50 = 35 nM), GM-CSF, TNF_ (IC50 = 10 nM), IFN_ and Myc from activated T cells in vitro. Exhibits potent immunosuppressive, neuroprotective and anticonvulsant activity in vivo. Analog (ascomycin, Cat. No. 4210) also available."	"Fruman et al (1995) The complex of FK506-binding protein 12 and FK506 inhibits calcineurin phosphatase activity and IgE activation-induced cytokine transcripts, but not exocytosis, in mouse mast cells. J.Immunol. 154 1846. PMID:7530743. Baughman et al (1997) Tissue distribution and abundance of human FKBP51, and FK506-binding protein that can mediate calcineurin inhibition. Biochem.Biophys.Res.Commun. 232 437. PMID:9125197. Sierra-Paredes and Sierra-Marcuno (2008) Ascomycin and FK506: Pharmacology and therapeutic potential as anticonvulsants and neuroprotectants. CNS Neurosci.Ther. 14 36. PMID:18482098."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=233411	SQ1533			Aug-2009
3634	VU 0238429	[1160247-92-6]	O=C(C1=CC(OC(F)(F)F)=CC=C1N2CC3=CC=C(OC)C=C3)C2=O	Selective positive allosteric modulator of M5 receptors	"Selective positive allosteric modulator of M5 receptors (EC50 values are 1.16, >30 and >30 _M at M5, M1 and M3 receptors respectively). Displays no activity at M2 and M4 receptors."	"Bridges et al (2009) Discovery of the first highly M5-preferring muscarinic acetylcholine receptor ligand, an M5 positive allosteric modulator derived from a series of 5-trifluoromethoxy N-benzyl isatins. J.Med.Chem. 52 3445. PMID:19438238."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=234001	SQ1070			Nov-2009
3635	BPIPP	[325746-94-9]	O=C(C5=C4C=CC=C5)C2=C4NC(N1C)=C(C2C3=CC(Br)=CC=C3)C(N(C)C1=O)=O	Non-competitive GC inhibitor. Also AC inhibitor	"Non-competitive guanylyl cyclase (GC) and adenylyl cyclase (AC) inhibitor. Downregulates cAMP and cGMP synthesis, and suppresses cGMP accumulation in a variety of cell lines (IC50 = 3.4 - 11.2 _M). Inhibits GC-stimulated Cl- transport in vitro and suppresses toxin-induced intestinal fluid accumulation in vivo."	Kots et al (2008) Pyridopyrimidine derivatives as inhibitors of cyclic nucleotide synthesis: application for treatment of diarrhea. Proc.Natl.Acad.Sci.USA 105 8440.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=234346	SQ1070			Sep-2009
3636	Meptazinol hydrochloride	[59263-76-2]	OC1=CC=CC(C2(CC)CN(C)CCCC2)=C1.Cl	_1 partial agonist	Centrally active opioid analgesic. Partial agonist at the _1 opioid receptor. Also shown to inhibit acetylcholinesterase.	Spiegel and Pasternak (1984) Meptazinol: a novel Mu-1 selective opioid analgesic. J.Pharmacol.Exp.Ther. 228 414. PMID:6141283. Galli et al (1996) Reversible inhibition of cholinesterases by opioids: possible pharmacological consequences. J.Pharm.Pharmacol. 48 116.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=235404	SQ1533			Sep-2009
3639	SX 011	[309913-42-6]	O=C(C(N(C)C)=O)C2=CN(C)C1=CC(Cl)=C(C(N3CCC(CC4=CC=C(F)C=C4)CC3)=O)C=C12	p38 MAPK inhibitor	"Potent p38_ inhibitor (IC50 = 9 nM). Also inhibits p38_ and JNK-2 (IC50 values are 90 nM and 100 nM respectively). Displays no significant activity at p38_, p38_, ERK-2 and JNK-1."	Lee and Dominguez (2005) MAP kinase p38 inhibitors: clinical results and an intimate look at their interactions with p38_ protein. Curr.Med.Chem. 12 2979. PMID:16378500.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=235472	SQ1070			Aug-2010
3640	A 987306	[1082954-71-9]	NC3=NC1=C(C(N4CCNCC4)=N3)CCC2=C1[C@@](CCCC5)([H])[C@@]5([H])O2	Potent and selective H4 receptor antagonist	"Potent histamine H4 receptor antagonist (pKi values are 8.24 and 8.47 in human and rat H4 receptors respectively). Displays 162-fold, 620-fold, and > 1600-fold selectivity over human H3, H1 and H2 receptors. Blocks zymosan-induced neutrophil reflux and attenuates thermal hypersensitivity in vivo (ED50 = 42 _mol/kg, ip)."	"Liu et al (2008) cis-4-(Piperazin-1-yl)-5,6,7a,8,9,10,11,11a-octahydrobenzofuro[2,3-h]quinazolin-2-amine (A-987306), a new histamine H4R antagonist that blocks pain responses against carrageenan-induced hyperalgesia. J.Med.Chem. 51 7094. PMID:18983139. Leurs et al (2009) Molecular and biochemical pharmacology of the histamine H4 receptor. Br.J.Pharmacol. 157 14. PMID:19413568."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=235642	SQ1070			Apr-2010
3642	Src I1	[179248-59-0]	COC(C(OC)=C3)=CC1=C3N=CN=C1NC2=CC=C(OC4=CC=CC=C4)C=C2	Dual site Src kinase inhibitor	"Potent, competitive dual site (ATP- and peptide-binding) Src kinase inhibitor (IC50 values are 44 and 88 nM for Src and Lck respectively). Inhibits VEGFR2 and c-fms at higher concentrations (IC50 values are 0.32 and 30 _M respectively). Can be used in parallel with PP 1 (Cat. No. 1397) and PP 2 (Cat. No. 1407) to inhibit Src family kinases."	"Tian et al (2001) Structural determinants for potent, selective dual site inhibition of human pp60c-src by 4-anilinoquinazolines. Biochem. 40 7084. Bain et al (2007) The selectivity of protein kinase inhibitors: a further update. Biochem.J. 408 297. PMID:17850214."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=235650	SQ1070			Oct-2009
3643	FR 171113	[173904-50-2]	O=C(/N=C(N(C3=CC=C(Cl)C=C3)C2=O)\S/C2=C/C(OC)=O)C1=CC=C(Cl)C=C1Cl	PAR1 antagonist	Protease-activated receptor 1 (PAR1) antagonist. Exhibits potent antiplatelet activity in vitro; inhibits thrombin TRAP-6-induced platelet aggregation (IC50 = 2.5 _M) with no effect on coagulation time.	"Kato et al (1999) In vitro antiplatelet profile of FR171113, a novel non-peptide thrombin receptor antagonist. Eur.J.Pharmacol. 384 197. PMID:10611442. Kato et al (2003) Inhibition of arterial thrombosis by a protease-activated receptor 1 antagonist, FR171113, in the guinea pig. Eur.J.Pharmacol. 473 163. PMID:12892834."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=235806				Nov-2010
3645	NXY 059	[168021-79-2]	[Na+].[Na+].CC(C)(C)[N+](\[O-])=C\C1=C(C=C(C=C1)S([O-])(=O)=O)S([O-])(=O)=O	Free radical trapping agent; neuroprotectant	Free radical trapping agent. Reduces infarct size and preserves brain function in several animal models of acute ischemic stroke. Neuroprotectant.	"Peeling et al (2001) Efficacy of disodium 4-[(tert-butylimino)methyl]benzene-1,3-disulfonate N-oxide (NXY-059), a free radical trapping agent, in a rat model of hemorrhagic stroke. Neuropharmacology 40 433. PMID:11166336. Sydserff et al (2002) Effect of NXY-059 on infarct volume after transient or permanent middle cerebral artery occlusion in the rat; studies on dose, plasma concentration and therapeutic time window. Br.J.Pharmacol. 135 103. PMID:11786485. Culot et al (2009) Cerebrovascular protection as a possible mechanism for the protective effects of NXY-059 in preclinical models: an in vitro study. Brain Res. 1294 144. PMID:19631615."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=235838				Oct-2009
3650	SB 328437	[247580-43-4]	O=C(C2=CC=CC3=C2C=CC=C3)N[C@H](C(OC)=O)CC1=CC=C([N+]([O-])=O)C=C1	Potent and selective CCR3 antagonist	"Potent and selective CCR3 antagonist (IC50 = 4 nM). Displays > 2500-fold selectivity over C5aR, LTD4, CCR7, CXCR1 and CXCR2 receptors. Inhibits eotaxin-, eotaxin-2- and MCP-4-induced Ca2+ mobilization (IC50 values are 38, 35 and 20 nM respectively) and inhibits eotaxin-, eotaxin-2- and MCP-4-induced eosinophil chemotaxis with similar potencies."	"White et al (2000) Identification of potent, selective non-peptide CC chemokine receptor-3 antagonist that inhibits eotaxin-, eotaxin-2-, and monocyte chemotactic protein-4-induced eosinophil migration. J.Biol.Chem. 275 36626. PMID:10969084. Abonyo et al (2005) Autoregulation of CCL26 synthesis and secretion in A549 cells: a possible mechanism by which alveolar epithelial cells modulate airway inflammation. Am.J.Physiol.Lung Cell.Mole.Physiol. 289 L478. Mori et al (2007) Selective suppression of Th2-mediated airway eosinophil infiltration by low-molecular weight CCR3 antagonists. Int.Immunol. 19 913. PMID:17804691."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=236048	SQ1070			Jan-2010
3652	Pregnanolone	[128-20-1]	C[C@@]12[C@@](CC[C@]3([H])[C@@]([H])2CC[C@@]4(C)[C@]([H])3CC[C@@H]4[C@](C)=O)([H])C[C@H](O)CC1	GABAA receptor positive allosteric modulator	GABAA receptor positive allosteric modulator. Neuroactive steroid.	Harrison et al (1987) Structure-activity relationships for steroid interaction with the _-aminobutyric acidA receptor complex. J.Pharmacol.Exp.Ther. 241 346. PMID:3033209. Morris et al (1999) Differential modulation of the _-aminobutyric acid type C receptor by neuroactive steroids. Mol.Pharmacol. 56 752. PMID:10496958.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=236050	SQ1070			Oct-2009
3653	Allopregnanolone	[516-54-1]	C[C@@]12[C@](CC[C@]3([H])[C@@]([H])2CC[C@@]4(C)[C@]([H])3CC[C@@H]4[C@](C)=O)([H])C[C@H](O)CC1	GABAA receptor positive allosteric modulator	GABAA receptor positive allosteric modulator. Neuroactive steroid.	Puia et al (1990) Neurosteroids act on recombinant human GABAA receptors. Neuron 4 759. PMID:2160838. Belelli and Lambert (2005) Neurosteroids: endogenous regulators of the GABAA receptor. Nat.Rev.Neurosci. 6 565. PMID:15959466. Agis-Balboa et al (2006) Characterization of brain neurons that express enzymes mediating neurosteroid biosynthesis. Proc.Natl.Acad.Sci.USA 103 14602.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=236051	SQ1070			Oct-2009
3656	Neurodazine	[937807-66-4]	ClC1=CC=CC(C(O3)=CC=C3C2=NC(C5=CC=C(OC)C=C5)=C(C4=CC=C(OC)C=C4)N2)=C1	Induces neurogenesis in mature skeletal muscle cells	Induces neurogenesis of non-pluripotent C2C12 myoblasts and cells derived from mature human skeletal muscle. Upregulates the expression of neuron-specific markers in C2C12 cells.	Williams et al (2007) Synthetic small molecules that induce neurogenesis in skeletal muscle. J.Am.Chem.Soc. 129 9258. PMID:17622149.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=236228	SQ1070			Sep-2010
3657	Sal 003	[1164470-53-4]	S=C(NC(NC(/C=C/C2=CC=CC=C2)=O)C(Cl)(Cl)Cl)NC1=CC=C(Cl)C=C1	Cell-permeable inhibitor of eIF2_ dephosphorylation	Cell-permeable inhibitor of cellular phosphatase complexes that dephosphorylate eukaryotic translation initiation factor 2 subunit _ (eIF2_). Analog of salubrinal (Cat. No. 2347) with improved aqueous solubility. Shown to prevent the induction of hippocampal long-term potentiation (LTP) and memory formation (LTM) in mice.	Baltiz et al (2007) The eIF2_ kinases PERK and PKR activate glucogen synthase kinase 3 to promote the proteasomal degradation of p53. J.Biol.Chem. 282 31675. PMID:17785458. Costa-Mattioli et al (2007) eIF2_ phosphorylation bidirectionally regulates the switch from short- to long-term synaptic plasticity and memory. Cell 129 195. PMID:17418795. Raven et al (2008) PKR and PKR-like endoplasmic reticulum kinase induce the protease-dependent degradation of cyclin D1 via a mechanism requiring eukaryotic initiation factor 2_ phosphorylation. J.Biol.Chem. 283 3097. PMID:18063576.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=236229				Mar-2010
3658	GYY 4137 morpholine salt	[106740-09-4]	S=P(N1CCOCC1)(C2=CC=C(OC)C=C2)S.N3CCOCC3	Slow-releasing H2S donor	Slow-releasing H2S donor. Exhibits vasodilator and antihypertensive activity. Activity causes slow dilation of blood vessels in vitro and in vivo; does not influence vascular smooth muscle cell viability in culture. Water-soluble.	"Li et al (2008) Characterization of a novel, water-soluble hydrogen sulfide-releasing molecule (GYY4137). Circulation 117 2351. PMID:18443240. Whiteman et al (2010) The effect of hydrogen sulfide donors on lipopolysaccaride-induced formation of inflammatory mediators in macrophages. Antioxid.Redox.Signal. 12 1147. PMID:19769459. Lee et al (2011) The slow-releasing hydrogen sulfide donor, GYY4137, exhibits novel anti-cancer effects in vitro and in vivo. PLoS One 6 e21077. PMID:21701688. Liu et al (2013) Hydrogen sulfide donor, GYY4137, exhibits anti-atherosclerotic activity in high fat fed apolipoprotein E-/- mice. Br.J.Pharmacol. [Epub ahead of print]. PMID:23713790."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=236230				Jul-2011
3660	BMS 195614	[253310-42-8]	O=C(NC4=CC=C(C(O)=O)C=C4)C3=CC1=C(C=C3)C(C)(C)CC=C1C2=CN=C(C=CC=C5)C5=C2	Selective RAR_ antagonist	Neutral retinoic acid receptor (RAR) _-selective antagonist (Ki = 2.5 nM). Displays no significant effect on nuclear receptor corepressor (NCoR) binding; moderately decreases SMRT binding to RAR. Antagonizes agonist-induced coactivator (CoA) recruitment.	Gehin et al (1999) Structural basis for engineering of retinoic acid receptor isotype-selective agonists and antagonists. Chem.Biol. 6 519. PMID:10421757. Schoenermark et al (1999) Retinoid-mediated suppression of tumor invasion and matrix metalloproteinase synthesis. Ann.N.Y.Acad.Sci. 30 878. Germain et al (2009) Differential action on coregulator interaction defines retinoid agonists and neutral antagonists. Chem.Biol. 16 479. PMID:19477412.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=236276	SQ1070			Aug-2011
3661	BAN ORL 24	[1401463-54-4]	O=[C@@]([C@H]2CCCN2CC3=CC=CC=C3)NCCCN1CCC4(OCC5=C4C=CC=C5)CC1.Cl.Cl	Potent and selective NOP antagonist	"Potent and selective NOP receptor antagonist (IC50 values are 0.27, 2500, 6700 and > 10000 nM for NOP, _-, _- and _-receptors respectively). Inhibits nociceptin-induced stimulation of [35S]-GTP_S binding and Ca2+ mobilization in CHO cells in vitro and antagonizes NOP agonist-induced reduction in locomotor activity in vivo. Brain penetrant."	"Goto et al (2006) Identification of a novel spiropiperidine opioid receptor-like 1 antagonist class by a focused library approach featuring 3D-pharmacophore similarity. J.Med.Chem. 49 847. PMID:16451050. Liao et al (2009) 1-Benzyl-N-[spiroisobenzofuran-1(3H),4'-piperidin-1-yl]propyl]pyrrolidine-2-carboxamide (compound 24) antagonizes NOP receptor-mediated potassium channel activation in rat periaqueductal gray slices. Eur.J.Pharmacol. 606 84. PMID:19374842. Fischetti et al (2009) Pharmacological characterization of the nociceptin/orphanin FQ receptor non peptide antagonist compound 24. Eur.J.Pharmacol. 614 50. PMID:19445927."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=236281				Mar-2010
3663	GSK 4112	[1216744-19-2]	CC(C)(C)OC(CN(CC2=CC=C(Cl)C=C2)CC1=CC=C([N+]([O-])=O)S1)=O	Selective Rev-Erb_ agonist	Selective Rev-Erb_ agonist (EC50 = 250 nM). Enhances recruitment of nuclear receptor co-repressor (NCoR) peptide to Rev-Erb_; causes acute suppression of Bmal1 gene transcription. Induces phase shifts in the circadian clock.	"Meng et al (2008) Ligand modulation of REV-ERB_ function resets the peripheral circadian clock in a phasic manner. J.Cell Science 121 3629. Kojetin et al (2011) Identification of SR8278, a synthetic antagonist of the nuclear heme receptor REV-ERB. ACS Chem.Biol. 6 131. PMID:21043485."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=236305	SQ1533			May-2010
3664	Teijin compound 1	[1313730-14-1]	O=C(CNC(C3=CC=CC(C(F)(F)F)=C3)=O)N[C@@H]1CCN(CC2=CC=C(Cl)C=C2)C1.Cl	Potent CCR2b antagonist	Potent chemokine CCR2b receptor antagonist (IC50 = 180 nM). Potently inhibits cell chemotaxis induced by MCP-1 (EC50 = 24 nM).	Moree et al (2004) Small molecule antagonists of the CCR2b receptor. Part 2: discovery process and initial structure-activity relationships of diamine derivatives. Bioorg.Med.Chem.Letts. 14 5413. Moree et al (2008) Potent antagonists of the CCR2b receptor. Part 3: SAR of the (R)-3-aminopyrrolidine series. Bioorg.Med.Chem.Letts. 18 1869. Hall et al (2009) Elucidation of binding sites of dual antagonists in the human chemokine receptors CCR2 and CCR5. Mol.Pharmacol. 75 1325. PMID:19297521.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=236306	SQ1070			Nov-2009
3665	Donitriptan hydrochloride	[170911-68-9]	NCCC2=CNC1=CC=C(OCC(N3CCN(C4=CC=C(C#N)C=C4)CC3)=O)C=C12.Cl	5-HT1B/1D agonist	Brain penetrant 5-HT1B/1D agonist (pKi values are 9.3 and 9.4 for 5-HT1D and 5-HT1B respectively). Inhibits capsaicin-induced external carotid vasodilation and produces selective carotid vasoconstriction in various animal species. Displays antimigraine activity.	"Letienne et al (2003) Donitriptan selectively decreases jugular venous oxygen saturation in the anesthetized pig: further insights into its mechanism of action relevant to headache relief. J.Pharmacol.Exp.Ther. 305 749. PMID:12606602. Letienne et al (2005) Donitriptan decreases jugular venous oxygen saturation in rats in the absence of cranial vasoconstriction: an overlooked mechanism of antimigraine action? J.Pharmacol.Exp.Ther. 315 849. PMID:16027226. Munoz-Islas et al (2006) Donitriptan, but not sumatriptan, inhibits capsaicin-induced canine external carotid vasodilation via 5-HT1B rather than 5-HT1D receptors. Br.J.Pharmacol. 149 82. PMID:16880765."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=236311	SQ1070			May-2010
3666	Tenofovir	[147127-20-6]	C[C@@H](OCP(O)(O)=O)CN(C=N2)C1=C2C(N)=NC=N1	Reverse transcriptase inhibitor	Selectively inhibits HIV reverse transcriptase (RNA-dependent DNA polymerase). Prevents cytotoxicity in SIV-infected C-8166 cells in vitro (IC50 = 1.5 _M). Antiviral agent.	"Tsai et al (1995) Prevention of SIV infection in macaques by (R)-9-(2-phosphonylmethoxypropyl)adenine. Science 270 1197. PMID:7502044. Van Rompay et al (1996) 9-[2-(Phosphonomethoxy)propyl]adenine therapy of established simian immunodeficiency virus infection in infant rhesus macaques. Antimicrob.Agents Chemother. 40 2586. PMID:8913470. Suo et al (1998) Selective inhibition of HIV-1 reverse transcriptase by an antiviral inhibitor, (R)-9-(2-phosphonylmethoxypropyl)adenine. J.Biol.Chem. 273 27250. PMID:9765248."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=236409	SQ1533			Sep-2009
3667	SR 3677 dihydrochloride	[1072959-67-1]	O=C(C3COC(C=CC=C4)=C4O3)NC1=CC=C(C2=CNN=C2)C=C1OCCN(C)C.Cl.Cl	"Potent, selective Rho-kinase (ROCK) inhibitor"	Potent and selective Rho-kinase inhibitor (IC50 values are 3 and 56 nM for ROCK-II and ROCK-I respectively).	Feng et al (2008) Discovery of substituted 4-(pyrazol-4-yl)-phenylbenzodioxane-2-carboxamides as potent and highly selective Rho kinase (ROCK-II) inhibitors. J.Med.Chem. 51 6642. PMID:18834107.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=237220	SQ1533			Jun-2010
3670	SKA 31	[40172-65-4]	NC3=NC2=C(S3)C=CC1=CC=CC=C12	Activator of KCa3.1 and KCa2 channels	"Activator of KCa3.1 and KCa2 channels (EC50 values are 260, 2900, 2900 nM for KCa3.1, KCa2.1 and KCa2.2 respectively). Potentiates acetylcholine-induced EDHF-type dilations of mouse carotid arteries and lowers blood pressure in normotensive and hypertensive mice."	"Sankaranarayanan et al (2009) Naphtho[1,2-d]thaizol-2-ylamine (SKA-31), a new activator of KCa2 and KCa3.1 potassium channels, potentiates the endothelium-derived hyperpolarizing factor response and lowers blood pressure. Mol.Pharmacol. 75 281. PMID:18955585. Brahler et al (2009) Genetic deficit of SK3 and IK1 channels disrupts the endothelium-derived hyperpolarizing factor vasodilator pathway and causes hypertension. Circulation 119 2323. PMID:19380617."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=237351	SQ1070			Dec-2009
3671	AS 252424	[900515-16-4]	OC1=CC(F)=CC=C1C2=CC=C(\C=C3/SC(NC3=O)=O)O2	Selective inhibitor of PI 3-kinase _	Potent and selective inhibitor of PI 3-kinase _ (IC50 values are 33 and 935 nM for PI 3-K_ and PI 3-K_ respectively).	"Condliffe et al (2005) Sequential activation of class IB and IA PI3K is important for the primed respiratory burst of human but not murine neutrophils. Blood 106 1432. PMID:15878979. Pomel et al (2006) Furan-2-ylmethylene thiazolidinediones as novel, potent, and selective inhibitors of phosphoinositide 3-kinase _. J.Med.Chem. 49 3857. PMID:16789742."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=222714	SQ1533			Jan-2011
3675	TMCB	[905105-89-7]	BrC1=C2C(N(CC(O)=O)C(N(C)C)=N2)=C(Br)C(Br)=C1Br	Dual-kinase inhibitor; inhibits CK2 and ERK8	"Dual-kinase inhibitor; inhibits both casein kinase 2 (CK2) and extracellular-signal-regulated kinase 8 (ERK8) (IC50 = 0.50 _M for both CK2 and ERK8). Displays selectivity for CK2 over protein kinases normally susceptible to CK2 inhibitors (Ki values are 0.25, 8.65, 11.90 and 15.25 _M for CK2, PIM1, DYRK1a and HIPK2 respectively)."	Pagano et al (2008) The selectivity of inhibitors of protein kinase CK2: an update. Biochem.J. 415 353. PMID:18588507.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=237446				Mar-2011
3676	PF 514273	[851728-60-4]	O=C2C1=NN(C4=CC=CC=C4Cl)C(C3=CC=C(Cl)C=C3)=C1OCCN2CC(C)(F)F	Potent and selective CB1 antagonist	Potent and selective CB1 receptor antagonist (Ki values are 1 and > 10000 nM at CB1 and CB2 receptors respectively). Inhibits food intake in vivo following oral administration.	"Dow et al (2009) Discovery of 2-(2-chlorophenyl)-3-(4-chlorophenyl)-7-(2,2-difluoropropyl)-6,7-dihydro-2H-pyrazole[3,4-f][1,4]oxazepin-8-(5H)-one (PF-514273), a novel, bicyclic lactam-based cannabinoid-1 receptor antagonist for the treatment of obesity. J.Med.Chem. 52 2652. PMID:19351113."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=237569	SQ1070			Oct-2009
3677	NPY 5RA972	[439861-56-0]	CC1=C(NC(N4CCOCC4)=O)C=CC3=C1C2=CC=CC=C2N3C(C)C	Potent and selective NPY Y5 antagonist	"Potent and selective neuropeptide Y Y5 receptor antagonist (IC50 values are 3.1, >10000, >10000 and >10000 nM for Y5, Y1, Y2 and Y4 receptors respectively). Does not block NPY-induced feeding in vivo. Orally active and brain penetrant."	Block et al (2002) Discovery and optimization of a series of carbazole ureas as NPY5 antagonists for the treatment of obesity. J.Med.Chem. 45 3509. PMID:12139462. Turnbull et al (2002) Selective antagonism of the NPY Y5 receptor does not have a major effect on feeding in rats. Diabetes 51 2441. PMID:12145156. Morris et al (2007) Neuropeptide Y suppresses absence seizures in a genetic model primarily through effects on Y receptors. Eur.J.Neurosci. 25 1136. PMID:17331209.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=237570	SQ1070			Mar-2010
3678	G-15	[1161002-05-6]	BrC1=CC4=C(OCO4)C=[C@@]1[C@@H]2NC(C=CC=C5)=C5[C@@]3([H])[C@@]([H])2CC=C3.BrC6=CC9=C(OCO9)C=[C@@]6[C@H]7NC(C=CC=C%10)=C%10[C@]8([H])[C@]([H])7CC=C8	High affinity and selective GPR30 antagonist	High affinity and selective GPR30 receptor antagonist (Ki = 20 nM) that displays no affinity for ER_ and ER_ at concentrations up to 10 _M. Inhibits agonist-induced calcium mobilization in vitro (EC50 of ~185 nM) and antagonizes the antidepressive and renoprotective effects of estrogen in vivo.	Dennis et al (2009) In vivo effects of a GPR30 antagonist. Nat.Chem.Biol. 5 421. PMID:19430488. Hutchens et al (2012) Estrogen protects renal endothelial barrier function from ischemia-reperfusion in vitro and in vivo. Am.J.Physiol.Renal Physiol. 303 377. PMID:22622457.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=237717				Jan-2010
3679	DS2	[374084-31-8]	O=C(C4=CC=C(Cl)C=C4)NC2=C(C3=CC=CS3)N=C1C=CC=CN12	Positive allosteric modulator of _-containing GABAA receptors	Positive allosteric modulator of _-subunit containing GABAA receptors (EC50 = 142 nM for _4_3_ receptors). Displays no effects on GABA responses mediated by _4_3_2 and _1_3_2 receptors.	Wafford et al (2009) Novel compounds selectively enhance _ subunit containing GABAA receptors and increase tonic currents in thalamus. Neuropharmacology 56 182. PMID:18762200.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=237718	SQ1070			Dec-2009
3680	Ropinirole	[91374-20-8]	O=C2NC1=CC=CC(CCN(CCC)CCC)=C1C2.Cl	Selective D2-like agonist	Selective D2-like receptor agonist (D3 > D2 > D4). Causes biphasic spontaneous locomotor activity and contralateral circling in 6-OHDA-lesioned mice. Displays antiParkinsonian activity.	Eden et al (1991) Preclinical pharmacology of Ropinirole (SK&F 101468-A) a novel dopamine D2 agonist. Pharmacol.Biochem.Behav. 38 147. PMID:1673248. Tulloch (1997) Pharmacologic profile of ropinirole: a nonergoline dopamine agonist. Neurology 49 S58. PMID:9222275.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=237719	SQ1533			Oct-2009
3681	Bendamustine hydrochloride	[3543-75-7]	CN2C1=CC=C(N(CCCl)CCCl)C=C1N=C2CCCC(O)=O.Cl	Cytostatic agent; exhibits DNA alkylating and purine analog properties	Cytostatic agent that displays activity in non-Hodgkin's lymphomas. Exhibits bifunctionality; combines DNA alkylating properties with those of purine analogs.	Schwanen et al (2002) In vitro evaluation of bendamustine induced apoptosis in B-chronic lymphocytic leukemia. Leukemia. 16 2096. PMID:12357363. Keating et al (2008) Bendamustine. Nat.Rev.Drug Discov. 7 473. PMID:18511926. Masiello and Tulpule (2009) Bendamustine therapy in chronic lymphocytic leukemia. Expert Opin.Pharmacother. 10 1687. PMID:19527193.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=237722	SQ1533			Nov-2009
3683	CITCO	[338404-52-7]	ClC(C(Cl)=C4)=CC=C4CO/N=C/C1=C(C3=CC=C(Cl)C=C3)N=C2N1C=CS2	Selective CAR agonist	"Constitutive androstane receptor (CAR) agonist (EC50 = 49 nM). Displays > 100-fold selectivity over PXR receptors and no activity at LXR, ER_, ER_, PPAR, RAR, FXR, VDR and THR. Induces CAR nuclear translocation and expression of CYP2B6 in hepatocytes in vitro."	Maglich et al (2003) Identification of a novel human constitutive androstane receptor (CAR) agonist and its use in the identification of CAR target genes. J.Biol.Chem. 278 17277. PMID:12611900. Moreau et al (2007) Constitutive androstane receptor-vitamin D receptor crosstalk: consequence on CYP24 gene expression. Biochem.Biophys.Res.Comm. 360 76. Clen et al (2009) A single amino acid controls the functional switch of human CAR1 to the xenobiotic sensitive splicing variant CAR3. J.Pharmacol.Exp.Ther. 332 106. PMID:19820207.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=237724	SQ1533			Oct-2009
3685	Corticosterone	[50-22-6]	[H][C@@]23CCC1=CC(CC[C@@](C)1[C@]([H])2[C@@H](O)C[C@@]4(C)[C@]([H])3CC[C@@H]4[C@@](CO)=O)=O	Endogenous glucocorticoid	Endogenous glucocorticoid that acts as an agonist at glucocorticoid and mineralocorticoid receptors.	"Lu et al (2006) International union of pharmacology. LXV. The pharmacology and classification of the nuclear receptor superfamily: glucocorticoid, mineralocorticoid, progesterone, and androgen receptors. Pharmacol.Rev. 58 782. PMID:17132855."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=238058	SQ1533			Jan-2010
3688	SGS 518 oxalate	[445441-27-0]	CN2C1=CC=C(OS(C4=C(F)C=CC=C4F)(=O)=O)C=C1C(C3CCN(C)CC3)=C2.OC(C(O)=O)=O	Selective 5-HT6 antagonist	Selective antagonist of the 5-HT6 subtype of the serotonin receptor. Useful for the treatment of cognitive impairment that is associated with schizophrenia and Alzheimer's disease.	Romero et al (2006) Efficacy of selective 5-HT6 receptor ligands determined by monitoring 5-HT6 receptor-mediated cAMP signaling pathways. Br.J.Pharmocol. 148 1133. PMID:16865095. Kim et al (2008) New serotonin 5-HT6 ligands from common feature pharmacophore hypotheses. J.Chem.Inf.Model. 48 197. PMID:18044950.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=238061	SQ1070			Jan-2011
3689	Cevimeline hydrochloride	[107220-28-0]	C[C@@H](SC3)O[C@@]13CN2CCC1CC2.C[C@H](SC6)O[C@]46CN5CCC4CC5.Cl.Cl	Selective M1 agonist	Selective M1 receptor agonist. Induces atropine-sensitive contractions of isolated guinea pig ilea and trachea preparations (EC50 values are 3.5 and 3 _M respectively). Reverses AF64A-induced cognitive impairments in vivo.	"Wanibuchi et al (1990) Pharmacological studies on novel muscarinic agonists, 1-oxa-8-azaspiro[4.5]decane derivatives, YM796 and YM954. Eur.J.Pharmacol. 187 479. PMID:1963596. Fisher et al (1991) (+/-)-cis-2-methyl-spiro(1,3-oxathiolane-5,3')quinuclidine, an M1 selective cholinergic agonist, attenuates cognitive dysfunctions in an animal model of Alzheimer's disease. J.Pharmacol.Exp.Ther. 257 392. PMID:2019998. Hargreaves et al (1992) L-689,660, a novel cholinomimetic with functional selectivity for M1 and M3 muscarinic receptors. Br.J.Pharmacol. 107 494. PMID:1422595."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=238062	SQ1070			Jan-2010
3690	S26948	[353280-43-0]	O=C(C3=CC=CC=C3)C1=CC=C(N(CCOC4=CC=C(CC(C(OC)=O)C(OC)=O)C=C4)C(S2)=O)C2=C1	Selective PPAR_ agonist; antidiabetic agent	Selective PPAR_ agonist (EC50 = 8.83 nM). Drives normal adipocyte differentiation and exhibits a lipid-lowering effect; reduces atherosclerosis in E2-KI mice. Displays antidiabetic properties and improves hepatic insulin sensitivity in intralipid-infusion (IL) rats.	"Carmona et al (2007) S 26948: a new specific peroxisome proliferator-activated receptor _ modulator with potent antidiabetes and antiatherogenic effects. Diabetes 56 2797. PMID:17704298. Sohn et al (2009) S26948, a new specific peroxisome proliferator activated receptor gamma modulator improved in vivo hepatic insulin sensitivity in 48 h lipid infused rats. Eur.J.Pharmacol. 608 104. PMID:19250932."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=238063	SQ1070			Sep-2010
3691	N-Nonyldeoxynojirimycin	[81117-35-3]	O[C@H]1[C@H](O)[C@@H](CO)N(CCCCCCCCC)C[C@@H]1O	Glucosidase inhibitor	"Glucosidase inhibitor (IC50 values are 0.42 and 8.4 _M for acid _-glucosidase and _-1,6-glucosidase respectively). Inhibits liver glycogen breakdown in vivo. Also acts as a chemical chaperone; chaperones _-Glu folding at neutral p.H. allowing the stabilized enzyme to transit from the endoplasmic reticulum to the golgi, enabling proper trafficking to the lysosome."	Sawkar et al (2002) Chemical chaperones increase the cellular activity of N307S _-glucosidase: a therapeutic strategy for Gaucher disease. Proc.Natl.Acad.Sci.USA 99 15428. Andersson et al (2004) Inhibition of glycogen breakdown by imino sugars in vitro and in vivo. Biochem.Pharmacol. 67 697. PMID:14757169. Mellor et al (2004) Cellular effects of deoxyojirimycin analogues: inhibition of N-linked oligosaccharide processing and generation of free glucosylated oligosaccharides. Biochem.J. 381 867. PMID:15128289.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=238066	SQ1070			Nov-2009
3692	"4,4-Pentamethylenepiperidine hydrochloride"	[1125-01-5]	C1CCCCC21CCNCC2.Cl	M2 proton channel blocker	M2 proton channel blocker (IC50 = 0.92 _M). Inhibits influenza virus M2 protein (AM2).	Wang et al (2009) Discovery of spiro-piperidine inhibitors and their modulation of the dynamics of the M2 proton channel from Influenza A Virus. J.Am.Chem.Soc. 131 8066. PMID:19469531.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=238067				Nov-2009
3693	DL-AP5 Sodium salt	[1303993-72-7]	[Na+].NC(CCCP(O)([O-])=O)C(O)=O	Sodium salt of DL-AP5 (Cat. No. 0105)	Sodium salt of DL-AP5 (Cat. No. 0105). Potent NMDA antagonist.	Evans et al (1982) The effect of a series of _-phosphonic-_-carboxylic amino acids on electrically evoked and amino acid induced responses in isolated spinal cord preparations. Br.J.Pharmacol. 75 65. PMID:7042024. Davies and Watkins (1982) Actions of D and L forms of 2-amino-5-phosphonovalerate and 2-amino-4-phosphonobutyrate in the cat spinal cord. Brain Res. 235 378. PMID:6145492.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=238240				Jun-2010
3694	Kynurenic acid sodium salt	[2439-02-3]	[Na+].OC1=CC(=NC2=CC=CC=C12)C([O-])=O	Sodium salt of kynurenic acid (Cat. No. 0223)	"Sodium salt of kynurenic acid (Cat. No. 0223), a broad spectrum EAA antagonist."	"Perkins and Stone (1982) An iontophoretic investigation of the actions of convulsant kynurenines and their interaction with the endogenous excitant quinolinic acid. Brain Res. 247 184. PMID:6215086. Stone and Burton (1988) NMDA receptors and ligands in the vertebrate CNS. Progr.Neurobiol. 30 333. Pittaluga et al (1997) The 'kynurenate test', a biochemical assay for putative cognition enhancers. J.Pharmacol.Exp.Ther. 283 82. PMID:9336311. Wang et al (2006) Kynurenic acid as a ligand for orphan G protein-coupled receptor GPR35. J.Biol.Chem. 281 22021. PMID:16754668."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=238241	SQ1070			Aug-2010
3695	CHPG Sodium salt	[1303993-73-8]	[Na+].NC(C([O-])=O)C1=CC(O)=CC=C1Cl	Selective mGlu5 agonist. Sodium salt of CHPG (Cat. No. 1049)	Sodium salt of the selective mGlu5 agonist CHPG (Cat. No. 1049).	"Doherty et al (1997) (RS)-2-Chloro-5-hydroxyphenylglycine (CHPG) activates mGlu5, but not mGlu1, receptors expressed in CHO cells and potentiates NMDA responses in the hippocampus. Neuropharmacology 36 265. PMID:9144665. Salt et al (1999) Antagonism of the mGlu5 agonist 2-chloro-5-hydroxyphenylglycine by the novel selective mGlu5 antagonist 6-methyl-2-(phenylethynyl)-pyridine (MPEP) in the thalamus. Br.J.Pharmacol. 127 1057. PMID:10455248. Bao et al (2001) Selective mGluR5 receptor antagonist or agonist provides neuroprotection in a rat model of focal cerebral ischaemia. Brain Res. 922 173. PMID:11743947."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=238242				Jun-2010
3696	(RS)-MCPG disodium salt	[1303994-09-3]	[Na+].[Na+].CC(N)(C([O-])=O)C1=CC=C(C=C1)C([O-])=O	Sodium salt of (RS)-MCPG (Cat. No. 0336)	"Sodium salt of (RS)-MCPG (Cat. No. 0336), a non-selective group I/group II metabotropic glutamate receptor antagonist."	"Eaton et al (1993) Competitive antagonist at metabotropic glutamate receptors by (S)-4-carboxyphenylglycine (CPG) and (RS)-_-methyl-4-carboxyphenylglycine (MCPG). Eur.J.Pharmacol.Mol.Pharmacol.Sect. 244 195. Collingridge and Watkins (1994) Phenylglycine derivatives as metabotropic glutamate receptor antagonists. TiPS 15 333. PMID:7992387. Joly et al (1995) Molecular, functional and pharmacological characterization of the metabotropic glutamate receptor Type 5 splice variants: comparison with mGluR1. J.Neurosci. 15 3970. PMID:7751958."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=238243				Aug-2010
3697	7-Chlorokynurenic acid sodium salt	[1263094-00-3]	[Na+].OC1=CC(=NC2=CC(Cl)=CC=C12)C([O-])=O	Potent competitive inhibitor of L-glutamate uptake. Sodium salt of 7-Chlorokynurenic acid (Cat. No. 0237)	"Sodium salt of 7-Chlorokynurenic acid (Cat.No. 0237), an NMDA receptor antagonist acting at the glycine site. Potent competitive inhibitor of L-glutamate transport into synaptic vesicles."	"Kemp et al (1988) 7-Chlorokynurenic acid is a selective antagonist of the glycine modulatory site of the NMDA receptor complex. Proc.Natl.Acad.Sci.USA 85 6547. Donald et al (1988) Characterization of the [3H]-glycine binding to a modulatory site within the NMDA receptor complex from rat brain. Br.J.Pharmacol. 95 892P. Kretschmer et al (1995) Behavioral and neurochemical actions of the strychnine-insensitive glycine receptor antagonist, 7-chlorokynurenate, in rats. Eur.J.Pharmacol. 280 37. PMID:7498252. Bartlett et al (1998) Substituted quinolines as inhibitors of L-glutamate transport into synaptic vesicles. Neuropharmacology 37 839. PMID:9776380."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=238244	SQ1070			Feb-2010
3698	"5,7-Dichlorokynurenic acid sodium salt"	[1184986-70-6]	[Na+].OC1=CC(=NC2=CC(Cl)=CC(Cl)=C12)C([O-])=O	"Sodium salt of 5,7-Dichlorokynurenic acid (Cat. No. 0286). Potent NMDA antagonist, acts at glycine site"	"Sodium salt of 5,7-Dichlorokynurenic acid (Cat. No. 0286), a potent antagonist at the glycine site of the NMDA receptor (Ki = 79 nM vs. [3H]-glycine)."	"Baron et al (1990) Activity of 5,7-dichlorokynurenic acid. A potent antagonist at the NMDA receptor-associated glycine binding site. Mol.Pharmacol. 38 554. PMID:2172769. Moore et al (1990) Substituted kynurenic acid derivatives. Potent and selective antagonists at the glycine site on the NMDA receptor. Eur.Fed.Med.Chem. (under auspices of IUPAC) XIth I."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=238245				Feb-2010
3699	DL-AP4 Sodium salt	[1263093-79-3]	[Na+].NC(CCP(O)([O-])=O)C(O)=O	Broad spectrum EAA antagonist. Sodium salt of DL-AP4 (Cat. No. 0101)	Sodium salt of the broad spectrum EAA ligand DL-AP4 (Cat. No. 0101). Separate isomers D-AP4 and L-AP4 also available (Cat. Nos. 0102 and 0103).	Evans et al (1979) Antagonism of excitatory amino acid-induced responses and of synaptic excitation in the isolated spinal cord of the frog. Br.J.Pharmacol. 67 591. PMID:316343. Evans et al (1982) The effect of a series of _-phosphonic-_-carboxylic amino acids on electrically evoked and amino acid induced responses in isolated spinal cord preparations. Br.J.Pharmacol. 75 65. PMID:7042024.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=238246				Feb-2010
3700	Imiquimod	[99011-02-6]	CC(C)CN2C=NC1=C(N)N=C3C(C=CC=C3)=C12	Toll-like receptor 7 (TLR7) agonist	Immunomodulator that displays antiviral and antitumor activity. Acts as a Toll-like receptor 7 (TLR7) agonist; stimulates proinflammatory cytokine production and activates NF-_B.	Syed et al (2001) A review of the applications of imiquimod: a novel immune response modifier. Exp.Opin.Pharmacother. 2 877. Schon and Schon (2007) The antitumoral mode of action of imiquimod and other imidazoquinolines. Curr.Med.Chem. 14 681. PMID:17346155. Averett et al (2007) The pharmacology of endosomal TLR agonists in viral disease. Biochem.Soc.Trans. 35 1468. PMID:18031247.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=238650	SQ1533			Nov-2009
3701	A 740003	[861393-28-4]	CC(C)(C)C(NC(CC3=CC(OC)=C(OC)C=C3)=O)N/C(NC2=CC=CC1=NC=CC=C12)=N/C#N	Potent and selective P2X7 antagonist	"Potent, selective and competitive P2X7 receptor antagonist (IC50 values are 18 and 40 nM for rat and human receptors respectively). Displays selectivity over a variety of P2X and P2Y receptors up to a concentration of 100 _M. Reduces nociception in animal models of persistent neuropathic and inflammatory pain."	"Honore et al (2006) A-740003 [N-(1-{[(cyanoimino)(5-quinolinylamino)methyl]amino}-2,2-dimethylpropyl)-2-(3,4-dimethoxyphenyl)acetamide], a novel and selective P2X7 receptor antagonist, dose-dependently reduces neuropathic pain in the rat. J.Pharmacol.Exp.Ther. 319 1376. PMID:16982702. King (2007) Novel P2X7 receptor antagonists ease the pain. Br.J.Pharmacol. 151 565. PMID:17471176. Donnelly-Roberts et al (2009) Mammalian P2X7 receptor pharmacology: comparison of recombinant mouse, rat and human P2X7 receptors. Br.J.Pharmacol. 157 1203. PMID:19558545."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=238651	SQ1070			Jan-2010
3703	K 858	[72926-24-0]	CC1(C2=CC=CC=C2)N(C(C)=O)N=C(NC(C)=O)S1	Selective ATP-uncompetitive mitotic kinesin Eg5 inhibitor	"Selective ATP-uncompetitive mitotic kinesin Eg5 inhibitor (IC50 = 1.3 _M). Induces mitotic arrest, caspase-3 activation and cell growth inhibition in HCT116 cells. Displays no effect on microtubule dynamics. Preferentially induces mitotic arrest in cancer cells."	"Nakai et al (2009) K858, a novel inhibitor of mitotic kinesin Eg5 and antitumor agent, induces cell death in cancer cells. Cancer Res. 69 3901. PMID:19351824."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=238787	SQ1070			Nov-2009
3705	Endoxifen	[112093-28-4]	CCC(=C(C1=CC=C(O)C=C1)C1=CC=C(OCCNC)C=C1)C1=CC=CC=C1	Potent antiestrogen; ER_ ligand	Estrogen receptor _ (ER_) ligand; potent antiestrogen. Metabolite of tamoxifen (Cat. No. 0999). Primary metabolite responsible for the effectiveness of tamoxifen in ER-positive breast cancer.	"Lim et al (2006) Endoxifen, a secondary metabolite of tamoxifen, and 4-OH-tamoxifen induce similar changes in global gene expression patterns in MCF-7 breast cancer cells. J.Pharmacol.Exp.Ther. 318 503. PMID:16690721. Wu et al (2009) The tamoxifen metabolite, endoxifen, is a potent antiestrogen that targets estrogen receptor a for degradation in breast cancer cells. Cancer Res. 69 1722. PMID:19244106. Wu et al (2011) Estrogen receptor-beta sensitizes breast cancer cells to the anti-estrogenic actions of endoxifen. Breast Cancer Res. 13 R27. PMID:21392396."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=238964	SQ1533			Aug-2011
3706	FR 180204	[865362-74-9]	NC1=NNC2=C1C=C(C3=C(C=CC=C5)N5N=C3C4=CC=CC=C4)N=N2	Selective ERK inhibitor	"Selective ERK inhibitor (IC50 values are 0.14 and 0.31 _M for ERK2 and ERK1 respectively). Displays 30-fold selectivity for ERK over p38_ (IC50 = 10 _M); displays no activity against human recombinant MEK1, MKK4, IKK_, PKC_, Src, Syc and PDGF_ at concentrations less than 30 _M. Also inhibits TGF_-induced AP-1 activation in Mv1Lu cells (IC50 = 3.1 _M)."	Ohori et al (2005) Identification of a selective ERK inhibitor and structural determination of the inhibitor-ERK2 complex. Biochem.Biophys.Res.Comm. 336 357.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=238975	SQ1533			Jul-2010
3707	VU 0361737	[1161205-04-4]	ClC1=C(OC)C=C(NC(C2=NC=CC=C2)=O)C=C1	Selective positive allosteric modulator at mGlu4	"Selective positive allosteric modulator at mGlu4 receptors (EC50 values are 240 and 110 nM at human and rat receptors respectively). Inactive at mGlu1, mGlu2, mGlu3, mGlu6 and mGlu7 receptors and displays weak activity at mGlu5 and mGlu8 receptors. Brain penetrant."	"Engers et al (2009) Synthesis and evaluation of a series of heterobiarylamides that are centrally penetrant metabotropic glutamate receptor 4 (mGluR4) positive allosteric modulators (PAMs). J.Med.Chem. 52 4115. PMID:19469556. Engers et al (2011) Discovery, synthesis, and structure-activity relationship development of a series of N-(4-Acetamido)phenylpicolinamides as positive allosteric modulators of metabotropic glutamate receptor 4 (mGlu4) with CNS exposure in rats. J.Med.Chem. 54 1106. PMID:21247167."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=239089				Nov-2009
3709	MDL 72527	[93565-01-6]	C=C=CCNCCCCNCC=C=C.Cl.Cl	Polyamine oxidase (PAO) inhibitor	Polyamine oxidase (POA) inhibitor. Does not inhibit monoamine oxidase or D-Amino acid oxidase. Displays anticancer and neuroprotective activity in vivo.	"Bey et al (1985) N-2,3-butadienyl-1,4-butanediamine derivatives: potent irreversible inactivators of mammalian polyamine oxidase. J.Med.Chem. 28 1. PMID:3965702. Dogan et al (1999) Effects of MDL 72527, a specific inhibitor of polyamine oxidase, on brain edema, ischemic injury volume, and tissue polyamine levels in rats after temporary middle cerebral artery occlusion. J.Neurochem. 72 765. PMID:9930751. Basu et al (2009) A small molecule polyamine oxidase inhibitor blocks androgen-induced oxidative stress and delays prostate cancer progression in the transgenic adenocarcinoma of the mouse prostate model. Cancer Res. 69 7689. PMID:19773450."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=239248				Jan-2010
3710	PRIMA-1MET	[5291-32-7]	OCC1(COC)C(C2CCN1CC2)=O	Restores mutant p53 activity	Methylated derivative of PRIMA-1 (Cat. No. 1862). Restores mutant activity p53 activity. Acts synergistically with chemotherapeutic agents to inhibit tumor cell proliferation.	Bykov et al (2005) PRIMA-1MET synergizes with cisplatin to induce tumor cell apoptosis. Oncogene 24 3484. PMID:15735745. Shen et al (2008) PRIMA-1MET induces mitochondrial apoptosis through activation of caspase-2. Oncogene 27 6571. PMID:18663359. Stuber et al (2009) PRIMA-1MET induces nucleolar translocation of Epstein-Barr virus-encoded EBNA-5 protein. Mol.Cancer 8 23. PMID:19323829.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=239334	SQ1533			Oct-2009
3711	SK1-I	[1072443-89-0]	CCCCCC1=CC=C(/C=C/[C@H](O)[C@H](NC)CO)C=C1.Cl	Sphingosine kinase 1 (SphK1) inhibitor; antiproliferative	"Sphingosine kinase (SphK) inhibitor. Isoenzyme-selective for SphK1; displays no activity at SphK2. Also displays no inhibitory activity against a range of protein kinases including PKC, PKA, ERK1, EGFR and CDK2. Exhibits potent antileukemic activity in vivo; inhibits the growth of both U937 and Jurkat T cells. Also suppresses proliferation and induces apoptosis in several human glioblastoma cell lines."	"Paugh et al (2008) A selective sphingosine kinase 1 inhibitor integrates multiple molecular therapeutic targets in human leukemia. Neoplasia 112 1382. Kapitonov et al (2009) Targeting sphingosine kinase 1 inhibits Akt signaling, induces apoptosis, and suppresses growth of human glioblastoma cells and xenografts. Cancer Res. 69 6915. PMID:19723667. Paugh et al (2009) Interleukin-1 regulates the expression of sphingosine kinase 1 in glioblastoma cells. J.Biol.Chem. 284 3408. PMID:19074142."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=239337				Jun-2011
3712	NU 7441	[503468-95-9]	O=C1C3=C(C(C4=CC=CC5=C4SC6=C5C=CC=C6)=CC=C3)OC(N2CCOCC2)=C1	Potent and selective DNA-PK inhibitor	"Potent and selective DNA-dependent protein kinase (DNA-PK) inhibitor (IC50 values are 14, 1700, 5000, >100000 and >100000 nM for DNA-PK, mTOR, PI 3-K, ATM and ATR respectively). Displays no activity at a range of 60 diverse kinases at 10 _M. Potentiates the effects of radiation, doxorubicin (Cat. No. 2252) and etoposide (Cat. No. 1226) in human tumor cell lines in vitro and etoposide in a human tumor xenograft model in vivo."	Leahy et al (2004) Identification of a highly potent and selective DNA-dependent protein kinase (DNA-PK) inhibitor (NU7441) by screening of chromenone libraries. Bioorg.Med.Chem.Lett. 14 6083. Zhao et al (2006) Preclinical evaluation of a potent novel DNA-dependent protein kinase inhibitor NU7441. Cancer Res. 66 5354. PMID:16707462. Willmore et al (2008) DNA-dependent protein kinase is a therapeutic target and an indicator of poor prognosis in B-cell chronic lymphocytic leukemia. Clin.Cancer Res. 14 3984. PMID:18559621.	Small Molecule	Sold for research purposes only under agreement from KUDOS	http://www.tocris.com/dispprod.php?ItemId=239420	SQ1533			Nov-2009
3713	Cryptotanshinone	[35825-57-1]	O=C(C1=C(C4=C3[C@@H](C)CO4)C=CC2=C1CCCC(C)2C)C3=O	STAT3 inhibitor. Also displays multiple other activities	Major tanshinone isolated from Salvia miltiorrhiza that exhibits multiple activities. Exhibits antitumor activity via inhibition STAT3 activity (IC50 = 4.6 _M). Displays antibacterial and anti-inflammatory activity and acts as an antidiabetes and antiobesity agent via activation of AMP-activated protein kinase (AMPK). Also improves cognitive impairment in Alzheimer's disease transgenic mice by inhibition of acetylcholinesterase (IC50 = 4.09 _M) and reduction in A_ peptide generation.	"Kim et al (2007) Antidiabetes and antiobesity effect of cryptotanshinone via activation of AMP-activated protein kinase. Mol.Pharmacol. 72 62. PMID:17429005. Shin et al (2009) Cryptotanshinone inhibits constitutive signal transducer and activator of transcription 3 function through blocking the dimerization in DU145 prostate cancer cells. Cancer Res. 69 193. PMID:19118003. Zhang et al (2009) Cryptotanshinone, a compound from Saliva miltiorrhiza modulates amyloid precursor protein metabolism and attenuates _-amyloid deposition through upregulating _-secretase in vivo and in vitro. Neurosci.Letts. 452 90. Wong et al (2009) Cryptotanshinone, an acetylcholinesterase inhibitor from Salivia miltiorrhiza, ameliorates scopolamine-induced amnesia in morris water maze task. Planta Med. 76 288."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=239511	SQ1533			Jan-2010
3714	TCS PIM-1 4a	[438190-29-5]	O=C(/C(S2)=C/C1=CC(C(F)(F)F)=CC=C1)NC2=O	"Selective, ATP-competitive Pim kinase inhibitor"	"Selective, ATP-competitive Pim kinase inhibitor (IC50 values are 24 and 100 nM for Pim-1 and Pim-2 respectively). Displays selectivity over a panel of ~50 other kinases tested. Exhibits cytotoxicity in PC3 prostate carcinoma cells in vitro (IC50 = 17 _M)."	Xia et al (2009) Synthesis and evaluation of novel inhibitors of Pim-1 and Pim-2 protein kinases. J.Med.Chem. 52 74. PMID:19072652.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=239524	SQ1533			Jan-2010
3715	Narciclasine	[29477-83-6]	OC1=C(C(N[C@]4([H])C3=C[C@H](O)[C@@H](O)[C@H]4O)=O)C3=CC2=C1OCO2	Antiproliferative agent; slows cell cycle progression	Exhibits antiproliferative and pro-apoptotic effects in carcinoma cells and displays cytotoxic activity against a panel of 60 cancer cell lines (mean IC50 = 47 nM). Activity decreases rate of cell division and increases mitosis duration in vitro. Also modulates the Rho/ROCK/LIM kinase/cofilin pathway; stimulates RhoA activation and induces actin polymerization.	"Dumont et al (2007) The Amaryllidaceae isocarbostyril narciclasine induces apoptosis by activation of the death receptor and/or mitochondrial pathways in cancer cells but not in normal fibroblasts. Neoplasia 9 766. PMID:17898872. Ingrassia et al (2009) Structure-activity relationship analysis of novel derivatives of narciclasine (an Amaryllidaceae isocarbostyril derivative) as potential anticancer agents. J.Med.Chem. 52 1100. PMID:19199649. Lefranc et al (2009) Narciclasine, a plant growth modulator, activates Rho and stress fibers in glioblastoma cells. Mol.Cancer Ther. 8 1739. PMID:19531573."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=239525	SQ1070			Feb-2011
3716	Adaphostin	[241127-58-2]	O=C(C4=CC=C(NCC5=C(O)C=CC(O)=C5)C=C4)OC12CC(C3)CC(CC3C2)C1	p210bcr/abl kinase inhibitor	p210bcr/abl tyrosine kinase inhibitor (IC50 = 14 _M). Induces apoptosis in T-lymphoblastic human leukemia cell lines (IC50 values range from 16.8 to 216.3 nM) in vitro. Displays selectivity for chronic myelogenous leukemia (CML) myeloid progenitors in vitro.	Svingen et al (2000) Effects of the bcl/abl kinase inhibitors AG957 and NSC 680410 on chronic myelogenous leukemia cells in vitro. Clin.Cancer Res. 6 237. PMID:10656455. Avramis et al (2002) In vitro and in vivo evaluations of the tyrosine kinase inhibitor NSC 680410 against human leukemia and glioblastoma cell lines. Cancer Chemother.Pharmacol. 50 479. PMID:12451475. Mow et al (2002) Effects of bcr/abl kinase inhibitors STI571 and adaphostin (NSC 680410) on chronic myelogenous leukemia cells in vitro. Blood 99 664. PMID:11781252.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=240287	SQ1070			Dec-2009
3718	AS 1949490	[1203680-76-5]	ClC(C=C2)=CC=C2COC1=C(C(N[C@@H](C)C3=CC=CC=C3)=O)SC=C1	SH2 domain-containing inositol 5'-phosphatase 2 (SHIP2) inhibitor	Selective SHIP2 (SH2 domain-containing inositol 5'-phosphatase 2) inhibitor (IC50 values are 0.34 _M and 0.62 _M for mouse and human respectively); displays approximately 30-fold affinity for SHIP2 over SHIP1. Increases insulin-induced phosphorylation of Akt in L6 myotubules. Stimulates activation of glucose metabolism; regulates gluconeogenesis in vitro and in vivo and exhibits antidiabetic effects.	"Suwa et al (2009) Discovery and functional characterization of a novel small molecule inhibitor of the intracellular phosphatase, SHIP2. Br.J.Pharmcol. 158 879. Suwa et al (2010) Glucose metabolism activation by SHIP2 inhibitors via up-regulation of GLUT1 gene in L6 myotubes. Eur.J.Pharmacol. 642 177. PMID:20558154."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=240535	SQ1533			Aug-2010
3721	SR 48692	[146362-70-1]	O=C(NC5(C(O)=O)C4CC(CC5C6)CC6C4)C2=NN(C(C3=C(OC)C=CC=C3OC)=C2)C1=C(C=CC(Cl)=C7)C7=NC=C1	Selective nonpeptide NTS1 antagonist	"Neurotensin antagonist; selective for NTS1 over NTS2 (apparent affinity, Ke, is 36 nM for NTS1). Competitively inhibits binding of [125I]-neurotensin to HT29 and N1E115 cell membranes (IC50 values are 15.3 and 20.4 nM respectively). Orally bioavailable."	"Gully et al (1993) Biochemical and pharmacological profile of a potent and selective nonpeptide antagonist of the neurotensin receptor. Proc.Natl.Acad.Sci.USA 90 65. PMID:8380498. Oury-Donat et al (1995) Characterization of the effect of SR48692 on inositol monophosphate, cyclic GMP and cyclic AMP responses linked to neurotensin receptor activation in neuronal and non-neuronal cells. Br.J.Pharmacol. 116 1899. PMID:8528577. Thomas et al (2009) The identification of nonpeptide neurotensin receptor partial agonists from the potent antagonist SR48692 using a calcium mobilization assay. Bioorg.Med.Chem.Lett. 19 1438. PMID:19195889."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=240538	SQ1533			Sep-2011
3722	Reversan	[313397-13-6]	O=C(NCCCN5CCOCC5)C2=C1N=C(C4=CC=CC=C4)C=C(C3=CC=CC=C3)N1N=C2	Selective MRP1 and P-gp inhibitor	"Selective inhibitor of multidrug resistance-associated protein 1 (MRP1) and P-glycoprotein (P-gp). Increases the sensitivity of MRP1-overexpressing tumor cells (MCF7/VP) to doxorubicin (Cat. No. 2252), vincristine (Cat. No. 1257) and etoposide (Cat. No. 1226) by 3.8-, 14.6- and 11.6-fold respectively. Increases the efficacy of vincristine and etoposide in murine models of neuroblastoma in vivo. Does not sensitize MRP2, MRP3, MRP4 or MRP5 transporters to known substrates."	Burkhart et al (2009) Small-molecule multidrug resistance-associated protein 1 inhibitor reversan increases the therapeutic index of chemotherapy in mouse models of neuroblastoma. Cancer Res. 69 6573. PMID:19654298.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=240539	SQ1070			Jan-2010
3724	PD 161570	[192705-80-9]	ClC1=CC=CC(Cl)=C1C3=CC2=CN=C(NCCCCN(CC)CC)N=C2N=C3NC(NC(C)(C)C)=O	Selective FGFR inhibitor	"Selective FGFR inhibitor (IC50 values are 40, 262 and 3700 nM for FGFR, PDGFR and EGFR respectively). Inhibits FGFR receptor phosphorylation (IC50 = 622 nM) and growth of A121 cells in vitro."	"Hamby et al (1997) Structure-activity relationships for a novel series of pyrido[2,3-d]pyrimidine tyrosine kinase inhibitors. J.Med.Chem. 40 2296. PMID:9240345. Batley et al (1998) Inhibition of FGF-1 receptor tyrosine kinase activity by PD 161570, a new protein-tyrosine kinase inhibitor. Life Sci. 62 143. PMID:9488112. Stevens et al (2003) Thyroid hormone activates fibroblast growth factor receptor-1 in bone. Mol.Endocrinology 17 1751."	Small Molecule	Sold for research purposes under agreement from Pfizer Inc.	http://www.tocris.com/dispprod.php?ItemId=241117	SQ1070			Feb-2010
3725	KU 0063794	[938440-64-3]	OCC1=C(OC)C=CC(C3=NC2=NC(N5C[C@@H](C)O[C@@H](C)C5)=NC(N4CCOCC4)=C2C=C3)=C1	Selective mTOR inhibitor	"Selective inhibitor of mammalian target of rapamycin (mTOR) (IC50 ~10 nM for mTORC1 and mTORC2). Displays no activity at PI 3-kinase or 76 other kinases tested. Inhibits activation and hydrophobic motif phosphorylation of Akt, S6K and SGK, but not RSK. Suppresses cell growth and induces G1 cell cycle arrest in vitro."	Garcia-Martinez et al (2009) Ku-0063794 is a specific inhibitor of the mammalian target of rapamycin (mTOR). Biochem.J. 421 29. PMID:19402821.	Small Molecule	Sold for research purposes only under agreement from KUDOS	http://www.tocris.com/dispprod.php?ItemId=241120				Jan-2010
3726	GSK 429286	[864082-47-3]	O=C1CC(C2=CC=C(C(F)(F)F)C=C2)C(C(NC3=C(F)C=C(NN=C4)C4=C3)=O)=C(C)N1	Selective Rho-kinase (ROCK) inhibitor	"Selective Rho-kinase inhibitor (IC50 values are 14, 780 and 1940 nM for ROCK1, RSK and p70S6K respectively). Reverses adrenalin-induced contraction of the rat aortic ring (IC50 = 190 nM) and causes a dose-dependent decrease in mean arterial blood pressure in spontaneous hypertensive rats. Orally active."	"Goodman et al (2007) Development of dihydropyridone indazole amides as selective rho-kinase inhibitors. J.Med.Chem. 50 6. PMID:17201405. Nichols et al (2009) Substrate specificity and inhibitors of LRRK2, a protein kinase mutated in Parkinson's disease. Biochem.J. 424 47. PMID:19740074."	Small Molecule	Sold for research purposes under agreement from GlaxoSmithKline	http://www.tocris.com/dispprod.php?ItemId=241173	SQ1533			Nov-2009
3727	VU 0255035	[1135243-19-4]	O=C(CCNS(C4=CC=CC3=NSN=C34)(=O)=O)N(CC2)CCN2C1=CC=NC=C1	Highly selective muscarinic M1 antagonist	Highly selective muscarinic M1 antagonist (Ki = 14.87 nM). Targets the M1 orthosteric site with greater than 75-fold selectivity over the other receptor subtypes. Reduces pilocarpine-induced seizures in mice. Brain penetrant.	Sheffler et al (2009) A novel selective muscarinic acetylcholine receptor subtype 1 antagonist reduces seizures without impairing hippocampus-dependent learning. Mol.Pharmacol. 76 356. PMID:19407080.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=241252	SQ1070			Nov-2010
3728	Indibulin	[204205-90-3]	ClC(C=C3)=CC=C3CN2C1=CC=CC=C1C(C(C(NC4=CC=NC=C4)=O)=O)=C2	Microtubule destabilizer	Microtubule destabilizer that blocks tubulin polymerization (IC50 = 0.3 _M). Blocks cell cycle progression at metaphase and displays antitumor activity against a variety of malignancies in vitro (IC50 values ranging from 0.036 - 0.285 _M). Induces complete tumor remission in the Yoshida AH13 rat sarcoma model in vivo. Lacks neurotoxicity due to an ability to discriminate between posttranslationally modified tubulin in mature neuronal microtubules and less-modified tubulin present in immature neuronal or nonneuronal microtubules. Displays oral availability and efficacy towards MDR tumor cells.	"Bacher et al (2001) D-24851, a novel synthetic microtubule inhibitor, exerts curative antitumoral activity in vivo, shows efficacy toward multidrug-resistant tumor cells, and lacks neurotoxicity. Cancer Res. 61 392. PMID:11196193. Kanzawa et al (2005) Microtubule inhibitor D-24851 induces p53-independent apoptotic cell death in malignant glioma cells through Bcl-2 phosphorylation and Bax translocation. Int.J.Oncol. 26 589. PMID:15703812. Wienecke and Bacher (2009) Indibulin, a novel microtubule inhibitor, discriminates between mature and nonneuronal tubulin. Cancer Res. 69 171. PMID:19118000."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=241261	SQ1533			Dec-2009
3731	Pristimerin	[1258-84-0]	O=C2C(O)=C(C)C1=CC=C([C@](CC[C@]5(C)[C@]([H])4C[C@](C)([C@](OC)=O)CC5)(C)[C@@]4(C)CC3)[C@]3(C)C1=C2	"Potent, reversible MAGL inhibitor"	"Potent and reversible inhibitor of monoacylglycerol lipase (MGL) (IC50 = 93 nM). Also suppresses NF-_B activation via inhibition of proteasome chymotrypsin-like activity and IKK__. Displays antitumor, anti-inflammatory and antimicrobial activities."	Byun et al (2009) Reactive oxygen species-dependent activation of Bax and Poly(ADP)-ribose) polymerase-1 is requried for mitochondrial cell death induced by triterpenoid Pristimerin in human cervical cancer cells. Mol.Pharmacol. 76 734. PMID:19574249. Tiedemann et al (2009) Identification of a potent natural triterpenoid inhibitor of proteosome chymotrypsin-like activity and NF-_B with antimyeloma activity in vitro and in vivo. Blood 113 4027. PMID:19096011. King et al (2009) Discovery of potent and reversible monoacylglycerol lipase inhibitors. Chem.Biol. 16 1045. PMID:19875078.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=241264	SQ1070			Mar-2010
3732	Ceftriaxone disodium salt	[74578-69-1]	[Na+].[Na+].CO\N=C(/C(=O)NC1C(=O)N2C(C([O-])=O)=C(CSC3=NC(=O)C([O-])=NN3C)CS[C@]12[H])C1=CSC(N)=N1	Neuroprotective; increases EAAT2 expression and activity	_-lactam antibiotic. Displays neuroprotective activity in vivo via upregulation and increased activity of the EAAT2 glutamate transporter.	"Rothstein et al (2005) _-Lactam antibiotics offer neuroprotection by increasing glutamate transporter expression. Nature 433 73. PMID:15635412. Rawls et al (2007) The beta-lactam antibiotic, ceftriaxone, attenuates morphine-evoked hyperthermia in rats. Br.J.Pharmacol. 151 1095. PMID:17592517. Lipski et al (2007) Neuroprotective potential of ceftriaxone in in vitro models of stroke. Neuroscience 146 617. PMID:17363173."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=241265	SQ1533			Jan-2010
3733	Efonidipine hydrochloride monoethanolate	[111011-76-8]	CC1=C(P4(OCC(C)(C)CO4)=O)C(C3=CC([N+]([O-])=O)=CC=C3)C(C(OCCN(CC5=CC=CC=C5)C2=CC=CC=C2)=O)=C(C)N1.CCO.Cl	Ca2+ channel blocker (L- and T-type)	Selective blocker of L-type and T-type Ca2+ channels. Displays minimal inhibition of N- and P/Q-type channels and no inhibition of R-type channels. R(-) and S(+)-enantiomers display different channel selectivity; S(+)-Efonidipine blocks L-type and T-type channels whereas R(-)-Efonidipine displays selectivity for T-type channels. Exhibits antihypertensive activity.	Masumiya et al (1998) Inhibition of myocardial L- and T-type Ca2+ currents by efonidipine: possible mechanism for its chronotropic effect. Eur.J.Pharmacol. 349 351. PMID:9671117. Furukawa et al (2004) Identification of R(-)-isomer of efonidipine as a selective blocker of T-type Ca2+ channels. Br.J.Pharmacol. 143 1050. PMID:15545287. Shin et al (2008) A selective T-type Ca2+ channel blocker R(-) efonidipine. Naunyn-Schmied.Arch.Pharmacol. 377 411.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=241266	SQ1070			Jan-2010
3734	BYK 204165	[1104546-89-5]	O=C(NC3=O)C1=CC=CC=C1/C3=C/C2=CC=CN2C	Selective PARP-1 inhibitor	Potent and selective poly(ADP-ribose) polymerase (PARP)-1 inhibitor (pIC50 values are 5.38 and 7.35 for PARP-2 and PARP-1 respectively).	"Eltze et al (2008) Imidazoquinolinone, imidazopyridine, and isoquinolindione derivatives as novel and potent inhibitors of the poly(ADP-ribose) polymerase (PARP): a comparison with standard PARP inhibitors. Mol.Pharmacol. 74 1587. PMID:18809672."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=241267	SQ1070			Jun-2010
3735	BYK 49187	[163120-31-8]	O=C2CCN3C1=C(N=C3N4CCC(C5=C(C)N=CN5)CC4)C=CC=C12	PARP-1 and PARP-2 inhibitor	PARP-1 and PARP-2 inhibitor (pIC50 values are 8.36 and 7.50 for cell-free recombinant PARP-1 and murine PARP-2 respectively). Displays potent inhibitory activity against human PARP-1 in cell-free and cellular assays in vitro; reduces myocardial infarct size in vivo.	"Eltze et al (2008) Imidazoquinolinone, imidazopyridine, and isoquinolindione derivatives as novel and potent inhibitors of the poly(ADP-ribose) polymerase (PARP): a comparison with standard PARP inhibitors. Mol.Pharmacol. 74 1587. PMID:18809672. Sunderland et al (2011) 5-Benzamidoisoquinolin-1-ones and 5-(omega-carboxyalkyl)isoquinolin-1-ones as isoform-selective inhibitors of poly(ADP-ribose) polymerase 2 (PARP-2). J.Med.Chem. 54 2049. PMID:21417348."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=241268	SQ1070			Jul-2011
3736	UPF 1069	[1048371-03-4]	O=C2NC=CC1=C(OCC(C3=CC=CC=C3)=O)C=CC=C12	PARP-2 inhibitor	Selective poly(ADP-ribose) polymerase (PARP) 2 inhibitor (IC50 values are 0.3 and 8.0 _M for PARP-2 and PARP-1 respectively).	"Pellicciari et al (2008) On the way to selective PARP-2 inhibitors. Design, synthesis and preliminary evaluation of a series of isoquinolinone derivatives. Chem.Med.Chem 3 914. Moroni et al (2009) Selective PARP-2 inhibitors increase apoptosis in hippocampal slices but protect cortical cells in models of post-ischaemic brain damage. Br.J.Pharmacol. 157 854. PMID:19422384."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=241269	SQ1070			May-2010
3737	Asenapine maleate	[85650-56-2]	CN2C[C@]1([H])C3=C(C=CC=C3)OC4=C(C=C(Cl)C=C4)[C@]([H])1C2.CN6C[C@@]5([H])C7=C(C=CC=C7)OC8=C(C=C(Cl)C=C8)[C@@]([H])5C6	Novel antipsychotic agent	"Novel psychopharmacologic agent. Displays antagonist activity at 5-HT, dopamine, noradrenalin and histamine receptor subtypes (pKi values are 8.60, 8.40, 10.15, 9.75, 10.46, 8.84, 9.60, 9.94, 8.85, 8.90, 8.84, 9.38, 8.95, 8.93, 8.9, 9.49, 8.91, 9.00 and 8.21 for 5-HT1A, 5-HT1B, 5-HT2A, 5-HT2B, 5-HT2C, 5-HT5A, 5-HT6, 5-HT7, D1, D2L, D2S, D3, D4, _1A, _2A, _2B, _2C, H1 and H2 receptors respectively). Displays no appreciable affinity for muscarinic receptors. Exhibits potent activity in animal models predictive of antipsychotic efficacy."	Shahid et al (2009) Asenapine: a novel psychopharmacologic agent with a unique human receptor signature. J.Psychopharmacol. 23 65. PMID:18308814. Meltzer et al (2009) Asenapine. Nat.Rev.Drug Discov. 8 843. PMID:19876039. Marston et al (2009) Asenapine effects in animal models of psychosis and cognitive function. Psychopharmacol. 206 699.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=241509	SQ1533			Jan-2010
3739	Sarpogrelate hydrochloride	[135159-51-2]	O=C(CCC(O)=O)OC(CN(C)C)COC1=CC=CC=C1CCC2=CC(OC)=CC=C2.Cl	Selective 5-HT2A antagonist	"Selective 5-HT2A receptor antagonist (pKi values are 8.52, 7.43 and 6.57 for 5-HT2A, 5-HT2C and 5-HT2B receptors respectively). Displays selectivity over 5-HT1, 5-HT3, 5-HT4 H1, H2, M3, _1-adrenergic, _2-adrenergic and _-adrenergic receptors. Displays cardioprotective activity in vivo."	"Brasil et al (2002) Blockade of 5-HT(2A) receptors by sarpogrelate protects the heart against myocardial infarction in rats. J.Cardiovasc.Pharmacol.Ther. 7 53. PMID:12000979. Rashid et al (2003) Identification of the binding sites and selectivity of sarpogrelate, a novel 5-HT2 antagonist, to human 5-HT2A, 5-HT2B and 5-HT2C receptor subtypes by molecular modeling. Life Sci. 73 193. PMID:12738034. Nishiyama (2009) Acute effects of sarpogrelate, a 5-HT2A receptor antagonist on cytokine production in endotoxin shock model of rats. Eur.J.Pharmacol. 614 122. PMID:19318092."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=242512	SQ1533			Jan-2010
3742	RepSox	[446859-33-2]	CC1=NC(C2=NNC=C2C4=NC3=CC=CN=C3C=C4)=CC=C1	Potent and selective inhibitor of TGF-_RI	"Potent and selective inhibitor of the TGF-_ type I receptor/ ALK5 (IC50 values are 4 and 23 nM for TGF-_ type I receptor autophosphorylation and binding respectively). Selective for TGF-_ type I receptor over a range of kinases, including p38 MAPK, JNK1 and GSK3 (IC50 > 16 _M). Enhances the efficiency of cellular reprogramming; replaces Sox2 by inducing Nanog expression."	"Gellibert et al (2004) Identification of 1,5-naphthyridine derivatives as a novel series of potent and selective TGF-_ type I receptor inhibitors. J.Med.Chem. 47 4494. PMID:15317461. Li et al (2009) Generation of rat and human induced pluripotent stem cells by combining genetic reprogramming and chemical inhibitors. Cell Stem Cell 4 16. PMID:19097958. Ichida et al (2009) A small-molecule inhibitor of Tgf-_ signaling replaces Sox2 in reprogramming by inducing Nanog. Cell Stem Cell 5 491. PMID:19818703."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=242937	SQ1533			Jul-2010
3743	BF 2649 hydrochloride	[903576-44-3]	ClC1=CC=C(CCCOCCCN2CCCCC2)C=C1.Cl	H3 receptor inverse agonist/antagonist	Histamine H3 receptor inverse agonist (EC50 = 1.5 nM) and antagonist (Ki = 0.16 nM). Exhibits nootropic effects in cognitive disorders; reduces locomotor hyperactivity induced by methamphetamine. Brain penetrant.	"Ligneau et al (2007) Brain histamine and schizophrenia: potential therapeutic applications of H3-receptor inverse agonists studied with BF2.649. Biochem.Pharmacol. 73 1215. PMID:17343831. Ligneau et al (2007) BF2.649 [1-{3-{3-(4-chlorophenyl)propoxy]propyl}piperidine, hydrochloride], a nonimidazole inverse agonist/antagonist at the human histamine H3 receptor: Preclinical pharmacology. J.Pharm.Exp.Ther. 320 365."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=242938	SQ1070			Oct-2010
3745	RN 1747	[1024448-59-6]	ClC1=CC=C(S(N2CCN(CC3=CC=CC=C3)CC2)(=O)=O)C([N+]([O-])=O)=C1	Selective TRPV4 agonist	"Selective TRPV4 agonist (EC50 values are 0.77, 4.0 and 4.1 _M for hTRPV4, mTRPV4 and rTRPV4 respectively). Displays selectivity over other TRP channels (EC50 values are 0.77, >30, >30 and >100 _M for TRPV4, TRPM8, TRPV3 and TRPV1 receptors respectively). Also antagonizes TRPM8 at relevant concentrations (IC50 = 4 _M)."	Vincent et al (2009) Identification and characterization of novel TRPV4 modulators. Biochem.Biophys.Res.Comms. 389 490.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=243005	SQ1070			Jan-2010
3746	RN 1734	[946387-07-1]	CC(C)NCCN(C(C)C)S(C1=C(Cl)C=C(Cl)C=C1)(=O)=O	Selective TRPV4 antagonist	"Selective TRPV4 antagonist (IC50 values are 2.3, 3.2 and 5.9 _M for hTRPV4, rTRPV4 and mTRPV4 receptors respectively). Displays selectivity for TRPV4 over other TRP channels (IC50 values are 2.3, >30, >30 and >100 _M for TRPV4, TRPV3, TRPM8 and TRPV1 respectively). Blocks TRPV4-mediated arteriole vasodilation and increases myogenic tone ex vivo."	"Vincent et al (2009) Identification and characterization of novel TRPV4 modulators. Biochem.Biophys.Res.Comms. 389 490. PMID:19737537. Bagher et al (2012) Low intravascular pressure activates endothelial cell TRPV4 channels, local Ca2+ events, and IKCa channels, reducing arteriolar tone. Proc.Natl.Acad.Sci.U.S.A. 109 18174. PMID:23071308."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=243006	SQ1070			Jan-2010
3747	NCH 51	[848354-66-5]	O=C(CCCCCCSC(C(C)C)=O)NC1=NC(C2=CC=CC=C2)=CS1	Histone deacetylase inhibitor	Histone deacetylase (HDAC) inhibitor. Inhibits growth of various cancer cells in vitro (EC50 = 1.1 - 9.1 _M).	"Suzuki et al (2005) Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxamates. J.Med.Chem. 48 1019. PMID:15715470. Sanda et al (2007) Proteome analyses of the growth inhibitory effects of NCH-51, a novel histone deacetylase inhibitor, on lymphoid malignant cells. Leukemia 21 2344. PMID:17690692."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=243080	SQ1070			Apr-2010
3748	XAV 939	[284028-89-3]	OC1=C(CSCC2)C2=NC(C3=CC=C(C(F)(F)F)C=C3)=N1	Tankyrase inhibitor; inhibits Wnt signaling	Tankyrase (TNKS) inhibitor (IC50 values are 4 and 11 nM for TNKS2 and TNKS1 respectively). Antagonizes Wnt signaling via stimulation of _-catenin degradation and stabilization of axin. Inhibits proliferation of the _-catenin-dependent colon carcinoma cell line DLD-1. Promotes cardiomyogenic development in mesoderm progenitor cells.	Huang et al (2009) Tankyrase inhibition stabilizes axin and antagonizes wnt signalling. Nature 461 614. PMID:19759537. Adler (2009) Inhibiting wnt signaling. Sci.Signal. 91. Wang et al (2010) Cardiac induction of embryonic stem cells by a small molecule inhibitor of Wnt/_-catenin signaling. ACS Chem. Biol. 6 192. PMID:21077691.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=243282	SQ1533			Jan-2010
3751	Pyr3	[1160514-60-2]	O=C(/C(Cl)=C(Cl)\Cl)NC(C=C2)=CC=C2N1N=CC(C(OCC)=O)=C1C(F)(F)F	Selective TRPC3 blocker	Selective antagonist of the canonical transient receptor potential channel 3 (TRPC3). Inhibits TRPC3-mediated Ca2+ influx (IC50 = 0.7 _M) and suppresses activation of nuclear factor of activated T cells (NFAT). Inhibits hypertrophic responses in cardiomyocytes.	Kiyonaka et al (2009) Selective and direct inhibition of TRPC3 channels underlies biological activities of a pyrazole compound. Proc.Natl.Acad.Sci. 106 5400.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=243287	SQ1070			May-2010
3752	GSK 264220A	[685506-42-7]	CC1=C(NC(NC2=CC=CC=C2)=O)C=C(S(N3CCCCC3)(=O)=O)O1	Endothelial lipase and lipoprotein lipase inhibitor	Endothelial lipase and lipoprotein lipase inhibitor (IC50 values are 0.13 and 0.10 _M respectively).	"Keller et al (2008) A high-throughput screen for the endothelial lipase using HDL as substrate. J.Biomol.Screen. 13 468. PMID:18566479. Goodman et al (2009) Discovery of potent, selective sulfonylfuran urea endothelial lipase inhibitors. Bioorg.Med.Chem.Letts. 19 27."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=243288	SQ1070			Jan-2010
3753	A 943931 dihydrochloride	[1227675-50-4]	NC1=NC(N4C[C@H](N)CC4)=C2C(C(C=CC=C3)=C3CCC2)=N1.Cl.Cl	Potent and selective H4 antagonist	Potent and selective histamine H4 receptor antagonist (pKi values are 7.15 and 8.12 at human and rat receptors respectively). Blocks inflammation in a peritonitis mouse model and displays efficacy in inflammatory pain and neuropathic pain models.	"Cowart et al (2008) Rotationally constrained 2,4-diamino-5,6-disubstituted pyrimidines: a new class of histamine H4 receptor antagonists with improved druglikeness and in vivo efficacy in pain and inflammation models. J.Med.Chem. 51 6547. PMID:18817367. Leurs et al (2009) Molecular and biochemical pharmacology of the histamine H4 receptor. Br.J.Pharmacol. 157 14. PMID:19413568. Aldi et al (2014) Histamine H4-Receptors Inhibit Mast Cell Renin Release in Ischemia/Reperfusion via PKC{epsilon}-Dependent Aldehyde Dehydrogenase Type-2 Activation. J.Pharmacol.Exp.Ther. 349 508. PMID:24696042."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=243468	SQ1070			Apr-2010
3754	Varenicline tartrate	[375815-87-5]	C1(C=C([C@H]4CNC[C@@H]3C4)C3=C2)=C2N=CC=N1	"Orally active, subtype-selective _4_2 partial agonist"	"Orally active, subtype-selective partial agonist at _4_2 nicotinic receptors (Ki values are 0.06, 240, 322 and 3540 nM for _4_2, _3_4, _7, _1___ receptors respectively). Reduces nicotine-evoked dopamine release in vitro and decreases nicotine self-administration in vivo."	"Coe et al (2005) Varenicline: an _4_2 nicotinic receptor partial agonist for smoking cessation. J.Med.Chem. 48 3474. PMID:15887955. Rollema et al (2007) Pharmacological profile of the _4_2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid. Neuropharmacology 52 985. PMID:17157884. Rollema et al (2009) Preclinical pharmacology of the _4_2 nAChR partial agonist varenicline related to effects on reward, mood and cognition. Biochem.Pharmacol. 78 813. PMID:19501054."	Small Molecule	Sold for research purposes under agreement from Pfizer Inc.	http://www.tocris.com/dispprod.php?ItemId=243507	SQ1533			Feb-2010
3756	Maraviroc	[376348-65-1]	O=C(C4CCC(F)(F)CC4)N[C@@H](CCN2C3CCC2CC(N5C(C)=NN=C5C(C)C)C3)C1=CC=CC=C1	Selective CCR5 antagonist	"Selective CCR5 antagonist; displays potent anti-HIV-1 activity. Prevents the interaction of HIV-1 gp120 and CCR5 (IC50 = 6.4 nM), inhibiting HIV-1 entry. Also inhibits CCL3 (MIP-1_) binding to CCR5."	"Dorr et al (2005) Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob.Agents Chemother. 49 4721. PMID:16251317. Kuritzkes et al (2008) Fresh from the pipeline - maraviroc. Nat.Rev.Drug Discov. 7 15. Garcia-Perez et al (2011) New insights into the mechanisms whereby low molecular weight CCR5 ligands inhibit HIV-1 infection. J.Biol.Chem. 286 4978. PMID:21118814."	Small Molecule	Sold for research purposes under agreement from Viiv.	http://www.tocris.com/dispprod.php?ItemId=243513	SQ1533			Jan-2011
3757	Dofetilide	[115256-11-6]	CN(CCC2=CC=C(NS(=O)(C)=O)C=C2)CCOC1=CC=C(NS(=O)(C)=O)C=C1	KV11.1 (hERG) channel blocker; inhibits rapid delayed rectifier K+ current (IKr)	Selective potassium channel blocker. Blocks KV11.1 (hERG) channels; inhibits the rapid delayed-rectifier K+ current (IKr). Displays class III antiarrhythmic properties.	"Gwilt et al (1991) UK-68,798: a novel, potent and highly selective class III antiarrhythmic agent which blocks potassium channels in cardiac cells. J.Pharmacol.Exp.Ther. 256 318. PMID:1988662. Carmeliet (1992) Voltage- and time-dependent block of delayed K+ current in cardiac myocytes by dofetilide. J.Pharmacol.Exp.Ther. 262 809. PMID:1501123. Finlayson et al (2001) [3H]Dofetilide binding in SHSY5Y and HEK293 cells expressing a HERG-like K+ channel. Eur.J.Pharmacol. 412 203. PMID:11166283."	Small Molecule	Sold for research purposes under agreement from Pfizer Inc.	http://www.tocris.com/dispprod.php?ItemId=243575	SQ1533			Mar-2010
3758	SC 51089	[146033-02-5]	ClC3=CC2=C(C=C3)OC1=CC=CC=C1CN2C(NNC(CCC4=CC=NC=C4)=O)=O.Cl	Selective EP1 receptor antagonist	"Selective EP1 prostanoid receptor antagonist (Ki values are 1.3, 11.2, 17.5, 61.1, > 100, > 100, > 100, >100 and > 100 _M for EP1, TP, EP3, EP2, EP4, FP and DP receptors respectively). Attenuates PGE2-induced neuronal cell death in vitro and slows tumor growth in vivo."	"Abramovitz et al (2000) The utilization of recombinant prostanoid receptors determine the affinities and selectivities of prostaglandins and related analogs. Biochim.Biophys.Acta 1483 285. PMID:10634944. Matsuo et al (2004) Inhibition of human glioma cell growth by a PHS-2 inhibitor, NS398, and a prostaglandin E receptor subtype EP1-selective antagonist. J.Neurochem. 66 285. Saleem et al (2007) Effect of EP1 receptor on cerebral blood flow in the middle cerebral artery occlusion model of stroke in mice. J.Neurosci.Res. 85 2433. PMID:17600836."	Small Molecule	Sold for research purposes under agreement from Pfizer Inc.	http://www.tocris.com/dispprod.php?ItemId=243578	SQ1070			Feb-2010
3759	Exemestane	[107868-30-4]	C[C@@]12C(C(C[C@]3([H])[C@@]([H])2CC[C@@]4(C)[C@]([H])3CCC4=O)=C)=CC(C=C1)=O	Steroidal aromatase (CYP19) inhibitor	Irreversible steroidal aromatase inhibitor (IC50 = 20 nM). Destabilizes aromatase and lowers estrogen levels; orally active.	"di Salle et al (1992) Exemestane (FCE 24304), a new steroidal aromatase inhibitor. J.Steroid Biochem.Molec.Bio. 43 137. Goss et al (2004) The steroidal aromatase inhibitor exemestane prevents bone loss in ovariectomized rats. Bone 34 384. PMID:15003786. Wang and Chen (2006) Aromatase destabilizer: novel action of exemestane, a Food and Drug Administration-approved aromatase inhibitor. Cancer Res. 66 10281. PMID:17079446. Miller et al (2008) Aromatase inhibitors: are there differences between steroidal and nonsteroidal aromatase inhibitors and do they matter? Oncologist 13 829. PMID:18695261."	Small Molecule	Sold for research purposes under agreement from Pfizer Inc.	http://www.tocris.com/dispprod.php?ItemId=243581	SQ1533			Oct-2010
3760	Voriconazole	[137234-62-9]	O[C@]([C@@H](C)C2=NC=NC=C2F)(C3=C(F)C=C(F)C=C3)CN1C=NC=N1	Triazole antifungal agent	"Triazole antifungal agent. Displays potent activity against Candida, Cryptococcus and Aspergillus species."	"Marco et al (1998) In vitro activities of voriconazole (UK-190-496) and four other antifungal agents against 394 clinical isolates of Candida spp. Antimicrob.Agents Chemother. 42 161. PMID:9449278. Kappe (1999) Antifungal activity of the new azole UK-109,496 (voriconazole). Mycoses 42 82."	Small Molecule	Sold for research purposes under agreement from Pfizer Inc.	http://www.tocris.com/dispprod.php?ItemId=243584	SQ1533			Mar-2010
3761	Tolterodine L-tartrate	[124937-52-6 ]	OC1=C([C@@H]([C@]2=CC=CC=C2)CCN(C(C)C)C(C)C)C=C(C)C=C1.OC([C@H](O)[C@@H](O)C(O)=O)=O	"Potent, non-selective muscarinic receptor antagonist"	High affinity muscarinic receptor antagonist (Ki = 3.3 nM). Active at all muscarinic receptor subtypes (M1 - M5); exhibits a greater effect on the bladder than salivary glands in vivo.	Nilvebrant et al (1997) Tolterodine - a new bladder-selective antimuscarinic agent. Eur.J.Pharmacol. 327 195. PMID:9200560. Nilvebrant (2001) Clinical experiences with tolterodine. Life Sci. 68 2549. PMID:11392625.	Small Molecule	Sold for research purposes under agreement from Pfizer Inc.	http://www.tocris.com/dispprod.php?ItemId=243587	SQ1533			Oct-2010
3763	MCOPPB trihydrochloride	[1108147-88-1]	CC5(CCCCCCC5)N(CC4)CCC4N2C1=CC=CC=C1N=[C@@]2[C@H]3CNCCC3.Cl.Cl.Cl	Potent NOP receptor agonist	"High affinity NOP receptor agonist (pKi = 10.07 for the human NOP receptor). Exhibits anxiolytic effects with no effect on memory or locomotion. Regarded as one of the most potent, non-peptide NOP full agonists in vitro."	"Hirao et al (2008) Pharmacological characterization of the newly synthesized nociceptin/orphanin FQ-receptor agonist 1-[1-(1-methylcyclooctyl)-4-piperidinyl]-2-[(3R)-3-piperidinyl]-1H-benzimidazole as an anxiolytic agent. J.Pharmacol.Sci. 106 361. PMID:18319566. Hayashi et al (2009) Novel non-peptide nociceptin/orphanin FQ receptor agonist, 1-[1-(1-Methylcyclooctyl)-4-piperidinyl]-2-[(3R)-3-piperidinyl]-1H-benzimidazole: design, synthesis, and structure-activity relationship of oral receptor occupancy in the brain for orally potent antianxiety drug. J.Med.Chem. 52 610. PMID:19125610."	Small Molecule	Sold for research purposes under agreement from Pfizer Inc.	http://www.tocris.com/dispprod.php?ItemId=243593	SQ1533			Feb-2011
3764	Fluconazole	[86386-73-4]	OC(CN2N=CN=C2)(CN3N=CN=C3)C1=C(F)C=C(F)C=C1	Triazole antifungal agent	Triazole antifungal agent. Effective against Candida strains in vitro and in vivo.	Saag and Dismukes (1988) Azole antifungal agents: emphasis on new triazoles. Antimicrob.Agents Chemother. 32 1. PMID:2831809.	Small Molecule	Sold for research purposes under agreement from Pfizer Inc.	http://www.tocris.com/dispprod.php?ItemId=243594	SQ1533			May-2010
3765	Linezolid	[165800-03-3]	FC1=CC(N3C[C@H](CNC(C)=O)OC3=O)=CC=C1N2CCOCC2	Antibiotic; inhibits protein synthesis in gram-positive bacteria	Oxazolidinone antibiotic. Inhibits bacterial protein synthesis prior to chain initiation. Displays potent antibacterial activity against a variety of multidrug-resistant gram-positive microbes in vitro and in vivo.	"Brickner et al (1996) Synthesis and antibacterial activity of U-100592 and U-100766, two oxazolidinone antibacterial agents for the potential treatment of multi-drug-resistant gram-positive bacterial infections. J.Med.Chem. 39 673. PMID:8576909. Ford et al (1996) In vivo activities of U-100592 and U-100766, novel oxazolidinone antimicrobial agents, against experimental bacterial infections. Antimicrob.Agents Chemother. 40 1508. PMID:8726028. Brickner et al (2008) Linezolid (ZYVOX), the first member of a completely new class of antibacterial agents for treatment of serious gram-positive infections. J.Med.Chem. 51 1981. PMID:18338841."	Small Molecule	Sold for research purposes under agreement from Pfizer Inc.	http://www.tocris.com/dispprod.php?ItemId=243596	SQ1533			Feb-2010
3766	Nelfinavir mesylate	[159989-65-8]	[H][C@]12CCCC[C@]([H])1C[C@@H]([C@@](NC(C)(C)C)=O)N(C[C@@H](O)[C@H](CSC3=CC=CC=C3)NC(C4=C(C)C(O)=CC=C4)=O)C2.CS(=O)(O)=O	Potent HIV-1 protease inhibitor	Orally active human immunodeficiency virus protease inhibitor. Potently inhibits HIV-1 protease (Ki = 2 nM) in vitro.	"Shetty et al (1996) Preclinical pharmacokinetics and distribution to tissue of AG1343, an inhibitor of human immunodeficiency virus type 1 protease. Antimicrob.Agents Chemother. 40 110. PMID:8787890. Patick et al (1996) Antiviral and resistance studies of AG1343, an orally bioavailable inhibitor of human immunodeficiency virus protease. Antimicrob.Agents Chemother. 40 29. PMID:8787874. Gills et al (2007) Nelfinavir, a lead HIV protease inhibitor, is a broad-spectrum, anticancer agent that induces endoplasmic reticulum stress, autophagy and apoptosis in vitro and in vivo. Clin.Cancer Res. 13 5183."	Small Molecule	Sold for research purposes under agreement from Pfizer Inc.	http://www.tocris.com/dispprod.php?ItemId=243598	SQ1533			Feb-2010
3767	CP 20961	[35607-20-6]	OCCN(CCO)CCCN(CCCCCCCCCCCCCCCCCC)CCCCCCCCCCCCCCCCCC	Non-immunogenic adjuvant	Non-immunogenic adjuvant; used to induce arthritis in Lewis (LEW) and DA rats.	Meacock et al (1994) Arthritis in Lewis rats induced by the non-immunogenic adjuvant CP20961: an immunohistochemical analysis of the developing disease. Ann.Rheu.Dis. 53 653. Vingsbo et al (1995) Avridine-induced arthritis in rats; a T cell-dependent chronic disease influence both by MHC genes and by non-MHC genes. Clin.Exp.Immunol. 99 359. PMID:7882557.	Small Molecule	Sold for research purposes under agreement from Pfizer Inc.	http://www.tocris.com/dispprod.php?ItemId=243824	SQ1070			May-2010
3768	Sunitinib malate	[341031-54-7]	O=C(NCCN(CC)CC)C1=C(C)NC(/C=C2\C(NC3=C2C=C(F)C=C3)=O)=C1C.OC(C[C@H](O)C(O)=O)=O	"Potent VEGFR, PDGFR_ and KIT inhibitor"	"Potent, ATP-competitive VEGFR, PDGFR_ and KIT inhibitor (Ki values are 2, 9, 17, 8 and 4 nM for VEGFR -1, -2, -3, PDGFR_ and KIT respectively). Also inhibits cellular receptor phosphorylation of FLT3, RET and CSF-1R. Exhibits antiangiogenic and antitumor activity in multiple xenograft models."	"Mendel et al (2003) In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin.Cancer Res. 9 327. PMID:12538485. O'Farrell et al (2003) SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood 101 3597. PMID:12531805. Faivre et al (2007) Molecular basis for sunitinib efficacy and future clinical development Nat.Rev.Drug Discov. 6 734. PMID:17690708. Roskoski (2007) Sunitinib: a VEGF and PDGF receptor protein kinase and angiogenesis inhibitor. Biochem.Biophys.Res.Comm. 356 323."	Small Molecule	Sold for research purposes under agreement from Pfizer Inc.	http://www.tocris.com/dispprod.php?ItemId=243827	SQ1070			Mar-2010
3771	Azithromycin	[83905-01-5]	[H][C@@]1(O[C@@H]([C@H](C)[C@@H](O[C@@]3([H])[C@H](O)[C@@H](N(C)C)C[C@@H](C)O3)[C@](C)(O)C[C@@H](C)C2)[C@@H](C)C(O[C@H](CC)[C@](O)(C)[C@H](O)[C@@H](C)N2C)=O)O[C@@H](C)[C@H](O)[C@](C)(OC)C1	Antibiotic; inhibits 50S ribosomal subunit formation and elongation at transpeptidation	Macrolide antibiotic. Inhibits 50S ribosomal subunit formation and elongation at transpeptidation step in gram-positive and gram-negative organisms. Orally active with improved pharmacokinetics over erythromycin in mouse models.	"Retsema et al (1987) Spectrum and mode of action of azithromycin (CP-62,993), a new 15-membered-ring macrolide with improved potency against gram-negative organisms. Antimicrob.Agents Chemother. 31 1939. PMID:2449865. Girard et al (1987) Pharmacokinetic and in vivo studies with azithromycin (CP-62,993), a new macrolide with extended half-life and excellent tissue distribution. Antimicrob.Agents Chemother. 31 1948. PMID:2830841. Champney and Burdine (1995) Macrolide antibiotics inhibit 50S ribosomal subunit assembly in Bacillus subtilis and Staphylococcus aureas. Antimicrob.Agents Chemother. 39 2141. PMID:8540733."	Small Molecule	Sold for research purposes under agreement from Pfizer Inc.	http://www.tocris.com/dispprod.php?ItemId=243838	SQ1533			Feb-2010
3776	Atorvastatin hemicalcium salt	[134523-03-8]	[Ca++].CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(=C(N1CC[C@@H](O)C[C@@H](O)CC([O-])=O)C1=CC=C(F)C=C1)C1=CC=CC=C1.CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(=C(N1CC[C@@H](O)C[C@@H](O)CC([O-])=O)C1=CC=C(F)C=C1)C1=CC=CC=C1	HMG-CoA reductase inhibitor	Potent HMG-CoA reductase inhibitor (IC50 = 8 nM). Reduces circulating LDL-C by inhibiting cholesterol biosynthesis and inducing expression of LDL receptors. Inhibits smooth muscle cell proliferation in vitro and exhibits antinociceptive effects in the inflammatory hypernociception model.	Istvan et al (2001) Structural mechanism for statin inhibition of HMG-CoA reductase. Science 292 1160. PMID:11349148. Vaughan et al (2004) Update on statins: 2003. Circulation 110 886. PMID:15313959. Santodomingo-Garzon et al (2006) Atorvastatin inhibits inflammatory hypernociception. Br.J.Pharmacol. 149 14. PMID:16865092. Turner et al (2007) Comparison of the efficacies of five different statins on inhibition of human saphenous vein smooth muscle cell proliferation and invasion. J.Cardiovasc.Pharmacol. 50 458. PMID:18049315.	Small Molecule	Sold for research purposes under agreement from Pfizer Inc.	http://www.tocris.com/dispprod.php?ItemId=243855	SQ1533			Feb-2010
3780	CP 471474	[210755-45-6]	FC1=CC=C(OC2=CC=C(S(NC(C)(C)C(NO)=O)(=O)=O)C=C2)C=C1	Broad spectrum MMP inhibitor	"Broad spectrum MMP inhibitor (IC50 values are 0.7, 0.9, 13, 16 and 1170 nM for MMP-2, MMP-13, MMP-9, MMP-3 and MMP-1 respectively). Attenuates early left ventricular dilation after experimental myocardial infarction in mice."	"Rohde et al (1999) Matrix metalloproteinease inhibition attenuates early left ventricular enlargement after experimental myocardial infarction in mice. Circulation 99 3063. PMID:10368126. Lindsey et al (2002) Selective matrix metalloproteinase inhibition reduces left ventricular remodeling but does not inhibit angiogenesis after myocardial infarction. Circulation 105 753. PMID:11839633. Fang et al (2007) Differences in inflammation, MMP activation and collagen damage account for gender difference in murine cardiac rupture following myocardial infarction. J.Mol.Cell.Cardiol. 43 535. PMID:17689559."	Small Molecule	Sold for research purposes under agreement from Pfizer Inc.	http://www.tocris.com/dispprod.php?ItemId=243868	SQ1070			Feb-2010
3783	CP 135807	[151272-90-1]	CN(CCC4)[C@H]4CC1=CNC2=C1C=C(NC3=NC=CC=C3[N+]([O-])=O)C=C2	Selective 5-HT1D agonist	Selective 5-HT1D receptor agonist. Produces dose-dependent decreases in extracellular 5-HT concentration.	"Mansbach et al (1996) CP-135,807, a selective 5-HT1D agonist: effects in drug discrimination and punishment procedures in the pigeon. Psychopharmacology 128 313. PMID:8972551. Rollema et al (1996) Combined administration of a 5-hydroxytryptamine (5-HT)1D antagonist and a 5-HT reuptake inhibitor synergistically increases 5-HT release in guinea pig hypothalamus in vivo. J.Neurochem. 67 2204. PMID:8863532. Hertel et al (1999) The antipsychotic drug risperidone interacts with auto- and hetero-receptors regulating serotonin output in the rat frontal cortex. Neuropharmacology 38 1175. PMID:10462130."	Small Molecule	Sold for research purposes under agreement from Pfizer Inc.	http://www.tocris.com/dispprod.php?ItemId=243879	SQ1070			May-2010
3784	Sildenafil citrate	[171599-83-0]	O=C(O)C(O)(CC(O)=O)CC(O)=O.CN1CCN(S(C2=CC=C(OCC)C(C(NC4=C3N(C)N=C4CCC)=NC3=O)=C2)(=O)=O)CC1	"Orally active, potent PDE5 inhibitor"	"Orally active, potent inhibitor of phosphodiesterase 5 (PDE5) (IC50 = 4 nM). Enhances nitric oxide-dependent relaxation of human corpus cavernosum in vitro."	Ballard et al (1998) Effects of sildenafil on the relaxation of human corpus cavernosum tissue in vitro and on the activities of cyclic nucleotide phosphodiesterase isozymes. J.Urol. 159 2164. PMID:9598563. Turko et al (1999) Inhibition of cyclic cGMP-binding cyclic GMP-specific phosphodiesterase (type 5) by sildenafil and related compounds. Mol.Pharmacol. 56 124. PMID:10385692. Ghofrani et al (2006) Sildenafil: from angina to erectile dysfunction to pulmonary hypertension and beyond. Nat.Rev.Drug Discov. 5 689. PMID:16883306.	Small Molecule	Sold for research purposes under agreement from Pfizer Inc.	http://www.tocris.com/dispprod.php?ItemId=243882	SQ1070			Mar-2010
3785	PD 166285 dihydrochloride	[212391-63-4]	CN(C1=NC(NC4=CC=C(OCCN(CC)CC)C=C4)=NC=C1C=C2C3=C(Cl)C=CC=C3Cl)C2=O.Cl.Cl	"Potent Src inhibitor; also inhibits FGFR1, PDGFR_ and Wee1"	"Potent inhibitor of the tyrosine kinases c-Src, fibroblast growth factor receptor 1 (FGFR1), and platelet-derived growth factor receptor _ (PDGFR_) (IC50 values are 8.4, 39.3 and 98.3 nM respectively). Also inhibits the checkpoint kinases Wee1 and Myt1; abolishes Cdc2 phosphorylation in numerous tumor cell lines and abrogates the G2 checkpoint."	"Panek et al (1997) In vitro pharmacological characterization of PD 166285, a new nanomolar potent and broadly active protein tyrosine kinase inhibitor. J.Pharmacol.Exp.Ther. 283 1433. PMID:9400019. Wang et al (2001) Radiosensitization of p53 mutant cells by PD0166285, a novel G2 checkpoint abrogator. Cancer Res. 61 8211. PMID:11719452. Hashimoto et al (2006) Cell cycle regulation by the Wee1 inhibitor PD0166285, Pyrido [2,3-d] pyimidine, in the B16 mouse melanoma cell line. BMC Cancer 6 292. PMID:17177986."	Small Molecule	Sold for research purposes under agreement from Pfizer Inc.	http://www.tocris.com/dispprod.php?ItemId=243885	SQ1533			May-2010
3786	Celecoxib	[169590-42-5]	CC(C=C3)=CC=C3C1=CC(C(F)(F)F)=NN1C2=CC=C(S(=O)(N)=O)C=C2	Selective cyclooxygenase-2 (COX-2) inhibitor	Selective cyclooxygenase-2 (COX-2) inhibitor (IC50 values are 15 and 0.04 _M for COX-1 and COX-2 respectively). Anti-inflammatory with shorter plasma half-life in vivo than SC 58121 (Cat. No. 2895). Displays chemopreventive activity in in vivo tumor models.	"Penning et al (1997) Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib). J.Med.Chem. 40 1347. PMID:9135032. DeWitt (1999) Cox-2-selective Inhibitors: the new super aspirins. Mol.Pharmacol. 55 625. PMID:10101019. Harris et al (2000) Chemoprevention of breast cancer in rats by celecoxib, a cyclooxygenase 2 inhibitor. Cancer Res. 60 2101. PMID:10786667."	Small Molecule	Sold for research purposes under agreement from Pfizer Inc.	http://www.tocris.com/dispprod.php?ItemId=243888	SQ1533			Feb-2010
3787	Viomycin	[32988-50-4]	O[C@H](N1)C[C@@H]([C@H](C(NC[C@@H](C(N[C@@H](CO)C(N[C@H](C(N2)=O)CO)=O)=O)NC(C[C@@H](N)CCCN)=O)=O)NC(/C2=C/NC(N)=O)=O)NC1=N.OS(O)(=O)=O.OS(O)(=O)=O	Antibiotic; inhibits bacterial DNA synthesis	Member of the tuberactinomycin family of antibiotics. Inhibits group I intron splicing and prokaryotic protein synthesis. Freezes bacterial ribosomes in either the pre- or post-translational state. Facilitates trans-cleavage of the Neurospora VS ribozyme.	Hausner et al (1988) The allosteric three-site model for the ribosomal elongation cycle. J.Biol.Chem. 263 13103. PMID:2843509. Schroeder et al (2000) Modulation of RNA function by aminoglycoside antibiotics. EMBO J. 19 1. PMID:10619838. Ermolenko et al (2007) The antibiotic viomycin traps the ribosome in an intermediate state of translocation. Nat.Struct.Mol.Biol. 14 493. PMID:17515906.	Small Molecule	Sold for research purposes under agreement from Pfizer Inc.	http://www.tocris.com/dispprod.php?ItemId=243891	SQ1070			Jun-2010
3788	L-DOPA	[59-92-7]	OC1=C(O)C=CC(C[C@H](N)C(O)=O)=C1	Dopamine precursor	"Immediate precursor of dopamine, produced by tyrosine hydroxylase. Displays antiParkinsonian activity."	Pisani and Shen (2009) Levodopa-induced dyskinesia and striatal signaling pathways. Proc.Natl.Acad.Sci.USA 106 2973.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=244009	SQ1533			Jan-2010
3792	ITX 3	[347323-96-0]	CC4=C(C=C(C)N4C5=CC=CC=C5)\C=C3/C(N2C1=CC=CC=C1N=C2S3)=O	Selective inhibitor of TrioN RhoGEF activity	"Selective inhibitor of TrioN RhoGEF activity. Inhibits TrioN-mediated GTP exchange on RhoG and Rac1, formation of TrioN-induced cellular structures in REF52 fibroblasts and NGF-mediated neurite outgrowth in PC12 cells in vitro."	Bouquier et al (2009) A cell active chemical GEF inhibitor selectively targets the Trio/RhoG/Rac1 signaling pathway. Chem.Biol. 16 657. PMID:19549603.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=244114	SQ1533			Mar-2010
3793	A 1120	[1152782-19-8]	O=C(NC3=C(C(O)=O)C=CC=C3)N1CCC(C2=C(C(F)(F)F)C=CC=C2)CC1	High affinity retinol-binding protein 4 (RBP4) ligand	High affinity retinol-binding protein 4 (RBP4) ligand (Ki = 8.3 nM); non-retinoid. Selective against a range of different cellular targets. As efficacious as fenretinide (Cat. No. 1396) in the reduction of serum RBP4 and retinol. Displaces transthyretin (TTR) from RBP4-TTR complexes.	Manolescu et al (2009) All-trans retinoic acid lowers serum retinol-binding protein 4 concentrations and increases insulin sensitivity in diabetic mice. J.Nutr. 140 311. PMID:20032483. Motani et al (2009) Identification and characterization of a non-retinoid ligand for retinol-binding protein 4 which lowers serum retinol-binding protein 4 levels in vivo. J.Biol.Chem. 284 7673. PMID:19147488.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=244115	SQ1070			Apr-2011
3794	iMAC2	[335166-00-2]	BrC(C=C3)=CC1=C3N(CC(F)CN4CCNCC4)C2=C1C=C(Br)C=C2.Cl.Cl	Suppressor of mitochondrial apoptosis	Inhibitor of mitochondrial apoptosis-induced channel (MAC) (IC50 = 28 nM). Reduces STS-induced apoptosis in FL5.12 cells by over 50%. Inhibits release of cytochrome c by Bid-induced Bax activation (IC50 = 0.68 _M).	"Bombrun et al (2003) 3,6-dibromocarbazole piperazine derivatives of 2-propanol as first inhibitors of cytochrome c release via Bax channel modulation. J.Med.Chem. 46 4365. PMID:14521400. Peixoto et al (2009) MAC inhibitors suppress mitochondrial apoptosis. Biochem.J. 423 381. PMID:19691447."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=244116	SQ1070			Nov-2011
3795	TUG 424	[1082058-99-8]	CC1=CC=CC=C1C#CC2=CC=C(CCC(O)=O)C=C2	FFA1 (GPR40) agonist	Agonist of the free fatty acid receptor FFA1 (GPR40) (EC50 = 32 nM). Enhances glucose-stimulated insulin secretion in INS-1E cells at 100 nM.	"Christiansen et al (2008) Discovery of potent and selective agonists for the free fatty acid receptor 1 (FFA1/GPR40), a potential target for the treatment of type II diabetes. J.Med.Chem. 51 7061. PMID:18947221."	Small Molecule	Sold under license from the University of Southern Denmark.	http://www.tocris.com/dispprod.php?ItemId=244619	SQ1070			Oct-2010
3797	BL 1249	[18200-13-0]	C1(NC3=CC=CC4=C3CCCC4)=CC=CC=C1C2=NN=NN2	Putative K2P2.1 (TREK-1) channel opener	Putative potassium channel activator; thought to act as a K2P2.1 (TREK-1) channel opener. Exhibits selectivity for bladder over vascular tissue in vitro and in vivo (EC50 values are 1.26 and 21.0 _M for cultured bladder and aortic tissues respectively).	"Tertyshnikova et al (2005) BL-1249 [(5,6,7,8-tetrahydro-naphthalen-1-yl)-[2-(1H-tetrazol-5-yl)-phenyl]-amine]: a putative potassium channel opener with bladder-relaxant properties. J.Pharmacol.Exp.Ther. 313 250. PMID:15608074. Gonczi et al (2006) Investigation of the role of TASK-2 channels in rat pulmonary arteries; pharmacological and functional studies following RNA interference procedures. Br.J.Pharmacol. 147 496. PMID:16432512."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=244920	SQ1070			Jun-2011
3798	Losartan potassium	[124750-99-8]	CCCCC1=NC(Cl)=C(CO)N1CC2=CC=C(C3=CC=CC=C3C(N=N4)=NN4[K])C=C2	"Selective, non-peptide AT1 antagonist"	Selective non-peptide angiotensin AT1 receptor antagonist. Inhibits the contractile effects of angiotensin II on rabbit aorta and jugular vein (pA2 = 8.27). Orally active antihypertensive agent.	Wong et al (1990) Functional studies of nonpeptide angiotensin II receptor subtype-specific ligands: DuP 753 (AII-1) and PD123177 (AII-2). J.Pharmacol.Exp.Ther. 255 584. PMID:2243344. Wong et al (1990) Nonpeptide angiotensin II receptor antagonists. VIII. Characterization of functional antagonism displayed by DuP an orally active antihypertensive agent. J.Pharmacol.Exp.Ther. 252 719. PMID:2179531. Rhaleb et al (1991) DuP 753 is a specific antagonist for the angiotensin receptor. Hypertension 17 480. PMID:1672862.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=245560	SQ1070			Mar-2010
3800	CD 2665	[170355-78-9]	COCCOCOC(C(C3(CC5C4)CC(C5)CC4C3)=C2)=CC1=C2C=C(C6=CC=C(C(O)=O)C=C6)C=C1	Selective RAR_/_ antagonist	"Selective RAR__ antagonist (KD values are 110, 306 and > 1000 nM for RAR_, RAR_ and RAR_ respectively). Blocks retinoic acid-induced apoptosis ex vivo."	Szondy et al (1997) Induction of apoptosis by retinoids and retinoic acid receptor _-selective compounds in mouse thymocytes through a novel apoptosis pathway. Mol.Pharmacol. 51 972. PMID:9187263. Meister et al (1998) Antiproliferative activity and apoptosis induced by retinoic acid receptor-gamma selectivity binding retinoids in neuroblastoma. Anticancer Res. 18 1777. PMID:9673404. Kim et al (2000) The role of specific retinoid receptors in sebocyte growth and differentiation in culture. J.Invest.Dermatol. 114 349. PMID:10651997.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=245593	SQ1070			Jan-2010
3803	VER 155008	[1134156-31-2]	NC1=NC=NC2=C1N=C(NCC5=CC=C(Cl)C(Cl)=C5)N2[C@@H]3O[C@H](COCC4=CC=C(C#N)C=C4)[C@@H](O)[C@H]3O	Hsp70 inhibitor	Novel adenosine-derived inhibitor of Heat Shock Protein 70 (Hsp70) (IC50 = 0.5 _M). Inhibits cell proliferation of multiple human tumor cell lines in vitro. Also binds Hsc70 and Grp78; displays selectivity against Hsp90_ (IC50 >200 _M for Hsp90_).	"Massey et al (2009) A novel, small molecule inhibitor of Hsc70/Hsp70 potentiates Hsp90 inhibitor induced apoptosis in HCT116 colon carcinoma cells. Cancer Chemother.Pharmacol. 66 535. PMID:20012863. Williamson et al (2009) Novel adenosine-derived inhibitors of 70 kDa heat shock protein, discovered through structure-based design. J.Med.Chem. 52 1510. PMID:19256508. Massey et al (2010) ATPases as drug targets: insights from heat shock proteins 70 and 90. J.Med.Chem. 53 7280. PMID:20608738. Macias et al (2011) Adenosine-derived inhibitors of 78 kDa glucose regulated protein (Grp78) ATPase: insights into isoform selectivity. J.Med.Chem. 54 4034. PMID: 21526763."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=246125	SQ1533			Aug-2010
3804	NS 1619	[153587-01-0]	O=C2NC1=CC(C(F)(F)F)=CC=C1N2C3=CC(C(F)(F)F)=CC=C3O	Activator of BKCa (KCa1.1) channels	"Large-conductance Ca2+-activated potassium (BKCa, KCa1.1) channel activator. Induces a concentration-dependent decrease in mitochondrial membrane potential (EC50 = 3.6 _M)."	Olesen et al (1994) Selective activation of Ca(2+)-dependent K+ channels by novel benzimidazolone. Eur.J.Pharmacol. 251 53. PMID:8137869. Debska et al (2003) Large-conductance K+ channel openers NS1619 and NS004 as inhibitors of mitochondrial function in glioma cells. Biochem.Pharmacol. 65 1827. PMID:12781334. Han et al (2008) The potassium ion channel opener NS1619 inhibits proliferation and induces apoptosis in A2780 ovarian cancer cells. Biochem.Biophys.Res.Comm. 375 205.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=246140	SQ1070			Aug-2010
3805	Repaglinide	[135062-02-1]	O=C(CC3=CC(OCC)=C(C(O)=O)C=C3)N[C@@H](CC(C)C)C1=CC=CC=C1N2CCCCC2	Kir6 (KATP) channel blocker	Kir6 (KATP) channel blocker that binds with high affinity for SUR1 when co-expressed with Kir6.2 (Kd = 0.42 nM). Antidiabetic glucose regulator with hypoglycaemic effect in vivo.	Mark and Grell (1997) Hypoglycaemic effects of the novel antidiabetic agent repaglinide in rats and dogs. Br.J.Pharmacol. 121 1597. PMID:9283692. Hansen et al (2005) Kir6.2-dependent high-affinity repaglinide binding to _-cell KATP channels. Br.J.Pharmacol. 144 551. PMID:15678092.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=246141	SQ1533			Mar-2010
3807	Disulfiram	[97-77-8]	S=C(SSC(N(CC)CC)=S)N(CC)CC	Reversibly stimulates SERCA Ca2+-ATPase; displays a range of other activities	Inhibitor of aldehyde dehydrogenase that displays antialcoholism activity. Shown to reversibly stimulate Ca2+-ATPase activity and inhibit V-ATPase (EC50 = 26 _M). Also inhibits expression of MMP-2 and MMP-9 and displays anti-invasive activity.	Starling et al (1996) Stimulation of the Ca2+-ATPase of sarcoplasmic reticulum by disulfiram. Biochem.J. 320 101. PMID:8947473. Cho et al (2007) Disulfiram suppresses invasive ability of osteosarcoma cells via the inhibition of MMP-2 and MMP-9 expression. J.Biochem.Mol.Biol. 40 1069. PMID:18047805. Johnson et al (2009) Identification of inhibitors of vacuolar proton-translocating ATPase pumps in yeast by high-throughput screening flow cytometry. Anal.Biochem. 398 203. PMID:20018164. Fisher et al (2010) The ethanol metabolite acetaldehyde increases paracellular drug permeability in vitro and oral bioavailability in vivo. J.Pharmacol.Exp.Ther. 332 326. PMID:19820208.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=246147	SQ1533			Jan-2010
3810	SBHA	[38937-66-5]	O=C(CCCCCCC(NO)=O)NO	Histone deacetylase inhibitor	Histone deacetylase (HDAC) inhibitor (ID50 values are 0.25 and 0.3 _M for HDAC1 and HDAC3 respectively). Potentiates the cytostatic effects of 5-Fluorouracil (Cat. No. 3257) in colorectal cancer cells.	Richon et al (1998) A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. Proc.Natl.Acad.Sci.U.S.A 95 3003. PMID:9501205. Brinkmann et al (2001) Histone hyperacetylation induced by histone deacetylase inhibitors is not sufficient to cause growth inhibition in human dermal fibroblasts. J.Biol.Chem. 276 22491. PMID:11304533. Zhang et al (2004) The histone deacetylase inhibitor suberic bishydroxamate regulates the expression of multiple apoptotic mediators and induces mitochondria-dependent apoptosis of melanoma cells. Mol.Cancer.Ther. 3 425. PMID:15078986.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=246276				Apr-2012
3811	Emodin	[518-82-1]	O=C2C3=C(C=C(C)C=C3O)C(C1=CC(O)=CC(O)=C12)=O	"Naturally occurring anthraquinone; displays anti-inflammatory, antitumor and neuroprotective activity"	"Naturally occurring anthraquinone that displays a range of biological activities. Exhibits anti-inflammatory, antitumor and neuroprotective effects."	Wu et al (2007) Emodin-mediated protection from acute myocardial infarction via inhibition of inflammation and apoptosis in local ischemic myocardium. Life Sci. 81 1332. PMID:17939930. Chun-Guang et al (2010) Anti-tumor activity of emodin against human chronic myelocytic leukemia K562 cell lines in vitro and in vivo. Eur.J.Pharmacol. 627 33. PMID:19857484. Liu et al (2010) Neuroprotective effects of emodin in rat cortical neurons against _-amyloid-induced neurotoxicity. Brain Res. 1347 149. PMID:20573598.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=246320	SQ1533			Mar-2010
3812	Cl-4AS-1	[188589-66-4]	O=[C@](NC5=CC=CC=C5Cl)[C@H]4CC[C@@]3([H])[C@]2([H])CCC1N(C)C(C=C[C@@](C)1[C@]([H])2CC[C@]34C)=O	Steroidal androgen receptor agonist	Potent steroidal androgen receptor agonist (IC50 = 12 nM). Mimics the action of 5_-dihydrotestosterone (DHT). Transactivates the mouse mammary tumor virus (MMTV) promoter; represses MMP1 promoter activity. Inhibits 5_-reductase type I and II (IC50 values are 6 and 10 nM respectively).	Tolman et al (1997) 4-Methyl-3-oxo-4-aza-5_-androst-1-ene-17_-N-aryl-carboxamides: an approach to combined androgen blockade [5_-reductase inhibition with androgen receptor binding in vitro]. J.Steroid.Biochem.Mol.Biol. 60 303. PMID:9219921. Schmidt et al (2009) Identification of anabolic selective androgen receptor modulators with reduced activities in reproductive tissues and sebaceous glands. J.Biol.Chem. 284 36367. PMID:19846549.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=246392	SQ1070			Apr-2011
3813	TFM-4AS-1	[188589-61-9]	O=C1C=C[C@@]2(C)[C@](CC[C@]3([H])[C@@]([H])2CC[C@@]4(C)[C@]([H])3CC[C@@H]4[C@@](NC5=C(C(F)(F)F)C=CC=C5)=O)([H])N1C	Selective androgen receptor modulator (SARM)	Potent selective androgen receptor modulator (SARM) (IC50 = 30 nM). Steroidal compound. Exhibits limited effects on reproductive tissues and sebaceous glands; does not repress AP-1-sensitive MMP-1 reporter. Inhibits 5_-reductase type I and II (IC50 values are 2 and 3 nM respectively).	Schmidt et al (2009) Identification of anabolic selective androgen receptor modulators with reduced activities in reproductive tissues and sebaceous glands. J.Biol.Chem. 284 36367. PMID:19846549.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=246393				Apr-2011
3815	R 568 hydrochloride	[177172-49-5]	ClC(C=CC=C2)=C2CCCN[C@H](C)C1=CC=CC(OC)=C1.Cl	Positive allosteric modulator of the human calcium-sensing receptor	Positive allosteric modulator and allosteric agonist of the human calcium-sensing receptor (hCaSR). Exhibits calcimimetic activity. Has the ability to restore function to hCaSR mutants that cause familial hypocalciuric hypercalcemia (FHH) and neonatal severe hyperparathyroidism (NSHPT). Exerts a suppressive effect on parathyroid (PT) hormone secretion; inhibits PT cell proliferation in rats with renal insufficiency.	Wada et al (1997) The calcimimetic compound NPS R-568 suppresses parathyroid cell proliferation in rats with renal insufficiency. J.Clin.Invest. 100 2977. PMID:9399943. Fox et al (1999) NPS R-568: a type II calcimimetic compound that acts on parathyroid cell calcium receptor of rats to reduce plasma levels of parathyroid hormone and calcium. J.Pharmacol.Exp.Ther. 290 473. PMID:10411552. Ying Lin Lu et al (2009) Effect of the calcimimetic R-568 [3-(2-chlorophenyl)-N-((1R)-1-(3-methoxyphenyl)ethyl)-1-propanamine] on correcting inactivating mutations in the human calcium-sensing receptor. J.Pharmacol.Exp.Ther. 331 775. PMID:19759318.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=246757	SQ1533			Sep-2010
3817	MRK 016	[783331-24-8]	CC(C)(C)C2=C1C=NN=C(C4=NOC(C)=C4)N1N=C2OCC3=NC=NN3C	_5-selective GABAA inverse agonist	"GABAA receptor inverse agonist selective for the _5-subtype (EC50 = 3 nM). Exhibits affinity at benzodiazepine binding site of recombinant human GABAA receptors (Ki values are 0.77 nM, 0.83 nM, 0.85 nM and 1.4 nM for _3-, _1-, _2-, and _5-containing respectively). Increases long-term potentiation (LTP) in mouse hippocampal slices. Exhibits no anxiogenic or proconvulsant activity."	"Chambers et al (2004) An orally bioavailable, functionally selective inverse agonist at the benzodiazepine site of GABAA _5 receptors with cognition enhancing properties. J.Med.Chem. 47 5829. PMID:15537339. Atack et al (2009) In vitro and in vivo properties of 3-tert-butyl-7-(5-methylisoxazol-3-yl)-2-(1-methyl-1H-1,2,4-triazol-5-ylmethoxy)-pyrazolo[1,5-d]-[1,2,4]triazine (MRK-016), a GABAA receptor _5 subtype-selective inverse agonist. J.Pharmacol.Exp.Ther. 331 470. PMID:19704033."	Small Molecule	"Manufactured and sold under license from Merck & Co., Inc. for use solely for preclinical research purposes (ie: not for administration to or other use in humans)"	http://www.tocris.com/dispprod.php?ItemId=246855	SQ1070			Aug-2010
3818	TCS 1102	[916141-36-1]	O=C(CSC2=NC(C=CC=C5)=C5N2C)N1CCC[C@H]1[C@](NC3=CC=CC=C3C4=CC=CC=C4)=O	"Potent, dual orexin receptor antagonist"	"Potent, dual orexin receptor antagonist (Ki values are 0.2 and 3 nM for OX2 and OX1 receptors respectively). Inhibits ADL-orexin B-mediated locomotion following i.p. administration in vivo. Brain penetrant."	Bergman et al (2008) Proline bis-amides as potent dual orexin receptor antagonists. Bioorg.Med.Chem.Letts 18 1425. Winrow et al (2010) Orexin receptor antagonism prevents transcriptional and behavioral plasticity resulting from stimulant exposure. Neuropharmacology 58 185. PMID:19596018.	Small Molecule	"Manufactured and sold under license from Merck & Co., Inc. for use solely for preclinical research purposes (ie: not for administration to or other use in humans)"	http://www.tocris.com/dispprod.php?ItemId=246856	SQ1070			May-2010
3819	Liquiritigenin	[578-86-9]	OC(C=C3)=CC=[C@@]3[C@H](C2)OC1=CC(O)=CC=C1C2=O	Selective ER_ agonist	"Potent ER_ agonist isolated from licorice root (EC50 = 36.5 nM for activation of the ERE tk-Luc reporter by ER_ in transfected U2OS cells). Displays 20-fold selectivity for ER_; does not activate other nuclear receptors, including the androgen and glucocorticoid receptors. Displays anti-inflammatory effects."	Yahara (1984) Flavonoid glucosides from licorice. Phytochemistry 23 2108. Mersereau et al (2008) Liquiritigenin is a plant-derived highly selective estrogen receptor beta agonist. Mol.Cell.Endocrinol. 283 49. PMID:18177995. Kim et al (2008) Anti-inflammatory effects of liquiritigenin as a consequence of the inhibition of NK-kappaB-dependent iNOS and proinflammatory cytokines production. Br.J.Pharmacol. 154 165. PMID:18332856.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=246985	SQ1070			Feb-2012
3822	MM 11253	[345952-44-5]	CC1(C)C2=C(C=C(C5(SCCS5)C3=CC(C=CC(C(O)=O)=C4)=C4C=C3)C=C2)C(C)(C)CC1	RAR_-selective antagonist	Selective RAR_ antagonist. Blocks the growth inhibitory ability of RAR_-selective agonists in squamous cell carcinoma (SCC)-25 cells.	Holmes et al (2000) Induction of apoptosis in ovarian carcinoma cells by AHPN/CD437 is mediated by retinoic acid receptors. J.Cell.Physiol. 185 61. PMID:10942519. Le et al (2000) Modulation of retinoic acid receptor function alters the growth inhibitor response of oral SCC cells to retinoids. Oncogene 19 1457. PMID:10723137. Dawson et al (2001) Apoptosis induction in cancer cells by a novel analogue of 6-[3-(1-adamantyl)-4-hydroxyphenyl]-2-naphthalenecarboxylic acid lacking retinoid receptor transcriptional activation activity. Cancer Res. 61 4723. PMID:11406543.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=247004	SQ1070			Mar-2011
3823	ER 50891	[187400-85-7]	CC(C)C1=C2C(C(C3=CC=CC=C3)=CC(C4=CC=C(C5=CC=C(C(O)=O)C=C5)N4)=N2)=CC=C1	Selective RAR_ antagonist	"Antagonist of RAR_ receptors (IC50 = 31.2 nM). Displays selective affinity for RAR_ (relative IC50 values are 1.8, 432 and 535 nM for RAR_, RAR_ and RAR_ respectively)."	Kikuchi et al (2001) Syntheses and evaluation of quinoline derivatives as novel retinoic acid receptor _ antagonists. Bioorg.Med.Chem.Lett. 11 1215. PMID:11354380. Ren et al (2005) Impaired retinoic acid (RA) signal leads to RAR_2 epigenetic silencing and RA resistance. Mol.Cell.Biol. 25 10591. PMID:16287870. Somenzi et al (2007) Disruption of retinoic acid receptor alpha reveals the growth promoter face of retinoic acid. PLoS ONE 9 e836. PMID:17786207.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=247005	SQ1070			Oct-2011
3824	CD 2314	[170355-37-0]	CC(CCC(C)4C)(C)C1=C4C=C(C=CC(C3=CC(C(O)=O)=CS3)=C2)C2=C1	Selective RAR_ agonist	"Potent and selective RAR_ receptor agonist (Kd values are 145 and >3760 nM for RAR_ and RAR_ receptors respectively; no binding detected at RAR_). Inhibits growth of human HNSCC 22B, 183A and 22A cells (IC50 values are 3.0, 5.7 and 8.0 _M respectively)."	Szondy (1998) Inhibition of activation-induced apoptosis of thymocytes by all-trans- and 9-cis-retinoic acid is mediated via retinoic acid receptor alpha. Biochem.J. 3 767. PMID:9560303. Sun (2000) Identification of receptor-selective retinoids that are potent inhibitors of the growth of human head and neck squamous cell carcinoma cells. Clin.Cancer Res. 6 1563. PMID:10778990. Zhao (2009) Mechanism of regulation and suppression of melanoma invasiveness by novel retinoic acid receptor-gamma target gene carbohydrate sulfotransferase 10. Cancer Res. 69 5218. PMID: 19470764.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=247006	SQ1341			Feb-2014
3826	"7,8-Dihydroxyflavone"	[38183-03-8]	O=C2C1=CC=C(O)C(O)=C1OC(C3=CC=CC=C3)=C2	TrkB agonist	Tyrosine kinase receptor B (TrkB) agonist that binds to the extracellular domain of the receptor (Kd = 320 nM). Inhibits glutamate-triggered apoptosis in hippocampal neurons in vitro and in vivo. Exhibits neuroprotective effects in an HD mouse model.	"Jang et al (2010) A selective TrkB agonist with potent neurotrophic activities by 7,8-dihydroxyflavone. Proc.Natl.Acad.Sci.USA 107 268. Andero et al (2012) 7,8-dihydroxyflavone, a TrkB receptor agonist, blocks long-term spatial memory impairment caused by immobilzation stress in rats. Hippocampus 22 399. PMID:21136519. Jiang et al (2013) Small-molecule TrkB receptor agonists improve motor function and extend survival in a mouse model of Huntington's disease. Hum.Mol.Genet. 22 2462. PMID:23446639."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=247010				Mar-2010
3828	Rufinamide	[106308-44-5]	O=C(N)C1=CN(CC2=C(F)C=CC=C2F)N=N1	Prolongs inactivation of sodium channels; anticonvulsant	Board spectrum anticonvulsant. Prolongs the inactivation of sodium channels and limits the frequency of action potential firing in cultured and acutely isolated neurons. Displays anticonvulsive activity in a range of animal seizure models.	Rogawski et al (2006) Diverse mechanisms of antiepileptic drugs in the development pipeline. Epilepsy Res. 69 273. PMID:16621450. Arroyo (2007) Rufinamide. Neurotherapeutics 4 155. PMID:17199032. White et al (2008) The anticonvulsant profile of rufinamide (CGP 33101) in rodent seizure models. Epilepsia 49 1213. PMID:18325020.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=247229	SQ1533			Mar-2010
3829	UK 78282 hydrochloride	[136647-02-4]	COC(C=C3)=CC=C3CCCN1CCC(COC(C4=CC=CC=C4)C2=CC=CC=C2)CC1.Cl	Blocker of KV1.3 and KV1.4 channels	Blocker of the KV1.3 and KV1.4 voltage-gated potassium channels in T lymphocytes (IC50 values are 0.28 and 0.17 _M respectively). Suppresses T lymphocyte mitogenesis; leads to membrane depolarization. Also blocks KV1.4 expressed in heart and brain.	"Hanson et al (1999) UK-78,282, a novel piperidine compound that potently blocks the Kv1.3 voltage-gated potassium channel and inhibits human T cell activation. Br.J.Pharmacol. 126 1707. PMID:10372812. Chandy et al (2001) Potassium channels in T lymphocytes: toxins to therapeutic immunosuppressants. Toxicon 39 1269. PMID:11384714. Chandy et al (2004) K+ channels as targets for specific immunomodulation. Trends.Pharmacol.Sci. 25 280. PMID:15120495."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=247238	SQ1070			Oct-2010
3830	NF 340	[202982-98-7]	[Na+].[Na+].[Na+].[Na+].CC1=CC=C(C=C1NC(=O)NC1=C(C)C=CC(=C1)C(=O)NC1=CC(=CC2=C1C=C(C=C2)S([O-])(=O)=O)S([O-])(=O)=O)C(=O)NC1=CC(=CC2=C1C=C(C=C2)S([O-])(=O)=O)S([O-])(=O)=O	Selective P2Y11 antagonist	"P2Y11 antagonist; exhibits 520-fold selectivity for P2Y11 over P2Y1, P2Y2, P2Y4, P2Y6 and P2Y12 receptors. Displays competitive antagonism against ATP_S (pIC50 values are 6.43 and 7.14 in Ca2+ and cAMP assays respectively)."	"Meis et al (2010) NF546 [4,4'-(carbonylbis(imino-3,1-phenylene-carbonylimino-3,1-(4-methyl-phenylene)-carbonylimino))-bis(1,3-xylene-_,_'-diphosphonic acid) tetrasodium salt] is a non-nucleotide P2Y11 agonist and stimulates release of interleukin-8 from human monocyte-derived dendritic cells. J.Pharmacol.Exp.Ther. 332 238. PMID:19815812."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=247249				Jul-2010
3831	LG 100754	[180713-37-5]	CC1(C)C2=C(C=C(OCCC)C(/C(C)=C\C=C\C(C)=C\C(O)=O)=C2)C(C)(C)CC1	RXR:PPAR agonist	Novel RXR:PPAR_ agonist; sensitizes PPAR_ by enhancing its ligand binding activity. Also activates RXR:RAR and RXR:PPAR_ heterodimers in cotransfection assays. Displays selectivity over other permissive heterodimers such as RXR:LXR_ and RXR:BAR/FXR. Exhibits antidiabetic properties in vivo.	"Cesario et al (2001) The retinoid LG100754 is a novel RXR:PPAR_ agonist and decreases glucose levels in vivo. Mol.Endocrinol. 15 1360. PMID:11463859. Forman (2002) The antidiabetic agent LG100754 sensitizes cells to low concentrations of peroxisome proliferator-activated receptor _ ligands. J.Biol.Chem. 277 12503. PMID:11877384. Germain et al (2006) International union of pharmacology LXIII. Retinoid X receptors. Pharmacol.Rev. 58 760. PMID:17132853. Sato et al (2010) The ""Phantom Effect"" of the rexinoid LG100754: structural and functional insights. PLoS One 5 e15119. PMID:21152046."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=247856				Oct-2010
3834	KH 7	[330676-02-3]	OC(C=CC(Br)=C2)=C2/C=N/NC(C(C)SC1=NC(C=CC=C3)=C3N1)=O	Selective soluble adenylyl cyclase inhibitor	Selective soluble adenylyl cyclase (sAC) inhibitor (IC50 = 3 - 10 _M in vivo). Inert towards transmembrane adenylyl cyclase (tmAC) in vitro and in whole cells at concentrations up to 300 _M. Blocks synthesis of cAMP and displays an antiapoptotic effect at concentrations of 1 - 100 _M.	Hess et al (2005) The 'soluble' adenylyl cyclase in sperm mediates multiple signaling events required for fertilization. Develop.Cell 9 249. Stessin et al (2006) Soluble adenylyl cyclase mediates nerve growth factor-induced activation of Rap1. J.Biol.Chem. 281 17253. PMID:16627466. Kumar et al (2009) Soluble adenylyl cyclase controls mitochondria-dependent apoptosis in coronary endothelial cells. J.Biol.Chem. 284 14760. PMID:19336406.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=247964				Apr-2010
3835	TWS 119	[1507095-58-0]	FC(F)(F)C(O)=O.OC1=CC=CC(OC2=C3C(NC(C4=CC=CC(N)=C4)=C3)=NC=N2)=C1.FC(F)(F)C(O)=O	GSK-3_ inhibitor; induces neuronal differentiation in ESCs	Inhibitor of glycogen synthase kinase-3_ (IC50 = 30 nM). Induces neuronal differentiation in pluripotent murine embryonal carcinoma cells and embryonic stem cells (ESCs).	Ding et al (2003) Synthetic small molecules that control stem cell fate. Proc.Natl.Acad.Sci. 100 7632. Kordes et al (2008) Canonical wnt signaling maintains the quiescent stage of hepatic stellate cells. Biochem.Biophys.Res.Comm. 367 116.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=247967	SQ1533			Jun-2010
3836	JZL 184	[1101854-58-3]	O=C(OC6=CC=C([N+]([O-])=O)C=C6)N(CC5)CCC5C(C2=CC=C(OCO3)C3=C2)(O)C1=CC(OCO4)=C4C=C1	Monoacylglycerol lipase (MAGL) inhibitor	Potent and selective monoacylglycerol lipase (MAGL) inhibitor. Blocks hydrolysis of the endocannabinoid 2-arachidonyl glycerol (2-AG) in vivo in the mouse brain (IC50 = 8 nM). Potentiates depolarization-induced suppression of excitability in cerebellar Purkinje neurons. Exhibits >300-fold selectivity for MAGL over FAAH in vitro. Attenuates nociception in neuropathic and inflammatory pain models.	"Long et al (2009) Selective blockade of 2-arachidonylglycerol hydrolysis produces cannabinoid behavioral effects. Nat.Chem.Biol. 5 37. PMID:19029917. Pan et al (2009) Blockade of 2-arachidonylglycerol hydrolysis by selective monoacylglycerol lipase inhibitor 4-nitrophenyl 4-(dibenzo[d][1,3]dioxol-5-yl(hydroxy)methyl)piperidine-1-carboxylate (JZL184) enhances retrograde endocannabinoid signaling. J.Pharm.Exp.Ther. 331 591. PMID:19666749. Kinsey et al (2013) Repeated low-dose administration of the monoacylglycerol lipase inhibitor JZL184 retains cannabinoid receptor type 1-mediated antinociceptive and gastroprotective effects. J.Pharmacol.Exp.Ther. 345 492. PMID:23412396."	Small Molecule	Sold under license from The Scripps Research Institute.	http://www.tocris.com/dispprod.php?ItemId=247968	SQ1533			Apr-2011
3837	CCMI	[917837-54-8]	CC1=NOC(=C1)C(=CNC1=CC=C(Cl)C=C1)C(=O)NC1=CC=C(Cl)C=C1	Positive allosteric modulator of _7 nAChR	Positive allosteric modulator of _7 neuronal nicotinic acetylcholine receptors (nAChR). Evokes positive modulation of acetylcholine (ACh)-induced EC5 currents (EC50 = 0.7 _M). Exhibits cognitive-enhancing properties in rodent models; displays no cytotoxic effects in PC12 cells or rat primary cortical neurons.	Gronlien et al (2007) Distinct profiles of _7 nAChR positive allosteric modulation revealed by structurally diverse chemotypes. Mol.Pharmacol. 72 715. PMID:17565004. Ng et al (2007) Nootropic _7 nicotinic receptor allosteric modulator derived from GABAA receptor modulators. Proc.Natl.Acad.Sci. 104 8059. Hu et al (2009) Positive allosteric modulation of _7 neuronal nicotinic acetylcholine receptors: lack of cytotoxicity in PC12 cells and rat primary cortical neurons. Br.J.Pharmacol. 158 1857. PMID:20050184.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=247969	SQ1070			Jun-2010
3839	HPI 1	[599150-20-6]	CC2=C(C(OCCOC)=O)C(C3=CC(O)=CC=C3)C1=C(N2)CC(C4=C(OC)C=CC=C4)CC1=O	Inhibits Hedgehog signaling	"Hedgehog (Hh) signaling inhibitor. Inhibits Sonic hedgehog (Shh)-, SAG- and Gli-induced Hh pathway activation in Shh-LIGHT2 cells (IC50 values are 1.5, 1.5, 4 and 6 _M for Shh-, SAG-, Gli2- and Gli1-induced activation). Also inhibits Hh pathway activation in SmoM2-LIGHT cells (IC50 = 2.5 _M); inhibits the proliferation of cerebellar granule neuron precursors expressing SmoM2. Does not inhibit Wnt signaling."	Hyman et al (2009) Small-molecule inhibitors reveal multiple strategies for Hedgehog pathway blockade. Proc.Natl.Acad.Sci.USA 106 14132. PMID:19666565.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=247979	SQ1533			Mar-2013
3842	5-Azacytidine	[320-67-2]	O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N2C(N=C(N)N=C2)=O	DNA methyltransferase inhibitor	"DNA methyltransferase inhibitor. Incorporates into DNA forming covalent adducts with cellular DNMT1, depleting enzyme activity. Induces demethylation and reactivation of silenced genes. Improves the efficiency of reprogramming of stem cells; induces differentiation of mesenchymal stem cells into cardiomyocytes."	Schneider-Stock et al (2005) 5-aza-Cytidine is a potent inhibitor of DNA methyltransferase 3a and induces apoptosis in HCT-116 colon cancer cells via Gadd45- and p53-dependent mechanisms. J.Pharmacol.Exp.Ther. 312 525. PMID:15547111. Mikkelsen et al (2008) Dissecting direct reprogramming through integrative genomic analysis. Nature 454 49. PMID:18509334. Qian et al (2012) 5-Azacytidine induces cardiac differentiation of human umbilical cord-derived mesenchymal stem cells by activating extracellular regulated kinase. Stem Cells Dev. 21 67. PMID:21476855.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=248558	SQ1533			Mar-2010
3843	Cyclic Pifithrin-_ hydrobromide	[511296-88-1]	CC(C=C4)=CC=C4C1=CN(C2=C(S3)CCCC2)C3=N1.Br	p53 inhibitor	"Cyclic analog of pifithrin-_ (Cat. No. 1267), a small molecule inhibitor of p53. Prevents dexamethasone-induced cell death in murine thymocytes (EC50 = 2.01 _M). Sensitizes p53-deficient tumors to radiotherapy and chemotherapy; increases apoptosis in target cells when used in combination with antimicrotubule agents."	Barchechath et al (2005) Inhibitors of apoptosis in lymphocytes: synthesis and biological evaluation of compounds related to pifithrin-_. J.Med.Chem. 48 6409. PMID:16190767. Pietrancosta et al (2005) Novel cyclized Pifithrin-alpha p53 inactivators: synthesis and biological studies. Bioorg.Med.Chem.Lett. 15 1561. PMID:15745797. Zuco and Zunino (2008) Cyclic Pifithrin-_ sensitizes wild type p53 tumor cells to antimicrotubule agent-induced apoptosis. Neoplasia 10 587. PMID:18516295.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=248560	SQ1070			Apr-2010
3845	Thiazovivin	[1226056-71-8]	O=C(NCC3=CC=CC=C3)C1=CSC(NC2=CC=NC=N2)=N1	Improves the efficiency of fibroblast reprogramming and induction of iPSCs	Greatly enhances the efficiency of fibroblast reprogramming to generate induced pluripotent stem cells (iPSCs) when used in combination with SB 431542 (Cat. No. 1614) and PD 0325901 (Cat. No. 4192). Improves the survival of human embryonic stem cells (hESCs) upon trypsinization.	Lin et al (2009) A chemical platform for improved induction of human iPSCs. Nat.Methods. 6 805. PMID:19838168. Xu et al (2010) Revealing a core signaling regulatory mechanism for pluripotent stem cell survival and self-renewal by small molecules. Proc.Natl.Acad.Sci. USA 107 8129.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=248566	SQ1533			Mar-2011
3847	Theanine	[3081-61-6]	CCNC(CC[C@H](N)C(O)=O)=O	Glutamate receptor ligand	"Amino acid analog of glutamine and component of green tea. Shown to bind to AMPA, Kainate, NMDA and group I mGlu receptors. Displays neuroprotective effects in vivo. Promotes self-renewal of human embryonic stem cells (hESC)."	"Kakuda et al (2002) Inhibition by theanine of binding of [3H]AMPA, [3H]kainate, and [3H]MDL 105,519 to glutamate receptors. Biosci.Biotechnol.Biochem. 66 2683. PMID:12596867. Nagasawa et al (2004) Possible involvement of group I mGluRs in neuroprotective effect of theanine. Biochem.Biophys.Res.Comm. 320 116. Egashira et al (2008) Theanine prevents memory impairment induced by repeated cerebral ischemia in rats. Phytother.Res. 22 65. PMID:17705146. Desbordes et al (2008) High-throughput screening assay for the identification of compounds regulating self-renewal and differentiation in human embryonic stem cells. Cell Stem Cell. 2 602. PMID:18522853."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=248570				Mar-2010
3848	Sinomenine hydrochloride	[6080-33-7]	CN4C2[C@]3([H])[C@@](CC(C(OC)=C3)=O)(CC4)C1=C(O)C(OC)=CC=C1C2.Cl	Anti-inflammatory; causes mast cell degranulation and histamine release	"Natural anti-inflammatory morphinan analog. Causes degranulation of mast cells in mammalian tissues to release histamine and suppresses production of proinflammatory cytokines. Also displays antinociceptive activity, possibly through activation of the _-opioid receptor. Stimulates short-term renewal of human embryonic stem cells (ESCs) in vitro."	"Yamasaki (1976) Pharmacology of sinomenine, an anti-rheumatic alkaloid from Sinomenium acutum. Acta Med.Okayama 30 1. PMID:61710. Qian et al (2007) Sinomenine, a natural dextrorotatory morphinan analog, is anti-inflammatory and neuroprotective through inhibition of microglial NADPH oxidase. J.Neuroinflamm. 4 23. Desbordes et al (2008) High-throughput screening assay for the identification of compounds regulating self-renewal and differentiation in human embryonic stem cells. Cell Stem Cell 2 602. PMID:18522853. Wang et al (2008) Activation of opioid _-receptor by sinomenine in cell and mice. Neurosci.Lett. 443 209. PMID:18692550."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=248571				Apr-2010
3849	Gatifloxacin	[112811-59-3]	O=C2C(C(O)=O)=CN(C3CC3)C1=C(OC)C(N4CC(C)NCC4)=C(F)C=C12	Antibiotic; inhibits bacterial type II topoisomerase	Fluoroquinolone antibiotic. Inhibits bacterial type II topoisomerases (IC50 values are 0.109 and 13.8 _g/ml for E.coli DNA gyrase and S.aureus topoisomerase IV respectively). Displays potent activity against gram-positive and gram-negative bacteria. Stimulates short-term self-renewal in both human and mouse embryonic stem cells in vitro.	"Takei et al (1998) Inhibitory activities of gatifloxacin (AM-1155), a newly developed fluoroquinolone, against bacterial and mammalian type II topoisomerases. Antimicrob.Agents Chemother. 42 2678. PMID:9756776. Fukuda et al (1998) Antibacterial activity of gatifloxacin (AM-1155, CG5501, BMS-206584), a newly developed fluoroquinolone, against sequentially acquired quinolone-resistant mutants and the norA transformant of Staphylococcus aureus. Antimicrob.Agents Chemother. 42 1917. PMID:9687384. Desbordes et al (2008) High throughput screening assay for the identification of compounds regulating self-renewal and differentiation in human embryonic stem cells. Cell Stem Cell 2 602. PMID:18522853."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=248572				Apr-2010
3851	Cardiogenol C hydrochloride	[1049741-55-0]	OCCNC1=CC=NC(NC2=CC=C(OC)C=C2)=N1.Cl	Induces cardiomyocyte differentiation in ESCs	Induces differentiation of mouse embryonic stem cells (ESCs) into cardiomyocytes (EC50 = 100 nM).	Wu et al (2004) Small molecules that induce cardiomyogenesis in embryonic stem cells. J.Am.Chem.Soc. 126 1590. PMID:14871063.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=248589	SQ1533			Apr-2010
3852	Tranylcypromine hydrochloride	[1986-47-6]	N[C@H]1[C@H]([C@]2=CC=CC=C2)C1.Cl	Irreversible inhibitor of lysine-specific demethylase 1 (LSD1); also inhibits MAO	"Irreversible inhibitor of lysine-specific demethylase 1 (LSD1/BHC110) and monoamine oxidase (MAO). Inhibits histone demethylation. In combination with CHIR 99021 (Cat. No. 4423), enables reprogramming of mouse embryonic fibroblasts transduced by only two factors, Oct4 and Klf4, into induced pluripotent stem (iPS) cells."	Lee et al (2006) Histone H3 lysine 4 demethylation is a target of nonselective antidepressive medications. Chem.Biol. 13 563. PMID:16793513. Schmidt and McCafferty (2007) trans-2-Phenylcyclopropylamine is a mechanism-based inactivator of the histone demethylase LSD1. Biochemistry 46 4408. PMID:17367163. Li et al (2009) Generation of human-induced pluripotent stem cells in the absence of exogenous Sox2. Stem Cells 27 2992. PMID:19839055.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=248590	SQ1533			Apr-2010
3853	ID 8	[147591-46-6]	CC2=C([N+]([O-])=O)C1=CC=C(O)C=C1N2C3=CC=C(OC)C=C3	Sustains self-renewal and pluripotency of ESCs	Sustains self-renewal and pluripotency of mouse embryonic stem cells (ESCs) in vitro. Stimulates proliferation at a steady rate (observed in serum-free media supplemented with 10 _M over a 30 day period).	Miyabayashi et al (2008) Indole derivatives sustain embryonic stem cell self-renewal in long-term culture. Biosci.Biotechnol.Biochem. 72 1242. PMID:18460821. Firestone and Chen (2009) Controlling destiny through chemistry: small-molecule regulators of cell fate. ACS Chem.Biol. 5 15.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=248591	SQ1533			Apr-2010
3857	Dexrazoxane hydrochloride	[1263283-43-7]	C[C@@H](CN2CC(NC(C2)=O)=O)N(CC(N1)=O)CC1=O.Cl	Topoisomerase II inhibitor	Topoisomerase II inhibitor and intracellular ion chelator. Bridges and stabilizes an interface between two ATPase promoters to inhibit topoisomerase II activity. Cardioprotective when co-administered with doxorubicin; decreases formation of reactive oxygen species (ROS) and activates the PI3K/Akt survival pathway.	Classen et al (2003) Structure of the topoisomerase II ATPase region and its mechanism of inhibition by the chemotherapeutic agent ICRF-187. Proc.Natl.Acad.Sci. 100 10629. Lebrecht et al (2007) Dexrazoxane prevents doxorubicin-induced long-term cardiotoxicity and protects myocardial mitochondria from genetic and functional lesions in rats. Br.J.Pharmacol 151 771. PMID:17519947. Spallarossa et al (2010) Sublethal doses of an anti-erbB2 antibody leads to death by apoptosis in cardiomyocytes sensitized by low prosenescent doses of epirubicin: the protective role of dexrazoxane. J.Pharmacol.Exp.Ther. 332 87. PMID:19841470.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=248806	SQ1533			Jun-2010
3858	CH 223191	[301326-22-7]	CC1=C(/N=N/C2=CC=C(NC(C3=CC=NN3C)=O)C(C)=C2)C=CC=C1	Potent aryl hydrocarbon receptor (AhR) antagonist	"Potent and specific aryl hydrocarbon receptor (AhR) antagonist. Displays no AhR agonist activity (at concentrations up to 100 _M). Blocks binding of 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) to the AhR in a dose-dependent manner; also blocks TCDD-mediated translocation and DNA-binding activity of the AhR."	"Kim et al (2006) Novel compound 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazo-phenyl)-amide (CH-223191) prevents 2,3,7,8-TCDD-induced toxicity by antagonizing the aryl hydrocarbon receptor. Mol.Pharmacol. 69 1871. PMID:16540597. Veldhoen et al (2009) Natural agonists for aryl hydrocarbon receptor in culture medium are essential for optimal differentiation of TH17 T cells. J.Exp.Med. 206 43. PMID:19114668. Gramatzki et al (2009) Aryl hydrocarbon receptor inhibition downregulates the TGF-_/Smad pathway in human glioblastoma cells. Oncogene 28 2593. PMID:19465936. Dubrovska et al (2012) CXCR4 activation maintains a stem cell population in tamoxifen-resistant breast cancer cells through AhR signalling. Br.J.Cancer. 107 43. PMID:22644306."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=248879	SQ1070			May-2010
3859	"6,2',4'-Trimethoxyflavone"	[720675-74-1]	O=C1C3=C(C=CC(OC)=C3)OC(C2=CC=C(OC)C=C2OC)=C1	Aryl hydrocarbon receptor antagonist	Aryl hydrocarbon receptor antagonist (EC50 = 0.9 _M). Exhibits no short term agonist activity and no species or promoter dependence.	"Murray et al (2010) Antagonism of aryl hydrocarbon receptor signaling by 6,2',4'-trimethoxyflavone. J.Pharmacol.Exp.Ther. 332 135. PMID:19828881."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=248887	SQ1070			Mar-2010
3861	UNC 0224	[1197196-48-7]	CN(CC4)CCC4NC1=C2C(C=C(OCCCN(C)C)C(OC)=C2)=NC(N3CCCN(C)CC3)=N1	Potent G9a histone lysine methyltransferase inhibitor	Potent inhibitor of G9a histone lysine methyltransferase (IC50 = 15 nM).	"Liu et al (2009) Discovery of a 2,4-diamino-7-aminoalkoxyquinazoline as a potent and selective inhibitor of histone lysine methyltransferase G9a. J.Med.Chem. 52 7950. PMID:19891491."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=249021	SQ1070			Nov-2011
3862	Eletriptan hydrobromide	[177834-92-3]	CN1[C@@H](CC3=CNC2=CC=C(CCS(=O)(C4=CC=CC=C4)=O)C=C23)CCC1.Br	"Orally active, selective 5-HT1B/1D agonist"	"Orally active, selective 5-HT1B/1D receptor agonist. Produces a dose-dependent reduction in carotid artery blood flow in vivo. Displays antimigraine activity."	"Willems et al (1998) Porcine carotid vascular effects of eletriptan (UK-116,044): a new 5-HT1B/1D receptor agonist with anti-migraine activity. Naunyn-Schmied.Arch.Pharmacol. 358 212. Napier et al (1999) Characterisation of the 5-HT receptor binding profile of eletriptan and kinetics of [3H]-eletriptan binding at human 5-HT1B and 5-HT1D receptors. Eur.J.Pharmacol. 368 259. PMID:10193663. Gupta et al (2000) The in vivo pharmacological profile of eletriptan (UK-116,044): a potent and novel 5-HT(1B/1D) receptor agonist. Eur.J.Pharmacol. 398 73. PMID:10856450."	Small Molecule	Sold for research purposes under agreement from Pfizer Inc.	http://www.tocris.com/dispprod.php?ItemId=249024	SQ1533			Mar-2010
3863	Trovafloxacin mesylate	[147059-75-4]	O=C2C1=CC(F)=C(N4C[C@@]([C@H]5N)([H])[C@@]5([H])C4)N=C1N(C3=C(F)C=C(F)C=C3)C=C2C(O)=O.CS(=O)(O)=O	Antibiotic; inhibits bacterial DNA synthesis	Fluoroquinolone antibiotic. Inhibits bacterial DNA topoisomerase IV and DNA gyrase and forms a stable quinolone-DNA complex with these enzymes which reversibly inhibits DNA synthesis. Displays potent activity against gram-positive and gram-negative bacteria. Increases the production of mitochondrial NO in immortalized hepatocytes; also increases mitochondrial Ca2+. Inhibits Panx-1 (IC50 ~ 4_M).	"Neu and Chin (1994) In vitro activity of the new fluoroquinolone CP-99,219. Antimicrob.Agents Chemother. 38 2615. PMID:7872757. Gootz et al (1996) Activity of the new fluoroquinolone trovafloxacin (CP-99,219) against DNA gyrase and topoisomerase IV mutants of Streptococcus pneumoniae selected in vitro. Antimicrob.Agents Chemother. 40 2691. PMID:9124824. Poon et al (2014) Unexpected link between an antibiotic, pannexin channels and apoptosis. Nature 507 329. PMID:24646995."	Small Molecule	Sold for research purposes under agreement from Pfizer Inc.	http://www.tocris.com/dispprod.php?ItemId=249025	SQ1533			Mar-2010
3864	Oxcarbazepine	[28721-07-5]	NC(N(C(C=CC=C3)=C3C2)C1=CC=CC=C1C2=O)=O	Anticonvulsant; inhibits Na+ channel activity	Anticonvulsant; protects mice and rats against generalized tonic-clonic seizures induced by electroshock. Thought to act via inhibition of sodium channel activity.	"Schmutz et al (1994) Oxcarbazepine: preclinical anticonvulsant profile and putative mechanism of action. Epilepsia 35 S47. PMID:8039471. Ambrosio et al (2002) Mechanism of action of carbamazepine and its derivatives, oxcarbazepine, BIA 2-093, and BIA 2-024. Neurochem.Res. 27 121. PMID:11926264. Zheng et al (2009) Oxcarbazepine, not its active metabolite, potentiates GABAA activation and aggravates absence seizures. Epilepsia 50 83. PMID:18717705."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=249027	SQ1533			Apr-2010
3865	Licarbazepine	[29331-92-8]	NC(N2C1=CC=CC=C1C(O)CC3=C2C=CC=C3)=O	Active metabolite of oxcarbazepine (Cat. No. 3684)	Active metabolite of oxcarbazepine (Cat. No. 3864). Produces dose-dependent inhibition of glutamatergic excitatory postsynaptic potentials (EPSPs). Displays anticonvulsant activity; exhibits minor potentiation of GABAA receptor currents.	"Calabresi et al (1995) Action of GP 47779, the active metabolite of oxcarbazepine, on the corticostriatal system. I. Modulation of corticostriatal synaptic transmission. Epilepsia 36 990. PMID:7555963. Benes et al (1999) Anticonvulsant and sodium channel-blocking properties of novel 10,11-dihydro-5H-dibenz[b,f]azepine-5-carboxamide derivatives. J.Med.Chem. 42 2582. PMID:10411478. Zheng et al (2009) Oxcarbazepine, not its active metabolite, potentiates GABAA activation and aggravates absence seizures. Epilepsia 50 83. PMID:18717705."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=249030	SQ1070			Jul-2010
3866	SKF 86466 hydrochloride	[86129-54-6]	CN2CCC1=CC=CC(Cl)=C1CC2.Cl	Potent and selective _2 antagonist	Potent and selective _2 antagonist at pre- and post-junctional _2-adrenoceptors (Ki values are 13 and 17 nM respectively). Exhibits antihypertensive activity in a rat model.	"Hieble et al (1985) Selective Alpha-2 adrenoceptor blockade by SK&F 86466: in vitro characterization of receptor sensitivity. J.Pharmacol.Exp.Ther. 236 90. Roesler et al (1986) Characterization of the antihypertensive activity of SK&F 86466, a selective alpha-2 antagonist, in the rat. J.Pharmacol.Exp.Ther. 236 1. PMID:2867209. Schafers et al (1990) An evaluation of the alpha-adrenoceptor antagonism produced by SK&F 86466 in healthy normotensive males. Br.J.Clin.Pharmacol. 30 884. PMID:1981137."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=249093	SQ1070			May-2011
3868	CHM 1	[154554-41-3]	O=C2C=C(C3=CC=CC=C3F)NC1=CC4=C(OCO4)C=C12	Potent antitumor agent; inducer of apoptosis	Inducer of apoptosis; displays potent antitumor ability in human hepatocellular carcinoma. Inhibits tubulin polymerization in vitro and in vivo. Causes cell cycle arrest at G2/M phase by activation of Cdc2 kinase activity. Induces translocation of apoptosis inducing factor (AIF) from the mitochondria to nucleus. Also exhibits vascular targeting activity through upregulation of p53 and induction of death receptor (DR5)-mediated apoptosis in HUVEC cells.	"Wang et al (2008) CHM-1, a novel synthetic quinolone with potent and selective antimitotic antitumor activity against human hepatocellular carcinoma in vitro and in vivo. Mol.Cancer.Ther. 7 350. PMID:18281518. Tsai et al (2010) CHM-1, a new vascular targeting agent, induces apoptosis of human umbilical vein endothelial cells via p53-mediated death receptor 5 up-regulation. J.Biol.Chem. 285 5497. PMID:20007968."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=249098	SQ1070			Sep-2010
3869	TCS 2002	[1005201-24-0]	O=S(C)C(C=C3)=CC=C3C2=COC1=CC=C(C4=NN=C(C)O4)C=C12	Potent GSK-3_ inhibitor	Potent inhibitor of GSK-3_ (IC50 = 35 nM). Oral adminstration inhibits cold water stress-induced tau hyperphosphorylation in the mouse brain.	"Saitoh et al (2009) 2-{3-[4-(alkylsulfinyl)phenyl]-1-benzofuran-5-yl}-5-methyl-1,3,4-oxadiazole derivatives as novel inhibitors of glycogen synthase kinase-3_ with good brain permeability. J.Med.Chem. 52 6270. PMID:19775160."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=249103	SQ1070			Sep-2010
3870	()-PPCC oxalate	[932736-91-9]	CC(C=C3)=CC=C3[C@@]1(C(OC)=O)C[C@@H]1CN2CCC(C4=CC=CC=C4)(O)CC2.CC(C=C7)=CC=C7[C@]5([C@](OC)=O)C[C@H]5CN6CCC(C8=CC=CC=C8)(O)CC6.O=C(O)C(O)=O.O=C(O)C(O)=O	Selective sigma (_) agonist (_1> _2)	"Selective sigma (_) receptor ligand. Displays high affinity for _1; also binds at _2 sites (Ki = 1.5 nM and 50.8 nM respectively). Selective over a range of receptor types including dopaminergic and muscarinic receptors, DAT and SERT."	"Prezzavento et al (2007) Novel sigma receptor ligands: synthesis and biological profile. J.Med.Chem. 50 951. PMID:17328523. Prezzavento et al (2008) A new sigma ligand, ()-PPCC, antagonizes kappa opioid receptor-mediated antinociceptive effect. Life Sci. 82 549. PMID:18261749. Antonini et al (2009) Anti-amnesic properties of ()-PPCC, a novel sigma receptor ligand, on cognitive dysfunction induced by selective cholinergic lesion in rats. J.Neurochem. 109 744. PMID:19245662."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=249108	SQ1070			Aug-2010
3871	Etodolac	[41340-25-4]	CCC1(CC(O)=O)OCCC3=C1NC2=C(CC)C=CC=C23	Selective cyclooxygenase-2 (COX-2) inhibitor; NSAID	Non-steroidal anti-inflammatory drug (NSAID) that selectively inhibits cyclooxygenase-2 (COX-2) (IC50 values are 53 and >100 _M for COX-2 and COX-1 respectively). Displays anti-inflammatory effects in both adjuvant arthritic and normal rats.	"Kato et al (2001) Cyclooxygenase-1 and cyclooxygenase-2 selectivity of non-steroidal anti-inflammatory drugs: investigation using human peripheral monocytes. J.Pharm.Pharmacol. 53 1679. PMID:11804398. Tachibana et al (2003) Anti-inflammatory effect and low ulcerogenic activity of etodolac, a cyclooxygenase-2 selective non-steroidal anti-inflammatory drug, on adjuvant-induced arthritis in rats. Pharmacology 68 96. PMID:12711837. Shi et al (2004) Pharmacokinetic difference between S-(+)- and R-(-)-etodolac in rats. Acta Pharmacol.Sinica 25 996."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=249116	SQ1533			Apr-2010
3872	EHT 1864	[754240-09-0]	O=C1C=C(CN4CCOCC4)OC=C1OCCCCCSC3=CC=NC2=CC(C(F)(F)F)=CC=C23.Cl.Cl	Potent inhibitor of Rac family GTPases	"Inhibitor of Rac family GTPases. Blocks activation by direct binding to Rac1, Rac1b, Rac2 and Rac3 (KD values are 40, 50, 60 and 250 nM respectively). Inhibits Rac, Ras and Tiam-induced growth transformation of NIH-3T3 fibroblasts. Reduces _-amyloid peptide production in vivo."	"Desire et al (2005) RAC1 inhibition targets amyloid precursor protein processing by _-secretase and decreases A_ production in vitro and in vivo. J.Biol.Chem. 280 37516. PMID:16150730. Shutes et al (2007) Specificity and mechanism of action of EHT 1864, a novel small molecule inhibitor of rac family small GTPases. J.Biol.Chem. 282 35666. PMID:17932039. Onesto et al (2008) Characterization of EHT1864, a novel small molecule inhibitor of Rac family small GTPases. Methods Enzymol. 439 111. PMID:18374160."	Small Molecule	Sold for research use only under license from ExonHit Therapeutics S.A.	http://www.tocris.com/dispprod.php?ItemId=249169	SQ1533			Mar-2010
3873	MeBIO	[667463-95-8]	O/N=C(C1=CC=CC=C1N2)/C2=C3/C(N(C)C4=C3C=CC(Br)=C4)=O	Inactive analog of BIO (Cat. No. 3194)	"Control analog of 6-bromoindirubin-3'-oxime (BIO, Cat. No. 3194). Displays minimal activity against CDK1/Cyclin B, GSK-3 _/_, and CDK5/p25 (IC50 values are 92.0, 44-100 and >100 _M respectively). Aryl hydrocarbon receptor (AhR) agonist; causes redistribution of AhR to the nucleus."	Meijer et al (2003) GSK-3-selective inhibitors derived from tyrian purple indirubins. Chem.Biol. 10 1255. PMID:14700633. Polychronopoulos et al (2004) Structural basis for the synthesis of indirubins as potent and selective inhibitors of glycogen synthase kinase-3 and cyclin-dependent kinases. J.Med.Chem. 47 935. PMID:14761195. Knockaert et al (2004) Independent actions on cyclin-dependent kinases and aryl hydrocarbon receptor mediate the antiproliferative effects of indirubins. Oncogene 23 4400. PMID:15077192.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=249184				Jun-2010
3874	BIO-acetoxime	[667463-85-6]	O=C(NC4=C3C=CC(Br)=C4)/C3=C2NC1=CC=CC=C1/C/2=N\OC(C)=O	Selective GSK-3_/_ inhibitor	"Selective GSK-3_/_ inhibitor (IC50 values are 0.01, 2.4, 4.3 and 63 _M for GSK-3_/_, CDK5/p25, CDK2/cyclin A and CDK1/cyclin B respectively). Induces Wnt signaling and inhibits CD8+ T cell effector differentiation."	Meijer et al (2003) GSK-3-selective inhibitors derived from Tyrian purple indirubins. Chem.Biol. 10 1255. PMID:14700633. Polychronopoulos et al (2004) Structural basis for the synthesis of indirubins as potent and selective inhibitors of glycogen synthase kinase-3 and cyclin-dependent kinases. J.Med.Chem. 47 935. PMID:14761195. Gattinoni et al (2009) Wnt signaling arrests T cell differentiation and generates CD8+ memory stem cells. Nat.Med. 15 808. PMID:19525962.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=249185	SQ1533			Apr-2010
3875	BCTC	[393514-24-4]	ClC1=CC=CN=C1N2CCN(C(NC3=CC=C(C(C)(C)C)C=C3)=O)CC2	TRPV1 antagonist	Orally effective vanilloid receptor 1 (TRPV1 receptor) antagonist. Inhibits acid- and capsaicin-induced activation of rat TRPV1 receptors (IC50 values are 6.0 and 35 nM respectively). Displays analgesic properties in rat models of inflammatory and neuropathic pain. CNS penetrant.	"Pomonis et al (2003) N-(4-Tertiarybutylphenyl)-4-(3-cholorphyridin-2-yl)tetrahydropyrazine -1(2H)-carbox-amide (BCTC), a novel, orally effective vanilloid receptor 1 antagonist with analgesic properties: II. In vivo characterization in rat models of inflammatory and neuropathic pain. J.Pharmacol.Exp.Ther. 306 387. PMID:12721336. Valenzano et al (2003) N-(4-tertiarybutylphenyl)-4-(3-chloropyridin-2-yl)tetrahydropyrazine -1(2H)-carbox-amide (BCTC), a novel, orally effective vanilloid receptor 1 antagonist with analgesic properties: I. In vitro characterization and pharmacokinetic properties. J.Pharmacol.Exp.Ther. 306 377. PMID:12721338."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=249190	SQ1070			Jun-2010
3877	TCS 2210	[1201916-31-5]	O=C(NO)C3=CC1=C(C=C3)NC(C(CCCC2=CC=CC=C2)=N1)=O	Inducer of neuronal differentiation in MSCs	Inducer of neuronal differentiation in mesenchymal stem cells (MSCs) with specific phenotype change. Increases expression of neuronal markers _-III tubulin and NSE without cytotoxicity.	Kim et al (2009) Discovery of a new and efficient small molecule for neuronal differentiation from mesenchymal stem cell. J.Med.Chem. 52 7931. PMID:20014867.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=249239	SQ1070			Sep-2011
3878	FFN 511	[1004548-96-2]	NCCC(C1=C(O4)C3=C2C(CCCN2CCC3)=C1)=CC4=O	Fluorescent substrate for VMAT2	Fluorescent false neurotransmitter (FFN). Targets neuronal vesicular monoamine transporter (VMAT) 2; inhibits serotonin binding to VMAT2 (IC50 = 1 _M).	Gubernator et al (2009) Fluorescent false neurotransmitters visualize dopamine release from individual presynaptic terminals. Science 324 1441. PMID:19423778. Zhang et al (2009) Dopamine release at individual presynaptic terminals visualized with FFNs. J.Vis.Exp. 30. PMID:19721412.	Small Molecule	Sold with the permission of Columbia University	http://www.tocris.com/dispprod.php?ItemId=249378				Jul-2010
3887	PG 01037 dihydrochloride	[675599-62-9]	ClC(C(Cl)=CC=C4)=C4N(CC3)CCN3C/C=C/CNC(C1=CC=C(C2=NC=CC=C2)C=C1)=O.Cl.Cl	D3 receptor selective antagonist	"Dopamine D3 receptor antagonist; 133-fold selective for D3 over D2 receptors in vitro (Ki values are 0.70, 93.3 and 375 nM for D3, D2 and D4 receptors respectively). Attenuates abnormal involuntary movements associated with L-DOPA (Cat. No. 3788) in rat models of Parkinson's disease. Inhibits the effects of methamphetamine; attenuates drug-induced behaviors in vivo."	"Grundt et al (2005) Novel heterocyclic trans olefin analogues of N-{4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butyl}arylcarboxamides as selective probes with high affinity for the dopamine D3 receptor. J.Med.Chem. 48 839. PMID:15689168. Grundt et al (2007) Heterocyclic analogues of N-(4-(4-(2,3-dichlorophenyl)piperazin-1-butyl)arylcarboxamides with functionalized linking chains as novel dopamine D3 receptor ligands: potential substance abuse therapeutic agents. J.Med.Chem. 50 4135. PMID:17672446. Kumar et al (2009) Evaluation of the D3 dopamine receptor selective antagonist PG01037 on L-dopa-dependent abnormal involuntary movements in rats. Neuropharmacology 56 944. PMID:19371585. Mason et al (2010) Characterization of the transport, metabolism, and pharmacokinetics of the dopamine D3 receptor-delective fluorenyl-and 2-pyridylphenyl amides developed for treatment of psychostimulant abuse. J.Pharm.Exp.Ther. 333 854."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=250603	SQ1070			Dec-2010
3888	VU 0240551	[893990-34-6]	O=C(NC3=NC(C)=CS3)CSC(C=C2)=NN=C2C1=CC=CC=C1	KCC2 inhibitor	"Inhibitor of the neuronal K-Cl cotransporter, KCC2 (IC50 = 560 nM for K+ uptake assay in KCC2-overexpressing cells). Exhibits selectivity over the Na-K-2Cl cotransporter, NKCCl. Also inhibits hERG and L-type Ca2+ channels."	"Delpire et al (2009) Small-molecule screen identifies inhibitors of the neuronal K-Cl cotransporter KCC2. Proc.Natl.Acad.Sci.USA 106 5383. PMID:19279215. Delpire et al (2012) Further optimization of the K-Cl cotransporter KCC2 antagonist ML077: development of a highly selective and more potent in vitro probe. Bioorg.Med.Chem.Lett. 22 4532. PMID:22727639. Deisz et al (2014) Effects of VU0240551, a novel KCC2 antagonist, and DIDS on chloride homeostasis of neocortical neurons from rats and humans. Neuroscience 277 831. PMID:25086309."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=250604	SQ1070			Jun-2010
3889	GANT 58	[64048-12-0]	C1(C5=CC=NC=C5)=C(C3=CC=NC=C3)C(C2=CC=NC=C2)=C(C4=CC=NC=C4)S1	GLI1 antagonist; inhibits Hedgehog (Hh) signaling	GLI antagonist that inhibits GLI1-induced transcription (IC50 = 5 _M). Inhibits the hedgehog (Hh) signaling pathway downstream of SMO and SUFU causing GLI1 nuclear accumulation. Displays antiproliferative and antitumor activity in vivo.	Lauth et al (2007) Inhibition of GLI-mediated transcription and tumor cell growth by small-molecule antagonists. Proc.Natl.Acad.Sci. 104 8455. PMID:17494766. Beauchamp et al (2009) GLI1 is a direct transcriptional target of EWS-FLI1 oncoprotein. J.Biol.Chem. 284 9074. PMID:19189974. Joo et al (2009) GLI1 is a central mediator of EWS/FLI1 signaling in Ewing tumors. PLoS ONE 4 7608. PMID:19859563.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=250605	SQ1533			Aug-2010
3890	WAY 207024 dihydrochloride	[872002-73-8]	CC(C)(C)C(C=C6)=CC=C6C(N5)=NC1=C5C(N(CC4)CCN4CC2=CC=C(N=CC=N3)C3=C2)=CC=C1.Cl.Cl	GnRH receptor antagonist	Gonadotropin releasing hormone receptor (GnRH-R) antagonist. Exhibits potent affinity (IC50 values are 12 and 71 nM for human and rat GnRH receptors respectively). Lowers plasma leuteinizing hormone levels in the rat. Orally active.	Pelletier et al (2009) Discovery of 6-({4-[2-(4-tert-butylphenyl)-1H-benzimidazol-4-yl]piperazin-1-yl}methyl)quinoxaline (WAY-207024): an orally active antagonist of the gonadotropin releasing hormone receptor (GnRH-R). J.Med.Chem. 52 214. PMID:19072222.	Small Molecule	Sold for research purposes under agreement from Pfizer Inc.	http://www.tocris.com/dispprod.php?ItemId=250606	SQ1070			Mar-2011
3891	VU 590 dihydrochloride	[313505-85-0]	O=[N+](C(C=C2)=CC=C2CN1CCOCCOCCN(CC3=CC=C([N+]([O-])=O)C=C3)CCOCC1)[O-].Cl.Cl	Inhibitor of Kir1.1 (ROMK) and Kir7.1	"Inhibits the renal outer medullary potassium channel (Kir1.1, ROMK) (IC50 = 294 nM). Also inhibits the inward retifying K+ channel Kir7.1; displays no effect upon Kir2.1 or Kir4.1. Acts as an intracellular Kir1.1 channel pore blocker."	Lewis et al (2009) High-throughput screening reveals a small-molecule inhibitor of the renal outer medullary potassium channel and Kir7.1. Mol.Pharmacol. 76 1094. PMID:19706730.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=250607				Aug-2010
3892	NF 546	[1006028-37-0]	[Na+].[Na+].[Na+].[Na+].CC1=CC=C(C=C1NC(=O)C1=CC=CC(NC(=O)NC2=CC=CC(=C2)C(=O)NC2=C(C)C=CC(=C2)C(=O)NC2=CC=C(CP(O)([O-])=O)C=C2CP(O)([O-])=O)=C1)C(=O)NC1=C(CP(O)([O-])=O)C=C(CP(O)([O-])=O)C=C1	Selective P2Y11 agonist	P2Y11 agonist (pEC50 = 6.27). Exhibits selectivity for P2Y11 over a range of P2Y and P2X receptors.	"Meis et al (2010) NF546 [4,4'-(carbonylbis(imino-3,1-phenylene-carbonylimino-3,1-(4-methyl-phenylene)-carbonylimino))-bis(1,3-xylene-_,_'-diphosphonic acid) tetrasodium salt] is a non-nucleotide P2Y11 agonist and stimulates release of interleukin-8 from human monocyte-derived dendritic cells. J.Pharmacol.Exp.Ther. 332 238. PMID:19815812."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=250688				Feb-2011
3894	PP 121	[1092788-83-4]	NC1=C2C(N(C5CCCC5)N=C2C3=CN=C(NC=C4)C4=C3)=NC=N1	Dual kinase inhibitor; inhibits PI 3-K family kinases	"Dual inhibitor of receptor tyrosine kinases (RTKs) (IC50 < 0.02 _M for Abl, Src, VEGFR-2 and PDGFR) and PI 3-K family kinases (IC50 < 0.06 _M for p110_, DNA-PK and mTOR). Exhibits no significant effect on receptor serine/threonine kinases (RSTKs). Blocks the proliferation of tumor cells by direct inhibition of PI 3-K, mTOR, Src and the VEGF receptor."	Apsel et al (2008) Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases. Nat.Chem.Biol. 4 691. PMID:18849971.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=250776	SQ1533			Jan-2011
3895	NS 309	[18711-16-5]	ClC1=C2C(C(C(N2)=O)=NO)=CC=C1Cl	Positive modulator of KCa2 and KCa3.1 channels	Positive modulator of small- and intermediate- conductance Ca2+-activated K+ channels (KCa2 and KCa3.1 channels); increases Ca2+ sensitivity. Displays no activity at BK channels.	"Strobaek et al (2004) Activation of human IK and SK Ca2+-activated K+ channels by NS309 (6,7-dichloro-1H-indole-2,3-dione 3-oxime). Biochim.Biophys.Acta 1665 1. PMID:15471565. Morimura et al (2006) Voltage-dependent Ca2+-channel block by openers of intermediate and small conductance Ca2+-activated K+ channels in urinary bladder smooth muscle cells. J.Pharm.Sci. 100 237. Grgic et al (2009) Endothelial Ca2+-activated K+ channels in normal and impaired EDHF-dilator responses - relevance to cardiovascular pathologies and drug discovery. Br.J.Pharmacol. 157 509. PMID:19302590."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=250777				Jun-2010
3896	Rotigotine hydrochloride	[125572-93-2]	CCCN(CCC3=CC=CS3)[C@H]2CCC1=C(O)C=CC=C1C2.Cl	Dopamine D2/D3 agonist	Dopamine D2 and D3 receptor agonist. Ki values are 13 and 0.71 nM for D2 and D3 respectively. Also has significant affinity for 5-HT1A and adrenergic _2B receptors. Exhibits antiparkinsonian acitivity.	"Belluzzi et al (2004) N-0923, a selective dopamine D2 receptor agonist, is efficacious in rat and monkey models of Parkinson's disease. Mov.Disord. 9 147. Scheller et al (2009) The in vitro receptor profile of rotigotine: a new agent for the treatment of Parkinson's disease. Naunyn.Schmiedebergs.Arch.Pharmacol. 379 73. PMID:18704368."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=250778	SQ1533			Jul-2010
3897	API-1	[36707-00-3]	O[C@@H]1[C@@H](CO)O[C@@H](N2C(N=CN=C3N)=C3C(C(C(N)=O)=C2)=O)[C@@H]1O	Selective Akt/PKB inhibitor. Antitumor	"Akt/protein kinase B (PKB) inhibitor. Binds the pleckstrin homology domain of Akt and blocks Akt membrane translocation. Inhibits EGF-induced kinase activity of Akt1, AKT2 and AKT3. Activity results in cell growth arrest and apoptosis in human cancer cells with constitutively active Akt. Displays antitumor activity in vitro and in vivo."	Kim et al (2010) A small molecule inhibits Akt through direct binding to Akt and preventing Akt membrane translocation. J.Biol.Chem. 285 8383. PMID:20068047.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=250779	SQ1070			Oct-2010
3898	SF 11	[443292-81-7]	S=C(N2CCC(C(C4=CC=CC=C4)(O)C3=CC=CC=C3)CC2)NC1=CC=C(OCC)C=C1	NPY Y2 receptor antagonist	NPY Y2 antagonist (IC50 = 199 nM). Displays no affinity for Y1 receptor at concentrations up to 35 _M. Causes significant lethality in mice. Brain penetrant.	Brothers et al (2010) Selective and brain penetrant neuropeptide Y Y2 receptor antagonists discovered by whole-cell high-throughput screening. Mol.Pharmacol. 77 46. PMID:19837904.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=251315	SQ1070			May-2010
3899	JNJ 303	[878489-28-2]	O=C(C(C)(C)OC4=CC=C(Cl)C=C4)NC2C1CC(CC2C3)CC3(NS(=O)(C)=O)C1	Potent and selective IKs blocker	"Potent IKs blocker (IC50 = 64 nM). Displays no effects on other cardiac channels; IC50 values are 3.3, >10, 11.1 and 12.6 _M for INa, ICa, Ito and IKr currents respectively. Prolongs QT and causes unprovoked torsades de pointes (TdP)."	Towart et al (2009) Blockade of the IKs potassium channel: an overlooked cardiovascular liability in drug safety screening? J.Pharm.Toxicol.Meth 60 1.	Small Molecule	Sold with the permission of Janssen Pharmaceutica NV	http://www.tocris.com/dispprod.php?ItemId=251912	SQ1070			Apr-2010
3900	TCS 2314	[317353-73-4]	O=C(N2CCOC[C@H]2[C@@](N3CCC(CC(O)=O)CC3)=O)CC1=CC=C(NC(NC4=C(C)C=CC=C4)=O)C=C1	_4_1 (VLA-4) antagonist	Integrin very late antigen-4 (VLA-4; _4_1) antagonist (IC50 = 4.4 nM). Blocks the activation of inflammatory cells.	"Muro et al (2009) Discovery of trans-4-[1-[[2,5-Dichloro-4-(1-methyl-3-indolylcarboxamido)phenyl]acetyl]-(4S)-methoxy-(2S)-pyrrolidinylmethoxy]cyclohexanecarboxylic acid: an orally active, selective very late antigen-4 antagonist. J.Med.Chem. 52 7974. PMID:19891440."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=251944	SQ1070			Nov-2010
3904	WAY 208466 dihydrochloride	[1207064-61-6]	O=S(C2=CN(CCN(C)C)C1=NC=CC=C12)(C3=CC=CC(F)=C3)=O.Cl.Cl	Selective 5-HT6 agonist	"High affinity, selective 5-HT6 agonist (EC50 = 7.3 nM at the human 5-HT6 receptor). Elevates cortical GABA levels in vivo in rat frontal cortex. Exhibits antidepressant and anxiolytic-like effects."	Schechter et al (2008) Neuropharmacological profile of novel and selective 5-HT6 receptor agonists: WAY-181187 and WAY-208466. Neuropsychopharmacol 33 1323. PMID:17625499. Carr et al (2010) Antidepressant and anxiolytic effects of selective 5-HT6 receptor agonists in rats. Psychopharmacol.(Berl.) 213 49. PMID:20217056.	Small Molecule	Sold for research purposes under agreement from Pfizer Inc.	http://www.tocris.com/dispprod.php?ItemId=252034	SQ1070			Mar-2011
3906	Betulinic acid	[472-15-1]	O[C@H]1CC[C@@]2(C)[C@](CC[C@]3(C)[C@@]([H])2CC[C@@]4([H])[C@](C)3CC[C@]5([C@](O)=O)[C@@]([H])4[C@H]([C@@](C)=C)CC5)([H])C(C)1C	Antitumor and anti-HIV agent; activates NF-_B. Also TGR5 agonist	Natural triterpenoid that displays anti-HIV and antitumor activity. Induces the production of reactive oxygen species (ROS) and activates NF-_B. Exhibits TGR5 agonist activity (EC50 = 1.04 _M).	"Kashiwada et al (1996) Betulinic acid and dihydrobetulinic acid derivatives as potent anti-HIV agents. J.Med.Chem. 39 1016. PMID:8676334. Fulda (2008) Betulinic acid for cancer treatment and prevention. Int.J.Mol.Sci. 9 1096. PMID:19325847. Genet et al (2010) Structure-activity relationship study of betulinic acid, a novel and selective TGR5 agonist, and its synthetic derivatives: potential impact in diabetes. J.Med.Chem. 53 178. PMID:19911773."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=252964	SQ1533			May-2010
3908	Ibutilide hemifumarate	[122647-32-9]	CCCCCCCN(CC)CCCC(O)C1=CC=C(NS(C)(=O)=O)C=C1.O=C(/C=C/C(O)=O)O.CCCCCCCN(CC)CCCC(O)C2=CC=C(NS(C)(=O)=O)C=C2	"Blocks IKr, hERG and L-type Ca2+ channels; class III antiarrhythmic"	Class III antiarrhythmic. Blocks the rapid component of delayed rectifier K+ current (IKr); also blocks hERG channels and L-type Ca2+ channels. Shown to activate a slow inward Na+ current in guinea pig ventricular cells. Used to terminate atrial fibrillation and atrial flutter; can prolong QT.	Merck Index 12 4927. Murray (1998) Ibutilide. Circulation 97 493. PMID:9490245. Lee and Lee (1998) Ionic mechanism of ibutilide in human atrium: evidence for a drug-induced Na+ current through nifedipine inhibited inward channel. J.Pharmacol.Exp.Ther. 286 9. PMID:9655836. Perry et al (2004) Structural determinants of HERG channel block by clofilium and ibutilide. Mol.Pharmacol. 66 240. PMID:15266014.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=253444	SQ1533			Sep-2013
3909	Toceranib	[356068-94-5]	O=C2NC1=CC=C(F)C=C1/C2=C/C3=C(C)C(C(NCCN4CCCC4)=O)=C(C)N3	Potent PDGFR and VEGFR inhibitor	"Potent ATP-competitive PDGFR and VEGFR inhibitor (Ki = 5 and 6 nM, respectively); inhibits phosphorylation of c-Kit and suppresses the growth of mast cell lines expressing mutant Kit, inducing cell cycle arrest and apoptosis. Also inhibits FGFR1 (Ki = 0.5 _M). Effective in vivo."	Liao et al (2002) Inhibition of constitutively active forms of mutant kit by multitargeted indolinone tyrosine kinase inhibitors. Blood. 100 585. PMID:12091352.	Small Molecule	Sold for research purposes under agreement from Pfizer.	http://www.tocris.com/dispprod.php?ItemId=253448				Aug-2014
3911	S 18986	[175340-20-2]	O=S2(C1=CC=CC=C1N(CCC3)[C@@]3([H])N2)=O	Positive allosteric modulator of AMPA	Positive allosteric modulator of AMPA receptors. Exhibits cognitive enhancing properties in rodent behavioral models. Brain penetrant.	"Desos et al (1996) Enantioselective synthesis of a pyrrolo-benzothiadiazine derivative S 18986, a new AMPA receptor positive modulator. Bioorg.Med.Chem.Lett. 6 3003. Lockhart et al (2000) (S)-2,3-dihydro-[3,4]cyclopentano-1,2,4-benzothiadiazine-1,1-dioxide: (S18986-1) a positive modulator of AMPA receptors enhances (S)-AMPA-mediated [3H]noradrenaline release from rat hippocampal and frontal cortex slices. Eur.J.Pharmacol. 401 145. PMID:10924919. Bourasset et al (2005) Neuropharmacokinetics of a new _-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) modulator, S18986 [(S)-2,3-dihydro-[3,4]cyclopentano-1,2,4-benzothiadiazine-1,1-dioxide], in the rat. Drug Metab.Dispos. 33 1137. PMID:15860654."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=253457	SQ1070			Dec-2011
3912	HX 531	[188844-34-0]	CC1(C)C2=C(C=C(N(C)C(C=CC([N+]([O-])=O)=C5)=C5N=C3C4=CC=C(C(O)=O)C=C4)C3=C2)C(C)(C)CC1	Potent RXR antagonist	Potent RXR antagonist (IC50 = 18 nM).	"Ebisawa et al (1999) Retinoid X receptor-antagonistic diazepinylbenzoic acids. Chem.Pharm.Bull. 47 1778. PMID:10748721. Alique et al (2006) Vitamin A active metabolite, all-trans retinoic acid, induces spinal cord sensitization. II. Effects after intrathecal administration. Br.J.Pharmacol. 149 65. PMID:16847438. Suzuki et al (2009) Docosahexaenoic acid induces adipose differentiation-related protein through activation of retinoid X receptor in human choriocarcinoma BeWo cells. Biol.Pharm.Bull. 32 1177. PMID:19571381."	Small Molecule	Sold under licence.	http://www.tocris.com/dispprod.php?ItemId=253458	SQ1070			Jul-2011
3913	HX 630	[188844-52-2]	CC3(C)CCC(C)(C)C(C3=C4)=CC2=C4C(C5=CC=C(C(O)=O)C=C5)=NC1=CC=CC=C1S2	RXR synergist	RXR agonist. Acts as a retinoid synergist; enhances the potency of AM 80 (Cat. No. 3507) in a HL-60 cell differentiation assay.	Umemiya et al (1997) Regulation of retinoidal actions by diazepinylbenzoic acids. Retinoid synergists which activate the RXR-RAR heterodimers. J.Med.Chem. 40 4222. PMID:9435893. Ohashi et al (2002) Effect of natural and synthetic retinoids on the proliferation and differentiation of three canine melanoma cell lines. J.Vet.Med.Sci. 64 169. PMID:11913557. Ishida et al (2003) Clinically potential subclasses of retinoid synergists revealed by gene expression profiling. Mol.Cancer Ther. 2 49. PMID:12533672.	Small Molecule	Sold under licence.	http://www.tocris.com/dispprod.php?ItemId=253459	SQ1070			Aug-2011
3914	A 419259 trihydrochloride	[1435934-25-0]	NC1=C2C(N([C@H]5CC[C@H](N6CCN(C)CC6)CC5)C=C2C3=CC=C(OC4=CC=CC=C4)C=C3)=NC=N1.Cl.Cl.Cl	Inhibitor of Src family kinases	Inhibitor of Src family kinases (SFK) (IC50 = 0.1 - 0.3 _M). Suppresses proliferation and induces apoptosis in CML cell lines including CD34+. Blocks Stat5 and Erk activation in vivo. Displays no inhibition of EGFR kinase activity in HNSCC cells.	"Wilson et al (2002) Selective pyrrolo-pyrimidine inhibitors reveal a necessary role for Src family kinases in Bcr-Abl signal transduction and oncogenesis. Oncogene 21 8075. PMID:12444544. Zhang et al (2004) Src family kinases mediate epidermal growth factor receptor ligand cleavage, proliferation, and invasion of head and neck cancer cells. Cancer Res. 64 6166. PMID:15342401. Pene-Dumitrescu et al (2008) An inhibitor-resistant mutant of Hck protects CML cells against the antiproliferative and apoptotic effects of the broad spectrum Src family kinase inhibitor A-419259. Oncogene 27 7055. PMID:18794796."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=253548	SQ1070			Apr-2011
3915	VX 745	[209410-46-8]	O=C2N=CN1N=C(SC4=CC=C(F)C=C4F)C=CC1=C2C3=C(Cl)C=CC=C3Cl	Potent and selective p38_ inhibitor	"Highly potent and selective p38_ inhibitor (IC50 = 10 nM). Also blocks TNF_ production in LPS-stimulated HWB in vitro (IC50 = 177 nM). Displays 1000-fold selectivity over closely related kinases, including ERK1, MK2 and JNK1-3."	Bagley et al (2007) Rapid synthesis of VX-745: p38 MAP kinase inhibition in Werner syndrome cells. Bioorg.Med.Chem.Lett. 17 5107. PMID:17659871. Goldstein et al (2010) Selective p38alpha inhibitors clinically evaluated for the treatment of chronic inflammatory disorders. J.Med.Chem. 53 2345. PMID:19950901. Duffy et al (2011) The discovery of VX-745: a novel and selective p38_ kinase inhibitor. ACS Med.Chem.Lett. 2 758.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=253577	SQ1533			Jan-2011
3916	VX 702	[479543-46-9]	NC(N(C3=C(F)C=CC=C3F)C1=CC=C(C(N)=O)C(C2=C(F)C=C(F)C=C2)=N1)=O	Orally active p38_ and p38_ inhibitor	"Orally active, ATP-competitive inhibitor of p38_ MAPK; also inhibits p38_ (KD values are 3.7 and 17 nM respectively)."	"Din (2006) Drug evaluation: VX-702, a MAP kinase inhibitor for rheumatoid arthritis and acute coronary syndrome. Curr.Opin.Investig.Drugs 7 1020. PMID:17117592. Damjanov et al (2009) Efficacy, pharmacodynamics, and safety of VX-702, a novel p38 MAPK inhibitor, in rheumatoid arthritis. Arthrit.Rheumat. 60 1232. Goldstein et al (2010) Selective p38_ inhibitors clinically evaluated for the treatment of chronic inflammatory disorders. J.Med.Chem. 53 2345. PMID:19950901."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=253578	SQ1533			Jun-2010
3917	Daptomycin	[103060-53-3]	O=C(N[C@@H](CCCN)C(N[C@@H](CC(O)=O)C(N[C@H](C)C4=O)=O)=O)CN[C@]([C@H]([C@H](OC([C@@H](NC([C@@H](NC([C@@H](CO)NC(CNC([C@@H](N4)CC(O)=O)=O)=O)=O)[C@@H](C)CC(O)=O)=O)CC(C3=CC=CC=C3N)=O)=O)C)NC([C@H](CC(O)=O)NC([C@@H](CC(N)=O)NC([C@H](CC1=CNC2=C1C=CC=C2)NC(CCCCCCCCC)=O)=O)=O)=O)=O	"Antibiotic; inhibits protein, DNA and RNA synthesis in gram-positive bacteria"	"Lipopeptide, calcium-dependent antibiotic. Exhibits potent bacteriocidal activity against most gram-positive bacteria in vitro and in vivo, including antibiotic-resistant strains such as MRSA and VRE. Disrupts plasma membrane function; activity results in membrane depolarization leading to inhibition of protein, DNA and RNA synthesis."	"Tally and DeBruin (2000) Development of daptomycin for gram-positive infections. J.Antimicrob Chemother. 46 523. PMID:11020247. Jung et al (2004) Structural transitions as determinants of the action of the calcium-dependent antibiotic daptomycin. Chem.Biol. 11 949. PMID:15271353. Steenbergen et al (2005) Daptomycin: a lipopeptide antibiotic for the treatment of serious gram-positive infections. J.Antimicrob Chemother. 55 283. PMID:15705644. Robbel and Marahiel (2010) Daptomycin, a bacterial lipopeptide synthesized by a non-ribosomal machinery. J.Biol.Chem. 285 27501. PMID:20522545."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=254653	SQ1533			Aug-2010
3918	Pyrimethamine	[58-14-0]	ClC1=CC=C(C2=C(N)N=C(N)N=C2CC)C=C1	Potent inhibitor of multi-drug and toxin extrusion (MATE) transporters; also inhibits DHFR	Potent inhibitor of multi-drug and toxin extrusion (MATE) transporters (Ki values are 46 and 77 nM for human MATE2-K-HEK293 and MATE1-HEK293 cells respectively). Also inhibits dihydrofolate reductase (DHFR).	"Zimmerman et al (1987) Competitive inhibition of folate absorption by dihydrofolate reductase inhibitors, trimethoprim and pyrimethamine. Am.J.Clin.Nutr. 46 518. PMID:3630970. Ito et al (2010) Potent and specific inhibition of mMate1-mediated efflux of type I organic cations in the liver and kidney by pyrimethamine. J.Pharmacol.Exp.Ther. 333 341. PMID:20065018."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=254813	SQ1533			Jun-2010
3919	SC 236	[170569-86-5]	ClC(C=C3)=CC=C3C1=CC(C(F)(F)F)=NN1C2=CC=C(S(=O)(N)=O)C=C2	Selective cyclooxygenase-2 (COX-2) inhibitor	Selective COX-2 inhibitor (IC50 values are 0.005 and 17.8 _M for COX-2 and COX-1 respectively). Displays anti-inflammatory properties and potent antimetastatic activity against both experimental metastases and spontaneous metastases arising following primary tumor excision.	"Gierse et al (1996) A single amino acid difference between cyclooxygenase-1 (COX-1) and -2 (COX-2) reverses the selectivity of COX-2 specific inhibitors. J.Biol.Chem. 271 15810. PMID:8663121. Penning et al (1997) Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-Methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide (SC-58635, Celecoxib). J.Med.Chem. 40 1347. PMID:9135032. Roche-Nagle et al (2004) Antimetastatic activity of a cyclooxygenase-2 inhibitor. Br.J.Cancer 91 359. PMID:15213717."	Small Molecule	Sold for research purposes under agreement from Pfizer Inc.	http://www.tocris.com/dispprod.php?ItemId=254826	SQ1070			May-2010
3920	AMG 548	[864249-60-5]	O=C1N(C)C(NC[C@@H](N)CC5=CC=CC=C5)=NC(C4=CC=NC=C4)=C1C3=CC2=C(C=C3)C=CC=C2	Potent and selective p38_ inhibitor	"Potent and selective inhibitor of p38_ (Ki values are 0.5, 3.6, 2600 and 4100 nM for p38_, p38_, p38_ and p38_ respectively). Displays >1000-fold selectivity against 36 other kinases; inhibits whole blood LPS-stimulated TNF_ (IC50 = 3 nM). Efficacious in acute and chronic models of arthritis."	"Dominguez et al (2005) p38 MAP kinase inhibitors: many are made, but few are chosen. Curr.Opin.Drug Discov.Devel. 8 421. PMID:16022178. Lee and Dominguez (2005) MAP kinase p38 inhibitors: clinical results and an intimate look at their interactions with p38_ protein. Curr.Med.Chem. 12 2979. PMID:16378500."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=254827	SQ1070			Mar-2013
3921	NIDA 41020	[502486-89-7]	O=C(NN3CCCCC3)C1=NN(C2=CC=C(Cl)C=C2Cl)C(C4=CC=C(OC)C=C4)=C1C	High affinity CB1 antagonist	High affinity CB1 receptor antagonist (Ki = 4.1 nM). Exhibits significantly reduced lipophilicity compared to other CB1 antagonists.	"Katoch-Rouse et al (2003) Synthesis, structure-activity relationship and evaluation of SR141716 analogues: development of central cannabinoid receptor ligands with lower lipophilicity. J.Med.Chem. 46 642. PMID:12570386. Miller et al (2007) Analogs of SR-141716A (Rimonabant) alter d-amphetamine-evoked [3H] dopamine overflow from preloaded striatal slices and amphetamine-induced hyperactivity. Life Sci. 81 63. PMID:17532007."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=254828	SQ1070			Oct-2010
3922	Eeyarestatin I	[412960-54-4]	O=C1N(C2=CC=C(Cl)C=C2)C(N(O)C(NC4=CC=C(Cl)C=C4)=O)C(C)(C)N1CC(N/N=C/C=C/C3=CC=C([N+]([O-])=O)O3)=O	Potent inhibitor of ER-associated protein degradation and translocation	Potent inhibitor of endoplasmic reticulum associated protein degradation (ERAD). Specifically targets the p97-associated deubiquinating process (PAD) and inhibits ataxin-3 (atx3)-dependent deubiquitination. Also inhibits Sec61-mediated protein translocation at the ER. Displays cytotoxic activity preferentially against cancer cells; induces cell death via the proapoptotic protein NOXA.	Wang et al (2008) Inhibition of p97-dependent protein degradation by eeyarestatin I. J.Biol.Chem. 283 7445. PMID:18199748. Wang et al (2008) ERAD inhibitors integrate ER stress with an epigenetic mechanism to activate BH3-only protein NOXA in cancer cells. Proc.Natl.Acad.Sci.USA 106 2200. Cross et al (2009) Eeyarestatin I inhibits Sec61-mediated protein translocation at the endoplasmic reticulum. J.Cell Science 122 4393. Aletrari et al (2011) Eeyarestatin 1 interferes with both retrograde and anterograde intracellular trafficking pathways. PLoS One 6 e22713. PMID:21799938.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=254829	SQ1533			Jul-2010
3923	PF 998425	[1076225-27-8]	O[C@H](CCCC2)[C@H]2[C@]1=CC(C(F)(F)F)=C(C#N)C=C1	Non-steroidal androgen receptor antagonist	Selective non-steroidal androgen receptor (AR) antagonist (IC50 values are 26 nM and 90 nM in AR binding assays and cellular assays respectively). Displays low affinity for progesterone receptor (IC50 > 10 _M). Active in vivo.	"Li et al (2008) Rational design and synthesis of 4-((1R,2R)-2-hydroxycyclohexyl)-2(trifluoromethyl)benzonitrile (PF-998425), a novel, nonsteroidal androgen receptor antagonist devoid of phototoxicity for dermatological indications. J.Med.Chem. 51 7010. PMID:18921992."	Small Molecule	Sold for research purposes under agreement from Pfizer Inc.	http://www.tocris.com/dispprod.php?ItemId=254830	SQ1070			May-2010
3924	OPC 21268	[131631-89-5]	O=C2N(C3CCN(C(C4=CC=C(OCCCNC(C)=O)C=C4)=O)CC3)C1=CC=CC=C1CC2	Orally active vasopressin V1 antagonist	Nonpeptide vasopressin V1 receptor antagonist. Displays greater affinity for rat V1 than human V1 (Ki values are 25 and 8800 nM respectively). Exhibits 1000-fold selectivity for V1 receptors over V2 receptors. Orally active.	"Yamamura et al (1991) OPC-21268, an orally effective, nonpeptide vasopressin V1 receptor antagonist. Science 252 572. PMID:1850553. Imaizumi et al (1992) Effects of OPC-21268, an orally effective vasopressin V1 receptor antagonist in humans. Hypertension 20 54. PMID:1319959. Thibonnier et al (2000) A molecular model of agonist and nonpeptide antagonist binding to the human V1 vascular vasopressin receptor. J.Pharmacol.Exp.Ther. 294 195. PMID:10871312."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=254831	SQ1070			Dec-2011
3928	XCT 790	[725247-18-7]	O=C(NC3=NN=C(C(F)(F)F)S3)/C(C#N)=C/C(C=C2OC)=CC=C2OCC1=C(C(F)(F)F)C=C(C(F)(F)F)C=C1	Selective ERR_ antagonist/inverse agonist	Selective ERR_ antagonist/inverse agonist (IC50 = ~400 nM). Displays no antagonist activity at ERR_ or ER_ at concentrations below 10 _M. Interferes with PPAR_ coactivator-1_ (PGC-1_)/ERR_-dependent signaling: inhibits PGC-1_ induction of ERR_ and MAO-B gene expression and downregulates the constitutive transcriptional activity of ERR_ in numerous cell lines.	"Willy et al (2004) Regulation of PPAR_ coactivator 1_ (PGC-1_) signaling by an estrogen-related receptor alpha (ERR_) ligand. Proc.Natl.Acad.Sci.USA 101 8912. Lanvin et al (2007) Potentiation of ICI182,780 (Fulvestrant)-induced estrogen receptor-alpha degradation by the estrogen receptor-related receptor-_ inverse agonist XCT790. J.Biol.Chem. 282 28328. PMID:17631492. Kong et al (2009) Peroxisome proliferator-activated receptor _ coactivator-1_ enhances antiproliferative activity of 5'-deoxy-5-fluorouridine in cancer cells through induction of uridine phosphorylase. Mol.Pharmacol. 76 854. PMID:19602572."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=254835	SQ1070			Jul-2010
3929	SJ 172550	[431979-47-4]	O=C(N(C3=CC=CC=C3)N=C2C)/C2=C/C1=CC(OCC)=C(OCC(OC)=O)C(Cl)=C1	MDMX inhibitor. Disrupts MDMX-p53 interaction	MDMX inhibitor. Reversibly binds MDMX (EC50 = 2.3 _M). Inhibits the MDMX-p53 interaction in cultured retinoblastoma cells; frees p53 to induce apoptosis.	Reed et al (2010) Identification and characterization of the first small molecule inhibitor of MDMX. J.Biol.Chem. 285 10786. PMID:20080970.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=254928	SQ1533			Jul-2010
3931	Ticlopidine hydrochloride	[53885-35-1]	ClC(C=CC=C3)=C3CN1CCC2=C(C=CS2)C1.Cl	Selective P2Y12 antagonist	Selective P2Y12 receptor antagonist. Inhibits ADP-induced platelet aggregation and displays antithrombotic activity following oral administration in vivo.	Sharis et al (1998) The antiplatelet effects of ticlopidine and clopidogrel. Ann.Int.Med. 129 394. Savi and Herbert (2005) Clopidogrel and ticlopidine: P2Y12 adenosine diphosphate-receptor antagonists for the prevention of atherothrombosis. Semin.Thromb.Haemostas. 31 174. Michelson (2008) P2Y12 antagonism: promises and challenges. Arterioscler.Thromb.Vasc.Biol. 28 33.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=255022	SQ1533			Jun-2010
3933	WAY 267464 dihydrochloride	[1432043-31-6]	CN(N=C3)C1=C3CN(C(C4=CC=C(CNC(N5CCN(CC6=CC(O)=CC(O)=C6)CC5)=O)C(C)=C4)=O)C(C=CC=C2)=C2N1.Cl.Cl	Potent non-peptide oxytocin receptor agonist	"Potent, selective non-peptide oxytocin receptor (OTR) agonist (Ki = 58.4 nM at human OTR). Exhibits anxiolytic-like effects. May have therapeutic potential for the treatment of psychosis and schizophrenia."	"Ring et al (2010) Receptor and behavioral pharmacology of WAY-267464, a non-peptide oxytocin receptor agonist. Neuropharmacology 58 6. PMID:19615387."	Small Molecule	Sold for research purposes under agreement from Pfizer Inc.	http://www.tocris.com/dispprod.php?ItemId=255368	SQ1070			Mar-2011
3934	Benidipine hydrochloride	[91599-74-5]	CC1=C(C(OC)=O)[C@@H]([C@]2=CC([N+]([O-])=O)=CC=C2)C(C(O[C@H]3CN(CC4=CC=CC=C4)CCC3)=O)=C(C)N1.CC5=C(C(OC)=O)[C@H]([C@]6=CC([N+]([O-])=O)=CC=C6)C(C(O[C@@H]7CN(CC8=CC=CC=C8)CCC7)=O)=C(C)N5.Cl.Cl	Calcium channel blocker	"Orally active antihypertensive agent which displays a wide range of activities in vitro and in vivo. Inhibits L-, N- and T-type Ca2+ channels. Also inhibits aldosterone-induced mineralocorticoid receptor activation. Exhibits cardioprotective and antiartherosclerotic effects."	"Yao et al (2006) Pharmacological, pharmacokinetic, and clinical properties of benidipine hydrochloride, a novel long-acting calcium channel blocker. J.Pharmacol.Sci. 100 243. PMID:16565579. Kosaka et al (2010) The L-, N-, T-type triple calcium channel blocker benidipine acts as an antagonist of mineralocorticoid receptor, a member of nuclear receptor family. Eur.J.Pharmacol. 635 49. PMID:20307534."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=255369	SQ1533			Jun-2010
3935	RWJ 52353	[245744-10-9]	C1(SC=C2)=C2C(C3=CN=CN3)=CCC1.Cl	_2D agonist	"Agonist of the _2D adrenergic receptor (Ki values are 1.5, 254, 443 and 621 nM for _2D, _2A, _1 and _2B adrenergic receptors respectively)."	"Ross et al (2000) _2 adrenoceptor agonists as potential analgesic agents. 2. Discovery of 4-(4-imidazo)-1,3-dimethyl-6,7-dihydrothianaphthene as a high-affinity ligand for the _2D adrenergic receptor. J.Med.Chem. 43 765. PMID:10753480. Amphoux et al (2010) Inhibitory and facilitatory actions of isocyanine derivatives at human and rat organic cation transporters 1, 2 and 3: a comparison to human _1- and _2-adrenoceptor subtypes. Eur.J.Pharmacol. 634 1. PMID:20170649."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=255370				Nov-2011
3936	CDP 840 hydrochloride	[162542-90-7]	COC1=C(OC2CCCC2)C=C([C@@H]([C@]4=CC=CC=C4)CC3=CC=NC=C3)C=C1.Cl	Potent and selective PDE4 inhibitor	"Potent and selective inhibitor of phosphodiesterase (PDE) 4 (IC50 = 12 nM for native PDE4). Competitively inhibits all PDE4 isoenzymes (IC50 values are 4, 9, 9 and 45 nM for PDE4A, PDE4B, PDE4C and PDE4D human recombinant isoforms expressed in yeast)."	"Hughes et al (1996) The inhibition of antigen-induced eosinophilia and bronchoconstriction by CDP840, a novel stereo-selective inhibitor of phosphodiesterase type 4. Br.J.Pharmacol. 118 1183. PMID:8818342. Perry et al (1998) CDP840: a novel inhibitor of PDE-4. Cell Biochem.Biophys. 29 113. PMID:9631241. Cooper et al (1999) A comparison of the inhibitory activity of PDE4 inhibitors on leukocyte PDE4 activity in vitro and eosinophil trafficking in vivo. Br.J.Pharmacol. 126 1863. PMID:10372831."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=255424				Oct-2011
3937	ANR 94	[634924-89-3]	CCN2C1=NC=NC(N)=C1N=C2OCC	Adenosine A2A antagonist	Adenosine A2A receptor (AA2AR) antagonist (Ki values are 643 and 46 nM for rat and human AA2ARs respectively). Most active AA2AR antagonist for human receptors. Displays activity in the treatment of Parkinson's disease in vivo; improves parkinsonian motor deficits and tremors. Exhibits neuroprotective and anti-inflammatory effects.	Pinna et al (2010) A new ethyladenine antagonist of adenosine A2A receptors: Behavioral and biochemical characterization as an antiparkinsonian drug. Neuropharmacology 58 613. PMID:19951715. Volpini et al (2010) Adenosine A2A receptor antagonists: New 8-substituted 9-ethyladenines as tools for in vivo rat models of Parkinson's disease. Chem.Med.Chem. 4 1010.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=255490				Nov-2010
3938	TCS 5861528	[332117-28-9]	O=C1C2=C(N=CN2CC(NC3=CC=C(C(C)CC)C=C3)=O)N(C)C(N1C)=O	TRPA1 blocker	TRPA1 channel blocker that antagonizes AITC- and 4-HNE-evoked calcium influx (IC50 values are 14.3 and 18.7_M respectively). Attenuates diabetic hypersensitivity in in vivo rat model.	Wei et al (2009) Attenuation of mechanical hypersensitivity by an antagonist of the TRPA1 ion channel in diabetic animals. Anesthesiology 111 147. PMID:19512877. Wei et al (2010) Roles of cutaneous versus spinal TRPA1 channels in mechanical hypersensitivity in the diabetic or mustard oil-treated non-diabetic rat. Neuropharmacology. 58 578. PMID:20004676. Wei et al (2010) Spinal TRPA1 ion channels contribute to the cutaneous neurogenic inflammation in the rat. Neurosci.Letts. 479 253.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=255492	SQ1070			Jun-2010
3939	YM 58483	[223499-30-7]	O=C(C3=C(C)N=NS3)NC1=CC=C(N2N=C(C(F)(F)F)C=C2C(F)(F)F)C=C1	Inhibitor of SOCE in non-excitable cells	"Blocker of store-operated Ca2+ entry (SOCE), which mediates the activation of non-excitable cells (e.g. lymphocytes). Inhibits calcium release-activated calcium (CRAC) channels; suppresses thapsigargin-induced sustained Ca2+ influx (IC50 = 100 nM). Displays immuno-modulatory and anti-inflammatory effects; suppresses cytokine production and proliferation of T cells in vitro."	"Ishikawa et al (2003) A pyrazole derivative, YM-58483, potently inhibits store-operated sustained Ca2+ influx and IL-2 production in T lymphocytes. J.Immunol. 170 4441. PMID:12707319. Zitt et al (2004) Potent inhibition of Ca2+ release-activated Ca2+ channels and T-lymphocyte activation by the pyrazole derivative BTP2. J.Biol.Chem. 26 12427. Ohga et al (2008) Characterization of YM-58483/BTP2, a novel store-operated Ca2+ entry blocker, on T cell-mediated immune responses in vivo. Int.Immunopharmocol. 8 1787."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=255508	SQ1070			Aug-2010
3940	GSK 789472 hydrochloride	[1257326-24-1]	O=C1N(CC3CCCCN3)CCN1C2=CC=CC=C2.Cl	D3 antagonist. Also D2 partial agonist	Selective dopamine D3 receptor antagonist and D2 partial agonist (pEC50 values are <5.5 and 8.3 respectively). Selective against the D4 receptor in both agonist and antagonist assays. Brain penetrant.	"Holmes et al (2010) The identification of a selective dopamine D2 partial agonist, D3 antagonist displaying high levels of brain exposure. Bioorg.Med.Chem.Lett. 20 2013. PMID:20153647."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=255598	SQ1070			Jul-2010
3941	TCS 1205	[355022-97-8]	O=C(C(N[C@H](C)C3=CC=CC=C3)=O)C2=CNC1=CC=C([N+]([O-])=O)C=C12	Subtype-selective GABAA receptor agonist	GABAA _2 agonist and GABAA _1 partial agonist in vitro (Ki values are 14 and 121 nM respectively). Exhibits non-sedative anxiolytic activity in vivo.	"Primofiore et al (2001) Novel N-(arylalkyl)indol-3-ylglyoxylamides targeted as ligands of the benzodiazepine receptor: synthesis, biological evaluation, and molecular modeling analysis of the structure-activity relationships. J.Med.Chem. 44 2286. PMID:11428922. Taliani et al (2009) Identification of anxiolytic/nonsedative agents among indol-3-ylglyoxylamides acting as functionally selective agonists at the _-aminobutyric acid-A (GABAA) _2 benzodiazepine receptor. J.Med.Chem. 52 3723. PMID:19469479."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=255599	SQ1070			Jul-2010
3942	TCS 1105	[185391-33-7]	O=C(C(NCC3=CC=C(F)C=C3)=O)C2=CNC1=CC=CC=C12	GABAA _2 benzodiazepine receptor agonist	GABAA benzodiazepine receptor (BZR) ligand. Acts as an agonist at _2 and antagonist at _1 benzodiazepine receptors (Ki values are 118 and 245 nM respectively). Anxiolytic agent lacking sedative activity.	Taliani et al (2009) Identification of anxiolytic/nonsedative agents among indol-3-ylglyoxylamides acting as functionally selective agonists at the _-aminobutyric acid-A (GABAA) _2 benzodiazepine receptor. J.Med.Chem 52 3723. PMID:19469479.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=255600	SQ1070			Sep-2010
3943	PG 01	[853138-65-5]	O=C(C(C2=CC=CC=C2)N(C)C(CC3=CNC4=C3C=CC=C4)=O)NC1=CC=C(C(C)C)C=C1	CFTR mutants potentiator	"Cystic fibrosis transmembrane conductance regulator (CFTR) potentiator. Corrects gating defects of CFTR mutants such as _F508 (Ka = 0.3 _M), E193K and G970R (Kd values are 0.22 _M and 0.45 _M respectively). Increases _F508-CFTR Cl- currents in the presence of forskolin; displays no effect on Ca2+-activated Cl- current."	Pedemonte et al (2005) Phenylglycine and sulphonamide correctors of defective DF508 and G551D cystic fibrosis transmembrane conductance regulator chloride-channel gating. Mol.Pharmacol. 67 1797. PMID:15722457. Caputo et al (2009) Mutation-specific potency and efficacy of cystic fibrosis transmembrane conductance regulator chloride channel potentiators. J.Pharmacol.Exp.Ther. 330 783. PMID:19491324. Pedemonte et al (2010) Influence of cell background on pharmacological rescue of mutant CFTR. Am.J.Physiol.Cell Physiol 298 C866. PMID:20053923.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=255819	SQ1070			Aug-2010
3946	TNP	[519178-28-0]	O=[N+](C(C=C4)=CC=C4CNC1=C2C(NC=N2)=NC(NCC3=CC=CC(C(F)(F)F)=C3)=N1)[O-]	Inhibitor of IP6K; also inhibits IP3K	"Reversible inositol hexakisphosphate kinase (IP6K) inhibitor (IC50 = 0.47 _M for inhibition of InsP7 formation). Also inhibits inositol 1,4,5-trisphosphate 3-kinase (IP3K) (IC50 = 10.2 _M). Binds to the ATP binding site of IP3K (Ki = 4.3 _M)."	"Chang et al (2002) Purine-based inhibitors of inositol-1,4,5-trisphosphate-3-kinase. Chembiochem 3 897. PMID:12210991. Padmanabhan et al (2009) Characterization of a selective inhibitor of inositol hexakisphosphate kinases. Use in defining biological roles and metabolic relationships of inositol pyrophosphates. J.Biol.Chem. 284 10571. PMID:19208622."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=255842	SQ1341			Apr-2013
3947	exo-IWR 1	[1127442-87-8]	O=C(NC5=CC=CC6=C5N=CC=C6)C(C=C4)=CC=C4N2C([C@@]1([H])[C@@H](C3)C=C[C@@H]3[C@]([H])1C2=O)=O	Negative control for endo-IWR 1 (Cat. No. 3532)	Negative control for endo-IWR 1 (Cat.No. 3532). 25-fold less active than endo-IWR 1; exhibits decreased activity against the Wnt/_-catenin pathway.	Chen et al (2008) Small molecule-mediated disruption of Wnt-dependent signaling in tissue regeneration and cancer. Nature Chem.Biol. 5 100. Lu et al (2009) Structure-activity relationship studies of small-molecule inhibitors of Wnt response. Bioorg.Med.Chem.Lett. 19 3825. PMID:19410457.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=255872				Oct-2010
3948	Terfenadine	[50679-08-8]	OC(C3=CC=CC=C3)(C4=CC=CC=C4)C1CCN(CCCC(O)C2=CC=C(C(C)(C)C)C=C2)CC1	H1 antagonist. Also KV11.1 (hERG) and Kir6 (KATP) channel blocker	Histamine H1 receptor antagonist. Also blocks KV11.1 (hERG) and Kir6 (KATP) channels (IC50 values are 204 nM and 1.2 _M respectively). Inhibits the delayed rectifier K+ current (IKr) in guinea pig ventricular myocytes (IC50 = 50 nM). Activity prolongs QT and induces Torsades de pointes (TdP); cardiotoxic in vivo.	Crumb (2000) Loratadine blockade of K+ channels in human heart: comparison with terfenadine under physiological conditions. J.Pharmacol.Exp.Ther. 292 261. PMID:10604956. Zunkler et al (2000) Mechanism of terfenadine block of ATP-sensitive K+ channels. Br.J.Pharmacol. 130 1571. PMID:10928959. Stork et al (2007) State dependent dissociation of HERG channel inhibitors. Br.J.Pharmacol. 151 136.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=255905	SQ1533			Jun-2010
3949	CBiPES hydrochloride	[856702-40-4]	O=S(N(CC2=CC=CN=C2)C1=CC(C3=CC=C(C#N)C=C3)=CC=C1)(CC)=O.Cl	Positive allosteric modulator of mGlu2	Selective positive allosteric modulator of the mGlu2 receptor (IC50 = 98.2 nM). Mimics the action of LY 379268 (Cat. No. 2453); attenuates ketamine-evoked histamine release in vivo.	"Johnson et al (2005) Metabotropic glutamate 2 receptor potentiators: receptor modulation, frequency-dependent synaptic activity, and efficacy in preclinical anxiety and psychosis model(s). Psychopharmacology. 179 271. PMID:15717213. Fell et al (2010) Activation of metabotropic glutamate receptors (mGlu)2 receptors suppresses histamine release in limbic brain regions following acute ketamine challenge. Neuropharmacology. 58 632. PMID:19951716."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=256066	SQ1070			Aug-2010
3950	CK 666	[442633-00-3]	FC1=CC=CC=C1C(NCCC2=C(C)NC3=C2C=CC=C3)=O	Arp2/3 inhibitor; inhibits actin polymerization	Inhibitor of the Arp2/3 complex; inhibits actin polymerization (IC50 = 4 _M).	Nolen et al (2009) Characterization of two classes of small molecule inhibitors of Arp2/3 complex. Nature 460 1031. PMID:19648907. Han and Nolen (2009) X-ray crystal structures and molecular mechanism of improved Arp2/3 complex inhibitors. 1751 ACSB 2009 Abstracts. American Society for Cel.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=256067	SQ1070			Sep-2010
3951	WZ 811	[55778-02-4]	C1(CNC3=NC=CC=C3)=CC=C(CNC2=NC=CC=C2)C=C1	Potent CXCR4 antagonist	Potent chemokine receptor type 4 (CXCR4) antagonist (EC50 = 0.3 nM). Inhibits CXCR4/stromal cell-derived factor-1 (SDF-1)-mediated modulation of cAMP in vitro (EC50 = 1.2 nM).	Reyes et al (2002) Pyridinium N-(2'-azinyl)aminides: regioselective synthesis of N-(2-pyridyl) substituted polyamines. Chem.Inform. 34. Zhan et al (2007) Discovery of small molecule CXCR4 antagonists. J.Med.Chem. 50 5655. PMID:17958344.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=256069				Nov-2010
3953	cis-Ned 19	[1137264-00-6]	FC1=CC=CC=C1N(CC6)CCN6CC2=C[C@@]([C@H]3C4=C(C(C=CC=C5)=C5N4)C[C@@H]([C@@](O)=O)N3)=CC=C2OC	NAADP antagonist; inhibits Ca2+ release	Irreversible nicotinic acid adenine dinucleotide phosphate (NAADP) antagonist; inhibits Ca2+ release (IC50 = 800 nM) and [32P]NAADP binding (IC50 = 15 _M). Stereoisomer of trans-Ned 19 (Cat. No. 3954). Fluorescently labels NAADP receptors in intact cells (excitation 351 and 365 nm using an ultraviolet Argon laser).	Naylor et al (2009) Identification of a chemical probe for NAADP by virtual screening. Nat.Chem.Biol. 5 220. PMID:19234453.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=256115	SQ1341			Feb-2013
3954	trans-Ned 19	[1354235-96-3]	FC1=CC=CC=C1N(CC6)CCN6CC2=C[C@@]([C@@H]3C4=C(C(C=CC=C5)=C5N4)C[C@@H](C(O)=O)N3)=CC=C2OC	NAADP antagonist; inhibits Ca2+ release	Nicotinic acid adenine dinucleotide phosphate (NAADP) antagonist. Inhibits NAADP-mediated Ca2+ release (IC50 = 6 nM); also inhibits [32P]NAADP binding (IC50 = 0.4 nM). Fluorescently labels NAADP receptors in intact cells. Stereosiomer of cis-Ned 19 (Cat. No. 3953).	Naylor et al (2009) Identification of a chemical probe for NAADP by virtual screening. Nat.Chem.Biol. 5 220. PMID:19234453. Rosen et al (2009) Analogues of the nicotinic acid adenine dinucleotide phosphate (NAADP) antagonist Ned-19 indicate two binding sites on the NAADP receptor. J.Biol.Chem. 284 34930. PMID:19826006. Thai et al (2009) NAADP receptors mediate calcium signaling stimulated by endothelin-1 and norepinephrine in renal afferent arterioles. Am.J.Physiol.Renal Physiol. 297 F510. PMID:19439521.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=256116	SQ1070			Aug-2011
3959	YIL 781	[875258-85-8]	O=C2C1=CC(OC4=CC=C(F)C=C4)=CC=C1N=C(C)N2C[C@@H]3CN(C(C)C)CCC3.Cl	Ghrelin receptor (GHS-R1a) antagonist	Ghrelin receptor antagonist (GHS-R1a) (Ki = 17 nM). Displays no significant affinity for the motilin receptor (Ki = 6 _M). Blocks the effects of ghrelin on insulin secretion both in vivo and in vitro. Improves glucose homeostasis in vivo.	"Esler et al (2007) Small-molecule ghrelin receptor antagonists improve glucose tolerance, suppress appetite, and promote weight loss. Endocrinology 148 5175. PMID:17656463. Moran and Dailey (2009) Gut peptides: targets for antiobesity drug development? Endocrinology 150 2526. PMID:19372201."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=256127	SQ1070			Apr-2011
3960	NVP 231	[362003-83-6]	O=C(C3=CC=CC=C3)NC2=NC(C=C1)=C(S2)C=C1NC(C45CC(C6)CC(CC6C5)C4)=O	"Potent, selective and reversible CerK inhibitor"	"Potent, selective and reversible ceramide kinase (CerK) inhibitor (IC50 = 12 nM in vitro). Displays selectivity for CerK over sphingosine kinases (IC50 100 _M) and other lipid kinases."	Graf et al (2009) A secondary assay for ceramide kinase inhibitors based on cell growth inhibition by short-chain ceramides. Anal.Biochem. 384 166. PMID:18831956. Niwa et al (2009) Ceramide kinase deficiency impairs microendothelial cell angiogenesis in vitro. Microvasc.Res. 77 389. PMID:19323974. Graf et al (2009) Targeting ceramide metabolism with a potent and specific ceramide kinase inhibitor. Mol.Pharmacol. 74 925.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=256130	SQ1070			Sep-2010
3961	GSK 3787	[188591-46-0]	O=C(C2=CC=C(Cl)C=C2)NCCS(C1=CC=C(C(F)(F)F)C=N1)(=O)=O	Potent and selective PPAR_ antagonist	Potent and selective peroxisome proliferator-activated receptor _ (PPAR_) antagonist (pIC50 = 6.6). Displays no measurable affinity for PPAR_ or PPAR_ in vitro (pIC50< 5).	"Shearer et al (2010) Identification and characterization of 4-chloro-N(2-{[5-trifluoromethyl)-2-pyridyl]sulfonyl}ethyl)benzamide (GSK3787), a selective and irreversible peroxisome proliferator-activated receptor delta (PPARdelta) antagonist. J.Med.Chem. 53 1857. PMID:20128594. Palkar et al (2010) Cellular and pharmacological selectivity of the peroxisone proliferator-activated receptor-_/_ antagonist GSK3787. Mol.Pharmacol. 78 419. PMID:20516370."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=256227	SQ1070			Jul-2010
3962	kb NB 142-70	[1233533-04-4]	OC1=CC=C(SC3=C2SCCNC3=O)C2=C1	Selective PKD inhibitor; analog of CID 755673 (Cat. No. 3327)	"Selective protein kinase D (PKD) inhibitor (IC50 values are 28.3, 58.7 and 53.2 nM for PKD1, 2 and 3 respectively). More potent analog of CID 755673 (Cat. No. 3327) with 7-fold greater inhibition. Inhibits prostrate cancer cell migration and invasion and reduces wound healing in vitro; displays prominent cytotoxic and anti-proliferative effects."	LaValle et al (2010) Novel protein kinase D inhibitors cause potent arrest in cancer cell growth and motility. BMC Chemical Biology 10 5. PMID:20444281. Bravo-Altamirano et al (2011) Synthesis and structure-activity relationships of benzothienothiazepinone inhibitors of protein kinase D. ACS Med.Chem.Lett. 2 154. PMID:21617763. Ni et al (2013) PKD1 mediates negative feedback of PI3K/Akt activation in response to G protein-coupled receptors. PLoS One 8 e73149. PMID:24039875.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=267626	SQ1070			Aug-2010
3963	AZM 475271	[476159-98-5]	ClC1=CC=C(OC)C=C1NC3=NC=NC2=CC(OCC4CCN(C)CC4)=C(OC)C=C23	Src tyrosine kinase inhibitor	"Src tyrosine kinase inhibitor. Reduces tumor size, vascularity and metastasis, and increases apoptosis in human pancreatic cells grown in nude mice. Also exhibits antiangiogenic activity in vitro and in vivo. Sensitizes tumor cells to the cytotoxic effects of gemcitabine (Cat. No. 3259)."	"Yezhelyev et al (2004) Inhibition of Src tyrosine kinase as treatment for human pancreatic cancer growing orthotopically in nude mice. Clin.Cancer Res. 10 8028. PMID:15585638. Summy et al (2005) AP23846, a novel and highly potent Src family kinase inhibitor, reduces vascular endothelial growth factor and interleukin-8 expression in human solid tumor cell lines and abrogates downstream angiogenic processes. Mol.Cancer Ther. 4 1900. PMID:16373705."	Small Molecule	Sold with the permission of AstraZeneca UK Ltd.	http://www.tocris.com/dispprod.php?ItemId=267631	SQ1070			Apr-2011
3964	AR-R 17779 hydrochloride	[178419-42-6]	O=C(NC3)O[C@@]13CN2CCC1CC2.Cl	_7-selective agonist	Selective agonist of _7 nAChRs (Ki values are 190 and 16000 nM for rat _7 and _4_2 receptors respectively). CNS penetrant after systemic administration.	"Grottick et al (2000) Evidence that nicotinic _7 receptors are not involved in the hyperlocomotor and rewarding effects of nicotine. J.Pharmacol.Exp.Ther. 294 1112. PMID:10945867. Mullen et al (2000) (-)-spiro[1-azabicyclo[2.2.2]octane-3,5'-oxazolidin-2'-one], a conformationally restricted analogue of acetylcholine, is a highly selective full agonist at the _7 nicotinic acetylcholine receptor. J.Med.Chem. 43 4045. PMID:11063601. Huang et al (2010) Activation of presynaptic _7 nicotinic receptors evokes an excitatory response in hippocampal CA3 neurones in anaesthetized rats: an in vivo iontophoretic study. Br.J.Pharmacol. 159 554. PMID:20105181."	Small Molecule	Sold with the permission of AstraZeneca UK Ltd.	http://www.tocris.com/dispprod.php?ItemId=267632	SQ1070			Aug-2011
3965	Tesaglitazar	[251565-85-2]	CS(OC1=CC=C(CCOC2=CC=C(C[C@H](OCC)C(O)=O)C=C2)C=C1)(=O)=O	PPAR_/_ agonist	Dual-specificity PPAR_/_ agonist (IC50 values are 0.35 and 3.8 _M for PPAR_ and PPAR_ respectively). Prevents atherosclerosis progression in E3L.CETP transgenic mice. Also reduces insulin resistance in obese Zucker rats. Orally active.	"Cronet et al (2001) Structure of the PPAR_ and -_ ligand binding domain in complex with AZ 242; ligand selectivity and agonist activation in the PPAR family. Structure 9 699. PMID:11587644. Ljung et al (2002) AZ 242, a novel PPAR_/_ agonist with beneficial effects on insulin resistance and carbohydrate and lipid metabolism in ob/ob mice and obese Zucker rats. J.Lipid Res. 43 1855. PMID:12401884. Ebdrup et al (2003) Synthesis and biological and structural characterization of the dual-acting peroxisome proliferator-activated receptor _/_ agonist ragaglitazar. J.Med.Chem. 46 1306. PMID:12672231. van der Hoorn et al (2009) The dual PPAR_/_ agonist tesaglitazar blocks progression of pre-existing atherosclerosis in APOE*3Leiden.CETP transgenic mice. Br.J.Pharmacol. 156 1067. PMID:19220285."	Small Molecule	Sold with the permission of AstraZeneca UK Ltd.	http://www.tocris.com/dispprod.php?ItemId=267633	SQ1533			May-2011
3966	AR-A 014418	[487021-52-3]	O=C(NCC2=CC=C(OC)C=C2)NC1=NC=C([N+]([O-])=O)S1	Selective GSK-3 inhibitor	Selective glycogen synthase kinase 3 (GSK-3) inhibitor (IC50 = 104 nM). Exhibits specificity for GSK-3 over cdk2 and cdk5 (IC50 values are > 100 _M) and over 26 other kinases. Inhibits _-amyloid-mediated neurodegeneration in hippocampal slices.	"Bhat and Budd (2002) GSK3_ signalling: casting a wide net in Alzheimer's disease. Neurosignals 11 251. PMID:12566926. Bhat et al (2003) Structural insights and biological effects of glycogen synthase kinase 3-specific inhibitor AR-A014418. J.Biol.Chem. 278 45937. PMID:12928438. Gould et al (2004) AR-A014418, a selective GSK-3 inhibitor, produces antidepressant-like effects in the forced swim test. Int.J.Neuropsychopharmacol. 7 387. PMID:15315719."	Small Molecule	Sold with the permission of AstraZeneca UK Ltd.	http://www.tocris.com/dispprod.php?ItemId=267635				Jul-2010
3967	GPi 688	[918902-32-6]	OC[C@H](O)CN(C1=CC=CC=C1CC2NC(C3=CC4=C(SC(Cl)=C4)N3)=O)C2=O	Allosteric glycogen phosphorylase inhibitor	Allosteric glycogen phosphorylase inhibitor; acts at the indole site of glycogen phosphorylase. Inhibits glucagon-mediated hyperglycemia in vivo in the rat.	Freeman et al (2006) Sensitivity of glycogen phosphorylase isoforms to indole site inhibitors is markedly dependent on the activation state of the enzyme. Br.J.Pharmacol. 149 775. PMID:17016495. Poucher et al (2007) An assessment of the in vivo efficacy of the glycogen phosphorylase inhibitor GPi688 in rat models of hyperglycaemia. Br.J.Pharmacol. 152 1239. PMID:17934512.	Small Molecule	Sold with the permission of AstraZeneca UK Ltd.	http://www.tocris.com/dispprod.php?ItemId=267688	SQ1070			Mar-2011
3968	AZD 5438	[602306-29-6]	CS(C(C=C3)=CC=C3NC1=NC(C2=CN=C(C)N2C(C)C)=CC=N1)(=O)=O	"Potent cyclin-dependent kinase (cdk) 1, 2 and 9 inhibitor"	"Potent inhibitor of cyclin-dependent kinase (cdk) 1, 2 and 9 (IC50 values are 16, 6 and 20 nM respectively). Exhibits antiproliferative activity in human tumor cell lines. Blocks cell cycling at G2-M, S and G1 phases; reduces the proportion of actively cycling cells in vivo."	"Byth et al (2009) AZD5438, a potent oral inhibitor of cyclin-dependent kinases 1, 2 and 9, leads to pharmacodynamic changes and potent antitumor effects in human tumor xenografts. Mol.Cancer Ther. 8 1856. PMID:19509270."	Small Molecule	Sold with the permission of AstraZeneca UK Ltd.	http://www.tocris.com/dispprod.php?ItemId=267689	SQ1070			Feb-2011
3969	AR-C 102222	[253771-21-0]	O=C(C4=CC=C(C#N)N=C4)N(CC3)CCC23N=C(N)C1=C(F)C=CC(F)=C1N2.Cl	Selective iNOS inhibitor	Inducible nitric oxide synthase (iNOS) inhibitor; selective for iNOS over eNOS (IC50 values are 0.037 and >100 _M for iNOS and eNOS respectively). Exhibits antinociceptive and anti-inflammatory activity in rodent pain models.	"Tinker et al (2003) 1,2-Dihydro-4-quinazolinamines: potent, highly selective inhibitors of inducible nitric oxide synthase which show antiinflammatory activity in vivo. J.Med.Chem. 46 913. PMID:12620067. LaBuda et al (2006) Antinociceptive activity of the selective iNOS inhibitor AR-C102222 in rodent models of inflammatory, neuropathic and postoperative pain. Eur.J.Pain 10 505. PMID:16125426. Bonnefous et al (2009) Discovery of inducible nitric oxide synthase (iNOS) inhibitor development candidate KD7332, Part 1: Identification of a novel, potent, and selective series of quinolinone iNOS dimerization inhibitors that are orally active in rodent pain models. J.Med.Chem. 52 3047. PMID:19374401."	Small Molecule	Sold with the permission of AstraZeneca UK Ltd.	http://www.tocris.com/dispprod.php?ItemId=267698	SQ1070			Jun-2011
3972	AA 29504	[945828-50-2]	NC1=C(NC(OCC)=O)C=CC(NCC2=C(C)C=C(C)C=C2C)=C1	Positive allosteric modulator of GABAA receptors	"Positive allosteric modulator of GABAA receptors. Modulates both _4_3_-containing extrasynaptic receptors and _1_3_2S-containing receptors in Xenopus oocytes, displaying a stronger modulatory effect at the former. Reduces motor coordination and exhibits anxiolytic effects in vivo."	Hoestgaard-Jensen et al (2010) Pharmacological characterization of a novel positive modulator at _4_3_-containing extrasynaptic GABAA receptors. Neuropharmacology 58 702. PMID:20060846.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=268026	SQ1070			Apr-2011
3975	Zearalenone	[17924-92-4]	O=C(C1=C(O)C=C(O)C=C1/C=C/CCC2)O[C@@H](C)CCCC2=O	Estrogen receptor ligand; mycotoxin	Mycotoxin produced by several species of Fusarium fungi. Binds to the estrogen receptor (ER) (IC50 values are 166 and 240 nM for ER_ and ER_ respectively) and stimulates the transcriptional activity of both subtypes at concentrations between 1 - 10 nM. Also stimulates growth of T47D breast cancer cells.	Kuiper et al (1998) Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor _. Endocrinology 139 4252. PMID:9751507. Takemura et al (2007) Characterization of the estrogenic activities of zearalenone and zeranol in vivo and in vitro. J.Steroid Biochem.Molec.Biol. 103 170. Khosrokhavar et al (2009) Effects of zearalenone and _-Zearalenol in comparison with Raloxifene on T47D cells. Toxicol.Mech.Methods 19 246. PMID:19730705.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=268762	SQ1070			Jul-2010
3977	3-Methyladenine	[5142-23-4]	NC(N=CN2C)=C1C2=NC=N1	Class III PI 3-kinase inhibitor; also inhibits autophagy	Inhibitor of class III phosphatidylinositol 3-kinase (PI 3-kinase); also inhibits the autophagic sequestration of cell proteins in rat hepatocytes. Blocks apoptosis in cerebellar granule cells (CGCs) following serum and potassium deprivation.	Seglen and Gordon (1982) 3-methyladenine: specific inhibitor of autophagic/lysosomal protein degradation in isolated rat hepatocytes. Proc.Natl.Acad.Sci. USA 79 1889. Blommaart et al (1997) The phosphatidylinositol 3-kinase inhibitors wortmannin and LY294002 inhibit autophagy in isolated rat hepatocytes. Eur.J.Biochem. 243 240. PMID:9030745. Canu et al (2005) Role of the autophagic-lysosomal system on low potassium-induced apoptosis in cultured cerebellar granule cells. J.Neurochem. 92 1228. PMID:15715672.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=268840	SQ1533			Aug-2010
3979	Alexidine dihydrochloride	[1715-30-6]	N=C(NC(NCC(CC)CCCC)=N)NCCCCCCNC(NC(NCC(CC)CCCC)=N)=N.Cl.Cl	Selective inhibitor of PTPMT1	Selective inhibitor of protein tyrosine phosphatases localized to mitochondrion 1 (PTPMT1) (IC50 = 1.08 _M in vitro). Stimulates increased insulin secretion by _-cells in rat pancreatic islets. Displays antitcancer properties in FaDu cells.	Coburn et al (1978) In vitro antiplaque properties of a series of alkyl bis(biguanides). J.Med.Chem. 21 828. PMID:691009. Yip et al (2006) Potential use of alexidine dihydrochloride as an apoptosis-promoting anticancer agent. Mol.Cancer Ther. 5 2234. PMID:16985057. Doughty-Shenton et al (2010) Pharmacological targeting of the mitochondrial phosphatase PTPMT1. J.Pharmacol.Exp.Ther. 333 584. PMID:20167843.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=268870	SQ1533			Jul-2010
3982	Mdivi 1	[338967-87-6]	O=C2N(C3=C(Cl)C=C(Cl)C(OC)=C3)C(S)=NC1=CC=CC=C12	Dynamin inhibitor; attenuates mitochondrial division and apoptosis	Selective inhibitor of Dnm1 GTPase (IC50 = 1 - 10 _M); attenuates Dnm1- and Drp1-mediated mitochondrial division. Inhibits mitochondrial outer membrane permeabilization (MOMP) and attenuates apoptosis.	Tanaka and Youle (2008) A chemical inhibitor of DRP1 uncouples mitochondrial fission and apoptosis. Mol.Cell 29 409. PMID:18313377. Cassidy-Stone et al (2008) Chemical inhibition of the mitochondrial division dynamin reveals its role in Bax/Bak-dependent mitochondrial outer membrane permeabilization. Develop.Cell 14 193. Lackner et al (2010) Small molecule inhibitors of mitochondrial division: tools that translate basic biological research into medicine. Chem.Biol. 17 57. PMID:20142041.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=268875				Aug-2010
3983	PSB 0739	[1052087-90-7]	[Na+].[Na+].NC1=C(C=C(NC2=CC(=C(NC3=CC=CC=C3)C=C2)S([O-])(=O)=O)C2=C1C(=O)C1=CC=CC=C1C2=O)S([O-])(=O)=O	Highly potent P2Y12 receptor antagonist	"Highly potent P2Y12 receptor antagonist (Ki = 24.9 nM). Unlike clopidogrel (Cat. No. 2490), does not require bioactivation."	"Hoffmann et al (2009) Interaction of new, very potent non-nucleotide antagonists with Arg256 of the human platelet P2Y12 receptor. J.Pharmacol.Exp.Ther. 331 648. PMID:19690189. Baqi et al (2009) High-affinity, non-nucleotide-derived competitive antagonists of platelet P2Y12 receptors. J.Med.Chem. 52 3784. PMID:19463000. Felix et al (2011) Development of a comprehensive set of P2 receptor pharmacological research compounds. Purinerg.Sig. 8 101. PMID:22052555."	Small Molecule	Sold with the permission of the University of Bonn.	http://www.tocris.com/dispprod.php?ItemId=268977				Jul-2012
3984	Nutlin-3	[548472-68-0]	ClC1=CC=[C@@]([C@@H]3[C@@H](N(C(N5CC(NCC5)=O)=O)C(C4=CC=C(OC)C=C4OC(C)C)=N3)[C@]2=CC=C(Cl)C=C2)C=C1	MDM2 antagonist; inhibits MDM2-p53 interaction	MDM2 antagonist; inhibits the MDM2-p53 interaction (IC50 = 0.09 _M) and activates p53. Antiproliferative agent; induces apoptosis in cancer cells.	Vassilev et al (2004) In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303 844. PMID:14704432.	Small Molecule	Sold under license from F. Hoffmann-La Roche Ltd.	http://www.tocris.com/dispprod.php?ItemId=269287	SQ1533			Jul-2011
3986	SR 58611A hydrochloride	[121524-09-2]	O=C(OCC)COC1=CC=C(CC[C@H](NC[C@H](O)C3=CC(Cl)=CC=C3)C2)C2=C1.Cl	_3 agonist; displays anxiolytic and antidepressant effects	Selective _3-adrenergic receptor agonist. Displays both anxiolytic and antidepressant effects in rodent models. Orally active and brain penetrant.	"Consoli et al (2007) Behavioral effects of the _3 adrenoceptor agonist SR58611A: is it the putative prototype of a new class of antidepressant/anxiolytic drugs? Eur.J.Pharmacol 573 139. PMID:17669397. Claustre et al (2008) Effects of the _3-adrenoceptor (Adrb3) agonist SR58611A (amibegron) on serotonergic and noradrenergic transmission in the rodent: relevance to its antidepressant/anxiolytic-like profile. Neuroscience 156 353. PMID:18691638. Stemmelin et al (2008) Stimulation of the _3-adrenoceptor as a novel treatment strategy for anxiety and depressive disorders. Neuropsychopharmacology 33 574. PMID:17460614. Tamburella et al (2010) The beta(3) adrenoceptor agonist, amibegron (SR58611A) counteracts stress-induced behavioral and neurochemical changes. Eur.Neuropsychopharmacol. 20 704. PMID:20537869."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=270206	SQ1070			Mar-2011
3988	Hesperadin hydrochloride	[422513-13-1]	O=C3/C(C2=CC(NS(CC)(=O)=O)=CC=C2N3)=C(C4=CC=CC=C4)\NC1=CC=C(CN5CCCCC5)C=C1.Cl	Potent Aurora kinase B inhibitor	ATP-competitive inhibitor of Aurora B kinase (IC50 = 250 nM). Prevents chromosome alignment and segregation; also induces polyploidy and prevents histone H3-Ser10 phosphorylation. Overrides the spindle assembly checkpoint and induces mitotic exit in monastrol- and taxol-treated HeLa cells.	Hauf et al (2003) The small molecule Hesperadin reveals a role for Aurora B in correcting kinetochore-microtubule attachment and in maintaining the spindle assembly checkpoint. J.Cell.Biol. 161 281. PMID:12707311. Sessa et al (2005) Mechanism of Aurora B activation by INCENP and inhibition by Hesperadin. Mol.Cell. 18 379. PMID:15866179. Jetton et al (2009) The cell cycle as a therapeutic target against Trypanosoma brucei: Hesperadin inhibits Aurora kinase-1 and blocks mitotic progression in bloodstream forms. Mol.Microbiol. 72 442. PMID:19320832.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=270563	SQ1070			Mar-2012
3989	AMTB hydrochloride	[926023-82-7]	O=C(N(CC2=CC=CS2)CCCN)C1=C(OCC3=CC(C)=CC=C3)C=CC=C1.Cl	TRPM8 blocker	TRPM8 channel blocker. Inhibits icilin-induced TRPM8 channel activation in a rat model (pIC50 = 6.23).	"Lashinger et al (2008) AMTB, a TRPM8 channel blocker: evidence in rats for activity in overactive bladder and painful bladder syndrome. Am.J.Physiol.Renal Physiol. 295 F803. PMID:18562636."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=270564	SQ1070			Oct-2010
3994	AZ 3146	[1124329-14-1]	CN(C1=CN=C(NC4=CC=C(OC5CCN(C)CC5)C=C4OC)N=C1N2C3CCCC3)C2=O	Potent and selective monopolar spindle 1 (Mps1) kinase inhibitor	"Potent and selective monopolar spindle 1 (Mps1) kinase inhibitor (IC50 = 35 nM). Displays selectivity over 46 other kinases including Cdk1 and aurora kinase B. Interferes with chromosome alignment and overrides spindle assembly checkpoint. Inhibits the recruitment of Mad1, Mad2 and centromere protein E (CENP-E) to kinetochores."	Hewitt et al (2010) Sustained Mps1 activity is required in mitosis to recruit O-Mad2 to the Mad1-C-Mad2 core complex. J.Cell Biol. 190 25. PMID:20624899. Lan and Cleveland (2010) A chemical tool box defines mitotic and interphase roles for Mps1 kinase. J.Cell.Biol. 190 21. PMID:20624898. Maciejowski et al (2010) Mps1 directs the assembly of Cdc20 inhbitory complexes during interphase and mitosis to control M phase timing and spindle checkpoint signaling. J.Cell Biol. 190 89. PMID:20624902.	Small Molecule	Sold for research purposes only under agreement from AstraZeneca UK Ltd.	http://www.tocris.com/dispprod.php?ItemId=270571	SQ1533			Jan-2011
3996	Zotepine	[26615-21-4]	ClC3=CC=C2SC1=CC=CC=C1C=C(OCCN(C)C)C2=C3	5-HT2A/D2 antagonist; atypical antipsychotic	5-HT2A receptor and dopamine D2 receptor antagonist (Ki values are 0.69 and 2.3 nM respectively). Also a potent histamine H1 receptor antagonist (IC50 = 8.0 nM). Atypical antipsychotic; exhibits antidepressive and anxiolytic effects in vivo.	"Herrick-Davis et al (2000) Inverse agonist activity of atypical antipsychotic drugs at human 5-hydroxytryptamine2C receptors. J.Pharmacol.Exp.Ther. 295 226. PMID:10991983. Yamamura et al (2009) Effects of zotepine on extracellular levels of monamine, GABA and glutamate in rat prefrontal cortex. Br.J.Pharmacol. 157 656. PMID:19371334. Shobo et al (2010) Norzotepine, a major metabolite of zotepine, exerts atypical antipsychotic-like and antidepressant-like actions through its potent inhibition of norepinephrine reuptake. J.Pharmacol.Exp.Ther. 333 772. PMID:20223878."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=270988	SQ1533			Aug-2010
3997	Tazarotene	[118292-40-3]	CC1(C)C2=C(C=CC(C#CC3=NC=C(C(OCC)=O)C=C3)=C2)SCC1	Receptor-selective retinoid; binds RAR-_ and -_	"Receptor-selective acetylenic retinoid; binds at retinoid acid receptors (RAR) -_ and -_. Topically used for the treatment of skin disorders, particularly psoriasis and acne. Implicated in the treatment of basal cell carcinomas; induces upregulation of Bax in vivo. Exhibits antiproliferative and proapoptotic activity. Upregulates TIGs (Tazarotene-induced genes), including the cell adhesion molecule TIG1 and the tumor-suppressor TIG3."	"Higuchi et al (2003) Induction of TIG3, a putative class II tumor suppressor gene, by retinoic acid in head and neck and lungcarcinoma cells and its association with suppression of the transformed phenotype. Oncogene 22 4627. PMID:12879006. Orlandi et al (2004) Evidence of increased apoptosis and reduced proliferation in basal cell carcinomas treated with Tazarotene. J.Invest.Dermatol. 122 1037. PMID:15102095. Son et al (2009) Expression and mutation analysis of TIG1 (Tazarotene-induced gene 1) in human gastric cancer. Oncol.Res. 17 571. PMID:19806788."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=271049	SQ1533			Sep-2010
3998	LDN 57444	[668467-91-2]	ClC1=CC=C(N(CC3=CC(Cl)=CC=C3Cl)C(C2=NOC(C)=O)=O)C2=C1	Ubiquitin C-terminal hydrolase-L1 (UCH-L1) inhibitor	Inhibitor of ubiquitin C-terminal hydrolase-L1 (UCH-L1) activity (Ki = 0.4 _M). Causes cell death through the apoptosis pathway; increases levels of highly ubiquitinated proteins and decreases ubiquitin proteasome activity. Activity leads to dramatic alterations in synaptic protein distribution and spine morphology in vivo.	Liu et al (2003) Discovery of inhibitors that elucidate the role of UCH-L1 activity in the H1299 lung cancer cell line. Chem.Biol. 10 837. PMID:14522054. Tan et al (2008) Endoplasmic reticulum stress contributes to the cell death induced by UCH-L1 inhibitor. Mol.Cell.Biochem. 318 109. PMID:18622688. Cartier et al (2009) Regulation of synaptic structure by ubiquitin C-terminal hydrolase L1. J.Neurosci. 29 7857. PMID:19535597.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=271056	SQ1070			Oct-2010
3999	Cyclofenil	[2624-43-3]	CC(OC(C=C3)=CC=C3/C(C2=CC=C(OC(C)=O)C=C2)=C1/CCCCC1)=O	Selective estrogen receptor modulator (SERM)	Non-steroidal selective estrogen receptor modulator (SERM). Displays higher affinity for estrogen receptor _ (ER_) than for ER_.	Seo et al (2006) Fluorine-substituted cyclofenil derivatives as estrogen receptor ligands: synthesis and structure-affinity relationship study of potential PET agents for imaging estrogen receptors in breast cancer. J.Med.Chem. 49 2496. PMID:16610793. Kieser et al (2010) Characterization of the pharmacore properties of novel selective estrogen receptor downregulators (SERDs). J.Med.Chem. 53 3320. PMID:20334372.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=271121	SQ1533			Aug-2010
4000	MRK 560	[677772-84-8]	ClC(C=C3)=CC=C3[S@]([C@@]1([C@]2=C(F)C=CC(F)=C2)CC[C@@H](NS(=O)(C(F)(F)F)=O)CC1)(=O)=O	_-secretase inhibitor; attenuates amyloid plaque deposition	_-secretase inhibitor; inhibits proteolytic cleavage of amyloid precursor protein (APP) over the Notch pathway. Reduces levels of A_ in the brain (inhibits A_40 and A_42 in SH-SY5Y neuroblastoma cells with an IC50 of 0.65 nM); attenuates plaque deposition. Orally bioavailable.	"Best et al (2006) In vivo characterization of A_(40) changes in brain and cerebrospinal fluid using the novel _-secretase inhibitor N-[cis-4-[(4-chlorophenyl)sulfonyl]-4-(2,5-difluorophenyl)cyclohexyl]-1,1,1-trifluoromethanesulfonamide (MRK-560) in the rat. J.Pharm.Exp.Ther. 317 786. PMID:16443723. Best et al (2007) The novel _-secretase inhibitor N-[cis-4-[(4-chlorophenyl)sulfonyl]-4-(2,5-difluorophenyl)cyclohexyl]-1,1,1-trifluoromethanesulfonamide (MRK-560) reduces amyloid plaque deposition without evidence of Notch-related pathology in the Tg2576 mouse. J.Pharm.Exp.Ther. 320 552. PMID:17099072."	Small Molecule	"Manufactured and sold under license from Merck & Co., Inc. for use solely for preclinical research purposes (ie: not for administration to or other use in humans)."	http://www.tocris.com/dispprod.php?ItemId=271664	SQ1070			Jul-2011
4001	KD 5170	[940943-37-3]	O=C(CSC(C)=O)C(C=N2)=CC=C2NS(C1=CC=C(OCCCN(C)C)C=C1)(=O)=O	Class I and II histone deacetylase inhibitor	"Class I and II histone deacetylase (HDAC) inhibitor (IC50 = 0.045 _M; EC50 = 0.025 _M in HeLa screening and HeLa cell-based assays, respectively). Exhibits broad spectrum inhibition of HDAC classes I and II in assays using purified recombinant human isoforms. Displays less potent inhibition of HDAC2 (IC50 values are 0.014, 0.020, 0.026, 0.075 and 2.0 _M for HDAC6, HDAC1, HDAC4, HDAC3 and HDAC2 respectively). Displays cytotoxicity against numerous cell lines derived from human tumors. Orally available."	"Feng et al (2008) KD5170, a novel mercaptoketone-based histone deacetylase inhibitor, exerts antimyeloma effects by DNA damage and mitochondrial signaling. Mol.Cancer Ther. 7 1494. PMID:18566220. Hassig et al (2008) KD5170, a novel mercaptoketone-based histone deacetylase inhibitor that exhibits broad-spectrum antitumor activity in vitro and in vivo. Mol.Cancer Ther. 7 1054. PMID:18483295. Payne et al (2008) Identification of KD5170: a novel mercaptoketone-based histone deacetylase inhibitor. Bioorg.Med.Chem.Lett. 18 6093. PMID:18954983."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=271571				Jul-2011
4002	FIIN 1 hydrochloride	[1256152-35-8]	CCN(CC)CCCCNC1=NC=C2C(N(CC3=CC=CC(NC(C=C)=O)=C3)C(N(C4=C(Cl)C(OC)=CC(OC)=C4Cl)C2)=O)=N1.Cl	"Potent, irreversible FGFR inhibitor"	"Potent, irreversible FGFR inhibitor (Kd values are 2.8, 5.4, 6.9 and 120 nM for FGFR1, FGFR3, FGFR2 and FGFR4 respectively); acts at the ATP binding site. Also irreversibly inhibits Flt-1, Flt-4 and VEGFR-2 (Kd values are 32, 120 and 210 nM respectively); displays limited activity (Kd >500 nM) at other kinases. Exhibits antiproliferative activity in FGFR3- and FGFR1-transformed Ba/F3 cells (EC50 values are 10 and 14 nM respectively). Derived from the reversible FGFR inhibitor, PD 173074 (Cat. No. 3044)."	Zhou (2010) A structure-guided approach to creating covalent FGFR inhibitors. Chem.Biol. 17 285. PMID:20338520.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=271572	SQ1341			Sep-2012
4005	Alda 1	[349438-38-6]	O=C(C3=C(Cl)C=CC=C3Cl)NCC1=CC(OCO2)=C2C=C1	ALDH2 activator; cardioprotective	Activator of aldehyde dehydrogenase 2 (ALDH2). Increases activity of wild-type ALDH2*1 and variant ALDH2*2 (by ~2-fold and 11-fold respectively). Capable of partly restoring mutant ALDH2*2 activity; protective against cardiac ischemia.	Chen et al (2008) An activator of mutant and wildtype aldehyde dehydrogenase reduces ischemic damage to the heart. Science 321 1493. PMID:18787169. Beretta et al (2010) Characterization of the East Asian variant of aldehyde dehydrogenase-2. Bioactivation of nitroglycerin and effects of alda-1. J.Biol.Chem. 285 943. PMID:19906643.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=271579	SQ1070			May-2011
4009	GSK 269962	[850664-21-0]	CCN(C(C4=NON=C4N)=N3)C1=C3C=NC(OC2=CC(NC(C5=CC=C(OCCN6CCOCC6)C=C5)=O)=CC=C2)=C1	Potent and selective ROCK inhibitor	Potent Rho kinase (ROCK) inhibitor (IC50 values are 1.6 and 4 nM for recombinant human ROCK1 and ROCK2 respectively). Displays greater than 30-fold selectivity for ROCK against a panel of serine/threonine kinases. Induces vasorelaxation in preconstricted rat aorta (IC50 = 35 nM); lowers blood pressure in a rat model of hypertension.	Doe et al (2007) Novel Rho kinase inhibitors with anti-inflammatory and vasodilatory activities. J.Pharmacol.Exp.Ther. 320 89. PMID:17018693. Stavenger et al (2007) Discovery of aminofurazan-azabenzimidazoles as inhibitors of Rho-kinase with high kinase selectivity and antihypertensive activity. J.Med.Chem. 50 2. PMID:17201404.	Small Molecule	Sold for research purposes under agreement from GlaxoSmithKline.	http://www.tocris.com/dispprod.php?ItemId=272125	SQ1533			Aug-2011
4011	EC 23	[104561-41-3]	CC1(C)C2=C(C=CC(C#CC3=CC=C(C(O)=O)C=C3)=C2)C(C)(C)CC1	Synthetic retinoid; induces differentiation of stem cells	Photostable synthetic retinoid; analog of ATRA (Cat. No. 0695). Displays similar activity to ATRA when tested on the embryonal carcinoma stem cell model TERA2.cl.SP12. Potently induces neural differentiation in human pluripotent embryonic stem cells.	Christie et al (2008) Synthesis and evaluation of synthetic retinoid derivatives as inducers of stem cell differentiation. Org.Biomol.Chem. 6 3497. PMID:19082150. Barnard et al (2009) Synthetic retinoids: structure-activity relationships. Chemistry 15 11430. PMID:19821467. Maltman et al (2009) Proteomic profiling of the stem cell response to retinoic acid and synthetic retinoid analogues: identification of major retinoid-inducible proteins. Mol.Biosyst. 5 458. PMID:19381361.	Small Molecule	"Sold under license from Reinnervate Limited, patent pending"	http://www.tocris.com/dispprod.php?ItemId=272185	SQ1070			Sep-2010
4012	SR 140333	[153050-21-6]	O=C(N2C[C@@](CC[N+]3(CC5)CCC(C4=CC=CC=C4)5CC3)([C@]6=CC=C(Cl)C(Cl)=C6)CCC2)CC1=CC(OC(C)C)=CC=C1.[Cl-]	Potent NK1 receptor antagonist	Potent NK1 receptor antagonist (Ki = 0.74 nM. IC50 = 1.6 nM). Inhibits substance P-invoked calcium mobilization and outward current (IC50 = 1.3 nM); blocks NK1-mediated nitric oxide-dependent vasodilation in vivo.	"Emonds-Alt et al (1993) In vitro and in vivo biological activities of SR140333, a novel non-peptide tachykinin NK1 receptor antagonist. Eur.J.Pharmacol. 250 403. PMID:7509286. Oury-Donat et al (1994) SR 140333, a novel, selective, and potent nonpeptide antagonist of the NK1 tachykinin receptor: characterization on the U373MG cell line. J.Neurochem. 62 1399. PMID:7510780. Hall and Brain (1994) Inhibition by SR140333 of NK1 tachykinin receptor-evoked, nitric oxide-dependent vasodilation in the hamster cheek pouch microvasculature in vivo. Br.J.Pharmacol. 113 522. PMID:7530573. Nieuwmeyer et al (2006) Ava[L-Pro9,N-MeLeu10] substance P(7-11) (GR 73632) and Sar9, Met(O2)11 increase distention-induced peristalsis through activation of neurokinin-1 receptors on smooth muscle and interstitial cells of Cajal. J.Pharmacol.Exp.Ther. 317 439. PMID:16330493."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=272186	SQ1070			Mar-2013
4013	L 760735	[188923-01-5]	FC(C=C3)=CC=[C@@]3[C@@H]1N(CC4=C(CN(C)C)NN=N4)CCO[C@@H]1O[C@H](C)C2=CC(C(F)(F)F)=CC(C(F)(F)F)=C2.Cl	High affinity NK1 receptor antagonist	High affinity NK1 receptor antagonist (IC50 = 0.19 nM at human NK1 receptors). Selective (>300-fold) over h-NK2 and h-NK3 receptors. Exhibits anxiolytic and antidepressant-like effects. Orally active.	"Harrison et al (2001) An orally active, water-soluble neurokinin-1 receptor antagonist suitable for both intravenous and oral clinical administration. J.Med.Chem. 44 4296. PMID:11708932. Duffy et al (2002) Correlation of neurokinin (NK) 1 receptor occupancy in gerbil striatum with behavioral effects of NK1 antagonists. J.Pharmacol.Exp.Ther 301 536. PMID:11961054."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=272187	SQ1070			Sep-2011
4014	MK 217	[129318-43-0]	[Na+].NCCCC(O)(P(O)(O)=O)P(O)([O-])=O	Inhibitor of farnesyl diphosphate synthase (FPPS) and osteoclast-mediated bone resorption	Osteoclast-mediated bone resorption inhibitor. Binds and blocks farnesyl diphosphate synthase (FPPS) in the HMG-CoA pathway (IC50 = 460 nM for recombinant human FPPS); causes macrophage apoptosis. Inhibits prenylation and sterol biosynthesis in purified osteoclasts.	"Fisher et al (1999) Alendronate mechanism of action; geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro. Proc.Natl.Acad.Sci. 96 133. Bergstrom et al (2000) Alendronate is a specific, nanomolar inhibitor of fanesyl diphosphate synthase. Arch.Biochem.Biophys. 373 231. PMID:10620343. Fournier et al (2008) Lowering bone mineral affinity of bisphosphonates as a therapeutic strategy to optimize skeletal tumor growth inhibition in vitro. Cancer Res. 68 8945. PMID:18974139."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=272188	SQ1533			Sep-2010
4015	IDE 1	[1160927-48-9]	OC(=O)CCCCCC(=O)NN=CC1=CC=CC=C1C(O)=O	Induces definitive endoderm formation in mouse and human ESCs	Induces definitive endoderm formation in mouse and human embryonic stem cells (ESCs) (EC50 = 125 nM). Thought to activate the TGF-_ signaling pathway; induces Smad2 phosphorylation and increases levels of Nodal expression.	Borowiak et al (2009) Small molecules efficiently direct endodermal differentiation of mouse and human embryonic stem cells. Cell Stem Cell 4 348. PMID:19341624. Zaret (2009) Using small molecules to great effect in stem cell differentiation. Cell Stem Cell 4 373. PMID:19427285. Filby et al (2011) Stimulation of activin A/Nodal signaling is insufficient to induce definitive endoderm formation of cord blood-derived unrestricted somatic stem cells. Stem Cell Res.Ther. 2 16. PMID:21463501.	Small Molecule	Sold for research purpose under license from Harvard University.	http://www.tocris.com/dispprod.php?ItemId=272189				Jun-2011
4016	IDE 2	[1136466-93-7]	O=C(N/N=C1/CCCC1)CCCCCC(O)=O	Induces definitive endoderm formation in mouse and human ESCs	"Cell-permeable inducer of definitive endoderm formation in mouse and human embryonic stem cells (ESCs) (EC50 = 223 nM for induction of Sox17 expression in ESCs). Reported to activate TGF-_ signaling and downstream Smad2 phosphorylation; upregulates Nodal expression. Promotes pancreatic progenitor cell formation in vitro, and gut tube formation in vivo."	Borowniak et al (2009) Small molecules efficiently direct endodermal differentiation of mouse and human embryonic stem cells. Cell Stem Cell 4 348. PMID:19341624. Zaret (2009) Using small molecules to great effect in stem cell differentiation. Cell Stem Cell 4 373. PMID:19427285. Filby et al (2011) Stimulation of Activin A/Nodal signaling is insufficient to induce definitive endoderm formation of cord blood-derived unrestricted somatic stem cells. Stem Cell Res.Ther. 2 16. PMID:21463501.	Small Molecule	Sold for research purpose under license from Harvard University.	http://www.tocris.com/dispprod.php?ItemId=272190				May-2012
4018	JNJ 5207787	[683746-68-1]	O=C(C)N2CCC1=CC=C(N(C(/C=C/C5=CC=CC(C#N)=C5)=O)C3CCN(CCC4CCCC4)CC3)C=C12	Selective NPY Y2 receptor antagonist	"Selective NPY Y2 antagonist (IC50 = 0.1 _M). Displays 100-fold selectivity over NPY Y1, Y4 and Y5 receptors; also displays selectivity against a panel of 50 receptors, ion channels and transporters. Brain penetrant."	"Bonaventure et al (2004) Characterization of N-(1-Acetyl-2,3-dihydro-1H-indol-6-yl)-3-(3-cyano-phenyl)-N-[1-(2-cyclopentyl-ethyl)-piperidin-4yl]acrylamide (JNJ-5207787), a small molecule antagonist of the neuropeptide Y Y2 receptor. J.Pharmacol.Exp.Ther. 308 1130. PMID:14617685. Jablonowski et al (2004) Novel non-peptide neuropeptide Y Y2 receptor antagonists. Bioorg.Med.Chem.Lett. 14 1239. PMID:14980673."	Small Molecule	Sold with the permission of Janssen Pharmaceutica N.V.	http://www.tocris.com/dispprod.php?ItemId=272943	SQ1070			Feb-2011
4019	JNJ 10181457 dihydrochloride	[544707-20-2]	C1(CN2CCOCC2)=CC=CC(C#CCCN3CCCCC3)=C1.Cl.Cl	H3 antagonist	Histamine H3 receptor antagonist (pKi values are 8.15 and 8.93 for rat and human H3 receptors respectively). Increases extracellular norepinephrine and acetylcholine levels in rat frontal cortex but does not stimulate dopamine release. Brain penetrant.	"Bonaventure et al (2007) Histamine H3 receptor antagonists: from target identification to drug leads. Biochem.Pharmacol. 73 1084. PMID:17129577. Esbenshade et al (2008) The histamine H3 receptor: an attractive target for the treatment of cognitive disorders. Br.J.Pharmacol. 154 1166. PMID:18469850. Boggs et al (2009) JNJ-10181457, a selective non-imidazole histamine H3 receptor antagonist, normalizes acetylcholine neurotransmission and has efficacy in translational rat models of cognition. Neuropharmacology 56 1131. PMID:19345233."	Small Molecule	"Sold with the permission of Ortho-McNeil-Janssen Pharmaceuticals, Inc."	http://www.tocris.com/dispprod.php?ItemId=272944	SQ1070			Apr-2011
4020	JNJ 5207852 dihydrochloride	[398473-34-2]	C1(CN2CCCCC2)=CC=C(OCCCN3CCCCC3)C=C1.Cl.Cl	High affinity H3 receptor antagonist	High affinity histamine H3 receptor neutral antagonist (pKi values are 8.9 and 9.2 in rat and human respectively). Brain penetrant and orally active. Has 3- and 100-fold higher affinity than thioperamide (Cat. No. 0644) for rat and human H3 receptors respectively. Suppresses slow-wave sleep; exhibits wake-promoting effects in rodent arousal models.	"Barbier et al (2004) Acute wake-promoting actions of JNJ-5207852, a novel, diamine-based H3 antagonist. Br.J.Pharmacol. 143 649. PMID:15466448. Jia et al (2005) Effects of histamine H3 antagonists and donepezil on learning and mnemonic deficits induced by pentylenetetrazol kindling in weanling mice. Neuropharmacology 50 404. PMID:16310812. Le et al (2008) Correlation between ex vivo receptor occupancy and wake-promoting activity of selective H3 receptor antagonists. J.Pharmacol.Exp.Ther. 325 902. PMID:18305012."	Small Molecule	"Sold with the permission of Ortho-McNeil-Janssen Pharmaceuticals, Inc."	http://www.tocris.com/dispprod.php?ItemId=272945	SQ1070			May-2011
4021	JNJ 7777120	[459168-41-3]	ClC1=CC=C(NC(C(N3CCN(C)CC3)=O)=C2)C2=C1	Selective H4 receptor antagonist	Histamine H4 receptor antagonist; displays high affinity (Ki = 4.5 nM) and is >1000-fold selective for H4 over other histamine receptors.	Jablanowski et al (2003) The first potent and selective non-imidazole human histamine H4 receptor antagonists. J.Med.Chem. 46 3957. PMID:12954048. Thurmond et al (2004) A potent and selective histamine H4 receptor antagonist with anti-inflammatory properties. J.Pharmacol.Exp.Ther. 309 404. PMID:14722321. Strakhova et al (2009) In vitro and in vivo characterization of A-940894: a potent histamine H4 receptor antagonist with anti-inflammatory properties. Br.J.Pharmacol. 157 44. PMID:19413570.	Small Molecule	"Sold with the permission of Ortho-McNeil-Janssen Pharmaceuticals, Inc."	http://www.tocris.com/dispprod.php?ItemId=272946	SQ1070			Sep-2010
4022	ES 936	[192820-78-3]	O=C(C=C1OC)C2=C(C(COC3=CC=C([N+]([O-])=O)C=C3)=C(C)N2C)C1=O	Mechanism-based inhibitor of NAD(P)H:quinone oxidoreductase (NQO1)	Mechanism-based inhibitor of NAD(P)H:quinone oxidoreductase (NQO1). Induces growth inhibition in human pancreatic carcinoma (MIA PaCa-2) and adenocarcinoma (BxPC-3) cell lines with IC50 values of 108 and 365 nM respectively. Also inhibits TNF-_-induced E-selectin protein expression in human bone marrow endothelial cells. Exhibits no effects on other cellular reductases or levels of acid-soluble thiols.	"Dehn et al (2003) Biochemical, cytotoxic, and genotoxic effects of ES936, a mechanism-based inhibitor of NAD(P)H:quinone oxidoreductase 1, in cellular systems. Mol.Pharmacol. 64 714. PMID:12920209. Dehn et al (2006) 5-Methoxy-1,2-dimethyl-3-[(4-nitrophenoxy)methyl]indole-4,7-dione, a mechanism-based inhibitor of NAD(P)H:quinone oxidoreductase 1, exhibits activity against human pancreatic cancer in vitro and in vivo. Mol.Cancer Ther. 5 1702. PMID:16891456. Zhou et al (2010) NAD(P)H:quinone oxidoreductase 1-compromised human bone marrow endothelial cells exhibit decreased adhesion molecule expression and CD34 hematopoietic cell adhesion. J.Pharm.Exp.Ther. 334 260. PMID:20378716."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=272947	SQ1070			Oct-2011
4026	GSK 1059615	[958852-01-2]	O=C(/C(S4)=C/C1=CC=C2C(C(C3=CC=NC=C3)=CC=N2)=C1)NC4=O	Potent PI 3-kinase inhibitor	Potent inhibitor of PI 3-kinase _ (PI3K_) (IC50 = 2 nM). Inhibits proliferation in BT474 cells and attenuates MAPK signaling.	"Saadia et al (2009) Phosphatidylinositol-3-kinase as a therapeutic target in melanoma. Clin.Cancer Res. 15 3029. PMID:19383818. Knight et al (2010) Discovery of GSK2126458, a highly potent inhibitor of PI3K and the mammalian target of rapamycin. ACS Med.Chem.Lett. 1 39."	Small Molecule	Sold for research purposes under agreement from GlaxoSmithKline	http://www.tocris.com/dispprod.php?ItemId=273200	SQ1533			Jan-2011
4028	CCG 63802	[620112-78-9]	O=C1C(/C=C(C#N)/C3=NC(C=CC=C4)=C4S3)=C(OC5=CC(C)=CC=C5)N=C2N1C=CC=C2C	Inhibitor of regulator of G-protein signaling 4 (RGS4) protein	"Reversible inhibitor of regulator of G-protein signaling (RGS) proteins. Selective amongst RGS proteins, with greatest potency at RGS4. Inhibits GTPase accelerating protein activity of RGS4 and blocks its interaction with G_o. Retains activity under reducing conditions."	"Blazer et al (2010) Reversible, allosteric small-molecule inhibitors of regulator of G protein signaling proteins. Mol.Pharmacol. 78 524. PMID:20571077."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=273255	SQ1070			May-2011
4029	Ralfinamide mesylate	[202825-45-4]	FC(C=CC=C2)=C2COC1=CC=C(CN[C@@H](C)C(N)=O)C=C1.CS(=O)(O)=O	Na+ channel blocker	Sodium channel blocker. Suppresses tetrodotoxin (TTX)-resistant Na+ currents approximately twice as selectively as TTX-sensitive currents. Antinociceptive; displays analgesic effects in animal models of inflammatory and neuropathic pain.	"Veneroni et al (2003) Anti-allodynic effect of NW-1029, a novel Na+ channel blocker, in experimental animal models of inflammatory and neuropathic pain. Pain 102 17. PMID:12620593. Yamane et al (2007) Effects of ralfinamide, a Na+ channel blocker, on firing properties of nociceptive dorsal root ganglion neurons of adult rats. Exp.Neurol. 208 63. PMID:17707373. Zhang et al (2008) Ralfinamide administered orally before hindpaw neurectomy or postoperatively provided long-lasting suppression of spontaneous neuropathic pain-related behavior in the rat. Pain 139 293. PMID:18583049."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=273478	SQ1070			Jul-2011
4032	PF 4708671	[1255517-76-0]	CCC(C=NC=N2)=C2N1CCN(CC4=NC3=CC(C(F)(F)F)=CC=C3N4)CC1	S6K1 inhibitor	"Cell-permeable inhibitor of p70 ribosomal S6 kinase (S6K1 isoform) (Ki = 20 nM; IC50 = 160 nM). Suppresses the S6K1-mediated phosphorylation of S6, Rictor and mTOR in response to IGF1; displays no effect on the activity of RSK and MSK in vivo. Exhibits no significant inhibition of S6K2 or other AGC kinases (e.g. Akt, PKA and ROCK) in vitro."	Pearce et al (2010) Characterisation of PF-4708671 a novel and highly specific inhibitor of p70 ribosomal S6 kinase (S6K1). Biochem.J. 431 245. PMID:20704563.	Small Molecule	Sold for research purposes under agreement from Pfizer Inc.	http://www.tocris.com/dispprod.php?ItemId=274028	SQ1533			Sep-2010
4033	5'-Fluoroindirubinoxime	[861214-33-7]	O=C(NC4=C3C=C(F)C=C4)/C3=C2NC1=CC=CC=C1C/2=NO	FLT3 inhibitor; displays antiproliferative activity	"Inhibitor of FMS-like receptor tyrosine kinase-3 (FLT3) (IC50 = 15 nM). Displays selectivity for FLT3 against 6 other kinases including EGFR. Displays antiproliferative activity against the MV4;11 cell line (expressing constitutively active FLT3) and a number of cancer cell lines, including SNU-638 (stomach carcinoma) and HT-1080 (fibrosarcoma)."	Kim et al (2007) Antitumor activity of novel indirubin derivatives in rat tumor model. Clin.Cancer Res. 13 253. PMID:17200363. Krivogorsky et al (2008) Inhibition of Toxoplasma gondii by indirubin and tryptanthrin analogs. Antimicrob.Agents Chemother. 52 4466. PMID:18824607. Choi et al (2010) Indiribuin derivatives as potent FLT3 inhibitors with anti-proliferative activity of acute myeloid leukemic cells. Bioorg.Med.Chem.Lett. 20 2033. PMID:20153646.	Small Molecule	Sold under licence from Anygen Co. Ltd.	http://www.tocris.com/dispprod.php?ItemId=274031				Dec-2010
4035	Org 24598 lithium salt	[722456-08-8]	[Li+].CN(CC[C@@H](OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1)CC([O-])=O	Selective GlyT1 inhibitor	"Selective inhibitor of the glial glycine transporter (GlyT1) (pIC50 values are 6.9, <4 and <3 for GlyT1, GABA transporter and Glyt2 respectively)."	Bradaia et al (2004) Role of glial and neuronal glycine transporters in the control of glycinergic and glutamatergic synaptic transmission in lamina X of the rat spinal cord. J.Physiol. 559 169. PMID:15235081. Beato (2008) The time course of transmitter at glycinergic synapses onto motoneurons. J.Neurosci. 28 7412. PMID:18632945.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=274207	SQ1070			Jul-2011
4037	BRD 7389	[376382-11-5]	O=C(C3=C2C(N4)=CC=C3)C1=CC=CC=C1C2=C(NCCC5=CC=CC=C5)C4=O	p90 ribosomal S6 kinase inhibitor	"p90 ribosomal S6 kinase (RSK) inhibitor (IC50 values are 1.2, 1.5 and 2.4 _M for RSK3, RSK1 and RSK2 respectively). Upregulates insulin expression in terminally differentiated pancreatic _-cells."	Fomina-Yadlin et al (2010) Small molecule inducers of insulin expression in pancreatic alpha cells. Proc.Natl.Acad.Sci. USA 107 15099.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=274491	SQ1070			Nov-2010
4038	TW 37	[877877-35-5]	OC1=C(CC2=C(C(C)C)C=CC=C2)C=C(C(NC3=CC=C(S(C4=C(C(C)(C)C)C=CC=C4)(=O)=O)C=C3)=O)C(O)=C1O	Bcl-2 inhibitor; induces apoptosis	Bcl-2 inhibitor (Ki values are 0.29 _M and 1.11 _M for Bcl-2 and Bcl-XL respectively). Inhibits the angiogenic potential of endothelial cells in vitro. Induces S-phase arrest and apoptosis in pancreatic cancer cell lines; also inhibits the activation of Notch-1 and Jagged-1 in vitro and in vivo.	"Wang et al (2006) Structure-based design of potent small-molecule inhibitors of anti-apoptotic Bcl-2 proteins. J.Med.Chem. 49 6139. PMID:17034116. Zeitlin et al (2006) Antiangiogenic effect of TW37, a small-molecule inhibitor of Bcl-2. Cancer Res. 66 8698. PMID:16951185. Ashimori et al (2009) TW-37, a small molecule inhibitor of Bcl-2, mediates S phase cell cycle arrest and suppresses head and neck tumor angiogenesis. Mol.Cancer.Ther. 8 893. PMID:19372562. Wang et al (2009) TW-37, a small molecule inhibitor of Bcl-2, inhibits cell growth and induces apoptosis in pancreatic cancer: involvement of Notch-1 signaling pathway. Cancer Res. 69 2757. PMID:19318573."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=274492	SQ1070			Nov-2010
4039	PT 1	[331002-70-1]	ClC1=C(C(O)=O)C=C(/N=C3/NC(/C(S3)=C/C2=CC=C(C4=C([N+]([O-])=O)C=C(C)C(C)=C4)O2)=O)C=C1	AMPK activator	AMP-activated protein kinase (AMPK) activator. Stimulates AMPK heterotrimer (_1_1_1) activity (EC50 = 0.3 _M). Thought to directly activate AMPK by antagonizing autoinhibition.	Pang et al (2007) Small molecule antagonizes autoinhibition and activates AMP-activated protein kinase in cells. J.Biol.Chem. 283 16051. Zorn and Wells (2010) Turning enzymes ON with small molecules. Nat.Chem.Biol. 6 179. PMID:20154666.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=274493				Jan-2011
4041	MRE 3008F20	[252979-43-4]	O=C(NC4=CC=C(OC)C=C4)NC2=NC1=NN(CCC)C=C1C3=NC(C5=CC=CO5)=NN23	Highly potent and selective adenosine A3 receptor antagonist	"Potent adenosine A3 receptor competitive antagonist. Selective for human A3 receptors over human A1 and A2A receptors (Ki values are 0.29, 141 and 1197 nM respectively). Potently inhibits agonist-induced cyclic AMP elevation in resting T lymphocytes (IC50 = 5 nM)."	"Baraldi et al (1999) Pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine derivatives as highly potent and selective human A(3) adenosine receptor antagonists. J.Med.Chem. 42 4473. PMID:10579811. Gessi et al (2004) Expression of A3 adenosine receptors in human lymphocytes: up-regulation in T cell activation. Mol.Pharmacol. 65 711. PMID:14978250. Varani et al (2010) Expression and functional role of adenosine receptors in regulating inflammatory responses in human synoviocytes. Br.J.Pharmacol. 160 101. PMID:20331607."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=251261	SQ1341			Apr-2012
4044	Sipatrigine	[130800-90-7]	ClC1=CC(Cl)=C(Cl)C(C2=C(N)N=C(N3CCN(C)CC3)N=C2)=C1	NaV blocker; neuroprotective	Blocker of voltage-dependent sodium channels (NaV). Inhibits glutamate release; displays neuroprotective activity in rat models of cerebral ischemia. Also thought to block Ca2+ channels. Analog of lamotrigine (Cat. No. 1611).	"Leach et al (1993) BW619C89, a glutamate release inhibitor, protects against focal cerebral ischemic damage. Stroke 24 1063. PMID:8100654. Graham et al (1994) Neuroprotective effects of a use-dependent blocker of voltage-dependent sodium channels, BW619C89, in rat middle cerebral artery occlusion. J.Pharmacol.Exp.Ther. 269 854. PMID:7910213. Stefani et al (1998) On the inhibition of voltage activated calcium currents in rat cortical neurones by the neuroprotective agent 619C89. Br.J.Pharmacol. 125 1058. PMID:9846645."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=274498	SQ1533			Oct-2011
4046	AC 261066	[870773-76-5]	CC1=C(OCCOCCCC)N=C(C2=CC=C(C(O)=O)C(F)=C2)S1	RAR_2 agonist	"Potent RAR_2 agonist (pEC50 = 8.1). Selective over RAR_1, RAR_ and RAR_ (pEC50 values are 6.4, 6.2 and 6.3 respectively). More potent and orally available than AC 55649 (Cat. No. 2436)."	"Lund et al (2005) Discovery of a potent, orally available, and isoform-selective retinoic acid _2 receptor agonist. J.Med.Chem. 48 7517. PMID:16302793. Lund et al (2009) Design, synthesis, and structure-activity analysis of isoform-selective retinoic acid receptor _ ligands. J.Med.Chem. 52 1540. PMID:19239230."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=274760	SQ1533			Nov-2010
4048	BINA	[866823-73-6]	CC1=C(C)C(C(C(C5CCCC5)C4)=O)=C4C=C1OCC2=CC(C3=CC=C(C(O)=O)C=C3)=CC=C2	Selective positive allosteric modulator of mGlu2	Selective positive allosteric modulator of mGlu2 (EC50 = 33.2 nM in CHO cells expressing human mGlu2). Displays no effect on glutamate-induced activation of other mGlu receptor subtypes. Exhibits antipsychotic and anxiolytic properties in mice.	"Bonnefous et al (2005) Biphenyl-indanones: allosteric potentiators of the metabotropic glutamate subtype 2 receptor. Bioorg.Med.Chem.Lett. 15 4354. PMID:16046122. Galici et al (2006) Biphenyl-indanone A, a positive allosteric modulator of the metabotropic glutamate receptor subtype 2, has antipsychotic- and anxiolytic-like effects in mice. J.Pharmacol.Exp.Ther. 318 173. PMID:16608916. Benneyworth et al (2007) A selective positive allosteric modulator of metabotropic glutamate receptor subtype 2 blocks a hallucinogenic drug model of psychosis. Mol.Pharmacol. 72 477. PMID:17526600."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=276135	SQ1070			Feb-2011
4050	8-Aminoadenine	[28128-33-8]	NC2=NC1=NC=NC(N)=C1N2	Adenine receptor agonist	Adenine receptor agonist (Ki = 0.0341 _M in HEK293 cells expressing an adenine binding site). Displays 190-fold increased potency at the human binding site over the rat adenine receptor (rAde1R) (Ki = 6.51 _M).	"Bender et al (2002) Characterization of an orphan G protein-coupled receptor localized in the dorsal root ganglia reveals adenine as a signaling molecule. Proc.Natl.Acad.Sci. 99 8573. Borrmann et al (2009) Structure-activity relationships of adenine and deazaadenine derivatives as ligands for adenine receptors, a new purinergic receptor family. J.Med.Chem. 52 5974. PMID:19731917."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=276297				Feb-2011
4052	Lisuride maleate	[19875-60-6]	OC(/C=C\C(O)=O)=O.[H][C@@]1(C2)C(C3=C4C2=CNC4=CC=C3)=C[C@H](NC(N(CC)CC)=O)CN1C	DA receptor agonist; antiparkinson's agent.	"Dopamine receptor agonist and anti-Parkinson's agent. Displays high affinity for D2, D3 and D4 receptors along with 5-HT1A. Exhibits some 5-HT2B receptor antagonist properties. Decreases prolactin release; reduces inflammatory mediators such as TNF-_ and IL6. Exhibits anticonvulsive effects. Acts similar to bromocriptine (Cat. No. 0427)."	"Woitalla et al (2004) Transdermal lisuride delivery in the treatment of Parkinson's disease. J.Neural Transm. 68 89. Hofmann et al (2006) Lisuride, a dopamine receptor agonist with 5-HT2B receptor antagonist properties: absence of cardiac valvulopathy adverse drug reaction reports supports the concept of a crucial role for 5-HT2B receptor agonism in cardiac valvular fibrosis. Clin.Neuropharmacol. 29 80. PMID:16614540. Zweckberger et al (2010) Anticonvulsive effects of the dopamine agonist lisuride maleate after experimental traumatic brain injury. Neurosci.Lett. 470 150. PMID:20056133."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=276312	SQ1533			Nov-2010
4053	BMS 470539 dihydrochloride	[457893-92-4]	O=C(N2CCC(C(CCC)=O)(C4=CC=CC=C4)CC2)[C@H](NC([C@@H](N)CC3=CN=CN3C)=O)CC1=CC=C(OC)C=C1.Cl.Cl	"Potent, selective MC1 receptor agonist"	"Potent, selective melanocortin MC1 receptor agonist (IC50 = 120 nM). Exhibits anti-inflammatory properties following ischemia-reperfusion in the vasculature. Inhibits leukocyte trafficking."	Herpin et al (2003) Discovery of tyrosine-based potent and selective melanocortin-1 receptor small-molecule agonists with anti-inflammatory properties. J.Med.Chem. 46 1123. PMID:12646021. Kang (2006) A selective small molecule agonist of the melanocortin-1 receptor inhibits lipopolysaccharide-induced cytokine accumulation and leukocyte infiltration in mice. J.Leukoc.Biol. 80 897. PMID:16888084. Leoni et al (2010) The melanocortin MC1 receptor agonist BMS-470539 inhibits leukocyte trafficking in the inflamed vasculature. Br.J.Pharmacol. 160 171. PMID:20331604.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=277258	SQ1070			Jul-2011
4055	L-Ascorbic acid	[50-81-7]	OC1=C(O)[C@]([C@@H](O)CO)([H])OC1=O	Enhances the generation of iPSCs; increases reprogramming efficiency	Inhibitor of Cav3.2 channels (IC50 = 6.5 _M); displays no effect on Cav3.1 or Cav3.3 channels heterologously expressed in HEK 293 cells. Also enhances the generation of induced pluripotent stem cells (iPSCs) from mouse and human somatic cells by increasing reprogramming efficiency. Naturally occurring antioxidant.	Padayatty et al (2003) Vitamin C as an antioxidant: evaluation of its role in disease prevention. J.Am.Coll.Nutr. 22 18. PMID:12569111. Nelson et al (2007) Molecular mechanisms of subtype-specific inhibition of neuronal T-type calcium channels by ascorbate. J.Neurosci. 27 12577. PMID:18003836. Esteban et al (2010) Vitamin C enhances the generation of mouse and human induced pluripotent stem cells. Cell Stem Cell 6 71. PMID:20036631.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=277432				Oct-2010
4056	Docetaxel	[114977-28-5]	O[C@@H]1C4=C(C)[C@@H](OC([C@H](O)[C@H]([C@]5=CC=CC=C5)NC(OC(C)(C)C)=O)=O)C[C@@](C(C)4C)(O)[C@@H](OC(C6=CC=CC=C6)=O)[C@@]([C@@]3(OC(C)=O)[C@H](OC3)C[C@@H]2O)([H])[C@]2(C)C1=O	Microtubule stabilizer	Binds and stabilizes microtubules; leads to cell cycle arrest and apoptosis. Displays significant antitumor activity in ovarian and gastric tumors. Prevents microtubule depolymerization and disassembly in the absence of GTP. Exhibits cytotoxic activity.	Lyseng-Williamson and Fenton (2005) Docetaxel: a review of its use in metastatic breast cancer. Drugs 65 2513. PMID:16296875. Ramaswamy and Puhalla (2006) Docetaxel: a tubulin-stabilizing agent approved for the management of several solid tumors. Drugs Today (Barc) 42 265. PMID:16703123.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=277494	SQ1533			Nov-2010
4057	Flupenthixol dihydrochloride	[2413-38-9]	Cl.Cl.OCCN1CCN(CCC=C2C3=CC(=CC=C3SC3=C2C=CC=C3)C(F)(F)F)CC1	Dopamine receptor antagonist	Antipsychotic drug. Exhibits antagonistic activity at dopamine D1-5 receptors. Used in schizophrenia treatment.	Peuch et al (1981) Pharmacological properties of new antipsychotic agents: Use of animal models. Neuropharmacology 20 1279. PMID:6119637.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=277662	SQ1533			Dec-2010
4060	LY 78335	[39959-66-5]	NC(C)C1=C(Cl)C(Cl)=CC=C1.Cl	Phenylethanolamine-N-methyltransferase inhibitor	High affinity inhibitor of phenylethanolamine-N-methyltransferase (PNMT) (Ki = 0.09 _M in vitro). Suppresses the release of growth hormone in an in vivo rat model.	"Fuller et al (1973) Inhibition of phenylethanolamine N-methyltransferase by benzylamines. 2. In vitro and in vivo studies with 2,3-dichloro-_-methylbenzylamine. J.Med.Chem. 16 106. PMID:4683104. Terry et al (1982) Regulation of episodic growth hormone secretion by the central epinephrine system. J.Clin.Invest. 69 104. PMID:7054231. Grunewald et al (1988) Synthesis and evaluation of 3-substituted analogues of 1,2,3,4-tetrahydroisoquinoline as inhibitors of phenylethanolamine N-methyltransferase. J.Med.Chem. 31 824. PMID:3351861."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=277859				Jan-2011
4061	6-Thioguanine	[154-42-7]	NC1=NC(S)=C2C(NC=N2)=N1	Anticancer and immunosuppressive agent	Anticancer and immunosuppressive agent often used to treat immune disorders and leukemia. Displays cytotoxic and antineoplastic properties; disrupts cytosine methylation by DNA methyltransferases after incorporation into DNA. Selectively kills BRCA2-defective tumors in a xenograft model. Also facilitates proteasome-mediated degradation of DNA (cytosine-5)-methyltransferase 1 (DNMT1).	Wang and Wang (2009) 6-Thioguanine perturbs cytosine methylation at CgP dinucleotide site by DNA methyltransferases in vitro and acts as a DNA demethylating agent in vivo. Biochemistry 48 2290. PMID:19236003. Issaeva et al (2010) 6-Thioguanine selectively kills BRCA2-defective tumors and overcomes PARP inhibitor resistance. Cancer Res. 70 6268. PMID:20631063. Yuan et al (2011) 6-thioguanine reactivates epigenetically silenced genes in acute lymphoblastic leukemia cells by facilitating proteasome-mediated degradation of DNMT1. Cancer Res. 71 1904. PMID:21239472.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=278183	SQ1533			Nov-2010
4063	MJ 15	[944154-76-1]	ClC1=CC(Cl)=CC=C1N2C(C3=CC=C(Cl)C=C3)=C(C)C(C(NCC4=CC=CN=C4)=O)=N2	Potent and selective CB1 antagonist	"Potent and selective CB1 receptor antagonist (Ki = 27.2 pM, IC50 = 118.9 pM for rat CB1 receptors). Exhibits potency in obesity and hyperlipidemia models; inhibits food intake and increases in body weight in diet-induced obese rats and mice."	"Chen et al (2010) Novel, selective antagonist of the cannabinoid CB1 receptor, MJ15, with prominent anti-obesity effect in rodent models. Eur.J.Pharmacol. 637 178. PMID:20380831."	Small Molecule	Sold under licence.	http://www.tocris.com/dispprod.php?ItemId=278261	SQ1070			Mar-2011
4064	Fluorobexarotene	[1190848-23-7]	CC(C(C(C3=CC=C(C(O)=O)C(F)=C3)=C)=C2)=CC1=C2C(C)(C)CCC(C)1C	RXR agonist	RXR agonist (Ki = 12 nM; EC50 = 43 nM at RXR_ receptors). Displays similar RAR agonist activity to bexarotene; exhibits an apparent RXR binding affinity 75% greater than bexarotene.	"Wagner et al (2009) Modeling, synthesis and biological evaluation of potential retinoid X receptor (RXR) selective agonists: novel analogues of 4-[1-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)ethynyl]benzoic acid (bexarotene). J.Med.Chem. 52 5950. PMID:19791803."	Small Molecule	Manufactured and sold under license from Arizona State University - Patent Pending	http://www.tocris.com/dispprod.php?ItemId=278262	SQ1070			May-2011
4066	TC-A 2317 hydrochloride	[1245907-03-2]	CC1=CC(NC2=NNC(C)=C2)=NC(NC(C)CCCC(C)(C)O)=C1C#N.Cl	"Potent, selective Aurora kinase A inhibitor"	Potent Aurora kinase A inhibitor (Ki = 1.2 nM compared to 101 nM for inhibition of Aurora kinase B). Selective over 60 other kinases (IC50 values > 1000 nM). Exhibits good cell permeability and antitumor activity.	Ando et al (2010) 3-Cyano-6-(-5-methyl-3-pyrazoloamino)pyridines: Selective Aurora A kinase inhibitors. Bioorg.Med.Chem.Lett. 20 4709. PMID:20573509.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=278270				May-2011
4067	YK 4-279	[1037184-44-3]	O=C2NC1=C(Cl)C=CC(Cl)=C1C(CC(C3=CC=C(OC)C=C3)=O)2O	Inhibitor of RNA helicase A (RHA)	Inhibitor of RNA Helicase A (RHA) binding to the oncogenic transciption factor EWS-FLI1. Inhibits Ewing's sarcoma family tumor (ESFT) cell growth; induces apoptosis.	Erkizan et al (2009) Small molecule selected to disrupt oncogenic protein EWS-FLI1 interaction with RNA helicase A inhibits Ewing's sarcoma. Nat.Med. 15 750. PMID:19584866.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=278271	SQ1533			Mar-2011
4072	TCN 237 dihydrochloride	[700878-19-9]	FC1=CC=CC=C1CC(CC4)CCN4CC3=NC2=CC=C(O)C=C2N3.Cl.Cl	Highly potent and selective NR2B antagonist	Highly potent NR2B-selective NMDA receptor antagonist (Ki = 0.8 nM); blocks NR2B-mediated calcium influx in Ltk cells (Ki = 9.7 nM). Selective for NR2B subunit over _1-adrenergic receptors and hERG channels (IC50 values are 730 nM and 2900 nM respectively). Displays efficacy in the rat carrageenan-induced mechanical hyperalgesia assay.	McCauley et al (2004) NR2B-selective N-methyl-D-aspartate antagonists: synthesis and evaluation of 5-substituted benzimidazoles. J.Med.Chem. 47 2089. PMID:15056006.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=278784	SQ1341			Nov-2012
4075	SNS 032	[345627-80-7]	CC(C)(C)C1=CN=C(CSC2=CN=C(NC(C3CCNCC3)=O)S2)O1	"Potent cdk2, cdk7 and cdk9 inhibitor"	"Potent inhibitor of cyclin-dependent kinases (cdks) 9, 2 and 7 (IC50 values are 4, 38 and 62 nM respectively). Displays no activity against 190 additional kinases (IC50 >1000 nM). Arrests the cell cycle at G2/M; inhibits transcription, proliferation and colony formation, and induces apoptosis in RPMI-8226 multiple myeloma cells. Prevents tumor cell-induced VEGF secretion and in vitro angiogenesis."	"Misra et al (2004) N-(Cycloalkylamino)acyl-2-aminothiazole inhibitors of cyclin-dependent kinase 2. N-[5-[[[5-(1,1-Dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl]-4- piperidinecarboxamide (BMS-387032), a highly efficacious and selective antitumor agent. J.Med.Chem. 47 1719. PMID:15027863. Ali et al (2007) SNS-032 prevents tumor cell-induced angiogenesis by inhibiting vascular endothelial growth factor. Neoplasia 9 370. PMID:17534442. Conroy et al (2009) SNS-032 is a potent and selective CDK 2, 7 and 9 inhibitor that drives target modulation in patient samples. Cancer Chemother.Pharmacol. 64 723. PMID:19169685. Chen et al (2010) Responses in mantle cell lymphoma cells to SNS-032 depend on the biological context of each cell line. Cancer Res. 70 6587. PMID:20663900."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=278790	SQ1533			Jun-2011
4076	P7C3	[301353-96-8]	BrC(C=C3)=CC1=C3N(CC(O)CNC4=CC=CC=C4)C2=C1C=C(Br)C=C2	Neuroprotective compound	"Proneurogenic, neuroprotective compound. Protects newborn neurons in the dentate gyrus by mitigating cell death. Also enhances learning and memory in aged rats. Orally available and brain penetrant."	"Pieper et al (2010) Discovery of a proneurogenic, neuroprotective chemical. Cell 142 39. PMID:20603013. Wang et al (2014) P7C3 neuroprotective chemicals function by activating the rate-limiting enzyme in NAD salvage. Cell 158 1324. PMID:25215490."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=278831	SQ1070			Jul-2011
4077	MC 1568	[852475-26-4]	CN1C=C(/C=C/C(C2=CC(F)=CC=C2)=O)C=C1/C=C/C(NO)=O	Selective HDAC class II (IIa) inhibitor	Selective inhibitor of class IIa histone deacetylases (HDACs). Exhibits tissue-selective inhibition between members of class II deacetylases in vivo; inhibits HDAC4 and HDAC5 in skeletal muscle and the heart without affecting HDAC3 activity. Arrests myogenesis through the stabilization of myocyte enhancer factor 2D (MEF2D)-HDAC3/4 complex. Displays no inhibition of class I HDAC activity or expression.	Mai et al (2005) Class II (IIa)-selective histone deacetylase inhibitors. 1. Synthesis and biological evaluation of novel (aryloxopropenyl)pyrrolyl hydroxyamines. J.Med.Chem. 48 3344. PMID:15857140. Mai et al (2007) Identification of two new synthetic histone deacetylase inhibitors that modulate globin gene expression in erythroid cells from healthy donors and patients with thalassemia. Mol.Pharmacol. 72 1111. PMID:17666592. Nebbioso et al (2009) Selective class II HDAC inhibitors may impaor myogenesis by modulating the stability and activity of HDAC-MEF2 complexes. EMBO J. 10 776.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=278832	SQ1533			Sep-2011
4078	PF 8380	[1144035-53-9]	O=C(C2=CC(OC(N4)=O)=C4C=C2)CCN1CCN(C(OCC3=CC(Cl)=CC(Cl)=C3)=O)CC1	Potent autotaxin inhibitor	Potent autotaxin inhibitor (IC50 = 2.8 nM in isolated enzyme assay; 101 nM in human whole blood). Modulates lysophosphatidic acid (LPA) levels in vivo and in vitro by directly inhibiting autotaxin; reduces LPA levels both in plasma and at site of inflammation. Orally available.	Gierse et al (2010) A novel autotaxin inhibitor reduces lysophosphatidic acid levels in plasma and the site of inflammation. J.Pharmacol.Exp.Ther. 334 310. PMID:20392816. Jankowski (2011) Autotaxin: its role in biology of melanoma cells and as a pharmacological target. Enzyme Res. 194857. PMID:21423677.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=278934	SQ1341			Feb-2014
4079	Niclosamide	[50-65-7]	O=C(NC2=C(Cl)C=C([N+]([O-])=O)C=C2)C1=C(O)C=CC(Cl)=C1	STAT3 inhibitor; also inhibits mTORC1 signaling	"Inhibitor of the STAT3 signaling pathway; inhibits the activation, nuclear translocation and transactivation of STAT3. Displays selectivity for STAT3 over STAT1, STAT5, JAK1, JAK2 and Src kinases. Inhibits the transcription of STAT3 target genes and induces cell growth inhibition, apoptosis and cell cycle arrest of cancer cells with constitutively active STAT3. Also reversibly inhibits mTORC1 signaling and stimulates autophagy in vitro; displays antineoplastic effects in acute myelogenous leukemia (AML) stem cells."	Balgi et al (2009) Screen for chemical modulators of autophagy reveals novel therapeutic inhibitors of mTORC1 signaling. PLoS One 4 e7124. PMID:19771169. Jin et al (2010) Antineoplastic mechanisms of niclosamide in acute myelogenous leukemia stem cells: inactivation of the NF-_B pathway and generation of reactive oxygen species. Cancer Res. 70 2516. PMID:20215516. Ren et al (2010) Identification of niclosamide as a new small-molecule inhibitor of the STAT3 signaling pathway. ACS Med.Chem.Lett. 1 454.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=278936				Nov-2010
4081	LY 266097 hydrochloride	[172895-39-5]	CC1=CC=C(NC3=C2CCNC3CC4=CC=C(OC)C(OC)=C4Cl)C2=C1.Cl	Selective 5-HT2B receptor antagonist	Selective 5-HT2B receptor antagonist (pKi = 9.3). More than 100-fold selective over 5-HT2A and 5-HT2C. Attenuates amphetamine-induced locomotion in the rat.	"Audia et al (1996) Potent, selective tetrahydro-_-carboline antagonists of the serotonin 2B (5-HT2B) contractile receptor in the rat stomach fundus. J.Med.Chem. 39 2773. PMID:8709108. Auclair et al (2010) The central serotonin2B receptor: a new pharmacological target to modulate the mesoaccumbens dopaminergic pathway activity. J.Neurochem. 114 1323. PMID:20534001."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=279165	SQ1070			Apr-2011
4083	3F8	[159109-11-2]	O=C(NC3=O)C2=C3C1=CC(OC)=C(OC)C=C1C(CC)=N2	Potent and selective GSK-3_ inhibitor	Potent and selective GSK-3_ inhibitor (IC50 values are 34 and 304 nM in the presence of 10 and 100 _M ATP respectively).	"Zhong et al (2009) Characterization and development of novel small-molecules inhibiting GSK3 and activating wnt signaling. Mol.Biosyst. 5 1356. PMID:19823752. Zou et al (2010) Benzo[e]isoindole-1,3-diones as potential inhibitors of glycogen synthase kinase-3 (GSK-3). Synthesis, kinase inhibitory activity, zebrafish phenotype, and modeling of binding mode. J.Med.Chem. 53 994. PMID:20030405."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=279168	SQ1070			Jan-2011
4085	Nalmefene hydrochloride	[58895-64-0]	C=C3[C@H]5[C@]24C1=C(O5)C(O)=CC=C1C[C@@H](N(CC6CC6)CC4)[C@@](O)2CC3.Cl	Opioid receptor antagonist	"Opioid receptor antagonist; displays a longer half life than Naloxone (Cat. No. 0599). Exhibits neuroprotective effects after traumatic brain injury in the rat. Deuterated version, Nalmefene d3 (Cat. No. 3971), also available."	"Vink et al (1990) Opiate antagonist nalmefene improves intracellular free Mg2+, bioenergetic state, and neurologic outcome following traumatic brain injury in rats. J.Neurosci. 10 3524. PMID:2230942."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=279170	SQ1533			Jan-2011
4086	PE 154	[1192750-33-6]	O=C(CC4=CC=C(N/C=C5/C(OC(C=C(N(CC)CC)C=C6)=C6C5=O)=O)C=C4)NNC2=C3C(CCCC3)=NC1=CC=CC=C12	"Fluorescent, potent AChE and BChE inhibitor"	Potent fluorescent inhibitor of human acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) (IC50 values are 280 pM and 16 nM respectively). Targets and labels _-amyloid plaques in histochemical analysis.	"Elsinghorst et al (2009) A gorge-spanning, high-affinity cholinesterase inhibitor to explore _-amyloid plaques. Org.Biomol.Chem. 7 3940. PMID:19763296. Kacza et al (2010) In vivo labelling of hippocampal beta-amyloid in triple-transgenic mice with a fluorescent acetylcholinesterase inhibitor released from nanoparticles. Eur.J.Neurosci. 31 99. PMID:20092557."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=279172	SQ1070			Nov-2011
4087	PS 48	[1180676-32-7]	ClC1=CC=C(CC/C(C2=CC=CC=C2)=C/C(O)=O)C=C1	PDK1 activator	"Phosphoinositide-dependent protein kinase-1 (PDK1) activator (Kd = 10.3 _M). Binds exclusively to the PIF-binding pocket of PDK1, distinct from the ATP binding site."	"Hindie et al (2009) Structure and allosteric effects of low-molecular-weight activators on the protein kinase PDK1. Nat.Chem.Biol. 5 758. PMID:19718043. Stroba et al (2009) 3,5-diphenylpent-2-enoic acids as allosteric activators of the protein kinase PDK1: structure-activity relationships and thermodynamic characterization of binding as paradigms for PIF-binding pocket-targeting compounds. J.Med.Chem. 52 4683. PMID:19606904. Williams (2010) Elastic network model of allosteric regulation in protein kinase PDK1. BMC Struct.Biol. 10 11. PMID:20500829. Zhu et al (2010) Reprogramming of human primary somatic cells by OCT4 and chemical compounds. Cell Stem Cell. 7 651. PMID:21112560."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=279178				Mar-2011
4088	IU1	[314245-33-5]	O=C(CN2CCCC2)C1=C(C)N(C3=CC=C(F)C=C3)C(C)=C1	USP14 inhibitor	Selective inhibitor of Usp14; inhibits the catalytic activity of proteasome-associated Usp14 in vitro (IC50 < 4 _M). Stimulates proteasome activity and substrate degradation.	Lee et al (2010) Enhancement of proteasome activity by a small-molecule inhibitor of USP14. Nature 467 179. PMID:20829789. Lee et al (2010) Trimming of ubiquitin chains by proteasome-associated deubiquitinating enzymes. Mol.Cell.Proteomics 10 R110. PMID:20823120.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=280013	SQ1070			Feb-2011
4089	Puromycin dihydrochloride	[58-58-2]	O[C@@H]1[C@H](NC([C@@H](N)CC4=CC=C(OC)C=C4)=O)[C@@H](CO)O[C@H]1N3C2=NC=NC(N(C)C)=C2N=C3.Cl.Cl	Protein synthesis inhibitor	Protein synthesis inhibitor; leads to the premature release of polypeptide chains as polypeptidyl purine derivatives. Analog of the 3' end of aminoacyl-tRNA. Aminonucleoside antibiotic. Inhibits translation in both in vitro and in vivo systems. Also inhibits the transport of proteins into the mitochondria in vitro.	Azzam and Algranati (1973) Mechanism of puromycin action: fate of ribosomes after release of nascent polypeptide chains from polysomes. Proc.Nat.Acad.Sci. 70 3866. Price and Verner (1993) Puromycin inhibits protein import into mitochondria by interfering with an intramitochondrial ATP-dependent reaction. Biochim.Biophys.Acta. 1150 89. PMID:8334141.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=280014	SQ1070			Nov-2010
4090	Doxycycline hyclate	[1293992-19-4]	OC1=C(C(C2=C(O)[C@@](C(C(C(N)=O)=C(O)[C@H]4N(C)C)=O)(O)[C@@]4([H])[C@@H](O)[C@@]([H])2[C@H]3C)=O)C3=CC=C1.Cl	Broad-spectrum MMP inhibitor; tetracycline derivative	Broad-spectrum antibiotic and MMP inhibitor; tetracycline derivative. Increases and promotes smooth muscle cell adhesion; inhibits proliferation and migration. Protects the microvasculature by inhibiting plasminogen systems.	"Franco et al (2006) Doxycycline alters vascular smooth muscle cell adhesion, migration, and reorganization of fibrillar collagen matrices. Am.J.Pathol. 168 1697. PMID:16651635. Burggraf et al (2007) Doxycycline inhibits MMPs via modulation of plasminogen activators in focal cerebral ischemia. Neurobiol.Dis. 25 506. PMID:17166729. Wernig et al (2008) A drug-inducible transgenic system for direct reprogramming of multiple somatic cell types. Nat.Biotechnol. 26 916. PMID:18594521."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=280061	SQ1533			Nov-2010
4091	Cyclophosphamide	[50-18-0]	O=P1(N(CCCl)CCCl)OCCCN1	Alkylating agent; chemotherapeutic	Nitrogen mustard alkylating agent and prodrug. Phosphoramide mustard (active metabolite) forms DNA cross-links leading to cell death. Inhibits aldehyde dehydrogenase 1 (ALDH1) through its degradation product acrolein. Chemotherapeutic for the treatment of breast cancer; regulates Bax and Bcl-2 expression when administered with etoposide (Cat. No. 1226) in breast cancer cell lines.	Hengstler et al (1992) DNA strand breaks and DNA cross-links in peripheral mononuclear blood cells of ovarian cancer patients during chemotherapy with cyclophosphamide/carboplatin. Cancer Res. 15 52. Ren et al (1999) Inhibition of human aldehyde dehydrogenase 1 by the 4-hydroxycyclophosphamide degradation product acrolein. Drug Metab.Disp. 27 133. Gibson et al (1999) Regulation of BAX and BCL-2 expression in breast cancer cells by chemotherapy. Breast Cancer Research and Treatment 55 107. PMID:10481938.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=280094	SQ1533			Nov-2010
4092	Aspirin	[50-78-2]	CC(OC1=C(C(O)=O)C=CC=C1)=O	Cyclooxygenase inhibitor; NSAID	Inhibitor of cyclooxygenase (COX)-1. Blocks the production of prostaglandins and thromboxanes. Exhibits antiplatelet and antithrombotic activities. Displays anticancer effects in some solid tumors. One of the first described NSAID drugs.	Sanduja et al (1991) Aspirin inhibits interleukin 1-induced prostaglandin H synthase expression in cultured endothelial cells. Proc.Natl.Acad.Sci. 15 88. Baron (1995) Aspirin and cancer. Preventative Medicine 24 121. Schror (1997) Aspirin and platelets: the antiplatelet action of aspirin and its role in thrombosis treatment and prophylaxis. Semin.Thromb.Hemost. 23 349. PMID:9263351.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=280121	SQ1533			Nov-2010
4093	Hydrocortisone	[50-23-7]	O=C1CC[C@@]2(C)C(CC[C@]3([H])[C@@]([H])2[C@@H](O)C[C@@]4(C)[C@]([H])3CC[C@@](O)4[C@@](CO)=O)=C1	Adrenal glucocorticoid; immunosuppressant	Adrenal glucocorticoid released in the stress response. Increases glucose production by gluconeogenesis. Immunosuppressant and antidiuretic hormone.	Khani and Tayek (2001) Cortisol increases gluconeogenesis in humans; its role in the metabolic syndrome. Clin.Sci.(Lond) 101 739. PMID:11724664.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=280182	SQ1533			Nov-2010
4094	Flutamide	[13311-84-7]	CC(C)C(NC1=CC(C(F)(F)F)=C([N+]([O-])=O)C=C1)=O	Non-steroidal androgen receptor antagonist	Non-steroidal antiandrogen; competitive antagonist of the androgen receptor. Blocks the biological activity of testosterone (Cat. No. 2822) in vivo.	Sufrin and Coffey (1976) Flutamide. Mechanism of action of a new nonsteroidal antiandrogen. Invest.Urol. 13 429. PMID:1270239. Butcher et al (2007) Induction of human arylamine N-acetyltransferase type I by androgens in human prostate cancer cells. Cancer Res. 67 85. PMID:17210686. Foster et al (2011) Drug safety is a barrier to the discovery and development of new androgen receptor antagonists. Prostate 71 480. PMID:20878947.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=280192	SQ1533			Nov-2010
4095	Amiodarone hydrochloride	[19774-82-4]	CCCCC2=C(C(C3=CC(I)=C(OCCN(CC)CC)C(I)=C3)=O)C1=CC=CC=C1O2.Cl	Broad spectrum ion channel blocker; antiarrhythmic	"Broad-spectrum ion channel blocker; blocks late INa, ICa, IKr and IKs and increases QT. Displays class III antiarrhythmic properties. Also exhibits fungicidal activity; elicits Ca2+ influx in Saccharomyces cerevisiae and causes mitochondrial fragmentation and cell death. Thought to stimulate autophagy by targeting upstream mTORC1 control pathways. Selectively inhibits proliferation of NSCs in hESC-derived cell populations."	"di Matola et al (2000) Amiodarone induces cytochrome c release and apoptosis through an iodine-dependent mechanism. J.Clin.Endocrin.Metab. 85 4323. PMID:11095475. Antzelevitch et al (2004) Electrophysiological effects of ranolazine, a novel antianginal agent with antiarrhythmic properties. Circulation 110 904. PMID:15302796. Balgi et al (2009) Screen for chemical modulators of autophagy reveals novel therapeutic inhibitors of mTORC1 signaling. PLoS One 4 e7124. PMID:19771169. Han et al (2009) Identification by automated screening of a small molecule that selectively eliminates neural stem cells derived from hESCs but not dopamine neurons. PLoS One. 4 7155. PMID:19774075."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=280238	SQ1533			Nov-2010
4096	Clotrimazole	[23593-75-1]	ClC1=CC=CC=C1C(C3=CC=CC=C3)(C4=CC=CC=C4)N2C=CN=C2	Cytochrome P450 inhibitor; antifungal	Imidazole antimycotic and cytochrome P450 inhibitor. Inhibits Ca2+-activated K+ current (IC50 = 3 _M) and L-type Ca2+ current; increases the firing rate of action potentials. Exhibits antiproliferative activity in vitro and in vivo. Also an inverse agonist of the human constitutive androstane receptor (hCAR).	"Snajdrova et al (1998) Clomitrazole, an antimycotic drug, inhibits the sarcoplasmic reticulum calcium pump and contractile function in heart muscle. J.Biol.Chem. 273 28032. PMID:9774419. Wu et al (1999) Inhibition of Ca2+-activated K+ current by clotrimazole in rat anterior pituitary GH3 cells. Neuropharmacology 38 979. PMID:10428416. Thomas et al (1999) The antifungal antibiotic clotrimazole potently inhibits L-type calcium current in guinea-pig ventricular myocytes. Br.J.Pharmacol. 126 1531. PMID:10323582. Lempiainen et al (2005) Antagonist- and inverse agonist-driven interactions of the vitamin D receptor and the constitutive androstane receptor with corepressor protein. Mol.Endocrinol. 19 2258. PMID:15905360."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=280240	SQ1533			Nov-2010
4098	Carbamazepine	[298-46-4]	NC(N1C3=C(C=CC=C3)C=CC2=C1C=CC=C2)=O	Inhibitor of neuronal voltage-gated Na+ channels; anticonvulsant	Inhibitor of neuronal voltage-gated Na+ channels. Exhibits anticonvulsant activity. Potentiates GABA-induced Cl- currents in HEK 293 cells expressing the GABAA receptor _1_2_2 subtype combination. Can induce autophagy by inhibiting inositol synthesis.	Granger et al (1995) Modulation of the gamma-aminobutyric acid type A receptor by the antiepileptic drugs carbamazepine and phenytoin. Mol.Pharmacol. 47 1189. PMID:7603459. Afanas'ev et al (1999) Lamotrigine and carbamazepine affect differently the release of D-[3H] aspartate from mouse cerebral cortex slices: involvement of NO. Neurochem.Res. 24 1153. PMID:10485587. Sarkar et al (2009) Rapamycin and mTOR-independent autophagy inducers ameliorate toxicity of polyglutamine-expanded huntingtin and related proteinopathies. Cell Death Differ. 16 46. PMID:18636076. Lipkind and Fozzard (2010) Molecular model of anticonvulsant drug binding to the voltage-gated sodium channel inner pore. Mol.Pharmacol. 78 631. PMID:20643904.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=280244	SQ1533			Nov-2010
4099	Azathioprine	[446-86-6]	CN1C=NC([N+]([O-])=O)=C1SC2=C3C(N=CN3)=NC=N2	Purine analog; prodrug of 6-mercaptopurine (Cat. No. 4103)	Purine analog. Blocks DNA replication and the de novo pathway of purine synthesis. Immunosuppressive and anti-inflammatory drug; induces apoptosis in human T-lymphocytes. Prodrug of 6-mercaptopurine (Cat. No. 4103).	"Maltzman and Koretzky (2003) Azathioprine: old drug, new actions. J.Clin.Invest. 111 1122. PMID:12697731."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=280275	SQ1533			Dec-2010
4100	HC 067047	[883031-03-6]	CC1=C(C(NC4=CC(C(F)(F)F)=CC=C4)=O)C=C(C3=CC=CC=C3)N1CCCN2CCOCC2	Potent and selective TRPV4 antagonist	"Potent and selective TRPV4 antagonist. Reversibly inhibits currents through mouse, human and rat TRPV4 orthologs (IC50 values are 17, 48 and 133 nM respectively). Also inhibits the endogenous TRPV4-mediated response to 4_-PDH (IC50 = 22 nM). Selective for TRPV4 over TRPV1, TRPV2, TRPV3 and TRPM8 channels."	Everaerts et al (2010) Inhibition of the cation channel TRPV4 improves bladder function in mice and rats with cyclophosphamide-induced cystitis. Proc.Natl.Acad.Sci. 107 19084.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=280334	SQ1533			Jan-2011
4101	SU 11274	[658084-23-2]	CC1=C(\C=C(C3=CC(S(N(C)C5=CC(Cl)=CC=C5)(=O)=O)=CC=C3N4)/C4=O)NC(C)=C1C(N2CCN(C)CC2)=O	Selective inhibitor of MET kinase activity	Selective inhibitor of MET tyrosine kinase activity (IC50 = 0.01 _M in vitro). Reduces cell growth in a dose-dependent manner; induces cell cycle arrest and apoptosis. Abrogates cell motility and migration in vitro and tumor angiogenesis in vivo.	Sattler et al (2003) A novel small molecule Met inhibitor induces apoptosis in cells transformed by the oncogenic TPR-MET tyrosine kinase. Cancer Res. 63 5462. PMID:14500382. Wang et al (2003) Potent and selective inhibitors of the Met [hepatocyte growth factor/scatter factor (HGF/SF) receptor] tyrosine kinase block HGF/SF-induced tumor cell growth. Mol.Cancer Ther. 2 1085. PMID:14617781. Seiwert et al (2009) The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Res. 69 3021. PMID:19318576.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=280335	SQ1533			Mar-2011
4102	Mycophenolate mofetil	[128794-94-5]	O=C(OC2)C1=C2C(C)=C(OC)C(C/C=C(C)/CCC(OCCN3CCOCC3)=O)=C1O	Inhibitor of inosine monophosphate dehydrogenase	"Immunosuppressant prodrug of mycophenolic acid (MPA) (Cat. No. 1505). Hydrolyzed by esterases to release MPA (a reversible inhibitor of inosine monophosphate dehydrogenase). Used to prevent organ rejection after transplantation. Displays inhibitory activity of lymphocyte functions. Inhibits type 1 collagen expression, enhances MMP-1 expression, and reduces _-smooth muscle actin gene expression."	Allison and Eugui (1996) Purine metabolism and immunosuppressive effects of mycophenolate mofetil (MMF). Clin.Transplant. 10 77. PMID:8680053. Roos et al (2007) In vitro evidence for a direct antifibrotic role of the immunosuppressive drug mycophenolate mofetil. J.Pharm.Exp.Ther. 321 583.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=280355	SQ1533			Dec-2010
4103	6-Mercaptopurine	[50-44-2]	S=C1C2C(N=CN2)N=CN1	Purine analog; inhibits DNA and RNA synthesis	Inhibitor of de novo purine synthesis through interference with DNA and RNA synthesis. Immunosuppressive and antileukemic drug; reduces the anticoagulation elicited by warfarin. Active metabolite of azathioprine (Cat. No. 4099).	Sahasranaman et al (2008) Clinical pharmacology and pharmacogenetics of thiopurines. Eur.J.Clin.Pharmacol. 64 753. PMID:18506437.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=280395				Dec-2010
4104	MM-22	[956605-71-3]	O=C(NCCOCCOCCNC(CCCC[C@H]1[C@](NC(N2)=O)([H])[C@]2([H])CS1)=O)CCC\C=C/C\C=C/C/C=C\C/C=C\CCCCC	Biotinylated anandamide analog; blocks anandamide uptake	"Biotinylated anandamide analog; acts as a probe for visualizing the accumulation and intracellular trafficking of anandamide. Blocks anandamide uptake (IC50 = 0.5 _M in HaCaT cells); prevents interaction with FAAH, CB1 and TRPV1."	"Fezza et al (2008) Characterization of biotin-anandamide, a novel tool for the visualization of anandamide accumulation. J.Lipid.Res. 49 1216. PMID:18316795. Oddi et al (2008) Evidence for the intracellular accumulation of anandamide in adiposomes. Cell Mol.Life Sci. 65 840. PMID:18213445. Oddi et al (2009) Molecular identification of albumin and Hsp70 as cytosolic anandamide-binding proteins. Chem.Biol. 16 624. PMID:19481477. Oddi et al (2010) Pitfalls and solutions in assaying anandamide transport in cells. J.Lipid.Res. 51 2435. PMID:20447929."	Small Molecule	Sold under licence from the University of Rome and the University of Teramo	http://www.tocris.com/dispprod.php?ItemId=280487				Oct-2012
4105	CIQ	[486427-17-2]	O=C(C3=CC(Cl)=CC=C3)N2C(COC4=CC=C(OC)C=C4)C1=CC(OC)=C(OC)C=C1CC2	Potentiator of NMDA receptors containing NR2C/NR2D	Subunit-selective potentiator of NMDA receptors containing the NR2C or NR2D subunit. Increases channel opening efficiency and enhances NMDA receptor responses.	Mullasseril et al (2010) A subunit-selective potentiator of NR2C- and NR2D-containing NMDA receptors. Nat.Commun. 1 1. PMID:20975674.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=280490	SQ1070			Jan-2011
4106	Nicotinamide	[98-92-0]	O=C(C1=CC=CN=C1)N	PARP-1 inhibitor	Anti-inflammatory agent. Inhibitor of poly(ADP-ribose) polymerase (PARP-1) enzymes. NAD+ precursor.	Cimadamore et al (2009) Nicotinamide rescues human embryonic stem cell-derived neuroectoderm from parthanatic cell death. Stem Cells. 27 1772. PMID:19544437. Suzuki et al (2010) Protective effect of nicotinamide against poly(ADP-ribose) polymerase-1-mediated astrocyte death depends on its transporter-mediated uptake. Life.Sci. 86 676. PMID:20188745.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=280736	SQ1533			Dec-2010
4107	Probenecid	[57-66-9]	O=S(C1=CC=C(C(O)=O)C=C1)(N(CCC)CCC)=O	MRP inhibitor	Inhibitor of multidrug resistance-associated proteins (MRP). Inhibits organic acid transport in the kidney and other organs. Also exhibits inhibitory activity against pannexin 1 channels (IC50 ~ 150 _M).	"Cunningham et al (1981) Clinical pharmacokinetics of probenecid. Clin.Pharmacokinet. 6 135. PMID:7011657. Hammond et al (2007) Glutathione export during apoptosis requires functional multidrug resistance-associated proteins. J.Biol.Chem. 282 14337. PMID:17374608. Silverman et al (2008) Probenecid, a gout remedy, inhibits pannexin 1 channels. Am.J.Physiol.Cell Physiol. 295 C761. PMID:18596212. Ishikawa et al (2010) Function and expression of ATP-binding cassette transporters in cultured human Y79 retinoblastoma cells. Biol.Pharm.Bull. 33 504. PMID:20190417."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=280741	SQ1070			Dec-2010
4108	Quinidine	[56-54-2]	O[C@H](C3N(CC4C=C)CCC4C3)C2=CC=NC1=CC=C(OC)C=C12	Blocks sodium and potassium channels	"Class IA antiarrythmic; reduces both Na+ and K+ channel currents, including INa, IKr and IKs. Prolongs QT and induces torsade de pointes (TdP)."	Caballero et al (2003) Effects of flecainide and quinidine on Kv4.2 currents: voltage dependence and role of S6 valines. Br.J.Pharmacol. 138 1475. PMID:12721103. Borggrefe et al (2005) Short QT syndrome genotype-genotype correlations. J.Electrocardiol. 38 75. PMID:16226079. Wu et al (2008) Role of late sodium current in modulating the proarrhythmic and antiarrhythmic effects of quinidine. Heart Rhythm. 5 1726. PMID:19084812.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=280742	SQ1533			Dec-2010
4109	Chloroquine diphosphate	[50-63-5]	CCN(CC)CCCC(C)NC2=CC=NC1=CC(Cl)=CC=C12.O=P(O)(O)O.O=P(O)(O)O	Antimalarial; inhibits apoptosis and autophagy	Antimalarial drug. Inhibits cell growth and induces cell death in numerous cancer cell lines; inhibits cell proliferation and viability and induces apoptosis in 4T1 mouse breast cancer cells in vitro. Exhibits antimetastatic activity. Also inhibits autophagy via a mechanism distinct from that of 3-methyladenine (Cat. No. 3977).	Jiang et al (2010) Antitumor and antimetastatic activities of chloroquine diphosphate in a murine model of breast cancer. Biomed.Pharmacother. 64 609. PMID:20888174. Sasaki et al (2010) Chloroquine potentiates the anti-cancer effect of 5-fluorouracil on colon cancer cells. BMC Cancer 10 370. PMID:20630104.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=280745	SQ1533			Dec-2010
4111	Hexamethonium bromide	[55-97-0]	C[N+](C)(C)CCCCCC[N+](C)(C)C.[Br-].[Br-]	Nicotinic receptor blocker	Nicotinic receptor (nAChR) blocker at autonomic ganglia; prevents nicotine-mediated inhibition of apoptosis. Induces changes in neuronal activity similar to the influences of glutamate in vitro. Inhibits nicotine-mediated induction of XIAP and survivin.	Karavaev et al (2008) The nicotinic receptor blocker hexamethonium alters neuronal responses to glutamate in the medial septal area of the brain of the ground squirrel in vitro. Neurosci.Behav.Physiol. 38 297. PMID:18264777. Dasgupta et al (2010) Nicotine inhibits apoptosiis induced by chemotherapeutic drugs by up-regulating XIAP and survivin. Proc.Natl.Acad.Sci. 103 6332.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=280749	SQ1533			Dec-2010
4112	Niflumic acid	[4394-00-7]	O=C(C1=CC=CN=C1NC2=CC=CC(C(F)(F)F)=C2)O	Cyclooxygenase-2 (COX-2) inhibitor; GPR35 agonist	Nonsteroidal anti-inflammatory drug (NSAID); selectively inhibits COX-2. Also activates human TRPA1 inducibly expressed in HEK293 cells; displays agonist activity at GPR35.	"Ottolia and Toro (1994) Potentiation of large conductance KCa channels by niflumic, flufenamic and mefenamic acids. Biophys.J. 67 2272. PMID:7535111. Famaey (1997) In vitro and in vivo pharmacological evidence of selective cyclooxygenase-2 inhibition by nimesulide: an overview. Inflamm.Res. 46 437. PMID:9427063. Hu et al (2010) Activation of TRPA1 channels by fenamate nonsteroidal anti-inflammatory drugs. Pflugers Arch. 459 579. PMID:19888597. Deng et al (2012) Multiple tyrosine metabolites are GPR35 agonists. Sci.Rep. 2 373. PMID:22523636."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=280752	SQ1533			Dec-2010
4113	Fenofibrate	[49562-28-9]	CC(C)OC(C(C)(C)OC(C=C2)=CC=C2C(C1=CC=C(Cl)C=C1)=O)=O	PPAR_ agonist	PPAR_ agonist; hypolipidemic. Attenuates insulin resistance and increases high-density lipoprotein-cholesterol in db/db mice.	Mandard et al (2004) The direct peroxisome proliferator-activated receptor target fasting-induced adipose factor (FIAF/PGAR/ANGPTL4) is present in blood plasma as a truncated protein that is increased by fenofibrate treatment. J.Biol.Chem. 279 34411. PMID:15190076. Park et al (2006) PPAR_ agonist fenofibrate improves diabetic nephropathy in db/db mice. Kidney Int. 69 1511. PMID:16672921. Balakumar et al (2011) Pleiotropic actions of fenofibrate on the heart. Pharmacol.Res. 63 8. PMID:21093591.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=280753	SQ1533			Dec-2010
4114	Quinine hydrochloride	[130-89-2]	O[C@@H](C3N(CC4C=C)CCC4C3)C2=CC=NC1=CC=C(OC)C=C12.Cl	Antimalarial	Displays antimalarial and muscle relaxant properties. Stereoisomer of quinidine (Cat. No. 4108); closely related to chloroquine (Cat. No. 4109).	Merck Index 14 8061.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=280756	SQ1533			Jan-2011
4115	Mometasone furoate	[83919-23-7]	O=C1C=C[C@@]2(C)C(CC[C@]3([H])[C@@](Cl)2[C@@H](O)C[C@@]4(C)[C@]([H])3C[C@@H](C)[C@@](OC(C5=CC=CO5)=O)4[C@@](CCl)=O)=C1	Synthetic corticosteroid; anti-inflammatory agent	Potent synthetic corticosteroid; displays agonist activity at glucocorticoid and progesterone receptors. Exhibits anti-inflammatory effects.	Austin et al (2002) Mometasone furoate is a less specific glucocorticoid than fluticasone propionate. Eur.Respir.J. 20 1386. PMID:12503693. Ogawa et al (2009) Dissociation of local anti-inflammatory effect and systemic effects of mometasone furoate in mice. Immunopharmacol.Immunotoxicol. 31 601. PMID:19874229.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=281851	SQ1533			Jan-2011
4116	GSK 9027	[1229096-88-1]	FC(C=C3)=CC=C3N2C1=CC=C(C4=C(C(F)(F)F)C=C(NS(CC5=CC=CC=C5)(=O)=O)C=C4)C=C1C=N2	Glucocorticoid receptor agonist	Glucocorticoid receptor agonist (pIC50 = 8). Inhibits production of the proinflammatory mediator IL-6 in vivo.	Yates et al (2010) Structure guided design of 5-arylindazole glucocorticoid receptor agonists and antagonists. J.Med.Chem. 53 4531. PMID:20469868.	Small Molecule	Sold for research purposes under agreement from GlaxoSmithKline.	http://www.tocris.com/dispprod.php?ItemId=281856	SQ1070			Feb-2011
4117	Bepridil hydrochloride	[68099-86-5]	CC(C)COCC(N3CCCC3)CN(C2=CC=CC=C2)CC1=CC=CC=C1.Cl	Non-selective calcium channel blocker	"Calcium channel blocker. Also inhibits Na+/Ca2+ exchange (NCX), sodium channels and cardiac sarcolemmal KATP channels; opens mitochondrial KATP channels. Antiarrhythmic and antihypertensive; acts as a calcium sensitizer."	"Yatani et al (1986) Bepridil block of cardiac calcium and sodium channels. J.Pharmacol.Exp.Ther. 237 9. PMID:2420970. Gill et al (1992) Pharmacology of bepridil. Am.J.Cardiol. 69 11D. PMID:1372785. Wantanabe and Kimura (2001) Blocking effect of bepridil on Na+/ Ca2+ exchange current in gunea pig cardiac ventricular myocytes. Jpn.J.Pharmacol. 85 370. PMID:11388640. Sato et al (2006) Bepridil, an antiarrythmic drug, opens mitochondrial KATP channels, blocks sarcolemmal KATP channels, and confers cardioprotection. J.Pharmacol.Exp.Ther. 316 182. PMID:16174795."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=281997	SQ1533			Jan-2011
4118	SB 772077B dihydrochloride	[607373-46-6]	NC1=NON=C1C3=NC2=CN=CC(C(N4CC[C@H](N)C4)=O)=C2N3CC.Cl.Cl	Potent Rho-kinase inhibitor; vasodilator	Potent Rho-kinase (ROCK) inhibitor (IC50 value of approximately 5.6 nM at recombinant human ROCK1 and 2). Decreases pulmonary and systemic arterial blood pressures and increases cardiac output. Exhibits vasodilator activity that is more potent than Y-27632 (Cat.No 1254) or Fasudil (Cat.No. 0541).	"Doe et al (2007) Novel Rho kinase inhibitors with anti-inflammatory and vasodilatory activities. J.Pharm.Exp.Ther. 320 89. Dhaliwal et al (2009) Analysis of pulmonary vasodilator responses to SB-772077-B [4-(7-((3-amino-1-pyrrolidinyl)carbonyl)-1-ethyl-1H-imidazo(4,5-c)pyridin-2-yl)-1,2,5-oxadiazol-3-amine], a novel aminofurazan-based Rho kinase inhibitor. J.Pharm.Exp.Ther. 330 334."	Small Molecule	Sold for research purposes under agreement from GlaxoSmithKline	http://www.tocris.com/dispprod.php?ItemId=282001	SQ1070			Jul-2011
4119	Cinnabarinic acid	[606-59-7]	O=C2C(N)=C(C(O)=O)C1=NC3=C(C=CC=C3C(O)=O)OC1=C2	Selective mGlu4 agonist	"mGlu4 receptor agonist. Activates mGlu4 receptors in transiently transfected HEK293 cells; selective over all other mGlu subtypes (mGlu1, mGlu2 and mGlu5-8). Decreases cAMP levels in native cultured cerebellar granule cells. Also counteracts excitotoxic neuronal cell death induced by NMDA in mixed cultures of cortical cells; displays neuroprotective activity."	"Fazio (2012) Cinnabarinic acid, an endogenous metabolite of the kynurenine pathway, activates type-4 metabotropic glutamate receptors. Mol.Pharmacol. Feb 6 Epub ahead of print. PMID:22311707."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=282567				Mar-2011
4120	Xanthurenic acid	[59-00-7]	OC1=C2C(C(O)=CC(C(O)=O)=N2)=CC=C1	Selectively activates group II mGlu receptors	Shown to selectively activate group II mGlu receptors in transfected HEK293 cells at nanomolar concentrations. Attenuates cAMP formation in mouse cortical slices expressing mGlu2 and mGlu3 receptors.	"Han et al (2007) The tryptophan oxidation pathway in mosquitoes with emphasis on xanthurenic acid biosynthesis. J.Insect.Physiol. 53 254. PMID:17070835. Mauro et al (2010) Xanthurenic acid, a novel endogenous ligand for metabotropic glutamate receptors. Program No. 643.1/F2. 2010 Neuroscience Meeting Pl 2010 (Online)."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=282568				Jan-2011
4121	Rifampicin	[13292-46-1]	CN(CC3)CCN3/N=C/C2=C(O)C1=C(C5=O)C4=C(C)C(O)=C1C(O)=C2NC(/C(C)=C\C=C\[C@H](C)[C@H](O)[C@H]([C@H]([C@@H](C)[C@H](OC(C)=O)[C@H](C)[C@@H](OC)/C=C/O[C@@]5(C)O4)O)C)=O	Pregnane X receptor agonist; antibiotic	Antibiotic; inhibits bacterial RNA polymerase. Prototypical activator of the pregnane X receptor (PXR).	Wehrli (1983) Rifampin: mechanisms of action and resistance. Rev.Infect.Dis. 5 S407. PMID:6356275. Moore et al (2000) Orphan nuclear receptors constitutive androstane receptor and pregnane X receptor share xenobiotic and steroid ligands. J.Biol.Chem. 275 15122. PMID:10748001. Artsimovitch et al (2005) Allosteric modulation of the RNA polymerase catalytic reaction is an essential component of transcription control by rifamycins. Cell 122 351. PMID:16096056. Hu et al (2010) Pregnane X receptor is SUMOylated to repress the inflammatory response. J.Pharmacol.Exp.Ther. 335 342. PMID:20719936.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=282668	SQ1533			Jan-2011
4124	Pioglitazone hydrochloride	[112529-15-4]	O=C(S3)NC(C3CC(C=C2)=CC=C2OCCC1=NC=C(CC)C=C1)=O.Cl	Selective PPAR_ agonist; antidiabetic agent	Selective PPAR_ agonist (EC50 = 0.69 _M). Thiazolidinedione (TZD) derivative and antidiabetic agent; improves insulin sensitivity.	"Willson et al (1996) The structure-activity relationship between peroxisome proliferator-activated receptor _ agonism and the antihyperglycemic activity of thiazolidinediones. J.Med.Chem. 39 665. PMID:8576907. Sakamoto et al (2000) Activation of human peroxisome proliferator-activated receptor (PPAR) subtypes by pioglitazone. Biochem.Biophys.Res.Commun. 278 704. PMID:11095972. Smith (2001) Pioglitazone: mechanism of action. Int.J.Clin.Pract.Suppl. 121 13. PMID:11594239. Momose et al (2002) Novel 5-substituted 2,4-thiazolidinedione and 2,4-oxazolidinedione derivatives as insulin sensitizers with antidiabetic activities. J.Med.Chem. 45 1518. PMID:11906293."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=282754	SQ1533			Jan-2011
4125	3-pyr-Cytisine	[948027-43-8]	O=C2N1C[C@@]([H])(C4)CNC[C@@]([H])4C1=CC=C2C3=CC=CN=C3	"High affinity, partial agonist of _4_2 receptors"	"High affinity _4_2 partial agonist (Ki values are 0.91, 119 and 1100 nM for _4_2, _3_4 and _7 receptors respectively). Shows little activity at _3_4 and _7 receptors. Exhibits antidepressant-like effects in mouse models of antidepressant efficacy."	Mineur et al (2009) Cytisine-based nicotinic partial agonists as novel antidepressant compounds. J.Pharmacol.Exp.Ther. 329 377. PMID:19164465. Papke et al (2010) Activation and inhibition of mouse muscle and neuronal nicotinic acetylcholine receptors expressed in Xenopus oocytes. J.Pharmacol.Exp.Ther. 333 501. PMID:20100906. Papke et al (2011) Electrophysiological perspectives on the therapeutic use of nicotinic acetylcholine receptor partial agonists. J.Pharmacol.Exp.Ther. 337 1.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=282755	SQ1070			May-2011
4126	DMH-1	[1206711-16-1]	CC(C)OC(C=C3)=CC=C3C(C=N2)=CN1C2=C(C4=CC=NC5=C4C=CC=C5)C=N1	BMP inhibitor; selectively inhibits ALK2	"Selective inhibitor of the bone morphogenic protein (BMP) ALK2 receptor (IC50 = 108 nM). Exhibits no detectable inhibition of AMPK, ALK5, KDR (VEGFR-2) or PDGFR_ receptors. Blocks BMP4-induced phosphorylation of Smads 1, 5 and 8 in HEK293 cells. Promotes neurogenesis in human induced pluripotent stem cells (iPSCs) when used in combination with SB 431542 (Cat. No. 1614)."	"Bowman and Zon (2010) Swimming into the future of drug discovery: in vivo chemical screens in zebrafish. ACS Chem.Biol. 5 159. PMID:20166761. Hao et al (2010) In vivo structure-activity relationship study of dorsomorphin analogues identifies selective VEGF and BMP inhibitors. ACS Chem.Biol. 5 245. PMID:20020776. Neely et al (2012) DMH1, a highly selective small molecule BMP inhibitor, promotes neurogenesis of hiPSCs: comparison of PAX6 and SOX1 expression during neural induction. ACS Chem.Neurosci. 3 482. PMID:22860217."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=282756	SQ1070			Jan-2011
4127	Salermide	[1105698-15-4]	O=C(C(C)C4=CC=CC=C4)NC1=CC=CC(/N=C/C3=C(O)C=CC2=CC=CC=C23)=C1	SIRT1 and SIRT2 inhibitor	SIRT1 and SIRT2 inhibitor. Exhibits a stronger inhibitory effect on SIRT2 than on SIRT1 in vitro. Induces the reactivation of proapoptotic genes repressed by SIRT1 and causes massive apoptosis in cancer cells within 24 hours.	"Mai et al (2005) Design, synthesis, and biological evaluation of sirtinol analogues as class III histone/protein deacetylase (sirtuin) inhibitors. J.Med.Chem. 48 7789. PMID:16302818. Lara et al (2009) Salermide, a sirtuin inhibitor with a strong cancer-specific proapoptotic effect. Oncogene 28 781. PMID:19060927. Pasco et al (2010) Characterization of sirtuin inhibitors in nematodes expressing a muscular dystrophy protein reveals muscle cell and behavioral protection by specific sirtinol analogues. J.Med.Chem. 53 1407. PMID:20041717."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=282757	SQ1070			Feb-2011
4128	Bisindolylmaleimide II	[137592-45-1]	O=C(NC3=O)C(C4=CNC5=C4C=CC=C5)=C3C1=CN(CCC6CCCN6C)C2=CC=CC=C12	Potent PKC inhibitor and nicotinic receptor antagonist	"Potent, ATP-competitive protein kinase C (PKC) inhibitor (IC50 = 0.01 _M). Displays selectivity for PKC over protein kinase A (PKA) and phosphorylase kinase (PK) (IC50 values are 0.75 and 2_M for PK and PKA respectively). Also displays potent, noncompetitive antagonism at nicotinic cholinergic receptors (IC50 ~ 0.03 _M for inhibition of catecholamine secretion in nicotine-stimulated PC-12 cells)."	Toullec et al (1991) The bisindolylmaleimide GF 109203X is a potent and selective inhibitor of protein kinase C. J.Biol.Chem. 266 15771. PMID:1874734. Mahata et al (2002) Chromaffin cell catecholamine secretion: bisindolylmaleimide compounds exhibit novel and potent antagonist effects at the nicotinic cholinergic receptor in pheochromocytoma cells. Mol.Pharmacol. 61 1340. PMID:12021395.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=282758	SQ1341			Nov-2012
4131	G418 disulfate salt	[108321-42-2]	N[C@H]1[C@H](O[C@]2([H])[C@H](O)[C@@H](NC)[C@@](C)(O)CO2)[C@@H](O)[C@H](O[C@]3([H])[C@H](N)[C@@H](O)[C@H](O)[C@]([C@H](O)C)([H])O3)[C@@H](N)C1.OS(O)(=O)=O.OS(O)(=O)=O	Aminoglycoside antibiotic; used in cell culture	Aminoglycosidic antibiotic. Inhibits protein synthesis in both prokaryotic and eukaryotic cells. Used for selection of eukaryotic cells transfected with the neo gene.	"Wagman et al (1974) Antibiotic G-418, a new Micromonospora-produced aminoglycoside with activity against protozoa and helminths: fermentation, isolation and preliminary characterization. Antimicrob.Agents Chemother. 6 144. PMID:15828184. Bar-Nun et al (1983) G-418, an elongation inhibitor of 80 S ribosomes. Biochim.Biophys.Acta. 741 123. PMID:6193810. Burke and Mogg (1985) Suppression of a nonsense mutation in mammalian cells in vivo by the aminoglycoside antibiotics G-418 and paromomycin. Nucleic Acids Res. 13 6265. PMID:2995924."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=282859	SQ1070			Mar-2011
4132	XMD 8-92	[1234480-50-2]	O=C2C3=C(C=CC=C3)N(C)C1=NC(NC4=C(OCC)C=C(N5CCC(O)CC5)C=C4)=NC=C1N2C	Selective ERK5/BMK1 inhibitor	"Highly selective ERK5/BMK1 inhibitor (KD values are 80, 190, 600 and 890 nM for BMK1, DCAMKL2, PLK4 and TNK1 respectively). Displays selectivity over 402 diverse kinases. Blocks growth factor-induced activation of cellular BMK1 and reduces BMK1 activity in in vitro kinase assays. Also reduces BMK1-dependent transactivating activity of MEF2C. Inhibits proliferation in a variety of cancer cell lines; blocks tumor cell proliferation and tumor-associated angiogenesis."	"Yang et al (2010) Pharmacological inhibition of BMK1 suppresses tumor growth through promyelocytic leukemia protein. Cancer Cell 18 258. PMID:20832753. Yang and Lee (2011) Targeting the BMK1 MAP kinase pathway in cancer therapy. Clin.Cancer Res. 17 3527. PMID:21385929. Deng et al (2011) Discovery of a benzo[e]pyrimido-[5,4-b][1,4]diazepin-6(11H)-one as a potent and selective inhibitor of big MAP kinase 1. ACS Med.Chem.Lett. 2 195. PMID:21412406. Erazo et al (2013) Canonical and kinase activity-independent mechanisms for extracellular signal-regulated kinase 5 (ERK5) nuclear translocation require dissociation of Hsp90 from the ERK5-Cdc37 complex. Mol.Cell Biol. 33 1671. PMID:23428871."	Small Molecule	Sold under license from the Dana-Farber Cancer Institute.	http://www.tocris.com/dispprod.php?ItemId=282866	SQ1533			Apr-2011
4133	U 73343	[142878-12-4]	[H][C@]23[C@@]([C@]([H])(CC[C@@H]4NCCCCCCN5C(CCC5=O)=O)[C@]4(C)CC3)([H])CCC1=CC(OC)=CC=C12	Inactive analog of U 73122 (Cat. No. 1268)	Inactive analog of U 73122 (Cat. No. 1268). Can be used as a negative control.	"Muto et al (1997) The putative phospholipase C inhibitor U73122 and its negative control, U73343, elicit unexpected effects on the rabbit parietal cell. J.Pharmacol.Exp.Ther. 282 1379. PMID:9316850. Kataoka et al (2009) Activation of P2X7 receptors induces CCL3 production in microglial cells through transcription factor NFAT. J.Neurochem. 108 115. PMID:19014371."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=282871				Aug-2011
4134	NPS 2390	[226878-01-9]	O=C(C4=NC(C=CC=C5)=C5N=C4)NC1(CC3C2)CC(C3)CC2C1	Group I mGlu antagonist	Group I mGlu antagonist; displays noncompetitive antagonist activity at both mGlu1 and mGlu5 receptors. Thought to act on a site separate from the glutamate binding pocket.	"van Wagenen et al (2000) Structure-activity relationship studies of NPS 2390: a potent and selective group I metabotropic glutamate receptor antagonist. Abstr.Soc.Neurosci. Program No. 618.3.. Lavreysen et al (2003) [3H]R214127: a novel high-affinity radioligand for the mGlu1 receptor reveals a common binding site shared by multiple allosteric antagonists. Mol.Pharmacol. 63 1082. PMID:12695537. Mabire et al (2005) Synthesis, structure-activity relationship, and receptor pharmacology of a new series of quinoline derivatives acting as selective, noncompetitive mGlu1 antagonists. J.Med.Chem. 48 2134. PMID:15771457."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=283014	SQ1070			May-2011
4138	ABT 751	[141430-65-1]	OC(C=C2)=CC=C2NC1=NC=CC=C1NS(C3=CC=C(OC)C=C3)(=O)=O	Inhibitor of microtubule polymerization; antimitotic and antitumor	"Antimitotic agent, inhibits microtubule polymerization. Binds to _-tubulin on the colchine site; blocks cell cycle at G2M phase and induces apoptosis. Exhibits antitumor activity. Also displays activity in cell lines resistant to vincristine, doxorubicin and cisplatin. Orally bioavailable."	"Hande et al (2006) The pharmacokinetics and safety of ABT-751, a novel, orally bioavailable sulfonamide antimitotic agent: results of a phase 1 study. Clin.Cancer Res. 12 2834. PMID:16675578."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=283083	SQ1070			Apr-2011
4140	EB 47	[1190332-25-2]	O=C(NC2=CC=CC3=C2CNC3=O)CN(CC1)CCN1[C@]([C@@H]4O[C@H](N5C=NC6=C5N=CN=C6N)[C@@H](O)[C@H]4O)=O.Cl.Cl	Potent PARP-1 inhibitor	Potent inhibitor of PARP-1 (IC50 = 45 nM). Reduces infarct volume in both a rat transient middle cerebral arterial occlusion model and a cardiac reperfusion model.	"Jagtap et al (2004) The discovery and synthesis of novel adenosine substituted 2,3-dihydro-1H-isoindol-1-ones: potent inhibitors of poly(ADP-ribose) polymerase-1 (PARP-1). Bioorg.Med.Chem.Lett. 14 81. PMID:14684303. Gaymes et al (2009) Inhibitors of poly ADP-ribose polymerase (PARP) induce apoptosis of myeloid leukemic cells: potential for therapy of myeloid leukemia and myelodysplastic syndromes. Haematologica 94 638. PMID:19407318. Ferraris et al (2010) Evolution of poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors. From concept to clinic. J.Med.Chem. 53 4561. PMID:20364863."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=283214	SQ1070			Nov-2011
4141	LY 2087101	[913186-74-0]	O=C(C3=CSC=C3)C1=C(C)N=C(NC2=CC=C(F)C=C2)S1	Potentiator of _7 nAChRs	"Allosteric potentiator of _7, _4_2 and _4_4 nAChRs; displays selectivity against _3_4 nAChRs. Thought to potentiate agonist-evoked _7 responses by binding within the nAChR transmembrane region."	Broad et al (2006) Identification and pharmacological profile of a new class of selective nicotinic acetylcholine receptor potentiators. J.Pharmacol.Exp.Ther. 318 1108. PMID:16738207. Young et al (2008) Potentiation of _7 nicotinic acetylcholine receptors via an allosteric transmembrane site. Proc.Natl.Acad.Sci. 105 14686.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=283215	SQ1070			Mar-2011
4143	GSK 2334470	[1227911-45-6]	C[C@H]1N(C3=NC(NC)=NC(C4=CC(NN=C5N)=C5C=C4)=C3)C[C@@H]([C@](NC2CCCCC2)=O)CC1	"Highly potent, selective PDK1 inhibitor"	"Potent 3-phosphoinositide-dependent protein kinase (PDK1) inhibitor (IC50 ~ 10 nM). Exhibits no effect on other kinases including Aurora, ROCK, p38 MAPK and PI 3-K. Suppresses T-loop phosphorylation and subsequent activation of PDK1 substrates S6K1, SGK and RSK in HEK293, U87 and mouse embryonic fibroblast cell lines; exhibits limited inhibitory effect on Akt activation."	"Najafov et al (2011) Characterization of GSK2334470, a novel and highly specific inhibitor of PDK1. Biochem.J. 433 (2) 357. PMID:21087210."	Small Molecule	Sold for research purposes only under agreement from GlaxoSmithKline	http://www.tocris.com/dispprod.php?ItemId=283217	SQ1533			Apr-2012
4144	GSK 690693	[937174-76-0]	NC1=NON=C1C(N3CC)=NC2=C3C(CO[C@@H]4CNCCC4)=CN=C2C#CC(C)(C)O	Akt kinase inhibitor. Antitumor	"ATP-competitive pan-Akt kinase inhibitor (IC50 values are 2, 13 and 9 nM of Akt1, 2 and 3 respectively). Also exhibits some inhibition for AMPK, PKA and PAK and PKC isoforms (IC50 < 100 nM). Displays antiproliferative and apoptotic effects in tumor cell lines."	"Heerding et al (2008) Identification of 4-[2-(4-Amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-{(3S)-3-piperidinylmethoxyl]oxy}-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl-3-butyn-2-ol (GSK690693), a novel inhibitor of AKT kinase. J.Med.Chem. 51 5663. PMID:18800763. Rhodes et al (2008) Characterization of an Akt inhibitor with potent pharmacodynamic and antitumor activity. Cancer Res. 68 2366. PMID:18381444."	Small Molecule	Sold for research purposes only under agreement from GlaxoSmithKline	http://www.tocris.com/dispprod.php?ItemId=283218	SQ1070			May-2011
4145	PK 44 phosphate	[1017682-66-4]	N[C@@H](CC(N4CC3=NN=C(C(F)(F)F)N3CC4)=O)CC2=NNC1=C(F)C(F)=CC=C12.OP(O)(O)=O	Potent and selective dipeptidyl peptidase IV (DPP-IV) inhibitor	Potent inhibitor of dipeptidyl peptidase IV (DPP-IV) (IC50 = 15.8 nM). Displays >1000-fold selectivity for DPP-IV over DPP-8 and DPP-9. Improves glucose tolerance in a mouse oral glucose tolerance assay.	Tozer et al (2010) Indole- and indazole-based inhibitors of dipeptidyl peptidase IV for the treatment of type 2 diabetes. 32nd Annual National Medicinal Chemistry Symposium Poster 52.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=283219	SQ1070			Apr-2011
4148	Abacavir hemisulfate	[188062-50-2]	NC1=NC(NC3CC3)=C2C(N(C4C[C@H](CO)C=C4)C=N2)=N1.NC5=NC(NC7CC7)=C6C(N(C8C[C@H](CO)C=C8)C=N6)=N5.O=S(O)(O)=O	Reverse transcriptase inhibitor; antiretroviral	Competitive reverse transcriptase inhibitor; inhibits HIV replication. Orally active and brain penetrant. Antiretroviral agent.	"Daluge et al (1997) 1592U89, a novel carbocyclic nucleoside analog with potent, selective anti-human immunodeficiency virus activity. Antimicrob Agents Chemother. 41 1082. PMID:9145874. Harrigan et al (2000) Resistance profile of the human immunodeficiency virus type 1 reverse transcriptase inhibitor abacavir (1592U89) after monotherapy and combination therapy. CNA2001 Investigative Group. J.Infect.Dis. 181 912. PMID:10720512. Charneira et al (2012) N-terminal valine adduct from the anti-HIV drug abacavir in rat haemoglobin as evidence for abacavir metabolism to a reactive aldehyde in vivo. Br.J.Pharmacol. 167 1353. PMID:22725138."	Small Molecule	Sold for research purposes under agreement from Viiv.	http://www.tocris.com/dispprod.php?ItemId=283374				Aug-2014
4149	Delavirdine mesylate	[147221-93-0]	O=C(N3CCN(C4=NC=CC=C4NC(C)C)CC3)C2=CC1=CC(NS(=O)(C)=O)=CC=C1N2.CS(O)(=O)=O	Non-nucleoside reverse transcriptase inhibitor	"Non-nucleoside reverse transcriptase inhibitor (NNRTI). Selectively inhibits HIV-1 reverse transcriptase (RNA-dependent DNA polymerase) over other cellular polymerases (IC50 values are 0.26, 440 and >550 _M for HIV-1 reverse transcriptase, DNA polymerase _ and DNA polymerase _). Prevents HIV-1 spread in vivo and blocks viral replication in peripheral blood lymphocytes. Orally active."	"Dueweke et al (1993) U-90152, a potent inhibitor of human immunodeficiency virus type 1 replication. Antimicrob.Agents Chemother. 37 1127. PMID:7685995. Pagano and Chong (1995) In vitro inhibition of human immunodeficiency virus type 1 by a combination of delavirdine (U-90152) with protease inhibitor U-75875 or interferon-alpha. J.Infect.Dis. 171 61. PMID:7528253."	Small Molecule	Sold for research purposes under agreement from Viiv.	http://www.tocris.com/dispprod.php?ItemId=283375	SQ1533			Feb-2012
4150	Azidothymidine	[30516-87-1]	O=C1N([C@@H]2O[C@H](CO)[C@@H](N=[N+]=[N-])C2)C=C(C)C(N1)=O	Selective reverse transcriptase inhibitor; antiretroviral	Selective reverse transcriptase inhibitor. Exhibits 100-fold selectivity for HIV reverse transcriptase over DNA polymerase _. Suppresses HIV-1 replication and enhances cell viability in a HIV-1 infected T cell line. Also suppresses growth of a multiple myeloma (MM) cell line and reduces the growth of MM tumor xenografts in mice. Orally bioavailable and brain penetrant. Antiretroviral agent.	Mitsuya et al (1985) 3'-Azido-3'-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro. Proc.Natl.Acad.Sci.U.S.A. 82 7096. PMID:2413459. Furman et al (1986) Phosphorylation of 3'-azido-3'-deoxythymidine and selective interaction of the 5'-triphosphate with human immunodeficiency virus reverse transcriptase. Proc.Natl.Acad.Sci.U.S.A. 83 8333. PMID:2430286. Broder (2010) The development of antiretroviral therapy and its impact on the HIV-1/AIDS pandemic. Antiviral Res. 85 1. PMID:20018391. Pereira et al (2013) Azidothymidine is effective against human multiple myeloma: a new use for an old drug? Anticancer Agents Med.Chem. 13 186. PMID:22931421.	Small Molecule	Sold for research purposes under agreement from Viiv.	http://www.tocris.com/dispprod.php?ItemId=283378				Aug-2014
4152	TMN 355	[1186372-20-2]	ClC1=C(C(NC(NC2C(C=CC=C4)=C4C3=C2C=CC=C3)=O)=O)C(F)=CC=C1	Cyclophilin A inhibitor	Potent cyclophilin A inhibitor (IC50 = 1.52 nM). Approximately 27 times more potent than cyclosporin A (Cat. No. 1101).	Ni et al (2009) Discovering potent small molecule inhibitors of cyclophilin A using de novo drug design approach. J.Med.Chem. 52 5295. PMID:19691347.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=283387	SQ1070			Apr-2011
4154	TCN 201	[852918-02-6]	ClC1=C(F)C=CC(S(NCC2=CC=C(C(NNC(C3=CC=CC=C3)=O)=O)C=C2)(=O)=O)=C1	Selective NR1/NR2A receptor antagonist	NMDA receptor antagonist selective for NR1/NR2A over NR1/NR2B-containing receptors (pIC50 values are 6.8 and <4.3 respectively in human recombinant NR1/NR2A and NR1/NR2B FLIPR/Ca2+ assays).	Bettini et al (2010) Identification and characterization of novel NMDA receptor antagonists selective for NR2A- over NR2B-containing receptors. J.Pharm.Exp.Ther. 335 644. PMID:20810618. Shin et al (2011) Subtype selective NMDA receptor antagonists induce recovery of synapses lost following exposure to HIV-1 Tat. Br.J.Pharmacol. 166 1002. PMID:22142193. Edman et al (2012) TCN 201 selectively blocks GluN2A-containing NMDARs in a GluN1 co-agonist dependent but non-competitive manner. Neuropharmacology 63 441. PMID:22579927. Hansen et al (2012) Subunit-selective allosteric inhibition of glycine binding to NMDA receptors. J.Neurosci. 32 6197. PMID:22553026. Gipson et al (2013) Reinstatement of nicotine seeking is mediated by glutamatergic plasticity. Proc.Natl.Acad.Sci.U S A [Epub ahead of print]. PMID:23671067.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=283882	SQ1070			Mar-2011
4156	Vitamin D3	[67-97-0]	C[C@@](CCC2)3[C@](CC[C@@H]3[C@@H](CCCC(C)C)C)([H])/C2=C/C=C(C[C@@H](O)CC1)\C1=C	Precursor of calcifediol (Cat. No. 4036). Naturally occurring form of vitamin D	Precursor of calcifediol (Cat. No. 4036). Naturally occurring form of vitamin D; predominantly active form found in humans.	"Welsh et al (2003) Vitamin D-3 receptor as a target for breast cancer prevention. J.Nutr. 133 (7 Suppl) 2425S. PMID:12840219. Lane (2010) Vitamin D and systemic lupus erythematosus: bones, muscles, and joints. Curr.Rheumatol.Rep. 12 259. PMID:20429045."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=283904				Jan-2011
4163	TCN 213	[556803-08-8]	O=C(NCC2CCCCC2)CSC1=NN=C(NCC3=CC=CC=C3)S1	NMDA antagonist; selective for NR2A over NR2B	"NMDA receptor antagonist, selective for NR1/NR2A (pIC50 = 5.4) over NR1/NR2B."	"Bettini et al (2010) Identification and characterization of novel NMDA receptor antagonists selective for NR2A- over NR2B-containing receptors. J.Pharmacol.Exp.Ther. 335 644. PMID:20810618. McKay et al (2012) Direct pharmacological monitoring of the developmental switch in NMDAR subunit composition using TCN 213, a GluN2A-selective, glycine-dependent antagonist. Br.J.Pharmacol. 166 924. PMID:22022974."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=283951	SQ1070			Apr-2011
4165	Gisadenafil besylate	[334827-98-4]	O=S(C1=CN=C(OCC)C(C3=NC(C2=NN(CCOC)C(CC)=C2N3)=O)=C1)(N4CCN(CC)CC4)=O.O=S(C5=CC=CC=C5)(O)=O	PDE5 inhibitor	PDE5 inhibitor.	Hashim and Abrams (2010) Emerging drugs for the treatment of benign prostatic obstruction. Exp.Opin.Invest.Drugs 15 159.	Small Molecule	Sold for research purposes under agreement from Pfizer Inc.	http://www.tocris.com/dispprod.php?ItemId=284960	SQ1070			Feb-2011
4166	NS 5806	[426834-69-7]	BrC1=CC(Br)=CC(C2=NN=NN2)=C1NC(NC3=CC(C(F)(F)F)=CC(C(F)(F)F)=C3)=O	KV4.3 channel activator	KV4.3 channel activator; mediates the transient outward K+ current (Ito). Increases IKv4.3 peak current amplitude in CHO-K1 cells expressing KV4.3 and KChIP2 (EC50 = 5.3 _M). Inhibits KV1.4-mediated currents independently of KChIP2. Also slows the decay of KV4.2 and KV4.3 currents in the presence of KChIP2.	Calloe et al (2009) A transient outward potassium current activator recapitulates the electrocardiographic manifestations of Brugada syndrome. Cardiovasc.Res. 81 686. PMID:19073629. Calloe et al (2010) Differential effects of the transient outward K+ current activator NS5806 in the canine left ventricle. J.Mol.Cell.Cardiol. 48 191. PMID:19632239. Lundby et al (2010) Effect of the Ito activator NS5806 on cloned Kv4 channels depends on the accessory protein KChIP2. Br.J.Pharmacol. 160 2028. PMID:20649599.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=285227	SQ1070			Jun-2011
4167	KW 3902	[136199-02-5]	O=C1C2=C(NC(C34CC(CC4C5)CC5C3)=N2)N(CCC)C(N1CCC)=O	Selective A1 antagonist	Selective adenosine A1 receptor antagonist; displays 890-fold selectivity for rat A1 receptors over A2A receptors (Ki values are 0.19 and 170 nM respectively). Displays no effect on recombinant rat A3 receptors expressed on CHO cells at concentrations up to 10 _M. Exhibits diuretic and renal protective effects in rats.	"Shimada et al (1992) 8-polycycloalkyl-1,3-dipropylxanthines as potent and selective antagonists for A1-adenosine receptors. J.Med.Chem. 35 924. PMID:1548682. Nonaka et al (1996) KW-3902, a selective high affinity antagonist for adenosine A1 receptors. Br.J.Pharmacol. 117 1645. PMID:8732272. Nishiyama et al (1999) Adenosine A1 receptor antagonist KW-3902 prevents hypoxia-induced renal vasoconstriction. J.Pharmacol.Exp.Ther. 291 988. PMID:10565815."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=285228	SQ1533			May-2011
4168	PIT 1	[53501-41-0]	ClC1=C(O)C(NC(NC(C2=CC=CC=C2)=O)=S)=CC([N+]([O-])=O)=C1	Inhibits Akt signaling	Selective PIP3 antagonist. Blocks the binding of PIP3 to the pleckstrin homology (PH) domain of Akt (IC50 = 31.03 _M). Inhibits cancer cell survival and induces apoptosis by inhibition of PIP3-dependent PI 3-kinase/Akt signaling. Exhibits antitumor activity in vivo.	"Miao et al (2010) Small molecule inhibition of phosphatidylinositol-3,4,5-triphosphate (PIP3) binding to pleckstrin homology domains. Proc.Natl.Acad.Sci. 107 2012."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=285229				Mar-2011
4169	KS 176	[1253452-78-6]	OCCC1=CC=C(NC(C2=C(NC(C3=CC=C([N+]([O-])=O)C=C3)=O)C=CC=C2)=O)C=C1	Selective BCRP inhibitor	Selective inhibitor of the breast cancer resistance protein (BCRP) multidrug transporter (IC50 values are 0.59 and 1.39 _M in Pheo A and Hoechst 33342 assays respectively). Displays no inhibitory activity against P-gp or MRP1.	Pick et al (2010) Specific inhibitors of the breast cancer resistance protein (BCRP). ChemMedChem 5 1498. PMID:20632361.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=285230	SQ1341			Jul-2014
4171	VU 0364739 hydrochloride	[1244640-48-9]	O=C(NCCN3CCC(C(NCN4C5=CC(F)=CC=C5)=O)4CC3)C2=CC1=CC=CC=C1C=C2.Cl	Potent and selective PLD2 inhibitor	Potent and selective phospholipase D2 (PLD2) inhibitor (IC50 = 20 nM); displays 75-fold selectivity against PLD1 (IC50 = 1500 nM).	"Lavieri et al (2010) Design, synthesis, and biological evaluation of halogenated N-(2-(4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]decan-8-yl)-ethyl)benzamides: discovery of an isoform-selective small molecule phospholipase D2 inhibitor. J.Med.Chem. 53 6709."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=285267	SQ1070			Jul-2011
4172	ML 145	[1164500-72-4]	O=C(NC3=CC=C(C(O)=O)C(O)=C3)CCCN2C(/C(SC2=S)=C/C(C)=C/C1=CC=CC=C1)=O	GPR35 antagonist	Selective antagonist for the GPR35 orphan receptor GPCR (IC50 = 20.1 nM). Over 1000-fold more selective for GPR35 compared to GPR55 antagonists.	Heynen-Genel et al (2010) Antagonists for the orphan receptor GPR35. Probe Reports from the Molecular Libraries Program NBK5070. Jenkins et al (2012) Antagonists of GPR35 display high species ortholog selectivity and varying modes of action. J.Pharmacol.Exp.Ther. 343 683. PMID:22967846.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=285268				Mar-2011
4173	MDL 100907	[139290-65-6]	FC(C=C3)=CC=C3CCN(CC2)CCC2[C@@H](O)C1=C(OC)C(OC)=CC=C1	Potent and selective 5-HT2A antagonist	Potent and selective 5-HT2A receptor antagonist (Ki = 0.36 nM). Exhibits > 80-fold selectivity for 5-HT2A over other serotonergic receptor subtypes. Antipsychotic agent in vivo.	"Sorensen et al (1993) Characterization of the 5-HT2 receptor antagonist MDL 100907 as a putative atypical antipsychotic: behavioral, electrophysiological and neurochemical studies. J.Pharmacol.Exp.Ther. 266 684. PMID:8102646. Kehne et al (1996) Preclinical characterization of the potential of the putative atypical antipsychotic MDL 100,907 as a potent 5-HT2A antagonist with a favorable CNS safety profile. J.Pharmacol. 277 968. PMID:8627580. Ardayfio et al (2008) The 5-hydroxytryptamine2A receptor antagonist R-(+)-alpha-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl-4-piperidinemethanol (M100907) attenuates impulsivity after both drug-induced disruption (dizocilpine) and enhancement (antidepressant drugs) of differential-reinforcement-of-low-rate 72-s behavior in the rat. J.Pharmacol.Exp.Ther. 327 891. PMID:18772320."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=285355	SQ1341			Feb-2014
4174	Pramipexole dihydrochloride	[104632-25-9]	NC(S2)=NC1=C2C[C@@H](NCCC)CC1.Cl.Cl	Selective D3 agonist	"Dopamine receptor agonist exhibiting selectivity for the D3 receptor (Ki values are 0.5, 3.3, 3.9 and 3.9 nM for D3, D2S, D2L and D4 receptors respectively). Exhibits negligible affinity for D1 and D5 receptors. Displays activity in the treatment of Parkinson's disease."	"Mierau et al (1995) Pramipexole binding and activation of cloned and expressed dopamine D2, D3 and D4 receptors. Eur.J.Pharmacol. 290 29. PMID:7664822."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=285523	SQ1533			Mar-2011
4175	PF 3845	[1196109-52-0]	O=C(NC2=CN=CC=C2)N1CCC(CC3=CC=CC(OC4=NC=C(C(F)(F)F)C=C4)=C3)CC1	Selective FAAH inhibitor	Selective fatty acid amide hydrolase (FAAH) inhibitor (Ki = 0.23 _M). Reduces inflammatory pain via a cannabinoid receptor-dependent mechanism. Highly efficacious and selective in vivo. Displays no activity at FAAH-2 (IC50 >10 _M).	Ahn et al (2009) Discovery and characterization of a highly selective FAAH inhibitor that reduces inflammatory pain. Chem.Biol. 16 411. PMID:19389627. Ahn et al (2009) Fatty acid amide hydrolase as a potential therapeutic target for the treatment of pain and CNS disorders. Expert Opin.Drug Discov. 4 763. PMID:20544003.	Small Molecule	Sold for research purposes under agreement from Pfizer Inc.	http://www.tocris.com/dispprod.php?ItemId=286510	SQ1533			Feb-2011
4176	KU 60019	[925701-46-8]	O=C(CN4C[C@H](C)O[C@H](C)C4)NC(C=C3)=CC2=C3SC1=C(C5=CC(C=C(N6CCOCC6)O5)=O)C=CC=C1C2	Potent ATM kinase inhibitor	Potent ATM kinase inhibitor (IC50 = 6.3 nM). Exhibits little to no nonspecific target effects against a panel of 229 protein kinases; displays similar target selectivity to KU 55933 (Cat. No. 3544). Inhibits migration and invasion of human glioma cells in vitro.	"Golding et al (2009) Improved ATM kinase inhibitor KU-60019 radiosensitizes glioma cells, compromises insulin, AKT and ERK prosurvival signaling, and inhibits migration and invasion. Mol.Cancer Ther. 8 2894. PMID:19808981."	Small Molecule	Sold with the permission of AstraZeneca.	http://www.tocris.com/dispprod.php?ItemId=286517	SQ1533			Jul-2011
4177	AS 1269574	[330981-72-1]	BrC(C=C2)=CC=C2C1=NC(NCCO)=CC(C)=N1	GPR119 receptor agonist	GPR119 receptor agonist (EC50 = 2.5 _M in HEK293 cells expressing human GPR119). Enhances insulin secretion stimulated by glucose in vivo. Stimulates proglucagon gene promoter actvity. Orally available.	"Yoshida et al (2010) Identification of a novel GPR119 agonist, AS1269574, with in vitro and in vivo glucose-stimulated insulin secretion. Biochem.Biophys.Res.Commun. 400 437. PMID:20804735. Chepurny et al (2013) Stimulation of Proglucagon Gene Expression by Human GPR119 in Enteroendocrine L-cell Line GLUTag. Mol.Endocrinol. 27 1267. PMID:23798572."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=286579	SQ1070			Apr-2011
4179	AMD 3465 hexahydrobromide	[185991-07-5]	C1(CN3CCCNCCNCCCNCC3)=CC=C(CNCC2=NC=CC=C2)C=C1.Br.Br.Br.Br.Br.Br	"Potent, selective CXCR4 antagonist"	"Potent, selective CXCR4 antagonist; exhibits 8-fold higher affinity than AMD 3100 (Cat.No. 3299). Inhibits SDF-1_-ligand binding (Ki = 41.7 nM). Potently inhibits HIV cell entry in vitro; causes leukocytosis and mobilizes haematopoietic stem cells in vivo."	Rosenkilde et al (2007) Molecular mechanism of action of monocyclam versus bicyclam non-peptide antagonists of the CXCR4 chemokine receptor. J.Biol.Chem. 282 27354. PMID:17599916. Bodart et al (2009) Pharmacology of AMD3465: A small molecule antagonist of the chemokine receptor CXCR4. Biochem.Pharmacol. 78 993. PMID:19540208.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=286831	SQ1070			Oct-2011
4181	Ro 3306	[872573-93-8]	O=C2/C(SC(NCC3=CC=CS3)=N2)=C/C1=CC=C(N=CC=C4)C4=C1	Cyclin-dependent kinase (cdk) 1 inhibitor	"ATP-competitive, potent cyclin-dependent kinase (cdk) 1 inhibitor (Ki values are 35 and 110 nM for cdk1/cyclin B1 and cdk1/cyclin A respectively). Induces G2/M phase cell cycle arrest and apoptosis. Downregulates the expression of antiapoptotic proteins such as Bcl-2 and survivin and enhances downstream p53 signaling in acute myeloid leukemia (AML)."	Vassilev et al (2006) Selective small-molecule inhibitor reveals critical mitotic functions of human CDK1. Proc.Natl.Acad.Sci. 103 10660. Kojima et al (2009) The CDK1 inhibitor RO-3306 enhances p53-mediated Bax activation and mitochondrial apoptosis in AML. Cancer Sci. 100 1128. PMID:19385969. Yu et al (2012) CDK1 regulates mediator of DNA damage checkpoint 1 during mitotic DNA damage. Cancer Res. 72 5448. PMID:22962268.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=286833				May-2011
4184	Torcetrapib	[262352-17-0]	CC[C@H]2N(C(OCC)=O)C1=CC=C(C(F)(F)F)C=C1[C@@H](N(CC3=CC(C(F)(F)F)=CC(C(F)(F)F)=C3)C(OC)=O)C2	Inhibitor of cholesteryl ester transfer protein (CETP)	Inhibitor of cholesteryl ester transfer protein (CETP). Also impairs endothelial function in vivo; induces hypertension and inhibits acetylcholine-induced vasodilation in rabbit central ear artery.	Forrest et al (2008) Torcetrapib-induced blood pressure elevation is independent of CETP inhibition and is accompanied by increasing circulating levels of aldosterone. Br.J.Pharmacol. 154 1465. PMID:18536749. Connelly et al (2010) Torcetrapib produces endothelial dysfunction independent of cholesteryl ester transfer protein inhibition. J.Cardiovascular Pharmacol. 55 459. PMID:20051879.	Small Molecule	Sold for research purposes under agreement from Pfizer Inc.	http://www.tocris.com/dispprod.php?ItemId=286850	SQ1533			Feb-2011
4185	Sonepiprazole	[170858-33-0]	O=S(C1=CC=C(N2CCN(CC[C@H]3C(C=CC=C4)=C4CCO3)CC2)C=C1)(N)=O	Selective D4 receptor antagonist	"Selective, high affinity antagonist for the rat and human dopamine D4 receptor (Ki = 10 nM). Exhibits low affinity at other monoamine receptors (Ki > 2000 nM). Induces c-fos gene expression in medial prefrontal cortex in a similar manner to clozapine (Cat. No. 0444). Brain penetrant and orally available."	"Merchant et al (1996) Pharmacological characterization of U-101387, a dopamine D4 receptor selective antagonist. J.Pharm.Exp.Ther. 279 1392."	Small Molecule	Sold for research purposes under agreement from Pfizer Inc.	http://www.tocris.com/dispprod.php?ItemId=286904	SQ1070			Jun-2011
4186	UK 5099	[56396-35-1]	O=C(/C(C#N)=C/C2=CN(C3=CC=CC=C3)C1=CC=CC=C12)O	Inhibitor of pyruvate transport	Inhibitor of plasma membrane monocarboxylate transporters (MCTs) and the mitochondrial pyruvate carrier (MPC).	Wiemer et al (1995) The inhibition of pyruvate transport across the plasma membrane of the bloodstream form of Trypanosoma brucei and its metabolic implications. Biochem.J. 312 479. PMID:8526859. Hildyard et al (2003) Identification of the mitochondrial pyruvate carrier in Saccharomyces cerevisiae. Biochem.J. 374 607. PMID:12887330. Hinoi et al (2006) A molecular mechanism of pyruvate protection against cytotoxicity of reactive oxygen species in osteoblasts. Mol.Pharmacol. 70 925. PMID:16766717.	Small Molecule	Sold for research purposes under agreement from Pfizer Inc.	http://www.tocris.com/dispprod.php?ItemId=286905				Feb-2011
4187	UK 356618	[230961-08-7]	CC1=C(C2=CC=CC=C2)C=CC(CCC[C@H](CC(NO)=O)C(N[C@H]([C@@](N[C@H](C)C3=CC=CC=C3)=O)C(C)(C)C)=O)=C1	Potent and selective MMP-3 inhibitor	"Potent and selective inhibitor of MMP-3 (IC50 = 5.9 nM). Displays selectivity over a range of MMPs (IC50 values are 73, 840, 1790, 1900 and 51000 for MMP-13, MMP-9, MMP-2, MMP-14 and MMP-1 respectively)."	Fray and Dickinson (2001) Discovery of potent and selective succinyl hydroxamate inhibitors of matrix metalloprotease-3 (stromelysin-1). Bioorg.Med.Chem.Lett. 11 571. PMID:11229774.	Small Molecule	Sold for research purposes under agreement from Pfizer Inc.	http://www.tocris.com/dispprod.php?ItemId=286906	SQ1070			Feb-2011
4188	UK 383367	[348622-88-8]	ONC(C[C@H](C2=NC(C(N)=O)=NO2)CCCC1CCCCC1)=O	Potent and selective BMP-1 (PCP) inhibitor	"Potent and selective inhibitor of BMP-1 (procollagen C-proteinase; PCP) (IC50 = 44 nM). Selective for BMP-1 over MMPs 1, 2, 3, 9 and 14 (IC50 values are >10,000 nM for listed MMPs)."	"Allan et al (2006) Pharmacokinetics and metabolism of UK-383,367 in rats and dogs: a rationale for long-lived plasma radioactivity. Xenobiotica 36 399. PMID:16854779. Fish et al (2007) Potent and selective nonpeptidic inhibitors of procollagen C-proteinase. J.Med.Chem. 50 3442. PMID:17591762. Bailey et al (2008) Succinyl hydroxamates as potent and selective non-peptidic inhibitors of procollagen C-proteinase: design, synthesis, and evaluation as topically applied, dermal anti-scarring agents. Bioorg.Med.Chem.Lett. 18 6562. PMID:18945617."	Small Molecule	Sold for research purposes under agreement from Pfizer Inc.	http://www.tocris.com/dispprod.php?ItemId=286907	SQ1533			Feb-2011
4189	SC 26196	[218136-59-5]	N#CC(C3=CC=CC=C3)(C4=CC=CC=C4)CCCN1CCN(/N=C/C2=CN=CC=C2)CC1	Selective _6 desaturase inhibitor	Selective _6 desaturase inhibitor (IC50 = 0.2 _M in vitro). Displays selectivity over _5 and _9 desaturases (IC50 values are >200 _M in vitro). Exhibits anti-inflammatory properties in a mouse edema model.	"Obukowicz et al (1998) Novel, selective _6 or _5 fatty acid desaturase inhibitors as antiinflammatory agents in mice. J.Pharmacol.Exp.Ther. 287 157. PMID:9765335. Hansen-Petrik et al (2002) Selective inhibition of delta-6 desaturase impedes intestinal tumorigenesis. Cancer Lett. 175 157. PMID:11741743. Zhang et al (2010) A multiplexed cell assay in HepG2 cells for the identification of delta-5, delta-6, and delta-9 desaturase and elongase inhibitors. J.Biomol.Screen. 15 169. PMID:20086206."	Small Molecule	Sold for research purposes under agreement from Pfizer Inc.	http://www.tocris.com/dispprod.php?ItemId=286908				Feb-2011
4190	CP 775146	[702680-17-9]	O=C(CC3=CC=C(C(C)C)C=C3)N(C2)CCC[C@H]2[C@@]1=CC(OC(C)(C)C(O)=O)=CC=C1	"Selective, high affinity PPAR_ agonist"	"Selective, high affinity PPAR_ agonist (Ki values are 24.5 nM for PPAR_ and >10 _M for PPAR_ and PPAR_ in vitro). Exhibits hypolipidemic activity in vivo."	Kane et al (2009) Molecular characterization of novel and selective peroxisome proliferator-activated receptor _ agonists with robust hypolipidemic activity in vivo. Mol.Pharmacol. 75 296. PMID:18971326.	Small Molecule	Sold for research purposes under agreement from Pfizer Inc.	http://www.tocris.com/dispprod.php?ItemId=286911	SQ1070			Mar-2011
4191	PF 3716556	[928774-43-0]	OCCN(C)C(C2=CN1C(C(N[C@H]4C3=C(C)C=CC=C3OCC4)=C2)=NC(C)=C1)=O	"Selective H+,K+-ATPase inhibitor"	"H+,K+-ATPase inhibitor (pIC50 = 6 in human recombinant ion-leaky assays); more potent in acidic conditions. Highly selective for H+,K+-ATPase in vitro; displays no activity at Na+,K+-ATPase. Also displays selectivity for H+,K+-ATPase over a range of 50 receptors and ion channels (IC50 > 10 _M). Inhibits gastric acid secretion in rat and dog models."	"Mori et al (2009) N-(2-hydroxyethyl)-N,2-dimethyl-8-{[(4R)-5-methyl-3,4-dihydro-2H-chromen-4-yl]amino}imidazo[1,2-a]pyridine-6-carboxamide (PF-03716556), a novel, potent, and selective acid pump antagonist for the treatment of gastroesophageal reflux disease. J.Pharmacol.Exp.Ther. 328 671. PMID:18981288."	Small Molecule	Sold for research purposes under agreement from Pfizer Inc.	http://www.tocris.com/dispprod.php?ItemId=286912	SQ1533			Mar-2011
4192	PD 0325901	[391210-10-9]	FC1=CC(I)=CC=C1NC2=C(C(NOC[C@H](O)CO)=O)C=CC(F)=C2F	Potent inhibitor of MEK1/2	Potent MEK1 and MEK2 inhibitor. Inhibits MEK activity in mouse colon 26 cells (IC50 = 0.33 nM). Inhibits the growth of melanoma cell lines in vitro and in vivo; induces G1-phase cell cycle arrest and apoptosis in a mouse xenograft model. Also inhibits production of proangiogenic cytokines such as VEGF. Enhances generation of induced pluripotent stem cells (iPSCs). Orally active.	Sebolt-Leopold et al (2004) The biological profile of PD 0325901: a second generation analog of CI-1040 with improved pharmaceutical potential. Proc.Amer.Assoc.Cancer Res. 45 925. Barrett et al (2008) The discovery of the benzhydroxamate MEK inhibitors CI-1040 and PD 0325901. Bioorg.Med.Chem.Lett. 18 6501. PMID:18952427. Ciuffreda et al (2009) Growth-inhibitor and antiangiogenic activity of the MEK inhibitor PD0325901 in malignant melanoma with or without BRAF mutations. Neoplasia 11 720. PMID:19649202. Lin et al (2009) A chemical platform for improved induction of human iPSCs. Nat.Methods. 6 805. PMID:19838168.	Small Molecule	Sold for research purposes under agreement from Pfizer Inc.	http://www.tocris.com/dispprod.php?ItemId=286974	SQ1533			Feb-2011
4193	CP 100356 hydrochloride	[142715-48-8]	COC2=CC1=C(N3CCC(C=C(OC)C(OC)=C5)=C5C3)N=C(NCCC4=CC=C(OC)C(OC)=C4)N=C1C=C2OC.Cl	P-gp inhibitor	"High affinity P-glycoprotein (P-gp) inhibitor (Ki values are 58 and 94 nM for mouse Pgp1a and Pgp1b isoforms). Inhibits calcein-AM uptake in MDR1-transfected MDCKII cells (IC50 = 0.5 _M) and prazosin transport in BCRP-transfected MDCKII cells (IC50 = 1.5 _M). Displays weak or no inhibitory activity against MRP1, OATP1B1 and several major human P450 enzymes (IC50 > 50 _M)."	"Taylor et al (1999) The equilibrium and kinetic drug binding properties of the mouse P-gp1a and P-gp1b P-glycoproteins are similar. Br.J.Cancer 81 783. PMID:10555746. Wandel et al (1999) P-glycoprotein and cytochrome P-450 3A inhibition: dissociation of inhibitory potencies. Cancer Res. 59 3944. PMID:10463589. Kalgutkar et al (2009) N-(3,4-dimethoxyphenethyl)-4-(6,7-dimethoxy-3,4-dihydroisoquinolin-2[1H]-yl)-6,7-dimethoxyquinazolin-2-amine (CP-100,356) as a ""chemical knock-out equivalent"" to assess the impact of efflux transporters on oral drug absorption in the rat. J.Pharm.Sci. 98 4914. PMID:19373887."	Small Molecule	Sold for research purposes under agreement from Pfizer Inc.	http://www.tocris.com/dispprod.php?ItemId=287034	SQ1070			Mar-2011
4194	WY 45233 succinate	[448904-47-0]	OC1(C(CN(C)C)C2=CC=C(O)C=C2)CCCCC1.O=C(CCC(O)=O)O	Dual serotonin/noradrenalin re-uptake inhibitor	Serotonin and noradrenalin reuptake inhibitor (SNRI); selective for human serotonin (SERT) and noradrenalin (NET) transporters against 96 other targets (Ki values are 40.2 and 558.4 nM for SERT and NET respectively). Inhibits [3H]5-HT and [3H]NE uptake (IC50 values are 47.3 and 531.3 nM). Salt form of the major active metabolite of venlafaxine (Cat. No. 2917).	Alfinito et al (2006) Pharmacokinetic and pharmacodynamic profiles of the novel serotonin and norepinephrine reuptake inhibitor desvenlafaxine succinate in ovariectomized Sprague-Dawley rats. Brain Res. 1098 71. PMID:16764833. Deecher et al (2006) Desvenlafaxine succinate: a new serotonin and norepinephrine reuptake inhibitor. J.Pharmacol.Exp.Ther. 318 657. PMID:16675639. Mason et al (2007) Desvenlafaxine succinate identifies novel antagonist binding determinants in the human norepinephrine transporter. J.Pharmacol.Exp.Ther. 323 720. PMID:17673606.	Small Molecule	Sold for research purposes under agreement from Pfizer Inc.	http://www.tocris.com/dispprod.php?ItemId=287341	SQ1070			Mar-2011
4195	VPC 23019	[449173-19-7]	O=C([C@H](N)COP(O)(O)=O)NC1=CC(CCCCCCCC)=CC=C1	S1P1 and S1P3 antagonist	Sphingosine-1-phosphate receptor antagonist; inhibits S1P1 and S1P3 receptors (pKi values are 7.86 and 5.93 respectively).	Davis et al (2005) Sphingosine-1-phosphate analogs as receptor antagonists. J.Biol.Chem. 280 9833. PMID:15590668. Aoki et al (2007) The suppressive effect of sphingosine-1-phosphate on monocyte-endothelium adhesion may be mediated by the rearrangement of the endothelial integrins _5_1 and _V_3. J.Thromb.Haemost. 5 1292. PMID:17403093. Mihovilovic et al (2007) High-fat/cholesterol diet promotes a S1P receptor-mediated antiapoptotic activity for VLDL. J.Lipid Res. 48 806. PMID:17264352.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=287344				Jul-2011
4196	HA 130	[1229652-21-4]	FC1=CC=C(CN3C(/C(SC3=O)=C/C2=CC=C(OCC4=CC(B(O)O)=CC=C4)C=C2)=O)C=C1	Selective autotaxin inhibitor	"Selective autotaxin inhibitor (IC50 = 28 nM). Binds and inhibits autotaxin reversibly. Displays no activity against the proteasome, recombinant NPP1 or alkaline phosphatase. Inhibits ATX-mediated cell migration in an A2058 melanoma cell assay."	Albers et al (2010) Discovery and optimization of boronic acid based inhibitors of autotaxin. J.Med.Chem. 53 4958. PMID:20536182. Albers et al (2010) Boronic acid-based inhibitor of autotaxin reveals rapid turnover of LPA in the circulation. Proc.Natl.Acad.Sci.USA 107 7257. PMID:20360563.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=287345				Aug-2011
4197	VU 591 hydrochloride	[1315380-70-1]	O=[N+]([O-])C(C=C4)=CC2=C4N=C(N2)COCC1=NC(C=CC([N+]([O-])=O)=C3)=C3N1.Cl	Selective Kir1.1 (ROMK) inhibitor	"Selective renal outer medullary potassium channel (Kir1.1, ROMK) antagonist (IC50 = 300 nM). Thought to block the intracellular pore of the Kir1.1 channel. Exhibits no effect on Kir7.1 at concentrations up to 10 _M; does not inhibit Kir2.1, Kir2.3 or Kir4.1. Displays similar potency to VU 590 (Cat. No. 3891)."	"Bhave et al (2011) Development of a selective small-molecule inhibitor of Kir1.1, the renal outer medullary potassium channel. Mol.Pharmacol. 79 42. PMID:20926757."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=287408	SQ1070			Jun-2011
4198	IEM 1925 dihydrobromide	[258282-23-4]	NCCCCCNC1(C2=CC=CC=C2)CCCCC1.Br.Br	Voltage- and use-dependent open-channel antagonist of AMPA receptors	Voltage- and use-dependent open-channel antagonist of AMPA receptors. Selective between subtypes; blocks GluR2 subunit-lacking receptors more potently than GluR2-containing receptors (KD for GluR2-containing AMPAR is 210 times higher at -80 mV). More potent than IEM 1460 (Cat. No. 1636) and IEM 1754 (Cat. No. 4199) due to a slower unblocking rate.	Tikhonov et al (2000) Voltage-dependent block of native AMPA receptor channels by dicationic compounds. Br.J.Pharmacol. 129 265. PMID:10694232.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=287721				Jul-2011
4199	IEM 1754 dihydrobromide	[162831-31-4]	NCCCCCNCC1(CC3C2)CC(C3)CC2C1.Br.Br	"Voltage-dependent, open-channel blocker of AMPA currents"	Voltage-dependent open-channel blocker of AMPA receptors. Selective between subtypes; blocks GluR2 subunit-lacking (Ca2+-permeable) receptors more potently than GluR2-containing receptors. Also potently blocks NMDA receptor channels. Less sensitive than IEM 1460 (Cat. No. 1460) at a holding potential between -40 and -80mV.	Magazanik et al (1997) Block of open channels of recombinant AMPA receptors and native AMPA/kainate receptors by adamantane derivatives. J.Physiol. 505 655. PMID:9457643. Tikhonov et al (2000) Voltage-dependent block of native AMPA receptor channels by dicationic compounds. Br.J.Pharmacol. 129 265. PMID:10694232.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=287722				Jul-2011
4200	C 646	[328968-36-1]	CC/2=NN(C(C2=C/C3=CC=C(C4=CC(C)=C(C)C=C4[N+]([O-])=O)O3)=O)C1=CC=C(C(O)=O)C=C1	Selective p300/CBP HAT inhibitor	Selective p300/CREB-binding protein (CBP) inhibitor (Ki = 400 nM). Selective against six other histone acetyltransferases (HATs). Suppresses histone H3 and H4 acetylation in mouse fibroblast cell lines.	"Bowers et al (2010) Virtual ligand screening of the p300/CBP histone acetyltransferase: identification of a selective small molecule inhibitor. Chem.Biol. 17 471. PMID:20534345. Mali et al (2010) Butyrate greatly enhances derivation of human induced pluripotent stem cells by promoting epigenetic remodeling and the expression of pluripotency-associated genes. Stem Cells 28 713. PMID:20201064. Ott and Verdi (2010) HAT trick: p300, small molecule, inhibitor. Chem.Biol. 17 417. PMID:20534339. Crump et al (2011) Dynamic acetylation of all lysine-4 trimethylated histone H3 is evolutionarily conserved and mediated by p300/CBP. Proc.Natl.Acad.Sci. USA 108 7814."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=287727	SQ1070			May-2011
4202	Adenine	[6055-72-7]	NC1=C2C(NC=N2)=NC=N1.Cl	Adenine receptor agonist	High affinity adenine receptor agonist (Ki = 18 nM at rat adenine receptor). Inhibits forskolin-stimulated cAMP formation in CHO cells transfected with the adenine receptor; also stimulates GTP_S binding (pEC50 values are 8.54 and 7.21 respectively).	Bender et al (2002) Characterization of an orphan G protein-coupled receptor localized in the dorsal root ganglia reveals adenine as a signaling molecule. Proc.Natl.Acad.Sci. 99 8573. Gorzalka et al (2005) Evidence for the functional expression and pharmacological characterization of adenine receptors in native cells and tissues. Mol.Pharmacol. 67 955. PMID:15604413.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=287970	SQ1533			Mar-2011
4204	BTZO 1	[99420-15-2]	O=C2C1=CC=CC=C1SC(C3=NC=CC=C3)=N2	MIF binder	Macrophage migration inhibitory factor (MIF) binder (Kd = 68.6 nM). Activates antioxidant response element (ARE)-mediated gene expression. Suppresses oxidative stress-induced cardiomyocyte apoptosis in vitro. Cardioprotective.	"Kimura et al (2010) BTZO-1, a cardioprotective agent, reveals that macrophage migration inhibitor factor regulates ARE-mediated gene expression. Chem.Biol. 17 1282. PMID:21168764."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=287972				Jun-2011
4205	MDA 19	[1048973-47-2]	O=C(C3=CC=CC=C3)N\N=C(C1=CC=CC=C1N2CCCCCC)/C2=O	CB2 agonist	CB2 receptor agonist. Displays 4-fold higher affinity for the human CB2 receptor than the human CB1 receptor (Ki values are 43.3 and 162.4 nM respectively); shows 70-fold affinity for the rat CB2 receptor over the rat CB1 receptor (Ki values are 16.3 and 1130 nM respectively). Attenuates tactile allodynia in a rat model; does not affect rat locomotor activity.	"Diaz et al (2008) Design and synthesis of a novel series of N-alkyl isatin acylhydrazone derivatives that act as selective cannabinoid receptor 2 agonists for the treatment of neuropathic pain. J.Med.Chem. 51 4932. PMID:18666769. Xu et al (2010) Pharmacological characterization of a novel cannabinoid ligand, MDA19, for treatment of neuropathic pain. Anesth.Analg. 111 99. PMID:20522703."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=287973				May-2011
4206	Valdecoxib	[181695-72-7]	CC1=C(C3=CC=C(S(=O)(N)=O)C=C3)C(C2=CC=CC=C2)=NO1	Selective and potent COX-2 inhibitor	Selective and potent COX-2 inhibitor (in vitro IC50 values are 0.005 and 140 _M for human recombinant COX-2 and COX-1 respectively). Displays potent anti-inflammatory activity in vivo.	"Talley et al (2000) 4-[5-methyl-3-phenylisoxazol-4-yl]-benzenesulfonamide, valdecoxib: a potent and selective inhibitor of COX-2. J.Med.Chem. 43 775. PMID:10715145. Walker et al (2001) A three-step kinetic mechanism for selective inhibition of cyclo-oxygenase-2 by diarylheterocyclic inhibitors. Biochem.J. 357 709. PMID:11463341. Gierse et al (2005) Valdecoxib: assessment of cyclooxygenase-2 potency and selectivity. J.Pharmacol.Exp.Ther. 312 1206. PMID:15494548."	Small Molecule	Sold for research purposes under agreement from Pfizer Inc.	http://www.tocris.com/dispprod.php?ItemId=288559	SQ1533			Mar-2011
4207	SB 277011A dihydrochloride	[1226917-67-4]	O=C(N[C@@H]3CC[C@@H](CCN4CC(C=CC(C#N)=C5)=C5CC4)CC3)C1=C2C(C=CC=C2)=NC=C1.Cl.Cl	Selective D3 antagonist	"Selective dopamine D3 receptor antagonist (pKi values are 8.0, 6.0, 5.0 and <5.2 for D3, D2, 5-HT1D and 5-HT1B respectively). Brain penetrant."	"Reavill et al (2000) Pharmacological actions of a novel, high-affinity, and selective human dopamine D3 receptor antagonist, SB-277011-A. J.Pharmacol.Exp.Ther. 294 1154. PMID:10945872. Stemp et al (2000) Design and synthesis of trans-N-[4-[2-(6-cyano-1,2,3,4-tetrahydroisoquinolin-2-yl)ethyl]cyclohexyl]-4-quinolinecarboxamide (SB-277011): a potent and selective dopamine D3 receptor antagonist with high oral bioavailability and CNS penetration in the rat. J.Med.Chem. 43 1878. PMID:10794704."	Small Molecule	Sold for research purposes under agreement from GlaxoSmithKline.	http://www.tocris.com/dispprod.php?ItemId=288970	SQ1070			Jan-2012
4208	MS 245 oxalate	[275363-58-1]	O=S(N2C1=CC=C(OC)C=C1C(CCN(C)C)=C2)(C3=CC=CC=C3)=O.OC(C(O)=O)=O	High affinity 5-HT6 antagonist	High affinity 5-HT6 antagonist (Ki = 2.1 nM). Potentiates the hypolocomotor actions of (-)-nicotine in mice.	Glennon et al (2000) 2-substituted tryptamines: agents with selectivity for 5-HT6 serotonin receptors. J.Med.Chem. 43 1011. PMID:10715164. Young et al (2006) Effect of the 5-HT6 serotonin antagonist MS-245 on the actions of (-)nicotine. Pharmacol.Biochem.Behav. 85 170. PMID:16950502. Dukat et al (2008) Binding of serotonin and N1-benzenesulfonyltryptamine-related analogs at human 5-HT6 serotonin receptors: receptor modeling studies. J.Med.Chem. 51 603. PMID:18201064. Nirogi et al (2010) Novel and potent 5-piperazinyl methyl-N1-aryl sulfonyl indole derivatives as 5-HT6 receptor ligands. ACS Med.Chem.Lett. 1 340.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=289521	SQ1070			Jun-2011
4209	EMDT oxalate	[263744-72-5]	CCC2=C(CCN(C)C)C1=CC(OC)=CC=C1N2.O=C(C(O)=O)O	Selective 5-HT6 agonist	Selective 5-HT6 agonist (with a Ki value of 16 nM at human 5-HT6 receptors). Exhibits potency comparable to serotonin for the activation of adenylate cyclase. Displays antidepressant-like effects.	Glennon et al (2000) 2-Substituted tryptamines: Agents with selectivity for 5-HT6 serotonin receptors. J.Med.Chem. 43 1011. PMID:10715164. Svenningsson et al (2007) Biochemical and behavioral evidence for antidepressant-like effects of 5-HT6 receptor stimulation. J.Neurosci. 27 4201. PMID:17428998.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=289534				Jul-2011
4212	PIR 3.5	[6088-51-3]	OC1=CC=C2C(C=CC(SSC3=CC(C=CC(O)=C4)=C4C=C3)=C2)=C1	Negative control of IPA 3 (Cat. No. 3622)	"Negative control of IPA 3 (Cat. No. 3622) a direct, non-competitive inhibitor of group I p21-activated kinase (Pak1)."	"Deacon et al (2008) An isoform-selective, small-molecule inhibitor targets the autoregulatory mechanism of p21-activated kinase. Chem.Biol. 15 322. PMID:18420139."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=289922				Mar-2011
4213	SB 297006	[58816-69-6]	O=C(C2=CC=CC=C2)N[C@H](C(OCC)=O)CC1=CC=C([N+]([O-])=O)C=C1	Potent and selective CCR3 antagonist	"Potent and selective CCR3 antagonist (IC50 = 39 nM). Displays 250-fold selectivity for CCR3 over other chemokine receptors, including CXCR1, CXCR2, CCR1 and CCR7 (IC50 >27 _M). Inhibits calcium mobilization induced by MCP-4, eotaxin-2 and eotaxin in RBL-2H3 cells transfected with CCR3 (IC50 values are 80, 90 and 210 nM respectively)."	"Yoshimoto and Hansch (1976) Quantitative structure-activity relationships of D- and L-N-actyl-alpha-aminoamide ligands binding to chymotrypsin. On the problem of combined treatment of stereoisomers. J.Org.Chem. 41 2269. PMID:932854. White et al (2000) Identification of a potent, selective non-peptide CC chemokine receptor-3 antagonist that inhibits eotaxin-, eotaxin-2-, and monocyte chemotactic protein-4-induced eosinophil migration. J.Biol.Chem. 275 36626. PMID:10969084."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=289966	SQ1070			Jun-2011
4214	Prostaglandin F2_	[38562-01-5]	O[C@@H]1[C@H](C/C=C\CCCC(O)=O)[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C1.NC(CO)(CO)CO	Naturally-occurring prostanoid; potent vasoconstrictor	Prostaglandin E2 and F2_ receptor agonist. Naturally-occurring prostaglandin and potent vasoconstrictor. Induces cardiomyocyte hypertrophy in vitro. Exhibits luteolytic activity.	Samuelsson et al (1978) Prostaglandins and throboxanes. Annu.Rev.Biochem. 47 997. PMID:209733. Lai et al (1996) Prostaglandin F2 alpha induces cardiac myocyte hypertrophy in vitro and cardiac growth in vivo. Am.J.Physiol. 271 2197. Girsh and Dekel (2002) Involvement of endothelin-1 and its receptors in PGF2_-induced luteolysis in the rat. Mol.Reprod.Dev. 63 71. PMID:12211063.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=290443	SQ1070			Apr-2011
4215	4E1RCat	[328998-25-0]	O=C1N(C3=CC=C(C(O)=O)C=C3)C(C4=CC=CC=C4)=C/C1=C\C2=CC=C(C5=CC=C([N+]([O-])=O)C=C5)O2	Protein translation inhibitor; blocks eIF4F subunit interaction	Inhibitor of protein translation; blocks eIF4E:eIF4G and eIF4E:4E-BP1 interaction. Prevents assembly of the eIF4F complex and inhibits cap-dependent translation (IC50 ~4 _M). Exhibits chemosensitizing properties.	Cencic et al (2010) Reversing chemoresistance by small molecule inhibition of the translation initiation complex eIF4F. Proc.Natl.Acad.Sci.USA 108 1046.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=290445	SQ1070			Apr-2011
4216	Valsartan	[137862-53-4]	CC(C)[C@@H]([C@@](O)=O)N(C(CCCC)=O)CC(C=C3)=CC=C3C1=CC=CC=C1C2=NN=NN2	"High affinity, selective AT1 antagonist"	"High affinity AT1 receptor antagonist (Ki = 2.38 nM). Displays 30,000-fold selectivity over AT2 receptors. Inhibits angiotensin II-induced release of aldosterone in vitro. Orally active."	"Criscione et al (1993) Pharmacological profile of valsartan: a potent, orally active, nonpeptide antagonist of the angiotensin II AT1-receptor subtype. Br.J.Pharmacol. 110 761. PMID:8242249. Wexler et al (1996) Nonpeptide angiotensin II receptor antagonists: the next generation in antihypertensive therapy. J.Med.Chem. 39 625. PMID:8576904. Hanafy et al (2008) Effects of angiotensin II blockade on inflammation-induced alterations of pharmacokinetics and pharmacodynamics of calcium channel blockers. Br.J.Pharmacol. 153 90. PMID:17965735."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=290868	SQ1070			Apr-2011
4219	Banoxantrone dihydrochloride	[252979-56-9]	OC1=CC=C(O)C2=C1C(C(C(NCC[N+]([O-])(C)C)=CC=C3NCC[N+]([O-])(C)C)=C3C2=O)=O.Cl.Cl	Prodrug topoisomerase II inhibitor	Bioreductive prodrug; activated by hypoxia to yield the topoisomerase II inhibitor AQ4. Displays little to no cytotoxic activity against 60 tumor cell lines tested under oxic conditions (IC50 >100 _M). Exhibits anti-tumor efficacy in vivo when combined with oxic cell cytotoxins; enhances the anti-tumor effect of cyclophosphamide (Cat. No. 4091) in a mouse tumor model.	Friery et al (2000) Enhancement of the anti-tumour effect of cyclophosphamide by the bioreductive drugs AQ4N and tirapazamine. Br.J.Cancer 82 1469. PMID:10780528. Patterson and McKeown (2000) AQ4N: a new approach to hypoxia-activated cancer chemotherapy. Br.J.Cancer 83 1589. PMID:11104551. Mehibel et al (2009) Effects of cytokine-induced macrophages on the response of tumor cells to banoxantrone (AQ4N). Mol.Cancer Ther. 8 1261. PMID:19435866.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=290875	SQ1533			Jun-2011
4220	XCC	[96865-83-7]	O=C1N(CCC)C(C(NC(C3=CC=C(OCC(O)=O)C=C3)=N2)=C2N1CCC)=O	Adenosine receptor antagonist	"Adenosine receptor antagonist (Ki values are 42, 68 and 1130 nM for A1, A2B and A2A receptors)."	"Jarvis et al (1989) Autoradiographic characterization of high-affinity adenosine A2 receptors in the rat brain. Brain Res. 484 111. PMID:2713675. Sebastiao et al (1990) The inhibitory adenosine receptor at the neuromuscular junction and hippocampus of the rat: antagonism by 1,3,8-substituted xanthines. Br.J.Pharmacol. 101 453. PMID:2257444. Thummler and Dunwiddie (2000) Adenosine receptor antagonists induce persistent bursting in the rat hippocampal CA3 region via an NMDA receptor-dependent mechanism. J.Neurophysiol. 83 1787. PMID:10758091."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=290898	SQ1070			Apr-2011
4221	TCS 21311	[1260181-14-3]	O=C(N1)C(C3=CNC4=C3C=CC=C4)=C(C2=C(C(F)(F)F)C=CC(N5CCN(C(C(O)(C)C)=O)CC5)=C2)C1=O	Potent JAK3 inhibitor. Also inhibits GSK-3_ and PKC	"Potent JAK3 inhibitor (IC50 = 8 nM). Selective for JAK3 over JAK1, JAK2 and TYK2 (IC50 values are 1017, 2550 and 8055 nM respectively). Also inhibits GSK-3_, PKC_ and PKC_ (IC50 values are 3, 13 and 68 nM respectively)."	Thoma et al (2010) Identification of a potent Janus kinase 3 inhibitor with high selectivity within the Janus kinase family. J.Med.Chem. 54 284.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=291077				Aug-2011
4222	Dynole 34-2	[1128165-88-7]	CN(C)CCCN2C1=CC=CC=C1C(/C=C(C(NCCCCCCCC)=O)\C#N)=C2	Dynamin I inhibitor	Dynamin I inhibitor (IC50 = 1.3 _M). Inhibits receptor-mediated endocytosis (RME) (IC50 = 5.0 _M).	Hill et al (2009) Inhibition of dynamin mediated endocytosis by the dynoles - synthesis and functional activity of a family of indoles. J.Med.Chem. 52 3762. PMID:19459681. Hill et al (2010) Iminochromene inhibitors of dynamins I and II GTPase activity and endocytosis. J.Med.Chem. 53 4094. PMID:20426422.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=284180	SQ1070			Jul-2011
4227	RWJ 50271	[162112-37-0]	CC1=C(C(NCCCO)=O)C=NN1C2=NC(C3=CC(C(F)(F)F)=CC=C3)=CS2	Inhibitor of LFA-1/ICAM mediated cell adhesion	Selective inhibitor of LFA-1 (lymphocyte function-associated antigen-1) adhesion to soluble intercellular adhesion molecule (sICAM) (IC50 = 5 _M in HL60 cells).	Sanfilippo et al (1995) Novel thiazole based heterocycles as inhibitors of LFA-1/ICAM-1 mediated cell adhesion. J.Med.Chem. 38 1057. PMID:7707308.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=291725	SQ1070			Jul-2011
4228	A 286982	[280749-17-9]	O=C(C)N1CCN(C(/C=C/C2=CC([N+]([O-])=O)=C(SC3=CC=CC=C3C(C)C)C=C2)=O)CC1	Potent inhibitor of the LFA-1/ICAM-1 interaction	Potent inhibitor of the LFA-1/ICAM-1 interaction (IC50 values are 44 and 35 nM in LFA-1/ICAM-1 binding and LFA-1-mediated cell adhesion assays respectively).	Liu et al (2000) Discovery of novel p-arylthio cinnamides as antagonists of leukocyte function-associated antigen-1/intracellular adhesion molecule-1 interaction. Identification of an additional binding pocket based on an anilino diaryl sulfide lead. J.Med.Chem. 43 4025. PMID:11052808.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=291726	SQ1070			Jul-2011
4230	NPEC-caged-D-AP5	[1416943-27-5]	O=C(OC(C)C1=CC=CC=C1[N+]([O-])=O)N[C@H](CCCP(O)(O)=O)C(O)=O	Caged D-AP5 (Cat.No. 0106)	D-AP5 (Cat.No. 0106) caged with the photosensitive 1-(2-nitrophenyl)ethoxycarbonyl (NPEC) group. NMDA receptor antagonist.	Murphy et al (1997) Activation of NMDA receptors is necessary for the induction of associative long-term potentiation in area CA1 of the rat hippocampal slice. J.Physiol. 504 379. PMID:9365912.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=291755				Nov-2011
4231	Nateglinide	[105816-04-4]	O=[C@](N[C@@H](C(O)=O)CC2=CC=CC=C2)[C@H]1CC[C@H]([C@H](C)C)CC1	Kir6 (KATP) blocker; displays high affinity for SUR1/Kir6.2 channels	Kir6 (KATP) blocker. Exhibits in vitro tissue selectivity for pancreatic _-cell-type Kir6 channels over cardiovascular Kir6 channels; displays high affinity for SUR1/Kir6.2 channels. Hypoglycemic agent; stimulates insulin secretion from pancreatic _-cells by increasing cytosolic Ca2+ concentration.	"Shinkai et al (1989) N-(cyclohexylcarbonyl)-D-phenylalanines and related compounds. A new class of hypoglycemic agents. J.Med.Chem. 32 1436. PMID:2738878. Fujitani et al (1997) The ability of a new hypoglycemic agent, A-4166, compared to sulphonylureas, to increase cytosolic Ca2+ in pancreatic beta-cells under metabolic inhibition. Br.J.Pharmacol. 120 1191. PMID:9105692. Hu et al (1999) Tissue selectivity of antidiabetic agent nateglinide: study on cardiovascular and _-cell KATP channels. J.Pharmacol.Exp.Ther. 291 1372. PMID:10565863. Chachin et al (2003) Nateglinide, a D-phenylalanine derivative lacking either a sulfonylurea or benzamido moiety, specifically inhibits pancreatic _-cell-type KATP channels. J.Pharmacol.Exp.Ther. 304 1025. PMID:12604678."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=291901	SQ1533			Apr-2011
4232	A 839977	[870061-27-1]	ClC(C(Cl)=CC=C4)=C4N1N=NN=C1NCC2=CC=CC=C2OC3=NC=CC=C3	Potent P2X7 antagonist	"Potent P2X7 antagonist; blocks BzATP-evoked calcium influx at recombinant human, rat and mouse P2X7 receptors (IC50 values are 20, 42 and 150 nM respectively). Displays antinociceptive effects in rat and mice models of inflammatory pain. CNS penetrant."	"Honore et al (2009) The antihyperalgesic activity of a selective P2X7 receptor antagonist, A-839977, is lost in IL-1__ knockout mice. Behav.Brain.Res. 204 77. PMID:19464323. Friedle et al (2010) Recent patents on novel P2X7 receptor antagonists and their potential for reducing central nervous system inflammation. Recent Pat.CNS Drug Discov. 5 35. PMID:19705995."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=292223	SQ1533			Aug-2011
4233	TQS	[353483-92-8]	O=S(C3=CC1=C(C=C3)NC(C4=C(C=CC=C5)C5=CC=C4)C2C1C=CC2)(N)=O	Positive allosteric modulator of _7 nAChRs	Type II positive allosteric modulator of _7 nACh receptors (pEC50 = 5.5). Displays no agonist activity at _7 receptors at concentrations up to 0.1 mM; potentiates agonist-evoked responses and reduces rate of desensitization of _7 nAChRs. Exhibits potency and efficacy similar to PNU 120596 (Cat. No. 2498).	Gronlien et al (2007) Distinct profiles of _7 nAChR positive allosteric modulation revealed by structurally diverse chemotypes. Mol.Pharmacol. 72 715. PMID:17565004. Gill et al (2011) Agonist activation of _7 nicotinic acetylcholine receptors via an allosteric transmembrane site. Proc.Natl.Acad.Sci. 108 5867.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=292224				Jun-2011
4234	4BP-TQS	[360791-49-7]	BrC1=CC=C(C2NC(C=CC(S(=O)(N)=O)=C4)=C4C3C2CC=C3)C=C1	Allosteric agonist at _7 nAChR	"Allosteric agonist at _7 nAChR. Binds at a separate site and exhibits more efficacious receptor agonism compared to acetylcholine (Cat. No. 2809), displays 8-fold lower EC50 value and 45-fold larger maximal response."	Gill et al (2011) Agonist activation of _7 nicotinic acetylcholine receptors via an allosteric transmembrane site. Proc.Natl.Acad.Sci.U.S.A. 108 5867. PMID:21436053.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=292226				Feb-2015
4236	CP 945598 hydrochloride	[686347-12-6]	CCNC(CC4)(C(N)=O)CCN4C1=NC=NC2=C1N=C(C5=C(Cl)C=CC=C5)N2C3=CC=C(Cl)C=C3.Cl	CB1 receptor antagonist	"Selective, high affinity CB1 antagonist (Ki values are 0.7 and 0.12 nM in binding and functional assays respectively). Displays low affinity for CB2 receptors (Ki = 7600 nM)."	"Griffith et al (2009) Discovery of 1-[9-(4-Chlorophenyl)-8-(2-chlorophenyl)-9H-purin-6-yl]-4-ethylaminopiperidine-4-carboxylic acid amide hydrochloride (CP-945,598), a novel, potent, and selective cannabinoid type 1 receptor antagonist. J.Med.Chem. 52 234. PMID:19102698. Hadcock et al (2010) In vitro and in vivo pharmacology of CP-945,598, a potent and selective cannabinoid CB1 receptor antagonist for the management of obesity. Biochem.Biophys.Res.Commun. 394 366. PMID:20211605."	Small Molecule	Sold for research purposes under agreement from Pfizer Inc.	http://www.tocris.com/dispprod.php?ItemId=292346	SQ1070			Apr-2011
4237	PD 184352	[212631-79-3]	FC1=C(NC2=CC=C(I)C=C2Cl)C(C(NOCC3CC3)=O)=CC=C1F	Selective MEK inhibitor	Selective MEK inhibitor (Ki = 300 nM in vitro). Suppresses FGF-mediated angiogenesis in vivo and decreases VEGF expression. Enhances the therapeutic efficacy of taxol (Cat. No. 1097) in vivo. Orally active.	"Allen et al (2003) CI-1040 (PD184252), a targeted signal transduction inhibitor of MEK (MAPKK). Semin.Oncol. 30 105. PMID:14613031. McDaid et al (2005) Enhancement of the therapeutic efficacy of taxol by the mitogen-activated protein kinase kinase inhibitor CI-1040 in nude mice bearing human heterotransplants. Cancer Res. 65 2854. PMID:15805287. Solit et al (2006) BRAF mutation predicts sensitivity to MEK inhibition. Nature 439 358. PMID:16273091."	Small Molecule	Sold for research purposes under agreement from Pfizer Inc.	http://www.tocris.com/dispprod.php?ItemId=292349	SQ1533			Apr-2011
4238	PF 184	[1187460-81-6]	FC(C=C4)=CC=C4N(N=C3C(N)=O)C2=C3CCC1=CC=C(NC(C5=CC(N(C6)C[C@@](C)(CO)[C@]6(CO)C)=NC=C5Cl)=O)C=C12	Potent and selective IKK_ inhibitor	Potent and selective IKK_ inhibitor (IC50 = 37 nM). Displays selectivity over 85 other kinases. Inhibits IL-1_-induced TNF-_ production in a steroid-insensitive in vitro model of oxidative stress.	Sommers et al (2009) Novel tight-binding inhibitory factor-_B kinase (IKK-2) inhibitors demostrate target-specific anti-inflammatory activities in cellular assays and following oral and local delivery in an in vivo model of airway inflammation. J.Pharmacol.Exp.Ther. 330 377. PMID:19478133.	Small Molecule	Sold for research purposes under agreement from Pfizer Inc.	http://www.tocris.com/dispprod.php?ItemId=292350	SQ1533			Apr-2011
4239	PF 04217903 mesylate	[956906-93-7]	OCCN1N=CC(C2=CN=C3C(N(CC4=CC=C(N=CC=C5)C5=C4)N=N3)=N2)=C1.CS(=O)(O)=O	Highly selective c-Met inhibitor	"Highly selective, high affinity c-Met inhibitor (Ki = 6-7 nM against wild type c-Met). Displays >1000-fold selectivity for c-Met over a panel of 208 kinases."	"Eder et al (2009) Novel therapeutic inhibitors of the c-Met signaling pathway in cancer. Clin.Cancer Res. 15 2207. PMID:19318488. Timofeevski et al (2009) Enzymatic characterization of c-Met receptor tyrosine kinase oncogenic mutants and kinetic studies with aminopyridine and triazolopyrazine inhibitors. Biochemistry 48 5339. PMID:19459657. Underiner et al (2010) Discovery of small molecule c-Met inhibitors: evolution and profiles of clinical candidates. Anticancer Agents Med.Chem. 10 7. PMID:20015007. Cui et al (2012) Discovery of a novel class of exquisitely selective mesenchymal-epithelial transition factor (c-MET) protein kinase inhibitors and identification of the clinical candidate 2-(4-(1-(quinolin-6-ylmethyl)-1H-[1,2,3]triazolo[4,5-b]pyrazin-6-yl)-1H-pyrazol-1-yl)ethanol (PF-04217903) for the treatment of cancer. J.Med.Chem. 55 8091. PMID:22924734."	Small Molecule	Sold for research purposes under agreement from Pfizer Inc.	http://www.tocris.com/dispprod.php?ItemId=293202	SQ1533			Jun-2011
4240	SCH 529074	[922150-11-6]	CN(C)CCCNC2=NC(CN3CCN(C(C5=CC=C(Cl)C=C5)C4=CC=C(Cl)C=C4)CC3)=NC1=CC=CC=C12	Restores mutant p53 activity	Restores mutant p53 activity. Binds p53 DNA binding domain (Kd = 1-2 _M) and restores wild-type function to many oncogenic mutants by acting as a chaperone. Inhibits ubiquitination of p53 by HDM2. Triggers apoptosis in tumor cell lines and reduces tumor growth in a xenograft model.	"Demma et al (2010) SCH529074, a small molecule activator of mutant p53, which binds p53 DNA binding domain (DBD), restores growth-suppressive function to mutant p53 and interrupts HDM2-mediated ubiquitination of wild type p53. J.Biol.Chem. 285 10198. PMID:20124408. Essmann & Schulze-Osthoff (2012) Translational approaches targeting the p53 pathway for anti-cancer therapy. Br.J.Pharmacol. 165 328. PMID:21718309."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=293278				Dec-2013
4241	Olopatadine hydrochloride	[140462-76-6]	O=C(CC(C=C3)=CC/1=C3OCC(C=CC=C2)=C2C1=C\CCN(C)C)O.Cl	H1 antagonist; ocular antiallergic agent	"Histamine H1 receptor antagonist (Ki = 31.6 nM). Inhibits the release of histamine, prostaglandin D2 and tryptase in a concentration-dependent manner. Mast cell stabilizer; inhibits mast cell mediator release. Also suppresses inflammation by inhibition of cytokine production."	"Sharif et al (1996) Characterization of the ocular antiallergic and antihistaminic effects of olopatidine (AL-4943A), a novel drug for treating ocular allergic diseases. J.Pharm.Exp.Ther. 278 1252. Tamura et al (2007) Olopatidine ameliorates rat experimental cutaneous inflammation by improving skin barrier function. Pharmacology 81 118. PMID:17962722."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=293279	SQ1533			May-2011
4242	GW 803430	[515141-51-2]	ClC(C=C3)=CC=C3C(S2)=CC1=C2C(N(C4=CC(OC)=C(OCCN5CCCC5)C=C4)C=N1)=O	MCH1 antagonist	Selective melanin-concentrating hormone receptor 1 (MCH1) antagonist (IC50 = 9.3 nM). Displays antiobesity and antidepressant-like effects in rats and mice. Orally active.	Rivera et al (2008) Melanin-concentrating hormone receptor 1 antagonists: a new perspective for the pharmacologic treatment of obesity. Curr.Med.Chem. 15 1025. PMID:18393860. Gehlert et al (2009) Preclinical evaluation of melanin-concentrating hormone receptor 1 antagonism for the treatment of obesity and depression. J.Pharmacol.Exp.Ther. 329 429. PMID:19182070.	Small Molecule	Sold for research purposes under agreement from GlaxoSmithKline.	http://www.tocris.com/dispprod.php?ItemId=293305	SQ1070			Jul-2011
4244	TCS 3035	[871085-49-3]	O=C(/C(S2)=C/C1=CC=C(OCC(O)=O)C=C1)NC2=O	GPR35 agonist	"GPR35 agonist (pEC50 values are 5.13 and 5.86 for rat and human GPR35 orthologs, respectively)."	Jenkins et al (2011) Agonist activation of the G protein-coupled receptor GPR35 involves transmembrane domain III and is transduced via G_13 and _-arrestin-2. Br.J.Pharmacol. 162 733. PMID:20958291.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=294540				Sep-2014
4245	Meclizine dihydrochloride	[1104-22-9]	CC1=CC(CN(CC4)CCN4C(C3=CC=C(Cl)C=C3)C2=CC=CC=C2)=CC=C1.Cl.Cl	Human pregnane X receptor agonist; H1 antagonist	Human pregnane X receptor (hPXR) agonist; stronger activator of hPXR than rat PXR. Increases hPXR target gene expression in human hepatocyte primary cultures. Also acts as a histamine H1 receptor antagonist. Confers neuroprotection in models of polyQ toxicity.	Parada et al (2001) The major role of peripheral release of histamine and 5-hydroxytryptamine in formalin-induced nociception. Neuroscience 102 937. PMID:11182255. Gohil et al (2010) Meclizine is neuroprotective in models of Huntington's disease. Hum.Mol.Genet. 20 294. PMID:20977989. Lau et al (2011) Differential effect of meclizine on the activity of human pregnane X receptor and constitutive androstane receptor. J.Pharmacol.Exp.Ther. 336 816. PMID:21131266.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=294628	SQ1533			Jun-2011
4246	CID 2858522	[758679-97-9]	OCCCNC2=NC1=CC(C)=C(C)C=C1N2CC(C3=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C3)=O	Selectively inhibits PKC-induced NF-_B activation	"Selectively inhibits protein kinase C (PKC)-induced activation of the NF-_B pathway (IC50 < 0.1 _M for PMA-stimulated IL-8 production). Inhibits antigen receptor-stimulated NF-_B activation in chronic lymphocytic leukemia (CLL) B cells. Does not inhibit other NF-_B pathways, including that activated by tumor necrosis factor (TNF)."	"Peddibhotla et al (2010) Inhibition of protein kinase C-driven NF-_B activation: synthesis, SAR, and pharmacological profiling of pathway specific benzimidazole probe molecules. J.Med.Chem. 53 4793. PMID:20481485. Shi et al (2010) Chemical biology strategy reveals pathway-selective inhibitor of NF-_B activation induced by protein kinase C and antigen receptors. ACS Chem.Bio. 5 287."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=294709	SQ1341			Dec-2012
4247	Torin 1	[1222998-36-8]	O=C(N5C6=CC(C(F)(F)F)=C(N7CCN(C(CC)=O)CC7)C=C6)C=CC2=C5C1=CC(C3=CN=C(C=CC=C4)C4=C3)=CC=C1N=C2	Potent and selective mTOR inhibitor	"Potent and selective mTOR inhibitor (IC50 = 2 - 10 nM for mTORC1 and mTORC2). Displays 200-fold selectivity for mTOR over DNA-PK, ATM and hVps34. Induces autophagy in HeLa cells."	"Guertin and Sabatini (2009) The pharmacology of mTOR inhibition. Sci.Signal. 2 pe24. PMID:19383975. Thoreen et al (2009) An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1. J.Biol.Chem. 284 8023. PMID:19150980. Liu et al (2010) Discovery of 1-(4(-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo[h][1,6]naphthyridin-2(1H)-one as a highly potent, selective mammalian target of rapamycin (mTOR) inhibitor for the treatment of cancer. J.Med.Chem. 53 7146. PMID:20860370. Peterson et al (2011) mTOR complex 1 regulates lipin 1 localization to control the SREBP pathway. Cell. 146 408. PMID:21816276."	Small Molecule	Sold under license from Whitehead Institute for Biomedical Research.	http://www.tocris.com/dispprod.php?ItemId=294888	SQ1533			Jul-2011
4248	Torin 2	[1223001-51-1]	O=C(C=C3)N(C5=CC=CC(C(F)(F)F)=C5)C2=C3C=NC1=CC=C(C4=CC=C(N)N=C4)C=C12	Potent and selective mTOR inhibitor	Potent and selective mTOR inhibitor (IC50 = 2.1 nM). Displays 800-fold cellular selectivity for mTOR over PI3K (cellular EC50 values are 0.25 and 200 nM for mTOR and PI3K respectively). Orally available.	"Liu et al (2011) Discovery of 9-(6-aminopyridin-3-yl)-1-(3-(trifluoromethyl)phenyl)benzo[h][1,6]naphthyridin-2(1H)-one (Torin2) as a potent, selective, and orally available mammalian target of rapamycin (mTOR) inhibitor for treatment of cancer. J.Med.Chem. 54 1473. PMID:21322566."	Small Molecule	Sold under license from Whitehead Institute for Biomedical Research.	http://www.tocris.com/dispprod.php?ItemId=294892	SQ1533			Jun-2011
4249	A 887826	[1266212-81-0]	ClC1=C(OCCCC)C=CC(C2=CN=CC(C(NCC3=CC=CN=C3N4CCOCC4)=O)=C2)=C1	Potent voltage-dependent NaV1.8 channel blocker	Potent voltage-dependent NaV1.8 channel blocker (IC50 = 11 nM in recombinant human NaV1.8 channels). Reduces tactile allodynia in neuropathic rat models. 3- and 28-fold more potent at NaV1.8 channels compared to NaV1.2 and NaV1.7 channels respectively.	"Zhang et al (2010) A-887826 is a structurally novel, potent and voltage-dependent NaV1.8 sodium channel blocker that attenuates neuropathic tactile allodynia in rats. Neuropharmacology 59 201. PMID:20566409."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=295099	SQ1070			Sep-2011
4250	Mitoxantrone dihydrochloride	[70476-82-3]	O=C2C3=C(C(O)=CC=C3O)C(C1=C(NCCNCCO)C=CC(NCCNCCO)=C12)=O.Cl.Cl	Topoisomerase II inhibitor; immunosuppressive and antineoplastic agent	"Type II DNA topoisomerase inhibitor. Disrupts DNA synthesis and repair and induces damage by DNA cross-linking. Also inhibits PIM1 kinase (IC50 = 51 nM). Immunomodulatory, antineoplastic and chemotherapeutic agent."	Crespi et al (1986) Mitoxantrone affects topoisomerase activities in human breast cancer cells. Biochem.Biophys.Res.Comm. 136 521. PMID:3010982. Scott and Figgit (2004) Mitoxantrone: a review of its uses in multiple sclerosis. CNS Drugs. 18 379. PMID:15089110. Wan et al (2013) A new target for an old drug: identifying mitoxantrone as a nanomolar inhibitor of PIM1 kinase via kinome-wide selectivity modeling. J.Med.Chem. 56 2619. PMID:23442188.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=295156	SQ1533			May-2011
4252	PF 4981517	[1390637-82-7]	CN1N=C(C5=C(C6=CC=C(C)C=C6)N(C)N=C5)C2=C1N=CN=C2N3C[C@@H](N4CCCCC4)CC3	Selective CYP3A4 inhibitor	"Potent and selective inhibitor of CYP3A4 (IC50 values are 0.03, 17 and 70 _M for CYP3A4, CYP3A5 and CYP3A7 respectively)."	Walsky et al (2012) Selective mechanism-based inactivation of cytochrome P4503A4 by cyp3cide (PF-04981517) and its utility as an in vitro tool for delineating the relative roles of cytochrome P4503A4 versus P4503A5 in the metabolism of drugs. Am.Soc.Pharmacol.Exp.Ther. Epub ahead of print.	Small Molecule	Sold for research purposes under agreement from Pfizer Inc.	http://www.tocris.com/dispprod.php?ItemId=295167	SQ1341			Jun-2012
4253	TMPyP4 tosylate	[36951-72-1]	C[N+](C=C9)=CC=C9/C(C2=CC=C(/C(C8=CC=[N+](C)C=C8)=C3/C=CC4=N3)N2)=C1N=C(/C(C7=CC=[N+](C)C=C7)=C(N6)/C=C\C6=C4/C5=CC=[N+](C)C=C5)C=C\1.CC%10=CC=C(S(=O)([O-])=O)C=C%10.CC%11=CC=C(S(=O)([O-])=O)C=C%11.CC%12=CC=C(S(=O)([O-])=O)C=C%12.CC%13=CC=C(S(=O)([O-])=O)C=C%13	Inhibitor of human telomerase	Cationic porphyrin; inhibits human telomerase. Stacks with G tetrads to stabilize quadruplex DNA. Inhibits cell proliferation and induces cell death in three myeloma cell lines. Activity results in telomere shortening at concentrations between 1 and 5 _M.	Wheelhouse et al (1998) Cationic porphyrins as telomerase inhibitors: the interaction of tetra-(N-methyl-4-pyridyl)porphine with quadruplex DNA. J.Am.Chem.Soc. 120 3261. Rha et al (2000) Effect of telomere and telomerase interactive agents on human tumor and normal cell lines. Clin.Cancer Res. 6 987. PMID:10741725. Shi et al (2001) Quadruplex-interactive agents as telomerase inhibitors: synthesis of porphyrins and structure-activity relationship for the inhibition of telomerase. J.Med.Chem. 474 4509. Shammas et al (2003) Telomerase inhibition and cell growth arrest by G-quadruplex interactive agent in multiple myeloma. Mol.Cancer Ther. 2 825. PMID:14555701.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=295197				Jun-2011
4254	TAK 715	[303162-79-0]	CCC1=NC(C3=CC(C)=CC=C3)=C(C2=C(NC(C4=CC=CC=C4)=O)N=CC=C2)S1	Potent p38 MAPK inhibitor; anti-inflammatory	"Inhibitor of p38 MAPK (IC50 = 7.1 nM for p38 MAPK_). Also inhibits Wnt-3a-stimulated _-catenin signaling. Inhibits 22 kinases by more than 80%, including CK1_/_. Anti-inflammatory and anti-rheumatoid arthritis agent. Orally bioavailable."	"Miwatashi et al (2005) Novel inhibitor of p38 MAP kinase as an anti-TNF-_ drug: discovery of N-[4-{2-ethyl-4-(3-methylphenyl)-1,3-thiazol-5-yl]-2-pyridyl]benzamide (TAK-715) as a potent and orally active anti-rheumatoid arthritis agent. J.Med.Chem. 48 5966. PMID:16162000. Verkaar et al (2011) Inhibition of Wnt/_-catenin signaling by p38 MAP kinase inhibitors is explained by cross-reactivity with casein kinase I_/_. Chem.Biol. 18 485. PMID:21513885."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=295560				Jul-2011
4255	TC-O 9311	[444932-31-4]	O=C(NNC(NC2=CC=CC3=C2C=CC=C3)=O)C1=CC(OC)=CC(OC)=C1	Potent and selective GPR139 agonist	Potent GPR139 agonist (EC50 = 39 nM in CHO-K1 cells expressing human GPR139). Displays no activity against a range of 90 diverse targets.	Shi et al (2011) Discovery and SAR of a series of agonists at orphan G protein-coupled receptor 139. ACS Med.Chem.Lett. 2 303.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=295822				Jun-2011
4256	Tiagabine hydrochloride	[145821-59-6]	CC3=C(SC=C3)/C(C2=C(C)C=CS2)=C\CCN1C[C@H](C(O)=O)CCC1.Cl	GABA uptake inhibitor; anticonvulsant	GABA uptake inhibitor (IC50 = 67 nM in vivo). Exhibits high affinity and selectivity for the GAT-1 GABA transporter. Anticonvulsant; also attenuates established dynorphin-induced allodynia in a mouse model after systemic administration.	"Andersen et al (1993) The synthesis of novel GABA uptake inhibitors. 1. Elucidation of the structure-activity studies leading to the choice of (R)-1-[4,4-bis(3-methyl-2-thienyl)-3-butenyl]-3-butenyl]-3-piperidinecarboxylic acid (tiagabine) as an anticonvulsant drug candidate. J.Med.Chem. 36 1716. PMID:8510100. Dhar et al (1994) Design, synthesis and evaluation of substituted triarylnipecotic acid derivatives as GABA updake inhibitors: identification of a ligand with moderate affinity and selectivity for the cloned human GABA transporter GAT-3. J.Med.Chem. 37 2334. PMID:8057281. Laughlin et al (2002) Comparison of antiepileptic drugs tiagabine, lamotrigine, and gabapentin in mouse models of acute, prolonged, and chronic nociception. J.Pharmacol.Exp.Ther. 302 1168. PMID:12183677."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=295823	SQ1533			Jun-2011
4257	PP 242	[1092351-67-1]	OC1=CC2=C(NC(C3=NN(C(C)C)C4=C3C(N)=NC=N4)=C2)C=C1	Dual mTORC1/mTORC2 inhibitor	"ATP-competitive mTORC1/mTORC2 inhibitor (IC50 = 8 nM). Displays selectivity for mTOR over other PI 3K family kinases (IC50 values are 0.102, 0.408, 1.27, 1.96 and 2.2 _M for p110_, DNA-PK, p110_, p110_ and p110_ respectively) and 215 further kinases. Displays modest inhibition of PKC_, JAK2, PKC_I, PKC_II and RET (IC50 values are 0.049, 0.110, 0.185, 0.198 and 0.224 _M respectively). Inhibits both S6K and 4EBP1 phosphorylation; activity causes a decrease in cap-dependent protein translation. Also triggers donwregulation of cFLIPS and augments TRAIL-induced apoptosis of cancer cells."	Apsel et al (2008) Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases. Nat.Chem.Biol. 4 691. PMID:18849971. Feldman et al (2009) Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2. PLoS Biol. 7 371. Janes et al (2010) Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor. Nat.Med. 16 205. PMID:20072130. Zhao et al (2013) mTOR complex 2 is involved in regulation of Cbl-dependent c-FLIP regulation and sensitivity of TRAIL-induced apoptosis. Cancer Res. 73 1946. PMID:23319802.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=295824	SQ1533			Jun-2011
4259	TCN 238	[125404-04-8]	NC1=NC(/C=C/C2=CC=CC=C2)=CC=N1	Positive allosteric modulator of mGlu4	Positive allosteric modulator of mGlu4 receptors (EC50 = 1.0 _M for human and rat mGlu4 receptors). Orally available and brain penetrant.	East et al (2010) An orally bioavailable positive allosteric modulator of the mGlu4 receptor with efficacy in an animal model of motor dysfunction. Bioorg.Med.Chem.Lett. 20 4901. PMID:20638279.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=295961				Aug-2011
4264	TG 100713	[925705-73-3]	NC1=NC(N)=C2C(N=CC(C3=CC=CC(O)=C3)=N2)=N1	PI 3-kinase inhibitor	"Inhibitor of PI3-kinase (IC50 values are 24, 50, 165 and 215 nM for PI3K_, _, _ and _ isoforms respectively). Inhibits endothelial cell proliferation."	"Doukas et al (2006) Phosphoinositide 3-kinase _/_ inhibition limits infarct size after myocardial ischemia/reperfusion injury. Proc.Natl.Acad.Sci.USA 103 19866. PMID:17172449. Palanki et al (2007) Discovery of 3,3'-(2,4-diaminopteridine-6,7-diyl)diphenol as an isozyme-selective inhibitor of PI3K for the treatment of ischemia reperfusion injury associated with myocardial infarction. J.Med.Chem. 50 4279. PMID:17685602."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=296839				Sep-2011
4266	ML 141	[71203-35-5]	COC(C=C4)=CC=C4C1CC(C3=CC=CC=C3)=NN1C2=CC=C(S(=O)(N)=O)C=C2	Selective inhibitor of Cdc42 Rho family GTPase	"Allosteric inhibitor of Cdc42 GTPase (EC50 = 2.1 _M). Selective for Cdc42 over other members of the Rho GTPase family including Rac1, Rab2 and Rab7. Inhibits ovarian cancer cell migration in vitro."	Surviladze et al (2010) A potent and selective inhibitor of Cdc42 GTPase. Probe Reports from the Molecular Libraries Program NBK5196. PMID:21433396. Hong et al (2013) Characterization of a Cdc42 GTPase Inhibitor and its Use as a Molecular Probe. J.Biol.Chem. Epub. PMID:23382385.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=296841	SQ1070			Jul-2011
4270	TC-H 106	[937039-45-7]	NC1=CC=CC=C1NC(CCCCCC(NC2=CC=C(C)C=C2)=O)=O	Class I histone deacetylase inhibitor	"Class I histone deacetylase (HDAC) inhibitor (IC50 values are 150, 370, 760 and 5000 nM for HDAC1, HDAC3, HDAC2 and HDAC8 respectively). Exhibits slow, tight-binding inhibitory activity. Displays no activity against class II HDACs. Brain penetrant."	"Chou et al (2008) Pimelic diphenylamide 106 is a slow, tight-binding inhibitor of class I histone deacetylases. J.Biol.Chem. 283 35402. PMID:18953021. Rai et al (2008) HDAC inhibitors correct frataxin deficiency in a Friedreich ataxia mouse model. PLoS ONE 3 e1958. PMID:18463734. Xu et al (2009) Chemical probes identify a role for histone deacetylase 3 in Friedrich's ataxia gene silencing. Chem.Biol. 16 980. PMID:19778726."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=297052				Aug-2011
4273	LRRK2-IN-1	[1234480-84-2]	O=C2C3=C(C=CC=C3)N(C)C1=NC(NC4=C(OC)C=C(C(N5CCC(N6CCN(C)CC6)CC5)=O)C=C4)=NC=C1N2C	Potent and selective LRRK2 inhibitor	Potent and selective inhibitor of leucine-rich repeat kinase 2 (LRRK2). Inhibits both G2019S mutant and wild-type LRRK2 kinase activity (IC50 values are 6 and 13 nM respectively).	Deng et al (2011) Characterization of a selective inhibitor of the Parkinson's disease kinase LRRK2. Nat.Chem.Biol. 7 203. PMID:21378983.	Small Molecule	Sold under license from the Dana-Farber Cancer Institute.	http://www.tocris.com/dispprod.php?ItemId=298334	SQ1533			Jun-2012
4274	AP 24534	[943319-70-8]	CC1=CC=C(C(NC4=CC=C(CN5CCN(C)CC5)C(C(F)(F)F)=C4)=O)C=C1C#CC2=CN=C3N2N=CC=C3	Potent multi-kinase and pan-BCR-ABL inhibitor	"Potent multi-kinase and pan-BCR-ABL inhibitor. Displays potent activity against cell lines expressing native BCR-ABL or BCR-ABLT3151 (IC50 values are 0.37 and 2.0 nM respectively); also inhibits other ABL kinase domain mutants at nanomolar potencies. Exhibits inhibitory activity against PDGFR_, c-Src and c-Kit (IC50 values are 1.1, 5.4 and 12.5 nM respectively); potently inhibits FGFR and VEGFR family kinases. Orally active."	"O'Hare et al (2009) AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell 16 401. PMID:19878872. Huang et al (2010) Discovery of 3-[2-(imidazo[1,2-b]pyridazin-3-yl)ethynyl]-4-methyl-N-{4-[(4-methylpiperazin-1-yl)-methyl]-3-(trifluoromethyl)phenyl}benzamide (AP24534), a potent, orally active pan-inhibitor of breakpoint cluster region-Abelson (BCR-ABL) kinase including the T3151 mutant. J.Med.Chem. 53 4701. PMID:20513156. Gozgit et al (2011) Potent activity of ponatinib (AP24534) in models of FLT3-driven acute myeloid leukemia and other hematologic malignancies. Mol.Cancer Ther. 10 1028. PMID:21482694."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=298351	SQ1533			Jun-2011
4276	ERB 041	[524684-52-4]	C=CC1=C2C(N=C(C3=CC=C(O)C(F)=C3)O2)=CC(O)=C1	Potent ER_ agonist	Potent ER_ agonist; displays >200-fold selectivity for ER_ over ER_ (IC50 values are 5 and 1216 nM for human ER_ and ER_; 3.1 and 620 nM for rat ER_ and ER_; and 3.7 and 750 nM for mouse ER_ and ER_ respectively).	Harris et al (2003) Evaluaton of an estrogen receptor-_ agonist in animal models of human disease. Endocrinology 144 4241. PMID:14500559. Malamas et al (2004) Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-_ ligands. J.Med.Chem. 47 5021. PMID:15456246. Cvoro et al (2008) Selective estrogen receptor-_ agonists repress transcription of proinflammatory genes. J.Immunol. 180 630. PMID:18097065.	Small Molecule	Sold for research purposes under agreement from Pfizer Inc.	http://www.tocris.com/dispprod.php?ItemId=298648	SQ1070			Jun-2011
4277	PF 477736	[952021-60-2]	O=C([C@H](N)C4CCCCC4)NC1=CC3=C(C(C=NNC3=O)=C(C5=CN(C)N=C5)N2)C2=C1	Selective Chk1 inhibitor	Selective checkpoint kinase 1 (Chk1) inhibitor (Ki values are 0.49 and 47 nM for Chk1 and Chk2 respectively). Abrogates cell cycle arrest at S and G2-M checkpoints; sensitizes cells to DNA damage. Enhances docetaxel (Cat. No. 4056) efficacy in tumor cells and xenografts.	"Ashwell and Zabludoff (2008) DNA damage detection and repair pathways - recent advances with inhibitors of checkpoint kinases in cancer therapy. Clin.Cancer Res. 14 4032. PMID:18593978. Blasina et al (2008) Breaching the DNA damage checkpoint via PF-00477736, a novel small-molecule inhibitor of checkpoint kinase 1. Mol.Cancer Ther. 7 2394. PMID:18723486. Zhang et al (2009) PF-00477736 mediates checkpoint kinase 1 signaling pathways and potentiates docetaxel-induced efficacy in xenografts. Clin.Cancer Res. 15 4630. PMID:19584159."	Small Molecule	Sold for research purposes under agreement from Pfizer Inc.	http://www.tocris.com/dispprod.php?ItemId=298651	SQ1533			Jun-2011
4278	PF 431396	[717906-29-1]	O=C2NC1=CC=C(NC3=NC=C(C(F)(F)F)C(NCC4=CC=CC=C4N(C)S(=O)(C)=O)=N3)C=C1C2	Dual FAK/PYK2 inhibitor	"Dual focal adhesion kinase (FAK) and proline-rich tyrosine kinase 2 (PYK2) inhibitor (IC50 values are 2 and 11 nM respectively). Promotes osteoblast recruitment and activity, and stimulates bone formation in ovariectomized rats."	"Buckbinder et al (2007) Proline-rich tyrosine kinase 2 regulates osteoprogenitor cells and bone formation, and offers an anabolic treatment approach for osteoporosis. Proc.Natl.Acad.Sci.USA 104 10619. PMID:17537919. Han et al (2009) Structural characterization of proline-rich tyrosine kinase 2 (PYK2) reveals a unique (DFG-out) conformation and enables inhibitor design. J.Biol.Chem. 284 13193. PMID:19244237. Allen et al (2010) Emerging targets in osteoporosis disease modification. J.Med.Chem. 53 4332. PMID:20218623."	Small Molecule	Sold for research purposes under agreement from Pfizer Inc.	http://www.tocris.com/dispprod.php?ItemId=298656	SQ1070			Sep-2011
4279	PF 3644022	[1276121-88-0]	O=C(N[C@H](C)CN4)C3=C4C1=C(S3)C=CC2=C1C=CC(C5=CC=C(C)N=C5)=N2	Potent MK2 inhibitor	"Potent, ATP-competitive inhibitor of mitogen-activated protein kinase (MAPK)-activated protein kinase-2 (MK2) (IC50 = 5.2 nM; Ki = 3 nM). Inhibits tumor necrosis factor _ (TNF_) production in U937 monocytic cells and peripheral blood mononuclear cells (PBMCs) (IC50 = 160 nM); exhibits oral efficacy in acute and chronic inflammatory models."	Mourey et al (2010) A benzothiophene inhibitor of mitogen-activated protein kinase-activated protein kinase 2 inhibits tumor necrosis factor _ production and has oral anti-inflammatory efficacy in acute and chronic models of inflammation. J.Pharmacol.Exp.Ther. 333 797. PMID:20237073.	Small Molecule	Sold for research purposes under agreement from Pfizer Inc.	http://www.tocris.com/dispprod.php?ItemId=298657	SQ1070			Apr-2012
4281	PF 4800567 hydrochloride	[1391052-28-0]	NC1=C(C(COC4=CC(Cl)=CC=C4)=NN2C3CCOCC3)C2=NC=N1.Cl	Selective casein kinase 1_ inhibitor	Selective casein kinase 1_ inhibitor; displays 22-fold greater potency towards CK1_ than CK1_ (IC50 values are 32 and 711 nM for CK1_ and CK1_ respectively). ATP competitive. Displays minimal effect on the circadian clock.	Walton et al (2009) Selective inhibition of casein kinase 1_ minimally alters circadian clock period. J.Pharmacol.Exp.Ther. 330 430. PMID:19458106. Etchegaray et al (2010) Casein kinase 1 delta (CK1_) regulates period length of the mouse suprachiasmatic circadian clock in vitro. PLoS One 5 e10303. PMID:20421981. Meng et al (2010) Entrainment of disrupted circadian behavior through inhibition of casein kinase 1 (CK1) enzymes. Proc.Natl.Acad.Sci.USA 107 15240. PMID:20696890.	Small Molecule	Sold for research purposes under agreement from Pfizer Inc.	http://www.tocris.com/dispprod.php?ItemId=298659	SQ1070			Nov-2011
4282	WYE 687 dihydrochloride	[1062161-90-3]	O=C(OC)NC(C=C4)=CC=C4C1=NC(N3CCOCC3)=C2C(N(C5CCN(CC6=CN=CC=C6)CC5)N=C2)=N1.Cl.Cl	Potent and selective mTOR inhibitor	"Potent, ATP-competitive inhibitor of mammalian target of rapamycin (mTOR) (IC50 = 7 nM). Displays selectivity for mTOR over PI 3-K_ (~100-fold) and PI 3-K_ (~500-fold). Inhibits phosphorylation of mTORC1 and mTORC2 substrates including S6K, SGK and Akt; blocks VEGF secretion and HIF-1_ expression. Exhibits antiproliferative effects in cancer cell lines through G1 cell cycle arrest and selective apoptosis."	"Yu et al (2009) Biochemical, cellular, and in vivo activity of novel ATP-competitive and selective inhibitors of the mammalian target of rapamycin. Cancer.Res. 69 (15) 6232. PMID:19584280."	Small Molecule	Sold for research purposes under agreement from Pfizer Inc.	http://www.tocris.com/dispprod.php?ItemId=298660	SQ1533			Dec-2012
4283	Begacestat	[769169-27-9]	ClC1=CC=C(S(N[C@H](CO)C(C(F)(F)F)C(F)(F)F)(=O)=O)S1	_-secretase inhibitor; lowers A_40 and A_42 levels	_-secretase inhibitor; selectively inhibits cleavage of amyloid precursor protein (APP) over Notch. Lowers levels of A_42 and A_40 (EC50 values are 12.4 and 14.8 nM respectively in cells expressing human recombinant APP). Orally active.	"Mayer et al (2008) Discovery of begacestat, a Notch-1-sparing gamma secretase inhibitor for the treatment of Alzheimer's disease. J.Med.Chem. 51 7348. PMID:19012391. Martone et al (2009) Begacestat (GSI-953): a novel, selective thiophene sulfonamide inhibitor of amyloid precursor protein _-secretase for the treatment of Alzheimer's disease. J.Pharmacol.Exp.Ther. 331 598. PMID:19671883."	Small Molecule	Sold for research purposes under agreement from Pfizer Inc.	http://www.tocris.com/dispprod.php?ItemId=298661	SQ1070			Jun-2011
4285	HBX 41108	[924296-39-9]	O=C2C1=CC(Cl)=CC=C1C3=C2N=C(C#N)C(C#N)=N3	Selective USP7 inhibitor	Inhibitor of ubiquitin-specific protease (USP) 7 activity (IC50 = 424 nM). Displays uncompetitive inhibition. Also inhibits USP7-mediated p53 deubiquitination (IC50 = 0.8 _M). Stabilizes p53 and inhibits cancer cell growth; induces p53-dependent apoptosis in p53 wild type and null isogenic cancer cell lines.	"Colland et al (2009) Small-molecule inhibitor of USP7/HAUSP ubiquitin protease stabilizes and activates p53 in cells. Mol.Cancer Ther. 8 2286. PMID:19671755. Colombo et al (2010) Synthesis and biological evaluation of 9-oxo-9H-indeno[1,2-b]pyrazine-2,3-dicarbonitrile analogues as potential inhibitors of deubiquitinating enzymes. ChemMedChem 5 552. PMID:20186914."	Small Molecule	Sold for research use only under patent license from Hybrigenics S.A.	http://www.tocris.com/dispprod.php?ItemId=299551				Nov-2011
4286	UA 62784	[313367-92-9]	O=C2C1=CC=CC(C4=NC=C(C5=CC=C(OC)C=C5)O4)=C1C3=C2C=CC=C3	Inhibits microtubule polymerization	Inhibitor of microtubule polymerization in vitro. Interacts with tubulin dimers and promotes the accumulation of mammalian cells in apoptosis. Potentiates antiproliferative effects of vinblastine (Cat. No. 1256) in H2B-GFP HeLa cells. Originally thought to inhibit CENP-E ATPase activity.	"Tcherniuk et al (2011) UA62784 is a cytotoxic inhibitor of microtubules, not CENP-E. Chem.Biol. 18 631. PMID:21609844. Maiato and Logarinho et al (2011) Motor-dependent and -independent roles of CENP-E at kinetochores: the cautionary tale of UA62784. Chem.Biol. 18 679. PMID:21700202."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=299577	SQ1341			Apr-2012
4288	ISO 1	[478336-92-4]	OC(C=C2)=CC=C2C1=NOC(CC(OC)=O)C1	Macrophage migration inhibitory factor (MIF) inhibitor	Macrophage migration inhibitory factor (MIF) inhibitor (IC50 = 7 _M); inhibits MIF tautomerase activity in vitro and in vivo. Protective against mouse models of streptozotocin-induced diabetes mellitus; blocks anti-inflammatory response following LPS exposure and increases survival. Inhibits airway remodeling in a mouse model of chronic asthma. Cell permeable; orally bioavailable.	"Lubetsky et al (2002) The tautomerase active site of macrophage migration inhibitory factor is a potential target for discovery of novel anti-inflammatory agents. J.Biol.Chem. 277 24976. PMID:11997397. Al-Abed et al (2005) ISO-1 binding to the tautomerase active site of MIF inhibits its pro-inflammatory activity and increases survival in severe sepsis. J.Biol.Chem. 280 36541. PMID:16115897. Cvetkovic et al (2005) Critical role of macrophage migration inhibitory factor activity in experimental autoimmune diabetes. Endocrinology 146 2942. PMID:15790730. Chen et al (2010) ISO-1, a macrophage migration inhibitory factor antagonist, inhibits airway remodeling in a murine model of chronic asthma. Mol.Med. 16 400. PMID:20485865."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=300590	SQ1341			Feb-2014
4289	RP 001 hydrochloride	[1306761-53-4]	CC(C)OC1=C(C#N)C=C(C2=NC(C3=C(CCC4NCCC(O)=O)C4=CC=C3)=NO2)C=C1.Cl	Potent S1P1 agonist	Potent agonist of S1P1 receptors (EC50 = 9 pM). Induces internalization and polyubiquitination of S1P1 in vitro. Selective for S1P1 over S1P2 - S1P4.	Cahalan et al (2011) Actions of a picomolar short-acting S1P1 agonist in S1P1-eGFP knock-in mice. Nat.Chem.Biol. 7 254. PMID:21445057.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=300591	SQ1070			Nov-2011
4291	CCT 137690	[1095382-05-0]	CN(CC4)CCN4C(C=C3)=CC=C3C2=NC1=C(N5CCN(CC6=NOC(C)=C6)CC5)C(Br)=CN=C1N2	Potent pan-Aurora kinase inhibitor	"Potent inhibitor of Aurora kinases (IC50 values are 0.015, 0.019 and 0.025 _M at Aurora A, Aurora C and Aurora B respectively). Displays antiproliferative activity in a range of human tumor cell lines. Orally bioavailable."	"Bavetsias et al (2010) Imidazo[4,5-b]pyridine derivatives as inhibitors of Aurora kinases: lead optimization studies toward the identification of an orally bioavailable preclinical development candidate. J.Med.Chem. 53 5213. PMID:20565112. Faisal et al (2011) The Aurora kinase inhibitor CCT137690 downregulates MYCN and sensitizes MYCN-amplified neuroblastoma in vivo. Mol.Cancer Ther. 10 2115. PMID:21885865."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=300649	SQ1533			Nov-2011
4292	SBE 13 hydrochloride	[1052532-15-6]	ClC(N=C3)=CC=C3COC1=C(OC)C=C(CNCCC2=CC(OC)=C(OC)C=C2)C=C1.Cl	Potent and selective PLK1 inhibitor	"Selective inhibitor of PLK1 (IC50 values are 200 pM, 875 nM and 66 _M for PLK1, PLK3 and PLK2 respectively). Targets the inactive conformation of PLK1. Exhibits no effect on Aurora kinase A activity. Binds and stabilizes the inactive form of PLK1. Delays cell cycle progression, reduces cell proliferation and induces apoptosis in a range of human cancer cell lines."	Eckerdt (2010) Freezing Polo in its sleep: targeting the inactive conformation of Polo-like kinase 1 in cancer cells. Cell Cycle 9 (5) 862. PMID:20348843. Keppner et al (2010) Biological impact of freezing Plk1 in its inactive conformation in cancer cells. Cell Cycle 9 761. PMID:20139717. Liu (2010) SBE13 joins the family of Polo-like kinase 1 (Plk1) inhibitors. Cell Cycle 9 445. PMID:20130451.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=300682				Oct-2011
4293	CID 2745687	[264233-05-8]	FC1=CC(F)=CC=C1N2C(/C=N/NC(NC(C)(C)C)=S)=C(C(OC)=O)C=N2	GPR35 antagonist	"Competitive, reversible antagonist of the orphan receptor GPR35 (Ki = 12.8 nM). Blocks the GPR35-mediated increase in ERK1/2 phosphorylation and _-arrestin recruitment induced by pamoic acid (Cat. No. 4298)."	Zhao et al (2010) Targeting of the orphan receptor GPR35 by pamoic acid: a potent activator of extracellular signal-regulated kinase and _-arrestin2 with antinociceptive activity. Mol.Pharmacol. 78 560. PMID:20826425. Jenkins et al (2012) Antagonists of GPR35 display high species ortholog selectivity and varying modes of action. J.Pharmacol.Exp.Ther. 343 683. PMID:22967846.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=300684				Jul-2011
4294	LB 42708	[226929-39-1]	O=C(N4CCOCC4)C1=CN(CC5=CN=CN5CC6=CC=C(Br)C=C6)C=C1C2=CC=CC3=C2C=CC=C3	Selective farnesyltransferase (FTase) inhibitor	"Selective inhibitor of farnesyltransferase (FTase). Blocks farnesylation of H-Ras, N-Ras and K-Ras4B (IC50 values are 0.8, 1.2 and 2.0 nM respectively). Displays >50,000-fold selectivity for FTase over geranylgeranyltransferase (GGTase) I. Inhibits VEGF-induced Ras activation; suppresses angiogenesis in vivo and in vitro (IC50 = 75 nM). Orally active."	Na et al (2004) Inhibition of farnesyltransferase prevents collagen-induced arthritis by down-regulation of inflammatory gene expression through suppresion of p21ras-dependent NF-_B activation. J.Immunol. 173 1276. PMID:15240720. Kim et al (2010) The farnesyltransferase inhibitor LB42708 suppresses vascular endothelial growth factor-induced angiogenesis by inhibiting Ras-dependent mitogen-activated protein kinase and phosphatidylinositol 3-kinase/Akt signal pathways. Mol.Pharmacol. 78 142. PMID:20406854.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=300692	SQ1070			Jan-2012
4295	VU 0357017 hydrochloride	[1135242-13-5]	CC1=CC=CC=C1C(NCCNC2CCN(C(OCC)=O)CC2)=O.Cl	Positive allosteric modulator of M1 receptors	Positive allosteric modulator of muscarinic M1 receptors (EC50 = 198 nM). Displays no activity at M2-M5 at concentrations up to 30 _M. Potentiates NMDA receptor currents in hippocampal neurons; activity reverses cognitive decifits in a rodent model of hippocampal-dependent memory. CNS penetrant.	"Bridges et al (2010) Chemical lead optimization of a pan Gq mAChR M1, M3, M5 positive allosteric modulator (PAM) Lead. Part II. Development of potent and highly selective M1 PAM. Bioorg.Med.Chem.Lett. 20 1972. PMID:20156687. Lebois et al (2010) Discovery and characterization of novel subtype-selective allosteric agonists for the investigation of M1 receptor function in the central nervous system. ACS Chem.Neurosci. 1 104."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=300693				Aug-2011
4297	SMER 28	[307538-42-7]	C=CCNC2=NC=NC1=CC=C(Br)C=C12	Positive regulator of autophagy	"Positive regulator of autophagy in a mechanism independent from the mTOR pathway. Increases autophagosome synthesis and enhances clearance of model autophagy substrates such as mutant huntingtin and A53T _-synuclein, associated with Huntington's disease and Parkinson's disease, respectively."	Renna et al (2010) Chemical inducers of autophagy that enhance the clearance of mutant proteins in neurodegenerative diseases. J.Biol.Chem. 285 11061. PMID:20147746. Sarkar et al (2010) Small molecules enhance autophagy and reduce toxicity in Huntington's disease models. Nat.Chem.Biol. 3 331. PMID:17486044.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=300789				Nov-2011
4298	Pamoic acid disodium salt	[6640-22-8]	[Na+].[Na+].OC1=C(CC2=C3C=CC=CC3=CC(C([O-])=O)=C2O)C2=CC=CC=C2C=C1C([O-])=O	GPR35 agonist	GPR35 agonist. Induces GPR35 internalization and activates ERK1/2 (EC50 values are 22 and 65 nM respectively). Mediates recruitment of _-arrestin2 to GPR35. Also exhibits antinociceptive effects in a mouse model of visceral pain.	Zhao et al (2010) Targeting of the orphan receptor GPR35 by pamoic acid: a potent activator of extracellular signal-regulated kinase and _-arrestin2 with antinociceptive activity. Mol.Pharmacol. 78 560. PMID:20826425. Jenkins et al (2012) Antagonists of GPR35 display high species ortholog selectivity and varying modes of action. J.Pharmacol.Exp.Ther. 343 683. PMID:22967846.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=300790	SQ1533			Jul-2011
4299	iCRT 14	[677331-12-3]	CC(N(C4=CN=CC=C4)C(C)=C3)=C3/C=C(SC2=O)/C(N2C1=CC=CC=C1)=O	Inhibits _-catenin-responsive transcription (CRT)	Potent inhibitor of _-catenin-responsive transcription (CRT) (IC50 = 40.3 nM in assays of Wnt pathway activity). Thought to directly influence the interaction between _-catenin and TCF4. Induces marked G0/G1 cell cycle arrest in HCT-116 and HT29 cell lines.	Gonsalves et al (2011) An RNAi-based chemical genetic screen identifies three small-molecule inhibitors of the Wnt/wingless signaling pathway. Proc.Natl.Acad.Sci.USA 108 5954. Watanabe and Dai (2011) Winning WNT: race to Wnt signaling inhibitors. Proc.Natl.Acad.Sci.USA 108 5929.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=300793				Aug-2011
4301	TC-DAPK 6		O=C1OC(/C=C/C3=CC=CC=C3)=N\C1=C/C2=CC=CN=C2	Potent and selective inhibitor of DAPK1	"Potent and selective, ATP-competitive inhibitor of death-associated protein kinase 1 (DAPK1) (IC50 values are 69 and 225 nM for DAPK1 and DAPK3 respectively, when assayed with 10 _M ATP). Displays selectivity for DAPK1 over a range of 48 other kinases, including Abl, AMPK, Chk1, Met and Src (IC50 > 10 _M)."	Okamoto et al (2009) Identification of death-associated protein kinases inhibitors using structure-based virtual screening. J.Med.Chem. 52 7323. PMID:19877644.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=300876				Jan-2012
4302	Perindopril erbumine	[107133-36-8]	C[C@H](N[C@H]([C@@](OCC)=O)CCC)C(N1[C@H]([C@@](O)=O)C[C@@]2([H])[C@@]([H])1CCCC2)=O.NC(C)(C)C	Angiotensin-converting enzyme (ACE) inhibitor	Angiotensin-converting enzyme (ACE) inhibitor (IC50 = 1.05 nM). Brain penetrant. Suppresses the increase in hippocampal ACE activity and improves cognition in PS2APP-transgenic mice.	"Takai et al (2004) Significant target organs for hypertension and cardiac hypertrophy by angiotensin-converting enzyme inhibitors. Hypertens.Res. 27 213. PMID:15080380. Ceconi et al (2007) Angiotensin-converting enzyme (ACE) inhibitors have different selectivity for bradykinin binding sites of human somatic ACE. Eur.J.Pharmacol. 577 1. PMID:17716647. Dong et al (2011) Perindopril, a centrally active angiotensin-converting enzyme inhibitor, prevents cognitive impairment in mouse models of Alzheimer's disease. FASEB J. 25 2911. PMID:21593435."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=300879	SQ1533			Jul-2011
4303	PPQ 102	[931706-15-9]	O=C(N2C)C1=C(C3=CC=CC=C3)N4C(C(C6=CC=C(C)O6)NC5=C4C=CC=C5)=C1N(C)C2=O	"Potent, voltage-independent CFTR chloride channel inhibitor"	"Potent, voltage-independent CFTR chloride channel inhibitor (IC50 = 90 nM). Reduces the size and number of renal cysts in an embryonic kidney culture model of polycystic kidney disease. Also increases VEGF-A production from airway epithelial cells in vitro."	Tradtrantip et al (2009) Nanomolar potency pyrimido-pyrrolo-quinoxalinedione CFTR inhibitor reduces cyst size in a polycystic kidney disease model. J.Med.Chem. 52 6447. PMID:19785436. Martin et al (2013) CFTR dysfunction induces vascular endothelial growth factor synthesis in airway epithelium. Eur.Resp.J. 42 1553. PMID:23520314.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=300880				Aug-2014
4305	ICA 069673	[582323-16-8]	ClC1=NC=C(NC(C2=CC(F)=C(F)C=C2)=O)C=N1	KV7.2/KV7.3 channel opener	"Selective KV7.2/KV7.3 (KCNQ2/3) potassium channel opener (EC50 = 0.69 _M). 20-fold selective for KV7.2/KV7.3 over KV7.3/KV7.5 with no measurable activity over a panel of cardiac ion channels (IC50 >30 _M for KV11.1 (hERG), NaV1.5, L-type channels and KV7.1). Orally active in several animal models of epilepsy."	Amato et al (2011) N-pyridyl and pyrimidine benzamides as KCNQ2/Q3 potassium channel openers for the treatment of epilepsy. ACS Med.Chem.Lett. 2 481.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=301489				Oct-2011
4306	INCB 3284 dimesylate	[887401-93-6]	O=C(NCC(N[C@@H]2CCN([C@H]3CC[C@](C4=CC=C(OC)N=C4)(O)CC3)C2)=O)C1=CC(C(F)(F)F)=CC=C1.CS(=O)(O)=O.CS(=O)(O)=O	Selective CCR2 antagonist	"Potent, selective hCCR2 antagonist. Exhibits potent antagonism against monocyte chemoattractant molecule binding to hCCR2 and chemotaxis activity (IC50 values are 3.7 and 4.7 nM respectively). Also displays weak hERG activity; inhibits the hERG potassium current (IC50 = 84_M). Orally bioavailable."	"Xue et al (2011) Discovery of INCB3284, a potent, selective, and orally bioavailable hCCR2 antagonist. ACS.Med.Chem.Lett. 2 450."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=301492	SQ1070			Oct-2011
4307	YC 1	[170632-47-0]	OCC4=CC=C(O4)C2=NN(CC3=CC=CC=C3)C1=CC=CC=C12	Soluble guanylyl cyclase (sGC) activator; induces G1 cell cycle arrest	"Nitric oxide-independent activator of soluble guanylyl cyclase (sGC). Significantly elevates cGMP levels and inhibits collagen-stimulated aggregation of washed rabbit platelets (IC50 = 14.6 _M); induces relaxation in denuded phenylephrine-contracted rabbit aortic rings (EC50 = 1.9 _M). Also displays antiproliferative activity in vitro and in vivo by inducing G1 cell cycle arrest in two human hepatocellular carcinoma (HCC) cell lines, and in HCC xenografts in athymic SCID mice. Exhibits low cytotoxicity in non-malignant cells."	"Ko et al (1994) YC-1, a novel activator of platelet guanylate cyclase. Blood. 84 4226. PMID:7527671. Martin et al (2001) YC-1 activation of human soluble guanylyl cyclase has both heme-dependent and heme-independent components. Proc.Natl.Sci.U.S.A. 98 12938. PMID:11687640. Wang et al (2005) YC-1 [3-(5'-hydroxymethyl-2'-furyl)-1-benzyl indazole] exhibits a novel antiproliferative effect and arrests the cell cycle in G0-G1 in human hepatocellular carcinoma cells. J.Pharmacol.Exp.Ther. 312 917. PMID:15525795. Teixeira et al (2006) Molecular mechanisms underlying rat mesenteric artery vasorelaxation induced by the nitric oxide-independent soluble guanylyl cyclase stimulators BAY 41-2272 [5-cyclopropyl-2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-4-ylamine] and YC-1 [3-(5'-hydroxymethyl-2'furyl)-1-benzyl indazole]. J.Pharmacol.Exp.Ther. 317 258. PMID:16352702."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=302097	SQ1533			Mar-2012
4308	Rasagiline mesylate	[161735-79-1]	C#CCN[C@@H]2CCC1=CC=CC=C12.CS(=O)(O)=O	"Selective, irreversible MAO-B inhibitor"	Selective irreversible MAO-B inhibitor. Displays antiParkinsonian activity; exhibits neuroprotective and antiapoptotic activity against several neurotoxins in cell culture.	"Finberg and Youdim (2002) Pharmacological properties of the anti-Parkinson drug rasagiline; modification of endogenous brain amines, reserpine reversal, serotonergic and dopaminergic behaviours. Neuropharmacology 43 1110. PMID:12504917. Maruyama et al (2002) The anti-parkinson drug, rasagiline, prevents apoptotic DNA damage induced by peroxynitrite in human dopaminergic neuroblastoma SH-SY5Y cells. J.Neural Transm. 109 467. PMID:11956966. Youdim and Weinstock (2002) Molecular basis of neuroprotective activities of rasagiline and the anti-Alzheimer drug TV3326 [(N-propargyl-(3R)aminoindan-5-YL)-ethyl methyl carbamate]. Cell.Mol.Neurobiol. 21 555."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=302224	SQ1533			Aug-2011
4309	TPEN	[16858-02-9]	N(CC3=CC=CC=N3)(CC4=CC=CC=N4)CCN(CC2=CC=CC=N2)CC1=CC=CC=N1	Cell-permeable Zn2+ chelator	"Heavy metal chelator. Reacts with both Zn-proteome and Zn-metallothionein (MT) in LLC-PK1 cells; acts as an intracellular chelator of proteomic Zn2+. Activity decreases intracellular zinc levels, and induces apoptosis in HeLa and cultured human retinal pigment epithelium (RPE) cells. Cell permeable."	"Chimienti et al (2001) Role of cellular zinc in programmed cell death: temporal relationship between zinc depletion, activation of caspases, and cleavage of Sp family transcription factors. Biochem.Pharmacol. 62 51. PMID:11377396. Hyun et al (2001) Depletion of intracellular zinc and copper with TPEN results in apoptosis of cultured human retinal pigment epithelial cells. Invest.Opthalmol.Vis.Sci. 42 460. Rana et al (2008) Zinc binding ligands and cellular zinc trafficking: apo-metallothionein, glutathione, TPEN, proteomic zinc, and Zn-Sp1. J.Inorg.Biochem. 102 489. PMID:18171589. Matias et al (2010) Validation of TPEN as a zinc chelator in fluorescence probing of calcium in cells with the indicator Fura-2. J.Fluoresc. 20 377. PMID:19821015."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=302225	SQ1070			Aug-2011
4310	ML 7 hydrochloride	[110448-33-4]	IC1=C(C=CC=C2S(N3CCCNCC3)(=O)=O)C2=CC=C1.Cl	Selective inhibitor of myosin light chain kinase	"Selective inhibitor of myosin light chain kinase (MLCK) (Ki = 0.3 _M). Exhibits more potent inhibition than the parent compound ML 9 hydrochloride (Cat. No. 0431) Displays reversible, ATP-competitive inhibition of Ca2+-calmodulin-dependent and -independent smooth muscle MLCKs."	Saitoh et al (1987) Selective inhibition of catalytic activity of smooth muscle myosin light chain kinase. J.Biol.Chem. 262 7796. PMID:3108259.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=302226	SQ1070			Oct-2011
4311	GW 542573X	[660846-41-3]	O=C(OC(C)(C)C)N1CCC(COC(NC2=CC=CC=C2OC)=O)CC1	Selective activator of KCa2.1 channels	Activator of small-conductance Ca2+-activated K+ channels (KCa2); selective for KCa2.1 (EC50 = 8.2 _M in HEK293 cells expressing hKCa2.1) with the profile hKCa2.1 > hKCa2.2 = hKCa2.3 > hKCa3.1 (IK).	Hougaard et al (2009) Selective activation of the SK1 subtype of human small-conductance Ca2+-activated K+ channels by 4-(2-methyoxy-phenylcarbamoyloxymethyl)-piperidine-1-carboxylic acid tert-butyl ester (GW542573X) is dependent on serine 298 in the S5 segment. Mol.Pharmacol. 76 569. PMID:19515965.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=302304	SQ1070			Nov-2011
4314	SB 268262	[217438-17-0]	O=S(C2=NC=CS2)C1=CC=C(C(N(C)C3=CC=CC=C3C)=O)C=C1[N+]([O-])=O	Selective non-peptide CGRP1 antagonist	Selective non-peptide CGRP1 antagonist. Inhibits [125I]CGRP binding and CGRP-activated adenylyl cyclase stimulation in SK-N-MC cell membranes (IC50 values are 0.24 and 0.83 nM respectively).	"Aiyar et al (2001) Pharmacology of SB-273779, a nonpeptide calcitonin gene-related peptide 1 receptor antagonist. J.Pharmacol.Exp.Ther. 296 768. PMID:11181905."	Small Molecule	Sold with the permission of GlaxoSmithKline.	http://www.tocris.com/dispprod.php?ItemId=302611	SQ1070			Nov-2011
4315	NGD 98-2 hydrochloride		CC1=NC(NC(CC)CC)=C(OC)N=C1C2=CC=C(OC(F)(F)F)C=C2OC.Cl	High affinity CRF1 antagonist	High affinity antagonist of corticotropin-releasing factor receptor 1 (CRF1) (Ki = 1 nM). Orally available and brain penetrant.	Hodgetts et al (2011) Discovery of N-(1-ethylpropyl)-[3-methoxy-5-(2-methoxy-4-trifluoromethoxyphenyl)-6-methyl-pyrazin-2-yl]amine 59 (NGD 98-2): an orally active corticotropin releasing factor-1 (CRF-1) receptor antagonist. J.Med.Chem. 54 4187. PMID:21618986.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=302692	SQ1341			Dec-2013
4316	Bropirimine	[56741-95-8]	O=C1N=C(N)NC(C2=CC=CC=C2)=C1Br	Immunomodulatory and antitumor compound	Immunomodulatory and antitumor compound. Induces interferon (IFN)-_/_ production; augments natural killer (NK) cell activity. Orally active.	"Fujioka et al (1995) Antitumor effects of oral administration of an interferon-inducing pyrimidinone, Bropirimine, on murine renal-cell carcinoma. Cancer Chemother.Pharmacol. 36 7. PMID:7536641. Tei et al (2002) In vitro antitumor activity of bropirimine against urinary bladder tumor cells. Anticancer Res. 22 1667. PMID:12168852."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=302806	SQ1533			Aug-2011
4317	JNJ 10397049	[708275-58-5]	O=C(N[C@@H]2[C@H](C3=CC=CC=C3)OC(C)(C)OC2)NC1=C(Br)C=C(Br)C=C1	Selective OX2 receptor antagonist	Selective OX2 receptor antagonist (pIC50 = 7.4 for chimeric OX2 receptors; pKB values are 5.9 and 8.5 for OX1 and OX2 receptors respectively). Shows no significant activity in a panel of over 50 other neurotransmitters and neuropeptide receptors. Achieves high level of OX2 receptor occupancy in the rat brain; exhibits sleep-promoting effects in rats.	"Dugovic et al (2009) Blockade of orexin-1 receptors attenuates orexin-2 receptor antagonism-induced sleep promotion in the rat. J.Pharmacol.Exp.Ther. 330 142. PMID:19363060. Tran et al (2011) Chimeric, mutant orexin receptors show key interactions between orexin receptors, peptides and antagonists. Eur.J.Pharmacol. 667 120. PMID:21679703. Gozzi et al (2011) Functional magnetic resonance imaging reveals different neural substrates for the effects of orexin-1 and orexin-2 receptor antagonists. PLoS ONE 6 e16406. PMID:21307957."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=302807	SQ1341			Jan-2013
4318	BX 795	[702675-74-9]	IC1=C(NCCCNC(C4=CC=CS4)=O)N=C(NC2=CC(NC(N3CCCC3)=O)=CC=C2)N=C1	PDK1 inhibitor	"Inhibitor of 3-phosphoinositide-dependent kinase 1 (PDK1). Inhibits Akt phosphorylation at Thr308 in PC3 cells; also inhibits anchorage-independent growth of PC3 and MDA-MB-468 cells. Exhibits activity at other kinases, including TANK-binding kinase 1 (TBK1), Aurora B and I_B kinase _ (IKK_)."	Feldman et al (2005) Novel small molecule inhibitors of 3-phosphoinositide-dependent kinase-1. J.Biol.Chem. 280 19867. PMID:15772071. Tamguney et al (2008) Analysis of 3-phosphoinositide-dependent kinase-1 signaling and function in ES cells. Exp.Cell Res. 314 2299. PMID:18514190. Clark et al (2009) Use of the pharmacological inhibitor BX795 to study the regulation and physiological roles of TBK1 and I_B kinase _: a distinct upstream kinase mediates Ser-172 phosphorylation and activation. J.Biol.Chem. 284 14136. PMID:19307177.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=302871	SQ1533			Aug-2012
4319	A 784168	[824982-41-4]	O=C(NC3=CC=C(S(=O)(C(F)(F)F)=O)C=C3)C(CC2)=CCN2C1=C(C(F)(F)F)C=CC=N1	Potent and selective TRPV1 antagonist	"Potent TRPV1 antagonist (IC50 = 25 nM for inhibition of TRPV1 activation by 50 nM capsaicin). Displays no activity against a range of receptors, including TRPA1, GABA, opioid, and purinergic receptors."	"Cui et al (2006) TRPV1 receptors in the CNS play a key role in broad-spectrum analgesia of TRPV1 antagonists. J.Neurosci. 26 9385. PMID:16971522. Bianchi et al (2007) [3H]-A-778317 [1-((R-5-tert-butyl-indan-1-yl)-3-isoquinolin-5-yl-urea]: a novel, stereoselective, high-affinity antagonist is a useful radioligand for the human transient receptor potential vanilloid-1 (TRPV1) receptor. J.Pharmacol.Exp.Ther. 323 285. PMID:17660385."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=302872	SQ1070			Feb-2012
4323	VU 0360172 hydrochloride	[1309976-62-2]	FC1=CC=CC(C#CC2=CC=C(C(NC3CCC3)=O)C=N2)=C1.Cl	Positive allosteric modulator at mGlu5	"Positive allosteric modulator of mGlu5 receptors (EC50 = 16 nM; Ki = 195 nM). Selective for mGlu5; displays no significant activity at mGlu1, mGlu2 or mGlu4 receptors. Exhibits antipsychotic-like activity in a rodent model. Also reduces spontaneous spike and wave discharges without affecting motor behaviour in a rat model of absence epilepsy."	"Rodriguez et al (2010) Discovery of novel allosteric modulators of metabotropic glutamate receptor subtype 5 reveals chemical and functional diversity and in vivo activity in rat behavioral models of anxiolytic and antipsychotic activity. Mol.Pharmacol. 78 (6) 1105. PMID:20923853. D'Amore et al (2013) Potentiation of mGlu5 receptors with the novel enhancer, VU0360172, reduces spontaneous absence seizures in WAG/Rij rats. Neuropharmacology 66 330. PMID:22705340."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=303622	SQ1341			Nov-2012
4324	KC7F2	[927822-86-4]	ClC1=CC=C(Cl)C(S(NCCSSCCNS(C2=C(Cl)C=CC(Cl)=C2)(=O)=O)(=O)=O)=C1	HIF-1_ inhibitor; down-regulates HIF-1_ protein synthesis	"Inhibitor of HIF-1_. Thought to act via down-regulation of HIF-1_ protein synthesis; reduces phosphorylation of eIF4E binding protein 1 (4EBP1) and p70 S6K in hypoxic conditions. Also blocks hypoxia-induced HIF-1_ accumulation in a range of human cancer cell lines. Inhibits the expression of HIF target genes, such as carbonic anhydrase IX and MMP2."	Narita et al (2009) Identification of a novel small molecule HIF-1_ translation inhibitor. Clin.Cancer Res. 15 6128. PMID:19789328. Koh et al (2009) Inhibiting the hypoxia response for cancer therapy: the new kid on the block. Clin.Cancer Res. 15 5945. PMID:19789327.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=303623				Dec-2012
4325	Phosphocreatine disodium salt	[922-32-7]	[Na+].[Na+].CN(CC(O)=O)C(=N)NP([O-])([O-])=O	Phosphate reservoir	Phosphate reservoir; used to regenerate ATP during skeletal muscle contraction.		Small Molecule		http://www.tocris.com/dispprod.php?ItemId=303624				Aug-2011
4326	PhiKan 083	[880813-36-5]	CCN1C3=C(C=CC=C3)C2=C1C=CC(CNC)=C2.Cl	p53 stabilizing agent	p53 stabilizing agent; preferentially binds mutated (Y220C) p53 over wild-type p53 at a site distinct from functional DNA/protein interaction regions. Slows rate of thermal denaturation of p53-Y220C.	Boeckler et al (2008) Targeted rescue of a destabilized mutant of p53 by an in silico screened drug. Proc.Natl.Acad.Sci. 105 10360. PMID:18650397. Wiman (2010) Pharmacological reactivation of mutant p53: from protein structure to the cancer patient. Oncogene. 29 4245. PMID:20498645.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=303625	SQ1341			Aug-2012
4327	JW 480	[1354359-53-7]	CC(C)C1=CC=CC=C1OC(NCCC2=CC=C(C=CC=C3)C3=C2)=O	Potent and selective inhibitor of serine hydrolase KIAA1363 (AADACL1)	"Potent and selective inhibitor of the serine hydrolase enzyme KIAA1363 (AADACL1) (IC50 = 20 nM in mouse brain). Impairs migration, invasion, survival and tumor growth of prostate cancer cell lines in vivo. Reduces monoalkylglycerol ether (MAGE) levels."	Chang et al (2011) A potent and selective inhibitor of KIAA1363/AADACL1 that impairs prostate cancer pathogenesis. Chem.Biol. 18 476. PMID:21513884.	Small Molecule	Sold under license from The Scripps Research Institute.	http://www.tocris.com/dispprod.php?ItemId=304121				Oct-2011
4334	PSB 0777 ammonium salt		NC1=C3C(N([C@@H]4O[C@H](CO)[C@@H](O)[C@@H]4O)C=N3)=NC(SCCC2=CC=C(S(=O)(O)=O)C=C2)=N1.N	Potent adenosine A2A agonist	"Potent adenosine A2A receptor full agonist (Ki = 44.4 nM for rat brain striatal A2A receptors). Exhibits subtype selectivity for A2A receptors over A1, A2B and A3 receptors (Ki  10 000 nM for rat A1, human A2B and human A3 receptors). Potentiates acetylcholine-induced contractions in ex vivo rat ileum/jejunum segments."	El-Tayeb et al (2012) Development of polar adenosine A2A receptor agonists for inflammatory bowel disease: synergism with A2B antagonists. ACS Med.Chem.Lett. 2 890.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=304700	SQ1341			Nov-2013
4335	AR-M 1000390 hydrochloride	[209808-47-9]	O=C(N(CC)CC)C1=CC=C(/C(C3=CC=CC=C3)=C2\CCNCC2)C=C1.Cl	Low-internalizing _ opioid receptor agonist	"Non-peptidic, low-internalizing _-selective opioid receptor agonist; derivative of SNC 80 (Cat. No. 0764). Does not trigger acute desensitization of the analgesic response; reduces CFA-induced hyperalgesia. Brain penetrant following systemic administration."	Marie et al (2003) Pharmacological characterization of AR-M1000390 at human opioid delta receptors. Life Sci. 73 1691. PMID:12875901. Pradhan et al (2010) Ligand-directed trafficking of the _-opioid receptor in vivo: Two paths toward analgesic tolerance. J.Neurosci. 30 16459. PMID:21147985.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=304755	SQ1070			Dec-2011
4336	TG 003	[719277-26-6]	O=C(C)/C=C2SC1=CC=C(OC)C=C1N/2CC	Potent inhibitor of Clk-family kinases; also inhibits DYRK1A/B	"Potent, ATP-competitive inhibitor of Clk-family kinases (IC50 values are 15, 20 and 200 nM for mClk4, 1 and 2 respectively and >10 _M for mClk3). Also inhibits DYRK1A/B (IC50 values are 24 and 34 nM respectively). Suppresses serine/arginine-rich protein phosphorylation; affects the regulation of alternative splicing by phosphorylation of SR protein both in vitro and in vivo."	"Muraki et al (2004) Manipulation of alternative splicing by a newly developed inhibitor of Clks. J.Biol.Chem. 279 24246. PMID:15010457. Foucourt et al (2014) Design and synthesis of thiazolo[5,4-f]quinazolines as DYRK1A inhibitors, part II. Molecules 19 15411. PMID:25264830."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=304768				Nov-2011
4337	ST 1936 oxalate	[1210-81-7]	ClC1=CC=C(NC(C)=C2CCN(C)C)C2=C1.OC(C(O)=O)=O	"Selective, high affinity 5-HT6 agonist"	"High affinity, selective agonist of 5-HT6 receptors (Ki values are 13, 168, and 245 nM for human 5-HT6, 5-HT7 and 5-HT2B receptors respectively). Displays moderate affinity for human _2 adrenergic receptors (Ki = 300 nM). Shown to increase Ca2+ concentration and phosphorylation of Fyn kinase, and regulate the activation of ERK1/2 in cloned cells."	"Riccioni et al (2011) ST1936 stimulates cAMP, Ca2+, ERK1/2 and Fyn kinase through a full activation of cloned 5-HT6 receptors. Eur.J.Pharmacol. 661 8. PMID:21549693. Valentini et al (2011) A microdialysis study of ST1936, a novel 5-HT6 receptor agonist. Neuropharmacology 60 602. PMID:21185318."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=305269	SQ1341			Jul-2012
4338	NSC 33994	[82058-16-0]	CC/C(C2=CC=C(O)C(CN(CC)CC)=C2)=C(CC)\C1=CC(CN(CC)CC)=C(O)C=C1	JAK2 inhibitor	Selective inhibitor of JAK2 (IC50 = 60 nM). Displays no effect on Src and TYK2 tyrosine kinase activity at a concentration of 25 _M.	Kiss et al (2009) Identification of a novel inhibitor of JAK2 tyrosine kinase by structure-based virtual screening. Bioorg.Med.Chem.Lett. 19 3598. PMID:19447617.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=305276				Sep-2011
4341	A 582941	[848591-90-2]	[H][C@@]12[C@@](CN(C3=CC=C(C4=CC=CC=C4)N=N3)C2)([H])CN(C)C1	Partial agonist at _7 nAChR	Selective _7 nAChR partial agonist; exhibits high affinity for both rat and human _7 receptors (Ki values are 10.8 and 16.7 nM respectively). Displays ~15-fold selectivity for _7 over 5-HT3 receptors (Ki = 150 nM for 5-HT3).	"Anderson et al (2008) [3H]A-585539 [(1S,4S)-2,2-dimethyl-5-(6-phenylpyridazin-3-yl)-5-aza-2-azoniabicyclo[2.2.1]heptane], a novel high-affinity _7 neuronal nicotinic receptor agonist: radioligand binding characterization to rat and human brain. J.Pharmacol.Exp.Ther. 324 179. PMID:17959745."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=305289	SQ1070			Nov-2011
4342	UNC 0646	[1320288-17-2]	CC(C)N(CC6)CCCN6C1=NC(NC3CCN(C5CCCCC5)CC3)=C2C(C=C(OCCCN4CCCCC4)C(OC)=C2)=N1	Potent and selective G9a/GLP inhibitor	"Potent and selective inhibitor of the homologous protein lysine methyltransferases, G9a and GLP (IC50 values are 6 nM and 15 nM for G9a and GLP, respectively). Potently blocks G9a/GLP methyltransferase activity in cells (IC50 = 10 nM in MCF7 cells); exhibits low cellular toxicity (EC50 = 4.7 _M in MCF7 cells). Selective for G9a/GLP over a range of other protein lysine methyltransferases and protein arginine methyltransferases."	Liu et al (2011) Optimization of cellular activity of G9a inhibitors 7-aminoalkoxy-quinazolines. J.Med.Chem. 54 6139. PMID:21780790.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=305310	SQ1341			Jun-2012
4343	UNC 0638	[1255517-77-1]	CC(C)N(CC5)CCC5NC1=C2C(C=C(OCCCN4CCCC4)C(OC)=C2)=NC(C3CCCCC3)=N1	Selective G9a and GLP histone lysine methyltransferase inhibitor	"Selective inhibitor of G9a and GLP histone lysine methyltransferases (IC50 values are < 15 nM and 19 nM for G9a and GLP respectively, and > 10000 nM for a range of other histone methyltransferases). Potently inhibits dimethylation of H3K9 in MCF-7 cells (IC50 = 70 nM). Cell permeable."	Vedadi et al (2011) A chemical probe selectively inhibits G9a and GLP methyltransferase activity in cells. Nat.Chem.Biol. 7 566. PMID:21743462. Liu et al (2011) Optimization of cellular activity of G9a inhibitors 7-aminoalkoxy-quinazolines. J.Med.Chem. 54 6139. PMID:21780790.	Small Molecule	"This probe is supplied in conjunction with the Structural Genomics Consortium. For further characterization details, please visit the UNC 0638 probe summary on the SGC website."	http://www.tocris.com/dispprod.php?ItemId=305312	SQ1533			Mar-2012
4344	FH 535	[108409-83-2]	ClC1=CC(S(NC2=C(C)C=C([N+]([O-])=O)C=C2)(=O)=O)=C(Cl)C=C1	Inhibitor of Wnt/_-catenin signaling	"Inhibitor of Wnt/_-catenin signaling and dual antagonist of PPAR_/_ activity. Suppresses _-catenin/Tcf-mediated transcription; inhibits _-catenin and GRIP1 recruitment to PPAR_ and _. Exhibits antiproliferative effects in transformed colon, lung and liver cancer cell lines."	Handeli and Simon (2008) A small-molecule inhibitor of Tcf/_-catenin signaling down-regulates PPAR_ and PPAR_ activities. Mol.Cancer Ther. 7 521. PMID:18347139.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=305313	SQ1070			Oct-2011
4345	TC-C 14G	[656804-72-7]	FC1=CC2=C(OC(C3=C(Cl)C=C(Cl)C=C3)(C4=CC=C(F)C=C4)O2)C=C1C(N5CCOCC5)=O	"Potent, high affinity CB1 receptor inverse agonist"	"Potent, high affinity CB1 receptor inverse agonist (EC50 = 11 nM in cAMP assay; Ki = 4 nM). Demonstrates high efficacy in a hypothermia assay (ID50 = 5 mg/kg) in vivo."	Alig et al (2008) Benzodioxoles: novel cannabinoid-1 receptor inverse agonists for the treatment of obesity. J.Med.Chem. 51 2115. PMID:18335976.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=319919	SQ1341			Mar-2013
4346	Ro 67-7476	[298690-60-5]	FC(C=C2)=CC=[C@@]2[C@@H]1CCCN1S(C3=CC=C(C)C=C3)(=O)=O	Positive allosteric modulator of mGlu1	Positive allosteric modulator of mGlu1 receptors. Potentiates glutamate-induced calcium release (EC50 = 60.1 nM at rat mGluR1a). Displays no activity at human mGlu1 receptors.	"Knoflach et al (2001) Positive allosteric modulators of metabotropic glutamate 1 receptor: characterization, mechanism of action, and binding site. Proc.Natl.Acad.Sci.USA 98 13402. PMID:11606768. Hemstapat et al (2006) A novel class of positive allosteric modulators of metabotropic glutamate receptor subtype 1 interact with a site distinct from that of negative allosteric modulators. Mol.Pharmacol. 70 616. PMID:16645124."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=319931	SQ1070			Nov-2011
4347	Ro 67-4853	[302841-89-0]	O=C(NC(OCCCC)=O)C2C3=C(C=CC=C3)OC1=CC=CC=C12	Positive allosteric modulator of group I mGlu receptors	"Positive allosteric modulator of mGlu group I receptors (pEC50 value is 7.16 for the rat mGlu1a receptor). Exhibits activity at all group I receptors, including human and rat mGlu1 and rat mGlu5. Enhances the effects of (S)-DHPG in CA3 neurons (EC50 = 95 nM)."	"Knoflach et al (2001) Positive allosteric modulators of metabotropic glutamate receptor: Characterizationn, mechanism of action, and binding site. Proc.Natl.Acad.Sci. 98 13402. PMID:11606768. Hempstapat et al (2006) A novel class of positive allosteric modulators of metabotropic glutamate receptor subtype 1 interact with a site distinct from that of negative allosteric modulators. Mol.Pharmacol. 70 616. PMID:16645124."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=319932	SQ1070			Nov-2011
4348	Ro 01-6128	[302841-86-7]	O=C(NC(OCC)=O)C(C2=CC=CC=C2)C1=CC=CC=C1	Positive allosteric modulator of mGlu1	Positive allosteric modulator of mGlu1 receptors. Potentiates glutamate-induced calcium release (EC50 = 104.2 nM at rat mGluR1a).	"Knoflach et al (2001) Positive allosteric modulators of metabotropic glutamate 1 receptor: characterization, mechanism of action, and binding site. Proc.Natl.Acad.Sci.USA 98 13402. PMID:11606768. Hemstapat et al (2006) A novel class of positive allosteric modulators of metabotropic glutamate receptor subtype 1 interact with a site distinct from that of negative allosteric modulators. Mol.Pharmacol. 70 616. PMID:16645124. Brock et al (2007) Activation of a dimeric metabotropic glutamate receptor by intersubunit rearrangement. J.Biol.Chem. 282 33000. PMID:17855348."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=319933	SQ1070			Nov-2011
4349	Olanzapine	[132539-06-1]	CC4=CC2=C(S4)NC1=CC=CC=C1N=C2N3CCN(C)CC3	5-HT2A/D2 antagonist; atypical antipsychotic	"Antagonist of 5-HT2A and dopamine D2 receptors (Ki values are 4 and 11 nM respectively). Also displays affinity for a range of other receptors including D1 and D4, 5-HT2C, _1, H1 and M1-4 receptors (Ki values range between 1.9 and 31 nM) . Atypical antipsychotic. Displays anticholinergic properties."	"Moore et al (1992) The behavioral pharmacology of olanzapine, a novel ""atypical"" antipsychotic agent. J.Pharmacol.Exp.Ther. 262 545. PMID:1354253. Bymaster et al (1996) Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology 14 87. PMID:8822531. Tollefson and Taylor (2000) Olanzapine: preclinical and clinical profiles of a novel antipsychotic agent. CNS Drug Reviews 6 303."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=319934	SQ1533			Oct-2011
4350	Axitinib	[319460-85-0]	O=C(NC)C1=C(SC2=CC=C(C(/C=C/C4=CC=CC=N4)=NN3)C3=C2)C=CC=C1	"Potent VEGFR-1, -2 and -3 inhibitor"	"Potent inhibitor of VEGFR-1, -2 and -3 (IC50 values are 0.2, 0.1 to 0.3, and 1.2 nM for VEGFR-2, VEGFR-3 and VEGFR-1 respectively). Inhibits angiogenesis and vascular permeability. Displays little activity at 'off-target' protein kinases and exhibits no significant activity in a broad protein kinase screen. Orally available."	"Hu-Lowe et al (2008) Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2 and 3. Clin.Cancer Res. 14 7272. PMID:19010843. Ma and Waxman (2008) Modulation of the antitumor activity of metronomic cyclophosphamide by the angiogenesis inhibitor axitinib. Mol.Cancer Ther. 7 79. PMID:18202011."	Small Molecule	Sold for research purposes under agreement from Pfizer Inc.	http://www.tocris.com/dispprod.php?ItemId=320029	SQ1533			Oct-2011
4351	JHW 007 hydrochloride	[202645-74-7]	[H][C@@]12CC[C@@](C[C@H](OC(C4=CC=C(F)C=C4)C3=CC=C(F)C=C3)C2)([H])N1CCCC.Cl	High affinity dopamine uptake inhibitor	Dopamine uptake inhibitor; displays high affinity for the dopamine transporter (DAT) (Ki = 25 nM compared to 1330 and 1730 for NET and SERT respectively). Suppresses the effects of cocaine administration in a dose-dependent manner.	"Kopajtic et al (2010) Dopamine transporter-dependent and -independent striatal binding of the benztropine analog JHW 007, a cocaine antagonist with low abuse liability. J.Pharmacol.Exp.Ther. 335 703. PMID:20855444. Velaquez-Sanchez et al (2010) The high affinity dopamine uptake inhibitor, JHW 007, blocks cocaine-induced reward, locomotor stimulation and sensitization. Eur.Neuropsychopharmacol. 20 501. PMID:20413276. Kristensen et al (2011) SLC6 neurotransmitter transporters: structure, function, and regulation. Pharm.Rev. 63 (3) 585."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=320051	SQ1070			Nov-2011
4352	Talsupram hydrochloride	[25487-28-9]	CC2(C)SC(C3=CC=CC=C3)(CCCNC)C1=CC=CC=C12.Cl	Selective inhibitor of noradrenalin transporters	"Selective noradrenalin re-uptake inhibitor; exhibits a high affinity for the human noradrenalin transporter (NET) against SERT and DAT (IC50 values are 0.79, 850 and 9300 nM for inhibition of monoamine uptake by NET, SERT and DAT respectively). Antidepressant."	"McConathy et al (2004) Synthesis and biological evaluation of [11C]talopram and [11C]talsupram: candidate PET ligands for the norepinephrine transporter. Nucl.Med.Biol. 31 (6) 705. PMID:15246361. Rowlett et al (2004) Cocaine-like discriminative stimulus effects of heroin: modulation by selective monoamine transport inhibitors. J.Pharmacol.Exp.Ther. 310 342. PMID:14985417. Schou et al (2006) Synthesis and positron emission tomography evaluation of three norepinephrine transporter radioligands: [C-11]desipramine, [C-11]talopram and [C-11]talsupram. Mol.Imaging Biol. 8 1."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=320063	SQ1070			Dec-2011
4353	TC-G 24	[1257256-44-2]	CC(C=C3)=C(Cl)C=C3NC1=NN=C(C2=CC=C([N+]([O-])=O)C=C2)O1	Potent and selective GSK-3_ inhibitor	Potent GSK-3_ inhibitor (IC50 = 17 nM); displays selectivity for GSK-3_ over CDK2 (22% inhibition at 10 _M). Increases liver glycogen reserves in rodents. Brain penetrant.	Khanfar et al (2010) Discovery of novel GSK-3_ inhibitors with potent in vitro and in vivo activities and excellent brain permeability using combined ligand- and structure-based virtual screening. J.Med.Chem. 53 8534. PMID:21082766.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=320091	SQ1341			Jun-2012
4354	ML 130	[799264-47-4]	NC2=NC1=CC=CC=C1N2S(=O)(C3=CC=C(C)C=C3)=O	Inhibits NOD1-induced NF-_B activation	Potent and selective inhibitor of NOD1; displays 36-fold selectivity for NOD1 over NOD2 (IC50 values are 0.56 and >20 _M for NOD1 and NOD2 respectively). Inhibits NOD1-induced NF-_B activation in HEK293 cells with no cytotoxicity. Shown to alter subcellular targeting of NOD1; also thought to alter the conformation of NOD1 protein in vitro.	Correa et al (2011) Discovery and characterization of 2-aminobenzimidazole derivatives as selective NOD1 inhibitors. Chem.Biol. 18 825. PMID:21802003. Khan et al (2011) Identification of inhibitors of NOD1-induced nuclear factor-_B activation. ACS Med.Chem.Lett. 2 780. PMID:22003428.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=320092	SQ1341			May-2012
4355	TC-F 2	[1304778-15-1]	O=C(N(CC)C6=C5C=CC=C6)N5[C@H]1CCCN(C2=NC(C3=CC(C=CC=C4)=C4O3)=CC=N2)C1	"Potent, reversible and selective FAAH inhibitor"	"Potent, reversible inhibitor of fatty acid amide hydrolase (FAAH) (IC50 values are 28 and 100 nM for human and rat FAAH respectively). Noncovalent inhibitor; displays selectivity for FAAH over cannabinoid-related targets (IC50 > 20 _M for CB1, CB2 and TRPV1). Active in vivo."	"Min et al (2011) Discovery and molecular basis of potent noncovalent inhibitors of fatty acid amide hydrolase (FAAH). Proc.Natl.Acad.Sci.U.S.A. 108 7379. PMID:21502526. Gustin et al (2011) Identification of potent, noncovalent fatty acid amide hydrolase (FAAH) inhibitors. Bioorg.Med.Chem.Lett. 21 2492. PMID:21392988."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=320093	SQ1341			May-2012
4357	Bicifadine hydrochloride	[66504-75-4]	CC(C=C3)=CC=C3C12CNCC1C2.Cl	"Noradrenalin, 5-HT and dopamine re-uptake inhibitor"	"Potent antagonist of the noradrenalin transporter (IC50 = 55 nM); also displays antagonist activity at the 5-HT and dopamine transporters (IC50 values are 117 nM and 910 nM respectively). Orally active. Exhibits antinociceptive and antiallodynic activity in rodent models of acute, persistent, and chronic pain."	"Epstein (1981) 1-Aryl-3-azabicyclo[3.1.0]hexanes, a new series of nonnarcotic analgesic agents. J.Med.Chem. 24 (5) 481. PMID:7241504. Basile (2007) Characterization of the antinociceptive actions of bicifadine in models of acute, persistent, and chronic pain. J.Pharmacol.Exp.Ther 321 (3) 1208. PMID:17325229."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=320112	SQ1070			Mar-2012
4358	Dapoxetine hydrochloride	[129938-20-1]	CN([C@H]([C@]3=CC=CC=C3)CCOC1=CC=CC2=C1C=CC=C2)C.Cl	Selective serotonin reuptake inhibitor	Selective serotonin reuptake inhibitor (SSRI).	Merck Index 14 2818.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=320119	SQ1533			Sep-2011
4359	Lomeguatrib	[192441-08-0]	NC1=NC(OCC3=CC(Br)=CS3)=C2C(N=CN2)=N1	MGMT inhibitor	Inhibitor of O6-methylguanine-DNA methyltransferase (MGMT); (IC50 = 0.009 _M in cell-free extracts from HeLa S3 cells); attenuates MGMT activity in vitro and in vivo. Enhances the antitumor activity of temozolomide (Cat. No. 2706) in both human melanoma and MCF-7 xenografts.	"Reinhard et al (2001) Monosaccharide-linked inhibitors of O6-methylguanine-DNA methyltransferase (MGMT): synthesis, molecular modeling, and structure-activity relationships. J.Med.Chem. 44 4050. PMID:11708909. Barvaux et al (2004) Sensitization of a human ovarian cancer cell line to temozolomide by simultaneous attenuation of the Bcl-2 antiapoptotic protein and DNA repair by O6-alkylguanine-DNA alkyltransferase. Mol.Cancer Ther. 3 1215. PMID:15486188. Clemons et al (2005) O6-(4-bromothenyl)guanine reverses temozolomide resistance in human breast tumor MCF-7 cells and xenografts. Br.J.Cancer 93 1152. PMID:16278661."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=320258	SQ1070			Sep-2011
4361	Bosutinib	[380843-75-4]	ClC1=CC(Cl)=C(OC)C=C1NC3=C(C#N)C=NC2=CC(OCCCN4CCN(C)CC4)=C(OC)C=C23	Dual Src-Abl inhibitor; antiproliferative	"Dual inhibitor of Abl and Src kinases (IC50 = 1.2 nM for Src in an enzymatic assay). Displays antiproliferative activity against chronic myelogenous leukemia (CML) cells and decreases the motility and invasion of breast cancer cell lines. Also exhibits potent antiproliferative activity in anchorage-independent, Src-transformed rat fibroblasts (IC50 = 100 nM). Displays selectivity for Src over non-Src family kinases such as growth factor receptor tyrosine kinases."	"Boschelli et al (2001) Optimization of 4-phenylamino-3-quinolinecarbonitriles as potent inhibitors of Src kinase activity. J.Med.Chem. 44 3965. PMID:11689083. Golas et al (2003) SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice. Cancer Res. 63 375. PMID:12543790. Golas et al (2005) SKI-606, a Src/Abl inhibitor with in vivo activity in colon tumor xenograft models. Cancer Res. 65 5358. PMID:15958584. Vultur et al (2008) SKI-606 (bosutinib), a novel Src kinase inhibitor, suppresses migration and invasion of human breast cancer cells. Mol.Cancer.Ther. 7 1185. PMID:18483306."	Small Molecule	Sold for research purposes under agreement from Pfizer Inc.	http://www.tocris.com/dispprod.php?ItemId=320358	SQ1533			Oct-2011
4362	PF 5081090	[1312473-63-4]	O=C1N(CC[C@]([S@@](C)(=O)=O)(C)C(NO)=O)C=CC(C2=CC=C(OC)C=C2F)=C1	Potent LpxC inhibitor	Potent antibacterial agent which disrupts lipid bilayer synthesis through inhibition of LpxC (IC50 = 1.1 nM in Pseudomonas aeruginosa); effective against a range of gram negative bacteria.	Montgomery et al (2012) Pyridone methylsulfone hydroxamate LpxC inhibitors for the treatment of serious gram-negative infections. J.Med.Chem. 55 (4) 1662. PMID:22257165.	Small Molecule	Sold for research purposes under agreement from Pfizer Inc.	http://www.tocris.com/dispprod.php?ItemId=320363	SQ1341			Jun-2012
4363	TC-SP 14	[1257093-40-5]	FC(C=C(CN4CC(C(O)=O)C4)C=C3)=C3C2=NC1=CC(CC5=CC=CC=C5F)=CC=C1S2	Potent S1P1 receptor agonist	Potent and selective S1P1 agonist (EC50 values are 0.042 and 3.47 _M for human S1P1 and S1P3 respectively). Attenuates immune response to antigen challenge and reduces circulating blood lymphocyte counts in a rodent model of delayed-type hypersensitivity. Orally bioavailable.	"Lanman et al (2011) Discovery of a potent, S1P3-sparing benzothiazole agonist of sphingosine-1-phosphate receptor 1 (S1P1). ACS Med.Chem.Lett. 2 102."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=320459	SQ1341			May-2012
4365	TC-MCH 7c	[864756-35-4]	O=C1C=C(OCC3=CC=C(F)C=C3)C=CN1C2=CC=C(OCCN4CCCC4)C=C2	Selective melanin-concentrating hormone receptor 1 (MCH1R) antagonist	"Potent, selective melanin-concentrating hormone receptor 1 (MCH1R) antagonist (IC50= 5.6 nM in hMCH1R-expressing CHO cells). Displays selectivity for MCH1R over MCH2R (IC50 = > 10 _M). Decreases body weight in a mouse model of diet-induced obesity. Brain penetrant; orally active."	Ito et al (2009) Melanin-concentrating hormone 1-receptor antagonist suppresses body weight gain correlated with high receptor occupancy levels in diet-induced obesity mice. Eur.J.Pharmacol. 624 77. PMID:19836369. Haga et al (2011) Discovery of novel phenylpyridone derivatives as potent and selective MCH1R antagonists. Bioorg.Med.Chem. 19 883. PMID:21190859.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=320461	SQ1341			Feb-2013
4366	SAG	[912545-86-9]	ClC2=C(C(N([C@H]4CC[C@H](NC)CC4)CC3=CC=CC(C5=CC=NC=C5)=C3)=O)SC1=CC=CC=C12	Potent Smoothened receptor agonist; activates the Hedgehog signaling pathway	Potent Smoothened (Smo) receptor agonist (Kd = 59 nM); antagonizes Cyclopamine action at the Smo receptor. Potently activates the Hedgehog signaling pathway in Shh-light 2 cells (EC50 ~ 3 nM). Induces pathway activation independently of Ptch proteins. Putatively believed to also inhibit a cellular component required for Hedgehog signaling. Enhances neuronal differentiation of iPSCs into dopaminergic neurons.	Chen et al (2002) Small molecule modulation of Smoothened activity. Proc.Natl.Acad.Sci.USA. 99 14071. PMID:12391318. Stanton et al (2009) A small molecule that binds Hedgehog and blocks its signaling in human cells. Nat.Chem.Biol. 5 154. PMID:19151731. Mak et al (2012) Small molecules greatly improve conversion of human-induced pluripotent stem cells to the neuronal lineage. Stem Cells Int. 2012 140427. PMID:22567022.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=320462				Dec-2014
4367	Psora 4	[724709-68-6]	O=C2OC1=CC3=C(C=CO3)C(OCCCCC4=CC=CC=C4)=C1C=C2	Potent KV1.3 channel blocker	"Potent KV1.3 channel blocker (EC50 = 3 nM). Preferentially binds the C-type inactivated state of the channel, similar to the activity of CP 339818 (Cat. No. 1399). Displays 17- to 70-fold selectivity over closely-related KV1 channels (KV1, KV2, KV4 and KV7); exhibits activity at KV1.5 (IC50 = 7.7 nM). Suppresses proliferation of human and rat myelin-specific effector memory T cells (EC50 values are 25 and 60 nM respectively)."	"Vennekamp et al (2004) Kv1.3-blocking 5-phenylalkoxypsoralens: a new class of immunomodulators. Mol.Pharmacol. 65 1364. PMID:15155830. Schmitz et al (2005) Design of PAP-1, a selective small molecule Kv1.3 blocker, for the suppression of effector memory T cells in autoimmune diseases. Mol.Pharmacol. 68 1254. PMID:16099841. Li et al (2006) Voltage-gated potassium channel Kv1.3 regulates GLUT4 trafficking to the plasma membrane via a Ca2+-dependent mechanism. Am.J.Physiol.Cell Physiol. 290 C345. PMID:16403947."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=321452	SQ1341			May-2012
4368	Crizotinib	[877399-52-5]	ClC1=[C@@]([C@H](OC2=C(N)N=CC(C3=CN(C4CCNCC4)N=C3)=C2)C)C(Cl)=CC=C1F	Potent c-MET/ALK inhibitor	"Potent inhibitor of c-MET and anaplastic lymphoma kinase (ALK) (cell IC50 values are 8.0 and 20 nM respectively). Selective for c-MET and ALK against >120 different kinases. Displays antitumor efficacy in multiple tumor models; inhibits c-MET-dependent proliferation, migration and invasion of human tumor cells in vitro. Orally bioavailable."	"Christensen et al (2007) Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma. Mol.Cancer Ther. 6 3314. PMID:18089725. Zou et al (2007) An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms. Cancer Res. 67 4408. PMID:17483355. Cui et al (2011) Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK). J.Med.Chem. 54 6342. PMID:21812414."	Small Molecule	Sold for research purposes under agreement from Pfizer Inc.	http://www.tocris.com/dispprod.php?ItemId=321506				Oct-2011
4370	TC-N 22A	[1314140-00-5]	C2(SC(NC4=NC=CC=C4)=N3)=C3C1=CNN=C1CCC2	"Potent, selective mGlu4 positive allosteric modulator"	"Potent and selective mGlu4 receptor positive allosteric modulator (EC50 = 9 nM in human mGlu4-expressing BHK cells). Selective for mGlu4 over mGlu1, mGlu2, mGlu3, mGlu5 and mGlu7 receptors (EC50 values are > 10 _M). Brain penetrant."	Hong et al (2011) Tricyclic thiazolopyrazole derivatives as metabotropic glutamate receptor 4 positive allosteric modulators. J.Med.Chem. 54 5070. PMID:21688779.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=321614	SQ1070			Mar-2012
4371	VU 0364439	[1246086-78-1]	O=C(NC2=CC(Cl)=C(S(NC3=C(Cl)C=CC=C3)(=O)=O)C=C2)C1=NC=CC=C1	Positive allosteric modulator at mGlu4	Positive allosteric modulator (PAM) of mGlu4 receptors (EC50 = 19.8 nM in vitro for human mGlu4).	"Engers et al (2010) Synthesis and SAR of novel, 4-(phenylsulfamoyl)phenylacetamide mGlu4 positive allosteric modulators (PAMs) identified by functional high-throughput screening (HTS). Bioorg.Med.Chem.Lett. 20 5175. PMID:20667732. Robichaud et al (2011) Recent progress on the identification of metabotropic glutamate 4 receptor ligands and their potential utility as CNS therapeutics. ACS Chem.Neurosci. 2 433."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=321615				Mar-2012
4372	BC 11 hydrobromide	[443776-49-6]	NC(SCC1=CC=C(B(O)O)C=C1)=N.Br	Selective urokinase (uPA) inhibitor	Selective urokinase (uPA) inhibitor (IC50 = 8.2 _M). Exhibits no activity at 8 other related enzymes. Inhibits clot lysis with no effect on clot formation.	Smith et al (2011) Elucidating novel urokinase-type plasminogen activator inhibitors. Int.Soc.Thromb.Haemost. (Abstract) 9 819.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=321684				Oct-2011
4373	CMPDA	[380607-77-2]	O=S(NCCC1=CC=C(CCNS(=O)(C(C)C)=O)C=C1)(C(C)C)=O	Positive allosteric modulator of GluR2 receptors	"Positive allosteric modulator of GluR2 receptors (EC50 values are 45.4 and 63.4 nM at GluR2i and GluR2o respectively, in a calcium influx screening assay). Binds at the modulator binding pocket located at the interdimer interface and the clamshell hinges."	Timm et al (2011) Structural and functional analysis of two new positive allosteric modulators of GluA2 desensitization and deactivation. Mol.Pharmacol. 80 267. PMID:21543522.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=321685				Apr-2013
4374	BIMU 8	[134296-40-5]	[H][C@]12CC[C@](CC(NC(N3C(C=CC=C4)=C4N(C(C)C)C3=O)=O)C2)([H])N1C.Cl	Potent 5-HT4 receptor full agonist	Potent 5-HT4 receptor full agonist (KD = 77 nM and EC50 = 18 nM for wild type 5-HT4 receptors). Binds to receptors in a mechanism different to that of the endogenous ligand 5-HT.	Schaus et al (1998) Synthesis and structure-activity relationships of potent and orally active 5-HT4 receptor antagonists: Indazole and benzimidazoline derivatives. J.Med.Chem. 41 1943. PMID:9599243. Pellissier et al (2009) Conformational toggle switches implicated in basal constitutive and agonist-induced activated states of 5-hydroxytryptamine-4 receptors. Mol.Pharmacol. 75 982. PMID:19168624.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=321686	SQ1070			Nov-2011
4375	SMER 3	[67200-34-4]	O=C4C2=NC1=NON=C1N=C2C3=CC=CC=C34	Selective inhibitor of E3 ubiquitin ligase	Selective inhibitor of a yeast SCF family E3 ubiquitin ligase (SCFMet30) in vitro and in vivo. Induces the expression of MET genes; blocks cell proliferation. Enhancer of rapamycin (Cat. No. 1292).	Aghajanyy et al (2010) Chemical genetics of TOR identifies an SCF family E3 ubiquitin ligase inhibitor. Nat.Biotechnol. 28 738. PMID:20581845.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=321695	SQ1070			Dec-2011
4378	DLPC	[18194-25-7]	[O-]P(OC[C@H](OC(CCCCCCCCCCC)=O)COC(CCCCCCCCCCC)=O)(OCC[N+](C)(C)C)=O	Selective liver receptor homolog-1 (LRH-1) agonist	"Selective agonist of the orphan nuclear receptor LRH-1 (liver receptor homolog-1, NR5A2) in vitro. Induces bile acid biosynthetic enzymes; increases bile acid and decreases hepatic triglycerides and serum glucose. Exhibits antidiabetic effects."	Lee et al (2011) A nuclear-receptor-dependent phosphatidylcholine pathway with antidiabetic effects. Nature 474 506. PMID:21614002.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=321802	SQ1070			Oct-2011
4380	WAY 100635 maleate	[634908-75-1]	O=C(C4CCCCC4)N(C3=NC=CC=C3)CCN(CC2)CCN2C1=C(OC)C=CC=C1.O=C(\C=C/C(O)=O)O	"Potent, 5-HT1A silent antagonist. Also D4 agonist"	"Potent, silent antagonist of 5-HT1A receptors (IC50 = 2.2 nM; Ki = 0.84 nM for rat 5-HT1A receptors). Displays 100-fold selectivity for 5-HT1A over other 5-HT subtypes. Also exhibits agonist activity at dopamine D4 receptors."	"Zhuang et al (1994) Synthesis and evaluation of 4-(2'-methoxyphenyl)-1-[2'-[N-(2''-pyridinyl)-p-iodobenzamido]ethyl]piperazine (p-MPPI): a new iodinated 5-HT1A ligand. J.Med.Chem. 37 1406. PMID:8182697. Forster et al (1995) A pharmacological profile of the selective silent 5-HT1A receptor antagonist, WAY-100635. Eur.J.Pharmacol. 281 81. PMID:8566121. Mensonides-Harsema et al (2000) Synthesis and in vitro and in vivo functional studies of ortho-substituted phenylpiperazine and N-substituted 4-N-(o-methoxyphenyl)aminopiperidine analogues of WAY100635. J.Med.Chem. 43 432. PMID:10669570. Chemel et al (2006) WAY-100635 is a potent dopamine D4 receptor agonist. Psychopharmacology (Berl). 188 244. PMID:16915381."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=322125	SQ1533			Feb-2012
4381	VU 0285683	[327056-22-4]	FC1=CC(C#N)=CC(C2=NC(C3=NC=CC=C3)=NO2)=C1	Negative allosteric modulator at mGlu5	"Negative allosteric modulator of mGlu5 receptors. Displays high affinity for the MPEP (Cat. No. 1212) binding site; acts as a full antagonist and blocks the glutamate response to mGlu5 (IC50 = 24.4 nM). Selective for mGlu5 over mGlu1, mGlu3 and mGlu4. Exhibits anxiolytic activity in rodent models of anxiety. Analog available (Cat. No. 4323)."	Rodriguez (2010) Discovery of novel allosteric modulators of metabotropic glutamate receptor subtype 5 reveals chemical and functional diversity and in vivo activity in rat behavioral models of anxiolytic and antipsychotic activity. Mol.Pharmacol. 78 (6) 1105. PMID:20923853.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=323419	SQ1341			Jan-2013
4382	Letrozole	[112809-51-5]	N#CC(C=C2)=CC=C2C(N3N=CN=C3)C1=CC=C(C#N)C=C1	"Potent, reversible non-steroidal aromatase inhibitor"	"Potent, reversible non-steroidal aromatase inhibitor (IC50 = 11.5 nM). Displays antitumor effects in several animal models. Suppresses the endogenous aromatase-induced proliferation of MCF-7 cells."	"Bhatnagar et al (1990) Highly selective inhbition of estrogen biosynthesis by CGS 20267, a new non-steroidal aromatase inhibitor. J.Steroid Biochem.Mol.Biol. 37 1021. PMID:2149502. Mitropoulou et al (2003) Letrozole as a potent inhibitor of cell proliferation and expression of metalloproteinases (MMP-2 and MMP-9) by human epithelial breast cancer cells. Int.J.Cancer 104 155. PMID:12569569. Bhatnagar (2007) The discovery and mechanism of action of letrozole. Breast Cancer Res.Treat. 105 7. PMID:17912633."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=323444	SQ1533			Dec-2011
4385	Donepezil hydrochloride	[120011-70-3]	O=C2C(CC3CCN(CC4=CC=CC=C4)CC3)CC1=CC(OC)=C(OC)C=C12.Cl	Potent AChE inhibitor	Potent acetylcholinesterase inhibitor (IC50 = 5.7 nM). Displays 1252-fold selectivity for AChE over BuChE (IC50 = 7138 nM for BuChE). Orally active.	"Sugimoto et al (1995) Synthesis and structure-activity relationships of acetylcholinesterase inhibitors: 1-benzyl-4-[(5,6-dimethoxy-1-oxoindan-2-yl)methyl]piperidine hydrochloride and related compounds. J.Med.Chem. 38 4821. PMID:7490731. Kryger et al (1999) Structure of acetylcholinesterase complexed with E2020 (Aricept): implications for the design of new anti-Alzheimer drugs. Structure 7 297. PMID:10368299. Sugimoto et al (2000) Donepezil hydrochloride (E2020) and other acetylcholinesterase inhibitors. Curr.Med.Chem. 7 303. PMID:10637367."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=323650	SQ1533			Feb-2012
4386	TC-P 262	[873398-67-5]	NC1=NC(N)=NC=C1OC2=C(C(C)C)C=CC(C)=C2	"Selective P2X3, P2X2/3 antagonist"	"Selective P2X3 and P2X2/3 receptor antagonist (pIC50 values are 7.39 and 6.68 respectively). Displays no detectable activity at P2X1, P2X2, P2X4 and P2X7 receptors (pIC50 < 4.7)."	Ballini et al (2011) Characterization of three diaminopyrimidines as potent and selective antagonists of P2X3 and P2X2/3 receptors with in vivo efficacy in a pain model. Br.J.Pharmacol. 163 1315. PMID:21410458.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=323655	SQ1341			Dec-2012
4387	Calhex 231 hydrochloride	[652973-93-8]	O=C(C4=CC=C(Cl)C=C4)N[C@@H](CCCC3)[C@H]3N[C@H](C)C1=C2C(C=CC=C2)=CC=C1.Cl	Negative allosteric modulator of the calcium-sensing receptor	Negative allosteric modulator of the calcium sensing receptor (CaSR). Blocks increases in [3H]inositol phosphate levels elicited by wild-type hCasR activation (IC50= 0.39 _M in transiently transfected HEK293 cells).	"Petrel et al (2003) Modeling and mutagenesis of the binding site of Calhex 231, a novel negative allosteric modulator of the extracellular Ca2+-sensing receptor. J.Biol.Chem. 278 49487. PMID:14506236. Kessler et al (2006) N1-Benzoyl-N2-[1-(1-naphthyl)ethyl]-trans-1,2-diaminocyclohexanes: Development of 4-chlorophenylcarboxamide (Calhex 231) as a new calcium sensing receptor ligand demonstrating potent calcilytic activity. J.Med.Chem. 49 5119. PMID:16913701. Weston et al (2008) The expression and function of Ca2+-sensing receptors in rat mesenteric artery; comparative studies using a model of type II diabetes. Br.J.Pharmacol. 154 652. PMID:18414396."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=323657	SQ1533			Feb-2012
4388	MNI 137	[946619-21-2]	O=C1CC(C3=CC=NC(C#N)=C3)=NC2=C(C=C(Br)C=C2)N1	Selective negative allosteric modulator of group II mGlu receptors	"Selective negative allosteric modulator of group II mGlu receptors (IC50 values are 8.3 and 12.6 nM for human and rat mGlu2 inhibition of glutamate-induced calcium mobilization). Displays no activity at mGlu1, mGlu4, mGlu5 or mGlu8 receptors in a calcium mobilization assay."	Hemstapat et al (2007) A novel family of potent negative allosteric modulators of group II metabotropic glutamate receptors. J.Pharmacol.Exp.Ther. 322 254. PMID:17416742.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=323659	SQ1341			Feb-2013
4390	Thiamet G	[1009816-48-1]	CCNC2=N[C@]1([H])[C@@H](O)[C@H](O)[C@@H](CO)O[C@@]([H])1S2	Potent O-GlcNAcase inhibitor	"Potent, selective inhibitor of O-GlcNAcase (Ki = 21 nM for human O-GlcNAcase). Decreases the phosphorylation of tau protein in vivo. Orally bioavailable and blood brain barrier permeable."	Yuzwa et al (2008) A potent mechanism-inspired O-GlcNAcase inhibitor that blocks phosphorylation of tau in vivo. Nat.Chem.Biol. 4 483. PMID:18587388.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=323849	SQ1070			Nov-2011
4391	Ro 51	[1050670-85-3]	NC1=NC(NC(CO)CO)=NC=C1OC2=C(C(C)C)C=C(OC)C(I)=C2	"Potent P2X3, P2X2/3 antagonist"	"Potent, dual P2X3 and P2X2/3 antagonist (IC50 values are 2 and 5 nM for rP2X3 and hP2X2/3 respectively). Selective for P2X3 and P2X2/3 over other P2X receptors (IC50 values are > 10 _M for P2X1, P2X2, P2X4, P2X5, and P2X7). Cell permeable."	"Jahangir et al (2009) Identification and SAR of novel diaminopyrimidines. Part 2: The discovery of RO-51, a potent and selective, dual P2X3/P2X2/3 antagonist for the treatment of pain. Bioorg.Med.Chem.Lett. 19 1632. PMID:19231178. Syed and Kennedy (2012) Pharmacology of P2X receptors WIREs.Membr.Transp.Signal. 1 16."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=323850	SQ1533			Jun-2012
4392	680C91	[163239-22-3]	FC1=CC=C2C(NC=C2/C=C/C3=CN=CC=C3)=C1	"Potent and selective inhibitor of tryptophan 2,3-dioxygenase"	"Potent and selective inhibitor of tryptophan 2,3-dioxygenase (TDO) (Ki = 51 nM). Exhibits no activity against indoleamine 2,3-dioxygenase, monoamine oxidase A and B, 5-HT uptake or 5-HT1A, 1D, 2A and 2C receptors. Produces large increases in brain tryptophan and serotonin in vitro and in vivo in the rat."	"Salter et al (1995) The effects of a novel and selective inhibitor of tryptophan 2,3-dioxygenase on tryptophan and serotonin metabolism in the rat. Biochem.Pharmacol. 17 1435. PMID:7539265. Salter et al (1995) The effects of an inhibitor of tryptophan 2,3-dioxygenase and a combined inhibitor of tryptophan 2,3-dioxygenase and 5-HT reuptake in the rat. Neuropharmacology 34 217. PMID:7617147. Opitz et al (2011) An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor. Nature 478 197. PMID:21976023."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=324015	SQ1070			Dec-2011
4393	L-Kynurenine	[2922-83-0]	O=C(C[C@H](N)C(O)=O)C1=C(N)C=CC=C1	Tryptophan catabolite; endogenous aryl hydrocarbon receptor ligand	Tryptophan catabolite; endogenous activator of the aryl hydrocarbon receptor (AhR). Immunosuppressant; suppresses allogeneic T cell proliferation.	Opitz et al (2011) An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor. Nature 478 197. PMID:21976023.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=324024				Dec-2011
4394	VU 0360223	[1274859-33-4]	CC2=NC1=CC(C3=CC(F)=CC(C#N)=C3)=CC=C1S2	Negative allosteric modulator at mGlu5	Potent negative allosteric modulator of mGlu5 (IC50 = 61 nM). Displays no activity at mGlu1-4 and mGlu7-8.	Lindsley et al (2011) (3-cyano-5-fluorophenyl)biaryl negative allosteric modulators of mGlu5: discovery of a new tool compound with activity in the OSS mouse model of addiction. ACS Chem.Neurosci. 2 471. PMID:21927650.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=324027	SQ1070			Jan-2012
4395	Moclobemide	[71320-77-9]	O=C(NCCN2CCOCC2)C1=CC=C(Cl)C=C1	Reversible MAO-A inhibitor	Reversible monoamine oxidase A (MOA-A) inhibitor.	"Merck Index 12 6309. Burkard et al (1989) Pharmacological profile of moclobemide, a short-acting and reversible inhibitor of monoamine oxidase type A. J.Pharmacol.Exp.Ther. 248 391. PMID:2913284. Prada et al (1989) Neurochemical profile of moclobemide, a short-acting and reversible inhibitor of monoamine oxidase type A. J.Pharmacol.Exp.Ther. 248 400. PMID:2783611."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=324197	SQ1533			Nov-2011
4396	Piperlongumine	[20069-09-4]	O=C1N(C(/C=C/C2=CC(OC)=C(OC)C(OC)=C2)=O)CCC=C1	Induces apoptosis; increases p53 and ROS levels in cancer cells	"Induces cell death and increases the level of reactive oxygen species (ROS) in cancer cells with both wild-type and normal p53. Also inhibits the growth of spontaneous malignant breast tumors in mice. Displays little effect on normal cells. Rapidly depletes androgen receptor expression in human prostate cancer cells via a ROS-dependent, proteasome-mediated mechanism."	Raj et al (2011) Selective killing of cancer cells by a small molecule targeting the stress response to ROS. Nature 475 231. PMID:21753854. Golovine et al (2012) Piperlongumine induces rapid depletion of the androgen receptor in human prostate cancer cells. Prostate [Epub ahead of print]. PMID:22592999.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=324249	SQ1070			Jul-2012
4398	SC 66	[871361-88-5]	O=C(/C(CCC3)=C/C2=CC=NC=C2)/C3=C/C1=CC=NC=C1	Allosteric Akt inhibitor	Allosteric inhibitor of Akt; interferes with pleckstrin homology domain binding to PIP3 and facilitates Akt ubiquitination. Exhibits anticancer activity in vitro and in vivo.	Jo et al (2011) Deactivation of Akt by a small molecule inhibitor targeting pleckstrin homology domain and facilitating Akt ubiquitination. Proc.Natl.Acad.Sci.USA 108 6486. PMID:21464312.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=324466				Dec-2011
4399	GNF 2	[778270-11-4]	NC(C1=CC(C2=NC=NC(NC3=CC=C(OC(F)(F)F)C=C3)=C2)=CC=C1)=O	Selective allosteric inhibitor of Bcr-Abl tyrosine kinase activity	"Allosteric inhibitor of Bcr-Abl tyrosine kinase activity (IC50 = 267 nM); inhibits proliferation and induces apoptosis in Bcr-Abl-expressing cells. Selective for Bcr-Abl over a panel of serine, threonine and tyrosine kinases. Non-ATP-competitive."	Adrin et al (2006) Allosteric inhibitors of Bcr-abl-dependent cell proliferation. Nat.Chem.Biol. 2 95. PMID:16415863. Ohren & Sebolt-Leopold et al (2006) Inhibitors of Bcr-abl... breaking new ground again. Nat.Chem.Biol. 2 63. PMID:16421581. Zhang et al (2010) Targeting Bcr-Abl by combining allosteric with ATP-binding site inhibitors. Nature 463 501. PMID:20072125.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=324467	SQ1533			May-2012
4400	()-CPSI 1306	[1309793-47-2]	FC(C=C2F)=CC=C2C1=NOC(CC(N3CCOCC3)=O)C1	Reported macrophage migration inhibitory factor (MIF) inhibitor	Reported to be a macrophage inhibitory factor (MIF) inhibitor.	Kithcart et al (2010) A small-molecule inhibitor of macrophage migration inhibitory factor for the treatment of inflammatory disease. FASEB J. 24 4459. PMID:20624927. Sanchez-Zamora et al (2010) Macrophage migration inhibitory factor is a therapeutic target in treatment of non-insulin-dependent diabetes mellitus. FASEB J. 24 2583. PMID:20203087.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=324508	SQ1341			Oct-2013
4401	SMIFH2	[340316-62-3]	O=C(/C(C(N2)=O)=C/C1=CC=CO1)N(C3=CC=CC(Br)=C3)C2=S	FH2 domain inhibitor; prevents actin nucleation	Inhibitor of formin homology 2 (FH2) domains. Prevents formin-mediated actin nucleation and barbed end elongation. Disrupts formin-dependent actin cytoskeletal structures in fission yeast and mammalian NIH 3T3 fibroblasts.	Rizvi et al (2009) Identification and characterization of a small molecule inhibitor of formin-mediated actin assembly. Chem.Biol. 16 1158. PMID:19942139. Poincloux et al (2011) Contractility of the cell rear drives invasion of breast tumor cells in 3D Matrigel. Proc.Natl.Acad.Sci.USA 108 1943. PMID:21245302.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=324509				Dec-2011
4403	Pyroxamide	[382180-17-8]	O=C(CCCCCCC(NO)=O)NC1=CC=CN=C1	Histone deacetylase inhibitor	Inhibitor of histone deacetylase (HDAC); potently inhibits affinity purified HDAC1. Also inhibits the growth of tumor cells in vitro and in vivo. Induces p21/WAF1 expression in tumor cells.	"Butler et al (2001) Inhibition of transformed cell growth and induction of cellular differentiation by pyroxamide, an inhibitor of histone deacetylase. Clin.Cancer Res. 7 962. PMID:11309347. Remiszewski et al (2002) Inhibitors of human histone deacetylase: synthesis and enzyme and cellular activity of straight chain hydroxamates. J.Med.Chem. 45 755. PMID:11831887. Bradner et al (2010) Chemical phylogenetics of histone deacetylases. Nat.Chem.Biol. 6 238. PMID:20139990."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=324545	SQ1533			Jan-2012
4404	VU 0365114	[1208222-39-2]	O=C(C1=CC(OC(F)(F)F)=CC=C1N2CC3=CC=C(C4=CC=CC=C4)C=C3)C2=O	Positive allosteric modulator of M5 receptors	"Selective positive allosteric modulator of M5 (EC50 values are 2.7 _M for human M5, and >30 _M for M1, M2, M3 and M4 receptors)."	"Bridges et al (2010) Chemical lead optimization of a pan Gq mAChR M1, M3, M5 positive allosteric modulator (PAM) lead. Part I: development of the first highly selective M5 PAM. Bioorg.Med.Chem.Lett. 20 558. PMID:20004578. Bridges et al (2010) Heterobiaryl and heterobiaryl ether derived M5 positive allosteric modulators. Bioorg.Med.Chem.Lett. 20 5617. PMID:20801651."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=324773	SQ1341			Jul-2012
4405	NVP BHG 712	[940310-85-0]	CN1N=CC2=C1N=C(C4=CC=CN=C4)N=C2NC3=CC(C(NC5=CC=CC(C(F)(F)F)=C5)=O)=CC=C3C.OC(C(F)(F)F)=O	Potent EphB4 kinase inhibitor	"Selective inhibitor of EphB4 kinase; exhibits selectivity for EphB4 over more than 40 other kinases in vitro, including FGFR3. Inhibits EphB4 autophosphorylation in transiently transfected HEK 293 cells. Also inhibits VEGF-induced angiogenesis in vivo; thought to inhibit EphB4 forward signaling. Orally active."	Martiny-Baron et al (2010) The small molecule specific EphB4 kinase inhibitor NVP-BHG712 inhibits VEGF driven angiogenesis. Angiogenesis. 13 259. PMID:20803239. Wnuk et al (2012) Podocyte EphB4 signaling helps recovery from glomerular injury. Kidney Int. 81 1212. PMID:22398409.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=324774	SQ1533			Mar-2012
4406	10058-F4	[403811-55-2]	O=C(NC(S2)=S)/C2=C\C1=CC=C(CC)C=C1	Inhibits c-Myc-Max dimerization	"Cell permeable c-Myc-Max dimerization inhibitor. Inhibits proliferation, induces apoptosis and arrests cells in G0/G1 in rat1a-c-Myc cells. Also reduces tumor growth in vivo."	"Yin et al (2003) Low molecular weight inhibitors of Myc-Max interaction and function. Oncogene 22 6151. PMID:13679853. Huang et al (2006) A small-molecule c-Myc inhibitor, 10058-F4, induces cell-cycle arrest, apoptosis, and myeloid differentiation of human acute myeloid leukemia. Exp.Hematol. 34 1480. PMID:17046567. Guo et al (2009) Efficacy, pharmacokinetics, tisssue distribution, and metabolism of the Myc-Max disruptor, 10058-F4 [Z,E]-5-[4-ethylbenzylidine]-2-thioxothiazolidin-4-one, in mice. Cancer Chemother.Pharmacol. 63 615. PMID:18509642."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=324775	SQ1533			Jan-2014
4407	TC-G 1004	[1061747-72-5]	CC1=CC(C)=NN1C2=NC(C3=CC=CC(N4CCC(OC)CC4)=N3)=CC(NC(C)=O)=N2	Potent and selective A2A antagonist	Potent antagonist of adenosine A2A receptors; displays >100-fold selectivity for A2A over A1 receptors (Ki values are 0.44 and 85 nM respectively). Potentiates L-DOPA-induced rotational behavior in 6-OHDA-lesioned rats.	"Zhang et al (2008) Lead optimization of 4-acetylamino-2-(3,5-dimethylpyrazol-1-yl)-6-pyridylpyrimidines as A2A adenosine receptor antagonists for the treatment of Parkinson's disease. J.Med.Chem. 51 7099. PMID:18947224."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=324776	SQ1341			Dec-2013
4408	DMOG	[89464-63-1]	O=C(C(OC)=O)NCC(OC)=O	Prolyl hydroxylase inhibitor	Prolyl 4-hydroxylase (P4H) inhibitor; inhibits hypoxia-inducible factor _ (HIF-_) prolyl hydroxylase (HIF-PH). Increases levels of HIF-1_; promotes cell survival under hypoxic conditions.	Jaakkola et al (2001) Targeting of HIF-_ to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 292 468. PMID:11292861. Lomb et al (2009) Prolyl hydroxylase inhibitors depend on extracellular glucose and hypoxia-inducible factor (HIF)-2_ to inhibit cell death caused by nerve growth factor (NGF) deprivation: evidence that HIF-2_ has a role in NGF-promoted survival of sympathetic neurons. Mol.Pharmacol. 75 1198. PMID:19204094. Ayrapetov et al (2011) Activation of Hif1_ by the prolylhydroxylase inhibitor dimethyoxalyglycine decreases radiosensitivity. PLoS One 6 e26064. PMID:22016813. Barnucz et al (2013) Prolyl-hydroxylase inhibition preserves endothelial cell function in a rat model of vascular ischemia reperfusion injury. J.Pharmacol.Exp.Ther. 345 25. PMID: 23388095.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=324777				Nov-2011
4409	SR 1664	[1338259-05-4]	CC2=C(C)N(CC3=CC=C(C4=CC=CC=C4C(O)=O)C=C3)C1=CC=C(C(N[C@H](C5=CC=C([N+]([O-])=O)C=C5)C)=O)C=C12	High affinity PPAR_ ligand; blocks Cdk5-dependent PPAR_ phosphorylation	Antidiabetic agent; binds to PPAR_ and potently inhibits Cdk5-mediated PPAR_ phosphorylation (IC50 = 80 nM; Ki = 28.67 nM) without exhibiting PPAR_ agonist activity. Does not inhibit Cdk5-dependent phosphorylation of Rb. Reduces fasting insulin levels and improves insulin sensitivity in a mouse model of diabetes.	Choi et al (2011) Antidiabetic actions of a non-agonist PPAR_ ligand blocking Cdk5-mediated phosphorylation. Nature 477 477. PMID:21892191. Norris and Sigmund (2012) A second chance for a PPAR_ targeted therapy? Circ.Res. 110 8. PMID:22223206.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=324778	SQ1533			Dec-2012
4410	Ocinaplon	[96604-21-6]	O=C(C4=CC=CC=N4)C2=C1N=CC=C(C3=CC=NC=C3)N1N=C2	GABAA modulator; anxiolytic	"Modulator of GABAA receptors. Displays modest selectivity for GABAA _1 receptors; displays partial agonist activity at _2-, _3- and _5-containing receptors. Exhibits anxiolytic activity."	"Lippa et al (2005) Selective anxiolysis produced by ocinaplon, a GABAA receptor modulator. Proc.Natl.Acad.Sci.USA 102 7380. PMID:15870187. Rupprecht et al (2006) GABAA receptors as targets for novel anxiolytic drugs. World J.Biol.Psychiatry 7 231. PMID:17071543. Mirza et al (2006) Comparative cue generalization profiles of L-838,417, SL651498, zolpidem, CL218,872, ocinaplon, bretazenil, zopiclone, and various benzodiazepines in chlordiazepoxide and zolpidem drug discrimination. J.Pharmacol.Exp.Ther. 316 1291. PMID:16339395."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=325438	SQ1070			Feb-2012
4414	TP 003	[628690-75-5]	FC1=C(C(C)(O)C)C=CN2C1=NC=C2C3=CC=C(F)C(C4=CC=C(F)C=C4C#N)=C3	Functionally selective GABAA receptor (_3 subtype) partial agonist	Functionally selective GABAA receptor (_3 subtype) partial agonist. Exhibits affinity for the benzodiazepine binding site on human GABAA receptors. Potentiates the GABA (_3 subtype) response selectively with high efficacy. Produces anxiolytic-like effects in rodent behavioral models of anxiety.	Dias et al (2005) Evidence for a significant role of _3-containing GABAA receptors in mediating the anxiolytic effects of benzodiazepines. J.Neurosci. 25 10682. PMID:16291941. Fischer et al (2011) Contribution of GABA(A) receptors containing _3 subunits to the therapeutic-related and side effects of benzodiazepine-type drugs in monkeys. Psychopharmacology (Berl.) 215 311. PMID:21190016.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=325482	SQ1341			Nov-2012
4415	MK 0343	[233275-76-8]	FC(C=CC=C3F)=C3C1=NN=C2N1N=C(OCC5=NC=NN5C)C(C4CCC4)=C2	Subtype-selective GABAA receptor partial agonist	"Subtype-selective GABAA partial agonist (Ki values are 0.21, 0.22, 0.23 and 0.40 for _3, _1, _5 and _2 respectively); occupies the benzodiazepine site of GABAA receptors. Displays greater agonist efficacy at _3 compared to _1. Exhibits anxiolytic and non-sedating properties in rodent models. Brain penetrant."	"de Haas et al (2008) Pharmacodynamic and pharmacokinetic effects of MK-0343, a GABAA _2,3 subtype-selective agonist, compared to lorazepam and placebo in healthy male volunteers. J.Psychopharmacol. 22 24. PMID:18187530. Atack et al (2010) Benzodiazepine binding site occupancy by the novel GABAA receptor subtype-selective drug 7-(1,1-dimethylethyl)-6-(2-ethyl-2H-1,2,4-triazol-3-ylmethoxy)-3-(2-fluorophenyl)-1,2,4-triazolo[4,3-b]pyridazine (TPA023) in rats, primates, and humans. J.Pharmacol.Exp.Ther. 332 17. Atack et al (2011) MRK-409 (MK-0343), a GABAA receptor subtype-selective partial agonist, is a non-sedating anxiolytic in preclinical species but causes sedation in humans. J.Psychopharmacol. 25 314. PMID:20147571."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=325566	SQ1341			Apr-2012
4416	ADX 10059 hydrochloride	[757949-98-7]	CC1=CC(C)=NC(C#CC2=CC=CC(F)=C2)=C1N.Cl	Negative allosteric modulator at mGlu5	Reported to be a negative allosteric modulator at the mGlu5 receptor. Analog of MPEP (Cat. No. 1212).	"Keywood et al (2009) A proof-of-concept study evaluating the effect of ADX10059, a metabotropic glutamate receptor-5 negative allosteric modulator, on acid exposure and symptoms in gastro-oesophageal reflux disease. Gut. 58 1192. PMID:19460767. Marin and Goadsby (2010) Glutamatergic fine tuning with ADX-10059: a novel therapeutic approach for migraine? Expert Opin.Invest.Drugs 19 555. PMID:20218930. Weiss et al (2011) 6-Aryl-3-pyrrolidinylpyridines as mGlu5 receptor negative allosteric modulators. Bioorg.Med.Chem.Lett. 21 4891. PMID:21757343."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=325922	SQ1070			Mar-2012
4417	DBeQ	[177355-84-9]	C12=CC=CC=C1N=C(NCC4=CC=CC=C4)N=C2NCC3=CC=CC=C3	Selective and reversible p97 inhibitor	Selective and reversible inhibitor of p97 ATPase (IC50 = 1.5 _M). Induces executioner caspases (caspase-3 and caspase-7) rapidly. Blocks the degradation of endoplasmic reticulum-associated degradation (ERAD) reporters; also blocks autophagosome maturation and promotes accumulation of LC3-II.	"Chou et al (2011) Reversible inhibitor of p97, DBeQ, impairs both ubiquitin-dependent and autophagic protein clearance pathways. Proc.Natl.Acad.Sci.USA 108 4834. PMID:21383145. Chou and Deshaies (2011) Development of p97 AAA ATPase inhibitors. Autophagy 7 1091. PMID:21606684."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=325923	SQ1533			Jan-2012
4418	Saquinavir mesylate	[149845-06-7]	O=C(N[C@@H](CC(N)=O)C(N[C@@H](CC4=CC=CC=C4)[C@H](O)CN3C[C@](CCCC5)([H])[C@]5([H])C[C@H]3[C@@](NC(C)(C)C)=O)=O)C2=NC1=CC=CC=C1C=C2.CS(=O)(O)=O	HIV protease inhibitor	Inhibitor of human immunodeficiency virus (HIV) protease (Ki values are <0.1 and 0.12 nM for HIV-2 and HIV-1 protease respectively). Exhibits high antiviral activity and low cytotoxicity.	"Roberts et al (1990) Rational design of peptide-based HIV proteinase inhibitors. Science 248 358. PMID:2183354. Krausslich et al (1992) Specific inhibitor of human immunodeficiency virus proteinase prevents the cytotoxic effects of a single-chain proteinase dimer and restores particle formation. J.Virol. 66 567. PMID:1727499. Tucker et al (1992) A series of potent HIV-1 protease inhibitors containing a hydroxyethyl secondary amine transition state isostere: synthesis, enzyme inhibition, and antiviral activity. J.Med.Chem. 35 2525. PMID:1635054. Kaldor et al (1995) Isophthalic acid derivatives: amino acid surrogates for the inhibition of HIV-1 protease. Bioorg.Med.Chem.Lett. 5 721."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=325924	SQ1070			Nov-2011
4419	PF 945863	[893556-85-9]	O=C(N2C3CN([C@H](C)C4=C(C=CC=N5)C5=NC=C4)C3)O[C@](C2[C@H]1C)(C)[C@@H](CC)OC([C@H](C)C([C@H](C)[C@@H](O[C@@]6([H])[C@H](O)[C@@H](N(C)C)C[C@@H](C)O6)[C@](C)(OC)C[C@@H](C)C1=O)=O)=O	Macrolide antibiotic	Macrolide antibiotic. Active against multidrug resistant respiratory tract bacterial strains. Does not have the hepatotoxic side effects associated with telithromycin. Orally active.	Magee et al (2009) Discovery of azetidinyl ketolides for the treatment of susceptible and multidrug resistant community-acquired respiratory tract infections. J.Med.Chem. 52 7446. PMID:19775168. Zientek et al (2010) In vitro-in vivo correlation for intrinsic clearance for drugs metabolized by human aldehyde oxidase. Drug Metab.Dispos. 38 1322. PMID:20444863.	Small Molecule	Sold for research purposes under agreement from Pfizer Inc.	http://www.tocris.com/dispprod.php?ItemId=325928	SQ1341			Sep-2013
4420	Carbazeran citrate	[153473-94-0]	O=C(NCC)OC(CC3)CCN3C2=NN=CC1=CC(OC)=C(OC)C=C12.OC(CC(C(O)=O)(O)CC(O)=O)=O	Aldehyde oxidase substrate; PDE inhibitor	Aldehyde oxidase (AO) substrate. Exhibits activities as a phosphodiesterase inhibitor; produces concentration-dependent positive inotropic responses in isolated right atria.	"Shahid and Rodger et al (1989) Chronotropic and inotropic actions of amrinone, carbazeran and isobutylmethyl xanthine: role of phosphodiesterase inhibition. Br.J.Pharmacol. 98 291. PMID:2478244. Hutzler et al (2011) Characterization of aldehyde oxidase enzyme activity in cryopreserved human hepatocytes. Drug Metab.Dispos. 40 267. PMID:22031625."	Small Molecule	Sold for research purposes under agreement from Pfizer Inc.	http://www.tocris.com/dispprod.php?ItemId=325929				Sep-2013
4423	CHIR 99021	[252917-06-9]	ClC(C=C3Cl)=CC=C3C1=NC(NCCNC4=CC=C(C#N)C=N4)=NC=C1C2=NC(C)=CN2	Highly selective GSK-3 inhibitor	"Potent and highly selective inhibitor of glycogen synthase kinase 3 (GSK-3) (IC50 values are 6.7 and 10 nM for GSK-3_ and GSK-3_ respectively). Exhibits >500-fold selectivity for GSK-3 over closely related kinases; also displays >800-fold selectivity against 45 additional enzymes and receptors. In combination with tranylcypromine, enables reprogramming of mouse embryonic fibroblasts, transduced by Oct4 and Klf4 only, into iPSCs. Enhances mouse and human ESC self-renewal when used in combination with PD 0325901 (Cat. No. 4192)."	Ring et al (2003) Selective glycogen synthase kinase 3 inhibitors potentiate insulin activation of glucose transport and utilization in vitro and in vivo. Diabetes 52 588. PMID:12606497. Li et al (2009) Generation of human-induced pluripotent stem cells in the absence of exogenous Sox2. Stem Cells 27 2992. PMID:19839055. Pan et al (2011) AKT kinase activity is required for lithium to modulate mood-related behaviors in mice. Neuropsychopharmacology 36 1397. PMID:21389981. Ye et al (2012) Pleiotropy of glycogen synthase kinase-3 inhibition by CHIR99021 promotes self-renewal of embyronic stem cells from refractory mouse strains. PLoS One 7 e35892. PMID:22540008.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=326457	SQ1533			Aug-2012
4424	SR 16584	[1150153-86-8]	O=C(CC3=C2C=CC=C3)N2[C@H]1C[C@@H](N4C)CCC[C@@H]4C1	Selective _3_4 nAChR antagonist	"Selective _3_4 nAChR antagonist (IC50 = 10.2 _M). Selectively binds _3_4 over _4_2 and _7 subtypes (Ki values are 0.508, >100 and >100 _M, respectively)."	"Zaveri et al (2012) Novel _3_4 nicotinic acetylcholine receptor-selective ligands. Discovery, structure-activity studies, and pharmacological evaluation. J.Med.Chem. 53 8187. PMID:20979364."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=328271	SQ1341			Dec-2012
4426	Tanshinone IIA	[568-72-9]	O=C(C1=C(C4=C3C(C)=CO4)C=CC2=C1CCCC(C)2C)C3=O	Inhibits NF-_B and AP-1 DNA binding. Displays antioxidant properties	Major tanshinone isolated from Salvia miltiorrhiza. Inhibits NF-_B and AP-1 DNA binding. Exhibits cytotoxic activity in a number of different cancer cells. Inhibits _-amyloid aggregation and protects PC12 cells from _-amyloid-induced apoptosis. Displays antioxidant and anti-inflammatory properties.	Wang et al (2007) Growth inhibition and induction of apoptosis and differentiation of tanshinone IIA in human glioma cells. J.Neurooncol. 82 11. PMID:16955220. Jin et al (2008) Tanshinone IIA from Salvia miltiorrhiza BUNGE inhibits human aortic smooth muscle cell migration and MMP-9 activity through AKT signaling pathway. J.Cell Biochem. 104 15. PMID:17979138. Lee et al (2008) Anticancer effects of tanshinone I in human non-small cell lung cancer. Mol.Cancer Ther. 7 3527. PMID:19001436. Dong et al (2012) Tanshinone IIA protects PC12 cells from _-amyloid(25-35)-induced apoptosis via PI3K/Akt signaling pathway. Mol.Biol.Rep. 39 6495. PMID:22314911.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=328299	SQ1533			Dec-2011
4427	Febuxostat	[144060-53-7]	CC1=C(C(O)=O)SC(C2=CC(C#N)=C(OCC(C)C)C=C2)=N1	Xanthine oxidase inhibitor	Non-purine inhibitor of xanthine oxidase (Ki = 1.2 nM). Binds to a channel leading to the enzyme active site; obstructs substrate binding.	"Osada et al (1993) Hypouricemic effect of the novel xanthine oxidase inhibitor, TEI-6720, in rodents. Eur.J.Pharmacol. 241 183. PMID:8243554. Okamoto et al (2003) An extremely potent inhibitor of xanthine oxidoreductase. Crystal structure of the enzyme-inhibitor complex and mechanism of inhibition. J.Biol.Chem. 278 1848. PMID:12421831. Xu et al (2008) Xanthine oxidase inhibition with febuxostat attenuates systolic overload-induced left ventricular hypertrophy and dysfunction in mice. J.Card.Fail. 14 746. PMID:18995179."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=328328	SQ1533			Dec-2011
4429	NQDI 1	[175026-96-7]	O=C2NC1=CC=CC4=C1C(C3=CC=CC=C3C4=O)=C2C(OCC)=O	Inhibitor of apoptosis signal-regulating kinase 1 (ASK1)	"Selective inhibitor of apoptosis signal-regulating kinase 1 (ASK1, MAP3K5) (IC50 = 3 _M, Ki = 500 nM)."	"Bu et al (2001) Synthesis and cytotoxic activity of 7-oxo-7H-dibenz[f,ij]isoquinoline and 7-oxo-7H-benzo[e]perimidine derivatives. J.Med.Chem. 44 (12) 2004. PMID:11384245. Volynets et al (2011) Identification of 3H-naphtho[1,2,3-de]quinoline-2,7-diones as inhibitors of apoptosis signal-regulating kinase 1 (ASK1). J.Med.Chem. 54 (8) 2680. PMID:21449566."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=329743				Feb-2012
4430	BAY 41-2272	[256376-24-6]	FC(C=CC=C3)=C3CN2N=C(C4=NC=C(C5CC5)C(N)=N4)C1=CC=CN=C12	Soluble guanylyl cyclase (sGC) activator	Activator of soluble guanylyl cyclase (sGC); acts at a nitric oxide (NO)-independent regulatory site in the sGC _1 subunit. Inhibits platelet aggregation (IC50 = 36 nM) and phenylephrine-induced contractions of rabbit aorta (IC50 = 0.30 _M). Also reduces vascular smooth muscle growth through cAMP- and cGMP-dependent PKA and PKG pathways.	"Mittendorf et al (2009) Discovery of Riociguat (BAY 63-2521): a potent, oral stimulator of soluble guanylate cyclase for the treatment of pulmonary hypertension. ChemMedChem 4 853. PMID:19263460. Stasch et al (2010) NO-independent regulatory site on soluble guanylate cyclase. Nature 410 212. PMID:11242081. Joshi et al (2011) The soluble guanylate cyclase stimulator BAY 41-2272 inhibits vascular smooth muscle growth through the cAMP-dependent protein kinase and cGMP-dependent protein kinase pathways. J.Pharmacol.Exp.Ther. 339 394. PMID:21825001."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=330183	SQ1070			Feb-2012
4431	A 1070722	[1384424-80-9]	O=C(NC3=NC(C(F)(F)F)=CC=C3)NC2=CC=NC1=CC(OC)=CC=C12	"Highly potent, selective GSK-3 inhibitor"	"Potent glycogen synthase kinase-3 (GSK-3) inhibitor (Ki = 0.6 nM for GSK-3_ and GSK-3_). Displays high selectivity (> 50-fold) for GSK-3 over a panel of other kinases tested, including CDK family members. Decreases phosphorylation of microtubule-associated protein Tau in vitro; protects rat primary cortical neurons against _ amyloid and glutamate challenge. Brain penetrant."	"Bakker et al (2011) A-1070722, a potent, selective, and centrally active glycogen synthase kinase-3 (GSK-3) inhibitor for the treatment of psychiatric and neurodegenerative disorders. Society for Neuroscience (Abstract) 568."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=330184	SQ1341			May-2012
4432	TTP 22	[329907-28-0]	CC(C=C3)=CC=C3C1=CSC2=C1C(SCCC(O)=O)=NC=N2	"High affinity, selective CK2 inhibitor"	"High affinity, ATP-competitive casein kinase 2 (CK2) inhibitor (IC50 = 0.1 _M, Ki = 40 nM). Displays selectivity for CK2 over JNK3, ROCK1 and MET (no inhibitory effects at 10 _M)."	"Golub et al (2011) Synthesis and biological evaluation of substituted (thieno[2,3-d]pyrimidin-4-ylthio)carboxylic acids as inhibitors of human protein kinase CK2. Eur.J.Med.Chem. 46 870. PMID:21276643."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=330185				Mar-2012
4434	Wiskostatin	[253449-04-6]	BrC(C=C3)=CC1=C3N(CC(O)CN(C)C)C2=C1C=C(Br)C=C2	N-WASP inhibitor; inhibits Arp2/3 activation	Inhibitor of neural Wiskott-Aldrich syndrome protein (N-WASP) activity. Interacts with the regulatory GTPase-binding domain of N-WASP; inhibits activation of Arp2/3 complex by maintaining N-WASP in an inactive conformation. Also inhibits PIP2-induced actin polymerization (EC50 ~ 4_M).	Peterson et al (2004) Chemical inhibition of N-WASP by stabilization of a native autoinhibited conformation. Nat.Struct.Mol.Biol. 11 747. PMID:15235593. Guerriero and Weisz et al (2006) N-WASP inhibitor wiskostatin nonselectively perturbs membrane transport by decreasing cellular ATP levels. Am.J.Physiol.Cell Physiol. 292 C1562. PMID:17092993. Wegner et al (2008) N-WASP and the Arp2/3 complex are critical regulators of actin in the development of dendritic spines and synapses. J.Biol.Chem. 283 15912. PMID:18430734.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=330223	SQ1070			Jan-2012
4435	TC-N 1752	[1211866-85-1]	CC(C(NC(C)=O)=CC=C4)=C4NC1=NC=NC(N2CCC(OCC3=CC=C(OC(F)(F)F)C=C3)CC2)=N1	Selective NaV1.7 channel blocker	"Selective blocker of human NaV1.7 channels (IC50 values are 0.17, 0.3, 0.4 and 1.1 _M at hNaV1.7, hNaV1.3, hNaV1.4 and hNaV1.5 respectively). Also inhibits tetrodotoxin-sensitive sodium channels. Displays analgesic efficacy in the formalin pain model."	"Bregman et al (2011) Identification of a potent, state-dependent inhibitor of Nav1.7 with oral efficacy in the formalin model of persistent pain. J.Med.Chem. 54 4427. PMID:21634377."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=330224	SQ1341			Apr-2012
4436	8-Chloroadenosine	[34408-14-5]	O[C@@H]1[C@@H](CO)OC(N3C2=NC=NC(N)=C2N=C3Cl)[C@@H]1O	Cytotoxic nucleoside analog; inhibits RNA synthesis	"Nucleoside analog; metabolized in vivo to 8-Chloro-ATP. Incorporates into RNA during transcription and inhibits RNA synthesis. Exhibits cytotoxicity in MM.1S, RPMI-8226 and U266 cancer cell lines; induces G2/M cell cycle arrest and mitotic catastrophe in A549 and H1299 cells."	Zhang et al (2004) Exposure of human lung cancer cells to 8-chloro-adenosine induces G2/M arrest and mitotic catastrophe. Neoplasia 6 802. PMID:15720807. Gu et al (2006) 8-Chloro-adenosine inhibits growth at least partly by interfering with actin polymerization in cultured human lung cancer cells Biochem.Pharmacol. 72 541. PMID:16844099. Cervantes-Gomez et al (2011) ATP analog enhances the actions of a heat shock protein 90 inhibitor in multiple myeloma cells. J.Pharmacol.Exp.Ther. 339 545. PMID:21821695.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=330278	SQ1533			Nov-2012
4437	VU 0357121	[433967-28-3]	O=C(NC2=C(F)C=C(F)C=C2)C1=CC=C(OCCCC)C=C1	Positive allosteric modulator of mGlu5	Positive allosteric modulator of mGlu5 receptors (EC50 = 33 nM). Binds to a site distinct from that bound by MPEP (Cat. No. 1212).	Hammond et al (2010) Discovery of a novel chemical class of mGlu5 allosteric ligands with distinct modes of pharmacology. ACS Chem.Neurosci. 1 702. PMID:20981342.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=330281	SQ1533			Apr-2012
4438	MFZ 10-7	[1224431-15-5]	CC1=NC(C#CC2=CC(C#N)=CC(F)=C2)=CC=C1.Cl	Negative allosteric modulator at mGlu5	High affinity negative allosteric modulator at the mGlu5 receptor (Ki = 0.67 nM). Potently inhibits mGlu5 glutamate-mediated calcium mobilization (IC50 = 1.22 nM). Inhibits cocaine-taking and cocaine-seeking behavior in rats.	"Alagille et al (2011) Potent mGluR5 antagonists: pyridyl and thiazolyl-ethynyl-3,5-disubstituted-phenyl series. Bioorg.Med.Chem.Lett. 21 3243. PMID:21546249. Keck et al (2012) Metabotropic glutamate receptor 5 negative allosteric modulators as novel tools for in vivo investigation. ACS Med.Chem.Lett. 3 544. PMID:22924094. Keck et al (2014) A novel mGluR5 antagonist, MFZ 10-7, inhibits cocaine-taking and cocaine-seeking behavior in rats. Addict.Biol. 19 195. PMID:24001208."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=330282	SQ1341			Jul-2012
4439	ISX 9	[832115-62-5]	O=C(NC2CC2)C1=NOC(C3=CC=CS3)=C1	Neurogenic agent; induces neuronal differentiation of SVZ progenitors. Also induces cardiomyogenic differentiation	"Neurogenic agent. Mediates neuroD reporter gene induction via activation of Ca2+ influx; increases expression of neurogenic differentiation 1 (NeuroD1) transcription factor. Induces neuronal differentiation in human cortical neuronal cells (HCN), adult mouse whole brain (MWB) and subventricular zone (SVZ) progenitors. Also shown to induce cardiomyogenic differentiation of Notch-activated epicardium-derived cells in vitro."	Schneider et al (2008) Small-molecule activation of neuronal cell fate. Nat.Chem.Biol 4 408. PMID:18552832. Dioum et al (2011) A small molecule differentiation inducer increases insulin production by pancreatic _ cells. Proc.Natl.Acad.Sci.U.S.A. 108 20713. PMID:22143803. Zhang et al (2011) Small-molecule blocks malignant astrocyte proliferation and induces neuronal gene expression. Differentiation 81 233. PMID:21419563. Russell et al (2012) Targeting native adult heart progenitors with cardiogenic small molecules. ACS Chem.Biol. 7 1067. PMID:22413910.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=330409	SQ1070			Feb-2012
4440	Rivastigmine tartrate	[129101-54-8]	O[C@H]([C@@H](O)C(O)=O)C(O)=O.CCN(C)C(=O)OC1=CC=CC(=C1)[C@H](C)N(C)C	Dual AChE and BChE inhibitor	Dual cholinesterase inhibitor (ChEI); inhibits both butyrylcholinesterase (BChE) and acetylcholinesterase (AChE). Brain penetrant.	"Luo et al (2006) Inhibition of human acetyl- and butyrylcholinesterase by novel carbamates of (-)- and (+)-tetrahydrofurobenzofuran and methanobenzodioxepine. J.Med.Chem. 49 2174. PMID:16570913. Groner et al (2007) The kinetics of inhibition of human acetylcholinesterase and butyrylcholinesterase by two series of novel carbamates. Mol.Pharmacol. 71 1610. PMID:17347320. Bailey et al (2011) Rivastigmine lowers A_ and increases sAPP_ levels, which parallel elevated synaptic markers and metabolic activity in degenerating primary rat neurons. PLoS One 6 e21954. PMID:21799757. Mehta et al (2012) New acetylcholinesterase inhibitors for Alzheimer's disease. Int.J.Alzheimers Dis. Epub 2011. PMID:22216416."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=330410	SQ1533			Jan-2012
4441	SEN 12333	[874450-44-9]	O=C(CCCCN3CCOCC3)NC(C=C2)=CC=C2C1=CC=CN=C1	_7 nAChR agonist; histamine H3 antagonist	"_7 nicotinic acetylcholine receptor (nAChR) agonist (EC50 = 1.6 _M, Ki = 260 nM at rat _7 nAChRs). Also displays functional antagonism at histamine H3 receptors (IC50 = 103 nM) and weak agonist activity at human ganglionic _3 nAChRs (IC50 = 8.5 _M). Neuroprotective in a rodent model of quisqualic acid-induced cholinergic degeneration. Brain penetrant and orally bioavailable."	"Roncarati et al (2009) Procognitive and neuroprotective activity of a novel _7 nicotinic acetylcholine receptor agonist for treatment of neurodegenerative and cognitive disorders. J.Pharmacol.Exp.Ther. 329 459. PMID:19223665. Beinat et al (2012) Consequences of linker length alteration of the _7 nicotinic acetylcholine receptor (nAChR) agonist, SEN12333. Bioorg.Med.Chem.Lett. 22 2380. PMID:22410083."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=330654	SQ1341			May-2012
4444	Fatostatin A	[298197-04-3]	CCCC1=CC(C2=NC(C3=CC=C(C)C=C3)=CS2)=CC=N1.Br	Cell permeable inhibitor of SREBP activation	Inhibitor of sterol regulatory element binding protein (SREBP); impairs the activation of SREBP-1 and SREBP-2. Exhibits antiproliferative effects in DU 145 cells independently of IGF-1 signaling (IC50 = 0.1 _M); reverses hyperglycemia in diabetic (ob/ob) mice. Cell permeable.	Choi et al (2003) Identification of bioactive molecules by adipogenesis profiling of organic compounds. J.Biol.Chem. 278 7320. PMID:12496288. Kamisuki et al (2009) A small molecule that blocks fat synthesis by inhibiting the activation of SREBP. Chem.Biol. 16 882. PMID:19716478.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=330668	SQ1341			Apr-2012
4445	PFI 1	[1403764-72-6]	O=C2NC1=CC=C(NS(C3=CC=CC=C3OC)(=O)=O)C=C1CN2C	BET bromodomain inhibitor	Potent BET bromodomain inhibitor; exhibits inhibitory activity at bromodomain-containing protein (BRD) 2 and BRD4 (IC50 values are 98 and 220 nM respectively). Induces apoptosis and G1 cell cycle arrest in BET inhibitor-sensitive cell lines (MV4;11). Also downregulates Aurora B expression in MV4;11 cells. Cell permeable.	Fish et al (2012) Identification of a chemical probe for bromo and extra c-terminal bromodomain inhibition through optimization of a fragment-derived hit. J.Med.Chem. [Epub ahead of print]. PMID:23095041. Picaud et al (2013) PFI-1 - a highly selective protein interaction inhibitor targeting BET bromodomains. Cancer Res. [Epub ahead of print].	Small Molecule	"This probe is supplied in conjunction with the Structural Genomics Consortium. For further characterization details, please visit the PFI 1 probe summary on the SGC website."	http://www.tocris.com/dispprod.php?ItemId=330983	SQ1341			Aug-2012
4446	CID 5951923	[749872-43-3]	O=C(OCC(N(C)C2CS(CC2)(=O)=O)=O)/C=C/C1=CC([N+]([O-])=O)=CC=C1	Krppel-like factor 5 (KLF5) inhibitor	Inhibitor of Krppel-like factor 5 (KLF5) transcription factor (IC50 = 2.3 _M). Selectively active against colon cancer cells in a panel of 60 different cancer cell lines.	Bialkowska et al (2011) Identification of small-molecule inhibitors of the colorectal cancer oncogene Krppel-like factor 5 expression by ultrahigh-throughput screening. Mol.Cancer Ther. 10 2043. PMID:21885866.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=331163	SQ1070			Feb-2012
4448	Ceranib 1	[328076-61-5]	O=C2C(C(/C=C/C4=CC=C(OC)C=C4)=O)=C(C3=CC=CC=C3)C1=CC(C)=CC=C1N2	Ceramidase inhibitor; antiproliferative	Ceramidase inhibitor; inhibits proliferation in SKOV3 ovarian carcinoma cells (IC50 = 3.9 _M). Induces accumulation of ceramide species and decreases sphingosine and sphingosine-1-phosphate (S1P) levels in SKOV3 cells.	Draper et al (2011) Discovery and evaluation of inhibitors of human ceramidase. Mol. Cancer Ther. 10 2052. PMID:21885864.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=331165	SQ1341			Jul-2012
4451	IOX 2	[931398-72-0]	OC(C1=CC=CC=C1N2CC3=CC=CC=C3)=C(C(NCC(O)=O)=O)C2=O	"Potent, selective HIF-1_ prolyl hydroxylase-2 (PHD2) inhibitor"	"Potent inhibitor of HIF-1_ prolyl hydroxylase-2 (PHD2) (IC50 = 21 nM). Displays over 100-fold selectivity for PHD2 over factor inhibiting HIF-1 (FIH-1) and histone demethylases JMJD2A, JMJD2C, JMJD2E and JMJD3. Cell permeable."	"Murray et al (2010) Dipeptidyl-quinolone derivatives inhibit hypoxia inducible factor-1_ prolyl hydroxylases-1, -2, and -3 with altered selectivity. J.Comb.Chem. 12 676. PMID:20666436."	Small Molecule	"This probe is supplied in conjunction with the Structural Genomics Consortium. For further characterization details, please visit the IOX 2 probe summary on the SGC website."	http://www.tocris.com/dispprod.php?ItemId=331885	SQ1533			May-2012
4452	GGsTop	[926281-37-0]	NC(C(O)=O)CCP(OC1=CC=CC(CC(O)=O)=C1)(OC)=O	Inhibitor of _-glutamyl transpeptidase (GGT)	"Selective, irreversible _-glutamyl transpeptidase (GGT) inhibitor; displays no inhibitory effects on glutamine amidotransferases or asparagine synthetase. Suppresses oxidative stress by inhibiting GGT activation. Prevents ischemia/reperfusion-induced acute kidney injury in rats in vivo."	"Han et al (2007) Design, synthesis, and evaluation of _-phosphono diester analogues of glutamate as highly potent inhibitors and active site probes of _-glutamyl transpeptidase. Biochemistry 46 1432. PMID:17260973. Yamamoto et al (2011) Preventive effect of GGsTop, a novel and selective _-glutamyl transpeptidase inhibitor, on ischemia/reperfusion-induced renal injury in rats. J.Pharmacol.Exp.Ther. 339 945. PMID:21937737."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=332424	SQ1341			Jan-2014
4453	GDC 0879	[905281-76-7]	OCCN1N=C(C3=CC=NC=C3)C(C2=CC=C(/C(CC4)=N/O)C4=C2)=C1	Potent B-Raf inhibitor	Potent and selective B-Raf inhibitor (IC50 = 0.13 nM against purified B-Raf V600E). Activity reduces phospho-ERK (pERK) levels (IC50 = 63 nM in the Malme-3M cell line). Inhibits the Raf/MEK/ERK signaling pathway in V600E B-Raf mutant cell lines. Does not activate apoptotic pathways in A375 or Colo205 cell lines. Orally bioavailable.	"Wong et al (2009) Pharmacodynamics of 2-{4-[(1E)-1-(hydroxyimino)-2,3-dihydro-1H-inden-5-yl]-3-(pyridine-4-yl)-1H-pyrazol-1-yl}ethan-1-ol (GDC-0879), a potent and selective B-Raf kinase inhibitor: understanding relationships between systemic concentrations, phosphorylated mitogen-activated protein kinase kinase 1 inhibition, and efficacy. J.Pharmacol.Exp.Ther. 329 360. PMID:19147858. Hoeflich et al (2009) Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression. Cancer Res. 69 3042. PMID:19276360. Hatzivassiliou et al (2010) RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature 464 431. PMID:20130576."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=332437	SQ1533			Feb-2012
4454	Diclofenac sodium salt	[15307-79-6]	[Na+].[O-]C(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl	Cyclooxygenase inhibitor; NSAID	"Nonsteroidal, anti-inflammatory drug (NSAID); inhibits COX-1 and COX-2 (IC50 values are 0.075 _M for COX-1 and 0.038 _M for COX-2 in human whole blood assay)."	Laneuville et al (1994) Differential inhibition of human prostaglandin endoperoxide H synthases-1 and -2 by nonsteroidal anti-inflammatory drugs. J.Pharmacol.Exp.Ther. 271 927. PMID:7965814. Bort et al (1998) Diclofenac toxicity to hepatocytes: a role for drug metabolism in cell toxicity. J.Pharmacol.Exp.Ther. 288 65. PMID:9862754. Warner et al (1999) Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc.Natl.Acad.Sci.USA 96 7563. PMID:10377455.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=332562	SQ1533			Jan-2012
4455	Captopril	[62571-86-2]	O=C([C@H](C)CS)N1[C@H](C(O)=O)CCC1	ACE inhibitor; also inhibits LTA4 hydrolase	"Angiotensin-converting enzyme (ACE) inhibitor (IC50 = 0.022 _M). Also displays reversible, competitive inhibition of leukotriene A4 (LTA4) hydrolase."	Orning et al (1991) Inhibition of leukotriene A4 hydrolase/aminopeptidase by captopril. J.Biol.Chem. 266 16507. PMID:1885582. Zhang et al (1996) Effects of early captopril treatment and its removal on plasma angiotensin converting enzyme (ACE) activity and arginine vasopressin in hypertensive rats (SHR) and normotensive rats (WKY). Clin.Exp.Hypertens. 18 201. PMID:8869001. Fujita and Yoshikawa (1999) LKPNM: a prodrug-type ACE-inhibitory peptide derived from fish protein. Immunopharmacology. 44 123. PMID:10604535.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=332565	SQ1533			Feb-2012
4456	Amitriptyline hydrochloride	[549-18-8]	CN(CC\C=C2/C3=C(C=CC=C3)CCC1=CC=CC=C12)C.Cl	5-HT and noradrenalin re-uptake inhibitor	Inhibitor of serotonin and noradrenalin uptake; also activates _2A-adrenoceptors and antagonizes 5-HT2 receptors. Displays antinociceptive activity. Tricyclic antidepressant (TCA).	Merck Index 12 85. Sanchez and Hyttel (1999) Comparison of the effects of antidepressants and their metabolites on reuptake of biogenic amines and on receptor binding. Cell.Mol.Neurobiol. 19 467. PMID:10379421. Ghelardini et al (2000) Antinociception induced by amitriptyline and imipramine is mediated by _2A-adrenoceptors. Jpn.J.Pharmacol. 82 130. PMID:10877531. Sawynok et al (2001) Antidepressants as analgesics: an overview of central and peripheral mechanisms of action. J.Psychiatry Neurosci. 26 21. PMID:11212590.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=332568	SQ1533			Jan-2012
4457	YE 120	[383124-82-1]	CC(C(C2=CC=C(Cl)C(Cl)=C2)(C)O1)=C(C#N)/C1=C(C#N)\C#N	GPR35 agonist	GPR35 agonist (EC50 = 32 nM in DMR assays). Also displays partial agonist activity in a _-arrestin translocation assay (EC50 = 10.2 _M).	"Deng et al (2011) Discovery of 2-(4-methylfuran-2(5H)-ylidene)malononitrile and thieno[3,2-b]thiophene-2-carboxylic acid derivatives as G protein-coupled receptor 35 (GPR35) agonists. J.Med.Chem. 54 7385. PMID:21950657."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=332802				Aug-2012
4458	VU 29	[890764-36-0]	O=C(C4=CC=C([N+]([O-])=O)C=C4)NC1=CC(C3=CC=CC=C3)=NN1C2=CC=CC=C2	Potent mGlu5 allosteric potentiator	Potent allosteric potentiator at the rat mGlu5 receptor (EC50 = 9 nM); binds to the MPEP (Cat. No. 1212) allosteric site (Ki app = 244 nM). Selective for mGlu5 over mGlu1 and mGlu2 receptors (EC50 values are 557 nM and 1.51 _M for mGlu1 and mGlu2 respectively). Potentiates both DHPG-induced LTP and threshold _-burst stimulation (TBS)-induced LTP in rat hippocampal slices. Analog of CDPPB (Cat. No. 3235).	"de Paulis et al (2006) Substituent effects of N-(1,3-diphenyl-1H-pyrazol-5-yl)benzamides on positive allosteric modulation of the metabotropic glutamate-5 receptor in rat cortical astrocytes. J.Med.Chem. 49 3332. PMID:16722652. Chen et al (2007) Interaction of novel positive allosteric modulators of metabotropic glutamate receptor 5 with the negative allosteric antagonist site is required for potentiation of receptor responses. Mol.Pharmacol. 71 1389. PMID:17303702. Ayala et al (2009) mGluR5 positive allosteric modulators facilitate both hippocampal LTP and LTD and enhance spatial learning. Neuropsychopharmacology 34 2057. PMID:19295507."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=333148	SQ1070			Mar-2012
4459	TC-S 7005	[1082739-92-1]	C[C@H](NC2=CC(C(C4=CC=C(OCO5)C5=C4)=NO3)=C3C=N2)C1=CC=CC=C1	Potent and selective PLK2 inhibitor	Potent and selective polo-like kinase 2 (PLK2) inhibitor (IC50 = 4 nM). Shows selectivity for PLK2 over PLK3 and PLK1 (IC50 values are 24 and 214 nM respectively). Induces mitotic arrest and cell death in HCT 116 colorectal cells.	Hanan et al (2008) Design and synthesis of 2-amino-isoxazolopyridines as Polo-like kinase inhibitors. Bioorg.Med.Chem.Lett. 18 5186. PMID:18790636.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=333512	SQ1341			Feb-2014
4460	Trifluorothymidine	[70-00-8]	O=C1C(C(F)(F)F)=CN(C2O[C@H](CO)[C@@H](O)C2)C(N1)=O	Thymidylate synthase inhibitor; induces DNA fragmentation	Nucleoside analog; inhibitor of thymidylate synthase. Incorporation of the triphosphate form into DNA induces DNA fragmentation. Exhibits antitumor activity.	"Emura et al (2005) Potentiation of the antitumor activity of _, _, _-trifluorothymidine by the co-administration of an inhibitor of thymidine phosphorylase at a suitable molar ratio in vivo. Int.J.Oncol. 27 449. PMID:16010427. Okayama et al (2012) Involvement of concentrative nucleoside transporter 1 in intestinal absorption of trifluorothymidine, a novel antitumor nucleoside, in rats. J.Pharmacol.Exp.Ther. 340 457. PMID:22076553."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=334168	SQ1533			Mar-2012
4462	NS 3623	[343630-41-1]	BrC1=CC(C2=NN=NN2)=C(NC(NC3=CC(C(F)(F)F)=CC=C3)=O)C=C1	KV11.1 (hERG) channel activator; antiarrhythmic	"Human ether-a-go-go (hERG) KV11.1 potassium channel activator. Activates the IKr current and displays antiarrhythmic activity. Exhibits potential dual mode of action at the hERG inhibitory site; may also act as a partial blocker of KV11.1 (hERG) channels. Displays selectivity over the key cardiac potassium ion channels, KV7.1 (KCNQ1), KV1.5, and KV4.3. Suitable for both in vitro and in vivo use."	Hansen et al (2006) Biophysical characterization of the new human ether-a-go-go-related gene channel opener NS3623 [N-(4-bromo-2-(1H-tetrazol-5-yl)-phenyl)-N'-(3'-trifluoromethylphenyl)urea]. Mol.Pharmacol. 70 1319. PMID:16825484. Hansen et al (2007) Pharmacological activation of rapid delayed rectifier potassium current suppresses bradycardia-induced triggered activity in the isolated guinea pig heart. J.Pharmacol.Exp.Ther. 321 996. PMID:17325228. George (2009) Restoring repolarization in LQT3. Heart Rhythm. 6 107. PMID:19121809 .	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=334484	SQ1341			Jun-2012
4463	SR 8278	[1254944-66-5]	CCOC(=O)C1CC2=CC=CC=C2CN1C(=O)C1=CC=C(SC)S1	Rev-Erb_ antagonist	"Rev-Erb_ antagonist; inhibits Rev-Erb_ transcriptional repression (EC50 = 0.47 _M). Blocks activity of Rev-Erb_ agonist GSK 4112 (Cat. No. 3663) in HEK293 cells. Increases expression of glucose-regulating genes, G6Pase and PEPCK in HepG2 cells."	"Kojetin et al (2011) Identification of SR8278, a synthetic antagonist of the nuclear heme receptor REV-ERB. ACS Chem. Biol. 6 131. PMID:21043485."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=334489	SQ1341			Jan-2013
4464	IOX 1	[5852-78-8]	OC2=CC=C(C(O)=O)C1=CC=CN=C12	Histone demethylase inhibitor; cell permeable	"Histone demethylase JMJD inhibitor (IC50 values are 0.12, 0.17, 0.2, 0.3, 0.6 and 1 _M for JMJD3, JMJD1A, JMJD2A, JMJD2E, JMJD2C and UTX respectively). Cell permeable; inhibits JMJD2A-mediated H3K9me3 demethylation in HeLa cells."	King et al (2010) Quantitative high-throughput screening identifies 8-hydroxyquinolines as cell-active histone demethylase inhibitors. PLoS One. 5 e15535. PMID:21124847.	Small Molecule	"This compound is supplied in conjunction with the Structural Genomics Consortium. For further characterization details, please visit the IOX 1 summary on the SGC website."	http://www.tocris.com/dispprod.php?ItemId=334626				Dec-2012
4465	TCS ERK 11e	[896720-20-0]	O=C(N[C@H](CO)C3=CC(Cl)=CC=C3)C1=CC(C2=NC(NC4=CC=C(F)C=C4Cl)=NC=C2C)=CN1	Potent and selective ERK2 inhibitor	"Potent and selective extracellular signal-related kinase 2 (ERK2) inhibitor (Ki values are <2, 395, 540 and 852 nM for ERK2, GSK-3, Aurora Kinase A and Cdk2 respectively). Potently blocks proliferation of HT29 cells (IC50 = 48 nM). Orally bioavailable."	Aronov et al (2009) Structure-guided design of potent and selective pyrimidylpyrrole inhibitors of extracellular signal-related kinase (ERK) using conformational control. J.Med.Chem. 52 6362. PMID:19827834.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=334709	SQ1533			Dec-2012
4466	PHP 501 trifluoroacetate	[1236105-75-1]	ON1N=CC(C3CCNCC3)=C1C2=CC=CC(C4=CC=CC=C4)=C2.FC(F)(C(O)=O)F	Potent GABAA antagonist	"Potent GABAA antagonist (Ki = 0.0028 _M at rat GABAA receptors; IC50 = 0.024 _M at human _1_2_2 GABAA-expressing tsA201 cells). Displays no inhibitory activity at hGAT-1, hGAT-2, hGAT-3 or hBGT-1 GABA transporters."	"Mller et al (2010) Novel 4-(piperidin-4-yl)-1-hydroxypyrazoles as gamma-aminobutyric acid(A) receptor ligands: synthesis, pharmacology, and structure-activity relationships. J.Med.Chem. 53 3417. PMID:20355712."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=334710	SQ1341			Apr-2012
4468	AT 1015	[190508-50-0]	O=C(C5CCN(C=O)CC5)NCCN(CC3)CC/C3=C1C(C=CC=C4)=C4C=CC2=C\1C=CC=C2.Cl	Long-acting 5-HT2A antagonist	Long-acting 5-HT2A receptor antagonist; inhibits vasoconstriction and blocks platelet aggregation. Prolongs clotting time in a rat model of thrombus formation; ameliorates laurate-induced peripheral vascular lesions in rodents.	"Kihara et al (2000) AT-1015, a novel serotonin (5-HT)2 receptor antagonist, blocks vascular and platelet 5-HT2A receptors and prevents the laurate-induced peripheral vascular lesions in rats. J.Cardiovasc.Pharmacol. 35 523. PMID:10774780. Kihara et al (2001) Antithrombotic activity of AT-1015, a potent 5-HT(2A) receptor antagonist, in rat arterial thrombosis model and its effect on bleeding time. Eur.J.Pharmacol. 433 157. PMID:11755147. Rashid et al (2001) Assessment of affinity and dissociation ability of a newly synthesized 5-HT2 antagonist, AT-1015: comparison with other 5-HT2 antagonists. Jpn.J.Pharmacol. 87 189. PMID:11885967."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=334990				Jul-2012
4469	VU 0364770	[61350-00-3]	O=C(C2=NC=CC=C2)NC1=CC=CC(Cl)=C1	Positive allosteric modulator at mGlu4	Positive allosteric modulator at mGlu4 receptors (EC50 = 290 nM in mGlu4-expressing HEK 293 cells). Reverses haloperidol-induced catalepsy in rats; prevents attentional deficit and forelimb asymmetry in a rodent model of Parkinson's disease. Exhibits affinity for MAO-B and MAO-A (Ki values are 0.72 _M and 8.5 _M respectively). Brain penetrant.	Jones et al (2012) The metabotropic glutamate receptor 4-positive allosteric modulator VU0364770 produces efficacy alone and in combination with L-DOPA or an adenosine 2A antagonist in preclinical rodent models of Parkinson's disease. J.Pharmacol.Exp.Ther. 340 404. PMID:22088953.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=334993	SQ1070			Mar-2012
4470	EMD 281014 hydrochloride	[443144-27-2]	O=C(N3CCN(CCC4=CC=C(F)C=C4)CC3)C1=C2C(C(C#N)=CN2)=CC=C1.Cl	Selective 5-HT2A antagonist	"Selective 5-HT2A antagonist; displays high affinity for human 5-HT2A over 5-HT2C receptors (Ki values are 0.87 and 557 nM respectively). Exhibits low off-target activity (Ki values are >1000 and 1268 nM for human D2 receptors and IKr channels, respectively)."	"Bartoszyk et al (2003) EMD 281014, a new selective serotonin 5-HT2A receptor antagonist. Eur.J.Pharmacol. 473 229. Patel et al (2004) The highly selective 5-hydroxytryptamine (5-HT)2A receptor antagonist, EMD 281014, significantly increases swimming and decreases immobility in male congenital learned helpless rats in the forced swim test. Synapse 52 73. PMID:14755634. Ladduwahetty et al (2006) A new class of selective, non-basic 5-HT2A receptor antagonists. Bioorg.Med.Chem.Lett. 16 3201. PMID:16632354."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=335080	SQ1070			Jan-2013
4471	DMH4	[515880-75-8]	C(C=N2)(C4=CC=C(OCCN5CCOCC5)C=C4)=CN1C2=C(C3=CC=CC=C3)C=N1	Selective VEGFR-2 inhibitor	"Selective VEGFR-2 inhibitor (IC50 values are 161, 3558, 8038 and > 30000 nM for VEGFR-2, BMPR-I, AMPK and TGF_R-I respectively). Displays antiangiogenic activity in vitro and in vivo."	"Fraley et al (2002) Optimization of a pyrazolo[1,5-a]pyrimidine class of KDR kinase inhibitors: improvements in physical properties enhance cellular activity and pharmacokinetics. Bioorg.Med.Chem.Lett. 12 3537. PMID:12443771. Hao et al (2010) In vivo structure-activity relationship study of dorsomorphin analogues identifies selective VEGF and BMP inhibitors. ACS Chem.Biol. 5 245. PMID:20020776."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=335366	SQ1070			Mar-2012
4472	BAY 60-6583	[910487-58-0]	NC1=NC(SCC(N)=O)=C(C#N)C(C2=CC=C(OCC3CC3)C=C2)=C1C#N	Potent A2B receptor agonist; cardioprotective	"Potent adenosine A2B receptor agonist (EC50 = 2.83 nM for murine A2B receptor). Displays selectivity for A2B over A1, A2A and A3 receptors. Decreases fMLP-induced superoxide production in neutrophils at low concentrations (1-10 nM). Cardioprotective; attenuates infarct size in a mouse model of myocardial ischemia."	"Eckle et al (2007) Cardioprotection by ecto-5'-nucleotidase (CD73) and A2B adenosine receptors. Circulation 115 1581. PMID:17353435. Auchampach et al (2009) Characterization of the A2B adenosine receptor from mouse, rabbit, and dog. J.Pharmacol.Exp.Ther. 329 2. PMID:19141710. van der Hoeven et al (2011) A role for the low-affinity A2B adenosine receptor in regulating superoxide generation by murine neutrophils. J.Pharmacol.Exp.Ther. 338 1004. PMID:21693629."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=335373				Jun-2012
4473	A 804598	[1125758-85-1]	C[C@@H](C3=CC=CC=C3)NC(NC2=CC=CC1=NC=CC=C12)=NC#N	Potent and selective P2X7 antagonist	"Potent, competitive P2X7 receptor antagonist (IC50 values are 8.9, 9.9 and 10.9 nM for mouse, rat and human P2X7 receptors respectively). Selective for P2X7 receptors (IC50 > 5-10 _M for a wide array of cell surface receptors and ion channels). Binds with high affinity (Ki app = 2.4 nM for rat P2X7 receptors)."	"Donnelly-Roberts et al (2009) [3H]A-804598 ([3H]2-cyano-1-[(1S)-1-phenylethyl]-3-quinolin-5-ylguanidine) is a novel, potent, and selective antagonist radioligand for P2X7 receptors. Neuropharmacology 56 223. PMID:18602931. Able et al (2011) Receptor localization, native tissue binding and ex vivo occupancy for centrally penetrant P2X7 antagonists in the rat. Br.J.Pharmacol. 162 405. PMID:20840537."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=335507				May-2012
4475	Cardionogen 1	[577696-37-8]	C12=NN=C(C3=CC=CO3)N1N=C(C4CCCCC4)S2	Inhibitor of Wnt/_-catenin signaling	Wnt signaling modulator. Potently inhibits Wnt/_-catenin-dependent transcription in murine ES cells (EC50 = 23 nM) and zebrafish embryos. Enlarges heart size via cardiomyocyte hyperplasia; induces ES cell cardiac differentiation.	Ni et al (2011) Discovering small molecules that promote cardiomyocyte generation by modulating Wnt signaling. Chem.Biol. 18 1658. PMID:22195568.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=335509	SQ1341			May-2013
4477	A 844606	[861119-08-6]	O=C2C3=C(C=CC(N4CC(CN(C)C5)C5C4)=C3)OC1=CC=CC=C12	Selective _7 nAChR partial agonist	Selective _7 nicotinic acetylcholine receptor (nAChR) partial agonist (EC50 values are 1.4 and 2.2 _M at human and rat receptors respectively). Displays no measurable effect on _4_2 nAChRs. Stimulates _7 nAChR-induced ERK1/2 phosphorylation in PC12 cells.	Briggs et al (2008) Alpha7 nicotinic acetylcholine receptor agonist properties of tilorone and related tricyclic analogues. Br.J.Pharmacol. 153 1054. PMID:18157163.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=335511	SQ1070			Oct-2012
4478	GPBAR-A	[877052-79-4]	O=C(CO3)N(CC4=CC(C(F)(F)F)=CC(C(F)(F)F)=C4)CC1=C3N=CC=C1C2=C(F)C=CC=C2	Bile acid receptor TGR5 (GPBA) agonist	Bile acid receptor TGR5 (GPBA) agonist. Upregulates GLP-1 secretion from intestinal cultures. Increases MQAE-fluorescence suggesting a decrease in intracellular chloride concentration in gallbladder epithelial cells.	Keitel et al (2009) The membrane-bound bile acid receptor TGR5 is localized in the epithelium of human gallbladders. Hepatology 50 861. PMID:19582812. Parker et al (2012) Molecular mechanisms underlying bile acid-stimulated glucagon-like peptide-1 secretion. Br.J.Pharmacol. 165 414. PMID:21718300.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=336105	SQ1341			Nov-2013
4479	4_8C	[14003-96-4]	CC(C1=CC=C(O)C(C=O)=C1O2)=CC2=O	Inhibits IRE1_ endoribonuclease activity	Selective inhibitor of IRE1_ ribonuclease (RNase) activity (IC50 = 60 nM). Blocks substrate access to the active site of IRE1_. Inactivates IRE1_-mediated mRNA degradation. Displays no effect on the IRE1_-related endoribonuclease RNase L.	Cross et al (2012) The molecular basis for selective inhibition of unconventional mRNA splicing by an IRE1-binding small molecule. Proc.Natl.Acad.Sci.USA 109 E869. PMID:22315414.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=336106	SQ1341			May-2012
4480	DV 7028 hydrochloride	[133364-62-2]	O=C(C4=CC=C(F)C=C4)C(CC3)CCN3CCN2C(N1CCCCC1=NC2=O)=O.Cl	Selective 5-HT2A antagonist; antithrombotic	"Selective 5-HT2A receptor antagonist (Ki = 22 nM for at 5-HT2 receptors). Exhibits no affinity for 5-HT1A, 5-HT1B or 5-HT1D receptors. Inhibits collagen-induced serotonin secretion and platelet aggregation; displays no effect on serotonin uptake by platelets. Shown to inhibit arterial thrombus formation, but not venous thrombosis, in rat models."	"Shibano et al (1992) Pharmacological profile of a new 5-hydroxytryptamine 2 receptor antagonist, DV-7028. Arch.Int.Pharmacodyn.Ther. 319 114. PMID:1285670. Pawlak et al (1998) A potent 5-hydroxytryptamine receptor (5-HT2A) antagonist, DV-7028, delays arterial thrombosis development in rats. Thromb.Res. 90 259. PMID:9700856."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=336107	SQ1341			Oct-2012
4481	Ki 20227	[623142-96-1]	O=C(NC(C)C3=NC=CS3)NC(C(OC)=C2)=CC=C2OC1=C4C(C=C(OC)C(OC)=C4)=NC=C1	c-Fms inhibitor; suppresses osteolysis and osteoclast accumulation	"Inhibitor of c-Fms tyrosine kinase (M-CSFR, CSF1R) (IC50 values are 2, 12, 217 and 451 nM for c-Fms, VEGFR-2, PDGFR_ and c-Kit respectively). Does not inhibit Flt3, EGFR or c-Src. Suppresses osteoclast differentiation and osteolysis in a rat bone metastasis model."	"Ohno et al (2006) A c-fms tyrosine kinase inhibitor, Ki20227, suppresses osteoclast differentiation and osteolytic bone destruction in a bone metastasis model. Mol.Cancer Ther. 5 2634. PMID:17121910. Ohno et al (2007) The orally-active and selective c-Fms tyrosine kinase inhibitor Ki20227 inhibits disease progression in a collagen-induced arthritis mouse model. Eur.J.Immunol. 38 283. PMID:18085662. Kubota et al (2009) M-CSF inhibition selectively targets pathological angiogenesis and lymphangiogenesis. J.Exp.Med. 206 1089. PMID:19398755."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=336159	SQ1533			Mar-2012
4483	A 484954	[142557-61-7]	O=C(N(C3CC3)C2=C1C=C(C(N)=O)C(N)=N2)N(CC)C1=O	CaM kinase III (eEF-2 kinase) inhibitor	Inhibitor of eukaryotic elongation factor-2 (eEF-2) kinase (IC50 = 0.28 _M in enzymatic assay). Reduces eEF-2 phosphorylation with little effect on cancer cell growth.	Chen et al (2011) 1-Benzyl-3-cetyl-2-methylimidazolium iodide (NH125) induces phosphorylation of eukaryotic elongation factor-2 (eEF2): a cautionary note on the anticancer mechanism of an eEF2 kinase inhibitor. J.Biol.Chem. 286 43951. PMID:22020937.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=337647	SQ1341			Jul-2012
4484	STF 31	[724741-75-7]	O=C(NC2=CN=CC=C2)C1=CC=C(CNS(C3=CC=C(C(C)(C)C)C=C3)(=O)=O)C=C1	GLUT1 inhibitor	Inhibitor of GLUT1; inhibits glucose uptake in renal cell carcinoma (RCC) 4 cells. Activity causes necrotic cell death in von Hippel-Lindau (VHL)-deficient RCC cells.	Chan et al (2011) Targeting GLUT1 and the Warburg effect in renal cell carcinoma by chemical synthetic lethality. Sci.Transl.Med. 3 94ra70. PMID:21813754.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=337648	SQ1341			Jul-2012
4485	P 22077	[1247819-59-5]	CC(C1=CC([N+]([O-])=O)=C(SC2=CC=C(F)C=C2F)S1)=O	USP7 inhibitor	Inhibitor of ubiquitin-specific protease (USP) 7 (EC50 = 8.6 _M); also inhibits the closely related deubiquitinase (DUB) USP47. Demonstrates downstream inhibition of HDM2 and claspin in vitro. Inhibits USP7-mediated p53 deubiquitination. Blocks deubiquitination of Tip60 (KAT5) histone lysine acetyltransferase.	"Loch et al (2011) Deubiquitylase, deSUMOylase, and deISGylase activity microarrays for assay of substrate preference and functional modifiers. Mol.Cell.Proteomics 10 M100.002402. PMID:20956615. Tian et al (2011) Characterization of selective ubiquitin and ubiquitin-like protease inhibitors using a fluorescence-based multiplex assay format. Assay Drug Dev.Technol. 9 165. PMID:21133675. Altun et al (2011) Activity-based chemical proteomics accelerates inhibitor development for deubiquitylating enzymes. Chem.Biol. 18 1401. PMID:22118674. Dar et al (2013) Deubiquitination of Tip60 by USP7 determines the activity of the p53-dependent apoptotic pathway. Mol.Cell Biol. 33 3309. PMID:23775119."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=337649	SQ1341			Jul-2012
4487	()-AMG 487		CCOC(C=C3)=CC=C3N2C(C1=CC=CN=C1N=C2C(N(CC4=CC=CN=C4)C(CC5=CC=C(OC(F)(F)F)C=C5)=O)C)=O	CXCR3 antagonist; inhibits cell migration and metastasis	"Antagonist of CXCR3; inhibits binding of 125I-IP-10 and 125I-ITAC to CXCR3 (IC50 values are 8.0 and 8.2 nM respectively). Inhibits CXCR3-mediated cell migration by the chemokines IP-10, ITAC and MiG in vitro (IC50 values are 8, 15 and 36 nM respectively). Also shown to inhibit lung metastasis in a mouse model of metastatic breast cancer."	Walser et al (2006) Antagonism of CXCR3 inhibits lung metastasis in a murine model of metastatic breast cancer. Cancer Res. 66 7701. PMID:16885372. Johnson et al (2007) Discovery and optimization of a series of quinazolinone-derived antagonists of CXCR3. Bioorg.Med.Chem.Lett. 17 3339. PMID:17448658. Cambien et al (2009) Organ-specific inhibition of metastatic colon carcinoma by CXCR3 antagonism. Br.J.Cancer 100 1755. PMID:19436305.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=339325	SQ1070			Nov-2013
4488	1-Deazaadenosine	[14432-09-8]	NC1=C2C(N([C@H]3[C@H](O)[C@H](O)[C@@H](CO)O3)C=N2)=NC=C1	Adenosine deaminase inhibitor	Inhibitor of adenosine deaminase (Ki = 0.66 _M). Demonstrates antitumor activity in a range of leukemia cell lines.	Cristalli et al (1987) Improved synthesis and antitumor activity of 1-deazaadenosine. J.Med.Chem. 30 1686. PMID:3625714. Cristalli et al (1993) Adenosine deaminase inhibitors: Structure-activity relationships in 1-deazaadenosine and erythro-9-(2-hydroxy-3-nonyl)adenine analogues. Drug Dev.Res. 28 253.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=339326	SQ1341			Sep-2012
4489	DBZ	[209984-56-5]	CN1C2=C(C=CC=C2)C3=C(C=CC=C3)[C@H](NC([C@@H](NC(CC4=CC(F)=CC(F)=C4)=O)C)=O)C1=O	_-secretase inhibitor; inhibits Notch pathway	Inhibitor of _-secretase. Blocks Notch cleavage (IC50< 2 nM) in a cell-based assay; inhibits the Notch pathway.	van Es et al (2005) Notch/_-secretase inhibition turns proliferative cells in intestinal crypts and adenomas into goblet cells. Nature 435 959. PMID:15959515. Groth et al (2010) Pharmacological analysis of Drosophila melanogaster _-secretase with respect to differential proteolysis of Notch and APP. Mol.Pharmacol. 77 567. PMID:20064975.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=339327	SQ1533			Apr-2013
4490	Alantolactone	[546-43-0]	O=C3C([C@@]2([H])C=C1[C@@H](C)CCC[C@@](C)1C[C@]([H])2O3)=C	Antiproliferative; induces activin/SMAD3 signaling	Sesquiterpene lactone. Induces activin/SMAD3 signaling and disrupts Cripto-1/activin receptor type II A interaction. Displays antiproliferative activity in human colon adenocarcinoma HCT-8 cells.	Dupuis & Brisson et al (1976) Toxic effect of alantolactone and dihydroalantolactone in in vitro cultures of leukocytes. Chem.Biol.Interact. 15 205. PMID:1000726. Pal et al (2010) Activation of caspases and poly (ADP-ribose) polymerase cleavage to induce apoptosis in leukemia HL-60 cellsby Inula racemosa. Toxicol.In Vitro. 24 1599. PMID:20600805. Shi et al (2011) Alantolactone inhibits cell proliferation by interrupting the interaction between Cripto-1 and activin receptor type II A in activin signaling pathway. J.Biomol.Screen. 16 525. PMID:21378277.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=339328	SQ1070			May-2012
4491	DQP 1105	[380560-89-4]	O=C2C(C4=NN(C(CCC(O)=O)=O)C(C5=CC=C(Br)C=C5)C4)=C(C3=CC=CC=C3)C1=CC(C)=CC=C1N2	Selective NR2C/NR2D receptor antagonist	"Noncompetitive NMDA receptor antagonist; displays over 50-fold selectivity for GluN2D- and GluN2C-containing receptors over GluN2B-, GluK2-, GluA1- and GluN2A-containing receptors (IC50 values are 2.7, 8.5, 121, 153, 198 and 206 _M respectively). Reduces frequency of channel opening."	Acker et al (2011) Mechanism for noncompetitive inhibition by novel GluN2C/D N-methyl-D-aspartate receptor subunit-selective modulators. Mol.Pharmacol. 80 782. PMID:21807990.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=339329	SQ1341			Jun-2012
4493	Paliperidone	[144598-75-4]	FC1=CC2=C(C(C3CCN(CCC4=C(C)N=C(C(O)CCC5)N5C4=O)CC3)=NO2)C=C1	Atypical antipsychotic; 5-HT2A and D2 antagonist	Atypical antipsychotic; metabolite of risperidone (Cat. No. 2865). Exhibits high affinity for 5-HT2A receptors (Ki = 0.4 nM for cloned human 5-HT2A receptors). Also displays nanomolar affinity for human D2 receptors.	"Megens and Awouters et al (1994) In vivo pharmacological profile of 9-hydroxyrisperidone, the major metabolite of the novel antipsychotic risperidone. 33 399. Leysen et al (1994) Risperidone: a novel antipsychotic with balanced serotonin-dopamine antagonism, receptor occupancy profile, and pharmacologic activity. J.Clin.Psychiatry 55 5. PMID:7520908. Schotte et al (1996) Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology 124 57. PMID:8935801. Dremencov et al (2007) Distinct electrophysiological effects of paliperidone and risperidone on the firing activity of rat serotonin and norepinephrine neurons. Psychopharmacology 194 63. PMID:17530476."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=339333	SQ1533			Apr-2012
4494	(R)-DPN	[524047-78-7]	OC(C=C2)=CC=C2C[C@@H](C#N)C1=CC=C(O)C=C1	Enantiomer of DPN (Cat. No. 1494)	Enantiomer of DPN (Cat. No. 1494). Displays higher affinity for estrogen receptor (ER) _ over ER_ (Ki values are 1.82 and 147 nM respectively).	Weiser et al (2009) Estrogen receptor-_ agonist diarylpropionitrile: biological activities of R- and S-enantiomers on behavior and hormonal response to stress. Endocrinology 150 1817. PMID:19074580. Carroll et al (2011) Diarylpropionitrile (DPN) enantiomers: synthesis and evaluation of estrogen receptor _-selective ligands. J.Med.Chem. 55 528. PMID:22122563.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=340184				May-2013
4495	Flurizan	[51543-40-9]	FC1=C(C2=CC=CC=C2)C=CC([C@@H](C)C(O)=O)=C1	_-secretase inhibitor; lowers A_42 levels in vitro	Nonsteroidal anti-inflammatory drug (NSAID) that inhibits _-secretase activity. Selectively lowers A_42 levels in human neuroglioma cells; displays no effect on A_40 levels at a concentration of 100 _M.	Eriksen et al (2003) NSAIDs and enantiomers of flurbiprofen target _-secretase and lower A_42 in vivo. J.Clin.Invest. 112 440. PMID:12897211. Kukar et al (2007) Chronic administration of R-flurbiprofen attenuates learning impairments in transgenic amyloid precursor protein mice. BMC Neurosci. 8 54. PMID:17650315.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=340201	SQ1533			Apr-2012
4496	BC 11-38	[686770-80-9]	CCCSC1=NC(CCS3)=C3C(N1C2=CC=CC=C2)=O	Selective PDE11 inhibitor	Selective phosphodiesterase (PDE) 11 inhibitor (IC50 = 0.28 _M for PDE11; IC50 values are >100 _M for PDE1 - PDE10). Significantly elevates cAMP levels and cortisol production in H295R human adenocarcinoma cells.	Ceyhan et al (2012) Identification of biologically active PDE11-selective inhibitors using a yeast-based high-throughput screen. Chem.Biol. 19 155. PMID:22284362.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=340332	SQ1341			May-2012
4498	Y 11	[1086639-59-9]	OCC[N+]1(CN3C2)CN(C3)CN2C1.[Br-]	Potent and selective FAK inhibitor	Potent inhibitor of focal adhesion kinase (FAK); prevents FAK autophosphorylation at the Y397 site (IC50 ~ 50 nM in an in vitro kinase assay). Displays selectivity for FAK over a panel of other kinases (concentration used in assay = 1 _M). Decreases cell viability in a number of cancer cell lines; blocks colony formation in SW620 and BT474 cell lines.	"Golubovskaya et al (2008) A small molecule inhibitor, 1,2,4,5-benzenetetraamine tetrahydrochloride, targeting the Y397 site of focal adhesion kinase decreases tumor growth. J.Med.Chem. 51 7405. PMID:18989950. Golubovskaya et al (2012) A small molecule focal adhesion kinase (FAK) inhibitor, targeting Y397 site: 1-(2-hydroxyethyl) -3, 5, 7-triaza-1-azoniatricyclo [3.3.1.13,7]decane; bromide effectively inhibits FAK autophosphorylation activity and decreases cancer cell viability, clonogenicity and tumor growth in vivo. Carcinogenesis. PMID:22402131."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=340336				May-2012
4499	(+)-JQ1	[1268524-70-4]	O=C(OC(C)(C)C)C[C@@H]1N=C(C4=CC=C(Cl)C=C4)C3=C(SC(C)=C3C)N2C1=NN=C2C	"Potent, selective BET bromodomain inhibitor; cell permeable"	"Potent, high affinity, selective BET bromodomain inhibitor (IC50 values are 17.7, 32.6, 76.9 and 12942 nM for BRD2 (N-terminal (N)), BRD4 (C-terminal (C)), BRD4 (N) and CREBBP respectively; Kd values are 49, 59.5, 82, 90.1, 128 and 190 nM for BRD4 (N), BRD3 (N), BRD3 (C), BRD4 (C), BRD2 (N) and BRDT (N) respectively). Induces squamous differentiation in NUT midline carcinoma (NMC) cell lines; inhibits tumor growth in NMC xenograft models in vivo. Exhibits reversible contraceptive effects in germ cells from male mice."	Filippakopoulos et al (2010) Selective inhibition of BET bromodomains. Nature 468 1067. PMID:20871596. Herrmann et al (2012) Small-molecule inhibition of BRD4 as a new potent approach for eliminate leukemic stem- and progenitor cells in acute myeloid leukemia AML. Oncotarget. [Epub ahead of print]. PMID:23249862. Matzuk et al (2012) Small-molecule inhibition of BRDT for male contraception. Cell 150 673. PMID:22901802.	Small Molecule	"This probe is supplied in conjunction with the Structural Genomics Consortium. For further characterization details, please visit the (+)-JQ1 probe summary on the SGC website."	http://www.tocris.com/dispprod.php?ItemId=340357	SQ1533			Jan-2013
4501	Ribavirin	[36791-04-5]	O[C@@H]1[C@@H](CO)O[C@@H](N2C=NC(C(N)=O)=N2)[C@@H]1O	Antiviral guanosine analog; blocks eIF4E activity	"Antiviral guanosine ribonucleoside analog; misincorporated into mRNA by viral-dependent RNA polymerases. Binds to and redistributes mammalian eIF4E from the nucleus to the cytoplasm (Ki ~ 0.3 _M for the active metabolite, ribavirin triphosphate). Represses colony formation of primary AML-M5 progenitor cells (IC50 ~ 1 _M); reduces disease severity in acute myeloid leukemia (AML). Orally available."	Kentsis et al (2004) Ribavirin suppresses eIF4E-mediated oncogenic transformation by physical mimicry of the 7-methyl guanosine mRNA cap. Proc.Natl.Acad.Sci.U.S.A. 101 18105. PMID:15601771. Assouline et al (2009) Molecular targeting of the oncogene eIF4E in acute myeloid leukemia (AML): a proof-of-principle clinical trial with ribavirin. Blood 114 257. PMID:19433856.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=341010	SQ1533			May-2012
4502	DIM	[1968-05-4]	C12=CC=CC=C1C(CC3=CC(C=CC=C4)=C4N3)=CN2	Activates Chk2; induces G2/M cell cycle arrest	Activator of Chk2 that causes G2/M cell cycle arrest in various cancer cell lines. Antiproliferative and inducer of apoptosis; promotes proteasomal degradation of Cdc25C and Cdk1. Inhibits phosphorylation of EGFR and downstream activation of ERK.	"Kandala & Srivastava (2010) Activation of checkpoint kinase 2 by 3,3'-diindolylmethane is required for causing G2/M cell cycle arrest in human ovarian cancer cells. Mol.Pharmacol. 78 297. PMID:20444961. Shorey et al (2012) 3,3'-diindolylmethane induces G1 arrest and apoptosis in human acute T-cell lymphoblastic leukemia cells. PLoS One. 7 e34975. PMID:22514694. Kandala et al (2012) Blocking epidermal growth factor receptor activation by 3,3'-diindolylmethane suppresses ovarian tumor growth in vitro and in vivo. J.Pharmacol.Exp.Ther. 341 24. PMID:22205686."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=341022	SQ1341			May-2012
4505	ICG 001	[847591-62-2]	O=C1CCN(C(NCC5=CC=CC=C5)=O)[C@]2([H])N1[C@@H](CC6=CC=C(O)C=C6)C(N(CC3=C(C=CC=C4)C4=CC=C3)C2)=O	Inhibits TCF/_-catenin-mediated transcription	Inhibitor of TCF/_-catenin-mediated transcription. Selectively inhibits _-catenin/CBP interaction; displays no effect on _-catenin/p300 interaction. Exhibits growth inhibitory effects in colon carcinoma cell lines (SW480 and HCT-116 cells); also displays efficacy in Min mouse and nude mouse SW620 xenograft models.	Emami et al (2004) A small molecule inhibitor of _-catenin/CREB-binding protein transcription. Proc.Natl.Acad.Sci.USA 101 12682. PMID:15314234. De Sousa et al (2011) Targeting wnt signaling in colon cancer stem cells. Clin.Cancer Res. 17 647. PMID:21159886. Zhou et al (2012) Interactions between _-catenin and transforming growth factor-_ signaling pathways mediate epithelial-mesenchymal transition and are dependent on the transcriptional co-activator cAMP-response element-binding protein (CREB)-binding protein (CBP). J.Biol.Chem. 287 7026. PMID:22241478.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=341069				May-2012
4506	TAME hydrochloride	[1784-03-8]	NC(NCCC[C@H](NS(C1=CC=C(C)C=C1)(=O)=O)C(OC)=O)=N.Cl	Ubiquitin ligase APC/C inhibitor; promotes Cdc20 autoubiquitination	Competitive inhibitor of the ubiquitin ligase anaphase-promoting complex/cyclosome (APC/C); promotes Cdc20 autoubiquitination. Inhibits cyclin proteolysis in mitotic Xenopus oocyte extracts (IC50 = 12 _M) and blocks cyclin degradation in interphase extract.	Zeng et al (2010) Pharmacologic inhibition of the anaphase-promoting complex induces a spindle checkpoint-dependent mitotic arrest in the absence of spindle damage. Cancer Cell. 18 382. PMID:20951947. Zeng & King (2012) An APC/C inhibitor stabilizes cyclin B1 by prematurely terminating ubiquitination. Nat.Chem.Biol. 8 383. PMID:22366722.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=341070	SQ1341			Apr-2012
4507	ML 218 hydrochloride	[1346233-68-8]	CC(C)(C)CCN1C[C@@]2([H])[C@@]([C@@H]2CNC(C3=CC(Cl)=CC(Cl)=C3)=O)([H])C1.Cl	Ca2+ channel blocker (T-type)	"Selective inhibitor of T-type calcium channels (IC50 values are 270 and 310 nM for Cav3.3 and Cav3.2 respectively in a patch EP assay). Decreases burst activity in STN neurons; reduces cataleptic behaviour in an in vivo rat model of Parkinson's disease. Displays no significant inhibition of L- or N-type calcium channels, Kir6 (KATP) or KV11.1 (hERG) potassium channels. Orally active."	"Xiang et al (2011) The discovery and characterization of ML218: A novel, centrally active T-type calcium channel inhibitor with robust effects in STN neurons and in a rodent model of Parkinson's disease. ACS Chem.Neurosci. 2 730. PMID:22368764."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=341071	SQ1341			Oct-2012
4508	S 32212 hydrochloride	[847871-78-7]	CN(CC2)CCN2C1=C(OC)C=CC(NC(N3C(C=CC5=C4C=CC=C5)=C4CC3)=O)=C1.Cl	5-HT2C inverse agonist; _2 antagonist	"Inverse agonist of 5-HT2C receptors (pKi = 8.18 at human 5-HT2C INI receptors). Also an antagonist of human _2-adrenoceptors. Displays negligible affinity for _1A-adrenoceptors, histamine H1 receptors and muscarinic M1 receptors."	"Millan et al (2012) S32212, a novel serotonin type 2C receptor inverse agonist/_2-adrenoceptor antagonist and potential antidepressant: I. A mechanistic characterization. J.Pharmacol.Exp.Ther. 340 750. PMID:22178752. Dekeyne et al (2012) S32212, a novel serotonin type 2C receptor inverse agonist/_2-adrenoceptor antagonist and potential antidepressant: II. A behavioral, neurochemical, and electrophysiological characterization. J.Pharmacol.Exp.Ther. 340 765. PMID:22178753."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=341184	SQ1341			Dec-2012
4509	STF 083010	[307543-71-1]	OC1=CC=C(C=CC=C2)C2=C1/C=N/S(C3=CC=CS3)(=O)=O	Inhibits IRE1_ endonuclease activity	Inhibitor of IRE1_ endonuclease activity; blocks endogenous XBP1 mRNA splicing. Displays cytostatic and cytotoxic effects in CD138+ multiple myeloma (MM) cells in vitro; inhibits bortezomib-induced XBP1 activity in myeloma xenografts in vivo. Does not alter IRE1_ kinase activity.	Papandreou et al (2011) Identification of an Ire1alpha endonuclease specific inhibitor with cytotoxic activity against human multiple myeloma. Blood. 117 1311. PMID:21081713. Kraskiewicz and FitzGerald (2012) InterfERing with endoplasmic reticulum stress. Trends Pharmacol.Sci. 33 53. PMID:22112465.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=341437				May-2012
4510	SHA 68	[847553-89-3]	O=C(NCC4=CC=C(F)C=C4)N1CC2N(C(OC(C5=CC=CC=C5)2C3=CC=CC=C3)=O)CC1	Selective neuropeptide S receptor antagonist	"Selective neuropeptide S receptor (NPSR) antagonist (IC50 values are 22.0 and 23.8 nM for human NPSR Asn107 and Ile107 variants respectively). Displays no activity against a range of 14 GPCRs, including vasopressin and oxytocin receptors."	"Okamura et al (2008) Synthesis and pharmacological in vitro and in vivo profile of 3-oxo-1,1-diphenyl-tetrahydro-oxazolo[3,4-a]pyrazine-7-carboxylic acid 4-fluoro-benzylamide (SHA 68), a selective antagonist of the neuropeptide S receptor. J.Pharmacol.Exp.Ther. 325 893. PMID:18337476. Okamura et al (2011) Neuropeptide S enhances memory during the consolidation phase and interacts with noradrenergic systems in the brain. Neuropsychopharmacology 36 744. PMID:21150909. Trapella et al (2011) Synthesis and separation of the enantiomers of the neuropeptide S receptor antagonist (9R/S)-3-oxo-1,1-diphenyl-tetrahydro-oxazolo[3,4a]pyrazine-7-carboxylic acid 4-fluoro-benzylamide (SHA 68). J.Med.Chem. 54 2738. PMID:21466221."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=343123	SQ1341			Nov-2012
4511	MMF	[2756-87-8]	O=C(/C=C/C(O)=O)OC	Activator of Nrf2 pathway; primary metabolite of DMF (Cat. No. 4512)	Nuclear factor (erythroid-derived-2)-like 2 (Nrf2) pathway activator. Also exhibits agonist activity at GPR109A. Primary metabolite of DMF (Cat. No. 4512).	Rao & Mishra (1998) Antihepatotoxic activity of monomethyl fumarate isolated from Fumaria indica. J.Ethnopharmacol. 60 207. PMID:9613834. Tang et al (2008) The psoriasis durg monomethylfumarate is a potent nicotinic receptor agonist. Biochem.Biophys.Res.Commun. 375 562. PMID:18722346. Hanson et al (2010) Nicotinic acid- and monomethyl fumarate-induced flushing involves GPR109A expressed by keratinocytes and COX-2-dependent prostanoid formation in mice. J.Clin.Invest. 120 2910. PMID:20664170. Scannevin et al (2012) Fumarates promote cytoprotection of central nervous system cells against oxidative stress via the nuclear factor (erythroid-derived 2)-like 2 pathway. J.Pharmacol.Exp.Ther. 341 274. PMID:22267202.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=343196				May-2012
4512	DMF	[624-49-7]	O=C(/C=C/C(OC)=O)OC	Nrf2 pathway activator; neuroprotective	"Nuclear factor (erythroid-derived)-like 2 (Nrf2) pathway activator; induces upregulation of antioxidant gene expression. Displays cytoprotective effects in human spinal cord astrocytes, oligodendrocyte precursor cells and hippocampal neurons following hydrogen peroxide challenge. Exerts neuroprotective effects in vivo in experimental autoimmune encephalomyelitis. Primary metabolite (MMF, Cat. No. 4511) available."	Linker et al (2011) Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway. Brain 134 678. PMID:21354971. Scannevin et al (2012) Fumarates promote cytoprotection of central nervous system cells against oxidative stress via the nuclear factor (erythroid-derived)-like 2 pathway. J.Pharmacol.Exp.Ther. 341 274. PMID:22267202.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=343197	SQ1533			May-2012
4513	Kartogenin	[4727-31-5]	O=C(NC2=CC=C(C3=CC=CC=C3)C=C2)C1=CC=CC=C1C(O)=O	Potently induces chondrogenesis in MSCs	Potently induces differentiation of human mesenchymal stem cells into chondrocytes (EC50 = 100 nM). Reduces disease severity in a mouse model of osteoarthritis; displays protective effects against osteoarthritic stimuli in mature chondrocytes in vitro.	Johnson et al (2012) A stem cell-based approach to cartilage repair. Science 336 717. PMID:22491093.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=343331	SQ1533			Jul-2012
4514	JW 55	[664993-53-7]	O=C(NCC2(C3=CC=C(OC)C=C3)CCOCC2)C1=CC=C(NC(C4=CC=CO4)=O)C=C1	Tankyrase inhibitor; inhibits canonical Wnt signaling	Inhibitor of the PARP domain of tankyrase 1 and 2 (TNKS1/2). Activity results in stabilization of Axin2 and increased degradation of _-catenin; inhibits the _-catenin signaling pathway. Also shown to decrease canonical Wnt signaling in SW480 and HCT-15 colon carcinoma cell lines; reduces cell cycle progression and proliferation in SW480 cells in vitro.	Waaler et al (2012) A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice. Cancer Res. 72 2822. PMID:22440753.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=343332	SQ1341			Aug-2012
4515	2-Deoxy-D-glucose	[154-17-6]	OC1C[C@@H](O)[C@H](O)[C@@H](CO)O1	Non-metabolizable glucose analog; hexokinase substrate	Non-metabolizable glucose analog. Inhibits phosphorylation of glucose by hexokinase; causes depletion of cellular ATP. Also inhibits phosphoglucose isomerase (PGI) competitively. Causes cell cycle inhibition and cell death in in vitro models of hypoxia; blocks tumor cell growth in animal models. Also shown to induce the unfolded protein response (UPR).	"Maher et al (2004) Greater cell cycle inhibition and cytotoxicity induced by 2-deoxy-D-glucose in tumor cells treated under hypoxic vs aerobic conditions. Cancer Chemother.Pharmacol. 53 116. PMID:14605866. Kang and Hwang (2006) 2-deoxyglucose: an anticancer and antiviral therapeutic, but not any more a low glucose mimetic. Life Sci. 78 1392. PMID:16111712. Ralser et al (2008) A catabolic block does not sufficiently explain how 2-deoxy-D-glucose inhibits cell growth. Proc.Natl.Acad.Sci.USA 105 17807."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=344023	SQ1533			Jul-2012
4516	UNC 926 hydrochloride	[1184136-10-4]	BrC1=CC=CC(C(N2CCC(N3CCCC3)CC2)=O)=C1.Cl	L3MBTL1 domain inhibitor	Methyl-lysine (Kme) reader domain inhibitor; binds to the MBT domain of the L3MBTL1 protein (Kd = 3.9 _M). Selectively inhibits the L3MBTL13XMBT-H4K20me1 interaction in a peptide pull down assay.	Herold et al (2012) Structure-activity relationships of methyl-lysine reader antagonists. Med.Chem.Comm 3 45.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=344024	SQ1341			Aug-2012
4517	NS 2028	[204326-43-2]	BrC1=CC=C(OCC(N23)=NOC3=O)C2=C1	Potent soluble guanylyl cyclase (sGC) inhibitor	Potent soluble guanylyl cyclase (sGC) inhibitor (Ki = 8 nM). Blocks sGC activity in murine cerebellum induced by S-nitroso-glutathione and NMDA (IC50 values are 17 and 20 nM respectively). Inhibits VEGF-induced cGMP accumulation; abolishes VEGF-induced migration in postcapillary venular endothelial cells (CVEC).	Olesen et al (1998) Characterization of NS 2028 as a specific inhibitor of soluble guanylyl cyclase. Br.J.Pharmacol. 123 299. PMID:9489619. von Wantoch Rekowski et al (2010) Synthesis and biological evaluation of oxadiazole derivatives as inhibitors of soluble guanylyl cyclase. Bioorg.Med.Chem. 18 1288. PMID:20036129. Morbidelli et al (2010) The soluble guanylyl cyclase inhibitor NS-2028 reduces vascular endothelial growth factor-induced angiogenesis and permeability. Am.J.Physiol.Regul.Integr.Comp.Physiol. 298 R824. PMID:20032260.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=344025	SQ1341			Aug-2012
4518	EPPTB	[1110781-88-8]	O=C(NC3=CC(OCC)=CC=C3)C1=CC(C(F)(F)F)=C(N2CCCC2)C=C1	Trace amine 1 (TA1) receptor antagonist/inverse agonist	"Trace amine 1 (TA1) receptor antagonist/inverse agonist; exhibits a higher potency at the mouse TA1 receptor than the rat and human TA1 receptors (IC50 values are 27.5, 4539 and 7487 nM, respectively). Blocks the TA1 receptor-mediated activation of an inwardly rectifying K+ current, which increases the firing frequency of dopamine (DA) neurons in the ventral tegmental area. Increases DA potency at the D2 receptor. Also displays inverse agonism, reducing basal cAMP levels in vitro (IC50 = 19 nM)."	Bradaia et al (2009) The selective antagonist EPPTB reveals TAAR1-mediated regulatory mechanisms in dopaminergic neurons of the mesolimbic system. Proc.Natl.Acad.Sci.U.S.A. 106 20081. PMID:19892733.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=344039				Nov-2014
4519	ML 213	[489402-47-3]	O=C(NC3=C(C)C=C(C)C=C3C)C1CC2CCC1C2	KV7.2 and KV7.4 channel opener	"Selective KV7.2 (KCNQ2) and KV7.4 (KCNQ4) channel opener (EC50 values are 230 and 510 nM for KV7.2 and KV7.4 respectively). Displays > 80-fold selectivity against KV7.1, KV7.3 and KV7.5 in a thallium-based fluorescence assay."	"Yu et al (2011) Discovery, synthesis, and structure activity relationship of a series of N-aryl-bicyclo[2.2.1]heptane-2-carboxamides: Characterization of ML213 as a novel KCNQ2 and KCNQ4 potassium channel opener. ACS Chem.Neurosci. 2 572. PMID:22125664."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=344040	SQ1341			Jul-2012
4520	Cytarabine	[147-94-4]	O[C@@H]1[C@@H](CO)OC(N2C=CC(N)=NC2=O)[C@H]1O	Nucleoside analog; inhibits DNA replication	Nucleoside analog of deoxycytidine; inhibits DNA replication by incorporating into DNA (IC50 = 0.04 _M in L1210 and CEM cell lines). Displays no inhibitory effects on RNA synthesis. Causes S phase cell cycle arrest in ML-1 cell lines; cytotoxic in L5817Y leukemia cells. Antineoplastic and antileukemic agent.	Yang et al (1986) Effect of cytarabine upon metabolism of phospholipids in leukemia L5178Y cells. Acta Pharmacol. Sin. 7 368. PMID:2954403. Breistl et al (1999) Antitumor activity of P-4055 (elaidic acid-cytarabine) compared to cytarabine in metastatic and s.c. human tumor xenograft models. Cancer Res. 59 2944. PMID:10383159. Sampath et al (2006) Pharmacodynamics of cytarabine alone and in combination with 7-hydroxystaurosporine (UCN-01) in AML blasts in vitro and during a clinical trial. Blood. 107 2517. PMID:16293603.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=344239	SQ1533			May-2012
4521	TAS 301	[193620-69-8]	O=C2NC1=CC=CC=C1/C2=C(C4=CC=C(OC)C=C4)\C3=CC=C(OC)C=C3	Inhibitor of smooth muscle cell migration and proliferation	Inhibitor of smooth muscle cell migration and proliferation. Blocks voltage-independent calcium influx and downstream PKC signaling. Inhibits neointimal thickening after balloon catheter injury to the rat common carotid artery.	"Muranaka et al (1998) TAS-301, an inhibitor of smooth muscle cell migration and proliferation, inhibits intimal thickening after balloon injury to rat carotid arteries. J.Pharmacol.Exp.Ther. 285 1280. PMID:9618434. Sasaki et al (2000) TAS-301 blocks receptor-operated calcium influx and inhibits rat vascular smooth muscle cell proliferation induced by basic fibroblast growth factor and platelet-derived growth factor. Jpn.J.Pharmacol. 84 252. PMID:11138725."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=344584	SQ1341			Aug-2013
4522	Flufenamic acid	[530-78-9]	O=C(C1=C(NC2=CC=CC(C(F)(F)F)=C2)C=CC=C1)O	Activates TRPC6; NSAID	Nonsteroidal anti-inflammatory drug (NSAID). Inhibits calcium-activated chloride channels (CaCCs). Also increases currents through TRPC6 channels and inhibits currents through TRPC3 and TRPC7 channels.	White and Aylwin (1990) Niflumic and flufenamic acids are potent reversible blockers of Ca2(+)-activated Cl- channels in Xenopus oocytes. Mol.Pharmacol. 37 720. PMID:1692608. Tu et al (2009) Diacylglycerol analogues activate second messenger-operated calcium channels exhibiting TRPC-like properties in cortical neurons. J.Neurochem. 108 126. PMID:19094061. Foster et al (2009) Flufenamic acid is a tool for investigating TRPC6-mediated calcium signalling in human conditionally immortalised podocytes and HEK293 cells. Cell Calcium 45 384. PMID:19232718. Chi et al (2011) Nonsteroidal anti-inflammatory drug flufenamic acid is a potent activator of AMP-activated protein kinase. J.Pharmacol.Exp.Ther. 339 257. PMID:21765041.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=344598	SQ1533			May-2012
4523	DIDS	[67483-13-0]	[Na+].[Na+].[O-]S(=O)(=O)C1=C(\C=C\C2=C(C=C(C=C2)N=C=S)S([O-])(=O)=O)C=CC(=C1)N=C=S	Chloride channel blocker; TRPV1 modulator; RAD51 recombinase inhibitor	ClC-Ka chloride channel blocker (IC50 = 100 _M). Blocks the maxi chloride channel in apical membranes from human placenta. Displays antagonistic activity at TRPM4 and TRPC4 channels; potentiates agonist-induced TRPV1 currents (IC50 = 4.88 _M in rat DRG neurons). Inhibits RAD51 recombinase activity (KD = 2 _M).	"Riquelme and Parra et al (1999) Regulation of human placental chloride channel by arachidonic acid and other cis unsaturated fatty acids. Am.J.Obstet.Gynecol. 180 469. PMID:9988821. Wulff (2008) New light on the ""old"" chloride channel blocker DIDS. ACS Chem.Biol. 3 399. PMID:18642798. Ishida et al (2009) DIDS, a chemical compound that inhibits RAD51-mediated homologous pairing and strand exchange. Nucleic Acids Res. 37 3367. PMID:19336413. Zhang et al (2012) Agonist-dependent potentiation of vanilloid receptor transient receptor potential vanilloid type 1 function by stilbene derivatives. Mol.Pharmacol. 81 689. PMID:22328719."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=344599	SQ1070			Jun-2012
4524	EGCG	[989-51-5]	O=C(C4=CC(O)=C(O)C(O)=C4)O[C@@H]2CC1=C(O)C=C(O)C=C1O[C@@H]2[C@]3=CC(O)=C(O)C(O)=C3	Inhibits formation of amyloid fibrils	"Inhibitor of amyloid assembly; inhibits the formation of amyloid fibrils by proteins such as A_, _-synuclein and huntingtin. Also inhibits _-secretase (IC50 = 1.6 _M). Reduces A_42-induced cell death in three different cell types. Also inhibits cell growth and selectively induces apoptosis in A431 and human pancreatic cancer cells."	"Ahmad et al (2000) Green tea polyphenol epigallocatechin-3-gallate differentially modulates nuclear factor _B in cancer cells versus normal cells. Ach.Biochem.Biophys. 376 338. PMID:10775421. Jeon et al (2003) Green tea catechins as a BACE1 (_-secretase) inhibitor. Bioorg.Med.Chem.Lett. 13 3905. PMID:14592472. Lee et al (2005) Mechanisms for the inhibition of DNA methyltransferases by tea catechins and bioflavonoids. Mol.Pharmacol. 68 1018. PMID:16037419. Shankar et al (2008) EGCG inhibits growth, invasion, angiogenesis and metastastasis of pancreatic cancer. Front.Biosci. 13 440. PMID:17981559. Sinha et al (2012) Comparison of three amyloid assembly inhibitors: the sugar scyllo-inositol, the polyphenol epigallocatechin gallate, and the molecular tweezer CLR01. ACS Chem.Neurosci. 3 451. PMID:22860214."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=344801				May-2012
4525	Piclamilast	[144035-83-6]	O=C(NC3=C(Cl)C=NC=C3Cl)C1=CC(OC2CCCC2)=C(OC)C=C1	Potent and selective PDE4 inhibitor	"Potent and selective inhibitor of phosphodiesterase (PDE) 4 (IC50 = 1 nM at PDE4 from human neutrophils). Displays >19,000-fold selectivity over other PDE isoenzymes. Exhibits anti-inflammatory effects in models of allergic inflammation. Also inhibits LTB4 synthesis in human neutrophils (IC50 = 2 nM)."	"Raeburn et al (1994) Anti-inflammatory and bronchodilator properties of RP 73401, a novel and selective phosphodiesterase type IV inhibitor. Br.J.Pharmacol. 113 1423. PMID:7889300. Hatzelmann and Schudt (2001) Anti-inflammatory and immunomodulatory potential of the novel PDE4 inhibitor roflumilast in vitro. J.Pharmacol.Exp.Ther. 297 267. PMID:11259554. Zhao et al (2003) Inhibitor binding to type 4 phosphodiesterase (PDE4) assessed using [3H]piclamilast and [3H]rolipram. J.Pharmacol.Exp.Ther. 305 565. PMID:12704225."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=344802	SQ1070			Aug-2012
4527	TC-I 15	[916734-43-5]	CC1(C)SCN(S(C3=CC=CC=C3)(=O)=O)[C@@H]1[C@@](N[C@H](C(O)=O)CNC(NCC2=CC=CC=C2)=O)=O	Potent _2_1 inhibitor; displays antithrombotic activity in vivo	"Potent _2_1 integrin inhibitor (IC50 values for the inhibition of human platelet adhesion to type I collagen are 12 and 715 nM for platelets under static conditions and under flow, respectively). Displays selectivity for _2_1 over _v_3, _5_1, _6_1 and _IIb_3 at concentrations exceeding 1000 nM. Reduces collagen IV production in mesangial cells. Active in vivo; prevents ferric chloride-induced clot formation in mice."	Miller et al (2009) Small-molecule inhibitors of integrin _2_1 that prevent pathological thrombus formation via an allosteric mechanism. Proc.Natl.Acad.Sci.U.S.A. 106 719. PMID:19141632. Borza et al (2012) Inhibition of integrin _2_1 ameliorates glomerular injury. J.Am.Soc.Nephrol. 23 1027. PMID:22440900.	Small Molecule	Sold under license from the University of Pennsylvania.	http://www.tocris.com/dispprod.php?ItemId=345234	SQ1341			Jul-2013
4528	()-NBI 74330	[473722-68-8]	CCOC(C=C3)=CC=C3N2C(C1=CC=CN=C1N=C2C(N(CC4=CC=CN=C4)C(CC5=CC(C(F)(F)F)=C(F)C=C5)=O)C)=O	Potent and selective CXCR3 antagonist	Potent and selective CXCR3 antagonist; potently inhibits 125I-CXCL10 binding to CXCR3 (pKi = 8.13). Inhibits calcium mobilization in response to CXCL11 and CXCL10 in RBL cells. Exhibits no significant effect on chemotaxis induced by CXCR4 or CCR7. Displays a five-fold greater affinity for CXCR3 than ()-AMG 487 (Cat. No. 4487).	"Heise et al (2005) Pharmacological characterization of CXC chemokine receptor 3 ligands and a small molecule antagonist. J.Pharmacol.Exp.Ther. 313 1263. PMID:15761110. Storelli et al (2007) Synthesis and structure-activity relationships of 3H-quinazolin-4-ones and 3H-pyrido[2,3-d]pyrimidin-4-ones as CXCR3 receptor antagonists. Arch.Pharm. 340 281. PMID:17562560. Verzijl et al (2008) Noncompetitive antagonism and inverse agonism as mechanism of action of nonpeptidergic antagonists at primate and rodent CXCR3 chemokine receptors. J.Pharmacol.Exp.Ther. 325 544. PMID:18270317."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=345348	SQ1341			Mar-2014
4529	Ciliobrevin A	[302803-72-1]	O=C(C1=CC=CC=C1N2)N/C2=C(C(C3=C(Cl)C=C(Cl)C=C3)=O)\C#N	Hedgehog (Hh) pathway antagonist; inhibits ciliogenesis	Hedgehog (Hh) pathway antagonist; blocks Sonic hedgehog (Shh)-induced Hh pathway activation (IC50 = 7 _M) downstream of Smo. Peturbs primary cilia formation; inhibits cytoplasmic AAA+ ATPase dynein-dependent microtubule gliding and ATPase activity.	Hyman et al (2009) Small-molecule inhibitors reveal multiple strategies for Hedgehog pathway blockade. Proc.Natl.Acad.Sci.U.S.A. 106 14132. PMID:19666565. Firestone et al (2012) Small-molecule inhibitors of the AAA+ ATPase motor cytoplasmic dynein. Nature 484 7392. PMID:22425997.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=345424	SQ1341			Aug-2012
4531	NCX 4040	[287118-97-2]	O=C(C)OC1=C(C(OC2=CC=C(CO[N+]([O-])=O)C=C2)=O)C=CC=C1	NO-donating aspirin; anti-inflammatory and antitumor	"NO-donating aspirin; anti-inflammatory. Blocks inflammatory mediator production in isolated human monocytes (IC50 values are 0.07, 0.13, 0.15 and 0.18 _M for IL-1_, PGE2, IL-10 and TNF-_ respectively). Decreases COX-2 expression (IC50 = 0.13 _M); disrupts proteasome-mediated degradation of i_B-_. Antiproliferative in HCT116 colon cancer cells; sensitizes drug-resistant ovarian tumor cells to cisplatin (Cat. No. 2251)."	"Yamakawa et al (2008) Growth inhibition of human colon cancer cell line HCT116 by bis[2-(acylamino)phenyl] disulfide and its action mechanism. Biol.Pharm.Bull. 31 916. PMID:18451518. Bratasz et al (2008) NCX-4040, a nitric oxide-releasing aspirin, sensitizes drug-resistant human ovarian xenograft tumors to cisplatin by depletion of cellular thiols. J.Transl.Med. 6 9. PMID:18302761. Ricciotti et al (2010) NCX 4040, a nitric oxide-donating aspirin, exerts anti-inflammatory effects through inhibition of I kappa B-alpha degradation in human monocytes. J.Immunol. 184 2140. PMID:20065114."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=345928	SQ1341			Jun-2012
4532	VUF 10166	[155584-74-0]	ClC2=NC1=CC=CC=C1N=C2N3CCN(C)CC3	High affinity 5-HT3 receptor antagonist	High affinity 5-HT3 receptor antagonist (IC50 values are 0.04 and 22 nM for human 5HT3A and 5-HT3AB receptors respectively). Exhibits partial agonist activity at 5-HT3A receptors at higher concentrations (EC50 = 5.2 _M). Also histamine H4 receptor antagonist (pKi = 6.64 in HEK cells).	"Smits et al (2008) Fragment based design of new H4 receptor-ligands with anti-inflammatory properties in vivo. J.Med.Chem. 51 2457. PMID:18357976. Thompson et al (2012) VUF10166, a novel compound with differing activities at 5-HT3A and 5-HT3AB receptors. J.Pharmacol.Exp.Ther. 341 350. PMID:22306960."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=345948	SQ1341			Jun-2012
4534	CZC 54252 hydrochloride	[1191911-27-9]	ClC1=C(NC3=CC=CC=C3NS(C)(=O)=O)N=C(NC2=C(OC)C=C(N4CCOCC4)C=C2)N=C1.Cl	Potent LRRK2 inhibitor; neuroprotective	Potent inhibitor of leucine-rich repeat kinase 2 (LRRK2) (IC50 values are 1.28 nM and 1.85 nM for wild-type and G2019S mutant forms of LRRK2 respectively). Attenuates neuronal injury induced by LRRK2-G2019S mutant activity in primary human neurons (EC50 = 1 nM).	Ramsden et al (2011) Chemoproteomics-based design of potent LRRK2-selective lead compounds that attenuate Parkinson's disease-related toxicity in human neurons. ACS Chem.Biol. 6 1021. PMID:21812418. Kramer et al (2012) Small molecule kinase inhibitors for LRRK2 and their application to Parkinson's disease models. ACS Chem.Neurosci. 3 151. PMID:22860184.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=346276	SQ1341			Nov-2012
4536	Resiquimod	[144875-48-9]	NC1=C3C(N(CC(C)(O)C)C(COCC)=N3)=C2C(C=CC=C2)=N1	Toll-like receptor 7 (TLR7) agonist	"Toll-like receptor 7 (TLR7) agonist. Induces upregulation of IL-6, IL-12, IFN-_ and iNOS expression in mouse bone marrow-derived macrophages (BMMs). Inhibits RANKL-induced osteoclast differentiation in mouse BMMs and human peripheral blood monocytes. Pro-inflammatory and antiviral."	"Wagner et al (1999) Modulation of TH1 and Th2 cytokine production with the immune response modifiers, R-848 and imiquimod. Cell Immunol. 191 10. PMID:9918682. Dockrell and Kinghorn (2001) Imiquimod and resiquimod as novel immunomodulators. J.Antimicrob.Chemother. 48 751. PMID:11733457. Miyamoto et al (2012) R848, a toll-like receptor 7 agonist, inhibits osteoclast differentiation but not survival or bone-resorbing function of mature osteoclasts. Cytotechnology. 64 331. PMID:22358541."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=346280	SQ1070			Jun-2012
4538	T16Ainh - A01	[552309-42-9]	CC1=NC(SCC(NC2=NC(C3=CC=C(OC)C=C3)=CS2)=O)=NC(O)=C1CC	Ca2+-activated Cl- channel transmembrane protein 16A (TMEM16A) inhibitor	Inhibitor of Ca2+-dependent Cl- channel (CaCC) transmembrane protein 16A (TMEM16A) (IC50 = 1.8 _M in A253 salivary gland epithelial cells). Inhibits EGF-induced increases in CaCC currents; blocks proliferation of tumor cells in vitro.	Namkung et al (2011) TMEM16A inhibitors reveal TMEM16A as a minor component of calcium-activated chloride channel conductance in airway and intestinal epithelial cells. J.Biol.Chem. 286 2365. PMID:21084298. Mroz and Keely (2012) Epidermal growth factor chronically upregulates Ca2+-dependent Cl- conductance and TMEM16A expression in intestinal epithelial cells. J.Physiol. 590 1907. PMID:22351639. Duvvuri et al (2012) TMEM16A induces MAPK and contributes directly to tumorigenesis and cancer progression. Cancer Res. [Epub ahead of print]. PMID:22564524.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=346419	SQ1341			Jul-2012
4539	(R)-(+)-Etomoxir sodium salt	[828934-41-4]	[Na+].[O-]C(=O)[C@@]1(CCCCCCOC2=CC=C(Cl)C=C2)CO1	Carnitine palmitoyltransferase I (CPT1) inhibitor	Inhibitor of carnitine palmitoyltransferase I (CPT1); inhibits _-oxidation in mitochondria. Shown to inhibit cardiolipin biosynthesis from exogenous fatty acid in H9c2 cells.	"Agius et al (1991) Stereospecificity of the inhibition of etomoxir of fatty acid and cholesterol synthesis in isolated rat hepatocytes. Biochem.Pharmacol. 42 1717. PMID:1930298. Rupp et al (1992) Modification of subcellular organelles in pressure-overloaded heart by etomoxir, a carnitine palmitoyltransferase I inhibitor. FASEB J. 6 2349. PMID:1531968. Xu et al (2003) Etomoxir mediates differential metabolic channeling of fatty acid and glycerol precursors into cardiolipin in H9c2 cells. J.Lipid Res. 44 415. PMID:12576524."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=346420	SQ1341			Aug-2012
4540	U 104	[178606-66-1]	FC1=CC=C(NC(NC2=CC=C(S(=O)(N)=O)C=C2)=O)C=C1	Potent carbonic anhydrase (CA) IX and XII inhibitor	"Potent carbonic anhydrase (CA) inhibitor (Ki values are 4.5, 45.1, 5080 and 9640 nM for CA XII, CA IX, CA I and CA II respectively in MDA-MB-231 cells). Inhibits tumor metastasis in the rat 4T1 metastasis model."	Lou et al (2011) Targeting tumor hypoxia: suppression of breast tumor growth and metastasis by novel carbonic anhydrase IX inhibitors. Cancer Res. 71 3364. PMID:21415165.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=346572	SQ1341			Jul-2012
4541	SGC 0946		O[C@H]([C@H](O)[C@@H](CN(C(C)C)CCCNC(NC4=CC=C(C(C)(C)C)C=C4)=O)O3)[C@@H]3N1C2=C(C(N)=NC=N2)C(Br)=C1	Highly potent and selective DOT1L inhibitor; cell permeable	"Potent DOT1L methyltransferase inhibitor (KD = 0.06 nM, IC50 = 0.3 nM in a radioactive assay); blocks H3K79 methylation in A431 cells and MCF10A cells. Inactive at 12 histone methyltransferases and DNMT1. Selectively kills cells transformed with the MLL-AF9 fusion oncogene in an in vitro model of leukemia; lowers levels of MLL target genes HOXA9 and Meis1."	Yu et al (2012) Catalytic site remodelling of the DOT1L methyltransferase by selective inhibitors. Nat.Commun. 3 1288. PMID:23250418.	Small Molecule	"This probe is supplied in conjunction with the Structural Genomics Consortium. For further characterization details, please visit the SGC 0946 probe summary on the SGC website."	http://www.tocris.com/dispprod.php?ItemId=346884	SQ1533			Mar-2013
4543	CS 2100	[913827-99-3]	CCC1=C(C2=NOC(C4=CC=C(OC5=CC=CC=C5)C=C4)=N2)SC(CN3CC(C(O)=O)C3)=C1	Selective S1P1 agonist	Sphingosine-1-phosphate receptor 1 (S1P1) agonist (EC50 = 4.0 nM). Exhibits 5000-fold selectivity for human S1P1 over S1P3. Displays efficacy in a rat adjuvant-induced arthritis model.	"Nakamura et al (2012) Synthesis and evaluation of CS-2100, a potent, orally active and S1P3-sparing S1P1 agonist. Eur.J.Med.Chem. 51 92. PMID:22405291. Nakamura et al (2012) Discovery of CS-2100, a potent, orally active and S1P3-sparing S1P1 agonist. Bioorg.Med.Chem.Lett. 22 1788. PMID:22264485."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=347240	SQ1341			Feb-2013
4544	YM 244769	[837424-39-2]	NC1=CC=CC(CNC(C2=CN=C(OC3=CC=C(OCC4=CC=CC(F)=C4)C=C3)C=C2)=O)=C1.Cl.Cl	Na+/Ca2+ exchange inhibitor (reverse mode); neuroprotective	"Inhibitor of the reverse mode of Na+/Ca2+ exchange (NCX). Potently inhibits Na+-dependent 45Ca2+ uptake (IC50 values are 18, 68 and 96 nM for CCL39 cells transfected with NCX3, NCX1 and NCX2 respectively). Displays selectivity for NCX over other Na+ and Ca2+ transporters. Protects against hypoxia/reoxygenation-induced cell damage in neuronal SH-SY5Y cells expressing NCX1 and NCX3."	"Iwamoto and Kita (2006) YM-244769, a novel Na+/Ca2+ exchange inhibitor that preferentially inhibits NCX3, efficiently protects against hypoxia/reoxygenation-induced SH-SY5Y neuronal cell damage. Mol.Pharmacol. 70 2075. PMID:16973719. Iwamoto et al (2007) Na+/Ca2+ exchange inhibitors: a new class of calcium regulators. Cardiovasc.Hematol.Disord.Drug Targets 7 188. PMID:17896959."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=347241	SQ1341			Jan-2013
4547	ACHP	[406208-42-2]	OC1=CC=CC(OCC3CC3)=C1C2=NC(N)=C(C#N)C(C4CCNCC4)=C2	Selective IKK_ and IKK_ inhibitor	"I_B kinase inhibitor (IC50 values are 8.5 and 250 nM for IKK_ and IKK_ respectively). Selective for IKK_ and IKK_ over IKK3, Syk and MAPKKK4 (IC50 values are > 20 _M). Inhibits DNA binding activity of NF-_B. Blocks NF-_B pathway in multiple myeloma cell lines; induces cell growth arrest and apoptosis."	Sanda et al (2005) Growth inhibition of multiple myeloma cells by a novel I_B kinase inhibitor. Clin.Cancer Res. 11 1974. PMID:15756023.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=348066	SQ1533			Mar-2013
4549	ML 133 hydrochloride	[1222781-70-5]	COC(C=C3)=CC=C3CNCC1=C(C=CC=C2)C2=CC=C1.Cl	Kir2 channel blocker	"Selective blocker of inwardly rectifying Kir2 potassium channels (IC50 values are 1.8, 2.8, 2.9 and 4.0 _M at pH 7.4 for mKir2.1, hKir2.6, hKir2.2 and hKir2.3 respectively). Exhibits no effect on rKir1.1 (IC50 > 300 _M); displays weak activity at hKir7.1 and rKir4.1 (IC50 values are 33 and 76 _M)."	"Wu et al (2010) A potent and selective small molecule Kir2.1 inhibitor. Probe Reports from the NIH Molecular Libraries Pro. PMID:21433384. Wang et al (2011) Selective inhibition of the Kir2 family of inward rectifier potassium channels by a small molecule probe: the discovery, SAR, and pharmacological characterization of ML133. ACS Chem.Biol. 6 845. PMID:21615117."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=348240	SQ1341			Aug-2012
4550	IQ 3	[312538-03-7]	O=C(C5=CC=CO5)O/N=C3C2=NC1=CC=CC=C1N=C2C4=C/3C=CC=C4	Selective JNK3 inhibitor	"Selective JNK3 inhibitor (Kd values are 66, 240 and 290 nM for JNK3, JNK1 and JNK2 respectively). Inhibits NF-_B/AP1 transcriptional activity in THP1-Blue cells (IC50 = 1.4 _M). Also inhibits TNF-_ and IL-6 production in vitro."	Schepetkin et al (2012) Identification and characterization of a novel class of c-Jun N-terminal kinase inhibitors. Mol.Pharmacol. 81 832. PMID:22434859.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=348241	SQ1341			Feb-2014
4551	Purmorphamine	[483367-10-8]	C1(OC4=CC=CC5=C4C=CC=C5)=NC(NC3=CC=C(N6CCOCC6)C=C3)=C2C(N(C7CCCCC7)C=N2)=N1	Smo receptor agonist	"Smoothened (Smo) receptor agonist (EC50 ~ 1 _M). Induces osteogenesis in mouse mesenchymal progenitor cells (C3H10T1/2). When combined with BMP-4, can transdifferentiate pre-adipocytes (3T3-L1) and myoblasts (C2C12) into osteoblasts. Induces differentiation of multipotent mesenchymal progenitor cells into osteoblasts."	Wu et al (2002) A small molecule with osteogenesis-inducing activity in multipotent mesenchymal progenitor cells. J.Am.Chem.Soc. 124 14520. PMID:12465946. Wu et al (2004) Purmorphamine induces osteogenesis by activation of the hedgehog signaling pathway. Chem.Biol. 11 1229. PMID:15380183. Sinha et al (2006) Purmorphamine activates the Hedgehog pathway by targeting Smoothened. Nat.Chem.Biol. 2 29. PMID:16408088.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=348242	SQ1341			Mar-2014
4552	A 412997 dihydrochloride	[1347744-96-0]	O=C(CN2CCC(C3=CC=CC=N3)CC2)NC1=CC=CC(C)=C1.Cl.Cl	Selective D4 agonist	Selective agonist for the dopamine D4 receptor (Ki values are 7.9 and 12.1 nM for human D4 and rat D4 receptors). Displays no affinity (<1000 nM) for other dopamine receptors. Shows efficacy in rat models of ADHD and short-term memory.	"Browman et al (2005) A-412997, a selective dopamine D4 agonist, improves cognitive performance in rats. Pharmacol.Biochem.Behav. 82 148. PMID:16154186. Moreland et al (2005) A-412997 is a selective dopamine D4 receptor agonist in rats. Pharmacol.Biochem.Behav. 82 140. PMID:16153699. Patel et al (2006) Discovery of 3-methyl-N-(1-oxy-3',4',5',6'-tetrahydro-2'H-[2,4'-bipyridine]-1'-ylmethyl)benzamide (ABT-670), an orally bioavailable dopamine D4 agonist for the treatment of erectile dysfunction. J.Med.Chem. 49 7450. PMID:17149874."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=348516	SQ1070			Jul-2012
4553	Azilsartan	[147403-03-0]	O=C1NC(C2=CC=CC=C2C(C=C5)=CC=C5CN4C3=C(C(O)=O)C=CC=C3N=C4OCC)=NO1	Potent AT1 receptor inverse agonist; antihypertensive	Potent angiotensin II type 1 (AT1) receptor inverse agonist (IC50 = 2.6 nM at the human AT1 receptor). Inhibits angiotensin II-induced IP1 accumulation in COS-7 cells; decreases maximal contraction of rabbit aortic strips in a concentration-dependent manner (pD'2 = 9.9). Antihypertensive; prevents vascular cell proliferation and expression of PAI-1.	"Kajiya et al (2011) Molecular and cellular effects of azilsartan: a new generation angiotensin II receptor blocker. J.Hypertens. 29 2476. PMID:21986624. French et al (2011) The angiotensin receptor blocker, azilsartan medoxomil (TAK-491), suppresses vascular wall expression of plasminogen activator inhibitor type-I protein potentially facilitating the stabilization of atherosclerotic plaques. J.Cardiovasc.Pharmacol. 58 143. PMID:21558880. Ojima et al (2011) In vitro antagonistic properties of a new angiotensin type 1 receptor blocker, azilsartan, in receptor binding and function studies. J.Pharmacol.Exp.Ther. 336 801. PMID:21123673."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=348517	SQ1070			Jul-2012
4554	GC 1	[211110-63-3]	CC1=CC(OCC(O)=O)=CC(C)=C1CC2=CC(C(C)C)=C(O)C=C2	High affinity thyroid receptor _ (TR_) and TR_ agonist; thyromimetic	Thyromimetic; high affinity agonist at thyroid hormone receptor (TR) _ and TR_ receptors (KD values are 67 and 440 pM respectively). Displays 5- and 100-fold greater potency than the endogenous agonist T3 in vitro at TR_1 and TR_1 receptors respectively. Promotes reverse cholesterol transport in chow- and fat-fed mice. Induces proliferation of hepatocytes and pancreatic acinar cells in rats independent of prior tissue injury.	Chiellini et al (1998) A high-affinity subtype-selective agonist ligand for the thyroid hormone receptor. Chem.Biol. 5 299. PMID:9653548. Johansson et al (2005) Selective thyroid receptor modulation by GC-1 reduces serum lipids and stimulates steps of reverse cholesterol transport in euthyroid mice. Proc.Natl.Acad.Sci. U S A 102 10297. PMID:16006512. Columbano et al (2006) The thyroid hormone receptor-_ agonist GC-1 induces cell proliferation in rat liver and pancreas. Endocrinology 147 3211. PMID:16574785.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=349544	SQ1070			Feb-2013
4555	HI TOPK 032	[487020-03-1]	O=C(C5=CC=CS5)NC4=CC3=C(C#N)C2=NC1=CC=CC=C1N=C2N3C=C4	Selective T-LAK-cell-originated protein kinase (TOPK) inhibitor	"T-LAK-cell-originated protein kinase (TOPK) inhibitor; exhibits selectivity for TOPK over other MAPKK family members including ERK1, JNK1 and p38. Blocks proliferation of HCT116 colon cancer cells; suppresses tumor growth in a colon cancer xenograft model. Also inhibits Chk1 (IC50 = 9.6 _M)."	Li et al (2011) Discovery of novel checkpoint kinase 1 inhibitors by virtual screening based on multiple crystal structures. J.Chem.Inf.Model. 51 2904. PMID:21955044. Kim et al (2012) Novel TOPK inhibitor HI-TOPK-032 effectively suppresses colon cancer growth. Cancer Res. 72 3060. PMID:22523035.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=349545	SQ1341			Jan-2013
4556	CP 690550 citrate	[540737-29-9]	C[C@H]1[C@@H](N(C2=NC=NC3=C2C=CN3)C)CN(C(CC#N)=O)CC1.OC(CC(O)=O)(C(O)=O)CC(O)=O	Potent JAK inhibitor	"Potent JAK inhibitor (IC50 values are 1, 20, and 112 nM for JAK3, JAK2 and JAK1 respectively). Orally active immunosuppressant; exhibits efficacy in rodent rheumatoid arthritis models."	"Jiang et al (2008) Examining the chirality, conformation and selective kinase inhibition of 3-((3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile (CP-690,550). J.Med.Chem. 51 8012. PMID:19053756. Flanagan et al (2010) Discovery of CP-690,550: a potent and selective Janus kinase (JAK) inhibitor for the treatment of autoimmune diseases and organ transplant rejection. J.Med.Chem. 53 8468. PMID:21105711. Dowty et al (2013) Preclinical to clinical translation of tofacitinib, a Janus kinase inhibitor, in rheumatoid arthritis. J.Pharmacol.Exp.Ther. 348 165. PMID:24218541."	Small Molecule	Sold for research purposes under agreement from Pfizer Inc.	http://www.tocris.com/dispprod.php?ItemId=349546	SQ1533			Dec-2012
4557	GTS 21 dihydrochloride	[156223-05-1]	COC(C=C3OC)=CC=C3\C=C1C(C2=CC=CN=C2)=NCCC/1.Cl.Cl	Partial agonist at _7 nAChR	Partial agonist of _7 nicotinic acetylcholine receptors (nAChRs); also a weak _4_2 and 5-HT3 antagonist at micromolar concentrations. Exhibits improved sensory inhibition in DBA/2 mice following both acute and chronic administration. Also shown to improve memory in several animal models; facilitates hippocampal long-term potentiation.	"Meyer et al (1994) Effects of anabaseine-related analogs on rat brain nicotinic receptor binding and on avoidance behaviors. Drug Dev.Res. 31 127. Stevens et al (2010) Continuous administration of a selective alpha7 nicotinic partial agonist, DMXBA, improves sensory inhibition without causing tachyphylaxis or receptor upregulation in DBA/2 mice. Brain.Res. 1352 140. PMID:20599427. Olincy et al (2012) Nicotinic mechanisms in the treatment of psychotic disorders: a focus on the a7 nicotinic receptor. Handb.Exp.Pharmacol. 213 211. PMID:23027417."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=349580	SQ1341			Apr-2014
4558	EMPA	[680590-49-2]	O=C(CN(C2=CN=C(OC)C=C2)S(C3=C(C)C=CC=C3)(=O)=O)N(CC)CC1=CN=CC=C1	Highly potent and selective OX2 antagonist; brain penetrant	"Highly potent, selective OX2 receptor antagonist (IC50 values are 2.3 nM and 1900 nM for OX2 and OX1 respectively). Displays negligible or no inhibition of a panel of 80 receptors. Blocks orexin-B- and orexin-A-invoked calcium mobilization in hOX2-expressing CHO cells (IC50 values are 7.9 nM and 8.8 nM respectively); reverses orexin-B-induced hyperlocomotion in mice. Brain penetrant."	"Malherbe et al (2009) Biochemical and behavioural characterization of EMPA, a novel high-affinity, selective antagonist for the OX2 receptor. Br.J.Pharmacol. 156 1326. PMID:19751316. Malherbe et al (2010) Mapping the binding pocket of dual antagonist almorexant to human orexin 1 and orexin 2 receptors: comparison with the selective OX1 antagonist SB-674042 and the selective OX2 antagonist N-ethyl-2-[(6-methoxy-pyridin-3-yl)-(toluene-2-sulfonyl)-amino]-N-pyridin-3-ylmethyl-acetamide (EMPA). Mol.Pharmacol. 78 81. PMID:20404073. Mochizuki et al (2011) Orexin receptor 2 expression in the posterior hypothalamus rescues sleepiness in narcoleptic mice. Proc.Natl.Acad.Sci.U.S.A 108 4471. PMID:21368172."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=349581				Jan-2013
4559	GNF 5837	[1033769-28-6]	O=C2NC1=CC(NC4=C(C)C=CC(NC(NC5=C(F)C=CC(C(F)(F)F)=C5)=O)=C4)=CC=C1/C2=C/C3=CC=CN3	"Potent Trk inhibitor; inhibits TrkA, TrkB and TrkC"	"Potent pan-Trk inhibitor. Displays antiproliferative effects in cellular Ba/F3 assays (IC50 values are 7, 9 and 11 nM for cells containing the fusion proteins Tel-TrkC, Tel-TrkB and Tel-TrkA, respectively). Exhibits selectivity for Trk receptors over a range of kinases, with some activity at PDGFR and c-Kit (IC50 values are 0.87 and 0.91 _M respectively). Orally bioavailable."	"Albaugh et al (2012) Discovery of GNF-5837, a selective TRK inhibitor with efficacy in rodent cancer tumor models. ACS Med.Chem.Lett. 3 140."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=349582	SQ1533			Jul-2013
4561	BIBN 4096	[204697-65-4]	O=C(N[C@H](CC4=CC(Br)=C(O)C(Br)=C4)C(N[C@@H](CCCCN)C(N5CCN(C6=CC=NC=C6)CC5)=O)=O)N(CC3)CCC3N2CC1=CC=CC=C1NC2=O	Potent and selective CGRP receptor antagonist	Potent and selective CGRP receptor antagonist (IC50 values are 0.03 and 6.4 nM for human and rat CGRP receptors respectively). Displays high affinity for human CGRP receptors (Ki = 14.4 pM); exhibits no significant affinity for 75 other receptors.	"Doods et al (2000) Pharmacological profile of BIBN4096BS, the first selective small molecule CGRP antagonist. Br.J.Pharmacol. 129 420. PMID:10711339. Rudolf et al (2005) Development of human calcitonin gene-related peptide (CGRP) receptor antagonists. 1. Potent and selective small molecule CGRP antagonists. 1-[N2-[3,5-Dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1- piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)piperazine: the first CGRP antagonist for clinical trials in acute migraine. J.Med.Chem. 48 5921. PMID:16161996."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=350358	SQ1070			Aug-2012
4562	Topotecan hydrochloride	[119413-54-6]	OC1=CC=C(N=C(C(N3C4)=CC([C@](CC)(O)C(OC5)=O)=C5C3=O)C4=C2)C2=C1CN(C)C.Cl	DNA topoisomerase I inhibitor; Camptothecin (Cat. No. 1100) analog	DNA topoisomerase I inhibitor; induces rapid apoptotic death in human B-lineage acute lymphoblastic leukemia (ALL) cells. Improves survival in three mouse models of poor prognosis ALL; downregulates B-Myb and MycN expression in neuroblastoma cells. Water-soluble analog of Camptothecin (Cat. No. 1100). Orally bioavailable.	Uckun et al (1995) In vitro and in vivo activity of topotecan against human B-lineage acute lymphoblastic leukemia cells. Blood 85 2817. PMID:7742543. Schellens et al (1996) Bioavailability and pharmacokinetics of oral topotecan: a new topoisomerase I inhibitor. Br.J.Cancer 73 1268. PMID:8630291. Sottile et al (2012) A chemical screen identifies the chemotherapeutic drug topotecan as a specific inhibitor of the B-MYB/MYCN axis in neuroblastoma. Oncotarget. 3 535. PMID:22619121.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=350359	SQ1533			Jul-2012
4565	ML 228	[1357171-62-0]	C1(C2=NC(NCC4=CC=C(C5=CC=CC=C5)C=C4)=C(C3=CC=CC=C3)N=N2)=NC=CC=C1	HIF pathway activator	"HIF pathway activator (EC50 values are 1.23 and 1.4 _M for HRE gene reporter assay and HIF-1_ nuclear translocation assay respectively); acts via chelation of iron, independently of PHD. Also exhibits > 80% inhibition of the human A3 receptor, dopamine transporter, _ receptor, hERG and 5-HT2B receptor, and rat sodium channel site 2, at a concentration of 10 _M."	Theriault et al (2012) Discovery of a new molecular probe ML228: an activator of the hypoxia inducible factor (HIF) pathway. Bioorg.Med.Chem.Lett. 22 76. PMID:22172704.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=350487	SQ1341			Apr-2013
4566	NSC 687852	[1009817-63-3]	O=C(/C(CN(C(C=C)=O)C3)=C/C2=CC=C([N+]([O-])=O)C=C2)/C3=C/C1=CC=C([N+]([O-])=O)C=C1	Inhibitor of UCHL5 and USP14	"Inhibitor of 19S regulatory particle associated deubiquitylating enzymes (DUBs), UCHL5 and USP14. Shows minimal inhibition of UCHL-1, UCHL-3, USP2, USP7, USP, BAP1 and proteasome activity. Induces apoptosis by cathepsin D-dependent caspase-cleavage (IC50 = 0.5 _M). Displays antitumor activity in vivo."	Berndtsson et al (2009) Induction of the lysosomal apoptosis pathway by inhibitors of the ubiquitin-proteasome system. Int.J.Cancer 124 1463. PMID:19089926. D'Arcy et al (2011) Inhibition of proteasome deubiquitinating activity as a new cancer therapy. Nat.Med. 17 1636. PMID:22057347.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=350488				Sep-2013
4567	CCG 50014	[883050-24-6]	FC(C=C3)=CC=C3CN(C(N(C2=CC=C(C)C=C2)S1)=O)C1=O	Potent and selective inhibitor of regulator of G-protein signaling 4 (RGS4) protein	Potent and selective inhibitor of regulator of G-protein signaling 4 (RGS4) protein (IC50 values are 30.1 nM and 11.0 _M for RGS4 and RGS8 respectively). Exhibits >20-fold selectivity for RGS4 over other RGS proteins.	Blazer et al (2011) A nanomolar potency small molecule inhibitor of regulator of G protein signaling (RGS) proteins. Biochemistry 50 3181. PMID:21329361. Turner et al (2012) Small molecule inhibitors of regulators of G protein signalling (RGS) proteins. ACS Med.Chem.Lett. 3 146. PMID:22368763. Vashisth et al (2013) Conformational dynamics of a regulator of g-protein signaling protein reveals a mechanism of allosteric inhibition by a small molecule. ACS Chem.Biol. 8 2778. PMID:24093330.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=350489				Aug-2012
4569	PS 1145 dihydrochloride	[1049743-58-9]	ClC1=CC(NC(C4=CC=CN=C4)=O)=C(NC3=C2C=CN=C3)C2=C1.Cl.Cl	Selective IKK inhibitor; orally active	"Selective I_B kinase (IKK) inhibitor (IC50 = 100 nM). Has no effect on PKA, PKC and CKII activity. Inhibits I_B-_ phosphorylation and NF_B activation in HeLa cells. Inhibits NF_B-mediated proinflammatory gene expression in human airway epithelial cells. Enhances TNF-_-induced apoptosis in a multiple myeloma cell line. Attenuates LPS-induced TNF-_ production in vivo. Orally active."	Hideshima et al (2002) NF-kappa B as a therapeutic target in multiple myeloma. J.Biol.Chem. 277 16639. PMID:11872748. Castro et al (2003) Novel IKK inhibitors: beta-carbolines. Bioorg.Med.Chem.Lett. 13 2419. PMID:12824047. Newton et al (2007) Repression of inflammatory gene expression in human pulmonary epithelial cells by small-molecule IkappaB kinase inhibitors. J.Pharmacol.Exp.Ther. 321 734. PMID:17322026.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=350491	SQ1341			Apr-2014
4570	ML 161	[423735-93-7]	O=C(NC2=CC(NC(CCC)=O)=CC=C2)C1=CC=CC=C1Br	Inhibits PAR1-mediated platelet activation	Inhibitor of protease-activated receptor 1 (PAR1)-mediated platelet activation (IC50 = 0.26 _M for the inhibition of platelet P-selectin expression on human platelets). Thought to act allosterically. Also inhibits thrombin-induced platelet activation.	"Dockendorff et al (2012) Discovery of 1,3-diaminobenzenes as selective inhibitors of platelet activation at the PAR1 receptor. ACS Med.Chem.Lett. 3 232. PMID:22408714."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=350492				Aug-2012
4571	A 867744	[1000279-69-5]	O=C(CC)C1=C(C)N(C3=CC=C(S(N)(=O)=O)C=C3)C(C2=CC=C(Cl)C=C2)=C1	Positive allosteric modulator of _7 nAChR	"Positive allosteric modulator of _7 nAChRs (IC50 values are 0.98 and 1.12 _M for human and rat _7 receptor ACh-evoked currents respectively, in X. laevis oocytes). Displays no activity at 5-HT3A, _3_4 or _4_2 nAChRs. Brain penetrant."	"Malysz et al (2009) In vitro pharmacological characterization of a novel allosteric modulator of _ 7 neuronal acetylcholine receptor, 4-(5-(4-chlorophenyl)-2-methyl-3-propionyl-1H-pyrrol-1-yl)benzenesulfonamide (A-867744), exhibiting unique pharmacological profile. J.Pharmacol.Exp.Ther. 330 257. PMID:19389923. Faghih et al (2009) Discovery of 4-(5-(4-chlorophenyl)-2-methyl-3-propionyl-1H-pyrrol-1-yl)benzenesulfonamide (A-867744) as a novel positive allosteric modulator of the _7 nicotinic acetylcholine receptor. J.Med.Chem. 28 3377. PMID:19419141."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=350665	SQ1070			Mar-2013
4572	TC-E 5005	[959705-64-7]	CC2=NC1=CC=C(OC)N=C1N3C2=C(C)N=C3CCC	Potent and selective PDE10A inhibitor	"Potent and selective PDE10A inhibitor (IC50 values are 7.28, 239, 779, 919, 3100 and 3700 nM at PDE10A, 2A, 11A, 5A, 7B and 3A respectively and >5000 nM at PDE1B, 4A, 6, 8A and 9A). Reverses MK 801-induced hyperactivity in vivo."	"Hofgen et al (2010) Discovery of imidazo[1,5-a]pyrido[3,2-e]pyrazines as a new class of phosphodiesterase 10A inhibitiors. J.Med.Chem. 53 4399. PMID:20450197."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=350666	SQ1341			Dec-2013
4575	TC HSD 21	[330203-01-5]	S=C(S/C(C3=O)=C\C2=CC=C(O)C(Br)=C2)N3C1=CC=C(OC)C=C1	Potent and selective 17_-hydroxysteroid dehydrogenase type 3 inhibitor	"Potent 17_-hydroxysteroid dehydrogenase type 3 (17_-HSD3) inhibitor (IC50 values are 6 and 40 nM at human and mouse 17_-HSD3 respectively). Displays no activity at 17_-HSD1, 17_-HSD2, ER_, androgen receptors or glucocorticoid receptors."	Harada et al (2012) Identification of oxazolidinediones and thiazolidinediones as potent 17_-hydroxysteroid dehydrogenase type 3 inhibitors. Bioorg.Med.Chem.Lett. 22 504. PMID:22137341.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=350962				Dec-2012
4580	Atiprimod dihydrochloride	[130065-61-1]	CCCC1(CCC)CCC2(CN(CCCN(CC)CC)CC2)CC1.Cl.Cl	JAK2 inhibitor	JAK2 inhibitor (IC50 = 397 nM). Also inhibits STAT3 and STAT5 phosphorylation. Inhibits cell growth and induces apoptosis in cells expressing the JAK2V617F mutation.	"Manshouri et al (2011) Bone marrow stroma-secreted cytokines protect JAK2(V617F)-mutated cells from the effects of a JAK2 inhibitor. Cancer Res. 71 3831. PMID:21512135. Quints-Cardama et al (2011) Preclinical characterization of atiprimod, a novel JAK2 AND JAK3 inhibitor. Invest.New Drugs 29 818. PMID:20372971."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=350977	SQ1341			Mar-2014
4582	MLR 1023	[41964-07-2]	CC1=CC(OC2=CNC(N=C2)=O)=CC=C1	Selective allosteric activator of Lyn kinase	"Selective allosteric activator of Lyn kinase (EC50 = 63 nM); displays no significant activity against a range of 47 other kinases, including other Src family kinases such as Fyn, Lck and Src kinase. Reduces blood glucose levels without affecting in vivo insulin secretion. Orally bioavailable."	Ochman et al (2012) The Lyn kinase activator MLR-1023 is a novel insulin receptor potentiator that elicits a rapid-onset and durable improvement in glucose homeostasis in animal models of type 2 diabetes. J.Pharmacol.Exp.Ther. 342 23. PMID:22431203. Saporito et al (2012) MLR-1023 is a potent and selective allosteric activator of Lyn kinase in vitro that improves glucose tolerance in vivo. J.Pharmacol.Exp.Ther. 342 15. PMID:22473614.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=351339	SQ1070			Oct-2012
4583	Digoxin	[20830-75-5]	O=C1OC[C@]([C@H]5CC[C@]4(O)[C@]3([H])CC[C@]2([H])C[C@@H](O[C@]6([H])O[C@H](C)[C@@H](O[C@@]7([H])C[C@H](O)[C@H](O[C@]8([H])O[C@H](C)[C@@H](O)[C@@H](O)C8)[C@@H](C)O7)[C@@H](O)C6)CC[C@@](C)2[C@]([H])3C[C@@H](O)[C@]45C)=C1	Na+/K+ ATPase inhibitor	Inhibits membrane-bound _-subunits of the Na+/K+ ATPase pump in myocytes. Increases RGS2 protein levels in primary vascular smooth muscle cells through an Na+/K+ ATPase pump-dependent mechanism.	Gheorghiade et al (2004) Digoxin in the management of cardiovascular disorders. Circulation 109 2959. PMID:15210613. Buckalew (2005) Endogenous digitalis-like factors. An historical overview. Front.Biosci. 10 2325. PMID:15970498. Sjogren et al (2012) Cardiotonic steroids stabilize regulator of g protein signaling 2 protein levels. Mol.Pharmacol. 82 500. PMID:22695717.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=351340	SQ1533			Aug-2012
4584	SNS 314 mesylate	[1146618-41-8]	O=C(NC4=CC(Cl)=CC=C4)NC3=NC=C(S3)CCNC1=NC=NC2=C1SC=C2.CS(=O)(O)=O	Potent pan-Aurora kinase inhibitor	"Potent, ATP-competitive Aurora kinase inhibitor (IC50 values are 3, 9 and 31 nM for Aurora C, A and B, respectively). Exhibits both in vitro and in vivo activity against human cancer cell lines and tumor xenograft models. Displays additive antiproliferative effects in combination with chemotherapeutics such as carboplatin (Cat. No. 2626), gemcitabine (Cat. No. 3259) and 5-fluorouracil (Cat. No. 3257)."	"Oslob et al (2008) Discovery of a potent and selective Aurora kinase inhibitor. Bioorg.Med.Chem.Lett. 18 4880. PMID:18678489. VanderPorten et al (2009) The Aurora kinase inhibitor SNS-314 shows broad therapeutic potential with chemotherapeutics and synergy with microtubule-targeted agents in a colon carcinoma model. Mol.Cancer Ther. 8 930. PMID:19372566. Arbitrario et al (2010) SNS-314, a pan-Aurora kinase inhibitor, shows potent and anti-tumor activity and dosing flexibility in vivo. Cancer Chemother. Pharmacol. 65 707. PMID:19649632."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=351341	SQ1533			Aug-2013
4585	MRT 10	[330829-30-6]	O=C(NC(NC2=CC(NC(C3=CC=CC=C3)=O)=CC=C2)=S)C1=CC(OC)=C(OC)C(OC)=C1	Smoothened (Smo) antagonist	Smoothened (Smo) receptor antagonist (IC50 = 0.5 _M in HEK293 cells transiently expressing mouse Smo). Inhibits ShhN-induced Gli luciferase reporter activity in Shh-light 2 cells (IC50 = 2.5 _M); acts as an inverse agonist during nontranscriptional Hedgehog pathway activation (IC50 = 2.5 _M in HEK293 cells).	"Manetti et al (2010) Virtual screening-based discovery and mechanistic characterization of the acylthiourea MRT-10 family as smoothened antagonists. Mol.Pharmacol. 78 658. PMID:20664000. Solinas et al (2012) Acylthiourea, acylurea, and acylguanidine derivatives with potent hedgehog inhibiting activity. J.Med.Chem. 55 1559. PMID:22268551."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=351342				Sep-2012
4586	ML 3403	[549505-65-9]	FC(C=C3)=CC=C3C(N=C(SC)N2)=C2C1=CC=NC(NC(C)C4=CC=CC=C4)=C1	p38 inhibitor	p38 MAPK inhibitor (IC50 = 0.38 _M). Inhibits the release of IL-1_ and TNF-_ in a peripheral blood mononuclear cell (PBMC) assay (IC50 values are 0.039 and 0.16 _M respectively).	"Laufer et al (2003) Novel substituted pyridinyl imidazoles as potent anticytokine agents with low activity against hepatic cytochrome P450 enzymes. J.Med.Chem. 46 3230. PMID:12852754. Kammerer et al (2007) Pharmacokinetics of ML3403 ({4-[5-(4-fluorophenyl)-2-methylsulfanyl-3H-imidazol-4-yl]-pyridin-2-yl}-(1-phenylethyl)-amine), a 4-pyridinylimidazole-type p38 mitogen-activated protein kinase inhibitor. Drug Metab.Dispos. 35 875. PMID:17344341."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=351343	SQ1341			Sep-2012
4590	Honokiol	[35354-74-6]	OC1=C(C2=CC(CC=C)=C(O)C=C2)C=C(CC=C)C=C1	Blocks NF-_B activation. Displays anti-inflammatory and antioxidant properties	"Anti-inflammatory, antioxidant, antitumor and antiangiogenic agent. Blocks NF-_B activation by a variety of stimuli, including TNF and okadaic acid. Shown to scavenge superoxide and peroxyl radicals. Also inhibits a variety of inflammatory responses."	"Bai et al (2003) Honokiol, a small molecular weight natural product, inhibits angiogenesis in vitro and tumor growth in vivo. J.Biol.Chem. 278 35501. PMID:12816951. Ahn et al (2006) Honokiol potentiates apoptosis, suppresses osteoclastogenesis, and inhibits invasion through modulation of nuclear factor-_B activation pathway. Mol.Cancer Res. 4 621. PMID:16966432. Kim and Cho (2008) Anti-inflammatory effect of honokiol is mediated by PI3K/Akt pathway suppression. Acta Pharmacol.Sinica 29 113. PMID:18158873. Dikalov et al (2008) Honokiol is a potent scavenger of superoxide and peroxyl radicals. Biochem.Pharmacol. 76 589. PMID:18640101."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=352559	SQ1533			Aug-2012
4593	GSK J1	[1373422-53-7]	O=C(CCNC1=NC(C2=CC=CC=N2)=NC(N3CCC(C=CC=C4)=C4CC3)=C1)O	Potent histone demethylase JMJD3/UTX inhibitor	"Potent inhibitor of the H3K27 histone demethylases JMJD3 (KDM6B) and UTX (KDM6A) (IC50 values are 28 and 53 nM respectively). Also inhibits KDM5B, KDM5C and KDM5A (IC50 values are 170, 550 and 6,800 nM respectively). Exhibits no activity against a panel of other histone demethylases (IC50 >20 _M), and displays no significant inhibitory activity against 100 protein kinases at a concentration of 30 _M. Ethyl ester derivative also available."	Kruidenier et al (2012) A selective jumonji H3K27 demethylase inhibitor modulates the proinflammatory macrophage response. Nature 488 404. PMID:22842901. Heinemann et al (2014) Inhibition of demethylases by GSK-J1/J4. Nature 514 E1. PMID:25279926.	Small Molecule	"This probe is supplied in conjunction with the Structural Genomics Consortium. For further characterization details, please visit the GSK J1 probe summary on the SGC website."	http://www.tocris.com/dispprod.php?ItemId=352682	SQ1533			Sep-2012
4594	GSK J4	[1373423-53-0]	O=C(CCNC1=NC(C2=CC=CC=N2)=NC(N3CCC(C=CC=C4)=C4CC3)=C1)OCC	Histone lysine demethylase (KDM) inhibitor; cell permeable	Histone lysine demethylase (KDM) inhibitor; blocks demethylation of histone H3K27. Attenuates lipopolysaccharide (LPS)-induced proinflammatory cytokine production in primary human macrophages (IC50 = 9 _M for the inhibition of TNF_ release). Cell permeable. Ethyl ester derivative of GSK J1 (Cat. No. 4593).	Kruidenier et al (2012) A selective jumonji H3K27 demethylase inhibitor modulates the proinflammatory macrophage response. Nature 488 404. PMID:22842901. Heinemann et al (2014) Inhibition of demethylases by GSK-J1/J4. Nature 514 E1. PMID:25279926.	Small Molecule	"This probe is supplied in conjunction with the Structural Genomics Consortium. For further characterization details of GSK J4, a cell permeable derivative of GSK J1, please visit the GSK J1 probe summary on the SGC website."	http://www.tocris.com/dispprod.php?ItemId=352683				Sep-2012
4596	IT1t dihydrochloride	[1092776-63-0]	CC1(C)CN(C(CS/C(NC4CCCCC4)=N/C3CCCCC3)=CS2)C2=N1.Cl.Cl	Potent CXCR4 antagonist	"Potent CXCR4 antagonist (IC50 = 1.1 nM in calcium mobilization assays). Orally available. Blocks interaction with the HIV envelope protein, gp120 (IC50 = 7 nM, inhibition of X4-tropic HIV-1IIIB attachment)."	Thoma et al (2008) Orally bioavailable isothioureas block function of the chemokine receptor CXCR4 in vitro and in vivo. J.Med.Chem. 51 7915. PMID:19053768.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=352906	SQ1341			Dec-2012
4598	PHT 427	[1191951-57-1]	O=S(C(C=C1)=CC=C1CCCCCCCCCCCC)(NC2=NN=CS2)=O	Dual Akt and PDK1 inhibitor; antitumor	"Dual Akt and PDK1 inhibitor; binds the pleckstrin homology (PH) domain of Akt and PDK1 (Ki values are 2.7 and 5.2 _M, respectively). Inhibits Akt phosphorylation and Akt downstream targets; also induces apoptosis in vitro. Displays synergistic antitumor effect when combined with chemotherapeutics in breast cancer mouse models."	"Moses et al (2009) In vitro and in vivo activity of novel small-molecule inhibitors targeting the pleckstrin homology domain of protein kinase B/AKT. Cancer Res. 69 5073. PMID:19491272. Meuillet et al (2010) Molecular pharmacology and antitumor activity of PHT-427, a novel Akt/phosphatidylinositide-dependent protein kinase 1 pleckstrin homology domain inhibitor. Mol.Cancer Ther. 9 706. PMID:20197390."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=353452	SQ1341			Jun-2014
4599	"3,5-DHBA"	[99-10-5]	OC1=CC(O)=CC(C(O)=O)=C1	Selective HCA1 agonist	"Selective agonist of hydroxycarboxylic acid receptor 1 (HCA1, also known as GPR81) (EC50 ~150 _M). Inhibits lipolysis in wild-type mouse adipocytes. Displays minimal activity at HCA2 (at concentrations >10 mM) and no activity at HCA3, free fatty acid receptor (FFAR) 2 or FFAR3."	"Liu et al (2012) 3,5-dihydroxybenzoic acid, a specific agonist for hydroxycarboxylic acid 1, inhibits lipolysis in adipocytes. J.Pharmacol.Exp.Ther. 341 794. PMID:22434674."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=353581				Aug-2012
4600	Auranofin	[34031-32-8]	CCP(CC)(CC)=[Au]S[C@H]1[C@H](OC(C)=O)[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@@H](COC(C)=O)O1	Thioredoxin reductase inhibitor; induces MPT	Inhibitor of thioredoxin reductase (TrxR) (IC50 = 20 nM; Ki = 4 nM for the NADPH-reduced form of human cytosolic TrxR). Thought to induce the mitochondrial permeability transition via inhibition of mitochondrial TrxR. Also exhibits anti-inflammatory and immunosuppressive activities; inhibits 5-lipoxygenase at high concentrations and stimulates LTA hydrolase at low concentrations.	"Betts et al (1990) Auranofin stimulates LTA hydrolase and inhibits 5-lipoxygenase/LTA synthase activity of isolated human neutrophils. Biochem.Pharmacol. 39 1233. PMID:2157444. Gromer et al (1998) Human placenta thioredoxin reductase. Isolation of the selenoenzyme, steady state kinetics, and inhibition by therapeutic gold compounds. J.Biol.Chem. 273 20096. PMID:9685351. Rigobello et al (2002) Induction of mitochondrial permeability transition by auranofin, a gold(I)-phosphine derivative. Br.J.Pharmacol. 136 1162. PMID:12163349. Kim et al (2007) Auranofin blocks interleukin-6 signalling by inhibiting phosphorylation of JAK1 and STAT3. Immunology 122 607. PMID:17645497."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=353589	SQ1533			Aug-2012
4601	TUG 891	[1374516-07-0]	FC1=CC(COC2=CC=C(CCC(O)=O)C=C2)=C(C3=CC=C(C)C=C3)C=C1	Potent and selective FFA4 (GPR120) agonist	Potent FFA4 (GPR120) agonist (pEC50 values are 7.36 and 7.77 for human and mouse GPR120 respectively). Selective for GPR120 over free fatty acid receptors (pEC50 = 4.19 for FFA1; displays no activity at FFA2 or FFA3). Cell permeable.	Shimpukade et al (2012) Discovery of a potent and selective GPR120 agonist. J.Med.Chem. 55 4511. PMID:22519963.	Small Molecule	Sold under license from the University of Southern Denmark.	http://www.tocris.com/dispprod.php?ItemId=353591	SQ1341			Jan-2013
4602	LDN 27219	[312946-37-5]	O=C(NN)CSC(N1C2=CC=CC=C2)=NC3=C(C(C4=CC=CC=C4)=CS3)C1=O	Transglutaminase 2 (TG2) inhibitor; reversible	Transglutaminase 2 (TG2) inhibitor (IC50 = 0.25 _M). Binds at GTPase site; reversible.	Duval et al (2005) Structure-activity relationship study of novel tissue transglutaminase inhibitors. Bioorg.Med.Chem.Lett. 15 1885. PMID:15780627. Case and Stein (2007) Kinetic analysis of the interaction of tissue transglutaminase with a nonpeptidic slow-binding inhibitor. Biochemistry 46 1106. PMID:17240993. Prime et al (2012) Discovery and structure-activity relationship of potent and selective covalent inhibitors of transglutaminase 2 for Huntington's disease. J.Med.Chem. 55 1021. PMID:22224594.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=353726	SQ1341			Nov-2012
4603	LUF 5834	[333962-91-7]	NC1=NC(SCC3=NC=CN3)=C(C#N)C(C2=CC=C(O)C=C2)=C1C#N	Potent adenosine A2A and A2B receptor partial agonist	Potent A2A and A2B adenosine receptor partial agonist ( Ki = 2.6 nM and EC50 = 12 nM respectively). Also exhibits selectivity for A1 over A3 (Ki values are 2.6 and 538 nM respectively).	"Beukers et al (2004) New, non-adenosine, high potency agonists for the human adenosine A2B receptor with an improved selectivity profile compared to the reference agonist N-ethylcarboxamidoadenosine J.Med.Chem 47 (15) 3707. PMID:15239649. Lane et al (2012) A novel nonribose agonist, LUF5834, engages residues that are distinct from those of adenosine-like ligands to activate the adenosine A2a receptor Mol.Pharmacol. 81 (3) 475. PMID:22188926."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=353771				Feb-2014
4604	PTIQ	[1032822-42-6]	O=C(CC)N2CC1=CC(O)=C(OC)C=C1CC2	Potent MMP-3 expression inhibitor; neuroprotective	"Potent inhibitor of MMP-3 expression (IC50 = 60 nM); down-regulates induction of MMP-3 in both stressed dopaminergic cells and activated microglia. Also suppresses proinflammatory responses and inhibits NO production in activated microglia. Attenuates motor deficits, prevents neurodegeneration and suppresses microglial activation in a Parkinson's disease mouse model. Brain penetrant."	Seo et al (2008) Syntheses of tetrahydroisoquinoline derivatives that inhibit NO production in activated BV-2 microglial cells. Eur.J.Med.Chem. 43 1160. PMID:17980460. Son et al (2012) A novel compound PTIQ protects the nigral dopaminergic neurones in an animal model of Parkinsons disease induced by MPTP. Br.J.Pharmacol. 165 2213. PMID:21951056.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=353772				Apr-2014
4605	()-SLV 319	[362519-49-1]	ClC(C=C4)=CC=C4C1=NN(/C(NS(C3=CC=C(Cl)C=C3)(=O)=O)=N\C)CC1C2=CC=CC=C2	Potent and selective CB1 receptor antagonist	"Potent and selective CB1 receptor antagonist (Ki = 7.8 nM). Exhibits 1000-fold selectivity for CB1 over CB2 receptors. Inhibits CP 55,940-induced hypotension and WIN 55,212-2-induced hypothermia in vivo. Orally active."	"Lange et al (2004) Synthesis, biological properties, and molecular modeling investigations of novel 3,4-diarylpyrazolines as potent and selective CB1 cannabinoid receptor antagonists. J.Med.Chem. 47 627. PMID:14736243. Lange et al (2005) Novel 3,4-diarylpyrazolines as potent cannabinoid CB1 receptor antagonists with lower lipophilicity. Bioorg.Med.Chem.Lett. 15 4794. PMID:16140010."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=354218	SQ1341			Apr-2014
4606	CYM 9484	[1383478-94-1]	OC(C2=CC=CC=C2)(C3=CC=CC=C3)C1CCN(C(NC4=CC=C(S(=O)(N(C)C)=O)C=C4)=S)CC1	Potent NPY Y2 receptor antagonist	Potent neuropeptide Y (NPY) Y2 receptor antagonist (IC50 = 19 nM).	Mittapalli et al (2012) Synthesis and SAR of selective small molecule neuropeptide Y Y2 receptor antagonists. Bioorg.Med.Chem.Lett. 22 3916. PMID:22607676.	Small Molecule	Sold under license from The Scripps Research Institute	http://www.tocris.com/dispprod.php?ItemId=354222	SQ1341			Dec-2012
4607	LM 22A4	[37988-18-4]	O=C(NCCO)C1=CC(C(NCCO)=O)=CC(C(NCCO)=O)=C1	Potent TrkB agonist	"Potent tropomyosin-related kinase B (TrkB) agonist (IC50 = 47 nM). Induces activation of Trk, Akt and ERK in mouse hippocampus and striatum. Reverses deficits in motor task learning in mice following traumatic brain injury; restores respiratory function in a rat model of Rett syndrome."	Massa et al (2010) Small molecule BDNF mimetics activate TrkB signaling and prevent neuronal degeneration in rodents. J.Clin.Invest. 120 1774. PMID:20407211. Schmid et al (2012) A TrkB small molecule partial agonist rescues TrkB phosphorylation deficits and improves respiratory function in a mouse model of Rett syndrome. J.Neurosci. 32 1803. PMID:22302819.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=354224				Oct-2012
4608	BIIB 021	[848695-25-0]	ClC1=C2C(N(CC3=NC=C(C)C(OC)=C3C)C=N2)=NC(N)=N1	Selective Hsp90 inhibitor	"Selective, Hsp90 competitive inhibitor (Ki = 1.7 nM). Displays no significant activity at a range of ATP-binding kinases or Na+K+ ATPase. Induces degradation of HER-2 in vitro (EC50 = 38 nM in MCF-7 cells). Inhibits growth and promotes cell death in a variety of human tumor cells. Orally bioavailable."	"Lundgren et al (2009) BIIB021, an orally available, fully synthetic small-molecule inhibitor of the heat shock protein Hsp90. Mol.Cancer Ther. 8 921. PMID:19372565. Yin et al (2010) BIIB021, a novel Hsp90 inhibitor, sensitizes head and neck squamous cell carcinoma to radiotherapy. Int.J.Cancer 126 1216. PMID:19662650."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=354225	SQ1533			Sep-2012
4609	BMS 303141	[943962-47-8]	ClC1=CC(Cl)=C(O)C=C1S(NC2=C(C3=CC=CC=C3)C=CC(OC)=C2)(=O)=O	ATP-citrate lyase inhibitor; orally bioavailable	ATP citrate lyase (ACL) inhibitor (IC50 = 0.13 _M for human recombinant ACL); blocks lipid synthesis (IC50 = 8 _M in HepG2 cells). Displays no cytotoxicity up to a concentration of 50 _M. Lowers plasma glucose and triglycerides in a mouse model of hyperlipidemia. Orally bioavailable.	Li et al (2007) 2-hydroxy-N-arylbenzenesulfonamides as ATP-citrate lyase inhibitors. Bioorg.Med.Chem.Lett. 17 3208. PMID:17383874. Ma et al (2009) A novel direct homogeneous assay for ATP citrate lyase. J.Lipid Res. 50 2131. PMID:19286649.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=354227	SQ1341			Nov-2012
4612	URB 597	[546141-08-6]	NC(C1=CC(C2=CC=CC(OC(NC3CCCCC3)=O)=C2)=CC=C1)=O	Potent and selective FAAH inhibitor	"Potent and selective fatty acid amide hydrolase (FAAH) inhibitor (IC50 values are 3 and 5 nM in human liver and rat brain, respectively). Exhibits no significant inhibitory activity against a variety of receptors, ion channels and enzymes, including human cannabinoid receptors and rat monoacylglycerol lipase. Displays antiallodynic and antihyperalgesic activity in an inflammatory pain model."	Hohmann et al (2005) An endocannabinoid mechanism for stress-induced analgesia. Nature 435 1108. PMID:15973410. Piomelli et al (2006) Pharmacological profile of the selective FAAH inhibitor KDS-4103 (URB597). CNS Drug Rev. 12 21. PMID:16834756. Jayamanne et al (2006) Actions of the FAAH inhibitor URB597 in neuropathic and inflammatory chronic pain models. Br.J.Pharmacol. 147 281. PMID:16331291.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=354419	SQ1533			Nov-2013
4613	Tegaserod maleate	[189188-57-6]	O=C(/C=C\C(O)=O)O.CCCCCNC(N/N=C/C1=CNC2=C1C=C(OC)C=C2)=N	5-HT4 partial agonist	Partial agonist of 5-HT4 (Ki = 12 nM).	Buchheit et al (1995) The serotonin 5-HT4 receptor. 2. Structure-activity studies of the indole carbazimidamide class of agonists. J.Med.Chem. 38 2331. PMID:7608899.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=354435	SQ1533			Aug-2012
4615	MEDICA 16	[87272-20-6]	CC(CC(O)=O)(C)CCCCCCCCCCC(C)(C)CC(O)=O	FFA1 (GPR40) agonist; also inhibits ATP-citrate lyase	"Free fatty acid 1 (FFA1/GPR40) receptor agonist; exhibits selectivity for FFA1 (GPR40) over GPR120. Also inhibits ATP citrate lyase; reduces intracellular triacylglycerol levels in muscle, inhibits lipogenesis and increases insulin sensitivity in rodents in vivo."	Atkinson et al (2002) MEDICA 16 inhibits hepatic acetyl-CoA carboxylase and reduces plasma triacylglycerol levels in insulin-resistant JCR:LA-cp rats. Diabetes 51 1548. PMID:11978655. Hara et al (2009) Novel selective ligands for free fatty acid receptors GPR120 and GPR40. Naunyn Schmiedebergs Arch.Pharmacol. 380 247. PMID:19471906.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=354438	SQ1341			Apr-2013
4616	Olmesartan	[144689-24-7]	CCCC1=NC(C(C)(C)O)=C(C(O)=O)N1CC2=CC=C(C3=CC=CC=C3C4=NN=NN4)C=C2	Potent AT1 antagonist; metabolite of Olmesartan medoxomil (Cat. No. 4620)	Potent angiotensin II type I (AT1) receptor antagonist (IC50 = 6.7 nM at hAT1 receptors). Improves cognitive function in a mouse model of hypertension- and hyperlipidemia-associated cognitive decline; ameliorates arterial stiffness in a rat model of chronic renal failure. Metabolite of Olmesartan medoxomil (Cat. No. 4620).	"Mogi et al (2007) Inhibition of cognitive decline in mice fed a high-salt and cholesterol diet by the angiotensin receptor blocker, olmesartan. Neuropharmacology 53 899. PMID:18028965. Ojima et al (2011) In vitro antagonistic properties of a new angiotensin type 1 receptor blocker, azilsartan, in receptor binding and function studies. J.Pharmacol.Exp.Ther. 336 801. PMID:21123673. Chuang et al (2012) Effects of olmesartan on arterial stiffness in rats with chronic renal failure. Cardiovasc.Diabetol. 11 66. PMID:22694778."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=354439	SQ1533			Sep-2012
4618	GW 6471	[880635-03-0]	CC2=C(N=C(C4=CC=CC=C4)O2)CCOC(C=C1)=CC=C1C[C@@H](CNC(CC)=O)N/C(C)=C\C(C3=CC=C(C(F)(F)F)C=C3)=O	PPAR_ antagonist	PPAR_ antagonist (IC50 = 0.24 _M). Enhances the binding affinity of the PPAR_ ligand-binding domain to the co-repressor proteins SMRT and NCoR.	Xu et al (2002) Structural basis for antagonist-mediated recruitment of nuclear co-repressors by PPAR_. Nature 415 813. PMID:11845213. Muller et al (2009) An innovative method to study target protein-drug interactions by mass spectrometry. J.Med.Chem. 52 2875. PMID:19379014.	Small Molecule	Sold with the permission of GlaxoSmithKline.	http://www.tocris.com/dispprod.php?ItemId=354853	SQ1533			Aug-2012
4619	Melphalan	[148-82-3]	ClCCN(CCCl)C1=CC=C(C[C@H](N)C(O)=O)C=C1	DNA alkylating agent; cytotoxic and antineoplastic	DNA alkylating agent; induces cytotoxicity through the formation of stable interstrand and intrastrand crosslinks within DNA. Inhibits growth of PC-3 cells (IC50 values are 0.074 and 0.77 _M for sequential dosing and single dosing respectively).	Merck Index 12 5872. Blumberg et al (1965) An alkylating agent for multiple myeloma: melphalan. JAMA. 191 547. PMID:14239026. Bauer and Povirk (1997) Specificity and kinetics of interstrand and intrastrand bifunctional alkylation by nitrogen mustards at a G-G-C sequence. Nucleic Acids Res. 25 1211. PMID:9092631. Mougenot et al (2006) In vitro cytotoxic effect of melphalan and pilot phase II study in hormone-refractory prostate cancer. Anticancer Res. 26 2197. PMID:16821586.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=354994	SQ1533			Nov-2012
4620	Olmesartan medoxomil	[144689-63-4]	CCCC1=NC(C(C)(C)O)=C(C(OCC(O5)=C(C)OC5=O)=O)N1CC2=CC=C(C3=CC=CC=C3C4=NN=NN4)C=C2	Selective non-peptide AT1 antagonist; prodrug of Olmesartan	"Prodrug metabolised in vivo to Olmesartan (Cat. No. 4616), a selective non-peptide angiotensin II type I receptor (AT1) antagonist. Selectively inhibits angiotensin II binding to AT1 receptors in bovine adrenal cortical membranes (IC50 = 7.7 nM), with no effect on AT2 receptors."	"Mizuno et al (1995) Pharmacology of CS-866, a novel nonpeptide angiotensin II receptor antagonist. Eur.J.Pharmacol. 285 181. PMID:8566137. Kim et al (1997) Effects of angiotensin AT1 receptor antagonist on volume overload-induced cardiac gene expression in rats. Hypertens.Res. 20 133. PMID:9220278."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=354995				Aug-2012
4621	MKT 077	[147366-41-4]	CN(C1=CC=CC=C1S2)/C2=C4/C(N(CC)/C(S4)=C\C3=CC=CC=[N+]3CC)=O.[Cl-]	Binds mot-2; selectively cytotoxic in cancer cells	"Occupies mortalin-2 (mot-2), a member of the Hsp70 family, at its p53 binding site and enables p53 translocation to the nucleus. Selectively cytotoxic; causes growth arrest of cancer cells in culture. Also inhibits telomerase activity and cross-links F-actin."	"Tikoo et al (1999) Treatment of Ras-induced cancers by the F-actin cappers tensin and chaetoglobosin K, in combination with the caspase-1 inhibitor N1445. Cancer J.Sci.Am. 5 293. PMID:10526670. Wadhwa et al (2000) Selective toxicity of MKT-077 to cancer cells is mediated by its binding to the hsp70 family protein mot-2 and reactivation of p53 function. Cancer Res. 60 6818. PMID:11156371 . Wadhwa et al (2002) Rhodacyanine dye MKT-077 inhibits in vitro telomerase activity but has no detectable effects on telomerase activity in vivo. Cancer Res. 62 4434. PMID:12154051. Patury et al (2009) Pharmacological targeting of the Hsp70 chaperone. Curr.Top.Med.Chem. 9 1337. PMID:19860737."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=354998	SQ1341			Feb-2013
4622	MK 1903	[1268882-43-4]	[H][C@@]12CC3=C(NN=C3C(O)=O)[C@@]([H])1C2	Potent and selective GPR109A (HCA2) agonist	"Potent and selective hydroxycarboxylic acid receptor 2 (HCA2, GPR109A) full agonist; exhibits greater potency than niacin in a whole cell HTRF-cAMP assay (EC50 values are 12.9 and 51 nM respectively). Exhibits no binding at the GRP109B receptor."	"Boatman (2012) (1aR,5aR)1a,3,5,5a-Tetrahydro-1H-2,3-diaza-cyclopropa[_]pentalene-4-carboxylic acid (MK-1903): a potent GPR109a agonist that lowers free fatty acids in humans. J.Med.Chem. 55 3644. PMID:22435740. Lauring (2012) Niacin lipid efficacy is independent of both the niacin receptor GPR109A and free fatty acid suppression. Sci.Transl.Med. 4 148ra115. PMID:22914621."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=354999	SQ1341			Feb-2014
4624	TC-FPR 43	[903895-98-7]	CC(C)C1=C(NC(NC3=CC=C(Cl)C=C3)=O)C(N(C2=CC=CC=C2)N1C)=O	Potent FPR2 agonist	Potent formyl peptide receptor 2 (FPR2) agonist (EC50 = 44 nM). Inhibits fMLP- and IL-8-induced neutrophil migration. Suppresses inflammation in a mouse model of acute inflammation. Orally bioavailable.	Brli et al (2006) Potent hFPRL1 (ALXR) agonists as potential anti-inflammatory agents. Bioorg.Med.Chem.Lett. 16 3713. PMID:16697190. Dufton et al (2010) Anti-inflammatory role of the murine formyl-peptide receptor 2: ligand-specific effects on leukocyte responses and experimental inflammation. J.Immunol. 184 2611. PMID:20107188. Forsman et al (2011) Stable formyl peptide receptor agonists that activate the neutrophil NADPH-oxidase identified through screening of a compound library. Biochem.Pharmacol. 81 402. PMID:21095183.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=355001				Feb-2015
4625	TC OT 39	[479232-57-0]	O=C(N5[C@H]([C@](N6CCN(C)CCC6)=S)CCC5)NCC(C(C)=C2)=CC=C2C(N1C(C=CC=C3)=C3NC(N(C)N=C4)=C4C1)=O	Potent non-peptide oxytocin receptor partial agonist; also V1a receptor antagonist	Potent non-peptide oxytocin receptor partial agonist (EC50 values are 33 nM and 850 nM for the oxytocin receptor and V2 vasopressin receptor respectively). Also a V1a vasopressin receptor antagonist (Ki = 330 nM). Active in vivo in a rat model of uterine response.	Pitt et al (2004) Non-peptide oxytocin agonists. Bioorg.Med.Chem.Lett. 14 4585. PMID:15357997. Frantz et al (2010) Subtlety of the structure-affinity and structure-efficacy relationships around a nonpeptide oxytocin receptor agonist. J.Med.Chem. 53 1546. PMID:20104850.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=355208	SQ1341			Jul-2014
4626	Andrographolide	[5508-58-7]	C=C1CC[C@@]([C@@](CO)(C)[C@H](O)CC3)([H])[C@]3(C)[C@@H]1C/C=C2[C@H](O)COC/2=O	Inhibits NF_B; blocks androgen receptor (AR) expression	Inhibitor of NF-_B signaling; also attenuates concanavaline-induced IFN_ production in murine T cells (IC50 = 1.7 _M). Blocks androgen receptor (AR) expression in AR-expressing C4-2 cells. Activates Nrf2 in BEAS-2B cells in response to cigarette smoke extract.	Burgos et al (2005) Andrographolide inhibits IFN-gamma and IL-2 cytokine production and protects against cell apoptosis. Planta.Med. 71 429. PMID:15931581. Liu et al (2011) Andrographolide targets androgen receptor pathway in castration-resistant prostate cancer. Genes Cancer. 2 151. PMID:21779488. Guan et al (2012) Andrographolide protects against cigarette smoke-induced oxidative lung injury via augmentation of Nrf2 activity. Br.J.Pharmacol. [Epub ahead of print]. PMID:23146110.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=355209	SQ1533			Sep-2012
4627	Phlorizin	[60-81-1]	O=C(CCC2=CC=C(O)C=C2)C1=C(O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)C=C(O)C=C1O	Na+-glucose cotransporter inhibitor	Inhibitor of Na+-glucose cotransporters (SGLT). Produces renal glycosuria and blocks intestinal glucose absorption. Normalizes insulin sensitivity in diabetic rats.	Rossetti et al (1987) Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats. J.Clin.Invest. 79 1510. PMID:3571496. Wright (2001) Renal Na+-glucose cotransporters. Am.J.Physiol.Renal.Physiol. 280 F10. PMID:11133510. Ehrenkranz et al (2005) Phlorizin: a review. Diabetes Metab Res Rev. 21 31. PMID:15624123.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=355307	SQ1533			Aug-2012
4628	DiMNF	[14756-24-2]	O=C2C=C(C4=CC(OC)=C(OC)C=C4)OC1=C3C(C=CC=C3)=CC=C12	Selective aryl hydrocarbon receptor modulator (SAhRM)	Selective aryl hydrocarbon receptor (AHR) modulator (SAhRM). Suppresses expression of CD55 and CD46 induced by IL-1_ in an inflammatory tumor cell microenvironment; exhibits no effect on basal CD55 or CD46 expression.	"Murray et al (2011) Suppression of cytokine-mediated complement factor gene expression through selective activation of the Ah receptor with 3',4'-dimethoxy-_-naphthoflavone. Mol.Pharmacol. 79 508. PMID:21127131. Narayanan et al (2012) Selective aryl hydrocarbon receptor modulator-mediated repression of CD55 expression induced by cytokine exposure. J.Pharmacol.Exp.Ther. 342 345. PMID:22553215. Labrecque et al (2012) Distinct roles for aryl hydrocarbon receptor nuclear translocator and Ah receptor in estrogen-mediated signaling in human cancer cell lines. PLoS ONE 7 e29545. PMID:22235307."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=355323				Sep-2012
4629	GSK2578215A	[1285515-21-0]	FC1=NC=CC(C2=CC=C(OCC3=CC=CC=C3)C(C(NC4=CC=CN=C4)=O)=C2)=C1	"Potent, selective LRRK2 inhibitor; brain penetrant"	Potent leucine-rich repeat kinase 2 (LRRK2) inhibitor (IC50 values are 8.9 and 10.1 nM for LRRK2[G2019S] mutant and wild-type LRRK2 respectively). Displays selectivity for LRRK2 against a panel of 460 other kinases. Blocks Ser910 and Ser935 phosphorylation in vitro and in peripheral tissues in vivo. Brain penetrant.	Reith et al (2012) GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substituent-N-arylbenzamide LRRK2 kinase inhibitor. Bioorg.Med.Chem.Lett. 22 5625. PMID:22863203.	Small Molecule	Sold for research purposes under agreement from GlaxoSmithKline.	http://www.tocris.com/dispprod.php?ItemId=355324	SQ1070			Apr-2013
4630	SB 747651A dihydrochloride		NC1=NON=C1C3=NC2=CN=CC(CNC4CCNCC4)=C2N3CC.Cl.Cl	Potent MSK1 inhibitor; also inhibits other AGC group kinases	"Potent, ATP-competitive mitogen- and stress-activated kinase 1 (MSK1) inhibitor (IC50 = 11 nM in an in vitro kinase assay); targets the N-terminal kinase domain. Inhibits MSK1, MSK2, PKA, PKB, RSK and p70S6K activity in cells. Blocks IL-10 production in macrophages."	"Bamford et al (2005) (1H-imidazo[4,5-c]pyridin-2-yl)-1,2,5-oxadiazol-3-ylamine derivatives: a novel class of potent MSK-1-inhibitors. Bioorg.Med.Chem.Lett. 15 3402. PMID:15950465. Bamford et al (2005) (1H-imidazo[4,5-c]pyridin-2-yl)-1,2,5-oxadiazol-3-ylamine derivatives: further optimisation as highly potent and selective MSK-1-inhibitors. Bioorg.Med.Chem.Lett. 15 3407. PMID:15955699. Naqvi et al (2012) Characterization of the cellular action of the MSK inhibitor SB-747651A. Biochem.J. 441 347. PMID:21970321."	Small Molecule	Sold with the permission of GlaxoSmithKline.	http://www.tocris.com/dispprod.php?ItemId=355414	SQ1533			Jun-2013
4632	TC-I 2000	[1159996-20-9]	O=C(NC3=CC=C(F)C=C3)N2C(C4=CC=C(C(F)(F)F)C=C4)C1=CC=CC=C1CC2	TRPM8 blocker	TRPM8 channel blocker. Inhibits icilin-induced TRPM8 channel activation in rTRPM8-expressing CHO cells (IC50 = 53 nM).	Tamayo et al (2012) Fused piperidines as a novel class of potent and orally available transient receptor potential melastatin type 8 (TRPM8) antagonists. J.Med.Chem. 55 1593. PMID:22329507.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=355543	SQ1341			Jan-2014
4635	SC 79	[305834-79-1]	NC2=C(C(OCC)=O)C(C(C(OCC)=O)C#N)C1=CC(Cl)=CC=C1O2	Akt activator	Activator of Akt; binds to the pleckstrin homology domain of Akt. Enhances Akt phosphorylation by upstream protein kinases; also enables cytosolic activation of Akt. Shown to suppress excitotoxicity-induced neuronal death in vitro and in vivo. Exhibits brain penetrance.	Jo et al (2012) Small molecule-induced cytosolic activation of protein kinase Akt rescues ischemia-elicited neuronal death. Proc.Natl.Acad.Sci.USA 109 10581. PMID:22689977.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=355723				Aug-2013
4641	BI 6015	[93987-29-2]	CC2=NC1=CC=CC=C1N2S(C3=C(C)C=CC([N+]([O-])=O)=C3)(=O)=O	Hepatocyte nuclear factor 4_ (HNF4_) antagonist	"Hepatocyte nuclear factor 4_ (HNF4_) antagonist. Represses expression of known HNF4_ target genes. Decreases HNF4_ DNA binding. Exhibits cytotoxic activity in a range of tumor cell lines, including human hepatocellular carcinoma."	Kiselyuk et al (2012) HNF4_ antagonists discovered by a high-throughput screen for modulators of the human insulin promoter. Chem.Biol. 19 806. PMID:22840769.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=356858	SQ1341			Oct-2012
4642	4-CMTB	[300851-67-6]	ClC1=CC=C(C(C(C)C)C(NC2=NC=CS2)=O)C=C1	FFA2 agonist; also exhibits positive allosteric modulatory activity	Free fatty acid receptor FFA2 agonist (pEC50 = 6.38) and positive allosteric modulator. Binds at a site distinct from the orthosteric site; modulates the activity of short-chain fatty acids at FFA2 via the FFA2 second extracellular loop (ECL2).	Milligan et al (2009) Agonism and allosterism: the pharmacology of the free fatty acid receptors FFA2 and FFA3. Br.J.Pharmacol. 158 146. PMID:19719777. Smith et al (2011) Extracellular loop 2 of the free fatty acid receptor 2 mediates allosterism of a phenylacetamide ago-allosteric modulator. Mol.Pharmacol. 80 163. PMID:21498659.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=356859	SQ1341			Nov-2012
4643	PCI 34051	[950762-95-5]	O=C(NO)C1=CC=C2C(N(CC3=CC=C(OC)C=C3)C=C2)=C1	Potent and selective histone deacetylase 8 (HDAC8) inhibitor; induces apoptosis in T cell-derived cell lines	"Potent and selective histone deacetylase 8 (HDAC8) inhibitor (IC50 = 10 nM). Displays >200 fold selectivity over HDAC isoforms 1, 2, 3, 6 and 10. Induces apoptosis in cell lines derived from T cell lymphomas or leukemias."	Balasubramanian et al (2008) A novel histone deacetylase 8 (HDAC8)-specific inhibitor PCI-34051 induces apoptosis in T-cell lymphomas. Leukemia 22 1026. PMID: 18256683. Pipalia et al (2011) Histone deacetylase inhibitor treatment dramatically reduces cholesterol accumulation in Niemann-Pick type C1 mutant human fibroblasts. Proc.Natl.Acad.Sci.U.S.A. 108 5620. PMID:21436030.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=356863	SQ1341			Mar-2014
4644	CID 2011756	[638156-11-3]	O=C(NC3=CC=C(CN4CCOCC4)C=C3)C1=CC=C(C2=CC=CC(Cl)=C2)O1	Pan protein kinase D (PKD) inhibitor; cell permeable	"Protein kinase D (PKD) inhibitor (IC50 values are 0.6, 0.7 and 3.2 _M for PKD2, PKD3 and PKD1 respectively). Cell permeable (EC50 = 10 _M for PKD1 inhibition). ATP-competitive."	Sharlow et al (2011) Discovery of diverse small molecule chemotypes with cell-based PKD1 inhibitory activity. PLoS One 6 e25134. PMID:21998636.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=356864				Nov-2012
4646	Elacridar hydrochloride	[143851-98-3]	O=C1C3=C(C(C(NC4=CC=C(CCN5CC(C=C(OC)C(OC)=C6)=C6CC5)C=C4)=O)=CC=C3)NC2=C1C=CC=C2OC.Cl	P-gp inhibitor	P-glycoprotein (P-gp/ABCG1) inhibitor. Blocks P-gp-mediated multidrug resistance (MDR) of the cytotoxic drugs doxorubicin (Cat. No. 2252) and vincristine (Cat. No. 1257) in CHRC5 cells. Also inhibits breast cancer resistance protein (BCRP/ABCG2). Orally active.	"Hyafil et al (1993) In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative. Cancer Res. 53 4595. PMID:8402633. Myer et al (1999) The chemosensitizing potential of GF120918 is independent of the magnitude of P-glycoprotein-mediated resistance to conventional chemotherapeutic agents in a small cell lung cancer line. Oncol Rep. 6 217. PMID:9864431."	Small Molecule	Sold for research purposes under agreement from GlaxoSmithKline.	http://www.tocris.com/dispprod.php?ItemId=357241	SQ1533			Nov-2012
4650	I-BET 151 hydrochloride		O=C(N3[C@H](C)C4=NC=CC=C4)NC2=C3C1=CC(OC)=C(C5=C(C)ON=C5C)C=C1N=C2.Cl	BET bromodomain inhibitor	"BET bromodomain inhibitor; blocks recruitment of BET to chromatin. Induces apoptosis and G0/G1 cell cycle arrest in MLL-fusion leukemic cell lines in vitro (IC50 values are 15, 26, 120 and 192 nM for NOMO1, MV4;11, MOLM13 and RS4;11 cell lines respectively); reduces BCL2 expression in NOMO1 cells. Improves survival in two rodent models of MLL-fusion leukemia in vivo."	Dawson et al (2011) Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia. Nature 478 529. PMID:21964340.	Small Molecule	Sold for research purposes under agreement from GlaxoSmithKline	http://www.tocris.com/dispprod.php?ItemId=357247	SQ1533			Oct-2012
4651	JW 67	[442644-28-2]	O=C1NC6=C(C=CC=C6)C21OCC3(COC(C(NC5=C4C=CC=C5)=O)4OC3)CO2	Wnt pathway inhibitor; induces degradation of active _-catenin	Inhibitor of canonical Wnt pathway signaling (IC50 = 1.17 _M); targets the _-catenin destruction complex (GSK-3_/AXIN/APC) to induce _-catenin degradation. Selective for the canonical Wnt pathway over the Sonic hedgehog (Shh) and NF-_B pathways. Blocks G1/S cell cycle progression in colorectal cancer (CRC) cell lines (GI50 = 7.8 _M).	"Waaler et al (2011) Novel synthetic antagonists of canonical Wnt signaling inhibit colorectal cancer cell growth. Cancer Res. 71 197. PMID:21199802. Shultz et al (2012) [1,2,4]triazol-3-ylsulfanylmethyl)-3-phenyl-[1,2,4]oxadiazoles: antagonists of the Wnt pathway that inhibit tankyrases 1 and 2 via novel adenosine pocket binding. J.Med.Chem. 55 1127. PMID:22260203."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=357254	SQ1341			Nov-2012
4652	SAHA	[149647-78-9]	O=C(CCCCCCC(NO)=O)NC1=CC=CC=C1	Class I and II HDAC inhibitor	"Inhibits Class I and II histone deacetylases (HDACs); induces accumulation of acetylated histones H2A, H2B, H3 and H4 in transformed cultured cells. Suppresses cell growth in a range of cancer cell lines; induces apoptosis in cutaneous T cell lymphoma cells in vitro."	"Butler et al (2000) Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. Cancer Res. 60 5165. PMID:11016644. Leoni et al (2002) The antitumor histone deacetylase inhibitor suberoylanilide hydroxamic acid exhibits antiinflammatory properties via suppression of cytokines. Proc.Natl.Acad.Sci.U.S.A 99 2995. PMID:11867742. Marks and Breslow (2007) Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug. Nat.Biotechnol. 25 84. PMID:17211407. Huangfu et al (2008) Induction of pluripotent stem cells by defined factors is greatly improved by small-molecule compounds. Nat.Biotechnol. 26 795. PMID:18568017."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=357255	SQ1533			Oct-2012
4653	ML 171	[6631-94-3]	CC(C1=CC2=C(C=C1)SC3=CC=CC=C3N2)=O	Selective NADPH oxidase 1 (NOX1) inhibitor	NADPH oxidase 1 (NOX1) inhibitor; blocks NOX1-dependent ROS generation (IC50 = 0.25 _M in a HEK293-NOX1 recombinant cell system). Selective for NOX1 over other NADPH oxidases (IC50 values are > 3 _M). Inhibits SrcYF-induced invadopodia formation in human DLD1 colon cancer cells.	Gianni et al (2010) A novel and specific NADPH oxidase-1 (Nox1) small-molecule inhibitor blocks the formation of functional invadopodia in human colon cancer cells. ACS Chem.Biol. 5 981. PMID:20715845. Drummond et al (2011) Combating oxidative stress in vascular disease: NADPH oxidases as therapeutic targets. Nat.Rev.Drug Discov. 10 453. PMID:21629295.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=357536				Oct-2012
4655	NSC 74859	[501919-59-1]	CC1=CC=C(S(OCC(NC2=CC=C(C(O)=O)C(O)=C2)=O)(=O)=O)C=C1	Selective STAT3 inhibitor	"Selectively inhibits STAT3 DNA-binding activity in vitro (IC50 values are 86, 160, and >300 _M for STAT3-STAT3, STAT1-STAT3 and STAT1-STAT1 DNA-binding activity respectively). Blocks growth and induces apoptosis preferentially in tumor cells that contain persistently active STAT3 in vitro and arrests tumor growth in a murine xenograft model in vivo."	"Siddiquee et al (2007) Selective chemical probe inhibitor of Stat3, identified through structure-based virtual screening, induces antitumor activity. Proc.Natl.Acad.Sci.U.S.A. 104 7391. PMID:17463090. Lin et al (2009) The STAT3 inhibitor NSC 74859 is effective in hepatocellular cancers with disrupted TGF-beta signaling. Oncogene 28 961. PMID:19137011."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=357973	SQ1070			Nov-2012
4656	(D)-(+)-Neopterin	[2009-64-5]	OC[C@@H](O)[C@@H](O)C2=NC1=C(N=C2)N=C(N)NC1=O	Stimulated by IFN-_; marker of immune activation	Precursor of biopterin synthesis. Synthesized in response to interferon-_ stimulation; used as a marker of T helper cell-induced immune activation. Also an indicator of oxidative stress; modulates the effects of reactive oxygen species (ROS).	Huber et al (1984) Immune response-associated production of neopterin. J.Exp.Med. 160 310. PMID:6429267. Murr et al (2002) Neopterin as a marker for immune system activation. Curr.Drug Metab. 3 175. PMID:12003349.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=357974	SQ1070			Nov-2012
4657	Zolmitriptan	[139264-17-8]	CN(C)CCC2=CNC1=CC=C(C[C@H](N3)COC3=O)C=C12	Potent 5-HT1B/1D/1F agonist	"Potent 5-HT1B/1D/1F agonist (Ki values are 0.63, 5.01 and 63.09 nM for h5-HT1D, h5-HT1B and h5-HT1F receptors respectively). Inhibits trigeminal nerve stimulation-mediated neurogenic plasma protein extravasation in guinea pigs; blocks long excitatory postsynaptic potentials (EPSPs) in a rat model of spinal cord injury."	"Pauwels et al (1997) How efficacious are 5-HT1B/D receptor ligands: an answer from GTP gamma S binding studies with stably transfected C6-glial cell lines. Neuropharmacology 36 499. PMID:9225275. Martin et al (1997) Receptor specificity and trigemino-vascular inhibitory actions of a novel 5-HT1B/1D receptor partial agonist, 311C90 (zolmitriptan). Br.J.Pharmacol. 121 157. PMID:9154322. Murray et al (2011) Polysynaptic excitatory postsynaptic potentials that trigger spasms after spinal cord injury in rats are inhibited by 5-HT1B and 5-HT1F receptors. J.Neurophysiol. 106 925. PMID:21653728."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=357975	SQ1533			Oct-2012
4659	Floxuridine	[50-91-9]	O[C@H]1C[C@H](N2C=C(F)C(NC2=O)=O)O[C@@H]1CO	Inhibitor of thymidylate synthetase; anticancer agent	Antineoplastic antimetabolite. Exhibits antiproliferative activity; inhibits thymidylate synthetase and disrupts DNA replication in human cells. Induces double-strand DNA breaks; activates ATR and ATM signaling pathways. Induces phosphorylation of Chk1 and Chk2 in OVCAR-8 and SKOV3ip ovarian cancer cell lines.	Bapat et al (1983) Human leukemic cells resistant to 5-fluoro-2'-deoxyuridine contain a thymidylate synthetase with lower affinity for nucleotides. J.Biol.Chem. 258 4130. PMID:6220000. Wyatt and Wilson (2009) Participation of DNA repair in the response to 5-fluorouracil. Cell.Mol.Life Sci. 66 788. PMID:18979208. Huehls et al (2012) Poly(ADP-ribose) polymerase inhibition synergizes with 5-fluorodeoxyuridine but not 5-fluorouracil in ovarian cancer cells. Cancer Res. 71 4944. PMID:21613406.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=358091	SQ1533			Oct-2012
4660	KB SRC 4	[1380088-03-8]	NC1=C2C(N(C4=CC=CC(C5=CN=NN5CC6=CC(C7=CC=CC=C7)=CC=C6)=C4)N=C2C3=CC=C(Cl)C=C3)=NC=N1	Potent and selective c-Src inhibitor	"Potent and selective c-Src inhibitor (Ki = 44 nM); does not inhibit c-Abl at concentrations up to 125 _M. Selective between Src family members (Kd values are 86, 160, 240, 720, 3200, 4400, and >40,000 nM for c-Src, Lck, Fgr, Yes, Lyn, Hck and Fyn respectively). Significantly inhibits cell growth in 4T1 mammary carcinoma tumor cells."	Brandvold et al (2012) Development of a highly selective c-Src kinase inhibitor. ACS Chem.Biol. 7 1393. PMID:22594480.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=358170	SQ1341			Oct-2013
4662	SMANT hydrochloride	[1177600-74-6]	BrC1=CC=C(NC(CCN2CC(C)CC(C)C2)=O)C=C1.Cl	Inhibits Smoothened (Smo) accumulation	Inhibitor of Smoothened (Smo) signaling via a unique mechanism. Inhibits Shh-induced accumulation of Smo::EGFP fusion protein in the primary cilium (IC50 = 1.1 _M). Inhibits both wild-type Smo and an oncogenic form (SmoM2) with similar efficacy.	Wang et al (2012) Selective identification of Hedgehog pathway antagonists by direct analysis of Smoothened ciliary translocation. ACS Chem.Biol. 7 1040. PMID:22554036.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=358172	SQ1341			Jan-2013
4663	Apocynin	[498-02-2]	CC(C1=CC(OC)=C(O)C=C1)=O	NADPH-oxidase inhibitor	NADPH oxidase inhibitor. Demonstrates anti-inflammatory properties in a mouse model of carrageenan-induced pleurisy. Bioactivated by intracellular peroxidases; acts as an antioxidant in endothelial cells and vascular smooth muscle cells.	"Stolk et al (1994) Characteristics of the inhibition of NADPH oxidase activation in neutrophils by apocynin, a methoxy-substituted catechol. Am.J.Respir.Cell Mol.Biol. 11 95. PMID:8018341. Heumller et al (2008) Apocynin is not an inhibitor of vascular NADPH oxidases but an antioxidant. Hypertension 51 211. PMID:18086956. Impellizzeri et al (2011) Effect of apocynin, a NADPH oxidase inhibitor, on acute lung inflammation. Biochem.Pharmacol. 81 636. PMID:21147071."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=358173				Oct-2012
4666	UNC 1215		O=C(N2CCC(N3CCCC3)CC2)C1=C(NC6=CC=CC=C6)C=C(C(N4CCC(N5CCCC5)CC4)=O)C=C1	Potent inhibitor of L3MBTL3 Kme reader domain; cell permeable	"Potent inhibitor of L3MBTL3 methyllysine (Kme) reader domain (IC50 = 40 nM; Kd = 120 nM). Displays >100-fold selectivity over a panel of histone methyltransferases, kinases, ion channels and 7-TM receptors. Disrupts subnuclear localization and foci formation of fluorescently-labeled L3MBTL3 in HEK293 cells."	James et al (2013) Discovery of a chemical probe for the L3MBTL3 methyllysine reader domain. Nat.Chem.Biol. [Epub ahead of print]. PMID:23292653.	Small Molecule	"This probe is supplied in conjunction with the Structural Genomics Consortium. For further characterization details, please visit the UNC 1215 probe summary on the SGC website."	http://www.tocris.com/dispprod.php?ItemId=358432	SQ1533			Jan-2013
4667	SB 706375	[733734-61-7]	BrC1=CC(OC)=C(OC)C=C1S(NC2=CC=C(C(F)(F)F)C(O[C@H]3CN(C)CC3)=C2)(=O)=O	"High affinity, non-peptide UT receptor antagonist"	"High affinity, non-peptide antagonist of the urotensin-II (UT) receptor. Exhibits high affinity for mammalian UT receptors, including human, mouse and rat (Ki values are 9.3, 19.1 and 20.7 nM respectively, in HEK293 cells expressing recombinant UT receptors). Also inhibits binding of radiolabeled urotensin to endogenous human UT receptors (Ki = 5.4 nM in a whole-cell binding assay). Displays 100-fold selectivity for the human UT receptor over 86 different receptors, ion channels, enzymes, transporters and nuclear hormones."	Douglas et al (2005) Nonpeptidic urotensin-II receptor antagonists I: in vitro pharmacological characterization of SB-706375. Br.J.Pharmacol. 145 620. PMID:15852036.	Small Molecule	Sold for research purposes under agreement from GlaxoSmithKline.	http://www.tocris.com/dispprod.php?ItemId=358681	SQ1341			Jul-2013
4668	GW 627368	[439288-66-1]	O=C(NS(C5=CC=CC=C5)(=O)=O)CC(C=C4)=CC=C4N3CC2=C(OCC)C1=CC=CC=C1C(OCC)=C2C3=O	Selective EP4 receptor competitive antagonist	Selective prostanoid EP4 receptor competitive antagonist with additional affinity at TP receptors (pKi values are 7.0 and 6.8 in competition radioligand bioassays). Affinity for all other prostanoid receptors is < 5.3. Inhibits U-46619 induced human platelet aggregation.	"Jones and Chan et al (2005) Investigation of the agonist activity of prostacyclin analogues on prostanoid EP4 receptors using GW 627368 and taprostene: evidence for species differences. Prostaglandins Leukot.Essent.Fatty.Acids. 72 289. PMID:15763441. Wilson et al (2006) GW627368X ((N-{2-[4-(4,9-diethoxy-1-oxo-1,3-dihydro-2H-benzo[f]isoindol-2-yl)phenyl]acetyl} benzene sulphonamide): a novel, potent and selective prostanoid EP4 receptor antagonist. Br.J.Pharmacol. 148 326. PMID:16604093."	Small Molecule	Sold for research purposes under agreement from GlaxoSmithKline.	http://www.tocris.com/dispprod.php?ItemId=358682	SQ1070			Oct-2013
4670	SB 611812	[345892-71-9]	ClC1=CC=C(NS(C2=C(Cl)C=C(C(F)(F)F)C=C2Cl)(=O)=O)C=C1OCCN(C)C	Urotensin-II (UT) antagonist; attenuates cardiac dysfunction	"Urotensin-II (UT) antagonist. Inhibits urotensin-II-induced proliferation of neonatal cardiac fibroblasts. Attenuates cardiac dysfunction in a rat model of coronary artery ligation; decreases cardiomyocyte hypertrophy, ventricular dilatation and cardiac remodeling."	Bousette et al (2006) Urotensin-II receptor blockade with SB-611812 attenuates cardiac remodeling in experimental ischemic heart disease. Peptides 27 2919. PMID:16919371. Bousette et al (2006) Urotensin-II blockade with SB-611812 attenutes cardiac dysfunction in a rat model of coronary artery ligation. J.Mol.Cell Cardiol. 41 285. PMID:16797584. Papadopoulos et al (2008) Urotensin-II and cardiovascular remodeling. Peptides 29 764. PMID:17988761.	Small Molecule	Sold for research purposes under agreement from GlaxoSmithKline.	http://www.tocris.com/dispprod.php?ItemId=358762	SQ1341			Feb-2013
4672	SB 223412	[174636-32-9]	OC1=C(C(N[C@@H](CC)C2=CC=CC=C2)=O)C3=CC=CC=C3N=C1C4=CC=CC=C4	"Potent, selective non-peptide NK3 antagonist. Brain penetrant"	"Potent and selective non-peptide NK3 receptor antagonist (Ki values are 1, 144 and >100000 nM for human NK3, NK2 and NK1 receptors respectively). Selective over a panel of >60 receptors, enzymes and ion channels at concentrations of 1 or 10 _M. Inhibits NKB-induced Ca2+ mobilization in vitro (IC50 = 16.6 nM) and inhibits NK3-agonist-induced behavioral responses in vivo. Orally active and brain penetrant."	"Sarau et al (1997) Nonpeptide tachykinin receptor antagonists: I. Pharmacological and pharmacokinetic characterization of SB 223412, a novel, potent and selective neurokinin-3 receptor antagonist. J.Pharmacol.Ther.Exp. 281 1303. PMID:9190866. Sarau et al (2001) Molecular and pharmacological characterization of the murine tachykinin NK3 receptor. Eur.J.Pharmacol. 413 143. PMID:11226387. de la Flor and Dawson (2009) Augmentation of antipsychotic-induced neurochemical changes by the NK3 receptor antagonist talnetant (SB-223412). Neuropharmacol. 56 342. PMID:18822303."	Small Molecule	Sold for research purposes under agreement from GlaxoSmithKline.	http://www.tocris.com/dispprod.php?ItemId=358766	SQ1070			Nov-2013
4673	SB 674042	[483313-22-0]	O=C(C2=C(C5=CC=CC=C5F)SC(C)=N2)N1[C@H](CC3=NN=C(C4=CC=CC=C4)O3)CCC1	Potent and selective non-peptide OX1 antagonist	"Potent and selective non-peptide orexin OX1 receptor antagonist (Kd = 3.76 nM). Exhibits 100-fold selectivity for OX1 over OX2 receptors. Has no effect at serotonergic, dopaminergic, adrenergic or purinergic receptors. Inhibits orexin 1-induced Ca2+ mobilization in CHO-DG44 cells stably transfected with the OX1 receptor."	"Langmead et al (2004) Characterisation of the binding of [3H]-SB-674042, a novel nonpeptide antagonist, to the human orexin-1 receptor. Br.J.Pharmacol. 141 340. PMID:14691055. Ellis et al (2006) Orexin-1 receptor-cannabinoid CB1 receptor heterodimerization results in both ligand-dependent and -independent coordinated alterations of receptor localization and function. Biol.Chem. 281 38812. PMID:17015451."	Small Molecule	Sold for research purposes under agreement from GlaxoSmithKline.	http://www.tocris.com/dispprod.php?ItemId=358979	SQ1341			Feb-2014
4674	CZC 24832	[1159824-67-5]	NC2=NN1C=C(C3=CN=CC(S(NC(C)(C)C)(=O)=O)=C3)C=C(F)C1=N2	Selective inhibitor of PI 3-kinase _	Selective inhibitor of PI 3-kinase _ (IC50 = 1.0 _M in a PI 3-K_-dependent fMLP-induced neutrophil migration assay). Exhibits limited off-target effects in kinome profiling of 154 identified lipid and protein kinases and 922 other proteins. Orally effective in a rodent model of inflammatory disease.	Bergamini et al (2012) A selective inhibitor reveals PI3K_ dependence of T(H)17 cell differentiation. Nat.Chem.Biol. 8 576. PMID:22544264.	Small Molecule	Sold for research purposes under agreement from GlaxoSmithKline	http://www.tocris.com/dispprod.php?ItemId=358980	SQ1341			Feb-2013
4675	CCT 031374 hydrobromide	[1219184-91-4]	O=C(C4=CC=C(C5=CC=CC=C5)C=C4)CN1C3=C(C=CC=C3)N2C1=NCC2.Br	Inhibits TCF-dependent transcription; lowers _-catenin levels	Inhibitor of TCF-dependent transcription. Blocks BIO-induced _-catenin stabilization; reduces nuclear and cytosolic _-catenin levels in mouse L-cells. Inhibits growth and reduces TCF-dependent transcription in SW480 colon carcinoma cells.	Ewan et al (2010) A useful approach to identify novel small-molecule inhibitors of Wnt-dependent transcription. Cancer Res. 70 5963. PMID:20610623.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=358989	SQ1341			Dec-2012
4676	ARRY 520 trifluoroacetate	[885060-09-3]	FC1=CC=C(F)C=C1C2=NN(C(N(C)OC)=O)[C@](CCCN)([C@]3=CC=CC=C3)S2.FC(F)(F)C(O)=O	Potent and selective kinesin spindle protein (KSP) inhibitor; induces Mcl-1 degradation	Potent kinesin spindle protein (KSP) inhibitor (IC50 = 6 nM); selective for KSP over >250 other receptors and kinases at a concentration of 10 _M. Displays robust antitumor activity in bortezomib-resistant xenografts either alone or in combination with bortezomib. Induces degradation of Mcl-1; exhibits comparable cytotoxic activity to taxol (Cat. No. 1097) in epithelial ovarian cancer cells. Active in vivo.	"Woessner et al (2009) ARRY-520, a novel KSP inhibitor with potent activity in hematological and taxane-resistant tumor models. Anticancer Res. 29 4373. PMID:20032381. Kim et al (2009) KSP inhibitor ARRY-520 as a substitute for Paclitaxel in type I ovarian cancer cells. J.Transl.Med. 7 63. PMID:19619321. Tunquist et al (2010) Mcl-1 stability determines mitotic cell fate of human multiple myeloma tumor cells treated with the kinesin spindle protein inhibitor ARRY-520. Mol.Cancer.Ther. 9 2046. PMID:20571074."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=358992	SQ1533			Feb-2013
4677	CYM 50260	[1355026-60-6]	ClC1=CC(Cl)=C(OCCOC2=CC=C(CF)N=C2Cl)C=C1	Potent and selective S1P4 agonist	Potent sphingosine-1-phosphate receptor 4 (S1P4) agonist (EC50 = 45 nM). Displays no activity at other S1P receptor subtypes (S1P1-3 and S1P5) at concentrations up to 25 _M.	"Guerrero et al (2011) Discovery, design and synthesis of novel potent and selective sphingosine-1-phosphate 4 receptor (S1P4-R) agonists. Bioorg.Med.Chem.Lett. 22 537. PMID:22119461."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=358993	SQ1341			Mar-2013
4678	CYM 50308	[1345858-76-5]	FC1=CC(F)=C(N2C(C)=CC(/C=C3\S/C(N(C)C3=O)=N\CCOC)=C2C)C=C1	Potent and selective S1P4 agonist	"Potent and selective sphingosine-1-phosphate receptor 4 (S1P4) agonist (EC50 values are 56 nM and 2100 nM for S1P4 and S1P5 receptors, respectively). Displays no activity at S1P1, S1P2 and S1P3 receptors at concentrations up to 25 _M."	"Urbano et al (2011) Discovery, synthesis and SAR analysis of novel selective small molecule S1P4-R agonists based on a (2Z,5Z)-5-((pyrrol-3-yl)methylene)-3-alkyl-2-(alkylimino)thiazolidin-4-one chemotype. Bioorg.Med.Chem.Lett. 21 6739. PMID:21982495."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=358994				May-2013
4679	CYM 50358 hydrochloride		O=C(NC3=C(C)C=C(CN)C=C3C)C1=CC=C(C2=C(Cl)C=CC(Cl)=C2)O1.Cl	Potent and selective S1P4 antagonist	"Potent S1P4 antagonist (IC50 = 25 nM). Displays selectivity for S1P4 against S1P1, S1P2, S1P3 and S1P5 receptors."	"Guerrero et al (2011) Discovery, design and synthesis of the first reported potent and selective sphingosine-1-phosphate 4 (S1P4) receptor antagonists. Bioorg.Med.Chem.Lett. 21 3632. PMID:21570287. Cencetti et al (2013) TGF_1 evokes myoblast apoptotic response via a novel signaling pathway involving S1P4 transactivation upstream of Rho-kinase-2 activation. FASEB J. 27 4532. PMID:23913862."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=358999	SQ1341			Dec-2013
4684	Daminozide	[1596-84-5]	O=C(NN(C)C)CCC(O)=O	Selective histone demethylase KDM2/7 subfamily inhibitor	"Histone demethylase KDM2/7 subfamily inhibitor (IC50 values are 0.55, 1.5 and 2.1 _M for PHF8, KDM2A and KDM7A respectively). Exhibits  60-fold selectivity for KDM2/7 demethylases over other histone demethylases and 2-oxoglurate oxygenases (IC50 > 100 _M)."	Rose et al (2012) Plant growth regulator daminozide is a selective inhibitor of human KDM2/7 histone demethylases. J.Med.Chem. 55 6639. PMID:22724510.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=359080	SQ1533			Nov-2012
4685	KL 001	[309928-48-1]	OC(CN(CC4=CC=CO4)S(C)(=O)=O)CN2C1=CC=CC=C1C3=C2C=CC=C3	Cryptochrome protein stabilizer; lengthens circadian period	Cryptochrome protein (CRY) stabilizer; blocks proteasome-mediated degradation of CRY1 and CRY2. Lengthens circadian period in mouse NIH-3T3 fibroblasts without altering casein kinase activity. Represses glucagon-induced hepatic gluconeogenesis through the induction of Pck1 and G6pc expression.	Hirota et al (2012) Identification of small molecule activators of cryptochrome. Science 337 1094. PMID:22798407.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=359081	SQ1533			Nov-2012
4686	Xanthohumol	[6754-58-1]	OC1=C(C(/C=C/C2=CC=C(O)C=C2)=O)C(OC)=CC(O)=C1C/C=C(C)/C	Valosin-containing protein (VCP) inhibitor	"Valosin-containing protein (VCP) inhibitor. Binds to the N domain of VCP, suppressing function and impairing autophagosome maturation. Inhibits growth of a wide variety of human cancer cell lines by inhibiting proliferation and inducing apoptosis."	Sasazawa et al (2012) Xanthohumol impairs autophagosome maturation through direct inhibition of valosin-containing protein. ACS Chem.Biol. 7 892. PMID:22360440.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=359082	SQ1070			Oct-2012
4688	GSK J2	[1394854-52-4]	O=C(CCNC1=NC(C2=CC=CN=C2)=NC(N3CCC(C=CC=C4)=C4CC3)=C1)O	Inactive isomer of GSK J1 (Cat. No. 4593)	"Inactive control of GSK J1 (Cat No.4593) (IC50 > 100 _M for inhibition of JMJD3/UTX). Cell permeable ester derivative, GSK J5 (Cat. No. 4689), also available."	Kruidenier et al (2012) A selective jumonji H3K27 demethylase inhibitor modulates the proinflammatory macrophage response. Nature 488 404. PMID:22842901.	Small Molecule	"This compound is supplied in conjunction with the Structural Genomics Consortium. For further details of GSK J2, an inactive isomer of GSK J1, please visit the GSK J1 probe summary on the SGC website."	http://www.tocris.com/dispprod.php?ItemId=359587				Jan-2014
4689	GSK J5	[1394854-51-3]	O=C(CCNC1=NC(C2=CC=CN=C2)=NC(N3CCC(C=CC=C4)=C4CC3)=C1)OCC	Inactive isomer of GSK J4 (Cat. No. 4594); cell permeable	"Inactive isomer of GSK J4 (Cat. No. 4594); also cell permeable ester derivative of the inactive control, GSK J2 (Cat. No. 4688)"	Kruidenier et al (2012) A selective jumonji H3K27 demethylase inhibitor modulates the proinflammatory macrophage response. Nature 488 404. PMID:22842901.	Small Molecule	"This compound is supplied in conjunction with the Structural Genomics Consortium. For further characterization details of GSK J5, a cell permeable inactive isomer of GSK J1, please visit the GSK J1 probe summary on the SGC website."	http://www.tocris.com/dispprod.php?ItemId=359588				Jan-2014
4691	NAV 26	[1198160-14-3]	O=C2C1=CC=CC=C1C(C(NCC4=CC=C(OC(F)(F)F)C=C4)=O)N2C3CCOCC3	Selective Nav1.7 channel blocker	Selective Nav1.7 channel blocker (IC50 = 370 nM). Exhibits >85-fold selectivity for Nav1.7 over Nav1.5 and hERG channels.	"Macsari et al (2012) 3-Oxoisoindoline-1-carboxamides: potent, state-dependent blockers of voltage-gated sodium channel Na(V)1.7 with efficacy in rat pain models. J.Med.Chem. 55 6866. PMID:22770500."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=359713				Oct-2014
4694	Ro 5-3335	[30195-30-3]	O=C1CN=C(C3=CC=CN3)C2=C(C=CC(Cl)=C2)N1	Core binding factor inhibitor; attenuates hematopoiesis	Core binding factor (CBF) inhibitor; preferentially kills human leukemia cell lines with CBF fusion proteins (IC50 = 1.1 _M). Represses RUNX1/CBF_-dependent transactivation in reporter assays and inhibits transcriptional regulation by RUNX1 and CBF_. Reduces leukemia burden in a mouse model. Attenuates RUNX1-dependent hematopoiesis in zebrafish embryos. Also a Tat antagonist; inhibits HIV-1 replication in vitro.	"Cupelli et al (1995) The human immunodeficiency virus type 1 Tat antagonist, Ro 5-3335, predominantly inhibits transcription initiation from the viral promoter. J.Virol. 69 2640. PMID:7884917. Okuda et al (2001) RUNX1/AML1: a central player in hematopoiesis. Int. J. Hematol. 74 252. PMID:11721959. Cunningham et al (2012) Identification of benzodiazepine Ro5-3335 as an inhibitor of CBF leukemia through quantitative high throughput screen against RUNX1-CBF interaction. Proc.Natl.Acad.Sci.USA 109 14592. PMID:22912405."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=359716	SQ1341			Jul-2014
4695	Ischemin sodium salt		CC1=CC(/N=N/C2=C(C)C=C(C)C(S(=O)(O[Na])=O)=C2)=C(N)C=C1O	CBP bromodomain inhibitor; cell permeable	CBP bromodomain inhibitor. Inhibits p53 interaction with CBP and decreases p53 transcriptional activity. Protects against Doxorubicin-induced apoptosis in cardiomyocytes in vitro. Cell permeable.	Borah et al (2011) A small molecule binding to the coactivator CREB-binding protein blocks apoptosis in cardiomyocytes. Chem.Biol. 18 531. PMID:21513889.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=359717				Jan-2015
4696	Eprosartan mesylate	[144143-96-4]	CCCCC1=NC=C(/C=C(C(O)=O)\CC3=CC=CS3)N1CC2=CC=C(C(O)=O)C=C2.CS(=O)(O)=O	Potent and selective AT1 receptor antagonist	"Potent angiotensin II receptor 1 (AT1) antagonist (IC50 values are 1.5, 1.7, 3.9 and 9.2 nM at rat mesenteric artery, human liver membrane, human adrenal cortical membrne and rat adrenal cortical membrane respectively). Displays no effect on vasopressin or CGRP binding, or angiotensin-converting enzyme (ACE) activity. Inhibits the angiotensin II-induced pressor response in normotensive rats."	"Edwards et al (1992) Pharmacological characterization of the nonpeptide angiotensin II receptor antagonist, SK&F 108566. J.Pharmacol.Exp.Ther. 260 175. PMID:1309870. Oh et al (2011) Angiotensin II inhibits insulin binding to endothelial cells. Diabetes Metab.J. 35 243. PMID:21785744."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=359718	SQ1070			Nov-2012
4697	A 331440 dihydrochloride	[1049740-32-0]	CN(C)[C@H](CC3)CN3CCCOC1=CC=C(C2=CC=C(C#N)C=C2)C=C1.Cl.Cl	Selective H3 antagonist	"High affinity histamine H3 receptor antagonist (Ki values are 21.7 and 22.7 nM for rat and human H3 receptors, respectively). Exhibits selectivity for human H3 over H1, H2 and H4 receptors (Ki values are 2940, 14400 and >10000 nM respectively). Shown to reduce weight in a diet-induced obesity model."	"Hancock et al (2004) Antiobesity effects of A-331440, a novel non-imidazole histamine H3 receptor antagonist. Eur.J.Pharmacol. 487 183. PMID:15033391. Hancock et al (2004) In vitro optimization of structure activity relationships by analogues of A-331440 combining radioligand receptor binding assays and micronucleus assays of potential antiobesity histamine H3 receptor antagonists. Basic Clin.Pharmacol.Toxicol. 95 144. PMID:15447739."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=359806	SQ1341			Mar-2014
4700	PU 02	[313984-77-9]	C12=NC=NC(SCC3=C(C=CC=C4)C4=CC=C3)=C1NC=N2	Negative allosteric modulator of 5-HT3	Negative allosteric modulator of 5-HT3 receptors (IC50 values are 0.36 and 0.73 _M in HEK293 cells transfected with human 5-HT3A and 5-HT3AB receptors respectively).	Trattnig et al (2012) Discovery of a novel allosteric modulator of 5-HT3 receptors: inhibition and potentiation of Cys-loop receptor signaling through a conserved transmembrane intersubunit site. J.Biol.Chem. 287 25241. PMID:22589534.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=360096	SQ1341			Feb-2013
4701	EC 144	[911397-80-3]	ClC1=C2C(N(CC3=C(C)C(OC)=C(C)C=N3)C=C2C#CCC(C)(C)O)=NC(N)=N1	"High affinity, potent and selective Hsp90 inhibitor"	"High affinity, potent and selective Hsp90 inhibitor (Ki = 0.2 nM and IC50 = 1.1 nM). Exhibits selectivity for Hsp90 over Grp94 and TRAP1 (Ki values are 61 and 255 nM respectively) and has no effect (IC50 >10 _M) against a panel of 285 kinases. Degrades Her-2 in MCF-7 breast cancer cells (EC50 = 14 nM). Blocks tumor growth and induces partial tumor regression in an N87 gastric tumor mouse model. Also inhibits LPS-induced TNF_ release in an LPS shock mouse model and suppresses disease development in a rat model of collagen-induced arthritis. Exhibits <20-fold efficacy over BIIB 021 (Cat. No. 4608) in mice. Orally available and brain penetrant."	"Yun et al (2011) EC144, a synthetic inhibitor of heat shock protein 90, blocks innate and adaptive immune responses in models of inflammation and autoimmunity. J.Immunol. 186 563. PMID:21131419. Shi et al (2012) EC144 is a potent inhibitor of the heat shock protein 90. J.Med.Chem. 55 7786. PMID:22938030."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=360366				Oct-2014
4704	LP 20 hydrochloride	[1386928-34-2]	COC(C=C3)=CC=C3C1=CC=CC=C1N2CCNCC2.Cl	Selective 5-HT7 ligand	Ligand of the 5-HT7 receptor (Ki = 2.6 nM); exhibits agonist and antagonist activity. Displays selectivity over adrenergic _1 and 5-HT1A receptors (Ki values are 156 and 476 nM respectively).	Lacivita et al (2012) Investigations on the 1-(2-biphenyl)piperazine motif: identification of new potent and selective ligands for the serotonin7 (5-HT7) receptor with agonist or antagonist action in vitro or ex vivo. J.Med.Chem. 55 6375. PMID:22738316.	Small Molecule	Sold under license from the University of Bari	http://www.tocris.com/dispprod.php?ItemId=360902	SQ1070			Dec-2012
4708	TC LPA5 4	[1393814-38-4]	ClC(C=C(C3=CC(C(O)=O)=NN3C4=CC=CC(OC)=C4)C=C2)=C2C1CCCCC1	LPA5 receptor antagonist	LPA5 receptor antagonist (IC50 = 0.8 _M in LPA5-RH7777 cells). Inhibits LPA-induced aggregation of isolated human platelets. Exhibits selectivity for LPA5 against 80 other screened targets.	Kozian et al (2012) Selective non-lipid modulator of LPA5 activity in human platelets. Bioorg.Med.Chem.Lett. 22 5239. PMID:22801643.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=360906	SQ1341			Sep-2013
4710	PF 06465469	[1407966-77-1]	NC1=C2C(N([C@@H]4CCCN(C(C=C)=O)C4)N=C2C3=CC(C(NC5=CC(C)=C(C(C)C)C=C5)=O)=CC=C3)=NC=N1	Potent inhibitor of interleukin-2 inducible T cell kinase (ITK). Also inhibits BTK	Potent inhibitor of interleukin-2 inducible T cell kinase (ITK) (IC50 = 2 nM). Also exhibits inhibitory activity against Bruton's tyrosine kinase (BTK) (IC50 = 2 nM). Displays nanomolar potencies in a cell-based IP1 assay and human whole blood assay (IC50 values are 31 and 48 nM respectively).	Zapf et al (2012) Covalent inhibitors of interleukin-2 inducible T cell kinase (Itk) with nanomolar potency in a whole-blood assay. J.Med.Chem. 55 10047. PMID:23098091.	Small Molecule	Sold for research purposes under agreement from Pfizer Inc.	http://www.tocris.com/dispprod.php?ItemId=362108	SQ1341			Jan-2013
4712	Salmeterol xinafoate	[94749-08-3]	OC(C2=CC(CO)=C(O)C=C2)CNCCCCCCOCCCCC1=CC=CC=C1.OC4=C(C(O)=O)C=CC3=CC=CC=C34	Long-acting _2 agonist; bronchodilator	"Long-acting _2 adrenergic receptor agonist. Inhibits the release of histamine, leukotrienes and prostaglandin D2, and blocks GM-CSF production from human cultured mast cells. Exhibits efficacious bronchodilatory activity in patients with asthma or chronic obstructive pulmonary disease (COPD)."	"Roberts et al (1999) The long-acting beta2-agonist salmeterol xinafoate: effects on airway inflammation in asthma. Eur.Respir.J. 14 275. PMID:10515401. Rennard et al (2001) Use of a long-acting inhaled beta2-adrenergic agonist, salmeterol xinafoate, in patients with chronic obstructive pulmonary disease. Am.J.Respir.Crit.Care Med. 163 1087. PMID:11316640. Akabane et al (2006) Effects of salmeterol xinafoate and fluticasone propionate on immunological activation of human cultured mast cells. Allergol.Int. 55 387. PMID:17130681."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=363318	SQ1533			Nov-2012
4713	IQ 1	[331001-62-8]	CC(C(C=C3)=CC=C3/N=N/C(C(N)=O)=C2\C1=CC=CC=C1CC(C)(C)N2)=O	Enables Wnt/_-catenin-driven expansion of ESCs; prevents spontaneous differentiation	Maintains embryonic stem cell (ESC) pluripotency in Wnt3a-treated cells; enables Wnt/_-catenin-driven expansion of mouse ESCs and prevents spontaneous differentiation. Upregulates expression of Oct4 and Sox2 transcription factors. Binds to serine/threonine phosphatase PP2A and prevents PP2A/Nkd interaction.	Miyabayashi et al (2007) Wnt/beta-catenin/CBP signaling maintains long-term murine embryonic stem cell pluripotency. Proc.Natl.Acad.Sci.U S A 104 5668. PMID:17372190.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=363339	SQ1341			Jan-2013
4715	JZL 195	[1210004-12-8]	O=C(OC4=CC=C([N+]([O-])=O)C=C4)N(CC3)CCN3CC1=CC(OC2=CC=CC=C2)=CC=C1	Dual FAAH and MAGL inhibitor	Dual inhibitor of fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL) (IC50 values are 2 and 4 nM respectively). Elevates anandamide and 2-arachidonoylglycerol levels in vivo. Shown to impair short-term memory in mice.	Long et al (2009) Dual blockade of FAAH and MAGL identifies behavioral processes regulated by endocannabinoid crosstalk in vivo. Proc.Natl.Acad.Sci.USA 106 20270. PMID:19918051. Wiskerke et al (2012) Characterization of the effects of reuptake and hydrolysis inhibiton on interstitial endocannabinoid levels in the brain: an in vivo microdialysis study. ACS Chem.Neurosci. 3 407. PMID:22860210. Wise et al (2012) Dual fatty acid amide hydrolase and monoacylglycerol lipase blockade produces THC-like Morris water maze deficits in mice. ACS Chem.Neurosci. 3 369. PMID:22860205.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=363638	SQ1533			Dec-2013
4716	A 967079	[1170613-55-4]	FC1=CC=C(/C=C(C)/C(CC)=N/O)C=C1	Selective TRPA1 channel blocker	"Selective TRPA1 channel blocker (IC50 values are 67 and 289 nM at human and rat TRPA1 receptors respectively). Displays 1000-fold selectivity for TRPA1 over other TRP channels, and is >150-fold selective over 75 other ion channels, enzymes and G-protein-coupled receptors. Exhibits analgesic effects in a rat osteoarthritic pain model."	"McGaraughty et al (2010) TRPA1 modulation of spontaneous and mechanically evoked firing of spinal neurons in uninjured, osteoarthritic, and inflamed rats. Mol.Pain 6 14. PMID:20205719. Chen et al (2011) Selective blockade of TRPA1 channel attenuates pathological pain without altering noxious cold sensation or body temperature regulation. Pain 152 1165. PMID:21402443."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=363639				Dec-2012
4717	Jervine	[469-59-0]	O[C@H](C2)CC[C@@]1(C)C2=CC[C@]([C@@](CC[C@@]54O[C@@](C[C@H](C)CN6)([H])[C@]6([H])[C@H]5C)([H])C3=[C@@]4C)([H])[C@@]([H])1C3=O	Inhibitor of Hedgehog (Hh) signaling; binds directly to Smo	"Inhibitor of Hedgehog signaling (IC50 = 500 - 700 nM); binds directly to Smoothened (Smo). Inhibits the response of target tissues to Sonic hedgehog signaling, possibly via the sterol sensing domain of Patched. Teratogenic."	Cooper et al (1998) Teratogen-mediated inhibition of target tissue response to Shh signaling. Science 280 1603. PMID:9616123. ten Berge et al (2001) Prx1 and Prx2 are upstream regulators of sonic hedgehog and control cell proliferation during mandibular arch morphogenesis. Development 128 2929. PMID:11532916. Williams et al (2003) Identification of a small molecule inhibitor of the hedgehog signaling pathway: effects on basal cell carcinoma-like lesions. Proc.Natl.Acad.Sci.USA 100 4616. PMID:12679522.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=363762	SQ1070			Feb-2013
4719	VU 0463271	[1391737-01-1]	O=C(N(C4CC4)C3=NC(C)=CS3)CSC(C=C2)=NN=C2C1=CC=CC=C1	Potent and selective inhibitor of the neuronal K-Cl cotransporter (KCC2)	"Potent and selective inhibitor of the neuronal K-Cl cotransporter, KCC2 (IC50 = 61 nM); displays >100-fold selectivity versus the Na-K-2Cl cotransporter 1 (NKCC1) and no activity against a panel of 68 GPCRs, ion channels and transporters."	Delpire et al (2012) Further optimization of the K-Cl cotransporter KCC2 antagonist ML077: development of a highly selective and more potent in vitro probe. Bioorg.Med.Chem.Lett. 22 4532. PMID:22727639.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=363772				Dec-2014
4720	Entacapone	[130929-57-6]	OC1=CC(/C=C(C#N)/C(N(CC)CC)=O)=CC([N+]([O-])=O)=C1O	Potent COMT inhibitor; blocks _-synuclein aggregation	"Potent catechol O-methyltransferase (COMT) inhibitor (IC50 values are 14.3, 20.1 and 73.3 nM for rat liver soluble COMT, total COMT and membrane-bound COMT respectively). Increases bioavailability of levodopa when given as an adjunct therapy for Parkinson's disease. Inhibits _-synuclein aggregation in an in vitro assay; blocks _-synuclein-induced cell death in PC-12 cells."	"Merello et al (1994) Effect of entacapone, a peripherally acting catechol-O-methyltransferase inhibitor, on the motor response to acute treatment with levodopa in patients with Parkinson's disease. J.Neurol.Neurosurg.Psychiatry 57 186. PMID:8126502. Forsberg et al (2003) Pharmacokinetics and pharmacodynamics of entacapone and tolcapone after acute and repeated administration: a comparative study in the rat. J.Pharmacol.Exp.Ther. 304 498. PMID:12538800. Di Giovanni et al (2010) Entacapone and tolcapone, two catechol O-methyltransferase inhibitors, block fibril formation of alpha-synuclein and beta-amyloid and protect against amyloid-induced toxicity. J.Biol.Chem. 285 14941. PMID:20150427."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=363788				Dec-2012
4722	Decynium 22	[977-96-8]	CC[N+]2=C(/C=C3/N(CC)C(C=CC=C4)=C4C=C3)C=CC1=CC=CC=C12.[I-]	PMAT inhibitor	Inhibitor of the plasma membrane monoamine transporter (PMAT) (Ki = 0.10 _M).	Engel and Wang (2005) Interaction of organic cations with a newly identified plasma membrane monoamine transporter. Mol.Pharmacol. 68 1397. PMID:16099839. Xia et al (2009) Podocyte-specific expression of organic cation transporter PMAT: implication in puromycin aminonucleoside nephrotoxicity. Am.J.Physiol.Renal Physiol. 296 F1307. PMID:19357181.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=364182				Dec-2012
4724	BTT 3033	[1259028-99-3]	FC1=CC=C(N2N=CC(S(N(C3=CC=C(NC(NC4=CC=CC=C4)=O)C=C3)C)(=O)=O)=C2)C=C1	Selective inhibitor of integrin _2_1	"Selective inhibitor of integrin _2_1 (EC50 = 130 nM for _2_1 binding to collagen I). Binds to the _2I domain. Exhibits selectivity for _2_1 over integrins _3_1, _4_1, _5_1 and _v. Inhibits platelet aggregation to collagen I coated capillaries under flow. Also inhibits binding of _2-expressing CHO cells to collagen I under shear stress conditions."	Nissinen et al (2012) Novel a21 integrin inhibitors reveal that integrin binding to collagen under shear stress conditions does not require receptor preactivation. J.Cell Biol. 287 44694. PMID:23132859.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=364184				Oct-2014
4725	Eptifibatide	[188627-80-7]	NC(=N)NCCCC[C@@H]1NC(=O)CCSSC[C@H](NC(=O)[C@@H]2CCCN2C(=O)[C@H](Cc2cnc3ccccc23)NC(=O)[C@H](CC(O)=O)NC(=O)CNC1=O)C(N)=O	Glycoprotein IIb/IIIa inhibitor; inhibits platelet aggregation	"Glycoprotein (GP) IIb/IIIa inhibitor. Reversibly and competitively binds to GPIIa/IIIb on platelets, inhibiting aggregation."	O'Shea and Tcheng (2002) Eptifibatide: a potent inhibitor of the platelet receptor integrin glycoprotein IIb/IIIa. Expert Opin.Pharmacother. 3 1199. PMID:12150697.	Peptide		http://www.tocris.com/dispprod.php?ItemId=364185	SQ1341			Jan-2013
4727	GS 6201	[752222-83-6]	O=C(N(CC)C2=C1NC(C3=CN(CC4=CC=CC(C(F)(F)F)=C4)N=C3)=N2)N(CCC)C1=O	Selective A2B antagonist	"Selective antagonist of adenosine A2B receptors (Ki values are 22, 1070, 1940 and 3280 nM for human A2B, A3, A1 and A2A receptors respectively). Attenuates allergen-, NECA- and AMP-induced airway reactivity in an allergic mouse model of asthma. Also shown to attenuate the inflammatory response during acute myocardial infarction in mice; reduces caspase-1 activity in the heart."	"Mustafa et al (2007) Effect of a specific and selective A2B adenosine receptor antagonist on adenosine agonist AMP and allergen-induced airway responsiveness and cellular influx in a mouse model of asthma. J.Pharmacol.Exp.Ther. 320 1246. PMID:17159162. Elzein et al (2008) Discovery of a novel A2B adenosine receptor antagonist as a clinical candidate for chronic inflammatory airway diseases. J.Med.Chem. 51 2267. PMID:18321039. Toldo et al (2012) GS-6201, a selective blocker of the A2B adenosine receptor, attenuates cardiac remodeling after acute myocardial infarction in the mouse. J.Pharmacol.Exp.Ther. 343 587. PMID:22923737."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=364301	SQ1533			May-2013
4730	PPY A	[875634-01-8]	O=C(N(C)C)C1=CN=CC(C2=CN=C(NC=C3C4=C(OC)C=CC=C4)C3=C2)=C1	Potent inhibitor of Abl T315l mutant and wild-type Abl kinases	"Potent inhibitor of T315l mutant and wild-type Abl kinases (IC50 values are 9 and 20 nM, respectively). Inhibits growth of cells transformed with either the Bcr-Abl T315l mutant or wild-type Bcr-Abl gene."	Zhou et al (2007) Crystal structure of the T315I mutant of AbI kinase. Chem.Biol.Drug.Des. 70 171. PMID:17718712. Noronha et al (2008) Inhibitors of ABL and the ABL-T315I mutation. Curr.Top.Med.Chem. 8 905. PMID:18673174.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=363341	SQ1341			May-2013
4731	KY 02111	[1118807-13-8]	O=C(CCC3=CC=C(OC)C(OC)=C3)NC2=NC1=CC=C(Cl)C=C1S2	Inhibits canonical Wnt signaling. Promotes differentiation of human ESCs and iPSCs into cardiomyocytes	Promotes differentiation of human ESCs and iPSCs into cardiomyocytes when used after day three in culture; differentiation efficiency increases when used after initial culture with CHIR 99021 (Cat. No. 4423). Induces downregulation of Wnt signaling target genes; inhibits canonical Wnt signaling in a manner distinct from other known Wnt inhibitors.	"Minami et al (2012) A small molecule that promotes cardiac differentiation of humam pluripotent stem cells under defined, cytokine- and xeno-free conditions. Cell Rep. 2 1448. PMID:23103164."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=364943	SQ1533			Feb-2013
4732	ML 204	[5465-86-1]	CC2=CC(N3CCCCC3)=NC1=CC=CC=C12	Selective TRPC4 blocker	"Blocker of TRPC4 channels (IC50 values are 0.96 and 2.6 _M in fluorescent and electrophysiological assays, respectively). Exhibits 19-fold selectivity against TRPC6 and 9-fold selectivity against TRPC5; displays no significant activity at TRPV1, TRPV3, TRPA1 and TRPM8 channels at concentrations up to 22 _M."	"Miller et al (2011) Novel chemical inhibitor of TRPC4 channels. Probe Reports from the Molecular Libraries Program. PMID:22049577. Miller et al (2011) Identification of ML204, a novel potent antagonist that selectively modulates native TRPC4/5 ion channels. J.Biol.Chem. 286 33436. PMID:21795696."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=364944	SQ1341			Dec-2012
4733	P005091	[882257-11-6]	CC(=O)C1=CC(=C(SC2=CC=CC(Cl)=C2Cl)S1)[N+]([O-])=O	USP7 inhibitor	"Selective inhibitor of ubiquitin-specific protease (USP) 7 (IC50 = 4.2 _M). Displays little-to-no inhibition of other USP variants or proteases such as caspase, cathepsins and serine proteases; exhibits some activity at USP47. Induces elevated p53 and apoptosis in cancer cell lines; displays antiangiogenic activity in vivo."	Weinstock et al (2012) Selective dual inhibitors of the cancer-related deubiquitylating proteases USP7 and USP47. J.Med.Chem. 3 789. Chauhan et al (2012) A small molecule inhibitor of ubiquitin-specific protease-7 induces apoptosis in multiple myeloma cells and overcomes bortezomib resistance. Cancer Cell. 22 345. PMID:22975377.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=364945	SQ1341			Jan-2013
4734	TRC 051384	[867164-40-7]	O=C(C3=CC=C(NC(NCCN4CCOCC4)=O)C=C3)/C=C/C1=CC=CC(N2CCOCC2)=N1	Inducer of heat shock protein Hsp70	Inducer of heat shock protein Hsp70; reduces stroke-associated neuronal injury and increases survival in a rat model of transient ischemic stroke. Activates heat shock factor-1 and results in elevated chaperone and anti-inflammatory activity. Enhances Hsp72 expression in neurons and glial cells.	Mohanan et al (2011) Delayed intervention in experimental stroke with TRC051384--a small molecule HSP70 inducer. Neuropharmacology. 60 991. PMID:21167846.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=364946	SQ1341			Jul-2014
4735	Quetiapine hemifumarate	[111974-72-2]	OCCOCCN(CC4)CCN4C2=NC1=CC=CC=C1SC3=C2C=CC=C3.O=C(/C=C/C(O)=O)O.OCCOCCN(CC8)CCN8C6=NC5=CC=CC=C5SC7=C6C=CC=C7	5-HT2/D2 antagonist; atypical antipsychotic	Atypical antipsychotic. Displays antagonist activity at serotonin (5-HT2) and dopamine (D2) receptors (IC50 values are 148 and 329 nM respectively). Lacks affinity at either D1 or muscarinic receptors.	"Saller and Salama (1993) Seroquel: biochemical profile of a potential atypical antipsychotic. Psychopharmacology (Berl.) 112 285. PMID:7871032. Ellenbroek et al (1996) Activity of ""seroquel"" (ICI 204,636) in animal models for atypical properties of antipsychotics: a comparison with clozapine. Neuropsychopharmacology 15 406. PMID:8887995."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=365377	SQ1533			Jan-2013
4736	WIN 18446	[1477-57-2]	ClC(Cl)C(NCCCCCCCCNC(C(Cl)Cl)=O)=O	ALDH1a2 inhibitor	Inhibitor of aldehyde dehydrogenase 1a2 (ALDH1a2) (IC50 = 0.3 _M). Inhibits the biosynthesis of retinoic acid from retinol in neonatal and adult murine testis.	"Amory et al (2011) Suppression of spermatogenesis by bisdichloroacetyldiamines is mediated by inhibition of testicular retinoic acid biosynthesis. J.Androl. 32 111. PMID:20705791. Hogarth et al (2011) Suppression of Stra8 expression in the mouse gonad by WIN 18,446. Biol.Reprod. 84 957. PMID:21209416."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=365511				Jan-2013
4742	Gue 1654	[397290-30-1]	O=C(C(C5=CC=CC=C5)C4=CC=CC=C4)NC(S3)=NC1=C3C(SC(SC)=N2)=C2C=C1	Selective inhibitor of OXE-R G__ signaling	Oxoeicosanoid receptor 1 (OXE-R) modulator. Selectively inhibits G__ but not G_i signaling upon activation of the G_i-__ heterotrimer by OXE-R. Inhibits G__-mediated opening of GIRK1/2 channels in HEK293 cells.	Blttermann et al (2012) A biased ligand for OXE-R uncouples G_ and G__ signaling within a heterotrimer Nat.Chem.Biol. 8 631. PMID:22634634.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=366958	SQ1341			Jan-2013
4745	LIMKi 3	[1338247-35-0]	FC(F)C1=NN(C2=C(Cl)C=CC=C2Cl)C(C3=CN=C(NC(C(C)C)=O)S3)=C1	Potent LIM kinase inhibitor; antitumor	Potent LIM kinase inhibitor (IC50 values are 7 and 8 nM for LIMK1 and LIMK2 respectively). Inhibits cofilin phosphorylation in MDA-MB-231 breast cancer cells. Reduces MDA-MB-231 tumor cell invasion in a 3D matrigel invasion assay.	Ross-Macdonald et al (2008) Identification of a nonkinase target mediating cytotoxicity of novel kinase inhibitors. Mol.Cancer Ther. 7 3490. PMID:19001433. Scott et al (2010) LIM kinases are required for invasive path generation by tumor and tumor-associated stromal cells. J.Cell Biol. 191 169. PMID:20876278. Sparrow et al (2012) The actin-severing protein cofilin is downstream of neuregulin signaling and is essential for Schwann cell myelination. J.Neurosci. 32 5284. PMID:22496574.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=366964	SQ1341			Jul-2014
4746	ML SA1	[332382-54-4]	CC2CC(C)(C)N(C(CN3C(C(C=CC=C4)=C4C3=O)=O)=O)C1=CC=CC=C12	Activator of TRPML channels	"Activator of TRPML channels (TRPML1, 2 and 3); does not activate TRPM2, TRPV2, TRPV3, TRPC6 or TRPA1 channels. Induces TRPML-mediated Ca2+ release from lysosomes; activity corrects trafficking defects and reduces cholesterol accumulation in Niemann-Pick type C macrophages."	"Shen et al (2012) Lipid storage disorders block lysosomal trafficking by inhibiting TRP channel and calcium release. Nat.Commun. 3 731. PMID:22415822. Weiss et al (2012) Cross-talk between TRPML1 channel, lipids and lysosomal storage diseases. Commun.Integr.Biol. 5 111. PMID:22808310."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=366966	SQ1341			Mar-2013
4747	TC-G 1006	[1324003-64-6]	O=C(NC(C2=C(OC)C=CN=C2)=O)NC1=CC=C(C3=CC=CC=C3)C(C(F)(F)F)=C1	Potent and selective sphingosine-1-phosphate receptor 1 (S1P1) agonist	"Potent and selective sphingosine-1-phosphate receptor 1 (S1P1) agonist (EC50 = 35 nM), displays >100-fold selectivity against receptor subtypes S1P2-5. Induces a dose-dependent reduction in circulating blood lymphocyte counts in rodent models. Orally bioavailable."	Pennington et al (2011) 4-Methoxy-N-[2-(trifluoromethyl)biphenyl-4-ylcarbamoyl]nicotinamide: A Potent and Selective Agonist of S1P1. ACS Med.Chem.Lett. 2 752. PMID:24900263.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=366967	SQ1341			Mar-2014
4748	ML 221	[877636-42-5]	O=C(C3=CC=C([N+]([O-])=O)C=C3)OC1=COC(CSC2=NC=CC=N2)=CC1=O	Apelin receptor (APJ) antagonist	"Apelin receptor (APJ) antagonist (IC50 values are 0.70 and 1.75 _M in a cAMP assay and _-arrestin assay, respectively). Displays >37-fold selectivity over the closely related angiotensin II type 1 (AT1) receptor. Exhibits no toxicity towards human hepatocytes at concentrations >50 _M."	Maloney et al (2012) Discovery of 4-oxo-6-((pyrimidin-2-ylthio)methyl)-4H-pyran-3-yl 4-nitrobenzoate (ML221) as a functional antagonist of the apelin (APJ) receptor. Bioorg.Med.Chem.Lett. 22 6656. PMID:23010269.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=366969	SQ1341			Mar-2013
4750	TC Mps1 12	[1206170-62-8]	NC1=C(C#N)C(NC(C)(C)C)=NC(NC2=CC=C(C(N)=O)C=C2)=C1	Potent and selective monopolar spindle 1 (Mps1) kinase inhibitor; orally active	Potent and selective monopolar spindle 1 (Mps1) inhibitor (IC50 = 6.4 nM). Selective for Mps1 over a panel of 95 kinases including JNK. Inhibits A549 lung carcinoma cell proliferation and attenuates A549 cell xenograft growth in mice. Orally active.	Kusakabe et al (2012) Diaminopyridine-based potent and selective mps1 kinase inhibitors binding to an unusual flipped-Peptide conformation. ACS Med.Chem.Lett. 3 560. PMID:24900510.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=366975	SQ1341			Jul-2014
4752	SA 57	[1346169-63-8]	ClC(C=C2)=CC=C2CCC1CCN(C(OCC(NC)=O)=O)CC1	Potent FAAH inhibitor	"Potent inhibitor of fatty acid amide hydrolase (FAAH) (IC50 <10 nM). Inhibits both human and mouse FAAH enzymes; also inhibits mouse and human MAGL at higher concentrations (IC50 values are 410 nM and 1.4 _M respectively). Also displays inhibitory activity against FAAH, MAGL and ABHD6 in vivo."	Niphakis et al (2012) O-hydroxyacetamide carbamates as a highly potent and selective class of endocannabinoid hydrolase inhibitors. ACS Chem.Neurosci. 3 418. PMID:22860211.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=366979	SQ1341			Jun-2013
4753	AL 8697	[1057394-06-5]	CC1=C(F)C=C(C(NC4CC4)=O)C=C1C3=C(F)C2=NN=C(C(C)(C)C)N2C=C3F	Potent and selective p38_ inhibitor	Potent and selective p38_ inhibitor (IC50 = 6 nM). Exhibits 14-fold greater inhibition of p38_ compared to p38_; also displays 300-fold selectivity for p38_ compared to a panel of 91 kinases. Exhibits anti-inflammatory properties.	"Balagu et al (2012) Profiling of dihydroorotate dehydrogenase, p38 and JAK inhibitors in the rat adjuvant-induced arthritis model: a translational study. Br.J.Pharmacol. 166 1320. PMID:22229697. Aiguad et al (2012) Novel triazolopyridylbenzamides as potent and selective p38_ inhibitors. Bioorg.Med.Chem.Lett. 22 3431. PMID:22521646."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=367356				Aug-2014
4754	AK 7	[420831-40-9]	O=C(NC2=CC(Br)=CC=C2)C1=CC(S(N3CCCCCC3)(=O)=O)=CC=C1	Selective SIRT2 inhibitor; brain penetrant	Selective SIRT2 inhibitor (IC50 = 15.5 _M); displays no effect on SIRT1 or SIRT3. Decreases neuronal cholesterol levels; improves motor function and ameliorates brain atrophy in a mouse model of Huntington's disease. Brain penetrant.	Taylor et al (2011) A brain-permeable small molecule reduces neuronal cholesterol by inhibiting activity of sirtuin 2 deacetylase. ACS Chem.Biol. 6 540. PMID:21370928. Chopra et al (2012) The sirtuin inhibitor AK-7 is neuroprotective in Huntington's disease mouse models. Cell Rep. 2 1492. PMID:23200855.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=367357	SQ1070			Feb-2013
4755	Q94 hydrochloride	[1052076-77-3]	ClC(C=C4)=CC=C4CN2C1=CC=CC=C1N=C2CC3=CC=CC=C3.Cl	Negative allosteric modulator at PAR1 receptor	"PAR1 negative allosteric modulator (IC50 = 916 nM); inhibits PAR1-G_q interaction. Selective for PAR1 over PAR2. Blocks thrombin-induced intracellular calcium mobilization (IC50 = 10.3 nM), CCL2 expression, ERK1/2 and MLC phosphorylation, and IP3 production in cells."	Deng et al (2008) Thrombin induces fibroblast CCL2/JE production and release via coupling of PAR1 to G_q and cooperation between ERK1/2 and Rho kinase signaling pathways. Mol.Biol.Cell 19 2520. PMID:18353977. Scotton et al (2009) Increased local expression of coagulation factor X contributes to the fibrotic response in human and murine lung injury. J.Clin.Invest. 119 2550. PMID:19652365. Asteriti et al (2012) Modulation of PAR1 signalling by benzimidazole compounds. Br.J.Pharmacol. 167 80. PMID:22519452.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=367358	SQ1341			Mar-2013
4756	COR 170	[1048039-15-1]	O=C(C4=CN(CCCCC)C5=C(C=C(C6=CC=CC=C6)C=C5)C4=O)NC12CC(C3)CC(CC3C2)C1	Selective CB2 receptor inverse agonist	"Selective inverse agonist of CB2 receptors (Ki values are 3.8 and >10,000 nM for CB2 and CB1, respectively)."	"Pasquini et al (2008) Investigations on the 4-quinolone-3-carboxylic acid motif. 2. Synthesis and structure-activity relationship of potent and selective cannabinoid-2 receptor agonists endowed with analgesic activity in vivo. J.Med.Chem. 51 5075. PMID:18680276. Contartese et al (2012) A novel CB2 agonist, COR167, potently protects rat brain cortical slices against OGD and reperfusion injury. Pharmacol.Res. 66 555. PMID:23036353."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=367359	SQ1341			Jan-2014
4758	Bromosporine		CC1=C(NS(=O)(C)=O)C=C(C3=NN2C(C(NC(OCC)=O)=C3)=NN=C2C)C=C1	Broad spectrum bromodomain inhibitor	Broad spectrum bromodomain inhibitor. Accelerates FRAP recovery of BRD4 and CREBBP in cells at a concentration of 1 _M.	Gallenkamp et al (2014) Bromodomains and their pharmacological inhibitors. ChemMedChem 9 438. PMID:24497428.	Small Molecule	"This compound is supplied in conjunction with the Structural Genomics Consortium. For further characterization details, please visit the Bromosporine probe summary on the SGC website."	http://www.tocris.com/dispprod.php?ItemId=368254	SQ1341			Oct-2013
4759	G-36	[1392487-51-2]	BrC1=CC4=C(OCO4)C=[C@@]1[C@@H]2NC(C=CC(C(C)C)=C5)=C5[C@@]3([H])[C@@]([H])2CC=C3	Selective GPR30 antagonist	"Antagonist of GPR30; selectively inhibits estrogen-mediated activation of PI3-K by GPR30, but not by ER_. Also inhibits estrogen-mediated calcium mobilization (IC50 = 112 nM). Analog of G-1 (Cat. No. 3577)."	Prossnitz and Barton (2011) The G-protein-coupled estrogen receptor GPER in health and disease. Nat.Rev.Endocrinol. 7 715. PMID:21844907. Dennis et al (2011) Identification of a GPER/GPR30 antagonist with improved estrogen receptor counterselectivity. J.Steroid Biochem.Mol.Biol. 127 358. PMID:21782022.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=368736				Feb-2013
4761	Plumbagin	[481-42-5]	CC2=CC(C1=C(C2=O)C=CC=C1O)=O	Induces G2/M cell cycle arrest; anticancer	Anticancer agent. Induces G2/M cell cycle arrest and apoptosis in A549 cells through JNK-dependent p53 Ser15 phosphorylation; inhibits A549 and MDA-MD-231 tumour xenograft growth in nude mice. Promotes autophagic cell death in MDA-MB-231 and MCF-7 cells and inhibits Akt/mTOR signaling. Induces intracellular ROS generation in a PI 5-kinase-dependent manner.	"Hsu et al (2006) Plumbagin (5-hydroxy-2-methyl-1,4-napthoquinone) induces apoptosis and cell cycle arrest in A549 cells through p53 accumulation via c-Jun NH2-terminal kinase mediated phosphorylation at serine 15 in vitro and in vivo. J.Pharmacol.Exp.Ther. 318 484. PMID:16632641. Kuo et al (2006) Plumbagin induces G2-M arrest and autophagy by inhibiting the AKT/mammalian target of rapamycin pathway in breast cancer cells. Mol.Cancer Ther. 5 3209. PMID:17172425. Lee et al (2012) The natural anticancer agent plumbagin induces potent cytotoxicity in MCF-7 human breast cancer cells by inhibiting a PI-5 kinase for ROS generation. PLoS One. 7 e45023. PMID:23028742."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=369082				Feb-2013
4762	MIM1		CC2=CS/C(N2/N=C/C3=CC=C(O)C(O)=C3O)=N\C1CCCCC1	Mcl-1 inhibitor; proapoptotic	Inhibitor of Mcl-1; selectively targets the BH3-binding pocket. Induces caspase-3/7 activation and cell death in Mcl-1-dependent leukemia cells. Also blocks Mcl-1-mediated suppression of tBID-induced Bax activation in vitro.	Cohen et al (2012) A competitive stapled peptide screen identifies a selective small molecule that overcomes MCL-1-dependent leukemia cell survival. Chem.Biol. 19 1175. PMID:22999885.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=369083				Apr-2013
4763	Pyridostatin pentahydrochloride		NCCOC1=CC(C(NC2=NC(C=CC=C3)=C3C(OCCN)=C2)=O)=NC(C(NC4=CC(OCCN)=C(C=CC=C5)C5=N4)=O)=C1.Cl.Cl.Cl.Cl.Cl	Stabilizes G-quadruplexes; induces DNA damage and cell cycle arrest	"Binds and stabilizes G-quadruplexes, inducing DNA damage and cell cycle arrest (Kd = 490 nM); targets the proto-oncogene Src, reducing Src protein abundance and Src-dependent motility in human breast cancer cells. Also targets telomeric G-quadruplexes, inducing telomerase dysfunction. Activates the DNA-dependent protein kinase catalytic sunbunit (DNA-PKcs)."	Mller et al (2010) Small-molecule-mediated G-quadruplex isolation from human cells. Nat.Chem. 2 1095. PMID:21107376. Koirala et al (2011) A single-molecule platform for investigation of interactions between G-quadruplexes and small-molecule ligands. Nat.Chem. 3 782. PMID:21941250 . Rodriguez et al (20112) Small-molecule-induced DNA damage identifies alternative DNA structures in human genes. Nat.Chem.Biol. 8 301. PMID:22306580.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=369084				Apr-2014
4764	SIB 1553A hydrochloride	[191611-89-9]	CN1CCCC1CCSC2=CC=C(O)C=C2.Cl	Subunit selective nAChR agonist	Nicotinic acetylcholine receptor (nAChR) agonist. Displays selectivity for _4 subunit-containing receptors. Stimulates acetylcholine levels and other neurotransmitters relevant for cognitive processes. Improves attention deficits and memory performance in a Parkinson's disease model.	"Vernier et al (1999) 4-[[2-(1-Methyl-2-pyrrolidinyl)ethyl]thio]phenol hydrochloride (SIB-1553A): a novel cognitive enhancer with selectivity for neuronal nicotinic acetylcholine receptors. J.Med.Chem. 42 1684. PMID:10346920. Rao et al (2003) In vitro pharmacological characterization of (+/-)-4-[2-(1-methyl-2-pyrrolidinyl)ethyl]thio]phenol hydrochloride (SIB-1553A), a nicotinic acetylcholine receptor ligand. Brain Res. 981 85. PMID:12885429. Schneider et al (2003) The subtype-selective nicotinic acetylcholine receptor agonist SIB-1553A improves both attention and memory components of a spatial working memory task in chronic low dose 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkeys. J.Pharmacol.Exp.Ther. 306 401. PMID:12721323."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=369087	SQ1341			Jul-2013
4766	SIB 1508Y maleate	[192231-16-6]	CN1CCC[C@H]1[C@]2=CC(C#C)=CN=C2.O=C(\C=C/C(O)=O)O	"Potent agonist of _4_2, _2_4, _4_4 and _3_4 nACh receptors"	"Potent neuronal nicotinic ACh receptor agonist (EC50 values are 1.8, 5, 9 and 23 nM for _4_2, _2_4, _4_4 and _3_4 receptors respectively). Improves cognitive function in a MPTP-induced model of Parkinson's Disease in vivo."	Cosford et al (1996) (S)-(-)-5-ethynyl-3-(1-methyl-2-pyrrolidinyl)pyridine maleate (SIB-1508Y): a novel anti-parkinsonian agent with selectivity for neuronal nicotinic acetylcholine receptors. J.Med.Chem. 39 3235. PMID:8765504. Schneider et al (1999) Nicotinic acetylcholine receptor agonist SIB-1508Y improves cognitive functioning in chronic low-dose MPTP-treated monkeys. J.Pharmacol.Exp.Ther. 290 731. PMID:10411585.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=369309	SQ1341			Apr-2014
4767	WAY 316606 hydrochloride		O=S(C1=CC=C(C(F)(F)F)C(S(NC3CCNCC3)(=O)=O)=C1)(C2=CC=CC=C2)=O.Cl	Secreted Frizzled-related protein-1 (sFRP-1) inhibitor; increases Wnt signaling	Secreted Frizzled-Related Protein-1 (sFRP-1) inhibitor (IC50 = 0.65 _M); prevents sFRP-1 from interacting with Wnt and thus increases Wnt signaling. Increases total bone area in a murine calvarial organ culture assay.	Moore et al (2009) Modulation of Wnt signaling through inhibition of secreted frizzled-related protein I (sFRP-1) with N-substituted piperidinyl diphenylsulfonyl sulfonamides. J.Med.Chem. 52 105. PMID:19072540. Bodine et al (2009) A small molecule inhibitor of the Wnt antagonist secreted frizzled-related protein-1 stimulates bone formation. Bone 44 1063. PMID:19254787. Moore et al (2010) Modulation of Wnt signaling through inhibition of secreted frizzled-related protein I (sFRP-1) with N-substituted piperidinyl diphenylsulfonyl sulfonamides: part II. Bioorg.Med.Chem. 18 190. PMID:19932972.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=369372				Jul-2014
4769	VUF 10460	[1028327-66-3]	NC1=NC(C2=CC=CC=C2)=CC(N3CCN(C)CC3)=N1	Selective H4 agonist	Selective histamine H4 receptor agonist; displays 50-fold selectivity for the rat H4 receptor over the H3 subtype (pKi values are 5.75 and 7.46 for rat H3 and H4 receptors respectively). Also exhibits affinity for the human H4 receptor (pKi = 8.22).	"Altenbach et al (2008) Structure-activity studies on a series of a 2-aminopyrimidine-containing histamine H4 receptor ligands. J.Med.Chem. 51 6571. PMID:18811133. Cowart et al (2008) Rotationally constrained 2,4-diamino-5,6-disubstituted pyrimidines: a new class of histamine H4 receptor antagonists with improved druglikeness and in vivo efficacy in pain and inflammation models. J.Med.Chem. 51 6547. PMID:18817367. Coruzzi et al (2011) Selective histamine H3 and H4 receptor agonists exert opposite effects against the gastric lesions induced by HCl in the rat stomach. Eur.J.Pharmacol. 669 121. PMID:21839070."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=369499	SQ1341			May-2013
4774	BMS 536924	[468740-43-4]	O=C1NC=CC(NC[C@H](C5=CC=CC(Cl)=C5)O)=C1C3=NC2=CC(N4CCOCC4)=CC(C)=C2N3	Dual IR/IGF1R inhibitor	Dual inhibitor of the insulin receptor (IR) and insulin-like growth factor-1 receptor (IGF1R) (IC50 values are 73 and 100 nM respectively). Inhibits receptor autophosphorylation and downstream MEK1/2 and Akt signaling. Induces G1 arrest and apoptosis in ML-1 cells; also inhibits cell proliferation in multiple tumor types.	Wittman et al (2005) Discovery of a (1H-benzoimidazol-2-yl)-1H-pyridin-2-one (BMS-536924) inhibitor of insulin-like growth factor I receptor kinase with in vivo antitumor activity. J.Med.Chem. 48 5639. PMID:16134929. Huang et al (2009) The mechanisms of differential sensitivity to an insulin-like growth factor-1 receptor inhibitor (BMS-536924) and rationale for combining with EGFR/HER2 inhibitors. Cancer Res. 69 161. PMID:19117999. Hendrickson et al (2009) Expression of insulin receptor isoform A and insulin-like growth factor-1 receptor in human acute myelogenous leukemia: effect of the dual-receptor inhibitor BMS-536924 in vitro. Cancer Res. 69 7635. PMID:19789352.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=369583	SQ1533			May-2013
4776	BIRT 377	[213211-10-0]	CN([C@@](CC3=CC=C(Br)C=C3)(C)C(N1C2=CC(Cl)=CC(Cl)=C2)=O)C1=O	Potent negative allosteric modulator of LFA-1	Potent negative allosteric modulator of LFA-1 (lymphocyte function-associated antigen-1) (Kd = 26 nM). Binds to the I-domain of LFA-1. Reversibly inhibits LFA-1 mediated binding of SKW3 leukemia cells to ICAM-1. Inhibits superantigen (SEB)-induced IL-2 production from lymphocytes in vitro and attenuates the SEB-induced increase in IL-2 plasma levels in a mouse model in vivo. Orally available.	"Kelly et al (1999) Cutting edge: a small molecule antagonist of LFA-1-mediated cell adhesion. J.Immunol. 163 5173. PMID:10553036. Last-Barney et al (2001) Binding site elucidation of hydantoin-based antagonists of LFA-1 using multidisciplinary technologies: evidence for the allosteric inhibition of a protein--protein interaction. J.Am.Chem.Soc. 123 5643. PMID:11403595. Wu et al (2004) Second-generation lymphocyte function-associated antigen-1 inhibitors: 1H-imidazo[1,2-alpha]imidazol-2-one derivatives. J.Med.Chem. 47 5356. PMID:15481974 ."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=369740				Oct-2014
4777	ML 277	[1401242-74-7]	O=[C@@]([C@H]3CCCCN3S(C4=CC=C(C)C=C4)(=O)=O)NC1=NC(C2=CC=C(OC)C=C2)=CS1	Selective Kv7.1 (KCNQ1) potassium channel activator; augments IKs current	"Selective Kv7.1 (KCNQ1) potassium channel activator (EC50 = 260 nM). Exhibits >100-fold selectivity versus KCNQ2, KCNQ4 and hERG potassium channels. Augments IKs current of cultured human cardiomyocytes and shortens action potential duration."	"Mattmann et al (2012) Identification of (R)-N-(4-(4-methoxyphenyl)thiazol-2-yl)-1-tosylpiperidine-2-carboxamide, ML277, as a novel, potent and selective Kv7.1 (KCNQ1) potassium channel activator. Bioorg.Med.Chem.Lett. 22 5936. PMID:22910039. Yu et al (213) Dynamic subunit stoichiometry confers a progressive continuum of pharmacological sensitivity by KCNQ potassium channels. Proc.Natl.Acad.Sci.U.S.A. 110 8732. PMID:23650380."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=369741	SQ1341			Apr-2014
4778	BETP	[1371569-69-5]	CCS(C1=NC(C2=CC=CC(OCC3=CC=CC=C3)=C2)=CC(C(F)(F)F)=N1)=O	Positive allosteric modulator of GLP-1 receptors	"Selective positive allosteric modulator and partial agonist of the glucagon-like peptide 1 (GLP-1) receptor. Increases binding affinity of oxyntomodulin for the GLP-1 receptor. Potentiates oxyntomodulin-mediated GLP-1 receptor signaling in vitro and insulin secretion in vivo. Has no effect on GLP-2, GIP, PTH or glucagon receptors."	Sloop et al (2010) Novel small molecule glucagon-like peptide-1 receptor agonist stimulates insulin secretion in rodents and from human islets. Diabetes 59 3099. PMID:20823098. Cheong et al (2012) Two small molecule agonists of glucagon-like peptide-1 receptor modulate the receptor activation response differently. Biochem.Biophys.Res.Comm. 417 558. PMID:22177947. Willard et al (2012) Small molecule allosteric modulation of the glucagon-like Peptide-1 receptor enhances the insulinotropic effect of oxyntomodulin. Mol.Pharmacol. 82 1066. PMID:22930710.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=369742	SQ1341			Feb-2014
4779	GRI 977143	[325850-81-5]	O=C(C2=CC=CC3=CC=CC(C4=O)=C23)N4CCCSC1=CC=CC=C1C(O)=O	Selective LPA2 receptor non-lipid agonist	"Selective lysophosphatidic acid 2 (LPA2) receptor non-lipid agonist (EC50 = 3.3 _M). Does not activate other LPA GPCRs at concentrations up to 10 _M. Antiapoptotic; inhibits activation of caspases 3, 7, 8 and 9, Bax translocation and PARP-1 cleavage. Activates ERK1/2 survival pathway."	Kiss et al (2012) Virtual screening for LPA2-specific agonists identifies a nonlipid compound with antiapoptotic actions. Mol.Pharmacol. 82 1162. PMID:22968304. Kiss et al (2013) Mitigation of radiation injury by selective stimulation of the LPA(2) receptor. Biochim.Biophys.Acta 1831 117. PMID:23127512.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=369745	SQ1070			Mar-2013
4780	VUF 11207 fumarate		C\C(CN(CCC2N(C)CCC2)C(C3=CC(OC)=C(OC)C(OC)=C3)=O)=C/C1=C(F)C=CC=C1.OC(/C=C/C(O)=O)=O	Potent CXCR7 agonist	Potent CXCR7 chemokine receptor agonist (EC50 = 1.6 nM). Induces recruitment of _-arrestin to CXCR7 in HEK293-CXCR7 cells.	"Wijtmans et al (2012) Synthesis, modeling and functional activity of substituted styrene-amides as small-molecule CXCR7 agonists. Eur.J.Med.Chem. 51 184. PMID:22424612."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=369752	SQ1341			Mar-2014
4781	ANA 12	[219766-25-3]	O=C(NC4C(NCCCC4)=O)C1=C(NC(C2=CC3=C(C=CC=C3)S2)=O)C=CC=C1	TrkB receptor antagonist	"TrkB receptor antagonist. Demonstrates a 2-site mode of action, preventing activation by BDNF non-competitively (IC50 values are 45.6 nM and 41.1 _M for the high and low affinity sites respectively). Displays no effect on TrkA and TrkC in an assay of neurite outgrowth. Demonstrates antidepressant properties."	Cazorla et al (2011) Identification of a low-molecular weight TrkB antagonist with anxiolytic and antidepressant activity in mice. J.Clin.Invest. 121 1846. PMID:21505263.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=369761	SQ1341			Feb-2013
4782	Org 25543 hydrochloride	[495076-64-7]	O=C(NCC2(N(C)C)CCCC2)C1=CC(OC)=C(OCC3=CC=CC=C3)C(OC)=C1.Cl	Potent and selective GlyT2 inhibitor	"Potent and selective glycine transporter type 2 (GlyT2) inhibitor (IC50 = 16 nM for hGlyT2). Displays no activity at GlyT1 or 56 other common biological targets ( 100 _M), in a glycine uptake assay in CHO cells. Ameliorates mechanical allodynia after partial sciatic nerve ligation injury in mice."	Caulfield et al (2001) The first potent and selective inhibitors of the glycine transporter type 2. J.Med.Chem. 44 2679. PMID:11495577. Morita et al (2008) Spinal antiallodynia action of glycine transporter inhibitors in neuropathic pain models in mice. J.Pharmacol.Exp.Ther. 326 633. PMID:18448867.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=369978	SQ1341			Apr-2013
4783	Lu AA 47070	[913842-25-8]	FC1=C(NC(CC(C)(C)C)=O)C(F)=CC(C(/N=C2\SC=CN2COP(O)(O)=O)=O)=C1	Prodrug of a potent and selective adenosine A2A receptor antagonist	"Prodrug of a potent and selective adenosine A2A receptor antagonist (Ki values are 5.9, 260, 410 and <10,000 nM for A2A, A2B, A1 and A3 receptors respectively. Reverses parkinsonian motor impairment and motivational effects produced by dopamine D2 receptor blockade in rats. Orally bioavailable."	"Sams et al (2011) Discovery of phosphoric acid mono-{2-[(E/Z)-4-(3,3-dimethyl-butyrylamino)-3,5-difluoro-benzoylimino]-thiazol-3-ylmethyl} ester (Lu AA47070): a phosphonooxymethylene prodrug of a potent and selective hA2A receptor antagonist. J.Med.Chem. 54 751. PMID:21210664. Collins et al (2012) The novel adenosine A2A antagonist Lu AA47070 reverses the motor and motivational effects produced by dopamine D2 receptor blockade. Pharmacol.Biochem.Behav. 100 498. PMID:22037410."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=369983				Jul-2014
4785	SA 47	[792236-07-8]	CC1=CC=CC(N2CCC(CCNC(OCC(NC)=O)=O)CC2)=N1	Selective FAAH inhibitor	Selective inhibitor of fatty acid amide hydrolase (FAAH). Exhibits greater selectivity for FAAH than URB 597 against multiple carboxylesterases.	Zhang et al (2007) Fatty acid amide hydrolase inhibitors display broad selectivity and inhibit multiple carboxylesterases as off-targets. Neuropharmacology 52 1095. PMID:17217969. Ahn et al (2009) Fatty acid amide hydrolase as a potential therapeutic target for the treatment of pain and CNS disorders. Expert Opin.Drug Discov. 4 763. PMID:20544003.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=370048	SQ1341			Oct-2013
4786	PD 0332991 isethionate	[827022-33-3]	O=C1C(C(C)=O)=C(C)C(C=NC(NC4=NC=C(N5CCNCC5)C=C4)=N3)=C3N1C2CCCC2.OCCS(=O)(O)=O	"Potent, selective Cdk4/6 inhibitor; brain penetrant"	Potent Cdk4/6 inhibitor (IC50 values are 11 and 15 nM for Cdk4 and Cdk6 respectively). Selective for Cdk4/6 over a panel of 34 additional protein kinases (IC50 values are > 10 _M). Induces G1 cell cycle arrest and senescence in retinoblastoma protein (Rb)-proficient cell lines; blocks growth of intracranial glioblastoma multiforme xenografts in mice. Brain penetrant.	Fry et al (2004) Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol.Cancer Ther. 3 1427. PMID:15542782. Toogood et al (2005) Discovery of a potent and selective inhibitor of cyclin-dependent kinase 4/6. J.Med.Chem. 48 2388. PMID:15801831. Michaud et al (2010) Pharmacologic inhibition of cyclin-dependent kinases 4 and 6 arrests the growth of glioblastoma multiforme intracranial xenografts. Cancer Res. 70 3228. PMID:20354191.	Small Molecule	Sold for research purposes under agreement from Pfizer Inc.	http://www.tocris.com/dispprod.php?ItemId=370056	SQ1533			Feb-2013
4787	CPPHA	[693288-97-0]	ClC1=CC(CN3C(C(C=CC=C4)=C4C3=O)=O)=C(NC(C2=CC=CC=C2O)=O)C=C1	Positive allosteric modulator at mGlu1 and mGlu5	Positive allosteric modulator at mGlu1 and mGlu5; thought to act at a novel allosteric site. Potentiates mGlu5 responses by a mechanism distinct from that of VU 29 (Cat. No. 4458).	"O'Brien et al (2004) A novel selective allosteric modulator potentiates the activity of native metabotropic glutamate receptor subtype 5 in rat forebrain. J.Pharmacol.Exp.Ther. 309 568. PMID:14747613. Chen et al (2008) N-{4-Chloro-2-[(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]phenyl}-2-hydroxybenzamide (CPPHA) acts through a novel site as a positive allosteric modulator of group 1 metabotropic glutamate receptors. J.Pharmacol.Exp.Ther. 73 909. PMID:18056795."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=370168	SQ1341			Nov-2013
4788	NS 11021	[956014-19-0]	BrC1=CC(C2=NN=NN2)=C(NC(NC3=CC(C(F)(F)F)=CC(C(F)(F)F)=C3)=S)C=C1	Activator of BKCa (KCa1.1) channels	"Activator of large-conductance Ca2+-activated potassium channels (BKCa, KCa1.1). Exhibits no modulatory effect on a variety of K+ (KV), Na+ and Ca2+ currents at concentrations <10 _M. Alters gating kinetics, but does not affect single channel conductance. Shown to bind BKCa in open and closed conformations; thought to bind the _ subunit."	"Bentzen et al (2007) The small molecule NS11021 is a potent and specific activator of Ca2+-activated big-conductance K+ channels. Mol.Pharmacol. 72 1033. PMID:17636045. Kun et al (2009) NS11021, a novel opener of large-conductance Ca2+-activated K+ channels, enhances erectile responses in rats. Br.J.Pharmacol. 158 1465. PMID:19845682. Layne et al (2009) BK channel activation by NS11021 decreases excitability and contractility of urinary bladder smooth muscle. Am.J.Physiol.Regul.Integr.Comp.Physiol. 298 R378. PMID:19923353."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=370440				Nov-2013
4791	Candesartan	[139481-59-7]	CCOC1=NC(C=CC=C5C(O)=O)=C5N1CC2=CC=C(C3=CC=CC=C3C4=NN=NN4)C=C2	AT1 receptor antagonist	"Angiotensin II receptor 1 (AT1) antagonist (IC50 values are 1.12 and 2.86 nM in bovine adrenal cortex and rabbit aorta, respectively). Exhibits antihypertensive effects in animal models. Also available as a prodrug, candesartan cilexetil (Cat. No. 4792)."	"Shibouta et al (1993) Pharmacological profile of a highly potent and long-acting angiotensin II receptor antagonist, 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]-1H-benzimidazole-7-carboxylic acid (CV-11974), and its prodrug, ()-1-(cyclohexyloxycarbonyloxy)-ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]-1H-benzimidazole-7-carboxylate (TCV-116). J.Pharmacol.Exp.Ther. 266 114. PMID:8331552."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=370443	SQ1533			Mar-2013
4792	Candesartan cilexetil	[145040-37-5]	CCOC1=NC(C=CC=C5C(OC(C)OC(OC6CCCCC6)=O)=O)=C5N1CC2=CC=C(C3=CC=CC=C3C4=NN=NN4)C=C2	"Prodrug of candesartan (Cat. No. 4791), an AT1 receptor antagonist"	"Prodrug of the angiotensin II receptor 1 (AT1) antagonist candesartan (Cat. No. 4791), which exhibits antihypertensive effects in animal models."	"Shibouta et al (1993) Pharmacological profile of a highly potent and long-acting angiotensin II receptor antagonist, 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4- yl]methyl]-1H-benzimidazole-7-carboxylic acid (CV-11974), and its prodrug, ()-1-(cyclohexyloxycarbonyloxy)-ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5- yl)biphenyl-4-yl]methyl]-1H-benzimidazole-7-carboxylate (TCV-116). J.Pharmacol.Exp.Ther. 266 114. PMID:8331552. Nishikawa et al (1997) Candesartan cilexetil: a review of its preclinical pharmacology. J.Hum.Hypertens. Suppl2 9. PMID:9330999."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=370448	SQ1070			Mar-2013
4793	CE3F4	[143703-25-7]	BrC1=C(F)C(Br)=C(CCC(C)N2C=O)C2=C1	Uncompetitive Epac1 inhibitor	Uncompetitive Epac1 inhibitor. Blocks Epac-induced Rap activation and prevents isoprenaline-induced autophagy flux in cardiomyocytes. Has no effect on PKA activity in the presence of cAMP.	Courilleau et al (2012) Identification of a tetrahydroquinoline analog as a pharmacological inhibitor of the cAMP-binding protein Epac. J.Biol.Chem. 287 44192. PMID:23139415. Laurent et al (2015) Exchange protein directly activated by cAMP 1 promotes autophagy during cardiomyocyte hypertrophy. Cardiovasc.Res. 105 55. PMID:25411381.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=370449				Jan-2015
4794	ZCL 278	[587841-73-4]	ClC1=C(OCC(NC(NC2=CC=C(S(NC3=NC(C)=CC(C)=N3)(=O)=O)C=C2)=S)=O)C=CC(Br)=C1	Cdc42 inhibitor	"Selective inhibitor of Cdc42. Targets the binding site of the Cdc42 guanine nucleotide exchange factor, intersectin (ITSN). Inhibits Cdc42-mediated cellular effects, including microspike formation in 3T3 fibroblasts and neuronal branching in primary neonatal cortical neurons. Also suppresses cell motility and migration in PC3 cells, without cytotoxic effects."	Friesland et al (2013) Small molecule targeting Cdc42-intersectin interaction disrupts Golgi organization and suppresses cell motility. Proc.Natl.Acad.Sci.USA 110 1261. PMID:23284167.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=370452				Jun-2013
4795	Galloflavin		[K+].OC1=C(O)C(O)=C2C3=C(OC(=O)C2=C1)C=C([O-])C(=O)O3	Lactate dehydrogenase inhibitor; impairs aerobic glycolysis	"Inhibitor of human lactate dehydrogenase (LDH) (Ki values are 5.46 and 15.1 _M for LDH-A and LDH-B, respectively, in competition with pyruvate). Inhibits lactate production and decreases ATP synthesis in PLD/PRF/5 cells; thought to decrease cell viability via impairment of aerobic glycolysis."	"Manerba et al (2012) Galloflavin (CAS 568-80-9): a novel inhibitor of lactate dehydrogenase. ChemMedChem 7 311. PMID:22052811. Farabegoli et al (2012) Galloflavin, a new lactate dehydrogenase inhibitor, induces the death of human breast cancer cells with different glycolytic attitude by affecting distinct signaling pathways. Eur.J.Pharm.Sci. 47 729. PMID:22954722. Fiume et al (2013) Galloflavin prevents the binding of lactate dehydrogenase A to single stranded DNA and inhibits RNA synthesis in cultured cells. Biochem.Biophys.Res.Commun. 430 466. PMID:23237800."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=370453				Jun-2013
4796	Escitalopram oxalate	[219861-08-2]	FC(C=C3)=CC=C3[C@]1(CCCN(C)C)OCC2=C1C=CC(C#N)=C2.OC(C(O)=O)=O	Selective serotonin reuptake inhibitor (SSRI)	"Selective serotonin reuptake inhibitor (SSRI) (Ki values are 0.89, 8150, and 10500 nM for serotonin, noradrenalin, and dopamine transporters respectively). Is a S-enantiomer and eutomer of citalopram (Cat. No. 1427)."	"Zhang et al (2010) Structure-activity relationships for a novel series of citalopram (1-(3-(dimethylamino)propyl)-1-(4-fluorophenyl)-1,3-dihydroisobenzofuran-5-carbonitrile) analogues at monoamine transporters. J.Med.Chem. 53 6112. PMID:20672825."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=371092	SQ1533			Feb-2013
4797	Org 37684	[213007-95-5]	COC1=CC=C(CCC3)C3=C1O[C@H]2CCNC2.Cl	5-HT2 agonist	"Agonist of 5-HT2 receptors. Exhibits a rank order of potency of 5-HT2C >5-HT2B >5-HT2A (pEC50 values are 8.17, 7.96 and 7.11 respectively, in transfected CHO-K1 cells)."	"Porter et al (1999) Functional characterization of agonists at recombinant human 5-HT2A, 5-HT2B and 5-HT2C receptors in CHO-K1 cells. Br.J.Pharmacol. 128 13. PMID:10498829. De Vry and Schreiber (2000) Effects of selected serotonin 5-HT1 and 5-HT2 receptor agonists on feeding behavior: possible mechanisms of action. Neurosci.Biobehav.Rev. 24 341. PMID:10781694."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=371101	SQ1341			Nov-2013
4798	(S)-Duloxetine hydrochloride	[136434-34-9]	CNCC[C@@H](C3=CC=CS3)OC2=CC=CC1=CC=CC=C12.Cl	Potent 5-HT and NA reuptake inhibitor; also blocks dopamine reuptake	"High affinity, competitive 5-HT and noradrenaline (NA) re-uptake inhibitor (Ki values are 8.5 and 45 nM for 5-HT and NA reuptake respectively in cortical synaptosomes; IC50 values are 28 and 46 nM for 5-HT and NA reuptake respectively in rat hippocampal slices). Also blocks dopamine reuptake (Ki = 300 nM in striatal synaptosomes). Exhibits antidepressant and anxiolytic effects. Orally bioavailable."	"Wong et al (1988) LY227942, an inhibitor of serotonin and norepinephrine uptake: biochemical pharmacology of a potential antidepressant drug. Life Sci. 43 2049. PMID:2850421. Kasamo et al (1996) Blockade of the serotonin and norepinephrine uptake processes by duloxetine: in vitro and in vivo studies in the rat brain. J.Pharmacol.Exp.Ther. 277 278. PMID:8613930."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=371108	SQ1533			Feb-2013
4799	Capecitabine	[154361-50-9]	C[C@H]1O[C@@H](N2C=C(F)C(NC(OCCCCC)=O)=NC2=O)[C@H](O)[C@@H]1O	Prodrug of 5-Fluorouracil (Cat. No. 3257). Inhibits DNA synthesis	Prodrug of 5-Fluorouracil (5-FU) (Cat. No. 3257). Selectively activated in tumor cells by thymidine phosphorylase; inhibits DNA synthesis upon conversion to 5-FU. Orally available.	"Bhuyan et al (1972) Cell cycle phase specificity of antitumor agents. Cancer Res. 32 398. PMID:4258018. Shimma et al (2000) The design and synthesis of a new tumor-selective fluoropyrimidine carbamate, capecitabine. Bioorg.Med.Chem.Lett. 8 1697. PMID:10976516. Desmoulin et al (2002) Metabolism of capecitabine, an oral fluorouracil prodrug: 19F NMR studies in animal models and human urine. Drug Metab.Dispos. 30 1221. PMID:12386128."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=371260	SQ1533			Feb-2013
4800	4EGI-1	[315706-13-9]	OC(=O)C(\CC1=CC=CC=C1[N+]([O-])=O)=N/NC1=NC(=CS1)C1=CC(Cl)=C(Cl)C=C1	Inhibitor of eIF4E:eIF4G interaction	Inhibitor of eIF4E:eIF4G interaction; prevents eIF4E binding to eIF4G. Binds eIF4E and inhibits cap-dependent translation but not initiation factor-independent translation. Exhibits activity against Jurkat and A549 cells.	Moerke et al (2007) Small-molecule inhibition of the interaction between the translation initiation factors eIF4E and eIF4G. Cell 128 257. PMID:17254965. Gkogkas et al (2013) Autism-related deficits via dysregulated eIF4E-dependent translational control. Nature 493 371. PMID:23172145.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=371261				Dec-2013
4801	QNZ 46	[1237744-13-6]	O=C2C1=CC(OC)=CC=C1N=C(/C=C/C4=CC([N+]([O-])=O)=CC=C4)N2C3=CC=C(C(O)=O)C=C3	NR2C/NR2D-selective NMDA receptor non-competitive antagonist	"NR2C/NR2D-selective NMDA receptor non-competitive antagonist (IC50 values are 3, 6, 229, and >300, >300 _M for NR2D, NR2C, NR2A, NR2B, and GluR1, respectively). Requires binding of glutamate to the GluN2 subunit."	Mosley et al (2010) Quinazolin-4-one derivatives: A novel class of noncompetitive NR2C/D subunit-selective N-methyl-D-aspartate receptor antagonists. J.Med.Chem. 53 5476. PMID:20684595. Hansen and Traynelis (2011) Structural and mechanistic determinants of a novel site for noncompetitive inhibition of GluN2D-containing NMDA receptors. J.Neurosci. 31 3650. PMID:21389220.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=371303	SQ1341			Jul-2013
4805	TCS HDAC6 20b	[956154-63-5]	O=C([C@@H](NC(OC(C)(C)C)=O)CCCCCSC(C(C)C)=O)NC1(CC3C2)CC(C3)CC2C1	Selective HDAC6 inhibitor	Selective inhibitor of histone deacetylase 6 (HDAC6). Inhibits HCT116 growth in combination with taxol (Cat. No. 1097). Also inhibits growth of MCF-7 cells stimulated by estrogen.	"Itoh et al (2007) Design, synthesis, structure-selectivity relationship, and effect on human cancer cells of a novel series of histone deacetylase 6-selective inhibitors. J.Med.Chem. 50 5425. PMID:17929798."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=371309				Aug-2013
4808	FK 866 hydrochloride		O=C(C2=CC=CC=C2)N1CCC(CCCCNC(/C=C/C3=CN=CC=C3)=O)CC1.Cl	Non-competitive and potent NAMPT inhibitor; induces apoptosis and autophagy	"Non-competitive and potent inhibitor of NAMPT (nicotinamide phosphoribosyltransferase, visfatin, PBEF1) (Ki = 0.3 nM); inhibits NAD biosynthesis. Induces delayed cell death by apoptosis in HepG2 human liver carcinoma cells (IC50 ~1 nM). Induces apoptosis in four different neuroblastoma cell lines; also induces autophagy in SH-SY5Y cells. Potentiates the cytotoxic effects induced by etoposide (Cat. No. 1226) and cisplatin (Cat. No. 2251)."	"Hasmann et al (2003) FK866, a highly specific noncompetitive inhibitor of nicotinamide phosphoribosyltransferase, represents a novel mechanism for induction of tumor cell apoptosis. Cancer Res. 63 7436. PMID:14612543. Galli et al (2008) Synthesis and biological evaluation of isosteric analogues of FK866, an inhibitor of NAD salvage. ChemMedChem 3 771. PMID:18247435. Travelli et al (2011) Reciprocal potentiation of the antitumoral activities of FK866, an inhibitor of nicotinamide phosphoribosyltransferase, and etoposide or cisplatin in neuroblastoma cells. J.Pharmacol.Exp.Ther. 338 829. PMID:21685314."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=372038	SQ1341			Feb-2014
4810	BAM 7	[331244-89-4]	CC(/C1=N\NC2=C(OCC)C=CC=C2)=NN(C3=NC(C4=CC=CC=C4)=CS3)C1=O	Selective Bax activator; induces Bax-mediated apoptosis	Bax activator (EC50 = 3.3 _M); binds at the BH3-binding site. Selective for Bax over other antiapoptotic and proapoptotic proteins. Triggers Bax oligomerization in vitro; induces Bax-mediated apoptosis in mouse embryonic fibroblasts.	Gavathiotis et al (2012) Direct and selective small-molecule activation of proapoptotic BAX. Nat.Chem.Biol. 8 639. PMID:22634637.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=372040	SQ1533			Apr-2013
4813	Paprotrain	[57046-73-8]	N#C/C(C3=CNC2=CC=CC=C23)=C\C1=CN=CC=C1	Reversible inhibitor of MKLP-2	"Reversible, non-ATP competitive inhibitor of mitotic kinesin-like protein 2 (MKLP-2) (Ki = 3.4 _M). Inhibits the basal ATPase activity of MKLP-2 (IC50 = 1.35 _M). Exhibits selectivity for MKLP-2 over 12 other members of the kinesin superfamily, including the closely-related MKLP-1. Cell permeable."	Tcherniuk et al (2010) Relocation of Aurora B and survivin from centromeres to the central spindle impaired by a kinesin-specific MKLP-2 inhibitor. Agnew Chem.Int.Ed.Engl. 49 8228. PMID:20857469.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=372043				Apr-2013
4814	Methoxyresorufin	[5725-89-3]	O=C2C=CC1=NC3=C(C=C(OC)C=C3)OC1=C2	Fluorometric CYP450 substrate	Fluorometric substrate of cytochrome P450; displays preferential metabolism by rodent cytochrome P4501A2 (CYP1A2).	"Nerurkar et al (1993) Methoxyresorufin and benzyloxyresorufin: substrates preferentially metabolized by the cytochromes P4501A2 and 2B, respectively, in the rat and mouse. Biochem.Pharmacol. 46 933. PMID:8373445."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=372046				Jul-2013
4815	3-Cyano-7-ethoxycoumarin	[117620-77-6]	O=C2C(C#N)=CC1=CC=C(OCC)C=C1O2	Fluorescent cytochrome P450 substrate	Fluorescent P450 substrate (excitation/emission wavelengths = 408/455 nm); metabolized to cyano-hydroxycoumarin.	White et al (1988) A continuous fluorometric assay for cytochrome P-450-dependent mixed function oxidases using 3-cyano-7-ethoxycoumarin. Anal.Biochem. 172 304. PMID:3189781. Donato et al (2004) Fluorescence-based assays for screening nine cytochrome P450 (P450) activities in intact cells expressing individual human P450 enzymes. Drug Metab.Dispos. 32 699. PMID:15205384.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=372053				Mar-2013
4816	Pentoxyresorufin	[87687-03-4]	O=C2C=CC1=NC3=C(C=C(OCCCCC)C=C3)OC1=C2	Fluorometric cytochrome P450 substrate	Fluorometric cytochrome P450 substrate.	Lubet et al (1985) Dealkylation of pentoxyresorufin: a rapid and sensitive assay for measuring induction of cytochrome(s) P-450 by phenobarbital and other xenobiotics in the rat. Arch.Biochem.Biophys. 238 43. PMID:3985627.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=372062				Jul-2013
4817	SKPin C1	[432001-69-9]	BrC1=CC=C(OCC(O)=O)C(/C=C2\SC(N(CC3=CN=CC=C3)C2=O)=S)=C1	Inhibits Skp2-mediated p27 degradation; induces cell cycle arrest	Inhibitor of Skp2-mediated p27 degradation. Induces p27 accumulation in metastatic melanoma cell lines. Promotes G1/S cell cycle arrest in T47D cells and LNCaP cells; induces G2/M cell cycle arrest in MCF-7 cells.	Rico-Bautista and Wolf (2012) Skipping cancer: small molecule inhibitors of SKP2-mediated p27 degradation. Chem.Biol. 19 1497. PMID:23261592. Wu et al (2012) Specific small molecule inhibitors of Skp2-mediated p27 degradation. Chem.Biol. 19 1515. PMID:23261596.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=372071				Apr-2013
4818	PF 04418948	[1078166-57-0]	FC(C=C4)=CC=C4C(N(C3)CC3(C(O)=O)COC2=CC1=CC=C(OC)C=C1C=C2)=O	Potent and selective EP2 receptor antagonist	"Potent EP2 receptor antagonist (IC50 = 16 nM for human EP2 receptors). Displays over 2000-fold selectivity for EP2 receptors over EP1, EP3, EP4, DP1 amd CRTH2 receptors; exhibits <30% binding at a diverse panel of GPCRs and ion channels at a concentration of 10 _M. Inhibits PGE2-induced increases in intracellular cAMP; reverses PGE2-invoked relaxation of mouse trachea (IC50 = 2.7 nM)."	"af Forselles et al (2011) In vitro and in vivo characterization of PF-04418948, a novel, potent and selective prostaglandin EP2 receptor antagonist. Br.J.Pharmacol. 164 1847. PMID:21595651. Birrell et al (2013) Selectivity profiling of the novel EP2 receptor antagonist, PF-04418948, in functional bioassay systems: atypical affinity at the guinea pig EP2 receptor. Br.J.Pharmacol. 168 129. PMID:22747912."	Small Molecule	Sold for research purposes under agreement from Pfizer Inc.	http://www.tocris.com/dispprod.php?ItemId=372163	SQ1070			Apr-2013
4819	Methylprednisolone	[83-43-2]	O=C1C=C[C@@]2(C)C([C@@H](C)C[C@]3([H])[C@@]([H])2[C@@H](O)C[C@@]4(C)[C@]([H])3CC[C@](C(CO)=O)4O)=C1	Glucocorticoid receptor agonist	Glucocorticoid receptor (GR) agonist. Displays anti-inflammatory and antioxidant properties. Attenuates apoptosis in oligodendrocytes after injury stimuli. Upregulates expression of Bcl-xL via direct binding of the GR/STAT5 complex. Neuroprotective.	Lee et al (2008) Methylprednisolone protects oligodendrocytes but not neurons after spinal cord injury. J.Neurosci. 29 3141. PMID:18354017. Xu et al (2009) STAT5 mediates antiapoptotic effects of methylprednisolone on oligodendrocytes. J.Neurosci. 29 2022. PMID:19228956.	Small Molecule	Sold for research purposes under agreement from Pfizer Inc.	http://www.tocris.com/dispprod.php?ItemId=372250	SQ1533			Sep-2013
4820	PF 04691502	[1013101-36-4]	O=C2C(C4=CC=C(OC)N=C4)=CC1=C(C)N=C(N)N=C1N2[C@@H]3CC[C@@H](OCCO)CC3	Potent and selective dual PI 3-K/mTOR inhibitor	"Potent and selective dual ATP-competitive PI 3-K/mTOR inhibitor (Ki values are 1.6, 1.8, 1.9, 2.1 and 16 nM for human PI 3-K _, _, _, _, and mTOR, respectively). Displays no significant inhibitory activity at more than 80 protein kinases (concentration  10 _M) including hVps34, PI 3-K downstream kinases, and MAPK family members. Orally available. Induces robust cell cycle arrest at the G1 phase in U87MG cancer cells and antitumor activity in SKOV3 ovarian cancer xenograft models."	"Yuan et al (2011) PF-04691502, a potent and selective oral inhibitor of PI3K and mTOR kinases with antitumor activity. Mol.Cancer Ther. 10 2189. PMID:21750219."	Small Molecule	Sold for research purposes under agreement from Pfizer Inc.	http://www.tocris.com/dispprod.php?ItemId=372265	SQ1533			Apr-2013
4821	PF 03814735	[942487-16-3]	[H][C@@]3(N5C(CNC(C)=O)=O)CC[C@@]5([H])C(C3=C4)=CC=C4NC1=NC(NC2CCC2)=C(C(F)(F)F)C=N1	Aurora kinase A and B inhibitor	"ATP-competitive inhibitor of Aurora kinases A and B (IC50 values are 0.8 and 5 nM for recombinant Aurora B and Aurora A, respectively). Inhibits phosphorylation of Aurora B, histone H3 and Aurora A in cultured MDA-MB-231 cells (IC50 values are approximately 20, 50 and 150 nM respectively). Shown to block cytokinesis; inhibits cellular proliferation in several human tumor cell lines, including HCT-116, HL-60, A549 and H125, and in human xenograft mouse models. Orally available."	"Jani et al (2010) PF-03814735, an orally bioavailable small molecule aurora kinase inhibitor for cancer therapy. Mol.Cancer Ther. 9 883. PMID:20354118. Hook et al (2012) An integrated genomic approach to identify predictive biomarkers of response to the Aurora kinase inhibitor PF-03814735. Mol.Cancer Ther. 11 710. PMID:22222631. Kollareddy et al (2012) Aurora kinase inhibitors: progress towards the clinic. Invest.New Drugs 30 2411. PMID:22350019."	Small Molecule	Sold for research purposes under agreement from Pfizer Inc.	http://www.tocris.com/dispprod.php?ItemId=372266	SQ1533			Apr-2013
4822	Clindamycin hydrochloride	[21462-39-5]	CN1[C@H]([C@@](N[C@@]([H])([C@@]2([H])O[C@H](SC)[C@H](O)[C@@H](O)[C@H]2O)[C@@H](Cl)C)=O)C[C@@H](CCC)C1.Cl	Antibiotic; inhibits protein synthesis	Lincosamide antibiotic. Inhibits protein synthesis by binding to the 50S ribosomal subunit and preventing early peptide chain elongation in bacteria.	"Dhawan and Thadepalli (1982) Clindamycin: a review of fifteen years of experience. Rev.Infect.Dis. 4 1133. PMID:6818656. Champney and Tober (2000) Specific inhibition of 50S ribosomal subunit formation in Staphylococcus aureus cells by 16-membered macrolide, lincosamide, and streptogramin B antibiotics. Curr.Microbiol. 41 126. PMID:10856379."	Small Molecule	Sold for research purposes under agreement from Pfizer Inc.	http://www.tocris.com/dispprod.php?ItemId=372268	SQ1533			Sep-2013
4823	PF 05212384	[1197160-78-3]	O=C(NC5=CC=C(C(N6CCC(N(C)C)CC6)=O)C=C5)NC(C=C4)=CC=C4C1=NC(N2CCOCC2)=NC(N3CCOCC3)=N1	Potent and selective dual PI 3-K/mTOR inhibitor	"Potent and selective dual inhibitor of PI 3-kinase/mTOR (IC50 values are 0.4, 1.6 and 5.4 nM for PI 3-K_, mTOR and PI 3-K_ respectively). Exhibits selectivity over 234 other protein kinases (IC50 >10 _M). Potently inhibits tumor cell growth in 37 different tumor cell lines (IC50 < 100 nM). Also exhibits antitumor activity in MDA-361, HCT-116, H1975 and U87MG xenograft models."	"Venkatesan et al (2010) Bis(morpholino-1,3,5-triazine) derivatives: potent adenosine 5'-triphosphate competitive phosphatidylinositol-3-kinase/mammalian target of rapamycin inhibitors: discovery of compound 26 (PKI-587), a highly efficacious dual inhibitor. J.Med.Chem. 53 2636. PMID:20166697. Mallon et al (2011) Antitumor efficacy of PKI-587, a highly potent dual PI3K/mTOR kinase inhibitor. Clin.Cancer Res. 17 3193. PMID:21325073."	Small Molecule	Sold for research purposes under agreement from Pfizer Inc.	http://www.tocris.com/dispprod.php?ItemId=372269	SQ1070			Apr-2013
4824	PD 334581	[548756-68-9]	FC1=CC(I)=CC=C1NC2=C(F)C(F)=CC=C2C3=NN=C(NCCN4CCOCC4)O3	MEK1 inhibitor	Inhibitor of MEK1. Analog of PD 184352 (Cat. No. 4237).	Ohren et al (2004) Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel competitive kinase inhibition. Nat.Struct.Mol.Biol. 11 1192. PMID:15543157. Zhang et al (2009) Targeting cancer with small molecule kinase inhibitors. Nat.Rev.Cancer 9 28. PMID:19104514.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=372407	SQ1341			Jul-2013
4825	TC ASK 10	[1005775-56-3]	O=C(C4=CC=C(C(C)(C)C)C=C4)NC1=CN2C(C=CC(N3C=NC=C3)=C2)=N1.Cl.Cl	Potent and selective ASK1 inhibitor; orally bioavailable	"Potent ASK1 inhibitor (IC50 = 14 nM); displays selectivity for ASK1 over other kinases including ASK2 (IC50 = 0.51 _M), MEKK1, TAK1, IKK_, ERK1, JNK1, p38_, GSK-3_, PKC_ and B-raf (IC50 values are > 10 _M). Blocks downstream JNK1/p38 phosphorylation in cells. Orally bioavailable."	"Terao et al (2012) Design and biological evaluation of imidazo[1,2-a]pyridines as novel and potent ASK1 inhibitors. Bioorg.Med.Chem.Lett. 22 7326. PMID:23147077."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=372547	SQ1341			Sep-2013
4826	SUN 11602	[704869-38-5]	NC1=C(C)C(C)=C(NCC(N(C)C2CCN(CC3=CC=C(C(N)=O)C=C3)CC2)=O)C(C)=C1C	Basic fibroblast growth factor (bFGF) mimetic; neuroprotective	"Basic fibroblast growth factor (bFGF) mimetic. Mimics the neuroprotective effects of bFGF; prevents glutamate-induced neuronal death. Increases levels of CALB1 gene expression in cerebrocortical neurons. Triggers phosphorylation of FGFR, ERK1 and ERK2."	"Murayama et al (2013) SUN11602, a novel aniline compound, mimics the neuroprotective mechanisms of basic fibroblast growth factor. ACS Chem.Neurosci. 4 266. PMID:23421678."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=372548	SQ1341			Apr-2014
4827	Garcinol	[78824-30-3]	O=C1C(C(C2=CC(O)=C(O)C=C2)=O)=C(O)[C@](C[C@H](C/C=C(C)/C)C(C)=C)([C@@]3=O)C[C@@H](C/C=C(C)/C)C(C)(C)[C@]31C/C=C(C)\C	PCAF/p300 HAT inhibitor; anticancer	"Inhibitor of PCAF and p300 histone acetyltransferase (HAT) activity (IC50 values are 5 and 7 _M, respectively). Promotes expansion of human HSCs ex vivo. Causes reversal of EMT and inhibits _-catenin in breast cancer cell lines MDA-MB-231 and BT-549."	"Balasubramanyam et al (2004) Polyisoprenylated benzophenone, garcinol, a natural histone acetyltransferase inhibitor, represses chromatin transcription and alters global gene expression. J.Biol.Chem. 279 33716. PMID:15155757. Nishino et al (2011) Ex vivo expansion of human hematopoietic stem cells by garcinol, a potent inhibitor of histone acetyltransferase. PLoS One 6 e24298. PMID:21931675. Ahmad et al (2012) Garcinol regulates EMT and Wnt signaling pathways in vitro and in vivo, leading to anticancer activity against breast cancer cells. Mol.Cancer.Ther. 11 2193. PMID:22821148."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=372549				Jan-2015
4828	LDN 209929 dihydrochloride		ClC1=CC=C(N=C(C=CC(OC)=C3)C3=C2SCCCN)C2=C1.Cl.Cl	Potent and selective haspin kinase inhibitor	Potent and selective haspin kinase inhibitor (IC50 = 55 nM). Displays 180-fold selectivity over DYRK2.	Cuny et al (2010) Structure-activity relationship study of acridine analogs as haspin and DYRK2 kinase inhibitors. Bioorg.Med.Chem.Lett. 20 3491. PMID:20836251.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=372550				Aug-2014
4830	LMK 235	[1418033-25-6]	CC1=CC(C(NOCCCCCC(NO)=O)=O)=CC(C)=C1	Selective HDAC4/HDAC5 inhibitor	"Selective histone deacetylase (HDAC) 4 and HDAC5 inhibitor (IC50 values are 4.22, 11.9, 55.7, 320, 852, 881, and 1278 nM for HDAC 5, 4, 6, 1, 11, 2, and 8, respectively). Demonstrates activity against chemoresistant cancer cell lines in an MTT assay for cytotoxicity using human ovarian cancer cell lines A2780 and cisplatin resistant A2780CisR (IC50 = 0.49 and 0.32 _M respectively)."	Marek et al (2013) Histone deacetylase (HDAC) inhibitors with a novel connecting unit linker region reveal a selectivity profile for HDAC4 and HDAC5 with improved activity against chemoresistant cancer cells. J.Med.Chem. 56 427. PMID:23252603.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=372694	SQ1341			Aug-2013
4832	AZ 12216052	[1290628-31-7]	BrC1=CC=C(CSCC(NC2=CC=C(C(C)CC)C=C2)=O)C=C1	Positive allosteric modulator at mGlu8	Positive allosteric modulator at mGlu8 receptors. Exhibits anxiolytic effects in mouse models of anxiety.	Duvoisin et al (2010) Acute pharmacological modulation of mGluR8 reduces measures of anxiety. Behav.Brain Res. 212 168. PMID:20385173. Duvoisin et al (2011) Opposing roles of mGluR8 in measures of anxiety involving non-social and social challenges. Behav.Brain Res. 221 50. PMID:21382421. Chruscicka et al (2013) Expression of metabotropic glutamate receptors in mammalian cells as a method for identification of new chemical compounds with drug-like activity. Pharmacol.Rep. 65 38.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=372777				Dec-2014
4833	Levonorgestrel	[797-63-7]	[H][C@@]12C(CC[C@]3([H])[C@@]([H])2CC[C@@]4(CC)[C@]([H])3CC[C@@](C#C)4O)=CC(CC1)=O	Synthetic progesterone analog	"Synthetic progesterone analog; binds to the progesterone receptor (relative binding affinities are < 0.02, 7.5, 17, 58 and 323 % for estrogen receptors, glucocorticoid receptors, mineralocorticoid receptors, androgen receptors and progesterone receptors respectively)."	Sitruk-Ware et al (2006) New progestagens for contraceptive use. Hum.Reprod.Update 12 169. PMID:16291771.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=372802	SQ1533			Mar-2013
4835	GPP 78 hydrochloride		O=C(NC3=C(C4=CC=CC=C4)C=CC=C3)CCCCCCCN1N=NC(C2=CC=CN=C2)=C1.Cl	NMPRTase inhibitor; also induces autophagy	Inhibitor of nicotinamide phosphoribosyltransferase (NAMPT); potently depletes NAD levels and exhibits cytotoxicity in vitro (IC50 values are 3.0 and 3.8 nM respectively). Also shown to induce autophagy in neuroblastoma cells.	Colombano et al (2010) A novel potent nicotinamide phosphoribosyltransferase inhibitor synthesized via click chemistry. J.Med.Chem. 53 616. PMID:19961183.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=373197	SQ1341			Oct-2013
4836	AZ 628	[878739-06-1]	CC(C)(C#N)C1=CC=CC(C(NC2=CC(NC3=CC(C(N(C)C=N4)=O)=C4C=C3)=C(C)C=C2)=O)=C1	Potent Raf kinase inhibitor	"Potent, ATP-competitive inhibitor of Raf kinases (IC50 values are 29, 34 and 105 nM for c-Raf1, B-RafV600E and wild-type B-Raf, respectively). Displays selectivity for Raf kinases over a panel of 150 other kinases; inhibits activation of tyrosine protein kinases such as VEGFR2, Lyn, Flt1 and Fms. Also inhibits growth, and induces cell cycle arrest and apoptosis in colon and melanoma cell lines with the B-RafV600E mutation."	Khazak et al (2007) Selective Raf inhibition in cancer therapy. Expert Opin.Ther.Targets 11 1587. PMID:18020980. Montagut et al (2008) Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma. Cancer Res. 68 4853. PMID:18559533. Hatzivassiliou et al (2010) RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature 464 431. PMID:20130576.	Small Molecule	Sold with the permission of AstraZeneca UK Ltd.	http://www.tocris.com/dispprod.php?ItemId=373198	SQ1533			Nov-2013
4837	AZD 3988	[892489-52-0]	O=C(NC3=CC=[C@@]([C@H]4CC[C@H](CC(O)=O)CC4)C=C3)C1=NN=C(NC2=CC(F)=C(F)C=C2)O1	Potent and selective diacylglycerol acyltransferase 1 (DGAT-1) inhibitor	"Potent and selective diacylglycerol acyltransferase (DGAT-1) inhibitor (IC50 = 0.6 nM). Exhibits selectivity for DGAT-1 over DGAT-2, Kv11.1 (hERG) and cytochrome P450 enzymes. Suppresses triacylglyceride (TAG) plasma excursion and adipose tissue TAG synthesis in rats. Reduces body weight of diet-induced obese rats. Cell permeable and orally bioavailable."	"McCoull et al (2012) Identification, optimisation and in vivo evaluation of oxadiazole DGAT-1 inhibitors for the treatment of obesity and diabetes. Bioorg.Med.Chem.Lett. 22 3873. PMID:22608962."	Small Molecule	Sold with the permission of AstraZeneca UK Ltd.	http://www.tocris.com/dispprod.php?ItemId=373199				Feb-2015
4838	AZ 12080282 dihydrochloride		CC1=CC=C(C2=NC=CN2)C=C1NC(C3=CC=C(OCC4=CC=CC=N4)C=C3)=O.Cl.Cl	Inhibitor of Hedgehog (Hh) signaling	Inhibitor of Hedgehog (Hh) signaling (IC50 <0.012 _M in a firefly reporter assay against the Hh pathway). Shown to displace cyclopamine in HeLa cells expressing Smoothened. Exhibits selectivity against p38_. Orally bioavailable.	Yang et al (2012) Discovery of novel hedgehog antagonists from cell-based screening: isoteric modification of p38 bisamides as potent inhibitors of SMO. Bioorg.Med.Chem.Lett. 22 4907. PMID:22704236.	Small Molecule	Sold with the permission of AstraZeneca UK Ltd.	http://www.tocris.com/dispprod.php?ItemId=366574	SQ1341			Dec-2013
4839	AZD 6482	[1173900-33-8]	OC(C1=C(N[C@@H](C2=CC(C)=CN3C2=NC(N4CCOCC4)=CC3=O)C)C=CC=C1)=O	Potent and selective PI 3-K_ inhibitor	"Potent and selective inhibitor of PI 3-kinase _ (PI 3-K_) (IC50 values are 0.69, 13.6, 47.8 and 136 nM for PI 3-K_, PI 3-K_, PI 3-K_ and PI 3-K_, respectively). Selectively inhibits in vivo growth of the PTEN-deficient tumor xenografts HCC70 and PC3. Also exhibits antithrombotic activity."	"Nylander et al (2012) Human target validation of phosphoinositide 3-kinase (PI3K)_: effects on platelets and insulin sensitivity, using AZD6482 a novel PI3K_ inhibitor. J.Thromb.Haemost. 10 2127. PMID:22906130. Ni et al (2012) Functional characterization of an isoform-selective inhibitor of PI3K-p110_ as a potential anticancer agent. Cancer Discov. 2 425. PMID:22588880."	Small Molecule	Sold with the permission of AstraZeneca UK Ltd.	http://www.tocris.com/dispprod.php?ItemId=373421	SQ1533			Oct-2013
4840	KU 0060648	[881375-00-4]	O=C1C3=C(C(C4=CC=C(NC(CN7CCN(CC)CC7)=O)C5=C4SC6=C5C=CC=C6)=CC=C3)OC(N2CCOCC2)=C1	Dual DNA-PK and PI 3-K inhibitor	"Dual, ATP-competitive inhibitor of DNA-dependent protein kinase (DNA-PK) and PI 3-K (IC50 = 19 nM for DNA-PK autophosphorylation in MCF7 cells). Inhibits proliferation of MCF7 cells and delays growth of MCF7 xenografts. Also thought to inhibit PI 3-K in a cell line-dependent manner (IC50 values are <0.1, 0.5 and 4 nM for PI 3-K_, PI 3-K_ and PI 3-K_ in a cell-free assay)."	"Dumont et al (2009) Radiosensitising agents for the radiotherapy of cancer: novel molecularly targeted approaches. Expert Opin.Ther.Patents 19 775. PMID:19456277. Munck et al (2012) Chemosensitization of cancer cells by KU-0060648, a dual inhibitor of DNA-PK and PI-3K. Mol.Cancer Ther. 11 1789. PMID:22576130."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=373422				Nov-2013
4842	BIX 02189	[1265916-41-3]	O=C2NC1=CC(C(N(C)C)=O)=CC=C1/C2=C(C4=CC=CC=C4)/NC3=CC(CN(C)C)=CC=C3	Selective MEK5 and ERK5 inhibitor	"Selective MEK5 and ERK5 inhibitor (IC50 values are 1.5 and 59 nM respectively). Inhibits sorbitol-induced ERK5 phosphorylation in HeLa cells. Selective for MEK5 and ERK5 over MEK1/2, ERK1/2 and a panel of 87 kinases. Induces apoptosis in acute myeloid leukemia tumor cells."	Tatake et al (2008) Identification of pharmacological inhibitors of the MEK5/ERK5 pathway. Biochem.Biophys.Res.Comm. 377 120. PMID:18834865. Kimura et al (2010) Targeted deletion of the extracellular signal-regulated protein kinase 5 attenuates hypertrophic response and promotes pressure overload-induced apoptosis in the heart. Circ.Res. 106 961. PMID:20075332. Lopez-Royuela et al (2014) Extracellular-signal-regulated kinase 5 modulates the antioxidant response by transcriptionally controlling Sirtuin 1 expression in leukemic cells. Int.J.Biochem.Cell Biol. 53 253. PMID:24880091.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=373424	SQ1341			Jul-2014
4844	HJC 0350	[885434-70-8]	CC1=CC(C)=C(S(N2C(C)=CC(C)=C2)(=O)=O)C(C)=C1	Selective Epac2 inhibitor	Selective Epac2 inhibitor (IC50 = 0.3 _M). Displays no effect on Epac1. Blocks stimulation of the Epac2-FL FRET sensor in HEK293 cells.	Chen et al (2013) Identification and characterization of small molecules as potent and specific EPAC2 antagonists. J.Med.Chem. 56 952. PMID:23286832.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=373426	SQ1341			Jul-2013
4847	PluriSln 1	[91396-88-2]	O=C(NNC2=CC=CC=C2)C1=CC=NC=C1	Inhibitor of SCD1; selectively eliminates undifferentiated hPSCs from culture	"Stearoyl-CoA desaturase 1 (SCD1) inhibitor. Used to selectively eliminate undifferentiated human pluripotent stem cells (hPSCs) from culture; induces ER stress, attenuates protein synthesis and induces apoptosis in hPSCs. Prevents teratoma formation in immunocompromised mice."	Ben-David et al (2013) Selective elimination of human pluripotent stem cells by an oleate synthesis inhibitor discovered in a high-throughput screen. Cell Stem Cell 12 167. PMID:23318055.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=373429				Apr-2013
4848	MI 2 (MALT1 inhibitor)	[1047953-91-2]	O=C(CCl)NC(C=C3)=CC=C3N1C(C2=CC(Cl)=C(Cl)C=C2)=NC(OCCOC)=N1	MALT1 inhibitor	MALT1 inhibitor (IC50 = 5.84 _M). Binds directly to MALT1 and irreversibly suppresses protease function. Decreases NF-_B activity induced by MALT1. Inhibits cell proliferation and MALT1-mediated cleavage activity. Suppresses human TMD8 and HBL-1 activated B cell-like diffuse large B cell lymphoma (ABC-DLBCL) tumor xenografts in mice and primary human ABC-DLBCLs ex vivo.	Fontan et al (2012) MALT1 small molecule inhibitors specifically suppress ABC-DLBCL in vitro and in vivo. Cancer Cell 22 812. PMID:23238016.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=373559	SQ1533			Sep-2013
4854	ML 00253764 hydrochloride		BrC1=CC(CCC2=C(F)C=CC=C2C3=NCCN3)=C(OC)C=C1.Cl	Melanocortin MC4 receptor antagonist; brain penetrant	"Non-peptide, melanocortin MC4 receptor antagonist (IC50 values are 0.32, 0.81 and 2.12 _M for MC4, MC3 and MC5 receptors respectively). Decreases cAMP accumulation in HEK-293 cells expressing the MC4 receptor. Increases food intake and reduces loss of lean body mass in tumor bearing mice. Brain penetrant."	"Vos et al (2004) Identification of 2-[2-[2-(5-bromo-2- methoxyphenyl)-ethyl]-3-fluorophenyl]-4,5-dihydro-1H-imidazole (ML00253764), a small molecule melanocortin 4 receptor antagonist that effectively reduces tumor-induced weight loss in a mouse model. J.Med.Chem. 47 1602. PMID:15027849. Tucci et al (2005) Potent and orally active non-peptide antagonists of the human melanocortin-4 receptor based on a series of trans-2-disubstituted cyclohexylpiperazines. Bioorg.Med.Chem.Lett. 15 4389. PMID:16098742. Nicholson et al (2006) Peripheral administration of a melanocortin 4-receptor inverse agonist prevents loss of lean body mass in tumor-bearing mice. J.Pharmacol.Exp.Ther. 317 771. PMID:16436498."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=374315	SQ1341			Jun-2014
4855	WIKI4	[838818-26-1]	O=C(C5=C4C(C6=O)=CC=CC4=CC=C5)N6CCCSC1=NN=C(C3=CC=NC=C3)N1C2=CC=C(OC)C=C2	Tankyrase inhibitor; inhibits Wnt signaling	Inhibitor of Wnt/_-catenin signaling (EC50 ~ 75 nM). Inhibits auto-ADP-ribosylation of tankyrase 2 (TNKS2) (IC50 ~15 nM); prevents the ubiquitination and degradation of axin.	"James et al (2012) WIKI4, a novel inhibitor of tankyrase and Wnt/_-catenin signaling. PLoS One 7 e50457. PMID:23227175."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=374316	SQ1341			Apr-2013
4857	Amlexanox	[68302-57-8]	CC(C)C1=CC=C2C(C(C(C=C(C(O)=O)C(N)=N3)=C3O2)=O)=C1	Inhibitor of TBK1 and IKK_; antiallergic agent	"Selective inhibitor of TANK-binding kinase 1 (TBK1) and IKK_ (IC50 values are ~1-2 _M). Displays no effect on IKK_ or IKK_ at these concentrations. Reversibly lowers weight, increases insulin sensitivity, and reduces inflammation and steatosis in three mouse models of obesity. Exhibits antiallergic activity; inhibits the release of histamine from rat mast cells. Also binds to Hsp90 and inhibits C-terminal chaperone activity in vitro."	"Makino et al (1987) Mechanism of action of an antiallergic agent, amlexanox (AA-673), in inhibiting histamine release from mast cells. Acceleration of cAMP generation and inhibition of phosphodiesterase. Int.Arch.Allergy Appl.Immunol. 82 66. PMID:2433225. Okada et al (2003) Hsp90 is a direct target of the anti-allergic drugs disodium cromoglycate and amlexanox. Biochem.J. 374 433. PMID:12803546. Reilly et al (2012) An inhibitor of the protein kinases TBK1 and IKK-_ improves obesity-related metabolic dysfunctions in mice. Nat.Med. 19 313. PMID:23396211."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=374318	SQ1533			Apr-2013
4858	NSC 697923	[343351-67-7]	CC(C=C2)=CC=C2S(C1=CC=C([N+]([O-])=O)O1)(=O)=O	Selective UBE2N inhibitor	Selective inhibitor of the E2 ubiquitin (Ub) conjugating enzyme UBE2N (Ubc13). Inhibits UBE2N-Ub conjugation and activity of the UBE2N-Ueva1A complex. Has no effect on UbcH5c activity. Inhibits NF-_B activation in diffuse large B-cell lymphoma (DLBCL) cells. Inhibits cell growth and induces apoptosis in DLBCL and neuroblastoma (NB) cell lines. Supresses NB cell xenograft tumor growth in vivo.	Pulvino et al (2012) Inhibition of proliferation and survival of diffuse large B-cell lymphoma cells by a small-molecule inhibitor of the ubiquitin-conjugating enzyme Ubc13-Uev1A. Blood 120 1668. PMID:22791293. Cheng et al (2014) A small-molecule inhibitor of UBE2N induces neuroblastoma cell death via activation of p53 and JNK pathways. Cell Death Dis. 5 e1079. PMID:24556694.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=374319	SQ1341			Nov-2013
4859	ML 202	[1221186-52-2]	O=C1N(CC4=CC=CC(OC)=C4)N=CC2=C1N(C)C3=C2SC(S(C)=O)=C3	Pyruvate kinase M2 activator	"Potent activator of pyruvate kinase M2 (PKM2) (IC50 = 73 nM). Exhibits little or no activity against the pyruvate kinase isozymes PKM1, PKL and PKR."	"Boxer et al (2010) Identification of activators for the M2 isoform of human pyruvate kinase version 3. Probe Reports from the Molecular Libraries Program. PMID:21735594. Jiang et al (2010) Evaluation of thieno[3,2-b]pyrrole[3,2-d]pyridazinones as activators of the tumor cell specific M2 isoform of pyruvate kinase. Bioorg.Med.Chem.Lett. 20 3387. PMID:20451379."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=374322				Mar-2014
4864	NS 6180	[353262-04-1]	O=C2N(CC3=CC=CC(C(F)(F)F)=C3)C1=CC=CC=C1SC2	Potent KCa3.1 channel blocker	"Potent KCa3.1 channel blocker (IC50 values are 9, 14 and 15 nM for rat, human and mouse erythrocyte KCa3.1 channels respectively). Exhibits ~ 50% inhibition of KCa1.1, KV1.3, and KV11.1 channels, noradrenaline and dopamine transporters, L-type Ca2+ channels and melatonin receptors at a concentration of 10 _M. Potently inhibits IL-2 and IFN-_ production in rat lymphocytes (IC50 ~ 50 nM); reduces DBNS-induced experimental colitis in rats."	"Strbk et al (2013) NS6180, a new KCa3.1 channel inhibitor prevents T-cell activation and inflammation in a rat model of inflammatory bowel disease. Br.J.Pharmacol. 168 432. PMID:22891655."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=374917	SQ1341			May-2013
4865	APY 29	[1216665-49-4]	C1(NC2=CC(NC=N3)=C3C=C2)=NC=CC(NC4=CC(C5CC5)=NN4)=N1	Inhibits IRE1_ autophosphorylation; activates IRE1_ endoribonuclease activity	Allosteric modulator of IRE1_. Inhibits IRE1_ autophosphorylation (IC50 = 280 nM) and activates IRE1_ ribonuclease activity.	Korennykh et al (2009) The unfolded protein response signals through high-order assembly of Ire1. Nature 457 687. PMID:19079236. Wang et al (2012) Divergent allosteric control of the IRE1a endoribonuclease using kinase inhibitors. Nat.Chem.Biol. 8 982. PMID:23086298.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=374918	SQ1341			Jan-2014
4866	ML 190	[1355244-02-8]	O=C(CN4C(C3=CC=CN3C5=C4N=CC=C5C)=O)NCCCN(CC2)CCN2C1=CC=C(OC)C=C1	Selective _ opioid receptor antagonist	Selective _ opioid receptor (KOP) antagonist (IC50 = 120 nM in a _-arrestin assay); displays >267-fold selectivity over _ and _ opioid receptors.	Hedrick et al (2011) Antagonist for the kappa opioid receptor. Probe Reports from the NIH Molecular Libraries Pro. PMID: 22091479. Frankowski et al (2012) Discovery of small molecule kappa opioid receptor agonist and antagonist chemotypes through a HTS and hit refinement strategy. ACS Chem.Neurosci. 3 221. PMID:22737280.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=374931	SQ1341			Feb-2014
4868	SR 1001	[1335106-03-0]	CC1=C(S(NC2=CC=C(C(O)(C(F)(F)F)C(F)(F)F)C=C2)(=O)=O)SC(NC(C)=O)=N1	ROR_/_ inverse agonist	Retinoic acid receptor-related orphan receptor (ROR) _ and _ inverse agonist (Ki values are 172 and 111 nM for ROR_ and ROR_ respectively). Demonstrates no activity at ROR_ or LXR. Suppresses Th17 cell differentiation and cytokine expression and reduces the severity of disease in an animal model of mulitple sclerosis.	Solt et al (2011) Suppression of TH17 differentiation and autoimmunity by a synthetic ROR ligand. Nature 472 491. PMID:21499262. Crumbley et al (2012) Regulation of expression of citrate synthase by the retinoic acid receptor-related orphan receptor _ (ROR_). PLoS ONE 7 33804. PMID:22485150. Beurel et al (2013) Inflammatory T helper 17 cells promote depression-like behavior in mice. Biol.Psychiatry 73 622. PMID:23174342.	Small Molecule	Sold under license from The Scripps Research Institute.	http://www.tocris.com/dispprod.php?ItemId=374932	SQ1341			Dec-2013
4869	SR 2211	[1359164-11-6]	FC(C=C(C(O)(C(F)(F)F)C(F)(F)F)C=C4)=C4C(C=C3)=CC=C3CN(CC2)CCN2CC1=CC=NC=C1	Selective ROR_ inverse agonist	"Selective inverse agonist of retinoic acid receptor-related orphan receptor _ (ROR_) (Ki = 105 nM; IC50 ~320 nM). Exhibits weak activity at liver X receptor _ (LXR_); does not affect the transcriptional activity of farnesoid X receptors (FXR), and has no impact on the transcriptional activity of ROR_."	Kumar et al (2012) Identification of SR2211: a potent synthetic ROR_-selective modulator. ACS Chem.Biol. 7 672. PMID:22292739.	Small Molecule	Sold under license from The Scripps Research Institute.	http://www.tocris.com/dispprod.php?ItemId=374935	SQ1341			Dec-2013
4870	H2L 5765834	[420841-84-5]	O=C2N(C3=CC=CC(OC4=CC=C([N+]([O-])=O)C=C4)=C3)C(C1=CC(C(O)=O)=CC=C12)=O	"LPA1,3,5 antagonist"	"Antagonist of the lysophosphatidic acid receptors LPA1, LPA5 and LPA3 (IC50 values are 94, 463 and 752 nM respectively). Exhibits no effect at LPA2 or LPA4 receptors."	Williams et al (2009) Unique ligand selectivity of the GPR92/LPA5 lysophosphatidate receptor indicates role in human platelet activation. J.Biol.Chem. 284 17304. PMID:19366702. Fells et al (2010) 2D binary QSAR modeling of LPA3 receptor antagonism. J.Mol.Graph Model. 28 828. PMID:20356772. Tigyi (2010) Aiming drug discovery at lysophosphatidic acid targets. Br.J.Pharmacol. 161 241. PMID:20735414.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=374977				May-2013
4872	KML 29	[1380424-42-9]	O=C(OC(C(F)(F)F)C(F)(F)F)N(CC5)CCC5C(C2=CC=C(OCO3)C3=C2)(O)C1=CC(OCO4)=C4C=C1	Highly potent and selective monoacylglycerol lipase (MAGL) inhibitor	"Highly selective and potent monoacylglycerol lipase (MAGL) inhibitor. Exhibits potent inhibition of human, mouse and rat MAGL (IC50 values are 5.9, 15 and 43 nM, respectively). Exhibits no detectable inhibition of FAAH (IC50 > 50000 nM). Potently and selectively blocks hydrolysis of 2-arachidonoylglycerol (2-AG) in mice (IC50 = 2.5 nM and >50 _M for 2-AG and AEA respectively)."	Ueda et al (2012) Discrimination between two endocannabinoids. Chem.Biol. 19 545. PMID:22633404. Chang et al (2012) Highly selective inhibitors of monoacylglycerol lipase bearing a reactive group that is bioisosteric with endocannabinoid substrates. Chem.Biol. 19 579. PMID:22542104.	Small Molecule	Sold under license from The Scripps Research Institute	http://www.tocris.com/dispprod.php?ItemId=374979	SQ1341			Feb-2014
4874	SR 1078	[1246525-60-9]	OC(C(F)(F)F)(C(F)(F)F)C(C=C1)=CC=C1NC(C2=CC=C(C(F)(F)F)C=C2)=O	ROR_/_ agonist	Agonist of retinoic acid receptor-related orphan receptors (ROR) ROR_/_. Increases transcription of ROR_ target genes; thought to increase p53 stability.	"Wang et al (2010) Identification of a synthetic agonist for the orphan nuclear receptors ROR_ and ROR_, SR1078. ACS Chem.Biol. 5 1029. PMID:20735016. Wang et al (2012) Regulation of p53 stability and apoptosis by a ROR agonist. PLoS One 7 e34921. PMID:22509368."	Small Molecule	Sold under license from The Scripps Research Institute.	http://www.tocris.com/dispprod.php?ItemId=374981	SQ1341			Dec-2013
4875	Senexin A		N#CC1=CC=C2C(C(NCCC3=CC=CC=C3)=NC=N2)=C1.Cl	Cyclin-dependent kinase 8 (cdk8) inhibitor	Cyclin-dependent kinase 8 (cdk8) inhibitor (IC50 = 280 nM). Also binds to cdk19 in an ATP-competitive manner. Inhibits p21-induced transcription. Reverses doxorubicin-induced tumor-promoting paracrine activities in vivo.	Porter et al (2012) Cyclin-dependent kinase 8 mediates chemotherapy-induced tumor-promoting paracrine activities. Proc.Natl.Acad.Sci.U.S.A. 109 13799. PMID:22869755.	Small Molecule	Sold under license from Senex Biotechnology.	http://www.tocris.com/dispprod.php?ItemId=375059	SQ1341			May-2014
4876	Eact	[461000-66-8]	O=C(C3=CC(OC)=C(OC)C(OC)=C3)N(CCOC)C1=NC(C2=CC=CC=C2)=CS1	Activator of Ca2+-activated Cl- channel transmembrane protein 16A (TMEM16A)	TMEM16A (ANO1) calcium-activated chloride channel (CaCC) activator (EC50 = 3 _M). Ca2+-independent. Displays no effect on CFTR Cl- or ENaC Na+ conductance. Stimulates submucosal gland secretion in human bronchi.	"Namkung et al (2011) Small-molecule activators of TMEM16A, a calcium-activated chloride channel, stimulate epithelial chloride secretion and intestinal contraction. FASEB J. 25 4048. PMID:21836025."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=375287	SQ1341			May-2013
4877	CaCCinh-A01	[407587-33-1]	CC(C)(C)C1CCC2=C(SC(NC(C3=CC=CO3)=O)=C2C(O)=O)C1	Calcium-activated chloride channel (CaCC) inhibitor	"Calcium-activated chloride channel (CaCC) inhibitor (IC50 ~ 10 _M). Inhibits CaCC currents in human bronchial and intestinal cells. Also inhibits TMEM16A channels (IC50 = 2.1 _M, in TMEM16A-expressing FRT cells)."	De La Fuente et al (2008) Small-molecule screen identifies inhibitors of a human intestinal calcium-activated chloride channel. Mol.Pharmacol. 73 758. PMID:18083779. Namkung et al (2011) TMEM16A inhibitors reveal TMEM16A as a minor component of calcium-activated chloride channel conductance in airway and intestinal epithelial cells. J.Biol.Chem. 286 2365. PMID:21084298.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=375414				May-2013
4878	H2L5186303	[139262-76-3]	O=C(/C=C\C(O)=O)NC(C=C3)=CC=C3OC1=CC(OC2=CC=C(NC(/C=C\C(O)=O)=O)C=C2)=CC=C1	Potent and selective LPA2 receptor antagonist	"Potent and selective lysophosphatidic acid 2 (LPA2) receptor antagonist (IC50 values are 8.9, 1230 and 27354 nM for LPA2, LPA3 and LPA1 receptors respectively, in a LPA-elicited calcium mobilization assay)."	Fells et al (2008) Identification of non-lipid LPA3 antagonists by virtual screening. Bioorg.Med.Chem. 16 6207. PMID:18467108. Fells et al (2009) Structure-based drug design identifies novel LPA3 antagonists. Bioorg.Med.Chem. 17 7457. PMID:19800804.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=375415				May-2013
4879	TC-G 1001	[494191-73-0]	O=C1N=C(NC3=CC=CC=C3F)S/C1=C\C2=CC=C(C(O)=O)C=C2	GPR35 agonist; more potent than zaprinast (Cat. No. 0947)	GPR35 agonist (pEC50 values are 7.59 and 8.36 for _-arrestin and G_q-i5 Ca2+ assays respectively). Displays 1000-fold greater potency at human GPR35 receptors relative to mouse and rat GPR35 orthologs in an IP1 accumulation assay. More potent than zaprinast (Cat. No. 0947).	"Neetoo-Isseljee et al (2013) High-throughput identification and characterization of novel, species-selective GPR35 agonists. J.Pharmacol.Exp.Ther. 344 568. PMID:23262279."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=375669				May-2013
4880	ML 281	[1404437-62-2]	CC(C)C1=CC(C2=NC(C=CC=C3)=C3NC2=O)=C(NC(C4=CC=CS4)=O)C=C1	STK33 inhibitor	Inhibitor of the serine/threonine kinase STK33 (IC50 = 14 nM). Exhibits >700-fold selectivity for STK33 over the structurally related protein kinase A (PKA); also exhibits 550-fold selectivity over Aurora kinase B.	Weiwer et al (2012) A potent and selective quinoxaline-based STK33 inhibitor does not show synthetic lethality in KRAS-dependent cells. ACS Med.Chem.Lett. 3 1034. PMID:23256033.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=375692	SQ1341			Dec-2013
4881	LUF 6283	[92933-48-7]	CCCCC1=CC(C(O)=O)=NN1	HCA2 (GPR109A) partial agonist	Partial agonist of hydroxycarboxylic acid receptor 2 (HCA2) (Ki = 0.55 _M). Thought to lower plasma very-low-density lipoprotein (VLDL)-triglyceride levels by affecting hepatic VLDL production in normolipidemic C57BL/6 mice.	Li et al (2012) Effects of pyrazole partial agonists on HCA2-mediated flushing and VLDL-triglyceride levels in mice. Br.J.Pharmacol. 167 818. PMID:22616721.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=375693				Oct-2013
4883	CU CPT 4a	[1279713-77-7]	O=C(N[C@H](CC3=CC=CC=C3)[C@@](O)=O)C2=C(Cl)C1=CC=C(F)C=C1S2	Selective TLR3 inhibitor	"Selective TLR3 inhibitor (IC50 = 3.44 _M in RAW 264.7 cells); suppresses downstream signaling pathways mediated by the TLR3/dsRNA complex, inhibiting TNF-_ and IL-1_ production in whole cells."	Cheng et al (2011) Small-molecule inhibitors of the TLR3/dsRNA complex. J.Am.Chem.Soc. 133 3764. PMID:21355588.	Small Molecule	Sold under license from the University of Colorado	http://www.tocris.com/dispprod.php?ItemId=376147	SQ1341			Feb-2014
4884	CU CPT 22	[1416324-85-0]	O=C1C(O)=CC(C(OCCCCCC)=O)=CC2=C1C(O)=C(O)C(OC)=C2	Selective TLR1/2 inhibitor	"Selective toll-like receptor 1/2 (TLR1/2) inhibitor (IC50 = 0.58 _M). Exhibits no activity at TRL2/TLR6, TLR3, TLR4 and TLR7 or a panel of 10 representative kinases. Inhibits the release of proinflammatory cytokines TNF-_ and IL-1_."	Cheng et al (2012) Discovery of small-molecule inhibitors of the TLR1/TLR2 complex. Angew Chem.Int.Ed.Engl. 51 12246. PMID:22969053.	Small Molecule	Sold under license from the University of Colorado	http://www.tocris.com/dispprod.php?ItemId=376148				Oct-2013
4885	R 1530	[882531-87-5]	FC(C(OC)=C1)=CC2=C1NC3=NNC(C)=C3N=C2C4=C(Cl)C=CC=C4	Multi-RTK inhibitor; inhibits angiogenesis	"Multi-kinase inhibitor. Exhibits inhibitory activity against Chk2, KDR, FGFR, Aurora A kinase and Cdk2 (IC50 values are 24, 34, 50, 58 and 88 nM respectively). Also binds VEGFR-2, FGFR1 and PDGFR_ (Kd values are 0.015, 0.061 and 0.088 _M respectively). Displays antiproliferative activity in vitro; inhibits mitosis and angiogenesis. Orally bioavailable."	"Tovar et al (2010) Small-molecule inducer of cancer cell polyploidy promotes apoptosis or senescence: implications for therapy. Cell Cycle 9 3364. PMID:20814247. Liu et al (2013) Discovery of a highly potent, orally active mitosis/angiogenesis inhibitor R1530 for the treatment of solid tumors. ACS Med.Chem.Lett. 4 259."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=376348	SQ1341			Sep-2013
4886	RU-SKI 43 hydrochloride		O=C(CNCC(CC)C)N1CCC3=C(C=CS3)C1COC2=CC(C)=CC=C2.Cl	Hedgehog acyltransferase (Hhat) inhibitor; cell permeable	Hedgehog acyltransferase (Hhat) inhibitor (IC50 = 850 nM). Inhibits Sonic Hedgehog N (ShhN) palmitoylation in vitro. Has no effect on porcupine-induced fatty acid acylation of Wnt39a. Attenuates pancreatic cancer cell proliferation. Cell permeable.	Petrova et al (2013) Inhibitors of Hedgehog acyltransferase block Sonic Hedgehog signaling. Nat.Chem.Biol. 9 247. PMID:23416332. Petrova et al (2014) Hedgehog acyltransferase as a target in pancreatic ductal adenocarcinoma. Oncogene. PMID:24469057.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=376349	SQ1341			May-2014
4887	OAC-1	[300586-90-7]	O=C(C3=CC=CC=C3)NC1=NC=C2C(C=CN2)=C1	Oct4 activator; enhances iPSC reprogramming efficiency	"Oct4 activator. Enhances and accelerates iPSC reprogramming in the presence of 4F (Oct4, Sox2, c-Myc and Klf4) by ~20-fold compared to 4F alone. Induces mRNA expression of Oct4, Sox2 and Nanog and also Tet1. Displays no effects on p53-p21 pathway or Wnt-_-catenin signaling."	Li et al (2012) Identification of Oct4-activating compounds that enhance reprogramming efficiency. Proc.Natl.Acad.Sci.U S A 109 20853. PMID:23213213.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=376350	SQ1533			Jul-2013
4888	KHS 101 hydrochloride		CC(C)CNC1=NC(NCC2=CSC(C3=CC=CC=C3)=N2)=NC=C1.Cl	Selective inducer of neuronal differentiation in hippocampal neural progenitors	Selective inducer of neuronal differentiation; induces neuronal differentiation in cultured hippocampal neural progenitor cells (NPCs) by interacting with TACC3 (EC50 ~1 _M). Suppresses astrocyte formation. Also induces acceleration of neuronal differentiation in the hippocampal dentate gyrus in vivo.	Wurdak et al (2010) A small molecule accelerates neuronal differentiation in the adult rat. Proc.Natl.Acad.Sci.USA. 107 16542. PMID:20823227.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=376351	SQ1341			Jun-2014
4889	SGC-CBP30		CC1=C(C(C)=NO1)C2=CC=C3C(N=C(CCC4=CC(Cl)=C(OC)C=C4)N3C[C@@H](N5CCOCC5)C)=C2	Potent CBP/p300 bromodomain inhibitor	Potent CBP/p300 bromodomain (BRD) inhibitor (Kd values are 21 and 32 nM for CBP and p300 BRDs respectively). Exhibits 40-fold and 250-fold selectivity for CBP over the first BRD of BRD4 (BRD4(1)) and BRD4(2) respectively. Accelerates FRAP recovery in cells at a concentration of 1 _M.	Gallenkamp et al (2014) Bromodomains and their pharmacological inhibitors. ChemMedChem 9 438. PMID:24497428. Hay et al (2014) Discovery and optimization of small-molecule ligands for the CBP/p300 bromodomains. J.Am.Chem.Soc. 136 9308. PMID:24946055.	Small Molecule	"This probe is supplied in conjunction with the Structural Genomics Consortium. For further characterization details, please visit the SGC-CBP30 probe summary on the SGC website."	http://www.tocris.com/dispprod.php?ItemId=376368	SQ1341			Aug-2013
4890	AR-C 118925XX	[216657-60-2]	CC(C=C1)=CC2=C1C(C3=CN(CC4=CC=C(C(NC5=NN=NN5)=O)O4)C(NC3=S)=O)C(C=CC(C)=C6)=C6C=C2	"Selective, competitive P2Y2 receptor antagonist"	"Selective, competitive P2Y2 receptor antagonist. Inactive against a panel of 37 other receptors at a concentration of 10 _M. Inhibits ATP-_S-induced mucin secretion in bronchial epithelial cells (IC50 = 1 _M)."	"Meghani (2002) The design of P2Y2 antagonists for the treatment of inflammatory diseases. Abstract of papers, 224th ACS National Meeting, Boston, MA. Kemp et al (2004) Nucleotide-mediated mucin secretion from differentiated human bronchial epithelial cells. Am.J.Respir.Cell Mol.Biol. 31 446. PMID:15231488."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=376996				Dec-2014
4891	I-CBP 112		COC(C(OC)=C1)=CC=C1C2=CC(OC[C@H]3CCCN(C)C3)=C(OCCN(C(CC)=O)C4)C4=C2	Selective CBP/p300 bromodomain inhibitor	"CBP/p300 bromodomain inhibitor (IC50 values are 0.142-0.17 and 0.625 _M for CBP and p300 respectively). Selective for CBP and p300 over ATAD2, BAZ2B, BRD2(2), BRD4(1), PB1(5), PCAF, PHIP(2) and TIF1_ bromodomains in a BLI assay. Accelerates FRAP recovery in cells at a concentration of 1 _M."	Gallenkamp et al (2014) Bromodomains and their pharmacological inhibitors. ChemMedChem 9 438. PMID:24497428.	Small Molecule	"This probe is supplied in conjunction with the Structural Genomics Consortium. For further characterization details, please visit the I-CBP 112 probe summary on the SGC website."	http://www.tocris.com/dispprod.php?ItemId=377137	SQ1341			Jul-2013
4892	(R)-PFI 2 hydrochloride		O=C(N4CCCC4)[C@@H](CC3=CC=CC(C(F)(F)F)=C3)NS(C2=CC1=C(C(F)=C2)CNCC1)(=O)=O.Cl	Potent and selective SETD7 histone lysine methyltransferase inhibitor	Potent and selective SETD7 histone lysine methyltransferase inhibitor (IC50 = 2 nM). Exhibits >1000-fold selectivity over DNMT1 and a panel of 18 other methyltransferases. Inhibits YAP nuclear translocation and function following activation of the Hippo signaling pathway in MCF7 cells. Negative control (S)-PFI 2 hydrochloride (Cat. No. 5400) available.	Barsyte-Lovejoy et al (2014) (R)-PFI-2 is a potent and selective inhibitor of SETD7 methyltransferase activity in cells. Proc.Natl.Acad.Sci.U S A 111 12853. PMID:25136132.	Small Molecule	"This probe is supplied in conjunction with the Structural Genomics Consortium. For further characterization details, please visit the (R)-PFI 2 probe summary on the SGC website."	http://www.tocris.com/dispprod.php?ItemId=377151	SQ1070			Mar-2014
4893	XL 388	[1251156-08-7]	NC1=NC=C(C2=CC=C(OCCN(C(C4=CC=C(S(C)(=O)=O)C(F)=C4C)=O)C3)C3=C2)C=C1	Potent and selective mTOR inhibitor; antitumor	Potent and selective mTOR inhibitor (IC50 = 9.9 nM). Inhibits mTOR activity in an ATP-competitive manner. Exhibits >300-fold selectivity for mTOR over PI 3-K and a range of other kinases. Displays antitumor activity in athymic nude mice implanted with tumor xenografts.	"Takeuchi et al (2013) Discovery of a novel class of highly potent, selective, ATP-competitive, and orally bioavailable inhibitors of the mammalian target of rapamycin (mTOR). J.Med.Chem. 56 2218. PMID:23394126."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=377309	SQ1070			Apr-2014
4895	ML 298 hydrochloride		O=C(NCCN2CCC(C(NCN3C4=CC(F)=CC=C4)=O)3CC2)C1=CC=C(F)C(F)=C1.Cl	Selective PLD2 inhibitor	"Selective inhibitor of phospholipase D2 (PLD2) (IC50 values are 355 and >20,000 nM for PLD2 and PLD1, respectively). Decreases invasive migration in U87-MG glioblastoma cells, without affecting cell viability."	"O'Reilly et al (2013) Development of dual PLD1/2 adn PLD2 selective inhibitors from a common 1,3,8-triazaspiro[4.5]decane core: discovery of ML298 and ML299 that decrease invasive migration in U87-MG glioblastoma cells. J.Med.Chem. 56 2695. PMID:23445448."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=377315	SQ1341			Nov-2013
4896	LH 846	[639052-78-1]	O=C(CC3=CC=CC=C3)NC(S2)=NC1=C2C=C(C)C(Cl)=C1	Selective casein kinase 1_ inhibitor	"Selective inhibitor of casein kinase (CK) 1_ (IC50 values are 290 nM, 1.3 _M and 2.5 _M for CK1_, _ and _); displays no inhibitory activity at CK2. Inhibits CK1_-dependent phosphorylation and degradation of PER1 protein. Shown to lengthen the circadian period in U2OS cells, with minimal effect on amplitude."	Lee et al (2011) A small molecule modulates circadian rhythms through phosphorylation of the period protein. Agnew Chem.Int.Ed.Engl. 50 10608. PMID:21954091.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=377320	SQ1341			May-2013
4897	CYM 5541	[945128-26-7]	O=C(N(C3CCCCC3)C2CCCCC2)C1=NOC(C4CC4)=C1	Selective S1P3 receptor allosteric agonist	"Selective sphingosine-1-phosphate receptor 3 (S1P3) allosteric agonist (EC50 = 72-132 nM). Occupies a different space within the ligand binding pocket of S1P3 than S1P. Displays no activity at S1P1, S1P2, S1P4 and S1P5 receptors at concentrations up to 10 _M. Shows no significant activities in a profiling panel of 55 GPCRs, ion channels and transporters."	Jo et al (2012) Novel selective allosteric and bitopic ligands for the S1P3 receptor. ACS Chem.Biol. 7 1975. PMID:22971058.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=377835	SQ1341			Sep-2013
4898	TC-E 5006	[1257395-14-4]	CC(CC1)CCN1C(C2=C(C3=CC=C(C(F)(F)F)C=C3)C=C(C(C)C(O)=O)C=C2)C4=CC=C(F)C=C4	_-secretase modulator; reduces A_42 levels	_-secretase modulator. Reduces A_42 levels in vitro (EC50 = 390 nM) and in vivo. Orally bioavailable.	"Peng et al (2011) Discovery of BIIB042, a potent, selective, and orally bioavailable _-secretase modulator. ACS Med.Chem.Lett. 2 786. PMID:24900267."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=377836	SQ1070			May-2014
4899	ML 120B dihydrochloride		ClC1=C(OC)C(NC(C4=CC=CN=C4C)=O)=C2C(C(C=CN=C3)=C3N2)=C1.Cl.Cl	Novel IKK2-selective inhibitor	"Novel, ATP-competitive IKK2-selective inhibitor (IC50 = 60 nM at 50 _M ATP). Exhibits no inhibition at IKK1 (EC50 >100 _M), IKK_ (EC50 >100 _M) or a panel of 28 other kinases (EC50 >50 _M). Exhibits antitumor activity in lymphoma-bearing SCID mice. Demonstrates synergistic cytotoxic effects with vincristine (Cat. No. 1257)."	Catley et al (2006) Validation of the anti-inflammatory properties of small-molecule IkappaB Kinase (IKK)-2 inhibitors by comparison with adenoviral-mediated delivery of dominant-negative IKK1 and IKK2 in human airways smooth muscle. Mol.Pharmacol. 70 697. PMID:16687566. Nagashima et al (2006) Rapid TNFR1-dependent lymphocyte depletion in vivo with a selective chemical inhibitor of IKKbeta. Blood 107 4266. PMID:16439676. Al-Katib et al (2010) I-kappa-kinase-2 (IKK-2) inhibition potentiates vincristine cytotoxicity in non-Hodgkin's lymphoma. Mol.Cancer 9 1476. PMID:20809973.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=377837	SQ1070			Mar-2014
4900	PF 4778574	[1219633-99-4]	O=S(N[C@H]1CCOC[C@@H]1[C@]2=CC=C(C3=CC=C(C#N)S3)C=C2)(C(C)C)=O	Positive allosteric modulator of AMPA receptors	Positive allosteric modulator of AMPA receptors (Ki = 85 nM). Prevents ketamine-induced working memory impairments. Brain penetrant.	Roberts et al (2010) Prevention of ketamine-induced working memory impairments by AMPA potentiators in a nonhuman primate model of cognitive dysfunction. Behav.Brain Res. 212 41. PMID:20347881. Doran et al (2012) An evaluation of using rat-derived single-dose neuropharmacokinetic parameters to project accurately large animal unbound brain drug concentrations. Drug Metab.Dispos. 40 2162. PMID:22899853. Shaffer et al (2013) Positive allosteric modulation of AMPA receptors from efficacy to toxicity: the interspecies exposure-response continuum of the novel potentiator PF-4778574. J.Pharmacol.Exp.Ther. 347 212. PMID:23899905.	Small Molecule	Sold for research purposes under agreement from Pfizer Inc.	http://www.tocris.com/dispprod.php?ItemId=378037				May-2013
4901	Optovin	[348575-88-2]	S=C(N2)S/C(C2=O)=C/C1=C(C)N(C3=CN=CC=C3)C(C)=C1	Reversible photoactive TRPA1 activator	"Reversible photoactive TRPA1 activator. Stimulates human TRPA1 channels in vitro and enables repeated photoactivation of motor behaviors in wild-type zebrafish (EC50 = 2 _M) and mice, in vivo."	Kokel et al (2013) Photochemical activation of TRPA1 channels in neurons and animals. Nat.Chem.Biol. 9 257. PMID:23396078.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=378038				Jun-2013
4902	NSC 405020	[7497-07-6]	ClC1=CC=C(C(NC(C)CCC)=O)C=C1Cl	Inhibitor of MT1-MMP; antitumor	"Membrane type-1 matrix metalloproteinase (MT1-MMP) inhibitor (IC50 > 100 _mol/L). Directly interacts with the hemopexin domain (PEX) of MT1-MMP, affecting homodimerization and repressing its pro-tumorigenic activity in vivo. Displays no effect on the catalytic activity of MT1-MMP or MMP-2."	Remacle et al (2012) Novel MT1-MMP small-molecule inhibitors based on insights into hemopexin domain function in tumor growth. Cancer Res. 72 2339. PMID:22406620.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=378044				Jun-2013
4904	UNC 1999	[1431612-23-5]	CC(C)N1CCN(C2=NC=C(C3=CC(N(C(C)C)N=C4)=C4C(C(NCC5=C(CCC)C=C(C)NC5=O)=O)=C3)C=C2)CC1	Potent and selective EZH2/EZH1 histone lysine methyltransferase inhibitor	Potent and SAM-competitive EZH2/EZH1 lysine methyltransferase inhibitor (IC50 values are 2 and 45 nM respectively). Selective for EZH2/EZH1 over a panel of other methyltransferases and non-epigenetic targets. Reduces H3K27me3 levels in vitro. Prolongs survival of MLL-AF9 bearing mice. Orally bioavailable.	Konze et al (2013) An orally bioavailable chemical probe of the Lysine Methyltransferases EZH2 and EZH1. ACS Chem.Biol. 8 1324. PMID:23614352. Xu et al (2015) Selective inhibition of EZH2 and EZH1 enzymatic activity by a small molecule suppresses MLL-rearranged leukemia. Blood 125 346. PMID:25395428.	Small Molecule	"This probe is supplied in conjunction with the Structural Genomics Consortium. For further characterization details, please visit the UNC 1999 probe summary on the SGC website."	http://www.tocris.com/dispprod.php?ItemId=378334				Jan-2015
4905	UNC 2400	[1433200-49-7]	CC(C)N1CCN(C2=NC=C(C3=CC(N(C(C)C)N=C4)=C4C(C(N(C)CC5=C(CCC)C=C(C)N(C)C5=O)=O)=C3)C=C2)CC1	Negative control of UNC 1999 (Cat. No. 4904)	"Negative control of UNC 1999 (Cat. No. 4904). Exhibits 1000-fold lower potency than active analog (IC50 values are 62 and >200 _M for EZH1 and EZH2, respectively)."	Konze et al (2013) An orally bioavailable chemical probe of the lysine methyltransferases EZH2 and EZH1. ACS Chem.Biol. 8 1324. PMID:23614352. Xu et al (2015) Selective inhibition of EZH2 and EZH1 enzymatic activity by a small molecule suppresses MLL-rearranged leukemia. Blood 125 346. PMID:25395428.	Small Molecule	"This compound is supplied in conjunction with the Structural Genomics Consortium. For further characterization details, please visit the UNC 1999 probe summary on the SGC website."	http://www.tocris.com/dispprod.php?ItemId=378335				Feb-2015
4906	JW 642	[1416133-89-5]	O=C(OC(C(F)(F)F)C(F)(F)F)N(CC3)CCN3CC1=CC(OC2=CC=CC=C2)=CC=C1	Monoacylglycerol lipase (MAGL) inhibitor	Potent and selective monoacylglycerol lipase (MAGL) inhibitor (IC50 = 3.7 nM). Displays >1000-fold selectivity for MAGL over fatty acid amide hydrolase (IC50 = 20.6 _M). Analog of JZL 195 (Cat. No. 4715).	Chang et al (2012) Highly selective inhibitors of monoacylglycerol lipase bearing a reactive group that is bioisosteric with endocannabinoid substrates. Chem.Biol. 19 579. PMID:22542104.	Small Molecule	Sold under license from The Scripps Research Institute	http://www.tocris.com/dispprod.php?ItemId=378475	SQ1341			Jan-2014
4907	SN 2	[823218-99-1]	CC1=CC(C)=CC(C)=C1C2=NOC3C2C4CCC3C4	Selective TRPML3 channel activator	Selective TRPML3 channel activator (EC50 = 1.13 _M).	Grimm et al (2010) Small molecule activators of TRPML3. Chem.Biol. 17 135. PMID:20189104. Jrs (2010) Genetic inactivation of Trpml3 does not lead to hearing and vestibular impairment in mice. PLoS ONE 5 e14317. PMID:21179200.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=378605	SQ1341			Jan-2014
4908	GNF 5	[778277-15-9]	O=C(NCCO)C1=CC(C2=NC=NC(NC3=CC=C(OC(F)(F)F)C=C3)=C2)=CC=C1	Selective allosteric inhibitor of Bcr-Abl; analog of GNF 2 (Cat. No. 4399)	"Selective, non-ATP competitive allosteric inhibitor of Bcr-Abl (IC50 = 220 nM for wild-type Abl). Binds the myristate-binding site of Abl. Acts in combination with nilotinib to inhibit T315I Bcr-Abl in vitro and in vivo. Analog of GNF 2 (Cat. No. 4399)."	Zhang et al (2010) Targeting Bcr-Abl by combining allosteric with ATP-binding-site inhibitors. Nature 463 501. PMID:20072125. Deng et al (2010) Expanding the diversity of allosteric Bcr-Abl inhibitors. J.Med.Chem. 53 6934. PMID:20828158. Iacob et al (2011) Allosteric interactions between the myristate- and ATP-site of the Abl kinase. PLoS One 6 e15929. PMID:21264348.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=378606	SQ1070			Feb-2014
4916	PF 04885614		CC(C)(N)C1=NC(C2=CC=C(OC(F)(F)F)C=C2)=CN1	Potent and selective NaV1.8 channel blocker; active in vivo	"Potent NaV1.8 inhibitor (IC50 = 53 nM for human NaV1.8 channel). Exhibits selectivity for hNaV1.8 over hNaV1.6, hNaV1.7, hNaV1.1, hNaV1.2 and hNaV1.5 (IC50 values are 4.2, 7.0, 11, 16 and 27 _M respectively). Orally bioavailable."	Bagal et al (2013) Discovery of selective NaV1.8 modulators for the treatment of chronic pain. Abstract. 4th RSC/SCI Symp. on Ion Channels as Ther. Targ.	Small Molecule	Sold for research purposes under agreement from Pfizer Inc.	http://www.tocris.com/dispprod.php?ItemId=378990	SQ1341			May-2013
4917	M 25		O=C(C(CCC)CCC)NCC1=CC=C(N(C3=CC=CC=C3OC)N=C2)C2=C1	Potent Smoothened (Smo) receptor antagonist	"Potent Smoothened (Smo) receptor antagonist (IC50 = 5 nM). Inhibits the Hedgehog signaling pathway. Inhibits Shh induced Gli luciferase reporter activity in Shh-light 2 cells (IC50 = 5 nM). Antagonizes GSA-10 and SAG-mediated differentiation of the C3H10T1/2 cell line (IC50 values are 69 and 115 nM, respectively)."	"Dessole et al (2009) Discovery of N-[(1-aryl-1H-indazol-5-yl)methyl]amides derivatives as smoothened antagonists for inhibition of the hedgehog pathway. Bioorg.Med.Chem.Lett. 19 4191. PMID:19540115. Gorojankina et al (2013) Discovery, molecular and pharmacological characterization of GSA-10, a novel small-molecule positive modulator of Smoothened. Mol.Pharmacol. 83 1020. PMID:23448715."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=379158	SQ1070			Jan-2014
4918	GSA 10	[300833-95-8]	OC(C1=CC=CC=C1N2CCCCCC)=C(C(NC3=CC=C(C(OCCC)=O)C=C3)=O)C2=O	Smo receptor agonist	Smoothened (Smo) receptor agonist (EC50 = 1.2 _M). Does not recognize the classic cyclopamine (Cat. No. 1623) binding site. Does not promote Smo translocation to the primary cilium; is strongly potentiated by forskolin and cholera toxin. Promotes differentiation of multipotent mesenchymal progenitor cells into osteoblasts.	"Gorojankina et al (2013) Discovery, molecular and pharmacological characterization of GSA-10, a novel small-molecule positive modulator of Smoothened. Mol.Pharmacol. 83 1020. PMID:23448715."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=379159				Jul-2013
4920	Methoxy-X04	[863918-78-9]	OC(C=C3)=CC=C3/C=C/C1=CC(OC)=C(/C=C/C2=CC=C(O)C=C2)C=C1	Fluorescent amyloid _ detector; brain penetrant	"Fluorescent amyloid _ (A_) probe for the detection and quantification of plaques, tangles and cerebrovascular amyloid. Displays high in vitro binding affinity (Ki = 26.8 nM); binds selectively to fibrillar _-sheet deposits. Brain penetrant."	"Klunk et al (2002) Imaging A_ plaques in living transgenic mice with multiphoton microscopy and methoxy-X04, a systemically administered Congo red derivative. J.Neuropathol.Exp.Neurol. 61 797. PMID:12230326. Bolmont et al (2008) Dynamics of the microglial/amyloid interaction indicate a role in plaque maintenance. J.Neurosci. 28 4283. PMID:18417708. Yamanaka et al (2012) PPAR_/RXR_-induced and CD36-mediated microglial amyloid-_ phagocytosis results in cognitive improvement in amyloid precursor protein/presenilin 1 mice. J.Neurosci. 32 17321. PMID:23197723."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=380689				Jun-2013
4921	Leukadherin 1	[344897-95-6]	S=C(N(CC3=CC=CC=C3)C2=O)S/C2=C\C1=CC=C(C4=CC=C(C(O)=O)C=C4)O1	Allosteric activator of CD11b/CD18	"Allosteric activator of CD11b/CD18. Increases CD11b/CD18-dependent cell adhesion to fibrinogen (EC50 = 4 _M). Decreases leukocyte motility and transendothelial migration; reduces inflammation. Also activates complement receptor 3 (CR3), and promotes CR3-dependent leukocyte adhesion to fibrinogen-coated surfaces."	Maiguel et al (2011) Small molecule-mediated activation of the integrin CD11b/CD18 reduces inflammatory disease. Sci.Signal. 4 1. PMID:21900205. Reed et al (2013) Complement receptor 3 influences Toll-like receptor 7/8-dependent inflammation. J.Biol.Chem. 288 9077. PMID:23386618.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=380692				Jul-2013
4923	Shz 1	[326886-05-9]	OC1=C(/C=N/NS(C2=CC=CC=C2)(=O)=O)C=C(Br)C=C1	Activator of early cardiac genes in pluripotent stem cells; induces differentiation in M-PBMCs	Activator of early cardiac genes (including Nkx2.5) in pluripotent stem cells. Induces phenotypic differentiation in human mobilized peripheral blood mononuclear cells. Enhances myocardial regenerative repair by stem cells in a rat myocardial cryoinjury model.	Sadek et al (2008) Cardiogenic small molecules that enhance myocardial repair by stem cells. Proc.Natl.Acad.Sci.U.S.A. 105 6063. PMID:18420817.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=380694	SQ1341			Sep-2013
4927	AS 1892802	[928320-12-1]	O=C(N[C@H](CO)C3=CC=CC=C3)NC(C=C2)=CC=C2C1=CC=NC=C1	Potent ROCK inhibitor; orally bioavailable	"Potent, ATP-competitive ROCK inhibitor (IC50 values are 52, 57 and 122 nM for human ROCK2, rat ROCK2 and human ROCK1 respectively by ELISA); also inhibits PKAC-_ and PRKX (IC50 values are 200 and 325 nM respectively). Exhibits analgesic effects in rat models of inflammatory (AIA) and noninflammatory (MIA) arthritic pain. Orally bioavailable."	"Yoshimi et al (2010) Antinociceptive effects of AS1892802, a novel Rho kinase inhibitor, in rat models of inflammatory and noninflammatory arthritis. J.Pharmacol.Exp.Ther. 334 955. PMID:20534789. Li et al (2012) Fragment-based and structure-guided discovery and optimization of Rho kinase inhibitors. J.Med.Chem. 55 2474. PMID:22272748."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=381210	SQ1341			Sep-2013
4928	OXF BD 02	[1429129-68-9]	OC1=CC(C2=C(C)ON=C2C)=CC(C(O)C3=CC=CC=C3)=C1	Selective BRD4(1) inhibitor	Selective inhibitor of the first bromodomain of BRD4 (BRD4(1)) (IC50 = 382 nM). Exhibits 2-3-fold selectivity for BRD4(1) over the CBP bromodomain and has little affinity for a range of other bromodomains. Reduces viability of lung adenocarcinoma cell lines and attenuates proliferation of MV-4-11 leukemia cells. Cell permeable.	"Hewings et al (2011) 3,5-dimethylisoxazoles act as acetyl-lysine-mimetic bromodomain ligands. J.Med.Chem. 54 6761. PMID:21851057. Hewings et al (2013) Optimization of 3,5-dimethylisoxazole derivatives as potent bromodomain ligands. J.Med.Chem. 56 3217. PMID:23517011."	Small Molecule	Sold with the agreement of the University of Oxford	http://www.tocris.com/dispprod.php?ItemId=381312				Oct-2014
4931	EG 00229	[1018927-63-3]	O=S(C1=CC=CC2=NSN=C12)(NC3=C(C(N[C@H](C(O)=O)CCCNC(N)=N)=O)SC=C3)=O	Neuropilin 1 (NRP1) receptor antagonist; inhibits VEGFA binding to NRP1	Neuropilin 1 (NRP1) receptor antagonist; inhibits VEGFA binding to the NRP1 b1 domain. Has no effect on VEGFA binding to VEGFR-1 and VEGFR-2. Reduces VEGFA-induced VEGFR-2 tyrosine phosphorylation in HUV-EC-C endothelial cells. Also attenuates VEGFA-induced HUV-EC-C cell migration and reduces A549 lung carcinoma cell viability in vitro. Increases chemo-sensitivity of A549 cells in combination with Taxol (Cat. No. 1097).	Jarvis et al (2010) Small molecule inhibitors of the neuropilin-1 vascular endothelial growth factor A (VEGF-A) interaction. J.Med.Chem. 53 2215. PMID:20151671.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=381533				Oct-2014
4934	MA 2029	[287206-61-5]	FC1=CC=C(C[C@H](NC)C(N(C)[C@@H]([C@H](C)C)C(N[C@@H](CC2=CC=C(O)C(C(C)(C)C)=C2)[C@@](NCC)=O)=O)=O)C=C1	"Potent and selective, competitive motilin receptor antagonist; orally active"	"Potent and selective, competitive motilin receptor antagonist (IC50 = 4.9 nM). Selective for the motilin receptor over a range of other receptors and ion channels. Inhibits motilin-induced duodenal muscle contractions in vitro. Also inhibits motilin-induced colonic and abdominal contractions in vivo. Orally active."	"Sudo et al (2008) Oral administration of MA-2029, a novel selective and competitive motilin receptor antagonist, inhibits motilin-induced intestinal contractions and visceral pain in rabbits. Eur.J.Pharmacol. 581 296. PMID:18164286."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=381911	SQ1070			May-2014
4935	Sulfasalazine	[599-79-1]	OC1=CC=C(/N=N/C2=CC=C(S(NC3=NC=CC=C3)(=O)=O)C=C2)C=C1C(O)=O	Inhibitor of NF-_B activation; also inhibits SXC	"Inhibitor of NF-_B activation. Inhibits in vitro growth of the human pancreatic cancer cell lines MIA PaCa-2 and PANC-1, and induces apoptosis in glioblastoma cell lines. Also inhibits the cystine-glutamate antiporter, system Xc (SXC). Anti-inflammatory."	"Robe et al (2004) In vitro and in vivo activity of the nuclear factor-_B inhbitor sulfasalazine in human glioblastomas. Clin.Cancer Res. 10 5595. PMID:15328202. Lo et al (2010) Potential use fo the anti-inflammatory drug, sulfasalazine, for targeted therapy of pancreatic cancer. Curr.Oncol. 17 9. PMID:20567622. Sontheimer and Bridges (2012) Sulfasalazine for brain cancer fits. Expert Opin.Invest.Drugs 21 575. PMID:22404218."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=381912	SQ1533			Jun-2013
4936	Clozapine N-oxide	[34233-69-7]	ClC(C=C3)=CC1=C3NC(C=CC=C2)=C2C(N4CC[N+](C)([O-])CC4)=N1	Clozapine (Cat. No. 0444) metabolite	Metabolite of clozapine (Cat. No. 0444).	Eiermann et al (1997) The involvement of CYP1A2 and CYP3A4 in the metabolism of clozapine. Br.J.Clin.Pharmacol. 44 439. PMID:9384460. Zhang et al (2007) Impaired microsomal oxidation of the atypical antipsychotic agent clozapine in hepatic steatosis. J.Pharmacol.Exp.Ther. 322 770. PMID:17522342.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=381913	SQ1341			Dec-2013
4941	PKI 166 hydrochloride		OC(C=C3)=CC=C3C2=CC1=C(N[C@@H]([C@]4=CC=CC=C4)C)N=CN=C1N2.Cl	Potent EGFR-kinase inhibitor	Potent EGFR-kinase inhibitor (IC50 = 0.7 nM). Displays >3000-fold selectivity against a panel of serine/threonine kinases. Reduces metastasis and angiogenesis in a mouse model of pancreatic cancer. Antihypertensive and orally bioavailable.	"Bruns et al (2000) Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma. Cancer Res. 60 2926. PMID:10850439. Kaspersen et al (2012) Activity of 6-aryl-pyrrolo[2,3-d]pyrimidine-4-amines to Tetrahymena. Bioorg.Chem. 44 35. PMID:22832269. Ulu et al (2013) Epidermal growth factor receptor inhibitor PKI-166 governs cardiovascular protection without beneficial effects on the kidney in hypertensive 5/6 nephrectomized rats. J.Pharmacol.Exp.Ther. 345 393. PMID:23528611."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=383279				Jan-2015
4942	Pitavastatin calcium	[147526-32-7]	[Ca++].O[C@H](C[C@H](O)\C=C\C1=C(C2=CC=C(F)C=C2)C2=CC=CC=C2N=C1C1CC1)CC([O-])=O.O[C@H](C[C@H](O)\C=C\C1=C(C2=CC=C(F)C=C2)C2=CC=CC=C2N=C1C1CC1)CC([O-])=O	HMG-CoA reductase inhibitor	"Synthetic inhibitor of HMG-CoA reductase (Ki = 1.7 nM). Lowers low-density lipoprotein (LDL) cholesterol levels. Displays minimal metabolism by cytochrome P450 enzymes, with little involvement of CYP3A4. Shown to improve cardiac function and survival in a rat model of hypertensive heart failure."	Aoki et al (1997) Pharmacological profile of a novel synthetic inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. Arzneimittelforschung. 47 904. PMID:9296275. Mukhtar et al (2005) Pitavastatin. Int.J.Clin.Pract. 59 239. PMID:15854203. Saka et al (2006) Pitavastatin improves cardiac function and survival in association with suppression of the myocardial endothelin system in a rat model of hypertensive heart failure. J.Cardiovasc.Pharmacol. 47 770. PMID:16810078.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=383281	SQ1533			Jul-2013
4945	ML 347	[1062368-49-3]	COC(C=C3)=CC=C3C(C=N2)=CN1C2=C(C4=CC=CC5=C4C=CC=N5)C=N1	Potent and selective ALK1 and ALK2 inhibitor	"Potent and selective ALK2 and ALK1 inhibitor (IC50 values are 32 and 46 nM, respectively); displays >200 fold selectivity over ALK3 and ALK6 and >400 fold selectivity over VEGF2. Exhibits no activity at ALK4, ALK5 or in a panel of related kinases. Inhibits BMP4 signaling in a functional assay (IC50 = 152 nM)."	Engers et al (2013) Synthesis and structure-activity relationships of a novel and selective bone morphogenetic protein receptor (BMP) inhibitor derived from the pyrazolo[1.5-a]pyrimidine scaffold of dorsomorphin: the discovery of ML347 as an ALK2 versus ALK3 selective MLPCN probe. Bioorg Med Chem Lett. 23 3248. PMID:23639540.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=383361	SQ1341			Jun-2014
4946	AIM 100	[873305-35-2]	C1(C(C4=CC=CC=C4)=C(C5=CC=CC=C5)O3)=C3N=CN=C1NC[C@H]2OCCC2	Potent and selective Ack1 inhibitor	"Potent Ack1 inhibitor (IC50 = 22 nM). Exhibits selectivity for Ack1 over ABL1, BTK, Lck and LYN; exhibits no inhibition of 25 other kinases. Suppresses phosphorylation of Tyr267 of the androgen receptor in prostate cancer cells. Also suppresses growth of radioresistant castration-resistant prostate cancer in xenograft tumors in mice."	Mahajan et al (2010) Effect of Ack1 tyrosine kinase inhibitor on ligand-independent androgen receptor activity. Prostate 70 1274. PMID:20623637. Mahajan et al (2012) Ack1-mediated androgen receptor phosphorylation modulates radiation resistance in castration-resistant prostate cancer. J.Biol.Chem. 287 22112. PMID:22566699.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=383362	SQ1070			Mar-2014
4948	CYM 50769	[1421365-63-0]	ClC(C=N4)=C(OC5=CC=C(OC)C=C5)C(N4C2C3=C(C=CC=C3)C1=CC=CC=C12)=O	Novel non-peptide NPBWR1 antagonist	"Novel non-peptide antagonist of neuropeptide W/B receptor 1 (NPBWR1, GPR7) (IC50 = 0.12 _M)."	Guerrero et al (2013) SAR analysis of novel non-peptidic NPBWR1 (GPR7) antagonists. Bioorg.Med.Chem.Lett. 23 614. PMID:23287738.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=383364	SQ1341			Jan-2014
4949	MaxiPost	[187523-35-9]	O=C2[C@]([C@]3=CC(Cl)=CC=C3OC)(F)C1=CC=C(C(F)(F)F)C=C1N2	Potassium channel modulator; exerts subtype-specific effects	Potassium channel modulator. Acts as a positive modulator at neuronal Kv7 channels and calcium-activated K+ channels (BKCa) in HEK293 cells. Displays negative modulatory activity at Kv7.1 channels (Ki = 3.7 _M) and GABAA receptors. Displays anxiolytic activity in vivo.	Korsgaard et al (2005) Anxiolytic effects of Maxipost (BMS-204352) and retigabine via activation of neuronal Kv7 channels. J.Pharmacol.Exp.Ther. 314 282. PMID:15814569. Hamashima et al (2005) Catalytic enantioselective fluorination of oxindoles. J.Am.Chem.Soc. 127 10164. PMID:16028916. Jepps et al (2012) One man's side effect is another man's therapeutic opportunity: targeting Kv7 channels in smooth muscle disorders. Br.J.Pharmacol. 168 19. PMID:22880633.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=383718	SQ1070			Apr-2014
4950	ICA 110381	[325457-99-6]	O=C(NC2=CC=C(Cl)N=C2)C1=CC=C(Cl)C=C1	KV7.2/7.3 activator; displays anticonvulsant properties	"KV7.2/7.3 activator (EC50 = 0.38 _M). Decreases neuronal excitability in CA1 hippocampal neurons. Exhibits anticonvulsive properties in amygdala-kindled rats, a model for complex partial seizures."	Amato et al (2011) N-Pyridyl and Pyrimidine Benzamides as KCNQ2/Q3 Potassium Channel Openers for the Treatment of Epilepsy. ACS Med.Chem.Lett. 2 481. Boehlen et al (2013) The new KCNQ2 activator 4-Chlor-N-(6-chlor-pyridin-3-yl)-benzamid displays anticonvulsant potential. Br.J.Pharmacol. 168 1182. PMID:23176257.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=383719	SQ1341			Jul-2013
4951	SA 4503 dihydrochloride	[165377-44-6]	COC1=C(OC)C=CC(CCN2CCN(CCCC3=CC=CC=C3)CC2)=C1.Cl.Cl	Selective _1 receptor agonist	Selective _1 receptor agonist (IC50 = 17.4 nM). Exhibits 100-fold greater selectivity for _1 over _2 receptors. Inhibits angiotensin II-induced cardiomyocyte hypertrophy in vitro; attenuates myocardial hypertrophy following chronic administration in vivo. Enhances brain plasticity and sensorimotor function following experimental stroke in vivo.	"Matsuno et al (1996) Binding properties of SA4503, a novel and selective sigma 1 receptor agonist. Eur.J.Pharmacol. 306 271. PMID:8813641. Ruscher (2011) The sigma-1 receptor enhances brain plasticity and functional recovery after experimental stroke. Brain 134 732. PMID:21278085. Tagashira et al (2013) Stimulation of s1-receptor restores abnormal mitochondrial Ca2+ mobilization and ATP production following cardiac hypertrophy. Biochim.Biophys.Acta 1830 3082. PMID:23298811."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=383720	SQ1070			Feb-2014
4952	TRAM 39	[197525-99-8]	ClC(C=CC=C3)=C3C(C2=CC=CC=C2)(C#N)C1=CC=CC=C1	Potent KCa3.1 blocker	Potent intermediate conductance Ca2+-activated K+ channel (KCa3.1) blocker (Kd = 60 nM). Has no effect on cytochrome p450 activity. Inhibits I-EBIO-stimulated increases in rat artery membrane potential ex vivo. Also diminishes LPS-induced cryptidin (mammalian _-defensin) release from paneth cells in vitro.	"Wulff et al (2000) Design of a potent and selective inhibitor of the intermediate-conductance Ca2+-activated K+ channel, IKCa1: a potential immunosuppressant. Proc.Natl.Acad.Sci.U.S.A. 97 8151. PMID:10884437. Ayabe et al (2002) Modulation of mouse Paneth cell alpha-defensin secretion by mIKCa1, a Ca2+-activated, intermediate conductance potassium channel. J.Biol.Chem. 277 3793. PMID:11724775. Burnham et al (2006) Impaired small-conductance Ca2+-activated K+ channel-dependent EDHF responses in Type II diabetic ZDF rats. Br.J.Pharmacol. 148 434. PMID:16682967."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=383730				Aug-2014
4953	CHIR 99021 trihydrochloride		ClC(C=C3Cl)=CC=C3C1=NC(NCCNC4=CC=C(C#N)C=N4)=NC=C1C2=NC(C)=CN2.Cl.Cl.Cl	Hydrochloride salt of CHIR 99021 (Cat. No. 4423); selective GSK-3 inhibitor	"Hydrochloride salt of CHIR 99021 (Cat. No. 4423), a highly selective GSK-3 inhibitor."	Ring et al (2003) Selective glycogen synthase kinase 3 inhibitors potentiate insulin activation of glucose transport and utilization in vitro and in vivo. Diabetes 52 588. PMID:12606497. Pan et al (2011) AKT kinase activity is required for lithium to modulate mood-related behaviors in mice. Neuropsychopharmacology 36 1397. PMID:21389981. Ye et al (2012) Pleiotropy of glycogen synthase kinase-3 inhibition by CHIR99021 promotes self-renewal of embyronic stem cells from refractory mouse strains. PLoS One 7 e35892. PMID:22540008.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=383732				Nov-2013
4954	UAMC 00039 dihydrochloride	[697797-51-6]	O=C([C@@H](N)CCNCC2=CC=C(Cl)C=C2)N1CCCCC1.Cl.Cl	Dipeptidyl peptidase II (DPP-II) inhibitor	"Potent inhibitor of dipeptidyl peptidase II (DPP-II) (IC50 = 0.48 nM). Exhibits selectivity for DPP-II against DPP-9, DPP-8 and DPP-IV (IC50 values are 78.6, 142 and 165 _M, respectively). Orally available."	"Maes et al (2007) Dipeptidyl peptidase 8/9-like activity in human leukocytes. J.Leukoc.Biol. 81 1252. PMID:17287297. Van Goethem et al (2011) Structure-activity relationship studies on isoindoline inhibitors of dipeptidyl peptidases 8 and 9 (DPP8, DPP9): is DPP8-selectivity an attainable goal? J.Med.Chem. 54 5737. PMID:21711053."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=383776	SQ1341			Dec-2013
4958	Eplivanserin hemifumarate	[130580-02-8]	OC(C=C2)=CC=C2/C=C/C(C1=CC=CC=C1F)=N/OCCN(C)C.O=C(/C=C/C(O)=O)O.OC(C=C4)=CC=C4/C=C/C(C3=CC=CC=C3F)=N/OCCN(C)C	Potent and selective 5-HT2A antagonist	"Potent and selective 5-HT2A antagonist (IC50 values are 5.8 and 120 and >100 nM for 5-HT2A, 5-HT2B and 5-HT2C, respectively). Attenuates cocaine-induced hyperactivity. Increases dopamine (DA) release in rat medial prefrontal cortex (mPFC); potentiates haloperidol-induced DA release in the mPFC and nucleus accumbens."	"Bonaccorso et al (2002) SR46349-B, a 5-HT(2A/2C) receptor antagonist, potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens. Neuropsychopharmacology. 27 430. PMID:12225700. Filip et al (2004) Contribution of serotonin (5-hydroxytryptamine; 5-HT) 5-HT2 receptor subtypes to the hyperlocomotor effects of cocaine: acute and chronic pharmacological analyses. J.Pharmacol.Exp.Ther. 310 1246. PMID:15131246. Yadav et al (2011) Antagonist functional selectivity: 5-HT2A serotonin receptor antagonists differentially regulate 5-HT2A receptor protein level in vivo. J.Pharmacol.Exp.Ther. 339 99. PMID:21737536."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=384569				Nov-2014
4959	CID 16020046	[834903-43-4]	O=C1N(C5=CC=C(C(O)=O)C=C5)C(C4=CC=CC(O)=C4)C2=C1NN=C2C3=CC=C(C)C=C3	Selective GPR55 antagonist	"Selective GPR55 antagonist. Inhibits LPI-induced Ca2+ signaling (IC50 = 0.21 _M in HEK-GPR55 cells), ERK1/2 phosphorylation and GPR55-mediated transcription factor activation. Displays weak inhibition of acetylcholinesterase, _-opioid receptor, KCNH2 and hERG. Decreases LPI-induced GPR55 internalization."	Kargl et al (2013) A selective antagonist reveals a potential role of G protein-coupled receptor 55 in platelet and endothelial cell function. J.Pharmacol.Exp.Ther. 346 54. PMID:23639801.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=384639	SQ1341			Sep-2013
4962	SB 204990	[154566-12-8]	ClC(C=C(Cl)C=C2)=C2CCCCCC[C@@H](OC1=O)C[C@]1(O)CC(O)=O	ATP-citrate lyase (ACL) inhibitor	ATP-citrate lyase (ACL) inhibitor. Prodrug of SB 201076. Inhibits cholesterol and fatty acid synthesis in a dose-dependent manner in HepG2 cells. Orally active in vivo.	"Pearce et al (1998) The role of ATP citrate-lyase in the metabolic regulation of plasma lipids. Hypolipidaemic effects of SB-204990, a lactone prodrug of the potent ATP citrate-lyase inhibitor SB-201076. Biochem.J. 334 113. PMID:9693110. Gribble et al (1998) ATP-Citrate lyase as a target for hypolipidemic intervention. 2. Synthesis and evaluation of (3R*,5S*)-_-substituted-3-carboxy-3, 5-dihydroxyalkanoic acids and their gamma-lactone prodrugs as inhibitors of the enzyme in vitro and in vivo. J.Med.Chem. 41 3582. PMID:9733484."	Small Molecule	Sold for research purposes under agreement from GlaxoSmithKline	http://www.tocris.com/dispprod.php?ItemId=384931	SQ1341			Oct-2013
4963	SC 144 hydrochloride	[917497-70-2]	O=C(C4=CN=CC=N4)NNC1=NC(C=C(F)C=C3)=C3N2C1=CC=C2.Cl	gp130 inhibitor; blocks cytokine-triggered gp130 signaling	"Inhibitor of gp130 (IC50 = 0.72 _M); blocks cytokine-triggered gp130 signaling. Induces gp130 phosphorylation and down regulates gp130 glycosylation; also abrogates STAT3 phosphorylation, nuclear translocation and inhibits the expression of downstream target genes. Delays tumor growth in a mouse xenograft model of human ovarian cancer. Orally active."	Xu et al (2013) Discovery of a novel orally active small-molecule gp130 inhibitor for the treatment of ovarian cancer. Mol.Cancer Ther. 12 937. PMID:23536726.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=384974				Aug-2014
4964	R 1485 dihydrochloride		FC(C=CC=C4)=C4S(N2CCOC1=C(N3CCNCC3)C=CC=C12)(=O)=O.Cl.Cl	Selective and high affinity 5-HT6 antagonist	Selective and high affinity 5-HT6 antagonist (pKi = 8.9); displays low hERG inhibition. Exhibits >100 fold selectivity against a panel of 50 targets including other 5-HT receptor subtypes. Brain penetrant.	"Zhao et al (2007) 3,4-Dihydro-2H-benzo[1,4]oxazine derivatives as 5-HT6 receptor antagonists. Bioorg.Med.Chem.Lett. 17 3504. PMID:17485206. Liu et al (2009) 5-HT6 antagonists as potential treatment for cognitive dysfunction. Drug Des.Rev. 70 145."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=385007	SQ1070			May-2014
4965	PD 180970	[287204-45-9]	CN(C(C(C4=C(Cl)C=CC=C4Cl)=C3)=O)C1=C3C=NC(NC2=CC(C)=C(F)C=C2)=N1	p210bcr/abl kinase inhibitor; also inhibits c-Src and KIT	"ATP-competitive inhibitor of p210bcr/abl tyrosine kinase; selectively induces apoptosis in chronic myeloid leukemia (CML) K562 cells. Inhibits in vivo tyrosine phosphorylation of Gab2, CrkL and p210bcr/abl (IC50 values are 80, 80 and 170 nM respectively). Potently inhibits p210bcr/abl autophosphorylation in vitro (IC50 = 5 nM). Also potently inhibits c-Src and KIT (IC50 values are 0.8 and 50 nM, respectively)."	"Dorsey et al (2000) The pyrido[2,3-d]pyrimidine derivative PD180970 inhibits p210bcr-abl tyrosine kinase and induces apoptosis of K562 leukemic cells. Cancer Res. 60 3127. PMID:10866298. La Rose et al (2002) Activity of the Bcr-Abl kinase inhibitor PD180970 against clinically relevant Bcr-Abl isoforms that cause resistance to imatinib mesylate (Gleevec, STI571). Cancer Res. 62 7149. PMID:12499247. Corbin et al (2004) Sensitivity of oncogenic KIT mutants to the kinase inhibitors MLN518 and PD180970. Blood 104 3754. PMID:15304388."	Small Molecule	Sold for research purposes under agreement from Pfizer Inc.	http://www.tocris.com/dispprod.php?ItemId=385012	SQ1341			Jul-2013
4969	LY 2389575 hydrochloride	[885104-09-6]	ClC1=CC(Cl)=CC=C1CN[C@@H]2CN(C3=NC=C(Br)C=N3)CC2.Cl	Selective negative allosteric modulator of mGlu3	Selective negative allosteric modulator of mGlu3 (IC50 = 190 nM). Exhibits > 65-fold selectivity for mGlu3 over other mGlu receptors. Abolishes the neuroprotective action of LY 379268 against amyloid _ toxicity in mixed cortical neuronal and astrocyte cell cultures.	"Caraci et al (2011) Targeting group II metabotropic glutamate (mGlu) receptors for the treatment of psychosis associated with Alzheimer's disease: selective activation of mGlu2 receptors amplifies beta-amyloid toxicity in cultured neurons, whereas dual activation of mGlu2 and mGlu3 receptors is neuroprotective. Mol.Pharmacol. 79 618. PMID:21159998."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=385145	SQ1070			Apr-2014
4972	JIB 04	[199596-05-9]	ClC(C=C3)=CN=C3N/N=C(C2=CC=CC=C2)/C1=CC=CC=N1	Pan Jumonji histone demethylase inhibitor; active in vivo	"Pan Jumonji histone demethylase inhibitor (IC50 values are 230, 340, 435, 445, 855 and 1100 nM for JARID1A, JMJD2E, JMJD2B, JMJD2A, JMJD3 and JMJD2C respectively). Exhibits negligible activity at PHD2 and TET1. Selectively blocks cancer cell growth in vitro and diminishes tumor growth in H358 and A549 mouse xenograft models in vivo. Prolongs survival in a mouse model of breast cancer."	Grunicke and Hofmann (1997) Azinyl and diazinyl hydrazones derived from aryl N-heteroaryl ketones: synthesis and antiproliferative activity. J. Med. Chem. 40 4420. PMID:9435912. Wang et al (2013) A small molecule modulates Jumonji histone demethylase activity and selectively inhibits cancer growth. Nat. Commun. 4 2035. PMID:23792809.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=385325				Nov-2013
4975	CRT 0066101		OC1=C(C3=NC(NC[C@@H](CC)N)=CC=N3)C=C(C2=CN(C)N=C2)C=C1.Cl.Cl.Cl	Potent protein kinase D (PKD) inhibitor	"Potent inhibitor of protein kinase D (PKD); inhibits all PKD isoforms (IC50 values are 1, 2 and 2.5 nM for PKD1, PKD3 and PKD2 respectively). Exhibits selectivity for PKD against a panel of >90 protein kinases, including PKC_, MEK, ERK, c-Raf and c-Src. Reduces proliferation and cell viability of pancreatic cancer cells expressing moderate levels of endogenous PKD1/2. Orally bioavailable."	Harikumar et al (2010) A novel small molecule inhibitor of protein kinase D blocks pancreatic cancer growth in vitro and in vivo. Mol.Cancer Ther. 9 1136. PMID:20442301. Ni et al (2013) PKD1 mediates negative feedback of PI3K/Akt activation in response to G protein-coupled receptors. PLoS ONE 9 e73149. PMID:24039875.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=385335				Dec-2013
4976	ML 289	[1382481-79-9]	O=C(N3CCC[C@@H](CO)C3)C(C=C2)=CC=C2C#CC1=CC=C(OC)C=C1	Selective negative allosteric modulator of mGlu3	Selective negative allosteric modulator at mGlu3 receptors (IC50 = 660 nM). Exhibits 15-fold selectivity for mGlu3 over mGlu2. Centrally penetrant.	"Sheffler et al (2012) Development of a novel, CNS-penetrant, metabotropic glutamate receptor 3 (mGlu3) NAM probe (ML289) derived from a closely related mGlu5 PAM. Bioorg.Med.Chem.Lett. 22 3921. PMID:22607673."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=385437	SQ1070			Mar-2014
4977	RN 1 dihydrochloride		O=C(N4CCN(C)CC4)CN[C@@H]1C[C@H]1[C@]2=CC=C(OCC3=CC=CC=C3)C=C2.Cl.Cl	LSD1 inhibitor	"Inhibitor of lysine specific demethylase 1 (LSD1); exhibits selectivity for LSD1 over monoamine oxidase (MAO)-A and MAO-B (IC50 values are 70 nM, 0.51 and 2.79 _M respectively, in a horseradish peroxidase-coupled assay). Shown to impair long-term, but not short-term memory in mice. Brain penetrant following systemic administration."	Neelamegam et al (2012) Brain-penetrant LSD1 inhibitors can block memory consolidation. ACS Chem.Neurosci. 3 120. PMID:22754608.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=385438	SQ1070			Feb-2014
4978	Pyrintegrin	[1228445-38-2]	OC(C=C3)=CC2=C3N(CCC2)C1=NC(NC4=CC=C(S(NCC5CC5)(=O)=O)C=C4)=NC=C1	Enhances survival of human ESCs following enzymatic dissociation	"Enhances survival of human embryonic stem cells (hESCs) following enzymatic dissociation. Thought to enhance cell-ECM adhesion and activate integrin signaling. Increases adhesion of hESCs to matrigel- and laminin-coated plates, but not to gelatin-coated plates."	Xu et al (2010) Revealing a core signaling regulatory mechanism for pluripotent stem cell survival and self-renewal by small molecules. Proc.Natl.Acad.Sci.USA 107 8129. PMID:20406903.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=385439	SQ1070			May-2014
4979	Methylmalonate	[516-05-2]	OC(C(C)C(O)=O)=O	Succinate dehydrogenase inhibitor	"Intracellularly produces malonate, a reversible succinate dehydrogenase inhibitor used to generate Huntington's disease models. Induces apoptotic cell death in striatal neurons."	McLaughlin et al (1998) Methylmalonate toxicity in primary neuronal cultures. Neuroscience 86 279. PMID:9692761. Beal and Ferrante (2004) Experimental therapeutics in transgenic mouse models of Huntington's disease. Nat.Rev.Neurosci. 5 373. PMID:15100720. Ehrlich (2012) Huntington's disease and the striatal medium spiny neuron: cell-autonomous and non-cell-autonomous mechanisms of disease. Neurotherapeutics 9 270. PMID:22441874.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=385440				Jul-2013
4981	Cystamine dihydrochloride	[56-17-7]	NCCSSCCN.Cl.Cl	Transglutaminase inhibitor; neuroprotective	"Transglutaminase inhibitor. Attenuates cell death induced by 3-nitropropionic acid (Cat. No. 4849) in Huntington's disease (HD) striatal cells. Also decreases aggregated and cross-linked huntingtin in transfected cells, and increases brain levels of BDNF. Shown to extend survival and improve motor performance in transgenic HD mice. Neuroprotective."	Dedeoglu et al (2002) Therapeutic effects of cystamine in a murine model of Huntington's disease. J.Neurosci. 22 8942. PMID:12388601. Mao et al (2006) Cystamine and cysteamine prevent 3-NP-induced mitochondrial depolarization of Huntington's disease knock-in striatal cells. Eur.J.Neurosci. 23 1701. PMID:16623826. Borrell-Pages et al (2006) Cystamine and cysteamine increase brain levels of BDNF in Huntington disease via HSJ1b and transglutaminase. J.Clin.Invest. 116 1410. PMID:16604191.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=385442				Jul-2013
4982	ML 337	[1443118-44-2]	O=C(N1CCC[C@@H](O)C1)C(C(F)=C2)=CC=C2C#CC3=CC=C(OC)C=C3	Selective negative allosteric modulator of mGlu3	"Selective negative allosteric modulator of mGlu3 (IC50 = 593 nM). Displays no activity at mGlu1, mGlu2 or mGlu4-8 at concentrations up to 30 _M. Brain penetrant."	"Wenthur et al (2013) Discovery of (R)-(2-fluoro-4-((-4-methoxyphenyl)ethynyl)phenyl) (3-hydroxypiperidin-1-yl)methanone (ML337), an mGlu3 selective and CNS penetrant negative allosteric modulator (NAM). J.Med.Chem. 56 5208. PMID:23718281."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=386696	SQ1341			Dec-2013
4983	ACT 335827	[1354039-86-3]	O=C(NC(C)C)[C@@H]([C@]4=CC=CC=C4)N2CCC1=CC(OC)=C(OC)C=C1[C@@H]2CC3=CC(OC)=C(OC)C=C3	Potent and selective OX1 antagonist	Potent and selective orexin OX1 receptor antagonist (Kb values are 41 and 560 nM for OX1 and OX2 receptors respectively). Elicits anxiolytic effects in vivo. Brain penetrant and orally available.	"Steiner et al (2013) Discovery and characterization of ACT-335827, an orally available, brain penetrant orexin receptor type 1 selective antagonist. ChemMedChem 8 898. PMID:23589487."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=387188	SQ1070			Mar-2014
4984	CK 869	[388592-44-7]	O=C1N(C3=CC=C(OC)C=C3OC)C(C2=CC=CC(Br)=C2)SC1	Arp2/3 inhibitor; inhibits actin polymerization	Inhibitor of human and bovine actin-related protein 2/3 (Arp2/3) complex. Inhibits actin polymerization (IC50= 11 _M). Does not inhibit budding or fission yeast Arp2/3 complexes.	Nolen et al (2009) Characterization of two classes of small molecule inhibitors of Arp2/3 complex. Nature 460 1031. PMID:19648907. Hetrick et al (2013) Small molecules CK-666 and CK-869 inhibit actin-related protein 2/3 complex by blocking an activating conformational change. Chem Biol. 20 701. PMID:23623350.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=387189	SQ1341			Oct-2013
4985	Miglitol	[72432-03-2]	OCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO	_-glucosidase inhibitor	Inhibitor of _-glucosidase; antihyperglycemic. Suppresses postprandial hyperglycemia in vivo and reduces plasma glucose concentration in normal rats and in several animal models of diabetes. Shown to inhibit the loss of pancreatic _ cells in type 2 diabetic rats. Also inhibits apoptosis and mitochondrial overproduction of reactive oxygen species in endothelial cells in vitro.	"Sels et al (1999) Miglitol, a new _-glucosidase inhibitor. Expert.Opin.Pharmacother. 1 149. PMID:11249557. Goda et al (2007) Effects of miglitol, an _-glucosidase inhibitor, on glycaemic staus and histopathological changes in islets in non-obese, non-insulin-dependent diabetic Goto-Kakizaki rats. Br.J.Nutr. 98 702. PMID:17537288. Aoki et al (2012) Miglitol, an anti-diabetic drug, inhibits oxdiative stress-induced apoptosis and mitochondrial ROS over-production in endothelial cells by enhancement of AMP-activated protein kinase. J.Pharmacol.Sci. 120 121. PMID:23018899."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=387190	SQ1533			Jul-2013
4986	K 02288	[1431985-92-0]	NC1=NC=C(C3=CC=CC(O)=C3)C=C1C2=CC(OC)=C(OC)C(OC)=C2	Type 1 BMP inhibitor	"Potent and selective inhibitor of type I bone morphogenic protein (BMP) receptors (IC50 values are 1.1, 1.8, 6.4, 34.4, 220, 302 and 321 nM for ALK2, ALK1, ALK6, ALK3, ActRIIA, ALK4 and ALK5 respectively). Reduces BMP4-induced Smad1/5/8 phosphorylation in vitro (IC50 = 100 nM) and induces dorsalization of zebrafish embryos."	Sanvitale et al (2013) A new class of small molecule inhibitor of BMP signaling. PLoS ONE 8 62721. PMID:23646137. Mohedas et al (2013) Development of an ALK2-biased BMP type I receptor kinase inhibitor. ACS Chem.Biol. 8 1291. PMID:23547776.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=387191	SQ1341			Dec-2013
4987	Ethacrynic acid - d5	[1330052-59-9]	O=C(C1=CC=C(OCC(O)=O)C(Cl)=C1Cl)C(C([2H])([2H])C([2H])([2H])[2H])=C	Deuterated ethacrynic acid	Deuterated ethacrynic acid. Used as an internal standard for GC- or LC-mass spectrometry.		Small Molecule		http://www.tocris.com/dispprod.php?ItemId=387192	SQ1533			Jul-2013
4989	Salirasib	[162520-00-5]	C\C(CC/C=C(C)/CC/C=C(C)/C)=C/CSC1=CC=CC=C1C(O)=O	Ras inhibitor; also induces autophagy	Inhibitor of active Ras proteins. Displaces active Ras from the plasma membrane; impairs downstream signaling and inhibits proliferation of endometrial carcinoma cells. Also facilitates Ras degradation. Shown to induce autophagy in several human cancer cell lines.	"Haklai et al (1998) Dislodgement and accelerated degradation of Ras. Biochemistry 37 1306. PMID:9477957. Schmukler et al (2013) Ras inhibition enhances autophagy, which partially protects cells from death. Oncotarget 4 142. PMID:23370967. Faigenbaum et al (2013) Growth of poorly differentiated endometrial carcinoma is inhibited by combined action of medroxyprogesterone acetate and the Ras inhibitor Salirasib. Oncotarget 4 316. PMID:23530112."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=387194	SQ1533			Nov-2013
4990	Stavudine	[3056-17-5]	[H]C1=C([H])[C@@H](O[C@@H]1CO)N1C=C(C)C(=O)NC1=O	Nucleoside analog; antiviral	Nucleoside analog; antiviral that inhibits HIV replication in vitro. Orally bioavailable.	"Baba et al (1987) Both 2',3'-dideoxythymidine and its 2',3'-unsaturated derivative (2',3'-dideoxythymidinene) are potent and selective inhibitors of human immunodeficiency virus replication in vitro. Biochem.Biophys.Res.Commun. 142 128. PMID:3028398. Riddler et al (1995) Antiretroviral activity of stavudine (2',3'-didehydro-3'-deoxythymidine, D4T). Antiviral Res. 27 189. PMID:8540743."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=387298	SQ1533			Jul-2013
4992	IWP L6	[1427782-89-5]	O=C1C3=C(CCS3)N=C(SCC(NC4=NC=C(C5=CC=CC=C5)C=C4)=O)N1C2=CC=CC=C2	Potent Porcn inhibitor	"Potent inhibitor of Porcupine (Porcn), a membrane-bound O-acyltransferase (MBOAT) (EC50 = 0.5 nM). Shown to inhibit Wnt-dependent processes such as tailfin regeneration and posterior axis formation in zebrafish; also reduces branching morphogenesis in cultured mouse embryonic kidneys."	Wang et al (2013) The development of highly potent inhibitors for Porcupine. J.Med.Chem. 56 2700. PMID:23477365.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=387300	SQ1341			Oct-2013
4993	NSC 624206	[13116-77-3]	ClC1=CC=C(CSSCCNCCCCCCCCCC)C=C1.Cl	Ubiquitin-activating enzyme (E1) inhibitor	"Ubiquitin-activating enzyme (E1) inhibitor; prevents tumour suppressor protein p27 ubiquitination in vitro. Blocks the ubiquitin-thioester formation step of the E1 activation reaction, but displays no effect on ubiquitin adenylation."	Ungermannova et al (2012) Identification and mechanistic studies of a novel ubiquitin E1 inhibitor. J.Biomol.Screen. 17 421. PMID:22274912.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=387301				Jul-2014
4994	PYZD 4409	[423148-78-1]	FC(C=C3)=C(Cl)C=C3N(C(/C1=C\C2=CC=C([N+]([O-])=O)O2)=O)NC1=O	Ubiquitin-activating enzyme (E1) inhibitor	Ubiquitin-activating enzyme (E1) inhibitor. Blocks degradation of p53 and cyclin D3. Inhibits NF-_B activation and induces cell death associated with ER stress. Displays antitumor effects in a mouse model of leukemia.	Xu et al (2010) The ubiquitin-activating enzyme E1 as a therapeutic target for the treatment of leukemia and multiple myeloma. Blood 115 2251. PMID:20075161.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=387302	SQ1070			Feb-2014
4995	Phortress	[328087-38-3]	FC1=CC=C2C(N=C(C3=CC=C(NC([C@H](CCCCN)N)=O)C(C)=C3)S2)=C1.Cl.Cl	Prodrug of the antitumor agent 5F 203	"Prodrug of the antitumor agent 5F 203, which acts via binding to aryl hydrocarbon receptors. Induces expression of CYP1A1 and generates adducts in the DNA of sensitive MCF7 and IGROV-1 cells."	"Leong et al (2003) Antitumour 2-(4-aminophenyl)benzothiazoles generate DNA adducts in sensitive tumour cells in vitro and in vivo. Br.J.Cancer 88 470. PMID:12569393. Trapani et al (2003) DNA damage and cell cycle arrest induced by 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole (5F 203, NSC 703786) is attenuated by aryl hydrocarbon receptor deficient MCF-7 cells. Br.J.Cancer 88 599. PMID:12592376. Bradshaw and Westwell (2004) The development of the antitumour benzothiazole prodrug, phortress, as a clinical candidate. Curr.Med.Chem. 11 1241. PMID:15078163. Leong et al (2004) In vitro, in vivo and in silico analyses of the antitumor activity of 2(-4-amino-3-methylphenyl)-5-fluorobenzothiazoles. Mol.Cancer Ther. 3 1565. PMID:15634650."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=387303	SQ1341			Nov-2013
4996	PMX 464	[485842-97-5]	O=C(C=C3)C=CC3(O)C2=NC1=CC=CC=C1S2	Putative inhibitor of the Trx-TrxR system; antiproliferative	Putative inhibitor of the thioredoxin-thioredoxin reductase (Trx-TrxR) system. Shown to inhibit Trx and induce a G1/S block in HT29 cells; inhibits cell proliferation in various colorectal cancer cell lines and MCF7 cells. Also elicits an anti-inflammatory response in A549 cells.	"Mukherjee et al (2005) Cytotoxic and antiangiogenic activity of AW464 (NSC 706704), a novel thioredoxin inhibitor: an in vitro study. Br.J.Cancer 92 350. PMID:15655539. Mukherjee et al (2007) A cellular and molecular investigation of the action of PMX464, a putative thioredoxin inhibitor, in normal and colorectal cancer cell lines. Br.J.Pharmacol. 151 1167. PMID:17572693. Callister et al (2008) PMX464, a thiol-reactive quinol and putative thioredoxin inhibitor, inhibits NF-_B-dependent proinflammatory activation of alveolar epithelial cells. Br.J.Pharmacol. 155 661. PMID:18587424."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=387304	SQ1070			Dec-2013
4997	INDY	[1169755-45-6]	O=C(C)/C=C2SC1=CC=C(O)C=C1N/2CC	Dyrk1A/B inhibitor	"Dyrk1A/B inhibitor (IC50 values are 0.23 and 0.24 _M, for Dyrk1B and Dyrk1A respectively). Binds at the ATP-binding cleft of the enzyme. Reverses aberrant tau-phosphorylation and rescues repressed calcineurin/NFAT signaling. Impairs the self-renewal capacity of subventricular zone neural stem cells. Also available as a prodrug, proINDY (Cat. No. 4998)."	Ogawa et al (2010) Development of a novel selective inhibitor of the Down syndrome-related kinase Dyrk1A. Nat.Commun. 1 86. PMID:20981014. Pozo et al (2013) Inhibition of DYRK1A destabilizes EGFR and reduces EGFR-dependent glioblastoma growth. J.Clin.Invest. 123 2475. PMID:23635774.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=387305				Oct-2013
4998	ProINDY	[719277-30-2]	O=C(C)/C=C2SC1=CC=C(OC(C)=O)C=C1N/2CC	Dyrk1A/B inhibitor; prodrug of INDY (Cat. No. 4997)	Dyrk1A/B inhibitor; prodrug form of INDY (Cat. No. 4997). Cell permeable. Inhibits phosphorylation of tau protein and rescues repressed calcineurin/NFAT signaling. Recovers Xenopus embryos from head malformation induced by Dyrk1A overexpression in vivo.	Ogawa et al (2010) Development of a novel selective inhibitor of the Down syndrome-related kinase Dyrk1A. Nat.Commun. 1 86. PMID:20981014.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=387306				Oct-2013
4999	9-Phenanthrol	[484-17-3]	OC2=CC1=C(C3=C2C=CC=C3)C=CC=C1	Selective TRPM4 blocker	Selective TRPM4 blocker (IC50 = 20 _M in HEK293 cells). Exhibits no effect on CFTR or TRPM5 (at 0.25 and 1 mM respectively). Abolishes arrhythmias induced by hypoxia in a mouse heart model.	Grand et al (2008) 9-phenanthrol inhibits human TRPM4 but not TRPM5 cationic channels. Br.J.Pharmacol. 153 1697. PMID:18297105. Simard et al (2012) Transient receptor potential melastatin 4 inhibitor 9-phenanthrol abolishes arrhythmias induced by hypoxia and re-oxygenation in mouse ventricle. Br.J.Pharmacol. 165 2354. PMID:22014185.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=387307				Sep-2013
5000	FTIDC	[873551-53-2]	O=C(N(C(C)C)C)N1CC=C(C2=C(C)N(C3=C(F)N=CC=C3)N=N2)CC1	Potent and selective negative allosteric modulator at mGlu1; also mGlu1 inverse agonist	"Potent and selective mGlu1 receptor negative allosteric modulator (IC50 values are 5.8 and 6200 nM for mGlu1 and mGlu5 respectively). Also acts as an mGlu1 receptor inverse agonist (IC50 = 7 nM) in the absence of ligand. Exhibits no effect at group II/III mGlu receptors. Inhibits L-glutamate-induced increases in intracellular calcium in mGlu1-expressing CHO cells. Inhibits nociceptive behavior, and exhibits anxiolytic and antipsychotic effects in vivo. Orally active."	"Suzuki et al (2007) Pharmacological characterization of a new, orally active and potent allosteric metabotropic glutamate receptor 1 antagonist, 4-[1-(2-fluoropyridin-3-yl)-5-methyl-1H-1,2,3-triazol-4-yl]-N-isopropyl-N-methyl-3,6-dihydropyridine-1(2H)-carboxamide (FTIDC). J.Pharmacol.Exp.Ther. 321 1144. PMID:17360958. Ito et al (2008) Discovery and biological profile of 4-(1-aryltriazol-4-yl)-tetrahydropyridines as an orally active new class of metabotropic glutamate receptor 1 antagonist. Bioorg.Med.Chem. 16 9817. PMID:18849168. Satow et al (2008) Pharmacological effects of the metabotropic glutamate receptor 1 antagonist compared with those of the metabotropic glutamate receptor 5 antagonist and metabotropic glutamate receptor 2/3 agonist in rodents: detailed investigations with a selective allosteric metabotropic glutamate receptor 1 antagonist, FTIDC [4-[1-(2-fluoropyridine-3-yl)-5-methyl-1H-1,2,3-triazol-4-yl]-N-isopropyl-N-methyl-3,6-dihydropyridine-1(2H)-carboxamide]. J.Pharmacol.Exp.Ther. 326 577. PMID:18487514."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=387971				Jan-2015
5005	DR 4485 hydrochloride	[402942-53-4]	ClC1=C2C(C3(CCCCN4CCC(C5=CC=C(Cl)C=C5)=CC4)CCC2)=C(NC3=O)C=C1.Cl	High affinity and selective 5-HT7 antagonist; orally bioavailable	High affinity and selective 5-HT7 antagonist (pKi = 8.14). Exhibits selectivity for 5-HT7 over other 5-HT receptors. Inhibits 5-HT-induced cAMP accumulation in HEK-293 cells expressing the 5-HT7 receptor. Orally bioavailable.	Kikuchi et al (2003) New tetrahydrobenzindoles as potent and selective 5-HT(7) antagonists with increased In vitro metabolic stability. Bioorg.Med.Chem.Lett. 13 61. PMID:12467617. Medina et al (2009) Synthesis of new serotonin 5-HT7 receptor ligands. Determinants of 5-HT7/5-HT1A receptor selectivity. J.Med.Chem. 52 2384. PMID:19326916.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=388953	SQ1070			Jun-2014
5009	BMS 509744	[439575-02-7]	COC1=CC(C)=C(SC3=CN=C(NC(C4=CC=C(CNC(C)C(C)(C)C)C=C4)=O)S3)C=C1C(N2CCN(C(C)=O)CC2)=O	Potent and selective ITK inhibitor	Potent and selective interleukin-2 inducible T cell kinase (ITK) inhibitor (IC50 = 19 nM). Displays 200-fold selectivity over Tec family kinases and 55-fold selectivity over other kinases tested. Reduces HIV infection of primary CD4+ T cells and attenuates the establishment of HIV infection in vitro. Reduces T cell proliferation and IL-2 production in vitro. Reduces lung inflammation in a mouse model of ovalbumin-induced allergy/asthma.	Das et al (2006) Discovery and SAR of 2-amino-5-(thioaryl)thiazoles as potent and selective Itk inhibitors. Bioorg.Med.Chem.Lett. 16 3706. PMID:16682193. Readinger et al (2008) Selective targeting of ITK blocks multiple steps of HIV replication. Proc.Natl.Acad.Sci.U.S.A. 105 6684. PMID:18443296. Kutach et al (2010) Crystal structures of IL-2-inducible T cell kinase complexed with inhibitors: insights into rational drug design and activity regulation. Chem Biol Drug Des. 76 154. PMID:20545945.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=390661				Jan-2015
5011	HMR 1556	[223749-46-0]	CC2(C)[C@H](O)[C@@H](N(S(C)(=O)=O)C)C1=CC(OCCCC(F)(F)F)=CC=C1O2	Potent and selective Iks channel blocker	"Potent and selective Iks channel blocker (IC50 values are 10.5 and 34 nM in canine and guinea pig ventricular myocytes respectively). Selectively inhibits IKs currents over IKr, IKI, Ito and L-type Ca2+ channel currents. Also has little or no effect on Kv11.1 Kv1.5, Kv1.3, Kir2.1 and HCN2 channel currents. Potentiates E-4031-induced arrhythmias in vivo."	"Gerlach et al (2001) Synthesis and activity of novel and selective I(Ks)-channel blockers. J.Med.Chem. 44 3831. PMID:11689069. Thomas et al (2003) HMR 1556, a potent and selective blocker of slowly activating delayed rectifier potassium current. J.Cardiovasc.Pharmacol. 41 140. PMID:12500032. Michael et al (2007) Potentiation of E-4031-induced torsade de pointes by HMR1556 or ATX-II is not predicted by action potential short-term variability or triangulation. Br.J.Pharmacol 152 1215. PMID:17965747."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=390741				Dec-2014
5015	5-BrdU	[59-14-3]	O[C@H]1C[C@H](N2C=C(Br)C(NC2=O)=O)O[C@@H]1CO	Synthetic thymidine analog; used for cell proliferation assays	Synthetic thymidine analog; incorporated into DNA during replication. Used in assays for cell proliferation.	"Stacey and Hitomi (2008) Cell cycle studies basd upon quantitative image analysis. Cytometry A 73A 270. PMID:18163464. Barker et al (2013) A new method for in vitro detection of bromodeoxyuridine in serum: a proof of concept in a songbird species, the canary. PLoS One 8 e63692. PMID:23691086."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=390745	SQ1533			Sep-2013
5016	Fisetin	[528-48-3]	OC2=C(C3=CC=C(O)C(O)=C3)OC1=CC(O)=CC=C1C2=O	Naturally occuring flavonoid and antioxidant; neuroprotective	"Naturally occuring flavonoid and antioxidant. Inhibits PI 3-K, Akt, mTOR and Cdk6. Displays antiproliferative activity in prostate cancer cells. Also shown to activate ERK; exhibits neuroprotective activity in Huntington's disease models."	"Lu et al (2005) Crystal structure of a human cyclin-dependent kinase 6 complex with a flavonol inhibitor, fisetin. J.Med.Chem. 48 737. PMID:15689157. Lee et al (2005) Mechanisms for the inhibition of DNA methyltransferases by tea catechins and bioflavonoids. Mol.Pharmacol. 68 1018. PMID:16037419. Haddad et al (2010) Antiproliferative mechanisms of the flavonoids 2,2'-dihydroxychalcone and fisetin in human prostate cancer cells. Nutr.Cancer 62 668. PMID:20574928. Maher et al (2011) ERK activation by the polyphenols fisetin and resveratrol provides neuroprotection in multiple models of Huntington's disease. Hum.Mol.Genet. 20 261. PMID:20952447. Adhami et al (2012) Dietary flavonoid fisetin: a novel dual inhibitor of PI3K/Akt and mTOR for prostate cancer management. Biochem.Pharmacol. 84 1277. PMID:22842629."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=390746	SQ1533			Oct-2013
5017	A 85380 dihydrochloride	[174740-86-4]	[C@@H]1(COC2=CC=CN=C2)CCN1.Cl.Cl	High affinity and selective _4_2 agonist	"High affinity and selective _4_2 nACh receptor agonist (Ki values are 0.05, 148 and 314 nM for _4_2, _7 and _1_1__ receptors respectively). Stimulates cation efflux in K177 cells expressing _4_2."	"Abreo et al (1996) Novel 3-Pyridyl ethers with subnanomolar affinity for central neuronal nicotinic acetylcholine receptors. J.Med.Chem. 39 817. PMID:8632405. Sullivan et al (1996) A-85380 [3-(2(S)-azetidinylmethoxy) pyridine]: in vitro pharmacological properties of a novel, high affinity _4_2 nicotinic acetylcholine receptor ligand. Neuropharmacology 35 725. PMID:8887981."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=391017				Feb-2015
5021	TC-G 1000	[245744-18-7]	CC1=C2C(C(C3=CNC=N3)=CCC2)=C(C)S1.O=C(\C=C/C(O)=O)O	Potent and selective _2D agonist	"Potent and selective _2D-adrenoceptor agonist (Ki values are 8.6 pM and 110 nM for rat _2D and _1 receptors respectively and 25, 26 and 100 nM for human _2A, _2C and _2B receptors respectively. Exhibits analgesic activity in a mouse model of abdominal irritation. Orally active."	"Ross et al (2000) _2 adrenoceptor agonists as potential analgesic agents. 2. Discovery of 4-(4-Imidazo)-1,3-dimethyl-6,7-dihydrothianaphthene as a high-affinity ligand for the _2D adrenergic receptor. J.Med.Chem. 43 1423. PMID:10715142."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=391298	SQ1070			May-2014
5022	BMS 599626 dihydrochloride		FC1=CC(CN2N=CC3=C2C=CC(NC4=NC=NN5C4=C(C)C(NC(OC[C@@H]6COCCN6)=O)=C5)=C3)=CC=C1.Cl.Cl	"Potent, selective EGFR and ErbB2 inhibitor"	Potent and selective EGFR and ErbB2 inhibitor (IC50 values are 22 nM and 32 nM respectively). Also inhibits HER4 (IC50 = 190 nM). Inhibits EGFR and ErbB2 with 100-fold greater potency than MEK and Lck. Antiproliferative agent in vitro and anti-tumorigenic agent in vivo. Orally bioavailable.	"Wong et al (2006) Preclinical antitumor activity of BMS-599626, a pan-HER kinase inhibitor that inhibits HER1/HER2 homodimer and heterodimer signaling. Clin.Cancer Res. 12 6186. PMID:17062696. Gavai et al (2009) Discovery and preclinical evaluation of [4-[[1-(3-fluorophenyl)methyl]-1H-indazol-5-ylamino]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]carbamic acid, (3S)-3-morpholinylmethyl ester (BMS-599626), a selective and orally efficacious inhibitor of human epidermal growth factor receptor 1 and 2 kinases. J.Med.Chem. 52 6527. PMID:19821562."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=391299	SQ1070			Jan-2014
5025	Necrosulfonamide	[1360614-48-7]	O=C(NC2=CC=C(S(NC3=C(OC)N=CC=N3)(=O)=O)C=C2)/C=C/C1=CC=C([N+]([O-])=O)S1	Necroptosis inhibitor	"Necroptosis inhibitor. Blocks mixed lineage kinase domain-like protein (MLKL), a critical substrate of receptor-interacting serine-threonine kinase 3 (RIP3) during necrosis. Prevents MLKL-RIP1-RIP3 necrosome complex from interacting with downstream necrosis effectors."	Zhou et al (2012) New components of the necroptotic pathway. Protein Cell 3 811. PMID:23073834. Sun et al (2012) Mixed lineage kinase domain-like protein mediates necrosis signaling downstream of RIP3 kinase. Cell 148 213. PMID:22265413. Kreuzaler et al (2012) Killing a cancer: what are the alternatives? Nat.Rev.Cancer. 12 411. PMID:22576162.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=391302	SQ1070			Mar-2014
5028	GMQ hydrochloride	[5361-15-9]	CC2=NC(NC(N)=N)=NC1=CC=CC=C12.Cl	ASIC3 channel opener	Selective opener of acid-sensing ion channel 3 (ASIC3) at pH 7.4. Alters the pH dependence of ASIC1a and ASIC1b; does not affect the activation curve of ASIC2a.	Li et al (2010) ASIC3 channels integrate agmatine and multiple inflammatory signals through the nonproton ligand sensing domain. Mol.Pain 6 88. PMID:21143836. Alijevic and Kellenberger (2012) Subtype-specific modulation of acid-sensing ion channel (ASIC) function by 2-guanidine-4-methylquinazoline. J.Biol.Chem. 287 36059. PMID: 22948146.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=391305	SQ1341			Nov-2013
5029	CHC	[28166-41-8]	OC1=CC=C(/C=C(C#N)/C(O)=O)C=C1	Monocarboxylic acid transport (MCT) inhibitor	"Monocarboxylic acid transport (MCT) inhibitor. Exhibits antitumoral and antiangiogenic activity in gliomas in vivo; decreases glycolytic metabolism, migration, and invasion in U251 cells. Enhances the effect of DNA-methylating antitumor agent temozolomide (Cat No. 2706)."	Dimmer et al (2000) The low-affinity monocarboxylate transporter MCT4 is adapted to the export of lactate in highly glycolytic cells. Biochem.J. 350 219. PMID:10926847. Fang et al (2006) The H+-linked monocarboxylate transporter (MCT1/SLC16A1): a potential therapeutic target for high-risk neuroblastoma. Mol.Pharmacol. 70 2108. PMID:17000864. Miranda-Gonalves et al (2013) Monocarboxylate transporters (MCTs) in gliomas: expression and exploitation as therapeutic targets. Neuro.Oncol. 15 172. PMID:23258846.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=391306				Oct-2013
5032	Talampanel	[161832-65-1]	NC(C=C4)=CC=C4C1=NN(C(C)=O)[C@H](C)CC2=C1C=C(OCO3)C3=C2	Non-competitive AMPA/kainate antagonist	Non-competitive AMPA/kainate receptor antagonist that displays 2.3-3-fold more potent activity than GYKI 52466 (Cat. No. 1454). Potentiates the anticonvulsive activity of antiepileptic drugs in animal models of seizures. Orally active.	"Czuczwar et al (1998) LY 300164, a novel antagonist of AMPA/kainate receptors, potentiates the anticonvulsive activity of antiepileptic drugs. Eur.J.Pharmacol. 359 103. PMID:9832379 . Borowicz et al (2000) The AMPA/kainate receptor antagonist, LY 300164, increases the anticonvulsant effects of diazepam. Naunyn-Schmied.Arch.Pharmacol. 361 629. PMID:10882038. Belayev et al (2001) Talampanel, a novel noncompetitive AMPA antagonist, is neuroprotective after traumatic brain injury in rats. J.Neurotrauma 18 1031. PMID:11686490."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=391309				Nov-2013
5035	AS 2034178	[1030846-42-4]	FC1=C(CCC(O)=O)C=CC(NCC2=C(CCCN3CCOC4=CC=CC=C4)C3=CC=C2)=C1	Selective FFA1 (GPR40) agonist	"Selective free fatty acid receptor 1 (FFA1/GPR40) agonist. Exhibits selectivity for GPR40 over GPR41, GPR43, GPR119, GPR120 and PPAR_. Induces glucose-dependent insulin secretion in pancreatic MIN6 cells and in vivo. Enhances insulin sensitivity in a type 2 diabetes model in vivo. Orally available."	Tanaka et al (2013) Chronic treatment with novel GPR40 agonists improve whole-body glucose metabolism based on the glucose-dependent insulin secretion. J.Pharmacol.Exp.Ther. 346 443. PMID:23853170.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=391563	SQ1070			Apr-2014
5036	ML 786 dihydrochloride	[1237536-18-3]	O=C(N[C@@H]2CCC(C=CC(OC4=C(CC5)C(NC=C4)=NC5=O)=C3)=C3C2)C1=CC(C(F)(F)F)=CC(C(N)(C)C)=C1.Cl.Cl	Potent Raf kinase inhibitor; orally bioavailable	"Potent Raf kinase inhibitor (IC50 values are 2.1, 2.5 and 4.2 nM for B-RafV600E, C-Raf and wild-type B-Raf respectively). Also inhibits Abl-1, DDR2, EPHA2 and RET tyrosine kinase activity. Inhibits pERK formation and attenuates tumor growth in melanoma cell xenografts expressing the B-RafV600E mutation in vivo. Orally bioavailable."	Gould et al (2011) Design and optimization of potent and orally bioavailable tetrahydronaphthalene Raf inhibitors. J.Med.Chem. 54 1836. PMID:21341678.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=391701	SQ1070			May-2014
5038	ABT	[1614-12-6]	NN2C1=CC=CC=C1N=N2	Cytochrome P450 inhibitor; inhibits 20-HETE synthesis	Cytochrome P450 inhibitor. Inhibits synthesis of the eicosanoid 20-hydroxyeicosatetraenoic acid (20-HETE). Reduces intimal hyperplasia and vascular remodeling following endothelial injury in rat carotid arteries.	Mathews et al (1985) Inactivation of rabbit pulmonary cytochrome P-450 in microsomes and isolated perfused lungs by the suicide substrate 1-aminobenzotriazole. J.Pharmacol.Exp.Ther. 235 186. PMID:4045721. Orozco et al (2013) 20-hydroxyeicosatetraenoic acid inhibition attenuates balloon injury-induced neointima formation and vascular remodeling in rat carotid arteries. J.Pharmacol.Exp.Ther. 346 67. PMID:23658377.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=391703	SQ1341			Oct-2013
5040	SB 706504	[911110-38-8]	N=C(NC#N)NCCNC1=NC(C4=C(C)C=C(F)C=C4)=C(C=CC(N2C3=C(F)C=CC=C3F)=O)C2=N1	p38 MAPK inhibitor	"p38 MAPK inhibitor. Inhibits LPS-induced transcription of a range of chemokines and cytokines in chronic obstructive pulmonary disease (COPD) monocyte derived macrophages (MDMs). Also inhibits LPS-induced protein expression of IL-6, IL-10, TNF_ and _-inducible protein 10 in COPD MDMs. Effects on suppression of LPS-induced gene and protein expression are enhanced in combination with dexamethasone (Cat. No. 1126)."	"Kent et al (2009) Inhibition of lipopolysaccharide-stimulated chronic obstructive pulmonary disease macrophage inflammatory gene expression by dexamethasone and the p38 mitogen-activated protein kinase inhibitor N-cyano-N'-(2-{[8-(2,6-difluorophenyl)-4-(4-fluoro-2-methylphenyl)-7-oxo-7,8-dihydropyrido[2,3-d] pyrimidin-2-yl]amino}ethyl)guanidine (SB706504). J.Pharmacol.Exp.Ther. 328 458. PMID:19004925."	Small Molecule	Sold for research purposes under agreement from GlaxoSmithKline	http://www.tocris.com/dispprod.php?ItemId=392847				Nov-2014
5041	PAOPA	[114200-31-6]	O=C1[C@H](N[C@]([C@H]2NCCC2)=O)CCN1CC(N)=O	Dopamine D2 receptor allosteric modulator	Allosteric modulator of dopamine D2 receptors. Prevents and reverses behavioral and biochemical abnormalities in an amphetamine-sensitized animal model of schizophrenia.	"Tan et al (2011) Preclinical pharmacokinetic and toxicological evaluation of MIF-1 peptidomimetic, PAOPA: examining the pharmacology of a selective dopamine D2 receptor allosteric modulator for the treatment of schizophrenia. Peptides 42 89. PMID:23416534. Dyck et al (2011) PAOPA, a potent analogue of Pro-Leu-glycinamide and allosteric modulator of the dopamine D2 receptor, prevents NMDA receptor antagonist (MK-801)-induced deficits in social interaction in the rat: implications for the treatment of negative symptoms in schizophrenia. Schizophr.Res. 125 89. PMID:21036015. Beyaert et al (2013) PAOPA, a potent dopamine D2 receptor allosteric modulator, prevents and reverses behavioral and biochemical abnormalities in an amphetamine-sensitized preclinical animal model of schizophrenia. Eur.Neuropsychopharmacol. 23 253. PMID:22658400."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=392918	SQ1070			Mar-2014
5044	SR 3576	[1164153-22-3]	O=C(NC3=CC(OC)=C(OC)C(OC)=C3)C1=CC=CC(N2C=C(NC(NC4=CC=CC(C)=C4)=O)C=N2)=C1	Highly potent and selective JNK3 inhibitor	Highly potent and selective JNK3 inhibitor (IC50 = 7 nM); exhibits > 2800-fold selectivity over p38.	Kamenecka et al (2009) Structure-activity relationships and X-ray structures describing the selectivity of aminopyrazole inhibitors for c-Jun N-terminal kinase 3 (JNK3) over p38. J Biol Chem. 284 12853. PMID:19261605.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=393176	SQ1341			Jun-2014
5045	L002	[321695-57-2]	O=C(C(C)=C2)C(C)=C\C2=N/OS(C1=CC=C(OC)C=C1)(=O)=O	p300 inhibitor	"p300 inhibitor (IC50 = 1.98 _M). Inhibits histone and p53 acetylation, and suppresses STAT3 activation in cell-based assays. Also suppresses tumor growth in a mouse MDA-MB-468 xenograft model."	Yang et al (2013) Small-molecule inhibitors of acetyltransferase p300 identified by high-throughput screening are potent anticancer agents. Mol.Cancer Ther. 12 610. PMID:23625935.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=393251				Feb-2014
5046	LM11A 31 dihydrochloride	[1243259-19-9]	O=C([C@@H](N)[C@@H](C)CC)NCCN1CCOCC1.Cl.Cl	Nonpeptide p75NTR ligand; neuroprotective	"Nonpeptide p75NTR ligand; blocks p75-mediated cell death and also increases proliferation and survival of hippocampal neural progenitors. Exhibits no effect on nerve growth factor (NGF) binding to TrkA. Prevents and reverses atrophy of cholinergic neurites, as well as reversing Alzheimer's Disease (AD) pathologies in mid- to late-stage AD mice models. Shown to promote functional recovery in a mouse model of spinal cord injury. Orally available and brain penetrant."	"Massa et al (2006) Small, nonpeptide p75NTR ligands induce survival signaling and inhibit proNGF-induced death. J.Neurosci. 26 5288. PMID:6707781. Tep et al (2013) Oral administration of a small molecule targeted to block proNGF binding to p75 promotes myelin sparing and functional recovery after spinal cord injury. J.Neurosci. 33 397. PMID:23303920. Shi et al (2013) A small molecule P75NTR ligand protects neurogenesis after traumatic brain injury. Stem Cells [Epub ahead of print]. PMID:23940017. Simmons et al (2014) A small molecule p75NTR ligand, LM11A-31, reverses cholinergic neurite dystrophy in Alzheimer's disease mouse models with mid- to late-stage disease progression. PLoS One 9 e102136. PMID:25153701."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=393252				Oct-2014
5047	PRT 4165	[31083-55-3]	O=C(C2=CC=CC=C2C3=O)/C3=C\C1=CC=CN=C1	Inhibitor of Bmi1/Ring1A; blocks histone H2A ubiquitination	"Inhibitor of Bmi1/Ring1A, subunits of the polycomb repressive complex 1 (PRC1); inhibits self-ubiquitination (IC50 = 3.9 _M) but does not increase cellular levels of either subunit. Prevents Bmi1/Ring1A-mediated ubiquitination and drug-induced degradation of topoisomerase 2_ (Top2_). Also shown to inhibit the in vitro E3 ubiquitin ligase activity of RNF2 and a Bmi1/RNF2 complex, inhibiting H2A/H2AX ubiquitination. Blocks polycomb repressor complex (PRC) 1-mediated histone H2A ubiquitination in vitro and in vivo."	Alchanati et al (2009) The E3 ubiquitin-ligase Bmi1/Ring1A controls the proteasomal degradation of Top2_ cleavage complex - a potentially new drug target. PLoS One 4 e8104. PMID:19956605. Ismail et al (2013) A small molecule inhibitor of polycomb repressive complex 1 inhibits ubiquitin signaling at DNA double-strand breaks. J.Biol.Chem. 288 26944. PMID:23902761.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=393253	SQ1341			Nov-2013
5048	YZ9	[6093-71-6]	O=C2C(C(OCC)=O)=CC1=CC=C(O)C=C1O2	PFKFB3 inhibitor; inhibits cell growth	"PFKFB3 (6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase) inhibitor (IC50 = 0.183 _M). Also competitively inhibits F-6-P (Ki = 0.094 _M). Inhibits cell growth (GI50 = 2.7 _M) in a XTT-based in vitro toxicology assay."	Seo et al (2011) Structure-based development of small molecule PFKFB3 inhibitors: a framework for potential cancer therapeutic agents targeting the Warburg effect. PLoS One 6 e24179. PMID:21957443.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=393254	SQ1341			Nov-2013
5049	TC-E 5001	[865565-29-3]	CC1=NN=C(SCC3=NC(C4=CC=C(OC)C=C4)=NO3)N1C2=CC=C(OC)C=C2	Tankyrase inhibitor	"Dual tankyrase (TNKS) inhibitor (Kd values are 79 and 28 nM for TNKS1 and TNKS2 respectively, IC50 = 33 nM for TNKS2) that is devoid of activity at PARP1 and PARP2 (IC50 >19 _M). Inhibits Wnt signaling and stabilizes Axin2 levels."	"Shultz et al (2012) [1,2,4]Triazole-3-ylsulfanylmethyl)-3-phenyl-[1,2,4]oxadiazoles: antagonists of the wnt pathway that inhibit tankyrases 1 and 2 via novel adenosine pocket binding. J.Med.Chem. 55 1127. PMID:22260203."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=393256	SQ1341			Nov-2013
5050	CASIN	[425399-05-9]	OCCNC1C2=C(C(C=C(C4=CC=CC=C4)C=C3)=C3N2)CCC1	Cdc42 GTPase inhibitor	Cdc42 GTPase inhibitor (IC50 = 2 _M). Reduces active levels of Cdc42 in aged hematopoietic stem cells (HSCs) to that in young HSCs. Reverses the aging-related and polarity phenotype of aged HSCs to that of young HSCs in vivo. Increases histone H4K16 acetylation in aged HSCs.	Peterson et al (2006) Biochemical suppression of small-molecule inhibitors: a strategy to identify inhibitor targets and signaling pathway components. Chem.Biol. 13 443. PMID:16632257. Florian et al (2012) Cdc42 activity regulates hematopoietic stem cell aging and rejuvenation. Cell Stem Cell 10 520. PMID:22560076. Li et al (2013) Chemical approaches to stem cell biology and therapeutics. Cell Stem Cell 13 270. PMID:24012368.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=393370	SQ1070			May-2014
5051	BIO 5192	[327613-57-0]	O=C(NC2=CC=C(CC(N(C)[C@@H](CC(C)C)C(NCC[C@@H]([C@@](O)=O)N[C@]([C@H]3N(S(C4=CC(Cl)=CC(Cl)=C4)(=O)=O)CCC3)=O)=O)=O)C=C2)NC1=CC=CC=C1C	Highly potent and selective inhibitor of integrin _4_1	"Highly selective and potent inhibitor of integrin _4_1 (Very Late Antigen-4; VLA-4) (Kd < 10 pM). Selectively binds _4_1 over a range of other integrins (IC50 values are 1.8, 138, 1053, > 500 and > 10,000 nM for _4_1, _9_1, _2_1, _4_7 and _11b_3, respectively). Induces a 30-fold increase in mobilization of murine hematopoietic stem and progenitor cells; displays a 3-fold additive effect with AMD 3100 (Cat. No. 3299)."	"Leone et al (2003) An assessment of the mechanistic differences between two integrin _4_1 inhibitors, the monoclonal antibody TA-2 and the small molecule BIO5192, in rat experimental autoimmune encephalomyelitis. J.Pharmacol.Exp.Ther. 305 1150. PMID:12626659. Xu et al (2008) A chemical approach to stem-cell biology and regenerative medicine. Nature 453 338. PMID:18480815. Ramirez et al (2009) BIO5192, a small molecule inhibitor of VLA-4, mobilizes hematopoietic stem and progenitor cells. Blood. 1340 1340. PMID:19571319."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=393740	SQ1070			May-2014
5052	TG 4-155	[1164462-05-8]	CC2=CC1=CC=CC=C1N2CCNC(/C=C/C3=CC(OC)=C(OC)C(OC)=C3)=O	High affinity and selective EP2 receptor antagonist	"High affinity and selective EP2 receptor antagonist (KB values are 2.4 and 34.5 nM for EP2 and DP1 receptors respectively). Exhibits >500-fold selectivity for EP2 over other prostanoid receptors. Inhibits butaprost-induced proinflammatory cytokine production, cell proliferation and invasion of PC-3 cells in vitro."	"Jiang and Dingledine (2013) Role of prostaglandin receptor EP2 in the regulations of cancer cell proliferation, invasion, and inflammation. J.Pharmacol.Exp.Ther. 344 360. PMID:23192657. Quan et al (2013) EP2 receptor signaling pathways regulate classical activation of microglia. J.Biol.Chem. 288 9293. PMID:23404506."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=393741				Feb-2015
5054	ME 0328	[1445251-22-8]	O=C2NC(CCC(N[C@@H](C)C3=CC=CC=C3)=O)=NC1=CC=CC=C12	Selective PARP-3 inhibitor	"Inhibitor of PARP-3 (IC50 = 0.89 _M). Displays selectivity for PARP-3 over PARP-1, PARP-2 and other ARDT enzymes (IC50 values are 6.3, 10.8 and >30 _M respectively). Cell permeable."	Lindgren et al (2013) PARP inhibitor with selectivity toward ADP-ribosyltransferase ARTD3/PARP3. ACS Chem.Biol. 8 1698. PMID:23742272.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=393743	SQ1341			Jan-2014
5055	Qc 1	[403718-45-6]	O=C(N2C3=CC(C(F)(F)F)=CC=C3)C1=CC=C(C(NCC4=CC=CC=C4)=O)C=C1NC2=S	Threonine dehydrogenase inhibitor	"Reversible, non-competitive inhibitor of threonine dehydrogenase (TDH) (IC50 ~500 nM). Induces autophagy and inhibits cell proliferation in mouse embryonic stem (ES) cells."	Alexander et al (2011) Targeted killing of a mammalian cell based upon its specialized metabolic state. Proc.Natl.Acad.Sci.USA 108 15828. PMID:21896756.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=393744	SQ1341			Dec-2013
5056	Ki 16425	[355025-24-0]	CC1=NOC(C2=CC=C(CSCCC(O)=O)C=C2)=C1NC(OC(C3=CC=CC=C3Cl)C)=O	LPA1 and LPA3 receptor antagonist	"Antagonist of the lysophosphatidic acid receptors LPA1 and LPA3 (Ki values are 0.25 and 0.36 _M respectively, in a GTP_S binding assay). Blocks LPA-induced dephosphorylation of Yes-associated protein (YAP) and WW domain-containing transcription regulator protein 1 (TAZ), inhibiting the Hippo signaling pathway, in HEK293A cells."	"Ohta et al (2003) Ki16425, a subtype-selective antagonist for EDG-family lysophosphatidic acid receptors. Mol.Pharmacol. 64 994. PMID:14500756. Yamada et al (2004) Lysophosphatidic acid (LPA) in malignant ascites stimulates motility of human pancreatic cancer cells through LPA1. J.Biol.Chem. 279 6595. PMID:14660630. Yu et al (2012) Regulation of the Hippo-YAP pathway by G-protein-coupled receptor signaling. Cell 150 780. PMID:22863277."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=393745				Dec-2013
5058	ANAVEX 2-73	[195615-84-0]	CN(CC1C(C2=CC=CC=C2)(C3=CC=CC=C3)OCC1)C.Cl	Mixed _1 and muscarinic receptor agonist; exhibits neuroprotective effects	"_1 agonist (IC50 = 860 nM); also displays affinity for muscarinic M1-M4 receptors (Ki values < 500 nM), but not for _2 receptors. Exhibits neuroprotective effects, prevents tau hyperphosphorylation, and attenuates scopolamine- and (+)-MK 801-induced learning deficits in a mouse model of amyloid toxicity."	"Villard et al (2010) Anti-amnesic and neuroprotective potentials of the mixed muscarinic receptor/sigma 1 (_1) ligand ANAVEX2-73, a novel aminotetrahydrofuran derivative. J.Psychopharmacol. 25 1101. PMID:20829307. Lahmy et al (2013) Blockade of tau hyperphosphorylation and A_1-42 generation by the aminotetrahydrofuran derivative ANAVEX2-73, a mixed muscarinic and _1 receptor agonist, in a nontransgenic mouse model of Alzheimer's disease. Neuropsychopharmacology 38 1706."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=393937				Dec-2014
5061	RKI 1447 dihydrochloride		O=C(NCC3=CC=CC(O)=C3)NC1=NC(C2=CC=NC=C2)=CS1.Cl.Cl	Potent and selective ROCK inhibitor; antitumor	"Potent and selective ROCK inhibitor (IC50 values are 6.2 and 14.5 nM for ROCK2 and ROCK1 respectively); suppresses phosphorylation of ROCK substrates MLC-2 and MYPT-1 in human cancer cells, but has no effect on the phosphorylation levels of Akt, MEK, and S6 kinase. Displays anti-invasive and antitumor activities in breast cancer cells."	Patel et al (2012) RKI-1447 is a potent inhibitor of the Rho-associated ROCK kinases with anti-invasive and antitumor activities in breast cancer. Cancer Res. 72 5025. PMID:22846914. Pireddu et al (2013) Pyridylthiazole-based ureas as inhibitors of Rho associated protein kinases (ROCK1 and 2) Medchemcomm. 3 699. PMID:23275831.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=394469				Aug-2014
5063	SRPIN340	[218156-96-8]	O=C(C3=CC=NC=C3)NC1=C(N2CCCCC2)C=CC(C(F)(F)F)=C1	Selective SRPK1 inhibitor	"Selective serine arginine protein kinase (SRPK) 1 inhibitor (Ki = 0.89 _M). Inhibits SRPK2 at higher concentrations. Does not significantly inhibit other SRPKs such as CLK1 and CLK4, or other classes of SR kinases. Down-regulates expression of VEGF165 but does not affect VEGF165b expression."	Fukuhara et al (2006) Utilization of host SR protein kinases and RNA-splicing machinery during viral replication. Proc.Natl.Acad.Sci.USA 103 11329. PMID:16840555. Oltean et al (2012) SRPK1 inhibition in vivo: modulation of VEGF splicing and potential treatment for multiple diseases. Biochem.Soc.Trans. 40 831. PMID:22817743. Gammons et al (2013) SRPK1 inhibition modulates VEGF splicing to reduce pathological neovascularization in a rat model of retinopathy of prematurity. Invest.Ophthalmol.Vis.Sci. 54 5797. PMID:23761094.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=394480	SQ1070			Feb-2014
5065	NSC 319726	[71555-25-4]	C/C(C1=NC=CC=C1)=N\NC(N2CCC2)=S	Reactivator of mutant p53	Reactivator of mutant p53. Restores wild type p53 structure and function to the p53R175 mutant. Inhibits growth of fibroblasts expressing the p53R175 mutation (IC50 = 8 nM). Also inhibits growth of xenograft tumors expressing the p53R175 mutation in vivo.	Yu et al (2012) Allele-specific p53 mutant reactivation. Cancer Cell 21 614. PMID:22624712.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=395732				Apr-2014
5066	ICA 121431	[313254-51-2]	O=S(C1=CC=C(NC(C(C4=CC=CC=C4)C3=CC=CC=C3)=O)C=C1)(NC2=NC=CS2)=O	Potent and selective NaV1.3 and NaV1.1 channel blocker	"Potent and selective inhibitor of human NaV1.3 and NaV1.1 channels (IC50 values are 13 and 23 nM respectively). Exhibits up to 1,000 fold selectivity against other TTX-sensitive or resistant sodium channels (IC50 values are >10 _M for human NaV1.5 and NaV1.8 channels). Interacts with an inhibitory interaction site distinct from those bound by TTX and local anesthetic-like modulators."	McCormack et al (2013) Voltage sensor interaction site for selective small molecule inhibitors of voltage-gated sodium channels. Proc.Natl.Acad.Sci. 110 2724. PMID:23818614.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=395733	SQ1341			Jan-2014
5068	ITD 1	[1099644-42-4]	CC(C3)(C)CC(C1=C3NC(C)=C(C(OCC)=O)C1C2=CC=C(C4=CC=CC=C4)C=C2)=O	Selective inhibitor of TGF-_ signaling; induces cardiomyocyte differentiation in ESCs	"Selective inhibitor of TGF-_ signaling (IC50 = 0.85 _M); displays little or no inhibition of activin, Wnt or BMP signaling pathways. Induces proteasomal degradation of the TGF-_ type II receptor. Inhibits TGF-_-induced mesoderm formation from mouse embryonic stem cells (ESCs) during early differentiation; selectively promotes the differentiation of ESCs to cardiomyocytes in vitro between days 3-5. Does not induce differentiation of vascular smooth muscle cells or endothelial cells."	Willems et al (2012) Small molecule-mediated TGF- type II receptor degradation promotes cardiomyogenesis in embryonic stem cells. Cell Stem Cell 11 242. PMID:22862949. Kinney et al (2013) Emerging strategies for spatiotemporal control of stem cell fate and morphogenesis. Trends Biotechnol. 31 78. PMID:23219200.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=395735				Jul-2014
5069	Teriflunomide	[108605-62-5]	O=C(/C(C#N)=C(O)/C)NC1=CC=C(C(F)(F)F)C=C1	Dihydroorotate dehydrogenase inhibitor	Inhibitor of dihydroorotate dehydrogenase (Kd = 12 nM; Ki = 179 nM). Inhibits proliferation of mitogen- or cytokine-stimulated lymphoid cells in vitro by inhibiting cell cycle progression from G1 to S. Imunosuppressive agent. Active metabolite of leflunomide (Cat. No. 2228).	Williamson et al (1995) Dihydroorotate dehydrogenase is a high affinity binding protein for A77 1726 and mediator of a range of biological effects of the immunomodulatory compound. J.Biol.Chem. 270 22467. PMID:7673235. Davis et al (1996) The immunosuppressive metabolite of leflunomide is a potent inhibitor of human dihydroorotate dehydrogenase. Biochemistry 35 1270. PMID:8573583. Iglesias-Bregna et al (2013) Effects of prophylactic and therapeutic teriflunomide in transcranial magnetic stimulation-induced motor-evoked potentials in the dark agouti rat model of experimental autoimmune encephalomyelitis. J.Pharmacol.Exp.Ther. 347 203. PMID:23892570.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=396053	SQ1533			Dec-2013
5071	NKY 80	[299442-43-6]	NC(N=C2)=NC1=C2C(CC(C3=CC=CO3)C1)=O	Adenylyl cyclase inhibitor	"Inhibitor of adenylyl cyclase (AC). Exhibits greater affinity for AC5 over AC3 and AC2 (IC50 values are 8.3 _M, 132 _M and 1.7 mM respectively)."	Onda et al (2001) Type-specific regulation regulation of adenylyl cyclase. Selective pharmacological stimulation and inhibition of adenylyl cyclase isoforms. J.Biol.Chem. 276 47785. PMID:11602596. Pierre et al (2009) Capturing adenylyl cyclases as potential drug targets. Nat.Rev.Drug Discov. 8 321. PMID:19337273.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=396227	SQ1341			Jan-2014
5072	PFI 3		O=C(C3=C(O)C=CC=C3)/C=C/N1[C@H](C4)CN(C2=NC=CC=C2)[C@H]4C1	Potent and selective SMARCA2/4 and polybromo 1 inhibitor	Potent and selective polybromo 1 and SMARCA4 inhibitor (Kd values are 48 and 89 nM respectively). Also inhibits SMARCA2. Displays 30-fold selectivity over other sub-family branches. Accelerates FRAP recovery in cells at a concentration of 1 _M.		Small Molecule	"This probe is supplied in conjunction with the Structural Genomics Consortium. For further characterization details, please visit the PFI 3 probe summary on the SGC website."	http://www.tocris.com/dispprod.php?ItemId=396427	SQ1070			Apr-2014
5075	Harmine	[442-51-3]	CC1=NC=CC2=C1NC3=C2C=CC(OC)=C3	Potent and selective Dyrk1A inhibitor	"Potent and selective inhibitor of Dyrk1A (IC50 values are 80, 800 and 900 nM for Dyrk1A, Dyrk3 and Dyrk2 respectively). Shown to inhibit direct phosphorylation of tau by Dyrk1A (IC50 = 700 nM). Also regulates PPAR_ expression; exhibits antidiabetic activity. Orally bioavailable."	"Bain et al (2007) The selectivity of protein kinase inhibitors: a further update. Biochem.J. 408 297. PMID:17850214. Waki et al (2007) The small molecule harmine is an antidiabetic cell-type-specific regulator of PPAR_ expression. Cell Metab. 5 357. PMID:17488638. Smith et al (2012) Recent advances in the design, synthesis, and biological evaluation of selective DYRK1A inhibitors: a new avenue for a disease modifying treatment of Alzheimer's? ACS Chem.Neurosci. 3 857. PMID:23173067."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=396508				Nov-2013
5076	SZL P1-41	[222716-34-9]	OC(C(CC)=C2)=C(CN3CCCCC3)C1=C2C(C(C4=NC5=C(C=CC=C5)S4)=CO1)=O	Selective Skp2 inhibitor; suppresses E3 ligase activity	Skp2 inhibitor; thought to prevent assembly of Skp2-Skp1 complexes. Selectively suppresses Skp2 SCF E3 ligase activity but exhibits no effect on the activity of other SCF complexes. Also inhibits Skp2-mediated p27 and Akt ubiquitination in vivo and in vitro. Suppresses the survival of cancer cells and cancer stem cells by triggering cell senescence and inhibiting glycolysis. Exhibits antitumor effects in multiple animal models and cancer cell lines.	Chan et al (2013) Pharmacological inactivation of Skp2 SCF ubiquitin ligase restricts cancer stem cell traits and cancer progression. Cell 154 556. PMID:23911321 .	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=397527	SQ1070			Apr-2014
5077	DDR1-IN-1 dihydrochloride		CC1=C(OC4=CC(CC(N5)=O)=C5C=C4)C=C(NC(C2=CC=C(CN3CCN(CC)CC3)C(C(F)(F)F)=C2)=O)C=C1.Cl.Cl	Selective DDR1 inhibitor	Selective discoidin domain receptor 1 (DDR1) tyrosine kinase inhibitor (IC50 values are 105 and 413 nM for DDR1 and DDR2 respectively). Inhibits integrin-induced DDR1 autophosphorylation in an osteosarcoma cell line.	Kim et al (2013) Discovery of a potent and selective DDR1 receptor tyrosine kinase inhibitor. ACS.Chem.Biol. 8 2145. PMID:23899692. Canning et al (2014) Structural Mechanisms Determining Inhibition of the Collagen Receptor DDR1 by Selective and Multi-Targeted Type II Kinase Inhibitors. J.Mol.Biol. 426 2457. PMID:24768818.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=397596	SQ1341			Jun-2014
5080	TC-G 1003	[1021912-42-4]	CC1=CC(C3=C(OCCCN)C2=CC(C4=CC=CC(O)=C4)=C(Cl)C=C2N=C3)=CC(C)=C1	High affinity somatostatin sst2 receptor agonist	High affinity somatostatin sst2 receptor agonist (Ki = 0.025 nM). Inhibits growth hormone secretion and attenuates laser-induced ocular neovascular lesion size in rats.	"Wolkenberg et al (2011) Design, synthesis, and evaluation of novel 3,6-diaryl-4-aminoalkoxyquinolines as selective agonists of somatostatin receptor subtype 2. J.Med.Chem. 54 2351. PMID:21395312."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=399879				Jan-2015
5081	J 147	[1146963-51-0]	O=C(C(F)(F)F)N(C2=C(C)C=C(C)C=C2)/N=C/C1=CC=CC(OC)=C1	Neuroprotective and neurotrophic compound; reduces A_40 and A_42 levels	"Potent neuroprotective and neurotrophic compound. Protects against neurotoxicity in cortical neurons in vitro (EC50 = 25 - 200 nM). Reduces soluble A_40 and A_42 levels and increases BDNF levels in the hippocampus in vivo. Enhances memory in wild type rats. Prevents memory deficits and rescues cognitive deficits in young and aged transgenic Alzheimer's Disease mice, respectively. Orally active."	Chen et al (2011) A novel neurotrophic drug for cognitive enhancement and Alzheimer's disease. PLoS One 6 e27865. PMID:22194796. Prior et al (2013) The neurotrophic compound J147 reverses cognitive impairment in aged Alzheimer's disease mice. Alzheimer's.Res.Ther. 5 25. PMID:23673233. Chiruta et al (2013) Metabolism of a potent neuroprotective hydrazide. Bioorg.Med.Chem. 21 2733. PMID:23582448.	Small Molecule	Sold for research use only under license from the Salk Institute for Biological Studies	http://www.tocris.com/dispprod.php?ItemId=399926	SQ1341			Dec-2013
5082	LDN 212320	[894002-50-7]	CC1=CC=CC=C1CSC(N=N3)=CC=C3C2=NC=CC=C2	Increases EAAT2 expression; neuroprotective	"Increases expression of glutamate transporter EAAT2 in PA-EAAT2 cells. Displays neuroprotective activity in vivo. Shown to improve learning and memory, restore synaptic integrity and reduce amyloid plaque burden in APPSw/Ind mice."	Xing et al (2011) Structure-activity relationship study of pyridazine derivatives as glutamate transporter EAAT2 activators. Bioorg.Med.Chem.Lett. 21 5774. PMID:21875806. Lin et al (2012) Glutamate transporter EAAT2: a new target for the treatment of neurodegenerative diseases. Future Med Chem 4 1689. PMID:22924507. Lin et al (2013) : Mechanism of LDN-212320 induction of glutamate transporter EAAT2 expression . Society for Neuroscience (Abstract) 99. Takahashi et al (2013) A small molecule modulator of glutamate transporter EAAT2 ameliorates Alzheimers-like pathologies and memory deficits in APPSw/Ind mice. Society for Neuroscience (Abstract) 103.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=399944	SQ1070			Mar-2014
5084	MN 64	[92831-11-3]	O=C2C1=CC=CC=C1OC(C3=CC=C(C(C)C)C=C3)=C2	Potent and selective tankyrase inhibitor	Potent and selective tankyrase (TNKS) inhibitor (IC50 values are 6 and 72 nM for TNKS1 and TNKS2 respectively). Has no significant effect on PARP-1 or PARP-2 (IC50 >19 _M). Inhibits WNT/_-catenin signaling-dependent Super-TopFlash (STF) luciferase activity.	Narwal et al (2013) Discovery of tankyrase inhibiting flavones with increased potency and isoenzyme selectivity. J.Med.Chem. 56 7880. PMID:24116873.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=400037				Oct-2014
5085	L 012 sodium salt	[143556-24-5]	NC1=C3C(C(O[Na])=NNC3=O)=C(Cl)N=C1C2=CC=CC=C2	Chemiluminescent ROS and RNS indicator	Luminal-based chemiluminescent probe. Detects NAPDH oxidase-derived reactive oxygen and nitrogen species (ROS and RNS). Active in vitro and in vivo.	Kielland et al (2009) In vivo imaging of reactive oxygen and nitrogen species in inflammation using the luminescent probe L-012. Free Radic.Biol.Med. 47 760. PMID:19539751. Zhou et al (2012) Noninvasive assessment of localized inflammatory responses. Free Radic.Biol.Med. 52 218. PMID:22080048. Ichibangase et al (2013) Evaluation of lophine derivatives as L-012 (luminol analog)-dependent chemiluminescence enhancers for measuring horseradish peroxidase and H2 O2. Luminescence. 29 118. PMID:23630098.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=400038				Feb-2014
5086	PA 452	[457657-34-0]	CC1(C)C2=C(C=C(N(C3=NC=C(C(O)=O)C=N3)C)C(OCCCCCC)=C2)C(C)(C)CC1	RXR antagonist	RXR antagonist (pA2 = 7.11). Triggers dissociation of RXR tetramers. Attenuates cell proliferation and induces apoptosis in MCF-7 breast cancer cells.	Takahashi et al (2002) Novel retinoid X receptor antagonists: specific inhibition of retinoid synergism in RXR-RAR heterodimer actions. J.Med.Chem. 45 3327. PMID:12139443. Yasmin et al (2010) Inhibition of mammary carcinoma cell growth by RXR is mediated by the receptor's oligomeric switch. J.Mol.Biol. 397 1121. PMID:20188110. Nakayama et al (2011) Discovery of a potent retinoid X receptor antagonist structurally closely related to RXR agonist NEt-3IBIB. J.Med.Chem.Lett 2 896. PMID:24900278.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=400039	SQ1070			Jun-2014
5089	TC-E 5002	[1453071-47-0]	O=C(N(CCC(O)=O)O)CCCCCCCCC1CC1	Selective histone demethylase KDM2/7 subfamily inhibitor	"Selective histone demethylase KDM2/7 subfamily inhibitor (IC50 values are 0.2, 1.2, 6.8, 55, 83, >100 and >120 _M for KDM7A, KDM7B, KDM2A, KDM5A, KDM4C, KDM6A and KDM4A respectively). Inhibits growth of HeLa and KYSE-150 cancer cells in vitro."	Suzuki et al (2013) Identification of the KDM2/7 histone lysine demethylase subfamily inhibitor and its antiproliferative activity. J.Med.Chem. 56 (7222). PMID:23964788.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=400232				Oct-2014
5095	DBM 1285 dihydrochloride		FC(C=C4)=CC=C4C1=C(C2=CC=NC(NC5CC5)=N2)SC(C3CCNCC3)=N1.Cl.Cl	p38 MAPK inhibitor; anti-inflammatory	p38 MAPK inhibitor. Supresses p38 phosphorylation and LPS-induced TNF-_ production in macrophages and in vivo. Attenuates zymosan-induced inflammation and adjuvant-induced arthritis in murine models. Orally active.	Kang et al (2010) DBM1285 suppresses tumor necrosis factor _ production by blocking p38 mitogen-activated protein kinase/mitogen-activated protein kinase-activated protein kinase 2 signaling pathway. J.Pharmacol.Exp.Ther. 334 657. PMID:20427474.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=400417	SQ1341			Jul-2014
5096	AdipoRon hydrochloride		O=C(C2=CC=C(OCC(NC3CCN(CC4=CC=CC=C4)CC3)=O)C=C2)C1=CC=CC=C1.Cl	Orally active AdipoR1 and AdipoR2 agonist; antidiabetic	"Agonist of adiponectin receptors AdipoR1 and AdipoR2 (Kd values are 1.8 and 3.1 _M respectively). Activates AMPK and PPAR_ signaling; ameliorates insulin resistance, dyslipidemia and glucose intolerance in db/db mice. Orally active antidiabetic agent."	Okada-Iwabu et al (2013) A small-molecule AdipoR agonist for type 2 diabetes and short life in obesity. Nature 503 493. PMID:24172895.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=400556	SQ1070			Feb-2014
5098	KRCA 0008	[1472795-20-2]	ClC1=C(NC2=C(OC)C=C(N3CCN(C(C)=O)CC3)C=C2)N=C(NC4=CC=C(N5CCN(C(C)=O)CC5)C=C4OC)N=C1	Potent Ack1 and ALK dual inhibitor; orally bioavailable	Potent Ack1 and anaplastic lymphoma kinase (ALK) dual inhibitor (IC50 values are 4 and 12 nM respectively). Inhibits lung cancer H3122 cell proliferation (IC50 = 80 nM). Attenuates H3122 cell xenograft tumor growth in mice. Orally bioavailable.	"Park et al (2013) Novel bis-ortho-alkoxy-para-piperazinesubstituted-2,4-dianilinopyrimidines (KRCA-0008) as potent and selective ALK inhibitors for anticancer treatment. Bioorg.Med.Chem.Lett. 23 6192. PMID:24095090. Lee et al (2014) ALK inhibitors of bis-ortho-alkoxy-para-piperazinesubstituted-pyrimidines and -triazines for cancer treatment. Arch.Pharm.Res. 37 1130. PMID:24446111."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=400734	SQ1341			Jun-2014
5099	TC-E 5003	[17328-16-4]	O=C(CCl)NC(C=C2)=CC=C2S(C1=CC=C(NC(CCl)=O)C=C1)(=O)=O	Selective PRMT1 arginine methyltransferase inhibitor	Selective protein arginine methyltransferase 1 (PRMT1) inhibitor (IC50 = 1.5 _M); exhibits no inhibitory activity against CARM1 and Set7/9 methyltransferases. Inhibits growth of MCF7a breast cancer cells and LNCaP prostate cancer cells. Attenuates androgen-induced gene expression in LNCaP cells.	Bissinger et al (2011) Acyl derivatives of p-aminosulfonamides and dapsone as new inhibitors of the arginine methyltransferase hPRMT1. Bioorg.Med.Chem. 19 3717. PMID:21440447.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=400735	SQ1070			May-2014
5101	PD 90780	[77422-99-2]	O=C(C4=CC=CC=C4)NC1=CC=C3C(C(N2C(N3C)=CC(C(O)=O)=N2)=O)=C1	Inhibits NGF binding to p75NTR 	"A nonpeptide inhibitor of NGF binding to p75NTR (IC50 ~ 1 _M in CHO cells); binds NGF, not p75NTR. Affinity maybe altered by the presence of TrkA receptors. Neuroprotective."	"Colquhoun et al (2004) Differential activity of the nerve growth factor (NGF) antagonist PD90780 [7-(benzolylamino)-4,9-dihydro-4-methyl-9-oxo-pyrazolo[5,1-b]quinazoline-2-carboxylic acid] suggests altered NGF-p75NTR interactions in the presence of TrkA. J.Pharmacol.Exp.Ther. 310 505. PMID:15051797. Longo et al (2008) Small molecule modulation of p75 neurotrophin receptor functions. CNS Neurol.Disord.Drug Targets 7 63. PMID:18289033. Eibl et al (2012) Structural, biological, and pharmacological strategies for the inhibition of nerve growth factor. Neurochem.Int. 61 1266. PMID:23103525."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=400737				Oct-2014
5102	PLX 647 dihydrochloride		FC(C(C=C4)=CC=C4CNC(N=C3)=CC=C3CC2=CNC1=NC=CC=C12)(F)F.Cl.Cl	Potent dual Fms/KIT inhibitor	"Potent dual KIT/Fms inhibitor (IC50 values are 16 and 28 nM respectively). Inhibits BCR-FMS cell proliferation and osteoclast differentiation in vitro (IC50 values are 92 and 170 nM respectively). Attenuates LPS-induced TNF_ and IL-6 release, mast cell activation and macrophage kidney proliferation in vivo."	Zhang et al (2013) Design and pharmacology of a highly specific dual FMS and KIT kinase inhibitor. Proc.Natl.Acad.Sci.U.S.A. 110 5689. PMID:23493555.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=400738	SQ1070			Jan-2014
5106	GSK 2193874	[1336960-13-4]	O=C(NC6(CC6)C5=CC=CC=C5)C2=C(CN4CCC(N7CCCCC7)CC4)C(C3=CC(C(F)(F)F)=CC=C3)=NC1=CC(Br)=CC=C12	Potent and selective TRPV4 inhibitor; orally active	"Potent and selectiveTRPV4 inhibitor (IC50 values are 2 and 40 nM for rat and human receptors, respectively); inhibits Ca2+ influx through TRPV4 channels. Prevents and reverses pulmonary edema after myocardial infarction in vivo models. Selective over a panel of ~200 human receptors, channels and enzymes. Orally active."	Thorneloe et al (2012) An orally active TRPV4 channel blocker prevents and resolves pulmonary edema induced by heart failure. Sci.Transl.Med. 4 159. PMID:23136043.	Small Molecule	Sold for research purposes under agreement from GlaxoSmithKline	http://www.tocris.com/dispprod.php?ItemId=401740	SQ1070			Apr-2014
5107	GSK 2606414	[1337531-36-8]	NC1=NC=NC2=C1C(C3=CC(CCN4C(CC5=CC=CC(C(F)(F)F)=C5)=O)=C4C=C3)=CN2C	Potent and selective PERK inhibitor; orally bioavailable	Potent and selective protein kinase R-like ER kinase (PERK) inhibitor (IC50 = 0.4 nM). Exhibits >1000-fold selectivity for PERK over HR1 and PKR. Inhibits thapsigargin-induced PERK phosphorylation in lung carcinoma A549 cells. Attenuates subcutaneous pancreatic human tumor xenograft growth in mice. Orally bioavailable.	"Axten et al (2012) Discovery of 7-methyl-5-(1-{[3-(trifluoromethyl)phenyl]acetyl}-2,3-dihydro-1H-indol-5-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine (GSK2606414), a potent and selective first-in-class inhibitor of protein kinase R (PKR)-like endoplasmic reticulum kinase (PERK). J.Med.Chem. 55 7193. PMID:22827572. Harding et al (2012) Uncoupling proteostasis and development in vitro with a small molecule inhibitor of the pancreatic endoplasmic reticulum kinase, PERK. J.Biol.Chem. 287 44338. PMID:23148209."	Small Molecule	Sold for research purposes only under agreement from GlaxoSmithKline	http://www.tocris.com/dispprod.php?ItemId=401795	SQ1341			Jun-2014
5108	TFC 007	[927878-49-7]	O=C(C2CCN(C3=CC=C(NC(C4=CN=C(OC5=CC=CC=C5)N=C4)=O)C=C3)CC2)N1CCOCC1	Potent hematopoietic prostaglandin D synthase (H-PGDS) inhibitor	"Potent hematopoietic prostaglandin D synthase (H-PGDS) inhibitor (IC50 = 83 nM). Inhibits PGD2 production and late phase nasal blockage in an animal model of allergic rhinitis. Exhibits negligible effects on COX-1, COX-2, 5-LOX, LTC4 synthase, TXA2 synthase and microsomal prostaglandin E2 synthase."	Nabe et al (2011) Inhibition of hematopoietic prostaglandin D synthase improves allergic nasal blockage in guinea pigs. Prostaglandins Other Lipid Mediat. 95 27. PMID:21601002.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=402408				Jan-2015
5109	SB 743921 hydrochloride	[940929-33-9]	ClC1=CC=C2C(OC([C@@H]([C@H](C)C)N(C(C4=CC=C(C)C=C4)=O)CCCN)=C(CC3=CC=CC=C3)C2=O)=C1.Cl	Potent kinesin spindle protein (KSP) inhibitor	"Potent kinesin spindle protein (KSP) inhibitor (Ki = 0.1 nM). Induces cell mitotic arrest and apoptosis in vitro. Inhibits the growth of a range of tumor cells in vitro, including colon (HCT 116), prostate (PC-3) and leukemia (K-562) cancer cell lines. Causes tumor regression in human tumor xenograft models in vivo, including colon (Colo205), lung (H69) and breast (MCF7) cancer cell xenografts."	"Jackson et al (2006) A second generation KSP inhibitor, SB-743921, is a highly potent and active therapeutic in preclinical models of cancer. First AACR International Conference on Molecular and Diagnostics in Cancer Therapeutic Development. Abstract (B11). Good et al (2013) Optimized S-trityl-L-cysteine-based inhibitors of kinesin spindle protein with potent in vivo antitumor activity in lung cancer xenograft models. J.Med.Chem. 56 1878. PMID:23394180. Talapatra et al (2013) Mitotic kinesin Eg5 overcomes inhibition to the phase I/II clinical candidate SB743921 by an allosteric resistance mechanism. J.Med.Chem. 56 6317. PMID:23875972."	Small Molecule	Sold with the permission of GlaxoSmithKline.	http://www.tocris.com/dispprod.php?ItemId=402934				Jul-2014
5110	GSK 1562590 hydrochloride	[1003878-07-6]	NC(C1=CC=CC(C2=CC=[C@@]([C@@H](N(C(CN4C(C=C(Cl)C(Cl)=C5)=C5OCC4=O)=O)C)CN3CCCC3)C=C2)=C1)=O.Cl	"High affinity, selective urotensin II (UT) receptor antagonist"	"High affinity and selective urotensin II (UT) receptor antagonist (pKi values are 9.14, 9.28, 9.34, 9.64 and 9.66 at monkey, human, mouse, cat and rat recombinant receptors respectively). Exhibits selectivity for UT receptors over a range of GPCRs, ion channels, enzymes and neurotransmitter transporters. Supresses human urotensin-II (hU-II)-induced contraction of isolated rat aorta in vitro and ex vivo. Inhibits the hU-II-induced increase in mean blood pressure in vivo. Orally active."	"Behm et al (2010) GSK1562590, a slowly dissociating urotensin-II receptor antagonist, exhibits prolonged pharmacodynamic activity ex vivo. Br.J.Pharmacol. 161 207. PMID:20718751."	Small Molecule	Sold for research purposes under agreement from GlaxoSmithKline.	http://www.tocris.com/dispprod.php?ItemId=403253	SQ1070			May-2014
5111	GSK 1838705	[1116235-97-2]	O=C(CN(C)C)N4CCC(C4=C5)=CC(OC)=C5NC1=NC(NC3=C(C(NC)=O)C(F)=CC=C3)=C2C(NC=C2)=N1	Potent IR and IGF1R inhibitor; also inhibits anaplastic lymphoma kinase (ALK)	"Potent insulin receptor (IR) and insulin-like growth factor-1 receptor (IGF1R) inhibitor (IC50 values are 1.6 and 2 nM, respectively). Also inhibits anaplastic lymphoma kinase (ALK) (IC50 = 0.5 nM). Displays > 800-fold selectivity for IR, IGFR1 and ALK over a panel of 44 kinases including JNK. Blocks proliferation of cancer cell lines in vitro, and causes complete regression of ALK-dependent tumors in vivo. Orally bioavailable."	"Sabbatini et al (2009) GSK1838705A inhibits the insulin-like growth factor-1 receptor and anaplastic lymphoma kinase and shows antitumor activity in experimental models of human cancers. Mol.Cancer.Ther. 8 2811. PMID:19825801. Chamberlain et al (2009) Optimization of 4,6-bis-anilino-1H-pyrrolo[2,3-d]pyrimidine IGF-1R tyrosine kinase inhibitors towards JNK selectivity. Bioorg.Med.Chem.Lett. 19 360. PMID:19071018. Gao et al (2014) Site-specific activation of AKT protects cells from death induced by glucose deprivation. Oncogene 33 745. PMID:23396361."	Small Molecule	Sold for research purposes under agreement from GlaxoSmithKline.	http://www.tocris.com/dispprod.php?ItemId=403254	SQ1070			Apr-2014
5112	NS 9283	[913830-15-6]	N#CC1=CC(C2=NC(C3=CN=CC=C3)=NO2)=CC=C1	Positive allosteric modulator of _4_2	Positive allosteric modulator of _4_2 receptor; increases the potency of Ach-evoked currents ~60 fold without effecting the maximum efficacy (HEK293-h_4_2 cells). Reduces the rate of recovery from desensitization and slows the rate of deactivation. Displays a synergistic effect on the Emax when given with NS206 at 3_:2_ receptors.	"Grupe et al (2013) Unravelling the mechanism of action of NS9283, a positive allosteric modulator of (_4)3(_2)2 nicotinic ACh receptors. Br.J.Pharmacol. 168 2000. PMID:23278456. Olsen et al (2013) Two distinct allosteric binding sites at _4_2 nicotinic acetylcholine receptors revealed by NS206 and NS9283 give unique insights to binding activity-associated linkage at Cys-loop receptors. J.Biol.Chem. 288 35997. PMID:24169695. Mohler et al (2014) Discriminative-stimulus effects of NS9283, a nicotinic _4_2* positive allosteric modulator, in nicotine-discriminating rats. Psychopharmacology (Berl). 231 67. PMID:23925734."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=403255				Oct-2014
5113	AbK	[1253643-88-7]	N[C@H](C(O)=O)CCCCNC(OCCC1(C)N=N1)=O	Photo-crosslinking probe	Unnatural amino acid. Acts as a UV light-activated photo-crosslinking probe when incorporated into proteins by pyrrolysyl tRNA synthetase/tRNACUA pairs.	Ai et al (2011) Probing protein-protein interactions with a genetically encoded photo-crosslinking amino acid. Chembiochem 12 1854. PMID:21678540. Lowder et al (2011) Visualizing protein partnerships in living cells and organisms. Curr.Opin.Cell Biol. 15 781. PMID:22104179. Chatterjee et al (2013) Efficient viral delivery system for unnatural amino acid mutagenesis in mammalian cells. Proc.Natl.Acad.Sci.U.S.A. 110 11803. PMID:23818609.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=403256				May-2014
5117	Hoechst 33342	[23491-52-3]	CN(CC2)CCN2C1=CC(N=C(C4=CC(NC(C6=CC=C(OCC)C=C6)=N5)=C5C=C4)N3)=C3C=C1.Cl.Cl.Cl	Fluorescent DNA stain	Cell permeable fluorescent DNA stain; binds minor groove of AT-rich regions. Used to quantify DNA in viable cells.	"Loken (1980) Simultaneous quantitation of Hoechst 33342 and immunofluorescence on viable cells using a fluorescence activated cell sorter. Cytometry 1 136. PMID:7028425. Portugal and Waring (1988) Assignment of DNA binding sites for 4',6-diamidine-2-phenylindole and bisbenzimide (Hoechst 33258). A comparative footprinting study. Biochim.Biophys.Acta. 949 158. PMID:2449244."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=403260				Feb-2014
5121	3PO	[13309-08-5]	O=C(/C=C/C2=CN=CC=C2)C1=CC=NC=C1	PFKFB3 inhibitor; antiangiogenic	"PFKFB3 (6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase) inhibitor; reduces glycolytic flux and suppresses glucose uptake. Inhibits endothelial cell proliferation and causes G2/M cell cycle arrest in vitro. Attenuates vessel sprouting and tumor growth in vivo. Amplifies the antiangiogenic effect of VEGFR blockade."	Clem et al (2008) Small-molecule inhibition of 6-phosphofructo-2-kinase activity suppresses glycolytic flux and tumor growth. Mol.Cancer Ther. 7 110. PMID:18202014. Schoors et al (2014) Partial and transient reduction of glycolysis by PFKFB3 blockade reduces pathological angiogenesis. Cell Metab. 19 37. PMID:24332967.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=403560				Feb-2015
5122	Dansyl-NECA	[219982-12-4]	CN(C)C1=C2C(C(S(NCCCCCCNC3=NC=NC4=C3N=CN4[C@H]5[C@H](O)[C@H](O)[C@@H]([C@@](NCC)=O)O5)(=O)=O)=CC=C2)=CC=C1	Potent and selective fluorescent adenosine A1 agonist	"Potent and selective fluorescent adenosine A1 receptor agonist (Ki values are 27, 3600 and 4300 nM for A1, A3 and A2 receptors, respectively). Permits visualization of A1 receptors in the rat cerebellar cortex."	Macchia et al (1998) Fluorescent probes for adenosine receptors: synthesis and biology of N6-dansylaminoalkyl-substituted NECA derivatives. Bioorg. Med. Chem. Lett. 8 3223. PMID:9873707. Kozma et al (2013) Fluorescent ligands for adenosine receptors. Bioorg. Med. Chem. Lett. 23 26. PMID:23200243.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=403561				Oct-2014
5126	iMDK	[881970-80-5]	FC(C=C5)=CC=C5CC4=CN1C(S4)=NC(C(C(O3)=O)=CC2=C3C=CC=C2)=C1	Potent suppressor of MDK expression; antitumor	Suppresses endogenous midkine (MDK) expression in H441 lung adenocarcinoma cells. Suppresses tumor growth and induces cell death by inhibiting the PI 3-kinase pathway and inducing apoptosis in a mouse model derived from H441 lung adenocarcinoma cells.	Hao et al (2013) Inhibition of the growth factor MDK/Midkine by a novel small molecule compound to treat non-small cell lung cancer. PLoS ONE 8 e71093. PMID:23976985.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=403958	SQ1070			Mar-2014
5131	NAB 2	[1504588-00-4]	O=C(NCC4=C(Cl)C=CC=C4)C1=CC=C2C(N=CN2C3=CC(C)=CC=C3C)=C1	Protects against _-synuclein toxicity; promotes Rsp5/Nedd4-dependent endosomal transport	Protects against _-synuclein toxicity. Reverses the _-synuclein-induced pathological phenotype in Parkinson's disease cortical neurons. Promotes E3 ubiquitin ligase Rsp5/Nedd4-dependent endosomal transport.	"Tardiff et al (2013) Yeast reveal a ""druggable"" Rsp5/Nedd4 network that ameliorates _-synuclein toxicity in neurons. Science 342 979. PMID:24158909. Chung et al (2013) Identification and rescue of _-synuclein toxicity in Parkinson patient-derived neurons. Science 342 983. PMID:24158904."	Small Molecule	Sold under license from Whitehead Institute for Biomedical Research.	http://www.tocris.com/dispprod.php?ItemId=404022				Jan-2015
5132	UNC 0642	[1481677-78-4]	CC(C)N(CC4)CCC4NC1=C2C(C=C(OCCCN3CCCC3)C(OC)=C2)=NC(N5CCC(F)(F)CC5)=N1	Potent and selective G9a and GLP histone lysine methyltransferase inhibitor	"Potent and selective G9a and GLP histone lysine methyltransferase inhibitor (IC50 < 2.5 nM). Exhibits >2,000-fold selectivity for G9a and GLP over PRC2-EZH2 and >20,000-fold selectivity over other methyltransferases. Reduces H3K9 dimethylation levels in MDA-MB-231 cells (IC50 = 110 nM). Displays modest brain penetration in vivo."	Liu et al (2013) Discovery of an in vivo chemical probe of the lysine methyltransferases G9a and GLP. J.Med.Chem. 56 8931. PMID:24102134.	Small Molecule	"This probe is supplied in conjunction with the Structural Genomics Consortium. For further characterization details, please visit the UNC 0642 probe summary on the SGC website."	http://www.tocris.com/dispprod.php?ItemId=404023	SQ1070			Apr-2014
5133	GKA 50	[851884-87-2]	O=C(NC3=NC=C(C(O)=O)C=C3)C1=CC(O[C@@H](C)COC)=CC(O[C@@H](C)CC2=CC=CC=C2)=C1	Glucokinase activator	Potent glucokinase activator (EC50 = 33 nM). Significantly reduces plasma glucose levels in diabetic rats; stimulates insulin release from mouse islets of Langerhans.	Coope et al (2006) Predictive blood glucose lowering efficacy by Glucokinase activators in high fat fed female Zucker rats. Br.J.Pharmacol. 149 328. PMID:16921397. Johnson et al (2007) Glucokinase activators: molecular tools for studying the physiology of insulin-secreting cells. Biochem.Soc.Trans. 35 1208. PMID:17956314.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=404024				Sep-2014
5134	MRT 67307 dihydrochloride		O=C(C5CCC5)NCCCNC1=C(C4CC4)C=NC(NC2=CC(CN3CCOCC3)=CC=C2)=N1.Cl.Cl	Salt inducible kinase (SIK) inhibitor	"Salt inducible kinase (SIK) inhibitor (IC50 values are 67, 250 and 430 nM for SIK2, SIK1 and SIK3 respectively). Also inhibits TBK1, MARK1-4, IKK_ and NUAK1 (IC50 values are 19, 27-52, 160 and 230 nM respectively). Has no effect on IKK_ or IKK_. Induces IL-10 secretion and inhibits TNF-_ and IL-6 secretion in bacterial LPS-stimulated macrophages. Also enhances IL-1-induced activation of NF_B-dependent gene transcription in mouse embryonic fibroblast (MEF) cells."	Clark et al (2011) Novel cross-talk within the IKK family controls innate immunity. Biochem.J. 434 93. PMID:21138416. Smith et al (2011) The role of TBK1 and IKKe in the expression and activation of Pellino 1. Biochem.J. 434 537. PMID:21204785. Clark et al (2012) Phosphorylation of CRTC3 by the salt-inducible kinases controls the interconversion of classically activated and regulatory macrophages. Proc.Natl.Acad.Sci.U.S.A. 109 16986. PMID:23033494.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=404025				Aug-2014
5136	Rizatriptan benzoate	[145202-66-0]	CN(CCC2=CNC1=CC=C(CN3N=CN=C3)C=C12)C.O=C(C4=CC=CC=C4)O	Potent 5-HT1B/1D agonist	5-HT1B/1D agonist. Antimigraine agent; attenuates effects of CGRP on light aversion in mice. Orally bioavailable.	"Street et al (1995) Synthesis and serotonergic activity of N,N-dimethyl-2-[5-(1,2,4-triazol-1-ylmethyl)-1H-indol-3-yl]ethylamine and analogues: potent agonists for 5-HT1D receptors. J.Med.Chem. 38 1799. PMID: 7752204. Kaiser et al (2012) Modulation of CGRP-induced light aversion in wild-type mice by a 5-HT1B/D agonist. J.Neurosci. 32 15439. PMID: 23115181."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=404027	SQ1070			Feb-2014
5138	RSVA 405	[140405-36-3]	O=C(N/N=C/C2=C(O)C=C(N(CC)CC)C=C2)C1=CC=NC=C1	AMPK activator; also STAT3 inhibitor	AMP-activated protein kinase (AMPK) activator (EC50 = 1 _M); activates AMPK indirectly through a CaMKK_-dependent mechanism. Also inhibits LPS-induced STAT3 phosphorylation (IC50 = 0.5 _M). Induces autophagy and promotes A_ degradation in vitro. Also inhibits adipogenesis in vitro and reduces weight gain in diet-induced obese mice.	"Vingtdeux et al (2011) Novel synthetic small-molecule activators of AMPK as enhancers of autophagy and amyloid- peptide degradation. FASEB J. 25 219. PMID:20852062. Vingtdeux et al (2011) Small-molecule activators of AMP-activated protein kinase (AMPK), RSVA314 and RSVA405, inhibit adipogenesis. Mol Med 17 1022. PMID:21647536. Capiralla et al (2012) Identification of potent small-molecule inhibitors of STAT3 with anti-inflammatory properties in RAW 264.7 macrophages. FASEB J. 279 3791. PMID:22909341."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=404029	SQ1070			Mar-2014
5139	Telmisartan	[144701-48-4]	CCCC4=NC(C(C)=C3)=C(N4CC5=CC=C(C6=CC=CC=C6C(O)=O)C=C5)C=C3C2=NC1=CC=CC=C1N2C	AT1 antagonist; PPAR_ partial agonist	Antagonist of the angiotensin II type 1 receptor (AT1) (Ki = 3.7 nM). Exhibits antihypertensive activity in a renin-dependent model of hypertension. Partial agonist of PPAR_ receptors; shown to improve insulin sensitivity in rodents receiving high fat diets.	"Ries et al (1993) 6-substituted benzimidazoles as new nonpeptide angiotensin II receptor antagonists: synthesis, biological activity, and structure-activity relationships. J.Med.Chem. 36 4040. PMID:8258826. Benson et al (2004) Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPAR _-modulating activity. Hypertension 43 993. PMID:15007034. Rong et al (2009) An adipose tissue-independent insulin-sensitizing action of telmisartan: a study in lipodystrophic mice. J.Pharmacol.Exp.Ther. 331 1096. PMID:19770292."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=404030	SQ1070			Feb-2014
5140	GSK 2830371	[1404456-53-6]	ClC1=CC(NCC2=CC=C(C(N[C@H]([C@@](NC4CC4)=O)CC3CCCC3)=O)S2)=C(C)N=C1	Potent and selective allosteric inhibitor of Wip1 phosphatase	"Potent and selective allosteric inhibitor of Wip1 phosphatase (IC50 = 6 nM). Exhibits selectivity for Wip1 over 21 other phosphatases. Increases phosphorylation of Wip1 substrates, including p53, Chk2, H2AX and ATM. Attenuates tumor cell growth in a variety of lymphoid cell lines. Also inhibits lymphoma xenograft growth in vivo. Orally bioavailable."	Gilmartin et al (2014) Allosteric Wip1 phosphatase inhibition through flap-subdomain interaction. Nat.Chem.Biol. 10 181. PMID:24390428.	Small Molecule	Sold for research purposes only under agreement from GlaxoSmithKline	http://www.tocris.com/dispprod.php?ItemId=404031				Sep-2014
5141	AZD 5582 dihydrochloride		CN[C@@H](C)C(N[C@@H]([C@H]1CCCCC1)C(N2[C@H]([C@](N[C@H]3C(C=CC=C5)=C5C[C@H]3OCC#CC#CCO[C@@H]4CC8=C(C=CC=C8)[C@@H]4N[C@@]([C@H](CCC7)N7C([C@H]([C@H]6CCCCC6)NC([C@H](C)NC)=O)=O)=O)=O)CCC2)=O)=O.Cl.Cl	Dimeric Smac mimetic; potent IAP inhibitor	"Dimeric Smac mimetic; potent inhibitor of X-linked (XIAP) and cellular (cIAP) inhibitor of apoptosis protein (IC50 values are 15, 15 and 21 nM for XIAP, cIAP1 and cIAP2 respectively). Binds to the BIR3 domain of XIAP to prevent interaction with caspase-9. Causes degradation of cIAP1 and cIAP2 and induces apoptosis in MDA-MB-231 breast cancer cells. Causes tumor regression in MDA-MB-231 xenograft-bearing mice."	Hennessy et al (2013) Discovery of a novel class of dimeric Smac mimetics as potent IAP antagonists resulting in a clinical candidate for the treatment of cancer (AZD5582). J.Med.Chem. 56 9897. PMID:24320998.	Small Molecule	Sold with the permission of AstraZeneca UK Ltd	http://www.tocris.com/dispprod.php?ItemId=404399				Jul-2014
5143	Ononetin	[487-49-0]	COC1=CC=C(CC(C2=C(O)C=C(O)C=C2)=O)C=C1	TRPM3 blocker	Naturally occurring deoxybenzoin. TRPM3 channel blocker (IC50 = 300 nM). Inhibits pregnenolone sulfate-induced intracellular Ca2+ accumulation in HEKmTRPM3 cells and dorsal root ganglia (DRG) neurons in vitro.	Straub et al (2012) Citrus fruit and fabacea secondary metabolites potently and selectively block TRPM3. Br.J.Pharmacol. 168 1835. PMID:23190005.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=404613	SQ1070			Mar-2014
5144	CFM 4	[331458-02-7]	O=C2N(CC4=CC=CC=C4Cl)C1=CC=CC=C1C32NN=C(C5=CC=CC=C5)S3	CARP-1 mimetic; proapoptotic	CARP-1 mimetic; interferes with CARP-1 binding to APC-2. Enhances CARP-1 expression and induces G2/M cell cycle arrest. Induces apoptosis and suppresses cell growth in cancer cells.	Puliyappadamba et al (2011) Antagonists of anaphase-promoting complex (APC)-2-cell cycle and apoptosis regulatory protein (CARP)-1 interaction are novel regulators of cell growth and apoptosis. J.Biol.Chem. 286 38000. PMID:21903591. Ashour et al (2013) CARP-1 functional mimetics: a novel class of small molecule inhibitors of medulloblastoma cell growth. PLoS ONE 8 e66733. PMID:23826121.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=404614	SQ1070			Apr-2014
5145	AI-3	[882288-28-0]	O=C1CC(C)(C)CC2=C(Cl)SC(S(=O)(C)=O)=C12	ARE activator; induces Nrf2-ARE-dependent transcription	Antioxidant response element (ARE) activator; disrupts Nrf2/Keap1 and Keap1/Cul3 interactions and stabilizes Nrf2. Activates ARE in an Nrf2 and PI 3-kinase dependent manner. Induces cytoprotective gene expression in vitro and in vivo.	Wang et al (2013) In vitro and in vivo characterization of a tunable dual-reactivity probe of the Nrf2-ARE pathway. ACS Chem.Biol. 8 1764. PMID:23773140.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=404615	SQ1070			Apr-2014
5146	Sulforhodamine 101	[60311-02-6]	O=S(C(C=C8)=CC(S(=O)([O-])=O)=C8C(C(C=C7C6=C5CCCN6CCC7)=C5O4)=C(C4=C2CCC3)C=C1C2=[N+]3CCC1)(O)=O	Fluorescent dye; selective astrocyte marker	Fluorescent dye. Selective astrocyte marker.	Nimmerjahn et al (2004) Sulforhodamine 101 as a specific marker of astroglia in the neocortex in vivo. Nat.Methods 1 31. PMID:15782150. roth et al (2014) Transcranial amelioration of inflammation and cell death after brain injury. Nature 505 223. PMID:24317693.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=404782				Mar-2014
5147	Istradefylline	[155270-99-8]	O=C1N(CC)C(C(N(C)C(/C=C/C3=CC(OC)=C(OC)C=C3)=N2)=C2N1CC)=O	Potent and selective adenosine A2A receptor antagonist	Potent and selective adenosine A2A receptor antagonist (Ki values are 2.2 and 150 nM for A2A and A1 receptors respectively). Anticataleptic and antiparkinson agent; reverses drug-induced motor dysfunction in animal models.	Shimada et al (1997) Adenosine A2A antagonists with potent anti-cataleptic activity. Bioorg.Med.Chem.Lett. 7 2349. Kanda et al (1998) Adenosine A2A receptors modify motor function in MPTP-treated common marmosets. Neuroreport 9 2857. PMID:9760134. Shiozaki et al (1999) Actions of adenosine A2A receptor antagonist KW-6002 on drug-induced catalepsy and hypokinesia caused by reserpine or MPTP. Psychopharmacology 147 90. PMID:10591873.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=404783	SQ1070			Feb-2014
5148	Wnt-C59	[1243243-89-1]	O=C(CC3=CC=C(C4=CC=NC(C)=C4)C=C3)NC1=CC=C(C2=CC=CN=C2)C=C1	Highly potent Porcn inhibitor	"Highly potent inhibitor of Porcupine (Porcn), a membrane-bound O-acyltransferase (MBOAT) (IC50 = 74 pM). Shown to inhibit Wnt signaling pathways. Blocks progression of mammary tumors in MMTV-WNT1 transgenic mice and downregulates Wnt/_-catenin target genes. Induces cardiomyocyte differentiation from human iPSCs following culture with CHIR 99021 (Cat. No. 4423). Cell permeable and orally bioavailable."	Youssef et al (2012) Adult interfollicular tumour-initiating cells are reprogrammed into an embryonic hair follicle progenitor-like fate during basal cell carcinoma initiation. Nat. Cell Biol. 14 1282. PMID:23178882. Proffitt et al (2013) Pharmacological inhibition of the Wnt acyltransferase PORCN prevents growth of WNT-driven mammary cancer. Cancer Res. 73 502. PMID:23188502. Wend et al (2013) WNT10B/_-catenin signalling induces HMGA2 and proliferation in metastatic triple-negative breast cancer. EMBO Mol.Med. 5 264. PMID:23307470. Burridge et al (2014) Chemically defined generation of human cardiomyocytes. Nat.Methods 11 855. PMID:24930130.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=404784	SQ1070			May-2014
5155	SGI 1027	[1020149-73-8]	O=C(NC4=CC=C(NC5=NC(N)=NC(C)=C5)C=C4)C(C=C3)=CC=C3NC2=CC=NC1=CC=CC=C12	DNA methyltransferase inhibitor	"DNA methyltransferase inhibitor. Inhibits the mammalian DNA methyltransferases DNMT3B, DNMT3A and DNMT1 (IC50 values are 7.5, 8 and 12.5 _M with Poly(dl-dC) as the substrate). Reactivates silenced tumor suppressor genes by reducing CpG island hypermethylation."	Datta et al (2009) A new class of quinoline-based DNA hypomethylating agents reactivates tumor suppressor genes by blocking DNA methyltransferase 1 activity and inducing its degradation. Cancer Res. 69 4277. PMID:19417133. Garca-Domnguez et al (2013) Synthetic approaches to DNMT inhibitor SGI-1027 and effects on the U937 leukemia cell line. Bioorg.Med.Chem.Lett. 23 1631. PMID:23402879.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=405876				Aug-2014
5156	Ivermectin B1a-d2		O[C@H]1[C@H](C)O[C@](O[C@H]2[C@@H](O[C@](O[C@H](/C(C)=C/C[C@@]4([H])O[C@@]7([C@H]([2H])C([2H])[C@H](C)[C@@]([H])([C@]([H])(C)CC)O7)C[C@@H]6C4)[C@@H](C)/C=C/C=C3/[C@]5(O)[C@]([C@H](O)C(C)=CC5C(O6)=O)([H])OC3)([H])C[C@@H]2OC)C)([H])C[C@@H]1OC	Deuterated ivermectin B1a (Cat. No. 1260)	Deuterated ivermectin B1a (Cat. No. 1260).		Small Molecule		http://www.tocris.com/dispprod.php?ItemId=405896	SQ1070			Feb-2014
5160	Medetomidine hydrochloride	[86347-15-1]	CC(C2=CN=CN2)C1=C(C)C(C)=CC=C1.Cl	"Potent, highly selective _2 agonist"	"Potent, highly selective _2-adrenoceptor agonist (Ki values are 1.08 and 1750 nM for _2- and _1-adrenoceptors respectively). Displays greater selectivity over _1-adrenoceptors than clonidine and UK 14,304 (1620-, 220- and 300-fold respectively). Inhibits twitch response in electrically stimulated mouse vas deferens (pD2 = 9.0). Active in vivo; displays hypotensive, bradycardic, sedative, anxiolytic, hypothermic and analgesic effects."	"Savola et al (1986) Evidence for medetomidine as a selective and potent agonist at alpha 2-adrenoceptors. J.Aut.Pharmacol. 6 275. PMID:2880852. Virtanen et al (1988) Characterization of the selectivity, specificity and potency of medetomidine as an _2-adrenoceptor agonist. Eur.J.Pharmacol. 150 9. PMID:2900154. Scheinin et al (1989) Medetomidine - a novel _2-adrenoceptor agonist: a review of its pharmacodynamic effects. Prog.Neuro-Psychopharm.Biol.Psychiat. 13 635. PMID:2571177."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=406817	SQ1070			Mar-2014
5161	ML 154	[1345964-89-7]	CC1=C(P(C4=CC=CC=C4)(C5=CC=CC=C5)=S)N3C(C=CC=C3)=[N+]1C/C=C/C2=CC=CC=C2.[Br-]	Potent neuropeptide S receptor (NPSR) antagonist	"Potent neuropeptide S receptor (NPSR) antagonist (pA2 = 9.98). Inhibits neuropeptide S-induced ERK phosphorylation over cAMP responses and calcium responses (IC50 values are 9.3, 22.1 and 36.5 nM, respectively). Appears to modulate addictive behavior in vivo. Displays no activity against vasopressin V1B receptors. Brain penetrant."	"Patnaik et al (2013) Structure-activity relationship of imidazopyridinium analogues as antagonists of neuropeptide s receptor. J Med Chem. 56 9045. PMID:24171469. Thorsell et al (2013) A novel brain penetrant NPS receptor antagonist, NCGC00185684, blocks alcohol-induced ERK-phosphorylation in the central amygdala and decreases operant alcohol self-administration in rats. J.Neurosci. 33 10132. PMID:23761908."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=407148				Jul-2014
5163	A 366	[1527503-11-2]	COC1=C(OCCCN4CCCC4)C=C(N=C(N)C32CCC3)C2=C1	Potent and selective G9a/GLP histone lysine methyltransferase inhibitor	Potent and selective G9a/GLP histone lysine methyltransferase inhibitor (IC50 = 3.3 nM). Exhibits >1000-fold selectivity for G9a/GLP over 21 other methyltransferases. Decreases levels of lysine 9 dimethylation on histone H3 (H3K9Me2) in PC3 cells.	Sweis et al (2014) Discovery and development of potent and selective inhibitors of histone methyltransferase G9a. ACS Med.Chem.Lett. 5 205. PMID:24900801.	Small Molecule	"This probe is supplied in conjunction with the Structural Genomics Consortium. For further characterization details, please visit the A 366 probe summary on the SGC website."	http://www.tocris.com/dispprod.php?ItemId=410182				Sep-2014
5164	CVT 10216	[1005334-57-5]	O=C2C1=CC=C(OCC4=CC(C(O)=O)=CC=C4)C=C1OC=C2C3=CC=C(NS(=O)(C)=O)C=C3	Potent and selective ALDH2 inhibitor	"Potent and selective, reversible inhibitor of aldehyde dehydrogenase 2 (ALDH2) (IC50 values are 29 and 1300 nM for ALDH2 and ALDH1, respectively). Exhibits anxiolytic effects in rat models."	"Overstreet et al (2009) A selective ALDH-2 inhibitor reduces anxiety in rats. Pharmacol.Biochem.Behav. 94 255. PMID:19747934. Yao et al (2010) Inhibition of aldehyde dehydrogenase-2 suppresses cocaine seeking by generating THP, a cocaine use-dependent inhibitor of dopamine synthesis. Nat.Med. 16 1024. PMID:20729865."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=410183				Dec-2014
5168	Rose Bengal	[632-69-9]	O=C2C(I)=CC(C(OC3=C(I)C(O[Na])=C(I)C=C34)=C2I)=C4C1=C(C(O[Na])=O)C(Cl)=C(Cl)C(Cl)=C1Cl	Potent VGlut and VMAT inhibitor; cell permeable	"Potent VGlut and vesicular monoamine transporter (VMAT) inhibitor (Ki values are 19 and 64 nM, respectively). Inhibits ATP dependent vesicular glutamate uptake (IC50 = 37 nM) and diminishes the amount of exocytotically released glutamate in synaptosomes. Decreases synaptic transmission in the dentate gyrus. Cell permeable."	Ogita et al (2001) Inhibition of vesicular glutamate storage and exocytotic release by Rose Bengal. J Neurochem. 77 34. PMID:11279259. Pietrancosta et al (2010) Rose Bengal analogs and vesicular glutamate transporters (VGLUTs). Bioorg.Med.Chem. 18 6922. PMID:20708942. Neale et al (2013) Modulation of hippocampal synaptic transmission by the kynurenine pathway member xanthurenic acid and other VGLUT inhibitors. Neuropsychopharmacology. Neuropsychopharmacology 38 1060. PMID:23303071.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=410207				Apr-2014
5169	Noradrenaline bitartrate	[108341-18-0]	O[C@@H](CN)C1=CC(O)=C(O)C=C1.OC([C@H](O)[C@@H](O)C(O)=O)=O	Endogenous adrenergic hormone and neurotransmitter	"Endogenous adrenergic hormone and neurotransmitter. A classical stress hormone; underlies the fight or flight response, along with adrenaline. Increases heart rate. Vasoconstrictor."	Bunney et al (1965) Norepinephrine in depressive reactions. A review. Arch.Gen.Psychiatry. 13 483. PMID:5320621. Gary et al (1985) Stress and brain noradrenaline: A review. Neuroscience & Biobehavioral Reviews 9 233. Lewitt et al (2012) Norepinephrine: the next therapeutics frontier for Parkinson's disease. Transl.Neurodegener. 1 4. PMID:23211006.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=410208	SQ1070			May-2014
5171	NBOH-2C-CN hydrochloride	[1539266-32-4]	OC(C=CC=C2)=C2CNCCC1=C(OC)C=C(C#N)C(OC)=C1.Cl	"High affinity, selective 5-HT2A agonist"	"High affinity, selective 5-HT2A agonist (Ki = 1.3 nM). Exhibits 100-fold selectivity for 5-HT2A over 5-HT2C. Elicits head twitch behavior in mice."	"Hansen et al (2014) Synthesis and structure-activity relationships of N-benzyl phenethylamines as 5-HT2A/2C agonists. ACS.Chem.Neurosci. 5 243. PMID:24397362. Fantegrossi et al (2014) Hallucinogen-like effects of 2-([2-(4-cyano-2,5-dimethoxyphenyl) ethylamino]methyl)phenol (25CN-NBOH), a novel N-benzylphenethylamine with 100-fold selectivity for 5-HT2A receptors, in mice. Psychopharmacology (Berl.). PMID:25224567."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=411964				Jul-2014
5172	FLI 06	[313967-18-9]	O=C(OC3CCCCC3)C1=C(C)NC(CC(C)(C)CC4=O)=C4C1C2=CC=C([N+]([O-])=O)C=C2	Inhibitor of Notch signaling	Inhibitor of Notch signaling (EC50 = 2.3 _M). Disrupts Notch trafficking and processing. Reduces amyloid _ secretion. Changes the maturation and abolishes shredding of APP. Inhibits ER exporting and converts tubular ER to sheets.	Krmer et al (2013) Small molecules intercept Notch signaling and the early secretory pathway. Nat.Chem.Biol. 9 731. PMID:24077179 .	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=411965	SQ1070			May-2014
5173	MS 436	[1395084-25-9]	NC1=C(/N=N/C2=CC=C(S(NC3=NC=CC=C3)(=O)=O)C=C2)C=C(C)C(O)=C1	Potent and selective BRD4(1) bromodomain inhibitor	"Potent and selective BRD4 bromodomain inhibitor (Ki = 30 - 50 nM for the first bromodomain (BRD4(1)). Exhibits 10-fold selectivity for BRD4(1) over BRD4(2). Blocks BRD4 transcriptional activity in lipopolysaccharide-induced production of both nitric oxide and IL-6 in mouse macrophages (IC50 values are 3.8 and 4.9 _M, respectively). Attenuates melanoma cell proliferation in vitro."	Zhang et al (2013) Structure-guided design of potent diazobenzene inhibitors for the BET bromodomains. J.Med.Chem. 56 9251. PMID:24144283. Segura et al (2013) BRD4 sustains melanoma proliferation and represents a new target for epigenetic therapy. Cancer Res. 73 6264. PMID:23950209.	Small Molecule	Sold under license from Icahn School of Medicine at Mount Sinai.	http://www.tocris.com/dispprod.php?ItemId=411966	SQ1341			Jul-2014
5175	AEBSF	[30827-99-7]	NCCC1=CC=C(S(=O)(F)=O)C=C1.Cl	"Broad spectrum, irreversible inhibitor of serine proteases"	"Broad spectrum, irreversible inhibitor of serine proteases. Also inhibits NADPH oxidase activation in vitro. Attenuates airway inflammation in a mouse model of airway allergy."	Diatchuk et al (1997) Inhibition of NADPH oxidase activation by 4-(2-aminoethyl)-benzenesulfonyl fluoride and related compounds. J.Biol.Chem. 272 13292. PMID:9148950. Saw et al (2012) Serine protease inhibitor attenuates ovalbumin induced inflammation in mouse model of allergic airway disease. PLoS ONE 7 e41107. PMID:22829914.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=411968				May-2014
5177	WZ 4003	[1214265-58-3]	CN(CC3)CCN3C(C=C2)=CC(OC)=C2NC1=NC=C(Cl)C(OC4=CC(NC(CC)=O)=CC=C4)=N1	Potent and selective NUAK1/2 inhibitor	"Potent and selective NUAK1/2 inhibitor (IC50 values are 20 and 100 nM respectively). Exhibits no significant inhibition against a panel of 139 kinases, including ten AMPK family members. Inhibits NUAK1-mediated MYPT1 phosphorylation. Also inhibits cell proliferation in U2OS cells."	"Zhou et al (2009) Novel mutant-selective EGFR kinase inhibitors against EGFR T790M. Nature 462 1070. PMID:20033049. Banerjee et al (2014) Interplay between Polo kinase, LKB1-activated NUAK1 kinase, PP1_MYPT1 phosphatase complex and the SCF_TrCP E3 ubiquitin ligase. Biochem.J. 461 233. PMID:24785407. Banerjee et al (2014) Characterization of WZ4003 and HTH-01-015 as selective inhibitors of the LKB1-tumour-suppressor-activated NUAK kinases. Biochem.J. 457 215. PMID:24171924."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=412773				Dec-2014
5179	TCID	[30675-13-9]	O=C(CC2=O)C1=C2C(Cl)=C(Cl)C(Cl)=C1Cl	Selective ubiquitin C-terminal hydrolase-L3 (UCH-L3) inhibitor	Selective ubiquitin C-terminal hydrolase-L3 (UCH-L3) inhibitor (IC50 = 0.6 _M). Exhibits >100-fold selectivity for UCH-L3 over UCH-L1. Diminishes glycine transporter GlyT2 ubiquitination in brain stem and spinal cord primary neurons.	Liu et al (2003) Discovery of inhibitors that elucidate the role of UCH-L1 activity in the H1299 lung cancer cell line. Chem.Biol. 10 837. PMID:14522054. de Juan-Sanz et al (2013) Constitutive endocytosis and turnover of the neuronal glycine transporter GlyT2 is dependent on ubiquitination of a C-terminal lysine cluster. PLoS ONE 8 e58863. PMID:23484054.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=412775				Jul-2014
5180	Ferrostatin 1	[347174-05-4]	O=C(OCC)C1=CC(N)=C(NC2CCCCC2)C=C1	Selective inhibitor of erastin induced ferroptosis	"Selective inhibitor of erastin induced ferroptosis (EC50 = 60 nM). Specifically inhibits Ras selective lethal compound -induced death, but not cell death induced by other oxidative lethal compounds and apoptosis-inducing agents. Inhibits ferroptosis in cancer cells; also inhibits glutamate-induced cell death in organotypic rat brain slices. Prevents erastin induced accumulation of cytosolic and lipid reactive oxygen species."	Dixon et al (2012) Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell 149 1060. PMID:22632970. Louandre et al (2013) Iron-dependent cell death of hepatocellular carcinoma cells exposed to sorafenib. Int.J.Cancer 133 1732. PMID:23505071. Skouta et al (2014) Ferrostatins inhibit oxidative lipid damage and cell death in diverse disease models. J.Am.Chem.Soc. 136 4551. PMID:24592866.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=413246	SQ1070			May-2014
5181	Tolvaptan	[150683-30-0]	OC1C2=C(C=CC(Cl)=C2)N(C(C3=C(C)C=C(NC(C4=CC=CC=C4C)=O)C=C3)=O)CCC1	Potent and selective vasopressin V2 receptor antagonist; renoprotective and orally active	Potent and selective competitive vasopressin V2 receptor antagonist (Ki values are 0.06 and 12.3 nM for V2 and V1a receptors respectively). Decreases urine osmolality and increases serum sodium concentrations. Delays the onset of end-stage renal disease in a mouse model of polycystic kidney disease. Exhibits myocardial and renal protective effects in hypertensive heart failure rats. Orally active.	"Kondo et al (1999) 7-Chloro-5-hydroxy-1-[2-methyl-4-(2-methylbenzoyl-amino)benzoyl ]-2,3,4,5-tetrahydro-1H-1-benzazepine (OPC-41061): a potent, orally active nonpeptide arginine vasopressin V2 receptor antagonist. Bioorg.Med.Chem. 7 1743. PMID:10482466. Ghali et al (2009) Tolvaptan. Nat.Rev.Drug Discov. 8 611. PMID:19644472. Morooka et al (2012) Chronic administration of oral vasopressin type 2 receptor antagonist tolvaptan exerts both myocardial and renal protective effects in rats with hypertensive heart failure. Circ.Heart.Fail. 5 484. PMID:22628529. Aihara et al (2014) Tolvaptan delays the onset of end-stage renal disease in a polycystic kidney disease model by suppressing increases in kidney volume and renal injury. J.Pharmacol.Exp.Ther. 349 258. PMID:24570071."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=413298	SQ1341			Jun-2014
5183	ETP 45835 dihydrochloride		C1(C2=CC(C3=CC=NC=C3)=NN2)CCNCC1.Cl.Cl	Mnk1 and Mnk2 inhibitor	"Mnk2 and Mnk1 inhibitor (IC50 values are 575 and 646 nM respectively). Exhibits selectivity against a panel of 24 protein kinases, including those upstream of Mnk1/2."	Oyarzabal et al (2010) Discovery of mitogen-activated protein kinase-interacting kinase 1 inhibitors by a comprehensive fragment-oriented virtual screening approach. J.Med.Chem. 53 6618. PMID:20722422.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=413935				Sep-2014
5186	Neuropathiazol	[880090-88-0]	O=C(OCC)C1=CC=C(N(C2=CSC(C3=CC=CC=C3)=N2)C)C=C1	Selective inducer of neuronal differentiation in hippocampal neural progenitors	"Selective inducer of neuronal differentiation in cultured hippocampal neural progenitor cells (NPCs). Selectively suppresses astrocyte differentiation when induced by LIF, BMP2 and FBS compared to retinoic acid. Enhances maturation of NPC derived neurons."	Warashina et al (2006) A synthetic small molecule that induces neuronal differentiation of adult hippocampal neural progenitor cells. Angew Chem. Int. Ed. Engl. 45 591. PMID:16323231.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=413991				Aug-2014
5188	S 07662	[883226-64-0]	CC2=C(CNC(NCC3=CC=CS3)=O)C1=CC=CC=C1O2	Inverse agonist of the constitutive androstane receptor (CAR)	Inverse agonist of the constitutive androstane receptor (CAR). Inhibits CAR activity via recruitment of nuclear receptor co-repressor (NCoR). Suppresses CITCO-induced CYP2B6 gene expression in human primary hepatocytes.	Kblbeck et al (2011) New in vitro tools to study human constitutive androstane receptor (CAR) biology: discovery and comparison of human CAR inverse agonists. Mol.Pharm. 8 2424. PMID:22044162.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=413993				Oct-2014
5189	GSK 2837808A	[1445879-21-9]	O=S(C2=C(NC3=CC(OC5=CC(F)=CC(F)=C5)=CC(C(O)=O)=C3)C1=CC=C(C6=CN=C(OC)N=C6OC)C=C1N=C2)(NC4CC4)=O	Potent and selective LDHA inhibitor	Potent and selective lactate dehydrogenase A (LDHA) inhibitor (IC50 values are 1.9 and 14 nM for LDHA and LDHB respectively). Inhibits lactate production in multiple cancer cell lines. Reduces glucose uptake and enhances mitochondrial oxygen consumption in Snu398 hepatocellular carcinoma cells. Inhibits proliferation and induces apoptosis in Snu398 cells. Cell permeable.	Billiard et al (2013) Quinoline 3-sulfonamides inhibit lactate dehydrogenase A and reverse aerobic glycolysis in cancer cells. Cancer Metab. 1 19. PMID:24280423. Xie et al (2014) Targeting lactate dehydrogenase-A inhibits tumorigenesis and tumor progression in mouse models of lung cancer and impacts tumor-initiating cells. Cell.Metab. 19 795. PMID:24726384.	Small Molecule	Sold for research purposes under agreement from GlaxoSmithKline.	http://www.tocris.com/dispprod.php?ItemId=415469				Sep-2014
5190	FRAX 486	[1232030-35-1]	FC1=CC(NC3=NC(N(CC)C(C(C5=CC=C(Cl)C=C5Cl)=C4)=O)=C4C=N3)=CC=C1N2CCNCC2	Potent p21-activated kinase (PAK) inhibitor; brain penetrant and orally bioavailable	"Potent p21-activated kinase (PAK) inhibitor (IC50 values are 14, 33, 39 and 575 nM for PAK1, PAK2, PAK3 and PAK4 respectively). Blocks and reverses the DISC1 knockdown-induced reduction in dendritic spine size in cortical neurons. Attenuates dendritic spine elimination and enhances spine generation in DISC1 knockdown mice. Ameliorates autism-like behavioral symptoms in fragile X mental retardation 1 (Fmr1) knockout mice. Brain penetrant and orally bioavailable."	Hayashi-Takagi et al (2013) PAKs inhibitors ameliorate schizophrenia-associated dendritic spine deterioration in vitro and in vivo during late adolescence. Proc.Natl.Acad.Sci.U.S.A. 111 6461. PMID:24706880. Dolan et al (2013) Rescue of fragile X syndrome phenotypes in Fmr1 KO mice by the small-molecule PAK inhibitor FRAX486. Proc.Natl.Acad.Sci.U.S.A. 110 5671. PMID:23509247.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=415470	SQ1341			Jul-2014
5191	PTC 209	[315704-66-6]	CC3=C(N(C=CC=N4)C4=N3)C1=CSC(NC2=C(Br)C=C(OC)C=C2Br)=N1	Bmi-1 inhibitor; antitumor	Bmi-1 inhibitor (IC50 ~ 0.5 _M); irreversibly impairs colorectal cancer-initiating cell (CIC) growth. Reduces tumor growth in CIC xenograft assays and results in reduced potential of colorectal cancer cells to initiate tumors in vivo.	Kreso et al (2014) Self-renewal as a therapeutic target in human colorectal cancer. Nat.Med. 20 29. PMID:24292392.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=415471				Aug-2014
5197	Spautin 1	[1262888-28-7]	FC1=CC=C(N=CN=C2NCC3=CC=C(F)C=C3)C2=C1	USP10 and USP13 inhibitor; inhibits autophagy	Inhibitor of autophagy; inhibits USP10 and USP13 activity (IC50 values are 0.6 and 0.7 _M respectively) and promotes degradation of Vps34 (class III PI 3-kinase) complexes. Selectively promotes apoptosis of cancer cells under starvation conditions. Prevents the PDGF-induced conversion from the contractile to synthetic phenotype in vascular smooth muscle cells.	Liu et al (2011) Beclin1 controls the levels of p53 by regulating the deubiquitination activity of USP10 and USP13. Cell 147 223. PMID:21962518. Salabei et al (2013) PDGF-mediated autophagy regulates vascular smooth muscle cell phenotype and resistance to oxidative stress. Biochem.J. 451 375. PMID:23421427.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=415477				Jan-2015
5198	AZ 20	[1233339-22-4]	CS(C4(CC4)C1=CC(N5[C@H](C)COCC5)=NC(C2=CC=CC3=C2C=CN3)=N1)(=O)=O	Potent and selective ATR kinase inhibitor; antitumor	"Potent and selective ATR kinase inhibitor (IC50 = 5 nM). Exhibits 7.6-fold selectivity over mTOR and selectivity over a panel of 442 kinases, including ATM kinase, PI3-K isoforms, and DNA-PK. Inhibits cell growth in cell lines with high baseline levels of replication stress. Displays antitumor effects in vivo."	Foote et al (2013) Discovery of 4-{4-[(3R)-3-Methylmorpholin-4-yl]-6-[1-(methylsulfonyl)cyclopropyl]pyrimidin-2-yl}-1H-indole (AZ20): a potent and selective inhibitor of ATR protein kinase with monotherapy in vivo antitumor activity. J.Med.Chem. 56 2125. PMID:23394205.	Small Molecule	Sold for research purposes under agreement from AstraZeneca	http://www.tocris.com/dispprod.php?ItemId=415746				Jun-2014
5199	AZD 7762 hydrochloride	[1246094-78-9]	FC1=CC=CC(C2=CC(NC(N)=O)=C(C(N[C@@H]3CNCCC3)=O)S2)=C1.Cl	Potent and selective ATP-competitive inhibitor of Chk1 and Chk2	Potent and selective ATP-competitive inhibitor of Chk1 and Chk2 (IC50 vales are 5 nM for both kinases); displays at least >10 fold selectivity over a panel of 164 kinases. Potentiates cytotoxicity of DNA-damaging agents. Active in vivo.	"Zabludoff et al (2008) AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies. Mol. Cancer Ther. 7 2955. PMID:18790776. Morgan et al (2010) Mechanism of radiosensitization by the Chk1/2 inhibitor AZD7762 involves abrogation of the G2 checkpoint and inhibition of homologous recombinational DNA repair. Cancer Res. 70 4972. PMID:20501833."	Small Molecule	Sold for research purposes under agreement from AstraZeneca	http://www.tocris.com/dispprod.php?ItemId=415747	SQ1341			Jun-2014
5203	NIBR 189	[1599432-08-2]	BrC1=CC=C(/C=C/C(N2CCN(C(C3=CC=C(OC)C=C3)=O)CC2)=O)C=C1	Potent and selective EBI2 (GPR183) receptor antagonist	"Potent and selective EBI2 (GPR183) receptor antagonist (IC50 values are 11 and 15 nM for human and mouse EBI2 receptors respectively). Exhibits selectivity for EBI2 over a panel of other receptors, enzymes and transporters. Blocks oxysterol-induced migration of U937 monocyte cells. Orally bioavailable."	Gessier et al (2014) Identification and characterization of small molecule modulators of the Epstein-Barr virus-induced gene 2 (EBI2) receptor. J.Med.Chem. 57 3358. PMID:24678947.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=416089				Oct-2014
5206	JJKK 048	[1515855-97-6]	O=C(N6C=NC=N6)N(CC5)CCC5C(C2=CC=C(OCO3)C3=C2)C1=CC(OCO4)=C4C=C1	Potent and selective monoacylglycerol lipase (MAGL) inhibitor	"Potent and selective monoacylglycerol lipase (MAGL) inhibitor (IC50 = 0.4 nM). Exhibits >13,000 and ~630-fold selectivity for MAGL over FAAH and ABHD6 respectively."	Aaltonen et al (2013) Piperazine and piperidine triazole ureas as ultrapotent and highly selective inhibitors of monoacylglycerol lipase. Chem.Biol. 20 379. PMID:23521796. Laitinen et al (2014) Mutation of Cys242 of human monoacylglycerol lipase disrupts balanced hydrolysis of 1- and 2-monoacylglycerols and selectively impairs inhibitor potency. Mol.Pharmacol. 85 510. PMID:24368842.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=416252				Feb-2015
5207	STF 118804	[894187-61-2]	O=C(C2=CC=C(C3=NC(CS(C4=CC=C(C)C=C4)(=O)=O)=C(C)O3)C=C2)NCC1=CN=CC=C1	NAMPT inhibitor	"Inhibitor of NAMPT (nicotinamide phosphoribosyltransferase, visfatin, PBEF1); inhibits NAD+ synthesis from nicotinamide. Potently inhibits the viability of multiple B-cell acute lymphoplastic leukemia (B-ALL) cell lines (IC50 < 10 nM); induces apoptosis in MF-411 cells. Also targets leukemia stem cells."	Matheny et al (2013) Next-generation NAMPT inhibitors identified by sequential high-throughput phenotypic chemical and functional genomic screens. Chem.Biol. 20 1352. PMID:24183972.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=416253				Sep-2014
5209	TAK 21d	[1143578-94-2]	FC1=CC(C2=NC(N3CCN(C(NC4=CC=CN=N4)=O)CC3)=NC=C2)=CC=C1F	Potent FAAH inhibitor	"Potent FAAH Inhibitor; (IC50 values are 0.28 and 0.72 nM, at rat and human FAAH respectively). Displays analgesic effects in vivo models of neuropathic and inflammatory pain. Brain penetrant."	"Kono et al (2014) Design, synthesis, and biological evaluation of a series of piperazine ureas as fatty acid amide hydrolase inhibitors. Bioorg.Med.Chem. 22 1468. PMID:24440478."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=416583				Dec-2014
5214	IWP 4	[686772-17-8]	O=C1C3=C(CCS3)N=C(SCC(NC4=NC(C=CC(C)=C5)=C5S4)=O)N1C2=C(OC)C=CC=C2	Potent inhibitor of Wnt/_-catenin signaling	Potent inhibitor of Wnt/_-catenin signaling (IC50 = 25 nM). Has minimal effect on Notch and Hedgehog signaling pathways. Induces differentiation of cardiomyocytes from human ESCs and iPSCs.	Chen et al (2009) Small molecule-mediated disruption of Wnt-dependent signaling in tissue regeneration and cancer. Nat.Chem.Biol. 5 100. PMID:19125156. Lian et al (2012) Robust cardiomyocyte differentiation from human pluripotent stem cells via temporal modulation of canonical Wnt signaling. Proc.Natl.Acad.Sci.U.S.A. 109 E1848-57. PMID:22645348. Frith et al (2013) Microbioreactor array screening of Wnt modulators and microenvironmental factors in osteogenic differentiation of mesenchymal progenitor cells. PLoS One 8 e82931. PMID:24376608.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=417202				Feb-2015
5230	BRD 7552	[1137359-47-7]	OC[C@@H]1[C@@H](OC(NC6=CC=C(C(OCC)=O)C=C6)=O)[C@H](OC(NC4=CC=C(OCO5)C5=C4)=O)[C@@H](OC(NC2=CC(OCO3)=C3C=C2)=O)[C@@H](OC)O1	PDX1 transcription factor inducer; increases insulin expression	"PDX1 transcription factor inducer; up regulates PDX1 expression in both primary human islets and ductal cells. Induces epigenetic changes in the PDX1 promoter consistent with transcriptional activation. Increases insulin expression in PANC-1 cells, primary human islets and human duct-derived cells."	Yuan et al (2013) A small-molecule inducer of PDX1 expression identified by high-throughput screening. Chem.Biol. 20 1513. PMID:24290880.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=419322	SQ1341			Jul-2014
5231	MPC 6827 hydrochloride	[917369-31-4]	CC2=NC1=CC=CC=C1C(N(C)C3=CC=C(OC)C=C3)=N2.Cl	Inhibitor of microtubule polymerization; antimitotic and antitumor	Potent inhibitor of microtubule formation (IC50 = 1.5 - 3.4 nM); inhibits polymerization of tubulin in vitro and disrupts microtubule formation in several cancer cell lines. Inhibits tumor growth in vitro and in vivo; exhibits pro-apoptotic characteristics. Brain penetrant.	"Kasibhatla et al (2007) MPC-6827: a small-molecule inhibitor of microtubule formation that is not a substrate for multidrug resistance pumps. Cancer Res. 67 5865. PMID:17575155 . Sirisoma et al (2009) Discovery of N-(4-methoxyphenyl)-N,2-dimethylquinazolin-4-amine, a potent apoptosis inducer and efficacious anticancer agent with high blood brain barrier penetration. J.Med.Chem. 52 2341. PMID:19296653. Mahal et al (2014) Effects of the tumor-vasculature-disrupting agent verubulin and two heteroaryl analogues on cancer cells, endothelial cells, and blood vessels. ChemMedChem. 9 847. PMID:24678059."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=419323				Aug-2014
5233	CCG 1423	[285986-88-1]	O=C(NOC(C)C(NC2=CC=C(Cl)C=C2)=O)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1	Induces intermediate mesoderm differentiation from ESCs; Rho/SRF pathway inhibitor	"Rho/SRF pathway inhibitor; stimulates apoptosis of a melanoma cell line overexpressing RhoC (A375M2). Suppresses Rho-dependent invasion of PC-3 prostate cancer cells in vitro and inhibits lysophosphatidic acid-induced DNA synthesis in PC-3 prostate cancer cells. When used in combination with Retinoic acid, LY 294002 and Pyridone 6, it induces intermediate mesoderm differentiation from ESCs."	Evelyn et al (2007) CCG-1423: a small-molecule inhibitor of RhoA transcriptional signaling. Mol.Cancer Ther. 6 2249. PMID:17699722. Mae et al (2010) Combination of small molecules enhances differentiation of mouse embryonic stem cells into intermediate mesoderm through BMP7-positive cells. Biochem.Biophys.Res.Commun. 393 877. PMID:20171952.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=419332				Dec-2014
5236	CC4	[492-02-4]	O=C1N2C([C@@](C3)([H])CN(CCN5C[C@](C6)([H])C(N4C[C@]6([H])C5)=CC=CC4=O)C[C@@]3([H])C2)=CC=C1	High affinity and subtype-selective _6_2 and _4_2 partial agonist	High Affinity and subtype selective _6_2 and _4_2 partial agonist (Ki values are 12 and 26nM for rat _6_2 and _4_2 receptors respectively). Has low affinity for _3_4 and _7 receptors (Ki values are 4.8 and 13 _M for human _3_4 and rat _7 receptors respectively). Stimulates dopamine release from striatal slices in vitro. Attenuates nicotine-induced self-administration and conditional place preference in rats.	"Carbonnelle et al (2003) Nitrogen substitution modifies the activity of cytisine on neuronal nicotinic receptor subtypes. Eur.J.Pharmacol. 471 85. PMID:12818695. Riganti et al (2005) Long-term exposure to the new nicotinic antagonist 1,2-bisN-cytisinylethane upregulates nicotinic receptor subtypes of SH-SY5Y human neuroblastoma cells. Br.J.Pharmacol. 146 1096. PMID:16273122. Sala et al (2013) CC4, a dimer of cytisine, is a selective partial agonist at _4_2/_6_2 nAChR with improved selectivity for tobacco smoking cessation. Br.J.Pharmacol. 168 835. PMID:22957729."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=419335				Dec-2014
5242	CLP 257	[1181081-71-9]	OC1=C(/C=C2/C(N=C(N3CCCCN3)S2)=O)C=CC(F)=C1	Selective KCC2 K+-Cl- cotransporter activator	"Selective KCC2 K+-Cl- cotransporter activator (EC50 = 616 nM). Exhibits selectivity for KCC2 over other KCC family members, NKCC1 and GABAA receptors, as well as 55 other receptors. Enhances Cl- transport and increases KCC2 plasma membrane expression in spinal slices with reduced KCC2 function. Alleviates hypersensitivity in rats with peripheral nerve injury."	Gagnon et al (2013) Chloride extrusion enhancers as novel therapeutics for neurological diseases. Nat.Med. 19 1524. PMID:24097188.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=419347				Dec-2014
5243	TC-S 7009	[1422955-31-4]	ClC1=CC(F)=CC(NC3=C([N+]([O-])=O)C2=NON=C2C=C3)=C1	High affinity and selective HIF-2_ inhibitor	High affinity and selective HIF-2_ inhibitor (Kd = 81 nM). Binds to the HIF-2_ PAS-B domain; disrupts HIF-2_-ARNT heterodimerization. Exhibits >60-fold selectivity for HIF-2_ over HIF-1_. Decreases HIF-2_ DNA-binding and attenuates expression of HIF-2_ target genes in vitro.	Scheuermann et al (2013) Allosteric inhibition of hypoxia inducible factor-2 with small molecules. Nat.Chem.Biol. 9 271. PMID:23434853. Rogers et al (2013) Development of inhibitors of the PAS-B domain of the HIF-2_ transcription factor. J.Med.Chem. 56 1739. PMID:23363003.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=419394				Feb-2015
5245	Ebselen	[60940-34-3]	O=C2C1=CC=CC=C1[Se]N2C3=CC=CC=C3	Glutathione peroxidase mimic; peroxynitrite scavenger	"Glutathione peroxidase mimic; peroxynitrite scavenger. Inhibits lipoxygenase, cyclooxygenase, nitric oxide synthase, protein kinase C and H+/K+-ATPase activity. Inhibits the hepatic carcinogenic effects of aflatoxin B1. Antioxidant and anti-inflammatory."	"Schewe (1995) Molecular actions of ebselen--an antiinflammatory antioxidant. Gen.Pharmacol. 26 1153. PMID:7590103. Yang et al (2000) Inhibition of ebselen on aflatoxin B(1)-induced hepatocarcinogenesis in Fischer 344 rats. Carcinogenesis 21 2237. PMID:11133813. Fujisawa and Kadoma (2005) Kinetic studies of the radical-scavenging activity of ebselen, a seleno-organic compound. Anticancer Res. 25 3989. PMID:16309189."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=419586				Jul-2014
5247	NVP ADW 742	[475488-23-4]	NC1=NC=NC2=C1C(C4=CC(OCC5=CC=CC=C5)=CC=C4)=CN2[C@@H]3C[C@@H](CN6CCCC6)C3	ATP-competitive inhibitor of IGF1R	"ATP-competitive inhibitor of IGF1R (IC50 in the range of 0.1-0.2 _M). Also inhibits c-Kit kinase activity (IC50 in the range of 3-5 _M). Exhibits a synergistic effect with Imatinib, enhancing the sensitivity of multiple small cell lung cancer cell lines to the chemotherapeutics etoposide (Cat. No. 1226) and carboplatin (Cat. No. 2626)."	"Warshamana-Greene et al (2004) The insulin-like growth factor-I (IGF-I) receptor kinase inhibitor NVP-ADW742, in combination with STI571, delineates a spectrum of dependence of small cell lung cancer on IGF-I and stem cell factor signaling. Mol.Cancer Ther. 3 527. PMID:15141010. Warshamana-Greene et al (2005) The insulin-like growth factor-I receptor kinase inhibitor, NVP-ADW742, sensitizes small cell lung cancer cell lines to the effects of chemotherapy. Clin.Cancer Res. 11 1563. PMID:15746061 . Zhou et al (2011) The insulin-like growth factor-I receptor kinase inhibitor NVP-ADW742 sensitizes medulloblastoma to the effects of chemotherapy. Oncol. Rep. 25 1565. PMID:21455580."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=419822				Aug-2014
5248	XAP 044	[196928-50-4]	OC1=CC=C(C(C(OC3=CC=C(I)C=C3)=CO2)=O)C2=C1	Potent and selective mGlu7 antagonist	Potent and selective mGlu7 antagonist (IC50 = 88 nM); inhibits lateral amygdala long term potentiation (LTP) in brain slices from wild type mice. Displays no effects on the LTP of mGlu7 deficient mice. Exhibits novel activity by binding to the mGlu7 Venus flytrap domain (VFTD). Exhibits anti-anxiety effects in rodent models. Brain penetrant.	"Gee et al (2014) Blocking metabotropic glutamate receptor subtype 7 (mGlu7) via the Venus flytrap domain (VFTD) inhibits amygdala plasticity, stress, and anxiety-related behavior. J.Biol.Chem. 289 10975. PMID:24596089."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=420352				Oct-2014
5250	Ramipril	[87333-19-5]	[H][C@@]12CCC[C@@]([H])1N(C([C@H](C)N[C@H]([C@@](OCC)=O)CCC3=CC=CC=C3)=O)[C@H]([C@@](O)=O)C2	"Non-peptide, competitive angiotensin-converting enzyme (ACE) inhibitor"	"Non-peptide, competitive angiotensin converting enzyme (ACE) inhibitor (IC50 = 5 nM). Prodrug which is hydrolyzed in vivo to the active metabolite ramiprilat. Displays protective effects on endothelium against high-glucose induced dysfunction. Exhibits antihypertensive effects."	Stevens et al (1988) Ramipril inhibition of rabbit (Oryctolagus cuniculus) small intestinal brush border membrane angiotensin converting enzyme. Comp.Biochem.Physiol C. 91 493. PMID:2905962. Levitt et al (2006) Human physiologically based pharmacokinetic model for ACE inhibitors: ramipril and ramiprilat. BMC Clin. Pharmacol. 6 1. PMID:16398929. Tian et al (2014) Ramipril protects the endothelium from high glucose-induced dysfunction through CaMKK/AMPK and heme oxygenase-1 activation. J.Pharmacol.Exp.Ther. 350 5. PMID:24741076.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=420448	SQ1341			Jul-2014
5251	UC 112	[383392-66-3]	OC1=C3C(C=CC=N3)=C(COCC4=CC=CC=C4)C=C1CN2CCCC2	IAP and XIAP inhibitor; antitumor	IAP inhibitor (IC50 values from 0.7 - 3.4 _M); inhibits cell growth in multiple cancer cell lines and in a melanoma xenograft model in vivo. Also suppresses X-linked inhibitor of apoptosis protein (XIAP) and survivin levels. Inhibits the growth of P-glycoproteins and activates caspase-3/7 and caspase-9.	Wang Discovery of novel second mitochondria-derived activator of caspase mimetics as selective inhibitor of apoptosis protein inhibitors. J.Pharmacol.Exp.Ther. 349 319. PMID:24623800.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=421303				Aug-2014
5254	FH 1	[2719-05-3]	CC(NC1=CC=C(CC2=CC=C(NC(C)=O)C=C2)C=C1)=O	Enhances iPSC-derived hepatocyte differentiation and maturation	Enhances differentiation of induced pluripotent stem cells (iPSCs) to hepatocytes; also promotes the maturation of iPSC-derived hepatocytes.	Shan et al (2013) Identification of small molecules for human hepatocyte expansion and iPS differentiation. Nat.Chem.Biol. 9 514. PMID:23728495.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=421780				Jul-2014
5256	AH 7614	[6326-06-3]	CC(C=C4)=CC=C4S(NC2C3=C(C=CC=C3)OC1=CC=CC=C12)(=O)=O	Selective FFA4 (GPR120) antagonist	Selective free fatty acid receptor 4 (FFA4/GPR120) antagonist (pIC50 values are 7.1 and <4.6 for human FFA4 and FFA1 receptors respectively). Inhibits linoleic acid and GSK 137647A-induced intracellular calcium accumulation in U2OS osteosarcoma cells expressing the FFA4 receptor.	Sparks et al (2014) Identification of diarylsulfonamides as agonists of the free fatty acid receptor 4 (FFA4/GPR120). Bioorg.Med.Chem.Lett. 24 3100. PMID:24881566.	Small Molecule	Sold for research purposes under agreement from GlaxoSmithKline	http://www.tocris.com/dispprod.php?ItemId=422015				Aug-2014
5257	GSK 137647	[349085-82-1]	CC1=CC(C)=CC(C)=C1NS(C2=CC=C(OC)C=C2)(=O)=O	Potent and selective FFA4 (GPR120) agonist	"Potent and selective FFA4 (GPR120) agonist (pEC50 values are 6.3, 6.2 and 6.1 at the human, mouse and rat receptor, respectively). Exhibits 100-fold selectivity against a panel of 61 targets including FFA1, FFA2 and FFA3. Enhances glucose-stimulated insulin secretion in MIN6 cells. Induces intracellular calcium accumulation in U2OS cells; this activity is inhibited by AH 7614 (Cat. No. 5256)."	Martin et al (2012) Lipid-mediated release of GLP-1 by mouse taste buds from circumvallate papillae: putative involvement of GPR120 and impact on taste sensitivity. J.Lipid Res. 53 2256. PMID:22904345. Sparks et al (2014) Identification of diarylsulfonamides as agonists of the free fatty acid receptor 4 (FFA4/GPR120). Bioorg.Med.Chem.Lett. 24 3100. PMID:24881566.	Small Molecule	Sold for research purposes under agreement from GlaxoSmithKline	http://www.tocris.com/dispprod.php?ItemId=422016				Aug-2014
5258	BMS 309403	[300657-03-8]	CCC1=C(C4=CC=CC=C4)C(C5=CC=CC=C5)=NN1C2=CC=CC=C2C3=CC=CC(OCC(O)=O)=C3	Potent and selective FABP4 inhibitor	"Potent and selective fatty acid binding protein 4, adipocyte (FABP4) inhibitor (Ki values are <2, 250 and 350 nM for FABP4, FABP3 and FABP5 respectively). Decreases fatty acid uptake in adipocytes in vitro and reduces atherosclerotic lesion area in a mouse model of atherosclerosis. Reduces blood glucose levels and increases insulin sensitivity in a mouse model of obesity. Orally active."	Furuhashi et al (2007) Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2. Nature 447 959. PMID:17554340. Sulsky et al (2007) Potent and selective biphenyl azole inhibitors of adipocyte fatty acid binding protein (aFABP). Bioorg.Med.Chem.Lett. 17 3511. PMID:17502136. Lin et al (2012) BMS309403 stimulates glucose uptake in myotubes through activation of AMP-activated protein kinase. PLoS ONE 7 e44570. PMID:22952994.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=422017				Sep-2014
5261	Dimethylenastron	[863774-58-7]	O=C1CC(C)(C)CC2=C1C(C3=CC=CC(O)=C3)NC(N2)=S	Inhibitor of mitotic motor kinesin Eg5	"Inhibitor of mitotic motor kinesin Eg5 (IC50 = 200 nM). Arrests mitosis, triggers apoptosis and up-regulates Hsp-70 expression in multiple human myeloma cell lines. Also inhibits the growth of several types of cancer cell lines (EC50 values are 330, 603, 743 and 881 nM in HCT116, Htert-HME1, BxPC3, K562 and NCI-H1299 cancer cells, respectively). Suppresses the migration and invasion of PANC1 cells in vitro. Cytoprotective."	"Liu et al (2006) Inhibition of the mitotic kinesin Eg5 up-regulates Hsp70 through the phosphatidylinositol 3-kinase/Akt pathway in multiple myeloma cells. J.Biol.Chem. 281 18090. PMID:16627469. Kaan et al (2010) Structural basis for inhibition of Eg5 by dihydropyrimidines: stereoselectivity of antimitotic inhibitors enastron, dimethylenastron and fluorastrol. J.Med.Chem. 53 5676. PMID:20597485. Sun et al (2011) Dimethylenastron suppresses human pancreatic cancer cell migration and invasion in vitro via allosteric inhibition of mitotic kinesin Eg5. Acta.Pharmacol Sin. 32 1543. PMID:21986572."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=422020				Nov-2014
5262	PF 5274857 hydrochloride	[1613439-62-5]	CC1=CN=C(C2=CC(N3CCN(C(CCS(C)(=O)=O)=O)CC3)=NC=C2Cl)C(C)=C1.Cl	High affinity and selective Smoothened (Smo) receptor antagonist	"High affinity and selective Smoothened (Smo) receptor antagonist (Ki = 4.6 nM). Exhibits >1000-fold selectivity for Smo over a panel of other receptors, ion channels and enzymes. Inhibits Shh-induced Hedgehog signaling in MEF cells. Induces tumor regression in a medulloblastoma allograft mouse model. Orally available and brain penetrant."	"Rohner et al (2011) Effective targeting of Hedgehog signaling in a medulloblastoma model with PF-5274857, a potent and selective Smoothened antagonist that penetrates the blood-brain barrier. Mol.Cancer Ther. 11 57. PMID:22084163."	Small Molecule	Sold for research purposes under agreement from Pfizer Inc.	http://www.tocris.com/dispprod.php?ItemId=423198				Sep-2014
5263	Bazedoxifene acetate	[198481-33-3]	CC2=C(C3=CC=C(O)C=C3)N(CC4=CC=C(OCCN5CCCCCC5)C=C4)C1=CC=C(O)C=C12.OC(C)=O	Potent and selective estrogen receptor modulator (SERM)	Potent selective estrogen receptor modulator (SERM) (IC50 values are 26 and 99 nM for ER_ and ER_ respectively). Inhibits 17_-estradiol-induced proliferation in MCF-7 cells. Co-treatment with Raloxifene (Cat No. 2280) completely abolishes raloxifene-induced stimulation of luminal epithelial cells and myometrium.	Komm et al (2005) Bazedoxifene acetate: a selective estrogen receptor modulator with improved selectivity. Endocrinology 146 3999. PMID:15961563.	Small Molecule	Sold for research purposes under agreement from Pfizer Inc.	http://www.tocris.com/dispprod.php?ItemId=423199				Sep-2014
5264	Temsirolimus	[162635-04-3]	O=C([C@H](C)\C=C([C@@H](O)[C@@H](OC)C([C@@H]4C)=O)/C)C[C@]([C@H](C)C[C@H]2C[C@@H](OC)[C@H](OC(C(CO)(C)CO)=O)CC2)([H])OC([C@@]1([H])N(C(C([C@@]3(O)[C@H](C)CC[C@](C[C@@H](/C(C)=C/C=C/C=C/[C@H](C4)C)OC)([H])O3)=O)=O)CCCC1)=O	mTOR inhibitor; antitumor	"mTOR inhibitor; inhibits tumor growth in breast cancer cell lines (IC50 values are 1.6 and 4.3 nM for SKBr3 and BT474, respectively). Inhibits HIF-1_-mediated VEGF production in breast cancer cell lines (BT474 and MDA-MB-231). Directly inhibits serum and VEGF mediated endothelial cell proliferation and morphogenesis in vitro and vessel formation in vivo. Causes G1/S cell cycle arrest in multiple cancer cell lines. Antiangiogenic."	Wu L et al (2005) Effects of the mammalian target of rapamycin inhibitor CCI-779 used alone or with chemotherapy on human prostate cancer cells and xenografts. Cancer Res. 65 2825. PMID:15805283. Del Bufalo et al (2006) Antiangiogenic potential of the Mammalian target of rapamycin inhibitor temsirolimus. Cancer Res. 66 5549. PMID:16740688. Wang et al (2012) Inhibition of mammalian target of rapamycin signaling by CCI-779 (temsirolimus) induces growth inhibition and cell cycle arrest in Cashmere goat fetal fibroblasts (Capra hircus). DNA Cell Biol. 31 1095. PMID:22320865. Li et al (2013) The novel mTOR inhibitor CCI-779 (temsirolimus) induces antiproliferative effects through inhibition of mTOR in Bel-7402 liver cancer cells. Cancer Cell Int. 13. PMID:23537100.	Small Molecule	Sold for research purposes under agreement from Pfizer Inc.	http://www.tocris.com/dispprod.php?ItemId=423200				Oct-2014
5266	BAZ2-ICR		CN(N=C4)C=C4CCN1C=NC(C3=CN(C)N=C3)=C1C2=CC=C(C#N)C=C2	Selective BAZ2 bromodomain inhibitor	Selective BAZ2 bromodomain inhibitor (Kd values are 109 and 170 nM for BAZ2A and BAZ2B respectively). Exhibits 15-fold selectivity for the BAZ2 bromodomain over the CERC2 bromodomain and >100-fold selectivity over a range of other bromodomains. Accelerates FRAP recovery in a BAZ2A FRAP assay.		Small Molecule	"This probe is supplied in conjunction with the Structural Genomics Consortium. For further characterization details, please visit the BAZ2-ICR probe summary on the SGC website."	http://www.tocris.com/dispprod.php?ItemId=424349				Nov-2014
5269	T 5601640	[924473-59-6]	O=C(C2=CC=CC(NC(C3=CC(C)=NO3)=O)=C2)NC1=CC(C(F)(F)F)=CC=C1	Selective LIMK2 inhibitor; antitumor	Selective LIM kinase 2 (LIMK2) inhibitor; inhibits cofilin phosphorylation in cells that overexpress LIMK2 but not LIMK1. Attenuates the growth of several cancer cell lines. Reduces phospho-cofilin levels and Panc-1 tumor size in a mouse xenograft model.	Mashiach-Farkash et al (2012) Computer-based identification of a novel LIMK1/2 inhibitor that synergizes with salirasib to destabilize the actin cytoskeleton. Oncotarget 3 629. PMID:22776759. Rak et al (2014) Novel LIMK2 inhibitor blocks Panc-1 tumor growth in a mouse xenograft model. Oncoscience 1 39. PMID:25593987.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=424456				Feb-2015
5270	Toyocamycin	[606-58-6]	NC1=C2C(N([C@@H]3O[C@H](CO)[C@H](O)[C@@H]3O)C=C2C#N)=NC=N1	Adenosine analog; antifungal antibiotic	Adenosine analog; antifungal antibiotic. Inhibits RNA self-cleavage in HEK79 cells and PI 3-kinase activity in A431 epidermoid carcinoma cell membrane fractions. Also inhibits thapsigargin-induced XBP1-luciferase activation and induces apoptosis in multiple myeloma cell lines.	"Nishioka et al (1990) Inhibition of phosphatidylinositol kinase by toyocamycin. J.Antibiot. (Tokyo). 43 1586. PMID:2177464. Yen et al (2006) Identification of inhibitors of ribozyme self-cleavage in mammalian cells via high-throughput screening of chemical libraries. RNA 12 797. PMID:16556935. Ri et al (2012) Identification of Toyocamycin, an agent cytotoxic for multiple myeloma cells, as a potent inhibitor of ER stress-induced XBP1 mRNA splicing. Blood.Cancer.J. 2 e79. PMID:22852048."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=424654				Sep-2014
5271	UNC 3230	[1031602-63-7]	O=C(N)C1=C(NC(C2CCCCC2)=O)SC(NC3=CC=CC=C3)=N1	Potent and selective PIP5K1C inhibitor; antinociceptive	"Potent and selective PIP5K1C inhibitor (IC50 = 41 nM). Exhibits selectivity for PIP5K1C over PIP5K1A, the PI 3-kinase family and a panel of other kinases. Reduces PIP2 levels and LPA-induced calcium signaling in dorsal root ganglia (DRG) neurons in vitro. Reduces nociception in mouse models of chronic pain."	Wright et al (2014) The lipid kinase PIP5K1C regulates pain signaling and sensitization. Neuron 82 836. PMID:24853942.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=424765				Jan-2015
5272	MK 0677	[159752-10-0]	O=S(N2C1=CC=CC=C1C3(CCN(C([C@H](NC(C(C)(N)C)=O)COCC4=CC=CC=C4)=O)CC3)C2)(C)=O.CS(O)(=O)=O	High affinity ghrelin receptor agonist	High affinity ghrelin receptor agonist (pKi = 8.14). Growth hormone (GH) secretagog; stimulates GH release from rat pituitary cells in vitro (EC50 = 1.3 nM) and enhances GH plasma levels in vivo. Also attenuates isoproterenol-induced lipolysis in rat adipocytes in vitro. Orally bioavailable.	"Patchett et al (1995) Design and biological activities of L-163,191 (MK-0677): a potent, orally active growth hormone secretagogue. Proc.Natl.Acad.Sci.U.S.A. 92 7001. PMID:7624358. Mucciolo et al (2004) Ghrelin and des-acyl ghrelin both inhibit isoproterenol-induced lipolysis in rat adipocytes via a non-type 1a growth hormone secretagogue receptor. Eur.J.Pharmacol. 498 27. PMID:15363972. Bennett et al (2009) Growth hormone secretagogues and growth hormone releasing peptides act as orthosteric super-agonists but not allosteric regulators for activation of the G protein Galpha(o1) by the Ghrelin receptor. Mol.Pharmacol. 76 802. PMID:19625579."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=424766				Nov-2014
5275	LSN 2463359	[1401031-52-4]	O=C(NC(C)C)C(C=C2)=NC=C2C#CC1=CC=NC=C1	Potent and selective positive allosteric modulator at mGlu5	"Potent and selective positive allosteric modulator at the mGlu5 receptor (EC50 = 24 nM). Has no activity at mGlu1-4, mGlu8 and GABAB receptors. Reverses methylazoxymethanol acetate (MAM)-induced deficits in reversal learning memory and normalizes SDZ 220-581 and RO 63-1908-induced alterations in instrumental responses in rat models. Promotes wakefulness in vivo. Brain penetrant and orally active."	"Gastambide et al (2012) Selective remediation of reversal learning deficits in the neurodevelopmental MAM model of schizophrenia by a novel mGlu5 positive allosteric modulator. Neuropsychopharmacology 37 1057. PMID:22129780. Gilmour et al (2013) In vitro characterisation of the novel positive allosteric modulators of the mGlu5 receptor, LSN2463359 and LSN2814617, and their effects on sleep architecture and operant responding in the rat. Neuropharmacology 64 224. PMID:22884720. Gastambide et al (2013) The mGlu5 positive allosteric modulator LSN2463359 differentially modulates motor, instrumental and cognitive effects of NMDA receptor antagonists in the rat. Neuropharmacology 64 240. PMID:22884612."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=424770				Oct-2014
5276	NS 19504	[327062-46-4]	NC1=NC=C(CC2=CC=C(Br)C=C2)S1	Activator of BKCa (KCa1.1) channels	"Selective activator of large-conductance Ca2+-activated potassium channels (BKCa, KCa1.1) (EC50 = 11 _M). Activates BK channels in native smooth muscle cells from guinea pig bladder and reduces spontaneous phasic contractions in bladder strips ex vivo. Displays no effect on contractions induced by a high K+ concentration or at 65 other receptors tested, including L- and N- type Ca2+ channels, Nav, KATP and hERG channels."	Nausch et al (2014) NS19504: a novel BK channel activator with relaxing effect on bladder smooth muscle spontaneous phasic contractions. J.Pharmacol.Exp.Ther. 350 520. PMID:24951278.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=425246				Dec-2014
5277	CCG 203971	[1443437-74-8]	O=C(N2CCCC(C(NC3=CC=C(Cl)C=C3)=O)C2)C1=CC=CC(C4=CC=CO4)=C1	Inhibits the MRTF/SRF gene transcription pathway; antifibrotic agent	"Antifibrotic agent; inhibits fibrosis by targeting the MRTF/SRF gene transcription pathway. Selectively inhibits proliferation of SSc-derived dermal fibroblasts but not that of normal fibroblasts. Inhibits expression of CTGF, _-SMA, and COL1A2 in SSc fibroblasts as well as in LPA and in TGF_-stimulated fibroblasts. Prevents bleomycin-induced skin thickening and collagen deposition in vivo. Also suppresses PC-3 cell migration in scratch wound assays (IC50 = 4.2 _M)."	Bell et al (2013) Optimization of novel nipecotic bis(amide) inhibitors of the Rho/MKL1/SRF transcriptional pathway as potential anti-metastasis agents. Bioorg.Med.Chem.Lett. 23 3826. PMID:23707258. Haak et al (2014) Targeting the myofibroblast genetic switch: inhibitors of myocardin-related transcription factor/serum response factor-regulated gene transcription prevent fibrosis in a murine model of skin injury. J.Pharmacol.Exp.Ther. 349 480. PMID:24706986. Michel et al (2014) Hope for disease-modifying treatment of systemic sclerosis/scleroderma. J.Pharmacol.Exp.Ther. 350 480. PMID:25053235.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=425254				Oct-2014
5279	IWP 12	[688353-45-9]	CC(S1)CC2=C1C(N(C)C(SCC(NC3=NC(C=CC(C)=C4)=C4S3)=O)=N2)=O	Potent Porcn inhibitor; active in vivo	"Potent inhibitor of Porcupine (Porcn), a membrane-bound O-acyltransferase (MBOAT) (IC50 = 15 nM). Inhibits Wnt/_-catenin and Wnt/planar cell polarity (PCP) signaling pathways. Blocks zebrafish tailfin regeneration in vivo."	Dodge et al (2012) Diverse chemical scaffolds support direct inhibition of the membrane-bound O-acyltransferase porcupine. J.Biol.Chem. 287 23246. PMID:22593577.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=425483				Feb-2015
5280	SCH 51344	[171927-40-5]	CC1=NN=C(N3)C1=C(NCCOCCO)C2=C3C=CC(OC)=C2	Potent MTH1 inhibitor	Potent MTH1 inhibitor (Kd = 49 nM). Inhibits Ras-induced malignant transformation and increases _-actin promoter-driven CAT activity in Ras-transformed cells. Has no effect on Ras-induced ERK and JNK activation. Inhibits Ras-induced membrane ruffling in REF-52 fibroblasts and blocks anchorage-independent growth of Ras-transformed tumor cell lines. Also induces DNA damage in SW480 colon cancer cells.	"Walsh et al (1997) SCH 51344-induced reversal of RAS-transformation is accompanied by the specific inhibition of the RAS and RAC-dependent cell morphology pathway. Oncogene 15 2553. PMID:9399643. Kumar et al (1999) SCH 51344, an inhibitor of RAS/RAC-mediated cell morphology pathway. Ann.N.Y.Acad.Sci. 886 122. PMID:10667210. Huber et al (2014) Stereospecific targeting of MTH1 by (S)-crizotinib as an anticancer strategy. Nature 508 222. PMID:24695225."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=425484				Sep-2014
5281	AC 5216	[226954-04-7]	O=C(N1C)N(CC(N(CC)CC2=CC=CC=C2)=O)C3=C1C=NC(C4=CC=CC=C4)=N3	Selective TSPO ligand	"Ligand of translocator protein (TSPO, peripheral benzodiazepine receptor). Exhibits high affinity for TSPO in rat whole brain (Ki = 0.297 nM), and high potency against human and rat glial TSPO (IC50 values are 2.73 and 3.04 nM respectively). Displays no noticeable binding to a number of other receptors, transporters or ion channels. Also displays anxiolytic and antidepressant effects in rodent models, without inducing benzodiazepine-like adverse effects."	"Kita et al (2004) Antianxiety and antidepressant-like effects of AC-5216, a novel mitochondrial benzodiazepine receptor ligand. Br.J.Pharmacol. 142 1059. PMID:15249420. Qiu et al (2013) Repeated administration of AC-5216, a ligand for the 18kDa translocator protein, improves behavioral deficits in a mouse model of post-traumatic stress disorder. Prog.Neuropsychopharmacol.Biol.Psychiatry 45 40. PMID:23624119."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=425867				Dec-2014
5283	HLM 006474	[353519-63-8]	CC1=C(OCC)C=CC(C(C3=C(O)C(N=C(C)C=C4)=C4C=C3)NC2=NC=CC=C2)=C1	E2F transcription factor inhibitor	E2F transcription factor inhibitor; inhibits E2F DNA binding activity. Inhibits E2F4 DNA binding and reduces E2F4 protein levels in A375 melanoma cells. Induces apoptosis of A375 and MDA-MB-231 breast cancer cells. Inhibits A375 proliferation and invasion in a three dimensional skin model of A375 invasion. Also attenuates human embryonic stem cell proliferation.	Ma et al (2008) A small-molecule E2F inhibitor blocks growth in a melanoma culture model. Cancer Res. 68 6292. PMID:18676853. Conklin et al (2012) The RB family is required for the self-renewal and survival of human embryonic stem cells. Nat.Commun. 3 1244. PMID:23212373.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=425869				Nov-2014
5284	trans-ISRIB	[1597403-47-8]	O=C(COC1=CC=C(Cl)C=C1)N[C@@H]2CC[C@@H](NC(COC3=CC=C(Cl)C=C3)=O)CC2	Integrated stress response (ISR) inhibitor	Integrated stress response (ISR) inhibitor; reverses the effects of eIF2_ phosphorylation (IC50 = 5 nM) and restores cell translation capacity. Acts downstream of PERK and all eIF2_ kinases. Blocks ATF4 production without altering the IRE1 or ATF6 responses in vitro. Displays memory enhancement in hippocampus-dependent spatial and fear-associated learning in rodents. Brain penetrant.	"Sidrauski et al (2013) Pharmacological brake-release of mRNA translation enhances cognitive memory. Elife 2 e00498. PMID:23741617. Pavitt (2013) Less translational control, more memory. Elife 2 e00895. PMID:23741622."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=425870				Jan-2015
5285	ZLN 024 hydrochloride		BrC1=C(OCCSC2=NC=CC=N2)C=CC(C)=C1.Cl	Allosteric AMPK activator	"Allosteric AMP-activated protein kinase (AMPK) activator; allosterically stimulates active AMPK heterotrimers, increasing the activity of _1_1_1 by 1.5-fold and _2_1_1 by 1.7-fold (EC50 values are 0.42 and 0.95 _M, respectively). Inhibits dephosphorylation of AMPK Thr-172 by PP2C_. Stimulates glucose uptake and fatty acid oxidation without increasing the ADP/ATP ratio. Also decreases fatty acid synthesis and glucose output in primary hepatocytes. Improves glucose tolerance and decreases cholesterol content in db/db mice."	Li et al (2013) Novel small-molecule AMPK activator orally exerts beneficial effects on diabetic db/db mice. Toxicol.Appl.Pharmacol. 273 325. PMID:24055643. Zhang et al (2013) Novel small-molecule AMP-activated protein kinase allosteric activator with beneficial effects in db/db mice. PLoS One 8 e72092. PMID:23977216.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=426007				Nov-2014
5286	TC-S 7010	[1158838-45-9]	O=C(NC3=CC=CC=C3Cl)C(C=C2)=CC=C2NC1=C(F)C=NC(NC4=CC=C(CC(N5CCN(CC)CC5)=O)C=C4)=N1	Potent and selective Aurora kinase A inhibitor	Potent and selective inhibitor of Aurora kinase A (IC50 = 3.4 nM); exhibits 1000-fold selectivity for Aurora kinase A over Aurora kinase B. Displays antiproliferative activity in HCT116 and HT29 cells (IC50 values are 0.19 and 2.9 _M respectively).	"Aliagas-Martin et al (2009) A class of 2,4-bisanilinopyrimidine Aurora A inhibitors with unusually high selectivity against Aurora B. J.Med.Chem. 52 3300. PMID:19402633. Yuan et al (2012) Overcoming CML acquired resistance by specific inhibition of Aurora A kinse in the KCL-22 cell model. Carcinogenesis 33 285. PMID:22116466."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=426008				Dec-2014
5289	OF 1	[919973-83-4]	CN1C2=C(C=C(OC)C(NS(C3=C(C)C=C(Br)C=C3)(=O)=O)=C2)N(C)C1=O	Selective BRPF1B and BRPF2 bromodomain inhibitor	Selective BRPF1B and BRPF2 bromodomain inhibitor (Kd values are 100 and 500 nM respectively). Exhibits 39-fold selectivity for BRPF1B and BRPF2 over BRD4. Accelerates FRAP recovery at 5 _M in a BRPF2 FRAP assay.		Small Molecule	"This probe is supplied in conjunction with the Structural Genomics Consortium. For further characterization details, please visit the OF 1 probe summary on the SGC website."	http://www.tocris.com/dispprod.php?ItemId=426135				Nov-2014
5292	Cladribine	[4291-63-8]	OC[C@H]1O[C@@H](N2C=NC3=C2N=C(Cl)N=C3N)C[C@@H]1O	Deoxyadenosine analog; pro-apoptotic	Adenosine deaminase (ADA)-resistant analog of deoxyadenosine. Exhibits anti-leukemic activity; Inhibits cell growth of lymphoid and myeloid neoplasm (IC50 = 20 - 87 nM). Pro-apoptotic; induces DNA double-strand breaks. Also inhibits ribonuclease reductase (IC50 = 0.11 - 0.28 _M). Displays activity in vitro and in vivo. Orally bioavailable.	Seto et al (1985) Mechanism of deoxyadenosine and 2-chlorodeoxyadenosine toxicity to nondividing human lymphocytes. J. Clin. Invest. 75 377. PMID:2579098. Bryson et al (1993) Cladribine. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in haematological malignancies. Drugs 46 872. PMID:7507037. Robak et al (2006) Older and new formulations of cladribine. Pharmacology and clinical efficacy in hematological malignancies. Recent Pat. Anticancer Drug Discov. 1 23. PMID:18221024.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=426201				Sep-2014
5294	Oltipraz	[64224-21-1]	CC1=C(SSC1=S)C2=CN=CC=N2	Nrf2 activator	"Nrf2 activator; activates Nrf, which binds to antioxidant response elements (AREs) and induces Phase-I and -II drug-metabolizing enzymes including CYP2B and NQO1. Also increases mRNA levels of multiple hepatic xenobiotic transporters. Elevates expression of genes encoding anti-oxidant and multidrug resistance-associated proteins. Displays chemopreventive activity."	"Manandhar et al (2007) Induction of Nrf2-regulated genes by 3H-1, 2-dithiole-3-thione through the ERK signaling pathway in murine keratinocytes. Eur J Pharmacol. 577 17. PMID:17854798. Maher et al (2007) Oxidative and electrophilic stress induces multidrug resistance-associated protein transporters via the nuclear factor-E2-related factor-2 transcriptional pathway. Hepatology 46 1597. PMID:17668877. Merrell et al (2008) Induction of drug metabolism enzymes and transporters by oltipraz in rats. J.Biochem.Mol.Toxicol. 22 128. PMID:18418891."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=426203				Dec-2014
5297	LY 404187	[211311-95-4]	N#CC1=CC=C(C2=CC=C(C(C)CNS(C(C)C)(=O)=O)C=C2)C=C1	Selective AMPA receptor positive allosteric modulator	"Selective AMPA receptor positive allosteric modulator (IC50 values are 0.15, 0.21, 1.66 and 5.65 _M for GluA2i, GluA4i, GluA3i and GluA1i respectively. Potentiates glutamate and AMPA-evoked currents in pre frontal cortex (PFC) pyramidal neurons in vitro. Has no effect on NMDA- or kainate-evoked currents; also has no effect on K+ or Na+ ion channels. Potentiates PFC glutamatergic synaptic transmission in vitro and in vivo. Induces neurite growth in combination with (S)-AMPA (Cat. No. 0254) in SH-SY5Y human neuroblastoma cells in vitro. Also reduces MPTP-induced toxicity in mice. Brain penetrant."	"Baumbarger et al (2001) Positive modulation of alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) receptors in prefrontal cortical pyramidal neurons by a novel allosteric potentiator. J.Pharmacol.Exp.Ther. 298 86. PMID:11408529. Quirk and Nisenbaum (2002) LY404187: a novel positive allosteric modulator of AMPA receptors. CNS Drug Rev. 8 255. PMID:12353058. O'Neill et al (2004) Neurotrophic actions of the novel AMPA receptor potentiator, LY404187, in rodent models of Parkinson's disease. Eur.J.Pharmacol. 486 163. PMID:14975705. Voss et al (2007) Molecular mechanisms of neurite growth with AMPA receptor potentiation. Neuropharmacology 52 590. PMID:17101156."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=426402				Dec-2014
5299	JNJ 47965567	[1428327-31-4]	O=C(NCC4(CCOCC4)N3CCN(C5=CC=CC=C5)CC3)C1=CC=CN=C1SC2=CC=CC=C2	Potent and selective P2X7 antagonist; brain penetrant	"Potent and selective P2X7 antagonist (pIC50 values are 8.3, 7.5 and 7.2 for human, mouse and rat receptors respectively). Selective over a panel of 50 other receptors, ion channels and transporters. Reduces BzATP-induced IL-1_ release from monocytes in vitro and from rat brain in vivo. Attenuates amphetamine-induced hyperactivity in rats. Brain penetrant."	"Bhattacharya et al (2013) Pharmacological characterization of a novel centrally permeable P2X7 receptor antagonist: JNJ-47965567. Br.J.Pharmacol. 170 624. PMID:23889535. Letavic et al (2013) Synthesis and pharmacological characterization of two novel, brain penetrating P2X7 antagonists. ACS Med.Chem.Lett. 12 419. PMID:24900687."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=426713				Feb-2015
5309	SP 100030	[154563-54-9]	O=C(NC2=CC(C(F)(F)F)=CC(C(F)(F)F)=C2)C1=C(C(F)(F)F)N=C(Cl)N=C1	NF-_B and AP-1 dual inhibitor	"Potent dual inhibitor of NF-_B and AP-1 transcriptional activity (IC50 = 50nM). Blocks production of IL-2, IL-8 and TNF-_ from Jurkat T cells. Inhibits cytokine production selectively in T cells; exhibits minimal inhibition of cytokine production in other cell types. Decreases arthritic severity in a mouse model of collagen-induced arthritis. Also ameliorates muscle wasting in a rat model of cancer cachexia."	"Sullivan et al (1998) 2-Chloro-4-(trifluoromethyl)pyrimidine-5-N-(3',5'- bis(trifluoromethyl)phenyl)-carboxamide: a potent inhibitor of NF-_B- and AP-1-mediated gene expression identified using solution-phase combinatorial chemistry. J.Med.Chem. 41 413. PMID: 9484492. Gerlag et al (2000) The effect of a T cell-specific NF-_B inhibitor on in vitro cytokine production and collagen-induced arthritis J.Immunol. 165 1652. PMID:10903776. Moore-Carrasco et al (2007) The AP-1/NF-_B double inhibitor SP100030 can revert muscle wasting during experimental cancer cachexia. Int.J.Oncol. 30 1239. PMID:17390027."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=429255				Dec-2014
5310	ASP 3026	[1097917-15-1]	CN1CCN(C2CCN(C3=CC=C(NC4=NC(NC5=C(S(C(C)C)(=O)=O)C=CC=C5)=NC=N4)C(OC)=C3)CC2)CC1	Potent anaplastic lymphoma kinase (ALK) inhibitor	"Potent anaplastic lymphoma kinase (ALK) inhibitor (IC50 = 3.5 nM). Also inhibits Ack and ROS1 activity (IC50 values are 5.8 and 8.9 nM respectively). Attenuates proliferation, and induces apoptosis of NPM-ALK+ T cell anaplastic large-cell lymphoma (ALCL) cells in vitro. Suppresses tumor growth of NPM-ALK+ ALCL cell xenografts in mice. Causes tumor shrinkage in hEML4-ALK transgenic mice. Orally available."	George et al (2014) The ALK inhibitor ASP3026 eradicates NPM-ALK+ T-cell anaplastic large-cell lymphoma in vitro and in a systemic xenograft lymphoma model. Oncotarget 5 5750. PMID:25026277. Awad and Shaw (2014) ALK Inhibitors in Non-Small Cell Lung Cancer: Crizotinib and Beyond. Clin.Adv.Hematol.Oncol. 12 429. PMID:25322323. Mori et al (2014) The selective anaplastic lymphoma receptor tyrosine kinase inhibitor ASP3026 induces tumor regression and prolongs survival in non-small cell lung cancer model mice. Mol.Cancer Ther. 13 329. PMID:24419060.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=429779				Nov-2014
5313	LY 315920	[172732-68-2]	OC(COC1=C2C(N(CC3=CC=CC=C3)C(CC)=C2C(C(N)=O)=O)=CC=C1)=O	Selective secreted phospholipase A2 (sPLA2) inhibitor	Selective secreted phospholipase A2 (sPLA2) inhibitor (IC50 = 50 - 750 nM for a range of sPLA2 isoforms). Has no effect on cytosolic PLA2 or COX-1 and COX-2 activity. Attenuates sPLA2-induced thromboxane formation in bronchoalveolar lavage (BAL) cells. Also suppresses sPLA2-induced contractions of lung pleural strips ex vivo. Orally available.	"Snyder et al (1999) Pharmacology of LY315920/S-5920, [[3-(aminooxoacetyl)-2-ethyl-1- (phenylmethyl)-1H-indol-4-yl]oxy] acetate, a potent and selective secretory phospholipase A2 inhibitor: A new class of anti-inflammatory drugs, SPI. J.Pharmacol.Exp.Ther. 288 1117. PMID:10027849. Oslund et al (2008) Highly specific and broadly potent inhibitors of mammalian secreted phospholipases A2. J.Med.Chem. 51 4708. PMID:18605714."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=429810				Nov-2014
5314	SMBA 1	[906440-37-7]	OC(C=CC=C4)=C4\C=C2C3=C(C=CC([N+]([O-])=O)=C3)C1=CC=CC=C1/2	High affinity and selective activator of Bax	"High affinity and selective activator of Bax (Ki = 43.3 nM). Binds to the S184 binding pocket to block Bax phosphorylation. Does not bind to other Bcl-2 family members, including Bcl-2, Bak and Bid. Facilitates Bax insertion into the mitochondrial membrane and promotes Bax-dependent cytochrome c release. Induces apoptosis in lung cancer cell lines expressing high levels of Bax selectively over normal cells expressing low levels of Bax. Represses tumor growth of A549 lung cancer xenografts in mice."	Xin et al (2014) Small-molecule Bax agonists for cancer therapy. Nat.Commun. 5 4935. PMID:25230299.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=429867				Dec-2014
5315	Rostafuroxin	[156722-18-8]	O[C@]4(C5=COC=C5)CC[C@]3(O)[C@]2([H])CC[C@]1([H])C[C@@H](O)CC[C@@](C)1[C@]([H])2CC[C@@]34C	Antihypertensive agent; Na+/K+ ATPase modulator	Antihypertensive agent. Modulates Na+/K+ ATPase activity by displacing [3H]-ouabain. Also normalizes renal Na+/K+ ATPase pump function in mutant adducin- and endogenous ouabain-dependent forms of hypertension; reduces blood pressure in Milan hypersensitive rats.	Ferrandi et al (2004) Organ hypertrophic signaling within caveolae membrane subdomains triggered by ouabain and antagonized by PST 2238. J.Biol.Chem. 279 33306. PMID:15161929. Ferrari (2006) Rostafuroxin: an ouabain antagonist that corrects renal and vascular Na+-K+- ATPase alterations in ouabain and adducin-dependent hypertension. Am.J.Physiol.Regul.Integr.Comp.Physiol. 290 529. PMID:16467500. Ferrari et al (2010) Rostafuroxin: an ouabain-inhibitor counteracting specific forms of hypertension. Biochim Biophys Acta. 1802 1254. PMID:20083196.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=429868				Nov-2014
5321	PSNCBAM-1	[877202-74-9]	ClC1=CC=C(NC(NC2=CC(C3=CC=CC(N4CCCC4)=N3)=CC=C2)=O)C=C1	CB1 receptor negative allosteric modulator	"CB1 receptor negative allosteric modulator (IC50 values are 45 and 209 nM for the inhibition of CP 55,940 and WIN 55,212-2 respectively). Has no effect at the CB2 receptor. Decreases food intake and body weight in rats."	"Horswill et al (2007) PSNCBAM-1, a novel allosteric antagonist at cannabinoid CB1 receptors with hypophagic effects in rats. Br.J.Pharmacol. 152 805. PMID:17592509. German et al (2014) Diarylureas as allosteric modulators of the cannabinoid CB1 receptor: structure-activity relationship studies on 1-(4-chlorophenyl)-3-{3-[6-(pyrrolidin-1-yl)pyridin-2-yl]phenyl}urea (PSNCBAM-1). J.Med.Chem. 57 7758. PMID:25162172."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=431141				Jan-2015
5323	WDR5 0103	[890190-22-4]	O=C(OC)C1=CC(NC(C3=CC=CC(OC)=C3)=O)=C(N2CCN(C)CC2)C=C1	WDR5 antagonist	"WD repeat-containing protein 5 (WDR5) antagonist (Kd = 450 nM). Disrupts WDR5 interaction with MLL and inhibits MLL core complex methyltransferase activity in vitro. Has no effect on a panel of seven other methyltransferases, including SETD7."	Senisterra et al (2013) Small-molecule inhibition of MLL activity by disruption of its interaction with WDR5. Biochem.J. 449 151. PMID:22989411.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=431342				Feb-2015
5325	Rosiglitazone	[122320-73-4]	CN(CCOC1=CC=C(CC2SC(NC2=O)=O)C=C1)C3=CC=CC=N3	Potent and selective PPAR_ agonist; antidiabetic agent.	Potent and selective PPAR_ agonist (EC50 = 60 nM); exhibits no activity at PPAR_ and PPAR_. Promotes differentiation of pluripotent C3H10T1/2 stem cells into adipocytes. Exhibits antihyperglycemic activity in diabetic ob/ob mouse model. Antidiabetic agent.	Lehmann et al (1995) An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J.Biol.Chem. 270 12953. PMID:7768881. Willson et al (1996) The structure-activity relationship between peroxisome proliferator-activated receptor gamma agonism and the antihyperglycemic activity of thiazolidinediones. J.Med.Chem. 39 665. PMID:8576907.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=431344				Nov-2014
5326	CHR 6494 trifluoroacetate	[1458630-17-5]	CCCNC2=NN1C(C3=CC(C=NN4)=C4C=C3)=CN=C1C=C2.OC(C(F)(F)F)=O	Potent and selective haspin kinase inhibitor	"Potent and selective haspin kinase inhibitor (IC50 = 2 nM). Selective over 27 other protein kinases including Aurora B kinase. Induces cell cycle arrest at G2/M, inhibits cell proliferation and promotes apoptosis in multiple cancer cell lines. Inhibits angiogenesis ex vivo and attenuates tumor growth of HCT-116 xenografts in rats."	Huertas et al (2012) Antitumor activity of a small-molecule inhibitor of the histone kinase Haspin. Oncogene 31 1408. PMID:21804608.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=431345				Jan-2015
5331	CPI 203	[1446144-04-2]	NC(C[C@@H]1N=C(C4=CC=C(Cl)C=C4)C3=C(SC(C)=C3C)N2C1=NN=C2C)=O	BET bromodomain inhibitor; arrests cell cycle at G1 phase	"BET bromodomain inhibitor. Downregulates Myc expression, causes G1 cell cycle arrest and attenuates cell proliferation in human pancreatic neuroendocrine tumors. Arrests the growth of T cell acute lymphoblastic leukemia cells in vitro (EC50 = 91.2 nM). Also enhances the antitumor effect of rapamycin (Cat. No. 1292) in vitro and attenuates rapamycin induced Akt activation. Orally bioavailable."	King et al (2013) The ubiquitin ligase FBXW7 modulates leukemia-initiating cell activity by regulating MYC stability. Cell 153 1552. PMID:23791182. Wong et al (2014) The bromodomain and extra-terminal inhibitor CPI203 enhances the antiproliferative effects of rapamycin on human neuroendocrine tumors. Cell Death Dis. 5 e1450. PMID:25299775.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=431350				Jan-2015
5337	ML 365	[947914-18-3]	CC1=CC=CC(C(NC2=CC(NC(C3=CC=CC=C3OC)=O)=CC=C2)=O)=C1	Potent and selective TASK-1 channel blocker	"Potent and selective TASK-1 (K2P3.1/KCNK3) channel blocker (IC50 values are 4 and 390 nM at TASK-1 and TASK-3, respectively). Displays little or no inhibition at Kir2.1, voltage-gated potassium channels, KCNQ2 and KV11.1 (hERG)."	Zou et al (2013) ML365: Development of bis-amides as selective inhibitors of the KCNK3/TASK1 two pore potassium channel. Probe Reports from the NIH Molecular Libraries Program. PMID:24479195. Flaherty et al (2014) Potent and selective inhibitors of the TASK-1 potassium channel through chemical optimization of a bis-amide scaffold. Bioorg.Med.Chem.Lett. 24 3968. PMID:25017033.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=431910				Jan-2015
5345	ML 348	[899713-86-1]	ClC1=C(NC(CN2CCN(C(C3=CC=CO3)=O)CC2)=O)C=C(C(F)(F)F)C=C1	Selective and reversible lysophospholipase 1 (LYPLA1) inhibitor	Selective and reversible lysophospholipase 1 (LYPLA1) inhibitor (IC50 = 210 nM). Exhibits 14-fold selectivity for LYPLA1 over LYPLA2. Also selective over a panel of ~30 other serine hydrolases.	"Adibekian et al (2013) Characterization of a Selective, Reversible Inhibitor of Lysophospholipase 2 (LYPLA2). Probe Reports from the NIH Molecular Libraries Program. PMID:24624465."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=432269				Jan-2015
5348	CPI 613	[95809-78-2]	OC(CCCCC(SCC2=CC=CC=C2)CCSCC1=CC=CC=C1)=O	PDH and KGDH inhibitor	"Pyruvate dehydrogenase (PDH) and _-ketoglutarate dehydrogenase (KGDH) inhibitor. Disrupts tumor cell mitochondrial metabolism, and increases mitochondrial reactive oxygen species (ROS) production in H460 lung carcinoma cells. Has no effect on KGDH activity in normal bronchial epithelial cells. Induces cell death of multiple tumor cell lines selectively over normal cells in vitro. Inhibits tumor growth of H460 and BxPC-3 tumor cell xenografts in mice."	Zachar et al (2011) Non-redox-active lipoate derivates disrupt cancer cell mitochondrial metabolism and are potent anticancer agents in vivo. J.Mol.Med. (Berl.) 89 1137. PMID:21769686. Stuart et al (2014) A strategically designed small molecule attacks alpha-ketoglutarate dehydrogenase in tumor cells through a redox process. Cancer Metab. 2 4. PMID:24612826.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=432272				Dec-2014
5357	DC 260126	[346692-04-4]	CCCCC(C=C2)=CC=C2NS(C1=CC=C(F)C=C1)(=O)=O	FFA1 (GPR40) antagonist	"Free fatty acid receptor 1 (FFA1/GPR40) antagonist. Inhibits FFA-induced increases in intracellular Ca2+ levels and suppresses palmitic acid potentiated glucose-stimulated insulin secretion in Min6 pancreatic _ cells in vitro. Decreases serum insulin levels, improves insulin sensitivity and reduces the number of apoptotic pancreatic _ cells in obese diabetic (db/db) rats."	"Hu et al (2009) A novel class of antagonists for the FFAs receptor GPR40. Biochem.Biophys.Res.Comm. 390 557. PMID:19818732. Zhang et al (2010) DC260126, a small-molecule antagonist of GPR40, improves insulin tolerance but not glucose tolerance in obese Zucker rats. Biomed.Pharmacother. 64 647. PMID:20888730. Sun et al (2013) DC260126: a small-molecule antagonist of GPR40 that protects against pancreatic _-Cells dysfunction in db/db mice. PLoS ONE 8 e66744. PMID:23776696."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=434015				Dec-2014
5359	Rifaximin	[80621-81-4]	O=C(/C(C)=C\C=C\[C@H](C)[C@H](O)[C@H]([C@H]([C@@H](C)[C@H](OC(C)=O)[C@H](C)[C@@H](OC)/C=C/O[C@@]5(C)O4)O)C)NC2=C(O)C1=C(O)C(C)=C4C(C5=O)=C1C3=C2N6C(C=C(C)C=C6)=N3	Pregnane X receptor agonist; antibiotic	"Pregnane X receptor (PXR) agonist; antibiotic. Reduces number of colon tumors and suppresses expression of TNF_ and Il-1_ induced in a colon cancer, PXR-humanized mouse model. Increases apoptosis and decreased proliferation in HT-29 cells. Exhibits low gastrointestinal absorption while retaining its antibacterial activity. Active against gram-positive and gram-negative bacteria."	Jiang et al (2005) Rifaximin: in vitro and in vivo antibacterial activity-a review. Chemotherapy 51 67. PMID:15855749. Stradi et al (2010) Structural elucidation of the Rifaximin Ph. Eur. Impurity H. J.Pharm.Biomed.Anal. 51 858. PMID:19926422. Cheng et al (2014) Activation of intestinal human pregnane X receptor protects against azoxymethane/dextran sulfate sodium-induced colon cancer. J.Pharmacol.Exp.Ther. 351 559. PMID:25277138.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=434019				Dec-2014
5371	Clemizole hydrochloride	[1163-36-6]	ClC(C=C4)=CC=C4CN2C(CN3CCCC3)=NC1=CC=CC=C12.Cl	TRPC5 blocker; also H1 antagonist	"TRPC5 channel blocker (IC50 values are 1.1, 6.4, 9.1, 11.3 and 26.5 _M for TRPC5, TRPC4, TRPC3, TRPC6 and TRPC7 respectively). Exhibits minimal effect on TRPM3, TRPM8 and TRPV1-4 channels. Also histamine H1 receptor antagonist."	Aguilar et al (1986) Pharmacological investigation into the effects of histamine and histamine analogues on guinea-pig and rat colon in vitro. Br.J.Pharmacol. 88 501. PMID:3742147. Richter et al (2014) Clemizole hydrochloride is a novel and potent inhibitor of transient receptor potential channel TRPC5. Mol.Pharm. 86 514. PMID:25140002.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=434512				Feb-2015
5373	C34	[40592-88-9]	CC(OC[C@@H]1[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@@H](NC(C)=O)[C@@H](OC(C)C)O1)=O	TLR4 inhibitor	"TLR4 inhibitor; attenuates TLR4 signaling in enterocytes and macrophages in vitro, and reduces systemic inflammation in mouse models of endotoxemia and necrotizing enterocolitis (NEC). Also suppresses LPS signaling in human ileum displaying NEC ex-vivo. Displays no significant effects on signaling via TLR2 or TLR9."	Neal et al (2013) Discovery and validation of a new class of small molecule Toll-like receptor 4 (TLR4) inhibitors. PLoS One 8 e65779. PMID:23776545.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=434514				Jan-2015
5376	Pregnenolone sulfate sodium salt	[1852-38-6]	O=[C@](C)[C@H]4CC[C@@]3([H])[C@]2([H])CC=C1C[C@@H](OS(=O)([O-])=O)CC[C@@](C)1[C@]([H])2CC[C@@]34C.[Na+]	NMDA Potentiator	"Highly potent neurosteroid; enhances intracellular Ca2+ upon NMDA receptor-mediated synaptic activity (EC50 = ~2 pM) and potentiates NMDA responses. Activates CREB phosphorylation, augments LTP and cognitive behavior in rat memory models. Also activates TRPM3 channels."	Li et al (2007) Neuroactive steroids and human recombinant rho1 GABAC receptors. J.Pharmacol.Exp.Ther. 323 236. PMID:17636008. Majeed et al (2010) Cis-isomerism and other chemical requirements of steroidal agonists and partial agonists acting at TRPM3 channels. Br.J.Pharmacol. 161 430. PMID:20735426. Smith et al (2014) A role for picomolar concentrations of pregnenolone sulfate in synaptic activity-dependent Ca2+ signaling and CREB activation. Mol.Pharmacol. 86 390. PMID:25057049.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=434543				Feb-2015
5383	TA 01		FC(C=C4)=CC=C4C(N=C(C3=C(F)C=CC=C3F)N2)=C2C1=CC=NC=C1	Induces cardiomyocyte differentiation from hESCs	"Induces cardiomyocyte differentiation from human embryonic stem cells following mesoderm induction at 1 _M. Inhibits cardiomyocyte differentiation at 5 _M. Potently inhibits CK1_, p38_, and CK1_ (IC50 values are 6.4, 6.7 and 6.8 nM respectively)."	Laco et al (2014) Cardiomyocyte differentiation of pluripotent stem cells with SB203580 analogues correlates with Wnt pathway CK1 inhibition independent of p38 MAPK signaling. J.Mol.Cell.Cardiol. PMID:25528965.	Small Molecule	Sold under agreement from ETPL and its Affiliates including Bioprocessing Technology Institute.	http://www.tocris.com/dispprod.php?ItemId=436343				Jan-2015
5384	TA 02		FC(C=C4)=CC=C4C(N=C(C3=C(F)C=CC=C3)N2)=C2C1=CC=NC=C1	Induces cardiomyocyte differentiation from hESCs	"Induces cardiomyocyte differentiation from human embryonic stem cells following mesoderm induction. Potently inhibits p38_, CK1_ and CK1_ (IC50 values are 20, 32 and 32 nM respectively)."	Laco et al (2014) Cardiomyocyte differentiation of pluripotent stem cells with SB203580 analogues correlates with Wnt pathway CK1 inhibition independent of p38 MAPK signaling. J.Mol.Cell.Cardiol. PMID:25528965.	Small Molecule	Sold under agreement from ETPL and its Affiliates including Bioprocessing Technology Institute.	http://www.tocris.com/dispprod.php?ItemId=436344				Jan-2015
5385	GSK 5959	[901245-65-6]	CN(C1=CC(NC(C4=C(OC)C=CC=C4)=O)=C(N3CCCCC3)C=C1N2C)C2=O	Potent and selective BRPF1 bromodomain inhibitor	"Potent and selective BRPF1 bromodomain inhibitor (IC50 = 80 nM). Exhibits >100-fold selectivity for BRPF1 over a panel of 35 other bromodomains, including BRPF2/3 and BET family bromodomains. Inhibits BRPF1 interaction with histone H3.3. Cell permeable."	"Demont et al (2014) 1,3-dimethyl benzimidazolones are potent, selective inhibitors of the BRPF1 bromodomain. ACS Med.Chem.Lett. 5 1190. PMID:25408830."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=436345				Feb-2015
5399	BTB1	[86030-08-2]	ClC1=CC([N+]([O-])=O)=C(S(C2=CC=CC=C2)(=O)=O)C=C1	Selective and ATP-competitive Kif18A inhibitor	Selective and ATP-competitive mitotic kinesin Kif18A inhibitor (IC50 = 1.7 _M); reversibly inhibits microtubule-stimulated Kif18A ATPase activity. Displays selectivity against a panel of other mitotic kinesins.	Catarinella et al (2009) BTB-1: a small molecule inhibitor of the mitotic motor protein Kif18A. Angew.Chem.Int.Ed.Engl. 48 9072. PMID:19856362. Braun et al (2014) Synthesis and biological evaluation of optimized Inhibitors of the mitotic kinesin Kif18A. ACS Chem.Biol. PMID:25402598.	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=437242				Feb-2015
5400	(S)-PFI 2 hydrochloride		O=C(N4CCCC4)[C@H](CC3=CC=CC(C(F)(F)F)=C3)NS(C2=CC1=C(C(F)=C2)CNCC1)(=O)=O.Cl	Negative control of (R)-PFI 2 hydrochloride (Cat. No. 4892)	Negative control of (R)-PFI 2 hydrochloride (Cat. No. 4892). Exhibits 500-fold lower activity in a SETD7 enzymatic assay (IC50 = 1 _M) compared to the active enantiomer.	Barsyte-Lovejoy et al (2014) (R)-PFI-2 is a potent and selective inhibitor of SETD7 methyltransferase activity in cells. Proc.Natl.Acad.Sci.U S A 111 12853. PMID:25136132.	Small Molecule	"This compound is supplied in conjunction with the Structural Genomics Consortium. For further characterization details, please visit the (R)-PFI 2 probe summary on the SGC website."	http://www.tocris.com/dispprod.php?ItemId=437364				Jan-2015
5422	XL 184	[849217-68-1]	COC1=CC2=C(C=C1OC)N=CC=C2OC3=CC=C(NC(C4(CC4)C(NC5=CC=C(F)C=C5)=O)=O)C=C3	Potent VEGFR inhibitor; also inhibits other RTKs	"Potent VEGFR inhibitor (IC50 = 0.035 nM); also inhibits c-Met, KIT, RET, FLT4, AXL, FLT3, FLT1 and Tie2 (IC50 values are 1.3, 4.6, 5.2, 6, 7, 11.3, 12 and 14.3 nM, respectively). Induces intratumoral hypoxia and apoptosis. Reduces tumor invasion and metastasis in vivo. Antiangiogenic."	"Yakes et al (2011) Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Mol.Cancer Ther. 10 2298. PMID:21926191. You et al (2012) VEGF and c-Met blockade amplify angiogenesis inhibition in pancreatic islet cancer. Cancer Res. 71 4758. PMID:21613405."	Small Molecule		http://www.tocris.com/dispprod.php?ItemId=439976				Feb-2015